PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Baxter, RM; Secrist, JP; Vaillancourt, RR; Kazlauskas, A				Baxter, RM; Secrist, JP; Vaillancourt, RR; Kazlauskas, A			Full activation of the platelet-derived growth factor beta-receptor kinase involves multiple events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; PROTEIN-TYROSINE KINASES; PDGF RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL-3 KINASE; AUTOPHOSPHORYLATION SITES; PHOSPHORYLATION SITE; INSULIN-RECEPTOR; DNA-SYNTHESIS; SRC FAMILY	Activation of receptor tyrosine kinases is thought to involve ligand-induced dimerization, which promotes receptor transphosphorylation and thereby increases the receptor's phosphotransferase activity. We used two platelet-derived growth factor beta-receptor (beta-PDGFR) mutants to identify events that are required for full engagement (autophosphorylation and activation of the kinase activity) of the beta-PDGFR kinase, The F79/81 receptor (Tyr to Phe substitution at 579 and 581 in the juxtamembrane domain of the receptor) was capable of only very modest ligand dependent autophosphorylation and also failed to associate with numerous SH2 domain-containing proteins, Furthermore, stimulation with platelet-derived growth factor (PDGF) did not increase the kinase activity of the F79/81 mutant toward exogenous substrates, However, the F79/81 receptor had basal kinase activity and could be artificially stimulated by incubation with ATP, Because the low kinase activity of the F857 mutant (Tyr to Phe substitution at 857 in the putative activation loop) could not be increased by incubation with ATP, failure to phosphorylate Tyr-857 may be the reason why the F79/81 mutant has low kinase activity. Surprisingly, the F857 mutant underwent efficient PDGF-dependent autophosphorylation, Thus the PDGF-dependent increase in the kinase activity of the receptor is not required for autophosphorylation. We conclude that full activation of the beta-PDGFR kinase requires at least two, apparently distinct events.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute	Kazlauskas, A (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.				NATIONAL EYE INSTITUTE [R01EY011693] Funding Source: NIH RePORTER; NEI NIH HHS [EY 11693] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAZENET CE, 1994, ONCOGENE, V9, P517; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; YU KT, 1985, J BIOL CHEM, V260, P5838	41	91	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17050	17055		10.1074/jbc.273.27.17050	http://dx.doi.org/10.1074/jbc.273.27.17050			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642269	hybrid			2022-12-25	WOS:000074545200059
J	Liberati, C; Ronchi, A; Lievens, P; Ottolenghi, S; Mantovani, R				Liberati, C; Ronchi, A; Lievens, P; Ottolenghi, S; Mantovani, R			NF-Y organizes the gamma-globin CCAAT boxes region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; BINDING FACTOR CBF; CLASS-II; DISPLACEMENT PROTEIN; TRANSCRIPTION FACTOR; GENE PROMOTER; DNA COMPLEX; HEREDITARY PERSISTENCE; REGULATORY ELEMENTS; FUNCTIONAL DOMAINS	The CCAAT-binding activator NF-Y is formed by three evolutionary conserved subunits, two of which contain putative histone-like domains. We investigated NF-Y binding to all CCAAT boxes of globin promoters in direct binding, competition, and supershift electrophoretic mobility shift assay; we found that the alpha, zeta, and proximal gamma CCAAT boxes of human and the prosimian Galago bind avidly, and distal gamma CCAAT boxes have intermediate affinity, whereas the epsilon and beta sequences bind NF-Y very poorly. We developed an efficient in vitro transcription system from erythroid K562 cells and established that both the distal and the proximal CCAAT boxes are important for optimal gamma-globin promoter activity. Surprisingly, NF-Y binding to a mutated distal CCAAT box (a C to T at position -114) is remarkably increased upon occupancy of the high affinity proximal element, located 27 base pairs away. Shortening the distance between the two CCAAT boxes progressively prevents simultaneous CCAAT binding, indicating that NF-Y interacts in a mutually exclusive way with CCAAT boxes closer than 24 base pairs apart. A combination of circular permutation and phasing analysis proved that (i) NF-Y-induced angles of the two gamma-globin CCAAT boxes have similar amplitudes; (ii) occupancy of the two CCAAT boxes leads to compensatory distortions; (iii) the two NF-Y bends are spatially oriented with combined twisting angles of about 100 degrees, Interestingly, such distortions are reminiscent of core histone-DNA interactions. We conclude that NF-Y binding imposes a high level of functionally important coordinate organization to the gamma-globin promoter.	Univ Milan, Dipartimento Genet & Biol Microorganismi, I-20133 Milan, Italy	University of Milan	Ottolenghi, S (corresponding author), Univ Milan, Dipartimento Genet & Biol Microorganismi, Via Celoria 26, I-20133 Milan, Italy.				Telethon [E.0596] Funding Source: Medline	Telethon(Fondazione Telethon)		ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; Bellorini M, 1996, MOL CELL BIOL, V16, P503; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; BIENZ M, 1986, CELL, V45, P753, DOI 10.1016/0092-8674(86)90789-0; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; COWIE A, 1988, MOL CELL BIOL, V8, P3122, DOI 10.1128/MCB.8.8.3122; DELVOYE NL, 1993, MOL CELL BIOL, V13, P6969, DOI 10.1128/MCB.13.11.6969; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FUCHAROEN S, 1990, NUCLEIC ACIDS RES, V18, P5245, DOI 10.1093/nar/18.17.5245; GROSVELD F, 1993, COLD SPRING HARB SYM, V58, P7, DOI 10.1101/SQB.1993.058.01.004; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; JACKSON SM, 1998, J LIPID RES, V10, P1; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; KERRPOLA T, 1991, CELL, V66, P316; KIM CG, 1990, J BIOL CHEM, V265, P13362; Kim IS, 1996, MOL CELL BIOL, V16, P4003; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LI XY, 1992, J BIOL CHEM, V267, P8984; LIWEBER M, 1994, J IMMUNOL, V153, P4122; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; Mantovani R, 1994, Methods Mol Biol, V31, P289; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MANTOVANI R, 1989, NUCLEIC ACIDS RES, V17, P6681, DOI 10.1093/nar/17.16.6681; Mason MM, 1996, J BIOL CHEM, V271, P25459, DOI 10.1074/jbc.271.41.25459; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; Osawa H, 1996, J BIOL CHEM, V271, P17296, DOI 10.1074/jbc.271.29.17296; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; PINKHAM JL, 1987, MOL CELL BIOL, V7, P578, DOI 10.1128/MCB.7.2.578; Pondel MD, 1996, NUCLEIC ACIDS RES, V24, P4158, DOI 10.1093/nar/24.21.4158; REDDY PMS, 1994, J BIOL CHEM, V269, P8287; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; Ronchi A, 1996, EMBO J, V15, P143, DOI 10.1002/j.1460-2075.1996.tb00342.x; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; RONCHI AE, 1995, J BIOL CHEM, V270, P21934, DOI 10.1074/jbc.270.37.21934; RUDDELL A, 1995, VIROLOGY, V206, P1, DOI 10.1016/S0042-6822(95)80013-1; SCHWEIZERGROYER G, 1994, NUCLEIC ACIDS RES, V22, P1583, DOI 10.1093/nar/22.9.1583; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SPEAR DH, 1994, J BIOL CHEM, V269, P25212; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	54	45	45	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16880	16889		10.1074/jbc.273.27.16880	http://dx.doi.org/10.1074/jbc.273.27.16880			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642249	hybrid			2022-12-25	WOS:000074545200039
J	Hashimoto, Y; Kohri, K; Kaneko, Y; Morisaki, H; Kato, T; Ikeda, K; Nakanishi, M				Hashimoto, Y; Kohri, K; Kaneko, Y; Morisaki, H; Kato, T; Ikeda, K; Nakanishi, M			Critical role for the 3(10) helix region of p57(Kip2) in cyclin-dependent kinase 2 inhibition and growth suppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK INHIBITORS; CELL-CYCLE; P21; IDENTIFICATION; P27(KIP1); CLONING; BINDING; MOTIF; GENE; P18	Although crystal structural analysis of cyclin A/cyclin-dependent kinase 2 (Cdk2)/p27 (Russo, A. A., Jeffrey, P. D., Pattern, A. K., Massague, J., and Pavletich, N. P. (1996) Nature 382, 325-331) has suggested that the 3(10) helix region in Cdk inhibitors of the Cip/Kip family may be involved in the inhibition of cyclin/Cdk activities, there is no biochemical evidence supporting this hypothesis. In the present study, we demonstrated that cyclin and Cdk binding domains of p57 were necessary but were not sufficient in themselves for the inhibition of cyclin A/Cdk2 and cyclin E/Cdk2, and that the 3(10) helix region of this protein is indispensable for the inhibition of these complexes. In contrast, the 3(10) helix regions of p21 and p27 were not required, and cyclin- and Cdk-binding domains alone were sufficient for the inhibition of all cyclin/Cdk complexes examined. Site-directed mutagenesis identified phenylalanine 79 and tyrosine 80 within the 3(10) helix region of p57 as crucial residues for kinase inhibition, supporting the structural evidence that the 3(10) helix binds deep inside the catalytic cleft of Cdk2, mimicking ATP. Mutations within the 3(10) helix region of the p57 molecule completely abolished the ability to arrest the cell cycle at G(1) in vivo. These results indicate that this region is specifically utilized by p57 in selectively inhibiting cyclin A or E/Cdk2 activities. Thus the 3(10) helix motif may confer a specific regulatory mechanism by which p57 differentially regulates Cdk2 and Cdk4 activities.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 474, Japan; Nagoya City Univ, Sch Med, Dept Urol, Mizuho Ku, Nagoya, Aichi 467, Japan; Nagoya City Univ, Sch Med, Dept Bioregulat Res, Mizuho Ku, Nagoya, Aichi 467, Japan	Nagoya City University; Nagoya City University	Nakanishi, M (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, 36-3 Gengo, Aichi 474, Japan.	mnakani@nils.go.jp						Adams PD, 1996, MOL CELL BIOL, V16, P6623; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; ELDEIRY WS, 1993, CELL, V74, P1009; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fotedar R, 1996, ONCOGENE, V12, P2155; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lin JY, 1996, MOL CELL BIOL, V16, P1786; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	29	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16544	16550		10.1074/jbc.273.26.16544	http://dx.doi.org/10.1074/jbc.273.26.16544			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632724	hybrid			2022-12-25	WOS:000074436600095
J	Kinoshita, T; Sato, H; Akiko; Okada; Ohuchi, E; Imai, K; Okada, Y; Seiki, M				Kinoshita, T; Sato, H; Akiko; Okada; Ohuchi, E; Imai, K; Okada, Y; Seiki, M			TIMP-2 promotes activation of progelatinase a by membrane-type 1 matrix metalloproteinase immobilized on agarose beads	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; IV COLLAGENASE; TISSUE INHIBITOR; GELATINASE-A; 72-KDA GELATINASE; HUMAN FIBROBLASTS; CATALYTIC DOMAIN; CANCER CELLS; SURFACE; EXPRESSION	Membrane-type 1 matrix metalloproteinase (MT1-MMP)/MMP-14 is the activator of progelatinase A (proGelA)/proMMP-2 on the cell surface. However, it was a paradox that a tissue inhibitor of metalloproteinase-2 (TIMP-2), which is an inhibitor of MT1-MMP, is required for proGelA activation by the cells expressing MT1-MMP. In this study, a truncated MT1-MMP having a FLAG-tag sequence at the C terminus (MT1-F) was immobilized onto agarose beads (MT1-F/B) and used to analyze the role of TIMP-2, The proteolytic activity of MT1-F/B against a synthetic peptide substrate was inhibited by TIMP-2 in a dose-dependent manner. In contrast, TIMP-2 promoted the processing of proGelA by MT1-F/B at low concentrations and inhibited it at higher concentrations. TIMP-2 promoted the binding of proGelA to the MT1-F on the beads by forming a trimolecular complex, which was followed by processing of proGelA. A stimulatory effect of TIMP-2 was observed under conditions in which unoccupied MT1-F was still available. Thus, the ternary complex is thought to act as a means to concentrate the substrate to the bead surface and to present it to the neighboring free MT1-F.	Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, Tokyo 108, Japan; Kanazawa Univ, Canc Res Inst, Dept Mol Virol & Oncol, Kanazawa, Ishikawa 920, Japan; Kanazawa Univ, Canc Res Inst, Dept Mol Pathol & Immunol, Kanazawa, Ishikawa 920, Japan; Fuji Chem Ind Ltd, Dept Biopharmaceut, Toyama 933, Japan; Keio Univ, Sch Med, Dept Pathol, Shinnjyuku Ku, Tokyo 160, Japan	University of Tokyo; Kanazawa University; Kanazawa University; Keio University	Seiki, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.	mseiki@ims.u-tokyo.ac.jp	Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015; Okada, Yasunori/B-5550-2014; Imai, Kazushi/E-7206-2012	Okada, Yasunori/0000-0001-9208-4755; 				Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1992, CANCER RES, V52, P4540; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWN PD, 1990, CANCER RES, V50, P6184; DECLERCK YA, 1993, BIOCHEM J, V289, P65, DOI 10.1042/bj2890065; EMONARD HP, 1992, CANCER RES, V52, P5845; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; Gervasi DC, 1996, BIOCHEM BIOPH RES CO, V228, P530, DOI 10.1006/bbrc.1996.1694; Gilles C, 1996, INT J CANCER, V65, P209; Imai K, 1996, CANCER RES, V56, P2707; Kinoshita T, 1996, CANCER RES, V56, P2535; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Lichte A, 1996, FEBS LETT, V397, P277, DOI 10.1016/S0014-5793(96)01206-9; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MONSKY WL, 1993, CANCER RES, V53, P3159; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, BIOCHEM J, V284, P935; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; NAGASE H, 1991, BIOCHEM SOC T, V19, P715, DOI 10.1042/bst0190715; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Puente XS, 1996, CANCER RES, V56, P944; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAKINO T, 1995, GENE, V155, P293, DOI 10.1016/0378-1119(94)00637-8; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yamamoto M, 1996, CANCER RES, V56, P384; YU M, 1995, CANCER RES, V55, P3272	44	244	249	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16098	16103		10.1074/jbc.273.26.16098	http://dx.doi.org/10.1074/jbc.273.26.16098			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632662	hybrid			2022-12-25	WOS:000074436600033
J	Kikkawa, Y; Sanzen, N; Sekiguchi, K				Kikkawa, Y; Sanzen, N; Sekiguchi, K			Isolation and characterization of laminin-10/11 secreted by human lung carcinoma cells - Laminin-10/11 mediates cell adhesion through integrin alpha 3 beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TISSUES; A-CHAIN; PROTEIN; EXPRESSION; BINDING; RECEPTORS; FIBRONECTIN; DOMAINS; LOCALIZATION; STIMULATION	A panel of human tumor cell lines was screened for selective expression of laminin alpha 5 chain, a newly identified laminin subunit comprising laminin-10 (alpha 5 beta 1 gamma 1) and -11 (alpha 5 beta 2 gamma 1). The lung adenocarcinoma cell line A549 was found to express the alpha 5 chain at relatively high levels but no detectable amounts of other alpha chains. The laminin variants containing alpha 5 chain were purified from the conditioned medium of A549 cells by immunoaffinity chromatography using the anti-laminin monoclonal antibody 4C7 which was shown recently to recognize the laminin alpha 5 chain (Tiger, C.-F., Champliaud, M.-F., Pedrosa-Domellof, F., Thornell, L.-E., Ekblom, P., and Gullberg, D. (1997) J. Biol. Chem. 272, 28590-28595). The purified laminin variants consisted of three chains with molecular masses of 350, 220, and 210 kDa. The 350-kDa chain was specifically recognized by another anti-alpha 5 chain monoclonal antibody capable of recognizing denatured alpha 5 chain on immunoblots, whereas the 810-kDa chain was recognized by an anti-gamma 1 chain antibody. The purified alpha 5 chain-containing laminin variants thereafter referred to as laminin-10/11) were highly active in mediating adhesion of A549 cells to the substratum with potency as high as that of laminin-5 and significantly higher than those of laminin-1, laminin-2/4, or fibronectin. Adhesion to substrata coated with laminin-10/11 was specifically inhibited by anti-integrin antibodies directed against the integrin alpha 3 or beta 1 subunit but not by those against alpha 2 or alpha 6 subunit, indicating that laminin-10/11 is specifically recognized by integrin alpha 3 beta 1. Given the wide distribution of laminin-10/11 in the basement membrane of various tissue types and dominant expression of integrin alpha 3 beta 1 in most epithelial cells, specific interaction of laminin-10/11 with integrin alpha 3 beta 1 may play an important role in in vivo regulation of proliferation and differentiation of epithelial cells through the basement membrane.	Osaka Med Ctr Maternal & Child Hlth, Inst Res, Osaka 5941101, Japan		Sekiguchi, K (corresponding author), Osaka Med Ctr Maternal & Child Hlth, Inst Res, 840 Murodo, Osaka 5941101, Japan.	sekiguch@protein.osaka-u.ac.jp	Kikkawa, Yamato/D-1503-2010	Sanzen, Noriko/0000-0001-6518-403X				Baker SE, 1996, J CELL SCI, V109, P2509; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BROWN JC, 1994, J CELL SCI, V107, P329; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Doliana R, 1997, FEBS LETT, V417, P65, DOI 10.1016/S0014-5793(97)01251-9; Durkin ME, 1997, FEBS LETT, V411, P296, DOI 10.1016/S0014-5793(97)00686-8; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; Ekblom P, 1996, CURR OPIN CELL BIOL, V8, P700, DOI 10.1016/S0955-0674(96)80112-8; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; Engvall E, 1996, J CELL BIOCHEM, V61, P493; ENGVALL E, 1986, J CELL BIOL, V103, P2457, DOI 10.1083/jcb.103.6.2457; Ferrigno O, 1997, J BIOL CHEM, V272, P20502, DOI 10.1074/jbc.272.33.20502; Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO;2-H; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; Giancotti FG, 1996, J CELL SCI, V109, P1165; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; IIVANAINEN A, 1995, MATRIX BIOL, V14, P489, DOI 10.1016/0945-053X(95)90006-3; Kikkawa Y, 1996, IN VITRO CELL DEV-AN, V32, P46; KIKKAWA Y, 1994, J BIOCHEM-TOKYO, V116, P862, DOI 10.1093/oxfordjournals.jbchem.a124608; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Mizushima H, 1996, J BIOCHEM-TOKYO, V120, P1196; Murayama O, 1996, J BIOCHEM-TOKYO, V120, P445; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; SEKIGUCHI K, 1983, J BIOL CHEM, V258, P3967; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Tiger CF, 1997, J BIOL CHEM, V272, P28590, DOI 10.1074/jbc.272.45.28590; Virtanen I, 1996, AM J RESP CELL MOL, V15, P184, DOI 10.1165/ajrcmb.15.2.8703474; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEWER U, 1983, J BIOL CHEM, V258, P2654	43	190	193	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15854	15859		10.1074/jbc.273.25.15854	http://dx.doi.org/10.1074/jbc.273.25.15854			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624186	Green Published, hybrid			2022-12-25	WOS:000074284200080
J	Rahman, A; Friedman, DS; Goldstein, LSB				Rahman, A; Friedman, DS; Goldstein, LSB			Two kinesin light chain genes in mice - Identification and characterization of the encoded proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST AXONAL-TRANSPORT; BOVINE BRAIN KINESIN; HEAVY-CHAIN; MONOCLONAL-ANTIBODIES; CONVENTIONAL KINESIN; SUPERFAMILY PROTEIN; SEQUENCE-ANALYSIS; MONOMERIC MOTOR; LOCALIZATION; ANTEROGRADE	Native kinesin consists of two light chains and two heavy chains in a 1:1 stoichiometric ratio. To date, only one gene for kinesin light chain has been characterized, while a second gene was identified in a genomic sequencing study but not analyzed biochemically, Here we describe new genes encoding kinesin light chains in mouse. One of these light chains is neuronally enriched, while another shows ubiquitous expression. The presence of multiple kinesin light chain genes in mice is especially interesting, since there are two kinesin heavy chain genes in humans (Niclas, J., Navone, F,, HomBooher, N,, and Vale, R, D. (1994) Neuron 12, 1059-1072), To assess the selectivity of kinesin light chain interaction with the heavy chains, we performed immunoprecipitation experiments. The data suggested that the light chains form homodimers with no specificity in their interaction with the two heavy chains. Immunofluorescence and biochemical subfractionation suggested differences in the subcellular localization of the two kinesin light chain gene products. Although both kinesin light chains are distributed throughout the central and peripheral nervous systems, there is enrichment of one in sciatic nerve axons, while the other shows elevated levels in olfactory bulb glomeruli, These results indicate that the mammalian nervous system contains multiple kinesin light chain gene products with potentially distinct functions.	Univ Calif San Diego, Howard Hughes Med Inst, Div Cellular & Mol Med, Program Biomed Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Francisco, Dept Pharmacol & Biochem, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco	Goldstein, LSB (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Div Cellular & Mol Med, Program Biomed Sci, Room 334,9500 Gilman Dr, La Jolla, CA 92093 USA.	lgoldstein@ucsd.edu						AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; AMARATUNGA A, 1993, J BIOL CHEM, V268, P17427; ARAI M, 1994, J NEUROSCI RES, V38, P348, DOI 10.1002/jnr.490380313; BARTON NR, 1995, MOL BIOL CELL, V6, P1563, DOI 10.1091/mbc.6.11.1563; BEUSHAUSEN S, 1993, DNA CELL BIOL, V12, P901, DOI 10.1089/dna.1993.12.901; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BLOOM GS, 1994, PROTEIN PROFILE, V1, P1059; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; CABEZAARVELAIZ Y, 1993, DNA CELL BIOL, V12, P881, DOI 10.1089/dna.1993.12.881; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELLURU RG, 1995, MOL BIOL CELL, V6, P21, DOI 10.1091/mbc.6.1.21; FAN J, 1994, J MOL BIOL, V240, P507, DOI 10.1006/jmbi.1994.1465; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; Gindhart JG, 1996, TRENDS BIOCHEM SCI, V21, P52, DOI 10.1016/0968-0004(96)80865-6; Goedert M, 1996, GENOMICS, V32, P173, DOI 10.1006/geno.1996.0102; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HALL DH, 1991, J CELL BIOL, V115, P389; Hanlon DW, 1997, NEURON, V18, P439, DOI 10.1016/S0896-6273(00)81244-1; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; Hoshimaru M, 1996, P NATL ACAD SCI USA, V93, P1518, DOI 10.1073/pnas.93.4.1518; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; *JACKS LAB, ENC MOUS GEN REL 3 0; KATO K, 1990, EUR J NEUROSCI, V2, P704, DOI 10.1111/j.1460-9568.1990.tb00460.x; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lamerdin JE, 1996, GENOMICS, V34, P399, DOI 10.1006/geno.1996.0303; MATUS A, 1988, TRENDS NEUROSCI, V11, P291, DOI 10.1016/0166-2236(88)90086-0; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; Sambrook J., 2002, MOL CLONING LAB MANU; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; STEINBERG G, 1995, MOL BIOL CELL, V6, P1605, DOI 10.1091/mbc.6.11.1605; Stenoien DL, 1997, MOL BIOL CELL, V8, P675, DOI 10.1091/mbc.8.4.675; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WEDAMAN KP, 1993, J MOL BIOL, V231, P155, DOI 10.1006/jmbi.1993.1267; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; Yang ZH, 1998, MOL BIOL CELL, V9, P249, DOI 10.1091/mbc.9.2.249	56	92	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15395	15403		10.1074/jbc.273.25.15395	http://dx.doi.org/10.1074/jbc.273.25.15395			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624122	hybrid			2022-12-25	WOS:000074284200016
J	Ivanov, AI; Christodoulou, J; Parkinson, JA; Barnham, KJ; Tucker, A; Woodrow, J; Sadler, PJ				Ivanov, AI; Christodoulou, J; Parkinson, JA; Barnham, KJ; Tucker, A; Woodrow, J; Sadler, PJ			Cisplatin binding sites on human albumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SERUM-ALBUMIN; NUCLEAR MAGNETIC-RESONANCE; HUMAN-BLOOD-PLASMA; METHIONINE COMPLEXES; SECONDARY STRUCTURE; PLATINUM COMPLEXES; NMR-SPECTROSCOPY; PROTEIN-BINDING; DRUG-BINDING; IN-VITRO	Reactions of cisplatin (cis-[PtCl2(NH3)(2)]) with albumin are thought to play an important role in the metabolism of this anticancer drug. They are investigated here via (i) labeling of cisplatin with N-15 and use of two-dimensional H-1,N-15 NMR spectroscopy, (ii) comparison of natural human serum albumin with recombinant human albumin (higher homogeneity and SH content), (iii) chemical modification of Cys, Met, and His residues, (iv) reactions of bound platinum with thiourea, and (v) gel filtration chromatography, In contrast to previous reports, it is shown that the major sulfur-containing binding site involves Met and not Cys-34, and also a N ligand, in the form of an S,N macrochelate. Additional monofunctional adducts involving other Met residues and Cys-34 are also observed. During the later stages of reactions of cisplatin with albumin, release of NH3 occurs due to the strong trans influence of Met sulfur, which weakens the Pt-NH3 bonds, and protein cross-linking is observed. The consequences of these findings for the biological activity of cisplatin-albumin complexes are discussed.	Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland; Univ London Birkbeck Coll, Dept Chem, London WC1H 0PP, England; Delta Biotechnol Ltd, Nottingham NG7 1FD, England	University of Edinburgh; University of London; Birkbeck University London	Sadler, PJ (corresponding author), Univ Edinburgh, Dept Chem, W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	pjs01@holyrood.ed.ac.uk		Parkinson, John Andrew/0000-0003-4270-6135; Christodoulou, John/0000-0002-6710-3843				Aull J.L., 1980, METAL IONS BIOL SYST, V11, P337; AULL JL, 1979, BIOCHIM BIOPHYS ACTA, V571, P352, DOI 10.1016/0005-2744(79)90105-0; Barnham KJ, 1996, J CHEM SOC DALTON, P2867, DOI 10.1039/dt9960002867; Barnham KJ, 1996, INORG CHEM, V35, P1065, DOI 10.1021/ic950973d; BERNERSPRICE SJ, 1992, J CHEM SOC CHEM COMM, P789, DOI 10.1039/c39920000789; BernersPrice SJ, 1996, COORDIN CHEM REV, V151, P1; BERNERSPRICE SJ, 1990, J INORG BIOCHEM, V38, P305, DOI 10.1016/0162-0134(90)80005-I; BORCH RF, 1979, P NATL ACAD SCI USA, V76, P6611, DOI 10.1073/pnas.76.12.6611; CANAL P, 1995, PLATINUM OTHER MET 2, P53; CARZER DC, 1994, ADV PROTEIN CHEM, V45, P153; CHEN RF, 1967, J BIOL CHEM, V242, P173; CHRISTODOULOU J, 1995, FEBS LETT, V376, P1, DOI 10.1016/0014-5793(95)01231-2; COLE WC, 1980, CHEM-BIOL INTERACT, V30, P223, DOI 10.1016/0009-2797(80)90128-3; CURLING JM, 1977, PROCESS BIOCHEM, V12, P22; DECONTI RC, 1973, CANCER RES, V33, P1310; DeJonge ETM, 1997, INT J GYNECOL CANCER, V7, P158, DOI 10.1046/j.1525-1438.1997.00438.x; DeSimone PA, 1987, P AM SOC CLIN ONCOL, V6, P33; DICKERSON RE, 1969, J MOL BIOL, V45, P77, DOI 10.1016/0022-2836(69)90210-1; Dodsworth N, 1996, BIOTECHNOL APPL BIOC, V24, P171; Eastman A, 1996, PLATINUM AND OTHER METAL COORDINATION COMPOUNDS IN CANCER CHEMOTHERAPY 2, P283; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; ELFERINK F, 1986, CLIN CHEM, V32, P641; ESPINOSA E, 1995, LUNG CANCER, V12, P67, DOI 10.1016/0169-5002(95)00407-R; FOUNTZILAS G, 1992, ANN ONCOL, V7, P553; FREEMAN R, 1988, HDB NUCL MAGNETIC RE, P250; GONIAS SL, 1981, J BIOL CHEM, V256, P2478; GONIAS SL, 1983, J BIOL CHEM, V258, P5764; GROSS KH, 1988, J MAGN RESON, V76, P87, DOI 10.1016/0022-2364(88)90203-X; GULLO JJ, 1980, CANCER CHEMOTH PHARM, V5, P21, DOI 10.1007/BF00578558; Guo ZJ, 1997, J CHEM SOC DALTON, P469, DOI 10.1039/a604210d; Gurd F R, 1972, Methods Enzymol, V25, P424, DOI 10.1016/S0076-6879(72)25038-8; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HADJILIADIS N, 1994, INORG CHEM, V33, P5057, DOI 10.1021/ic00100a034; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HEGEDUS L, 1987, CANCER CHEMOTH PHARM, V20, P211, DOI 10.1007/BF00570487; HERVE F, 1994, CLIN PHARMACOKINET, V26, P44, DOI 10.2165/00003088-199426010-00004; HOLDING JD, 1992, BRIT J CLIN PHARMACO, V33, P75, DOI 10.1111/j.1365-2125.1992.tb04003.x; HOLDING JD, 1991, BRIT J CLIN PHARMACO, V32, P173, DOI 10.1111/j.1365-2125.1991.tb03878.x; HOSHINO T, 1995, J PHARM SCI, V84, P216, DOI 10.1002/jps.2600840219; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; ISMAIL IM, 1982, POLYHEDRON, V1, P57, DOI 10.1016/S0277-5387(00)81069-4; Jarve RK, 1997, CANCER CHEMOTH PHARM, V39, P341, DOI 10.1007/s002800050581; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; JONES WC, 1976, J BIOL CHEM, V251, P7452; Kamal MA, 1996, ANTICANCER RES, V16, P3725; Kane SA, 1996, BIOCHEMISTRY-US, V35, P2180, DOI 10.1021/bi952240a; KELLAND LR, 1994, METAL COMPOUNDS CANC, P32; KERRISON JS, 1977, J CHEM SOC CHEM COMM, P861; Kratz F., 1993, METAL COMPLEXES CANC, P391; LAUTERMANN J, 1995, HEARING RES, V88, P47, DOI 10.1016/0378-5955(95)00097-N; Litterst C., 1976, J CLIN HEMATOL ONCOL, V7, P169; MA J, 1994, BRIT J CANCER, V69, P858, DOI 10.1038/bjc.1994.166; Miles E W, 1977, Methods Enzymol, V47, P431; MOMBURG R, 1987, J PHARM PHARMACOL, V39, P691, DOI 10.1111/j.2042-7158.1987.tb06971.x; Nagai N, 1996, J PHARM PHARMACOL, V48, P918, DOI 10.1111/j.2042-7158.1996.tb06002.x; NANJI AA, 1986, CANCER CHEMOTH PHARM, V17, P274; NORMAN RE, 1992, INORG CHEM, V31, P877, DOI 10.1021/ic00031a033; NORMAN RE, 1988, INORG CHEM, V27, P3583, DOI 10.1021/ic00293a028; OHTA N, 1993, BIOL PHARM BULL, V16, P631; OHTA N, 1992, INT J PHARM, V85, P39, DOI 10.1016/0378-5173(92)90131-K; Parnis FX, 1997, AM J CLIN ONCOL-CANC, V20, P319, DOI 10.1097/00000421-199706000-00024; PEEREY LM, 1987, INORG CHEM, V26, P2079, DOI 10.1021/ic00260a014; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PIZZO SV, 1988, J INORG BIOCHEM, V33, P67, DOI 10.1016/0162-0134(88)80035-7; Polyzos A, 1997, J CHEMOTHERAPY, V9, P102, DOI 10.1179/joc.1997.9.2.102; Reeder F, 1997, EUR J BIOCHEM, V249, P370, DOI 10.1111/j.1432-1033.1997.00370.x; Reedijk J, 1995, HDB METAL LIGAND INT, V2, P967; Repta A.J., 1980, CISPLATIN, P285, DOI [10.1016/b978-0-12-565050-2.50022-x, DOI 10.1016/B978-0-12-565050-2.50022-X]; RIORDAN JF, 1972, METHOD ENZYMOL, V25, P424; SADLER PJ, 1994, EUR J BIOCHEM, V220, P193, DOI 10.1111/j.1432-1033.1994.tb18614.x; SADLER PJ, 1992, EUR J BIOCHEM, V205, P631, DOI 10.1111/j.1432-1033.1992.tb16821.x; STONEHOUSE J, 1994, J MAGN RESON SER A, V107, P178, DOI 10.1006/jmra.1994.1066; SUGII A, 1991, CHEM PHARM BULL, V39, P408; TAKAHASHI K, 1985, JPN J CANCER RES, V76, P68; TOSETTI F, 1988, ANTICANCER RES, V8, P381; TRYNDA L, 1994, J INORG BIOCHEM, V53, P249, DOI 10.1016/0162-0134(94)85112-3; WRIGHT TL, 1987, HEPATOLOGY, V7, P294, DOI 10.1002/hep.1840070214; WRIGHT TL, 1988, GASTROENTEROLOGY, V94, P443, DOI 10.1016/0016-5085(88)90435-0; YOTSUYANAGI T, 1991, CHEM PHARM BULL, V39, P3003; Zeng HH, 1997, INT J BIOL MACROMOL, V20, P107, DOI 10.1016/S0141-8130(96)01144-0; ZHANG JG, 1994, BIOCHEM PHARMACOL, V47, P1127, DOI 10.1016/0006-2952(94)90383-2	81	302	311	5	63	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14721	14730		10.1074/jbc.273.24.14721	http://dx.doi.org/10.1074/jbc.273.24.14721			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614070	hybrid			2022-12-25	WOS:000074160400012
J	Williamson, EA; Xu, HN; Gombart, AF; Verbeek, W; Chumakov, AM; Friedman, AD; Koeffler, HP				Williamson, EA; Xu, HN; Gombart, AF; Verbeek, W; Chumakov, AM; Friedman, AD; Koeffler, HP			Identification of transcriptional activation and repression domains in human CCAAT enhancer binding protein epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER NUCLEAR-PROTEIN; DNA-BINDING; C/EBP FAMILY; SYNERGISTICALLY ACTIVATE; MYELOMONOCYTIC CELLS; NEGATIVE INHIBITOR; EXPRESSION NF-IL6; ALBUMIN GENE; PROMOTER; ELEMENTS	Human CCAAT/enhancer-bindimg protein epsilon (C/EBP epsilon), a new member of the C/EBP family, significantly upregulates both the mim-1 and human myeloperoxidase promoters, suggesting an important role for C/EBP epsilon in the transcriptional regulation of a subset of myeloid-specific genes. To elucidate the structure and function of C/EBP epsilon in transcriptional activation, amino acid residues 1-115, 147-249, or 1-249 of C/EBP epsilon were fused to the yeast GAL4 DNA binding domain. These expression vectors were cotransfected with a chloramphenicol acetyltransferase reporter gene and, in all cell lines tested, only the GAL-C/EBP epsilon-(1-115) fusion protein significantly tly activated expression from the chloramphenicol acetyltransferase reporter gene. Sixteen deletion mutants of C/EBP epsilon mapped the transactivation domain to amino acids 1-18 at the N terminus and revealed the presence of a transcription repression element between amino acid residues 116 and 162. Expression vectors containing the repression domain of C/EBP epsilon strongly inhibited gene transcription from TK, SV40, and adenoviral major late promoters bearing GAL4 binding sites. Fusion of this repression domain to the VP16 activation domain inhibited the transactivation function of VP16. Deletion of this repression domain increased gene transcription from a neutrophil elastase promoter-luciferase reporter. Taken together, these data suggest that C/EBP epsilon regulates transcription by utilizing both activation and repression functions.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med,Div Hematol Oncol, Los Angeles, CA 90048 USA; Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21287 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Johns Hopkins University	Williamson, EA (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med,Div Hematol Oncol, 8700 Beverly Blvd,B121, Los Angeles, CA 90048 USA.		Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chih DY, 1997, BLOOD, V90, P2987, DOI 10.1182/blood.V90.8.2987; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LUNDGREN M, 1994, J IMMUNOL, V153, P2983; Mink S, 1996, MOL CELL BIOL, V16, P1316; Moore DD, 1995, GLOB MOB SURV; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; POLL V, 1990, CELL, V63, P643; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1988, NATURE, V335, P559; SCOTT LM, 1992, BLOOD, V80, P1725; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	47	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14796	14804		10.1074/jbc.273.24.14796	http://dx.doi.org/10.1074/jbc.273.24.14796			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614080	hybrid			2022-12-25	WOS:000074160400022
J	Taketani, Y; Segawa, H; Chikamori, M; Morita, K; Tanaka, K; Kido, S; Yamamoto, H; Iemori, Y; Tatsumi, S; Tsugawa, N; Okano, T; Kobayashi, T; Miyamoto, K; Takeda, E				Taketani, Y; Segawa, H; Chikamori, M; Morita, K; Tanaka, K; Kido, S; Yamamoto, H; Iemori, Y; Tatsumi, S; Tsugawa, N; Okano, T; Kobayashi, T; Miyamoto, K; Takeda, E			Regulation of type II renal Na+-dependent inorganic phosphate transporters by 1,25-dihydroxyvitamin D-3 - Identification of a vitamin D-responsive element in the human NAPI-3 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; D-RECEPTOR; JUXTAMEDULLARY CORTEX; 24-HYDROXYLASE GENE; GLUCOSE-ABSORPTION; RAT; EXPRESSION; HORMONE; PROTEIN; KIDNEY	Vitamin D is an important regulator of phosphate homeostasis. The effects of vitamin D on the expression of renal Na+-dependent inorganic phosphate (P-i) transporters (types I and II) were investigated. In vitamin D-deficient rats, the amounts of type II Na+-dependent P-i transporter (NaPi-2) protein and mRNA were decreased in the juxtamedullary kidney cortex, but not in the superficial cortex, compared with control rats. The administration of 1,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) to vitamin D-deficient rats increased the initial rate of P-i uptake as well as the amounts of NaPi-2 mRNA and protein in the juxtamedullary cortex. The transcriptional activity of a luciferase reporter plasmid containing the promoter region of the human type II Na+-dependent P-i transporter NaPi-3 gene was increased markedly by 1,25-(OH)(2)D-3 in COS-7 cells expressing the human vitamin D receptor. A deletion and mutation analysis of the NaPi-3 gene promoter identified the vitamin D-responsive element as the sequence 5'-GGGGCAGCAAGGGCA-3' nucleotides -1977 to -1963 relative to the transcription start site. This element bound a heterodimer of the vitamin D receptor and retinoid X receptor, and it enhanced the basal transcriptional activity of the promoter of the herpes simplex virus thymidine kinase gene in an orientation-independent manner. Thus, one mechanism by which vitamin D regulates P-i homeostasis is through the modulation of the expression of type II Na+-dependent P-i transporter genes in the juxtamedullary kidney cortex.	Univ Tokushima, Sch Med, Dept Clin Nutr, Tokushima 770, Japan; Kobe Pharmaceut Univ, Dept Hyg Sci, Kobe, Hyogo 658, Japan	Tokushima University; Kobe Pharmaceutical University	Miyamoto, K (corresponding author), Univ Tokushima, Sch Med, Dept Clin Nutr, Kuramoto Cho 3, Tokushima 770, Japan.	miyamoto@nutr.med.tokusbima-u.ac.jp		Tatsumi, Sawako/0000-0002-4862-2955				Arai H, 1997, J BONE MINER RES, V12, P915, DOI 10.1359/jbmr.1997.12.6.915; ARAKAWA T, 1995, FEBS LETT, V363, P105, DOI 10.1016/0014-5793(95)00293-I; Berndt T. J., 1992, KIDNEY PHYSL PATHOPH, P2511; Biber J, 1996, KIDNEY INT, V49, P981, DOI 10.1038/ki.1996.139; Christakos S, 1996, BIOCHEM J, V316, P361, DOI 10.1042/bj3160361; CLARLBERG D, 1993, NAURE, V361, P657; DELORME AC, 1983, J BIOL CHEM, V258, P1878; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DOUSA TP, 1986, KIDNEY INT, V29, P352; ELSTEIN D, 1986, PFLUG ARCH EUR J PHY, V407, P451, DOI 10.1007/BF00652633; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Hartmann CM, 1996, P NATL ACAD SCI USA, V93, P7409, DOI 10.1073/pnas.93.14.7409; HAYASHI S, 1987, GENE DEV, V1, P818, DOI 10.1101/gad.1.8.818; HEINLE H, 1977, FEBS LETT, V73, P220, DOI 10.1016/0014-5793(77)80985-X; IIDA K, 1995, P NATL ACAD SCI USA, V92, P6112, DOI 10.1073/pnas.92.13.6112; KEMPSON SA, 1995, AM J PHYSIOL-RENAL, V268, pF784, DOI 10.1152/ajprenal.1995.268.4.F784; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KIMURA T, 1994, J BONE MINER MET, V12, pS7; KOSEKI C, 1980, FOLIA PHARMACOL JPN, V76, P59, DOI 10.1254/fpj.76.59; LEVI M, 1994, PFLUG ARCH EUR J PHY, V426, P5, DOI 10.1007/BF00374664; LEVI M, 1990, AM J PHYSIOL, V258, pF1616, DOI 10.1152/ajprenal.1990.258.6.F1616; LI H, 1991, ENDOCRINOLOGY, V128, P2844, DOI 10.1210/endo-128-6-2844; Li H, 1996, AM J PHYSIOL-ENDOC M, V271, pE1021, DOI 10.1152/ajpendo.1996.271.6.E1021; LI H, 1995, CELL MOL BIOL RES, V41, P4561; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; Mackey SL, 1996, MOL ENDOCRINOL, V10, P298, DOI 10.1210/me.10.3.298; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MARUYAMA K, 1991, METHODS NUCL ACIDS R, P283; MCKEOWN JW, 1979, AM J PHYSIOL, V237, pF312, DOI 10.1152/ajprenal.1979.237.4.F312; MINAMI H, 1993, GASTROENTEROLOGY, V105, P692, DOI 10.1016/0016-5085(93)90884-F; Murer H, 1997, PFLUG ARCH EUR J PHY, V433, P379, DOI 10.1007/s004240050292; MURER H, 1992, KIDNEY PHYSL PATHOPH, P2481; NAKAGAWA N, 1991, J BIOL CHEM, V266, P13616; Ohyama Y, 1996, J BIOL CHEM, V271, P30381, DOI 10.1074/jbc.271.48.30381; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; PIKE JW, 1987, J BIOL CHEM, V262, P1305; QUAMME GA, 1990, AM J PHYSIOL, V258, pF356, DOI 10.1152/ajprenal.1990.258.2.F356; REEVE LE, 1982, AM J CLIN NUTR, V36, P122, DOI 10.1093/ajcn/36.1.122; SONE T, 1990, J BIOL CHEM, V265, P21997; SUZUKI M, 1989, KIDNEY INT, V34, P268; TAKAHASHI Y, 1994, BBA-LIPID LIPID MET, V1212, P217, DOI 10.1016/0005-2760(94)90256-9; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Taketani Y, 1997, BIOCHEM J, V324, P927, DOI 10.1042/bj3240927; Tenenhouse HS, 1997, J BONE MINER RES, V12, P159, DOI 10.1359/jbmr.1997.12.2.159; TURNER ST, 1985, KIDNEY INT, V27, P879, DOI 10.1038/ki.1985.95; ULLRICH KJ, 1977, PFLUG ARCH EUR J PHY, V372, P269, DOI 10.1007/BF01063862; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YUSUFI ANK, 1994, BBA-BIOMEMBRANES, V1191, P117, DOI 10.1016/0005-2736(94)90239-9; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900	52	115	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14575	14581		10.1074/jbc.273.23.14575	http://dx.doi.org/10.1074/jbc.273.23.14575			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603973	hybrid			2022-12-25	WOS:000074021500075
J	Gill, EA; Imaizumi, TA; Carveth, H; Topham, MK; Tarbet, EB; McIntyre, TM; Prescott, SM; Zimmerman, GA				Gill, EA; Imaizumi, TA; Carveth, H; Topham, MK; Tarbet, EB; McIntyre, TM; Prescott, SM; Zimmerman, GA			Bacterial lipopolysaccharide induces endothelial cells to synthesize a degranulating factor for neutrophils	FASEB JOURNAL			English	Article						PMN; polymorphonuclear leukocytes; PMN degranulation; lactoferrin	PLATELET-ACTIVATING-FACTOR; LEUKOCYTE CHEMOATTRACTANT RECEPTORS; CHEMOTACTIC FACTOR; GENE-EXPRESSION; ENDOTOXIN; INTERLEUKIN-8; MECHANISMS; SECRETION; ELASTASE; INJURY	Enzymes and other factors secreted by degranulating neutrophils (polymorphonuclear leukocytes, PMNs) mediate endothelial injury, thrombosis, and vascular remodeling. In bacteremia and sepsis syndrome and their consequent complications (including acute respiratory distress syndrome and systemic ischemia-reperfusion resulting from septic shock), neutrophil degranulation is an important mechanism of injury. In related studies, we found that human endothelial cells regulate neutrophil degranulation and that inflammatory cytokines induce synthesis of degranulating factors by human endothelial cells. Here we show that lipopolysaccharides (LPS) from gram-negative bacteria were the most potent agonists for release of degranulating activity by endothelial cells when compared to several cytokines and stimulatory factors. LPS also induced the release of degranulating signals for PMNs from a human endothelial cell line, EA.hy 926. Interleukin 8 (IL-8) is synthesized by endothelial and EA.hy 926 cells in response to LPS and induces neutrophil degranulation. However, complementary strategies using receptor desensitization, translation of messenger RNA by Xenopus laevis oocytes, and purification and analysis of factors from conditioned supernatants demonstrated that degranulating factors distinct from IL-8 are generated in response to LPS. The characteristics of a partially purified degranulating factor isolated from conditioned supernatants distinguished it from known chemokines and other factors that induce PMN degranulation and are generated by endothelial cells in response to LPS. Thus, cultured human endothelial cells and endothelial cell lines synthesize several unique signaling molecules that can trigger neutrophil granular secretion. If produced in vivo in response to LPS or other pathologic agonists, these degranulating signals may activate PMNs in combination or in sequence, initiating or propagating vascular damage.	Univ Utah, Sch Med, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Zimmerman, GA (corresponding author), Univ Utah, Sch Med, Nora Eccles Harrison Cardiovasc Res & Training In, 95 S 2000 E Back, Salt Lake City, UT 84112 USA.			Tarbet, Bart/0000-0002-4255-9094	NHLBI NIH HHS [P50 HL50153] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050153] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERETZ A, 1989, BIOCHEM J, V259, P35, DOI 10.1042/bj2590035; Bozic CR, 1996, AM J RESP CELL MOL, V14, P302, DOI 10.1165/ajrcmb.14.3.8845182; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; COHEN MS, 1992, J INFECT DIS, V166, P1375, DOI 10.1093/infdis/166.6.1375; DAHINDEN C, 1983, J IMMUNOL, V130, P857; Delclaux C, 1997, AM J PHYSIOL-LUNG C, V272, pL442, DOI 10.1152/ajplung.1997.272.3.L442; DEWALD B, 1986, BIOCHIM BIOPHYS ACTA, V888, P42, DOI 10.1016/0167-4889(86)90069-8; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DONNELLY SC, 1995, AM J RESP CRIT CARE, V151, P1428, DOI 10.1164/ajrccm.151.5.7735596; Ebnet K, 1996, ANNU REV IMMUNOL, V14, P155, DOI 10.1146/annurev.immunol.14.1.155; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; EMEIS JJ, 1988, BLOOD, V71, P1669; GILL EA, 1992, CURR OPIN INFECT DIS, V5, P381, DOI 10.1097/00001432-199206000-00012; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; Green SP, 1996, J BIOL CHEM, V271, P25400, DOI 10.1074/jbc.271.41.25400; HARLAN JM, 1981, J CLIN INVEST, V68, P1394, DOI 10.1172/JCI110390; HARLAN JM, 1985, LAB INVEST, V52, P141; HENSON PM, 1992, INFLAMMATION BASIC P, P511; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; Imaizumi TA, 1997, AM J RESP CELL MOL, V17, P181, DOI 10.1165/ajrcmb.17.2.2818; Introna M, 1997, ARTERIOSCL THROM VAS, V17, P423, DOI 10.1161/01.ATV.17.3.423; ISSEKUTZ AC, 1993, IMMUNOLOGY, V79, P600; JAFFE EA, 1988, INFLAMMATION BASIC P, P559; JOCHUM M, 1994, AM J RESP CRIT CARE, V150, pS123, DOI 10.1164/ajrccm/150.6_Pt_2.S123; KEY NS, 1992, ARTERIOSCLER THROMB, V12, P836, DOI 10.1161/01.ATV.12.7.836; KUIJPERS TW, 1992, J CELL BIOL, V117, P565, DOI 10.1083/jcb.117.3.565; LASKY LA, 1993, CURR BIOL, V3, P366, DOI 10.1016/0960-9822(93)90203-Z; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; LUCHI M, 1993, J IMMUNOL, V151, P959; LYNN WA, 1992, IMMUNOL TODAY, V13, P271, DOI 10.1016/0167-5699(92)90009-V; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MELTON DA, 1987, METHOD ENZYMOL, V152, P288; Modur V, 1997, J CLIN INVEST, V100, P158, DOI 10.1172/JCI119508; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; OFLAHERTY JT, 1979, J CELL BIOL, V80, P564, DOI 10.1083/jcb.80.3.564; OKRENT DG, 1990, AM REV RESPIR DIS, V141, P179, DOI 10.1164/ajrccm/141.1.179; OSTERGAARD E, 1992, J LEUKOCYTE BIOL, V51, P316, DOI 10.1002/jlb.51.4.316; PATEL KD, 1994, J CLIN INVEST, V94, P631, DOI 10.1172/JCI117379; PEREIRA HA, 1990, J CLIN INVEST, V85, P1468, DOI 10.1172/JCI114593; ROCKER GM, 1989, LANCET, V1, P120; SCHRODER JM, 1989, J IMMUNOL, V142, P244; SCOPES RK, 1982, PROTEIN PURIFICATION, P1; SMEDLY LA, 1986, J CLIN INVEST, V77, P1233, DOI 10.1172/JCI112426; SMITH WB, 1993, IMMUNOLOGY, V78, P491; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; SUGGS JE, 1986, BLOOD, V68, P825; TATE SS, 1990, FASEB J, V4, P227, DOI 10.1096/fasebj.4.2.2298343; TOMPKINS DC, 1990, J CLIN INVEST, V85, P1248, DOI 10.1172/JCI114560; Topham MK, 1998, FASEB J, V12, P733, DOI 10.1096/fasebj.12.9.733; VANOOST BA, 1986, BIOCHEM CELL BIOL, V64, P699, DOI 10.1139/o86-096; VARANI J, 1989, AM J PATHOL, V135, P435; WEBSTER RO, 1980, IMMUNOPHARMACOLOGY, V2, P201, DOI 10.1016/0162-3109(80)90050-8; WEISS J, 1978, J BIOL CHEM, V253, P2664; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x; YAMADA Y, 1994, P NATL ACAD SCI USA, V91, P10320, DOI 10.1073/pnas.91.22.10320; YI ES, 1992, AM J PATHOL, V140, P659; ZIMMERMAN GA, 1990, METHOD ENZYMOL, V187, P520; Zimmerman GA, 1996, J CLIN INVEST, V98, P1699, DOI 10.1172/JCI118967; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2; ZIMMERMAN GA, 1997, LUNG SCI FDN, P289	63	19	20	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1998	12	9					673	684		10.1096/fasebj.12.9.673	http://dx.doi.org/10.1096/fasebj.12.9.673			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619446				2022-12-25	WOS:000074011000006
J	Deng, JB; Kawakami, Y; Hartman, SE; Satoh, T; Kawakami, T				Deng, JB; Kawakami, Y; Hartman, SE; Satoh, T; Kawakami, T			Involvement of Ras in Bruton's tyrosine kinase-mediated JNK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; CELL ANTIGEN RECEPTOR; FC-EPSILON-RI; SIGNAL-TRANSDUCTION PATHWAYS; COLONY-STIMULATING FACTOR; RHO-FAMILY GTPASES; PROTEIN-KINASE; CROSS-LINKING; C-JUN; HEMATOPOIETIC-CELLS	Defects in Bruton's tyrosine kinase (Btk) result in B cell immunodeficiencies in humans and mice. Recent studies showed that Btk is required for maximal activation of JNK, a family of stress-activated protein kinases, induced by several extracellular stimuli including interleukin (IL)-3. On the other hand, IL-3-induced JNK activation is dependent on Ras. In the present study we have investigated whether Ras is involved in Btk-mediated JNK activation in BaF3 mouse pro-B cells. Overexpression of wild-type Btk: protein in these cells enhanced JNK activation upon IL-3 stimulation, whereas expression of kinase-dead Btk partially suppressed JNK activation. Induced expression of the dominant negative Ras(N17) in the cells overexpressing wild-type Btk suppressed JNK activation. Importantly, overexpression of Btk enhanced the level of the GTP-bound, active form of Ras in response to IL-3 stimulation. Btk overexpression also increased the Shc-Grb2 association induced by IL-3 stimulation. Expression of either N17Ras or V12Ras did not impose any effects on Btk kinase activity. These data collectively indicate that Ras plays a role of an intermediary signaling protein in Btk-mediated JNK activation induced by the IL-3 signaling pathway.	La Jolla Inst Allergy & Immunol, Div Allergy, San Diego, CA 92121 USA; Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	La Jolla Institute for Immunology; Tokyo Institute of Technology	Kawakami, T (corresponding author), La Jolla Inst Allergy & Immunol, Div Allergy, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	toshi_kawakami@liai.org	Satoh, Takaya/K-2628-2014; Kawakami, Toshiaki/O-1616-2015		NIAID NIH HHS [AI33617, AI38348] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038348, R01AI033617] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; COSO OA, 1995, CELL, V81, P1187; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DORSCH M, 1994, BIOCHEM BIOPH RES CO, V200, P562, DOI 10.1006/bbrc.1994.1485; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; Hata D, 1998, J BIOL CHEM, V273, P10979, DOI 10.1074/jbc.273.18.10979; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; ISFORT R, 1988, J BIOL CHEM, V263, P19203; Ishizuka T, 1996, J BIOL CHEM, V271, P12762, DOI 10.1074/jbc.271.22.12762; JabrilCuenod B, 1996, J BIOL CHEM, V271, P16268, DOI 10.1074/jbc.271.27.16268; Kawakami Y, 1996, IMMUNOL LETT, V54, P113, DOI 10.1016/S0165-2478(96)02659-4; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1995, METHOD ENZYMOL, V255, P149; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SORENSEN PHB, 1989, BLOOD, V73, P406; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tarakhovsky A, 1997, CURR OPIN IMMUNOL, V9, P319, DOI 10.1016/S0952-7915(97)80076-3; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TORDAI A, 1994, J BIOL CHEM, V269, P7538; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	59	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16787	16791		10.1074/jbc.273.27.16787	http://dx.doi.org/10.1074/jbc.273.27.16787			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642236	hybrid			2022-12-25	WOS:000074545200026
J	Rezaie, AR				Rezaie, AR			Calcium enhances heparin catalysis of the antithrombin factor Xa reaction by a template mechanism - Evidence that calcium alleviates Gla domain antagonism of heparin binding to factor Xa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL CHANGE; ANTICOAGULANT ACTION; PROTEINASE REACTIONS; HIGH-AFFINITY; CA2+ BINDING; THROMBIN; ACCELERATION; OLIGOSACCHARIDES; RESOLUTION; ACTIVATION	It is believed that heparin accelerates factor Xa (FXa) inactivation by antithrombin (AT) by conformationally activating the inhibitor rather than by bridging AT and FXa in a ternary complex (template effect). This is derived from kinetic studies done in the absence of Ca(2+) or in the presence of EDTA. To test the possibility that the anionic Gla domain of FXa, when not neutralized by Ca(2+) ions, prevents heparin binding to FXa, the heparin and pentasaccharide dependence of FXa inactivation by AT in both the absence (100 mu M EDTA) and presence of Ca(2+) (2.5 mM) was studied using wild-type FXa and a FXa derivative that lacks the Gla domain (GDFXa). AT inactivated both FXa derivatives similarly in both the absence and presence of Ca(2+) (k(2) = 1.7-2.5 x 10(3) m(-1) s(-1)). The active AT-binding pentasaccharide also accelerated the inactivation rates of both derivatives similarly in both the absence and presence of Ca(2+) (K(2) = 5.7- 8.0 x 10(5) M(-1) s(-1)). However, in the presence of an optimum concentration of heparin (similar to 50 nM) the inactivation rate constant of FXa in the presence of Ca(2+) (k(2) = 4.4 x 10(7) M(-1) s(-1)) was 13-fold higher than the rate constant in the absence of Ca(2+) (k(2) = 3.5 x 10(6) M(-1) s(-1)). Heparin acceleration of GDFXa inactivation by AT was rapid and insensitive to the presence or absence of Ca(2+) (k(2) = 5.1-5.9 x 10(7) M(-1) s(-1)). The additional cofactor effect of heparin with all FXa derivatives was a bell-shaped curve, which disappeared if the ionic strength of the reaction was increased to similar to 0.4. These results suggest that although the major effect of heparin in acceleration of FXa inactivation is through a heparin-induced conformational change in the reactive site loop of AT, the template effect of heparin, nevertheless, contributes significantly to rapid FXa inactivation at physiological Ca(2+).	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation	Rezaie, AR (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13Th St, Oklahoma City, OK 73104 USA.	alireza-rezaie@omrf.ouhsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARROWCLIFFE TW, 1992, ADV EXP MED BIOL, V313, P205; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; OCKELFORD PA, 1982, THROMB RES, V28, P401, DOI 10.1016/0049-3848(82)90121-9; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OWEN BA, 1990, BIOCHEMISTRY-US, V29, P9412, DOI 10.1021/bi00492a015; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PLETCHER CH, 1983, J BIOL CHEM, V258, P1086; Rezaie AR, 1998, PROTEIN SCI, V7, P349; REZAIE AR, 1995, J BIOL CHEM, V270, P25336, DOI 10.1074/jbc.270.43.25336; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; Rezaie AR, 1998, BLOOD, V91, P4572, DOI 10.1182/blood.V91.12.4572.412k13_4572_4580; STENFLO J, 1991, BLOOD, V78, P1637; STREUSAND VJ, 1995, J BIOL CHEM, V270, P9043, DOI 10.1074/jbc.270.16.9043; THOMAS DP, 1982, THROMB HAEMOSTASIS, V47, P244	29	107	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16824	16827		10.1074/jbc.273.27.16824	http://dx.doi.org/10.1074/jbc.273.27.16824			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642241	hybrid			2022-12-25	WOS:000074545200031
J	Surinya, KH; Cox, TC; May, BK				Surinya, KH; Cox, TC; May, BK			Identification and characterization of a conserved erythroid-specific enhancer located in intron 8 of the human 5-aminolevulinate synthase 2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN GENE; TRANSCRIPTION FACTOR GATA-1; PORPHOBILINOGEN DEAMINASE GENE; LINKED SIDEROBLASTIC ANEMIA; I HYPERSENSITIVE SITES; KRUPPEL-LIKE FACTOR; DELTA-AMINOLEVULINATE SYNTHASE; IRON-RESPONSIVE ELEMENT; MESSENGER-RNA; 3' ENHANCER	Thirty five kilobases of sequence encompassing the human erythroid Fi-aminolevulinate synthase (ALAS2) gene have been determined. Analysis revealed a very low GC content, few repetitive elements, and evidence for the insertion of a reverse-transcribed mRNA sequence and a neighboring gene. We have investigated whether introns 1, 3, and 8, which correspond to DNase I-hypersensitivity sites in the structurally related mouse ALAS2 gene, affect expression of the human ALAS2 promoter in transient expression assays. Whereas intron 3 was marginally inhibitory, introns 1 and 8 of the human gene stimulated promoter activity. Intron 8 harbored a strong erythroid-specific enhancer activity which was orientation-dependent. Deletion analysis of this region localized enhancer activity to a fragment of 239 base pairs. Transcription factor binding sites clustered within this region include GATA motifs and CACCC boxes, critical regulatory sequences of many erythroid cell-expressed genes. These sites were also identified in the corresponding intron of both the murine and canine ALAS2 genes. Mutagenesis of these conserved sites in the human intron 8 sequence and transient expression analysis in erythroid cells established the functional importance of one GATA motif and two CACCC boxes. The GATA motif bound GATA-1 in vitro, The two functional CACCC boxes each bound Spl or a related protein in vitro, but binding of the erythroid Kruppel-like factor and the basic Kruppel-like factor could not be detected. The intron 8 enhancer region was not activated by GATA-1 together with Spl in transactivation experiments in COS-1 cells indicating the involvement of a related Spl protein or of another unidentified erythroid factor. Overall, these results demonstrate that a GATA-1-binding site and CACCC boxes located within the human ALAS2 intron 8 are critical for the erythroid-specific enhancer activity in transfected erythroid cells, and due to the conserved nature of these binding sites across species, it seems likely that these sites play a functional role in the tissue-restricted expression of the gene in vivo.	Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Genet, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	May, BK (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.	bmay@biochem.adelaide.edu.au						ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BEAUMONT C, 1984, EXP CELL RES, V154, P474, DOI 10.1016/0014-4827(84)90171-X; BHASKER CR, 1993, J BIOL CHEM, V268, P12699; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BISHOP DF, 1990, GENOMICS, V7, P207, DOI 10.1016/0888-7543(90)90542-3; BOTTOMLEY SS, 1995, J BIOENERG BIOMEMBR, V27, P161, DOI 10.1007/BF02110031; BOYER G, 1995, ANIM GENET, V26, P206, DOI 10.1111/j.1365-2052.1995.tb03172.x; CHOI OR, 1986, NATURE, V323, P731, DOI 10.1038/323731a0; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; CONBOY JG, 1992, J BIOL CHEM, V267, P18753; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; COX TC, 1990, AM J HUM GENET, V46, P107; COX TC, 1992, HUM MOL GENET, V1, P639, DOI 10.1093/hmg/1.8.639; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; Dierks P, 1990, BIOSYNTHESIS HEME CH, P201; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FUJIWARA J, 1994, J BIOL CHEM, V269, P18558; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kappas A, 1995, METABOLIC MOL BASES, P2103; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KAYA AH, 1994, GENOMICS, V19, P242, DOI 10.1006/geno.1994.1054; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LACRONIQUE V, 1995, J BIOL CHEM, V270, P14989, DOI 10.1074/jbc.270.25.14989; LIM KC, 1994, NUCLEIC ACIDS RES, V22, P1226, DOI 10.1093/nar/22.7.1226; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADHUSUDHAN KT, 1995, BIOCHEMISTRY-US, V34, P1288, DOI 10.1021/bi00004a023; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MAY BK, 1995, PROG NUCLEIC ACID RE, V51, P1, DOI 10.1016/S0079-6603(08)60875-2; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P7976, DOI 10.1073/pnas.94.15.7976; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Nemoto Y, 1996, J BIOL CHEM, V271, P13542, DOI 10.1074/jbc.271.23.13542; NICOLIS S, 1991, NUCLEIC ACIDS RES, V19, P5285, DOI 10.1093/nar/19.19.5285; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; PERKINS AC, 1995, NATURE, V375, P318; PORCHER C, 1995, J BIOL CHEM, V270, P17368, DOI 10.1074/jbc.270.29.17368; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHOENHAUT DS, 1989, NUCLEIC ACIDS RES, V17, P7013, DOI 10.1093/nar/17.17.7013; Surinya KH, 1997, J BIOL CHEM, V272, P26585, DOI 10.1074/jbc.272.42.26585; SUTHERLAND GR, 1988, AM J HUM GENET, V43, P331; Sutherland HGE, 1997, MOL CELL BIOL, V17, P1607, DOI 10.1128/MCB.17.3.1607; TAKETANI S, 1995, GENOMICS, V29, P698, DOI 10.1006/geno.1995.9949; TREISMAN R, 1985, NATURE, V315, P72, DOI 10.1038/315072a0; TRUDEL M, 1987, GENE DEV, V1, P954, DOI 10.1101/gad.1.9.954; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; WEBER F, 1985, NATURE, V315, P75, DOI 10.1038/315075a0; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; YOUSSOUFIAN H, 1994, BLOOD, V83, P1428; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	73	79	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16798	16809		10.1074/jbc.273.27.16798	http://dx.doi.org/10.1074/jbc.273.27.16798			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642238	hybrid			2022-12-25	WOS:000074545200028
J	Zhou, HL; Summers, SK; Birnbaum, MJ; Pittman, RN				Zhou, HL; Summers, SK; Birnbaum, MJ; Pittman, RN			Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; DEATH; PHOSPHORYLATION; DISEASE; SPHINGOMYELINASE; REQUIREMENT; PHOSPHATASE; STIMULATION	Ceramide is an important lipid messenger involved in mediating a variety of cell functions including apoptosis. However, mechanisms responsible for ceramide-induced apoptosis remain unclear. We investigated the possibility that ceramide may decrease antiapoptotic signaling in cells by inhibiting Akt kinase activity. Our data show that C-2-ceramide induces apoptosis in HMN1 motor neuron cells and decreases both basal and insulin- or serum-stimulated Akt kinase activity 65-70%. These results are consistent with decreased Akt kinase activity being involved in the apoptotic effects of ceramide, This possibility is further supported by studies showing that constitutively active Akt kinase decreases C-2-ceramide-induced death of HMN1 cells as well as COS-7 cells. Decreased Akt activity is not due to ceramide activating the ceramide-activated protein phosphatase or to a direct inhibition of Akt kinase by ceramide, suggesting that ceramide acts upstream of Akt kinase to decrease its activity. Treating cells with C-2-ceramide does not affect phosphorylation of insulin receptor substrate-1, interactions between insulin receptor substrate-1 and p85, or insulin-stimulated phosphatidylinositol 3-kinase activity, suggesting that the effects of C-2-ceramide on Akt kinase are not mediated through modulating phosphatidylinositol 3-kinase. In sum, our results suggest that inhibition of the key antiapoptotic kinase, Akt, may play an important role in ceramide-induced apoptosis.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Pittman, RN (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.			Birnbaum, Morris/0000-0001-9972-8680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032465] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09475] Funding Source: Medline; NINDS NIH HHS [NS32465] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BOSE R, 1995, CELL, V82, P404; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; D'Mello SR, 1997, J NEUROSCI, V17, P1548; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KNUDSON MC, 1997, NAT GENET, V16, P358; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LIU J, 1994, J BIOL CHEM, V269, P3047; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Parrizas M, 1997, J BIOL CHEM, V272, P154; PITTMAN RP, 1994, J NEUROSCI, V13, P3669; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; RINK A, 1995, AM J PATHOL, V147, P1575; SALAZARGRUESO EF, 1991, NEUROREPORT, V2, P505, DOI 10.1097/00001756-199109000-00002; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	45	307	316	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16568	16575		10.1074/jbc.273.26.16568	http://dx.doi.org/10.1074/jbc.273.26.16568			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632728	hybrid			2022-12-25	WOS:000074436600099
J	Dikov, MM; Reich, MB; Dworkin, L; Thomas, JW; Miller, GG				Dikov, MM; Reich, MB; Dworkin, L; Thomas, JW; Miller, GG			A functional fibroblast growth factor-1 immunoglobulin fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CARDIAC ALLOGRAFTS; HUMAN HEPATOMA-CELL; FACTOR-I; T-CELLS; RHEUMATOID-ARTHRITIS; TYROSINE KINASE; MESSENGER-RNA; BOVINE BRAIN; FACTOR FGF; BASIC FGF	Proteins of the fibroblast growth factor (FGF) family play diverse roles in embryonic development, angiogenesis, and wound healing. The most well studied targets of FGF activity typically are cells of mesodermal and neuroectodermal origin; in addition, expression of FGF-1 (acidic FGF) is increased at several sites of chronic immunologic injury, and recent studies show that FGF-1 also may interact with cells of the immune system. In some human T cells, FGF-1 can induce signals necessary for production of interleukin-a, a key cytokine required for T cell proliferation. To better characterize the interaction of FGF-1 with FGF receptors on T cells, a fusion protein was constructed containing a portion of the constant region of human IgG1 (Fc) at the amino terminus of FGF-1, The Fc-FGF-1 fusion protein retained FGF function as determined by stimulation of tyrosine phosphorylation and DNA synthesis in NIH 3T3 cells. Binding of the intact fusion protein to FGF receptor 1 (FGFR1) on T cells was demonstrated by immunoprecipitation of the receptor bound to Fc-FGF-1 and by flow cytometry showing binding of fusion protein to T cells expressing FGFR1. This functional Fc-FGF-1 protein should prove useful in identifying FGFR-expressing cells.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University	Miller, GG (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, A3310 Med Ctr N, Nashville, TN 37232 USA.	millergg@ctrvax.vanderbilt.edu		Thomas, James/0000-0002-2098-6458	NHLBI NIH HHS [R01 HL53771] Funding Source: Medline; NIAMS NIH HHS [R01 AR43563] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053771] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANAI S, 1991, CIRC RES, V69, P76, DOI 10.1161/01.RES.69.1.76; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; BOHLEN P, 1985, EMBO J, V4, P1951, DOI 10.1002/j.1460-2075.1985.tb03876.x; BROJI E, 1993, J CLIN INVEST, V92, P2408; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Byrd V, 1996, ARTHRITIS RHEUM, V39, P914, DOI 10.1002/art.1780390607; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; CROWE JS, 1992, CLIN EXP IMMUNOL, V87, P105; Estival A, 1996, J BIOL CHEM, V271, P5663, DOI 10.1074/jbc.271.10.5663; FERTENSTEIN R, 1996, EMBO J, V271, P1123; FLUGELMAN MY, 1993, CIRCULATION, V88, P2493, DOI 10.1161/01.CIR.88.6.2493; FOROUGH R, 1991, BIOCHIM BIOPHYS ACTA, V1090, P293, DOI 10.1016/0167-4781(91)90192-O; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; JOHNSON HM, 1985, J IMMUNOL, V134, P2824; KAN M, 1988, J BIOL CHEM, V263, P11306; Kerby JD, 1996, TRANSPLANTATION, V62, P190, DOI 10.1097/00007890-199607270-00008; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAPPI DA, 1994, J BIOL CHEM, V269, P12552; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; MCKEEHAN WL, 1987, ANAL BIOCHEM, V164, P563, DOI 10.1016/0003-2697(87)90534-3; Paul LC, 1996, AM J KIDNEY DIS, V28, P441, DOI 10.1016/S0272-6386(96)90504-1; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P6547, DOI 10.1073/pnas.92.14.6547; PRESTA M, 1986, MOL CELL BIOL, V6, P4060, DOI 10.1128/MCB.6.11.4060; Rudd CE, 1996, IMMUNITY, V4, P527, DOI 10.1016/S1074-7613(00)80479-3; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SANO H, 1993, J CLIN INVEST, V91, P553, DOI 10.1172/JCI116235; SIEGALL CB, 1991, FASEB J, V5, P2843, DOI 10.1096/fasebj.5.13.1717336; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; WAGNER CR, 1993, J CLIN INVEST, V92, P1269, DOI 10.1172/JCI116699; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; XU JM, 1992, J BIOL CHEM, V267, P17792; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; ZHAO XM, 1993, TRANSPLANTATION, V56, P1177; ZHAO XM, 1995, J IMMUNOL, V155, P3904; ZHAO XM, 1994, J CLIN INVEST, V94, P992, DOI 10.1172/JCI117466; ZHAO XM, 1994, CIRCULATION, V90, P677, DOI 10.1161/01.CIR.90.2.677	41	21	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15811	15817		10.1074/jbc.273.25.15811	http://dx.doi.org/10.1074/jbc.273.25.15811			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624181	hybrid			2022-12-25	WOS:000074284200075
J	Autieri, MV; Agrawal, N				Autieri, MV; Agrawal, N			IRT-1, a novel interferon-gamma-responsive transcript encoding a growth-suppressing basic leucine zipper protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; REGULATORY FACTOR-I; MESSENGER-RNA; CORONARY ANGIOPLASTY; NUCLEAR LOCATION; PROLIFERATION; EXPRESSION; SEQUENCE; ATHEROSCLEROSIS; RESTENOSIS	Interferon-gamma (IFN-gamma) inhibits proliferation of vascular smooth muscle cells (VSMCs) in culture and reduces arterial restenosis post-balloon angioplasty. The identification and characterization of IFN-gamma-specific transcripts in VSMCs are an important approach to discern the molecular mechanisms underlying vascular proliferative disease. In this report, we describe IRT-1, a novel mRNA transcript constitutively expressed in a number of human tissues, but expressed in human VSMCs only when they are stimulated with IFN-gamma. This mRNA expression is induced >200-fold 72 h after IFN-gamma treatment. IRT-1 mRNA is also acutely expressed in rat carotid arteries that are injured by balloon angioplasty. The IRT-1 cDNA transcript encodes a basic protein that contains a leucine zipper motif, a core nuclear localization sequence, and a single strongly hydrophobic region, Constitutive IRT-1 mRNA expression in human peripheral blood lymphocytes is reduced when these cells are stimulated to proliferate. Overexpression of IRT-1 protein in VSMCs alters their morphology and dramatically reduces their proliferative capacity. This study suggests that IRT-1 is an IFN-gamma-inducible factor that may regulate the progression of vascular proliferative diseases.	Deborah Heart & Lung Ctr, Res Inst, Dept Biol Mol, Browns Mills, NJ 08015 USA		Autieri, MV (corresponding author), Temple Univ, Sch Med, Dept Cardiol & Physiol, 3420 N Broad St, Philadelphia, PA 19140 USA.							AUSTIN GE, 1985, J AM COLL CARDIOL, V6, P369, DOI 10.1016/S0735-1097(85)80174-1; Autieri MV, 1996, BIOCHEM BIOPH RES CO, V228, P29, DOI 10.1006/bbrc.1996.1612; BANERJI J, 1990, P NATL ACAD SCI USA, V87, P2374, DOI 10.1073/pnas.87.6.2374; BANGE FC, 1994, J BIOL CHEM, V269, P1091; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BENNETT MR, 1994, CIRC RES, V74, P525, DOI 10.1161/01.RES.74.3.525; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Castronuovo J J Jr, 1995, Cardiovasc Surg, V3, P463, DOI 10.1016/0967-2109(95)94442-Y; CLOWES AW, 1983, LAB INVEST, V49, P208; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEMAEYER E, 1988, INTERFERONS OTHER RE, P91; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; HANSSON GK, 1991, CIRCULATION, V84, P1266, DOI 10.1161/01.CIR.84.3.1266; HANSSON GK, 1988, CIRC RES, V63, P712, DOI 10.1161/01.RES.63.4.712; HANSSON GK, 1991, P NATL ACAD SCI USA, V88, P19530; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; IRIS FJM, 1993, NAT GENET, V3, P137, DOI 10.1038/ng0293-137; JONASSON L, 1988, LAB INVEST, V58, P310; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIBBY P, 1992, CIRCULATION, V86, P47; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NILSSON J, 1993, CARDIOVASC RES, V27, P1184, DOI 10.1093/cvr/27.7.1184; NUNOKAWA Y, 1992, BIOCHEM BIOPH RES CO, V188, P409, DOI 10.1016/0006-291X(92)92400-R; OBRIEN ER, 1993, CIRC RES, V73, P223, DOI 10.1161/01.RES.73.2.223; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; ROLFE BE, 1995, ARTERIOSCL THROM VAS, V15, P1204, DOI 10.1161/01.ATV.15.8.1204; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHWARTZ RS, 1990, CIRCULATION, V82, P2190, DOI 10.1161/01.CIR.82.6.2190; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Stopeck AT, 1997, CELL TRANSPLANT, V6, P1, DOI 10.1016/S0963-6897(96)00183-2; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Wang IM, 1996, MOL CELL BIOL, V16, P6313; WANG WZ, 1995, CIRC RES, V77, P1095, DOI 10.1161/01.RES.77.6.1095; Wang XY, 1996, BIOCHEM BIOPH RES CO, V229, P316, DOI 10.1006/bbrc.1996.1799; WELIHUA X, 1997, P NATL ACAD SCI USA, V94, P103; WILLIAMS JG, 1993, J SURG RES, V54, P79, DOI 10.1006/jsre.1993.1013; YAMADA H, 1994, MOL CELL BIOCHEM, V136, P117, DOI 10.1007/BF00926071	46	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14731	14737		10.1074/jbc.273.24.14731	http://dx.doi.org/10.1074/jbc.273.24.14731			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614071	hybrid			2022-12-25	WOS:000074160400013
J	Batlle, E; Verdu, J; Dominguez, D; Llosas, MD; Diaz, V; Loukili, N; Paciucci, R; Alameda, F; de Herreros, AG				Batlle, E; Verdu, J; Dominguez, D; Llosas, MD; Diaz, V; Loukili, N; Paciucci, R; Alameda, F; de Herreros, AG			Protein kinase C-alpha activity inversely modulates invasion and growth of intestinal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COLON; CANCER-CELLS; E-CADHERIN; PHORBOL-ESTER; HT-29 CELLS; ISOZYMES; EXPRESSION; UROKINASE; METHOTREXATE; LOCALIZATION	The phorbol ester phorbol 12-myristate 13-acetate induces remarkable phenotypic changes in intestinal HT-29 M6 cells; these changes consist of loss of homotypic adhesion and inactivation of E-cadherin. In parallel, cell growth is retarded. We have transfected HT-29 M6 cells with an activated form of the conventional protein kinase C alpha (cPK-C alpha). Expression of this isoform induced the acquisition of a scattered phenotype, similar to that adopted by cells after addition of phorbol 12-myristate 13-acetate, with very low cell-to-cell aggregation and undetectable levels of functional E-cadherin. These cell clones were highly motile and rapidly invaded embryonic chick heart fragments. Furthermore, cells expressing activated-cPK-C alpha showed decreased proliferation in comparison to control clones. We have also studied how these two apparently antagonistic changes affect the tumorigenic ability of HT-29 M6 cells. When the different cell clones were xenografted into athymic mice, the effect on cell growth seemed to predominate. Expression of activated-cPK-C alpha significantly reduced the size of the tumors; the cells with the highest level of expression did not even form subcutaneous tumors. Besides their smaller size, the morphology of these tumors was clearly different from those originated by HT-29 Mg cells, and they could be defined as infiltrative on anatomo-pathological basis. These results indicate that cPK-C alpha controls both cell-to-cell adhesion and proliferation of intestinal cells.	Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain		de Herreros, AG (corresponding author), Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Calle Dr Aiguader 80, E-08003 Barcelona, Spain.	agarcia@imim.es	Paciucci, Rosanna/AGP-3844-2022; Díaz, Víctor Manuel/F-5013-2016; Batlle, Eduard/K-8080-2014; de Herreros, A Garcia/H-3104-2014	Paciucci, Rosanna/0000-0001-5651-5933; Díaz, Víctor Manuel/0000-0001-8561-7576; Batlle, Eduard/0000-0003-2422-0326; de Herreros, A Garcia/0000-0001-5270-0808				BAUM CL, 1990, CANCER RES, V50, P3915; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAVEN PA, 1994, DIGEST DIS SCI, V39, P481, DOI 10.1007/BF02088331; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; DOI S, 1994, MOL CARCINOGEN, V11, P197, DOI 10.1002/mc.2940110405; FABRE M, 1993, J CELL SCI, V106, P513; GUILLEM JG, 1987, CANCER RES, V47, P2036; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; JIANG YH, 1995, CELL GROWTH DIFFER, V6, P1381; KAHLRAINER P, 1994, CARCINOGENESIS, V15, P779, DOI 10.1093/carcin/15.4.779; KOPP R, 1991, CANCER RES, V51, P205; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUSUNOKI M, 1992, CANCER, V69, P24, DOI 10.1002/1097-0142(19920101)69:1<24::AID-CNCR2820690107>3.0.CO;2-1; LESUFFLEUR T, 1991, J CELL BIOL, V115, P1409, DOI 10.1083/jcb.115.5.1409; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; Llosas MD, 1996, BIOCHEM J, V315, P1049; MAREEL M, 1979, VIRCHOWS ARCH B, V30, P95; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McGarrity TJ, 1996, CELL GROWTH DIFFER, V7, P953; MURAMATSU M, 1992, FEBS LETT, V311, P75, DOI 10.1016/0014-5793(92)81371-R; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; OJAKIAN GK, 1981, CELL, V23, P95, DOI 10.1016/0092-8674(81)90274-9; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; ReifelMiller AE, 1996, J BIOL CHEM, V271, P21666, DOI 10.1074/jbc.271.35.21666; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; Rosson D, 1997, J BIOL CHEM, V272, P14950, DOI 10.1074/jbc.272.23.14950; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; Skoudy A, 1996, BIOCHEM J, V317, P279, DOI 10.1042/bj3170279; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; WALI RK, 1995, CANCER RES, V55, P5257; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872	36	44	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15091	15098		10.1074/jbc.273.24.15091	http://dx.doi.org/10.1074/jbc.273.24.15091			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614119	hybrid			2022-12-25	WOS:000074160400061
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Superfolding of the partially unfolded core-glycosylatled intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; MUTATIONAL ANALYSIS; NUCLEOTIDE; TRANSPORTER; RESISTANCE; PROTEASOME; MUTANTS; SITES; HALF; MDR1	Misprocessed mutants of human P-glycoprotein accumulate as core-glycosylated intermediates in the endoplasmic reticulum and are rapidly degraded. Trypsin digestion was used to test for structural differences between mature and core-glycosylated forms of P-glycoprotein. We found that the core-glycosylated wild-type and mutant P-glycoproteins were both 100-fold. more sensitive to trypsin compared with the mature form of the wild-type enzyme. This result suggested that the core-glycosylated forms of both wild-type and mutant P-glycoproteins have similar unfolded structures, whereas the mature enzyme is folded into a more compact structure. The core-glycosylated mutant P-glycoproteins could be converted to the mature trypsin-resistant form by synthesis in the presence of drug substrate. Addition of proteasome inhibitor MG-132 to stabilize the core-glycosylated intermediate resulted in the accumulation but not maturation of the mutant protein. Further analysis showed that the second transmembrane domain TMD2 also became more resistant to trypsin digestion only after coexpression with TMD1 in the presence of substrate. Taken together, these results suggest that simply stabilizing the core-glycosylated intermediate is not sufficient to promote maturation of the processing mutants and that drug substrates induce maturation by promoting superfolding of the transmembrane domains.	Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Room 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Chan HSL, 1996, EUR J CANCER, V32A, P1051, DOI 10.1016/0959-8049(96)00085-8; CHEN G, 1997, J BIOL CHEM, V272, P1051; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; HOOF T, 1994, J BIOL CHEM, V269, P20575; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 1996, J BIOL CHEM, V271, P15414, DOI 10.1074/jbc.271.26.15414; LOO TW, 1994, J BIOL CHEM, V269, P28683; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; SCHEUTZ EG, 1996, P NATL ACAD SCI USA, V93, P4001; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	24	91	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14671	14674		10.1074/jbc.273.24.14671	http://dx.doi.org/10.1074/jbc.273.24.14671			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614062	hybrid			2022-12-25	WOS:000074160400004
J	Thompson, PR; Hughes, DW; Cianciotto, NP; Wright, GD				Thompson, PR; Hughes, DW; Cianciotto, NP; Wright, GD			Spectinomycin kinase from Legionella pneumophila - Characterization of substrate specificity and identification of catalytically important residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLTRANSFERASE AAD(9) DETERMINANT; PHOSPHOTRANSFERASE TYPE-III; NUCLEOTIDE-SEQUENCE; STAPHYLOCOCCUS-AUREUS; RESISTANCE GENES; ENTEROCOCCUS; APH(3')-IIIA; MECHANISM; VISCOSITY; FAECALIS	The bacterium Legionella pneumophila is the responsible agent for Legionnaires' disease and has recently been shown to harbor a gene encoding a kinase that confers resistance to the aminoglycoside antibiotic spectinomycin (Suter, T. M., Viswanathan, V. H., and Cianciotto, N. P. (1997) Antimicrob. Agents Chemother. 41, 1385-1388). We report the overproduction, purification, and characterization of this spectinomycin kinase from an expressing system in Escherichia coli. The purified protein shows stringent substrate specificity for spectinomycin with K-m = 21.5 mu m and k(cat) = 24.2 s(-1) and does not bind other aminoglycosides including kanamycin, amikacin, neomycin, butirosin, streptomycin, or apramycin. Purification of spectinomycin phosphate followed by characterization by mass spectrometry and H-1, C-13, and P-31 NMR established the site of phosphorylation to be at the hydroxyl group at position 9. Thus this enzyme is designated APH(S)-Ia (where APH is aminoglycoside kinase). The enzyme was inactivated by the electrophilic ATP analogue 5'-[p-(fluorosulfonyl)benzoyl]adenosine, consistent with a nucleophilic residue such as Lys lining the nucleotide binding pocket. Site-directed mutagenesis of Lys-52 and Asp-212 to Ala confirmed that these residues were important for catalysis, with Lys-52 playing a potential role in ATP binding and Asp-212 in phosphoryl transfer. Thio and solvent isotope effect experiments in the presence of either Mg2+ or Mn2+ were consistent with a kinetic mechanism in which phosphate transfer does not contribute significantly to the rate-limiting step. These results establish that APII(9)-Ia is a highly specific antibiotic resistance kinase and provides the requisite mechanistic information for future structural studies.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Chem, Hamilton, ON L8S 4M1, Canada; Northwestern Univ, Dept Microbiol Immunol, Chicago, IL 60611 USA	McMaster University; McMaster University; Northwestern University	Wright, GD (corresponding author), McMaster Univ, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	wrightge@fhs.mcmaster.ca	Wright, G/ABB-7666-2021	Wright, Gerard/0000-0002-9129-7131				BARKER JE, 1990, J ANTIMICROB CHEMOTH, V26, P45, DOI 10.1093/jac/26.1.45; Bovey F. A., 1988, NUCL MAGNETIC RESONA; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHRAN TG, 1972, J CHEM SOC CHEM COMM, P494; COLE PA, 1995, J BIOL CHEM, V270, P22105, DOI 10.1074/jbc.270.38.22105; COLE PA, 1994, J BIOL CHEM, V269, P30880; Daigle DM, 1997, J BIOL CHEM, V272, P24755, DOI 10.1074/jbc.272.40.24755; Davies J, 1997, TRENDS MICROBIOL, V5, P234, DOI 10.1016/S0966-842X(97)01033-0; Fields BS, 1996, TRENDS MICROBIOL, V4, P286, DOI 10.1016/0966-842X(96)10041-X; GRAY GS, 1983, MOL BIOL EVOL, V1, P57; HOLLINGSHEAD S, 1985, PLASMID, V13, P17, DOI 10.1016/0147-619X(85)90052-6; Hon WC, 1997, CELL, V89, P887, DOI 10.1016/S0092-8674(00)80274-3; Leatherbarrow R. J., 1992, GRAFIT; LEBLANC DJ, 1991, ANTIMICROB AGENTS CH, V35, P1804, DOI 10.1128/AAC.35.9.1804; Lyutzkanova D, 1997, MICROBIOL-SGM, V143, P2135, DOI 10.1099/00221287-143-7-2135; MADHUSUDAN T, 1994, PROTEIN SCI, V3, P176; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P6936, DOI 10.1021/bi00188a024; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P14115, DOI 10.1021/bi00251a021; McKay GA, 1996, BIOCHEMISTRY-US, V35, P8680, DOI 10.1021/bi9603884; MURPHY E, 1985, MOL GEN GENET, V200, P33, DOI 10.1007/BF00383309; MURRAY PR, 1994, MED MICROBIOLOGY, P279; Payie KG, 1997, J BACTERIOL, V179, P4106, DOI 10.1128/jb.179.13.4106-4114.1997; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; Suter TM, 1997, ANTIMICROB AGENTS CH, V41, P1385, DOI 10.1128/AAC.41.6.1385; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRIEUCUOT P, 1983, GENE, V23, P331, DOI 10.1016/0378-1119(83)90022-7; WINN W C JR, 1988, Clinical Microbiology Reviews, V1, P60; Zhou J, 1997, BIOCHEMISTRY-US, V36, P2977, DOI 10.1021/bi9619132	28	18	18	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14788	14795		10.1074/jbc.273.24.14788	http://dx.doi.org/10.1074/jbc.273.24.14788			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614079	hybrid			2022-12-25	WOS:000074160400021
J	Walia, H; Chen, HY; Sun, JM; Holth, LT; Davie, JR				Walia, H; Chen, HY; Sun, JM; Holth, LT; Davie, JR			Histone acetylation is required to maintain the unfolded nucleosome structure associated with transcribing DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONALLY ACTIVE CHROMATIN; RNA-POLYMERASE-II; BETA-GLOBIN GENE; NUCLEAR MATRIX; CHICKEN ERYTHROCYTES; AFFINITY-CHROMATOGRAPHY; LINKER HISTONES; SEQUENCES; YEAST; ACETYLTRANSFERASE	Nucleosomes associated with transcribing chromatin of mammalian cells have an unfolded structure in which the normally buried cysteinyl-thiol group of histone H3 is exposed. In this study we analyzed transcriptionally active/competent DNA-enriched chromatin fractions from chicken mature and immature erythrocytes for the presence of thiol-reactive nucleosomes using organo-mercury-agarose column chromatography and hydroxylapatite dissociation chromatography of chromatin fractions labeled with [H-3]iodoacetate. In mature and immature erythrocytes, the active DNA-enriched chromatin fractions are associated with histones that are rapidly highly acetylated and rapidly deacetylated. When histone deacetylation was prevented by incubating cells with histone deacetylase inhibitors, sodium butyrate or trichostatin A, thiol-reactive H3 of unfolded nucleosomes was detected in the soluble chromatin and nuclear skeleton-associated chromatin of immature, but not mature, erythrocytes. We did not find thiol-reactive nucleosomes in active DNA-enriched chromatin fractions of untreated immature erythrocytes that had How levels of highly acetylated histones HS and H4 or in chromatin of immature cells incubated with inhibitors of transcription elongation. This study shows that transcription elongation is required to form, and histone acetylation is needed to maintain, the unfolded structure of transcribing nucleosomes.	Univ Manitoba, Fac Med, Dept Biochem & Mol Biol, Winnipeg, MB R3E 0W3, Canada	University of Manitoba	Davie, JR (corresponding author), Univ Manitoba, Fac Med, Dept Biochem & Mol Biol, 770 Bannatyne Ave, Winnipeg, MB R3E 0W3, Canada.	Davie@cc.umanitoba.ca		Davie, James/0000-0002-0420-6888				ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; ALLFREY VG, 1991, METHOD CELL BIOL, V35, P315; ANDREEVA M, 1992, EUR J BIOCHEM, V207, P887, DOI 10.1111/j.1432-1033.1992.tb17121.x; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BazettJones DP, 1996, NUCLEIC ACIDS RES, V24, P321, DOI 10.1093/nar/24.2.321; BOFFA LC, 1990, EUR J BIOCHEM, V194, P811, DOI 10.1111/j.1432-1033.1990.tb19474.x; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BROWN T, 1995, CURRENT PROTOCOLS MO; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chadee DN, 1997, J BIOL CHEM, V272, P8113, DOI 10.1074/jbc.272.13.8113; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN TA, 1991, J BIOL CHEM, V266, P6489; CHENCLELAND TA, 1993, J BIOL CHEM, V268, P23409; Davie JR, 1996, J CELL BIOCHEM, V62, P149, DOI 10.1002/(SICI)1097-4644(199608)62:2<149::AID-JCB2>3.0.CO;2-S; DAVIE JR, 1994, J CELL BIOCHEM, V55, P98, DOI 10.1002/jcb.240550112; DAVIE JR, 1981, NUCLEIC ACIDS RES, V9, P3205, DOI 10.1093/nar/9.13.3205; Davie JR, 1997, MOL BIOL REP, V24, P197, DOI 10.1023/A:1006811817247; Davie JR, 1995, INT REV CYTOL, V162A, P191; DELCUVE GP, 1992, ANAL BIOCHEM, V200, P339, DOI 10.1016/0003-2697(92)90475-M; DELCUVE GP, 1989, BIOCHEM J, V263, P179, DOI 10.1042/bj2630179; EBRALIDSE KK, 1993, NUCLEIC ACIDS RES, V21, P4734, DOI 10.1093/nar/21.20.4734; EBRALIDSE KK, 1988, NATURE, V331, P365, DOI 10.1038/331365a0; GARIGLIO P, 1981, NUCLEIC ACIDS RES, V9, P2589, DOI 10.1093/nar/9.11.2589; Gavin IM, 1998, J BIOL CHEM, V273, P2429, DOI 10.1074/jbc.273.4.2429; GERDES MG, 1994, J CELL BIOL, V126, P289, DOI 10.1083/jcb.126.2.289; GROSS DS, 1987, TRENDS BIOCHEM SCI, V12, P293, DOI 10.1016/0968-0004(87)90144-7; Halle JP, 1996, TRENDS GENET, V12, P161, DOI 10.1016/0168-9525(96)30035-8; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENDZEL MJ, 1994, J BIOL CHEM, V269, P22894; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HIROSE M, 1988, J BIOCHEM-TOKYO, V103, P31, DOI 10.1093/oxfordjournals.jbchem.a122234; Iborra FJ, 1996, J CELL SCI, V109, P1427; IMAI BS, 1986, J BIOL CHEM, V261, P8784; IP YT, 1988, J BIOL CHEM, V263, P14044; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LI W, 1993, BIOCHEM J, V296, P737, DOI 10.1042/bj2960737; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; Ljungman M, 1996, CARCINOGENESIS, V17, P31, DOI 10.1093/carcin/17.1.31; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; McNeil S, 1998, J CELL BIOCHEM, V68, P500, DOI 10.1002/(SICI)1097-4644(19980315)68:4<500::AID-JCB9>3.3.CO;2-T; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NELSON DA, 1982, J BIOL CHEM, V257, P1565; NORTON VG, 1990, J BIOL CHEM, V265, P19848; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; RIDSDALE JA, 1987, NUCLEIC ACIDS RES, V15, P1081, DOI 10.1093/nar/15.3.1081; RIDSDALE JA, 1988, NUCLEIC ACIDS RES, V16, P5915, DOI 10.1093/nar/16.13.5915; ROCHA E, 1984, J BIOL CHEM, V259, P8558; SMITH RM, 1989, J BIOL CHEM, V264, P10574; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STERNER R, 1987, NUCLEIC ACIDS RES, V15, P4375, DOI 10.1093/nar/15.11.4375; STEWART AF, 1987, CELL, V50, P1109, DOI 10.1016/0092-8674(87)90177-2; STEWART AF, 1990, CELL, V60, P141; STRATLING WH, 1986, BIOCHEMISTRY-US, V25, P495, DOI 10.1021/bi00350a033; STRATLING WH, 1987, BIOCHEMISTRY-US, V26, P7893, DOI 10.1021/bi00398a053; Sun JM, 1996, CHROMOSOMA, V104, P504; THOMSEN B, 1991, EUR J BIOCHEM, V201, P107, DOI 10.1111/j.1432-1033.1991.tb16262.x; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; ZHANG DE, 1988, BIOCHEM J, V250, P241, DOI 10.1042/bj2500241; ZHANG DE, 1988, BIOCHEM J, V250, P233, DOI 10.1042/bj2500233	65	91	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14516	14522		10.1074/jbc.273.23.14516	http://dx.doi.org/10.1074/jbc.273.23.14516			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603965	hybrid			2022-12-25	WOS:000074021500067
J	Oldham, SM; Cox, AD; Reynolds, ER; Sizemore, NS; Coffey, RJ; Der, CJ				Oldham, SM; Cox, AD; Reynolds, ER; Sizemore, NS; Coffey, RJ; Der, CJ			Ras, but not Src, transformation of RIE-1 epithelial cells is dependent on activation of the mitogen-activated protein kinase cascade	ONCOGENE			English	Article						autocrine; epidermal growth factor receptor; Raf	NUCLEOTIDE DISSOCIATION STIMULATOR; RECEPTOR TYROSINE KINASE; ONCOGENIC RAS; PLASMA-MEMBRANE; GROWTH-FACTORS; REQUIREMENT; SUFFICIENT; EFFECTOR; PATHWAY; CAAX	Src transformation of NIH3T3 mouse fibroblasts has been shown to be dependent on Ras function. Since we recently showed that the signaling pathways that mediate Ras transformation of RIE-1 rat intestinal epithelial cells are distinct from those that cause Ras transformation of fibroblasts, we utilized three approaches to determine if Src transformation of RIE-1 cells is dependent on Ras, First, although both Ras and Src cause upregulation of an epidermal growth factor (EGF) receptor-dependent autocrine growth loop, only Ras transformation required this activity, Second, whereas both Src and Ras caused upregulation of the p42 and p44 mitogen-activated protein kinases (MAPKs), only Ras transformation was blocked by the inhibition of MAPK activation by treatment with the PD 98059 MEK inhibitor, Third, treatment with the farnesyltransferase inhibitor FTI-277 blocked Ras, but not Src, transformation. Taken together, these observations suggest that Src transformation of RIE-1 cells is not dependent on Ras, Finally, we determined that Ras activation of Raf-independent pathways alone is sufficient to cause growth transformation of RIE-1 cells. Thus, both Ras and Src cause transformation of RIE-1 cells via pathways distinct from those required to cause transformation of NIH3T3 cells.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Vanderbilt Univ, Dept Med, Nashville, TN USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Der, CJ (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.			Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA 63071, CA 69577, CA 42978] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069577, R01CA063071, R01CA042978] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, J BIOL CHEM, V269, P19203; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LIU XQ, 1993, ONCOGENE, V8, P1119; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STACEY DW, 1991, ONCOGENE, V6, P2297; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1996, ONCOGENE, V13, P353; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	55	43	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2565	2573		10.1038/sj.onc.1201784	http://dx.doi.org/10.1038/sj.onc.1201784			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632133				2022-12-25	WOS:000073698200001
J	de Vries, A; Berg, RJW; Wijnhoven, S; Westerman, A; Wester, PW; van Kreijl, CF; Capel, PJA; de Gruijl, FR; van Kranen, HJ; van Steeg, H				de Vries, A; Berg, RJW; Wijnhoven, S; Westerman, A; Wester, PW; van Kreijl, CF; Capel, PJA; de Gruijl, FR; van Kranen, HJ; van Steeg, H			XPA-deficiency in hairless mice causes a shift in skin tumor types and mutational target genes after exposure to low doses of UVB	ONCOGENE			English	Article						XPA; UVB; p53; ras; papilloma; squamous cell carcinoma	XERODERMA-PIGMENTOSUM PATIENTS; SQUAMOUS-CELL CARCINOMAS; P53 GENE; ULTRAVIOLET-RADIATION; MOLECULAR ANALYSIS; EXCISION-REPAIR; RAS MUTATIONS; MOUSE SKIN; GROUP-A; CANCER	Xeroderma pigmentosum (XP) patients with a defect in the nucleotide excision repair gene XPA, develop tumors with a high frequency on sun-exposed areas of the skin. Here we describe that hairless XPA-deficient mice also develop skin tumors with a short latency time and a 100% prevalence after daily exposure to low doses of U.V.B. Surprisingly and in contrast to U.V.B.-exposed repair proficient hairless mice who mainly develop squamous cell carcinomas, the XPA-deficient mice developed papillomas with a high frequency (31%) at a U.V. dose of 32 J/m(2) daily, At the highest daily dose of 80 J/m(2) mainly squamous cell carcinomas (56%) and only 10% of papillomas were found in XPA-deficient hairless mice, p53 gene mutations were examined in exons 5, 7 and 8 and were detected in only 3 out of 37 of these skin tumors, whereas in tumors of control U.V.B.-irradiated wild type littermates this frequency was higher (45%) and more in line with our previous data. Strikingly, a high incidence of activating ras gene mutations were observed in U.V.B.-induced papillomas (in 11 out of 14 tumors analysed). In only two out of 14 squamous cell carcinomas we found similar ras gene mutations. The observed shift from squamous cell carcinomas in wild type hairless mice to papillomas in XPA-deficient hairless mice, and a corresponding shift in mutated cancer genes in these tumors, provide new clues on the pathogenesis of chemically-versus U.V.B.-induced skin carcinogenesis.	Natl Inst Publ Hlth & Environm, Dept Carcinogenesis Mutagenesis & Genet, Hlth Effects Res Lab, NL-3720 BA Bilthoven, Netherlands; Natl Inst Publ Hlth & Environm, Lab Pathol & Immunobiol, NL-3720 BA Bilthoven, Netherlands; Univ Utrecht, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Dept Dermatol, NL-3584 CX Utrecht, Netherlands	Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University	van Steeg, H (corresponding author), Natl Inst Publ Hlth & Environm, Dept Carcinogenesis Mutagenesis & Genet, Hlth Effects Res Lab, POB 1, NL-3720 BA Bilthoven, Netherlands.							Berg RJW, 1997, CANCER RES, V57, P581; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; Brown K, 1995, TOXICOL LETT, V82-3, P123, DOI 10.1016/0378-4274(95)03549-4; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; CAMPBELL C, 1993, BRIT J DERMATOL, V128, P111, DOI 10.1111/j.1365-2133.1993.tb15137.x; Cleaver JE, 1995, METABOLIC MOL BASES, VIII, P4393; DAYAGROSJEAN L, 1995, J PHOTOCH PHOTOBIO B, V28, P115, DOI 10.1016/1011-1344(95)07130-T; DEGRUIJL FR, 1993, CANCER RES, V53, P53; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; DORADO G, 1991, J MOL BIOL, V217, P217, DOI 10.1016/0022-2836(91)90533-C; DUMAZ N, 1994, MUTAT RES, V307, P375, DOI 10.1016/0027-5107(94)90311-5; Dumaz N, 1997, CARCINOGENESIS, V18, P897, DOI 10.1093/carcin/18.5.897; *IARC, 1992, MON EV CARC RISK HUM, V55; KANJILAL S, 1993, CANCER RES, V53, P2961; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; KRESS S, 1992, CANCER RES, V52, P6400; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; LUNGMANN M, 1996, ONCOGENE, V13, P823; MATSUMURA Y, 1995, J INVEST DERMATOL, V105, P399, DOI 10.1111/1523-1747.ep12321051; Matsumura Y, 1996, INT J CANCER, V65, P778; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; MiyauchiHashimoto H, 1996, J INVEST DERMATOL, V107, P343, DOI 10.1111/1523-1747.ep12363295; Mukhtar H, 1996, PHOTOCHEM PHOTOBIOL, V63, P355, DOI 10.1111/j.1751-1097.1996.tb03040.x; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P218, DOI 10.1111/j.1751-1097.1995.tb05262.x; REES J, 1994, J INVEST DERMATOL, V103, P747, DOI 10.1111/1523-1747.ep12412256; RUVEN HJT, 1994, ONCOGENE, V9, P3427; SATO M, 1993, CANCER RES, V53, P2944; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; vanKranen HJ, 1997, CANCER RES, V57, P1238; VANKRANEN HJ, 1995, CARCINOGENESIS, V16, P1141; YAGI T, 1991, CANCER RES, V51, P3177; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	36	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	1998	16	17					2205	2212		10.1038/sj.onc.1201744	http://dx.doi.org/10.1038/sj.onc.1201744			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619829				2022-12-25	WOS:000073298000005
J	Bursey, EH; Burgess, BK				Bursey, EH; Burgess, BK			Characterization of a variant iron protein of nitrogenase that is impaired is its ability to adopt the MgATP-induced conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; KLEBSIELLA-PNEUMONIAE; SIGNAL-TRANSDUCTION; MOLYBDENUM COFACTOR; NUCLEOTIDE-BINDING; FE-PROTEIN; CRYSTALLOGRAPHIC STRUCTURE; ADENOSINE 5'-TRIPHOSPHATE; CIRCULAR-DICHROISM; CRYSTAL-STRUCTURE	An Azotobacter vinelandii nitrogenase iron protein mutant has been created which contains an alanine to glycine substitution at amino acid 157, The strain expressing this mutant Fe protein is able to grow under nitrogen-fixing conditions. This contrasts with an A. vinelandii strain described previously which is unable to grow under nitrogen-fixing conditions and which expresses an Fe protein variant that has an alanine to serine mutation at position 157, The A157S Fe protein was unable to support substrate reduction by nitrogenase because of an inability to undergo a required MgATP-induced conformational change. Although the A157G strain grows at 55% of the rate of the wild-type strain, purified A157G; Fe protein is only able to support substrate reduction in in vitro assays at a rate that is approximately 20% of the rate supported by the wildtype Fe protein. Electron paramagnetic resonance, circular dichroism spectroscopies, and enzymatic activity data indicate that the A157G Fe protein adopts the correct conformation upon the binding of MgATP, However, kinetic studies using chelation show that this protein undergoes the conformational change more slowly than the wild-type protein. Thus, this mutant has lower activity because of an impaired ability to undergo this conformational change. Comparison of two available xray crystal structures of the native Fe protein alone and complexed with the MoFe protein has provided us with a model to explain the change in activity in alanine 157 mutants. Steric interactions with the side chain of residue 157 influence the protein's ability to undergo the initial MgATP-induced conformational change. In the case of the A157G mutant, however, once the correct conformation is attained, the protein can participate in all subsequent reactions including complex formation, electron transfer, and MgATP hydrolysis, Thus, the role of alanine 157 is to stabilize the proper initial conformation upon MgATP binding.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	bburgess@uci.edu			NIGMS NIH HHS [GM-45209] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045209] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angove HC, 1997, J AM CHEM SOC, V119, P8730, DOI 10.1021/ja9712837; ASHBY GA, 1987, BIOCHEM J, V246, P455, DOI 10.1042/bj2460455; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; CHEN L, 1994, J BIOL CHEM, V269, P3290; DEITS TL, 1989, J BIOL CHEM, V264, P6619; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; LANZILOTTA WN, 1995, BIOCHEMISTRY-US, V34, P10713, DOI 10.1021/bi00034a003; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P7188, DOI 10.1021/bi9603985; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PALMER G, 1972, ARCH BIOCHEM BIOPHYS, V153, P325, DOI 10.1016/0003-9861(72)90452-3; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; Ryle MJ, 1996, J BIOL CHEM, V271, P1551, DOI 10.1074/jbc.271.3.1551; RYLE MJ, 1995, J BIOL CHEM, V270, P13112, DOI 10.1074/jbc.270.22.13112; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P4766, DOI 10.1021/bi960026w; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; SEEFELDT LC, 1994, PROTEIN SCI, V3, P2073, DOI 10.1002/pro.5560031120; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SEEFELDT LC, 1993, PROTEIN SCI, V2, P93; STEPHENS PJ, 1979, P NATL ACAD SCI USA, V76, P2585, DOI 10.1073/pnas.76.6.2585; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATT GD, 1994, J INORG BIOCHEM, V53, P281, DOI 10.1016/0162-0134(94)85115-8; WEHR CT, 1980, NUCL ACID CONSTITUEN; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9	45	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16927	16934		10.1074/jbc.273.27.16927	http://dx.doi.org/10.1074/jbc.273.27.16927			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642255	hybrid			2022-12-25	WOS:000074545200045
J	Keller, SH; Lindstrom, J; Taylor, P				Keller, SH; Lindstrom, J; Taylor, P			Inhibition of glucose trimming with castanospermine reduces calnexin association and promotes proteasome degradation of the alpha-subunit of the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; ENDOPLASMIC-RETICULUM; BINDING-SITE; PROTEIN-DEGRADATION; LIGAND-BINDING; IN-VITRO; KAPPA-B; RESIDUES; PATHWAY; PHOSPHORYLATION	To identify factors involved in the expression of ligand-gated ion channels, we expressed nicotinic acetylcholine receptors in HEK cells to characterize roles for oligosaccharide trimming, calnexin association, and targeting to the proteasome. The homologous subunits of the acetylcholine receptor traverse the membrane four times, contain at least one oligosaccharide, and are retained in the endoplasmic reticulum until completely assembled into the circular arrangement of subunits of delta-alpha-gamma-alpha-beta to enclose the ion channel. We previously demonstrated that calnexin is associated with unassembled subunits of the receptor, but appears to dissociate when subunits are assembled in various combinations. We used the glucosidase inhibitor castanospermine to block oligosaccharide processing, and thereby inhibit calnexin's interaction with the oligosaccharides in the receptor subunits. Castanospermine treatment reduces the association of calnexin with the alpha-subunit of the receptor, and diminishes the intracellular accumulation of unassembled receptor subunit protein. However, treatment with castanospermine does not appear to alter subunit folding or assembly. In contrast, co-treatment with proteasome inhibitors and castanospermine enhances the accumulation of polyubiquitin-conjugated alpha-subunits, and generally reverses the castanospermine induced loss of alpha-subunit protein. Co-transfection of cDNAs encoding the alpha- and delta-subunits, which leads to the expression of assembled alpha- and delta- subunits, also inhibits the loss of cu-subunits expressed in the presence of castanospermine. Taken together, these observations indicate that calnexin association reduces the degradation of unassembled receptor subunits in the ubiquitin-proteasome pathway.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	University of California System; University of California San Diego; University of Pennsylvania; University of Pennsylvania	Keller, SH (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NIGMS NIH HHS [GM18360] Funding Source: Medline; NINDS NIH HHS [NS11323, NS09715] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018360, R37GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009715, R01NS011323] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN TJ, 1988, J CELL BIOL, V106, P469, DOI 10.1083/jcb.106.2.469; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; Chang W, 1997, J BIOL CHEM, V272, P28925, DOI 10.1074/jbc.272.46.28925; CHANGEUX JP, 1995, BIOCHEM SOC T, V23, P195, DOI 10.1042/bst0230195; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fu DX, 1996, J BIOL CHEM, V271, P31479, DOI 10.1074/jbc.271.49.31479; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; HELEKAR SA, 1994, NEURON, V12, P179, DOI 10.1016/0896-6273(94)90162-7; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HERBERT DN, 1996, EMBO J, V15, P2961; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KAO PN, 1986, J BIOL CHEM, V261, P8085; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MERLIE JP, 1982, J BIOL CHEM, V257, P2694; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; MOSS SJ, 1989, J BIOL CHEM, V264, P20199; NODA M, 1983, NATURE, V305, P818, DOI 10.1038/305818a0; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; ROMAGNOLI P, 1995, J EXP MED, V182, P2027, DOI 10.1084/jem.182.6.2027; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; Shtrom SS, 1996, J BIOL CHEM, V271, P25506, DOI 10.1074/jbc.271.41.25506; SINE SM, 1991, J BIOL CHEM, V266, P19369; SMITH MM, 1987, J BIOL CHEM, V262, P4367; SMITH MM, 1986, J BIOL CHEM, V261, P4825; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VanLeeuwen JEM, 1997, J BIOL CHEM, V272, P4179, DOI 10.1074/jbc.272.7.4179; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	51	86	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17064	17072		10.1074/jbc.273.27.17064	http://dx.doi.org/10.1074/jbc.273.27.17064			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642271	hybrid			2022-12-25	WOS:000074545200061
J	Sreenivas, A; Patton-Vogt, JL; Bruno, V; Griac, P; Henry, SA				Sreenivas, A; Patton-Vogt, JL; Bruno, V; Griac, P; Henry, SA			A role for phospholipase D (Pld1p) in growth, secretion, and regulation of membrane lipid synthesis in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSFER PROTEIN; IDENTIFICATION; GENE; MEIOSIS	The SEC14 gene encodes a phosphatidylinositol/phosphatidylcholine transfer protein essential for secretion and growth in yeast (1). Mutations (cki1, cct1, and cpt1) in the CDP-choline pathway for phosphatidylcholine synthesis suppress the sec14 growth defect (2), permitting sec14(ts) cki1, sec14(ts) cct1, and sec14(ts) cpt1 strains to grow at the sec14(ts) restrictive temperature. Previously, we reported that these double mutant strains also ex crete the phospholipid metabolites, choline and inositol (3). We now report that these choline and inositol excretion phenotypes are eliminated when the SPO14 (PLD1) gene encoding phospholipase DI is deleted. In contrast to sec14(ts) cki1 strains, sec14(ts) cki1 pld1 strains are not viable at the sec14(ts) restrictive temperature and exhibit a pattern of invertase secretion comparable with sec14(ts) strains, Thus, the PLD1 gene product appears to play an essential role in the suppression of the sec14(ts) defect by CDP-choline pathway mutations, indicating a role for phospholipase D1 in growth and secretion. Furthermore, sec14(ts) strains exhibit elevated Ca2+-independent, phophatidylinositol 4,5-bisphosphate-stimulated phospholipase D activity, We also propose that phospholipase D1-mediated phosphatidylcholine turnover generates a signal that activates transcription of INO1, the structural gene for inositol l-phosphate synthase.	Carnegie Mellon Univ, Dept Sci Biol, Pittsburgh, PA 15213 USA; Slovak Acad Sci, Inst Anim Biochem & Genet, Ivanka Pri Dunaj 90028, Czech Republic	Carnegie Mellon University; Slovak Academy of Sciences	Henry, SA (corresponding author), Carnegie Mellon Univ, Dept Sci Biol, 440 5th Ave, Pittsburgh, PA 15213 USA.		Henry, Susan/K-5464-2014; , Peter/ABA-9227-2020	, Peter/0000-0003-3538-0405	NIGMS NIH HHS [GM-19629] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019629, R01GM019629] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; CLEVES AE, 1991, CELL, V64, P7789; Cox JS, 1997, MOL BIOL CELL, V8, P1805, DOI 10.1091/mbc.8.9.1805; DAUM G, 1983, BIOCHIM BIOPHYS ACTA, V753, P430, DOI 10.1016/0005-2760(83)90067-X; Ella KM, 1996, BIOCHEM J, V314, P15, DOI 10.1042/bj3140015; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GRAVES JA, 1996, THESIS CARNEGIEMELLO; GREENBERG ML, 1982, GENETICS, V100, P19; Griac P, 1996, J BIOL CHEM, V271, P25692, DOI 10.1074/jbc.271.41.25692; HONIGBERG SM, 1992, GENETICS, V130, P703; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Liscovitch M, 1996, J LIPID MEDIAT CELL, V14, P215, DOI 10.1016/0929-7855(96)00528-7; Mayr JA, 1996, FEBS LETT, V393, P236, DOI 10.1016/0014-5793(96)00893-9; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; Rudge SA, 1998, J CELL BIOL, V140, P81, DOI 10.1083/jcb.140.1.81; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; Wakelam MJO, 1997, SEMIN CELL DEV BIOL, V8, P305, DOI 10.1006/scdb.1997.0152; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; Waksman M, 1997, J BIOL CHEM, V272, P36	29	124	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16635	16638		10.1074/jbc.273.27.16635	http://dx.doi.org/10.1074/jbc.273.27.16635			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642212	hybrid			2022-12-25	WOS:000074545200002
J	Kekuda, R; Prasad, PD; Wu, XA; Wang, HP; Fei, YJ; Leibach, FH; Ganapathy, V				Kekuda, R; Prasad, PD; Wu, XA; Wang, HP; Fei, YJ; Leibach, FH; Ganapathy, V			Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; COTRANSPORTER; MECHANISMS; ANIONS; KIDNEY; SYSTEM	We have isolated a cDNA from rat placenta which, when expressed heterologously, mediates the transport of a wide spectrum of organic cations, The cDNA codes for a protein of 551 amino acids containing 12 putative transmembrane domains, Northern blot analysis indicates that this transporter is expressed most abundantly in the placenta and moderately in the intestine, heart, and brain. The expression is comparatively low in the kidney and lung and is undetectable in the Liver. This transporter is distinct from the previously cloned organic cation transporters (OCT1, OCT2, NKT, NLT, RST, and OCTN1), When expressed in HeLa cells, the cDNA induces the transport of tetraethylammonium and guanidine, Competition experiments indicate that this transport process recognizes a large number of organic cations, including the neurotoxin 1-methyl-4-phenylpyridinium, as substrates, The cDNA-induced transport is markedly influenced by extracellular pH, However, when expressed in Xenopus laevis oocytes, the cDNA-induced transport is electrogenic, associated with the transfer of positive charge into the oocytes, Under voltage clamp conditions, tetraethylammonium evokes inward currents that are concentration- and potential-dependent. This potential-sensitive organic cation transporter, designated as OCT3, represents a new member of the OCT gene family.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.				NICHD NIH HHS [HD 10045] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Benson DA, 1996, NUCLEIC ACIDS RES, V24, P1, DOI 10.1093/nar/24.1.1; Busch AE, 1996, J BIOL CHEM, V271, P32599, DOI 10.1074/jbc.271.51.32599; Busch AE, 1996, FEBS LETT, V395, P153, DOI 10.1016/0014-5793(96)01030-7; FEI YJ, 1995, BIOCHEMISTRY-US, V34, P8744, DOI 10.1021/bi00027a025; GANAPATHY V, 1988, J BIOL CHEM, V263, P4561; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; Grundemann D, 1997, J BIOL CHEM, V272, P10408; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Kekuda R, 1997, AM J PHYSIOL-GASTR L, V272, pG1463, DOI 10.1152/ajpgi.1997.272.6.G1463; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; Mackenzie B, 1996, BBA-BIOMEMBRANES, V1284, P125, DOI 10.1016/S0005-2736(96)00170-8; Mori K, 1997, FEBS LETT, V417, P371, DOI 10.1016/S0014-5793(97)01325-2; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PRASAD PD, 1992, J BIOL CHEM, V267, P23632; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; RAMAMOORTHY S, 1994, BIOCHEM J, V300, P893, DOI 10.1042/bj3000893; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SIMONSON GD, 1994, J CELL SCI, V107, P1065; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; ULLRICH KJ, 1994, BBA-REV BIOMEMBRANES, V1197, P45, DOI 10.1016/0304-4157(94)90018-3; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Zevin S, 1997, PHARMACEUT RES, V14, P401, DOI 10.1023/A:1012022810550; Zhang L, 1997, MOL PHARMACOL, V51, P913, DOI 10.1124/mol.51.6.913	29	348	359	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15971	15979		10.1074/jbc.273.26.15971	http://dx.doi.org/10.1074/jbc.273.26.15971			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632645	hybrid			2022-12-25	WOS:000074436600016
J	Kobayashi, K; Tsubaki, M; Tagawa, S				Kobayashi, K; Tsubaki, M; Tagawa, S			Distinct roles of two heme centers for transmembrane electron transfer in cytochrome b(561) from bovine adrenal chromaffin vesicles as revealed by pulse radiolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION-REDUCTION PROPERTIES; ASCORBIC-ACID; ACHROMOBACTER-CYCLOCLASTES; GRANULE MEMBRANES; NITRITE REDUCTASE; POLYPEPTIDE; ABSORPTION; TRANSPORT; SPECTRUM; RADICALS	The reaction of monodehydroascorbate (MDA) radical with purified cytochrome b(561) from bovine adrenal chromaffin vesicles was investigated by the technique of pulse radiolysis. Radiolytically generated MDA radical oxidized rapidly the reduced form of cytochrome b(561) to yield the oxidized form. Subsequently the oxidized form of cytochrome b(561) was re-reduced by ascorbate in the medium. The second-order rate constants of the reaction of MDA radical were increased with decreasing pH, whereas a maximum of the second-order rate constant for the reaction with ascorbate was obtained around pH 6.8. At excess MDA radical to cytochrome b(561) concentration, only half of the heme in cytochrome b561 was oxidized, indicating that only one of the two heme centers can react with MDA radical. On the other hand, when the reactions were examined using cytochrome b(561) pretreated in a mild alkaline condition in the oxidized state, the cytochrome b(561) could not be oxidized with MDA radical, suggesting that the heme center specific for the electron donation to MDA radical is selectively modified upon the alkaline treatment. These results suggest that the two heme b centers have distinct roles for the electron donation to MDA radical and the electron acceptance from ascorbate, respectively.	Osaka Univ, Inst Sci & Ind Res, Osaka 5670047, Japan; Himeji Inst Technol, Fac Sci, Dept Life Sci, Kamigoori, Hyogo 6781297, Japan	Osaka University; University of Hyogo	Kobayashi, K (corresponding author), Osaka Univ, Inst Sci & Ind Res, Mihogaoka 8-1, Osaka 5670047, Japan.		Kobayashi, Kazuo/H-9279-2012	Kobayashi, Kazuo/0000-0002-5586-9112				APPS DK, 1984, BIOCHIM BIOPHYS ACTA, V764, P8, DOI 10.1016/0005-2728(84)90134-8; APPS DK, 1980, NEUROSCIENCE, V5, P2279, DOI 10.1016/0306-4522(80)90143-8; BABCOCK GT, 1985, BIOCHEMISTRY-US, V24, P3638, DOI 10.1021/bi00335a036; BERGSTROM J, 1983, FEBS LETT, V164, P71, DOI 10.1016/0014-5793(83)80021-0; BIELSKI BHJ, 1970, J AM CHEM SOC, V92, P3793, DOI 10.1021/ja00715a046; BIELSKI BHJ, 1971, J AM CHEM SOC, V93, P5624, DOI 10.1021/ja00751a006; CABELLI DE, 1983, J PHYS CHEM-US, V87, P1809, DOI 10.1021/j100233a031; DILIBERTO EJ, 1983, J BIOL CHEM, V258, P2886; DUONG LT, 1982, J BIOL CHEM, V257, P8561; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; IYANAGI T, 1985, BIOCHIM BIOPHYS ACTA, V806, P255, DOI 10.1016/0005-2728(85)90103-3; IYANAGI T, 1984, BIOCHEMISTRY-US, V23, P1418, DOI 10.1021/bi00302a013; JALUKAR V, 1991, J BIOL CHEM, V266, P6878; KELLEY PM, 1986, J BIOL CHEM, V261, P6429; KELLEY PM, 1990, J BIOL CHEM, V265, P19409; Kobayashi K, 1997, BIOCHEMISTRY-US, V36, P13611, DOI 10.1021/bi971045o; KOBAYASHI K, 1991, BIOCHEMISTRY-US, V30, P8310, DOI 10.1021/bi00098a005; KOBAYASHI K, 1995, J BIOL CHEM, V270, P27551, DOI 10.1074/jbc.270.46.27551; NJUS D, 1983, J BIOL CHEM, V258, P27; NJUS D, 1993, BIOCHIM BIOPHYS ACTA, V1144, P235, DOI 10.1016/0005-2728(93)90108-R; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; Okuyama E, 1998, BBA-PROTEIN STRUCT M, V1383, P269, DOI 10.1016/S0167-4838(97)00216-1; ORMEJOHN.NR, 1971, BIOCHEM BIOPH RES CO, V45, P871, DOI 10.1016/0006-291X(71)90419-0; PERIN MS, 1988, EMBO J, V7, P2697, DOI 10.1002/j.1460-2075.1988.tb03123.x; SALERNO JC, 1984, J BIOL CHEM, V259, P2331; SKOTLAND T, 1980, BIOCHIM BIOPHYS ACTA, V630, P30, DOI 10.1016/0304-4165(80)90134-8; SRIVASTAVA M, 1994, BIOCHEM J, V303, P915, DOI 10.1042/bj3030915; SUZUKI S, 1994, J AM CHEM SOC, V116, P11145, DOI 10.1021/ja00103a035; Suzuki S, 1997, J BIOL INORG CHEM, V2, P265, DOI 10.1007/s007750050132; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; Tsubaki M, 1997, J BIOL CHEM, V272, P23206, DOI 10.1074/jbc.272.37.23206; WAKEFIELD LM, 1984, J BIOCHEM BIOPH METH, V9, P331, DOI 10.1016/0165-022X(84)90017-4; WAKEFIELD LM, 1982, FED PROC, V41, P839	34	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16038	16042		10.1074/jbc.273.26.16038	http://dx.doi.org/10.1074/jbc.273.26.16038			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632654	hybrid			2022-12-25	WOS:000074436600025
J	Kuhlbrodt, K; Herbarth, B; Sock, E; Enderich, J; Hermans-Borgmeyer, I; Wegner, M				Kuhlbrodt, K; Herbarth, B; Sock, E; Enderich, J; Hermans-Borgmeyer, I; Wegner, M			Cooperative function of POU proteins and SOX proteins in glial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SCIP; DNA-BINDING; JC VIRUS; NUCLEOPROTEIN STRUCTURES; SCHWANN-CELLS; HMG DOMAIN; EXPRESSION; GENE; DIFFERENTIATION; ELEMENTS	Glial cells of the oligodendrocyte lineage express several highly related POU proteins including Tst-1/Oct6/ SCIP and Brn-1. Tst-1/Oct6/SCIP, but not Brn-1 efficiently cooperated with Sox10, the only SRY box protein so far identified in oligodendrocytes, Here we show that, in addition to Sox10, cells of the oligodendrocyte lineage contain significant amounts of the related SRY box proteins Sox4 and Sox11. During development, Sox11 was strongly expressed in the central nervous system. It was first detected in neural precursors throughout the neuroepithelium, During later stages of neural development, Sox11 was additionally expressed in areas of the brain in which neurons undergo differentiation. In agreement with its expression in neural precursors, Sox11 levels in cells of the oligodendrocyte lineage were high in precursors and down-regulated during terminal differentiation. Outside the nervous system, expression of Sox11 was also detected in the developing limbs, face, and kidneys, Structure function analysis revealed that Sox11 has a strong intrinsic transactivation capacity which is mediated by a transactivation domain in its carboxyl-terminal part. In addition, Sox11 efficiently synergized with Brn-1. Synergy was dependent on binding of both proteins to adjacent DNA elements, and required the presence of the respective transactivation domain in each protein. Our data suggest the existence of a specific code in which POU proteins require specific Sox proteins to exhibit cooperative effects in glial cells.	Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Wegner, M (corresponding author), ZMNH, Martinistr 52, D-20246 Hamburg, Germany.	wegner@plexus.uke.uni-hamburg.de		Sock, Elisabeth/0000-0001-9925-3136; Wegner, Michael/0000-0002-4586-3294				Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; COLLARINI EJ, 1992, DEVELOPMENT, V116, P193; CONNER F, 1994, NUCLEIC ACIDS RES, V22, P3339, DOI 10.1093/nar/22.16.3339; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Hargrave M, 1997, DEV DYNAM, V210, P79, DOI 10.1002/(SICI)1097-0177(199710)210:2<79::AID-AJA1>3.0.CO;2-6; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; Jay P, 1997, HUM MOL GENET, V6, P1069, DOI 10.1093/hmg/6.7.1069; JAY P, 1995, GENOMICS, V29, P541, DOI 10.1006/geno.1995.9970; KAMACHI Y, 1995, EMBO J, V14, P3510, DOI 10.1002/j.1460-2075.1995.tb07357.x; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEIJER D, 1992, NUCLEIC ACIDS RES, V20, P2241, DOI 10.1093/nar/20.9.2241; Miyata S, 1996, BBA-GENE STRUCT EXPR, V1308, P23, DOI 10.1016/0167-4781(96)00091-7; MONUKI ES, 1993, P NATL ACAD SCI USA, V90, P9978, DOI 10.1073/pnas.90.21.9978; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; PORTER S, 1986, J NEUROSCI, V6, P3070; Prior HM, 1996, MOL MED, V2, P405, DOI 10.1007/BF03401900; RENNER K, 1994, P NATL ACAD SCI USA, V91, P6433, DOI 10.1073/pnas.91.14.6433; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Schreiber J, 1997, P NATL ACAD SCI USA, V94, P4739, DOI 10.1073/pnas.94.9.4739; Schreiber J, 1997, J BIOL CHEM, V272, P32286, DOI 10.1074/jbc.272.51.32286; Sock E, 1996, J VIROL, V70, P1512, DOI 10.1128/JVI.70.3.1512-1520.1996; Sock E, 1997, J NEUROCHEM, V68, P1911; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; WEGNER M, 1993, P NATL ACAD SCI USA, V90, P4743, DOI 10.1073/pnas.90.10.4743; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	41	185	192	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16050	16057		10.1074/jbc.273.26.16050	http://dx.doi.org/10.1074/jbc.273.26.16050			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632656	hybrid			2022-12-25	WOS:000074436600027
J	Mora-Garcia, S; Rodriguez-Suarez, R; Wolosiuk, RA				Mora-Garcia, S; Rodriguez-Suarez, R; Wolosiuk, RA			Role of electrostatic interactions on the affinity of thioredoxin for target proteins - Recognition of chloroplast fructose-1,6-bisphosphatase by mutant Escherichia coli thioredoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; ACTIVATION; REDUCTASE; RESOLUTION; RESIDUES; MUTATION; IDENTIFICATION; RIBONUCLEASE; STIMULATION	Chloroplast thioredoxin-f functions efficiently in the light-dependent activation of chloroplast fructose-1,6-bisphosphatase by reducing a specific disulfide bond located at the negatively charged domain of the enzyme. Around the nucleophile cysteine of the active site (-W-C-G-P-C-), chloroplast thioredoxin-f shows lower density of negative charges than the inefficient modulator Escherichia coli thioredoxin, To examine the contribution of long range electrostatic interactions to the thiol/disulfide exchange between protein-disulfide oxidoreductases and target proteins, we constructed three variants off. coli thioredoxin in which an acidic (Glu-30) and a neutral residue (Leu-94) were replaced by lysines, After purification to homogeneity, the reduction of the unique disulfide bond by NADPH via NADP-thioredoxin reductase proceeded at similar rates for all variants. However, the conversion of cysteine residues back to cystine depended on the target protein. Insulin and difluoresceinthiocarbamyl-insulin oxidized the sulfhydryl groups of E30K and E30K/L94K mutants more effectively than those of wild type and L94K counterparts, Moreover, the affinity of E30g, L94R, and E30K/L94K E. coli thioredoxin for chloroplast fructose-1,6-bisphosphatase (A(0.5) = 9, 7, and 3 mu M, respectively) increased with the number of positive charges, and was higher than wild type thioredoxin (A(0.5)= 33 mu M), though still lower than that of thioredoxin-f (A(0.5) = 0.9 mu M). We also demonstrated that shielding of electrostatic interactions with high salt concentrations not only brings the A(0.5) for all bacterial variants to a limiting value of similar to 9 mu M but also increases the A,, of chloroplast thioredoxin-f, While negatively charged chloroplast fructose-1,6-bisphosphatase (pI = 4.9) readily interacted with mutant thioredoxins, the reduction rate of rapeseed napin (pI = 11.2) diminished with the number of novel lysine residues. These findings suggest that the electrostatic interactions between thioredoxin and (some of) its target proteins controls the formation of the binary noncovalent complex needed for the subsequent thiol/disulfide exchange.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Fdn Campomar,Consejo Nacl Invest Cient & Tecn, Inst Invest Bioquim, RA-1405 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; University of Buenos Aires	Wolosiuk, RA (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Fdn Campomar,Consejo Nacl Invest Cient & Tecn, Inst Invest Bioquim, Antonio Machado 151, RA-1405 Buenos Aires, DF, Argentina.	rwolo@iris.iib.uba.ar						BALLICORA MA, 1994, EUR J BIOCHEM, V222, P467, DOI 10.1111/j.1432-1033.1994.tb18887.x; Ballicora MA, 1998, CELL MOL BIOL, V44, P431; BRANDES HK, 1993, J BIOL CHEM, V268, P18411; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CORLEY E, 1983, BIOCHEM BIOPH RES CO, V115, P707, DOI 10.1016/S0006-291X(83)80202-2; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; DELAMOTTEGUERY F, 1991, EUR J BIOCHEM, V196, P287; DROUX M, 1988, CR HEBD ACAD SCI, V305, P335; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ERICSON ML, 1986, J BIOL CHEM, V261, P4576; Geck RK, 1996, J BIOL CHEM, V271, P24736, DOI 10.1074/jbc.271.40.24736; GENOVESIOTAVERNE JC, 1991, J MOL BIOL, V222, P459, DOI 10.1016/0022-2836(91)90488-R; GLEASON FK, 1992, PROTEIN SCI, V1, P609, DOI 10.1002/pro.5560010507; HABERLEIN I, 1995, BBA-PROTEIN STRUCT M, V1253, P169, DOI 10.1016/0167-4838(95)00153-1; HARTMAN H, 1990, MOL BIOL EVOL, V7, P247; HERTIG CM, 1983, J BIOL CHEM, V258, P984; Heuck AP, 1997, J BIOCHEM BIOPH METH, V34, P213, DOI 10.1016/S0165-022X(97)00014-6; Heuck AP, 1997, ANAL BIOCHEM, V248, P94, DOI 10.1006/abio.1997.2123; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HUBER HE, 1986, J BIOL CHEM, V261, P5006; Jacquot JP, 1997, FEBS LETT, V401, P143, DOI 10.1016/S0014-5793(96)01459-7; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; Jaramillo JL, 1997, PLANT PHYSIOL, V114, P1169, DOI 10.1104/pp.114.4.1169; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KALLIS GB, 1980, J BIOL CHEM, V255, P261; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Moore DD, 1995, GLOB MOB SURV; MOORE EC, 1964, J BIOL CHEM, V239, P3453; MoraGarcia S, 1996, FEBS LETT, V380, P123, DOI 10.1016/0014-5793(96)00022-1; MULLER EGD, 1995, ARCH BIOCHEM BIOPHYS, V318, P356, DOI 10.1006/abbi.1995.1240; NAVARRO JA, 1991, BIOCHEMISTRY-US, V30, P2192, DOI 10.1021/bi00222a024; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OBLONG JE, 1995, BIOCHEMISTRY-US, V34, P3319, DOI 10.1021/bi00010a022; PADROS E, 1982, EUR J BIOCHEM, V127, P117, DOI 10.1111/j.1432-1033.1982.tb06844.x; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; POWIS G, 1994, ONCOL RES, V6, P539; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; REUTIMANN H, 1981, J BIOL CHEM, V256, P6796; RIVERAMADRID R, 1995, P NATL ACAD SCI USA, V92, P5620, DOI 10.1073/pnas.92.12.5620; RodriguezSuarez RJ, 1997, BIOCHEM BIOPH RES CO, V232, P388, DOI 10.1006/bbrc.1997.6242; SAARINEN M, 1995, STRUCTURE, V3, P1097, DOI 10.1016/S0969-2126(01)00245-3; SALAMON Z, 1992, ARCH BIOCHEM BIOPHYS, V299, P193, DOI 10.1016/0003-9861(92)90262-U; SAMBROOK JE, 1989, MOL CLONING LB MANUA; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; SCHURMANN P, 1995, METHOD ENZYMOL, V252, P274; SCHURMANN P, 1985, PHYSIOL VEG, V23, P813; SCHURMANN P, 1993, SULFUR NUTRITION AND ASSIMILATION IN HIGHER PLANTS, P153; Schwarz O, 1997, J BIOL CHEM, V272, P16924, DOI 10.1074/jbc.272.27.16924; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; STEIN M, 1987, J BIOL CHEM, V262, P16171; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VILLERET V, 1995, BIOCHEMISTRY-US, V34, P4299, DOI 10.1021/bi00013a019; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; WILLIAMS CH, 1995, FASEB J, V9, P1267, DOI 10.1096/fasebj.9.13.7557016; WOLOSIUK RA, 1979, J BIOL CHEM, V254, P1627; WOLOSIUK RA, 1993, FASEB J, V7, P622, DOI 10.1096/fasebj.7.8.8500687	61	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16273	16280		10.1074/jbc.273.26.16273	http://dx.doi.org/10.1074/jbc.273.26.16273			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632687	hybrid			2022-12-25	WOS:000074436600058
J	Pappas, A; Yang, WL; Park, TS; Carman, GM				Pappas, A; Yang, WL; Park, TS; Carman, GM			Nucleotide-dependent tetramerization of CTP synthetase from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CYTIDINE 5'-TRIPHOSPHATE; URA7 GENE; PHOSPHORYLATION; MECHANISM; OLIGOMERIZATION; BIOSYNTHESIS; INHIBITION; MUTANTS; TUMORS	The nucleotide-dependent tetramerization of purified native URA7-encoded CTP synthetase (EC 6.3,4.2, UTP: ammonia ligase (ADP-forming)) from the yeast Saccharomyces cerevisiae was characterized. CTP synthetase existed as a dimer in the absence of ATP and UTP. In the presence of saturating concentrations of ATP and UTP, the CTP synthetase protein existed as a tetramer. Increasing concentrations of ATP and UTP caused a dose-dependent conversion of the dimeric species to a tetramer, The kinetics of enzyme tetramerization correlates with the kinetics of enzyme activity. The tetramerization of CTP synthetase was dependent on UTP and Mg2+ ions. ATP facilitated the UTP-dependent tetramerization of CTP synthetase by a mechanism that involved the ATP-dependent phosphorylation of UTP catalyzed by the enzyme. The glutaminase reaction that is catalyzed by the enzyme was not required for enzyme tetramerization. CTP, a potent inhibitor of CTP synthetase activity, did not inhibit the ATP/UTP-dependent tetramerization of the enzyme. Phosphorylation of the purified native CTP synthetase with protein kinase A and protein kinase C facilitated the nucleotide-dependent tetramerization. Dephosphorylation of native CTP synthetase with alkaline phosphatase prevented the nucleotide-dependent tetramerization of the enzyme. This correlated with the inactivation of CTP synthetase activity, Rephosphorylation of the dephosphorylated enzyme with protein kinase A and protein kinase C resulted in a partial restoration of the nucleotide-dependent tetramerization of the enzyme. This tetramerization correlated with the partial restoration of CTP synthetase activity. Taken together, these results indicated that enzyme tetramerization was required for CTP synthetase activity and that enzyme phosphorylation played an important role in the tetramerization and regulation of the enzyme.	Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.				NIGMS NIH HHS [GM-50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONOW B, 1987, J BIOL CHEM, V262, P5106; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BARFORD D, 1992, PROTEIN SCI, V1, P472; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUXEDA RJ, 1993, J BIOL CHEM, V268, P6248; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; DESAINTVINCENT BR, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; Hatch GM, 1996, J BIOL CHEM, V271, P25810, DOI 10.1074/jbc.271.42.25810; KIZAKI H, 1980, CANCER RES, V40, P3921; KOSHLAND DE, 1974, ENZYMES, P539; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LIBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; MEUTH M, 1979, P NATL ACAD SCI USA, V76, P6505, DOI 10.1073/pnas.76.12.6505; MONTENARH M, 1987, FEBS LETT, V221, P199, DOI 10.1016/0014-5793(87)80925-0; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBERTSON JG, 1993, BIOCHEMISTRY-US, V32, P3769, DOI 10.1021/bi00065a032; Segel IH, 1975, ENZYME KINETICS BEHA; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TRAUT TW, 1994, CRIT REV BIOCHEM MOL, V29, P125, DOI 10.3109/10409239409086799; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; VONDERSAAL W, 1985, J BIOL CHEM, V260, P4993; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; WEBER G, 1979, ADV ENZYME REGUL, V17, P1; Yang WL, 1996, J BIOL CHEM, V271, P28777, DOI 10.1074/jbc.271.46.28777; Yang WL, 1996, J BIOL CHEM, V271, P11113, DOI 10.1074/jbc.271.19.11113; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028; YANG WL, 1995, J BIOL CHEM, V270, P14983, DOI 10.1074/jbc.270.25.14983	39	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15954	15960		10.1074/jbc.273.26.15954	http://dx.doi.org/10.1074/jbc.273.26.15954			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632643	hybrid			2022-12-25	WOS:000074436600014
J	Fisher, DA; Smith, JF; Pillar, JS; St Denis, SH; Cheng, JB				Fisher, DA; Smith, JF; Pillar, JS; St Denis, SH; Cheng, JB			Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; CAMP-SPECIFIC PHOSPHODIESTERASE; MOLECULAR-CLONING; MESSENGER-RNA; CDNA; EXPRESSION; PROTEIN; BINDING; ROLIPRAM; DOMAIN	We have cloned and characterized the first human isozyme in a new family of cyclic nucleotide phosphodiesterases, PDE9A. By sequence homology in the catalytic domain, PDE9A is almost equidistant from all eight known mammalian PDE families but is most similar to PDE8A (34% amino acid identity) and least like PDE5A (28% amino acid identity). We report the cloning of human cDNA encoding a full-length protein of 593 amino acids, including a 261-amino acid region located near the C terminus that is homologous to the similar to 270-amino acid catalytic domain of other PDEs, PDE9A is expressed in all eight tissues examined as a similar to 2.0-kilobase mRNA, with highest levels in spleen, small intestine, and brain. The full-length PDE9A was expressed in baculovirus fused to an N-terminal g-amino acid FLAG tag. Kinetic analysis of the baculovirus-expressed enzyme shows it to be a very high affinity cGMP-specific PDE with a K-m of 170 nM for cGMP and 230 mu M for cAMP. The K-m for cGMP makes PDESA one of the highest affinity PDEs known. The V-max for cGMP (4.9 nmol/min/mu g recombinant enzyme) is about twice as fast as that of PDE4 for cAMP. The enzyme is about twice as active in vitro in 1-10 mM Mn2+ than in the same concentration of Mg2+ Or Ca2+. PDESA is insensitive (up to 100 mu M) to a variety of PDE inhibitors including rolipram, vinpocetine, SKF-94120, dipyridamole, and 3-isobutyl-1-methyl xanthine but is inhibited (IC50 = 35 mu M) by zaprinast, a PDEB inhibitor. PDE9A lacks a region homologous to the allosteric cGMP-binding regulatory regions found in the cGMP-binding PDEs: PDE2, PDE5, and PDE6.	Pfizer Inc, Pfizer Cent Res, Dept Mol Sci, Groton, CT 06340 USA; Pfizer Inc, Pfizer Cent Res, Dept Canc Immunol & Infect Dis, Groton, CT 06340 USA	Pfizer; Pfizer	Fisher, DA (corresponding author), Pfizer Inc, Pfizer Cent Res, Dept Mol Sci, Groton, CT 06340 USA.	douglas_a_fisher@groton.pfizer.com						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; FRANCIS SH, 1994, J BIOL CHEM, V269, P22477; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GRENS A, 1990, J BIOL CHEM, V265, P11810; Kleinman EF, 1998, J MED CHEM, V41, P266, DOI 10.1021/jm970685m; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNZ D, 1992, J BIOL CHEM, V267, P9101; Loomis WF, 1997, J CELL SCI, V110, P1141; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MCLAUGHLIN MM, 1993, J BIOL CHEM, V268, P6470; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; PITTLER SJ, 1990, GENOMICS, V6, P272, DOI 10.1016/0888-7543(90)90567-E; Proudfoot N J, 1976, Prog Nucleic Acid Res Mol Biol, V19, P123; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEGEL IH, 1976, BIOCH CALCULATIONS, P233; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; Shaulsky G, 1996, P NATL ACAD SCI USA, V93, P15260, DOI 10.1073/pnas.93.26.15260; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; Thompson W J, 1974, Methods Enzymol, V38, P205; TRONG HL, 1990, BIOCHEMISTRY-US, V29, P10280, DOI 10.1021/bi00496a018	28	291	324	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15559	15564		10.1074/jbc.273.25.15559	http://dx.doi.org/10.1074/jbc.273.25.15559			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624146	hybrid			2022-12-25	WOS:000074284200040
J	Hesselgesser, J; Ng, HP; Liang, M; Zheng, W; May, K; Bauman, JG; Monahan, S; Islam, I; Wei, GP; Ghannam, A; Taub, DD; Rosser, M; Snider, RM; Morrissey, MM; Perez, HD; Horuk, R				Hesselgesser, J; Ng, HP; Liang, M; Zheng, W; May, K; Bauman, JG; Monahan, S; Islam, I; Wei, GP; Ghannam, A; Taub, DD; Rosser, M; Snider, RM; Morrissey, MM; Perez, HD; Horuk, R			Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPEPTIDE ANTAGONIST; GENERATION COMPOUNDS; EXPRESSION; RANTES; POTENT; ENCEPHALOMYELITIS; INTERLEUKIN-8; CHEMOTAXIS; CYTOKINES; PROTEINS	The CC chemokines macrophage inflammatory pro tein-1 alpha (MIP-1 alpha) and RANTES (regulated on activation normal T cell expressed) have been implicated in rheumatoid arthritis and multiple sclerosis, Since their effects are mediated through the CCR1 chemokine receptor, we set up a small molecule CCR1 antagonist program to search for inhibitors. Through high capacity screening we discovered a number of 4-hydroxypiperidine compounds with CCR1 antagonist activity and report their synthesis and in vitro pharmacology here. Scatchard analysis of the competition binding data revealed that the compounds had K-i values ranging from 40 to 4000 nM. The pharmacological profile of the most potent member of this series, compound 1 (2-2-diphenyl-5-(4-chlorophenyl)piperidin-lyl)valeronitrite), was further evaluated. Compound 1 showed concentration-dependent inhibition of MIP-1 alpha-induced extracellular acidification and Ca2+ mobilization demonstrating functional antagonism. When given alone, the compound did not elicit any responses, indicating the absence of intrinsic agonist activity. Compound 1 inhibited MIP-1 alpha- and RANTES-induced migration in peripheral blood mononuclear cells in a dose-responsive manner. Selectivity testing against a panel of seven transmembrane domain receptors indicated that compound 1 is inactive on a number of receptors at concentrations up to 10 mu M. This is the first description of CCR1 receptor antagonists that may be useful in the treatment of chronic inflammatory diseases involving MIP-1 alpha, RANTES, and CCR1.	Berlex BioSci, Dept Immunol, Richmond, CA 94806 USA; Berlex BioSci, Dept Pharmaceut Discovery, Richmond, CA 94806 USA; NIA, Natl Inst Hlth, Immunol Lab, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Horuk, R (corresponding author), Berlex BioSci, Dept Immunol, 15049 San Pablo Ave, Richmond, CA 94806 USA.		Zheng, Wei/J-8889-2014; Zheng, Wei/GOE-5990-2022	Zheng, Wei/0000-0003-1034-0757; 				AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1994, ADV EXP MED BIOL, V351, P1; CHANG RSL, 1985, SCIENCE, V230, P177, DOI 10.1126/science.2994227; CUSACK B, 1994, PSYCHOPHARMACOLOGY, V114, P559, DOI 10.1007/BF02244985; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; KARPUS WJ, 1995, J IMMUNOL, V155, P5003; KATO K, 1997, Patent No. 24325; Mackay CR, 1997, CURR BIOL, V7, pR384, DOI 10.1016/S0960-9822(06)00181-3; Mackay CR, 1996, J EXP MED, V184, P799, DOI 10.1084/jem.184.3.799; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; Richelson E, 1996, J CLIN PSYCHIAT, V57, P4; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SAWUTZ DG, 1994, P NATL ACAD SCI USA, V91, P4693, DOI 10.1073/pnas.91.11.4693; SCHALL TJ, 1994, CYTOKINE HDB, P419; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; SNOWDEN N, 1994, LANCET, V343, P547, DOI 10.1016/S0140-6736(94)91503-2; TAUB DD, 1995, J IMMUNOL METHODS, V184, P187, DOI 10.1016/0022-1759(95)00087-Q; VADDI K, 1994, J LEUKOCYTE BIOL, V55, P756, DOI 10.1002/jlb.55.6.756	29	123	184	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15687	15692		10.1074/jbc.273.25.15687	http://dx.doi.org/10.1074/jbc.273.25.15687			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624164	hybrid			2022-12-25	WOS:000074284200058
J	Kyritsis, P; Hatzfeld, OM; Link, TA; Moulis, JM				Kyritsis, P; Hatzfeld, OM; Link, TA; Moulis, JM			The two [4Fe-4S] clusters in Chromatium vinosum ferredoxin have largely different reduction potentials - Structural origin and functional consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEINS; CLOSTRIDIUM-PASTEURIANUM FERREDOXIN; MAGNETIC CIRCULAR-DICHROISM; DIRECT ELECTRON-TRANSFER; GLASSY-CARBON ELECTRODE; 2<4FE-4S> FERREDOXIN; AZOTOBACTER-VINELANDII; ESCHERICHIA-COLI; REDOX POTENTIALS; SPECTROSCOPIC CHARACTERIZATION	The 2[4Fe-4S] ferredoxin from Chromatium vinosum arises as one prominent member of a recently defined family of proteins found in very diverse bacteria. The potentiometric circular dichroism titrations of the protein and of several molecular variants generated by site-directed mutagenesis have established that; the reduction potentials of the two clusters differ widely by almost 200 mV. This large difference has been confirmed by electrochemical methods, and each redox transition has been assigned to one of the clusters. The unusually Bow potential center is surprisingly the one that displays a conventional (CXXCXXC)-X-1-C-2-X-3-C-4 (X-n, variable amino acid) binding motif and a structural environment similar to that of clusters having less negative potentials. A comparison with other ferredoxins has highlighted factors contributing to the reduction potential of [4Fe-4S] clusters in proteins. (i) The loop between the coordinating cysteines 40 and 49 and the e terminus alpha-helix of C. vinosum ferredoxin cause a negative, but relatively moderate, shift of similar to 60 mV for the nearby cluster. (ii) Very negative potentials, below -600 mV, correlate with the presence of a bulky side chain in position X-4 of the coordinating triad of cysteines. These findings set the B?framework in which previous observations on ferredoxins can be better understood. They also shed light onto thee possible occurrence and properties of very low potential [4Fe-4S] clusters in less well characterized proteins.	CEA, DBMS, MEP, Lab Metalloprot, F-38054 Grenoble 9, France; Univ Frankfurt Klinikum, Inst Biochem 1, ZBC, D-60590 Frankfurt, Germany	CEA; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Moulis, JM (corresponding author), CEA, DBMS, MEP, Lab Metalloprot, 17 Rue Martyrs, F-38054 Grenoble 9, France.	jean-marc.moulis@cea.fr	Kyritsis, Panayotis/M-8222-2013	Kyritsis, Panayotis/0000-0002-3908-4649; Moulis, Jean-Marc/0000-0001-5615-9852				ALBRACHT PJA, 1997, BIOCHIM BIOPHYS ACTA, V1318, P92; ARMENGAUD J, 1994, THESIS U J FOURIER G; ARMSTRONG FA, 1987, J ELECTROANAL CHEM, V217, P331, DOI 10.1016/0022-0728(87)80228-0; ARMSTRONG FA, 1989, BIOCHEM J, V264, P265, DOI 10.1042/bj2640265; BACHOFEN R, 1966, BIOCHIM BIOPHYS ACTA, V120, P259, DOI 10.1016/0926-6585(66)90345-1; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; Brettel K, 1997, BBA-BIOENERGETICS, V1318, P322, DOI 10.1016/S0005-2728(96)00112-0; CAMMACK R, 1990, BIOCHEMISTRY-US, V29, P8410, DOI 10.1021/bi00488a030; DAAS PJH, 1994, FEBS LETT, V356, P342, DOI 10.1016/0014-5793(94)01313-6; Dauter Z, 1997, BIOCHEMISTRY-US, V36, P16065, DOI 10.1021/bi972155y; DAVASSE V, 1992, BIOCHEM BIOPH RES CO, V185, P341, DOI 10.1016/S0006-291X(05)80991-X; DUEE ED, 1994, J MOL BIOL, V243, P683, DOI 10.1016/0022-2836(94)90041-8; EVANS MCW, 1966, P NATL ACAD SCI USA, V55, P928, DOI 10.1073/pnas.55.4.928; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P5514, DOI 10.1074/jbc.273.10.5514; GEORGE SJ, 1991, NEW J CHEM, V15, P455; GUIGLIARELLI B, 1992, EUR J BIOCHEM, V207, P61, DOI 10.1111/j.1432-1033.1992.tb17020.x; HAGEN WR, 1989, EUR J BIOCHEM, V182, P523, DOI 10.1111/j.1432-1033.1989.tb14859.x; HEERING HA, 1995, BIOCHEMISTRY-US, V34, P14675, DOI 10.1021/bi00045a008; HUBER JG, 1995, BIOCHEMISTRY-US, V34, P194, DOI 10.1021/bi00001a024; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; JENSEN GM, 1994, BIOCHEMISTRY-US, V33, P10911, DOI 10.1021/bi00202a010; KE B, 1974, ARCH BIOCHEM BIOPHYS, V162, P301, DOI 10.1016/0003-9861(74)90129-5; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; LAMBETH DO, 1973, J BIOL CHEM, V248, P6095; Lanzilotta WN, 1997, BIOCHEMISTRY-US, V36, P12976, DOI 10.1021/bi9715371; Link TA, 1996, BIOCHEMISTRY-US, V35, P7546, DOI 10.1021/bi960004+; Macedo AL, 1996, BIOCHEM BIOPH RES CO, V229, P524, DOI 10.1006/bbrc.1996.1837; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; Mauk AG, 1997, J BIOL INORG CHEM, V2, P119, DOI 10.1007/s007750050115; MEYER J, 1994, BIOCHEMISTRY-US, V33, P13642, DOI 10.1021/bi00250a014; MOULIS JM, 1984, BIOCHEMISTRY-US, V23, P6605, DOI 10.1021/bi00321a050; MOULIS JM, 1982, BIOCHEMISTRY-US, V21, P4762, DOI 10.1021/bi00262a037; Moulis JM, 1996, PROTEIN SCI, V5, P1765, DOI 10.1002/pro.5560050902; Moulis JM, 1996, BBA-GENE STRUCT EXPR, V1308, P12, DOI 10.1016/0167-4781(96)00082-6; Moulis JM, 1995, BIOCHEMISTRY-US, V34, P16781, DOI 10.1021/bi00051a028; MOULIS JM, 1994, BIOMETALS, V7, P272, DOI 10.1007/BF00144121; NICHOLSON RS, 1965, ANAL CHEM, V37, P1351, DOI 10.1021/ac60230a016; OTAKA E, 1987, J MOL EVOL, V26, P257, DOI 10.1007/BF02099857; PISZKIEWICZ D, 1981, BIOCHEMISTRY-US, V20, P363, DOI 10.1021/bi00505a021; QUINKAL I, 1994, PROTEIN ENG, V7, P681, DOI 10.1093/protein/7.5.681; Quinkal I, 1996, BBA-PROTEIN STRUCT M, V1295, P201, DOI 10.1016/0167-4838(96)00042-8; Saeki K, 1996, J BIOL CHEM, V271, P31399, DOI 10.1074/jbc.271.49.31399; SALMON RT, 1980, J ELECTROANAL CHEM, V112, P253, DOI 10.1016/S0022-0728(80)80407-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN BH, 1994, J BIOL CHEM, V269, P8564; SMITH ET, 1990, J BIOL CHEM, V265, P14371; STEPHENS PJ, 1978, BIOCHEMISTRY-US, V17, P4770, DOI 10.1021/bi00615a026; Stephens PJ, 1996, CHEM REV, V96, P2491, DOI 10.1021/cr950045w; STOMBAUGH NA, 1976, BIOCHEMISTRY-US, V15, P2633, DOI 10.1021/bi00657a024; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; SWEENEY WV, 1980, ANNU REV BIOCHEM, V49, P139, DOI 10.1146/annurev.bi.49.070180.001035; TABOR S, 1990, CURRENT PROTOCOLS MO; VANDIJK C, 1984, FEBS LETT, V166, P76, DOI 10.1016/0014-5793(84)80048-4; VOLLMER SJ, 1983, J BIOL CHEM, V258, P4284; Warshel A, 1997, J BIOL INORG CHEM, V2, P143, DOI 10.1007/s007750050119	57	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15404	15411		10.1074/jbc.273.25.15404	http://dx.doi.org/10.1074/jbc.273.25.15404			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624123	hybrid			2022-12-25	WOS:000074284200017
J	Potter, LR; Hunter, T				Potter, LR; Hunter, T			Identification and characterization of the major phosphorylation sites of the B-type natriuretic peptide receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION ACTIVITIES; GUANYLYL CYCLASE RECEPTORS; ATP-REGULATORY MODULE; LIGAND-BINDING; ATRIAL; ACTIVATION; FAMILY; EXPRESSION; DEPHOSPHORYLATION; DESENSITIZATION	C-type natriuretic peptide (CNP) is a newly discovered factor that stimulates vasorelaxation and inhibits cell proliferation. Natriuretic peptide receptor-B (NPR-B) is the primary signaling molecule for CNP. Recently, the guanylyl cyclase activity of NPR-B was shown to correlate with its phosphorylation state, and it was suggested that receptor dephosphorylation is a mechanism of desensitization. We now report the identification and characterization of the major NPR-B phosphorylation sites. Mutagenesis and comigration studies using synthetic phosphopeptides were employed to identify five residues (Ser-513, Thr-516, Ser-518, Ser-523, and Ser-526) within the kinase homology domain that are phosphorylated when NPR-B is expressed in human 293 cells. Mutation of any of these residues to alanine reduced the receptor's phosphorylation state and CNP-dependent guanylyl cyclase activity. The reductions were not explained by decreases in receptor protein level as indicated by immunoblot analysis and determinations of cyclase activity in the absence of CNP or in the presence of detergent. Elimination of all of the phosphorylation sites resulted in a completely dephosphorylated receptor whose CNP-dependent cyclase activity was decreased by >90%. However, unlike NPR-A, the dephosphorylated receptor was not completely unresponsive to hormone. Finally, two additional residues (Gly-521 and Ser-522) were identified that when mutated to alanine reduced the overall phosphorylation state and hormone responsiveness of the receptor without abolishing the phosphorylation of a specific site. These data indicate that phosphorylation of the kinase homology domain is a critical event in the regulation of NPR-B.	Salk Inst Biol Studies, Mol Biol & Virol Lab, San Diego, CA 92186 USA	Salk Institute	Potter, LR (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, POB 85800, San Diego, CA 92186 USA.	potter@salk.edu			NCI NIH HHS [CA14195, F32 CA067452, CA39780, CA-67452] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA067452, R35CA039780, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPEL RG, 1992, AM J PHYSIOL, V262, pF911, DOI 10.1152/ajprenal.1992.262.6.F911; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; Brown J, 1997, AM J PHYSIOL-HEART C, V272, pH2919, DOI 10.1152/ajpheart.1997.272.6.H2919; CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; DUDA T, 1995, BIOCHEM BIOPH RES CO, V209, P286, DOI 10.1006/bbrc.1995.1501; DUDA T, 1993, FEBS LETT, V315, P143, DOI 10.1016/0014-5793(93)81151-O; Duda T, 1995, MOL CELL BIOCHEM, V152, P179, DOI 10.1007/BF01076081; FENRICK R, 1994, MOL CELL BIOCHEM, V137, P173, DOI 10.1007/BF00944079; FURUYA M, 1995, ANN NY ACAD SCI, V748, P517; FURUYA M, 1991, BIOCHEM BIOPH RES CO, V177, P927, DOI 10.1016/0006-291X(91)90627-J; GARBERS DL, 1994, MOL BIOL CELL, V5, P1; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GORACZNIAK RM, 1992, BIOCHEM J, V282, P533, DOI 10.1042/bj2820533; HAGIWARA H, 1994, J BIOL CHEM, V269, P10729; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KATAFUCHI T, 1994, EUR J BIOCHEM, V222, P835, DOI 10.1111/j.1432-1033.1994.tb18930.x; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MCDOWELL G, 1995, EUR J CLIN INVEST, V25, P291, DOI 10.1111/j.1365-2362.1995.tb01704.x; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; POTTER LR, 1992, J BIOL CHEM, V267, P14531; Potter LR, 1998, BIOCHEMISTRY-US, V37, P2422, DOI 10.1021/bi972303k; POTTER LR, 1994, J BIOL CHEM, V269, P14636; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; Ueno H, 1997, CIRCULATION, V96, P2272; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025	40	99	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15533	15539		10.1074/jbc.273.25.15533	http://dx.doi.org/10.1074/jbc.273.25.15533			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624142	hybrid			2022-12-25	WOS:000074284200036
J	Yamauchi, T; Kaburagi, Y; Ueki, K; Tsuji, Y; Stark, GR; Kerr, IM; Tsushima, T; Akanuma, Y; Komuro, I; Tobe, K; Yazaki, Y; Kadowaki, T				Yamauchi, T; Kaburagi, Y; Ueki, K; Tsuji, Y; Stark, GR; Kerr, IM; Tsushima, T; Akanuma, Y; Komuro, I; Tobe, K; Yazaki, Y; Kadowaki, T			Growth hormone and prolactin stimulate tyrosine phosphorylation of insulin receptor substrate-1, -2, and -3, their association with p85 phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly PI3-kinase activation via JAK2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOCYTES; INHIBITOR WORTMANNIN; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; PROTEIN; IRS-1; CELLS; MICE; SHC; IDENTIFICATION	Growth hormone (GH) and prolactin (PRL) binding to their receptors, which belong to the cytokine receptor superfamily, activate Janus kinase (JAK) 2 tyrosine kinase, thereby leading to their biological actions. We recently showed that GH mainly stimulated tyrosine phosphorylation of epidermal growth factor receptor and its association with Grb2, and concomitantly stimulated mitogen-activated protein kinase activity in liver, a major target tissue. Using specific antibodies, we now show that GH was also able to induce tyrosine phosphorylation of insulin receptor substrate (IRS)-1/IRS-8 in liver. In addition, the major tyrosine-phosphorylated protein in anti-p85 phosphatidylinositol 3-kinase (PI3-kinase) immunoprecipitate from liver of wild-type mice was IRS-l, and IRS-2 in IRS-1 deficient mice, but not epidermal growth factor receptor. These data suggest that tyrosine phosphorylation of IRS-1 may be a major mechanism for GH-induced PIS-kinase activation in physiological target organ of GH, liver. We also show that PRL was able to induce tyrosine phosphorylation of both IRS-1 and IRS-2 in COS cells transiently transfected with PRLR and in CHO-PRLR cells. Moreover, we show that tyrosine phosphorylation of IRS-3 was induced by both GH and PRL in COS cells transiently transfected with IRS-3 and their cognate receptors. By using the JAK2-deficient cell lines or by expressing a dominant negative JAK2 mutant, we show that JAK2 is required for the GH-and PRL-dependent tyrosine phosphorylation of IRS-1, -2, and -3, Finally, a specific PI3-kinase inhibitor, wortmannin, completely blocked the anti-lipolytic effect of GH in 3T3 L1 adipocytes. Taken together, the role of IRS-1, -2, and -3 in GH and PRL signalings appears to be phosphorylated by JAK2, thereby providing docking sites for p85 PI3-kinase and activating PI3-kinase and its downstream biological effects.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 1130033, Japan; Cleveland Clin Fdn, Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Imperial Canc Res Fund, London WC2A 3PX, England; Tokyo Womens Med Coll, Dept Internal Med 2, Tokyo 162, Japan; Adahi Life Fdn, Inst Diabet Care & Res, Tokyo 100, Japan	University of Tokyo; Cleveland Clinic Foundation; Cancer Research UK; Tokyo Women's Medical University	Kadowaki, T (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.							ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Berlanga JJ, 1997, J BIOL CHEM, V272, P2050; BIRNBAUM RS, 1976, ENDOCRINOLOGY, V99, P1336, DOI 10.1210/endo-99-5-1336; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; HONEYMAN TW, 1980, AM J PHYSIOL, V238, P389; KABURAGI Y, 1995, ENDOCRINOLOGY, V136, P3437, DOI 10.1210/en.136.8.3437; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; KADOWAKI T, 1996, ENDOCR J, V43, P33; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; NICOLL CS, 1985, PROLACTIN BASIC CLIN, P393; OKADA T, 1994, J BIOL CHEM, V269, P3568; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; RIDDERSTRALE M, 1994, BIOCHEM BIOPH RES CO, V203, P306, DOI 10.1006/bbrc.1994.2182; ROUPAS P, 1994, TRENDS ENDOCRIN MET, V5, P154, DOI 10.1016/1043-2760(94)90012-4; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUI H, 1994, J BIOL CHEM, V269, P5364; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WHITE MF, 1994, J BIOL CHEM, V268, P1; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	48	147	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15719	15726		10.1074/jbc.273.25.15719	http://dx.doi.org/10.1074/jbc.273.25.15719			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624169	hybrid			2022-12-25	WOS:000074284200063
J	Zhuang, JG; Ren, Y; Snowden, RT; Zhu, HJ; Gogvadze, V; Savill, JS; Cohen, GM				Zhuang, JG; Ren, Y; Snowden, RT; Zhu, HJ; Gogvadze, V; Savill, JS; Cohen, GM			Dissociation of phagocyte recognition of cells undergoing apoptosis from other features of the apoptotic program	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICE/CED-3 PROTEASE; POLY(ADP-RIBOSE) POLYMERASE; PHOSPHATIDYLSERINE EXPOSURE; VITRONECTIN RECEPTOR; ICE FAMILY; CLEAVAGE; MITOCHONDRIAL; DNA; FRAGMENTATION; LYMPHOCYTES	Apoptosis is a programmed form of cell death characterized by biochemical and morphological changes affecting the nucleus, cytoplasm, and plasma membrane. These changes in various cellular compartments are widely regarded as mechanistically linked events in a single "program" in which activation of caspases and proteolysis of intracellular substrates represent a final common pathway leading to cell death. To date there has been very limited exploration of the linkage of this program to the plasma membrane changes, which bring about swift recognition, uptake, and safe degradation of apoptotic cells by phagocytes. Using the mitochondrial inhibitors antimycin A and oligomycin in human monocytic THP.1 cells triggered into apoptosis, we report the uncoupling of plasma membrane changes from other features of apoptosis. These inhibitors blocked increased plasma membrane permeability, externalization of phosphatidylserine, and recognition by two classes of phagocytes but not activation of caspase-3, cleavage of poly(ADP-ribose) polymerase and DNA fragmentation. Externalization of phosphatidylserine in apoptotic human leukemic U937 cells was also dissociated from caspase activation. Thus changes governing safe clearance of apoptotic cells may be regulated by an independent pathway to those bringing about caspase activation. This finding could have important consequences for attempts to manipulate cell death for therapeutic gain in vivo.	Univ Leicester, Ctr Mechanisms Human Toxic, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Univ Nottingham Hosp, Dept Med, Div Renal & Inflammatory Dis, Nottingham NG7 2UH, England	University of Leicester; University of Nottingham	Cohen, GM (corresponding author), Univ Leicester, Ctr Mechanisms Human Toxic, MRC, Toxicol Unit, POB 138,Lancaster Rd,Hodgkin Bldg, Leicester LE1 9HN, Leics, England.	gmc2@le.ac.uk	Cohen, Gerald M/A-1687-2008; Gogvadze, Vladimir/A-4392-2014	Zhuang, Jianguo/0000-0003-3245-0789				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BICKNELL GR, 1994, J CELL SCI, V107, P2483; BROWN DG, 1993, J BIOL CHEM, V268, P3037; Castedo M, 1996, J IMMUNOL, V157, P512; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LIU X, 1996, CELL, V86, P1331; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; NICHOLLS DG, 1992, BIOENERGETICS, V2, P132; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ORMEROD MG, 1993, CYTOMETRY, V14, P595, DOI 10.1002/cyto.990140603; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V; Zhu HJ, 1997, CELL DEATH DIFFER, V4, P590, DOI 10.1038/sj.cdd.4400284	36	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15628	15632		10.1074/jbc.273.25.15628	http://dx.doi.org/10.1074/jbc.273.25.15628			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624155	hybrid			2022-12-25	WOS:000074284200049
J	Bouck, J; Fu, XD; Skalka, AM; Katz, RA				Bouck, J; Fu, XD; Skalka, AM; Katz, RA			Role of the constitutive splicing factors U2AF(65) and SAP49 in suboptimal RNA splicing of novel retroviral mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; POLYPYRIMIDINE TRACT; BRANCH POINT; SPLICEOSOME; SEQUENCE; ENHANCER; PROTEINS; SITE; IDENTIFICATION; COMPLEX	Retroviruses display a unique form of alternative splicing in which both spliced and unspliced RNAs accumulate in the cytoplasm, Simple retroviruses, such as avian sarcoma virus, do not encode regulatory proteins that affect splicing; this process is controlled solely through interactions between the viral RNA and the host cell splicing machinery. Previously, we described the selection and characterization of novel avian sarcoma virus mutants. These viruses were separated into two classes based upon analysis of splicing intermediates produced in infected cells and in a cell-free system. One class, which included mutants with altered polypyrimidine tract or branch point sequences, showed significant accumulation of intermediates, suggesting that splicing was regulated in step 2, The other class, which included mutants with deletions of exonic enhancer sequences, did not accumulate splicing intermediates, suggesting that splicing was regulated before step 1 of the splicing reaction. In this report, we show that a mutant blocked at step 1 fails to form a stable spliceosomal complex, whereas one blocked at step 2 shows a defect in its ability to transit through the last spliceosomal complex. Using UV cross-linking methods, we show that regulation at each step is associated with specific changes in the binding of cellular splicing factors. Regulation at step 1 is correlated with decreased crosslinking of the factor U2AF(65), whereas regulation at step 2 is correlated with enhanced cross-linking of the factor SAP49, Because these mutations were isolated by selection for replication-competent viruses, we conclude that retroviral splicing may be regulated in vivo through altered binding of constitutive splicing factors.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA; Univ Penn, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; Univ Calif San Diego, Div Cellular & Mol Med, La Jolla, CA 92093 USA	Fox Chase Cancer Center; University of Pennsylvania; University of California System; University of California San Diego	Katz, RA (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	r_katz@retro2.fccc.edu			NATIONAL CANCER INSTITUTE [R35CA047486, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47486, CA-06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achsel T, 1996, J BIOCHEM, V120, P53; Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2; Ashiya M, 1997, RNA, V3, P996; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BOUCK J, 1995, MOL CELL BIOL, V15, P2663; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; CHAMPIONARNAUD P, 1994, GENE DEV, V8, P1974, DOI 10.1101/gad.8.16.1974; Chiara MD, 1996, MOL CELL BIOL, V16, P3317; Coolidge CJ, 1997, NUCLEIC ACIDS RES, V25, P888, DOI 10.1093/nar/25.4.888; FU XD, 1995, RNA, V1, P663; FU XD, 1991, GENE DEV, V5, P211, DOI 10.1101/gad.5.2.211; Gozani O, 1996, GENE DEV, V10, P233, DOI 10.1101/gad.10.2.233; Inoue Kunio, 1995, Gene Expression, V4, P177; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KATZ RA, 1990, MOL CELL BIOL, V10, P696, DOI 10.1128/MCB.10.2.696; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LAMOND AI, 1993, BIOESSAYS, V15, P595, DOI 10.1002/bies.950150905; LEE CG, 1993, J BIOL CHEM, V268, P13472; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; McKeown M, 1993, CURR OPIN CELL BIOL, V5, P448, DOI 10.1016/0955-0674(93)90010-N; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Moore M.J., 1993, SPLICING PRECURSORS; NEWMAN A, 1994, CURR BIOL, V4, P462, DOI 10.1016/S0960-9822(00)00104-4; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; O'Farrell P H, 1977, Methods Cell Biol, V16, P407; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; STAKNIS D, 1994, MOL CELL BIOL, V14, P2994, DOI 10.1128/MCB.14.5.2994; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; WANG J, 1995, RNA, V1, P335; WILL CC, 1994, ANAL RIBONUCLEOPROTE, V1, P141; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	41	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15169	15176		10.1074/jbc.273.24.15169	http://dx.doi.org/10.1074/jbc.273.24.15169			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614130	hybrid			2022-12-25	WOS:000074160400072
J	Fromm, SV; Mey-Tal, SW; Coligan, JE; Schechter, C; Ehrlich, R				Fromm, SV; Mey-Tal, SW; Coligan, JE; Schechter, C; Ehrlich, R			MHC class I heavy chain mRNA must exceed a threshold level for the reconstitution of cell surface expression of class I MHC complexes in cells transformed by the highly oncogenic adenovirus 12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; HLA CLASS-I; INTRACELLULAR-TRANSPORT; T-CELLS; MONOCLONAL-ANTIBODIES; PEPTIDE TRANSPORTER; GENE-EXPRESSION; DOWN-REGULATION; MOLECULES; BETA-2-MICROGLOBULIN	In primary embryonal fibroblasts from transgenic mice expressing H-2(b) genes and a miniature swine class I transgene (PD1), transformation with adenovirus 12 results in suppression of assembly and cell surface expression of all class I complexes. Cell surface expression of PD1 can be recovered by transfecting the cells with peptide transporter genes. However, reconstitution of the H-2K(b) gene expression requires, in. addition, a 2-fold increase in the steady state level of the H-2K(b) mRNA that can be attained by treatment of the cells with interferons or by transfecting them with the H-2K(b) gene. A detailed analyses of the biogenesis of class I molecules has revealed the steady state expression of free class I heavy chains that are not converted into conformed complexes even when peptide transporter genes are overexpressed, The fact that class I complex assembly seems to be highly inefficient in certain cell lines might be a major in vivo obstacle for the elimination of trans formed or virus-infected cells by cytotoxic T lymphocytes, especially in view of the fact that the level of class I gene transcription is often down-regulated in cancel cells and/or that assembly of class I major histocompatibility complexes can be subverted by virus-encoded proteins.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; NIAID, Mol Struct Lab, NIH, Bethesda, MD 20892 USA	Tel Aviv University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Ehrlich, R (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.							ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BOYD LF, 1992, P NATL ACAD SCI USA, V89, P2242, DOI 10.1073/pnas.89.6.2242; CROMME FV, 1994, BRIT J CANCER, V69, P1176, DOI 10.1038/bjc.1994.231; CROMME FV, 1993, BRIT J CANCER, V67, P1372, DOI 10.1038/bjc.1993.254; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; DAVIS WC, 1987, VET IMMUNOL IMMUNOP, V15, P337, DOI 10.1016/0165-2427(87)90005-5; EHRLICH R, 1989, IMMUNOGENETICS, V30, P18, DOI 10.1007/BF02421465; EHRLICH RE, 1995, IMMUNOL RES, V14, P77, DOI 10.1007/BF02918170; GAVIOLI R, 1992, P NATL ACAD SCI USA, V89, P5862, DOI 10.1073/pnas.89.13.5862; Geginat G, 1997, J IMMUNOL, V158, P3303; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GOODENOW RS, 1985, SCIENCE, V230, P777, DOI 10.1126/science.2997918; GUSSOW D, 1987, J IMMUNOL, V139, P3132; HAMMERLING GJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P245, DOI 10.1016/0304-419X(87)90008-4; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; JACOBY WB, 1979, METHOD ENZYMOL, V58, P110; Jones TR, 1996, P NATL ACAD SCI USA, V93, P11327, DOI 10.1073/pnas.93.21.11327; KHANNA R, 1994, INT IMMUNOL, V6, P639, DOI 10.1093/intimm/6.4.639; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; LEBOUTEILLER P, 1994, CRIT REV IMMUNOL, V14, P89, DOI 10.1615/CritRevImmunol.v14.i2.10; MACHOLD RP, 1995, J EXP MED, V181, P1111, DOI 10.1084/jem.181.3.1111; MALOY WL, 1988, MOL IMMUNOL, V25, P453; MeyTal SV, 1997, J BIOL CHEM, V272, P353, DOI 10.1074/jbc.272.1.353; Min W, 1996, J IMMUNOL, V156, P3174; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; OTTEN GR, 1992, J IMMUNOL, V148, P3723; OZATO K, 1981, J IMMUNOL, V126, P317; REALINI C, 1994, J BIOL CHEM, V269, P20727; RESTIFO NP, 1993, J EXP MED, V177, P265, DOI 10.1084/jem.177.2.265; Rodriguez AM, 1997, EUR J IMMUNOL, V27, P45, DOI 10.1002/eji.1830270108; ROTEMYEHUDAR R, 1994, J EXP MED, V180, P477, DOI 10.1084/jem.180.2.477; RotemYehudar R, 1996, J EXP MED, V183, P499, DOI 10.1084/jem.183.2.499; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHEMESH J, 1993, J BIOL CHEM, V268, P15704; SHEMESH J, 1991, J VIROL, V65, P5544, DOI 10.1128/JVI.65.10.5544-5548.1991; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; Solheim JC, 1997, J IMMUNOL, V158, P2236; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; VILLANUEVA MS, 1994, IMMUNITY, V1, P479, DOI 10.1016/1074-7613(94)90090-6; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNAGEL R, 1979, ADV IMMUNOL, V22, P51	53	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15209	15216		10.1074/jbc.273.24.15209	http://dx.doi.org/10.1074/jbc.273.24.15209			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614135	hybrid			2022-12-25	WOS:000074160400077
J	Anderson, KP; Crable, SC; Lingrel, JB				Anderson, KP; Crable, SC; Lingrel, JB			Multiple proteins binding to a GATA-E box-GATA motif regulate the erythroid Kruppel-like factor (EKLF) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; BETA-THALASSEMIA; MICE LACKING; FAMILY; HEMATOPOIESIS; PROMOTER; RBTN2; LEUKEMIA; ABSENCE; GLOBIN	Erythroid Kruppel-like factor (EKLF) is a zinc finger transcription factor required for beta-globin gene expression and is implicated as one of the key factors necessary for the fetal to adult switch in globin gene expression, In an effort to identify factors involved in the expression of this important erythroid-specific regulatory protein, we have isolated the mouse EKLF gene and systematically analyzed the promoter region. Initially, a reporter construct with 1150 base pairs of the EKLF 5'-region was introduced into transgenic mice and shown to direct erythroid-specific expression. We continued the expression studies in erythroid cells and have identified a sequence element consisting of two GATA sites flanking an E box motif, The three sites act in concert to elevate the transcriptional activity of the EKLF promoter. Each site is essential for EKLF expression indicating that the three binding sites do not work additively, but rather function as a unit. We further show that GATA-1 binds to the two GATA sites and present evidence for binding of another factor from erythroid cell nuclear extracts to the E box motif. These results are consistent with the formation of a quaternary complex composed of an E box dimer and two GATA-1 proteins binding at a combined GATA-E box-GATA activator element in the distal EKLF promoter.	Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Anderson, KP (corresponding author), Univ Cincinnati, Dept Mol Genet Microbiol & Biochem, 231 Bethesda Ave,ML 524, Cincinnati, OH 45267 USA.		Ruiter, D.J./L-4617-2015		NIDDK NIH HHS [DK39585] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039585, R01DK039585] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; ASKEW GR, 1993, MOL CELL BIOL, V13, P4115, DOI 10.1128/MCB.13.7.4115; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; BOEHM T, 1990, ONCOGENE, V5, P1103; CROSSLEY M, 1994, J BIOL CHEM, V269, P15440; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; FENG WC, 1994, J BIOL CHEM, V269, P1493; HAGEN B, 1986, MANIPULATING MOUSE E; MCBURNEY MW, 1994, DEV DYNAM, V200, P278, DOI 10.1002/aja.1002000403; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MINIE M, 1993, J CELL CI S, V16, P15; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Orkin SH, 1996, CURR OPIN GENET DEV, V6, P597, DOI 10.1016/S0959-437X(96)80089-X; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PERKINS AC, 1995, NATURE, V375, P318; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEISS MJ, 1995, EXP HEMATOL, V23, P99; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894	28	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14347	14354		10.1074/jbc.273.23.14347	http://dx.doi.org/10.1074/jbc.273.23.14347			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603943	hybrid			2022-12-25	WOS:000074021500045
J	Angelo, R; Rubin, CS				Angelo, R; Rubin, CS			Molecular characterization of an anchor protein (AKAP(CE)) that binds the RI subunit (R-CE) of type I protein kinase A from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; A-KINASE; CATALYTIC SUBUNIT; MESSENGER-RNA; EXPRESSION; CLONING; GENE; SEQUENCE; BETA; CYTOSKELETON	Classical A kinase anchor proteins (AKAPs) preferentially tether type II protein kinase A (PKAII) isoforms to sites in the cytoskeleton and organelles. It is not known if distinct proteins selectively sequester regulatory (R) subunits of type I PKAs, thereby diversifying functions of these critical enzymes. In Caenorhabditis elegans, a single type I PKA mediates all aspects of cAMP signaling. We have discovered a cDNA that encodes a binding protein (AKAP(CE)) for the regulatory subunit (R-CE) of C. elegans PKAI(CE). AKAP(CE) is a novel, highly acidic RING finger protein composed of 1,280 amino acids. It binds RI-like R-CE with high affinity and neither RII alpha nor RII beta competitively inhibits formation of AKAP(CE).R-CE complexes. The R-CE-binding site was mapped to a segment of 20 amino acids in an N-terminal region of AKAP(CE). Several hydrophobic residues in the binding site align with essential Leu and Re residues in the RII-selective tethering domain of prototypic mammalian AKAPs. However, the R-CE-binding region in AKAP(CE) diverges sharply from consensus RII-binding sites by inclusion of three aromatic amino acids, exclusion of a highly conserved Leu or Ile at position 8 and replacement of C-terminal hydrophobic amino acids with basic residues. AKAP(CE). R-CE complexes accumulate in intact cells.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Rubin, CS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, 1300 Morris Pk Ave,F-229, Bronx, NY 10461 USA.	rubin@aecom.yu.edu			NIGMS NIH HHS [GM07260, GM22792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007260, R01GM022792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BUBIS J, 1987, J BIOL CHEM, V262, P14961; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GROSS RE, 1990, J BIOL CHEM, V265, P6896; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Han JD, 1997, J BIOL CHEM, V272, P26611, DOI 10.1074/jbc.272.42.26611; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOFMANN F, 1977, J BIOL CHEM, V252, P1441; HU ED, 1990, J BIOL CHEM, V265, P5072; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAND M, 1994, J BIOL CHEM, V269, P9234; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LU XY, 1990, J BIOL CHEM, V265, P3293; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; RUBIN CS, 1972, J BIOL CHEM, V247, P6135; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	41	88	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14633	14643		10.1074/jbc.273.23.14633	http://dx.doi.org/10.1074/jbc.273.23.14633			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603981	hybrid			2022-12-25	WOS:000074021500083
J	Guenzi, E; Galli, G; Grgurina, I; Pace, E; Ferranti, P; Grandi, G				Guenzi, E; Galli, G; Grgurina, I; Pace, E; Ferranti, P; Grandi, G			Coordinate transcription and physical linkage of domains in surfactin synthetase are not essential for proper assembly and activity of the multienzyme complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; PEPTIDE BIOSYNTHESIS; SIGNAL TRANSDUCTION; SRFA OPERON; REGION; GENES; COMPETENCE; BACTERIAL; TEMPLATES; CLEAVAGE	Bacterial peptide synthetases have two common features that appear to be strictly conserved. 1) The enzyme subunits are co-regulated at both transcriptional and translational level. 2) The organization of the different enzymatic domains constituting the enzyme fulfills the "colinearity rule" according to which the order of the domains along the chromosome parallels their functional hierarchy. Considering the high degree of conservation of these features, one would expect that mutations such as transcription uncoupling and domain dissociations, deletions, duplications, and reshuffling would result in profound effects on the quality and quantity of synthesized peptides, To start testing this hypothesis, we designed two mutants. In one mutant, the operon structure of surfactin synthetase was destroyed, thus altering the concerted expression of the enzyme subunits, In the other mutant, the thioesterase domain naturally fused to the last amino acid binding domain of surfactin was physically dissociated and independently expressed. When the lipopeptides secreted by the mutant Bacillus subtilis strains were purified and characterized, they appeared to be expressed approximately at the same level of the wild type surfactin and to be identical to it, indicating that specific domain-domain interactions rather than coordinated transcription and translation play the major role in determining the correct assembly and activity of peptide synthetases.	Chiron SPA, Dept Mol Biol, I-53100 Siena, Italy; Univ Rome La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Naples, Dept Food Sci, I-101 Naples, Italy	Novartis; Sapienza University Rome	Grandi, G (corresponding author), Chiron SPA, Dept Mol Biol, Via Fiorentina 1, I-53100 Siena, Italy.	grandi@iris02.biocine.it	Ferranti, Pasquale/ABF-8111-2021	FERRANTI, Pasquale/0000-0002-6250-6512; Grandi, Guido/0000-0001-9724-2185				Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; Davidson JN, 1997, TRENDS GENET, V13, P281, DOI 10.1016/S0168-9525(97)01127-X; deFerra F, 1997, J BIOL CHEM, V272, P25304, DOI 10.1074/jbc.272.40.25304; FRANCHI E, 1991, J BIOTECHNOL, V18, P41, DOI 10.1016/0168-1656(91)90234-M; GALLI G, 1994, BBA-PROTEIN STRUCT M, V1205, P19, DOI 10.1016/0167-4838(94)90087-6; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; HAHN J, 1991, J BACTERIOL, V173, P7275, DOI 10.1128/jb.173.22.7275-7282.1991; KAKINUMA A, 1969, AGR BIOL CHEM TOKYO, V33, P973, DOI 10.1080/00021369.1969.10859409; Kleinkauf H, 1996, EUR J BIOCHEM, V236, P335, DOI 10.1111/j.1432-1033.1996.00335.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipmann F, 1980, Adv Microb Physiol, V21, P227; NAKANO MM, 1991, J BACTERIOL, V173, P5487, DOI 10.1128/jb.173.17.5487-5493.1991; NAKANO MM, 1993, J BACTERIOL, V175, P3188, DOI 10.1128/JB.175.10.3188-3191.1993; PEREGO M, 1991, J BACTERIOL, V173, P2514, DOI 10.1128/jb.173.8.2514-2520.1991; SMITH DJ, 1990, EMBO J, V9, P741, DOI 10.1002/j.1460-2075.1990.tb08168.x; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1016/0378-1097(94)00459-5; STACHELHAUS T, 1995, SCIENCE, V269, P69, DOI 10.1126/science.7604280; Stein T, 1996, J BIOL CHEM, V271, P15428, DOI 10.1074/jbc.271.26.15428; TOGNONI A, 1995, MICROBIOL-UK, V141, P645, DOI 10.1099/13500872-141-3-645; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; VANSINDEREN D, 1993, MOL MICROBIOL, V8, P833; ZHANG JH, 1995, J BACTERIOL, V177, P4009, DOI 10.1128/jb.177.14.4009-4020.1995; Zuber Peter, 1993, P897	25	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14403	14410		10.1074/jbc.273.23.14403	http://dx.doi.org/10.1074/jbc.273.23.14403			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603952	hybrid			2022-12-25	WOS:000074021500054
J	Lin, XH; Hengartner, MO; Kolesnick, R				Lin, XH; Hengartner, MO; Kolesnick, R			Caenorhabditis elegans contains two distinct acid sphingomyelinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL SPHINGOMYELINASE; APOPTOSIS; SEQUENCE	Mounting evidence supports a role for acid sphingomyelinase (ASM) in cellular stress signaling Only murine and human sphingomyelinases have been defined at the molecular level. These enzymes are the products of a conserved gene and at the amino acid level share 82% identity. in this study, we show that the nematode Caenorhabditis elegans possesses two ASMs, termed ASM-1 and ASM-2 encoded by two distinct genes, but lacks detectable neutral sphingomyelinase activity. The C., elegans ASMs are about 30% identical with each other and with the human and murine enzymes, The conserved regions include a saposin-like domain, proline-rich domain, and a putative signal peptide, in addition, 16 cysteines distributed throughout the molecules, and selected glycosylation sites, are conserved, The expression of these genes in C. elegans is regulated during development Asm-l is preferentially expressed in the embryo, whereas asm-2 is predominantly expressed in postembryonic stages. Whets transfected as Flag-tagged proteins into COS-7 cells, ASM-P is found almost entirely in a secreted form whereas only 20% of ASM-2 is secreted. Only the secreted forms display enzymatic activity. Furthermore, ASM-S requires addition of Zn2+ to be fully active, whereas ASM-B is active in the absence of cation, C., elegans is the first organism to display two ASMs. This finding suggests the existence of an ASM gene family.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Memorial Sloan Kettering Cancer Center; Cold Spring Harbor Laboratory	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.		Hengartner, Michael O/E-6235-2011; Hengartner, Michael O/A-7058-2008	Hengartner, Michael/0000-0002-7584-596X	NIGMS NIH HHS [GM 53540] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bilderback TR, 1997, J BIOL CHEM, V272, P10922; BRENNER S, 1974, GENETICS, V77, P71; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; Castedo M, 1996, J IMMUNOL, V157, P512; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; Duan RD, 1996, DIGEST DIS SCI, V41, P1801, DOI 10.1007/BF02088748; DUAN RD, 1995, BBA-LIPID LIPID MET, V1259, P49, DOI 10.1016/0005-2760(95)00137-2; FERLINZ K, 1994, BIOCHEM J, V301, P855, DOI 10.1042/bj3010855; Ferlinz K, 1997, EUR J BIOCHEM, V243, P511, DOI 10.1111/j.1432-1033.1997.511_1a.x; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; MOLLBY R, 1973, BIOCHIM BIOPHYS ACTA, V321, P569, DOI 10.1016/0005-2744(73)90200-3; Newrzella D, 1996, J BIOL CHEM, V271, P32089, DOI 10.1074/jbc.271.50.32089; Nyberg L, 1996, BBA-LIPID LIPID MET, V1300, P42, DOI 10.1016/0005-2760(95)00245-6; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OTNAESS AB, 1980, FEBS LETT, V114, P202, DOI 10.1016/0014-5793(80)81114-8; PONTING CP, 1994, PROTEIN SCI, V3, P359; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Schuchman EH, 1997, GENET TEST, V1, P13, DOI 10.1089/gte.1997.1.13; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Sulston J., 1988, NEMATODE CAENORHABDI, P603; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; YEDGAR S, 1982, BIOCHEM J, V201, P597, DOI 10.1042/bj2010597	32	28	33	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14374	14379		10.1074/jbc.273.23.14374	http://dx.doi.org/10.1074/jbc.273.23.14374			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603947	hybrid, Green Accepted			2022-12-25	WOS:000074021500049
J	Perez-Vilar, J; Eckhardt, AE; DeLuca, A; Hill, RL				Perez-Vilar, J; Eckhardt, AE; DeLuca, A; Hill, RL			Porcine submaxillary mucin forms disulfide-linked multimers through its amino-terminal D-domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; VON-WILLEBRAND-FACTOR; VONWILLEBRAND-FACTOR; SUBCELLULAR-LOCALIZATION; INTESTINAL MUCIN; ESCHERICHIA-COLI; H+-ATPASES; CDNA; CLONING; CELLS	COS-7 cells expressing 1,360 residues from the amino terminus of porcine submaxillary mucin were used to determine whether this region, containing the D1, D2, and D3 domains, is involved in forming mucin multimers, Analysis of the proteins immunoprecipitated from the medium of transfected cells by reducing SDS-gel electrophoresis showed a single N-glycosylated protein with no indication of proteolytically processed forms. Without prior reduction, only two proteins, corresponding to monomeric and disulfide-linked trimeric species, were observed. The expressed protein devoid of N-linked oligosaccharides also formed trimers, but was secreted from cells in significantly less amounts than glycosylated trimers, Pulse-chase studies showed that the disulfide-linked trimers were assembled inside the cells no earlier than 30 min after protein synthesis commenced and after the intracellular precursors were N-glycosylated, Trimer formation was inhibited in cells treated with brefeldin A, monensin, chloroquine, or bafilolmycin A(1), although only brefeldin A prevented the secretion of the protein. These results suggest that trimerization takes place in compartments of the Golgi complex in which the vacuolar H+-ATPase maintains an acidic pH. Coexpression in the same cells of the amino-terminal region and the disulfide-rich carboxyl-terminal domain of the mucin showed that these structures were not disulfide-linked with one another, Cells expressing a DNA construct encoding a fusion protein between the amino-and carboxyl-terminal regions of the mucin secreted disulfide-linked dimeric and high molecular weight multimeric species of the recombinant mucin, The presence of monensin in the medium was without effect on dimerization, but inhibited the formation of disulfide-linked multimers, These studies suggest that disulfide-linked dimers of mucin are subsequently assembled into disulfide-linked multimers by the aminoterminal regions. They also suggest that the porcine mucin forms branched disulfide-linked multimers. This ability of the amino-terminal region of mucin to aid ire the assembly of multimers is consistent with its amino acid identities to the amino-terminal region of human von Willebrand factor, which also selves to form disulfide-linked multimers of this protein.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hill, RL (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	hill@biochem.duke.edu			NIGMS NIH HHS [GM 25766] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025766, R37GM025766] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZUMA H, 1993, J BIOL CHEM, V268, P2821; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; DESCHUYTENEER M, 1988, J BIOL CHEM, V263, P2452; Desseyn JL, 1997, J BIOL CHEM, V272, P16873, DOI 10.1074/jbc.272.27.16873; DONG ZG, 1994, J BIOL CHEM, V269, P6753; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; FRETTO LJ, 1986, J BIOL CHEM, V261, P5679; Gerken TA, 1997, J BIOL CHEM, V272, P9709; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; Joba W, 1997, J BIOL CHEM, V272, P1805, DOI 10.1074/jbc.272.3.1805; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLOMP LWJ, 1995, BIOCHEM J, V308, P831, DOI 10.1042/bj3080831; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; MEINDL A, 1992, NAT GENET, V2, P139, DOI 10.1038/ng1092-139; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; PALOKANGAS H, 1994, J BIOL CHEM, V269, P17577; Perez-Vilar J, 1997, J BIOL CHEM, V272, P33410, DOI 10.1074/jbc.272.52.33410; Perez-Vilar J, 1998, J BIOL CHEM, V273, P6982, DOI 10.1074/jbc.273.12.6982; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; SADLER JE, 1991, J BIOL CHEM, V266, P22777; SHEEHAN JK, 1986, BIOCHEM J, V239, P147, DOI 10.1042/bj2390147; Sheehan JK, 1996, BIOCHEM J, V315, P1055, DOI 10.1042/bj3151055; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Toribara NW, 1997, J BIOL CHEM, V272, P16398, DOI 10.1074/jbc.272.26.16398; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; XU GQ, 1992, J BIOL CHEM, V267, P5401; YILLA M, 1993, J BIOL CHEM, V268, P19092	43	63	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14442	14449		10.1074/jbc.273.23.14442	http://dx.doi.org/10.1074/jbc.273.23.14442			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603957	hybrid			2022-12-25	WOS:000074021500059
J	Schafer, H; Trauzold, A; Sebens, T; Deppert, W; Folsch, UR; Schmidt, WE				Schafer, H; Trauzold, A; Sebens, T; Deppert, W; Folsch, UR; Schmidt, WE			The proliferation-associated early response gene p22/PRG1 is a novel p53 target gene	ONCOGENE			English	Article						early response gene; tumor suppressor; transcription factor; growth control	WILD-TYPE P53; NUCLEAR ANTIGEN PROMOTER; TUMOR-SUPPRESSOR P53; CARCINOMA CELL-LINE; ADENYLATE-CYCLASE; DNA-BINDING; MUTANT P53; GROWTH ARREST; BAX GENE; APOPTOSIS	The novel early response gene p22/PRG1 is linked to cell cycle entry and the induction of proliferation in various cell types although its exact function is still unknown. The p22/PRG1 promoter region contains a 20 bp sequence matching the consensus binding motif for the tumor suppressor protein p53, Gel shift assays demonstrated that p53 specifically binds to an oligonucleotide derived from the p53 binding site of the p22/PRG1 promoter. Chloramphenicol acetyltransferase (CAT) reporter gene assays confirmed that this site confers p53-dependent transcriptional activity to the p22/PRG1 promoter. In Hela cells, p22/PRG1 promoter constructs induced CAT expression only when cotransfected with an expression plasmid for wild-type, but not for mutant p53, Similarly, CAT expression was inducible at the permissive (31 degrees C) but not at the non-permissive temperature (39 degrees C) in the rat embryo fibroblast-derived cell line clone-6 that expresses a temperature-sensitive mutant p53, Conversion of this mutant p53 to a functional p53 at the permissive temperature was accompanied by a significant increase of endogenous p22/PRG1 mRNA level in this cell line. gamma-irradiation of rat splenocytes or doxorubicin-treatment of Hela cells increased p53 levels followed by transcriptional activation of p22/PRG1 and p21/Waf1 in parallel. Our data demonstrate that p22/PRG1 transcription is induced by p53 during p53-dependent cell cycle arrest and apoptosis, Therefore, p22/PRG1 represents a novel target for transcriptional activation by p53.	Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany	University of Kiel; Heinrich Pette Institute; University of Hamburg	Schmidt, WE (corresponding author), Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, Schittenhelmstr 12, D-24105 Kiel, Germany.		Schäfer, Heiner/C-1055-2011; Trauzold, Anna/P-4398-2014					ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BAE IS, 1995, CANCER RES, V55, P2387; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; BUSCAIL L, 1992, GASTROENTEROLOGY, V103, P1002, DOI 10.1016/0016-5085(92)90035-W; CHARLES CH, 1993, ONCOGENE, V8, P797; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1988, ONCOGENE, V3, P313; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GISH WR, 1987, J VIROL, V61, P2864, DOI 10.1128/JVI.61.9.2864-2876.1987; Hecker D, 1996, ONCOGENE, V12, P953; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Knippschild U, 1996, ONCOGENE, V12, P1755; Kondratyev AD, 1996, CANCER RES, V56, P1498; KRUISBEEK AM, 1993, CURRENT PROTOCOLS IM, V1; LING YH, 1993, CANCER RES, V53, P1845; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Molinari M, 1996, ONCOGENE, V13, P2077; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; OLSON DC, 1994, CELL GROWTH DIFFER, V5, P61; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; SAITO Y, 1995, ONCOGENE, V11, P1013; Schafer H, 1996, CANCER RES, V56, P2641; Schafer H, 1996, BIOCHEM BIOPH RES CO, V221, P111, DOI 10.1006/bbrc.1996.0554; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6148; SEKI H, 1994, EUR J IMMUNOL, V24, P2914, DOI 10.1002/eji.1830241150; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TISHLER RB, 1993, CANCER RES, V53, P2212; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZERRAHN J, 1992, ONCOGENE, V7, P1371	48	38	38	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2479	2487		10.1038/sj.onc.1201788	http://dx.doi.org/10.1038/sj.onc.1201788			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627114				2022-12-25	WOS:000073672300006
J	Barsalou, A; Gao, WL; Anghel, SI; Carriere, J; Mader, S				Barsalou, A; Gao, WL; Anghel, SI; Carriere, J; Mader, S			Estrogen response elements can mediate agonist activity of anti-estrogens in human endometrial Ishikawa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; TRANSCRIPTIONAL ACTIVATION; BINDING-PROPERTIES; RECEPTOR; TAMOXIFEN; GENE; ANTIESTROGENS; GROWTH; PROMOTER; DOMAINS	Anti-estrogens like hydroxytamoxifen (OHT) have mixed agonist/antagonist activities, leading to tissue-specific stimulation of cellular proliferation. Partial agonist activity of OHT can be observed in vitro in endometrial carcinoma cells like Ishikawa. Here, we have compared several anti-estrogens (including extensively characterized OHT and pure anti-estrogens such as ICI164,384 and RU58,668, which are devoid of uterotrophic activity) for their capacity to stimulate promoters containing estrogen response elements (EREs) or AP1-binding sites (12-O-tetradecanoylphorbol-13-acetate response elements, TREs), the two types of DNA motifs known to mediate transcriptional stimulation by estrogen receptors. Assays were performed in Ishikawa cells either by transient transfection or by using cell lines with stably propagated reporter vectors. In transient transfection experiments, none of the anti-estrogens displayed agonist activity on the promoters tested. In contrast, significant transcriptional stimulation was observed with low concentrations of OHT and RU39,411 in Ishikawa cells stably propagating reporter constructs containing a minimal ERE3-TATA promoter. In addition, micromolar concentrations of OHT, but not of RU39,411, stimulated stably propagated AP1-responsive reporter constructs. No transcriptional stimulation of ERE- or TRE-containing promoters was observed with the pure anti-estrogens ICI164,384 and RU58,668. These results indicate that the presence of estrogen response elements in promoters is sufficient to mediate cell-specific agonism of anti-estrogens at the transcriptional level, and that stimulation of AP1 activity may be restricted to a subset of anti-estrogens possessing agonist activity on EREs. In addition, our results suggest that transient transfections do not fully recapitulate in vivo conditions required to observe agonist activity of anti-estrogens.	Univ Montreal, Fac Med, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Mader, S (corresponding author), Univ Montreal, Fac Med, Dept Biochim, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	maders@bch.umontreal.ca						Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ANZAI Y, 1989, CANCER RES, V49, P2362; Aumais JP, 1997, J BIOL CHEM, V272, P12229, DOI 10.1074/jbc.272.18.12229; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GOTTARDIS MM, 1988, CANCER RES, V48, P812; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; JAMIL A, 1991, J MOL ENDOCRINOL, V6, P215, DOI 10.1677/jme.0.0060215; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; JIN L, 1995, STEROIDS, V60, P512, DOI 10.1016/0039-128X(95)00079-6; JORDAN VC, 1990, BREAST CANCER RES TR, V15, P125, DOI 10.1007/BF01806350; KASTNER P, 1990, EMBO J, V9, P1608; KATZENELLENBOGEN BS, 1995, J STEROID BIOCHEM, V53, P387, DOI 10.1016/0960-0760(95)00084-D; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; McInerney EM, 1996, J BIOL CHEM, V271, P24172, DOI 10.1074/jbc.271.39.24172; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; RAYNAUD JP, 1978, CANCER RES, V38, P3044; SALMON J, 1983, J STEROID BIOCHEM, V18, P565, DOI 10.1016/0022-4731(83)90132-2; Schwartz LB, 1997, AM J OBSTET GYNECOL, V176, P129, DOI 10.1016/S0002-9378(97)80025-7; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; VANDEVELDE P, 1994, J STEROID BIOCHEM, V48, P187, DOI 10.1016/0960-0760(94)90144-9; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; WAKELING AE, 1990, J STEROID BIOCH MOL, V37, P71; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WHITE JH, 1994, BIO-TECHNOL, V12, P1003, DOI 10.1038/nbt1094-1003; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	51	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17138	17146		10.1074/jbc.273.27.17138	http://dx.doi.org/10.1074/jbc.273.27.17138			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642281	hybrid			2022-12-25	WOS:000074545200071
J	Long, JC; Wang, S; Vik, SB				Long, JC; Wang, S; Vik, SB			Membrane topology of subunit a of the F1F0 ATP synthase as determined by labeling of unique cysteine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; ALPHA-SUBUNIT; A-SUBUNIT; TRANSMEMBRANE TOPOLOGY; EPSILON-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; CRYOELECTRON MICROSCOPY; PROTON TRANSLOCATION; NUCLEOTIDE-SEQUENCE; MUTAGENIC ANALYSIS	The membrane topology of the a subunit of the F1F0 ATP synthase from Escherichia coli has been probed by surface labeling using 3-(N-maleimidylpropionyl) biocytin. Subunit a has no naturally occurring cysteine residues, allowing unique cysteines to be introduced at the following positions: 8, 24, 27, 69, 89, 128, 131, 172, 176, 196, 238, 241, and 277 (following the COOH-terminal 271 and a hexahistidine tag). None of the single mutations affected the function of the enzyme, as judged by growth on succinate minimal medium. Membrane vesicles with an exposed cytoplasmic surface were prepared using a French pressure cell, Before labeling the membranes were incubated with or without a highly charged sulfhydryl reagent, 4-acetamido-4'-maleimidylstilbene-2,2'disulfonic acid. After labeling with the less polar biotin maleimide, the samples were solubilized with octyl glucoside/cholate and the subunit a was purified via the oligohistidine at its COOH terminus using immobilized nickel chromatography. The purified samples were electrophoresed and transferred to nitrocellulose for detection by avidin conjugated to alkaline phosphatase. Results indicated cytoplasmic accessibility for residues 69, 172, 176, and 277 and periplasmic accessibility for residues 8, 24, 27, and 131. On the basis of these and earlier results, a transmembrane topology for the subunit a is proposed.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	Southern Methodist University	Vik, SB (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.	svik@mail.smu.edu		Vik, Steven/0000-0002-5285-015X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040508] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM040508, GM40508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; Akiyama Y, 1996, FEBS LETT, V399, P26, DOI 10.1016/S0014-5793(96)01283-5; AssadiPorter FM, 1995, BIOCHEMISTRY-US, V34, P16186, DOI 10.1021/bi00049a034; BAYER EA, 1985, ANAL BIOCHEM, V149, P529, DOI 10.1016/0003-2697(85)90609-8; BJORBAEK C, 1990, FEBS LETT, V260, P31, DOI 10.1016/0014-5793(90)80058-Q; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1994, J BIOL CHEM, V269, P2562; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; GIRVIN ME, 1994, BIOCHEMISTRY-US, V33, P665, DOI 10.1021/bi00169a006; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; Hagting A, 1997, BIOCHEMISTRY-US, V36, P6777, DOI 10.1021/bi963068t; HARTZOG PE, 1993, J BACTERIOL, V175, P1337, DOI 10.1128/JB.175.5.1337-1343.1993; HERMOLIN J, 1995, J BIOL CHEM, V270, P2815, DOI 10.1074/jbc.270.6.2815; HUMBERT R, 1983, J BACTERIOL, V153, P416, DOI 10.1128/JB.153.1.416-422.1983; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KRUMHOLZ LR, 1989, NUCLEIC ACIDS RES, V17, P7993, DOI 10.1093/nar/17.19.7993; KUMAMOTO CA, 1986, J BIOL CHEM, V261, P37; LEWIS MJ, 1992, J BIOL CHEM, V267, P3482; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Miller J. H., 1972, EXPT MOL GENETICS, P431; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sawada K, 1997, J BIOL CHEM, V272, P30047, DOI 10.1074/jbc.272.48.30047; SCHNEIDER E, 1984, P NATL ACAD SCI-BIOL, V81, P7279, DOI 10.1073/pnas.81.23.7279; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; VIK SB, 1992, BIOCHIM BIOPHYS ACTA, V1140, P199, DOI 10.1016/0005-2728(92)90009-Q; VIK SB, 1988, J BIOL CHEM, V263, P6599; VIK SB, 1994, J BIOL CHEM, V269, P30364; VIK SB, 1987, J BIOL CHEM, V262, P8340; Vik SB, 1998, J BIOL CHEM, V273, P16229, DOI 10.1074/jbc.273.26.16229; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONMEYENBURG K, 1985, EMBO J, V4, P2357, DOI 10.1002/j.1460-2075.1985.tb03939.x; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WANG S, 1994, J BIOL CHEM, V269, P3095; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Yamada H, 1996, FEBS LETT, V390, P34, DOI 10.1016/0014-5793(96)00621-7; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	67	109	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16235	16240		10.1074/jbc.273.26.16235	http://dx.doi.org/10.1074/jbc.273.26.16235			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632682	hybrid			2022-12-25	WOS:000074436600053
J	Weiner, JK; Chen, AP; Davis, BH				Weiner, JK; Chen, AP; Davis, BH			E-box-binding repressor is down-regulated in hepatic stellate cells during up-regulation of mannose 6-phosphate insulin-like growth factor-II receptor expression in early hepatic fibrogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1(I) COLLAGEN PROMOTER; FACTOR-BETA; GENE-TRANSCRIPTION; ACTIVATION; RAT; PROTEIN; LIVER; FIBROSIS; RETINOL; MYC	Hepatic stellate cells become activated during the early stages of hepatic injury associated with fibrogenesis, The mannose 6-phosphate/insulin-like growth factor-II receptor (M6P/IGFIIR) plays an important role in early fibrogenesis by participating in the activation of latent transforming growth factor-beta, a potent inducer of the matrix proteins in activated stellate cells that define the fibrotic phenotype. In this study we examined hepatic stellate cell regulation of M6P/IGFIIR expression and found that M6P/IGFIIR mRNA transcript levels increased in stellate cells from rats exposed to carbon tetrachloride (CCl4), a potent fibrogenic stimulant. Two E-boxes residing in the proximal promoter of M6P/IG-FIIR were found to each bind a novel 75-kDa transcription factor (P75) in quiescent stellate cells of normal livers. This E-box binding was down-regulated as an early response in stellate cells exposed to CCl4, coinciding with increased M6P/IGFIIR transcript levels. Mutagenized E-boxes in M6P/IGFIIR promoter-chloramphenicol acetyltransferase (CAT) reporter constructs produced a substantial increase in reporter expression when compared with the corresponding native promoter-CAT construct when transfected in culture-activated stellate cells, suggesting P75's role as a repressor, The results indicate P75's participation in the regulation of M6P/IGFIIR transcription in hepatic stellate cells during fibrogenesis.	Univ Chicago, Med Ctr, Dept Med, Gastroenterol Sect, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center	Davis, BH (corresponding author), Univ Chicago, Med Ctr, Dept Med, Gastroenterol Sect, MC 4076,5841 S Maryland Ave, Chicago, IL 60637 USA.	bhdavis@medicine.bsd.uchicago.edu			NIDDK NIH HHS [DK40223, DK 42086, DK02022] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086, K08DK002022, R29DK040223] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BRENNER DA, 1989, NUCLEIC ACIDS RES, V17, P6055, DOI 10.1093/nar/17.15.6055; Chen AP, 1996, J BIOL CHEM, V271, P25994, DOI 10.1074/jbc.271.42.25994; Davis BH, 1996, CLIN LAB MED, V16, P361, DOI 10.1016/S0272-2712(18)30274-9; DAVIS BH, 1987, J BIOL CHEM, V262, P10280; DAVIS BH, 1988, HEPATOLOGY, V8, P788, DOI 10.1002/hep.1840080416; DEBLESER PJ, 1995, HEPATOLOGY, V21, P1429, DOI 10.1016/0270-9139(95)90066-7; DeBleser PJ, 1997, J HEPATOL, V26, P886, DOI 10.1016/S0168-8278(97)80257-7; DeBleser PJ, 1996, HEPATOLOGY, V23, P1530; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; Flaumenhaft R, 1993, Adv Pharmacol, V24, P51, DOI 10.1016/S1054-3589(08)60933-3; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOUGLUM K, 1995, J CLIN INVEST, V96, P2269, DOI 10.1172/JCI118282; JIRTLE RL, 1993, CANCER RES, V53, P3849; JIRTLE RL, 1994, CARCINOGENESIS, V15, P1473, DOI 10.1093/carcin/15.8.1473; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; LIU D, 1995, MOL ENDOCRINOL, V9, P1477; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; Sambrook J., 2002, MOL CLONING LAB MANU; SAPERSTEIN LA, 1994, HEPATOLOGY, V19, P412; SUE SR, 1995, ANN SURG, V222, P171, DOI 10.1097/00000658-199508000-00009; SZEBENYI G, 1994, GENOMICS, V19, P120, DOI 10.1006/geno.1994.1021	34	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15913	15919		10.1074/jbc.273.26.15913	http://dx.doi.org/10.1074/jbc.273.26.15913			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632637	hybrid			2022-12-25	WOS:000074436600008
J	Zheleva, D; Sharma, J; Panico, M; Morris, HR; Barber, J				Zheleva, D; Sharma, J; Panico, M; Morris, HR; Barber, J			Isolation and characterization of monomeric and dimeric CP47-reaction center photosystem II complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-MASS PROTEINS; CORE COMPLEX; SPINACH; CHLOROPHYLL; POLYPEPTIDE; PLANTS	Using the detergents n-dodecyl beta-D-maltoside and heptyl thioglycopyranoside, a subcore complex of photosystem II (PSII) has been isolated that contains the chlorophyll-binding protein, CP47, and the reaction center components, D1, D2, and cytochrome b(559). We have found, by using sucrose density centrifugation, that the resulting preparation consisted of a mixture of dimeric and monomeric forms of the CP47 reaction center (RC) complex, having molecular masses of 410 +/- 30 and 200 +/- 28 kDa, respectively, as estimated by size exclusion chromatography. The level of the dimer in the preparation is significantly higher than the monomeric form. Both the monomer and dimer contain the proteins CP47, D1, and D2 and the alpha- and beta-subunits of cytochrome b(559). Analyses by mass spectrometry and N-terminal sequencing showed that both forms of the CP47-RC complex contain the products of the psbI, psbT(c) (chloroplast gene), and psbW with molecular masses of 4195,5, 3849.6, and 5927.4 Da, respectively. In contrast to the monomeric form, the CP47-RC dimer contained two extra proteins with low molecular weights, identified as the products of the psbL and psbK genes having molecular masses of 4365.5 and 4292.1, respectively, It was also found that the dimer contained slightly more molecules of chlorophyll a (21 +/- 2.5) than the monomer (18 +/- 1.5), a characteristic also observed in the room temperature absorption spectrum by comparing the ratio of absorption at 416 and 435 nm. Of particular note was the finding that the dimer, but not the monomer, contained plastoquinone-9 (estimated to be 1.5 +/- 0.3 molecules per RC). The results indicate that the CP47-RC monomer is derived from the dimeric form of the complex, and therefore the latter is likely to represent an in vivo conformation. The PsbT(c) as well as the PsbI and PsbW proteins are identified as being intimately associated with the D1 and D2 proteins, and in the case of the dimer, importance is placed on the PsbL and PsbK proteins in sustaining plastoquinone binding and maintenance of the dimeric organization. Assuming only one copy of the alpha- and beta-subunits of cytochrome b(559), the monomeric and dimeric forms of the complex mould be expected to contain 21 and 23 x 2 transmembrane helices, respectively.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wolfson Labs, London SW7 2AY, England	Imperial College London	Barber, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wolfson Labs, London SW7 2AY, England.	j.barber@ic.ac.uk	choudhary, jyoti/S-1232-2017	choudhary, jyoti/0000-0003-0881-5477				BARBATO R, 1991, FEBS LETT, V286, P86, DOI 10.1016/0014-5793(91)80947-2; BARBER J, 1989, OXFORD SURVEYS PLANT, V6, P115; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOEKEMA EJ, 1995, P NATL ACAD SCI USA, V92, P175, DOI 10.1073/pnas.92.1.175; BRICKER TM, 1990, PHOTOSYNTH RES, V24, P1, DOI 10.1007/BF00032639; DallaChiesa M, 1996, PHOTOSYNTH RES, V50, P79, DOI 10.1007/BF00018223; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; EIJCKELHOFF C, 1995, BBA-BIOENERGETICS, V1231, P21, DOI 10.1016/0005-2728(95)00055-N; GHANOTAKIS DF, 1989, BIOCHIM BIOPHYS ACTA, V974, P44, DOI 10.1016/S0005-2728(89)80164-1; GOUNARIS K, 1990, FEBS LETT, V265, P88, DOI 10.1016/0014-5793(90)80890-U; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; IKEUCHI M, 1989, FEBS LETT, V242, P263, DOI 10.1016/0014-5793(89)80482-X; IKEUCHI M, 1988, FEBS LETT, V241, P99, DOI 10.1016/0014-5793(88)81039-1; IRRGANG KD, 1995, J BIOL CHEM, V270, P17588, DOI 10.1074/jbc.270.29.17588; KOBAYASHI M, 1990, FEBS LETT, V260, P138, DOI 10.1016/0014-5793(90)80086-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM E, 1983, BIOCHIM BIOPHYS ACTA, V724, P201, DOI 10.1016/0005-2728(83)90139-1; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; MIYAZAKI A, 1989, BIOCHIM BIOPHYS ACTA, V933, P423; MONOD C, 1994, EMBO J, V13, P2747, DOI 10.1002/j.1460-2075.1994.tb06568.x; Morris EP, 1997, STRUCTURE, V5, P837, DOI 10.1016/S0969-2126(97)00237-2; MURATA N, 1988, FEBS LETT, V235, P283, DOI 10.1016/0014-5793(88)81280-8; NAGATSUKA T, 1991, BIOCHIM BIOPHYS ACTA, V1057, P223, DOI 10.1016/S0005-2728(05)80105-7; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; REDFEARN ER, 1962, PHYTOCHEMISTRY, V1, P147, DOI 10.1016/S0031-9422(00)82816-2; Rhee KH, 1997, NATURE, V389, P522, DOI 10.1038/39103; Sharma J, 1997, J BIOL CHEM, V272, P3935, DOI 10.1074/jbc.272.7.3935; WEBBER AN, 1989, FEBS LETT, V242, P251; Zechmeister L, 1943, J AM CHEM SOC, V65, P1522, DOI 10.1021/ja01248a025; Zheleva D, 1996, BIOCHEMISTRY-US, V35, P15074, DOI 10.1021/bi961382h	32	89	99	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16122	16127		10.1074/jbc.273.26.16122	http://dx.doi.org/10.1074/jbc.273.26.16122			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632665	hybrid			2022-12-25	WOS:000074436600036
J	Champigny, G; Voilley, N; Waldmann, R; Lazdunski, M				Champigny, G; Voilley, N; Waldmann, R; Lazdunski, M			Mutations causing neurodegeneration in Caenorhabditis elegans drastically alter the pH sensitivity and inactivation of the mammalian H+-gated Na+ channel MDEG1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS SUBUNITS; SODIUM-CHANNEL; CLONING; EXPRESSION; NEURONS	The mammalian degenerin MDEG1 belongs to the nematode degenerin/epithelial Na+ channel superfamily. It is constitutively activated by the same mutations that cause gain-of-function of the Caenorhabditis elegans degenerins and neurodegeneration. ASIC and DRASIC, which were recently cloned, are structural homologues of MDEG1 and behave as H+-gated cation channels, MDEG1 is also a H+-activated Na+ channel, but it differs from ASIC in its lower pH sensitivity and slower kinetics, In addition to the generation of a constitutive current, mutations in MDEG1 also alter the properties of the H+-gated current. Replacement of Gly-430 in MDEG1 by bulkier amino acids, such as Val, Phe, or Thr, drastically increases the H+ sensitivity of the channel (half-maximal pH (pH(m)) similar to 4.4 for MDEG1, pH(m) similar to 6.7 for the different mutants). Furthermore, these replacements completely suppress the inactivation observed with the wild-type channel and increase the sensitivity of the H+-gated channel to blockade by amiloride by a factor of 10 without modification of its conductance and ionic selectivity. These results as well as those obtained with other mutants clearly indicate that the region surrounding Gly-430, situated just before the second transmembrane segment, is essential for pH sensitivity and gating.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.	ipmc@ipmc.cnrs.fr	Waldmann, Rainer/Q-2108-2016	Waldmann, Rainer/0000-0002-4599-2926				AKAIKE N, 1994, PROG NEUROBIOL, V43, P73, DOI 10.1016/0301-0082(94)90016-7; Barbry P, 1997, AM J PHYSIOL-GASTR L, V273, pG571, DOI 10.1152/ajpgi.1997.273.3.G571; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GARTY H, 1994, FASEB J, V8, P522, DOI 10.1096/fasebj.8.8.8181670; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831, DOI 10.1152/jn.1983.49.3.831; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; RENARD S, 1994, J BIOL CHEM, V269, P12981; UENO S, 1992, J PHYSIOL-LONDON, V447, P309, DOI 10.1113/jphysiol.1992.sp019004; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	28	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15418	15422		10.1074/jbc.273.25.15418	http://dx.doi.org/10.1074/jbc.273.25.15418			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624125	hybrid			2022-12-25	WOS:000074284200019
J	Ohtaki, T; Ogi, K; Masuda, Y; Mitsuoka, K; Fujiyoshi, Y; Kitada, C; Sawada, H; Onda, H; Fujino, M				Ohtaki, T; Ogi, K; Masuda, Y; Mitsuoka, K; Fujiyoshi, Y; Kitada, C; Sawada, H; Onda, H; Fujino, M			Expression, purification, and reconstitution of receptor for pituitary adenylate cyclase-activating polypeptide - Large-scale purification of a functionally active G protein-coupled receptor produced in Sf9 insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; MOLECULAR-CLONING; PACAP RECEPTOR; MUSCARINIC RECEPTORS; SIGNAL-TRANSDUCTION; TISSUE DISTRIBUTION; SPLICE VARIANTS; I RECEPTOR; RAT-BRAIN; PEPTIDE	Human pituitary adenylate cyclase-activating polypeptide (PACAP) receptor was expressed in Sf9 insect cells and Chinese hamster ovary (CHO) cells. The recombinant receptor in Sf9 cell membranes had low affinity for I-125-PACAP27 (K-d = 155.3 pM) and was insensitive to guanosine 5'-O-3-thiotriphosphate (GTP gamma S), whereas the receptor in CHO membranes had a high affinity (K-d = 44.4 pM) and was GTP gamma S sensitive, The receptor in Sf9 membranes was converted to a high affinity state (K-d = 20-40 pM) following solubilization with digitonin, A large quantity (2 mg from 8 liters of insect cells) of the purified PACAP receptors (B-max = 23.9 nmol/mg of protein) were obtained in a digitonin-induced high affinity state (K-d = 17.3 pM) using biotinylated ligand affinity chromatography. The apparent molecular weight of the purified receptor (M-r = 48,000) was smaller than that of the receptor from CHO cells (M-r = 58,000) due to differences in asparagine-linked sugar chains, The purified receptor reverted to a low affinity state (K-d = 182.6 pM) upon reconstitution into lipid vesicles, however, the receptor reconstituted with G(s) protein had a high affinity (K-d = 40.2 pM) and was GTP gamma S sensitive. [S-35]GTP gamma S binding to the reconstituted G(s) protein was enhanced by PACAP27 and PACAP38 (EC50 = 42.8 and 9.4 pM, respectively) but not by antagonist PACAP(6-38), indicating that the purified receptor was functionally active.	Takeda Chem Ind Ltd, Discovery Res Labs 1, Pharmaceut Discovery Res Div, Tsukuba, Ibaraki 3004293, Japan; Kyoto Univ, Fac Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Takeda Chem Ind Ltd, Div Pharmaceut Res, Biotechnol Labs, Yodogawa Ku, Osaka 5328686, Japan	Takeda Chemical Industries; Kyoto University; Takeda Chemical Industries	Ohtaki, T (corresponding author), Takeda Chem Ind Ltd, Discovery Res Labs 1, Pharmaceut Discovery Res Div, Wadai 10, Tsukuba, Ibaraki 3004293, Japan.		Fujiyoshi, Yoshinori/E-5989-2012	Fujiyoshi, Yoshinori/0000-0002-8070-1493				Altmann F, 1996, TRENDS GLYCOSCI GLYC, V8, P101, DOI 10.4052/tigg.8.101; ARIMURA A, 1991, ENDOCRINOLOGY, V129, P2787, DOI 10.1210/endo-129-5-2787; ARIMURA A, 1994, ANN NY ACAD SCI, V739, P228, DOI 10.1111/j.1749-6632.1994.tb19825.x; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; Cavallaro S, 1996, MOL PHARMACOL, V50, P60; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226; CUBERO A, 1984, J BIOL CHEM, V259, P1344; CULLER MD, 1991, ENDOCRINOLOGY, V129, P2260, DOI 10.1210/endo-129-4-2260; DELPORTE C, 1995, MOL CELL ENDOCRINOL, V107, P71, DOI 10.1016/0303-7207(94)03424-R; Doi T, 1997, EUR J BIOCHEM, V248, P139, DOI 10.1111/j.1432-1033.1997.00139.x; Donnelly D, 1997, FEBS LETT, V409, P431, DOI 10.1016/S0014-5793(97)00546-2; FAUSSNER A, 1991, J BIOL CHEM, V266, P9442; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; GRIGORIADIS DE, 1989, ENDOCRINOLOGY, V125, P3068, DOI 10.1210/endo-125-6-3068; HAGA K, 1986, J BIOL CHEM, V261, P133; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HAZUM E, 1986, J BIOL CHEM, V261, P3043; HOSOYA M, 1993, BIOCHEM BIOPH RES CO, V194, P133, DOI 10.1006/bbrc.1993.1795; KIMURA C, 1990, BIOCHEM BIOPH RES CO, V166, P81, DOI 10.1016/0006-291X(90)91914-E; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Masuda Y, 1996, J PHARMACOL EXP THER, V279, P675; MATSUMOTO H, 1993, ENDOCRINOLOGY, V133, P2150, DOI 10.1210/en.133.5.2150; MICHEL H, 1980, P NATL ACAD SCI-BIOL, V77, P338, DOI 10.1073/pnas.77.1.338; MILLS A, 1993, FEBS LETT, V320, P130, DOI 10.1016/0014-5793(93)80077-8; MIYAMOTO Y, 1994, BBA-GENE STRUCT EXPR, V1218, P297, DOI 10.1016/0167-4781(94)90181-3; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; MORROW JA, 1993, FEBS LETT, V329, P99, DOI 10.1016/0014-5793(93)80202-6; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; Nekrasova E, 1996, EUR J BIOCHEM, V238, P28, DOI 10.1111/j.1432-1033.1996.0028q.x; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; OGI K, 1993, BIOCHEM BIOPH RES CO, V196, P1511, DOI 10.1006/bbrc.1993.2423; OGI K, 1990, BIOCHEM BIOPH RES CO, V173, P1271, DOI 10.1016/S0006-291X(05)80924-6; OHTAKI T, 1990, BIOCHEM BIOPH RES CO, V171, P838, DOI 10.1016/0006-291X(90)91222-E; Ohtaki T, 1996, ANN NY ACAD SCI, V805, P590; OHTAKI T, 1993, J BIOL CHEM, V268, P26650; OHTAKI T, 1996, BIOMETHODS, V7, P45; ONARAN HO, 1993, MOL PHARMACOL, V43, P245; PARKER EM, 1991, J BIOL CHEM, V266, P519; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; Pisegna JR, 1996, J BIOL CHEM, V271, P17267, DOI 10.1074/jbc.271.29.17267; POTTER LT, 1991, MOL PHARMACOL, V39, P211; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; ROBBERECHT P, 1992, EUR J BIOCHEM, V207, P239, DOI 10.1111/j.1432-1033.1992.tb17043.x; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; Sagne C, 1996, BIOCHEM J, V316, P825, DOI 10.1042/bj3160825; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHEIKH SP, 1991, J BIOL CHEM, V266, P23959; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SVOBODA M, 1993, BIOCHEM BIOPH RES CO, V195, P881, DOI 10.1006/bbrc.1993.2127; Tanaka T, 1998, J BIOL CHEM, V273, P3247, DOI 10.1074/jbc.273.6.3247; TATSUNO I, 1991, ENDOCRINOLOGY, V129, P1797, DOI 10.1210/endo-129-4-1797; TRIMBLE RB, 1991, J BIOL CHEM, V266, P1646; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; WATANABE T, 1992, BIOCHEM BIOPH RES CO, V182, P403, DOI 10.1016/S0006-291X(05)80159-7; WATANABE T, 1995, AM J PHYSIOL-ENDOC M, V269, pE903, DOI 10.1152/ajpendo.1995.269.5.E903; Wehmeyer A, 1997, J NEUROCHEM, V68, P1361; WIELAND T, 1994, METHOD ENZYMOL, V237, P3; YADA T, 1994, J BIOL CHEM, V269, P1290	62	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15464	15473		10.1074/jbc.273.25.15464	http://dx.doi.org/10.1074/jbc.273.25.15464			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624132	hybrid			2022-12-25	WOS:000074284200026
J	Maru, Y; Yamaguchi, S; Shibuya, M				Maru, Y; Yamaguchi, S; Shibuya, M			Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials	ONCOGENE			English	Article						Flt-1; VEGF; BCR-ABL; tyrosine kinase; transformation	BCR-ABL ONCOGENE; TYROSINE KINASE; SIGNAL-TRANSDUCTION; V-ABL; PHILADELPHIA-CHROMOSOME; C-ABL; PROTEIN; ACTIVATION; LEUKEMIA; DOMAIN	A paradox of Flt-1, a tyrosine kinase receptor for vascular endothelial growth factor (VEGF), is that the ligand cannot activate the receptor to stimulate growth of cells that exogenously overexpress the receptor. In order to find Flt-1 kinase-dependent biological systems, we obtained for the first time activated forms of the Flt-1 kinase in a ligand-independent manner. Replacement of the ABL sequences in the human leukemia oncoprotein BCR-ABL with the cytoplasmic domain of Flt-1 (BCR-FLT) followed by a retroviral random mutagenesis scheme gave constitutively active artificial chimera BCR-FLTm with mutations within the Flt-1 sequence. Like BCR-ABL it could, but not the original BCR-FLT, transform Rat1 fibroblasts, abrogate cytokine dependence in Ba/F3 cells, and induce neurite-like structures in neuronal PC12 cells. Interestingly, Rat1 cells transformed by BCR-FLTm formed tube-like structures in basement membrane matrix. BCR-FLTm retroviruses may be a very useful tool to investigate an as yet uncovered functions of the Flt-1 kinase.	Univ Tokyo, Inst Med Sci, Dept Genet, Tokyo, Japan	University of Tokyo	Maru, Y (corresponding author), Univ Tokyo, Inst Med Sci, Dept Genet, Tokyo, Japan.							AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Ahmed A, 1997, LAB INVEST, V76, P779; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FREEMAN AE, 1973, P NATL ACAD SCI USA, V70, P2415, DOI 10.1073/pnas.70.8.2415; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Maru Y, 1996, EXP CELL RES, V229, P438, DOI 10.1006/excr.1996.0389; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MATHEYPREVOT B, 1988, MOL CELL BIOL, V8, P234, DOI 10.1128/MCB.8.1.234; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; NILSEN T, 1995, CELL, V41, P719; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PAJUSOLA K, 1992, CANCER RES, V52, P5738; Parmar K, 1996, J VIROL, V70, P1009, DOI 10.1128/JVI.70.2.1009-1015.1996; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; SEETHARAM L, 1995, ONCOGENE, V10, P135; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Ziche M, 1997, LAB INVEST, V76, P517	58	49	50	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2585	2595		10.1038/sj.onc.1201786	http://dx.doi.org/10.1038/sj.onc.1201786			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632135				2022-12-25	WOS:000073698200003
J	Nees, M; van Wijngaarden, E; Bakos, E; Schneider, A; Durst, M				Nees, M; van Wijngaarden, E; Bakos, E; Schneider, A; Durst, M			Identification of novel molecular markers which correlate with HPV-induced tumor progression	ONCOGENE			English	Article						HPV (human papillomavirus); cervical cancer; prognostic markers; differential display; tumor progression	HUMAN PAPILLOMAVIRUS INFECTION; DIFFERENTIAL DISPLAY; TRANSMEMBRANE-4 SUPERFAMILY; EPITHELIAL-CELLS; ALVEOLAR RHABDOMYOSARCOMA; MI-2 AUTOANTIGEN; GENETIC-ANALYSIS; CERVICAL-CANCER; UTERINE CERVIX; MESSENGER-RNAS	High risk HPVs (human papillomaviruses) are causally involved in the development of cervical cancer, However, other factors, such as somatic genetic alterations also play a decisive role in malignant conversion of cervical keratinocytes, Mutations and chromosomal aberrations are known to influence the pattern of gene expression, Therefore we used the recently developed RT-PCR based method of differential display of mRNAs to detect differences in gene expression which correlate with tumorigenicity. Non-tumorigenic HPV16-immortalized human foreskin keratinocytes (HPK IA) were compared with their tumorigenic counterparts and 49 different genes were identified which were either up-or downregulated. The identified genes encode proteins of the cytoskeleton and the extracellular matrix, the nuclear splicing apparatus, transcription regulators and membrane-associated proteins. The expression pattern of all genes was also examined by RNA-RNA in situ hybridization in biopsies of normal cervical epithelium, precancerous lesions and cancers. Two genes, C4.8 and C21.7, are of particular interest because their expression is upregulated in a subset of high grade precancerous lesions and in over 58% of cancers. These two genes may therefore be considered as putative progression markers. C4.8 is a new member of the transmembrane 4 (TM-4) protein family which includes tumor-associated antigens such as CD63 and TAPA-1, whereas C21.7 shows no significant homologies to any known genes or proteins.	Univ Jena, Abt Frauenheilkunde, D-07740 Jena, Germany; Deutsch Krebsforschungszentrum, ATV 0615, D-69120 Heidelberg, Germany	Friedrich Schiller University of Jena; Helmholtz Association; German Cancer Research Center (DKFZ)	Durst, M (corresponding author), Univ Jena, Abt Frauenheilkunde, Bachstr 18, D-07740 Jena, Germany.		Nees, Matthias/AAT-5577-2020; Nees, Matthias/W-6596-2018	Nees, Matthias/0000-0002-9034-301X				Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; Barr FG, 1997, CURR TOP MICROBIOL, V220, P113; BAUER D, 1994, PCR METH APPL, V4, P97; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Berthod F, 1997, J INVEST DERMATOL, V108, P737, DOI 10.1111/1523-1747.ep12292122; BUIJS A, 1995, ONCOGENE, V10, P1511; CALVIO C, 1995, RNA, V1, P724; CHEN TM, 1993, CANCER RES, V53, P1167; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cuzick J, 1996, EUR J CANCER, V32A, P836, DOI 10.1016/0959-8049(95)00650-8; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; DEPREZ RHL, 1995, ONCOGENE, V10, P1521; DESPRES N, 1995, J CLIN INVEST, V95, P1891, DOI 10.1172/JCI117870; Durst M, 1995, CANCER GENET CYTOGEN, V85, P105, DOI 10.1016/0165-4608(95)00155-7; DURST M, 1987, ONCOGENE, V1, P251; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GE Q, 1995, J CLIN INVEST, V96, P1730, DOI 10.1172/JCI118218; Gerecke DR, 1997, GENOMICS, V41, P236, DOI 10.1006/geno.1997.4638; Gress TM, 1996, ONCOGENE, V13, P1819; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Herrington CS, 1996, J CLIN PATHOL, V49, P493, DOI 10.1136/jcp.49.6.493; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; HOPPESEYLER F, 1995, J MOL MED, V73, P529; KIVIAT NB, 1992, INT J GYNECOL PATHOL, V11, P197, DOI 10.1097/00004347-199207000-00005; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, METHOD ENZYMOL, V254, P304; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Londesborough P, 1996, INT J CANCER, V69, P364; Mannion BA, 1996, J IMMUNOL, V157, P2039; Muir C.S., 1987, CANC INCIDENCE 5 CON; Nindl I, 1996, J VIROL METHODS, V62, P81, DOI 10.1016/0166-0934(96)02084-8; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; PONTEN J, 1995, INT J CANCER, V63, P317, DOI 10.1002/ijc.2910630229; REID R, 1991, AM J OBSTET GYNECOL, V164, P1461, DOI 10.1016/0002-9378(91)91425-V; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SALAMINO F, 1994, CELL CALCIUM, V15, P28, DOI 10.1016/0143-4160(94)90101-5; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SCHIFFMAN MH, 1992, JNCI-J NATL CANCER I, V84, P394, DOI 10.1093/jnci/84.6.394; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; Schneider A, 1996, AM J OBSTET GYNECOL, V174, P1534, DOI 10.1016/S0002-9378(96)70602-6; SEAGON S, 1994, CANCER RES, V54, P5593; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; TSUTSUMI K, 1992, AM J PATHOL, V140, P255; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531; WOODWORTH CD, 1988, CANCER RES, V48, P4620; WOODWORTH CD, 1989, J VIROL, V57, P572; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; XI LF, 1995, J INFECT DIS, V172, P747, DOI 10.1093/infdis/172.3.747; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zinszner H, 1997, ONCOGENE, V14, P451, DOI 10.1038/sj.onc.1200854	59	27	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2447	2458		10.1038/sj.onc.1201785	http://dx.doi.org/10.1038/sj.onc.1201785			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627111				2022-12-25	WOS:000073672300003
J	Dahia, PLM; FitzGerald, MG; Zhang, X; Marsh, DJ; Zheng, ZM; Pietsch, T; von Deimling, A; Haluska, FG; Haber, DA; Eng, C				Dahia, PLM; FitzGerald, MG; Zhang, X; Marsh, DJ; Zheng, ZM; Pietsch, T; von Deimling, A; Haluska, FG; Haber, DA; Eng, C			A highly conserved processed PTEN pseudogene is located on chromosome band 9p21	ONCOGENE			English	Article						MMAC1; TEP1; 9p; Cowden; pseudogene	COWDEN DISEASE; DELETIONS; GENE	PTEN/MMAC1/TEP1, encoding a dual-specificity phosphatase, is a tumor suppressor gene which has recently been cloned and mapped to chromosome 10q23.3. We have shown that germline mutations of PTEN are present in individuals with two hamartoma syndromes: Cowden Syndrome, associated with a predisposition to breast and thyroid cancers, and Bannayan-Zonana syndrome. Somatic mutations of PTEN have been reported in a variety of human cancer cell lines, suggesting a potential role for this gene in the pathogenesis of human malignancies. We report the identification of a highly conserved PTEN processed pseudogene, psi PTEN, which shares over 98% homology with the coding region of functional PTEN, and its localisation to chromosome 9p21. The high sequence homology of psi PTEN with the PTEN transcript may potentially lead to misinterpretation when performing mutation analyses based on cDNA templates. Caution should be exerted when using such screening approaches.	Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Dept Adult Oncol, Translat Res Lab, Boston, MA 02115 USA; Dana Farber Canc Inst, Program Populat Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA; Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; Univ Cambridge, Canc Res Campaign, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Bonn; CRUK Cambridge Institute; University of Cambridge	Eng, C (corresponding author), Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Dept Adult Oncol, Translat Res Lab, SM822, Boston, MA 02115 USA.		Marsh, Deborah J/I-1491-2014; von Deimling, Andreas/F-7774-2013	Marsh, Deborah J/0000-0001-5899-4931; von Deimling, Andreas/0000-0002-5863-540X; Eng, Charis/0000-0002-3693-5145				Dahia PLM, 1997, CANCER RES, V57, P4710; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; EINHORN S, 1993, LEUKEMIA LYMPHOMA, V11, P191, DOI 10.3109/10428199309086995; Eng C, 1997, J Genet Couns, V6, P181, DOI 10.1023/A:1025664119494; GOJOBORI T, 1982, J MOL EVOL, V18, P36; Ivanchuk SM, 1997, ONCOGENE, V14, P1811, DOI 10.1038/sj.onc.1201016; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LI WH, 1987, J MOL EVOL, V25, P333; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Longy M, 1996, ANN GENET-PARIS, V39, P35; Maestre J, 1995, EMBO J, V14, P6333, DOI 10.1002/j.1460-2075.1995.tb00324.x; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253	18	80	84	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2403	2406		10.1038/sj.onc.1201762	http://dx.doi.org/10.1038/sj.onc.1201762			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620558				2022-12-25	WOS:000073428000013
J	Jefferson, AB; Klippel, A; Williams, LT				Jefferson, AB; Klippel, A; Williams, LT			Inhibition of mSOS-activity by binding of phosphatidylinositol 4,5-P-2 to the mSOS pleckstrin homology domain	ONCOGENE			English	Article						SOS; Ras; pleckstrin homology domain; phosphatidylinositol 4,5P(2)	NUCLEOTIDE EXCHANGE FACTOR; BRUTON TYROSINE KINASE; PH DOMAIN; G(BETA-GAMMA) SUBUNITS; SIGNAL-TRANSDUCTION; FACTOR SOS; RAS; PROTEINS; RECEPTOR; GRB2	There are several recently reported examples of inositol phospholipids binding to pleckstrin homology (PH) domains of proteins. The PH domain of SOS, a guanine nucleotide exchange factor for Ras, binds to phosphatidylinositol 4,5 bisphosphate (PtdIns4,5P(2)). We found that binding of PtdIns4,5P(2) to 6-his-tagged recombinant mSOS in vitro inhibits the ability of SOS to catalyze the association of GTP on p21(RAS). This inhibition was specific for PtdIns4,5P(2): a number of other phosphatidylinositols and phosphatidylserine failed to inhibit Ras GTP-association. We confirmed that the specificity of binding of PtdIns's to recombinant GST-SOS-PH domain is the same as the specificity of PtdIns's for inhibition of SOS activity: namely, that only Ptdins4,5P(2) binds significantly to the SOS-PH domain. In addition, the inhibition of Ras GTP-binding is not blocked by excess free inositols suggesting that SOS binds to PtdIns4,5P(2) with higher affinity than it binds to free inositols. Addition of SOS-PH domain protein prevented the inhibition of SOS by PtdIns4,5P(2) as did addition of the high affinity PtdIns4,5P(2)-binding drug neomycin. This confirmed that SOS inhibition is mediated by the SOS-PH domain binding to the inositol moiety of PtdIns4,5P(2). Binding of Grb2 to SOS did not prevent the inhibition of SOS by Ptdins4,5P(2) suggesting that there must be another mechanism for regulating this inhibition. These findings show that the phospholipid PtdIns4,5P(2) can suppress the activity of an enzyme involved in signal transduction and suggest that this inhibitory effect must be relieved when SOS is activated.	Chiron Corp, Emeryville, CA 94608 USA	Novartis	Jefferson, AB (corresponding author), Chiron Corp, 4560 Horton St, Emeryville, CA 94608 USA.							ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Byrne JL, 1996, ONCOGENE, V13, P2055; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLEY WB, 1994, INFECT DIS CLIN PRAC, V3, P168, DOI 10.1097/00019048-199405000-00004; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; INGLEY E, 1994, J CELL BIOCHEM, V56, P436, DOI 10.1002/jcb.240560403; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LODHI S, 1979, BIOCHIM BIOPHYS ACTA, V557, P1, DOI 10.1016/0005-2736(79)90084-1; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	41	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2303	2310		10.1038/sj.onc.1201891	http://dx.doi.org/10.1038/sj.onc.1201891			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620547				2022-12-25	WOS:000073428000002
J	Kruger, A; Sanchez-Sweatman, OH; Martin, DC; Fata, JE; Ho, AT; Orr, FW; Ruther, U; Khokha, R				Kruger, A; Sanchez-Sweatman, OH; Martin, DC; Fata, JE; Ho, AT; Orr, FW; Ruther, U; Khokha, R			Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line	ONCOGENE			English	Article						TIMP-1; metastasis inhibition; transgenic mice; lacZ tagging	EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; MELANOMA-CELLS; IN-VIVO; EXPRESSION; INVASION; TUMOR; ANGIOGENESIS; SUPPRESSION; PROTEIN	Within the tumor-stromal microenvironment a disrupted balance between matrix metalloproteinases (MMPs) and their inhibitors compromises the integrity of the extracellular matrix and promotes malignancy. Tissue inhibitors of metalloproteinases (TIMPs) have been linked to tumor suppression in studies of genetically altered tissue culture cells and in analyses of clinical specimens in situ. We generated transgenic mice as a model system to test the relationship between TIMP-1 levels in a host organ and susceptibility to experimentally targeted metastasis. Ectopically overexpressed TIMP-1 in the brain resulted in a tissue microenvironment with elevated protein levels of this natural MMP inhibitor. Metastatic challenge provided by lacZ-tagged fibrosarcoma cells permitted high-resolution analysis of metastatic load and pattern. We found that elevated host TIMP-1 imposed resistance to experimental metastasis of fibrosarcoma: In TIMP-1 overexpressing mice, brain metastases were significantly reduced by 75% compared to wild-type littermates. Our findings demonstrate that ectopic TIMP-1 expression efficiently exerts a suppressive effect on metastasizing tumor cells.	Univ Western Ontario, London Reg Canc Ctr, Dept Oncol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Biochem, London, ON N6A 4L6, Canada; Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Dept Pathol, Toronto, ON M5G 2M9, Canada; Univ Manitoba, Hlth Sci Ctr, Dept Pathol, Winnipeg, MB R3A 1R9, Canada; Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; Hannover Medical School	Khokha, R (corresponding author), Univ Western Ontario, London Reg Canc Ctr, Dept Oncol, London, ON N6A 4L6, Canada.		Ho, Andrew Tri Van/D-9681-2019	Ho, Andrew Tri Van/0000-0002-5501-6419				BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUGNO M, 1995, SCIENCE, V5, P1; DECLERCK YA, 1992, CANCER RES, V52, P701; DERCOLE AJ, 1994, DEV BRAIN RES, V82, P213; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; KHOKHA R, 1992, J NATL CANCER I, V84, P1017, DOI 10.1093/jnci/84.13.1017; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KOOP S, 1995, CANCER RES, V55, P2520; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Martinson I, 1996, J PALLIATIVE CARE, V12, P13, DOI 10.1177/082585979601200303; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MULLER M, 1995, PEDIATR NEUROSURG, V22, P204, DOI 10.1159/000120902; NUOVO GJ, 1995, CANCER RES, V55, P267; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; ROEB E, 1994, FEBS LETT, V349, P45, DOI 10.1016/0014-5793(94)00636-9; SanchezSweatman OH, 1996, INT J ONCOL, V8, P371; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0	21	80	88	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2419	2423		10.1038/sj.onc.1201774	http://dx.doi.org/10.1038/sj.onc.1201774			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620561				2022-12-25	WOS:000073428000016
J	Siddique, H; Zou, JP; Rao, VN; Reddy, ESP				Siddique, H; Zou, JP; Rao, VN; Reddy, ESP			The BRCA2 is a histone acetyltransferase	ONCOGENE			English	Article						BRCA2; histone acetyl transferase; protein-protein interaction; tumor suppressor	BREAST-CANCER SUSCEPTIBILITY; TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; GENE BRCA1; FAMILIES; ACETYLATION; MUTATION; YEAST; CBP	Patients carrying mutations in BRCA1 or BRCA2 tumor suppressor genes have shown to have high risk in developing breast and ovarian cancers. Two potential functions of BRCA2 were proposed which includes role in the regulation of transcription and also in DNA repair. Forty-five-amino acid region encoded by exon 3 of BRCA2 was shown to have transcriptional activation function. Recent studies of the several enzymes involved in acetylation and deacetylation of histone residues have revealed a possible relationship between gene transcriptional activation and histone acetylation, Since BRCA2 appear to function as a transcriptional factor, we have tested for Histone acetyl transferase (HAT) activity of BRCA2, Here, we present evidence that BRCA2 has intrinsic HAT activity, which maps to the aminoterminal region of BRCA2, Our results demonstrate that BRCA2 proteins acetylate primarily H3 and H4 of free histones. These observations suggest that HAT activity of BRCA2 may play an important role in the regulation of transcription and tumor suppressor function.	Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, Philadelphia, PA 19102 USA	Drexel University	Reddy, ESP (corresponding author), Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, MS 481,Broad & Vine St, Philadelphia, PA 19102 USA.				NCI NIH HHS [CA57322, CA51083, CA58642] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, R01CA058642, R01CA057322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CUI J, 1998, IN PRESS ONCOL REP; EASTON DF, 1993, AM J HUM GENET, V52, P678; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; Herrera JE, 1997, J BIOL CHEM, V272, P27253, DOI 10.1074/jbc.272.43.27253; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rao VN, 1996, ONCOGENE, V12, P523; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shao NS, 1996, ONCOGENE, V13, P1; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; TONIN P, 1995, J MED GENET, V32, P982, DOI 10.1136/jmg.32.12.982; Vaughn JP, 1996, CANCER RES, V56, P4590; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; WOOSTER R, 1995, TRENDS GENET, V11, P3, DOI 10.1016/S0168-9525(00)88974-X; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8	35	61	63	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2283	2285		10.1038/sj.onc.1202003	http://dx.doi.org/10.1038/sj.onc.1202003			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619837	Bronze			2022-12-25	WOS:000073298000013
J	Kojima, H; Endo, K; Moriyama, H; Tanaka, Y; Alnemri, ES; Slapak, CA; Teicher, B; Kufe, D; Datta, R				Kojima, H; Endo, K; Moriyama, H; Tanaka, Y; Alnemri, ES; Slapak, CA; Teicher, B; Kufe, D; Datta, R			Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; OVEREXPRESSION; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; CIS-DIAMMINEDICHLOROPLATINUM(II); INDUCTION; BCL-X(L); DRUGS	Acquired multidrug resistance to anti-cancer agents has been associated with overexpression of the P-glycoprotein and other members of the ATP-binding cassette superfamily. The present studies demonstrate that SCC-25 cells selected for resistance to the alkylating agent cisplatin (CDDP) overexpress the anti-apoptotic Bcl-x(L) protein. In contrast to parental cells, the SCC-25/CDDP-resistant variant failed to exhibit activation of caspase-3, cleavage of protein kinase C delta, and other characteristics of apoptosis in response to CDDP. Similar results were obtained when SCC-25/CDDP cells were exposed to the structurally and functionally unrelated antimetabolite l-beta-D-arabinofuranosyl-cytosine (ara-C). Other cells selected for resistance to doxorubicin or vincristine also exhibited overexpression of Bcl-x(L) and failed to respond to CDDP and ara-C with activation of caspase-3. The results further demonstrate that multidrug-resistant cells exhibit a block in the release of mitochondrial cytochrome c into the cytosol and that this effect is dependent on overexpression of Bcl-x(L). The demonstration that lysates from the resistant cells respond to the addition of cytochrome c with activation of caspase-3 confirms that the block in apoptosis is because of inhibition of mitochondrial cytochrome c release, These findings demonstrate that cells respond to diverse classes of anti-cancer drugs with overexpression of Bcl-x(L) and that this response represents another mechanism of acquired multidrug resistance.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Jikei Univ, Sch Med, Dept Otolaryngol, Tokyo 105, Japan; Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Jikei University; Jefferson University; Eli Lilly	Datta, R (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.	Rakesh_Datta@dfci.harvard.edu	Alnemri, Emad S/B-4526-2010		NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER; NCI NIH HHS [CA29431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FRAM RJ, 1982, CANCER RES, V42, P4050; FUTSCHER BW, 1994, BIOCHEM PHARMACOL, V47, P1601, DOI 10.1016/0006-2952(94)90538-X; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GRANT CE, 1994, CANCER RES, V54, P357; HOCKENBERY DM, 1990, NATURE, V38, P334; Huang Y, 1997, LEUKEMIA, V11, P253, DOI 10.1038/sj.leu.2400557; KAUFMANN SH, 1989, CANCER RES, V49, P5870; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LING V, 1997, CANC CHEMOTHER PHA S, V40, P3; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; TEICHER BA, 1987, CANCER RES, V47, P388; TEICHER BA, 1991, INT J CANCER, V47, P252, DOI 10.1002/ijc.2910470214; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMAN GJR, 1993, CANCER RES, V53, P1747; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	30	113	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16647	16650		10.1074/jbc.273.27.16647	http://dx.doi.org/10.1074/jbc.273.27.16647			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642215	hybrid			2022-12-25	WOS:000074545200005
J	Lee, SK; Kim, HJ; Na, SY; Kim, TS; Choi, HS; Im, SY; Lee, JW				Lee, SK; Kim, HJ; Na, SY; Kim, TS; Choi, HS; Im, SY; Lee, JW			Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; NUCLEAR-PROTEIN CBP; DNA-BINDING; LEUCINE-ZIPPER; TRANSCRIPTIONAL ACTIVATION; COILED COILS; GENE FAMILY; P300; ONCOGENE; COMPLEX	Steroid receptor coactivator-l (SRC-1) specifically bound to the transcription factor AP-I subunits c-Jun and c-Fos, as demonstrated by the yeast two-hybrid tests and glutathione S-transferase pull down assays. The c-Jun and c-Fos binding sites were localized to the C-terminal subregion of SRC-1 (amino acids 1101-1441) that encompasses the previously described histone acetyltransferase and receptor-binding domains. In mammalian cells, SRC-I, similar to the previous results with CBP-p300 (Arias, J., Alberts, A. S., Brindle, P., Claret, F. X., Smeal, T., Karin, M., Feramisco, J., and Montminy, M. (1994) Nature 370, 226-229; Bannister, A. J., and Kouzarides, T. (1995) EMBO J. 14, 4758-4762), potentiated the AP-l-mediated transactivations in a dose-dependent manner and derepressed the mutual inhibitions between nuclear receptors and AP-1. Furthermore, coexpression of p300 further enhanced this SRC-1-potentiated level of transactivations. Thus, we concluded that at least two distinct coactivator molecules may cooperate to regulate AP-l-dependent transactivations and mediate transrepression between AP-I and nuclear receptors in vivo.	Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Microbiol, Kwangju 500757, South Korea	Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University	Lee, JW (corresponding author), Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea.	jlee@chonnam.chonnam.ac.kr						ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AUSUBEL FM, 1995, CURRENT PROTOC0LS MO; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHOI HS, 1993, MOL ENDOCRINOL, V7, P1596, DOI 10.1210/me.7.12.1596; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KIM HJ, 1998, IN PRESS MOL ENDOCRI; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE JW, 1994, MOL ENDOCRINOL, V8, P1245, DOI 10.1210/me.8.9.1245; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	57	176	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16651	16654		10.1074/jbc.273.27.16651	http://dx.doi.org/10.1074/jbc.273.27.16651			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642216	hybrid			2022-12-25	WOS:000074545200006
J	Mannstadt, M; Luck, MD; Gardella, TJ; Juppner, H				Mannstadt, M; Luck, MD; Gardella, TJ; Juppner, H			Evidence for a ligand interaction site at the amino-terminus of the parathyroid hormone (PTH)/PTH-related protein receptor from cross-linking and mutational studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEO-SARCOMA CELLS; PEPTIDE RECEPTOR; PLASMA-MEMBRANE; BINDING; AGONIST; DETERMINANTS; MUTAGENESIS; EXPRESSION; PTH-(1-34); CALCITONIN	Low resolution mutational studies have indicated that the amino-terminal extracellular domain of the rat parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor (rP1R) interacts with the carboxyl-terminal portion of PTH-(1-34) or PTHrP-(1-36), To further define ligand-receptor interactions, we prepared a fully functional photoreactive analog of PTHrP, [Ile(5),Bpa(23),Tyr(36)] PTHrP-(1-36)-amide ([Bpa(23)]PTHrP, where Bpa is p-benzoyl-L-phenylalanine), Upon photolysis, radioiodinated [Bpa23]PTHrP covalently and specifically bound to the rP1R, CNBr cleavage of the broad approximate to 80-kDa complex yielded a radiolabeled approximate to 9-kDa nonglycosylated protein band that could potentially be assigned to rP1R residues 23-63, Tyr(23) being the presumed amino-terminus of the receptor. This assignment was confirmed using a mutant rP1R (rP1R-M63I) that yielded, upon photoligand binding and CNBr digestion, a broad protein band of approximate to 46 kDa, which was reduced to a sharp band of approximate to 20 kDa upon deglycosylation, CNBr digestion of complexes formed with two additional rP1R double mutants (rP1R-M63I/L40M and rP1R-M63I/L41M) yielded non-glycosylated protein bands that were approximate to 6 kDa in size, indicating that [Bpa23]PTHrP cross-links to amino acids 23-40 of the rP1R, This segment overlaps a receptor region previously identified by deletion mapping to be important for ligand binding. Alanine scanning of this region revealed two residues, Thr(33) and Gln(37), as being functionally involved in ligand binding. Thus, the convergence of photoaffinity cross-linking and mutational data demonstrates that the extreme amino-terminus of the rP1R participates in ligand binding.	Massachusetts Gen Hosp, Endocrine Unit, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Childrens Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Juppner, H (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Dept Med, Wellman 503,50 Blossom St, Boston, MA 02114 USA.		Mannstadt, Michael/AAO-1124-2020	Mannstadt, Michael/0000-0003-0867-9778	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-11794] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Behar V, 1996, ENDOCRINOLOGY, V137, P4217, DOI 10.1210/en.137.10.4217; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1997, J BONE MINER RES, V12, pS363; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; Clark JA, 1998, MOL ENDOCRINOL, V12, P193, DOI 10.1210/me.12.2.193; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; ORLOFF JJ, 1989, ENDOCR REV, V10, P476, DOI 10.1210/edrv-10-4-476; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; Segre Gino V., 1996, P377; SHIGENO C, 1988, J BIOL CHEM, V263, P3872; SHIGENO C, 1988, J BIOL CHEM, V263, P3864; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Suva LJ, 1997, J PHARMACOL EXP THER, V283, P876; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; Turner PR, 1998, J BIOL CHEM, V273, P3830, DOI 10.1074/jbc.273.7.3830; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; YAMAMOTO I, 1988, ENDOCRINOLOGY, V122, P1208, DOI 10.1210/endo-122-4-1208; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	33	90	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16890	16896		10.1074/jbc.273.27.16890	http://dx.doi.org/10.1074/jbc.273.27.16890			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642250	hybrid			2022-12-25	WOS:000074545200040
J	Fraser, RA; Heard, DJ; Adam, S; Lavigne, AC; Le Douarin, B; Tora, L; Losson, R; Rochette-Egly, C; Chambon, P				Fraser, RA; Heard, DJ; Adam, S; Lavigne, AC; Le Douarin, B; Tora, L; Losson, R; Rochette-Egly, C; Chambon, P			The putative cofactor TIF1 alpha is a protein kinase that is hyperphosphorylated upon interaction with liganded nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; HUMAN ESTROGEN-RECEPTOR; RETINOIC ACID RECEPTOR; ACTIVATING DOMAINS; TRANSCRIPTION; COACTIVATORS; ANTIBODIES; COMPLEX; DECADE; AF-2	Ligand-induced gene activation by nuclear receptors (NRs) is a complex process requiring dissociation of corepressors and recruitment of coactivators. The putative transcriptional intermediary factor TIF1 alpha has been previously characterized as a nuclear protein that interacts directly with the AF-2 ligand-dependent activating domain present in the ligand-binding domain of numerous steroid and nonsteroid receptors, including the estrogen (ER alpha) and retinoid X (RXR alpha) receptors. We report here that TIF1 alpha is both a phosphoprotein and a protein kinase. TIF1 alpha coexpressed in COS-l cells with RXRa or ERa! is phosphorylated and becomes hyperphosphorylated upon ligand treatment. This hyperphosphorylation requires the binding of TIF1 alpha to transcriptionally active NRs since it is prevented by mutations either in the core (alpha-helix 12 of the ligand-binding domain) of the AF-2 activating domains of RXR alpha and ER alpha or in the NR box of TIF1 alpha that are known to prevent TIF1 alpha-NR interactions. Thus, TIF1 alpha is a phosphoprotein that undergoes ligand-dependent hyperphosphorylation as a consequence of nuclear receptor binding. We further show that purified recombinant TIF1 alpha possesses intrinsic kinase activity and that, in addition to autophosphorylation, TIF1 alpha selectively phosphorylates the transcription factors TFIIE alpha, TAF(II)28, and TAF(II)55 in vitro. These latter results raise the possibility that TIF1 alpha may act, at least in part, by phosphorylating and modifying the activity of components of the transcriptional machinery.	Universite Louis Pasteur, Coll France, CNRS,INSERM, Inst Genet & Biol Mol Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chambon, P (corresponding author), Universite Louis Pasteur, Coll France, CNRS,INSERM, Inst Genet & Biol Mol Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, France.	igbmc@igbmc.u-strasbg.fr	Tora, Laszlo/E-9999-2018; Lavigne, Anne-Claire/O-8805-2015	Tora, Laszlo/0000-0001-7398-2250; 				ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Losson R, 1997, BIOL CHEM, V378, P579; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	39	47	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16199	16204		10.1074/jbc.273.26.16199	http://dx.doi.org/10.1074/jbc.273.26.16199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632676	Green Published, hybrid			2022-12-25	WOS:000074436600047
J	Jeyakumar, LH; Copello, JA; O'Malley, AM; Wu, GM; Grassucci, R; Wagenknecht, T; Fleischer, S				Jeyakumar, LH; Copello, JA; O'Malley, AM; Wu, GM; Grassucci, R; Wagenknecht, T; Fleischer, S			Purification and characterization of ryanodine receptor 3 from mammalian tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; CARDIAC SARCOPLASMIC-RETICULUM; CHICKEN SKELETAL-MUSCLE; FK506 BINDING-PROTEIN; CA2+ RELEASE; MICE LACKING; ELECTRON-MICROSCOPY; TERMINAL CISTERNAE; FEET STRUCTURES; SMOOTH-MUSCLE	The ryanodine receptors are intracellular Ca2+ release channels that play a key role in cell signaling via Ca2+. There are three isoforms, Isoform 1 from skeletal muscle and isoform 2 from heart have been characterized. Isoform 3 is widely distributed in many mammalian tissues although in minuscule amounts, Its low abundance has hampered its study. We now describe methodology to isolate mammalian isoform 3 in amounts sufficient for biochemical and biophysical characterization, Bovine diaphragm sarcoplasmic reticulum fractions enriched in terminal cisternae containing both isoforms 1 (>95%) and 3 (<5% of the ryanodine binding) served as starting source, Isoform 3 was selectively immunoprecipitated from the 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonic acid (CHAPS)-solubilized fraction and eluted with peptide epitope. Isoform 3 thus prepared is highly purified as characterized by SDS-polyacryamide gel electrophoresis, Coomassie Blue staining, and by high affinity ryanodine binding. The purified isoform 3 was incorporated into planar lipid bilayers, and its channel properties were studied. Channel characteristics in common with the other two isoforms are slope conductance, higher selectivity to Ca2+ versus K+ (P(Ca/K)similar to 6), and response to drugs and Ligands. In its response to Ca2+ and ATP, it more closely resembles isoform 2. The first two-dimensional structure of isoform 3 was obtained by cryoelectron microscopy and image enhancement techniques.	Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA; Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, New York State Dept Hlth, Albany, NY 12201 USA	Vanderbilt University; Vanderbilt University; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Fleischer, S (corresponding author), Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA.	fleiscs@ctrvax.Vanderbilt.edu			NHLBI NIH HHS [HL32711, 5 T32 HLO7411-19] Funding Source: Medline; NIAMS NIH HHS [AR40615] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711, T32HL007411] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040615] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIREY JA, 1990, J BIOL CHEM, V265, P14187; Barg S, 1997, AM J PHYSIOL-CELL PH, V272, pC1726, DOI 10.1152/ajpcell.1997.272.5.C1726; Bennett DL, 1996, J BIOL CHEM, V271, P6356, DOI 10.1074/jbc.271.11.6356; BULL R, 1993, FEBS LETT, V331, P223, DOI 10.1016/0014-5793(93)80341-Q; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; Conti A, 1996, BIOCHEM J, V316, P19, DOI 10.1042/bj3160019; Copello JA, 1997, BIOPHYS J, V73, P141, DOI 10.1016/S0006-3495(97)78055-X; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DiJulio DH, 1997, J BIOL CHEM, V272, P15687, DOI 10.1074/jbc.272.25.15687; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HERRMANNFRANK A, 1991, PFLUG ARCH EUR J PHY, V418, P353, DOI 10.1007/BF00550873; Ikemoto T, 1997, J PHYSIOL-LONDON, V501, P305, DOI 10.1111/j.1469-7793.1997.305bn.x; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Jeyakumar LH, 1998, BIOPHYS J, V74, pA58; KUWAJIMA G, 1992, NEURON, V9, P1133, DOI 10.1016/0896-6273(92)90071-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1992, BIOCHEM J, V288, P553, DOI 10.1042/bj2880553; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; LEDBETTER MW, 1994, J BIOL CHEM, V269, P31544; LEPAULT J, 1983, J MICROSC-OXFORD, V129, P89, DOI 10.1111/j.1365-2818.1983.tb04163.x; LESH RE, 1993, CIRC RES, V72, P481, DOI 10.1161/01.RES.72.2.481; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNN S, 1995, FEBS LETT, V372, P6, DOI 10.1016/0014-5793(95)00924-X; Marziah G, 1996, FEBS LETT, V394, P76, DOI 10.1016/0014-5793(96)00944-1; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; Miyatake R, 1996, FEBS LETT, V395, P123, DOI 10.1016/0014-5793(96)01022-8; Murayama T, 1997, J BIOL CHEM, V272, P24030, DOI 10.1074/jbc.272.38.24030; Murayama T, 1996, J BIOL CHEM, V271, P5079; OBRIEN J, 1993, BIOPHYS J, V65, P2418, DOI 10.1016/S0006-3495(93)81303-1; OBRIEN J, 1995, BIOPHYS J, V68, P471, DOI 10.1016/S0006-3495(95)80208-0; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; Ottini L, 1996, BIOCHEM J, V315, P207, DOI 10.1042/bj3150207; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; PERCIVAL AL, 1994, BIOPHYS J, V67, P1834, DOI 10.1016/S0006-3495(94)80665-4; RADERMACHER M, 1992, BIOPHYS J, V61, P936, DOI 10.1016/S0006-3495(92)81900-8; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCHINDLER H, 1989, METHOD ENZYMOL, V171, P225; SHARMA MR, 1997, BIOPHYS J, V71, pA332; SHOMER NH, 1994, BIOPHYS J, V67, P641, DOI 10.1016/S0006-3495(94)80524-7; Sonnleitner A, 1997, CELL CALCIUM, V21, P283, DOI 10.1016/S0143-4160(97)90116-0; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKEKURA H, 1995, P NATL ACAD SCI USA, V92, P3381, DOI 10.1073/pnas.92.8.3381; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; Verma V, 1996, BIOCHEM J, V319, P449, DOI 10.1042/bj3190449	66	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16011	16020		10.1074/jbc.273.26.16011	http://dx.doi.org/10.1074/jbc.273.26.16011			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632651	hybrid			2022-12-25	WOS:000074436600022
J	Jin, W; Huang, ESC; Bi, WQ; Cote, GJ				Jin, W; Huang, ESC; Bi, WQ; Cote, GJ			Exon sequence is required for regulated RNA splicing of the human fibroblast growth factor receptor-1 alpha-exon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ASTROCYTOMAS; SITE SELECTION	Alternative RNA processing of the human fibroblast growth factor receptor-1 transcript results in receptor forms that vary in their affinity for fibroblast growth factor. An alternative RNA processing event involving recognition of the alpha-exon is deregulated during neoplastic transformation of glial cells. We have previously established a splicing reporter/transfection cell culture model system to identify sequences involved in recognition of this exon. In this study, the system was used to identify two sequence elements that differentially function to regulate splicing of this exon. Exclusion of the alpha-exon in glioblastoma cells specifically required the downstream intron sequence comprising the 5'-splice site. Replacement or mutation of this sequence increasing complementarity to U1 RNA resulted in enhanced exon recognition in SNB-19 glioblastoma cells. Sequences within the exon were found to be required for alpha-exon inclusion. Deletion and gain-of-function experiments identified a 69-nucleotide exon sequence that was specifically required for alpha-exon inclusion. These studies indicate that multiple sequences are required for the regulated recognition of the alpha-exon.	Univ Texas, Md Anderson Canc Ctr, Endocrinol Sect, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Cote, GJ (corresponding author), Univ Texas, Md Anderson Canc Ctr, Endocrinol Sect, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA067946, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [2P30-CA16672, CA67946] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Cote GJ, 1997, J BIOL CHEM, V272, P1054, DOI 10.1074/jbc.272.2.1054; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FU XD, 1995, RNA, V1, P663; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; Hertel KJ, 1998, MOL CELL, V1, P449, DOI 10.1016/S1097-2765(00)80045-3; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; Inoue Kunio, 1995, Gene Expression, V4, P177; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Mason I, 1996, CURR BIOL, V6, P672, DOI 10.1016/S0960-9822(09)00446-1; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; MORRISON RS, 1994, J NEURO-ONCOL, V18, P207, DOI 10.1007/BF01328955; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484	25	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16170	16176		10.1074/jbc.273.26.16170	http://dx.doi.org/10.1074/jbc.273.26.16170			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632672	hybrid			2022-12-25	WOS:000074436600043
J	Kubrich, M; Rassow, J; Voos, W; Pfanner, N; Honlinger, A				Kubrich, M; Rassow, J; Voos, W; Pfanner, N; Honlinger, A			The import route of ADP/ATP carrier into mitochondria separates from the general import pathway of cleavable preproteins at the trans side of the outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-ATP CARRIER; YEAST MITOCHONDRIA; PROTEIN IMPORT; INNER MEMBRANE; INTERMEMBRANE SPACE; SACCHAROMYCES-CEREVISIAE; RECEPTOR COMPLEX; ENDOPLASMIC-RETICULUM; PRECURSOR PROTEINS; INSERTION PORE	The ADP/ATP carrier (AAC) of the mitochondrial inner membrane is synthesized in the cytosol without a cleavable presequence. The preprotein preferentially binds to the mitochondrial surface receptor Tom70 and joins the import pathway of presequence-carrying preproteins at the cis side of the outer membrane. Little is known about the translocation of the AAC across the outer membrane and where its import route separates from that of cleavable preproteins. Here we have characterized a translocation intermediate of AAC during transfer across the outer membrane. The major portion of the preprotein is exposed to the intermembrane space, while a short segment is still accessible to externally added protease, This intermediate can be quantitatively chased to the fully imported form in the inner membrane. Its accumulation depends on Tom7, but not on the intermembrane space domain of Tom22 in contrast to cleavable preproteins. Moreover, opening of the intermembrane space inhibits the import of AAC, but not that of cleavable preproteins into mitoplasts. We conclude that the import route of AAC diverges from the general import pathway of cleavable preproteins already at the trans side of the outer membrane.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	University of Freiburg	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	pfanner@ruf.uni-freiburg.de	Pfanner, Nikolaus/AAV-7878-2021					ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Alconada A, 1995, METHOD ENZYMOL, V260, P263, DOI 10.1016/0076-6879(95)60144-9; AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; BLOM J, 1993, MOL CELL BIOL, V13, P7364, DOI 10.1128/MCB.13.12.7364; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; DIETMEIER K, 1993, J BIOL CHEM, V268, P25958; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; Haucke V, 1997, EMBO J, V16, P4560, DOI 10.1093/emboj/16.15.4560; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; Jarosch E, 1997, MOL GEN GENET, V255, P157, DOI 10.1007/s004380050484; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; MARTIN J, 1991, J BIOL CHEM, V266, P18051; Moczko M, 1997, MOL CELL BIOL, V17, P6574, DOI 10.1128/MCB.17.11.6574; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; OHBA M, 1987, EMBO J, V6, P2117, DOI 10.1002/j.1460-2075.1987.tb02478.x; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SIKORSKI RS, 1989, GENETICS, V122, P19; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; SMAGULA CS, 1988, J CELL BIOCHEM, V36, P323, DOI 10.1002/jcb.240360402; SOLLNER T, 1988, FEBS LETT, V229, P25, DOI 10.1016/0014-5793(88)80790-7; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; Zara V, 1996, MOL CELL BIOL, V16, P6524	47	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16374	16381		10.1074/jbc.273.26.16374	http://dx.doi.org/10.1074/jbc.273.26.16374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632701	hybrid			2022-12-25	WOS:000074436600072
J	Thorelli, E; Kaufman, RJ; Dahlback, B				Thorelli, E; Kaufman, RJ; Dahlback, B			The c-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; COAGULATION FACTOR-V; THROMBIN-CATALYZED ACTIVATION; BOVINE FACTOR-V; FACTOR-VIII; ELECTRON-MICROSCOPY; FACTOR-XA; SECONDARY STRUCTURE; SULFATION; CLEAVAGE	Factor V (FV) is recently shown to express anticoagulant activity. It functions as a synergistic cofactor with protein S to activated protein C (APC) in the degradation of factor VIIIa (FVIIIa). FV is composed of multiple domains, A1-A2-B-A3-C1-C2. Thrombin cleaves FV at Arg-709, Arg-1018, and Arg-1545 that leads to the generation of a procoagulant FV species which functions as a cofactor to factor Xa (FXa) in the activation of prothrombin to thrombin. During the activation process, the B-domain is released from the heavy (A1-A2) and light chains (A3-C1-C2) which constitute the active FV (FVa). To elucidate which effect the different thrombin cleavages in FV have on the ability of FV to express APC-cofactor activity, seven recombinant FV mutants containing all possible combinations of mutated and native thrombin cleavage sites were tested in a FVIIIa degradation assay. Thrombin cleavage at Arg-709 and/or Arg-1018 yielded FV molecules that were still able to function as APC cofactors, whereas cleavage at Arg-1545 led to a complete loss in APC-cofactor function. This suggests that the APC-cofactor function of FV depends on the B-domain remaining attached to the A3 domain, The importance of the FV B-domain for expression of APC-cofactor activity was further investigated using two B-domain deleted FV molecules, FV des-709-1545 (with the whole B-domain deleted) and FV des-709-1476 (with amino acids 710-1476 of the B-domain being removed). FV des-709-1476 expressed APC cofactor activity, whereas the FV des-709-1545 was completely devoid of such activity. Thus, the C-terminal part of the B-domain (residues 1477-1545) was crucial for the APC-cofactor function. FV and factor VIII (FVIII) are homologous proteins having similar domain organization, A FV/FVIII chimera, harboring the B-domain from FVIII (FVBVIII) instead of the FV B-domain did not work as an APC cofactor, further illustrating the importance of the FV B-domain for the APC-cofactor function.	Univ Lund, Malmo Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden; Univ Michigan, Med Ctr, Dept Biol Chem, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Lund University; Skane University Hospital; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Dahlback, B (corresponding author), Univ Lund, Malmo Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden.			Dahlback, Bjorn/0000-0003-1546-0328				BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; DAHLBACK B, 1992, BIOCHEMISTRY-US, V31, P12769, DOI 10.1021/bi00166a009; DAHLBACK B, 1978, BIOCHEMISTRY-US, V17, P4938, DOI 10.1021/bi00616a013; DAHLBACK B, 1995, THROMB RES, V77, P1, DOI 10.1016/0049-3848(94)00138-4; DAHLBACK B, 1990, J BIOL CHEM, V265, P8127; DAHLBACK B, 1986, J BIOL CHEM, V261, P9495; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ESMON C T, 1973, Thrombosis Research, V2, P509, DOI 10.1016/0049-3848(73)90004-2; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; ESMON CT, 1979, J BIOL CHEM, V254, P964; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; FOWLER WE, 1990, P NATL ACAD SCI USA, V87, P7648, DOI 10.1073/pnas.87.19.7648; HORTIN GL, 1990, BLOOD, V76, P946; HTORELLI E, 1997, EUR J BIOCHEM, V247, P12; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1988, BLOOD, V71, P539; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; LAMPE PD, 1984, J BIOL CHEM, V259, P9959; LEYTE A, 1991, J BIOL CHEM, V266, P740; Lu DS, 1996, BLOOD, V87, P4708, DOI 10.1182/blood.V87.11.4708.bloodjournal87114708; MARQUETTE KA, 1995, BLOOD, V86, P3026; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; MOSESSON MW, 1990, J BIOL CHEM, V265, P8863; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; ORTEL TL, 1984, P NATL ACAD SCI-BIOL, V81, P4761, DOI 10.1073/pnas.81.15.4761; PITTMAN DD, 1994, BLOOD, V84, P4214, DOI 10.1182/blood.V84.12.4214.bloodjournal84124214; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; REST B, 1994, PROTEINS, V20, P216; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Shen L, 1997, THROMB HAEMOSTASIS, V78, P1030; SHEN L, 1994, J BIOL CHEM, V269, P18735; STOYLOVA S, 1994, FEBS LETT, V351, P330, DOI 10.1016/0014-5793(94)00881-7; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; THORELLI E, 1998, IN PRESS THROMB HAEM; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; Varadi K, 1996, THROMB HAEMOSTASIS, V76, P208; VARADI K, 1995, THROMB HAEMOSTASIS, V73, P730; VILLOUTREIX BO, 1998, IN PRESS PROTEIN SCI; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; YEGNESWARAN D, 1997, J BIOL CHEM, V272, P25013; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	48	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16140	16145		10.1074/jbc.273.26.16140	http://dx.doi.org/10.1074/jbc.273.26.16140			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632668	hybrid			2022-12-25	WOS:000074436600039
J	Yang, YD; Pham, CD; Vuyyuru, VB; Liu, H; Arlinghaus, RB; Singh, B				Yang, YD; Pham, CD; Vuyyuru, VB; Liu, H; Arlinghaus, RB; Singh, B			Evidence of a functional interaction between serine 3 and serine 25 Mos phosphorylation sites - A dominant inhibitory role of serine 25 phosphorylation on Mos protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; XENOPUS-OOCYTE MATURATION; MURINE SARCOMA-VIRUS; MEIOTIC MATURATION; NUCLEOTIDE-SEQUENCE; CYTOSTATIC FACTOR; ONCOGENE PRODUCT; MEIOSIS-II; ACTIVATION; EGGS	Recently, we identified the major in vivo phosphorylation site on v-Mos as Ser-56, which is phosphorylated by cyclic AMP dependent protein kinase (PKA). Others have shown that c-Mos phosphorylation at Ser-3 (equivalent to Ser-34 in v-Mos) is important for the interaction of c-Mos with its substrate MEK and for its stability and cytostatic factor activity in eggs. To investigate the role of Ser-56 phosphorylation, we generated site-directed mutants of v-Mos that would mimic phosphorylation in terms of charge at positions 56 and 34. After mutating serine (S) residues with alanine (A) or glutamic acid (E) in different combinations, various v-Mos mutants were expressed in a rabbit reticulocyte lysate in vitro translation system and in COS-1 or MIH/3T3 cells. The effect of mutations on Mos function was evaluated by in vitro protein kinase assays and by the ability of Mos to cause neoplastic transformation of NIH/3T3 cells. The S56E but not the S56A mutation inhibited v-Mos kinase activity suggesting that Ser-56 phosphorylation has an inhibitory role. As predicted from Xenopus c-Mos studies, S34A but not S34E mutation inhibited v-Mos activity. Studies with the double mutants showed that the S56E mutation but not S56A mutation inhibited v-Mos kinase activity of both S34A and S34E mutants. Interestingly, the S56A mutation blocked the inhibitory effect of the S34A mutation on v-Mos kinase suggesting that in c-Mos the corresponding serine (Ser-25) can influence the regulation of c-Mos by Ser-3. Results showing inhibition of v Mos kinase activity of the S34E mutant by the S56E mutation is significant as it suggests that doubly phosphorylated Mos at these residues would be inactive. Because residues corresponding to both v-Mos Ser-34 and Ser-56 are evolutionarily conserved in c-Mos, the kinase activity of c-Mos during meiosis may also be regulated in the same manner as v-Mos kinase activity.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Singh, B (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, 1515 Holcombe Blvd,Box 172, Houston, TX 77030 USA.	balraj_singh@path.mdacc.tmc.edu			NCI NIH HHS [CA45125, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045125] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BOLD RJ, 1985, MOL CELL BIOL, V5, P3131, DOI 10.1128/MCB.5.11.3131; CHEN MZ, 1995, MOL CELL BIOL, V15, P4727; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; Huang CYF, 1996, EMBO J, V15, P2169, DOI 10.1002/j.1460-2075.1996.tb00570.x; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OKAZAKI K, 1995, ONCOGENE, V10, P1149; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; Pham CD, 1997, INT J GYNECOL CANCER, V7, P314, DOI 10.1046/j.1525-1438.1997.00461.x; PHAM CD, 1995, ONCOGENE, V10, P1683; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; Roy LM, 1996, ONCOGENE, V12, P2203; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; Singh B, 1997, Prog Cell Cycle Res, V3, P251; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; Yang YD, 1996, MOL CELL BIOL, V16, P800; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P43	39	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15946	15953		10.1074/jbc.273.26.15946	http://dx.doi.org/10.1074/jbc.273.26.15946			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632642	hybrid			2022-12-25	WOS:000074436600013
J	Layne, MD; Endege, WO; Jain, MK; Yet, SF; Hsieh, CM; Chin, MT; Perrella, MA; Blanar, MA; Haber, E; Lee, ME				Layne, MD; Endege, WO; Jain, MK; Yet, SF; Hsieh, CM; Chin, MT; Perrella, MA; Blanar, MA; Haber, E; Lee, ME			Aortic carboxypeptidase-like protein, a novel protein with discoidin and carboxypeptidase-like domains, is up-regulated during vascular smooth muscle cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VIII; NEURAL CREST; MESSENGER-RNA; FACTOR-V; GROWTH; EXPRESSION; SEQUENCES; CLONING; KINASE; FIBRONECTIN	Phenotypic modulation of vascular smooth muscle cells plays an important role in the pathogenesis of arteriosclerosis, In a screen of proteins expressed in human aortic smooth muscle cells, we identified a novel gene product designated aortic carboxypeptidase-like protein (ACLP), The similar to 4-kilobase human cDNA and its mouse homologue encode 1158 and 1128 amino acid proteins, respectively, that are 85% identical. ACLP is a nonnuclear protein that contains a signal peptide, a lysine- and proline-rich Il-amino acid repeating motif, a discoidin-like domain, and a C-terminal domain with 39% identity to carboxypeptidase E, By Western blot analysis and in situ hybridization, we detected abundant ACLP expression in the adult aorta. ACLP was expressed predominantly in the smooth muscle cells of the adult mouse aorta but not in the adventitia or in several other tissues. In cultured mouse aortic smooth muscle cells, ACLP mRNA and protein were up-regulated 2-3-fold after serum starvation. Using a recently developed neural crest cell to smooth muscle cell in vitro differentiation system, we found that ACLP mRNA and protein were not expressed in neural crest cells but were up-regulated dramatically with the differentiation of these cells. These results indicate that ACLP may play a role in differentiated vascular smooth muscle cells.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA; Bristol Myers Squibb Pharmaceut Res Inst, Princeton, NJ 08543 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Bristol-Myers Squibb	Lee, ME (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Bldg 2,677 Huntington Ave, Boston, MA 02115 USA.	lee@cvlab.harvard.edu	Yet, Shaw-Fang/O-8583-2019; Yet, Shaw-Fang/B-1067-2010	Yet, Shaw-Fang/0000-0001-9097-3962; Layne, Matthew/0000-0003-0007-4870	NHLBI NIH HHS [HL03194] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; ELANAR MA, 1995, P NATL ACAD SCI USA, V92, P5870; ELANAR MA, 1992, SCIENCE, V256, P1014; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21; Hsieh CM, 1996, J BIOL CHEM, V271, P17354, DOI 10.1074/jbc.271.29.17354; Jain MK, 1998, J BIOL CHEM, V273, P5993, DOI 10.1074/jbc.273.11.5993; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KANE WH, 1988, BLOOD, V71, P539; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KIRBY ML, 1990, CIRCULATION, V82, P332, DOI 10.1161/01.CIR.82.2.332; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCCA D, 1991, CANCER RES, V51, P4994; LEE WS, 1993, ENDOCRINOLOGY, V132, P2136, DOI 10.1210/en.132.5.2136; LEE WS, 1994, J BIOL CHEM, V269, P12032; LI XM, 1994, J BIOL CHEM, V269, P19653; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; OWENS GK, 1995, PHYSIOL REV, V75, P487; PIERSCHBACHER MD, 1985, J CELL BIOCHEM, V28, P115, DOI 10.1002/jcb.240280205; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J., 2002, MOL CLONING LAB MANU; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Song LX, 1997, J BIOL CHEM, V272, P10543; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAN MS, 1994, KIDNEY INT, V46, P690, DOI 10.1038/ki.1994.322; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918	43	68	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15654	15660		10.1074/jbc.273.25.15654	http://dx.doi.org/10.1074/jbc.273.25.15654			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624159	hybrid			2022-12-25	WOS:000074284200053
J	McGaughey, GB; Gagne, M; Rappe, AK				McGaughey, GB; Gagne, M; Rappe, AK			pi-stacking interactions - Alive and well in proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENTIAL-ENERGY SURFACE; BENZENE DIMER; AROMATIC INTERACTIONS; 7-METHYLGUANINE BASE; ENERGETICS; PHASE; SET	A representative set of high resolution x-ray crystal structures of nonhomologous proteins have been examined to determine the preferred positions and orientations of noncovalent interactions between the aromatic side chains of the amino acids phenylalanine, tyrosine, histidine, sued tryptophan. To study the primary interactions between aromatic amino acids, care has been taken to examine only isolated pairs (dimers) of amino acids because trimers and higher order clusters of aromatic amino acids behave differently than their dimer counterparts, We find that pairs (dimers) of aromatic side chain amino acids preferentially align their respective aromatic rings in am off-centered parallel orientation, Further, we find that this parallel-displaced structure is 0.5-0.75 kcal/mol more stable than a T-shaped structure for phenylalanine interactions and I kcal/mol more stable than a T-shaped structure for the foil set of aromatic side chain amino acids. This experimentally determined structure and energy difference is consistent with ab initio and molecular mechanics calculations of benzene dinner, however, the results are not in agreement with previously published analyses of aromatic amino acids in proteins. The preferred orientation is referred to as parallel displaced pi-stacking.	Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA; Univ Colorado, Joint Inst Lab Astrophys, Boulder, CO 80309 USA; Wyeth Ayerst Res, Struct Biol, Princeton, NJ 08540 USA	Colorado State University; University of Colorado System; University of Colorado Boulder; Pfizer	Rappe, AK (corresponding author), Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA.	trappe@snail.chm.colostate.edu						ABOLA EE, 1987, PROTEIN DATA BANK CR, P107; ABRAHAM RJ, 1976, J CHEM SOC CHEM COMM, P699, DOI 10.1039/c39760000699; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLUNDELL T, 1986, SCIENCE, V234, P1005, DOI 10.1126/science.3775369; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; BURLEY SK, 1986, J AM CHEM SOC, V108, P7995, DOI 10.1021/ja00285a019; CASTONGUAY LA, 1991, J AM CHEM SOC, V113, P7177, DOI 10.1021/ja00019a013; Chipot C, 1996, J AM CHEM SOC, V118, P11217, DOI 10.1021/ja961379l; COZZI F, 1993, J AM CHEM SOC, V115, P5330, DOI 10.1021/ja00065a069; FAN CF, 1992, MACROMOLECULES, V25, P3667, DOI 10.1021/ma00040a010; Gilman AG, 1993, PHARM BASIS THERAPEU; HOBOHM U, 1994, PROTEIN SCI, V3, P522; HOBOHM U, 1992, PROTEIN SCI, V1, P409; HOBZA P, 1994, J AM CHEM SOC, V116, P3500, DOI 10.1021/ja00087a041; Hobza P, 1996, J PHYS CHEM-US, V100, P18790, DOI 10.1021/jp961239y; HUNTER CA, 1991, J MOL BIOL, V218, P837, DOI 10.1016/0022-2836(91)90271-7; HUNTER CA, 1990, J AM CHEM SOC, V112, P5525, DOI 10.1021/ja00170a016; HUNTER CA, 1993, PHILOS T R SOC A, V345, P77, DOI 10.1098/rsta.1993.0119; ISHIDA T, 1988, J AM CHEM SOC, V110, P2286, DOI 10.1021/ja00215a046; Jaffe RL, 1996, J CHEM PHYS, V105, P2780, DOI 10.1063/1.472140; KAMIICHI K, 1986, FEBS LETT, V195, P57, DOI 10.1016/0014-5793(86)80129-6; KOLB HC, 1994, J AM CHEM SOC, V116, P1278, DOI 10.1021/ja00083a014; Pietsch MA, 1996, J AM CHEM SOC, V118, P10908, DOI 10.1021/ja960293p; Shetty AS, 1996, J AM CHEM SOC, V118, P1019, DOI 10.1021/ja9528893; SINGH J, 1985, FEBS LETT, V191, P1, DOI 10.1016/0014-5793(85)80982-0; Singh J., 1992, ATLAS PROTEIN SIDE C, VI; Sun S, 1996, J PHYS CHEM-US, V100, P13348, DOI 10.1021/jp960739o; TANNER D, 1989, PROG RUBBER PLAST TE, V5, P229; THORNTON JM, 1988, BIOCHEM SOC T, V16, P927, DOI 10.1042/bst0160927; Tsuzuki S, 1996, CHEM PHYS LETT, V252, P206, DOI 10.1016/0009-2614(96)00173-X	30	902	927	1	127	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15458	15463		10.1074/jbc.273.25.15458	http://dx.doi.org/10.1074/jbc.273.25.15458			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624131	hybrid			2022-12-25	WOS:000074284200025
J	Pellicena, P; Stowell, KR; Miller, WT				Pellicena, P; Stowell, KR; Miller, WT			Enhanced phosphorylation of Src family kinase substrates containing SH2 domain binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; C-SRC; PP60C-SRC; PEPTIDES; SPECIFICITY	Src family protein-tyrosine kinases possess several modular domains important for regulation of catalytic activity and interaction with potential substrates, Here, we explore interactions between the SH2 domain of Hck, a Src family kinase, and substrates containing SH2 domain-binding sites, We have synthesized a series of peptide substrates containing a high affinity SH2 domain binding site, (phospho)Tyr-Glu-Glu-Ile. We show that the presence of this sequence in a peptide results in a dramatic increase in the phosphorylation rate of a second tyrosine located at the N terminus. Enhanced phosphorylation is not a consequence of stimulation of enzymatic activity by C-terminal tail displacement but is imparted instead by a 10-fold reduction in the Ii, of the phosphotyrosine-containing peptide when compared with a control, The isolated catalytic domain of the nonreceptor tyrosine kinase Abl does not show a preference for the pYEEI motif-containing peptide; however, the preference is restored when the SH2 domain of Src is introduced into Abl, Furthermore, enhanced phosphorylation is dependent on the distance between SH2 domain-binding site and phosphorylatable tyrosine, with the minimum distance requirement being seven amino acids. Reversing the orientation of the pYEEI motif with respect to the substrate sequence decreases phosphorylation by down-regulated Hck, but both orientations are utilized equally well by activated Hck, We discuss the possible implications of these results for processive phosphorylation of substrates in vivo by Src family kinases.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	miller@physiology.pnb.sunysb.edu			NCI NIH HHS [CA58530] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA058530, R01CA058530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Atherton E., 1990, SOLID PHASE PEPTIDE; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GARCIA P, 1993, J BIOL CHEM, V268, P25146; KING LA, 1995, BACULOVIRUS EXPRESSI; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; Lewis LA, 1997, J IMMUNOL, V159, P2292; LIU XQ, 1993, ONCOGENE, V8, P1119; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; OTTINGER EA, 1993, BIOCHEMISTRY-US, V32, P4354, DOI 10.1021/bi00067a027; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schulz G. E., 1979, PRINCIPLES PROTEIN S, P66; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TILL JH, 1994, J BIOL CHEM, V269, P7423; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15325	15328		10.1074/jbc.273.25.15325	http://dx.doi.org/10.1074/jbc.273.25.15325			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624111	hybrid			2022-12-25	WOS:000074284200005
J	Picard, V; Epsztejn, S; Santambrogio, P; Cabantchik, ZI; Beaumont, C				Picard, V; Epsztejn, S; Santambrogio, P; Cabantchik, ZI; Beaumont, C			Role of ferritin in the control of the labile iron pool in murine erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; RESPONSIVE ELEMENT; OXIDATIVE STRESS; ERYTHROID-CELLS; MESSENGER-RNA; NITRIC-OXIDE; SUBUNIT GENE; K562 CELLS; H-SUBUNIT; HYPERFERRITINEMIA	In vitro studies have shown that ferritin iron incorporation is mediated by a ferroxidase activity associated with ferritin H subunits (H-Ft) and a nucleation center-associated with ferritin L subunits (L-Ft). To assess the role played by the ferritin subunits in regulating intracellular iron distribution, we transfected mouse erythroleukemia cells with the H-Ft subunit gene mutated in the iron-responsive element, Stable transfectants displayed high H-Ft levels and reduced endogenous L-Ft levels, resulting in a marked change in the H:L subunit ratio from 1:1 in control cells to as high as 20:1 in some transfected clones. The effects of H-Ft overexpression on the labile iron pool were determined in intact cells by a novel method based on the fluorescent metallosensor calcein, H-Ft overexpression resulted in a significant reduction in the iron pool, from 1.3 mu m in control cells to 0.56 mu m in H-Ft transfectants, and in higher buffering capacity following iron loads. A fraction of the H-Ft-associated iron was labile, available to cell-permeant, but not cell-impermeant, chelators. The results of this study provide the first in vivo direct demonstration of the capacity of H-Ft to sequester cell iron and to regulate the levels of the labile iron pool.	Fac Xavier Bichat, INSERM U409, F-75870 Paris 18, France; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; San Raffaele Sci Inst, Dipartimento Ricerca Biol & Tecnol, I-20132 Milan, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Hebrew University of Jerusalem; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Beaumont, C (corresponding author), Fac Xavier Bichat, INSERM U409, BP416, F-75870 Paris 18, France.		Santambrogio, Paolo/AAN-3837-2020	Santambrogio, Paolo/0000-0002-5481-2130	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI020342, R01AI020342] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20342] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beaumont C, 1996, J BIOL CHEM, V271, P7923, DOI 10.1074/jbc.271.14.7923; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; BEAUMONT C, 1995, NAT GENET, V11, P444, DOI 10.1038/ng1295-444; BREUER W, 1995, AM J PHYSIOL-CELL PH, V268, pC1354, DOI 10.1152/ajpcell.1995.268.6.C1354; BREUER W, 1995, J BIOL CHEM, V270, P24209, DOI 10.1074/jbc.270.41.24209; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; Drapier JC, 1996, BIOESSAYS, V18, P549, DOI 10.1002/bies.950180706; Epsztejn S, 1997, ANAL BIOCHEM, V248, P31, DOI 10.1006/abio.1997.2126; Gerard B, 1996, EXP CELL RES, V228, P8, DOI 10.1006/excr.1996.0292; GIRELLI D, 1995, BLOOD, V86, P4050, DOI 10.1182/blood.V86.11.4050.bloodjournal86114050; GUO B, 1994, J BIOL CHEM, V269, P24252; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HOYES KP, 1993, BRIT J HAEMATOL, V85, P393, DOI 10.1111/j.1365-2141.1993.tb03184.x; JACOBS A, 1977, BLOOD, V50, P433; KWAK EL, 1995, J BIOL CHEM, V270, P15285, DOI 10.1074/jbc.270.25.15285; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LEVI S, 1988, J BIOL CHEM, V263, P18086; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; NEEDHAM M, 1992, NUCLEIC ACIDS RES, V20, P997, DOI 10.1093/nar/20.5.997; NUNEZ MT, 1980, BLOOD, V55, P1051; Okada S, 1996, PATHOL INT, V46, P311, DOI 10.1111/j.1440-1827.1996.tb03617.x; Picard V, 1996, BLOOD, V87, P2057; POLLACK S, 1980, BLOOD, V56, P564; Ponka P, 1998, SEMIN HEMATOL, V35, P35; Richardson DR, 1996, BLOOD, V87, P3477, DOI 10.1182/blood.V87.8.3477.bloodjournal8783477; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; SANTAMBROGIO P, 1997, INT S IR BIOL MED SA, P230; TANG CK, 1992, J BIOL CHEM, V267, P24466; Wu CG, 1997, INT J ONCOL, V11, P187	30	108	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15382	15386		10.1074/jbc.273.25.15382	http://dx.doi.org/10.1074/jbc.273.25.15382			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624120	hybrid			2022-12-25	WOS:000074284200014
J	Soderling, SH; Bayuga, SJ; Beavo, JA				Soderling, SH; Bayuga, SJ; Beavo, JA			Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CGMP-BINDING-SITES; PARTICULATE GUANYLATE-CYCLASE; EXPRESSED SEQUENCE TAGS; PHOTORECEPTOR PHOSPHODIESTERASE; ENDOGENOUS ATRIOPEPTIN; PHOSPHORYLATION; GMP; CHROMATOGRAPHY; TRANSDUCTION; SEARCH	We report the cloning, expression, and characterization of a new family of cyclic nucleotide phosphodiesterase (PDE) that has unique kinetic and inhibitor specificities, A clone corresponding to the C terminus of this PDE was initially identified by a bioinformatic approach and used to isolate a cDNA that is likely full-length, This novel PDE, designated as MMPDE9A1, shows highest mRNA expression in kidney with lower levels in liver, lung, and brain. The mRNA size by Northern blot analysis is approximately 2.0 kilobases, and the cDNA encoding PDE9A1 is 1929 base pairs in length. The largest open reading frame predicts a protein of 534 amino acids with a molecular mass of 62,000 Da. When expressed in COS-7 cells, PDE9A1 activity was not inhibited well by either the nonselective inhibitor 3-isobutyl-1-methyl-xanthine or the new selective PDE5 inhibitor, sildenafil, but it is inhibited by the PDE1/5 inhibitor (+)-cis-5,6a,7,8,9 hyl] phenylmethyl]-5-methyl-cylopent[4,5]imidao[2,1-b]]purin-49(3H)one (SCH51866) with an IC50 of 1.55 mu M. This new phosphodiesterase is highly specific for cGMP, Its K-m of similar to 0.07 mu M for cGMP is the lowest yet reported for a PDE, being at least 40-170 times lower than that of PDE5 and PDE6, respectively.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Beavo, JA (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.				NIDDK NIH HHS [DK21723] Funding Source: Medline; NIGMS NIH HHS [GM07750] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Boolell M, 1996, Int J Impot Res, V8, P47; BURNS F, 1994, BRIT J PHARMACOL, V113, P3, DOI 10.1111/j.1476-5381.1994.tb16164.x; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; CROVELLO CS, 1995, CELL, V82, P279, DOI 10.1016/0092-8674(95)90315-1; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; HANSEN RS, 1982, P NATL ACAD SCI-BIOL, V79, P2788, DOI 10.1073/pnas.79.9.2788; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Loomis WF, 1997, J CELL SCI, V110, P1141; MOTOJIMA K, 1994, J BIOL CHEM, V269, P9030; Shaulsky G, 1996, P NATL ACAD SCI USA, V93, P15260, DOI 10.1073/pnas.93.26.15260; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; TREMBLAY J, 1985, FEBS LETT, V181, P17, DOI 10.1016/0014-5793(85)81105-4; Vemulapalli S, 1996, J CARDIOVASC PHARM, V28, P862, DOI 10.1097/00005344-199612000-00018; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; WALDMAN SA, 1984, J BIOL CHEM, V259, P4332; WILKINS MR, 1990, P NATL ACAD SCI USA, V87, P6465, DOI 10.1073/pnas.87.16.6465; WILKINS MR, 1990, J CLIN INVEST, V85, P1274, DOI 10.1172/JCI114564; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495; ZEIDEL ML, 1987, AM J PHYSIOL, V252, pF551, DOI 10.1152/ajprenal.1987.252.3.F551	33	232	252	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15553	15558		10.1074/jbc.273.25.15553	http://dx.doi.org/10.1074/jbc.273.25.15553			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624145	hybrid			2022-12-25	WOS:000074284200039
J	Grishina, G; Berlot, CH				Grishina, G; Berlot, CH			Mutations at the domain interface of G(s alpha) impair receptor-mediated activation by altering receptor and guanine nucleotide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ADENYLATE-CYCLASE; BETA-ADRENERGIC RECEPTORS; HETEROTRIMERIC G-PROTEIN; TERNARY COMPLEX MODEL; GTP-GAMMA-S; ALPHA-SUBUNIT; MUSCARINIC RECEPTOR; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; SITE	G protein alpha subunits consist of two domains, a GTPase domain and a helical domain. Receptors activate G proteins by catalyzing replacement of GDP, which is buried between these two domains, with GTP, Substitution of the homologous alpha(i2) residues for four alpha(s) residues in switch III, a region that changes conformation upon GTP binding, or of one nearby helical domain residue decreases the ability of alpha(s) to be activated by the beta-adrenergic receptor and by aluminum fluoride. Both sets of mutations increase the affinity of alpha(s) for the beta-adrenergic receptor, based on an increased amount of high affinity binding of the beta-adrenergic agonist, isoproterenol, The mutations also decrease the rate of receptor-mediated activation and disrupt the ability of the beta-adrenergic receptor to increase the apparent affinity of alpha(s) for the GTP analog, guanosine 5'-O-(3-thiotriphosphate). Simultaneous replacement of the helical domain residue and one of the four switch III residues with the homologous alpha(i2) residues restores normal receptor-mediated activation, suggesting that the defects caused by mutations at the domain interface are due to altered interdomain interactions. These results suggest that interactions between residues across the domain interface are involved in two key steps of receptor-mediated activation, promotion of GTP binding and subsequent receptor-G protein dissociation.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Berlot, CH (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA.				NIGMS NIH HHS [GM50369] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050369, R01GM050369] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BOURNE HR, 1975, SCIENCE, V187, P750, DOI 10.1126/science.163487; BOURNE HR, 1981, MOL PHARMACOL, V20, P435; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; CASSEL D, 1977, J CYCLIC NUCL PROT, V3, P11; CODINA J, 1994, J BIOL CHEM, V269, P29339; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DELEAN A, 1980, J BIOL CHEM, V255, P7108; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; HILDEBRANDT JD, 1991, MOL CELL BIOL, V11, P4830, DOI 10.1128/MCB.11.10.4830; Iiri T, 1997, P NATL ACAD SCI USA, V94, P5656, DOI 10.1073/pnas.94.11.5656; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; INSEL PA, 1975, SCIENCE, V190, P896, DOI 10.1126/science.171770; JONES DT, 1987, J BIOL CHEM, V262, P14241; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; Krumins AM, 1997, MOL PHARMACOL, V52, P144, DOI 10.1124/mol.52.1.144; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; MARSH SR, 1998, IN PRESS MOL PHARM; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667	40	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15053	15060		10.1074/jbc.273.24.15053	http://dx.doi.org/10.1074/jbc.273.24.15053			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614114	hybrid			2022-12-25	WOS:000074160400056
J	Nara, M; Dhulipala, PDK; Wang, YX; Kotlikoff, MI				Nara, M; Dhulipala, PDK; Wang, YX; Kotlikoff, MI			Reconstitution of beta-adrenergic modulation of large conductance, calcium-activated potassium (maxi-K) channels in Xenopus oocytes - Identification of the cAMP-dependent protein kinase phosphorylation site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CYCLIC GUANOSINE-MONOPHOSPHATE; GUINEA-PIG TRACHEA; ARTERY; MYOCYTES; SUBUNIT; PURIFICATION; INHIBITORS; AGONISTS; CURRENTS	The human large conductance, calcium-activated potassium (maxi-R) channel (alpha and beta subunits) and beta(2)-adrenergic receptor genes were coexpressed in Xenopus oocytes in order to study the mechanism of beta-adrenergic modulation of channel function, Isoproterenol and forskolin increased maxi-K potassium channel currents in voltage-clamped oocytes expressing the receptor and both channel subunits by 33 +/- 5% and 35 +/- 8%, respectively, without affecting current activation or inactivation, The percentage of stimulation by isoproterenol and forskolin was not different in oocytes coexpressing the alpha and beta subunits versus those expressing the only the alpha subunit, suggesting that the ct subunit is the target for regulation, The stimulatory effect of isoproterenol was almost completely blocked by intracellular injection of the cyclic AMP dependent protein kinase (cAMP-PK) regulatory subunit, whereas injection of a cyclic GMP dependent protein kinase inhibitory peptide bad little effect, indicating that cellular coupling of beta(2)-adrenergic receptors to maxi-K channels involves endogenous cAMP-PK. Mutation of one of several potential consensus cAMP-PK phosphorylation sites (serine 869) on the alpha subunit almost completely inhibited beta-adrenergic receptor/channel stimulatory coupling, whereas forskolin still stimulated currents moderately (16 +/- 4%). These data demonstrate that physiological coupling between beta(2) receptors and maxi-K channels occurs by the cAMP-PK mediated phosphorylation of serine 869 on the alpha subunit on the channel.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Kotlikoff, MI (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.	mik@phila.vet.upenn.edu						ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ANWER K, 1992, AM J PHYSIOL, V263, pC1049; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BULBRING E, 1987, PHARMACOL REV, V39, P49; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CARL A, 1991, AM J PHYSIOL, V261, pC387, DOI 10.1152/ajpcell.1991.261.2.C387; Carrier GO, 1997, AM J PHYSIOL-HEART C, V273, pH76, DOI 10.1152/ajpheart.1997.273.1.H76; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; FAN SF, 1993, J GEN PHYSIOL, V102, P257, DOI 10.1085/jgp.102.2.257; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GEORGE MJ, 1995, J INVEST MED, V43, P451; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; JONES TR, 1993, J APPL PHYSIOL, V74, P1879, DOI 10.1152/jappl.1993.74.4.1879; JONES TR, 1990, J PHARMACOL EXP THER, V255, P697; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; KUME H, 1992, P NATL ACAD SCI USA, V89, P11051, DOI 10.1073/pnas.89.22.11051; KUME H, 1994, J CLIN INVEST, V93, P371, DOI 10.1172/JCI116969; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LEE MY, 1994, PFLUG ARCH EUR J PHY, V429, P150, DOI 10.1007/BF02584044; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; MEERA P, 1995, AM J PHYSIOL-CELL PH, V269, pC312, DOI 10.1152/ajpcell.1995.269.2.C312; MELTON DA, 1987, METHOD ENZYMOL, V152, P288; MIURA M, 1992, AM REV RESPIR DIS, V146, P132, DOI 10.1164/ajrccm/146.1.132; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; SADOSHIMA JI, 1988, AM J PHYSIOL, V255, pH754, DOI 10.1152/ajpheart.1988.255.4.H754; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARIA D, 1992, AM J PHYSIOL, V262, pL327, DOI 10.1152/ajplung.1992.262.3.L327; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; SCHREIBMAYER W, 1994, RECEPTOR CHANNEL, V2, P339; SCORNIK FS, 1993, AM J PHYSIOL, V265, pH1460, DOI 10.1152/ajpheart.1993.265.4.H1460; SONG YM, 1995, PFLUG ARCH EUR J PHY, V430, P984, DOI 10.1007/BF01837413; TANIGUCHI J, 1993, PFLUG ARCH EUR J PHY, V423, P167, DOI 10.1007/BF00374390; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760	44	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14920	14924		10.1074/jbc.273.24.14920	http://dx.doi.org/10.1074/jbc.273.24.14920			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614096	hybrid			2022-12-25	WOS:000074160400038
J	Prasad, R; Beard, WA; Strauss, PR; Wilson, SH				Prasad, R; Beard, WA; Strauss, PR; Wilson, SH			Human DNA polymerase beta deoxyribose phosphate lyase - Substrate specificity and catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; ALDEHYDIC ABASIC SITES; ESCHERICHIA-COLI; PYRIDOXAL 5'-PHOSPHATE; APURINIC ENDONUCLEASE; BOVINE TESTIS; DAMAGED DNA; ACTIVE-SITE; LIGASE-I; BINDING	DNA polymerase beta (beta-pol) cleaves the sugar-phosphate bond 3' to an intact apurinic/apyrimidinic (AP) site (i.e. AP lyase activity). The same bond is cleaved even if the AP site has been previously 5'-incised by AP endonuclease, resulting in a 5' 2-deoxyribose 5-phosphate (i.e. dRP lyase activity). We characterized these lyase reactions by steady-state kinetics with the aminoterminal 8-kDa domain of beta-pol and with the entire 39-kDa polymerase, Steady-state kinetic analyses show that the Michaelis constants for both the dRP and AP lyase activities of beta-pol are similar. However, k(cat) is approximately 200-fold lower for the AP lyase activity on an intact AP site than for an AP endonuclease-preincised site. The 8-kDa domain was also less efficient with an intact AP site than on a preincised site. The full-length enzyme and the 8-kDa domain efficiently remove the 5' dRP from a preincised AP site in the absence of Mg2+, and the pH profiles of beta-pol and 8-kDa domain dRP lyase catalytic efficiency exhibit a broad alkaline pH optimum. An inhibitory effect of pyridoxal 5'-phosphate on the dRP lyase activity is consistent with involvement of a primary amine (Lys(72)) as the Schiff base nucleophile during lyase chemistry.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Medical Branch Galveston	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, 111 TW Alexander Dr,Bldg 101,Rm B246, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BASU A, 1989, BIOCHEMISTRY-US, V28, P6305, DOI 10.1021/bi00441a023; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; BRIEMER LH, 1984, J BIOL CHEM, V259, P5543; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; CHETSANGA CJ, 1981, BIOCHEMISTRY-US, V20, P5201, DOI 10.1021/bi00521a016; CONE R, 1980, J BIOL CHEM, V255, P354; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P135; GOSSARD F, 1978, EUR J BIOCHEM, V82, P321, DOI 10.1111/j.1432-1033.1978.tb12026.x; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; KIM SJ, 1994, J MOL BIOL, V244, P224, DOI 10.1006/jmbi.1994.1720; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3618, DOI 10.1021/bi00769a019; LIU D, 1990, BIOCHEMISTRY-US, V35, P6188; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; MODAK MJ, 1976, BIOCHEMISTRY-US, V15, P3620, DOI 10.1021/bi00661a033; Mullen GP, 1997, TETRAHEDRON, V53, P12057, DOI 10.1016/S0040-4020(97)00768-0; MULLEN GP, 1997, BASE EXCISION REPAIR, P121; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; PRASAD R, 1993, J BIOL CHEM, V268, P22746; PRASAD R, 1994, J BIOL CHEM, V269, P18096; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SANDER M, 1991, NUCLEIC ACIDS RES, V19, P4523, DOI 10.1093/nar/19.16.4523; Sandigursky M, 1997, J BIOL CHEM, V272, P17480, DOI 10.1074/jbc.272.28.17480; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; Wang ZG, 1997, J BIOL CHEM, V272, P24064, DOI 10.1074/jbc.272.38.24064; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j	54	163	170	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15263	15270		10.1074/jbc.273.24.15263	http://dx.doi.org/10.1074/jbc.273.24.15263			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614142	hybrid			2022-12-25	WOS:000074160400084
J	Zhou, BP; Wu, B; Kwan, SW; Abell, CW				Zhou, BP; Wu, B; Kwan, SW; Abell, CW			Characterization of a highly conserved FAD-binding site in human monoamine oxidase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; 6-HYDROXY-D-NICOTINE OXIDASE; FLAVOPROTEIN SUBUNIT; COVALENT ATTACHMENT; ESCHERICHIA-COLI; BOVINE LIVER; MUTANT FORMS; DEHYDROGENASE; MITOCHONDRIA; REDUCTASE	Monoamine oxidase B (MAO B) catalyzes the oxidative deamination of biogenic and xenobiotic amines. The oxidative step is coupled to the reduction of an obligatory cofactor, FAD, which is covalently linked to the apoenzyme at Cys(397). Our previous studies identified two noncovalent flavin-binding regions in MAO B (residues 6-34 and 39-46) (Kwan, S.-W., Lewis, D. A., Zhou, B. P., and Abell, C. W. (1995) Arch. Biochem. Biophys. 316, 385-391; Zhou, B. P., Lewis, D. A, Kwan, S.-W., Kirksey, T. J., and Abell, C. W. (1995) Biochemistry 34, 9526-9531), In these regions, Glu(34) and Tyr(44) were found to be required for the initial binding of FAD. By comparing sequences with enzymes in the oxidoreductase family, we now have found an additional FAD-binding site in MAO B (residues 222-227), which is highly conserved across species (human, bovine, and rat). This conserved sequence contains adjacent glycine and aspartate residues (Gly(226) and Asp(227)). Based on the x-ray crystal structures of several oxidoreductases (Eggink, G., Engel, H., Vriend, G., Terpstra, P., and Witholt, B. (1990) J. Mol. Biol. 212, 135-142; Van Driessche, G., Kol, M., Chen, Z.-W., Mathews, F. S., Meyer, T. E., Bartsch, R. G., Cusanovich, M. A., and Van Beeumen, J. J. (1996) Protein Sci. 5, 1753-1764), the Gly residue at the end of a beta-strand facilitates a sharp turn and extends the beta-carbonyl group of Asp to interact with the 3'-hydroxyl group of the ribityl chain of FAD. To assess the hypothesis that Gly(226) and Asp(227) are involved in FAD binding in MAO B, site-specific mutants that encode substitutions sit these positions were prepared and expressed in mammalian COS-7 cells. Our results indicate that Gly(226) and the beta-carbonyl group of Asp(227) are required for covalent flavinylation and catalytic activity of MAO B, hut not for noncovalent binding of FAD. Our studies also reveal that mutagenesis at Glu(34) and Tyr(44) not only interferes with covalent flavinylation and catalytic activity of MAO B, but also with noncovalent binding of FAD. Based on these collective results, we propose that the coupling of FAD to the MAO B apoenzyme is a multistep process.	Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA; Univ Texas, Inst Neurosci, Austin, TX 78712 USA; Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Abell, CW (corresponding author), Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA.				NIAAA NIH HHS [AAO7471] Funding Source: Medline; NINDS NIH HHS [NS24932] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007471] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; DAPRADA M, 1989, J NEURAL TRANSM-GEN, P5; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENNEY RM, 1982, SCIENCE, V215, P1400, DOI 10.1126/science.7063850; DOSTERT PL, 1989, MED RES REV, V9, P45, DOI 10.1002/med.2610090104; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; FRIEDEN C, 1990, P NATL ACAD SCI USA, V87, P4413, DOI 10.1073/pnas.87.12.4413; Genzor CG, 1996, NAT STRUCT BIOL, V3, P329, DOI 10.1038/nsb0496-329; GONDRY M, 1995, PROTEIN SCI, V4, P925; GOTTOWIK J, 1993, FEBS LETT, V317, P152, DOI 10.1016/0014-5793(93)81512-X; GREENAWALT JW, 1970, J CELL BIOL, V46, P173, DOI 10.1083/jcb.46.1.173; Hiro I, 1996, J BIOCHEM-TOKYO, V120, P759; KEARNEY EB, 1971, EUR J BIOCHEM, V24, P321, DOI 10.1111/j.1432-1033.1971.tb19689.x; Kim J, 1995, J BIOL CHEM, V270, P31202, DOI 10.1074/jbc.270.52.31202; KOCHERSPERGER LM, 1985, J NEUROSCI, V5, P2874; KWAN SW, 1995, ARCH BIOCHEM BIOPHYS, V316, P385, DOI 10.1006/abbi.1995.1051; MANSTEIN DJ, 1986, J BIOL CHEM, V261, P6169; MASSEY V, 1966, J BIOL CHEM, V241, P3417; Ogata F, 1994, FLAVINS AND FLAVOPROTEINS 1993, P795; Otto A, 1996, J BIOL CHEM, V271, P9823, DOI 10.1074/jbc.271.16.9823; PACKMAN LC, 1995, J BIOL CHEM, V270, P13186, DOI 10.1074/jbc.270.22.13186; RASBAND W, 1997, NIH IMAGE; Robinson KM, 1996, J BIOL CHEM, V271, P4055; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; Shiloff BA, 1996, EUR J BIOCHEM, V242, P41, DOI 10.1111/j.1432-1033.1996.0041r.x; Stoltz M, 1996, J BIOL CHEM, V271, P25208, DOI 10.1074/jbc.271.41.25208; SWOBODA BEP, 1969, BIOCHIM BIOPHYS ACTA, V175, P365, DOI 10.1016/0005-2795(69)90014-2; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; Tsugeno Y, 1997, J BIOL CHEM, V272, P14033, DOI 10.1074/jbc.272.22.14033; VanDriessche G, 1996, PROTEIN SCI, V5, P1753; VONKORFF RW, 1979, MONOAMINE OXIDASE ST, P1; WESTLUND KN, 1988, NEUROSCIENCE, V25, P439, DOI 10.1016/0306-4522(88)90250-3; WESTLUND KN, 1985, SCIENCE, V230, P181, DOI 10.1126/science.3875898; WEYLER W, 1989, BIOCHEM J, V260, P725, DOI 10.1042/bj2600725; WEYLER W, 1990, PHARMACOL THERAPEUT, V47, P391, DOI 10.1016/0163-7258(90)90064-9; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WU HF, 1993, MOL PHARMACOL, V43, P888; WURTMAN RJ, 1963, BIOCHEM PHARMACOL, V12, P1439, DOI 10.1016/0006-2952(63)90215-6; YEOMANSON KB, 1992, BIOCHIM BIOPHYS ACTA, V1116, P261, DOI 10.1016/0304-4165(92)90038-V; ZHOU BP, 1995, BIOCHEMISTRY-US, V34, P9526, DOI 10.1021/bi00029a029; ZHOU BP, 1995, J BIOL CHEM, V270, P23653, DOI 10.1074/jbc.270.40.23653; ZIMMERMANN U, 1982, J MEMBRANE BIOL, V67, P165, DOI 10.1007/BF01868659	47	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14862	14868		10.1074/jbc.273.24.14862	http://dx.doi.org/10.1074/jbc.273.24.14862			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614088	hybrid			2022-12-25	WOS:000074160400030
J	Zhu, CY; Johansson, M; Permert, J; Karlsson, A				Zhu, CY; Johansson, M; Permert, J; Karlsson, A			Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguanosine kinase in cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYCYTIDINE KINASE; TOXICITY; CDNA	The cytotoxic anti-cancer purine nucleoside analogs 2-chloro-2'-deoxyadenosine (CdA), 9-beta-D-arabinofuranosylguanine (araG), and 2',2'-difluorodeoxyguanosine (dFdG) are phosphorylated by human mitochondrial deoxyguanosine kinase (dGK) in vitro. We overexpressed dGK as a fusion protein to the green fluorescent protein in the human pancreatic cancer cell lines PanC-1 and MIA PaCa-2 to determine the importance of dGK-mediated nucleoside analog phosphorylation, The transfected cells showed mitochondrial fluorescence patterns, and the mitochondrial locations of endogenous and overexpressed dGK were verified by Western blot analysis of cell extracts with polyclonal anti-dGK antibodies. The increase of dGR activity in the overexpressing cells was similar to 4-fold. These cell lines exhibited increased sensitivity to CdA, araG, and dFdG as compared with the untransfected parent cell lines. This is, to our knowledge, the first demonstration of a correlation between the activity of a mitochondrial deoxyribonucleoside kinase and the cytotoxicity of nucleoside analogs. Our data imply that the dGK activity is rate-limiting for the efficacy of nucleoside analogs in the cell lines investigated.	Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Div Surg, S-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Karlsson, A (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Stockholm, Sweden.		Karlsson, Anna/E-7945-2018	Karlsson, Anna/0000-0001-6843-6685				ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6; BERK AJ, 1973, J BIOL CHEM, V248, P2722; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; CARSON DA, 1980, P NATL ACAD SCI-BIOL, V77, P6865, DOI 10.1073/pnas.77.11.6865; CHEN CH, 1992, J BIOL CHEM, V267, P2856; GANDHI V, 1995, CANCER RES, V55, P1517; Hapke DM, 1996, CANCER RES, V56, P2343; HELM R, 1995, NATURE, V373, P663; Hui YF, 1997, AM J HEALTH-SYST PH, V54, P162, DOI 10.1093/ajhp/54.2.162; Johansson M, 1997, P NATL ACAD SCI USA, V94, P11941, DOI 10.1073/pnas.94.22.11941; Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258; Kurtzberg J., 1995, Blood, V86, p511A; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Manome Y, 1996, NAT MED, V2, P567, DOI 10.1038/nm0596-567; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OWENS JK, 1992, CANCER RES, V52, P2389; Plunkett W, 1996, HEMATOL CELL THER, V38, pS67; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; SNYDER FF, 1994, BBA-MOL BASIS DIS, V1227, P33, DOI 10.1016/0925-4439(94)90103-1; SODERLUND JCF, 1995, ADV EXP MED BIOL, V370, P201; WANG LY, 1993, J BIOL CHEM, V268, P22847	22	51	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14707	14711		10.1074/jbc.273.24.14707	http://dx.doi.org/10.1074/jbc.273.24.14707			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614068	hybrid			2022-12-25	WOS:000074160400010
J	Luberto, C; Hannun, YA				Luberto, C; Hannun, YA			Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation - Does sphingomyelin synthase account for the putative, phosphatidylcholine-specific phospholipase C?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; CANINE KIDNEY CELLS; PLASMA-MEMBRANE; GOLGI-APPARATUS; SUBCELLULAR-FRACTIONS; CULTURED FIBROBLASTS; SIGNAL-TRANSDUCTION; MOUSE FIBROBLASTS; ELEVATED LEVELS	Sphingomyelin synthase (SMS), an enzyme involved in sphingomyelin (SM) and ceramide metabolism, can potentially regulate, in opposite directions, the levels of ceramide and diacylglycerol. in this study SMS activity was investigated in normal and SV40-transformed human lung fibroblasts (WI38). The addition of [H-3]C-2-ceramide to cells resulted in a time-dependent formation of [H-3]C-2-SM. At 24 h after treatment, normal WI38 cells cleared 17% of [H-3]C-2-ceramide producing [H-3]C-2-SM, which accounted for 13% of total radioactivity. On the other hand, SV40-transformed cells cleared 45% of [H-3]C-2-ceramide and produced C-2-SM, which accounted for 24% of total radioactivity. This enhanced production of C-2-SM was also supported by an increase in the total SMS activity of cells (measured in vitro), such that SV40-transformed cells had SMS activity of 222 pmol/mg of protein/h, whereas wild type cells had 78 pmol/mg of protein/h of activity. Additional studies aimed at examining the SMS activity directed at ceramide produced in the plasma membrane. Treatment of cells with exogenous bacterial sphingomyelinase (SMase) for 25 min resulted in cleavage of 90-95% of total SM and the concomitant generation of ceramide, After bacterial SMase treatment, wild type WI38 cells cleared ceramide very slowly (19.2 pmol of ceramide/nmol of phosholipid P-i after 6 h of incubation) and hardly regenerated slay SM. On the other hand, SV40-transformed cells cleared ceramide much faster (41.1 pmol/nmol of P-i after 6 h of incubation) and regenerated approximately 80% of the original SM. These results show that the enhanced SMS activity of transformed cells is particularly pronounced when ceramide is produced in the plasma membrane. Finally, several observations led us to consider the relationship of SMS to the "putative" phosphatidylcholine-specific phospholipase C (PC-PLC), We, therefore, tested the effects of D609, a pur-ported PC-PLC-specific inhibitor on the activity of SMS, D609 inhibited SMS activity in vitro. In addition, cellular studies showed that SMS activity was dramatically inhibited by concentrations of D609 used previously to study PC-PLC (10-50 mu g/ml). These results suggest SMS as an important biochemical target for D609, and they raise the distinct possibility that many of the roles of PC-PLC, especially in cell transformation, may be attributable to SMS.	Duke Univ, Dept Med, Durham, NC 27710 USA; Duke Univ, Dept Cell Biol, Durham, NC 27710 USA	Duke University; Duke University	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem, 171 Ashley Ave, Charleston, SC 29425 USA.	hannun@musc.edu			NIGMS NIH HHS [GM-43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan David, 1994, Trends in Cell Biology, V4, P350, DOI 10.1016/0962-8924(94)90076-0; AMES BN, 1960, J BIOL CHEM, V235, P769; ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BERGELSO.LD, 1970, BIOCHIM BIOPHYS ACTA, V210, P287, DOI 10.1016/0005-2760(70)90173-6; BERNERT JT, 1981, BIOCHIM BIOPHYS ACTA, V666, P99, DOI 10.1016/0005-2760(81)90095-3; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bjorkoy G, 1997, J BIOL CHEM, V272, P11557; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HAMPTON RY, 1989, SCIENCE, V246, P1050, DOI 10.1126/science.2555921; Hannun, 1997, PR MED BIOL A, V7, P487, DOI 10.1016/S1569-2582(97)80129-8; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HATCH GM, 1992, J BIOL CHEM, V267, P12443; HEROLD P, 1988, HELV CHIM ACTA, V71, P354, DOI 10.1002/hlca.19880710208; HOSTETLER KY, 1979, CANCER RES, V39, P2978; HOSTETLER KY, 1976, BIOCHIM BIOPHYS ACTA, V441, P231, DOI 10.1016/0005-2760(76)90166-1; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KALLEN KJ, 1994, BBA-BIOMEMBRANES, V1191, P52, DOI 10.1016/0005-2736(94)90232-1; KALLEN KJ, 1993, BIOCHIM BIOPHYS ACTA, V1166, P305, DOI 10.1016/0005-2760(93)90111-L; KALLEN KJ, 1995, TRENDS CELL BIOL, V5, P149, DOI 10.1016/S0962-8924(00)88970-9; KIM MY, 1991, J BIOL CHEM, V266, P484; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOVAL M, 1995, TRENDS CELL BIOL, V5, P148, DOI 10.1016/S0962-8924(00)88969-2; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; Laurenz JC, 1996, BBA-LIPID LIPID MET, V1299, P146, DOI 10.1016/0005-2760(95)00202-2; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MARGGRAF WD, 1987, BIOCHIM BIOPHYS ACTA, V897, P57, DOI 10.1016/0005-2736(87)90315-4; MARGGRAF WD, 1982, BIOCHIM BIOPHYS ACTA, V710, P314, DOI 10.1016/0005-2760(82)90114-X; MARGGRAF WD, 1981, BIOCHIM BIOPHYS ACTA, V664, P61, DOI 10.1016/0005-2760(81)90028-X; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; NINKAR S, 1988, TETRAHEDRON LETT, V29, P3037; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Obradors MJM, 1997, BBA-MOL CELL RES, V1359, P1; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; POLYAKOV V M, 1977, Biokhimiya, V42, P799; PREISS J, 1986, J BIOL CHEM, V261, P8597; PRICE BD, 1989, J BIOL CHEM, V264, P16638; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHWEIZER A, 1994, J BIOL CHEM, V269, P4035; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; SRIBNEY M, 1971, CAN J BIOCHEM CELL B, V49, P306, DOI 10.1139/o71-044; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; ULLMAN MD, 1974, J BIOL CHEM, V249, P1506; UPRETI GC, 1983, J NATL CANCER I, V70, P567; VAN HELVOORT A, 1994, J BIOL CHEM, V269, P1763; van Helvoort A, 1997, J CELL SCI, V110, P781; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VANDENHILL A, 1985, BIOCHIM BIOPHYS ACTA, V833, P354, DOI 10.1016/0005-2760(85)90210-3; vanDijk MCM, 1997, J BIOL CHEM, V272, P11011; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; VANGOLDE LMG, 1974, BIOCHIM BIOPHYS ACTA, V360, P17; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; Walev I, 1996, INFECT IMMUN, V64, P2974, DOI 10.1128/IAI.64.8.2974-2979.1996; WILKISON WO, 1989, ONCOGENE, V4, P625; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WYKE AW, 1992, CELL SIGNAL, V4, P267, DOI 10.1016/0898-6568(92)90066-H; Zhang P, 1997, J BIOL CHEM, V272, P9609	82	253	270	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14550	14559		10.1074/jbc.273.23.14550	http://dx.doi.org/10.1074/jbc.273.23.14550			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603970	hybrid			2022-12-25	WOS:000074021500072
J	Okino, N; Tani, M; Imayama, S; Ito, M				Okino, N; Tani, M; Imayama, S; Ito, M			Purification and characterization of a novel ceramidase from Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRATUM-CORNEUM LIPIDS; ATOPIC-DERMATITIS; CELL-DIFFERENTIATION; ETIOLOGIC FACTOR; SPHINGOMYELIN; SKIN; CLEAVES; LINKAGE; ENZYME	We report here a novel type of ceramidase of Pseudomonas aeruginosa AN17 isolated from the skin of a patient with atopic dermatitis. The enzyme was purified 83,400-fold with an overall yield of 21.1% from a culture supernatant of strain AN17. After being stained with a silver staining solution, the purified enzyme showed a single protein band, and its molecular mass was estimated to be 70 kDa ore SDS-polyacrylamide gel electrophoresis. The enzyme showed quite wide specificity for various ceramides, i.e. it hydrolyzed ceramides containing C12:0-C18:0 fatty acids and 7-nitrobenz-2-oxa-1,3-diatole-labeled dodecanoic acid, and not only ceramide containing sphingosine (d18:1) or sphinganine (d18:0) but also phytosphingosine (t18:0) as the long-chain base, However, the enzyme did not hydrolyze galactosylceramide, sulfatide, GM1, or sphingomyelin, and thus was clearly distinguished from a Pseudomonas sphingolipid ceramide N-deacylase (Ito, M., Kurita, T., and Kita, Ii. (1995) J. Biol. Chem. 270, 24370-24374). This bacterial cerarmidase had a PEI optimum of 8.0-9.0, an apparent K-m, of 139 mu M, and a V-max of 5.3 mu mol/min/mg using N-palmitoylsphingosine as the substrate. The enzyme appears to require Ca2+ for expression of the activity. Interestingly, the 70-kDa protein catalyzed a reversible reaction ire which the N-acyl linkage of ceramide was either cleaved or synthesized. Our study demonstrated that ceramidase is widely distributed from bacteria to mammals.	Kyushu Univ, Fac Agr, Marine Biochem Lab, Higashi Ku, Fukuoka 8128581, Japan; Kyushu Univ, Fac Med, Dept Dermatol, Fukuoka 8128581, Japan	Kyushu University; Kyushu University	Ito, M (corresponding author), Kyushu Univ, Fac Agr, Marine Biochem Lab, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.		Okino, Nozomu/AAY-2635-2021	ito, Makoto/0000-0003-3159-7818; Tani, Motohiro/0000-0003-4316-8260				ANDERSON DS, 1951, BRIT J DERMATOL, V63, P283, DOI 10.1111/j.1365-2133.1951.tb13728.x; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BODEY GP, 1983, REV INFECT DIS, V5, P279; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Buchanan RE, 1974, BERGEYS MANUAL DETER, P217; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; GATT S, 1963, J BIOL CHEM, V238, P3131; GATT S, 1966, J BIOL CHEM, V241, P3724; HASSLER DF, 1993, ADV LIPID RES, V26, P49; IMAYAMA S, 1992, J AM ACAD DERMATOL, V27, P531, DOI 10.1016/0190-9622(92)70218-5; IMAYAMA S, 1994, J ALLERGY CLIN IMMUN, V94, P195, DOI 10.1016/0091-6749(94)90040-X; IMOKAWA G, 1986, J INVEST DERMATOL, V87, P758, DOI 10.1111/1523-1747.ep12456950; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P523, DOI 10.1111/1523-1747.ep12470233; ITO M, 1986, J BIOL CHEM, V261, P14278; ITO M, 1989, J BIOL CHEM, V264, P9510; ITO M, 1995, J BIOL CHEM, V270, P24370, DOI 10.1074/jbc.270.41.24370; KITAMIKADO M, 1981, J BIOL CHEM, V256, P3906; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPE MA, 1983, J LIPID RES, V24, P120; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; Mitsutake S, 1997, ANAL BIOCHEM, V247, P52, DOI 10.1006/abio.1997.2022; MITSUTAKE S, 1998, IN PRESS J BIOCH TOK, V123; MOORE GL, 1969, ANAL BIOCHEM, V32, P122, DOI 10.1016/0003-2697(69)90111-0; Murata Y, 1996, J INVEST DERMATOL, V106, P1242, DOI 10.1111/1523-1747.ep12348937; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; OHSAWA K, 1983, ANAL BIOCHEM, V135, P409, DOI 10.1016/0003-2697(83)90703-0; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; YADA Y, 1995, J BIOL CHEM, V270, P12677, DOI 10.1074/jbc.270.21.12677; YAMAMOTO A, 1991, ARCH DERMATOL RES, V283, P219, DOI 10.1007/BF01106105	33	83	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14368	14373		10.1074/jbc.273.23.14368	http://dx.doi.org/10.1074/jbc.273.23.14368			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603946	hybrid			2022-12-25	WOS:000074021500048
J	Vance, CL; Begg, CM; Lee, WL; Haase, H; Copeland, TD; McEnery, MW				Vance, CL; Begg, CM; Lee, WL; Haase, H; Copeland, TD; McEnery, MW			Differential expression and association of calcium channel alpha(1B) and beta subunits during rat brain ontogeny	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; DEPENDENT CA2+ CHANNELS; DEVELOPMENTAL REGULATION; FUNCTIONAL EXPRESSION; GLUTAMATE RELEASE; SYNAPSE FORMATION; CA-2+ CHANNELS; MESSENGER-RNAS; GROWTH CONES; CURRENTS	Calcium functions as an essential second messenger during neuronal development and synapse acquisition. Voltage-dependent calcium channels (VDCC), which are critical to these processes, are heteromultimeric complexes composed of alpha(1), alpha(2)/delta and beta subunits, beta subunits function to direct the VDCC complex to the plasma membrane as well as regulate its channel properties. The importance of beta to neuronal functioning was recently underscored by the identification of a truncated beta 4 isoform in the epileptic mouse lethargic (Ih) (Burgess, D. L., Jones, J. M., Meisler, M. H., and Noebels, J. L. (1997) Cell 88, 385-392). The goal of our study was to investigate the role of individual beta isoforms (beta 1b, beta 2, beta 3, and beta 4) in the assembly of N-type VDCC during rat brain development. By using quantitative Western blot analysis with anti-alpha(1B)-directed antibodies and [I-125-Tyr(22)]omega-conotoxin GVIA (I-125-CTX) radioligand binding assays, we observed that only a small fraction of the total alpha(1B) protein present in embryonic and early postnatal brain expressed high affinity I-125-CTX-binding sites. These results suggested that subsequent maturation of alpha(1B) or its assembly with auxiliary subunits was required to exhibit high affinity I-125-CTX binding. The temporal pattern of expression of beta subunits and their assembly with alpha(1B) indicated a developmental pattern of expression of beta isoforms: beta 1b increased 3-fold from PO to adult, beta 4 increased 10-fold, and both beta 2 and beta 3 expression remained unchanged, As the beta component of N-type VDCC changed during postnatal development, we were able to identify both immature and mature forms of N-type VDCC, At P2, the relative contribution of beta is beta 1b > beta 3 much greater than beta 2, whereas at P14 and adult the distribution is beta 3 > beta 1b = beta 4, Although we observed no beta 4 associated with the alpha(1B) at P2, beta 4 accounted for 14 and 25% of total alpha(1B)/beta subunit complexes in P14 and adult, respectively. Thus, of the beta isoforms analyzed, only the beta 4 was assembled with the rat a,, to form N-type VDCC with a time course that paralleled its level of expression during rat brain development. These results suggest a role for the beta 4 isoform in the assembly and maturation of the N-type VDCC.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	Case Western Reserve University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	McEnery, MW (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.							ALCANTARA AA, 1992, J COMP NEUROL, V319, P337, DOI 10.1002/cne.903190303; ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; BASARSKY TA, 1994, J NEUROSCI, V14, P6402; BIRNBAUMER L, 1998, IN PRESS J BIOENERG, V30; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Brice NL, 1997, EUR J NEUROSCI, V9, P749, DOI 10.1111/j.1460-9568.1997.tb01423.x; Brosenitsch TA, 1998, J NEUROSCI, V18, P1047; BRUST PF, 1993, NEUROPHARMACOLOGY, V32, P1089, DOI 10.1016/0028-3908(93)90004-M; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; CALLAWAY EM, 1987, NATURE, V328, P422, DOI 10.1038/328422a0; CALOVINI T, 1995, J CELL BIOCHEM, V59, P69, DOI 10.1002/jcb.240590109; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; COHAN CS, 1987, J NEUROSCI, V7, P3588; CONNOLD AL, 1986, DEV BRAIN RES, V28, P99, DOI 10.1016/0165-3806(86)90069-6; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; DUNG HC, 1972, TEX REP BIOL MED, V30, P23; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; GRUOL DL, 1992, J NEUROSCI, V12, P2838; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; Haus Stephanie, 1997, Society for Neuroscience Abstracts, V23, P2012; Hilaire C, 1996, NEUROSCIENCE, V75, P1219, DOI 10.1016/0306-4522(96)00347-8; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Jones OT, 1997, J NEUROSCI, V17, P6152; KATER SB, 1991, J NEUROSCI, V11, P891; KOMURO H, 1992, SCIENCE, V257, P806, DOI 10.1126/science.1323145; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; Lin ZX, 1997, NEURON, V18, P153, DOI 10.1016/S0896-6273(01)80054-4; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; Liu HY, 1996, J NEUROSCI, V16, P7557; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; MAHALIK TJ, 1992, DEV BRAIN RES, V67, P75, DOI 10.1016/0165-3806(92)90027-T; MANIVANNAN S, 1994, J NEUROSCI, V14, P5917; MATHEWS GC, 1994, NEURON, V13, P149, DOI 10.1016/0896-6273(94)90465-0; MCCOBB DP, 1989, NEURON, V2, P1633, DOI 10.1016/0896-6273(89)90052-4; McCool BA, 1996, MOL PHARMACOL, V50, P912; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; McEnery MW, 1997, FEBS LETT, V420, P74, DOI 10.1016/S0014-5793(97)01490-7; MCENERY MW, 1993, MOL CELLULAR BIOL PH, P3; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MOORMAN SJ, 1993, J NEUROSCI, V13, P4727; NELSON PG, 1990, J NEUROBIOL, V21, P138, DOI 10.1002/neu.480210110; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; Parent L, 1997, J MEMBRANE BIOL, V160, P127, DOI 10.1007/s002329900302; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; RANDALL A, 1995, J NEUROSCI, V15, P2995; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; ROSSI P, 1994, PFLUG ARCH EUR J PHY, V429, P107, DOI 10.1007/BF02584036; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SCHEINMAN RI, 1989, J BIOL CHEM, V264, P10660; SCHMIDT J, 1985, P NATL ACAD SCI USA, V82, P4847, DOI 10.1073/pnas.82.14.4847; SCHOLZ KP, 1995, J NEUROSCI, V15, P4612; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; SEWARD EP, 1990, PFLUG ARCH EUR J PHY, V417, P223, DOI 10.1007/BF00370703; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; STEA A, 1995, HDB RECEPTORS CHANNE, P113; STREIT J, 1987, PFLUG ARCH EUR J PHY, V408, P634, DOI 10.1007/BF00581167; TANAKA O, 1995, MOL BRAIN RES, V30, P1, DOI 10.1016/0169-328X(94)00265-G; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; USOWICZ MM, 1990, J PHYSIOL-LONDON, V426, P95, DOI 10.1113/jphysiol.1990.sp018128; VERDERIO C, 1995, P NATL ACAD SCI USA, V92, P6449, DOI 10.1073/pnas.92.14.6449; WAGNER JA, 1988, J NEUROSCI, V8, P3354; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; XIE HW, 1995, J NEUROSCI, V15, P5900; ZOLI M, 1995, J NEUROSCI, V15, P1912, DOI 10.1523/JNEUROSCI.15-03-01912.1995	78	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14495	14502		10.1074/jbc.273.23.14495	http://dx.doi.org/10.1074/jbc.273.23.14495			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603963	hybrid			2022-12-25	WOS:000074021500065
J	White, S; Hatton, SR; Siddiqui, MA; Parker, CD; Trowbridge, IS; Collawn, JF				White, S; Hatton, SR; Siddiqui, MA; Parker, CD; Trowbridge, IS; Collawn, JF			Analysis of the structural requirements for lysosomal membrane targeting using transferrin receptor chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DI-LEUCINE MOTIF; CYTOPLASMIC TAIL; PLASMA-MEMBRANE; MDCK CELLS; INTERNALIZATION SIGNAL; ENDOCYTIC PATHWAY; ACID-PHOSPHATASE; SORTING SIGNALS; FC-RECEPTORS; TYROSINE	The sorting of membrane proteins to the lysosome requires tyrosine-or dileucine-based targeting signals. Recycling receptors have similar signals, yet these proteins seldom enter the latter stages of the endocytic pathway. To determine how lysosomal and internalization signals differ, we prepared chimeric molecules consisting of the cytoplasmic tails of CDS gamma-chain, lysosomal acid phosphatase, and lysosomal-associated membrane glycoprotein-l, each fused to the transmembrane and extracellular domains of the transferrin receptor (TR), Each chimera was expressed on the cell surface and rapidly internalized. Metabolic pulse-chase experiments showed that the CD3 gamma-chain and lysosomal acid phosphatase chimeras, unlike the lysosomal-associated membrane glycoprotein chimera, were rapidly degraded in a post-Gels compartment following normal glycosylation. Transplantation of signals from CD3 gamma-chain and lysosomal acid phosphatase into the TR cytoplasmic tail in place of the native signal, (YTRF23)-T-20, indicated that each signal was sufficient to promote endocytosis but not lysosomal targeting of the resulting mutant. Transplantation of two CD3 signals at specific sites in the TR cytoplasmic tail or a single tyrosine-based signal in a truncated TR tail, however, was sufficient to promote lysosomal targeting. Our results therefore suggest that the relative position of the signal within the cytoplasmic tail is a critical feature that distinguishes lysosomal targeting signals from internalization signals.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Salk Inst, Dept Canc Biol, San Diego, CA 92186 USA	University of Alabama System; University of Alabama Birmingham; Salk Institute	Collawn, JF (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, BHSB 392,UAB Stn, Birmingham, AL 35294 USA.	jcollawn@uab.edu		Collawn, James/0000-0002-2528-2759	NIAID NIH HHS [R01-AI40389] Funding Source: Medline; NIDDK NIH HHS [R29-DK47339] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047339] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAUMELLE BD, 1990, J CELL BIOL, V111, P1811, DOI 10.1083/jcb.111.5.1811; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; BREMNES B, 1994, J CELL SCI, V107, P2021; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; HUGHES SH, 1990, J REPROD FERTIL, P39; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; OGATA S, 1994, J BIOL CHEM, V269, P5210; OMARY MB, 1981, J BIOL CHEM, V256, P2888; PIETERS J, 1993, J CELL SCI, V106, P831; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANNER LI, 1987, J BIOL CHEM, V262, P8975; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	44	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14355	14362		10.1074/jbc.273.23.14355	http://dx.doi.org/10.1074/jbc.273.23.14355			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603944	hybrid			2022-12-25	WOS:000074021500046
J	De Las Alas, MM; De Bruin, RAM; Ten Eyck, L; Los, G; Howell, SB				De Las Alas, MM; De Bruin, RAM; Ten Eyck, L; Los, G; Howell, SB			Prediction-based threading of the hMSH2 DNA mismatch repair protein	FASEB JOURNAL			English	Article						protein model; loop generation; structural homologue; glycogen phosphorylase	NONPOLYPOSIS COLORECTAL-CANCER; HUMAN MSH2 PROTEIN; ESCHERICHIA-COLI; SECONDARY STRUCTURE; STRUCTURE ALIGNMENT; NEURAL NETWORKS; TUMOR-CELLS; MUTATIONS; GENE; BINDING	Mutations in the genes whose products participate in DNA mismatch repair underlie the increased risk of cancer in families with. hereditary nonpolyposis colon carcinoma. Mutations in hMSH2 account for approximately 50% of the mutations found in these families, We sought to predict the 3-dimensional structure of hMSH2 by identifying structural homologues using prediction-based threading and by computer modeling using information from these putative structurally related proteins. Prediction-based threading identified three candidate structural homologues: glycogen phosphorylase (gpb), a 70 kDa soluble lyric transglycosylase, and ribonucleotide reductase protein R1. An independent approach utilizing a potential-based threading program also identified gpb as a structural homologue. The models based on the structures of these proteins suggest that the ATP binding domain and helix-turn-helix domain are exposed on the outside of the protein, All known bacterial MutS and hMSH2 mutations appear to be clustered in similar vicinities in the theoretical models of hMSH2; the major site is within the ATP binding domain and near the carboxyl-terminal end, whereas a smaller number map to the region coding for exon 5 and the amino-terminal domain. All point mutations also appear to affect amino acids that are exposed on the outside surface of the protein.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; San Diego Super Comp Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	De Las Alas, MM (corresponding author), 9500 Gilman Dr,0058, La Jolla, CA 92093 USA.	mdelasal@sdcc14.ucsd.edu						Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; *BIOS MSI, 1995, HOM US GUID; BLAKE CCF, 1979, NATURE, V280, P448, DOI 10.1038/280448a0; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BUERSTEDDE JM, 1995, J MED GENET, V32, P909, DOI 10.1136/jmg.32.11.909; Cama A, 1996, TUMORI J, V82, P122, DOI 10.1177/030089169608200206; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CHUNG DC, 1995, GASTROENTEROLOGY, V109, P1685, DOI 10.1016/0016-5085(95)90660-6; delaChapelle A, 1995, ANNU REV GENET, V29, P329, DOI 10.1146/annurev.ge.29.120195.001553; DOMBRADI V, 1981, INT J BIOCHEM, V13, P125, DOI 10.1016/0020-711X(81)90147-6; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; ENGEL H, 1991, J BACTERIOL, V173, P6773, DOI 10.1128/jb.173.21.6773-6782.1991; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FROGGATT NJ, 1995, J MED GENET, V32, P352, DOI 10.1136/jmg.32.5.352; HABRAKEN Y, 1996, CURR BIOL, V6, P1186; HALL NR, 1994, EUR J CANCER, V30A, P1550, DOI 10.1016/0959-8049(94)00326-Z; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; JONES DT, 1995, PROTEINS, V23, P384; KECK W, 1985, EUR J BIOCHEM, V148, P493, DOI 10.1111/j.1432-1033.1985.tb08866.x; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KOLODNER RD, 1994, GENOMICS, V54, P4590; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEMER CMR, 1995, PROTEINS, V23, P337, DOI 10.1002/prot.340230308; LESK AM, 1991, PROTEIN ARCHITECTURE; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; MOULT J, 1995, PROTEINS, V23, pR2, DOI 10.1002/prot.340230303; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NYSTROMLAHTI M, 1994, AM J HUM GENET, V55, P659; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; ORENGO CA, 1990, J THEOR BIOL, V147, P517, DOI 10.1016/S0022-5193(05)80263-2; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Rhyu MS, 1996, J NATL CANCER I, V88, P240, DOI 10.1093/jnci/88.5.240; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1997, J MOL BIOL, V270, P471, DOI 10.1006/jmbi.1997.1101; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Rost B, 1996, METHOD ENZYMOL, V266, P525; ROST B, 1995, 3 INT C INT SYST MOL, P314; ROST B, 1995, PROTEIN FOLDS DISTAN, P132; Russell RB, 1996, J MOL BIOL, V259, P349, DOI 10.1006/jmbi.1996.0325; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SHENKIN PS, 1987, BIOPOLYMERS, V26, P2053, DOI 10.1002/bip.360261207; TAYLOR WR, 1989, J MOL BIOL, V208, P1, DOI 10.1016/0022-2836(89)90084-3; Thibodeau SN, 1996, CANCER RES, V56, P4836; THUNNISSEN AMWH, 1994, NATURE, V367, P750, DOI 10.1038/367750a0; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; Weber TK, 1997, CANCER RES, V57, P3798; Whitehouse A, 1997, BIOCHEM BIOPH RES CO, V232, P10, DOI 10.1006/bbrc.1997.6211; Whitehouse A, 1996, BIOCHEM BIOPH RES CO, V229, P147, DOI 10.1006/bbrc.1996.1771; Whitehouse A, 1996, BIOCHEM BIOPH RES CO, V225, P289, DOI 10.1006/bbrc.1996.1168; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994	68	4	4	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1998	12	9					653	663						11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619444				2022-12-25	WOS:000074011000004
J	David, G; Alland, L; Hong, SH; Wong, CW; DePinho, RA; Dejean, A				David, G; Alland, L; Hong, SH; Wong, CW; DePinho, RA; Dejean, A			Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein	ONCOGENE			English	Article						mSin3; histone deacetylases; APL; PLZF; Kruppel-like proteins	ZINC-FINGER GENE; RETINOIC ACID; TRANSCRIPTIONAL REPRESSION; ENCODING GENE; RAR-ALPHA; TRANSLOCATION; DOMAIN; RECEPTORS; REGULATOR; SIN3	The PLZF gene was identified first by its fusion with the retinoic acid receptor alpha gene in the t(11;17) translocation associated with a retinoic acid resistant form of acute promyelocytic leukemia (APL). It encodes a kruppel-like zinc finger protein with a POZ domain shared with a subset of regulatory proteins including the BCL6 leukemogenic protein. PLZF, like BCL6, strongly represses transcription initiated from different promoters. Here we show that PLZF associates in vitro and in vivo with the Mad co-repressor mSin3A and the histone deacetylase HDAC1. Two domains in PLZF and the PAH1 structure of mSin3A mediate these interactions. Trichostatin A, a specific inhibitor of histone deacetylases, significantly reduces PLZF repression. These data strongly suggest that, like nuclear receptors and Mad, PLZF represses transcription by recruiting a histone deacetylase through the SMRT-mSin3-HDAC co-repressor complex. We also show that BCL6 associates with HDAC1 indicating that this type of regulation might be common to POZ/Zinc finger proteins involved in human leukemias. This work supports a role far deregulated histone deacetylation in the development of both lymphoid and myeloid neoplasia in human and suggests that targeted histone deacetylase inhibitors may be useful for treatment of certain types of malignancies.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris 15, France; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA; Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California Davis	Dejean, A (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, 28 Rue Dr Roux, F-75724 Paris 15, France.		Dejean, Anne/L-5145-2018	DePinho, Ronald/0000-0002-5625-577X; Hong, Suk-Hyun/0000-0001-7541-4847; , gregory/0000-0002-3371-4558				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BREITMAN TR, 1990, CANCER RES, V50, P6268; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, ANTURE, V377, P454; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Rao G, 1996, ONCOGENE, V12, P1165; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEYFERT VL, 1996, ONCOGENE, V12, P2113; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YEYATI PL, 1997, UNPUB; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	43	248	276	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2549	2556		10.1038/sj.onc.1202043	http://dx.doi.org/10.1038/sj.onc.1202043			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627120				2022-12-25	WOS:000073672300012
J	Halaban, R; Cheng, E; Zhang, Y; Mandigo, CE; Miglarese, MR				Halaban, R; Cheng, E; Zhang, Y; Mandigo, CE; Miglarese, MR			Release of cell cycle constraints in mouse melanocytes by overexpressed mutant E2F1(E132), but not by deletion of p16(INK4A) or p21(WAF/CIP1)	ONCOGENE			English	Review						E2F1; cyclin D1; cyclin A; Rb; TPA; transcription	RETINOBLASTOMA GENE-PRODUCT; UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR E2F1; ACTIVATED PROTEIN-KINASE; FAMILIAL MELANOMA; GROWTH-FACTOR; MURINE MELANOCYTES; MALIGNANT-MELANOMA; FIBROBLASTS LEADS; INHIBITOR P21	Compared to normal melanocytes, melanoma cell lines exhibit overexpression of hyperphosphorylated retinoblastoma tumor suppressor protein (Rb) or a marked decrease in, or lack of, expression of Rb. Hyperphosphorylation of Rb results in increased E2F-mediated transactivation of target genes and cell cycle progression. Using a combination of gene disruption and ectopic expression in growth factor-dependent mouse melanocytes, we studied the roles of E2F1 and the p16(INK4A) and p21(WAF1/CIP1) CKIs (cyclin dependent kinase inhibitors) in the acquisition of TPA (12-O-tetradecanoyl phorbol-13-acetate)-independent growth in culture, a hallmark of melanomas. Surprisingly, melanocytes from p16(INK4A)-or p21(WAF1/CIP1)-null mice remained TPA-dependent, and disruption of p21(WAF1/CIP1) accelerated cell death in the absence of this mitogen. Disruption of E2F1 had the most profound effect on melanocyte growth, resulting in a fourfold decrease in growth rate in the presence of TPA. Furthermore, enforced overexpression of the DNA-binding-defective E2F1(E132) mutant conferred TPA-independence upon melanocytes and was associated with sequestration of Rb and constitutive expression of E2F1 target genes, including p21(WAF1/CIP1). We conclude that neutralization of Rb by E2F1(E132), but not the disruption of pl6(INK4A) or p21(WAF1/CIP1), resulted in the accumulation of free E2F and cell cycle progression. Thus, mechanisms other than the loss of p16(INK4A) or p21(WAF1/CIP1) that activate E2F may play an important role in melanomas.	Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA	Yale University	Halaban, R (corresponding author), Yale Univ, Sch Med, Dept Dermatol, POB 208059, New Haven, CT 06520 USA.							Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Bartkova J, 1996, CANCER RES, V56, P5475; BATAILLE V, 1995, BRIT J DERMATOL, V132, P134, DOI 10.1111/j.1365-2133.1995.tb08639.x; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CannonAlbright LA, 1996, SEMIN ONCOL, V23, P667; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1994, J CELL SCI, P81; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Flores JF, 1997, ONCOGENE, V15, P2999, DOI 10.1038/sj.onc.1201470; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; Geng Y, 1996, ONCOGENE, V12, P1173; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GRUIS NA, 1995, MELANOMA RES, V5, P169, DOI 10.1097/00008390-199506000-00005; Guldberg P, 1997, INT J CANCER, V72, P780, DOI 10.1002/(SICI)1097-0215(19970904)72:5<780::AID-IJC13>3.0.CO;2-D; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; Halaban R, 1996, SEMIN ONCOL, V23, P673; HALABAN R, 1998, IN PRESS INT J MOL M, V1; Haluska FG, 1995, CANCER SURV, V25, P277; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Healy E, 1996, J INVEST DERMATOL, V107, P318, DOI 10.1111/1523-1747.ep12363118; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Jiang HP, 1996, MOL CELL DIFFER, V4, P67; JIANG HP, 1995, ONCOGENE, V10, P1855; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; LIU L, 1995, ONCOGENE, V11, P405; Liu Y, 1996, CANCER RES, V56, P31; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lukas J, 1996, MOL CELL BIOL, V16, P6917; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maelandsmo GM, 1996, AM J PATHOL, V149, P1813; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Moll AC, 1997, OPHTHALMIC GENET, V18, P27, DOI 10.3109/13816819709057880; Moore DD, 1995, GLOB MOB SURV; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PEEPER DS, 1995, ONCOGENE, V10, P39; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PUIG S, 1995, AM J HUM GENET, V57, P395; Puntoni F, 1997, BIOCHEM BIOPH RES CO, V235, P704, DOI 10.1006/bbrc.1997.6886; QUELLE DE, 1995, CELL, V83, P993; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REYMOND A, 1995, ONCOGENE, V11, P1173; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; TAMURA A, 1987, IN VITRO CELL DEV B, V23, P519; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Trotter MJ, 1997, J CUTAN PATHOL, V24, P265, DOI 10.1111/j.1600-0560.1997.tb00790.x; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Wang HS, 1997, CANCER RES, V57, P1750; Wang YP, 1996, ONCOGENE, V12, P1069; Weinberg RA, 1996, CYTOKINES MOL THER, V2, P105; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yang XH, 1997, BIOCHEM BIOPH RES CO, V232, P336, DOI 10.1006/bbrc.1997.6284; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	104	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2489	2501		10.1038/sj.onc.1201773	http://dx.doi.org/10.1038/sj.onc.1201773			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627115				2022-12-25	WOS:000073672300007
J	Bongarzone, I; Vigano, E; Alberti, L; Borrello, MG; Pasini, B; Greco, A; Mondellini, P; Smith, DP; Ponder, BAJ; Romeo, G; Pierotti, MA				Bongarzone, I; Vigano, E; Alberti, L; Borrello, MG; Pasini, B; Greco, A; Mondellini, P; Smith, DP; Ponder, BAJ; Romeo, G; Pierotti, MA			Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation	ONCOGENE			English	Article						RET; MEN2B; GDNF	MEDULLARY-THYROID CARCINOMA; NEOPLASIA TYPE 2B; TYROSINE KINASE; ADAPTER PROTEINS; C-RET; PROTOONCOGENE; DISEASE; RECEPTOR; GERMLINE; 2A	Germline mutations of RET gene, encoding a receptor tyrosine kinase, have been associated with the MEN2A and MEN2B inherited cancer syndromes, In MEN2A mutations affecting cysteine residues in the extracellular domain of the receptor cause constitutive activation of the tyrosine kinase by the formation of disulfide-bonded homodimers. In MEN2B a single mutation in the tyrosine kinase domain (Met918Thr) has been identified. This mutation does not lead to dimer formation, but has been shown (both biologically and biochemically) to cause ligand-independent activation of the Ret protein, but to a lesser extent than MEN2A mutations. Intramolecular activation by cis-autophosphorylation of RetMEN2B monomers has been proposed as a model for activation, although alternative mechanisms can be envisaged, Here we show that the activity of RetMEN2B can be increased by stable dimerization of the receptor. Dimerization was achieved experimentally by constructing a double mutant receptor with a MEN2A mutation (Cys634Arg) in addition to the MEN2B mutation, and by chronic exposure of RetMEN2B-expressing cells to the Ret ligand GDNF. In both cases full activation of RetMEN2B, measured by 'in vitro' transfection assays and biochemical parameters, was seen. These results indicate that the MEN2B phenotype could be influenced by the tissue distribution or concentration of Ret ligand(s).	Ist Nazl Tumori, Div Expt Oncol A, I-20133 Milan, Italy; Ist Nazl Tumori, Sci Direct, I-20133 Milan, Italy; Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England; Int Agcy Res Canc, F-69372 Lyon 08, France	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Cambridge; World Health Organization; International Agency for Research on Cancer (IARC)	Bongarzone, I (corresponding author), Ist Nazl Tumori, Div Expt Oncol A, Via Venezian 1, I-20133 Milan, Italy.		Pierotti, Marco Alessandro/AAC-4728-2022; Pasini, Barbara/AHI-2004-2022; Greco, Angela/C-1953-2017; Bongarzone, Italia/B-9544-2017; Borrello, Maria Grazia/C-3161-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Pasini, Barbara/0000-0002-4373-1212; Greco, Angela/0000-0003-2994-0349; Bongarzone, Italia/0000-0003-2530-9170; Borrello, Maria Grazia/0000-0002-6854-2848				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Borrello MG, 1995, ONCOGENE, V11, P2419; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec PL, 1996, DEVELOPMENT, V122, P349; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Eng C, 1996, CANCER RES, V56, P2167; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Marsh DJ, 1996, CANCER RES, V56, P1241; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; Ponder BAJ, 1996, ADV CANCER RES, V70, P179, DOI 10.1016/S0065-230X(08)60875-1; Rizzo C, 1996, J BIOL CHEM, V271, P29497, DOI 10.1074/jbc.271.46.29497; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Suvanto P, 1997, HUM MOL GENET, V6, P1267, DOI 10.1093/hmg/6.8.1267; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1997, J NEUROSCI, V17, P3554; Widenfalk J, 1997, J NEUROSCI, V17, P8506	34	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2295	2301		10.1038/sj.onc.1201759	http://dx.doi.org/10.1038/sj.onc.1201759			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620546				2022-12-25	WOS:000073428000001
J	Dugimont, T; Montpellier, C; Adriaenssens, E; Lottin, S; Dumont, L; Iotsova, V; Lagrou, C; Stehelin, D; Coll, J; Curgy, JJ				Dugimont, T; Montpellier, C; Adriaenssens, E; Lottin, S; Dumont, L; Iotsova, V; Lagrou, C; Stehelin, D; Coll, J; Curgy, JJ			The H19 TATA-less promoter is efficiently repressed by wild-type tumor suppressor gene product p53	ONCOGENE			English	Article						H19; p53; tumor suppressor; gene regulation; TATA-less promoter	SMOOTH-MUSCLE CELLS; BINDING PROTEIN; FUNCTIONAL INTERACTION; MOUSE EMBRYOGENESIS; IMPRINTED GENES; IGF2 EXPRESSION; BREAST-CANCER; DNA-BINDING; MUTANT P53; IN-VIVO	The developmentally regulated H19 gene displays several remarkable properties: expression of an apparently non-translated mRNA, genomic imprinting (maternal allele only expressed), relaxation of the imprinting and/or epigenetic lesions demonstrated in some tumors. Despite several observations after relaxation of imprinting status of the gene, data on tr ans and cis-acting factors required for the human H19 gene expression are still missing. As a first approach to address identification of factors involved in the regulation of the gene, we found that cells from a p53 antisense-transfected HeLa clone displayed increased amounts of H19 transcripts when compared to the non-transfected cells. Moreover, a HeLa clone stably transfected with a temperature sensitive (ts) 143 Ala p53 mutant exhibited temperature-dependent regulation of H19 expression. This preliminary indication of the repressing effect of the p53 protein on H19 expression has been confirmed by transient cotransfection experiments in HeLa cells, using luciferase surrogate constructs under the control of the 823 bp sequence immediately upstream of the transcription start point of the H19 gene, and different constructs containing sense, antisense or a ts 143 Ala mutant p53 cDNA. We observed an increase of H19 promoter-driven activity in transient cotransfections with the antisense p53 cDNA and the temperature sensitive mutant p53 at the non-permissive temperature, but a decrease with sense wild-type p53 cDNA. Furthermore, the cotransfection experiments were repeated in a cell line lacking endogenous p53, (Calu 6 cells) and the results provided additional evidence for a down regulation of the expression of the H19 gene by the p53 protein.	Univ Sci & Technol Lille, Ctr Biol Cellulaire, Unite Dynam Cellules Embryonnaires & Cancereuses, EA 1033, F-59655 Villeneuve Dascq, France; Univ Artois, Fac Sci Jean Perrin, F-62307 Lens, France; Inst Pasteur, Unite Oncol Mol, CNRS, URA 1160, F-59019 Lille, France	Universite de Lille - ISITE; Universite de Lille; Universite d'Artois; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Curgy, JJ (corresponding author), Univ Sci & Technol Lille, Ctr Biol Cellulaire, Unite Dynam Cellules Embryonnaires & Cancereuses, EA 1033, SN3, F-59655 Villeneuve Dascq, France.			MONTPELLIER, Claire/0000-0002-3112-8491				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Ariel I, 1997, J CLIN PATHOL-MOL PA, V50, P34, DOI 10.1136/mp.50.1.34; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barbareschi M, 1996, APPL IMMUNOHISTOCHEM, V4, P106; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cooper MJ, 1996, J UROLOGY, V155, P2120, DOI 10.1016/S0022-5347(01)66120-2; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEB SP, 1994, ONCOGENE, V9, P1341; DOUCRASY S, 1993, INT J ONCOL, V2, P753; DoucRasy S, 1996, ONCOGENE, V12, P423; Dugimont T, 1995, BIOL CELL, V85, P117, DOI 10.1016/0248-4900(96)85272-5; EDEN S, 1995, NATURE, V375, P16, DOI 10.1038/375016a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELKIN M, 1995, FEBS LETT, V374, P57, DOI 10.1016/0014-5793(95)01074-O; Elson DA, 1997, MOL CELL BIOL, V17, P309, DOI 10.1128/MCB.17.1.309; EVERSOLECIRE P, 1995, CELL GROWTH DIFFER, V6, P337; FAILLE A, 1994, BRIT J CANCER, V69, P1145, DOI 10.1038/bjc.1994.225; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FRIEDRICHS K, 1993, CANCER, V72, P3641, DOI 10.1002/1097-0142(19931215)72:12<3641::AID-CNCR2820721215>3.0.CO;2-8; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAN DKM, 1992, CIRC RES, V71, P711, DOI 10.1161/01.RES.71.3.711; Han DKM, 1996, J CLIN INVEST, V97, P1276, DOI 10.1172/JCI118543; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Iotsova V, 1996, ONCOGENE, V13, P2331; IOTSOVA V, 1995, EUR J CELL BIOL, V68, P122; JINNO Y, 1995, NAT GENET, V10, P318, DOI 10.1038/ng0795-318; JOOSS K, 1995, ONCOGENE, V10, P1529; Joubel A, 1996, CELL MOL BIOL, V42, P1159; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIM DK, 1994, J CLIN INVEST, V93, P355, DOI 10.1172/JCI116967; KONDO M, 1995, ONCOGENE, V10, P1193; LEIBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241, DOI 10.1016/S0006-291X(05)81329-4; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; Pellegata NS, 1996, EUR J HISTOCHEM, V40, P273; PERREM K, 1995, ONCOGENE, V11, P1299; POIRIER F, 1991, DEVELOPMENT, V113, P1105; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; RACHMILEWITZ J, 1992, MOL REPROD DEV, V32, P196, DOI 10.1002/mrd.1080320303; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Reid LH, 1996, HUM MOL GENET, V5, P239, DOI 10.1093/hmg/5.2.239; Sambrook J., 1989, MOL CLONING LABORATO, V2, P916; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMID P, 1991, DEVELOPMENT, V113, P857; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SURANI MA, 1993, NATURE, V366, P302, DOI 10.1038/366302a0; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; vanderKooy K, 1996, AM J EPIDEMIOL, V144, P924, DOI 10.1093/oxfordjournals.aje.a008862; Velculescu VE, 1996, CLIN CHEM, V42, P858; VOUTILAINEN R, 1994, ENDOCRINOLOGY, V134, P2051, DOI 10.1210/en.134.5.2051; WALSH C, 1995, CANCER RES, V55, P1111; WILES MV, 1988, DEVELOPMENT, V104, P403; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	90	91	96	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	1998	16	18					2395	2401		10.1038/sj.onc.1201742	http://dx.doi.org/10.1038/sj.onc.1201742			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620557				2022-12-25	WOS:000073428000012
J	Fujita, M; Yamada, C; Tsurumi, T; Hanaoka, F; Matsuzawa, K; Inagaki, M				Fujita, M; Yamada, C; Tsurumi, T; Hanaoka, F; Matsuzawa, K; Inagaki, M			Cell cycle- and chromatin binding state-dependent phosphorylation of human MCM heterohexameric complexes - A role for cdc2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION LICENSING SYSTEM; DNA-REPLICATION; S-PHASE; FISSION YEAST; NUCLEAR-LOCALIZATION; HUMAN MEMBER; PROTEINS; XENOPUS; MUTANT; FAMILY	The mammalian MCM protein family, presently with six members, exists in the nuclei in two forms, chromatin-bound and unbound. The former dissociates from chromatin with progression through the S phase. Recently, we have established a procedure to isolate chromatin-bound and unbound complexes containing all six human MCM (hMCM) proteins by immunoprecipitation. In the present study, we applied this procedure to HeLa cells synchronized in each of the G(1), S, and G(2)/M phases and could detect hMCM heterohexameric complexes in all three. In addition, depending on the cell cycle and the state of chromatin association, hMCM2 and 4 in the complexes were found to variously change their phosphorylation states. Concentrating attention on G(2)/M phase hyperphosphorylation, we found hMCM2 and 4 in the complexes to be good substrates for cdc2/cyclin B in vitro. Furthermore, when cdc2 kinase was inactivated in temperature-sensitive mutant murine FT210 cells, the G(2)/M hyperphosphorylation of the murine MCM2 and MCM4 and release of the MCMs from chromatin in the G(2) phase were severely impaired. Taken together, the data suggest that the six mammalian MCM proteins function and undergo cell cycle-dependent regulation as heterohexameric complexes and that phosphorylation of the complexes by cdc2 kinase may be one of mechanisms negatively regulating the MCM complex-chromatin association.	Aichi Canc Ctr, Res Inst, Lab Viral Oncol, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Biochem Lab, Chikusa Ku, Nagoya, Aichi 464, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 565, Japan; Hokkaido Univ, Inst Immunol Sci, Sapporo, Hokkaido 060, Japan	Aichi Cancer Center; Aichi Cancer Center; Osaka University; Hokkaido University	Fujita, M (corresponding author), Aichi Canc Ctr, Res Inst, Lab Viral Oncol, Chikusa Ku, Nagoya, Aichi 464, Japan.		Inagaki, Masaki/B-9920-2016	Fujita, Masatoshi/0000-0001-6617-2452				BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; COXON A, 1992, NUCLEIC ACIDS RES, V20, P5571, DOI 10.1093/nar/20.21.5571; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Fujita M, 1996, BIOCHEM BIOPH RES CO, V219, P604, DOI 10.1006/bbrc.1996.0280; Fujita M, 1996, J BIOL CHEM, V271, P4349; Fujita M, 1997, J BIOL CHEM, V272, P10928; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Krude T, 1996, J CELL SCI, V109, P309; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; Lei M, 1996, MOL CELL BIOL, V16, P5081; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAINE GT, 1984, GENETICS, V106, P365; MINEO C, 1986, EXP CELL RES, V167, P53, DOI 10.1016/0014-4827(86)90203-X; MIYAKE S, 1993, MOL BIOL CELL, V4, P1003, DOI 10.1091/mbc.4.10.1003; Miyake S, 1996, GENE, V175, P71, DOI 10.1016/0378-1119(96)00122-9; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Schulte D, 1996, EUR J BIOCHEM, V235, P144, DOI 10.1111/j.1432-1033.1996.00144.x; Su TT, 1996, MOL BIOL CELL, V7, P319, DOI 10.1091/mbc.7.2.319; TAKAHASHI K, 1994, MOL BIOL CELL, V5, P1145, DOI 10.1091/mbc.5.10.1145; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; TREISMAN JE, 1995, GENE DEV, V9, P1709, DOI 10.1101/gad.9.14.1709; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; YASUDA H, 1991, CELL STRUCT FUNCT, V16, P105, DOI 10.1247/csf.16.105	51	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17095	17101		10.1074/jbc.273.27.17095	http://dx.doi.org/10.1074/jbc.273.27.17095			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642275	hybrid			2022-12-25	WOS:000074545200065
J	Li, LQ; Lee, TK; Meier, PJ; Ballatori, N				Li, LQ; Lee, TK; Meier, PJ; Ballatori, N			Identification of glutathione as a driving force and leukotriene C-4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; FUNCTIONAL-CHARACTERIZATION; CYSTEINYL LEUKOTRIENES; REDUCED GLUTATHIONE; EXPRESSION CLONING; ANION TRANSPORTER; MEMBRANE-VESICLES; BILIARY-EXCRETION; XENOPUS-LAEVIS; HEPATOCYTES	oatp1 is an hepatic sinusoidal organic anion transporter that mediates uptake of various structurally unrelated organic compounds from blood, The driving force for uptake on oatp1 has not been identified, although a role for bicarbonate has recently been proposed. The present study examined whether oatp1-mediated uptake is energized by efflux (countertransport) of intracellular reduced glutathione (GSH), and whether hydrophobic glutathione S-conjugates such as leukotriene C-4 (LTC4) and S-dinitrophenyl glutathione (DNP-SG) form a novel class of substrates for oatp1, Xenopus laevis oocytes injected with the complementary RNA for oapt1 demonstrated higher uptake of 10 nM [H-3]LTC4 and 50 mu M [H-3]DNP-SG, and higher efflux of [H-3]GSH (2.5 mM endogenous intracellular GSH concentration). The oatp1-stimulated LTC4 and DNP-SG uptake was independent of the Na+ gradient, cis-inhibited by known substrates of this transport protein and by 1 mM GSH, and was saturable, with apparent K-m values of 0.27 +/- 0.06 and 408 +/- 95 mu M, respectively. Uptake of [H-3]taurocholate, an endogenous substrate of oatp1, was competitively inhibited by DNP-SG, Of significance, oatp1-mediated taurocholate and LTC4 uptake was cis-inhibited and trans-stimulated by GSH, and [H-3]GSH efflux was enhanced in the presence of extracellular taurocholate or sulfobromophthalein, indicating that GSH efflux down its large electrochemical gradient provides the driving force for uptake via oatp1, The stoichiometry of GSH/taurocholate exchange was 1:1, These findings identify a new class of substrates for oatp1 and provide evidence for GSH-dependent oatp1-mediated substrate transport.	Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA; Univ Zurich Hosp, Dept Med, Div Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland	University of Rochester; University of Zurich; University Zurich Hospital	Ballatori, N (corresponding author), Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006484, P30ES001247] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48823] Funding Source: Medline; NIEHS NIH HHS [ES06484, ES01247] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		APPELGREN LE, 1982, J BIOL CHEM, V257, P531; AW TY, 1984, J BIOL CHEM, V259, P9355; AW TY, 1986, AM J PHYSIOL, V251, P354; BALLATORI N, 1995, J BIOL CHEM, V270, P3594, DOI 10.1074/jbc.270.8.3594; BALLATORI N, 1994, J BIOL CHEM, V269, P19731; Ballatori N, 1996, AM J PHYSIOL-REG I, V270, pR1156, DOI 10.1152/ajpregu.1996.270.5.R1156; DELEVE LD, 1991, PHARMACOL THERAPEUT, V52, P287, DOI 10.1016/0163-7258(91)90029-L; FARRIS MW, 1987, METHOD ENZYMOL, V143, P101; FERNANDEZCHECA JC, 1990, AM J PHYSIOL, V258, pG967, DOI 10.1152/ajpgi.1990.258.6.G967; FERNANDEZCHECA JC, 1988, AM J PHYSIOL, V18, pG403; GARCIARUIZ C, 1992, J BIOL CHEM, V267, P22256; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HAGENBUCH B, 1990, J BIOL CHEM, V265, P5357; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HINCHMAN CA, 1991, J BIOL CHEM, V266, P22179; HINCHMAN CA, 1993, AM J PHYSIOL, V265, pG547, DOI 10.1152/ajpgi.1993.265.3.G547; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; KULLAKUBLICK GA, 1994, HEPATOLOGY, V20, P411; LEE TK, 1998, IN PRESS YALE J BIOL; LEIER I, 1992, EUR J BIOCHEM, V209, P281, DOI 10.1111/j.1432-1033.1992.tb17287.x; LI L, 1998, IN PRESS YALE J BIOL; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; LU SC, 1993, J CLIN INVEST, V92, P1188, DOI 10.1172/JCI116689; LU SC, 1994, MOL PHARMACOL, V46, P578; Meier PJ, 1997, HEPATOLOGY, V26, P1667, DOI 10.1002/hep.510260641; Noe B, 1997, P NATL ACAD SCI USA, V94, P10346, DOI 10.1073/pnas.94.19.10346; OOKHTENS M, 1988, J CLIN INVEST, V82, P608, DOI 10.1172/JCI113639; Paulusama C. C., 1997, Hepatology, V26, p292A; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; Satlin LM, 1997, J BIOL CHEM, V272, P26340, DOI 10.1074/jbc.272.42.26340; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SHI XY, 1995, J BIOL CHEM, V270, P25591, DOI 10.1074/jbc.270.43.25591; SIMONSON GD, 1994, J CELL SCI, V107, P1065; SNUTCH TP, 1992, METHOD ENZYMOL, V207, P279; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; WETTSTEIN M, 1989, EUR J BIOCHEM, V181, P115, DOI 10.1111/j.1432-1033.1989.tb14701.x; WETTSTEIN M, 1990, EUR J BIOCHEM, V191, P251, DOI 10.1111/j.1432-1033.1990.tb19117.x; WHELAN G, 1970, J LAB CLIN MED, V75, P542; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690	43	215	222	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16184	16191		10.1074/jbc.273.26.16184	http://dx.doi.org/10.1074/jbc.273.26.16184			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632674	hybrid			2022-12-25	WOS:000074436600045
J	Pommier, J; Mejean, V; Giordano, G; Iobbi-Nivol, C				Pommier, J; Mejean, V; Giordano, G; Iobbi-Nivol, C			TorD, a cytoplasmic chaperone that interacts with the unfolded trimethylamine N-oxide reductase enzyme (TorA) in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRATE REDUCTASE; DENITRIFICANS; RESPIRATION; INVOLVEMENT; CYTOCHROMES; INDUCTION; SEQUENCE; PROTEINS; CLONING; OPERON	Reduction of trimethylamine N-oxide (TMAO) in Escherichia coli involves the terminal molybdoreductase TorA, located in the periplasm, and the membrane anchored c type cytochrome TorC. In this study, the role of the Toro protein, encoded by the third gene of torCAD operon, is investigated. Construction of a mutant, in which the torD gene is interrupted, showed that the absence of Toro protein leads to a two times decrease of the final amount of TorA enzyme. However, specific activity and biochemical properties of TorA enzyme were similar to those of the enzyme produced in the wild type. Excess of Toro protein restores the normal level of TorA enzyme, and also, leads to the appearance of a new cytoplasmic form of TorA on SDS-polyacrylamide gel electrophoresis using gentle conditions. This probably indicates a new folding state of the cytoplasmic TorA protein when Toro is overexpressed. BIAcore techniques demonstrated direct specific interaction between the TorA and Toro proteins. This interaction was enhanced when TorA was previously unfolded by heating, Finally, as TorA is a molybdoenzyme, we demonstrated that Toro can interact with TorA before the molybdenum cofactor has been inserted. As Toro homologue encoding genes are found in various TMAO reductase loci, we propose that Toro is a chaperone protein specific for the TorA enzyme. It belongs to a family of TorD-like chaperones present in several bacteria, and, probably, involved in TMAO reductase folding.	CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS)	Iobbi-Nivol, C (corresponding author), CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, 31 Chemin Joseph Aiguier,BP71, F-13402 Marseille 20, France.	iobbi@ibsm.cnrs-mrs.fr		Mejean, Vincent/0000-0001-6533-5846				Aubert C, 1998, BIOCHEMISTRY-US, V37, P2120, DOI 10.1021/bi971656g; Blasco F, 1998, MOL MICROBIOL, V28, P435, DOI 10.1046/j.1365-2958.1998.00795.x; BRAGG PD, 1983, BIOCHIM BIOPHYS ACTA, V725, P168, DOI 10.1016/0005-2728(83)90237-2; CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; CRASKE A, 1986, EUR J BIOCHEM, V158, P429, DOI 10.1111/j.1432-1033.1986.tb09771.x; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GRAHAM A, 1980, FEMS MICROBIOL LETT, V7, P145, DOI 10.1111/j.1574-6941.1980.tb01595.x; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; IOBBINIVOL C, 1994, FEMS MICROBIOL LETT, V119, P89, DOI 10.1016/0378-1097(94)90397-2; IobbiNivol C, 1996, BBA-PROTEIN STRUCT M, V1294, P77, DOI 10.1016/0167-4838(95)00271-5; Jourlin C, 1996, MOL MICROBIOL, V20, P1297, DOI 10.1111/j.1365-2958.1996.tb02648.x; Jourlin C, 1997, J MOL BIOL, V267, P770, DOI 10.1006/jmbi.1997.0919; Knablein J, 1996, J MOL BIOL, V263, P40, DOI 10.1006/jmbi.1996.0554; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XL, 1997, J BIOL CHEM, V272, P24266, DOI 10.1074/jbc.272.39.24266; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; MERK AB, 1994, BIATECHNOLOGY HDB; MONCEY NJ, 1997, J BACTERIOL, V179, P7617; PALMER T, 1994, EUR J BIOCHEM, V222, P687, DOI 10.1111/j.1432-1033.1994.tb18913.x; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; SILVESTRO A, 1988, BIOCHIM BIOPHYS ACTA, V954, P1, DOI 10.1016/0167-4838(88)90049-0; SILVESTRO A, 1989, BIOCHIM BIOPHYS ACTA, V999, P208, DOI 10.1016/0167-4838(89)90220-3; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; TAWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350; Ujiiye T, 1996, BBA-BIOENERGETICS, V1277, P1, DOI 10.1016/S0005-2728(96)00101-6	30	111	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16615	16620		10.1074/jbc.273.26.16615	http://dx.doi.org/10.1074/jbc.273.26.16615			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632735	hybrid			2022-12-25	WOS:000074436600106
J	van de Poll, MLM; van Vugt, MJH; Lenferink, AEG; van Zoelen, EJJ				van de Poll, MLM; van Vugt, MJH; Lenferink, AEG; van Zoelen, EJJ			Identification of the minimal requirements for binding to the human epidermal growth factor (EGF) receptor using chimeras of human EGF and an EGF repeat of Drosophila notch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; COAGULATION FACTOR-X; FACTOR-ALPHA; HIGH-AFFINITY; TGF-ALPHA; ESCHERICHIA-COLI; DOMAIN; PROTEOLYSIS; SEQUENCE; PROTEINS	Many proteins contain so-called epidermal growth factor (EGF)-like domains that share the characteristic spacing of cysteines and glycines with members of the EGF family. They are, however, functionally unrelated, despite the fact that the three-dimensional structure of these EGF-like domains, also, is often very similar to that of the EGF receptor agonists. In the present study, we linked an EGF-like repeat from the Drosophila Notch protein to the N- and C-terminal linear tail sequences of human EGF (hEGF), and we showed that this chimera (E1N6E) is unable to bind or activate the hEGF receptor. This recombinant protein was then used as a basic construct for identifying the minimal requirements for high affinity EGF receptor binding and activation. We selectively reintroduced a limited number of important hEGF-derived residues, and by using this unique approach, we were able to make hEGF/Notch chimeras that, compared with wild type hEGF, showed nearly 100% binding affinity and mitogenic activity on HER-14 cells expressing the hEGF receptor.	Univ Nijmegen, Dept Cell Biol, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	van de Poll, MLM (corresponding author), Univ Nijmegen, Dept Cell Biol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	mvdpoll@sci.kun.nl						ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ARTEAGA CL, 1988, CANCER RES, V48, P5023; BARON M, 1992, PROTEIN SCI, V1, P81; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CAMPION SR, 1990, BIOCHEMISTRY-US, V29, P9988, DOI 10.1021/bi00494a032; CAMPION SR, 1993, PROTEIN ENG, V6, P651, DOI 10.1093/protein/6.6.651; CAMPION SR, 1993, J BIOL CHEM, V268, P1742; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; KOIDE H, 1992, FEBS LETT, V302, P39, DOI 10.1016/0014-5793(92)80279-P; KOIDE H, 1992, BIOCHIM BIOPHYS ACTA, V1120, P257, DOI 10.1016/0167-4838(92)90245-9; KOIDE H, 1994, BIOCHEMISTRY-US, V33, P7470, DOI 10.1021/bi00189a055; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; KUMAR V, 1995, CELL BIOL INT, V19, P373, DOI 10.1006/cbir.1995.1083; LEE DC, 1995, PHARMACOL REV, V47, P51; LEE DC, 1993, ONCOGENES TUMOR SUPP, P233; Lenferink AEG, 1997, BIOCHEM J, V327, P859; McInnes C, 1996, J BIOL CHEM, V271, P32204, DOI 10.1074/jbc.271.50.32204; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NILSSON B, 1990, METHOD ENZYMOL, V185, P144; Puddicombe SM, 1996, J BIOL CHEM, V271, P30392, DOI 10.1074/jbc.271.48.30392; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; SELANDER M, 1990, BIOCHEMISTRY-US, V29, P8111, DOI 10.1021/bi00487a018; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SIMPSON P, 1995, NATURE, V375, P736, DOI 10.1038/375736a0; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; vandePoll MLM, 1997, BIOCHEMISTRY-US, V36, P7425, DOI 10.1021/bi970227f; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; VANZOELEN EJJ, 1993, BIOCHEMISTRY-US, V32, P6275, DOI 10.1021/bi00075a022; VANZOELEN EJJ, 1985, J CELL PHYSIOL, V123, P151, DOI 10.1002/jcp.1041230202; WALKER F, 1990, BIOCHEMISTRY-US, V29, P10635, DOI 10.1021/bi00499a009; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6	35	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16075	16081		10.1074/jbc.273.26.16075	http://dx.doi.org/10.1074/jbc.273.26.16075			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632659	hybrid			2022-12-25	WOS:000074436600030
J	Brondijk, THC; van der Rest, ME; Pluim, D; de Vries, Y; Stingl, K; Poolman, B; Konings, WN				Brondijk, THC; van der Rest, ME; Pluim, D; de Vries, Y; Stingl, K; Poolman, B; Konings, WN			Catabolite inactivation of wild-type and mutant maltose transport proteins in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR-TRANSPORT; YEAST; GLUCOSE; ENDOCYTOSIS; TRANSFORMATION; KINASE	The maltose transporter of Saccharomyces cerevisiae is subject to rapid, irreversible inactivation in the presence of glucose. Loss of transport function was paralleled by a decrease in amount of transporter protein and most likely involves endocytosis and degradation of the protein in the vacuole, This (catabolite) inactivation of Mal61p was triggered not only by glucose but also by 2-deoxy-D-glucose, which cannot be metabolized beyond 2-deoxy-D-glucose phosphate. The signal that targets membrane proteins specifically for catabolite inactivation is unknown. To investigate whether or not specific modification of Mal61p triggers the inactivation putative protein kinase A and C phosphorylation sites were removed, and the transport activities and levels of the mutant proteins upon addition of glucose were followed in time. Three Mal61p mutants, i.e. S295A, T363A, and S487A, exhibited significantly reduced rates of inactivation in the presence of glucose. Likewise, in wild-type Mal61p the rate of inactivation and degradation of the protein paralleled each other in the case of T363A. On the contrary, for the S295A and S487A mutants the rates of protein degradation were slowed down more profoundly than was the loss of transport activity. These observations indicate that (i) some form of modification (e.,g. phosphorylation) of the protein precedes breakdown, (ii) the modification inactivates MaI61p, and (iii) the inactivation of Mal61p is not necessarily followed by proteolytic degradation.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Poolman, B (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	B.Poolman@biol.rug.nl	Konings, Wilhelmus N./C-7063-2013; Brondijk, Harma/AAD-6485-2019	Brondijk, Harma/0000-0002-0234-673X; Stingl, Kerstin/0000-0002-8338-717X				Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; BUSTURIA A, 1985, BIOCHIM BIOPHYS ACTA, V820, P324, DOI 10.1016/0005-2736(85)90128-2; CHENG Q, 1991, J BACTERIOL, V173, P1817, DOI 10.1128/jb.173.5.1817-1820.1991; DULEY JR, 1975, ANAL BIOCHEM, V64, P136; EILAM Y, 1990, J GEN MICROBIOL, V136, P2537, DOI 10.1099/00221287-136-12-2537; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Lucero P, 1997, FEMS MICROBIOL LETT, V147, P273, DOI 10.1016/S0378-1097(96)00538-1; LUCERO P, 1993, FEBS LETT, V333, P265; Medintz I, 1996, J BACTERIOL, V178, P2245, DOI 10.1128/jb.178.8.2245-2254.1996; Messing J, 1979, RECOMBINANT DNA TECH, V2, P43; NEEDLEMAN R, 1991, MOL MICROBIOL, V5, P2079, DOI 10.1111/j.1365-2958.1991.tb02136.x; NOVAK S, 1990, J IND MICROBIOL, V6, P149, DOI 10.1007/BF01576435; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEINADO JM, 1986, BIOCHIM BIOPHYS ACTA, V856, P189, DOI 10.1016/0005-2736(86)90027-1; POSTMA E, 1990, J BACTERIOL, V171, P3539; RAMOS J, 1989, J BACTERIOL, V171, P3545, DOI 10.1128/jb.171.6.3545-3548.1989; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; RIBALLO E, 1995, J BACTERIOL, V177, P5622, DOI 10.1128/jb.177.19.5622-5627.1995; RIBALLO E, 1994, BIOCHIM BIOPHYS ACTA, V1191, P143; ROOMANS GM, 1979, BIOCHIM BIOPHYS ACTA, V551, P187, DOI 10.1016/0005-2736(79)90364-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; THEVELEIN JM, 1995, TRENDS BIOCHEM SCI, V20, P3, DOI 10.1016/S0968-0004(00)88938-0; VANDERREST ME, 1995, J BACTERIOL, V177, P5440, DOI 10.1128/jb.177.19.5440-5446.1995; Walsh MC, 1996, J BACTERIOL, V178, P2593, DOI 10.1128/jb.178.9.2593-2597.1996	30	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15352	15357		10.1074/jbc.273.25.15352	http://dx.doi.org/10.1074/jbc.273.25.15352			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624116	hybrid, Green Published			2022-12-25	WOS:000074284200010
J	Kishimoto, H; Hoshino, S; Ohori, M; Kontani, K; Nishina, H; Suzawa, M; Kato, S; Katada, T				Kishimoto, H; Hoshino, S; Ohori, M; Kontani, K; Nishina, H; Suzawa, M; Kato, S; Katada, T			Molecular mechanism of human CD38 gene expression by retinoic acid - Identification of retinoic acid response element in the first intron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYL CYCLASE; LYMPHOCYTE ANTIGEN CD38; NAD GLYCOHYDROLASE; MONOCLONAL-ANTIBODY; LEUKEMIA-CELLS; MYELOID CELLS; B-CELLS; SURFACE; DIFFERENTIATION; ACTIVATION	CD38 is a nonlineage-restricted type II transmembrane glycoprotein possessing ecto-NAD(+) glycohydrolase activity. Because of its unique expression pattern in lymphocyte differentiation, it appears to function as an immunoregulatory molecule. We previously reported that CD38 was specifically induced by all-trans-retinoic acid (RA) in human promyelocytic leukemia HL-60 cells. Here we studied the molecular mechanism of the RA-dependent induction of human CD38, The expression of CD38 mRNA by RA appeared to be caused by the transcriptional stimulation of the gene, since it was blocked by an RNA synthesis inhibitor, but not by a protein synthesis inhibitor. In search of the RA response element (RARE) possibly present in human CD38 gene promoter, we isolated and sequenced the genomic DNA covering the 5'-flanking region, exon I, and partial intron 1. Transient transfection experiments revealed that the responsiveness to RA was conferred through an RARE consisting of two direct repeat TGACCT-like hexamer motifs with a 5-nucleotide spacer, which was located in the first intron rather than the 5'-flanking region of the CD38 gene. This RARE interacted with heterodimer composed of RA receptor and retinoid X receptor in vitro. Thus, the RA-induced expression of the human CD38 gene was demonstrated to be mediated through the RARE located in the first intron.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo; University of Tokyo	Katada, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 113, Japan.			Hoshino, Shinichi/0000-0001-6135-7896				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AUSIELLO CM, 1995, EUR J IMMUNOL, V25, P1477, DOI 10.1002/eji.1830250554; BHAN AK, 1981, J EXP MED, V154, P737, DOI 10.1084/jem.154.3.737; CHEN ZP, 1994, J BIOL CHEM, V269, P25770; DIANZANI U, 1994, J IMMUNOL, V153, P952; DRACH J, 1993, BIOCHEM BIOPH RES CO, V195, P545, DOI 10.1006/bbrc.1993.2080; DRACH J, 1994, CANCER RES, V54, P1746; FUNARO A, 1990, J IMMUNOL, V145, P2390; HEMMI H, 1982, BIOCHEM BIOPH RES CO, V109, P669, DOI 10.1016/0006-291X(82)91992-1; HOLTER W, 1985, CELL IMMUNOL, V90, P322, DOI 10.1016/0008-8749(85)90197-2; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; HROMAS R, 1991, J BIOL CHEM, V266, P14183; INAGEDA K, 1995, J BIOCHEM-TOKYO, V117, P125, DOI 10.1093/oxfordjournals.jbchem.a124698; JACKSON DG, 1990, J IMMUNOL, V144, P2811; JANOSSY G, 1981, J IMMUNOL, V126, P1608; KATO S, 1995, MOL CELL BIOL, V15, P5858; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KUMAGAI MA, 1995, J EXP MED, V181, P1101, DOI 10.1084/jem.181.3.1101; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; Mehta K, 1997, BLOOD, V89, P3607, DOI 10.1182/blood.V89.10.3607.3607_3607_3614; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Nata K, 1997, GENE, V186, P285, DOI 10.1016/S0378-1119(96)00723-8; NISHINA H, 1994, BIOCHEM BIOPH RES CO, V203, P1318, DOI 10.1006/bbrc.1994.2326; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; SANTOSARGUMEDO L, 1993, J IMMUNOL, V151, P3119; SIEFF C, 1982, BLOOD, V60, P703; STASHENKO P, 1981, P NATL ACAD SCI-BIOL, V78, P3848, DOI 10.1073/pnas.78.6.3848; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; Stoeckler JD, 1996, J IMMUNOL, V157, P4908; SUMMERHILL RJ, 1993, FEBS LETT, V335, P231, DOI 10.1016/0014-5793(93)80735-D; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TERSTAPPEN LWMM, 1990, J LEUKOCYTE BIOL, V48, P138, DOI 10.1002/jlb.48.2.138; YAMASHITA Y, 1995, IMMUNOLOGY, V85, P248; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416; ZUPO S, 1994, EUR J IMMUNOL, V24, P1218, DOI 10.1002/eji.1830240532	38	97	104	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15429	15434		10.1074/jbc.273.25.15429	http://dx.doi.org/10.1074/jbc.273.25.15429			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624127	hybrid			2022-12-25	WOS:000074284200021
J	Misko, TP; Highkin, MK; Veenhuizen, AW; Manning, PT; Stern, MK; Currie, MG; Salvemini, D				Misko, TP; Highkin, MK; Veenhuizen, AW; Manning, PT; Stern, MK; Currie, MG; Salvemini, D			Characterization of the cytoprotective action of peroxynitrite decomposition catalysts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MITOCHONDRIAL RESPIRATORY-CHAIN; TYROSINE NITRATION; OXIDATIVE DAMAGE; IN-VITRO; SUPEROXIDE; CELLS; RAT; INHIBITION; INDUCTION	The formation of the powerful oxidant peroxynitrite (PN) from the reaction of superoxide anion with nitric oxide has been shown to be a kinetically favored reaction contributing to cellular injury and death at sites of tissue inflammation. The PN molecule is highly reactive causing lipid peroxidation as well as nitration of both free and protein-bound tyrosine. We present evidence for the pharmacological manipulation of PN with decomposition catalysts capable of converting it to nitrate. hs target cells challenged with exogenously added synthetic PN, a series of metalloporphyrin catalysts (5,10,15,20-tetrakis(2,4,6-trimethyl-3,3-disulfonatophenyl)porphyrinato iron (III) (FeTMPS); 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron (III) (FeTPPS); 5,10,15,20-tetrakis(N-methyl-4'-pyridyl)porphyrinato iron (III) (FeTMPyP)) provided protection against PN-mediated injury with EC50 values for each compound 30-50-fold below the final concentration of PN added. Cytoprotection was correlated with a reduction in the level of measurable nitrotyrosine. In addition, we found our catalysts to be cytoprotective against endogenously generated PN in endotoxin-stimulated RAW 264.7 cells as well as in dissociated cultures of hippocampal neurons and glia that had been exposed to cytokines. Our studies thus provide compelling evidence for the involvement of peroxynitrite in cytokine-mediated cellular injury and suggest the therapeutic potential of PN decomposition catalysts in reducing cellular damage at sites of inflammation.	Searle R&D, Discovery Pharmacol, St Louis, MO 63167 USA; Monsanto Corp Res, St Louis, MO 63167 USA	Monsanto	Misko, TP (corresponding author), Searle R&D, Discovery Pharmacol, 800 N Lindbergh Blvd, St Louis, MO 63167 USA.			Misko, Thomas/0000-0001-7917-422X				Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; BARTLETT D, 1995, FREE RADICAL BIO MED, V18, P85, DOI 10.1016/0891-5849(94)E0133-4; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0; Ding MZ, 1997, J BIOL CHEM, V272, P11327; Douki T, 1996, CHEM RES TOXICOL, V9, P3, DOI 10.1021/tx950126n; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; ESTEVEZ AG, 1995, J NEUROCHEM, V65, P1543; Good PF, 1996, AM J PATHOL, V149, P21; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Ischiropoulos H, 1996, J CLIN INVEST, V97, P2260, DOI 10.1172/JCI118667; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; KASTEN TP, 1995, P SOC EXP BIOL MED, V208, P170; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; Lee JB, 1997, BIOORG MED CHEM LETT, V7, P2913, DOI 10.1016/S0960-894X(97)10109-3; LEWIS RS, 1995, J BIOL CHEM, V270, P29350, DOI 10.1074/jbc.270.49.29350; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; MARTIN BL, 1990, J BIOL CHEM, V265, P7108; MEBMER UK, 1995, MOL PHARMACOL, V47, P757; MISKO TP, 1995, J NEUROIMMUNOL, V61, P195, DOI 10.1016/0165-5728(95)00091-F; MISKO TP, 1993, EUR J PHARMACOL, V233, P119, DOI 10.1016/0014-2999(93)90357-N; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; Salvemini D, 1998, P NATL ACAD SCI USA, V95, P2659, DOI 10.1073/pnas.95.5.2659; Salvemini D, 1996, EUR J PHARMACOL, V303, P217, DOI 10.1016/0014-2999(96)00140-9; Shigenaga MK, 1997, P NATL ACAD SCI USA, V94, P3211, DOI 10.1073/pnas.94.7.3211; SKAPER SD, 1995, J NEUROCHEM, V64, P266; Stern MK, 1996, J AM CHEM SOC, V118, P8735, DOI 10.1021/ja961279f; Szabo C, 1996, FEBS LETT, V381, P82, DOI 10.1016/0014-5793(96)00087-7; Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676; YAMADA KA, 1989, J NEUROSCI, V9, P3230; YERMILOV V, 1995, CARCINOGENESIS, V16, P2045, DOI 10.1093/carcin/16.9.2045; YOON KW, 1993, J PHYSIOL-LONDON, V464, P423, DOI 10.1113/jphysiol.1993.sp019643; Zingarelli B, 1996, J IMMUNOL, V156, P350	52	212	220	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15646	15653		10.1074/jbc.273.25.15646	http://dx.doi.org/10.1074/jbc.273.25.15646			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624158	hybrid			2022-12-25	WOS:000074284200052
J	Mandala, SM; Thornton, RA; Milligan, J; Rosenbach, M; Garcia-Calvo, M; Bull, HG; Harris, G; Abruzzo, GK; Flattery, AM; Gill, CJ; Bartizal, K; Dreikorn, S; Kurtz, MB				Mandala, SM; Thornton, RA; Milligan, J; Rosenbach, M; Garcia-Calvo, M; Bull, HG; Harris, G; Abruzzo, GK; Flattery, AM; Gill, CJ; Bartizal, K; Dreikorn, S; Kurtz, MB			Rustmicin, a potent antifungal agent, inhibits sphingolipid synthesis at inositol phosphoceramide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SERINE PALMITOYLTRANSFERASE; CANDIDA-ALBICANS; YEAST; BIOSYNTHESIS; RESISTANCE; CERAMIDE; PROTEINS; GOLGI	Rustmicin is a 14-membered macrolide previously identified as an inhibitor of plant pathogenic fungi by a mechanism that was not defined. We discovered that rustmicin inhibits inositol phosphoceramide synthase, resulting in the accumulation of ceramide and the loss of all of the complex sphingolipids, Rustmicin has potent fungicidal activity against clinically important human pathogens that is correlated with its sphingolipid inhibition, It is especially potent against Cryptococcus neoformans, where it inhibits growth and sphingolipid synthesis at concentrations <1 ng/ml and inhibits the enzyme with an IC50 of 70 pM. This inhibition of the membrane-bound enzyme is reversible; moreover, rustmicin is nearly equipotent against the solubilized enzyme. Rustmicin was efficacious in a mouse model for cryptococcosis, but it was less active than predicted from its in vitro potency against this pathogen. Stability and drug efflux were identified as two factors limiting rustmicin's activity. in the presence of serum, rustmicin rapidly epimerizes at the C-2 position and is converted to a gamma-lactone, a product that is devoid of activity. Rustmicin was also found to be a remarkably good substrate for the Saccharomyces cerevisiae multidrug efflux pump encoded by PDR5.	Merck Res Labs, Dept Biochem, Rahway, NJ 07065 USA	Merck & Company	Mandala, SM (corresponding author), Merck Res Labs, Dept Biochem, R80Y-230,PO 2000, Rahway, NJ 07065 USA.							ABRUZZO GK, 1995, ANTIMICROB AGENTS CH, V39, P1077, DOI 10.1128/AAC.39.5.1077; Achenbach H, 1988, Ann N Y Acad Sci, V544, P128, DOI 10.1111/j.1749-6632.1988.tb40396.x; ACHENBACH H, 1985, TETRAHEDRON LETT, V26, P6167, DOI 10.1016/S0040-4039(00)95043-3; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BOAS MHSV, 1994, CHEM PHYS LIPIDS, V70, P11; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; FAUTH U, 1986, J ANTIBIOT, V39, P1760, DOI 10.7164/antibiotics.39.1760; GABER RF, 1989, MOL CELL BIOL, V9, P3447, DOI 10.1128/MCB.9.8.3447; GELDERBLOM WCA, 1988, APPL ENVIRON MICROB, V54, P1806, DOI 10.1128/AEM.54.7.1806-1811.1988; Graybill JR, 1996, CLIN INFECT DIS, V22, pS166, DOI 10.1093/clinids/22.Supplement_2.S166; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Horn W. S., 1992, J ANTIBIOT, V47, P376; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; KO J, 1995, J FOOD BIOCHEM, V19, P253; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; LESTER RL, 1993, ADV LIPID RES, V26, P253; MANDALA SM, 1995, J ANTIBIOT, V48, P349, DOI 10.7164/antibiotics.48.349; Mandala SM, 1997, J ANTIBIOT, V50, P339, DOI 10.7164/antibiotics.50.339; MANDALA SM, 1994, J ANTIBIOT, V47, P376, DOI 10.7164/antibiotics.47.376; Mandala SM, 1997, J BIOL CHEM, V272, P32709, DOI 10.1074/jbc.272.51.32709; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; Mundy LM, 1997, SEMIN RESP CRIT CARE, V18, P249, DOI 10.1055/s-2008-1070994; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; RILEY RT, 1994, J FOOD PROTECT, V57, P638, DOI 10.4315/0362-028X-57.7.638; SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378; Schneiter R, 1997, CELL, V88, P431, DOI 10.1016/S0092-8674(00)81882-6; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; TAKATSU T, 1985, J ANTIBIOT, V38, P1806, DOI 10.7164/antibiotics.38.1806; TAKESAKO K, 1993, J ANTIBIOT, V46, P1414, DOI 10.7164/antibiotics.46.1414; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tse B, 1997, J ORG CHEM, V62, P3236, DOI 10.1021/jo970106l; VINCENT VL, 1995, MICROBIOL-UK, V141, P1829, DOI 10.1099/13500872-141-8-1829; WANG E., 1991, J BIOL CHEM, V266, P1486; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	44	94	102	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14942	14949		10.1074/jbc.273.24.14942	http://dx.doi.org/10.1074/jbc.273.24.14942			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614099	hybrid			2022-12-25	WOS:000074160400041
J	Schwappach, B; Stobrawa, S; Hechenberger, M; Steinmeyer, K; Jentsch, TJ				Schwappach, B; Stobrawa, S; Hechenberger, M; Steinmeyer, K; Jentsch, TJ			Golgi localization and functionally important domains in the NH2 and COOH terminus of the yeast CLC putative chloride channel Gef1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-LIMITED GROWTH; VACUOLAR H+-ATPASE; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEIN; CYTOPLASMIC DOMAIN; SECRETORY PATHWAY; AMINO-TERMINUS; GENE; SIGNAL; EXPRESSION	GEF1 encodes the single CLC putative chloride channel in yeast. Its disruption leads to a defect in iron metabolism (Greene, J. R., Brown, N. H., DiDomenico, B. J., Haplan, J., and Eide, D. (1993) Mol. Gen. Genet. 241, 542-553). Since disruption of GEF2, a subunit of the vacuolar H+-ATPase, leads to a similar phenotype, it was previously suggested that the chloride conductance provided by Gef1p is necessary for vacuolar acidification. We now show that gef1 cells indeed grow less well at less acidic pH. However, no defect in vacuolar acidification is apparent from quinacrine staining, and Gef1p co-localizes with Mnt1p in the medial Golgi. Thus, Gef1p may be important in determining Golgi pH. Systematic alanine scanning of the amino and the carboxyl terminus revealed several regions essential for Gef1p localization and function. One sequence (FVTID) in the amino terminus conforms to a class of sorting signals containing aromatic amino acids. This was further supported by point mutations. Alanine scanning of the carboxyl terminus identified a stretch of roughly 25 amino acids which coincides with the second CBS domain, a conserved protein motif recently identified. Mutations in the first CBS domain also destroyed proper function and localization. The second CBS domain can be transplanted to the amino terminus without loss of function, but could not be replaced by the corresponding domain of the homologous mammalian channel CIC-2.	Univ Hamburg, Zentrum Mol Neurobiol Hamburg, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol Hamburg, Martinistr 52, D-20246 Hamburg, Germany.	Jentsch@plexus.uke.uni-hamburg.de		Jentsch, Thomas/0000-0002-3509-2553; Schwappach, Blanche/0000-0003-0225-6432				Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; BODE HP, 1995, EUR J BIOCHEM, V228, P337; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014-5793(95)01298-2; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; CHAPMAN RE, 1994, EMBO J, V13, P2305, DOI 10.1002/j.1460-2075.1994.tb06514.x; EIDE D, 1992, J GEN MICROBIOL, V138, P347, DOI 10.1099/00221287-138-2-347; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; GOLDSTEIN A, 1975, METHOD ENZYMOL, V42, P505; GRAHAM TR, 1994, J CELL BIOL, V127, P667, DOI 10.1083/jcb.127.3.667; GREENE JR, 1993, MOL GEN GENET, V241, P542, DOI 10.1007/BF00279896; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; Hebert SC, 1996, NATURE, V379, P398, DOI 10.1038/379398a0; Hechenberger M, 1996, J BIOL CHEM, V271, P33632, DOI 10.1074/jbc.271.52.33632; Hryciw DH, 1998, J BIOL CHEM, V273, P4304, DOI 10.1074/jbc.273.8.4304; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; LIM CR, 1995, J BIOCHEM-TOKYO, V118, P13, DOI 10.1093/oxfordjournals.jbchem.a124868; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Maduke M, 1998, BIOCHEMISTRY-US, V37, P1315, DOI 10.1021/bi972418o; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Morsomme P, 1996, EMBO J, V15, P5513, DOI 10.1002/j.1460-2075.1996.tb00936.x; MOUNTAIN HA, 1991, YEAST, V7, P873, DOI 10.1002/yea.320070814; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; NOTHWEHR SF, 1994, J BIOL CHEM, V269, P10185; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; Ponting CP, 1997, J MOL MED-JMM, V75, P160; Radisky DC, 1997, P NATL ACAD SCI USA, V94, P5662, DOI 10.1073/pnas.94.11.5662; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rose MD., 1990, METHODS YEAST GENETI; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; SchmidtRose T, 1997, J BIOL CHEM, V272, P20515, DOI 10.1074/jbc.272.33.20515; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; UAUSBEL FM, 1997, CURRENT PROTOCOLS MO, V2; vanWeert AWM, 1997, EUR J CELL BIOL, V74, P417; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; WILSON DW, 1993, J BIOL CHEM, V268, P7465	65	107	113	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15110	15118		10.1074/jbc.273.24.15110	http://dx.doi.org/10.1074/jbc.273.24.15110			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614122	hybrid			2022-12-25	WOS:000074160400064
J	Ohshima, K; Montermini, L; Wells, RD; Pandolfo, M				Ohshima, K; Montermini, L; Wells, RD; Pandolfo, M			Inhibitory effects of expanded GAA center dot TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SEQUENCE POLYMORPHISM; HUMAN HEREDITARY-DISEASES; ESCHERICHIA-COLI; TRINUCLEOTIDE REPEAT; TRANSGENIC MICE; SWITCH REGION; MUTATION-RATE; CTG; INSTABILITY; EXPRESSION	Friedreich ataxia (FRDA) is associated with the expansion of a GAA.TTC triplet repeat in the first intron of the frataxin gene, resulting in reduced levels of frataxin mRNA and protein. To investigate the mechanisms by which the intronic expansion produces its effect, GAA.TTC repeats of various lengths (9 to 270 triplets) were cloned in both orientations in the intron of a reporter gene. Plasmids containing these repeats were transiently transfected into COS-7 cells. A length- and orientation-dependent inhibition of reporter gene expression was observed. RNase protection and Northern blot analyses showed very low levels of mature mRNA when longer GAA repeats were transcribed, with no accumulation of primary transcript. Replication of plasmids carrying long GAA.TTC tracts (similar to 250 triplets) was greatly inhibited in COS-7 cells compared with plasmids carrying (GAA.TTC)(9) and (GAA.TTC)(90). Replication inhibition was five times greater for the plasmid whose transcript contains (GAA)(230) than for the plasmid whose transcript contains (UUC)(270). Our in vivo investigation revealed that expanded GAA . TTC repeats from intron I of the FRDA gene inhibit transcription rather than posttranscriptional RNA processing and also interfere with replication. The molecular basis for these effects may be the formation of non-B DNA structures.	CHUM, Ctr Rech Louis Charles Simard, Montreal, PQ H2L 4M1, Canada; Texas A&M Univ, Texas Med Ctr, Dept Biochem & Biophys, Ctr Genome Res,Inst Biosci & Technol, Houston, TX 77030 USA; Univ Montreal, Dept Med, Montreal, PQ H2L 4M1, Canada; McGill Univ, Dept Neurol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Neurosurg, Montreal, PQ H3A 2B4, Canada	Universite de Montreal; Baylor College of Medicine; Texas A&M University System; Universite de Montreal; McGill University; McGill University	Pandolfo, M (corresponding author), CHUM, Ctr Rech Louis Charles Simard, Campus Notre Dame,1560 Rue Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.		Pandolfo, Massimo/B-2853-2010		NINDS NIH HHS [NS34192] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034192] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIRHAERI S, 1995, J BIOL CHEM, V270, P3313, DOI 10.1074/jbc.270.7.3313; Andreassen R, 1996, AM J HUM GENET, V59, P360; Aoki T, 1997, J MOL BIOL, V267, P229, DOI 10.1006/jmbi.1997.0890; BEARD C, 1989, VIROLOGY, V172, P659, DOI 10.1016/0042-6822(89)90211-0; Bidichandani SI, 1997, AM J HUM GENET, V60, P1251; BINGHAM PM, 1995, NAT GENET, V9, P191, DOI 10.1038/ng0295-191; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; Cossee M, 1997, NAT GENET, V15, P337, DOI 10.1038/ng0497-337; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; GACY AM, 1995, CELL, V81, P533; Gourdon G, 1997, NAT GENET, V15, P190, DOI 10.1038/ng0297-190; GRABCZYK E, 1995, J BIOL CHEM, V270, P1791, DOI 10.1074/jbc.270.4.1791; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Kaytor MD, 1997, HUM MOL GENET, V6, P2135, DOI 10.1093/hmg/6.12.2135; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; Lavedan CN, 1997, HUM GENET, V100, P407, DOI 10.1007/s004390050525; Mandel JL, 1997, NATURE, V386, P767, DOI 10.1038/386767a0; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; Miret JJ, 1997, MOL CELL BIOL, V17, P3382, DOI 10.1128/MCB.17.6.3382; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Monckton DG, 1997, NAT GENET, V15, P193, DOI 10.1038/ng0297-193; MONCKTON DG, 1994, NAT GENET, V8, P162, DOI 10.1038/ng1094-162; Montermini L, 1997, HUM MOL GENET, V6, P1261, DOI 10.1093/hmg/6.8.1261; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; REABAN ME, 1994, J BIOL CHEM, V269, P21850; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; REABAN ME, 1991, NATURE, V351, P447; Rosche WA, 1996, J BACTERIOL, V178, P5042, DOI 10.1128/jb.178.16.5042-5044.1996; Rosenberg RN, 1996, NEW ENGL J MED, V335, P1222, DOI 10.1056/NEJM199610173351609; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 2002, MOL CLONING LAB MANU; Santee SM, 1996, J BIOL CHEM, V271, P21151, DOI 10.1074/jbc.271.35.21151; SARKAR PS, 1992, NUCLEIC ACIDS RES, V20, P5713, DOI 10.1093/nar/20.21.5713; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VANDENBERG MH, 1995, HUM GENET, V95, P723, DOI 10.1007/BF00209499; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WELLS RD, 1998, IN PRESS GENETIC INS	53	245	251	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14588	14595		10.1074/jbc.273.23.14588	http://dx.doi.org/10.1074/jbc.273.23.14588			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603975	hybrid			2022-12-25	WOS:000074021500077
J	Strauss, PR; Holt, CM				Strauss, PR; Holt, CM			Domain mapping of human apurinic/apyrimidinic endonuclease - Structural and functional, evidence for a disordered amino terminus and a tight globular carboxyl domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR ENZYME; ALDEHYDIC ABASIC SITE; IDENTIFICATION; BINDING; REDOX; CONFORMATION; POLYMERASE; STABILITY; RESIDUES; DUPLEX	We recently described the pre-steady state enzymatic binding kinetics of apurinic/apyrimidinic endonuclease (AP endo), In this report we describe the domain structure of the enzyme in solution determined by mild protease digestion in the presence and absence of substrate, product, and an efficient competitive inhibitor (HDP), AP endo is a 35.5-kDa protein with a high degree of homology to its prokaryotic counterpart, exonuclease III (Exo III), except for the amino terminus, which is lacking in the prokaryotic enzyme. The entire conserved region plus an additional 20 residues unique to the eukaryotic enzyme was inaccessible to trypsin and V8 protease, indicating that it forms a tight globular structure. In contrast, the amino-terminal 35 residues were readily accessible to all the proteases investigated, leading us to conclude that they associate poorly with the rest of the structure and constitute a highly fluid region, When AP endo was boiled with SDS and cooled prior to the addition of V8 protease, several acidic residues within the globular domain became protease-accessible, indicating rapid renaturation except along the nuclease fold with restoration of globular conformation for the carboxyl two-thirds of the molecule, Of all the proteases tested, only chymotrypsin was able to cleave internal to the globular portion without prior denaturation, Although AP endo cleaved with chymotrypsin retained full enzymatic activity, the activity was lost when the digested peptides were recovered after denaturation by heat and/or boiling in SDS, precipitation, and renaturation or when fragments were recovered from an SDS gel and renatured, Thus, the protein is probably held together strongly by noncovalent interactions that maintain enzymatic function after protease nicking. The three major chymotrypsin cleavage sites, Tyr-144, Leu-179, and Leu-205, became strikingly less accessible to protease digestion in the presence of abasic site-containing DNA, Since the three residues form a spherical triangle on the surface of the molecule on one side of the nuclease fold, there must be multiple means by which DNA containing an abasic site associates with the enzyme. The most likely explanation is that substrate and product, both of which were present during proteolysis, bind differently to the enzyme. Finally, the two cysteine residues thought to be involved in the redox reaction of AP endo with Jun protein were entirely inaccessible to proteolysis even after prolonged exposure of AP endo to reducing agents, Consequently, if AP endo plays a role in the physiological function of Jun, it must undergo major conformational changes in the process. Alternatively, the two cysteines could maintain an appropriate conformation such that other residues participate directly in the redox activity.	Northeastern Univ, Dept Biol, Boston, MA 02115 USA	Northeastern University	Strauss, PR (corresponding author), Northeastern Univ, Dept Biol, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA072702] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72702] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARZILAY G, 1995, NAT STRUCT BIOL, V2, P561, DOI 10.1038/nsb0795-561; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; CHAUDHRY MA, 1995, NUCLEIC ACIDS RES, V23, P3805, DOI 10.1093/nar/23.19.3805; Chaudhry MA, 1997, J BIOL CHEM, V272, P15650, DOI 10.1074/jbc.272.25.15650; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; GOLJER I, 1995, J BIOL CHEM, V270, P22980, DOI 10.1074/jbc.270.39.22980; GOLJER I, 1992, BIOCHEMISTRY-US, V31, P11614, DOI 10.1021/bi00161a047; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; Konigsberg WH, 1995, METHOD ENZYMOL, V262, P331; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LAHM A, 1991, J MOL BIOL, V222, P645, DOI 10.1016/0022-2836(91)90502-W; MATHEWS C, 1996, BIOCHEMISTRY-US, P101; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Moore DD, 1995, GLOB MOB SURV; RICKWOOD D, 1990, GEL ELECTROPHORESIS, P125; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; VESNAVER G, 1989, P NATL ACAD SCI USA, V86, P3614, DOI 10.1073/pnas.86.10.3614; WACHSSTOCK DH, 1994, BIOPHYS J, V67, P1260, DOI 10.1016/S0006-3495(94)80598-3; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23	27	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14435	14441		10.1074/jbc.273.23.14435	http://dx.doi.org/10.1074/jbc.273.23.14435			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603956	hybrid			2022-12-25	WOS:000074021500058
J	Yin, XY; Grove, L; Prochownik, EV				Yin, XY; Grove, L; Prochownik, EV			Lack of transcriptional repression by max homodimers	ONCOGENE			English	Article						myc; max; mad; mnt; USF; transcriptional repression	C-MYC PROTEIN; DNA-BINDING; EPIDERMAL DIFFERENTIATION; PHOSPHORYLATION SITES; OPPOSITE REGULATION; ONCOGENIC ACTIVITY; LEUCINE ZIPPER; B/HLH/Z DOMAIN; IN-VIVO; GENE	Max, a basic-helix-loop-helix-leucine zipper (bHLH-ZIP) protein, plays a central role in the transcriptional regulation of myc oncoprotein-responsive genes, Myc-max heterodimers bind to consensus E-box motifs near or within the promoters of these genes and activate gene expression, whereas heterodimers between max and members of the mad family of bHLH-ZIP proteins promote transcriptional repression. In contrast to all other members of the myc network, max readily homodimerizes and binds to identical E-box sites in vitro. However, the role for max homodimers in transcriptional repression in vivo is unclear. Upstream stimulatory factor (USF) is a bHLH-ZIP protein which does not interact with members of the myc-max-mad family. By replacing the HLH-ZIP domain of max with that from USF, we created a chimeric protein, max(USF), which was indistinguishable from max with respect to its ability to homodimerize and bind DNA. As expected, however, max(USF) was unable to heterodimerize with any of the tested max partner proteins and was incapable of suppressing c-myc target genes. Thus, transcriptional repression is an exclusive property of max-mad heterodimers and cannot be achieved by max homodimers alone.	Childrens Hosp Pittsburgh, Dept Pediat, Sect Hematol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat, Sect Hematol, Pittsburgh, PA 15213 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; AYER DE, 1998, CELL, P211; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BILLAUD M, 1993, P NATL ACAD SCI USA, V90, P2739, DOI 10.1073/pnas.90.7.2739; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUSSET K, 1993, ONCOGENE, V8, P3211; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Langlands K, 1997, ANAL BIOCHEM, V249, P250, DOI 10.1006/abio.1997.2184; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEE LA, 1995, J CLIN INVEST, V95, P900, DOI 10.1172/JCI117741; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; MIN S, 1992, ONCOGENE, V9, P1531; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZERVOS AS, 1994, CELL, V79, P389; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	54	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2629	2637		10.1038/sj.onc.1201777	http://dx.doi.org/10.1038/sj.onc.1201777			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632139				2022-12-25	WOS:000073698200007
J	Kristjuhan, A; Jaks, V; Rimm, I; Tooming, T; Maimets, T				Kristjuhan, A; Jaks, V; Rimm, I; Tooming, T; Maimets, T			Oligomerization of p53 is necessary to inhibit its transcriptional transactivation property at high protein concentration	ONCOGENE			English	Article						p53; oligomerization; transactivation	WILD-TYPE P53; DOWN-REGULATES TRANSCRIPTION; TATA-BINDING PROTEIN; REPRESSION FUNCTIONS; ACTIVATION DOMAINS; DNA; PROMOTERS; GROWTH; SITE; REGIONS	We have previously shown that transactivation by tumor suppressor protein p53 can be inhibited in vivo at elevated protein concentrations. In this study we characterize the structural requirements of this function. We show that oligomerization domain of p53 is involved in loss of transactivation at high protein concentrations: mutants not able to oligomerize are neither able to suppress transactivation, although these transactivating properties can be untouched.	Tartu State Univ, Estonian Bioctr, Inst Mol & Cell Biol, EE-2400 Tartu, Estonia	Estonian Biocentre; University of Tartu	Maimets, T (corresponding author), Tartu State Univ, Estonian Bioctr, Inst Mol & Cell Biol, Riia 23, EE-2400 Tartu, Estonia.		Jaks, Viljar/H-2467-2012; Maimets, Toivo/E-9268-2017	Jaks, Viljar/0000-0002-2221-6262; Maimets, Toivo/0000-0001-6461-3365; Kristjuhan, Arnold/0000-0002-5842-4952				BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DESAINTES C, 1995, ONCOGENE, V10, P2155; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; JACKSON P, 1993, ONCOGENE, V8, P589; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kristjuhan A, 1995, EUR J BIOCHEM, V234, P827, DOI 10.1111/j.1432-1033.1995.827_a.x; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LIU X, 1995, MOL CELL BIOL, V15, P6474; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu X, 1996, ONCOGENE, V13, P413; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MIYASHITA T, 1995, CELL, V80, P293; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PELLEGATA NS, 1995, ONCOGENE, V11, P337; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SANG BC, 1994, ONCOGENE, V9, P853; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SOUSSI T, 1990, ONCOGENE, V5, P945; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TARUNINA M, 1993, ONCOGENE, V8, P3165; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013	45	4	4	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2413	2418		10.1038/sj.onc.1201749	http://dx.doi.org/10.1038/sj.onc.1201749			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620560				2022-12-25	WOS:000073428000015
J	Kuroda, T; Okuda, N; Saitoh, N; Hiyama, T; Terasaki, Y; Anazawa, H; Hirata, A; Mogi, T; Kusaka, I; Tsuchiya, T; Yabe, I				Kuroda, T; Okuda, N; Saitoh, N; Hiyama, T; Terasaki, Y; Anazawa, H; Hirata, A; Mogi, T; Kusaka, I; Tsuchiya, T; Yabe, I			Patch clamp studies on ion pumps of the cytoplasmic membrane of Escherichia coli - Formation, preparation, and utilization of giant vacuole-like structures consisting of everted cytoplasmic membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; PROTEIN TRANSLOCATION; H+-ATPASE; DEGRADATION; F1-ATPASE; PROTEASES; EVOLUTION; SYSTEM; CELLS	Formation of giant protoplasts from normal Escherichia coli cells resulted in the formation of giant vacuole-type structures (which we designate as provacuoles) in the protoplasts. Electron microscopic observation revealed that these provacuoles were surrounded by a single membrane. We detected inner (cytoplasmic) membrane proteins in the provacuolar membrane but not outer membrane proteins. Biochemical analyses revealed that the provacuoles consist of everted cytoplasmic membranes. We applied the patch clamp method to the giant provacuoles. We have succeeded in measuring current that represents inward movement of H+ because of respiration and to ATP hydrolysis by the F0F1-ATPase. Such current was inhibited by inhibitors of the respiratory chain or F0F1-ATPase. This method is applicable for analyses of ion channels, ion pumps, or ion transporters in E. coli or other microorganisms.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Okayama Univ, Fac Pharmaceut Sci, Dept Microbiol, Okayama 700, Japan; Saitama Univ, Dept Biochem, Urawa, Saitama 38, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 194, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; Okayama University; Saitama University; Kyowa Kirin Ltd; University of Tokyo	Yabe, I (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.	yabe@bio.t.u-tokyo.ac.jp	KURODA, Teruo/B-2028-2011					AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6546; BRAUN V, 1972, P NATL ACAD SCI USA, V69, P970, DOI 10.1073/pnas.69.4.970; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BUECHNER M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P111, DOI 10.1016/0005-2736(90)90214-9; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CUI C, 1995, J MEMBRANE BIOL, V144, P31; EDA T, 1978, J BACTERIOL, V127, P1564; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; GIBSON SAW, 1988, J GEN MICROBIOL, V134, P2231; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRATA H, 1986, J BIOL CHEM, V261, P9839; INGLEDEW WJ, 1984, MICROBIOL REV, V48, P222, DOI 10.1128/MMBR.48.3.222-271.1984; ISHII N, 1993, J BIOCHEM-TOKYO, V113, P245, DOI 10.1093/oxfordjournals.jbchem.a124034; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Kolmar H, 1996, J BACTERIOL, V178, P5925, DOI 10.1128/jb.178.20.5925-5929.1996; KUBALSKI A, 1995, BBA-BIOMEMBRANES, V1238, P177, DOI 10.1016/0005-2736(95)00126-N; KURODA T, 1994, J BIOCHEM-TOKYO, V116, P1030, DOI 10.1093/oxfordjournals.jbchem.a124624; KUSAKA I, 1967, J BACTERIOL, V96, P884; LEDERBERG J, 1958, J BACTERIOL, V75, P143, DOI 10.1128/JB.75.2.143-160.1958; MATSUDA H, 1984, J PHYSIOL-LONDON, V357, P553, DOI 10.1113/jphysiol.1984.sp015517; MINAGAWA J, 1990, J BIOL CHEM, V265, P11198; MUNEYUKI E, 1989, J BIOL CHEM, V264, P6092; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; ONODA T, 1987, J GEN MICROBIOL, V133, P527; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; REINER AM, 1969, J BACTERIOL, V97, P1431, DOI 10.1128/JB.97.3.1431-1436.1969; Rosen B P, 1979, Methods Enzymol, V56, P233; RUTHE HJ, 1985, BIOCHIM BIOPHYS ACTA, V819, P105, DOI 10.1016/0005-2736(85)90200-7; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; SUZUKI H, 1978, MOL GEN GENET, V167, P1; TSURUOKA T, 1988, J BACTERIOL, V170, P5229, DOI 10.1128/jb.170.11.5229-5235.1988; Unden G, 1997, BBA-BIOENERGETICS, V1320, P217, DOI 10.1016/S0005-2728(97)00034-0; VanDenHazel HB, 1996, YEAST, V12, P1, DOI 10.1002/(SICI)1097-0061(199601)12:1<1::AID-YEA902>3.0.CO;2-N; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMANE K, 1987, J BIOL CHEM, V262, P2358	38	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16897	16904		10.1074/jbc.273.27.16897	http://dx.doi.org/10.1074/jbc.273.27.16897			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642251	hybrid			2022-12-25	WOS:000074545200041
J	Pagano, A; Cinque, G; Bassi, R				Pagano, A; Cinque, G; Bassi, R			In vitro reconstitution of the recombinant photosystem II light-harvesting complex CP24 and its spectroscopic characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A/B-BINDING-PROTEINS; CHLOROPHYLL SPECTRAL FORMS; ESCHERICHIA-COLI; PIGMENT-BINDING; GAUSSIAN DECOMPOSITION; ENERGY-DISSIPATION; ANTENNA COMPLEXES; MEMBRANES; PLANTS; FLUORESCENCE	The light-harvesting chlorophyll alb protein CP24, a minor subunit of the photosystem ii antenna system, is a major violaxanthin-binding protein involved in the regulation of excited state concentration of chlorophyll a. This subunit is poorly characterized due to the difficulty in isolation and instability during purification procedures. We have used an alternative approach in order to gain information on the properties of this protein; the Lhcb6 cDNA has been overexpressed in bacteria in order to obtain the CP24 apoprotein, which was then reconstituted in vitro with xanthophylls, chlorophyll a, and chlorophyll b, yielding a pigment-protein complex with properties essentially identical to the native protein extracted from maize thylakoids. Although all carotenoids were supplied during refolding, the recombinant holoprotein exhibited high selectivity in xanthophyll binding by coordinating violaxanthin and lutein but not neoxanthin or beta-carotene. Each monomer bound a total of 10 chlorophyll a plus chlorophyll b and two xanthophyll molecules. Moreover, the protein could be refolded in the presence of different chlorophyll a to chlorophyll b ratios for yielding a family of recombinant proteins with different chlorophyll alb ratios but still binding the same total number of porphyrins. A peculiar feature of CP24 was its refolding capability in the absence of lutein, contrary to the case of other homologous proteins, thus showing higher plasticity in xanthophyll binding. These characteristics of CP24 are discussed with respect to its role in binding zeaxanthin in high light stress conditions. The spectroscopic analysis of a recombinant CP24 complex binding eight chlorophyll b molecules and a single chlorophyll a molecule by Gaussian deconvolution allowed the identification of four subbands peaking at wavelengths of 638, 645, 653, and 659 nm, which have an increased amplitude with respect to the native complex and therefore identify the chlorophyll b absorption in the antenna protein environment. Gaussian subbands at wavelengths 666, 673, 679, and 686 nm are depleted in the high chlorophyll b complex, thus suggesting they derive from chlorophyll a.	Univ Verona, Fac Sci, MM FF NN, I-37134 Verona, Italy	University of Verona	Bassi, R (corresponding author), Univ Verona, Fac Sci, MM FF NN, St Grazie, I-37134 Verona, Italy.	bassi@biotech.sci.univr.it	Pagano, Aldo/AAF-3974-2019; Cinque, Gianfelice/K-5599-2018	Pagano, Aldo/0000-0001-8035-9299; Cinque, Gianfelice/0000-0001-6801-8010; bassi, roberto/0000-0002-4140-8446				BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; Bassi R, 1997, PHYSIOL PLANTARUM, V100, P769, DOI 10.1034/j.1399-3054.1997.1000404.x; BASSI R, 1992, EUR J BIOCHEM, V204, P317, DOI 10.1111/j.1432-1033.1992.tb16640.x; Bassi R, 1996, NATO ADV SCI INST SE, V287, P41; BERGANTINO E, 1995, J BIOL CHEM, V270, P8474, DOI 10.1074/jbc.270.15.8474; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CAMMARATA KV, 1992, BIOCHEMISTRY-US, V31, P2779, DOI 10.1021/bi00125a019; CATTANEO R, 1995, BIOCHEMISTRY-US, V34, P15267, DOI 10.1021/bi00046a035; Connelly JP, 1997, BIOCHEMISTRY-US, V36, P281, DOI 10.1021/bi962467l; CROFTS AR, 1994, FEBS LETT, V352, P265, DOI 10.1016/0014-5793(94)00976-7; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; DAINESE P, 1991, J BIOL CHEM, V266, P8136; DAINESE P, 1992, RES PHOTOSYNTHESIS, V1, P287; DAINESE P, 1992, DEV PHOTOSYNTHESIS R, V1, P199; Davies B., 1976, CAROTENOIDS CHEM BIO, P38, DOI [DOI 10.1590/S0101-20612001000200017, 10.1007/978-3-642-66632-2_11, DOI 10.1007/978-3-642-66632-2_11]; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DIPAOLO ML, 1990, PLANTA, V181, P275, DOI 10.1007/BF00195877; DUNAHAY TG, 1986, PLANT PHYSIOL, V80, P429, DOI 10.1104/pp.80.2.429; FOWLER GJS, 1992, NATURE, V355, P848, DOI 10.1038/355848a0; GILLIE JK, 1989, J PHYS CHEM-US, V93, P1620, DOI 10.1021/j100341a085; GILMORE AM, 1991, J CHROMATOGR, V543, P137, DOI 10.1016/S0021-9673(01)95762-0; Giuffra E, 1997, BIOCHEMISTRY-US, V36, P12984, DOI 10.1021/bi9711339; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; HEMELRIJK PW, 1992, BIOCHIM BIOPHYS ACTA, V1098, P159, DOI 10.1016/S0005-2728(05)80331-7; HENRYSSON T, 1989, BIOCHIM BIOPHYS ACTA, V977, P301, DOI 10.1016/S0005-2728(89)80084-2; HOBE S, 1994, EMBO J, V13, P3423, DOI 10.1002/j.1460-2075.1994.tb06647.x; IDE JP, 1987, BIOCHIM BIOPHYS ACTA, V893, P349, DOI 10.1016/0005-2728(87)90056-9; JAHNS P, 1995, PLANT PHYSIOL BIOCH, V33, P683; JENNINGS RC, 1993, BIOCHEMISTRY-US, V32, P3203, DOI 10.1021/bi00064a002; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KWA SLS, 1992, BIOCHIM BIOPHYS ACTA, V1101, P143, DOI 10.1016/0005-2728(92)90198-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARQUARDT J, 1993, PLANTA, V191, P265, DOI 10.1007/BF00199759; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; PAULSEN H, 1992, EUR J BIOCHEM, V205, P71, DOI 10.1111/j.1432-1033.1992.tb16752.x; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; Pesaresi P, 1997, FEBS LETT, V402, P151, DOI 10.1016/S0014-5793(96)01518-9; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; Pogson B, 1996, PLANT CELL, V8, P1627, DOI 10.1105/tpc.8.9.1627; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Press W., 1986, NUMERICAL RECIPES; REDDY NRS, 1994, J PHYS CHEM-US, V98, P4729, DOI 10.1021/j100068a040; ROS F, 1998, IN PRESS EUR J BIOCH; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; Ruban AV, 1996, BIOCHEMISTRY-US, V35, P674, DOI 10.1021/bi9524878; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER K, 1966, J AM CHEM SOC, V88, P2681, DOI 10.1021/ja00964a011; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SIMPSON DJ, 1979, CARLSBERG RES COMMUN, V44, P305, DOI 10.1007/BF02906493; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stepanov B.I., 1957, PHYS DOKL, V2, P81; THORNBER JP, 1993, BIOCHEM SOC T, V21, P15, DOI 10.1042/bst0210015; VERMAAS W, 1993, ANNU REV PLANT PHYS, V44, P457, DOI 10.1146/annurev.pp.44.060193.002325; VISSCHERS RW, 1994, BBA-BIOENERGETICS, V1183, P483, DOI 10.1016/0005-2728(94)90075-2; WALTERS RG, 1994, EUR J BIOCHEM, V226, P1063, DOI 10.1111/j.1432-1033.1994.01063.x; YAMAMOTO HY, 1996, OXYGENIC PHOTOSYNTHE, P539, DOI DOI 10.1007/0-306-48127-8_30; ZUCCHELLI G, 1994, BIOCHEMISTRY-US, V33, P8982, DOI 10.1021/bi00196a016; ZUCCHELLI G, 1992, BIOCHIM BIOPHYS ACTA, V1099, P163, DOI 10.1016/0304-4173(92)90023-8; Zucchelli G, 1996, BIOCHEMISTRY-US, V35, P16247, DOI 10.1021/bi9613178	64	61	64	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17154	17165		10.1074/jbc.273.27.17154	http://dx.doi.org/10.1074/jbc.273.27.17154			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642283	hybrid			2022-12-25	WOS:000074545200073
J	Santamaria, I; Velasco, G; Pendas, AM; Fueyo, A; Lopez-Otin, C				Santamaria, I; Velasco, G; Pendas, AM; Fueyo, A; Lopez-Otin, C			Cathepsin Z, a novel human cysteine proteinase with a short propeptide domain and a unique chromosomal location	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCES; MOLECULAR-CLONING; LYSOSOMAL PROTEINASE; GENOMIC ORGANIZATION; TISSUE DISTRIBUTION; THIOL PROTEASE; PROCATHEPSIN-L; EXPRESSION; LOCALIZATION; PRECURSOR	We have identified and characterized a novel human cysteine proteinase of the papain family. A full-length cDNA for this enzyme was cloned from a human brain cDNA library. Nucleotide sequence analysis revealed that the isolated cDNA codes for a polypeptide of 303 amino acids, tentatively called cathepsin Z, that exhibits structural features characteristic of cysteine proteinases. Fluorescent in. situ hybridization experiments revealed that the human cathepsin Z gene maps to chromosome 20q13, a location that differs from all cysteine proteinase genes mapped to date. The cDNA encoding cathepsin Z was expressed in Escherichia coli as a fusion protein with glutathione S-transferase, and after purification, the recombinant protein was able to degrade the synthetic peptide benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin, used as a substrate for cysteine proteinases. Northern blot analysis demonstrated that cathepsin Z is widely expressed in human tissues, suggesting that this enzyme could be involved in the normal intracellular protein degradation taking place in all cell types. Cathepsin Z is also ubiquitously distributed in cancer cell lines and in primary tumors from different sources, suggesting that this enzyme may participate in tumor progression as reported for other cathepsins. Finally, on the basis of a series of distinctive structural features, including diverse peptide insertions and an unusual short propeptide, together with its unique chromosomal location among cysteine proteinases, we propose that cathepsin Z may be the first representative of a novel subfamily of this class of proteolytic enzymes.	Univ Oviedo, Dept Bioquim & Biol Mol, Fac Med, E-33006 Oviedo, Spain	University of Oviedo	Lopez-Otin, C (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, Fac Med, E-33006 Oviedo, Spain.	CLO@DWARF1.QUIMICA.UNIOVI.ES	López-Otín, Carlos/AAB-2106-2020; Fueyo, Antonio/ABH-3243-2020; Pendas, Alberto M/L-1017-2014; Velasco, Gloria/AAS-5842-2021; Santamaria, Inigo/H-6727-2015	López-Otín, Carlos/0000-0001-6964-1904; Fueyo, Antonio/0000-0002-7121-9398; Velasco, Gloria/0000-0001-8032-5056; Santamaria, Inigo/0000-0001-8718-5359; Pendas, Alberto M/0000-0001-9264-3721				BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; CHAUHAN SS, 1993, J BIOL CHEM, V268, P1039; CHAUHAN SS, 1991, CANCER RES, V51, P1478; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOCHERTY K, 1982, P NATL ACAD SCI-BIOL, V79, P4613, DOI 10.1073/pnas.79.15.4613; Ferrando AA, 1997, J BIOL CHEM, V272, P33298, DOI 10.1074/jbc.272.52.33298; Ferrando AA, 1996, CANCER RES, V56, P1746; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; FUCHS R, 1988, BIOL CHEM H-S, V369, P469, DOI 10.1515/bchm3.1988.369.1.469; GAL S, 1986, J BIOL CHEM, V261, P1760; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; GOHDA E, 1981, J BIOL CHEM, V256, P2567; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GONG QM, 1993, DNA CELL BIOL, V12, P299, DOI 10.1089/dna.1993.12.299; HONIG J, 1984, ANN HUM GENET, V48, P49, DOI 10.1111/j.1469-1809.1984.tb00833.x; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; Linnevers C, 1997, FEBS LETT, V405, P253, DOI 10.1016/S0014-5793(97)00118-X; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; Maniatis T., 1982, MOL CLONING LAB MANU; MASON RW, 1986, BIOCHEM J, V233, P925, DOI 10.1042/bj2330925; MASON RW, 1985, BIOCHEM J, V226, P233, DOI 10.1042/bj2260233; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; PARIS A, 1995, FEBS LETT, V369, P326, DOI 10.1016/0014-5793(95)00777-7; PENDAS AM, 1994, CYTOGENET CELL GENET, V66, P263, DOI 10.1159/000133708; PETANCESKA S, 1992, J BIOL CHEM, V267, P26038; PONTREMOLI S, 1982, ARCH BIOCHEM BIOPHYS, V214, P376, DOI 10.1016/0003-9861(82)90042-X; Rao NV, 1997, J BIOL CHEM, V272, P10260; RECKLIES AD, 1982, BIOCHEM J, V207, P633, DOI 10.1042/bj2070633; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; RITONJA A, 1988, FEBS LETT, V228, P341, DOI 10.1016/0014-5793(88)80028-0; Rood JA, 1997, GENOMICS, V41, P169, DOI 10.1006/geno.1997.4614; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santamaria I, 1998, CANCER RES, V58, P1624; SANTAMARIA I, 1998, IN PRESS GENOMICS; SHI GP, 1992, J BIOL CHEM, V267, P7258; SHI GP, 1994, J BIOL CHEM, V269, P11530; Sloane B F, 1990, Semin Cancer Biol, V1, P137; SLOANE BF, 1981, SCIENCE, V212, P1151, DOI 10.1126/science.7233209; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; VELASCO G, 1994, J BIOL CHEM, V269, P27136; VERNET T, 1995, J BIOL CHEM, V270, P10838, DOI 10.1074/jbc.270.18.10838; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WANG X, 1987, CYTOGENET CELL GENET, V46, P710; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708; Yokoyama C, 1996, GENOMICS, V36, P296, DOI 10.1006/geno.1996.0465; YU H, 1993, GENOMICS, V15, P219, DOI 10.1006/geno.1993.1040	62	110	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16816	16823		10.1074/jbc.273.27.16816	http://dx.doi.org/10.1074/jbc.273.27.16816			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642240	hybrid			2022-12-25	WOS:000074545200030
J	Wu, WJ; Lin, R; Cerione, RA; Manor, D				Wu, WJ; Lin, R; Cerione, RA; Manor, D			Transformation activity of Cdc42 requires a region unique to Rho-related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DBL-ONCOGENE PRODUCT; GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEINS; RAS TRANSFORMATION; KINASE; GTPASES; ACTIVATION; IDENTIFICATION; CASCADE; PAK65	The Rho subfamily GTP-binding protein Cdc42 mediates actin cytoskeletal rearrangements and cell cycle progression and is essential for Ras transformation. Expression of a Cdc42 mutant (Cdc42(F28L)) that undergoes spontaneous activation (guanine nucleotide exchange) results in transformation of NIH3T3 fibroblasts. In this report, we show that deletion of residues 120-139 from Cdc42(F28L), which comprise an insert region unique to Rho subfamily proteins but is missing in other GTP-binding proteins, yields a Cdc42 molecule that still undergoes spontaneous GTP-GDP exchange and stimulates both actin cytoskeletal changes and the activation of the cellular targets pal-activated kinase and the c-Jun kinase (JNK1). However, this Cdc42 mutant is unable to transform cells. These findings indicate that the Rho subfamily insert region is dispensable for many of the known signaling pathways initiated by activated Cdc42 but is essential for its regulation of cell growth.	Cornell Univ, Ctr Vet Med, Dept Pharmacol, Ithaca, NY 14853 USA	Cornell University	Manor, D (corresponding author), Cornell Univ, Ctr Vet Med, Dept Pharmacol, Ithaca, NY 14853 USA.	dm43@cornell.edu			NIGMS NIH HHS [GM47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS RLP, 1980, CELL CULTURE BIOCH L; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEONARD D, 1992, J BIOL CHEM, V267, P22860; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; OLSON ME, 1995, SCIENCE, V269, P53; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; SUTCLIFF M, 1995, PROTEIN PEPTIDE LETT, V1, P84; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wu WJ, 1997, J BIOL CHEM, V272, P26153, DOI 10.1074/jbc.272.42.26153; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	38	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16655	16658		10.1074/jbc.273.27.16655	http://dx.doi.org/10.1074/jbc.273.27.16655			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642217	hybrid			2022-12-25	WOS:000074545200007
J	Valiyaveetil, FI; Fillingame, RH				Valiyaveetil, FI; Fillingame, RH			Transmembrane topography of subunit a in the Escherichia coli F1F0 ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; MEMBRANE TOPOLOGY; ALPHA-SUBUNIT; PROTEIN; PREDICTION; COMPONENT; MUTATIONS; FUSIONS; HELIX; PORE	Subunit a is the least understood of the three subunits that compose the F-0 sector in the Escherichia coli F0F1 ATP synthase. In this study, we have substituted Cys into predicted extramembranous loops of the protein and used chemical modification to obtain topographical information on the folding of subunit a. The extent of labeling of the substituted Cys residues by fluorescein-5'-maleimide was determined. The localization of reactive Cys residues was inferred from differences in the extent of labeling in inside out and right side out membrane vesicles. The NH2-terminal segment of subunit a was localized to the outside (periplasmic) surface and the COOH terminus to the cytoplasmic surface by these procedures. Loop residues in two periplasmic extramembranous loops and in two cytoplasmic extramembranous loops were also localized. The localization of two cytoplasmic Cys residues was confirmed by using 4-acetamido-4'-maleimidylstilbene-2,2 '-disulfonic acid to block fluorescein-5'-maleimide labeling. From the localization of the Cys residues, a model for the topography is proposed that consists of five transmembrane segments with the NH, terminus periplasmic and the COOH terminus cytoplasmic. The positions of second site suppressors, including several isolated here to the nonfunctional E219C and H245C substitutions, provide support for the topographical model proposed.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, 587 Med Sci Bldg, Madison, WI 53706 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALTENDORF KH, 1974, J BACTERIOL, V117, P888, DOI 10.1128/JB.117.2.888-899.1974; Barik S, 1996, Methods Mol Biol, V57, P203; BJORBAEK C, 1990, FEBS LETT, V260, P31, DOI 10.1016/0014-5793(90)80058-Q; BOYD D, 1994, MEMBRANE PROTEIN STR, P144; CAFISO DS, 1994, MEMBRANE PROTEIN STR, P127; ContiFine BM, 1996, ANNU REV BIOPH BIOM, V25, P197; DECKERSHEBESTRE.G, 1996, ANNU REV MICROBIOL, V50, P971; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FRAGA D, 1989, J BIOL CHEM, V264, P6797; GIRVIN ME, 1994, BIOCHEMISTRY-US, V33, P665, DOI 10.1021/bi00169a006; HARTZOG PE, 1994, J BIOL CHEM, V269, P32313; HATCH LP, 1995, J BIOL CHEM, V270, P29407, DOI 10.1074/jbc.270.49.29407; HOPPE J, 1983, EMBO J, V2, P105, DOI 10.1002/j.1460-2075.1983.tb01389.x; Jones PC, 1995, BIOCHEM J, V312, P739, DOI 10.1042/bj3120739; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Kimura T, 1997, J BIOL CHEM, V272, P580; KRISHNASASTRY M, 1994, FEBS LETT, V356, P66, DOI 10.1016/0014-5793(94)01240-7; LEWIS MJ, 1992, J BIOL CHEM, V267, P3482; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; PAULE CR, 1989, ARCH BIOCHEM BIOPHYS, V274, P270, DOI 10.1016/0003-9861(89)90439-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SENIOR AE, 1989, PHYSLR EV, V68, P177; SHORT SA, 1974, P NATL ACAD SCI USA, V71, P5032, DOI 10.1073/pnas.71.12.5032; Spannagel C, 1998, BIOCHEMISTRY-US, V37, P615, DOI 10.1021/bi9714971; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; VIK SB, 1992, BIOCHIM BIOPHYS ACTA, V1140, P199, DOI 10.1016/0005-2728(92)90009-Q; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Yamada H, 1996, FEBS LETT, V390, P34, DOI 10.1016/0014-5793(96)00621-7; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431	39	125	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16241	16247		10.1074/jbc.273.26.16241	http://dx.doi.org/10.1074/jbc.273.26.16241			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632683	hybrid			2022-12-25	WOS:000074436600054
J	Betuing, S; Daviaud, D; Pages, C; Bonnard, E; Valet, P; Lafontan, M; Saulnier-Blache, JS				Betuing, S; Daviaud, D; Pages, C; Bonnard, E; Valet, P; Lafontan, M; Saulnier-Blache, JS			G beta gamma-independent coupling of alpha(2)-adrenergic receptor to p21(rhoA) in preadipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; ACTIVATED PROTEIN-KINASE; ACTIN STRESS FIBERS; TYROSINE PHOSPHORYLATION; ADP-RIBOSYLATION; FOCAL ADHESIONS; GENE-PRODUCT; RHO; STIMULATION; EXPRESSION	In preadipocytes, alpha(2)-adrenergic receptor (alpha(2)-AR) stimulation leads to a G(1)/G(0)-dependent rearrangement of actin cytoskeleton. This is characterized by a rapid cell spreading, the formation of actin stress fibers, and the increase in tyrosyl phosphorylation of the focal adhesion kinase (pp125(FAK)). These cellular events being tightly controlled by the small GTPase p21(rhoA), the existence of a G(1)/G(0)-dependent coupling of alpha(2)-AR to p21(rhoA) in preadipocytes was proposed. In alpha 2AF2 preadipocytes (a cell clone derived from the 3T3F442A preadipose cell line and which stably expresses the human alpha 2C10-adrenergic receptor) alpha(2)-adrenergic-dependent induction of cell spreading, formation of actin stress fibers, and increase in tyrosyI phosphorylation of pp125(FAK) were abolished by pretreatment of the preadipocytes with the C3 exoenzyme, a toxin which impairs p21(rhoA ) activity by ADP-ribosylation, Conversely, C3 exoenzyme had no effect on the alpha(2)-adrenergic-dependent increase in tyrosyl phosphorylation and shift of ERK2 mitogen-activated protein kinase, alpha(2)-Adrenergic stimulation also led to an increase in GDP/GTP exchange on p21(rhoA) as well as to an increase in the amount of p21(rhoA) I m the particulate fraction of alpha 2AF2 preadipocytes. Stable transfection of alpha 2AF2 preadipocytes with the COOH-terminal domain of beta ARK1 (beta ARK-CT) (a blocker of G beta gamma-action), strongly inhibited the cu,adrenergic-dependent increase in tyrosyl phosphorylation and shift of ERK2, without modification of the tyrosyl phosphorylation of pp125(FAK) and spreading of preadipocytes. These results show that alpha(2)-adrenergic-dependent reorganization of actin cytoskeleton requires the activation of p21(rhoA) in,preadipocytes. Conversely to the activation of the p21(ras)/mitogen-activated protein kinase pathway, the ai-adrenergic activation of p21(rhoA)-dependent pathways are independent of the beta gamma-subunits of heterotrimeric G proteins.	Universite Paul Sabatier, Inst Louis Bugnard, INSERM U317, CHU Rangueil, F-31403 Toulouse 4, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Saulnier-Blache, JS (corresponding author), Universite Paul Sabatier, Inst Louis Bugnard, INSERM U317, CHU Rangueil, Batiment L3, F-31403 Toulouse 4, France.		Betuing, Sandrine/F-2967-2013; Valet, Philippe/N-7472-2017; Betuing, Sandrine/X-1957-2019; Betuing, Sandrine/X-2179-2018; Saulnier-Blache, Jean Sebastien/X-7729-2018	Valet, Philippe/0000-0001-6520-7393; Saulnier-Blache, Jean Sebastien/0000-0002-8971-7723				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARRY ST, 1994, J CELL SCI, V107, P2033; Betuing S, 1996, ENDOCRINOLOGY, V137, P5220, DOI 10.1210/en.137.12.5220; Betuing S, 1997, BIOCHEM BIOPH RES CO, V235, P765, DOI 10.1006/bbrc.1997.6887; BOULOUMIE A, 1994, J BIOL CHEM, V269, P30254; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Flinn HM, 1996, J CELL SCI, V109, P1133; Hein L, 1997, TRENDS CARDIOVAS MED, V7, P137, DOI 10.1016/S1050-1738(97)00034-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JinsiParimoo A, 1997, J BIOL CHEM, V272, P14556, DOI 10.1074/jbc.272.23.14556; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; Keller J, 1997, FEBS LETT, V403, P299, DOI 10.1016/S0014-5793(97)00067-7; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kranenburg O, 1997, J CELL SCI, V110, P2417; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LAFONTAN M, 1993, J LIPID RES, V34, P1057; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MABUCHI I, 1994, J CELL SCI, V107, P1853; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SATOH T, 1995, METHOD ENZYMOL, V255, P149; SECKINE A, 1989, J BIOL CHEM, V264, P8602; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	33	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15804	15810		10.1074/jbc.273.25.15804	http://dx.doi.org/10.1074/jbc.273.25.15804			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624180	hybrid			2022-12-25	WOS:000074284200074
J	Hodge, DR; Dunn, KJ; Pei, GK; Chakrabarty, MK; Heidecker, G; Lautenberger, JA; Samuel, KP				Hodge, DR; Dunn, KJ; Pei, GK; Chakrabarty, MK; Heidecker, G; Lautenberger, JA; Samuel, KP			Binding of c-Raf1 kinase to a conserved acidic sequence within the carboxyl-terminal region of the HIV-1 Nef protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GLUTATHIONE-S-TRANSFERASE; CD4 DOWN-REGULATION; HUMAN T-CELLS; SERINE PHOSPHORYLATION; PHYSICAL INTERACTION; PLASMA-MEMBRANE; GENE-PRODUCT; IN-VITRO; RAS-GTP	Nef is a membrane-associated cytoplasmic phosphoprotein that is well conserved among the different human (HIV-1 and HIV-8) and simian immunodeficiency viruses and has important roles in down-regulating the CD4 receptor and modulating T-cell signaling pathways. The ability to modulate T-cell signaling pathways suggests that Nef may physically interact with T-cell signaling proteins. In order to identify Nef binding proteins and map their site(s) of interaction, we targeted a highly conserved acidic sequence at the carboxyl-terminal region of Nef sharing striking similarity with an acidic sequence at the c-Raf1-binding site within the Ras effector region. Here, we used deletion and site-specific mutagenesis to generate mutant Nef proteins fused to bacterial glutathione S-transferase in in vitro precipitation assays and immunoblot analysis to map the specific interaction between the HIV-1(LAI) Nef and c-Raf1 to a conserved acidic sequence motif containing the core sequence Asp-Asp-X-X-X-Glu (position 174-179). Significantly, we demonstrate that substitution of the nonpolar glycine residue for either or both of the conserved negatively charged aspartic acid residues at positions 174 and 175 in the full-length recombinant Nef protein background completely abrogated binding of c-Raf1 in vitro. In addition, lysates from a permanent CEM T-cell line constitutively expressing the native HIV-1 Nef protein was used to coimmunoprecipitate a stable Nef c-Raf1 complex, suggesting that molecular interactions between Nef and c-Raf1, an important downstream transducer of cell signaling through the c-Raf1-MAP kinase pathway, occur in vivo. This interaction may account for the Nef-induced perturbations of T-cell signaling and activation pathways in vitro and in vivo.	Morgan State Univ, Dept Biol, Baltimore, MD 21251 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Leukocyte Biol, Frederick, MD 21702 USA; Natl Human Genome Res Lab, Lab Genet Dis Res, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Gen Divers, Frederick, MD 21702 USA; Frederick Canc Res & Dev Ctr, SAIC, Frederick, MD 21702 USA; Morgan State Univ, Dept Biol, Baltimore, MD 21239 USA	Morgan State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Morgan State University	Samuel, KP (corresponding author), Morgan State Univ, Dept Biol, Spencer Hall,Rm 110,1700 Cold Spring Ln, Baltimore, MD 21251 USA.	ksamuel@moac.morgan.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011606] Funding Source: NIH RePORTER; NCRR NIH HHS [2P20RR011606-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aiken C, 1996, VIROLOGY, V217, P293, DOI 10.1006/viro.1996.0116; Barnard D, 1995, ONCOGENE, V10, P1283; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; BODEUS M, 1995, J GEN VIROL, V76, P1337, DOI 10.1099/0022-1317-76-6-1337; CHOWERS MY, 1995, VIROLOGY, V212, P451, DOI 10.1006/viro.1995.1502; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Collette Y, 1996, J BIOL CHEM, V271, P6333, DOI 10.1074/jbc.271.11.6333; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DERONDE A, 1992, VIROLOGY, V188, P391, DOI 10.1016/0042-6822(92)90772-H; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FRANCHINI G, 1986, VIROLOGY, V155, P593, DOI 10.1016/0042-6822(86)90219-9; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Graziani A, 1996, J BIOL CHEM, V271, P6590, DOI 10.1074/jbc.271.12.6590; GREENWAY A, 1995, J VIROL, V69, P1842, DOI 10.1128/JVI.69.3.1842-1850.1995; GRIECO F, 1992, BIOTECHNIQUES, V13, P856; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HARRIS M, 1993, J GEN VIROL, V74, P1581, DOI 10.1099/0022-1317-74-8-1581; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; Iafrate A.J., 1997, EMBO J, V16, P673; KAMINCHIK J, 1994, AIDS RES HUM RETROV, V10, P1003, DOI 10.1089/aid.1994.10.1003; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KLOTMAN ME, 1991, P NATL ACAD SCI USA, V88, P5011, DOI 10.1073/pnas.88.11.5011; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mariani R, 1996, J VIROL, V70, P7752, DOI 10.1128/JVI.70.11.7752-7764.1996; Miller Michael D., 1994, Trends in Microbiology, V2, P294, DOI 10.1016/0966-842X(94)90007-8; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NIEDERMAN TMJ, 1993, VIROLOGY, V197, P420, DOI 10.1006/viro.1993.1605; NIEDERMAN TMJ, 1992, J VIROL, V66, P6213, DOI 10.1128/JVI.66.10.6213-6219.1992; NIEDERMAN TMJ, 1993, VIROLOGY, V194, P338, DOI 10.1006/viro.1993.1264; Nunn MF, 1996, J VIROL, V70, P6157, DOI 10.1128/JVI.70.9.6157-6161.1996; Pandori MW, 1996, J VIROL, V70, P4283, DOI 10.1128/JVI.70.7.4283-4290.1996; POULIN L, 1992, AIDS, V6, P787, DOI 10.1097/00002030-199208000-00003; RATNER L, 1985, NUCLEIC ACIDS RES, V13, P8219, DOI 10.1093/nar/13.22.8219; Richard A, 1997, AIDS, V11, pF1, DOI 10.1097/00002030-199701000-00001; Rossi F, 1996, VIROLOGY, V217, P397, DOI 10.1006/viro.1996.0130; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SALGHETTI S, 1995, P NATL ACAD SCI USA, V92, P349, DOI 10.1073/pnas.92.2.349; SAMUEL KP, 1987, FEBS LETT, V218, P81, DOI 10.1016/0014-5793(87)81023-2; SAMUEL KP, 1991, AIDS RES HUM RETROV, V7, P697, DOI 10.1089/aid.1991.7.697; SAWAI ET, 1995, J BIOL CHEM, V270, P15307, DOI 10.1074/jbc.270.25.15307; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; Smith BL, 1996, J BIOL CHEM, V271, P16753, DOI 10.1074/jbc.271.28.16753; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TERWILLIGER EF, 1991, P NATL ACAD SCI USA, V88, P10971, DOI 10.1073/pnas.88.23.10971; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Welker R, 1996, VIROLOGY, V219, P228, DOI 10.1006/viro.1996.0240; ZWEIG M, 1990, VIROLOGY, V179, P504, DOI 10.1016/0042-6822(90)90325-L	58	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15727	15733		10.1074/jbc.273.25.15727	http://dx.doi.org/10.1074/jbc.273.25.15727			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624170	hybrid			2022-12-25	WOS:000074284200064
J	Kumar, A; Middleton, A; Chambers, TC; Mehta, KD				Kumar, A; Middleton, A; Chambers, TC; Mehta, KD			Differential roles of extracellular signal-regulated kinase-1/2 and p38(MAPK) in interleukin-1 beta- and tumor necrosis factor-alpha-induced low density lipoprotein receptor expression in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; NERVE GROWTH-FACTOR; MAP KINASE; TRANSDUCTION PATHWAY; GENE-TRANSCRIPTION; INTERFERON-ALPHA; HEAT-SHOCK; CASCADE; PHOSPHORYLATION	The inflammatory cytokines interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF), elevated in inflammatory, malignant, and infectious diseases, induce low density lipoprotein (LDL) receptor transcription in HepG2 cells, and such are induction can account for hypocholesterolemia associated with these states. However, the signaling mechanisms of cytokine-mediated LDL receptor induction are largely unexplored, In the present studies, we examined the potential involvement of different mitogen-activated protein kinase (MAPK) pathways. Northern analysis demonstrated that IL-1 beta or TNF significantly increased LDL receptor transcript in HepG2 cells, whereas expression of another tightly regulated sterol-responsive squalene synthase gene was unaffected. IL-1 beta tread;ment resulted in transient activation of three MAPK cascades, namely p46/54(JNK), p38(MAPK), and ERK-1/2, with maximal activation of 20-, 25-, and 3-fold, respectively, occurring 15-30 min after cytokine addition. PD98059, a specific inhibitor of MAPK kinase activity, inhibited IL-lp-induced LDL receptor expression In contrast, SB202190, a specific inhibitor of p38(MAPK), enhanced IL-1 beta-induced LDL receptor expression, with a concomitant increase in ERK-1/2 activity. Similarly, TNF induced LDL receptor expression also required ERK-1/2 activation. Finally, sterols repressed IL-1 beta induced receptor expression, without affecting ERK-1/2 activation. These results show that IL-IP-or TNF-induced LDL receptor expression requires ERK-1/2 activation, that the p38(MAPK) pathway negatively regulates LDL receptor expression, and that sterols inhibit induction at a point downstream of ERK-1/2 in HepG2 cells.	Univ Arkansas Med Sci, Coll Med, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Mehta, KD (corresponding author), Univ Arkansas Med Sci, Coll Med, Dept Biochem & Mol Biol, 4301 W Markham, Little Rock, AR 72205 USA.	mehtakamald@exchange.uams.edu			NHLBI NIH HHS [HL-51592-04] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1993, ONCOGENE, V8, P2015; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Dhawan P, 1997, NUCLEIC ACIDS RES, V25, P4132, DOI 10.1093/nar/25.20.4132; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DINARELLO CA, 1991, BLOOD, V77, P162; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EVANS RD, 1989, CLIN SCI, V77, P357, DOI 10.1042/cs0770357; FEINBERG B, 1988, J CLIN ONCOL, V6, P1328, DOI 10.1200/JCO.1988.6.8.1328; FOA R, 1992, J CLIN ONCOL, V10, P954, DOI 10.1200/JCO.1992.10.6.954; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRIFFITH RL, 1988, J EXP MED, V168, P1041, DOI 10.1084/jem.168.3.1041; GROVE RI, 1991, J LIPID RES, V32, P1889; GRUNFELD C, 1989, CANCER RES, V49, P2554; GRUNFELD C, 1991, AM J MED, V90, P154, DOI 10.1016/0002-9343(91)80154-E; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; GUAM G, 1995, J BIOL CHEM, V270, P21958; GUY GR, 1991, J BIOL CHEM, V266, P14343; JONASSON L, 1990, BIOCHIM BIOPHYS ACTA, V1053, P43, DOI 10.1016/0167-4889(90)90024-8; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; Kumar A, 1997, NEUROSCI LETT, V231, P143, DOI 10.1016/S0304-3940(97)00549-1; KUMAR A, 1997, J LIPID RES, V38, P4220; Kusari AB, 1997, MOL ENDOCRINOL, V11, P1532, DOI 10.1210/me.11.10.1532; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; Mehta KD, 1996, J BIOL CHEM, V271, P33616, DOI 10.1074/jbc.271.52.33616; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MOORBY CD, 1992, ATHEROSCLEROSIS, V97, P21, DOI 10.1016/0021-9150(92)90047-K; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; ONeill LAJ, 1995, INT J CLIN LAB RES, V25, P169, DOI 10.1007/BF02592694; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Ridley SH, 1997, J IMMUNOL, V158, P3165; RIIKONEN P, 1992, J INFECT DIS, V166, P432, DOI 10.1093/infdis/166.2.432; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SCHECTMAN G, 1992, ARTERIOSCLER THROMB, V12, P1053, DOI 10.1161/01.ATV.12.9.1053; SEGER R, 1992, J BIOL CHEM, V267, P14373; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; STOUDEMIRE JB, 1991, BLOOD, V77, P750; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WILSON DE, 1989, J CLIN ONCOL, V7, P1573, DOI 10.1200/JCO.1989.7.10.1573; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	63	95	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15742	15748		10.1074/jbc.273.25.15742	http://dx.doi.org/10.1074/jbc.273.25.15742			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624172	hybrid			2022-12-25	WOS:000074284200066
J	Li, YF; Hata, Y; Fujii, T; Hisano, T; Nishihara, M; Kurihara, T; Esaki, N				Li, YF; Hata, Y; Fujii, T; Hisano, T; Nishihara, M; Kurihara, T; Esaki, N			Crystal structures of reaction intermediates of L-2-haloacid dehalogenase and implications for the reaction mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA/BETA-HYDROLASE FOLD; PSEUDOMONAS SP. YL; HALOALKANE DEHALOGENASE; CATALYTIC MECHANISM; ACID DEHALOGENASE; MUTAGENESIS	Crystal structures of L-2-haloacid dehalogenase from Pseudomonas sp, YL complexed with monochloroacetate, L-2-chlorobutyrate, L-2-chloro-3-methylbutyrate, or L-2-chloro-4-methylvalerate were determined at 1.83-, 2.0-, 2.2-, and 2.2-Angstrom resolutions, respectively, using the complex crystals prepared with the S175A mutant, which are isomorphous with those of the wild-type enzyme, These structures exhibit unique structural features that correspond to those of the reaction intermediates. In each case, the nucleophile Asp-10 is esterified with the dechlorinated moiety of the substrate. The substrate moieties in all but the monochloroacetate intermediate have a D-configuration at the C-2 atom. The overall polypeptide fold of each of the intermediates is similar to that of the wild-type enzyme. However, it is clear that the Asp-10-Ser-20 region moves to the active site in all of the intermediates, and the Tyr-91-Asp-102 and Leu-117-Arg-135 regions make conformational changes in all but the monochloroacetate intermediates. Ser-118 is located near the carboxyl group of the substrate moiety; this residue probably serves as a binding residue for the substrate carboxyl group. The hydrophobic pocket, which is primarily composed of the Tyr-12, Gln-42, Leu-45, Phe-60, Lys-151, Asn-177, and Trp-179 side chains, exists around the alkyl group of the substrate moiety, This pocket may play an important role in stabilizing the alkyl group of the substrate moiety through hydrophobic interactions, and may also play a role in determining the stereospecificity of the enzyme. Moreover, a water molecule, which is absent in the substrate-free enzyme, is present in the vicinities of the carboxyl carbon of Asp-10 and the side chains of Asp-180, Asn-177, and Ala-175 in each intermediate. This water molecule may hydrolyze the ester intermediate and its substrate. These findings crystallographically demonstrate that the enzyme reaction proceeds through the formation of an ester intermediate with the enzyme's nucleophile Asp-10.	Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan; Inst Phys & Chem Res, Wako, Saitama 3510106, Japan	Kyoto University; RIKEN	Esaki, N (corresponding author), Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan.							[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BENNING MW, 1996, BIOCHEMISTRY-US, V35, P3103; BRUNGER AT, 1992, XPLOR MANUAL; CROOKS GP, 1995, J AM CHEM SOC, V117, P10791, DOI 10.1021/ja00149a001; HASAN AKMQ, 1994, BIOSCI BIOTECH BIOCH, V58, P1599, DOI 10.1271/bbb.58.1599; Hisano T, 1996, PROTEINS, V24, P520, DOI 10.1002/(SICI)1097-0134(199604)24:4<520::AID-PROT12>3.0.CO;2-N; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; IWASAKI I, 1956, B CHEM SOC JPN, V29, P860, DOI 10.1246/bcsj.29.860; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KLAGES U, 1983, H-S Z PHYSIOL CHEM, V364, P529, DOI 10.1515/bchm2.1983.364.1.529; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIHARA T, 1995, J BIOCHEM, V117, P1317, DOI 10.1093/oxfordjournals.jbchem.a124861; LACOURCIERE GM, 1993, J AM CHEM SOC, V115, P10466, DOI 10.1021/ja00075a115; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; LIU JQ, 1994, APPL ENVIRON MICROB, V60, P2389, DOI 10.1128/AEM.60.7.2389-2393.1994; Liu JQ, 1997, J BIOL CHEM, V272, P3363, DOI 10.1074/jbc.272.6.3363; LIU JQ, 1994, J BIOCHEM-TOKYO, V116, P248, DOI 10.1093/oxfordjournals.jbchem.a124514; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; VANDERPLOEG J, 1991, J BACTERIOL, V173, P7925, DOI 10.1128/jb.173.24.7925-7933.1991; VERSCHUEREN KHG, 1993, J MOL BIOL, V232, P856, DOI 10.1006/jmbi.1993.1436; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; YANG G, 1994, BIOCHEMISTRY-US, V33, P3527	23	91	93	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15035	15044		10.1074/jbc.273.24.15035	http://dx.doi.org/10.1074/jbc.273.24.15035			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614112	hybrid			2022-12-25	WOS:000074160400054
J	Takeuchi, N; Kawakami, M; Omori, A; Ueda, T; Spremulli, LL; Watanabe, K				Takeuchi, N; Kawakami, M; Omori, A; Ueda, T; Spremulli, LL; Watanabe, K			Mammalian mitochondrial methionyl-tRNA transformylase from bovine liver - Purification, characterization, and gene structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; PROTEIN-SYNTHESIS; INITIAL CHARACTERIZATION; ELONGATION-FACTORS; SEQUENCE; FORMYLTRANSFERASE; IDENTIFICATION; DNA; GEL	The mammalian mitochondrial methionyl-tRNA transformylase (MTFmt) was partially purified 2,200-fold from bovine liver mitochondria using column chromatography, The polypeptide responsible for MTFmt activity was excised from a sodium dodecyl sulfate-polyacrylamide gel and the amino acid sequences of several peptides were determined. The cDNA encoding bovine MTFmt was obtained and its nucleotide sequence was determined. The deduced amino acid sequence of the mature form of MTFmt consists of 357 amino acid. residues. This sequence is about 30% identical to the corresponding Escherichia coli and yeast mitochondrial MTFs. Kinetic parameters governing the formylation of various tRNAs were obtained. Bovine MTFmt formylates its homologous mitochondrial methionyl-tRNA and the E. coli initiator methionyl-tRNA (Met-tRNA(fMet)) with essentially equal efficiency. The E. coli elongator methionyl-tRNA (Met-tRNA(mMet)) was also formylated although with somewhat less favorable kinetics. These results suggest that the substrate specificity of MTFmt is not as rigid as that of the E. coli MTF which clearly discriminates between the bacterial initiator and elongator Met-tRNAs. These observations are discussed in terms of the presence of a single tRNA(Met) gene in mammalian mitochondria.	Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 113, Japan; Nagoya Univ, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 46401, Japan; Mitsubishi Kasei Inst Life Sci, Tokyo 194, Japan; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of Tokyo; Nagoya University; University of North Carolina; University of North Carolina Chapel Hill	Watanabe, K (corresponding author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 113, Japan.	kw@kwl.t.u-tokyo.ac.jp	Ueda, Takuya/K-5217-2014	Ueda, Takuya/0000-0002-7760-8271	FDA HHS [GENBANK/AB004316] Funding Source: Medline	FDA HHS		ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; Arnez JG, 1994, RNA PROTEIN INTERACT, P52; ASTROM SU, 1994, CELL, V79, P535, DOI 10.1016/0092-8674(94)90262-3; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BLANQUET S, 1984, METHOD ENZYMOL, V106, P141; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; DICKERMA.HW, 1967, J BIOL CHEM, V242, P1522; Dirheimer G., 1995, P93; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1997, J MOL BIOL, V266, P939; GALPER JB, 1971, J MOL BIOL, V57, P363, DOI 10.1016/0022-2836(71)90354-8; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Gite S, 1997, J BIOL CHEM, V272, P5305, DOI 10.1074/jbc.272.8.5305; GOTTESMAN MM, 1987, METHOD ENZYMOL, V151, P363; GUILLON JM, 1992, J MOL BIOL, V224, P359, DOI 10.1016/0022-2836(92)91000-F; KOZAK M, 1983, MICROBIOL REV, V47, P1; KUMAZAWA Y, 1991, BIOCHIM BIOPHYS ACTA, V1090, P167, DOI 10.1016/0167-4781(91)90097-6; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO HX, 1990, J BIOL CHEM, V265, P13618; MAHLER H, 1973, CRIT REV BIOCH, V1, P625; MARCKER K, 1964, J MOL BIOL, V8, P835, DOI 10.1016/S0022-2836(64)80164-9; MEINNEL T, 1994, J BACTERIOL, V176, P7387, DOI 10.1128/JB.176.23.7387-7390.1994; NISHIMURA S, 1971, PROCEDURES NUCL ACID, V2; OMORI A, 1994, J PROTEIN CHEM, V13, P471; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; Ramesh V, 1997, P NATL ACAD SCI USA, V94, P13524, DOI 10.1073/pnas.94.25.13524; ROE BA, 1981, P 3 CLEV S MACR, P167; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmitt E, 1996, EMBO J, V15, P4749, DOI 10.1002/j.1460-2075.1996.tb00852.x; SCHWARTZ JH, 1967, J MOL BIOL, V25, P571, DOI 10.1016/0022-2836(67)90210-0; Schwartzbach C J, 1996, Methods Enzymol, V264, P248, DOI 10.1016/S0076-6879(96)64025-7; SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125; SKALA J, 1992, YEAST, V8, P777, DOI 10.1002/yea.320080911; WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P347, DOI 10.1093/nar/22.3.347; WALLIS NG, 1995, BIOCHEMISTRY-US, V34, P7668, DOI 10.1021/bi00023a013; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; YOSHIDA M, 1971, BIOCHIM BIOPHYS ACTA, V228, P153, DOI 10.1016/0005-2787(71)90555-7	40	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15085	15090		10.1074/jbc.273.24.15085	http://dx.doi.org/10.1074/jbc.273.24.15085			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614118	hybrid			2022-12-25	WOS:000074160400060
J	Wan, Y; Huang, XY				Wan, Y; Huang, XY			Analysis of the G(s)/mitogen-activated protein kinase pathway in mutant 549 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; SIGNAL-TRANSDUCTION; GS-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT ACTIVATION; COUPLED RECEPTORS; ADENYLATE-CYCLASE; TYROSINE KINASES; RAS; CASCADE	Heterotrimeric G protein-coupled receptors can activate the mitogen-activated protein kinase (MAPK) cascade. Recent studies using pharmacological inhibitors or dominant-negative mutants of signaling molecules have advanced our understanding of the pathways from G protein-coupled receptors to MAPK. However, molecular genetic analysis of these pathways is inadequate in mammalian cells. Here, using the well characterized G,cu-and protein kinase A-deficient S49 mouse lymphoma cells, we provide the molecular genetic evidence that G(s) alpha is responsible for transducing the beta-adrenergic receptor signal to MAPK in a protein kinase A-dependent pathway involving Rap1 and Raf (but not Ras) molecules.	Cornell Univ, Coll Med, Dept Physiol, New York, NY 10021 USA	Cornell University	Huang, XY (corresponding author), Cornell Univ, Coll Med, Dept Physiol, 1300 York Ave, New York, NY 10021 USA.							Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BOURNE HR, 1975, SCIENCE, V187, P750, DOI 10.1126/science.163487; BOURNE HR, 1975, J CELL PHYSIOL, V85, P611, DOI 10.1002/jcp.1040850313; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COFFINO P, 1975, J CELL PHYSIOL, V85, P603, DOI 10.1002/jcp.1040850312; Cosgaya JM, 1996, ONCOGENE, V12, P2651; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FAURE M, 1994, J BIOL CHEM, V269, P7851; FERBY IM, 1994, J BIOL CHEM, V269, P30485; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HAGA T, 1977, P NATL ACAD SCI USA, V74, P2016, DOI 10.1073/pnas.74.5.2016; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; INSEL PA, 1975, SCIENCE, V190, P896, DOI 10.1126/science.171770; ITOH H, 1991, J BIOL CHEM, V266, P16226; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; OBARA T, 1991, P NATL ACAD SCI USA, V88, P5877, DOI 10.1073/pnas.88.13.5877; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shibuya EK, 1996, CELL GROWTH DIFFER, V7, P235; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209	45	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14533	14537		10.1074/jbc.273.23.14533	http://dx.doi.org/10.1074/jbc.273.23.14533			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603967	hybrid			2022-12-25	WOS:000074021500069
J	Qian, Y; Baisden, JM; Westin, EH; Guappone, AC; Koay, TC; Flynn, DC				Qian, Y; Baisden, JM; Westin, EH; Guappone, AC; Koay, TC; Flynn, DC			Src can regulate carboxy terminal interactions with AFAP-110, which influence self-association, cell localization and actin filament integrity	ONCOGENE			English	Article						Src; AFAP-110; cytoskeleton; membrane; multimer	PP60C-SRC PROTEIN-KINASE; HUMAN-COLON CARCINOMA; LEUCINE-ZIPPER; V-SRC; MUTATIONAL ANALYSIS; STABLE ASSOCIATION; TYROSINE KINASES; IDENTIFICATION; ACTIVATION; DOMAIN	The SH2 and SH3 binding partner AFAP-110 is a tyrosine phosphorylated substrate of Src, AFAP-110 has been hypothesized to link Src to actin filaments, which may contribute to the effects of Src upon actin filament integrity, However, it has been unclear what effect activated Src (Src(527F)) has upon AFAP-110 structure or function and whether AFAP-110 plays a role in actin filament integrity. We report here that the carboxy terminal 127 amino acids of AFAP-110 are comprised of an alpha-helical region that contains a leucine zipper motif, This indicated the potential of AFAP-110 to self-associate, Expression of the carboxy terminus as a fusion protein (GST-cterm) mill permit affinity absorption of cellular AFAP-110, The integrity of the alpha-helical leucine zipper motif in GST-cterm is required for affinity absorption, but binding is not due to a classical leucine zipper interaction. Co-expression of Src(527F), unlike cSrc, mill abrogate affinity absorption of AFAP-110 with GST-cterm, These data indicate that Src(527F) has affected a change in the carboxy terminal structure that renders AFAP-110 unavailable for affinity absorption. Superose chromatography demonstrate that AFAP-110 will fractionate as a monomer or multimer, indicating AFAP-110 can be detected in a self-associated form in cell lysates. Go-expression of Src(527F) resulted in AFAP-110 fractionating with a molecular weight that predicts only a multimeric population. Deletional mutagenesis also indicate a biological role for the carboxy terminus in cellular localization and actin filament integrity. Deletion of the entire carboxy terminal alpha-helix (84 amino acids) will not permit AFAP-110 to efficiently colocalize with actin filaments or the cell membrane. Deletion of only the leucine zipper region of the carboxy terminal alpha-helix (44 amino acids) from AFAP-110 (AFAPA(Delta zip)) demonstrate that both AFAP(Delta lzip) and actin filaments are repositioned into rosette-like structures, similar to the effects of Src(527F), while co-expression of AFAP-110 with cSrc will not affect actin filaments. These data indicate that AFAP-110 can play an important role in modulating actin filament integrity through carboxy terminal interactions that can be affected by Sr-527F.	W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Microbiol & Immunol, Morgantown, WV 26506 USA	West Virginia University; West Virginia University	Flynn, DC (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr, POB 9300, Morgantown, WV 26506 USA.		Baisden, Joseph/AAN-7747-2021	Baisden, Joseph/0000-0002-8986-407X	NCI NIH HHS [CA 60731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060731, R29CA060731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bikle DD, 1996, J BIOL CHEM, V271, P9075, DOI 10.1074/jbc.271.15.9075; BLENIS J, 1985, P NATL ACAD SCI USA, V82, P7621, DOI 10.1073/pnas.82.22.7621; BLENIS J, 1987, J BIOL CHEM, V262, P14373; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; COOPER JA, 1996, BIOCH BIOPHYS ACTA G, V1287, P121; EARL PL, 1993, AIDS RES HUM RETROV, V9, P589, DOI 10.1089/aid.1993.9.589; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; FLYNN DC, 1995, J BIOL CHEM, V270, P3894, DOI 10.1074/jbc.270.8.3894; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; GUAPPONE AC, UNPUB; GUAPPONE AC, 1996, METH CELL SCI, V18, P1; HODGES RS, 1992, CURR BIOL, V2, P22; HURST HC, 1994, PROTEIN PROFILE, V1, P123; JACKSON P, 1989, J VIROL, V63, P311, DOI 10.1128/JVI.63.1.311-318.1989; JACOBS C, 1983, CANCER RES, V43, P1696; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; KLEIN NJ, 1993, INT IMMUNOL, V5, P293, DOI 10.1093/intimm/5.3.293; MAEKAWA T, 1993, J CELL SCI, V105, P589; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; PEARLMAN JA, 1994, FEBS LETT, V354, P183, DOI 10.1016/0014-5793(94)01119-2; QURESHI SA, 1991, ONCOGENE, V6, P995; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Ruth P, 1997, J BIOL CHEM, V272, P10522; SARAS J, 1994, J BIOL CHEM, V269, P24082; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; STERNBERG DW, 1993, EMBO J, V12, P323, DOI 10.1002/j.1460-2075.1993.tb05660.x; STURGILL TW, 1988, NATURE, V353, P174; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U	45	43	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2185	2195		10.1038/sj.onc.1201753	http://dx.doi.org/10.1038/sj.onc.1201753			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619827				2022-12-25	WOS:000073298000003
J	Krapivinsky, G; Kennedy, ME; Nemec, J; Medina, I; Krapivinsky, L; Clapham, DE				Krapivinsky, G; Kennedy, ME; Nemec, J; Medina, I; Krapivinsky, L; Clapham, DE			G(beta gamma) binding to GIRK4 subunit is critical for G protein-gated K+ channel activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; INWARD RECTIFIER; POTASSIUM CHANNEL; I-KACH; EXPRESSION; CLONING; BRAIN; IDENTIFICATION; CIR	The cardiac G protein-gated K+ channel, I-KACh, is directly activated by G protein beta gamma subunits (G(beta gamma)). I-KACh is composed of two inward rectifier K+ channel subunits, GIRK1 and GIRK4. G(beta gamma) binds to both GIRK1 and GIRK4 subunits of the heteromultimeric I-KACh. Here we delineate the G(beta gamma) binding regions of I-KACh by studying direct G(beta gamma) interaction with native purified I-KACh, competition of this interaction with peptides derived from GIRK1 or GIRK4 amino acid sequences, mutational analysis of regions implicated in G(beta gamma) binding, and functional expression of mutated subunits in mammalian cells. Only two GIRK4 peptides, containing amino acids 209-225 or 226-245, effectively competed for G beta gamma binding. A single point mutation introduced into GIRK4 at position 216 (C216T) dramatically reduced the potency of the peptide in inhibiting G(beta gamma) binding and G(beta gamma) activation of expressed GIRK1/GIRK4(C216T) channels. Conversion of 5 amino acids in GIRK4 (226-245) to the corresponding amino acids found in the G protein-insensitive IRK1 channel, completely abolished peptide inhibition of G(beta gamma) binding to I-KACh and G(beta gamma) activation of GIRK1/mutant GIRK4 channels. We conclude from this data that G(beta gamma) binding to GIRK4 is critical for I-KACh activation.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Pediat Childrens Hosp, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Clapham, DE (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Pediat Childrens Hosp, 1309 Enders,320 Longwood Ave, Boston, MA 02115 USA.	clapham@rascal.med.harvard.edu	Clapham, David/S-1123-2019; Medina, Igor/O-5532-2016; Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; Medina, Igor/0000-0001-6839-5414; 	PHS HHS [54873] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ackerman MJ, 1997, NEW ENGL J MED, V336, P1575, DOI 10.1056/NEJM199705293362207; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; HARTZELL HC, 1977, J PHYSIOL-LONDON, V271, P817, DOI 10.1113/jphysiol.1977.sp012027; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; INANOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022, DOI 10.1006/bbrc.1995.2072; Kennedy ME, 1996, NEUROPHARMACOLOGY, V35, P831, DOI 10.1016/0028-3908(96)00132-3; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; KURACHI Y, 1995, AM J PHYSIOL-CELL PH, V269, pC821, DOI 10.1152/ajpcell.1995.269.4.C821; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; Liao YJ, 1996, J NEUROSCI, V16, P7137; Loewi O, 1921, PFLUG ARCH GES PHYS, V189, P239, DOI 10.1007/BF01738910; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Luchian T, 1997, J PHYSIOL-LONDON, V505, P13, DOI 10.1111/j.1469-7793.1997.013bc.x; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; TUCKER SJ, 1996, AM J PHYSIOL, V40, P379; UEDA N, 1994, J BIOL CHEM, V269, P4388; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Woodward R, 1997, J BIOL CHEM, V272, P10823	34	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16946	16952		10.1074/jbc.273.27.16946	http://dx.doi.org/10.1074/jbc.273.27.16946			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642257	hybrid			2022-12-25	WOS:000074545200047
J	Liu, R; Takayama, S; Zheng, Y; Froesch, B; Chen, GQ; Zhang, X; Reed, JC; Zhang, XK				Liu, R; Takayama, S; Zheng, Y; Froesch, B; Chen, GQ; Zhang, X; Reed, JC; Zhang, XK			Interaction of BAG-1 with retinoic acid receptor and its inhibition of retinoic acid-induced apoptosis in cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; ACTIVATION FUNCTION AF-2; NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; CO-REPRESSOR; X RECEPTORS; PROTEIN; DEATH; MEDIATOR	BAG-1 (also known as RAP46) is an anti-apoptotic protein, which has been shown previously to interact with a number of nuclear hormone receptors, including receptors for glucocorticoid, estrogen, and thyroid hormone. We show here that BAG-I also interacts with retinoic acid receptor (RAR). Gel retardation assays demonstrated that in vitro translated BAG-1 protein could effectively inhibit the binding of RAR but not retinoid X receptor (RXR) to a number of retinoic acid (RA) response elements (RAREs), A glutathione S-transferase-BAG-1 fusion protein also specifically bound RAR but not RXR. Interaction of BAG-I and RAR could also be demonstrated by yeast two-hybrid assays. In transient transfection assays, co-transfection of BAG-1 expression plasmid inhibited the transactivation activity of RAR/RXR heterodimers but not RXR/RXR homodimers. When stably expressed in breast cancer cell lines, BAG-1 inhibited binding of RAR/RXR heterodimer to a number of RAREs and suppressed RA-induced growth inhibition and apoptosis. In addition, RA-induced suppression of Bcl-2 expression was abrogated by overexpression of BAG-1. These results demonstrate that BAG-1 can regulate retinoid activities through its interaction with RAR and suggest that elevated levels of BAG-I protein could potentially contribute to retinoid resistance in cancer cells.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Zhang, XK (corresponding author), Burnham Inst, Ctr Canc Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA067329, R01CA060988] Funding Source: NIH RePORTER; NCI NIH HHS [CA67329, CA60988] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chao WR, 1997, CANCER LETT, V115, P1, DOI 10.1016/S0304-3835(97)04598-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; Elstner E, 1996, CANCER RES, V56, P3570; Fanjul AN, 1996, CANCER RES, V56, P1571; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; Gudas Lorraine J., 1994, P443; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1734; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; HOLLEY SJ, 1995, MOL BIOL CELL, V6, P1833, DOI 10.1091/mbc.6.12.1833; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong Waun Ki, 1994, P597; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOCHHAR DM, 1993, PROG CLIN BIOL RES, V383, P815; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Li Y, 1998, INT J CANCER, V75, P88, DOI 10.1002/(SICI)1097-0215(19980105)75:1<88::AID-IJC14>3.0.CO;2-9; Liu Y, 1996, MOL CELL BIOL, V16, P1138; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; NAGY L, 1995, MOL CELL BIOL, V15, P3540; ONATE SA, 1995, SCIENCE, V270, P1354; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PONZONI M, 1995, CANCER RES, V55, P853; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TAKAYAMA S, 1998, IN PRESS CANC RES; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598; YANG Y, 1995, J BIOL CHEM, V270, P18672, DOI 10.1074/jbc.270.31.18672; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11456; ZHANG XK, 1993, TRENDS ENDOCRIN MET, V4, P156, DOI 10.1016/1043-2760(93)90105-N; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	52	105	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16985	16992		10.1074/jbc.273.27.16985	http://dx.doi.org/10.1074/jbc.273.27.16985			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642262	hybrid			2022-12-25	WOS:000074545200052
J	Ammanamanchi, S; Kim, SJ; Sun, LZ; Brattain, MG				Ammanamanchi, S; Kim, SJ; Sun, LZ; Brattain, MG			Induction of transforming growth factor-beta receptor type II expression in estrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2 '-deoxycytidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA CELLS; TGF-BETA; MICROSATELLITE INSTABILITY; DNA METHYLATION; PROTEIN-KINASE; GENE; MECHANISM; BINDING; TRANSCRIPTION; INHIBITION	Previous studies suggest that estrogen receptor-positive (ER+) breast cancer cells acquire resistance to transforming growth factor-beta (`TGF-beta) because of reduced expression levels of TGF-beta receptor type II (RII). We now report that treatment of ER+ breast cancer cells with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-aza-2'-dC) leads to accumulation of RII transcript and protein in three different cell lines. RII induction restored TGF-beta response in MCF-7L breast cancer cells as indicated by the enhanced activity of a TGF-beta responsive promoter-reporter construct (p3TP-Lux). A transiently transfected RII promoter-reporter element (RII-chloramphenicol acetyltransferase) showed an increase in activity in the 5-aza-2'-dC-treated MCF-7L cells compared with untreated cells, suggesting the activation of a transactivator of RII transcription. Using electrophoretic mobility shift assays, the enhanced binding: of proteins from 5-aza-2'-dC-treated MCF-7L nuclear extracts to radiolabeled Sp1 oligonucleotides was demonstrated. An RII promoter-chloramphenicol acetyltransferase construct containing a mutation in the Sp1 site was not expressed in the 5-aza-2'-dC-treated MCF-7L cells, further demonstrating that induction of Sp1 activity by 5-aza-2'-dC in the MCF-7L cells was critical to RII expression. Northern analysis indicated that 5-aza-2'-dC treatment did not affect the Sp1 transcript levels. Western blot analysis revealed an increase of Sp1 protein in the 5-aza-2'-dC-treated MCF-7L cells, but there was no change in the c-Jun levels. Studies after cyclohexamide treatment suggested an increase in the Sp1 protein stability from the 5-aza-2'-dC-treated MCF-7L extracts compared with untreated control extracts. These results indicate that the transcriptional repression of RII in the ER+ breast cancer cells is caused by suboptimal activity of Sp1, whereas treatment with 5-aza-2'-dC stabilizes the protein thus increasing steady-state Sp1 levels and thereby leads to enhanced RII transcription and subsequent restoration of TGF-beta sensitivity.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA; NCI, Chemoprevent Lab, NIH, Bethesda, MD 20892 USA; Univ Kentucky, Coll Med, Dept Pharmacol, Lexington, KY 40536 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Kentucky	Brattain, MG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		, LuZhe/AAW-4095-2021		NATIONAL CANCER INSTITUTE [R01CA072001, R37CA038173, R01CA038173, R01CA054807] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54807, CA 72001, CA 38173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1988, CANCER RES, V48, P3898; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Brattain MG, 1996, J MAMMARY GLAND BIOL, V1, P365, DOI 10.1007/BF02017392; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jones PA, 1996, CANCER RES, V56, P2463; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kim DH, 1997, J BIOL CHEM, V272, P688; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2	39	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16527	16534		10.1074/jbc.273.26.16527	http://dx.doi.org/10.1074/jbc.273.26.16527			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632722	hybrid			2022-12-25	WOS:000074436600093
J	Holloway, MP; Bram, RJ				Holloway, MP; Bram, RJ			Co-localization of calcium-modulating cyclophilin ligand with intracellular calcium pools	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-LYMPHOMA CELLS; INTEGRAL MEMBRANE-PROTEINS; INTERNAL CA2+ RELEASE; BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; TRITON X-114; CALRETICULIN; INFLUX; IDENTIFICATION; THAPSIGARGIN	The calcium-modulating cyclophilin ligand (CAML) protein activates Ca2+ influx signaling when overexpressed in Jurkat T cells. Although CAML appears to directly participate in Ca2+-dependent signaling initiated by the transmembrane activator and CAML interactor cell surface receptor, its mechanism of action is unknown. To address this issue, we have determined its membrane topology, subcellular localization, and ability to mobilize intracellular Ca2+ pools. Fractionation of cell extracts on discontinuous sucrose gradients and indirect immunofluorescence indicate that CAML colocalizes with sarcoplasmic/endoplasmic reticulum calcium/ATPase-2 and calreticulin at membrane-bound cytosolic vesicles. Limited trypsin digests indicate that the hydrophilic NH2-terminal domain of CAML is directed toward the cytoplasm. Functionally, CAML overexpression was shown to deplete thapsigargin-sensitive intracellular Ca2+ pools. These data suggest that CAML may initiate Ca2+ signaling through activation of a capacitative Ca2+ influx pathway.	St Jude Childrens Res Hosp, Dept Expt Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Tennessee, Dept Pediat, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Bram, RJ (corresponding author), St Jude Childrens Res Hosp, Dept Expt Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	richard.bram@stjude.org			NCI NIH HHS [CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIAN JH, 1991, J BIOL CHEM, V266, P8801; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; BOURGUIGNON LYW, 1986, J CELL PHYSIOL, V127, P146, DOI 10.1002/jcp.1041270118; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; Bram RJ, 1996, GENE, V174, P307, DOI 10.1016/0378-1119(96)00081-9; BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182; DUPUIS M, 1993, J EXP MED, V177, P1, DOI 10.1084/jem.177.1.1; Fleischer S., 1967, METHOD ENZYMOL, V10, P406; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GROVER AK, 1992, CELL CALCIUM, V13, P9, DOI 10.1016/0143-4160(92)90025-N; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; Holloway MP, 1996, J BIOL CHEM, V271, P8549, DOI 10.1074/jbc.271.15.8549; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1991, J BIOL CHEM, V266, P7155; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Sambrook J., 2002, MOL CLONING LAB MANU; Schwientek T, 1996, J BIOL CHEM, V271, P3398; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138	32	42	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16346	16350		10.1074/jbc.273.26.16346	http://dx.doi.org/10.1074/jbc.273.26.16346			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632697	hybrid			2022-12-25	WOS:000074436600068
J	Taylor, SV; Kelleher, NL; Kinsland, C; Chiu, HJ; Costello, CK; Backstrom, AD; McLafferty, FW; Begley, TP				Taylor, SV; Kelleher, NL; Kinsland, C; Chiu, HJ; Costello, CK; Backstrom, AD; McLafferty, FW; Begley, TP			Thiamin biosynthesis in Escherichia coli - Identification of this thiocarboxylate as the immediate sulfur donor in the thiazole formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; BIOTIN SYNTHASE; SALMONELLA-TYPHIMURIUM; PYRIMIDINE MOIETY; CONVERTING FACTOR; GENE-PRODUCT; LIPOIC ACID; ORIGIN; ATOM; MOLYBDOPTERIN	ThiFSGH and ThiI are required for the biosynthesis of the thiazole moiety of thiamin in Escherichia coli. The overproduction, purification, and characterization of ThiFS and the identification of two of the early steps in the biosynthesis of the thiazole moiety of thiamin are described here. ThiS isolated from E. coli thiI(+) is post-translationally modified by converting the carboxylic acid group of the carboxyl-terminal glycine into a thiocarboxylate. The thiI gene plays an essential role in the formation of the thiocarboxylate because ThiS isolated from a thiI(-) strain does not contain this modification. ThiF catalyzes the adenylation by ATP of the carboxyl-terminal glycine of ThiS. This reaction is likely to be involved in the activation of ThiS for sulfur transfer from cysteine or from a cysteine-derived sulfur donor.	Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA	Cornell University	Begley, TP (corresponding author), Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA.		Begley, Tadhg/B-5801-2015		NIDDK NIH HHS [DK44083] Funding Source: Medline; NIGMS NIH HHS [GM16609] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044083, R01DK044083, R56DK044083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM016609, R37GM016609] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKSTROM AD, 1995, J AM CHEM SOC, V117, P2351, DOI 10.1021/ja00113a025; Begley TP, 1996, NAT PROD REP, V13, P177, DOI 10.1039/np9961300177; BELLION E, 1976, BIOCHIM BIOPHYS ACTA, V437, P229, DOI 10.1016/0304-4165(76)90364-0; BEU SC, 1993, J AM SOC MASS SPECTR, V4, P557, DOI 10.1016/1044-0305(93)85017-R; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; DAVID S, 1982, J CHEM SOC PERK T, V1, P2131; DEMOLL E, 1985, BIOCHEM BIOPH RES CO, V132, P217, DOI 10.1016/0006-291X(85)91010-1; ESTRAMAREIX B, 1972, BIOCHIM BIOPHYS ACTA, V273, P275, DOI 10.1016/0304-4165(72)90217-6; ESTRAMAREIX B, 1986, BIOCHEM BIOPH RES CO, V134, P1136, DOI 10.1016/0006-291X(86)90369-4; Estramareix B, 1996, NEW J CHEM, V20, P607; ESTRAMAREIX B, 1990, BIOCHIM BIOPHYS ACTA, V1035, P154, DOI 10.1016/0304-4165(90)90110-I; FLORENTIN D, 1994, CR ACAD SCI III-VIE, V317, P485; GAUTHIER JW, 1991, ANAL CHIM ACTA, V246, P211, DOI 10.1016/S0003-2670(00)80678-9; HAYDEN MA, 1992, J BIOL CHEM, V267, P9512; Himmeldirk K, 1998, J AM CHEM SOC, V120, P3581, DOI 10.1021/ja973835r; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSETT MN, 1972, J BIOL CHEM, V247, P1458; MARSHALL AG, 1985, J AM CHEM SOC, V107, P7893, DOI 10.1021/ja00312a015; MCLAFFERTY FW, 1994, ACCOUNTS CHEM RES, V27, P379, DOI 10.1021/ar00047a009; Miller J. H., 1972, EXPT MOL GENETICS, P433; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; REED KE, 1993, J BACTERIOL, V175, P1325, DOI 10.1128/JB.175.5.1325-1336.1993; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; RYALS J, 1982, J BACTERIOL, V151, P899, DOI 10.1128/JB.151.2.899-904.1982; Sanyal I, 1996, ARCH BIOCHEM BIOPHYS, V326, P48, DOI 10.1006/abbi.1996.0045; SANYAL I, 1994, BIOCHEMISTRY-US, V33, P3625, DOI 10.1021/bi00178a020; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; STEWART GSAB, 1986, PLASMID, V15, P172, DOI 10.1016/0147-619X(86)90035-1; STEWART V, 1988, J BACTERIOL, V170, P1589, DOI 10.1128/jb.170.4.1589-1597.1988; TAZUYA K, 1987, BIOCHIM BIOPHYS ACTA, V924, P210, DOI 10.1016/0304-4165(87)90089-4; TAZUYA K, 1987, BIOCHEM INT, V14, P769; VANDERHORN PB, 1993, J BACTERIOL, V175, P982, DOI 10.1128/JB.175.4.982-992.1993; Webb E, 1997, J BACTERIOL, V179, P4399, DOI 10.1128/jb.179.13.4399-4402.1997; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; WHITE RH, 1978, BIOCHIM BIOPHYS ACTA, V542, P340, DOI 10.1016/0304-4165(78)90029-6; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; [No title captured]	40	134	145	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16555	16560		10.1074/jbc.273.26.16555	http://dx.doi.org/10.1074/jbc.273.26.16555			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632726	hybrid			2022-12-25	WOS:000074436600097
J	Agre, P; Bonhivers, M; Borgnia, MJ				Agre, P; Bonhivers, M; Borgnia, MJ			The aquaporins, blueprints for cellular plumbing systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							INTEGRAL MEMBRANE-PROTEIN; WATER CHANNEL; MIP FAMILY; CHIP; KIDNEY; PERMEABILITY; EXPRESSION; MUTATIONS; TISSUES; CDNA		Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Agre, P (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	peter.agre@qmail.bs.jhu.edu	Bonhivers, Melanie/Z-5889-2019	Bonhivers, Melanie/0000-0001-9179-8473; Borgnia, Mario/0000-0001-9159-1413	NATIONAL EYE INSTITUTE [R01EY011239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033991, R01HL048268, R37HL048268] Funding Source: NIH RePORTER; NEI NIH HHS [EY11239] Funding Source: Medline; NHLBI NIH HHS [HL33991, HL48268] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMI L, 1995, J MEMBRANE BIOL, V143, P199; BEURON F, 1995, J BIOL CHEM, V270, P17414, DOI 10.1074/jbc.270.29.17414; Calamita G, 1998, P NATL ACAD SCI USA, V95, P3627, DOI 10.1073/pnas.95.7.3627; Chou CL, 1998, AM J PHYSIOL-CELL PH, V274, pC549, DOI 10.1152/ajpcell.1998.274.2.C549; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Delporte C, 1996, J BIOL CHEM, V271, P22070, DOI 10.1074/jbc.271.36.22070; DENKER BM, 1988, J BIOL CHEM, V263, P15634; ECELBARGER CA, 1995, AM J PHYSIOL-RENAL, V269, pF663, DOI 10.1152/ajprenal.1995.269.5.F663; Flick KM, 1997, GENE, V195, P127, DOI 10.1016/S0378-1119(97)00078-4; FRIGERI A, 1995, J CELL SCI, V108, P2993; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HAMANN S, 1998, IN PRESS AM J PHYSL; Han ZQ, 1998, J BIOL CHEM, V273, P6001, DOI 10.1074/jbc.273.11.6001; HEYMANN JB, 1998, IN PRESS J STRUCT BI, V116; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Knepper MA, 1997, CURR OPIN CELL BIOL, V9, P560, DOI 10.1016/S0955-0674(97)80034-8; Knepper MA, 1996, KIDNEY INT, V49, P1712, DOI 10.1038/ki.1996.253; Koyama Y, 1997, J BIOL CHEM, V272, P30329, DOI 10.1074/jbc.272.48.30329; Kuriyama H, 1997, BIOCHEM BIOPH RES CO, V241, P53, DOI 10.1006/bbrc.1997.7769; Lee MD, 1997, MEDICINE, V76, P141, DOI 10.1097/00005792-199705000-00001; Loo DDF, 1996, P NATL ACAD SCI USA, V93, P13367, DOI 10.1073/pnas.93.23.13367; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 1996, GENOMICS, V35, P543, DOI 10.1006/geno.1996.0396; MARPLES D, 1995, J CLIN INVEST, V95, P1838, DOI 10.1172/JCI117863; Matthay MA, 1996, AM J PHYSIOL-LUNG C, V270, pL487, DOI 10.1152/ajplung.1996.270.4.L487; Maunsbach AB, 1997, J AM SOC NEPHROL, V8, P1; Maurel C, 1997, ANNU REV PLANT PHYS, V48, P399, DOI 10.1146/annurev.arplant.48.1.399; Nagelhus EA, 1998, J NEUROSCI, V18, P2506; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nielsen S, 1997, P NATL ACAD SCI USA, V94, P5450, DOI 10.1073/pnas.94.10.5450; Nielsen S, 1997, J NEUROSCI, V17, P171; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Ohara M, 1998, J CLIN INVEST, V101, P1076, DOI 10.1172/JCI649; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Sasaki S, 1998, ANNU REV PHYSIOL, V60, P199, DOI 10.1146/annurev.physiol.60.1.199; Shiels A, 1996, NAT GENET, V12, P212, DOI 10.1038/ng0296-212; SMITH BL, 1991, J BIOL CHEM, V266, P6407; Terris J, 1995, AM J PHYSIOL-RENAL, V269, pF775, DOI 10.1152/ajprenal.1995.269.6.F775; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Verbavatz JM, 1997, J CELL SCI, V110, P2855; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; Weig A, 1997, PLANT PHYSIOL, V114, P1347, DOI 10.1104/pp.114.4.1347; Yasui M, 1997, J PHYSIOL-LONDON, V505, P3, DOI 10.1111/j.1469-7793.1997.003bc.x; Yool AJ, 1996, SCIENCE, V273, P1216, DOI 10.1126/science.273.5279.1216; ZEIDEL ML, 1994, BIOCHEMISTRY-US, V33, P1606, DOI 10.1021/bi00172a042	53	372	397	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14659	14662		10.1074/jbc.273.24.14659	http://dx.doi.org/10.1074/jbc.273.24.14659			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614059	hybrid			2022-12-25	WOS:000074160400001
J	Delacoux, F; Fichard, A; Geourjon, C; Garrone, R; Ruggiero, F				Delacoux, F; Fichard, A; Geourjon, C; Garrone, R; Ruggiero, F			Molecular features of the collagen V heparin binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL HEP-2 REGION; ALPHA-1(V) CHAIN; ADHESION; CELLS; PROTEOGLYCAN; FIBRONECTIN; SULFATE; ALPHA-1-BETA-1; ORGANIZATION; DOMAINS	A heparin binding region is known to be present within the triple helical part of the alpha 1(V) chain. Here we show that a recombinant alpha 1(V) fragment (Ile(284) to Pro(950)), referred to as HepV, is sufficient for heparin binding at physiological ionic strength. Both native individual alpha 1(V) chains and HepV are eluted at identical NaCl concentrations (0.35 M) from a heparin-Sepharose column, and this binding can be inhibited specifically by the addition of free heparin or heparan sulfate. In contrast, a shorter as-residue synthetic peptide, containing the putative heparin binding site in HepV, fails to bind heparin, Interestingly, HepV promotes cell attachment, and HepV-mediated adhesion is inhibited specifically by heparin or heparan sulfate, indicating that this region might behave as an adhesive binding site. The same site is equally functional on triple helical molecules as shown by heparin-gold labeling. However, the affinities for heparin of each of the collagen V molecular forms tested are different and increase with the number of alpha 1(V) chains incorporated in the molecules. Molecular modeling of a sequence encompassing the putative HepV binding sequence region shows that all of the basic residues cluster on one side of the helical face. A highly positively charged ring around the molecule is thus particularly evident for the alpha 1(V) homotrimer, This could strengthen its interaction with the anionic heparin molecules. We propose that a single heparin binding site is involved in heparin-related glycosaiminoglycans-collagen V interactions, but the different affinities observed likely modulate cell and matrix interactions between collagen V and heparan sulfate proteoglycans in tissues.	Univ Claude Bernard, Inst Biol & Chim Prot, CNRS, UPR 412, Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Ruggiero, F (corresponding author), Univ Claude Bernard, Inst Biol & Chim Prot, CNRS, UPR 412, Passage Vercors, Lyon 07, France.	f.ruggiero@ibcp.fr		RUGGIERO, Florence/0000-0003-2915-5359				CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; DEPREZ PN, 1995, J BIOL CHEM, V270, P11043, DOI 10.1074/jbc.270.19.11043; Fichard A, 1997, J BIOL CHEM, V272, P30083, DOI 10.1074/jbc.272.48.30083; FICHARD A, 1994, MATRIX BIOL, V14, P515; GEOURJON C, 1995, J MOL GRAPHICS, V13, P209, DOI 10.1016/0263-7855(95)00035-5; HARALSON MA, 1980, P NATL ACAD SCI-BIOL, V77, P5206, DOI 10.1073/pnas.77.9.5206; HARALSON MA, 1984, ARCH BIOCHEM BIOPHYS, V229, P509, DOI 10.1016/0003-9861(84)90182-6; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; INGHAM KC, 1994, ARCH BIOCHEM BIOPHYS, V314, P242, DOI 10.1006/abbi.1994.1436; KELLER KM, 1986, BIOCHIM BIOPHYS ACTA, V882, P1, DOI 10.1016/0304-4165(86)90047-4; KODA JE, 1985, J BIOL CHEM, V260, P8157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; MANN K, 1992, BIOL CHEM H-S, V373, P69, DOI 10.1515/bchm3.1992.373.1.69; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MAYO KH, 1992, BIOCHEMISTRY-US, V31, P12255, DOI 10.1021/bi00163a040; Mizuno K, 1996, J BIOCHEM-TOKYO, V120, P934; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; RUGGIERO F, 1993, J HISTOCHEM CYTOCHEM, V41, P867, DOI 10.1177/41.6.8315278; Ruggiero F, 1996, J CELL SCI, V109, P1865; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; SANANTONIO JD, 1994, GLYCOBIOLOGY, V4, P327; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; SUZU S, 1992, J BIOL CHEM, V267, P16812; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; Tillet E, 1997, J BIOL CHEM, V272, P10769; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; YAOI Y, 1990, BIOCHIM BIOPHYS ACTA, V1035, P139, DOI 10.1016/0304-4165(90)90108-9	32	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15069	15076		10.1074/jbc.273.24.15069	http://dx.doi.org/10.1074/jbc.273.24.15069			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614116	hybrid			2022-12-25	WOS:000074160400058
J	Foukas, LC; Katsoulas, HL; Paraskevopoulou, N; Metheniti, A; Lambropoulou, M; Marmaras, VJ				Foukas, LC; Katsoulas, HL; Paraskevopoulou, N; Metheniti, A; Lambropoulou, M; Marmaras, VJ			Phagocytosis of Escherichia coli by insect hemocytes requires both activation of the Ras/mitogen-activated protein kinase signal transduction pathway for attachment and beta(3) integrin for internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; LIPOPOLYSACCHARIDE; DROSOPHILA; RECOGNITION; MACROPHAGES; STIMULATION; CAPITATA; CELLS	Insect hemocytes in response to lipopolysaccharide (LPS) of Gram-negative bacteria facilitate binding and internalization of either cell-associated or cell-free LPS (Charalambidis, N. D., Foukas L. C., and Marmaras V. J. (1996) Eur. J. Biochem. 236, 200-206), An early event in LPS signaling in hemocytes involves protein tyrosine phosphorylation (Charalambidis N. D., Zervas C. G., Lambropoulou M., Katsoris P. G., and Marmaras V. J. (1995) Eur. J. Cell Biol. 67, 32-41). Here we report further data of LPS-mediated signal transduction responsible for Escherichia coli phagocytosis. We demonstrate that both adhesion of hemocytes to substrata and LPS stimulation can cause activation of p44(MAPK) in Ceratitis capitata hemocytes but with distinct kinetics indicating different functions. In addition, we showed that Drk, a homolog protein to the mammalian GRB2, is implicated in the transmission of LPS signaling, indicating that the Ras/mitogen-activated protein kinase pathway is involved. Either the cell-free or the cell-associated LPS appears to attach to the hemocyte surface by the same mechanism that is based on the cross-linking of LPS to membrane-associated p47 via the intermediacy of tyrosine derivatives generated by the action of phenol oxidase, By contrast, the cell-free LPS internalization into the hemocytes differs from the cell-associated LPS internalization. For E. coli internalization integrin receptors as well as cytoskeletal rearrangements are required, as judged by inhibition of E. coli internalization in the presence of the RGD peptide, beta(3)-integrin antibodies, and cytochalasin D.	Univ Patras, Dept Biol, Patras 26500, Greece	University of Patras	Marmaras, VJ (corresponding author), Univ Patras, Dept Biol, Patras 26500, Greece.	marmaras@patreas.patras.gr						BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN EJ, 1995, BIOESSAYS, V17, P109, DOI 10.1002/bies.950170206; CHARALAMBIDIS ND, 1995, EUR J CELL BIOL, V67, P32; Charalambidis ND, 1996, EUR J BIOCHEM, V236, P200, DOI 10.1111/j.1432-1033.1996.00200.x; Charalambidis ND, 1996, INSECT BIOCHEM MOLEC, V26, P867, DOI 10.1016/S0965-1748(96)00053-7; CHARALAMBIDIS ND, 1994, INSECT BIOCHEM MOLEC, V7, P655; CHEN QM, 1994, J BIOL CHEM, V269, P26602; FOGERTY FJ, 1994, DEVELOPMENT, V120, P1747; GERNER AJ, 1995, J BIOL CHEM, V270, P5320; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Hannigan GE, 1997, J MOL MED, V75, P35, DOI 10.1007/s001090050084; JEWELL K, 1995, J CELL SCI, V108, P1165; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARMARAS VJ, 1994, ARCH INSECT BIOCHEM, V26, P1, DOI 10.1002/arch.940260102; MARMARAS VJ, 1988, DEV BIOL, V129, P294, DOI 10.1016/0012-1606(88)90376-4; OKADA CY, 1982, CELL, V29, P33, DOI 10.1016/0092-8674(82)90087-3; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PECH LL, 1995, J INSECT PHYSIOL, V41, P481, DOI 10.1016/0022-1910(94)00136-5; RAHLOFF LH, 1994, J INSECT PHYSL, V40, P1045; SCHAEFER J, 1987, SCIENCE, V235, P1200, DOI 10.1126/science.3823880; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Towbin H, 1979, 10 1073 PNAS 76 9 43, V76, P4350, DOI [10.1073/pnas.76.9.4350, DOI 10.1073/PNAS.76.9.4350]; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WEINSTEIN SL, 1993, J IMMUNOL, V151, P3829; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	30	90	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14813	14818		10.1074/jbc.273.24.14813	http://dx.doi.org/10.1074/jbc.273.24.14813			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614082	hybrid			2022-12-25	WOS:000074160400024
J	Gilmore, R; Coffey, MC; Lee, PWK				Gilmore, R; Coffey, MC; Lee, PWK			Active participation of Hsp90 in the biogenesis of the trimeric reovirus cell attachment protein sigma 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGESTERONE-RECEPTOR COMPLEXES; HEPTAD REPEAT REGION; GLUCOCORTICOID RECEPTOR; CONFORMATIONAL-CHANGES; RETICULOCYTE LYSATE; BINDING; KINASE; PROTEIN-SIGMA-1; HETEROCOMPLEX; DOMAINS	The reovirus cell attachment protein, sigma 1, is a lollipop-shaped homotrimer with an N-terminal fibrous tail and a C-terminal globular head. Biogenesis of this protein involves two trimerization events: N-terminal trimerization, which occurs cotranslationally and is Hsp70/ATP-independent, and C-terminal trimerization, which occurs posttranslationally and is Hsp70/ATP-dependent. To determine if Hsp90 also plays a role in sigma 1 biogenesis, we analyzed sigma 1 synthesized in rabbit reticulocyte lysate. Coprecipitation experiments using anti-Hsp90 antibodies revealed that Hsp90 was associated with immature sigma 1 trimers (hydra-like intermediates with assembled N-termini and unassembled C termini) but not with mature trimers, The use of truncated sigma 1 further demonstrated that only the C-terminal half of sigma 1 associated with Hsp90. In the presence of the Hsp90 binding drug geldanamycin, N-terminal trimerization proceeded normally, but C-terminal trimerization was blocked. Geldanamycin did not inhibit the association of Hsp90 with sigma 1 but prevented the subsequent release of Hsp90 from the immature al complex. We also examined the status of p23, an Hsp90-associated co-chaperone. Like Hsp90, p23 only associated with immature sigma 1 trimers, and this association was mapped to the C-terminal half of sigma 1. However, unlike Hsp90, p23 was released from the sigma 1 complex upon the addition of geldanamycin. These results highlight an all-or-none concept of chaperone involvement in different oligomerization domains within a single protein and suggest a possible common usage of chaperones in the regulation of general protein folding and of steroid receptor activation.	Univ Calgary, Hlth Sci Ctr, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Lee, PWK (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada.							ALIQUE R, 1994, EMBO J, V13, P6099; BANERJEA AC, 1988, VIROLOGY, V167, P601, DOI 10.1016/0042-6822(88)90123-7; BASSELDUBY R, 1985, NATURE, V315, P421, DOI 10.1038/315421a0; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Chavany C, 1996, J BIOL CHEM, V271, P4974; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; DUNCAN R, 1991, VIROLOGY, V182, P810, DOI 10.1016/0042-6822(91)90622-I; DUNCAN R, 1994, VIROLOGY, V203, P149, DOI 10.1006/viro.1994.1465; FERNANDES J, 1994, J BIOL CHEM, V269, P17043; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; FREEMAN BC, 1996, SCIENCE, V274, P17188; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; Gilmore R, 1996, EMBO J, V15, P2651, DOI 10.1002/j.1460-2075.1996.tb00625.x; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee PWK, 1998, CURR TOP MICROBIOL, V233, P137; LEE PWK, 1981, VIROLOGY, V108, P156, DOI 10.1016/0042-6822(81)90535-3; LEONE G, 1991, VIROLOGY, V182, P346, DOI 10.1016/0042-6822(91)90678-5; LEONE G, 1991, VIROLOGY, V182, P336, DOI 10.1016/0042-6822(91)90677-4; LEONE G, 1992, CELL, V71, P479, DOI 10.1016/0092-8674(92)90516-F; LEONE G, 1991, VIROLOGY, V184, P758, DOI 10.1016/0042-6822(91)90447-J; Leone G, 1996, J BIOL CHEM, V271, P8466, DOI 10.1074/jbc.271.14.8466; MAH DCW, 1990, VIROLOGY, V179, P95, DOI 10.1016/0042-6822(90)90278-Y; NIBERT ML, 1990, J VIROL, V64, P2976, DOI 10.1128/JVI.64.6.2976-2989.1990; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; PRATT WB, 1996, STRESS INDUCIBLE CEL, P79; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; STRONG JE, 1991, VIROLOGY, V184, P23, DOI 10.1016/0042-6822(91)90818-V; TURNER DL, 1992, VIROLOGY, V186, P219, DOI 10.1016/0042-6822(92)90076-2; Uma S, 1997, J BIOL CHEM, V272, P11648; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Xu ZY, 1997, EUR J BIOCHEM, V246, P461, DOI 10.1111/j.1432-1033.1997.t01-1-00461.x	52	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15227	15233		10.1074/jbc.273.24.15227	http://dx.doi.org/10.1074/jbc.273.24.15227			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614137	hybrid			2022-12-25	WOS:000074160400079
J	Kevil, CG; Payne, DK; Mire, E; Alexander, JS				Kevil, CG; Payne, DK; Mire, E; Alexander, JS			Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; BIOLOGICAL PROPERTIES; SIGNAL-TRANSDUCTION; FACTOR VEGF; IN-VIVO; ANGIOGENESIS; RECEPTOR; INHIBITION; ACTIVATION; BINDING	Vascular permeability factor/vascular endothelial growth factor stimulates endothelial proliferation, angiogenesis, and increased vascular permeability in vivo. We investigated mechanisms of vascular permeability factor-mediated endothelial monolayer permeability changes in vitro, [C-14]Albumin flux across endothelial monolayers was measured following a 90-min exposure to vascular permeability factor (660 pM). Vascular permeability factor increased albumin flux to 3.4 times that of control albumin flux. Endothelial monolayers were also incubated for 90 min with vascular permeability factor plus Go6976 (10 nM), staurosporine (1 mu M), wortmannin (10 nM), AG126 (1 and 2.67 mu M), and PD98059 (20 mu M). Vascular permeability factor-mediated permeability was not blocked by Go6976, an antagonist of "classical" protein kinase C, staurosporine, a pan-protein kinase C antagonist, nor wortmannin, a PI3-kinase blocker, but was blocked by incubation with AG126 or PD98059, inhibitors of mitogen-activated protein kinase activation, Immunofluorescent staining of the junctional proteins VE-cadherin and occludin showed a loss of these proteins from the endothelial junction that was prevented by co-incubation with AG126 or PD98059. These data demonstrate that vascular permeability factor increases albumin permeability across endothelial monolayers in vitro and suggests that permeability increases through rearrangement of endothelial junctional proteins involving the mitogen-activated protein kinase signal transduction pathway.	Louisiana State Univ, Med Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA; Louisiana State Univ, Med Ctr, Dept Med, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Alexander, JS (corresponding author), Louisiana State Univ, Med Ctr, Dept Mol & Cellular Physiol, 1501 Kings Hwy, Shreveport, LA 71130 USA.		Kevil, Christopher/G-9318-2011	Kevil, Christopher/0000-0003-0863-7260	NHLBI NIH HHS [HL47615] Funding Source: Medline; NIDDK NIH HHS [DK43785] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK043785] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALEXANDER JS, 1993, J CELL PHYSIOL, V156, P610, DOI 10.1002/jcp.1041560321; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; Brown L F, 1997, EXS, V79, P233; CHARNOCKJONES DS, 1994, BIOL REPROD, V51, P524, DOI 10.1095/biolreprod51.3.524; CRISCUOLO GR, 1989, J NEUROSURG, V71, P884, DOI 10.3171/jns.1989.71.6.0884; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DEJANA E, 1997, J CLIN INVEST S, V100, P7; DVORAK HF, 1995, INT ARCH ALLERGY IMM, V107, P233, DOI 10.1159/000236988; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Gaudry M, 1997, BLOOD, V90, P4153, DOI 10.1182/blood.V90.10.4153; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Haselton FR, 1997, J CELL PHYSIOL, V171, P243, DOI 10.1002/(SICI)1097-4652(199706)171:3<243::AID-JCP2>3.0.CO;2-O; Horiuchi T, 1997, AM J RESP CELL MOL, V17, P70, DOI 10.1165/ajrcmb.17.1.2796; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kan H, 1996, MOL PHARMACOL, V50, P1139; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kevil CG, 1998, FREE RADICAL BIO MED, V24, P1015, DOI 10.1016/S0891-5849(97)00433-4; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KEVIL CG, 1998, IN PRESS MICROCIRCUL; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOCH AE, 1994, J IMMUNOL, V152, P4149; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; MANISCALCO WM, 1995, AM J RESP CELL MOL, V13, P377, DOI 10.1165/ajrcmb.13.4.7546767; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Payne DK, 1996, FREE RADICAL RES, V25, P229, DOI 10.3109/10715769609149048; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; ROBERTS WG, 1995, J CELL SCI, V108, P2369; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; Seymour LW, 1996, LAB INVEST, V75, P427; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Taichman NS, 1997, J LEUKOCYTE BIOL, V62, P397, DOI 10.1002/jlb.62.3.397; Terman BI, 1996, CANCER METAST REV, V15, P159, DOI 10.1007/BF00437468; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang W, 1996, AM J PHYSIOL-CELL PH, V271, pC1973, DOI 10.1152/ajpcell.1996.271.6.C1973; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006	44	255	262	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15099	15103		10.1074/jbc.273.24.15099	http://dx.doi.org/10.1074/jbc.273.24.15099			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614120	hybrid			2022-12-25	WOS:000074160400062
J	Schmidt, VA; Nierman, WC; Maglott, DR; Cupit, LD; Moskowitz, KA; Wainer, JA; Bahou, WF				Schmidt, VA; Nierman, WC; Maglott, DR; Cupit, LD; Moskowitz, KA; Wainer, JA; Bahou, WF			The human proteinase-activated receptor-3 (PAR-3) gene - Identification within a PAR gene cluster and characterization in vascular endothelial cells and platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN RECEPTOR; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; PROMOTER; ELEMENTS; ENVIRONMENT; EXPRESSION; MECHANISM; RESPONSES; SEQUENCES	Proteolytically activated receptors (PARs) represent an emerging subset of seven transmembrane G protein-coupled receptors that mediate cell activation events by receptor cleavage at distinct scissile bonds located within receptor amino termini. Differential genomic blotting using a yeast artificial chromosome known to contain the PAR-1 and PAR-2 genes identified the PAR-3 gene within a PAR gene cluster spanning similar to 100 kilobases at 5q13. The PAR-3 gene is relatively small (similar to 12 kilobases); and, like the PAR-1 and PAR-2 genes, it displays a two-exon structure, with the majority of the coding sequence and the proteolytic cleavage site contained within the larger second exon, Sequence analysis of the 5'-flanking region demonstrates that the promoter is TATA-less, similar to that seen with PAR-1, with the identification of nucleic acid motifs potentially involved in transcriptional gene regulation, including AP-1, GATA, and octameric sequences. PAR-3 transcripts were apparent in human vascular endothelial cells, although at considerably lower levels than those of PAR-1 and not significantly modulated by the endothelial cell stimulus tumor necrosis factor-alpha. Likewise, although PAR-3 mRNA was evident in human platelets, receptor cell surface expression was modest (similar to 10%) compared with that of PAR-1, Thus, although PAR-3 is postulated to represent a second thrombin receptor, its modest endothelial cell and platelet expression suggest that PAR-3 activation by alpha-thrombin is less relevant for physiological responses in these mature cells. Rather, given its disparately greater expression in megakaryocytes land megakaryocyte-like human erythroleukemia cells), a regulatory role in cellular development (by protease activation) could be postulated.	SUNY Stony Brook, Div Hematol, Dept Med, Stony Brook, NY 11794 USA; Amer Type Culture Collect, Dept Mol Biol, Manassas, VA 20110 USA; SUNY Stony Brook, Genet Program, Stony Brook, NY 11794 USA; Accumetr Inc, San Diego, CA 92121 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bahou, WF (corresponding author), SUNY Stony Brook, Div Hematol, Dept Med, HSC T15-040, Stony Brook, NY 11794 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bahou WF, 1996, PLATELETS, V7, P253, DOI 10.3109/09537109609023586; BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; BRASS LF, 1992, J BIOL CHEM, V267, P13795; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Hollenberg MD, 1996, TRENDS PHARMACOL SCI, V17, P3, DOI 10.1016/0165-6147(96)81562-8; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li FZ, 1996, J BIOL CHEM, V271, P26320, DOI 10.1074/jbc.271.42.26320; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MCGOWAN EB, 1986, J BIOL CHEM, V261, P739; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; Mirza H, 1996, J CLIN INVEST, V97, P1705, DOI 10.1172/JCI118597; Mirza H, 1997, BLOOD, V90, P3914, DOI 10.1182/blood.V90.10.3914; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; NORTON KJ, 1993, BLOOD, V82, P2125; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; PUSTELL J, 1986, NUCLEIC ACIDS RES, V14, P479, DOI 10.1093/nar/14.1.479; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; QUINN PG, 1993, J BIOL CHEM, V268, P16999; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Schmidt VA, 1996, J BIOL CHEM, V271, P9307, DOI 10.1074/jbc.271.16.9307; Schmidt VA, 1997, BRIT J HAEMATOL, V97, P523, DOI 10.1046/j.1365-2141.1997.922907.x; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; VILLAGARCIA M, 1994, BLOOD, V83, P668, DOI 10.1182/blood.V83.3.668.bloodjournal833668; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	37	106	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15061	15068		10.1074/jbc.273.24.15061	http://dx.doi.org/10.1074/jbc.273.24.15061			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614115	hybrid			2022-12-25	WOS:000074160400057
J	Canard, B; Sarfati, SR; Richardson, CC				Canard, B; Sarfati, SR; Richardson, CC			Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3 '-azido-3 '-deoxythymidine 5 '-monophosphate-terminated primer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND DISPLACEMENT SYNTHESIS; ZIDOVUDINE AZT; CROSS-LINKING; TYPE-1; INHIBITION; TEMPLATE; HIV; 5'-TRIPHOSPHATE; TRIPHOSPHATE; SENSITIVITY	Human immunodeficiency virus type I is resistant to 3'-azido-3'-deoxythymidine (AZT) when four amino acid substitutions (D67N, K70R, T215F, and K219Q) are present simultaneously in its reverse transcriptase. Wildtype and AZT-resistant reverse transcriptases show identical binding to a 3'-azido-3'-deoxythymidine 5'-monophosphate (AZTMP)-terminated primer/RNA template. On DNA templates, the equilibrium dissociation constant (K-D) for primer/template and AZT-resistant reverse transcriptase (RT) (K-D = 4.1 nM) is similar to that of the wild-type enzyme (K-D = 6.2 nM). However, k(off) is 4-25-fold lower for the AZT-resistant enzyme than for the wild-type enzyme, depending on the nucleotide and the template. The kinetic decay of a wild-type RT/primer/AZTMP-terminated DNA template complex is biphasic, Seventy percent of the initial complex decays with a rate constant greater than 0.05 s(-1), and 30% with a rate constant of 0.0017 s(-1). Decay of an AZT-resistant RT/ AZTMP-terminated primer/DNA template complex is monophasic, with a rate constant of 0.0018 s(-1), The Past two nucleotides at the 3' end of the AZTMP-terminated DNA primer in complex with AZT-resistant RT, but not wild-type RT, and a DNA template are protected from exonuclease digestion, suggesting that enhanced binding of the 3' end of the AZTMP-terminated DNA primer to reverse transcriptase is involved in the mechanism of AZT resistance by human immunodeficiency virus type 1.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Inst Pasteur, F-75724 Paris, France	Harvard University; Harvard Medical School; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	ccr@bcmp.med.harvard.edu		Canard, Bruno/0000-0003-4924-1991	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; BARSHOP BA, 1991, ANAL BIOCHEM, V197, P266, DOI 10.1016/0003-2697(91)90387-9; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; Caliendo AM, 1996, J VIROL, V70, P2146, DOI 10.1128/JVI.70.4.2146-2153.1996; Canard B, 1997, P NATL ACAD SCI USA, V94, P11279, DOI 10.1073/pnas.94.21.11279; CARROLL SS, 1994, BIOCHEMISTRY-US, V33, P2113, DOI 10.1021/bi00174a018; CHENG YC, 1987, J BIOL CHEM, V262, P2187; DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119; deJong MD, 1996, P NATL ACAD SCI USA, V93, P5501, DOI 10.1073/pnas.93.11.5501; Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.2063; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JAJU M, 1995, J BIOL CHEM, V270, P9740, DOI 10.1074/jbc.270.17.9740; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LACEY SF, 1992, J BIOL CHEM, V267, P15789; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LARDER B, 1992, REVERSE TRANSCRIPTAS, P205; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LARDER BA, 1995, SCIENCE, V269, P969; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MAYER AN, 1995, GENE, V153, P1, DOI 10.1016/0378-1119(94)00752-E; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; PARKER WB, 1991, J BIOL CHEM, V266, P1754; Perach M, 1997, J MOL BIOL, V268, P648, DOI 10.1006/jmbi.1997.0927; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1993, J BIOL CHEM, V268, P8743; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; STAMMERS DK, 1994, J MOL BIOL, V242, P586, DOI 10.1006/jmbi.1994.1604; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; Tachedjian G, 1996, J VIROL, V70, P7171, DOI 10.1128/JVI.70.10.7171-7181.1996; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665	38	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14596	14604		10.1074/jbc.273.23.14596	http://dx.doi.org/10.1074/jbc.273.23.14596			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603976	hybrid, Green Published			2022-12-25	WOS:000074021500078
J	Hemenway, CS; Halligan, BW; Levy, LS				Hemenway, CS; Halligan, BW; Levy, LS			The Bmi-1 oncoprotein interacts with dinG and MPh2: the role of RING finger domains	ONCOGENE			English	Article						RING finger protein; polycomb group proteins; Bmi-1 oncoprotein	MYC TRANSGENIC MICE; ZINC-FINGER; AXIAL SKELETON; POLYCOMB; PROTEIN; DROSOPHILA; TRANSFORMATION; PROTOONCOGENE; GENE; IDENTIFICATION	Experimentally-induced mutations in the C3HC4 RING finger domain of the Bmi-1 oncoprotein block its ability to induce lymphomas in mice. In this report, the role of the Bmi-1 RING finger in mediating protein-protein interactions is examined using the yeast two-hybrid system. Bmi-1 interacts directly with the RING finger protein dinG/RING1B. Heterodimerization of the two proteins requires the intact RING finger structures of both Bmi-1 and dinG. Although the RING finger domains are necessary for dimerization, they are not sufficient for this process as residues outside the C3HC4 motif are also required. Thus, binding specificity may be partly conferred by residues outside the RING motif. Both Bmi-1 and dinG interact with the Polyhomeotic protein MPh2 through binding domains apart from the RING finger. The data suggest a model whereby Bmi-1, dinG, and MPh2 form a stable heterotrimeric complex in which each protein contributes to the binding of the others.	Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA	Tulane University; Tulane University; Tulane University	Hemenway, CS (corresponding author), Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA.				NATIONAL CANCER INSTITUTE [R55CA063483] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63483] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akasaka T, 1996, DEVELOPMENT, V122, P1513; ALKEMA MJ, 1993, HUM MOL GENET, V2, P1597, DOI 10.1093/hmg/2.10.1597; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Bienstock RJ, 1996, CANCER RES, V56, P2539; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; CORMACK B, 1995, CURRENT PROTOCOLS MO; Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EPSTEIN H, 1992, BIOESSAYS, V14, P411, DOI 10.1002/bies.950140612; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; James P, 1996, GENETICS, V144, P1425; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEVY LS, 1993, ONCOGENE, V8, P1833; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MULLER J, 1995, DEVELOPMENT, V121, P2847; PEARCE JJH, 1992, DEVELOPMENT, V114, P921; Rose MD., 1990, METHODS YEAST GENETI; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; SINGH PB, 1994, J CELL SCI, V107, P2653; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	39	57	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2541	2547		10.1038/sj.onc.1202042	http://dx.doi.org/10.1038/sj.onc.1202042			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627119				2022-12-25	WOS:000073672300011
J	Kondo, Y; Kondo, S; Tanaka, Y; Haqqi, T; Barna, BP; Cowell, JK				Kondo, Y; Kondo, S; Tanaka, Y; Haqqi, T; Barna, BP; Cowell, JK			Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis	ONCOGENE			English	Article						telomerase; apoptosis; cisplatin; glioma	COMBINATION THERAPY; ANTICANCER AGENTS; GLIOMA-CELLS; P53; RESISTANCE; CANCER; CIS-DIAMMINEDICHLOROPLATINUM(II); INDUCTION; IDENTIFICATION; ACCUMULATION	Malignant glioblastomas grow very rapidly and are generally resistant to either DNA-damaging drugs or gamma-irradiation, If tumor cells could be made more susceptible to cell death with treatments, this would clearly represent a significant improvement in the success of treatment. Recently, telomerase has become a focus of interest among oncologists as a target for treating cancer cells. Telomerase elongates telomeric DNA repeats (TTAGGG)(n) and is important in protecting and replicating DNA, The vast majority of tumor cells, indeed, express telomerase activity whereas normal somatic cells, except for a few cells, do not, Since telomerase is essential for protecting DNA, we may be able to make tumors more sensitive to treatments with DNA-damaging drugs by inhibiting telomerase activity, In this study, we used cis-diamminedichloroplatinum (cisplatin)-sensitive U87-MG cells and cisplatin-resistant U251-MG of human malignant glioblastoma cell lines, U87-MG cells did not express telomerase activity, whereas telomerase was highly detected in U251-MG cells. Interestingly, inhibition of telomerase with an antisense telomerase expression vector not only decreased telomerase activity but also increased susceptibility to cisplatin-induced apoptotic cell death in U251-MG cells. These findings suggest that treatment with antisense telomerase may represent a new chemosensitisation for tumors resistant to anticancer drugs.	Cleveland Clin Fdn, Brain Tumor Neurooncol Ctr, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Brain Tumor Neurooncol Ctr, Dept Neurosurg, Cleveland, OH 44195 USA; Tokyo Metropolitan Inst Med Sci, Dept Microbiol, Tokyo 113, Japan; Metrohlth Med Ctr, Rammel Kamp Ctr Educ & Res, Cleveland, OH 44109 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Tokyo Metropolitan Institute of Medical Science; MetroHealth System	Kondo, S (corresponding author), Cleveland Clin Fdn, Brain Tumor Neurooncol Ctr, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Cowell, John/0000-0002-2079-5950				ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; DeMasters BKK, 1997, AM J CLIN PATHOL, V107, P548; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FRITSCHE M, 1993, ONCOGENE, V8, P307; GATELY DP, 1993, BRIT J CANCER, V67, P1171, DOI 10.1038/bjc.1993.221; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hiyama E, 1997, CANCER RES, V57, P326; HIYAMA E, 1995, CANCER RES, V55, P3258; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; IKEDA H, 1987, CANCER RES, V47, P231; KATO H, 1997, P JAPAN CANC ASS, V56, P701; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAWAI K, 1990, J BIOL CHEM, V265, P13137; KELLEY SL, 1989, EUR J CANCER CLIN ON, V25, P1135, DOI 10.1016/0277-5379(89)90405-7; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KONDO S, 1995, J NEUROSURG, V82, P469, DOI 10.3171/jns.1995.82.3.0469; KONDO S, 1995, CANCER RES, V55, P6166; KONDO S, 1995, BRIT J CANCER, V71, P282, DOI 10.1038/bjc.1995.57; Kondo S, 1996, ONCOGENE, V13, P1279; KONDO S, 1995, ONCOGENE, V10, P2001; LANGFORD LA, 1995, LANCET, V346, P1267, DOI 10.1016/S0140-6736(95)91865-5; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; ONODA JM, 1989, CANCER RES, V49, P2844; OZOLS RF, 1987, J CLIN ONCOL, V5, P641, DOI 10.1200/JCO.1987.5.4.641; PEREZ RP, 1990, PHARMACOL THERAPEUT, V48, P19, DOI 10.1016/0163-7258(90)90015-T; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Sallinen P, 1997, AM J PATHOL, V150, P1159; Strahl C, 1996, MOL CELL BIOL, V16, P53; TIMMERBOSSCHA H, 1989, J NATL CANCER I, V81, P1069, DOI 10.1093/jnci/81.14.1069; VAN MEIR EG, 1994, CANCER RES, V54, P649	38	147	169	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2243	2248		10.1038/sj.onc.1201754	http://dx.doi.org/10.1038/sj.onc.1201754			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619833				2022-12-25	WOS:000073298000009
J	Wu, GS; Saftig, P; Peters, C; El-Deiry, WS				Wu, GS; Saftig, P; Peters, C; El-Deiry, WS			Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity	ONCOGENE			English	Article						p53; protease; apoptosis; transcription	PROGRAMMED CELL-DEATH; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; APOPTOSIS; P53; DEFICIENT; GENE; MICE; P21; BAX	Cathepsin D (CD), the major intracellular aspartyl protease, is a mediator of IFN-gamma and TNF-alpha induced apoptosis, Using subtractive hybridization screening we isolated CD as an upregulated transcript in PA1 human ovarian cancer cells undergoing adriamycin-induced apoptosis, CD mRNA levels increased in wild-type p53-expressing PA1, ML1 leukemia and U1752 lung cancer cells but not in mutant p53-expressing cells following adriamycin exposure, Overexpression of CD inhibited growth of colon, liver, and ovarian cancer cells, CD protein expression was increased by exposure of ML1 cells to etoposide, adriamycin or gamma-radiation. Inhibition of CD protease with Pepstatin A suppressed p53-dependent apoptosis in lymphoid cells, suggesting a possible role for CD in p53-dependent cell death, CD-/- fibroblasts mere found to be more resistant to killing by adriamycin and etoposide, as compared to CD+/+ cells, Two p53 DNA-binding sites located in the CD-promoter specifically bound to p53 protein in vitro and appeared to mediate transactivation of a CD-promoter luciferase-reporter during p53-dependent apoptosis, These observations link CD protease to p53-dependent tumor suppression and chemosensitivity.	Univ Penn, Sch Med, Dept Med,Lab Mol Oncol & Cell Cycle Regulat, Genet & Canc Ctr,Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany; Uniklin Freiburg Hugstetterstra DFe55, Innere Med Abt 1, Arbeitsgrp Med Mol Biol, D-79106 Freiburg, Germany	Howard Hughes Medical Institute; University of Pennsylvania; University of Gottingen	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Dept Med,Lab Mol Oncol & Cell Cycle Regulat, Genet & Canc Ctr,Howard Hughes Med Inst, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020; Saftig, Paul/A-7966-2010	El-Deiry, Wafik/0000-0002-9577-8266; 				Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wu GS, 1996, CLIN CANCER RES, V2, P623; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	31	192	198	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2177	2183		10.1038/sj.onc.1201755	http://dx.doi.org/10.1038/sj.onc.1201755			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619826				2022-12-25	WOS:000073298000002
J	Loechel, F; Gilpin, BJ; Engvall, E; Albrechtsen, R; Wewer, UM				Loechel, F; Gilpin, BJ; Engvall, E; Albrechtsen, R; Wewer, UM			Human ADAM 12 (meltrin alpha) is an active metalloprotease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNAKE-VENOM METALLOPROTEINASES; CONSTITUTIVE SECRETORY PATHWAY; CYSTEINE SWITCH; PRECURSOR PROTEINS; GENE FAMILY; DISINTEGRIN; ACTIVATION; CELL; STROMELYSIN-1; DROSOPHILA	The ADAMs (a disintegrin and metalloprotease) are a family of multidomain proteins with structural homology to snake venom metalloproteases. We recently described the cloning and sequencing of human ADAM 12 (meltrin alpha). In this report we provide evidence that the metalloprotease domain of ADAM 12 is catalytically active. We used the trapping mechanism of alpha(2)-macroglobulin to assay for protease activity of wild-type and mutant ADAM 12 proteins produced in a COS cell transfection system. We found that ADAM 12 is synthesized as a zymogen, with the prodomain maintaining the metalloprotease in a latent form, probably by means of a cysteine switch. The zymogen could be activated chemically by alkylation with N-ethylmaleimide. Cleavage of the prodomain at a site for a furin-like endopeptidase resulted in an ADAM 12 protein with proteolytic activity. The protease activity was sensitive to inhibition by 1,10-phenanthroline and could be eliminated by mutation of the critical glutamate residue at the active site. The demonstration that the ADAM 12 metalloprotease domain is functional may have important implications for future studies that explore the role of ADAM 12 protein in development and disease.	Univ Copenhagen, Inst Mol Pathol, DK-2100 Copenhagen, Denmark; Burnham Inst, La Jolla, CA 92037 USA	University of Copenhagen; Sanford Burnham Prebys Medical Discovery Institute	Engvall, E (corresponding author), Univ Copenhagen, Inst Mol Pathol, Frederik Vs Vej 11, DK-2100 Copenhagen, Denmark.	molera@inet.uni-c.dk	; Gilpin, Brent/E-3463-2013	Albrechtsen, Reidar/0000-0003-4180-1827; Gilpin, Brent/0000-0002-8109-2271				BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; BJARNASON JB, 1994, PHARMACOL THERAPEUT, V62, P325, DOI 10.1016/0163-7258(94)90049-3; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; CHEN LC, 1993, BIOCHEMISTRY-US, V32, P10289, DOI 10.1021/bi00090a003; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; FEINMAN RD, 1994, ANN NY ACAD SCI, V737, P245, DOI 10.1111/j.1749-6632.1994.tb44316.x; Galazka G, 1996, BIOCHEMISTRY-US, V35, P11221, DOI 10.1021/bi960618e; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GRAMS F, 1993, FEBS LETT, V335, P76, DOI 10.1016/0014-5793(93)80443-X; HANSEN HB, 1995, CURR OPIN CELL BIOL, V7, P728; HITE LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P182, DOI 10.1006/abbi.1994.1026; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; JENSEN LS, 1994, ANN NY ACAD SCI, V737, P172; Jia LG, 1996, TOXICON, V34, P1269, DOI 10.1016/S0041-0101(96)00108-0; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; MILHIET PE, 1995, BIOCHEM J, V309, P683, DOI 10.1042/bj3090683; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; NAGASE H, 1994, ANN NY ACAD SCI, V732, P294, DOI 10.1111/j.1749-6632.1994.tb24744.x; Nagase H, 1996, ZINC METALLOPROTEASE, P153; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PARK AJ, 1991, J BIOL CHEM, V266, P1584; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; Shilling FM, 1997, DEV BIOL, V186, P155, DOI 10.1006/dbio.1997.8586; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STOCKER W, 1995, PROTEIN SCI, V4, P823; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WATANABE T, 1993, FEBS LETT, V320, P215, DOI 10.1016/0014-5793(93)80589-M; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	42	170	183	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16993	16997		10.1074/jbc.273.27.16993	http://dx.doi.org/10.1074/jbc.273.27.16993			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642263	hybrid			2022-12-25	WOS:000074545200053
J	Delany, AM; Canalis, E				Delany, AM; Canalis, E			Dual regulation of stromelysin-3 by fibroblast growth factor-2 in murine osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MOUSE STROMELYSIN-3; GENE-EXPRESSION; POSTTRANSCRIPTIONAL MECHANISMS; TRANSCRIPTIONAL ACTIVATION; MATRIX METALLOPROTEINASES; INTERSTITIAL COLLAGENASE; MC3T3-E1 CELLS; BONE-CELLS; DIFFERENTIATION	Osteoblasts express stromelysin-3, a matrix metalloproteinase associated with normal remodeling processes and with stromal fibroblasts surrounding many invasive carcinomas. Fibroblast growth factors (FGFs) play an important role in skeletal development, fracture repair, and osteoblast function. The osteoblastic cell line MC3T3 was used to study the regulation of stromelysin-3 by FGF-2. Acutely, FGF-2 decreased stromelysin-3 mRNA levels, whereas prolonged treatment caused an induction of stromelysin-3 mRNA. RNA stability studies and nuclear run-off assays indicated that acute treatment with FGF-2 decreased stromelysin-3 mRNA stability but did not alter gene transcription. However, the induction of stromelysin-3 after prolonged treatment with FGF-2 resulted from increased gene transcription, with no effect on RNA stability. The stimulatory effect was protein synthesis-dependent, whereas the inhibitory effect was not. This study demonstrates dual regulation of stromelysin-3 by FGF-2: acute destabilization of stromelysin-3 mRNA, followed by induction of gene transcription. This complex regulation may be important in the function of stromelysin-3 in bone and in remodeling processes, such as wound and fracture repair.	St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06105 USA; St Francis Hosp & Med Ctr, Dept Med, Hartford, CT 06105 USA; Univ Connecticut, Sch Med, Farmington, CT 06030 USA	Saint Francis Hospital & Medical Center; Saint Francis Hospital & Medical Center; University of Connecticut	Delany, AM (corresponding author), St Francis Hosp & Med Ctr, Dept Res, 114 Woodland St, Hartford, CT 06105 USA.	adelany@stfranciscare.org			NIAMS NIH HHS [AR21707] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR021707, R37AR021707] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amara FM, 1996, J BIOL CHEM, V271, P20126, DOI 10.1074/jbc.271.33.20126; ANDERSON IC, 1995, CANCER RES, V55, P4120; ANGLARD P, 1995, J BIOL CHEM, V270, P20337, DOI 10.1074/jbc.270.35.20337; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; Delany A. M., 1997, GROWTH FACTORS CYTOK; DELANY AM, 1992, J CELL BIOCHEM, V50, P400, DOI 10.1002/jcb.240500409; Delany AM, 1998, AM J PHYSIOL-CELL PH, V274, pC734, DOI 10.1152/ajpcell.1998.274.3.C734; DELANY AM, 1995, J BIOL CHEM, V270, P26607, DOI 10.1074/jbc.270.44.26607; FOWLKES JL, 1994, ENDOCRINOLOGY, V135, P2810, DOI 10.1210/en.135.6.2810; Franchimont N, 1997, J BIOL CHEM, V272, P12144, DOI 10.1074/jbc.272.18.12144; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; GREENBERG ME, 1993, CONTROL MESSENGER RN, P161; Guerin E, 1997, J BIOL CHEM, V272, P11088; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; Heise T, 1997, J BIOL CHEM, V272, P20222, DOI 10.1074/jbc.272.32.20222; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; KAWAGUCHI H, 1994, ENDOCRINOLOGY, V135, P774, DOI 10.1210/en.135.2.774; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LEFEBVRE O, 1995, DEVELOPMENT, V121, P947; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; Mari BP, 1998, J BIOL CHEM, V273, P618, DOI 10.1074/jbc.273.1.618; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MEIKLE MC, 1992, J CELL SCI, V103, P1093; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; MURPHY G, 1993, J BIOL CHEM, V268, P15435; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; NOEL A, 1995, J BIOL CHEM, V270, P22866, DOI 10.1074/jbc.270.39.22866; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; OBERBAUMER I, 1992, NUCLEIC ACIDS RES, V20, P671; OKAZAKI R, 1992, J BONE MINER RES, V7, P1149; PARTRIDGE NC, 1987, ENDOCRINOLOGY, V120, P1956, DOI 10.1210/endo-120-5-1956; PATTERTON D, 1995, DEV BIOL, V167, P252, DOI 10.1006/dbio.1995.1021; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; RIFAS L, 1994, ENDOCRINOLOGY, V134, P213, DOI 10.1210/en.134.1.213; RODAN SB, 1989, J BIOL CHEM, V264, P19934; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; Sato T, 1997, J CELL SCI, V110, P589; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Sokal R. R, 1981, BIOMETRY; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TEZUKA K, 1994, J BIOL CHEM, V269, P15006; THRAILKILL KM, 1995, ENDOCRINOLOGY, V136, P3527, DOI 10.1210/en.136.8.3527; VARGHESE S, 1995, ENDOCRINOLOGY, V136, P2156, DOI 10.1210/en.136.5.2156; VINCENTI MP, 1994, NUCLEIC ACIDS RES, V22, P4818, DOI 10.1093/nar/22.22.4818; WOLF C, 1992, J INVEST DERMATOL, V99, P870, DOI 10.1111/1523-1747.ep12614846; YAMAGUCHI TP, 1995, CURR OPIN GENET DEV, V5, P485, DOI 10.1016/0959-437X(95)90053-J; ZANDOMENI R, 1983, J MOL BIOL, V167, P561, DOI 10.1016/S0022-2836(83)80098-9	56	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16595	16600		10.1074/jbc.273.26.16595	http://dx.doi.org/10.1074/jbc.273.26.16595			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632732	hybrid			2022-12-25	WOS:000074436600103
J	Kim, TSY; Reid, DM; Molday, RS				Kim, TSY; Reid, DM; Molday, RS			Structure-function relationships and localization of the Na/Ca-K exchanger in rod photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; OUTER SEGMENTS; NA+-CA2+ EXCHANGER; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; PLASMA-MEMBRANES; BOVINE; PROTEIN; PURIFICATION; RHODOPSIN	The structural and functional properties of the bovine rod photoreceptor Na/Ca-K exchanger and its distribution in vertebrate photoreceptor cells were studied using a panel of monoclonal antibodies. Antibodies that bind to distinct epitopes along the large hydrophilic N-terminal segment of the exchanger labeled the extracellular surface of the rod outer segment plasma membrane, whereas antibodies against a large hydrophilic loop between the two membrane domains labeled the intracellular side, Enzymatic deglycosylation studies indicated that the exchanger primarily contains O-linked sialo-oligosaccharides located within the N-terminal domain. Removal of the extracellular domain with trypsin or the large intracellular domain with kallikrein did not alter the Na+- or K+-dependent Ca2+ efflux activity of the exchanger when reconstituted into lipid vesicles. Anti-exchanger antibodies were also used to visualize the distribution of the exchanger in the retina by light and electron microscopy, The exchanger was localized to the plasma membrane of rod outer segments. No labeling was observed in the disk membranes, cone photoreceptor cells, or other retinal neurons, and only faint staining was seen in the rod inner segment. These results indicate that the O-linked glycosylated rod Na/Ca-K exchanger is specifically targeted to the plasma membrane of rod photoreceptors and has a topological organization similar to that reported for the cardiac Na/Ca exchanger. The large intracellular and extracellular domains do not directly function in the transport of ions across the rod outer segment plasma membrane, but instead may play a role in protein-protein interactions that maintain the spatial organization of the exchanger in the plasma membrane or possibly regulate transport activity of the exchanger.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	molday@unixg.ubc.ca			NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY 02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAUER PJ, 1992, J PHYSIOL-LONDON, V451, P109, DOI 10.1113/jphysiol.1992.sp019156; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; COOK NJ, 1988, J BIOL CHEM, V263, P11382; CREPSO LM, 1990, NATURE, V345, P618; FRIEDEL U, 1991, BIOCHIM BIOPHYS ACTA, V1061, P247, DOI 10.1016/0005-2736(91)90290-O; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; HAASE W, 1990, J NEUROSCI, V10, P1486; HICKS D, 1986, EXP EYE RES, V42, P55, DOI 10.1016/0014-4835(86)90017-5; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; MACKENZIE D, 1982, J BIOL CHEM, V257, P7100; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; Molday RS, 1998, VISION RES, V38, P1315, DOI 10.1016/S0042-6989(97)00409-4; NICOLL DA, 1989, J BIOL CHEM, V264, P16207; NICOLL DA, 1991, AM J PHYSIOL, V260, pC1212, DOI 10.1152/ajpcell.1991.260.6.C1212; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NIGGLI E, 1991, NATURE, V349, P621, DOI 10.1038/349621a0; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; RATTO GM, 1988, J NEUROSCI, V8, P3240; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; REEVES JP, 1980, SCIENCE, V208, P1461, DOI 10.1126/science.7384788; REEVES JP, 1984, J BIOL CHEM, V259, P7733; REID DM, 1990, BIOCHEMISTRY-US, V29, P1601, DOI 10.1021/bi00458a035; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22983; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; SCHNETKAMP PPM, 1991, ANN NY ACAD SCI, V639, P10, DOI 10.1111/j.1749-6632.1991.tb17285.x; Schwarzer A, 1997, BIOCHEMISTRY-US, V36, P13667, DOI 10.1021/bi9710232; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN WD, 1990, CHANNELS CARRIERS PU, P127; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Tucker JE, 1998, INVEST OPHTH VIS SCI, V39, P435; YAU KW, 1984, NATURE, V311, P661, DOI 10.1038/311661a0	38	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16561	16567		10.1074/jbc.273.26.16561	http://dx.doi.org/10.1074/jbc.273.26.16561			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632727	hybrid			2022-12-25	WOS:000074436600098
J	Song, W; Chen, JM; Dean, WL; Redinger, RN; Prough, RA				Song, W; Chen, JM; Dean, WL; Redinger, RN; Prough, RA			Purification and characterization of hamster liver microsomal 7 alpha-hydroxycholesterol dehydrogenase - Similarity to type I 11 beta-hydroxysteroid dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE; 7-OXOCHOLESTEROL; ISOFORM; TISSUES; KIDNEY	While studying the bile acid synthetic pathway of hamsters, we discovered an NADP(+)-dependent liver microsomal 7 alpha-hydroxycholesterol dehydrogenase (7 alpha-HCD) activity that was not observed in rat liver microsomal fractions. The hamster liver microsomal 7 alpha-HCD was purified to homogeneity using 2',5'-ADP and cholic acid-agarose affinity chromatography. 7 alpha-HCD displayed a molecular weight of approximately 34,000 on SDS-polyacrylamide gel electrophoresis; it is an intrinsic membrane protein of the hamster liver endoplasmic reticulum and exists as a multimeric aggregate in pure form. Partial N-terminal amino acid sequence analysis showed that 7 alpha-HCD had high sequence similarity to human Ilp-hydroxysteroid dehydrogenase (11 beta-HSD; 24/30 amino acid identity). The K-m values for corticosterone and 7 alpha-hydroxycholesterol were 1.2 and 1.9 mu M, respectively, for purified 7a-HCD; both reactions displayed identical V-max values (approximately 170 nmol/min/mg of protein). The IC50 of carbenoxolone, a competitive inhibitor of 11 beta-HSD, was 75 nM for 7 alpha-hydroxycholesterol dehydrogenation and 210 nM for corticosterone dehydrogenation. The tissue-specific expression in hamster was as follows: adrenal greater than or equal to liver > kidney > testis >> brain > lung. Microsomal 7 alpha-HCD is uniquely expressed in hamster liver and to some extent in human liver but not in rat liver. Western blot analysis with two antibodies elicited against an N-terminal peptide of the human 11 beta-HSD and purified hamster liver 7a-HCD, respectively, suggested the presence of multiple forms of 7 alpha-HCD in hamster liver, most likely due to the existence of a family of 11 beta-HSD proteins. Since 7-oxocholesterol is a potent inhibitor of cholesterol 7 alpha-hydroxylase, alternative mechanisms for regulation of bile acid synthesis may exist in human and hamster liver due to production of this metabolite and its potential as an oxysterol.	Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40292 USA; Univ Louisville, Dept Med, Louisville, KY 40292 USA	University of Louisville; University of Louisville	Prough, RA (corresponding author), Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40292 USA.		Russell A, Prough/AAH-5907-2020	Prough, Russell/0000-0001-8901-8490	NATIONAL CANCER INSTITUTE [R01CA043839] Funding Source: NIH RePORTER; NCI NIH HHS [CA43839] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL AK, 1994, J BIOL CHEM, V269, P25959; AGARWAL AK, 1990, MOL ENDOCRINOL, V4, P1827, DOI 10.1210/mend-4-12-1827; AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; BJORKHEM I, 1986, ANAL BIOCHEM, V154, P497, DOI 10.1016/0003-2697(86)90021-7; BREUER O, 1993, EUR J BIOCHEM, V215, P705, DOI 10.1111/j.1432-1033.1993.tb18082.x; BROWN RW, 1993, ENDOCRINOLOGY, V132, P2614, DOI 10.1210/en.132.6.2614; CANTFORT JV, 1972, LIFE SCI, V11, P773; Carey M.C., 1988, LIVER BIOL PATHOBIOL, V2nd, P573; EVDOKIMOVA NI, 1967, FARMAKOLOGIIA ALKALO, P222; Gontscharow N. P., 1971, J STEROID BIOCHEM, V2, P389; GONTSCHAROW VNP, 1975, ENDOKRINOLOGIE, V64, P213; GUSTAFSSON JA, 1974, EUR J BIOCHEM, V44, P225, DOI 10.1111/j.1432-1033.1974.tb03477.x; ICHIOKA H, 1968, GIFU DAIGAKU IGAKUBU, V15, P810; KOERNER DR, 1969, BIOCHIM BIOPHYS ACTA, V176, P377, DOI 10.1016/0005-2760(69)90196-9; LABRIE F, 1994, BAILLIERE CLIN ENDOC, V8, P451, DOI 10.1016/S0950-351X(05)80261-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONDER C, 1988, Steroids, V52, P515, DOI 10.1016/0039-128X(88)90118-3; MONDER C, 1993, VITAM HORM, V47, P187, DOI 10.1016/S0083-6729(08)60447-1; PETERSON RE, 1955, J CLIN INVEST, V34, P1779, DOI 10.1172/JCI103233; REMMER H, 1967, METHOD ENZYMOL, V10, P703; RUSVAI E, 1993, J BIOL CHEM, V268, P10717; Smith, 1981, CHOLESTEROL AUTOXIDA; Song W, 1996, ARCH BIOCHEM BIOPHYS, V328, P272, DOI 10.1006/abbi.1996.0173; SONG W, 1991, BIOCHEM PHARMACOL, V41, P1439, DOI 10.1016/0006-2952(91)90559-N; STEWART PM, 1994, J CLIN ENDOCR METAB, V78, P1529, DOI 10.1210/jc.78.6.1529; STEWART PM, 1987, LANCET, V2, P821; STRANDVIK B, 1994, SCAND J CLIN LAB INV, V54, P1, DOI 10.3109/00365519409086503; YANG K, 1994, J STEROID BIOCHEM, V49, P245, DOI 10.1016/0960-0760(94)90016-7	28	36	39	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16223	16228		10.1074/jbc.273.26.16223	http://dx.doi.org/10.1074/jbc.273.26.16223			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632680	hybrid			2022-12-25	WOS:000074436600051
J	Brown, V; Small, K; Lakkis, L; Feng, Y; Gunter, C; Wilkinson, KD; Warren, ST				Brown, V; Small, K; Lakkis, L; Feng, Y; Gunter, C; Wilkinson, KD; Warren, ST			Purified recombinant Fmrp exhibits selective RNA binding as an intrinsic property of the fragile X mental retardation protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; KH DOMAINS; GENE; REGION; RIBONUCLEOPROTEIN; TRANSCRIPTION; PURIFICATION; POLYMERASE; RIBOSOMES; SEQUENCES	Fragile X syndrome is caused by the transcriptional silencing of the FIMR1 gene due to a trinucleotide repeat expansion, The encoded protein, Fmrp, has been found to be a nucleocytoplasmic RNA-binding protein containing both KH domains and RGG boxes that associates with polyribosomes as a ribonucleoprotein particle. RNA binding has previously been demonstrated with in vitro-translated Fmrp; however, it remained uncertain whether the selective RNA binding observed was an intrinsic property of Fmrp or required an associated protein(s), Here, baculovirus-expressed and affinity-purified FLAG-tagged murine Fmrp was shown to bind directly to both ribonucleotide homopolymers and human brain mRNA, FLAG-Fmrp exhibited selectivity for binding poly(G) > poly(U) much greater than poly(C) or poly(A), Moreover, purified FLAG-Fmrp bound to only a subset of brain mRNA, including the 3' untranslated regions of myelin basic protein message and its own message. Recombinant isoform 4, lacking the RGG boxes but maintaining both KH domains, was also purified and was found to only weakly interact with RNA. FLAG-purified I304N Fmrp, harboring the mutation of severe fragile X syndrome, demonstrated RNA binding,:in contrast to previous suggestions. These data demonstrate the intrinsic property of Fmrp to selectively hindi RNA and show FLAG-Fmrp as a suitable reagent for structural. characterization and identification of cognate RNA ligands.	Emory Univ, Sch Med, Howard Hughes Med Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA	Emory University; Howard Hughes Medical Institute; Emory University; Emory University; Emory University	Warren, ST (corresponding author), Emory Univ, Sch Med, Howard Hughes Med Inst, 4035 Rollins Res Ctr,1510 Clifton Rd, Atlanta, GA 30322 USA.	swarren@bimcore.emory.edu	Gunter, Chris/AHA-7271-2022	Feng, Yue/0000-0002-7905-2182; Gunter, Chris/0000-0001-9369-7537	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020521, P01HD035576] Funding Source: NIH RePORTER; NICHD NIH HHS [P01 HD35576, R37 HD20521] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Amara FM, 1996, J BIOL CHEM, V271, P20126, DOI 10.1074/jbc.271.33.20126; ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; Dejgaard K, 1996, EUR J BIOCHEM, V241, P425, DOI 10.1111/j.1432-1033.1996.00425.x; DOLGANOV GM, 1981, EUR J BIOCHEM, V114, P247, DOI 10.1111/j.1432-1033.1981.tb05143.x; Eberhart DE, 1996, COLD SPRING HARB SYM, V61, P679; Eberhart DE, 1996, HUM MOL GENET, V5, P1083, DOI 10.1093/hmg/5.8.1083; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; Khandjian EW, 1996, NAT GENET, V12, P91, DOI 10.1038/ng0196-91; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KWON YK, 1991, P NATL ACAD SCI USA, V88, P3584, DOI 10.1073/pnas.88.9.3584; MORENO CS, 1995, J IMMUNOL, V155, P4313; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; POONIAN MS, 1971, BIOCHEMISTRY-US, V10, P424, DOI 10.1021/bi00779a011; REINES D, 1989, J BIOL CHEM, V264, P10799; ROZEMA D, 1995, J AM CHEM SOC, V117, P2373, DOI 10.1021/ja00113a036; Scandurro AB, 1997, KIDNEY INT, V51, P579, DOI 10.1038/ki.1997.83; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1995, NUCLEIC ACIDS RES, V2, P1193; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; SMALL K, 1995, MENTAL RETARDATION D, V1, P245; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Tamanini F, 1996, HUM MOL GENET, V5, P809, DOI 10.1093/hmg/5.6.809; VERKERK AJMH, 1993, HUM MOL GENET, V2, P399, DOI 10.1093/hmg/2.4.399; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WAGNER AF, 1971, BIOCHEM BIOPH RES CO, V45, P184, DOI 10.1016/0006-291X(71)90067-2; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Yeakley JM, 1996, P NATL ACAD SCI USA, V93, P7582, DOI 10.1073/pnas.93.15.7582	37	138	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15521	15527		10.1074/jbc.273.25.15521	http://dx.doi.org/10.1074/jbc.273.25.15521			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624140	hybrid			2022-12-25	WOS:000074284200034
J	Gerhardt, B; Kordas, TJ; Thompson, CM; Patel, P; Vida, T				Gerhardt, B; Kordas, TJ; Thompson, CM; Patel, P; Vida, T			The vesicle transport protein Vps33p is an ATP-binding protein that localizes to the cytosol in an energy-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; ENDOSOME-LIKE COMPARTMENT; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PREVACUOLAR COMPARTMENT; MEMBRANE-FUSION; GOLGI TRANSPORT; SHUTTLE VECTORS; GENE-PRODUCT; YEAST	Molecular mechanisms of vesicle transport between the prevacuolar compartment and the vacuole in yeast or the lysosome in mammalian cells are poorly understood. To learn more about the specificity of this intercompartmental step, we have examined the subcellular localization of a SEC1 homologue, Vps33p, a protein implicated to function in transport between the prevacuolar compartment and the vacuole, Following short pulses, 80-90% of newly synthesized Vps33p cofractionated with a cytosolic enzyme marker after making permeabilized yeast cells, However, during a chase, 20-40% of Vps33p fractionated with permeabilized cell membranes in a time-dependent fashion with a half-time of similar to 40 min. Depletion of cellular ATP increased the association rate to a half-time of similar to 4 min and caused 80-90% of newly synthesized Vps33p to be associated with permeabilized cell membranes. The association of Vps35p with permeabilized cell membranes was reversible after restoring cells with glucose before permeabilization. The N-ethylmaleimide-sensitive fusion protein homologue, Sec18p, a protein with known ATP binding and hydrolysis activity, displayed the same reversible energy-dependent sedimentation characteristics as Vps33p. We determined that the photosensitive analog 8-azido-[alpha-P-32]ATP, could bind directly to Vps33p with low affinity. Interestingly, excess unlabeled ATP could enhance photoaffinity labeling of 8-azido-[alpha-P-32]ATP to Vps33p, suggesting cooperative binding, which was not observed with excess GTP. Importantly, we did not detect significant photolabeling after deleting amino acid regions in Vps33p that show similarity to ATP interaction motifs, We visualized these events in living yeast cells after fusing the jellyfish green fluorescent protein (GFP) to the C terminus of full-length Vps33p, In metabolically active cells, the fully functional Vp33p-GFP fusion protein appeared to stain throughout the cytoplasm with one or two very bright fluorescent spots near the vacuole, After depleting cellular ATP, Vps33p-GFP appeared to localize with a punctate morphology, which was also reversible upon restoring cells with glucose. Overall, these data support a model where Vps33p cycles between soluble and particulate forms in an ATP-dependent manner, which may facilitate the specificity of transport vesicle docking or targeting to the yeast lysosome/vacuole.	Univ Texas, Sch Med, Dept Integrat Biol Pharmacol & Physiol, Houston, TX 77030 USA	University of Texas System	Vida, T (corresponding author), Univ Texas, Sch Med, Dept Integrat Biol Pharmacol & Physiol, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052092] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52092] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BARBER R, 1992, SEC MESS PHOSPHOPROT, V14, P77; BRIDGER WA, 1983, CELL ATP TRANSPORT L, V5; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Clarke AR, 1996, CURR OPIN STRUC BIOL, V6, P43, DOI 10.1016/S0959-440X(96)80093-5; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Corrales FJ, 1996, P NATL ACAD SCI USA, V93, P4509, DOI 10.1073/pnas.93.9.4509; COWLES CR, 1994, J CELL SCI, V107, P3449; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Dascher C, 1996, J BIOL CHEM, V271, P15866, DOI 10.1074/jbc.271.27.15866; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GRAHAM TR, 1994, J CELL BIOL, V127, P667, DOI 10.1083/jcb.127.3.667; Halachmi N, 1996, J NEUROCHEM, V66, P889; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hosaka M, 1998, J BIOL CHEM, V273, P1425, DOI 10.1074/jbc.273.3.1425; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; Kon N, 1996, J BIOL CHEM, V271, P19983, DOI 10.1074/jbc.271.33.19983; LACHER K, 1993, ARCH BIOCHEM BIOPHYS, V302, P391, DOI 10.1006/abbi.1993.1229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Ma XL, 1996, P NATL ACAD SCI USA, V93, P12998, DOI 10.1073/pnas.93.23.12998; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; Matveeva EA, 1997, J BIOL CHEM, V272, P26413, DOI 10.1074/jbc.272.42.26413; MAURER PJ, 1981, BIOCHEMISTRY-US, V20, P6894, DOI 10.1021/bi00527a024; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; OLCOTT MC, 1994, BIOCHEMISTRY-US, V33, P11935, DOI 10.1021/bi00205a032; PALMER G, 1993, J BIOENERG BIOMEMBR, V25, P145, DOI 10.1007/BF00762856; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PEVSNER J, 1994, CURR OPIN CELL BIOL, V6, P555, DOI 10.1016/0955-0674(94)90076-0; Pevsner J, 1996, J NEUROSCI RES, V45, P89, DOI 10.1002/(SICI)1097-4547(19960715)45:2<89::AID-JNR1>3.3.CO;2-K; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; PIPER RC, 1994, EUR J CELL BIOL, V65, P305; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; Rieder SE, 1997, MOL BIOL CELL, V8, P2307, DOI 10.1091/mbc.8.11.2307; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; SALVUCCI ME, 1994, BIOCHEMISTRY-US, V33, P14879, DOI 10.1021/bi00253a027; SALVUCCI ME, 1993, J BIOL CHEM, V268, P14239; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SIKORSKI RS, 1989, GENETICS, V122, P19; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1995, FEBS LETT, V369, P80, DOI 10.1016/0014-5793(95)00594-Y; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; VIDA TA, 1993, J CELL BIOL, V121, P1245, DOI 10.1083/jcb.121.6.1245; VIDA TA, 1990, J CELL BIOL, V111, P2871, DOI 10.1083/jcb.111.6.2871; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WOLFE KH, 1994, CURR GENET, V25, P379, DOI 10.1007/BF00351493	68	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15818	15829		10.1074/jbc.273.25.15818	http://dx.doi.org/10.1074/jbc.273.25.15818			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624182	hybrid			2022-12-25	WOS:000074284200076
J	Zurovec, M; Yang, CS; Kodrik, D; Sehnal, F				Zurovec, M; Yang, CS; Kodrik, D; Sehnal, F			Identification of a novel type of silk protein and regulation of its expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBYX-MORI SILKGLAND; GALLERIA-MELLONELLA L; MESSENGER-RNA; SERICIN; FIBROIN; GLAND; SEQUENCE; GENE; HORMONES; SITES	The silk of lepidopteran insects has been studied extensively as proteins of two categories the fibroins, which are produced in the posterior section of silk glands, and the sericins, which are secreted in the middle section. We now describe a third category that is named seroins to accentuate the fact that both the sericin- and the fibroin-producing cells participate in seroin secretion. Using a probe derived from the N-terminal sequences of a 23-kDa components of Galleria mellonella silk, we isolated silk gland-specific cDNA encoding 167 amino acids, of which 17 constitute the signal peptide. The following 14 residues match the N-terminal sequences of the 23- and 22.5-kDa silk proteins, The reaction of these proteins with concanavalin A and the presence of two glycosylation sites in the seroin peptide sequence indicate that seroin is secreted in two forms that both contain a mannose-rich sugar moiety, Seroin is distinguished from other silk proteins by high proline content (34 residues or 20.26% by weight), lack of cysteines, and the presence of two kinds of short amino acid repeats, The seroin gene is expressed in both the posterior and middle silk gland sections. The expression fluctuates during development in correlation with the feeding regime and the changes in hormone titers: seroin mRNA is high in the silk glands of feeding larvae, declines at ecdysis, reaches a maximum during cocoon spinning, and thereafter rapidly drops to an undetectable level. In vivo and in vitro experiments showed that the drop is caused by ecdysteroid hormones and is prevented by juvenile hormones. N-terminal sequencing of several silk proteins of Bombyx mori revealed that the 8- and 13-kDa proteins share 5 or 6 out of 10 identified amino acids with the N terminus of Galleria seroin and obviously represent seroin homologues, The result suggests that seroin-type proteins are a general component of lepidopteran silk.	Acad Sci Czech Republ, Inst Entomol, CR-37005 Ceske Budejovice, Czech Republic; Univ S Bohemia, Fac Biol Sci, Ceske Budejovice 370, Czech Republic	Czech Academy of Sciences; Biology Centre of the Czech Academy of Sciences; Czech Academy of Sciences; University of South Bohemia Ceske Budejovice	Sehnal, F (corresponding author), Acad Sci Czech Republ, Inst Entomol, Branisovska 31, CR-37005 Ceske Budejovice, Czech Republic.	sehnal@entu.cas.cz	Kodrik, Dalibor/H-1522-2014; Zurovec, Michal/H-2562-2014; Zurovec, Michal/AAE-8185-2021	Kodrik, Dalibor/0000-0001-6109-1979; Zurovec, Michal/0000-0002-0913-166X; Zurovec, Michal/0000-0002-0913-166X				Boman HG, 1996, SCAND J IMMUNOL, V43, P475, DOI 10.1046/j.1365-3083.1996.d01-76.x; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COUBLE P, 1983, DEV BIOL, V97, P398, DOI 10.1016/0012-1606(83)90096-9; COUBLE P, 1987, DEV BIOL, V124, P431, DOI 10.1016/0012-1606(87)90496-9; CYAMA F, 1984, J BIOCHEM-TOKYO, V96, P1689; FRUDHOMME JC, 1985, COMPREHENSIVE INSECT, V10, P571; GAMO T, 1977, INSECT BIOCHEM, V7, P285, DOI 10.1016/0020-1790(77)90026-9; GRUBHOFFER L, 1990, LECTINS BIOL BIOCH C, V7, P313; GRZELAK K, 1988, INSECT BIOCHEM, V18, P223, DOI 10.1016/0020-1790(88)90086-8; Jindra M, 1996, DEV GENES EVOL, V206, P305, DOI 10.1007/s004270050057; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KIMURA K, 1985, EXPERIENTIA, V41, P1167, DOI 10.1007/BF01951711; KODRIK D, 1992, ACTA ENTOMOL BOHEMOS, V87, P332; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI DOI 10.1083/JCB.108.2.229; KULDOVA J, 1990, ACTA ENTOMOL BOHEMOS, V87, P332; LEHLE L, 1984, BIOCHIM BIOPHYS ACTA, V799, P246, DOI 10.1016/0304-4165(84)90267-8; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MICHAILLE JJ, 1986, BIOCHIMIE, V68, P1165, DOI 10.1016/S0300-9084(86)80060-8; REMBOLD H, 1987, INSECT BIOCHEM, V17, P997, DOI 10.1016/0020-1790(87)90109-0; SASAKI T, 1973, BIOCHIM BIOPHYS ACTA, V310, P91, DOI 10.1016/0005-2795(73)90011-1; SEHNAL F, 1990, INT J INSECT MORPHOL, V19, P79, DOI 10.1016/0020-7322(90)90022-H; SEHNAL F, 1981, J INSECT PHYSIOL, V27, P535, DOI 10.1016/0022-1910(81)90041-X; SEHNAL F, 1966, Z WISS ZOOL ABT A, V174, P53; SEHNAL F, 1987, SERICOLOGIA, V27, P643; SHIMURA K, 1976, J BIOCHEM-TOKYO, V80, P693, DOI 10.1093/oxfordjournals.jbchem.a131328; SINOHARA H, 1979, COMP BIOCHEM PHYS B, V63, P87, DOI 10.1016/0305-0491(79)90239-6; SUZUKI Y, 1972, J MOL BIOL, V63, P409, DOI 10.1016/0022-2836(72)90437-8; TANAKA K, 1993, J BIOCHEM-TOKYO, V114, P1; TOKUTAKE S, 1980, J BIOCHEM-TOKYO, V187, P413; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Yang CS, 1996, ARCH INSECT BIOCHEM, V32, P353, DOI 10.1002/(SICI)1520-6327(1996)32:3/4&lt;353::AID-ARCH8&gt;3.0.CO;2-; ZUROVEC M, 1995, MOL GEN GENET, V247, P1, DOI 10.1007/BF00425815; ZUROVEC M, 1992, INSECT BIOCHEM MOLEC, V22, P55, DOI 10.1016/0965-1748(92)90100-S; Zurovec M, 1998, MOL GEN GENET, V257, P264, DOI 10.1007/s004380050647	34	48	56	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15423	15428		10.1074/jbc.273.25.15423	http://dx.doi.org/10.1074/jbc.273.25.15423			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624126	hybrid			2022-12-25	WOS:000074284200020
J	Beers, MF; Lomax, CA; Russo, SJ				Beers, MF; Lomax, CA; Russo, SJ			Synthetic processing of surfactant protein C by alevolar epithelial cells - The COOH terminus of proSP-C is required for post-translational targeting and proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B SP-B; PULMONARY SURFACTANT; RAT LUNG; II CELLS; STRUCTURAL REQUIREMENTS; HYDROPHOBIC PROTEINS; IN-VITRO; PRECURSOR; IDENTIFICATION; LOCALIZATION	Surfactant protein C (SP-C) is synthesized by alveolar type II cells as a 21-kDa propeptide (proSP-C-21) which is proteolytically processed in subcellular compartments distal to the trans-Golgi network to yield a 35-residue mature form, Initial synthetic processing events for SP-C include post-translational cleavages of the COOH terminus of proSP-C-21, yielding two intermediates (16 and 6 kDa). To test the role of specific COOH-terminal domains in intracellular targeting and proteolysis of proSP-C-21, synthesis and processing of SP-C was evaluated using a lung epithelial cell line (A549) transfected with a eukaryotic expression vector containing either the full-length cDNA for rat SP-C (SP-C-wt) or one of six polymerase chain reaction (PCR)-generated COOH terminally truncated forms (Sp-C1-185, SP-C1-175, SP-C1-147, Sp-C1-120, SP-C1-72, and SP-C1-59), Using in vitro transcription/translation, each of the seven constructs produced a S-35-labeled product of appropriate length which could be immunoprecipitated by epitope specific proSP-C antisera, Immunoprecipitation of S-35-labeled A549 cell lysates from SP-C-wt transfectants demonstrated rapid synthesis of [S-35]proSP-C-21 with processing to SP-C-16 and SP-C-6 intermediates via cleavages of the COOH-terminal propeptide. Both the intermediates as well as the kinetics of processing in A549 cells were similar to that observed in rat type II cells. In contrast, constructs SP-C1-185, SP-C1-175, SP-C1-147, SP-C1-120, SP- C1-72, and SP-C1-59 were each translated but degraded without evidence of proteolytic processing. Fluorescence immunocytochemistry identified proSP-C-wt in cytoplasmic vesicles of A549 cells while all COOH-terminal deletional mutants were restricted to an endoplasmic reticulum/Golgi compartment identified by co-localization with fluorescein isothiocyanate-concanavalin A. We conclude that SP-C-wt expressed in A549 cells is directed to cytoplasmic vesicles where it is proteolytically processed in a manner similar to native type II cells and that amino acids Cys(186)-Ile(194) located at the COOH terminus of proSP-C-21 are necessary for correct intracellular targeting and subsequent cleavage events.	Univ Penn, Sch Med, Inst Environm Med, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Med, Div Pulm & Crit Care, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Beers, MF (corresponding author), Univ Penn, Sch Med, Inst Environm Med, 1 John Morgan Bldg,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	mfbeers@mail.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737, P50HL056401, K08HL002869] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-19737, HL-02869, P50-HL56401] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSBEL FM, 1987, CURRENT PROTOCOLS MO; BALLARD PL, 1995, PEDIATRICS, V96, P1046; BEER SMF, 1995, AM J PHYSIOL, V269, pL744; BEERS MF, 1992, AM J PHYSIOL, V263, pL151, DOI 10.1152/ajplung.1992.263.2.L151; Beers MF, 1996, J BIOL CHEM, V271, P14361, DOI 10.1074/jbc.271.24.14361; BEERS MF, 1994, J BIOL CHEM, V269, P20318; BEERS MF, 1992, AM J RESP CELL MOL, V7, P368, DOI 10.1165/ajrcmb/7.4.368; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Comon P., 1995, IEEE ATHOS WORKSHOP, P217; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; CURSTEDT T, 1990, P NATL ACAD SCI USA, V87, P2985, DOI 10.1073/pnas.87.8.2985; DOBBS LG, 1982, BIOCHIM BIOPHYS ACTA, V713, P118, DOI 10.1016/0005-2760(82)90174-6; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Gough NR, 1997, J CELL BIOL, V137, P1161, DOI 10.1083/jcb.137.5.1161; HAWGOOD S, 1989, AM J PHYSIOL, V257, pL13, DOI 10.1152/ajplung.1989.257.2.L13; KALINA M, 1992, AM J RESP CELL MOL, V6, P594, DOI 10.1165/ajrcmb/6.6.594; KELLER A, 1992, AM J RESP CELL MOL, V6, P601, DOI 10.1165/ajrcmb/6.6.601; KELLER A, 1991, BIOCHEM J, V277, P493, DOI 10.1042/bj2770493; KING RJ, 1982, J APPL PHYSIOL, V53, P1; Lin S, 1996, BBA-MOL CELL RES, V1312, P177, DOI 10.1016/0167-4889(95)00201-4; Lin S, 1996, J BIOL CHEM, V271, P19689, DOI 10.1074/jbc.271.33.19689; MATHIALAGAN N, 1990, BIOCHIM BIOPHYS ACTA, V1045, P121, DOI 10.1016/0005-2760(90)90140-S; OOSTERLAKENDIJKSTERHUIS MA, 1991, BIOCHEM J, V274, P115, DOI 10.1042/bj2740115; PHELPS DS, 1991, EXP LUNG RES, V17, P985, DOI 10.3109/01902149109064330; PHIZACKERLEY PJR, 1979, BIOCHEM J, V183, P731, DOI 10.1042/bj1830731; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHANNON JM, 1990, AM J RESP CELL MOL, V2, P183, DOI 10.1165/ajrcmb/2.2.183; STULTS JT, 1991, AM J PHYSIOL, V261, pL118, DOI 10.1152/ajplung.1991.261.2.L118; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VOORHOUT WF, 1993, MICROSC RES TECHNIQ, V26, P366, DOI 10.1002/jemt.1070260504; VORBROKER DK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P161, DOI 10.1016/0005-2736(92)90175-L; Vorbroker DK, 1995, AM J PHYSIOL-LUNG C, V269, pL727, DOI 10.1152/ajplung.1995.269.6.L727; ZEN K, 1994, MOL BIOL CELL A, V77	35	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15287	15293		10.1074/jbc.273.24.15287	http://dx.doi.org/10.1074/jbc.273.24.15287			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614145	hybrid			2022-12-25	WOS:000074160400087
J	Foretz, M; Carling, D; Guichard, C; Ferre, P; Foufelle, F				Foretz, M; Carling, D; Guichard, C; Ferre, P; Foufelle, F			AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE ADIPOSE-TISSUE; LIPOGENIC ENZYME; OKADAIC ACID; PRIMARY CULTURE; MESSENGER-RNA; GAMMA-SUBUNIT; BETA-SUBUNIT; INSULIN; PHOSPHORYLATION; YEAST	Although it is now clearly established that a number of genes involved in glucose and lipid metabolism are up-regulated by high glucose concentrations in both liver and adipose tissue, the signaling pathway arising from glucose to the transcriptional machinery is still poorly understood. We have analyzed the regulation of fatty acid synthase gene expression by glucose in cultured rat hepatocytes. Glucose (25 mM) induces an activation of the transcription of the fatty acid synthase gene, and this effect is markedly reduced by incubation of the cells with okadaic acid, an inhibitor of protein phosphatases 1 and 2A. A similar reduction in glucose-activated fatty acid synthase gene expression is obtained by incubation with 5-amino-imidazolecarboxamide riboside, a cell-permeable activator of the AMP-activated protein kinase. Taken together, these results indicate that the glucose-induced expression of the fatty acid synthase gene involves a phosphorylation/dephosphorylation mechanism and suggest that the AMP-activated protein kinase plays an important role in this process. This is the first evidence that implicates the AMP-activated protein kinase in the regulation of gene expression. AMP-activated protein kinase is the mammalian analog of SNF1, a kinase involved in yeast in the transcriptional regulation of genes by glucose.	Hammersmith Hosp, Royal Postgrad Med Sch, Mol Med Grp, MRC,Clin Sci Ctr, London W12 0NN, England; Ctr Biomed Cordeliers, INSERM, U465, F-75270 Paris 06, France	Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Ferre, P (corresponding author), Ctr Biomed Cordeliers, INSERM, U465, 15 Rue Ecole Med, F-75270 Paris 06, France.		FORETZ, Marc/O-7334-2017; Carling, David/F-1943-2014; Ferré, Pascal/K-1250-2013	FORETZ, Marc/0000-0001-7017-9032; Carling, David/0000-0002-2316-1830; Ferré, Pascal/0000-0003-0115-7045; FOUFELLE, Fabienne/0000-0002-0752-622X				BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Cadefau J, 1997, BIOCHEM J, V322, P745, DOI 10.1042/bj3220745; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CARLING D, 1994, J BIOL CHEM, V269, P11442; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; COUPE C, 1990, AM J PHYSIOL, V258, pE126, DOI 10.1152/ajpendo.1990.258.1.E126; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; DUGAIL I, 1992, BIOCHEM J, V281, P607, DOI 10.1042/bj2810607; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; FERRE P, 1979, BIOCHEM J, V182, P593, DOI 10.1042/bj1820593; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; FOUFELLE F, 1994, EUR J BIOCHEM, V223, P893, DOI 10.1111/j.1432-1033.1994.tb19066.x; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; GARRISON JC, 1984, J BIOL CHEM, V259, P3283; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; HARDIE DG, 1993, PROTEIN PHOSPHORYLAT, P87; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; KINLAW WB, 1986, J CLIN INVEST, V78, P1091, DOI 10.1172/JCI112665; LALLI E, 1994, J BIOL CHEM, V269, P17359; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; Mourrieras F, 1997, BIOCHEM J, V326, P345, DOI 10.1042/bj3260345; NARKEWICZ MR, 1990, BIOCHEM J, V271, P585, DOI 10.1042/bj2710585; OBRIEN RM, 1994, BIOCHEM J, V303, P737, DOI 10.1042/bj3030737; PRIPBUUS C, 1995, EUR J BIOCHEM, V230, P309, DOI 10.1111/j.1432-1033.1995.tb20564.x; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; SPENCE JT, 1980, J CELL PHYSIOL, V103, P173, DOI 10.1002/jcp.1041030202; SUDO Y, 1994, ENDOCRINOLOGY, V134, P2532, DOI 10.1210/en.134.6.2532; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; SULLIVAN JE, 1994, BIOCHEM BIOPH RES CO, V200, P1551, DOI 10.1006/bbrc.1994.1627; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; WOODS A, 1994, J BIOL CHEM, V269, P19509	44	203	208	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14767	14771		10.1074/jbc.273.24.14767	http://dx.doi.org/10.1074/jbc.273.24.14767			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614076	hybrid			2022-12-25	WOS:000074160400018
J	Jung, SM; Moroi, M				Jung, SM; Moroi, M			Platelets interact with soluble and insoluble collagens through characteristically different reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVALENT-CATIONS; GLYCOPROTEIN-VI; BLOOD-PLATELETS; FLOW CONDITIONS; ADHESION; AGGREGATION; IDENTIFICATION; PROTEIN; COMPONENTS; ACTIVATION	Platelet interaction with soluble and insoluble collagens was characterized through binding studies. In contrast to resting platelets, cells reacted with activators, TS2/16 (integrin alpha(2) beta(1)-activating antibody), thrombin, collagen-related peptide, or ADP, exhibited specific soluble collagen binding that is Mg2+-dependent, but inhibited by prostaglandin I-2, Ca2+, and Gi9 (anti-integrin alpha(2) beta(1) antibody). Each platelet has 1500-3500 soluble collagen binding sites, with a dissociation constant of 3.5-9 x 10(-8) M. This is the first study to show the specific binding of soluble collagen to platelets; our data strongly suggest that the receptor is integrin alpha(2) beta(1) after it becomes activated upon platelet activation. These results suggest that activation of platelets transforms integrin alpha(2) beta(1) to a state with higher affinity binding sites for soluble collagen. The soluble collagen-platelet interaction was compared with the platelet interaction with fibrillar collagen, which has until now not been demonstrated to bind specifically to platelets. Here, we demonstrated specific, biphasic fibrillar collagen binding. One phase is rapid and metal ion-independent, and accounts for most of the binding. The other phase is slow and Mg2+-dependent. The characteristic differences in the specific bindings of soluble and fibrous collagens demonstrate the different contributions of two different collagen receptors.	Kurume Univ, Inst Life Sci, Dept Prot Biochem, Fukuoka 8398016, Japan	Kurume University	Jung, SM (corresponding author), Kurume Univ, Inst Life Sci, Dept Prot Biochem, 2432-3 Aikawa-machi, Fukuoka 8398016, Japan.							Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Barnes MJ, 1996, BIOPOLYMERS, V40, P383, DOI 10.1002/(SICI)1097-0282(1996)40:4<383::AID-BIP4>3.0.CO;2-S; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CLEMETSON KJ, 1995, THROMB HAEMOSTASIS, V74, P111; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; GORDON JL, 1974, J CELL SCI, V16, P157; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HUBBELL JA, 1986, REV SCI INSTRUM, V57, P892, DOI 10.1063/1.1138830; Ichinohe T, 1997, J BIOL CHEM, V272, P63; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; KLUNICKI TJ, 1997, BLOOD, V89, P1939; KUNICKI TJ, 1993, BLOOD, V82, P2693; LUQUE A, 1994, FEBS LETT, V346, P278, DOI 10.1016/0014-5793(94)00490-0; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MAZUROV AV, 1988, BIOKHIMIYA, V54, P1280; MOROI M, 1992, BIOCHIM BIOPHYS ACTA, V1137, P1, DOI 10.1016/0167-4889(92)90092-P; Moroi M, 1996, BLOOD, V88, P2081, DOI 10.1182/blood.V88.6.2081.bloodjournal8862081; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; Morton LF, 1997, J BIOL CHEM, V272, P11044; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; MUGGLI R, 1980, J LAB CLIN MED, V95, P195; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; SAELMAN EUM, 1994, BLOOD, V83, P1244; SAKARIASSEN KS, 1983, J LAB CLIN MED, V102, P522; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; SUGIYAMA T, 1987, BLOOD, V69, P1712; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Yanabu M, 1997, BLOOD, V89, P1590, DOI 10.1182/blood.V89.5.1590.1590_1590_1598	34	106	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14827	14837		10.1074/jbc.273.24.14827	http://dx.doi.org/10.1074/jbc.273.24.14827			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614084	hybrid			2022-12-25	WOS:000074160400026
J	Liu, YX; Christou, H; Morita, T; Laughner, E; Semenza, GL; Kourembanas, S				Liu, YX; Christou, H; Morita, T; Laughner, E; Semenza, GL; Kourembanas, S			Carbon monoxide and nitric oxide suppress the hypoxic induction of vascular endothelial growth factor gene via the 5 ' enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PERMEABILITY FACTOR; INDUCIBLE FACTOR-1; TRANSCRIPTIONAL ACTIVATION; MICROVASCULAR PERMEABILITY; MOLECULAR MECHANISMS; ERYTHROPOIETIN GENE; FACTOR EXPRESSION; ANGIOGENESIS; TENSION	Vascular endothelial growth factor (VEGF) plays an important role in angiogenesis and blood vessel remodeling. Its expression is up-regulated in vascular smooth muscle cells by a number of conditions, including hypoxia. Hypoxia increases the transcriptional rate of VEGF via a 28-base pair enhancer located in the 5'-upstream region of the gene. The gas molecules nitric oxide (NO) and carbon monoxide (CO) are important vasodilating agents. We report here that these biological molecules can suppress the hypoxia-induced production of VEGF mRNA and protein in smooth muscle cells. In transient expression studies, both NO and CO inhibited the ability of the hypoxic enhancer we have previously identified to activate gene transcription. Furthermore, electrophoretic mobility shift assays indicated decreased binding of hypoxia-inducible factor 1 (HIF-1) to this enhancer by nuclear proteins isolated from CO-treated cells, although HIF-1 protein levels were unaffected by CO, Given that both CO and NO activate guanylyl cyclase to produce cGMP and that a cGMP analog (8-Br-cGMP) showed a similar suppressive effect on the hypoxic induction of the VEGF enhancer, we speculate that the suppression of VEGF by these two gas molecules occurs via a cyclic GMP-mediated pathway.	Harvard Univ, Sch Med, Childrens Hosp, Dept Med,Div Dev & Newborn Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Med,Div Newborn Med, Boston, MA 02115 USA; Johns Hopkins Univ, Sch Med, Ctr Med Genet, Dept Pediat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Ctr Med Genet, Dept Med, Baltimore, MD 21287 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Johns Hopkins University; Johns Hopkins University	Kourembanas, S (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Dept Med,Div Dev & Newborn Biol, 300 Longwood Ave,Enders 9, Boston, MA 02115 USA.			Christou, Helen/0000-0002-3104-4570	NHLBI NIH HHS [R01 HL55338, HL-09008] Funding Source: Medline; NIDDK NIH HHS [R01 DK39869] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009008, R01HL055338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039869] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BRUNE B, 1987, MOL PHARMACOL, V32, P497; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CONNOLLY DT, 1991, J CELL BIOCHEM, V47, P219, DOI 10.1002/jcb.240470306; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; COOK MN, 1995, CAN J PHYSIOL PHARM, V73, P515, DOI 10.1139/y95-065; CULLINANBOVE K, 1993, ENDOCRINOLOGY, V133, P829, DOI 10.1210/en.133.2.829; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fritsch EF, 1986, MOL CLONING LAB MANU, V2nd; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342; KOUREMBANAS S, 1993, J CLIN INVEST, V92, P99, DOI 10.1172/JCI116604; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; KUBES P, 1993, AM J PHYSIOL, V265, pH1909, DOI 10.1152/ajpheart.1993.265.6.H1909; KUBES P, 1992, AM J PHYSIOL, V262, pH611, DOI 10.1152/ajpheart.1992.262.2.H611; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; McQuillan Lynda P., 1994, American Journal of Physiology, V267, pH1921; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STAVRI GT, 1995, FEBS LETT, V358, P311, DOI 10.1016/0014-5793(94)01458-D; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	48	201	220	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15257	15262		10.1074/jbc.273.24.15257	http://dx.doi.org/10.1074/jbc.273.24.15257			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614141	hybrid			2022-12-25	WOS:000074160400083
J	Roztocil, T; Matter-Sadzinski, L; Gomez, M; Ballivet, M; Matter, JM				Roztocil, T; Matter-Sadzinski, L; Gomez, M; Ballivet, M; Matter, JM			Functional properties of the neuronal nicotinic acetylcholine receptor beta 3 promoter in the developing central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT GENE; TRANSCRIPTION FACTOR; EXPRESSION; SPECIFICITY; PROTEIN; CELLS	Within the chick central nervous system, expression of the beta 3 nicotinic acetylcholine receptor gene is restricted to a subset of retinal neurons, the majority of which are ganglion cells. Transient transfection in retinal neurons and in neural and non-neural cells from other regions of the chick embryo allowed the identification of the cis-regulatory domain of the beta 3 gene. Within this domain, a 75-base pair fragment located immediately upstream of the transcription start site suffices to reproduce the neuron-specific expression pattern of beta 3, This fragment encompasses an E-box and a CAAT box, both of which are shown to be key positive regulatory elements of the beta 3 promoter. Co-transfection experiments into retinal, telencephalic, and tectal neurons with plasmid reporters of beta 3 promoter activity and a number of vectors expressing different neuronal (ASH-1, NeuroM, NeuroD, CTF-4) and non-neuronal (MyoD) basic helix-loop-helix transcription factors indicate that the cis-regulatory domain of beta 3 has the remarkable property of discriminating accurately between related members of the basic helix-loop-helix protein family. The sequence located immediately 3' of the E-box participates in this selection, and the E-box acts in concert with the nearby CAAT box.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva	Matter, JM (corresponding author), Univ Geneva, Dept Biochem, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.							CAMPOSORTEGA JA, 1995, MOL NEUROBIOL, V10, P75, DOI 10.1007/BF02740668; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DAUBAS P, 1990, NEURON, V5, P49, DOI 10.1016/0896-6273(90)90032-B; Feller MB, 1996, SCIENCE, V272, P1182, DOI 10.1126/science.272.5265.1182; Forsayeth JR, 1997, J NEUROSCI, V17, P1531; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HERNANDEZ MC, 1995, J BIOL CHEM, V270, P3224, DOI 10.1074/jbc.270.7.3224; JASONI CL, 1994, DEVELOPMENT, V120, P769; KLARSFELD A, 1987, MOL CELL BIOL, V7, P951, DOI 10.1128/MCB.7.2.951; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MATTER JM, 1990, EMBO J, V9, P1021, DOI 10.1002/j.1460-2075.1990.tb08205.x; MATTER JM, 1995, J NEUROSCI, V15, P5919; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; Roztocil T, 1997, DEVELOPMENT, V124, P3263; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; TAJBAKHSH S, 1994, NEURON, V13, P813, DOI 10.1016/0896-6273(94)90248-8; TSAY HJ, 1992, NUCLEIC ACIDS RES, V20, P2624, DOI 10.1093/nar/20.10.2624-b; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WANG Y, 1988, NEURON, V1, P527, DOI 10.1016/0896-6273(88)90183-3; Yuh CH, 1996, DEVELOPMENT, V122, P1069; ZOLI M, 1995, J NEUROSCI, V15, P1912, DOI 10.1523/JNEUROSCI.15-03-01912.1995	33	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15131	15137		10.1074/jbc.273.24.15131	http://dx.doi.org/10.1074/jbc.273.24.15131			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614125	hybrid			2022-12-25	WOS:000074160400067
J	Spitz, F; De Vasconcelos, ZA; Chatelet, F; Demignon, J; Kahn, A; Mira, JC; Maire, P; Daegelen, D				Spitz, F; De Vasconcelos, ZA; Chatelet, F; Demignon, J; Kahn, A; Mira, JC; Maire, P; Daegelen, D			Proximal sequences of the aldolase A fast muscle-specific promoter direct nerve- and activity-dependent expression in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; SKELETAL-MUSCLE; GENE-EXPRESSION; A GENE; ELECTRICAL-ACTIVITY; THYROID-HORMONE; MESSENGER-RNA; CONTRACTILE ACTIVITY; MOLECULAR DIVERSITY; UPSTREAM SEQUENCES	Muscle activity is known to modulate the muscle fiber phenotype, Changes in muscle activity (normal or experimentally induced) lead to modifications of the expression status of several muscle-specific genes. However, the transcription regulatory elements involved in the adaptative response are mainly unknown. The aldolase A muscle specific promoter, pM, is expressed in adult fast twitch muscle with a preferential expression in fast glycolytic-2B fibers. Its activity is induced during postnatal muscle maturation, suggesting a role of nerve and/or muscle activity. Indeed, denervation of gastrocnemius in newborn mice prevented the activation of the promoter in this muscle, despite the nerve-independent formation of 2B fibers. Although the nerve was necessary for pM onset during development, denervating the gastrocnemius in adults had only mild effects on pM activity. By contrast, a transgene including the pM proximal regulatory sequences that are sufficient to reproduce the 2B fiber-specific expression of the endogenous promoter was shown to be highly sensitive to both neonatal and adult denervation, Transgenes containing muscle-specific pM proximal promoter elements were used to delineate the regulatory elements involved in this response to innervation and changes in the contractile activity pattern. Nerve- and activity-dependent elements could be localized in the 130-base pair-long proximal promoter region of the human aldolase A gene.	Univ Paris 05, Inst Cochin Genet Mol, INSERM, U129, F-75014 Paris, France; Univ Paris 05, Neurobiol Lab, CNRS, URA 1448, F-75006 Paris, France; Ctr Hosp Univ St Antoine, CNRS, URA 1283, F-75012 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Centre National de la Recherche Scientifique (CNRS)	Daegelen, D (corresponding author), Univ Paris 05, Inst Cochin Genet Mol, INSERM, U129, 24 Rue Fbg St Jacques, F-75014 Paris, France.	daegelen@icgm.cochin.inserm.fr	Maire, Pascal/E-6339-2016	Maire, Pascal/0000-0001-7795-0029				AUSONI S, 1990, J NEUROSCI, V10, P153; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; BLANCHETOT A, 1986, EUR J BIOCHEM, V159, P469, DOI 10.1111/j.1432-1033.1986.tb09909.x; BUONANNO A, 1993, NUCLEIC ACIDS RES, V21, P5684, DOI 10.1093/nar/21.24.5684; Buonanno A, 1996, DEV GENET, V19, P95, DOI 10.1002/(SICI)1520-6408(1996)19:2<95::AID-DVG1>3.0.CO;2-V; BUTLERBROWNE GS, 1990, ANAT EMBRYOL, V181, P513; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLBERT MC, 1988, DEV BIOL, V130, P392, DOI 10.1016/0012-1606(88)90444-7; COLBERT MC, 1992, DEV BIOL, V149, P66, DOI 10.1016/0012-1606(92)90264-H; CONCORDET JP, 1993, MOL CELL BIOL, V13, P9, DOI 10.1128/MCB.13.1.9; DiMario JX, 1997, DEV BIOL, V188, P167, DOI 10.1006/dbio.1997.8619; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; ESSER K, 1993, DEV BIOL, V159, P173, DOI 10.1006/dbio.1993.1231; Firulli AB, 1997, TRENDS GENET, V13, P364, DOI 10.1016/S0168-9525(97)01171-2; Garry DJ, 1996, DEV GENET, V19, P146, DOI 10.1002/(SICI)1520-6408(1996)19:2<146::AID-DVG6>3.0.CO;2-9; GAUTRON S, 1991, NUCLEIC ACIDS RES, V19, P767, DOI 10.1093/nar/19.4.767; Gibney G, 1995, DEV BIOL, V172, P614, DOI 10.1006/dbio.1995.8057; GOBLET C, 1995, DEV BIOL, V170, P262, DOI 10.1006/dbio.1995.1213; GUNDERSEN K, 1988, J PHYSIOL-LONDON, V398, P177, DOI 10.1113/jphysiol.1988.sp017037; GUNDERSEN K, 1993, J CELL BIOL, V123, P1535, DOI 10.1083/jcb.123.6.1535; Hamalainen N, 1996, FEBS LETT, V399, P220, DOI 10.1016/S0014-5793(96)01325-7; HORI K, 1987, ISOZYMES-CURR T BIOL, V14, P153; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; JOCKUSCH H, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P429; KYSELOVIC J, 1994, J BIOL CHEM, V269, P21770; LEEUW T, 1993, EUR J BIOCHEM, V213, P1039, DOI 10.1111/j.1432-1033.1993.tb17851.x; MAIRE P, 1987, J MOL BIOL, V197, P425, DOI 10.1016/0022-2836(87)90556-0; MERLIE JP, 1994, J BIOL CHEM, V269, P2461; MILLER JB, 1993, BIOESSAYS, V15, P191, DOI 10.1002/bies.950150308; MUKAI T, 1986, J BIOL CHEM, V261, P3347; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; Pette D, 1997, Int Rev Cytol, V170, P143, DOI 10.1016/S0074-7696(08)61622-8; REININGHAUS J, 1988, MUSCLE NERVE, V11, P433, DOI 10.1002/mus.880110504; RUSSELL SD, 1993, DEV BIOL, V157, P359, DOI 10.1006/dbio.1993.1141; RUSSELL SD, 1988, J BIOL CHEM, V263, P6370; SALMINEN M, 1995, J MOL BIOL, V253, P17, DOI 10.1006/jmbi.1995.0532; Salminen M, 1996, MOL CELL BIOL, V16, P76; SALMINEN M, 1994, MOL CELL BIOL, V14, P6797, DOI 10.1128/MCB.14.10.6797; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SCHLEEF M, 1994, NEUROMUSCULAR DISORD, V4, P205, DOI 10.1016/0960-8966(94)90021-3; SCHWEIGHOFFER F, 1986, J BIOL CHEM, V261, P271; SEEDORF U, 1986, BIOCHEM J, V239, P115, DOI 10.1042/bj2390115; SHACKELFORD JE, 1981, J BIOL CHEM, V256, P6423; Spitz F, 1998, J BIOL CHEM, V273, P561, DOI 10.1074/jbc.273.1.561; Spitz F, 1997, MOL CELL BIOL, V17, P656, DOI 10.1128/MCB.17.2.656; STAUFFER JK, 1990, J BIOL CHEM, V265, P11773; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; TANG JC, 1994, DEVELOPMENT, V120, P1799; VOYTIK SL, 1993, DEV DYNAM, V198, P214, DOI 10.1002/aja.1001980307; WEYDERT A, 1983, J BIOL CHEM, V258, P3867; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764	54	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14975	14981		10.1074/jbc.273.24.14975	http://dx.doi.org/10.1074/jbc.273.24.14975			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614104	hybrid			2022-12-25	WOS:000074160400046
J	Gigoux, V; Escrieut, C; Silvente-Poirot, S; Maigret, B; Gouilleux, L; Fehrentz, JA; Gully, D; Moroder, L; Vaysse, N; Fourmy, D				Gigoux, V; Escrieut, C; Silvente-Poirot, S; Maigret, B; Gouilleux, L; Fehrentz, JA; Gully, D; Moroder, L; Vaysse, N; Fourmy, D			Met-195 of the cholecystokinin-A receptor interacts with the sulfated tyrosine of cholecystokinin and is crucial for receptor transition to high affinity state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEAKLY POLAR INTERACTIONS; NEUROKININ-1 RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; AGONIST; BINDING; GASTRIN; LOCALIZATION; ANTAGONIST; PANCREAS	Sulfation of the tyrosine at the seventh position from the C terminus of cholecystokinin (CCK) is crucial for CCK binding to the CCK A receptor. Using three-dimensional modeling, we identified methionine 195 of the CCK-A receptor as a putative amino acid in interaction with the aromatic ring of the sulfated tyrosine of CCK. We analyzed the role played by the two partners of this interaction, The exchange of Met-195 for a leucine caused a minor decrease (2.8-fold) on the affinity of the high affinity sites for sulfated CCK-9, a strong drop (73%) of their number, and a 30-fold decrease on the affinity of the Bow and very low affinity sites for sulfated CCK-9, with no change in their number, The mutation also caused a 54-fold decrease of the potency of the receptor to induce inositol phosphates production The high affinity sites of the wild-type CCK-A receptor were highly selective (800-fold) toward sulfated versus nonsulfated CCK, whereas low and very low affinity sites were poorly selective (PO-and 18-fold). in addition, the M195L mutant bound, and responded to, sulfated CCK analogues with decreased affinities and potencies, whereas it bound and responded to nonsulfated CCK identically to the wild-type receptor. Thus, Met-195 interacts with the aromatic ring of the sulfated tyrosine to correctly position the sulfated group of CCK in the binding site of the receptor. This interaction is essential for CCK-dependent transition of the CCK-A receptor to a high affinity state. Our data should represent an important step toward the identification of the residue(s) of the receptor in interaction with the sulfate moiety of CCK and the understanding of the molecular mechanisms that govern CCK-A receptor activation.	CHU Rangueil, Inst Louis Bugnard, INSERM, U151, F-31403 Toulouse, France; Univ Nancy, Chim Theor Lab, F-54506 Vandoeuvre Les Nancy, France; Fac Pharm Montpellier, CNRS, URA 1845, F-34060 Montpellier, France; Sanofi Rech, F-31036 Toulouse, France; Max Planck Inst Biochem, D-82143 Martinsried, Germany	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Sanofi-Aventis; Sanofi France; Max Planck Society	Fourmy, D (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U151, Bat L3, F-31403 Toulouse, France.	Daniel.Fourmy@rangueil.inserm.fr	Fourmy, Daniel/AAE-3703-2019; Poirot, Sandrine/D-5448-2017; Gigoux, Véronique/AAE-6090-2020	Fourmy, Daniel/0000-0001-9910-4827; Gigoux, Véronique/0000-0003-1408-5335; Silvente-Poirot, Sandrine/0000-0003-2245-9069; Moroder, Luis/0000-0001-9570-5713				AULD DS, 1993, PROTEIN SCI, V2, P2187, DOI 10.1002/pro.5560021218; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEWEERTH A, 1993, BIOCHEM BIOPH RES CO, V194, P811, DOI 10.1006/bbrc.1993.1894; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FOURMY D, 1989, EUR J BIOCHEM, V185, P397, DOI 10.1111/j.1432-1033.1989.tb15128.x; GULLY D, 1993, EUR J PHARMACOL, V232, P13, DOI 10.1016/0014-2999(93)90722-T; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; HUANG S, 1994, J BIOL CHEM, V269, P26121; INNIS RB, 1980, P NATL ACAD SCI-BIOL, V77, P6917, DOI 10.1073/pnas.77.11.6917; ITO M, 1993, J BIOL CHEM, V268, P18300; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P256, DOI 10.1016/S0165-6147(00)89037-9; KENNEDY K, 1995, BIOCHEM BIOPH RES CO, V213, P845, DOI 10.1006/bbrc.1995.2206; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MENOZZI D, 1991, J BIOL CHEM, V266, P10385; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NANEVICZ T, 1995, J BIOL CHEM, V270, P21619, DOI 10.1074/jbc.270.37.21619; REHFELD JF, 1994, ADV CANCER RES, V63, P295, DOI 10.1016/S0065-230X(08)60403-0; SAITO A, 1981, J NEUROCHEM, V37, P483, DOI 10.1111/j.1471-4159.1981.tb00481.x; SCHAFFER K, 1997, GASTROENTEROLOGY, V112, pA1601; SERRANO L, 1991, J MOL BIOL, V218, P465, DOI 10.1016/0022-2836(91)90725-L; Silvente-Poirot S, 1996, J BIOL CHEM, V271, P14698, DOI 10.1074/jbc.271.25.14698; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V215, P513, DOI 10.1111/j.1432-1033.1993.tb18061.x; SINGH J, 1990, J MOL BIOL, V211, P595, DOI 10.1016/0022-2836(90)90268-Q; TALKAD VD, 1994, P NATL ACAD SCI USA, V91, P1868, DOI 10.1073/pnas.91.5.1868; ULRICH CD, 1993, BIOCHEM BIOPH RES CO, V193, P204, DOI 10.1006/bbrc.1993.1610; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; WILLIAMS JA, 1993, PHYSIOL REV, V73, P701, DOI 10.1152/physrev.1993.73.4.701	33	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14380	14386		10.1074/jbc.273.23.14380	http://dx.doi.org/10.1074/jbc.273.23.14380			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603948	hybrid			2022-12-25	WOS:000074021500050
J	Mitkevich, OV; Shainoff, JR; DiBello, PM; Yee, VC; Teller, DC; Smejkal, GB; Bishop, PD; Kolotushkina, IS; Fickenscher, K; Samokhin, GP				Mitkevich, OV; Shainoff, JR; DiBello, PM; Yee, VC; Teller, DC; Smejkal, GB; Bishop, PD; Kolotushkina, IS; Fickenscher, K; Samokhin, GP			Coagulation factor XIIIa undergoes a conformational change evoked by glutamine substrate - Studies on kinetics of inhibition and binding of XIIIa by a cross-reacting antifibrinogen antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; MONOCLONAL-ANTIBODY; FIBRIN; LINKING; TRANSGLUTAMINASE; ACTIVATION; SUBUNIT; RESISTANCE; PEPTIDE	Coagulation factor XIIIa, plasma transglutaminase (endo-gamma-glutamine:epsilon-lysine transferase EC 2.3.2.13) catalyzes isopeptide bond formation between glutamine and lysine residues and rapidly cross-links fibrin clots. A monoclonal antibody (5A2) directed to a fibrinogen A alpha-chain segment 529-539 was previously observed from analysis of end-stage plasma clots to block fibrin or-chain cross-linking. This prompted the study of its effect on nonfibrinogen substrates, with the prospect that 5A2 was inhibiting XIIIa directly. It inhibited XIIIa-catalyzed incorporation of the amine donor substrate dansylcadaverine into the glutamine acceptor dimethylcasein in an uncompetitive manner with respect to dimethylcasein utilization and competitively with respect to dansylcadaverine, Uncompetitive inhibition was also observed with the synthetic glutamine substrate, LGPGQSKVIG. Theoretically, uncompetitive inhibition arises from preferential interaction of the inhibitor with the enzyme-substrate complex but is also found to inhibit gamma-chain cross-linking. The conjunction of the uncompetitive and competitive modes of inhibition indicates in theory that this bireactant system involves an ordered reaction in which docking of the glutamine substrate precedes the amine exchange. The presence of substrate enhanced binding of 5A2 to XIIIa, an interaction deemed to occur through a C-terminal segment of the XIIIa A-chain (643-658, GSDMTVTVQFTNPLKE), 55% of which comprises sequences occurring in the fibrinogen epitope A alpha-(529-540) (GSESGIFTNTKE). Removal of the C-terminal domain from XIIIa abolishes the inhibitory effect of 5A2 on activity. Crystallographic studies on recombinant XIIIa place the segment 643-658 in the region of the groove through which glutamine substrates access the active site and have predicted that for catalysis, a conformational change may accompany glutamine-substrate binding. The uncompetitive inhibition and the substrate-dependent binding of 5A2 provide evidence for the conformational change.	Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Russian Cardiol Res Ctr, Inst Expt Cardiol, Moscow 121552, Russia; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Zymogenet Inc, Seattle, WA 98102 USA; Behring Diagnost GMBH, D-35001 Marburg, Germany; E Carolina Univ, Sch Med, Dept Med, Greenville, NC 27853 USA	Cleveland Clinic Foundation; National Medical Research Center of Cardiology; University of Washington; University of Washington Seattle; Zymogenet Inc.; Siemens AG; Siemens Germany; University of North Carolina; East Carolina University	Shainoff, JR (corresponding author), Cleveland Clin Fdn, Res Inst FF4, Cleveland, OH 44195 USA.	shainoj@cesmtp.ccf.org			NHLBI NIH HHS [HL-50355, HL-16361] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016361, R01HL050355] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRY ELR, 1988, J BIOL CHEM, V263, P10464; BISHOP PD, 1990, BIOCHEMISTRY-US, V29, P1861, DOI 10.1021/bi00459a028; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3774, DOI 10.1021/bi00715a024; DADABAY CY, 1989, BIOCHEM J, V264, P679, DOI 10.1042/bj2640679; DANILOV SM, 1991, LAB INVEST, V64, P118; FICKENSCHER K, 1991, THROMB HAEMOSTASIS, V65, P535; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; Folk JE., 1970, METHOD ENZYMOL, V17, P889, DOI 10.1016/0076-6879(71)17302-8; FRANCIS CW, 1988, BLOOD, V71, P1361; GREENBERG CS, 1988, BIOCHEM J, V256, P10134; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P6900, DOI 10.1021/bi00370a025; Ichinose A, 1988, Adv Exp Med Biol, V231, P15; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUROCHKIN IV, 1995, J MOL BIOL, V248, P414, DOI 10.1016/S0022-2836(95)80060-3; LAKI K, 1948, SCIENCE, V108, P280, DOI 10.1126/science.108.2802.280; LORAND L, 1962, NATURE, V194, P1148, DOI 10.1038/1941148a0; LORAND L, 1964, ARCH BIOCHEM BIOPHYS, V105, P58, DOI 10.1016/0003-9861(64)90235-8; LORAND L, 1971, ANAL BIOCHEM, V44, P2221; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mitkevich O. V., 1994, Journal of Labelled Compounds and Radiopharmaceuticals, V35, P407; Mitkevich OV, 1996, BLOOD COAGUL FIBRIN, V7, P85, DOI 10.1097/00001721-199601000-00011; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; REED GL, 1992, THROMB HAEMOSTASIS, V68, P315; SAKATA Y, 1982, J CLIN INVEST, V69, P536, DOI 10.1172/JCI110479; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; Segel I. H., 1993, ENZYME KINETICS, P329; SHAINOFF JR, 1991, J BIOL CHEM, V266, P6429; SHAINOFF JR, 1962, J EXP MED, V116, P687, DOI 10.1084/jem.116.5.687; SHAINOFF JR, 1993, AD ELECTROP, V6, P61; SHAINOFF JR, 1970, THROMB DIATH HAEMO, V39, P203; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; TAUBENFELD SM, 1995, THROMB HAEMOSTASIS, V74, P923; VALENZUELA R, 1992, AM J PATHOL, V141, P861; YEE VC, 1995, THROMB RES, V78, P389, DOI 10.1016/0049-3848(95)00072-Y; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Yee Vivien C., 1996, Seminars in Thrombosis and Hemostasis, V22, P377, DOI 10.1055/s-2007-999035	37	16	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14387	14391		10.1074/jbc.273.23.14387	http://dx.doi.org/10.1074/jbc.273.23.14387			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603949	hybrid, Green Published			2022-12-25	WOS:000074021500051
J	Mostert, MC; Verkerk, AJMH; van de Pol, M; Heighway, J; Marynen, P; Rosenberg, C; van Kessel, AG; van Echten, J; de Jong, B; Oosterhuis, JW; Looijenga, LHJ				Mostert, MC; Verkerk, AJMH; van de Pol, M; Heighway, J; Marynen, P; Rosenberg, C; van Kessel, AG; van Echten, J; de Jong, B; Oosterhuis, JW; Looijenga, LHJ			Identification of the critical region of 12p over-representation in testicular germ cell tumors of adolescents and adults	ONCOGENE			English	Article						testicular germ cell tumors; 12p; overrepresentation; critical region; candidate gene(s)	COMPARATIVE GENOMIC HYBRIDIZATION; IN-SITU HYBRIDIZATION; LACTATE-DEHYDROGENASE ISOENZYME-1; MOLECULAR CYTOGENETIC ANALYSIS; CHROMOSOMAL LOCALIZATION; CARCINOMA-INSITU; SHORT ARM; ENDOPLASMIC-RETICULUM; EUROPEAN COUNTRIES; LECTIN SUPERFAMILY	Cytogenetically, testicular germ cell tumors of adolescents and adults (TGCTs) are characterized by gain of 12p-sequences, most often through isochromosome formation (i(12p)), Fluorescence in situ hybridization (FISH) has shown that i(12p))-negative TGCTs also cryptically contain extra 12p-sequences. The consistency of 12p-over-representation in all histological subtypes of TGCTs, including their preinvasive stage, suggests that gain of one or more genes on 12p is crucial in the development of this cancer. So far, studies aimed at the identification of the relevant gene(s) were based on the 'candidate-gene approach'. No convincing evidence in favor of or against a particular gene has been reported. We combined conventional karyotyping, comparative genomic hybridization, and FISH to identify TGCTs with amplifications of restricted regions of 12p, Out of 49 primary TGCTs (23 without i(12p), 13 with and 13 unknown), eight tumors (six without i(12p) and two unknown) showed amplifications corresponding to 12p11.1-p12.1. Using bicolour-FISH, physical mapping, and semi-quantitative polymerase chain reactions, the size of the shortest region of overlap of amplification (SROA) was estimated to be between 1750-3000 kb, In addition, we mapped a number of genes in and around this region. While fourteen known genes could be excluded as candidates based on their location outside this region, we demonstrate that KRAS2, JAW1 and SOX5 genes are localized within the SROA, While KRAS2 and JAW1 map to the proximal border of the SROA, SOX5 maps centrally in the SROA, KRAS2 and JAW1 are expressed in all TGCTs, whereas one 12p amplicon-positive TGCT lacks expression of SOX5, The critical region of 12p over-represented in TGCTs is less than 8% of the total length of the short arm of chromosome 12, It will be helpful in the identification of the gene(s) involved in TGCT-development.	Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Lab Expt Pathooncol, Rotterdam, Netherlands; Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Canc Genet, Manchester M20 4BX, Lancs, England; Katholieke Univ Leuven VIB, Ctr Human Genet, Louvain, Belgium; Leiden Univ, Dept Cytochem & Cytometry, Leiden, Netherlands; Univ Nijmegen, Dept Human Genet, Nijmegen, Netherlands; Univ Groningen Hosp, Dept Med Genet, Groningen, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Flanders Institute for Biotechnology (VIB); KU Leuven; Leiden University; Leiden University - Excl LUMC; Radboud University Nijmegen; University of Groningen	Mostert, MC (corresponding author), Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Lab Expt Pathooncol, Rotterdam, Netherlands.		van Kessel, Ad Geurts/A-2810-2010; rosenberg, carla/N-4148-2015; Looijenga, Leendert/B-8145-2019	rosenberg, carla/0000-0003-3253-4448; Looijenga, Leendert/0000-0002-8146-1911; Verkerk, Annemieke JMH/0000-0002-7523-3656				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; ATKIN NB, 1983, CANCER GENET CYTOGEN, V10, P199, DOI 10.1016/0165-4608(83)90125-5; BEHRENS TW, 1994, J IMMUNOL, V153, P682; Behrens TW, 1996, J BIOL CHEM, V271, P23528, DOI 10.1074/jbc.271.38.23528; Bergstrom R, 1996, J NATL CANCER I, V88, P727, DOI 10.1093/jnci/88.11.727; Betticher DC, 1996, BRIT J CANCER, V73, P294, DOI 10.1038/bjc.1996.52; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; CARICASOLE AAD, IN PRESS ONCOGENE; CASTEDO SMMJ, 1989, CANCER RES, V49, P439; CHANG CW, 1995, EUR J IMMUNOL, V25, P2433, DOI 10.1002/eji.1830250904; COTTER FE, 1991, GENOMICS, V9, P473, DOI 10.1016/0888-7543(91)90413-9; DMITROVSKY E, 1990, ONCOGENE, V5, P543; FEUER EJ, 1995, J NATL CANCER I, V87, P405; FUCHS P, 1992, GENOMICS, V13, P219, DOI 10.1016/0888-7543(92)90226-I; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GILLIS AJM, 1994, LAB INVEST, V71, P874; Heighway J, 1996, GENOMICS, V35, P207, DOI 10.1006/geno.1996.0340; HOOVERS JMN, 1993, GENOMICS, V15, P525, DOI 10.1006/geno.1993.1104; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KAWASE E, 1994, DEV BIOL, V161, P91, DOI 10.1006/dbio.1994.1011; Korn WM, 1996, GENE CHROMOSOME CANC, V17, P78, DOI 10.1002/(SICI)1098-2264(199610)17:2<78::AID-GCC2>3.0.CO;2-Y; KRAUTER K, 1995, NATURE, V377, P321; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; Larramendy ML, 1997, AM J PATHOL, V150, P685; LI SSL, 1988, CYTOGENET CELL GENET, V48, P16, DOI 10.1159/000132578; LOOIJENGA LHJ, 1990, CYTOGENET CELL GENET, V53, P216, DOI 10.1159/000132934; LOOIJENGA LHJ, 1991, LAB INVEST, V64, P113; LOOIJENGA LHJ, 1993, LAB INVEST, V68, P211; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; MANDICH P, 1994, GENOMICS, V22, P216, DOI 10.1006/geno.1994.1366; MANIATIS T, 1982, MOL CLONING LABORATO, P280; Marynen P, 1996, CYTOGENET CELL GENET, V73, P1, DOI 10.1159/000134308; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Mitelman F, 1995, ISCN INT SYSTEM HUMA; MOLLER H, 1995, INT J CANCER, V61, P761, DOI 10.1002/ijc.2910610604; Mostert MMC, 1996, CANCER GENET CYTOGEN, V87, P95, DOI 10.1016/0165-4608(95)00233-2; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; MOSTOFI FK, 1973, SEM DIAGN PATHOL; MOUL JW, 1992, GENE CHROMOSOME CANC, V5, P109, DOI 10.1002/gcc.2870050204; MUKHERJEE AB, 1991, GENE CHROMOSOME CANC, V3, P300, DOI 10.1002/gcc.2870030409; NEWGARD CB, 1986, P NATL ACAD SCI USA, V83, P8132, DOI 10.1073/pnas.83.21.8132; NUTTALL FQ, 1994, GENOMICS, V19, P404, DOI 10.1006/geno.1994.1086; OLIE RA, 1995, GENE CHROMOSOME CANC, V12, P110, DOI 10.1002/gcc.2870120205; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; POPESCU NC, 1985, SOMAT CELL MOLEC GEN, V11, P149, DOI 10.1007/BF01534703; PUGH RCB, 1976, PATHOLOGY TESTIS, P245; PURANAM KL, 1995, GENOMICS, V26, P595, DOI 10.1016/0888-7543(95)80181-K; RAAP AK, 1995, HUM MOL GENET, V4, P529, DOI 10.1093/hmg/4.4.529; RAEYMAEKERS P, 1995, GENOMICS, V29, P170, DOI 10.1006/geno.1995.1228; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; RODRIQUEZ E, 1993, CANCER RES, V52, P2285; Sandberg AA, 1996, J UROLOGY, V155, P1531, DOI 10.1016/S0022-5347(01)66124-X; SCHNITTGER S, 1993, EUR J IMMUNOL, V23, P2711, DOI 10.1002/eji.1830231051; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; SMOLAREK TA, 1995, GENE CHROMOSOME CANC, V14, P252, DOI 10.1002/gcc.2870140403; STAMP IM, 1995, AM J SURG PATHOL, V19, P489, DOI 10.1097/00000478-199504000-00019; SUIJKERBUIJK RF, 1993, CANCER GENET CYTOGEN, V70, P85, DOI 10.1016/0165-4608(93)90173-J; SUIJKERBUIJK RF, 1994, CANCER GENET CYTOGEN, V78, P145, DOI 10.1016/0165-4608(94)90082-5; TAYLOR RE, 1986, EUR J CANCER CLIN ON, V22, P647, DOI 10.1016/0277-5379(86)90161-6; VANECHTEN J, 1995, GENE CHROMOSOME CANC, V14, P133, DOI 10.1002/gcc.2870140208; VANKESSEL AG, 1989, CANCER GENET CYTOGEN, V40, P129, DOI 10.1016/0165-4608(89)90154-4; VONEYBEN FE, 1988, J UROLOGY, V140, P986, DOI 10.1016/S0022-5347(17)41906-9; VONEYBEN FE, 1992, MOL GEN GENET, V235, P140, DOI 10.1007/BF00286191; VOS A, 1990, CANCER GENET CYTOGEN, V46, P75, DOI 10.1016/0165-4608(90)90011-X; White GRM, 1996, BRIT J CANCER, V74, P863, DOI 10.1038/bjc.1996.449; Wunderle VM, 1996, GENOMICS, V36, P354, DOI 10.1006/geno.1996.0474	72	82	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2617	2627		10.1038/sj.onc.1201787	http://dx.doi.org/10.1038/sj.onc.1201787			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632138				2022-12-25	WOS:000073698200006
J	Orend, G; Hunter, T; Ruoslahti, E				Orend, G; Hunter, T; Ruoslahti, E			Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21(Cip1) and p27(Kip1) in anchorage-independent cells	ONCOGENE			English	Article						anchorage; p21Cip1; p27Kip1; cyclin E; cdk2; cell adhesion; cell cycle	BREAST-CANCER; NEOPLASTIC TRANSFORMATION; PROGNOSTIC MARKER; CDK INHIBITOR; EXPRESSION; GROWTH; OVEREXPRESSION; TRANSCRIPTION; PROLIFERATION; INACTIVATION	Loss of attachment to an extracellular matrix substrate arrests the growth of untransformed cells in the G1 phase. This anchorage-dependent cell cycle arrest is linked to increased expression of the p21(Cip1) (p21) and p27(Kip1) (p27) cyclin-dependent kinase inhibitors. The result is a loss of cdk2-associated kinase activity, especially that of cyclin E-cdk2, The levels of p21 and p27 are also upregulated in unattached transformed cells, but cyclin E-cdk2 activity remains high, and the cells are able to grow in an anchorage-independent manner. Increased expression of cyclin E and cdk2 appears to be partially responsible for the maintenance of cyclin E-cdk2 activity in transformed cells. To explore further the regulation of cyclin E-cdk2 in transformed cells, we have analysed the subcellular distribution of cyclin-cdk complexes and their inhibitors in normal human fibroblasts, their transformed counterparts, and in various human tumor cell lines. In substrate-attached normal fibroblasts, cyclin E and cdk2 were exclusively in the nuclear fraction, associated with one another. When normal fibroblasts were detached and held in suspension, cyclin E-cdk2 complexes remained nuclear, but were now found associated with the p21 and p27 cdk inhibitors and lacked histone I-Il phosphorylating activity. In contrast, the transformed fibroblasts and tumor cells, which are anchorage-independent, had more than half of their cyclin E, cdk2, p21 and p27 in the cytoplasmic fraction, both in attached and suspended cultures. The cytoplasmic p21 and p27 were bound to cyclin E-cdk2, as well as to complexes containing cyclin A and cyclin D. The nuclear cyclin E-cdk2 complexes from the transformed cells grown in suspension contained only low levels of p21 and p27 and had histone H1 kinase activity, Thus, at least three mechanisms contribute to keeping cyclin E-cdk2 complexes active in suspended anchorage-independent cells: cyclin E and cdk2 are upregulated, as reported previously, cdk inhibitors are sequestered away from the nucleus by cytoplasmic cyclin-cdk complexes, and the binding of the inhibitors to nuclear cyclin E-cdk2 complexes is impaired.	Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Salk Institute	Ruoslahti, E (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA.		Orend, Gertraud/E-8446-2015	Orend, Gertraud/0000-0003-2522-1195	NATIONAL CANCER INSTITUTE [P01CA028896, P30CA030199, R35CA042507] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42507, CA 28896, CA 30199] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dou QP, 1996, NAT MED, V2, P254, DOI 10.1038/nm0396-254a; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KAKUNAGA T, 1978, P NATL ACAD SCI USA, V75, P1334, DOI 10.1073/pnas.75.3.1334; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARIDOR G, 1993, J CELL SCI, V106, P535; Medcalf ASC, 1996, CANCER RES, V56, P4582; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miyajima M, 1996, J NEUROSCI RES, V46, P108, DOI 10.1002/(SICI)1097-4547(19961001)46:1<108::AID-JNR13>3.0.CO;2-1; Mumberg D, 1996, ONCOGENE, V13, P2493; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; RHEINWALD JG, 1974, CELL, V2, P287, DOI 10.1016/0092-8674(74)90023-3; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Samid D., 1989, CLIN BIOTECHNOL, V1, P21; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SEWING A, 1994, J CELL SCI, V107, P581; StCroix B, 1996, NAT MED, V2, P1204; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; ZerfassThome K, 1996, ONCOGENE, V13, P2323; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	44	123	126	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2575	2583		10.1038/sj.onc.1201791	http://dx.doi.org/10.1038/sj.onc.1201791			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632134				2022-12-25	WOS:000073698200002
J	Duerr, EM; Rollbrocker, B; Hayashi, Y; Peters, N; Meyer-Puttlitz, B; Louis, DN; Schramm, J; Wiestler, OD; Parsons, R; Eng, C; von Deimling, A				Duerr, EM; Rollbrocker, B; Hayashi, Y; Peters, N; Meyer-Puttlitz, B; Louis, DN; Schramm, J; Wiestler, OD; Parsons, R; Eng, C; von Deimling, A			PTEN mutations in gliomas and glioneuronal tumors	ONCOGENE			English	Article						PTEN mutations; glioblastoma; oligodendroglioma; ganglioglioma	LHERMITTE-DUCLOS DISEASE; HUMAN GLIOBLASTOMA-MULTIFORME; MOLECULAR-GENETIC-ANALYSIS; COWDEN SYNDROME; P53 MUTATIONS; CHROMOSOME-10; HETEROZYGOSITY; AMPLIFICATION; ASTROCYTOMA; LOCI	Cytogenetic and loss of heterozygosity studies have suggested the presence of at least one tumor suppressor gene on chromosome 10 involved in the formation of high grade gliomas, Recently, the PTEN gene, also termed MMAC1 or TEP1, on chromosomal band 10q23 has been identified. Initial studies revealed mutations of PTEN in limited series of glioma cell lines and glioblastomas. In order to systematically evaluate the involvement of PTEN in gliomas, we have analysed the entire PTEN coding sequence by SSCP and direct sequencing in a series of 331 gliomas and glioneuronal tumors. PTEN mutations mere detected in 20/142 glioblastomas, 1/7 giant cell glioblastomas, 1/2 gliosarcomas, 1/30 pilocytic astrocytomas and 2/22 oligodendrogliomas, No PTEN mutations were detected in 52 astrocytomas, 37 oligoastrocytomas, three subependymal giant cell astrocytomas, four pleomorphic xanthoastrocytomas, 15 ependymomas, 16 gangliogliomas and one dysembryoplastic neuroepithelial tumor. In addition, all tumors were examined for the presence of homozygous deletions of the PTEN gene; these were detected in 7 glioblastomas that did not have PTEN mutations. Therefore, PTEN mutations occur in approximately 20% of glioblastomas but are rare in lower grade gliomas, These findings confirm that PTEN is one of the chromosome 10 tumor suppressor genes involved in the development of glioblastomas.	Univ Bonn, Ctr Med, Dept Neuropathol, D-53105 Bonn, Germany; Massachusetts Gen Hosp, CS Kubik Lab Neuropathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Mol Neurooncol Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Univ Bonn, Med Ctr, Dept Neurosurg, D-53105 Bonn, Germany; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	University of Bonn; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Bonn; Columbia University; Columbia University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	von Deimling, A (corresponding author), Univ Kliniken Bonn, Inst Neuropathol, Sigmund Freud Str 25, D-53105 Bonn, Germany.		von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X; Eng, Charis/0000-0002-3693-5145; Parsons, Ramon/0000-0002-6656-3514	NCI NIH HHS [CA57683] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057683] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albarosa R, 1996, AM J HUM GENET, V58, P1260; ALBRECHT S, 1992, CANCER-AM CANCER SOC, V70, P869, DOI 10.1002/1097-0142(19920815)70:4<869::AID-CNCR2820700424>3.0.CO;2-E; BENDER B, 1994, BIOTECHNIQUES, V16, P204; Eng C, 1997, J Genet Couns, V6, P181, DOI 10.1023/A:1025664119494; ENG C, 1994, J MED GENET, V31, P458, DOI 10.1136/jmg.31.6.458; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1992, CANCER RES, V52, P674; FULTS D, 1990, CANCER RES, V50, P5784; Hayashi Y, 1997, BRAIN PATHOL, V7, P871, DOI 10.1111/j.1750-3639.1997.tb00890.x; Hsu SC, 1996, CANCER RES, V56, P5684; JAMES CD, 1988, CANCER RES, V48, P5546; Kleihues P, 1993, HISTOLOGICAL TYPING; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LOUIS DN, 1993, J NEUROPATH EXP NEUR, V52, P507, DOI 10.1097/00005072-199309000-00009; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MeyerPuttlitz B, 1997, AM J PATHOL, V151, P853; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; OHGAKI H, 1991, CANCER RES, V51, P6202; PADBERG GW, 1991, ANN NEUROL, V29, P517, DOI 10.1002/ana.410290511; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; REIFENBERGER G, 1994, CANCER RES, V54, P4299; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; Rollbrocker B, 1996, ACTA NEUROPATHOL, V92, P70, DOI 10.1007/s004010050491; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; VONDEIMLING A, 1992, J NEUROSURG, V77, P295, DOI 10.3171/jns.1992.77.2.0295; VONDEIMLING A, 1992, CANCER RES, V52, P4277; VONDEIMLING A, 1993, BRAIN PATHOL, V3, P19; VONDEIMLING A, 1993, NEUROPATH APPL NEURO, V19, P524; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827	37	292	304	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2259	2264		10.1038/sj.onc.1201756	http://dx.doi.org/10.1038/sj.onc.1201756			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619835				2022-12-25	WOS:000073298000011
J	Sicilia, RJ; Hibbs, ML; Bello, PA; Bjorge, JD; Fujita, DJ; Stanley, IJ; Dunn, AR; Cheng, HC				Sicilia, RJ; Hibbs, ML; Bello, PA; Bjorge, JD; Fujita, DJ; Stanley, IJ; Dunn, AR; Cheng, HC			Common in vitro substrate specificity and differential Src homology 2 domain accessibility displayed by two members of the Src family of protein-tyrosine kinases, c-Src and Hck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENT MICE; MUTANT MICE; HEMATOPOIESIS; OSTEOPETROSIS; INACTIVATION; PP60(C-SRC); FYN	Hck and Src are members of the Src family of protein-tyrosine kinases that carry out distinct and overlapping functions in vivo (Lowell, C. A., Niwa, M., Soriano, P., and Varmus, H. E. (1996) Blood 87, 1780-1792), In an attempt to understand how Hck and Src can function both independently and in concert, we have compared 1) their in vitro substrate specificity and 2) the accessibility of their Src homology 2 (SH2) domain. Using several synthetic peptides, we have demonstrated that Hck and Src recognize similar structural features in the substrate peptides, suggesting that both kinases have the intrinsic ability to carry out overlapping cellular functions by phosphorylating similar cellular proteins in vivo. Using a phosphotyrosine-containing peptide that has previously been shown to bind the SH2 domain of Src family kinases with high affinity, we found that although Src could bind to the phosphopeptide, Hck showed no interaction. The inability of Hck to bind the phosphopeptide was not a result of a stable intramolecular interaction between its SH2 domain and C-terminal regulatory phosphotyrosine residue (Tyr-520), as most Hck molecules in the purified Hck preparation were not tyrosine-phosphorylated. In contrast to intact Hck, a recombinant truncation analog of Hck was able to bind the phosphopeptide with an affinity similar to that of the Src SH2 domain, suggesting that conformational constraints are imposed on intact Hck that limit accessibility of its SH2 domain to the phosphopeptide. Furthermore, the difference in SH2 domain accessibility is a potential mechanism that enables Src and Hck to perform their respective unique functions by 1) targeting them to different subcellular compartments, whereupon they phosphorylate different cellular proteins, and/or 2) facilitating direct binding to their cellular substrates.	Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Melbourne, Vic 3050, Australia; Univ Calgary, Dept Med Biochem, Calgary, AB T2N 4N1, Canada	University of Melbourne; Ludwig Institute for Cancer Research; University of Calgary	Cheng, HC (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia.	Heung-Chin_Cheng.BioChem@muwaye.unimelb.edu.au	Hibbs, Margaret L/D-7013-2011	Hibbs, Margaret L/0000-0002-3751-6751; Cheng, Heung-Chin/0000-0002-4965-7148				AEBERSOLD R, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P71; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; ALLEN G, 1981, SEQUENCING PROTEINS, P53; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; Cheng HC, 1996, BIOCHEMISTRY-US, V35, P11874, DOI 10.1021/bi9603940; CHENG HC, 1992, J BIOL CHEM, V267, P9248; COURTNEIDGE SA, 1994, PROTEIN KINASES, P212; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lowell CA, 1996, BLOOD, V87, P1780; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SOTIRELLIS N, 1995, J BIOL CHEM, V270, P29773; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARMUS HE, 1994, BLOOD, V83, P5; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	28	13	13	1	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16756	16763		10.1074/jbc.273.27.16756	http://dx.doi.org/10.1074/jbc.273.27.16756			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642231	hybrid			2022-12-25	WOS:000074545200021
J	Ulrich, AS; Otter, M; Glabe, CG; Hoekstra, D				Ulrich, AS; Otter, M; Glabe, CG; Hoekstra, D			Membrane fusion is induced by a distinct peptide sequence of the sea urchin fertilization protein bindin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM ADHESIVE PROTEIN; PHOSPHOLIPID-VESICLES; MOLECULAR MECHANISMS; ABALONE SPERMATOZOA; LIPOSOMES; DOMAIN; DESIGN	Fertilization in the sea urchin is mediated by the membrane-associated acrosomal protein bindin, which plays a key role in the adhesion and fusion between sperm and egg. We have investigated the structure/function relationship of an 18-amino acid peptide fragment "B18," which represents the minimal membrane binding motif of the protein and resembles a putative fusion peptide. The peptide was found to mimic the behavior of its parent protein bindin with respect to (a) its high affinity for lipid bilayers, (b) the ability to aggregate and fuse vesicles, (c) the binding of Zn2+ by a histidine-rich motif, (d) the tendency to self-assemble, and (e), as indicated earlier, the adhesion to cell surface polysaccharides. Fluorescence and light scattering assays were used here to monitor peptide-induced lipid mixing, leakage, and aggregation of large unilamellar sphingomyelin/cholesterol vesicles. For these activities, B18 requires the presence of Zn2+ ions, with which it forms oligomeric complexes and assumes a partially cc-helical conformation, as observed by circular dichroism. We conclude that aggregation and fusion involves a "transcomplex" between peptides on apposing vesicles that are connected by Zn2+ bridges.	Univ Jena, Inst Mol Biol, D-07745 Jena, Germany; Univ Groningen, Dept Physiol Chem, NL-9713 AV Groningen, Netherlands; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA	Friedrich Schiller University of Jena; University of Groningen; University of California System; University of California Irvine	Ulrich, AS (corresponding author), Univ Jena, Inst Mol Biol, Winzerlaer Str 10, D-07745 Jena, Germany.		Ulrich, Anne S/H-5519-2013	Ulrich, Anne S/0000-0001-5571-9483				ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; ARTS EGJM, 1993, EUR J BIOCHEM, V217, P1001, DOI 10.1111/j.1432-1033.1993.tb18331.x; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Brasseur R, 1997, TRENDS BIOCHEM SCI, V22, P167, DOI 10.1016/S0968-0004(97)01047-5; DEANGELIS PL, 1990, BIOCHIM BIOPHYS ACTA, V1037, P100, DOI 10.1016/0167-4838(90)90107-Q; DEANGELIS PL, 1988, BIOCHEMISTRY-US, V27, P8189, DOI 10.1021/bi00421a030; DEANGELIS PL, 1990, PEPTIDE RES, V3, P1; DUZGUNES N, 1993, METHOD ENZYMOL, V220, P3, DOI 10.1016/0076-6879(93)20069-F; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; GLABE C G, 1990, Technique (Philadelphia), V2, P138; GLABE CG, 1985, J CELL BIOL, V100, P794, DOI 10.1083/jcb.100.3.794; GLABE CG, 1985, J CELL BIOL, V100, P800, DOI 10.1083/jcb.100.3.800; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; HOEKSTRA D, 1990, J BIOENERG BIOMEMBR, V22, P121, DOI 10.1007/BF00762943; Hofmann Angelika, 1994, Seminars in Developmental Biology, V5, P233, DOI 10.1006/sedb.1994.1031; HONG KL, 1986, BIOCHEMISTRY-US, V25, P543, DOI 10.1021/bi00351a004; HUGHSON FM, 1995, CURR OPIN STRUC BIOL, V5, P507, DOI 10.1016/0959-440X(95)80036-0; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KENNEDY L, 1989, BIOCHEMISTRY-US, V28, P9153, DOI 10.1021/bi00449a029; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; LENNARZ WJ, 1994, SEMIN DEV BIOL, V5; LoidlStahlhofen A, 1996, EUR BIOPHYS J BIOPHY, V25, P151, DOI 10.1007/s002490050026; LOPEZ A, 1993, DEV BIOL, V156, P24, DOI 10.1006/dbio.1993.1056; MATTHEWS DJ, 1995, CURR OPIN BIOTECH, V6, P419, DOI 10.1016/0958-1669(95)80071-9; Mauk R, 1997, DEV BIOL, V184, P31, DOI 10.1006/dbio.1997.8512; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MINOR JE, 1993, MOL BIOL CELL, V4, P375, DOI 10.1091/mbc.4.4.375; MIRAGLIA SJ, 1993, BIOCHIM BIOPHYS ACTA, V1145, P191, DOI 10.1016/0005-2736(93)90288-B; MIRAGLIA SJ, 1993, THESIS U CALIFORNIA; MOESBY L, 1995, BIOCHEMISTRY-US, V34, P10319, DOI 10.1021/bi00033a001; MUGA A, 1994, BIOCHEMISTRY-US, V33, P4444, DOI 10.1021/bi00181a002; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; Niidome T, 1997, J PEPT RES, V49, P563; Pecheur EI, 1998, BIOCHEMISTRY-US, V37, P2361, DOI 10.1021/bi972697f; REGAN L, 1995, TRENDS BIOCHEM SCI, V20, P280, DOI 10.1016/S0968-0004(00)89044-1; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SLOTTE JP, 1995, BBA-BIOMEMBRANES, V1235, P419, DOI 10.1016/0005-2736(95)80031-A; Stears RL, 1997, DEV BIOL, V187, P200, DOI 10.1006/dbio.1997.8608; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; SWANSON WJ, 1995, BIOCHEMISTRY-US, V34, P14202, DOI 10.1021/bi00043a026; VACQUIER VD, 1995, DEV GROWTH DIFFER, V37, P1; VIDAL M, 1995, J BIOL CHEM, V270, P17823, DOI 10.1074/jbc.270.30.17823; WASSARMAN PM, 1995, CURR OPIN CELL BIOL, V7, P658, DOI 10.1016/0955-0674(95)80107-3	44	72	77	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16748	16755		10.1074/jbc.273.27.16748	http://dx.doi.org/10.1074/jbc.273.27.16748			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642230	hybrid			2022-12-25	WOS:000074545200020
J	Kuwana, T; Smith, JJ; Muzio, M; Dixit, V; Newmeyer, DD; Kornbluth, S				Kuwana, T; Smith, JJ; Muzio, M; Dixit, V; Newmeyer, DD; Kornbluth, S			Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-FAS ANTIBODY; BCL-2 PROTECTS; CELL-DEATH; LAMIN-A; INHIBITION; PROTEASES; REQUIREMENT; ACTIVATION; EXTRACTS; PATHWAY	Apoptosis often involves the release of cytochrome c from mitochondria, leading to caspase activation. However, in apoptosis mediated by CD95 (Fas/APO-1), caspase-8 (FLICE/MACH/Mch5) is immediately activated and, in principle, could process other caspases directly. To investigate whether caspase-8 could also act through mitochondria, we added active caspase-8 to a Xenopus cell-free system requiring these organelles. Caspase-8 rapidly promoted the apoptotic program, culminating in fragmentation of chromatin and the nuclear membrane. In extracts devoid of mitochondria, caspase-8 produced DNA degradation, but left nuclear membranes intact. Thus, mitochondria were required for complete engagement of the apoptotic machinery. In the absence of mitochondria, high concentrations of caspase-8 were required to activate downstream caspases. However, when mitochondria were present, the effects of low concentrations of caspase-8 were vastly amplified through cytochrome c-dependent caspase activation. Caspase-8 promoted cytochrome c release indirectly, by cleaving at least one cytosolic substrate. Bcl-2 blocked apoptosis only at the lowest caspase-8 concentrations, potentially explaining why CD95-induced apoptosis can often evade inhibition by Bcl-2.	La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	La Jolla Institute for Immunology; Duke University; University of Michigan System; University of Michigan	Newmeyer, DD (corresponding author), La Jolla Inst Allergy & Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Muzio, Marta/J-9360-2018	Muzio, Marta/0000-0002-7761-759X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056518] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56518, GM50284] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asoh S, 1997, BIOCHEM BIOPH RES CO, V237, P659, DOI 10.1006/bbrc.1997.7210; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHIU VK, 1995, J IMMUNOL, V154, P2023; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Farschon DM, 1997, J CELL BIOL, V137, P1117, DOI 10.1083/jcb.137.5.1117; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Lee RK, 1996, INT IMMUNOL, V8, P991, DOI 10.1093/intimm/8.7.991; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEMON SA, 1995, J IMMUNOL, V155, P4644; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Sutton VR, 1997, J IMMUNOL, V158, P5783; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang XH, 1996, CELL IMMUNOL, V173, P149, DOI 10.1006/cimm.1996.0260; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	39	323	329	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16589	16594		10.1074/jbc.273.26.16589	http://dx.doi.org/10.1074/jbc.273.26.16589			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632731	hybrid			2022-12-25	WOS:000074436600102
J	Majello, B; Napolitano, G; De Luca, P; Lania, L				Majello, B; Napolitano, G; De Luca, P; Lania, L			Recruitment of human TBP selectively activates RNA polymerase II TATA-dependent promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; INITIATOR ELEMENTS; BINDING PROTEIN; GENE ACTIVATION; MAMMALIAN-CELLS; SEQUENCE; COMPLEX; HIV-1	An increasing body of evidence suggests that eukaryotic activators stimulate polymerase II transcription by facilitating the assembly of the functional basal machinery at the promoter. Here we describe experiments that provide added support for the idea that recruitment of TATA-binding protein (TBP) is a rate-limiting step for transcription activation in mammalian cells. We found that, in human cell lines, recruitment of TBP to a promoter, as a GAL4-TBP fusion protein, can provide a substantial activation of transcription. Activation mediated by the hTBP, tethered to promoter DNA, is strictly dependent upon the presence of a functional TATA element, and it directs faithful transcription initiation. Interestingly, GAL4-hTBP activation was not observed from initiator (Inr) -dependent TATA-less promoters. These results suggest that TBP binding to DNA is not a rate-limiting step for the initial stages of TFIID recruitment to initiator-dependent TATA-less promoters. Finally, we provide evidence that synergy between GAL4-hTBP and defined transcription domains is restricted to activators, such as VP16 and Tat, which are likely to function at steps subsequent to the TFIID recruitment. These findings strengthen the idea that recruitment of TBP represents an important mechanism of activation of TATA-dependent promoters, and on the other hand, they suggest that TBP-DNA interactions are largely dispensable for specific transcription of initiator dependent TATA-less promoters.	Univ Naples Federico II, Dipartimento Genet Biol Gen & Mol, I-80134 Naples, Italy; CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Lania, L (corresponding author), Univ Naples, Dipartimento Genet Biol Gen & Mol, Via Mezzocannone 8, I-80134 Naples, Italy.		De Luca, Pasquale/AAL-5673-2021	De Luca, Pasquale/0000-0003-4289-6784; Majello, Barbara/0000-0003-2789-3585; Napolitano, Giuliana/0000-0002-1637-6016				Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; Blau J, 1996, MOL CELL BIOL, V16, P2044; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; Kaufmann J, 1996, GENE DEV, V10, P873, DOI 10.1101/gad.10.7.873; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; LILLIE JW, 1989, NATURE, V338, P38; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pengue G, 1996, P NATL ACAD SCI USA, V93, P1015, DOI 10.1073/pnas.93.3.1015; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; SHINYA E, 1994, NUCLEIC ACIDS RES, V22, P2143, DOI 10.1093/nar/22.11.2143; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; Sune C, 1997, MOL CELL BIOL, V17, P6029, DOI 10.1128/MCB.17.10.6029; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; XIAO H, 1995, MOL CELL BIOL, V15, P5757; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	57	39	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16509	16516		10.1074/jbc.273.26.16509	http://dx.doi.org/10.1074/jbc.273.26.16509			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632719	hybrid			2022-12-25	WOS:000074436600090
J	Tanemura, M; Miyagawa, S; Koyota, S; Koma, M; Matsuda, H; Tsuji, S; Shirakura, R; Taniguchi, N				Tanemura, M; Miyagawa, S; Koyota, S; Koma, M; Matsuda, H; Tsuji, S; Shirakura, R; Taniguchi, N			Reduction of the major swine xenoantigen, the alpha-galactosyl epitope by transfection of the alpha 2,3-sialyltransferase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT REGULATORY PROTEINS; DECAY-ACCELERATING FACTOR; ANTI-GAL ANTIBODY; GAL-BETA-1,3(4)GLCNAC ALPHA-2,3-SIALYLTRANSFERASE; XENOGRAFT REJECTION; MOLECULAR-CLONING; CDNA SEQUENCE; EXPRESSION; XENOTRANSPLANTATION; GLYCOPROTEIN	alpha 2,3-Sialyltransferase represents a putative enzyme that reduces the Gal alpha 1-3Gal beta 1-4GlcNAc-R (the alpha-galactosyl epitope) by intracellular competition with alpha 1,3-galactosyltransferase for a common acceptor substrate. This study demonstrates that the overexpression of the alpha 2,3-sialyltransferase gene suppresses the antigenicity of swine endothelial cells to human natural antibodies by 77% relative to control cells and by 30% relative to cells transfected with alpha 1,2-fucosyltransferase, and in addition, it reduces the complement-mediated cell lysis by 75% compared with control cells and by 22% compared with cells transfected with alpha 1,2-fucosyltransferase. The mechanism by which the alpha-galactosyl epitope was reduced was also studied. Suppression of alpha 1,3-galactosyltransferase activity by 30-63% was observed in the transfectants with alpha 2,3-sialyltransferase, and mRNA expression of the alpha 1,3-galactosyltransferase gene was reduced as well. The data suggest that the alpha 2,3-sialyltransferase effectively reduced the cy-galactosyl epitope as well as or better than the alpha 1,2-fucosyltransferase did and that the reduction of the alpha-galactosyl epitope is due not only to substrate competition but also to an overall reduction of endogenous alpha 1,3-galactosyltransferase enzyme activity.	Osaka Univ, Sch Med, Biomed Res Ctr, Div Organ Transplantat, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Biochem, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Surg 1, Osaka 5650871, Japan; Inst Phys & Chem Res, Frontier Res Program, Wako, Saitama 3510100, Japan	Osaka University; Osaka University; Osaka University; RIKEN	Miyagawa, S (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Div Organ Transplantat, 2-2 Yamadaoka, Osaka 5650871, Japan.	miyagawa@orgtrp.med.osaka-u.ac.jp	Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				AUCHINCLOSS H, 1988, TRANSPLANTATION, V46, P1, DOI 10.1097/00007890-198807000-00001; CALNE RY, 1970, TRANSPL P, V2, P550; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GALILI U, 1987, P NATL ACAD SCI USA, V84, P1369, DOI 10.1073/pnas.84.5.1369; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; Hamamoto T, 1993, Bioorg Med Chem, V1, P141, DOI 10.1016/S0968-0896(00)82111-2; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; Hosenpud JD, 1997, J HEART LUNG TRANSPL, V16, P691; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; Kono M, 1997, GLYCOBIOLOGY, V7, P469, DOI 10.1093/glycob/7.4.469; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORZENIEWSKI C, 1983, J IMMUNOL METHODS, V64, P313, DOI 10.1016/0022-1759(83)90438-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LUBLIN DM, 1991, J EXP MED, V174, P35, DOI 10.1084/jem.174.1.35; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; Mikata S, 1998, TRANSPLANTATION, V65, P363, DOI 10.1097/00007890-199802150-00011; MIYAGAWA S, 1994, TRANSPLANTATION, V58, P834, DOI 10.1097/00007890-199410150-00015; MIYAGAWA S, 1988, TRANSPLANTATION, V46, P825, DOI 10.1097/00007890-198812000-00007; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; NICHOLSONWELLER A, 1982, J IMMUNOL, V129, P184; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1988, ANAL BIOCHEM, V170, P349, DOI 10.1016/0003-2697(88)90641-0; NISHIURA T, 1990, CANCER RES, V50, P5345; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PLATT JL, 1991, TRANSPLANTATION, V52, P937, DOI 10.1097/00007890-199112000-00001; ROSENGARD AM, 1995, TRANSPLANTATION, V59, P1325, DOI 10.1097/00007890-199505150-00018; Sambrook J, 1988, MOL CLONING LAB MANU; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SANDRIN MS, 1994, IMMUNOL REV, V141, P169, DOI 10.1111/j.1600-065X.1994.tb00877.x; SASAKI K, 1993, J BIOL CHEM, V268, P22782; Sepp A, 1997, J BIOL CHEM, V272, P23104, DOI 10.1074/jbc.272.37.23104; SEYA T, 1986, J EXP MED, V163, P837, DOI 10.1084/jem.163.4.837; Sharma A, 1996, P NATL ACAD SCI USA, V93, P7190, DOI 10.1073/pnas.93.14.7190; STRAHAN KM, 1995, IMMUNOGENETICS, V41, P101, DOI 10.1007/BF00182319; SUIGITA Y, 1988, J BIOCH, V104, P633; Tanemura M, 1997, BIOCHEM BIOPH RES CO, V235, P359, DOI 10.1006/bbrc.1997.6784; Taniguchi N, 1996, GLYCOBIOLOGY, V6, P691, DOI 10.1093/glycob/6.7.691; Tearle RG, 1996, TRANSPLANTATION, V61, P13, DOI 10.1097/00007890-199601150-00004; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; Waterworth PD, 1997, TRANSPL P, V29, P899, DOI 10.1016/S0041-1345(96)00224-2; WEN DX, 1992, J BIOL CHEM, V267, P21011; WESTON BW, 1992, J BIOL CHEM, V267, P4152; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	52	48	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16421	16425		10.1074/jbc.273.26.16421	http://dx.doi.org/10.1074/jbc.273.26.16421			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632707	hybrid			2022-12-25	WOS:000074436600078
J	Tarasova, NI; Stauber, RH; Michejda, CJ				Tarasova, NI; Stauber, RH; Michejda, CJ			Spontaneous and ligand-induced trafficking of CXC-chemokine receptor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE CHEMOATTRACTANT; RETROVIRAL VECTORS; HIV-1 ENTRY; INFECTION; SDF-1; 7-TRANSMEMBRANE; INTERNALIZATION; LESTR/FUSIN; CLONING; BLOCKS	A chimeric protein consisting of CXC-chemokine receptor 4 (CXCR4) and the green fluorescent protein (GFP) was used for studying receptor localization and trafficking in real time in stably transduced HeLa, U-937, GEM, and NIH/3T3 cells. CXCR4-GFP was fully active as a co-receptor in mediating human immunodeficiency virus (HIV) entry. Both CXCR4 and CXCR4-GFP were found to undergo significant spontaneous endocytosis, Only 51.5 +/- 7.8% of receptor molecules were found on the plasma membrane in CD4-positive cells, 43.9 +/- 8.5% were found in CD4-negative HeLa cells, 75.6 +/- 9.7% were found in U-937 cells, 72.5 +/- 7.9 were found in CEM cells, and almost none were found in in NIH/3T3 cells. Stromal cell-derived factor-1 alpha induced rapid endocytosis of cell surface receptor molecules. A significant part of CXCR4 was targeted to lysosomes upon binding of the ligands, and recycling of internalized CXCR4 was not efficient. Only about 30% of receptor molecules recycled back to the cell surface in HeLa cells, 5% recycled in U937, and 10% recycled in CEM cells, suggesting that the protective effect of chemokines against HIV infection can be attributed not only to competition for binding but also to depletion of the co-receptor molecules from the cell surface. Envelope glycoprotein gp120 of syncytia-inducing/lymphocyte tropic HIV-1 strains induced rapid internalization of CXCR4 in both CD4-negative and CD4-positive cells, suggesting that gp120 is a high affinity ligand of CXCR4.	NCI, Mol Aspects Drug Design Sect, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Inst Virol, D-91054 Erlangen, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Erlangen Nuremberg	Tarasova, NI (corresponding author), NCI, Mol Aspects Drug Design Sect, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, POB B, Frederick, MD 21702 USA.			Tarasova, Nadya/0000-0002-4949-0069; Stauber, Roland/0000-0002-1341-4523				Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Bandres JC, 1998, J VIROL, V72, P2500, DOI 10.1128/JVI.72.3.2500-2504.1998; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BERGER EA, 1997, AIDS, V11, P3; Bieniasz P. D., 1998, FRONT BIOSCI, V3, P44; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Bohm SK, 1997, BIOCHEM J, V322, P1; CONNOR RI, 1995, VIROLOGY, V206, P936; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Stauber RH, 1998, BIOTECHNIQUES, V24, P462, DOI 10.2144/98243rr01; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; YEE JK, 1994, METHOD CELL BIOL, V43, P99	26	147	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15883	15886		10.1074/jbc.273.26.15883	http://dx.doi.org/10.1074/jbc.273.26.15883			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632631	hybrid			2022-12-25	WOS:000074436600002
J	Uchida, K; Kanematsu, M; Morimitsu, Y; Osawa, T; Noguchi, N; Niki, E				Uchida, K; Kanematsu, M; Morimitsu, Y; Osawa, T; Noguchi, N; Niki, E			Acrolein is a product of lipid peroxidation reaction - Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCED MACROPHAGE DEGRADATION; SMOOTH-MUSCLE CELLS; ATHEROSCLEROTIC LESIONS; OXIDATIVE MODIFICATION; ENDOTHELIAL-CELLS; MYELOPEROXIDASE; ALDEHYDES; CATALYST; ADDUCTS; LDL	Lipoprotein peroxidation, especially the modification of apolipoprotein B-100, has been implicated to play an important role in the pathogenesis of atherosclerosis. However, there have been few detailed insights into the chemical mechanism of derivatization of apolipoproteins during oxidation, In the present study, we provide evidence that the formation of the toxic pollutant acrolein (CH2=CH-CHO) and its conjugate with lysine residues is involved in the oxidative modification of human low density lipoprotein (LDL), Upon incubation with LDL, acrolein preferentially reacted with lysine residues. To determine the structure of acrolein-lysine adduct in protein, the reaction of acrolein with a lysine derivative was carried out. Employing N-alpha-acetyllysine, we detected a single product, which was identified to be a novel acrolein-lysine adduct, N-alpha-acetyl-N-epsilon-(3-formyl-3,4-dehydropiperidino)lysine. The acid hydrolysis of the adduct led to the derivative that was detectable with amino acid analysis. It was revealed that, upon in vitro incubation of LDL with acrolein, the lysine residues that had disappeared were partially recovered by N-epsilon-(3-formyl-3,4-dehydropiperidino)lysine. In addition, we found that the same derivative was detected in the oxidatively modified LDL with Cu2+ and that the adduct formation was correlated with LDL peroxidation assessed by the consumption of alpha-tocopherol and cholesteryl ester and the concomitant formation of cholesteryl ester hydroperoxide. Enzyme-linked immunosorbent assay that measures free acrolein revealed that a considerable amount of acrolein was released from the Cu2+-oxidized LDL. Furthermore, metal-catalyzed oxidation of arachidonate was associated with the formation of acrolein, indicating that polyunsaturated fatty acids including arachidonate represent potential sources of acrolein generated during the peroxidation of LDL. These results indicate that acrolein is not just a pollutant but also a lipid peroxidation product that could be ubiquitously generated in biological systems.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 153, Japan	Nagoya University; University of Tokyo	Niki, E (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.	uchidak@nuagr1.agr.nagoya-u.ac.jp		Uchida, Koji/0000-0003-3894-5299				Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; GAN JC, 1987, RES COMMUN CHEM PATH, V55, P419; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HOBERMAN HD, 1988, J BIOCHEM TOXICOL, V3, P105, DOI 10.1002/jbt.2570030205; IZARD C, 1978, Mutation Research, V47, P115, DOI 10.1016/0165-1110(78)90016-7; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1180, P73, DOI 10.1016/0925-4439(92)90029-M; JOHNSTONE RAW, 1959, CHEM REV, V59, P885, DOI 10.1021/cr50029a004; KENSLER CJ, 1963, NEW ENGL J MED, V269, P1161, DOI 10.1056/NEJM196311282692202; LENZ ML, 1990, J LIPID RES, V31, P1043; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; Noguchi N, 1996, ATHEROSCLEROSIS, V123, P227, DOI 10.1016/0021-9150(96)05811-X; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; POCKER Y, 1988, J BIOL CHEM, V263, P6169; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RAMOS P, 1995, J LIPID RES, V36, P2113; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; UCHIDA K, 1995, BIOCHEM BIOPH RES CO, V212, P1068, DOI 10.1006/bbrc.1995.2078; Uchida K, 1997, ARCH BIOCHEM BIOPHYS, V346, P45, DOI 10.1006/abbi.1997.0266; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; Uchida K, 1995, ARCH BIOCHEM BIOPHYS, V324, P241, DOI 10.1006/abbi.1995.0036; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	34	442	455	1	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16058	16066		10.1074/jbc.273.26.16058	http://dx.doi.org/10.1074/jbc.273.26.16058			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632657	hybrid			2022-12-25	WOS:000074436600028
J	Wilk, S; Wilk, E; Magnusson, RP				Wilk, S; Wilk, E; Magnusson, RP			Purification, characterization, and cloning of a cytosolic aspartyl aminopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST AMINOPEPTIDASE; BLEOMYCIN HYDROLASE; MOLECULAR-CLONING; BP-1/6C3 ANTIGEN; RAT; BRAIN; INHIBITORS; DNA; LOCALIZATION; METABOLISM	An aminopeptidase with a preference for N-terminal aspartyl and glutamyl residues but distinct from glutamyl aminopeptidase (EC 3.4.11.7) was purified to near homogeneity from rabbit brain cytosol. Its properties were similar to an enzyme described previously (Kelly, J. A, Neidle, E, L., and Neidle, A. (1983) J. Neurochem. 40, 1727-1734). Aspartyl aminopeptidase had barely detectable activity toward simple aminoacyl-naphthylamide substrates. Its activity was determined with the substrate Asp-Ala-Pro-naphthylamide in the presence of excess dipeptidyl-peptidase IV (EC 3.4.14,5). The native enzyme has a molecular mass of 440 kDa and migrates as a single band of 55 kDa after SDS-polyacrylamide gel electrophoresis. The sequences of three tryptic peptides were used to screen the GenBank(TM) data base of expressed sequence tags. Human and mouse clones described as "similar to a yeast vacuolar aminopeptidase" and containing full-length cDNAs were identified and sequenced. The human cDNA was expressed in Escherichia coli. The amino acid sequence has significant homology to yeast aminopeptidase I, placing it as the first identified mammalian member of the M18 family of metalloproteinases. Homologous sequences in Caenorhabditis elegans and in prokaryotes revealed three conserved histidines, three conserved glutamates and five conserved aspartates. Aspartyl aminopeptidase is found at relatively high levels in all mammalian tissues examined and is likely to play an important role in intracellular protein and peptide metabolism.	CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Wilk, S (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017392] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-17392] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adachi H, 1997, EUR J BIOCHEM, V245, P283, DOI 10.1111/j.1432-1033.1997.t01-1-00283.x; CADEL S, 1995, MOL CELL ENDOCRINOL, V110, P149, DOI 10.1016/0303-7207(95)03529-G; CHANG YH, 1989, J BIOL CHEM, V264, P6979; CHEUNG HS, 1971, BIOCHIM BIOPHYS ACTA, V242, P190, DOI 10.1016/0005-2744(71)90098-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; FRIEDMAN TC, 1985, BIOCHEM BIOPH RES CO, V132, P787, DOI 10.1016/0006-291X(85)91201-X; GLENNER GG, 1962, NATURE, V194, P867, DOI 10.1038/194867a0; GLENNER GG, 1961, NATURE, V192, P338, DOI 10.1038/192338a0; GOLDBARG JA, 1958, CANCER, V11, P283, DOI 10.1002/1097-0142(195803/04)11:2<283::AID-CNCR2820110209>3.0.CO;2-8; Gonzales T, 1996, FEMS MICROBIOL REV, V18, P319, DOI 10.1111/j.1574-6976.1996.tb00247.x; HERSH LB, 1987, PEPTIDES, V8, P523, DOI 10.1016/0196-9781(87)90019-2; IRIBAR C, 1995, BRAIN RES, V687, P211, DOI 10.1016/0006-8993(95)00538-2; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KELLY JA, 1983, J NEUROCHEM, V40, P1727, DOI 10.1111/j.1471-4159.1983.tb08148.x; Kuda T, 1997, BIOCHEM BIOPH RES CO, V231, P526, DOI 10.1006/bbrc.1996.5920; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P148, DOI 10.1006/abbi.1995.0020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MELBYE SW, 1971, J BIOL CHEM, V246, P2459; METZ G, 1976, BIOCHIM BIOPHYS ACTA, V429, P933, DOI 10.1016/0005-2744(76)90338-7; Migaud M, 1996, PEPTIDES, V17, P601, DOI 10.1016/0196-9781(96)00036-8; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; ROHM KH, 1984, H-S Z PHYSIOL CHEM, V365, P1235, DOI 10.1515/bchm2.1984.365.2.1235; ROHM KH, 1985, ARCH BIOCHEM BIOPHYS, V239, P216, DOI 10.1016/0003-9861(85)90829-X; Sambrook J., 2002, MOL CLONING LAB MANU; Song LJ, 1997, BRAIN RES, V744, P1, DOI 10.1016/S0006-8993(96)00952-3; Takeda A, 1996, J BIOCHEM-TOKYO, V120, P353; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WILK S, 1993, ADV NEUROIMMUNOL, V3, P195, DOI 10.1016/S0960-5428(05)80021-X; WILK S, 1969, BIOCHEMISTRY-US, V8, P3168, DOI 10.1021/bi00836a006; WILK S, 1995, METABOLISM BRAIN PEP, P215; WRIGHT JW, 1992, BRAIN RES REV, V17, P227, DOI 10.1016/0165-0173(92)90018-H; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968	37	82	88	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15961	15970		10.1074/jbc.273.26.15961	http://dx.doi.org/10.1074/jbc.273.26.15961			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632644	hybrid			2022-12-25	WOS:000074436600015
J	Zhao, AC; Ansari, RA; Schmidt, MC; Khan, SA				Zhao, AC; Ansari, RA; Schmidt, MC; Khan, SA			An oligonucleotide inhibits oligomerization of a rolling circle initiator protein at the pT181 origin of replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMID REPLICATION; STAPHYLOCOCCUS-AUREUS; DNA; SEQUENCE; TERMINATION; SPECIFICITY; TOPOISOMERASE; HETERODIMER; MUTATIONS; ELEMENT	A large number of plasmids have been shown to replicate by a rolling circle (RC) mechanism. The initiators encoded by these plasmids have origin-specific, nicking-closing activity that is required for the initiation and termination of RC replication. Since the initiators of many RC plasmids are rate-limiting for replication, these proteins are usually inactivated after supporting one round of replication. In the case of the pT181 plasmid, inactivation of the initiator RepC protein occurs by the attachment of an oligonucleotide to its active tyrosine residue. We have generated the inactivated form of RepC, termed RepC*, in, vitro and investigated the effects of attachment of the oligonucleotide on its various biochemical activities. Our results demonstrate that while RepC* is inactive in nicking-closing and replication activities due to the blockage of its active tyrosine residue, it is competent in origin DNA binding and DNA religation activities. We have investigated the oligomeric state of RepC and RepC* and found that RepC exists as a dimer in solution and can oligomerize on the DNA, We have generated heterodimers in vitro between the wild-type and epitope-tagged RepC proteins. In electrophoretic mobility shift experiments, the initiator heterodimers generated a novel DNA-protein complex, demonstrating that it binds to DNA as a dimer, We have shown that a DNA binding mutant of RepC can be targeted to the origin in the presence of the wild-type protein primarily through a protein-protein interaction. Interestingly, RepC* is defective in its ability to oligomerize on the DNA. RepC* inhibited the DNA binding and replication activity of wild-type RepC to only a very limited extent, suggesting that it may play only a minor regulatory role in replication in vivo, Based on these and earlier results, we propose a model for the role of RepC during the initiation and termination of pT181 RC replication.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Khan, SA (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Room E 1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	Khan@med.pitt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031685] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAAS PD, 1988, CURR TOP MICROBIOL, V136, P31; BARGONETTI J, 1993, EMBO J, V12, P3659, DOI 10.1002/j.1460-2075.1993.tb06040.x; CARLETON S, 1984, EMBO J, V3, P2407, DOI 10.1002/j.1460-2075.1984.tb02147.x; DELSOLAR G, 1993, MOL MICROBIOL, V8, P789; DEMPSEY LA, 1992, P NATL ACAD SCI USA, V89, P3083, DOI 10.1073/pnas.89.7.3083; DEMPSEY LA, 1992, J BIOL CHEM, V267, P24538; GRUSS A, 1989, MICROBIOL REV, V53, P231, DOI 10.1128/MMBR.53.2.231-241.1989; GUAN C, 1988, GENE, V67, P21; IORDANESCU S, 1993, MOL GEN GENET, V241, P185, DOI 10.1007/BF00280216; IORDANESCU S, 1995, MOL MICROBIOL, V16, P477; Jin RZ, 1996, J BIOL CHEM, V271, P31086, DOI 10.1074/jbc.271.49.31086; Jin RZ, 1997, J BACTERIOL, V179, P141, DOI 10.1128/jb.179.1.141-147.1997; Jin RZ, 1997, EMBO J, V16, P4456, DOI 10.1093/emboj/16.14.4456; KHAN SA, 1983, PLASMID, V10, P251, DOI 10.1016/0147-619X(83)90039-2; Khan SA, 1997, MICROBIOL MOL BIOL R, V61, P442, DOI 10.1128/.61.4.442-455.1997; KOEPSEL RR, 1986, SCIENCE, V233, P1316, DOI 10.1126/science.3749879; KOEPSEL RR, 1985, J BIOL CHEM, V260, P8571; KOEPSEL RR, 1985, P NATL ACAD SCI USA, V82, P6845, DOI 10.1073/pnas.82.20.6845; KOEPSEL RR, 1986, P NATL ACAD SCI USA, V83, P5484, DOI 10.1073/pnas.83.15.5484; MURRAY RW, 1989, J BIOL CHEM, V264, P1051; NOIROT P, 1990, P NATL ACAD SCI USA, V87, P8560, DOI 10.1073/pnas.87.21.8560; NOVICK RP, 1989, CELL, V59, P395, DOI 10.1016/0092-8674(89)90300-0; RASOOLY A, 1994, EMBO J, V13, P5245, DOI 10.1002/j.1460-2075.1994.tb06856.x; RASOOLY A, 1993, SCIENCE, V262, P1048, DOI 10.1126/science.8235621; REINBERG D, 1983, J BIOL CHEM, V258, P529; Sambrook J., 1989, MOL CLONING LAB MANU, V2; THOMAS CD, 1988, BIOCHEM SOC T, V16, P758, DOI 10.1042/bst0160758; THOMAS CD, 1990, J BIOL CHEM, V265, P5519; WANG PZ, 1993, EMBO J, V12, P45, DOI 10.1002/j.1460-2075.1993.tb05630.x; Zhao AC, 1997, MOL MICROBIOL, V24, P535, DOI 10.1046/j.1365-2958.1997.3641730.x; Zhao AC, 1996, J BACTERIOL, V178, P5222, DOI 10.1128/jb.178.17.5222-5228.1996; ZINDER ND, 1985, MICROBIOL REV, V49, P101, DOI 10.1128/MMBR.49.2.101-106.1985	32	11	11	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16082	16089		10.1074/jbc.273.26.16082	http://dx.doi.org/10.1074/jbc.273.26.16082			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632660	hybrid			2022-12-25	WOS:000074436600031
J	Fan, CY; Pan, J; Usuda, N; Yeldandi, AV; Rao, MS; Reddy, JK				Fan, CY; Pan, J; Usuda, N; Yeldandi, AV; Rao, MS; Reddy, JK			Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase - Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; DIFFERENTIAL EXPRESSION; BETA-OXIDATION; PPAR-ALPHA; GENE; MOUSE; ACID; ADRENOLEUKODYSTROPHY; CLONING; MEMBER	Peroxisomal beta-oxidation system consists of fc,ur consecutive reactions to preferentially metabolize very long chain fatty acids. The first step of this system, catalyzed by acyl-CoA oxidase (AOX), converts fatty acyl-CoA to 2-trans-enoyl-CoA. Herein, we show that mice deficient in AOX exhibit steatohepatitis, increased hepatic H2O2 levels, and hepatocellular regeneration, leading to a complete reversal of fatty change by 6 to 8 months of age. The liver of AOX-/- mice with regenerated hepatocytes displays profound generalized spontaneous peroxisome proliferation and increased mRNA levels of genes that are regulated by peroxisome proliferator-activated receptor alpha (PPAR alpha). Hepatic adenomas and carcinomas develop in AOX-/- mice by 15 months of age due to sustained activation of PPAR alpha. These observations implicate acyl-CoA and other putative substrates for AOX, as biological ligands for PPAR alpha; thus, a normal AOX gene is indispensable for the physiological regulation of PPAR alpha.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA	Northwestern University	Reddy, JK (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	jkreddy@nwu.edu			NIGMS NIH HHS [GM 23750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023750, R37GM023750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARSLAND A, 1991, BIOCHEM PHARMACOL, V41, P53, DOI 10.1016/0006-2952(91)90010-3; AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; ASHBY J, 1994, HUM EXP TOXICOL S2, V13, P1; BERGE RK, 1985, BIOCHIM BIOPHYS ACTA, V837, P141, DOI 10.1016/0005-2760(85)90237-1; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Broustas CG, 1996, J BIOL CHEM, V271, P10470, DOI 10.1074/jbc.271.18.10470; CHU RY, 1995, J BIOL CHEM, V270, P29636; deDuve C, 1996, ANN NY ACAD SCI, V804, P1; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Fan CY, 1996, J BIOL CHEM, V271, P24698, DOI 10.1074/jbc.271.40.24698; FAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FURSTENBERGER G, 1991, J BIOL CHEM, V266, P15738; GOTTLICHER M, 1993, BIOCHEM PHARMACOL, V46, P2177, DOI 10.1016/0006-2952(93)90607-X; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Hashimoto T, 1996, ANN NY ACAD SCI, V804, P86, DOI 10.1111/j.1749-6632.1996.tb18610.x; HUANG Q, 1995, INT J ONCOL, V6, P307; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Johnson EF, 1996, FASEB J, V10, P1241, DOI 10.1096/fasebj.10.11.8836037; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kobayashi T, 1997, BIOCHEM BIOPH RES CO, V232, P631, DOI 10.1006/bbrc.1997.6340; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LI QL, 1990, J BIOCHEM-TOKYO, V107, P699, DOI 10.1093/oxfordjournals.jbchem.a123111; Lu JF, 1997, P NATL ACAD SCI USA, V94, P9366, DOI 10.1073/pnas.94.17.9366; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Peters JM, 1997, CARCINOGENESIS, V18, P2029, DOI 10.1093/carcin/18.11.2029; PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3; POLLTHE BT, 1987, EUR J PEDIATR, V146, P477, DOI 10.1007/BF00441598; RAO MS, 1987, CARCINOGENESIS, V8, P631; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; REDDY JK, 1986, TRENDS PHARMACOL SCI, V7, P438, DOI 10.1016/0165-6147(86)90416-5; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; Schoonjans K, 1996, J LIPID RES, V37, P907; SCHOONJANS K, 1995, J BIOL CHEM, V270, P16269; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; SVENSSON LT, 1995, EUR J BIOCHEM, V230, P813; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; Tugwood JD, 1996, ANN NY ACAD SCI, V804, P252, DOI 10.1111/j.1749-6632.1996.tb18620.x; Usuda N, 1996, ANN NY ACAD SCI, V804, P297, DOI 10.1111/j.1749-6632.1996.tb18624.x; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	58	293	304	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15639	15645		10.1074/jbc.273.25.15639	http://dx.doi.org/10.1074/jbc.273.25.15639			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624157	hybrid			2022-12-25	WOS:000074284200051
J	Groot-Kormelink, PJ; Luyten, WHML; Colquhoun, D; Sivilotti, LG				Groot-Kormelink, PJ; Luyten, WHML; Colquhoun, D; Sivilotti, LG			A reporter mutation approach shows incorporation of the "orphan" subunit beta 3 into a functional nicotinic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; DESENSITIZATION; CHANNELS; FAMILY; DOMAIN	We have investigated whether the neuronal nicotinic subunit beta 3 can participate in the assembly of functional recombinant receptors, Although beta 3 is expressed in several areas of the central nervous system, it does not form functional receptors when expressed heterologously together with an alpha or another beta nicotinic subunit, We inserted into the human beta 3 subunit a reporter mutation (V273T), which, if incorporated into a functional receptor, would be expected to increase its agonist sensitivity and maximum response to partial agonists, Expressing the mutant beta 3(V273T) in Xenopus oocytes together with both the alpha 3 and the beta 4 subunits resulted in the predicted changes in the properties of the resulting nicotinic receptor when compared with those of alpha 3 beta 4 receptors. This indicated that some of the receptors incorporated the mutant beta 3 subunit, as part of a "triplet" alpha 3 beta 4 beta 3 receptor. The proportion of triplet receptors was dependent on the ratios of the alpha 3:beta 4:beta 3 cRNA injected. We conclude that, like the related alpha 5 subunit, the beta 3 subunit can form functional receptors only if expressed together with both alpha and beta subunits.	Univ London Univ Coll, Dept Pharmacol, London WC1E 6BT, England; Janssen Res Fdn, Dept Expt Mol Biol, B-2340 Beerse, Belgium	University of London; University College London; Johnson & Johnson	Sivilotti, LG (corresponding author), Univ London, Sch Pharm, Dept Pharmacol, 2939 Brunswick Sq, London WC1N 1AX, England.	sivilo@cua.ulsop.ac.uk	Colquhoun, David/C-1664-2008; Sivilotti, Lucia/D-8919-2011	Colquhoun, David/0000-0002-4263-017X; Sivilotti, Lucia/0000-0003-2510-8424				Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; Bannon AW, 1998, SCIENCE, V279, P77, DOI 10.1126/science.279.5347.77; Chang YC, 1996, J NEUROSCI, V16, P5415; COLQUHOUN D, 1987, PERSPECTIVES RECEPTO, P103; DENERIS ES, 1989, J BIOL CHEM, V264, P6268; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; Forsayeth JR, 1997, J NEUROSCI, V17, P1531; Fucile S, 1997, NEUROREPORT, V8, P2433, DOI 10.1097/00001756-199707280-00005; Fucile S, 1998, EUR J NEUROSCI, V10, P172, DOI 10.1046/j.1460-9568.1998.00001.x; Gerzanich V, 1997, MOL PHARMACOL, V51, P320, DOI 10.1124/mol.51.2.320; Groot Kormelink P. J., 1997, FEBS LETT, V400, P309; LABARCA C, 1995, NATURE, V376, P415; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; LENOVERE N, 1995, J MOL EVOL, V40, P155, DOI 10.1007/BF00167110; Lewis TM, 1997, J PHYSIOL-LONDON, V505, P299, DOI 10.1111/j.1469-7793.1997.299bb.x; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; RamirezLatorre J, 1996, NATURE, V380, P347, DOI 10.1038/380347a0; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; SIVILOTTI L, 1995, SCIENCE, V269, P1681, DOI 10.1126/science.7569892; Sivilotti LG, 1997, J PHYSIOL-LONDON, V500, P123, DOI 10.1113/jphysiol.1997.sp022004; Wang F, 1996, J BIOL CHEM, V271, P17656, DOI 10.1074/jbc.271.30.17656; YAKEL JL, 1993, P NATL ACAD SCI USA, V90, P5030, DOI 10.1073/pnas.90.11.5030	22	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15317	15320		10.1074/jbc.273.25.15317	http://dx.doi.org/10.1074/jbc.273.25.15317			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624109	hybrid, Green Submitted			2022-12-25	WOS:000074284200003
J	Friesen, RHE; Lee, JC				Friesen, RHE; Lee, JC			The negative dominant effects of T340M mutation on mammalian pyruvate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY HEMOLYTIC-ANEMIA; DOMAIN INTERACTION; POINT MUTATIONS; MUSCLE; ISOZYMES; GENE	A fundamental issue in allosteric regulatory enzymes is the identification of pathways of signal transmission. Rabbit muscle and kidney pyruvate kinase isozymes are ideal to address this issue because these isozymes exhibit different enzymatic regulatory patterns, and the sequence differences between these isozymes have identified the amino acid residues that alter their kinetic behavior. In an earlier study, Cheng et al. (Cheng, X., Friesen, R. H. E., and Lee, J. C. (1996) J. Biol. Chem. 271, 6313-6321), reported the effects of a threonine to methionine mutation at residue 340 in the muscle isozyme. In this study, the same mutation was effected in the kidney isozyme. Qualitatively, the same negative effects are observed in both isozymes, namely a significant decrease in catalytic efficiency and decrease in apparent affinity for phosphoenolpyruvate but no change in affinity for ADP, and a decrease in responsiveness to the presence of effectors, be it activator or inhibitor. Because the diversity in the primary sequence between these two isozymes does molt alter the negative impact of the T340M mutation, it can be concluded that this mutation exerts a dominant, negative effect. The negative effects of T340M mutation on the kinetic properties imply that there is communication between residue 340 and the active site. Residue 340 is located at the 1,4 subunit interface; however, a T340M mutation enhances the dimerization affinity along the 1,2 subunit interface. Thus, this study has identified a communication network among the active site, residue 340, and the 1,2 subunit interface.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Lee, JC (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.		Lee, James C/A-7849-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045579] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45579] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beutler E, 1996, HUM MUTAT, V7, P1; BOYER PD, 1962, ENZYMES, V6, P95; BUCHER T, 1955, METHOD ENZYMOL, V1, P435, DOI 10.1016/0076-6879(55)01071-9; Cann J. R., 1970, INTERACTING MACROMOL; Cheng XD, 1996, J BIOL CHEM, V271, P6313, DOI 10.1074/jbc.271.11.6313; CONSLER TG, 1988, J BIOL CHEM, V263, P2794; CONSLER TG, 1992, BIOCHEMISTRY-US, V31, P7870, DOI 10.1021/bi00149a018; CONSLER TG, 1988, J BIOL CHEM, V263, P2787; COX DJ, 1971, ARCH BIOCHEM BIOPHYS, V119, P514; Engstrom L, 1978, Curr Top Cell Regul, V13, P28; FOTHERGILL LA, 1992, PROGR MOL BIOL BIOPH, V59, P105; FRIESEN RHE, 1997, THESIS U TEXAS MED B; Gilbert L M, 1973, Methods Enzymol, V27, P273; HALL ER, 1978, INT J BIOCHEM, V9, P785, DOI 10.1016/0020-711X(78)90027-7; HARRIS SJ, 1995, BIOCHEMISTRY-US, V34, P8752, DOI 10.1021/bi00027a026; Hill AV, 1910, J PHYSIOL-LONDON, V40, P190; KANNO H, 1992, BLOOD, V79, P1347, DOI 10.1182/blood.V79.5.1347.bloodjournal7951347; KANNO H, 1991, P NATL ACAD SCI USA, V88, P8218, DOI 10.1073/pnas.88.18.8218; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; LEE JC, 1994, MODERN ANAL ULTRACEN, P138; MATTEVI A, 1995, STRUCTURE, V3, P729, DOI 10.1016/S0969-2126(01)00207-6; Mesecar AD, 1997, BIOCHEMISTRY-US, V36, P6803, DOI 10.1021/bi962870s; Mesecar AD, 1997, BIOCHEMISTRY-US, V36, P6792, DOI 10.1021/bi962869t; NEUBAUER B, 1991, BLOOD, V77, P1871; NICHOL LW, 1964, PROTEINS; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; OBERFELDER RW, 1984, BIOCHEMISTRY-US, V23, P3813, DOI 10.1021/bi00312a004; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	31	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14772	14779		10.1074/jbc.273.24.14772	http://dx.doi.org/10.1074/jbc.273.24.14772			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614077	hybrid			2022-12-25	WOS:000074160400019
J	Koval, AP; Karas, M; Zick, Y; LeRoith, D				Koval, AP; Karas, M; Zick, Y; LeRoith, D			Interplay of the proto-oncogene proteins CrkL and CrkII in insulin-like growth factor-I receptor-mediated signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; MYELOGENOUS LEUKEMIA-CELLS; TYROSINE PHOSPHORYLATION; ADAPTER PROTEINS; PC12 CELLS; C-CRK; SH2; RAS; SRC; SUBSTRATE-1	The closely related proto-oncogene proteins CrkII and CrkL consist of cane SH2 and two SI43 domains and share 60% overall homology with the highest identity within their functional domains. In this study we show that CrkL and CrkII may play overlapping but different roles in insulin-like growth factor (IGF)-I receptor-mediated signal transduction. While both proteins are substrates involved in IGF-I receptor signaling, they apparently demonstrate important different properties and different biological responses. Evidence supporting this hypothesis includes (a) the oncogenic potential of CrkL versus the absence of this potential in CrkII overexpressing cell lines, (b) the inhibition of IGF-I-dependent cell cycle progression by overexpression of CrkII, and (c) the differential regulation of the phosphorylation status of selective proteins in CrkII and CrkL overexpressing cell lines. In addition we demonstrate the specific association of CrkL and CrkII with the newly characterized IRS-4 protein, again in a differential manner. Whereas CrkL strongly interacts with IRS-4 via its SH2 and N-terminal SH3 domains, CrkII interacts only via its SH2 domain, possibly explaining the unstable nature of IRS-4-CrkII association. The results obtained snow us to propose a unique mechanism of CrkL and CrkII tyrosine phosphorylation in response to IGF-I stimulation. Thus these highly homologous proteins apparently possess structural features that allow for the differential association of each protein with different effector molecules, thereby activating different signaling pathways and resulting in unique biological roles of these proteins.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; Weizmann Inst Sci, Dept MOl & Cell Biol, IL-76100 Rehovot, Israel	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Weizmann Institute of Science	LeRoith, D (corresponding author), NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA.		Zick, Yehiel/K-1479-2012					Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Butler AA, 1997, J BIOL CHEM, V272, P27660, DOI 10.1074/jbc.272.44.27660; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; DEJONG R, 1995, ONCOGENE, V11, P1469; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Higuchi R., 1989, PCR TECHNOLOGY, P61; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; Khwaja A, 1996, ONCOGENE, V12, P2491; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; Koval AP, 1998, BIOCHEM J, V330, P923; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; NICHOLS GL, 1994, BLOOD, V84, P2912; Okada S, 1996, J BIOL CHEM, V271, P25533, DOI 10.1074/jbc.271.41.25533; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; RIBON V, 1996, J BIOL CHEM, V271, P2375; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sattler M, 1997, J BIOL CHEM, V272, P10248; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5	52	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14780	14787		10.1074/jbc.273.24.14780	http://dx.doi.org/10.1074/jbc.273.24.14780			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614078	hybrid			2022-12-25	WOS:000074160400020
J	Larsen, CM; Wadt, KAW; Juhl, LF; Andersen, HU; Karlsen, AE; Su, MSS; Seedorf, K; Shapiro, L; Dinarello, CA; Mandrup-Poulsen, T				Larsen, CM; Wadt, KAW; Juhl, LF; Andersen, HU; Karlsen, AE; Su, MSS; Seedorf, K; Shapiro, L; Dinarello, CA; Mandrup-Poulsen, T			Interleukin-1 beta-induced rat pancreatic islet nitric oxide synthesis requires both the p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ATF2; BETA-CELLS; MAP KINASE; INSULIN-SECRETION; IN-VITRO; SYNTHASE EXPRESSION; INDUCED APOPTOSIS; RINM5F CELLS; KAPPA-B; INHIBITOR	Interleukin-1 beta (IL-1 beta) is cytotoxic to rat pancreatic beta-cells by inhibiting glucose oxidation, causing DNA damage and inducing apoptosis, Nitric oxide (NO) is a necessary but not sufficient mediator of these effects. IL-1 beta induced kinase activity toward Elk-1, activation transcription factor 2, c-Jun, and heat shock protein 25 in rat islets. By Western blotting with phosphospecific antibodies and by immunocomplex kinase assay, IL-1 beta was shown to activate extracellular signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (p38) in islets and rat insulinoma cells. Specific ERK1/2 and p38 inhibitors individually reduced but in combination blocked IL-1 beta-mediated islet NO synthesis, and reverse transcription-polymerase chain reaction of inducible NO synthase mRNA showed that ERK1/2 and p38 controlled IL-1 beta-induced islet inducible NO synthase expression at the transcriptional level. Hyperosmolarity caused phosphorylation of Elk-1, activation transcription factor 2, and heat shock protein 25 and activation of ERK1/2 and p38 in islets comparable to that induced by IL-1 beta but did not lead to NO synthesis. Inhibition of p38 but not of ERK1/2 attenuated IL-1 beta-mediated inhibition of glucose-stimulated insulin release, We conclude that ERK1/2 and p38 activation is necessary but not sufficient for IL-1 beta-mediated beta-cell NO synthesis and that p38 is involved in signaling of NO-independent effects of IL-1 beta in beta-cells.	Steno Diabet Ctr, DK-2820 Gentofte, Denmark; Hagedorn Res Inst, DK-2820 Gentofte, Denmark; Vertex Pharmaceut Inc, Cambridge, MA 02139 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA	Steno Diabetes Center; Novo Nordisk; Hagedorn Research Institute; Vertex Pharmaceuticals; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Mandrup-Poulsen, T (corresponding author), Steno Diabet Ctr, DK-2820 Gentofte, Denmark.	tmpo@novo.dk	Dinarello, Charles/C-8524-2013	Andersen, Henrik Ullits/0000-0001-8048-9720; Mandrup-Poulsen, Thomas/0000-0002-3215-9273	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015614, R01AI015614, R56AI015614] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKABANE A, 1995, BIOCHEM BIOPH RES CO, V215, P524, DOI 10.1006/bbrc.1995.2496; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSEN HU, 1994, DIABETES, V43, P770, DOI 10.2337/diabetes.43.6.770; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BRUNSTEDT J, 1984, METHODS DIABETES RES, P254; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; CORBETT JA, 1995, J EXP MED, V181, P559, DOI 10.1084/jem.181.2.559; CORBETT JA, 1993, FASEB J, V7, P369, DOI 10.1096/fasebj.7.2.8440413; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EIZIRIK DL, 1992, FEBS LETT, V308, P249, DOI 10.1016/0014-5793(92)81285-T; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; Kinugawa K, 1997, CIRC RES, V81, P911; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MANDRUPPOULSEN T, 1987, ACTA PATH MICRO IM C, V95, P55; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; RABINOVITCH A, 1990, J CLIN ENDOCR METAB, V71, P152, DOI 10.1210/jcem-71-1-152; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Reimers JI, 1996, DIABETES, V45, P771, DOI 10.2337/diabetes.45.6.771; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SALDEEN J, 1994, BIOCHEM BIOPH RES CO, V203, P149, DOI 10.1006/bbrc.1994.2161; SANDLER S, 1989, ENDOCRINOLOGY, V124, P1492, DOI 10.1210/endo-124-3-1492; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Uciechowski P, 1996, FEBS LETT, V394, P273, DOI 10.1016/0014-5793(96)00967-2; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; WELSH N, 1994, BIOSCIENCE REP, V14, P43, DOI 10.1007/BF01901637; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	57	153	157	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15294	15300		10.1074/jbc.273.24.15294	http://dx.doi.org/10.1074/jbc.273.24.15294			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614146	hybrid			2022-12-25	WOS:000074160400088
J	Madrid, R; Gomez, MJ; Ramos, J; Rodriguez-Navarro, A				Madrid, R; Gomez, MJ; Ramos, J; Rodriguez-Navarro, A			Ectopic potassium uptake in trk1 trk2 mutants of Saccharomyces cerevisiae correlates with a highly hyperpolarized membrane potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUBIDIUM TRANSPORT; NEUROSPORA-CRASSA; ESCHERICHIA-COLI; SHUTTLE VECTORS; YEAST; SYSTEM; ATPASE; PROTEIN; K+; ACTIVATION	Null trk1 trk2 mutants of Saccharomyces cerevisiae exhibit a low-affinity uptake of K+ and Rb+. We show that this low-affinity Rb+ uptake is mediated by several independent transporters, and that trk1 Delta cells and especially trk1 Delta trk2 Delta cells are highly hyperpolarized. Differences in the membrane potentials were assessed for sensitivity to hygromycin B and by flow cytometric analyses of cellular DiOC(6)(3) fluorescence. On the basis of the latter analyses, it is preposed that Tsk1p and Trk2p are involved in the control of the membrane potential, preventing excessive hyperpolarizations. K+ starvation and nitrogen starvation hyperpolarize both TRK1 TRK2 and trk1 Delta trk2 Delta cells, thus suggesting that other proteins, in addition to Trk1p and Trk2p, participate in the control of the membrane potential. The HAK1 K+-transporter from Schwanniomyces occidentalis suppresses the K+-defective transport of trk1 Delta trk2 Delta cells but not the high hyperpolarization, and the HKT1 K+ transporter from wheat suppresses both defects, in the presence of Na+. We discuss the mechanism involved in the control of the membrane potential by Trk1p and Trk2p and the causal relationship between the high membrane potential (negative inside) of trk1 Delta trk2 Delta cells and its ectopic transport of alkaki cations.	Univ Politecn Madrid, Escuela Tecn Super Ingn Agron, Dept Biotecnol, E-28040 Madrid, Spain; Univ Cordoba, Escuela Tecn Super Ingn Agron, Dept Microbiol, E-14071 Cordoba, Spain	Universidad Politecnica de Madrid; Universidad de Cordoba	Rodriguez-Navarro, A (corresponding author), Univ Politecn Madrid, Escuela Tecn Super Ingn Agron, Dept Biotecnol, E-28040 Madrid, Spain.	arodrignavar@bit.etsia.upm.es	Rodriguez-Navarro, Alonso/AAB-4574-2019	Rodriguez-Navarro, Alonso/0000-0003-0462-223X; Madrid Gonzalez, Ricardo/0000-0002-1350-9864				ALIJO R, 1993, BIOCHIM BIOPHYS ACTA, V1179, P224, DOI 10.1016/0167-4889(93)90145-F; BANUELOS MA, 1995, EMBO J, V14, P3021, DOI 10.1002/j.1460-2075.1995.tb07304.x; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; BOUILLAUD F, 1994, EMBO J, V13, P1990, DOI 10.1002/j.1460-2075.1994.tb06468.x; BRUNELLI JP, 1993, YEAST, V9, P1309, DOI 10.1002/yea.320091204; CRIDDLE RS, 1969, BIOCHEMISTRY-US, V8, P322, DOI 10.1021/bi00829a045; EDDY AA, 1989, METHOD ENZYMOL, V172, P95; Fu HH, 1998, PLANT CELL, V10, P63, DOI 10.1105/tpc.10.1.63; GABER RF, 1992, INT REV CYTOL, V137A, P299; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; Gassmann W, 1996, PLANT J, V10, P869, DOI 10.1046/j.1365-313X.1996.10050869.x; GOFFEAU A, 1990, MONOVALENT CATIONS B, P155; GonzalezBarroso MM, 1997, BIOCHEMISTRY-US, V36, P10930, DOI 10.1021/bi971104y; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Kim EJ, 1998, PLANT CELL, V10, P51, DOI 10.1105/tpc.10.1.51; KO CH, 1993, MOL CELL BIOL, V13, P638, DOI 10.1128/MCB.13.1.638; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KO CH, 1990, GENETICS, V125, P305; KONING AJ, 1993, CELL MOTIL CYTOSKEL, V25, P111, DOI 10.1002/cm.970250202; Liang H, 1998, MOL CELL BIOL, V18, P926, DOI 10.1128/MCB.18.2.926; LichtenbergFrate H, 1996, J MEMBRANE BIOL, V152, P169, DOI 10.1007/s002329900095; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; PENA A, 1984, ARCH BIOCHEM BIOPHYS, V231, P217, DOI 10.1016/0003-9861(84)90381-3; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; Petit PX, 1996, CYTOMETRY, V23, P28, DOI 10.1002/(SICI)1097-0320(19960101)23:1<28::AID-CYTO5>3.0.CO;2-I; QUINTERO J, 1997, FEBS LETT, V415, P206; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; RAMOS J, 1994, J BACTERIOL, V176, P249, DOI 10.1128/JB.176.1.249-252.1994; RAMOS J, 1990, BIOCHIM BIOPHYS ACTA, V1029, P211, DOI 10.1016/0005-2736(90)90156-I; RAMOS J, 1985, BIOCHIM BIOPHYS ACTA, V815, P97, DOI 10.1016/0005-2736(85)90479-1; RAMOS J, 1986, EUR J BIOCHEM, V154, P307, DOI 10.1111/j.1432-1033.1986.tb09398.x; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; RODRIGUEZNAVARRO A, 1986, J GEN PHYSIOL, V87, P649, DOI 10.1085/jgp.87.5.649; RUBIO F, 1995, SCIENCE, V270, P1660, DOI 10.1126/science.270.5242.1660; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santa-Maria GE, 1997, PLANT CELL, V9, P2281, DOI 10.1105/tpc.9.12.2281; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1985, PLASMA MEMBRANE ATPA; SIKORSKI RS, 1989, GENETICS, V122, P19; SKROWRONEK P, 1990, CURR GENET, V18, P265; ULASZEWSKI S, 1987, MOL GEN GENET, V207, P38, DOI 10.1007/BF00331488; ULASZEWSKI S, 1983, EUR J BIOCHEM, V130, P235, DOI 10.1111/j.1432-1033.1983.tb07141.x; Walker NA, 1996, SCIENCE, V273, P977, DOI 10.1126/science.273.5277.977; Wright MB, 1997, J BIOL CHEM, V272, P13647, DOI 10.1074/jbc.272.21.13647	47	165	170	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14838	14844		10.1074/jbc.273.24.14838	http://dx.doi.org/10.1074/jbc.273.24.14838			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614085	hybrid			2022-12-25	WOS:000074160400027
J	McLachlin, DT; Bestard, JA; Dunn, SD				McLachlin, DT; Bestard, JA; Dunn, SD			The b and delta subunits of the Escherichia coli ATP synthase interact via residues in their C-terminal regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; H+-ATPASE; ADENOSINE-TRIPHOSPHATASE; MONOCLONAL-ANTIBODIES; CROSS-LINKING; ALPHA-SUBUNIT; F1F0 ATPASE; BINDING; F1-ATPASE; MEMBRANE	An affinity resin for the F-1 sector of the Escherichia coli ATP synthase was prepared by coupling the b subunit to a solid support through a unique cysteine residue in the N-terminal leader. b(24-156), a form of b lacking the N-terminal transmembrane domain, was able to compete with the affinity resin for binding of F-1. Truncated forms of b(24-156), in which one or four residues from the C terminus mere removed, competed poorly for F-1 binding, suggesting that these residues play an important role in b-F-1 interactions. Sedimentation velocity analytical ultracentrifugation revealed that removal of these C-terminal residues from b(24-156) resulted in a disruption of its association with the purified delta subunit of the enzyme. To determine whether these residues interact directly with delta, cysteine residues were introduced at various C-terminal positions of b and modified with the heterobifunctional cross-linker benzophenone-4-maleimide, Cross-links between b and delta were obtained when the reagent was incorporated at positions 155 and 158 (two residues beyond the normal C terminus) in both the reconstituted b(24-156)-F-1 complex and the membrane-bound F1F0 complex. CNBr digestion followed by peptide sequencing showed the site of cross-linking within the 177-residue delta 6 subunit to be C-terminal to residue 148, possibly at Met-158. These results indicate that the b and delta subunits interact via their C-terminal regions and that this interaction is instrumental in the binding of the F-1 sector to the b subunit of F-0.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Dunn, SD (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.		Dunn, Stanley/D-3418-2013					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; ANGOV E, 1991, J BACTERIOL, V173, P407, DOI 10.1128/jb.173.1.407-411.1991; ARIS JP, 1983, J BIOL CHEM, V258, P4599; BECKERS G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P97, DOI 10.1016/0167-4838(92)90473-Q; Blair A, 1996, MICROBIOL-SGM, V142, P17, DOI 10.1099/13500872-142-1-17; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; COLLINSON IR, 1994, J MOL BIOL, V242, P408; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1980, J BIOL CHEM, V255, P6891; DUNN SD, 1985, J BIOL CHEM, V260, P418; DUNN SD, 1992, J BIOL CHEM, V267, P7630; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; ENGELBRECHT S, 1991, Z NATURFORSCH C, V46, P759; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HOPPE J, 1983, J BIOL CHEM, V258, P2882; JANS DA, 1985, J BACTERIOL, V162, P420, DOI 10.1128/JB.162.1.420-426.1985; JOSHI S, 1990, J BIOL CHEM, V265, P14518; Joshi S, 1997, BIOCHEMISTRY-US, V36, P10936, DOI 10.1021/bi9704109; Joshi S, 1996, BIOCHEMISTRY-US, V35, P12094, DOI 10.1021/bi9612327; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; Junge W, 1996, BER BUNSEN PHYS CHEM, V100, P2014, DOI 10.1002/bbpc.19961001215; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; Mao YQ, 1997, ARCH BIOCHEM BIOPHYS, V337, P8, DOI 10.1006/abbi.1996.9777; MCCLACHLIN DT, 1997, J BIOL CHEM, V272, P21233; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; MONTICELLO RA, 1994, J BACTERIOL, V176, P1383, DOI 10.1128/jb.176.5.1383-1389.1994; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; Penefsky H S, 1979, Methods Enzymol, V56, P527; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SAKUMI K, 1986, J BIOL CHEM, V261, P5761; Sambrook J., 2002, MOL CLONING LAB MANU; Sawada K, 1997, J BIOL CHEM, V272, P30047, DOI 10.1074/jbc.272.48.30047; SCHAIRER HU, 1982, BIOSCIENCE REP, V2, P631, DOI 10.1007/BF01314228; Smith SP, 1996, BIOCHEMISTRY-US, V35, P8805, DOI 10.1021/bi952698c; STAFFORD WF, 1992, ANAL BIOCHEM, V161, P70; STERNWEIS PC, 1977, BIOCHEMISTRY-US, V16, P4020, DOI 10.1021/bi00637a013; TAKEYAMA M, 1988, J BIOL CHEM, V263, P16106; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198	56	78	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15162	15168		10.1074/jbc.273.24.15162	http://dx.doi.org/10.1074/jbc.273.24.15162			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614129	hybrid			2022-12-25	WOS:000074160400071
J	Ohyama, C; Smith, PL; Angata, K; Fukuda, MN; Lowe, JB; Fukuda, M				Ohyama, C; Smith, PL; Angata, K; Fukuda, MN; Lowe, JB; Fukuda, M			Molecular cloning and expression of GDP-D-mannose-4,6-dehydratase, a key enzyme for fucose metabolism defective in Lec13 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; DEVELOPMENTALLY-REGULATED MEMBER; L-SELECTIN; CARBOHYDRATE LIGAND; POINT MUTATION; ADHESION; GENE; ELAM-1; CDNA; BIOSYNTHESIS	Subsets of mammalian cell surface oligosaccharides contain specific fucosylated moieties expressed in lineage- and/or temporal-specific patterns. The functional significance of these fucosylated structures is incompletely defined, although there is evidence that subsets of them, represented by the sialyl Le(x) determinant, are important participants in leukocyte adhesion and trafficking processes. Genetic deletion of these fucosylated structures in the mouse has been a powerful tool to address functional questions about fucosylated glycans, However, successful use of such approaches can be problematic, given the substantial redundancy in the mammalian alpha-1,3-fucosyltransferase and alpha-1,2-fucosyltransferase gene families. To circumvent this problem, we have chosen to clone the genetic locus encoding a mammalian GDP-D-mannose-4,6-dehydratase (GRD). This enzyme generates GDP-manmose-4-keto-6-D-deoxymaranose from GDP-mannose, which is then converted by the FX protein (GDP-4-keto-6-L-deoxymannose epimerase/GDP-4-keto-6-L-galactose reductase) to GDP-L-fucose. GMD is thus imperative for the synthesis of all fucosyliated oligosaccharides. An expression cloning approach and the GMD-deficient CHO host cell line Lec13 were used to generate a population of cDNA molecules enriched in GMD cDNAs, This enriched plasmid population was then screened using a human expressed sequence tag (EST AA065072) with sequence similarity to an Arabidopsis thaliana GMD cDNA. This approach, together with 5'-rapid amplification of cDNA ends, yielded a human cDNA that complements the fucosylation defect in the Lec13 cell line. Northern blot analyses indicate that the GMD transcript is absent in Lec13 cells, confirming the genetic deficiency of this locus in these cells. By contrast, the transcript encoding the FX protein, which forms GDP-L-fucose from the ketosugar intermediate produced by GMD, is present in increased amounts in the Lec13 cells. These results suggest that metabolites generated in this pathway may participate ire the transcriptional regulation of the FX protein and possibly the GMD protein. The results also suggest that the genomic structure encoding GMD in Lec13 cells likely has a defect different from a point mutation in the coding region.	Burnham Inst, La Jolla Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Sanford Burnham Prebys Medical Discovery Institute; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Fukuda, M (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Angata, Kiyohiko/M-2749-2018	Angata, Kiyohiko/0000-0001-5561-1368	NATIONAL CANCER INSTITUTE [R37CA033000, P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA71932, R37 CA33000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERG EL, 1991, J BIOL CHEM, V266, P14869; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; CURRIE HL, 1995, CLIN DIAGN LAB IMMUN, V2, P554, DOI 10.1128/CDLI.2.5.554-562.1995; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FUKUDA M, 1984, J BIOL CHEM, V259, P925; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; FUKUDA MN, 1990, P NATL ACAD SCI USA, V87, P7443, DOI 10.1073/pnas.87.19.7443; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GINSBURG V, 1960, J BIOL CHEM, V235, P2196; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1993, NATURE, V361, P555; Jarvis DL, 1997, GLYCOBIOLOGY, V7, P113, DOI 10.1093/glycob/7.1.113; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LIAO TH, 1971, BIOCHIM BIOPHYS ACTA, V230, P64; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MAQUAT LE, 1995, RNA, V1, P453; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NATSUKA S, 1994, CURR OPIN STRUC BIOL, V4, P683, DOI 10.1016/S0959-440X(94)90166-X; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; Puthalakath H, 1996, J BIOL CHEM, V271, P27818, DOI 10.1074/jbc.271.44.27818; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; Tan J, 1996, AM J HUM GENET, V59, P810; Tonetti M, 1996, J BIOL CHEM, V271, P27274, DOI 10.1074/jbc.271.44.27274; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Weinstein J, 1996, J BIOL CHEM, V271, P27462, DOI 10.1074/jbc.271.44.27462	43	71	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14582	14587		10.1074/jbc.273.23.14582	http://dx.doi.org/10.1074/jbc.273.23.14582			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603974	hybrid			2022-12-25	WOS:000074021500076
J	Marlovits, TC; Zechmeister, T; Gruenberger, M; Ronacher, B; Schwihla, H; Blaas, D				Marlovits, TC; Zechmeister, T; Gruenberger, M; Ronacher, B; Schwihla, H; Blaas, D			Recombinant soluble law density lipoprotein receptor fragment inhibits minor group rhinovirus infection in vitro	FASEB JOURNAL			English	Article						human rhinovirus; LDLR; viral inhibition; baculovirus expression	INTERCELLULAR-ADHESION MOLECULE-1; LDL RECEPTOR; NEUTRALIZING ANTIBODY; PROTEIN; EXPRESSION; SEROTYPE-2; BINDING; SIGNAL; ICAM-1; CELLS	A fragment of the low density lipoprotein receptor encompassing the seven ligand binding repeats was expressed in Sf9 insect cells as a fusion protein with a carboxyl-terminally linked hexa-his tag by using a baculovirus vector, Up to 10 mg/l of the fusion protein was secreted into the medium. The material was soluble in the absence of detergent and active in binding beta very low density lipoprotein and a member of the minor group of human rhinoviruses (HRV2) in ligand blots from sodium dodecyl sulfate-polyacrylamide gels run under nonreducing conditions, The receptor fragment specifically inhibits viral infection of HeLa cells by minor group HRVs in a concentration-dependent manner. Viral infectivity is neutralized by aggregation.	Univ Vienna, Inst Biochem, A-1030 Vienna, Austria; Univ Agr Forestry & Renewable Nat Resources, Inst Appl Genet, A-1190 Vienna, Austria	University of Vienna	Blaas, D (corresponding author), Univ Vienna, Inst Biochem, Dr Bohr Gasse 9-3, A-1030 Vienna, Austria.		Marlovits, Thomas/A-3568-2019	Marlovits, Thomas/0000-0001-8106-4038				ABRAHAM G, 1984, J VIROL, V51, P340, DOI 10.1128/JVI.51.2.340-345.1984; ARRUDA E, 1992, ANTIMICROB AGENTS CH, V36, P1186, DOI 10.1128/AAC.36.6.1186; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; Dirlam KA, 1996, PROTEIN EXPRES PURIF, V8, P489, DOI 10.1016/S1046-5928(96)90129-1; GREVE JM, 1991, J VIROL, V65, P6015, DOI 10.1128/JVI.65.11.6015-6023.1991; GRUENBERGER M, 1995, J VIROL, V69, P7244, DOI 10.1128/JVI.69.11.7244-7247.1995; Hewat EA, 1996, EMBO J, V15, P1515, DOI 10.1002/j.1460-2075.1996.tb00495.x; HOFER F, 1994, P NATL ACAD SCI USA, V91, P18839; HOOVERLITTY H, 1993, J VIROL, V67, P390, DOI 10.1128/JVI.67.1.390-397.1993; KORANT BD, 1972, VIROLOGY, V48, P71, DOI 10.1016/0042-6822(72)90115-8; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MISCHAK H, 1988, J GEN VIROL, V69, P2653, DOI 10.1099/0022-1317-69-10-2653; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; OLSON NH, 1993, P NATL ACAD SCI USA, V90, P507, DOI 10.1073/pnas.90.2.507; PATEL DD, 1995, BBA-LIPID LIPID MET, V1255, P285, DOI 10.1016/0005-2760(94)00243-R; Powell RM, 1997, J VIROL, V71, P9306, DOI 10.1128/JVI.71.12.9306-9312.1997; PRCHLA E, 1994, J VIROL, V68, P3713, DOI 10.1128/JVI.68.6.3713-3723.1994; PRCHLA E, 1995, J CELL BIOL, V131, P111, DOI 10.1083/jcb.131.1.111; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; SMITH TJ, 1993, J VIROL, V67, P1148, DOI 10.1128/JVI.67.3.1148-1158.1993; STIFANI S, 1990, P NATL ACAD SCI USA, V87, P1955, DOI 10.1073/pnas.87.5.1955; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; UNCAPHER CR, 1991, VIROLOGY, V180, P814, DOI 10.1016/0042-6822(91)90098-V; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOSHIMURA A, 1987, J BIOL CHEM, V262, P13299	28	35	36	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1998	12	9					695	703		10.1096/fasebj.12.9.695	http://dx.doi.org/10.1096/fasebj.12.9.695			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619448				2022-12-25	WOS:000074011000008
J	Fusetti, F; Erlandsen, H; Flatmark, T; Stevens, RC				Fusetti, F; Erlandsen, H; Flatmark, T; Stevens, RC			Structure of tetrameric human phenylalanine hydroxylase and its implications for phenylketonuria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE; CRYSTAL-STRUCTURES; RAT-LIVER; MUTATION; IDENTIFICATION; EXPRESSION; MECHANISM; PROTEIN; IRON; HYPERPHENYLALANINEMIA	Phenylalanine hydroxylase (PheOH) catalyzes the conversion of L-phenylalanine to L-tyrosine, the rate-limiting step in the oxidative degradation of phenylalanine. Mutations in the human PheOH gene cause phenylketonuria, a common autosomal recessive metabolic disorder that in untreated patients often results in varying degrees of mental retardation. We have determined the crystal structure of human PheOH (residues 118-452), The enzyme crystallizes as a tetramer with each monomer consisting of a catalytic and a tetramerization domain. The tetramerization domain is characterized by the presence of a domain swapping arm that interacts with the other monomers forming an antiparallel coiled-coil. The structure is the first report of a tetrameric PheOH and displays an overall architecture similar to that of the functionally related tyrosine hydroxylase. In contrast to the tyrosine hydroxylase tetramer structure, a very pronounced asymmetry is observed in the phenylalanine hydroxylase, caused by the occurrence of two alternate conformations in the hinge region that leads to the coiled-coil helix. Examination of the mutations causing PKU shows that some of the most frequent mutations are located at the interface of the catalytic and tetramerization domains. Their effects on the structural and cellular stability of the enzyme are discussed.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Univ Tromso, Prot Crystallog Grp, Dept Chem, N-9037 Tromso, Norway; Univ Bergen, Dept Biochem & Mol Biol, N-5009 Bergen, Norway	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; UiT The Arctic University of Tromso; University of Bergen	Stevens, RC (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	stevens@adrenaline.berkeley.edu	Stevens, Raymond/K-7272-2015	Stevens, Raymond/0000-0002-4522-8725				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALASUBRAMANIAN S, 1994, BIOCHEMISTRY-US, V33, P8532, DOI 10.1021/bi00194a019; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Bergdoll M, 1997, STRUCTURE, V5, P391, DOI 10.1016/S0969-2126(97)00196-2; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; CELIKEL R, 1991, J MOL BIOL, V218, P495, DOI 10.1016/0022-2836(91)90694-2; Chehin R, 1998, FEBS LETT, V422, P225, DOI 10.1016/S0014-5793(97)01596-2; Daubner SC, 1997, BIOCHEMISTRY-US, V36, P11574, DOI 10.1021/bi9711137; DAUBNER SC, 1993, PROTEIN SCI, V2, P1452, DOI 10.1002/pro.5560020909; Daubner SC, 1997, ARCH BIOCHEM BIOPHYS, V348, P295, DOI 10.1006/abbi.1997.0435; Davis MD, 1997, P NATL ACAD SCI USA, V94, P491, DOI 10.1073/pnas.94.2.491; DICKSON PW, 1994, J BIOL CHEM, V269, P20369; DILELLA AG, 1987, NATURE, V327, P333, DOI 10.1038/327333a0; DILELLA AG, 1986, NATURE, V322, P799, DOI 10.1038/322799a0; Doskeland AP, 1996, BIOCHEM J, V319, P941, DOI 10.1042/bj3190941; EIKEN HG, 1992, HUM GENET, V88, P608, DOI 10.1007/BF02265283; Erlandsen H, 1997, FEBS LETT, V406, P171, DOI 10.1016/S0014-5793(97)00259-7; Erlandsen H, 1997, NAT STRUCT BIOL, V4, P995, DOI 10.1038/nsb1297-995; FLATMARK T, 1968, J BIOL CHEM, V243, P1623; FOLLING I, 1994, ACTA PAEDIATR, V83, P4, DOI 10.1111/j.1651-2227.1994.tb13440.x; GIBBS BS, 1993, J BIOL CHEM, V268, P8046; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Hoang L, 1996, NUCLEIC ACIDS RES, V24, P127, DOI 10.1093/nar/24.1.127; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HUFTON SE, 1995, BIOCHEM J, V311, P353, DOI 10.1042/bj3110353; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kappock TJ, 1995, J BIOL CHEM, V270, P30532, DOI 10.1074/jbc.270.51.30532; Knappskog PM, 1996, EUR J BIOCHEM, V242, P813, DOI 10.1111/j.1432-1033.1996.0813r.x; Kobe B, 1997, PROTEIN SCI, V6, P1352, DOI 10.1002/pro.5560060626; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEDLEY FD, 1985, BIOCHEMISTRY-US, V24, P3389, DOI 10.1021/bi00335a001; LICHTERKONECKI U, 1988, BIOCHEMISTRY-US, V27, P2881, DOI 10.1021/bi00408a032; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; MARTINEZ A, 1993, EUR J BIOCHEM, V211, P259, DOI 10.1111/j.1432-1033.1993.tb19894.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OKANO Y, 1991, GENOMICS, V9, P96, DOI 10.1016/0888-7543(91)90225-4; OKANO Y, 1991, NEW ENGL J MED, V324, P1232, DOI 10.1056/NEJM199105023241802; OKANO Y, 1991, EUR J PEDIATR, V150, P347, DOI 10.1007/BF01955938; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAMSEY AJ, 1995, PROTEIN SCI, V4, P2082; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SHIMAN R, 1990, J BIOL CHEM, V265, P11633; SVENSSON E, 1994, J INHERIT METAB DIS, V17, P215, DOI 10.1007/BF00711621; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; WANG T, 1991, P NATL ACAD SCI USA, V88, P2146, DOI 10.1073/pnas.88.6.2146	48	140	148	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16962	16967		10.1074/jbc.273.27.16962	http://dx.doi.org/10.1074/jbc.273.27.16962			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642259	hybrid			2022-12-25	WOS:000074545200049
J	Han, CH; Freeman, JLR; Lee, TH; Motalebi, SA; Lambeth, JD				Han, CH; Freeman, JLR; Lee, TH; Motalebi, SA; Lambeth, JD			Regulation of the neutrophil respiratory burst oxidase - Identification of an activation domain in p67(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; CELL-FREE SYSTEM; ADENINE-DINUCLEOTIDE PHOSPHATE; SODIUM DODECYL-SULFATE; SRC HOMOLOGY-3 DOMAINS; SUPEROXIDE PRODUCTION; PLASMA-MEMBRANE; SH3 DOMAIN; FLAVOCYTOCHROME B(558); RECOMBINANT P47-PHOX	Superoxide generation by the neutrophil respiratory burst oxidase (NADPH oxidase) can be reconstituted in a cell-free system using flavocytochrome b(558) and the cytosolic proteins p47(phox), p67(phox), and Rac. p47(phox) functions as an adaptor protein; it increases the affinity of p67(phox) and Rac in the NADPH oxidase complex, but is not essential when high concentrations of these proteins are used (Freeman, J. L., and Lambeth, J. D. (1996) J, Biol. Chem. 271, 22578-22582), implying that p67(phox) and/or Rac directly regulates enzyme activity. Herein, we describe an activation domain in p67(phox) that is essential for NADPH oxidase activity. A series of C-terminal truncation mutants of p67(phox) showed that residues 211 to the C terminus (residue 526) are not needed for cell-free activity. However, shorter truncations were inactive, pointing to an activation domain within the region spanning residues 199-210, p67(phox) mutated at single amino acid residues within this region showed diminished activity, and p67(phox) V204A was completely inactive, The effects of mutations on activity were independent of p47(phox), and mutations did not affect the binding of p67(phox) to Rac. In the presence of wild-type p67(phox), the V204A mutant was a potent inhibitor of superoxide generation, and inhibition was partially reversed by high concentrations of p67(phox), but not by p47(phox) OF Rac, The V204A mutant competed with native p67(phox) for translocation to neutrophil plasma membrane, indicating that p67(phox) V204A assembles to form an inactive complex. The data imply a direct activation of flavocytochrome b(558) by an activation domain in p67(phox).	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Lambeth, JD (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22809] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1992, J BIOL CHEM, V267, P16767; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; CROSS AR, 1994, J BIOL CHEM, V269, P21448; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; FINAN P, 1994, J BIOL CHEM, V269, P13752; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; FREEMAN JLR, 1994, BIOCHEMISTRY-US, V33, P13431, DOI 10.1021/bi00249a031; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; ISHIDA K, 1989, FEBS LETT, V243, P169, DOI 10.1016/0014-5793(89)80123-1; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; KLEINBERG ME, 1994, BIOCHEMISTRY-US, V33, P2490, DOI 10.1021/bi00175a018; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; KRECK ML, 1994, J BIOL CHEM, V269, P4161; LAMBETH JD, 1988, J BIOL CHEM, V263, P3818; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LIGETI E, 1989, BIOCHEMISTRY-US, V28, P7116, DOI 10.1021/bi00443a050; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; NISIMOTO Y, 1995, J BIOL CHEM, V270, P16428, DOI 10.1074/jbc.270.27.16428; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; PEMBER SO, 1983, BLOOD, V61, P1105; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; UHLINGER DJ, 1991, J BIOL CHEM, V266, P20990; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	54	182	188	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16663	16668		10.1074/jbc.273.27.16663	http://dx.doi.org/10.1074/jbc.273.27.16663			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642219	hybrid			2022-12-25	WOS:000074545200009
J	Paunio, T; Kangas, H; Heinonen, O; Buc-Caron, MH; Robert, JJ; Kaasinen, S; Julkunen, I; Mallet, J; Peltonen, L				Paunio, T; Kangas, H; Heinonen, O; Buc-Caron, MH; Robert, JJ; Kaasinen, S; Julkunen, I; Mallet, J; Peltonen, L			Cells of the neuronal lineage play a major role in the generation of amyloid precursor fragments in gelsolin-related amyloidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINNISH TYPE FAF; FAMILIAL AMYLOIDOSIS; IN-VITRO; PROTEIN; PLASMA; DOMAIN; ASN-187; REVEALS; ACID; GENE	Gelsolin-related amyloidosis or familial amyloidosis, Finnish type (FAF) (OMIM No105120) is a hereditary amyloid disease caused by a mutation in a precursor protein for amyloid (gelsolin) and characterized by corneal dystrophy and polyneuropathy. In vitro expression of the FAF-mutant (Asp(187) --> Asn/Tyr) secretory gelsolin in COS cells leads to generation of an aberrant polypeptide presumably representing the precursor for tissue amyloid. Here, we provide evidence that this abnormal processing results from defective initial folding of the secreted FAF gelsolin due to the lack of the Cys(188)-Cys(201) disulfide bond, normally formed next to the FAF mutation site. We compared cells of different tissue origin and discovered a dramatic difference between the amount of cleavage of FAF gelsolin to the amyloid precursor in neuronal and non-neuronal cells. More than half of the mutant gelsolin was cleaved in PC12 and in vitro differentiated human neuronal progenitor cells. In contrast, human fibroblasts and Schwannoma cell cultures showed only a limited capacity to cleave FAF gelsolin, although the cleavage mechanism per se seems to be similar in the various cell types, The present findings of processing and distribution of secreted FAF gelsolin in the neuronal cells emphasize the role of neurons in the tissue pathogenesis of this amyloid polyneuropathy.	Univ Helsinki, Inst Biomed, Dept Human Mol Genet, SF-00300 Helsinki, Finland; CNRS, Lab Genet Neurotransmiss & Neurodegenerat Proc, F-75013 Paris, France; Haartman Inst, Dept Virol, Helsinki 00280, Finland; Natl Publ Hlth Inst, Dept Virol, SF-00300 Helsinki, Finland	University of Helsinki; Centre National de la Recherche Scientifique (CNRS); Finland National Institute for Health & Welfare	Peltonen, L (corresponding author), Univ Helsinki, Inst Biomed, Dept Human Mol Genet, SF-00300 Helsinki, Finland.	Leena.Peltonen@ktl.fi						BUCCARON MH, 1995, NEUROBIOL DIS, V2, P37, DOI 10.1006/nbdi.1995.0004; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; DELACHAPELLE A, 1992, NAT GENET, V2, P157, DOI 10.1038/ng1092-157; GHISO J, 1990, BIOCHEM J, V272, P827, DOI 10.1042/bj2720827; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; HALTIA M, 1990, BIOCHEM BIOPH RES CO, V167, P927, DOI 10.1016/0006-291X(90)90612-Q; HALTIA M, 1990, AM J PATHOL, V136, P1223; KAASINEN S, 1995, ACTA OTOLARYNGOL, V1, P25; Kangas H, 1996, HUM MOL GENET, V5, P1237, DOI 10.1093/hmg/5.9.1237; KIURU S, 1992, ACTA NEUROL SCAND, V86, P346, DOI 10.1111/j.1600-0404.1992.tb05099.x; KIVELA T, 1993, BRIT J OPHTHALMOL, V77, P799, DOI 10.1136/bjo.77.12.799; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LeBlanc AC, 1996, J NEUROCHEM, V66, P2300; Makishita H, 1996, AMYLOID, V3, P134, DOI 10.3109/13506129609014366; MAURY CPJ, 1990, BIOCHIM BIOPHYS ACTA, V1096, P84, DOI 10.1016/0925-4439(90)90016-I; Maury CPJ, 1997, LAB INVEST, V77, P299; MAURY CPJ, 1990, FEBS LETT, V260, P85, DOI 10.1016/0014-5793(90)80072-Q; MAURY CPJ, 1994, LAB INVEST, V70, P558; MERETOJA J, 1969, Annals of Clinical Research, V1, P314; MERETOJA J, 1972, OPHTHALMOLOGICA, V165, P15, DOI 10.1159/000308469; MERETOJA J, 1971, ACTA PATH MICRO IM A, VA 79, P432; PAUNIO T, 1992, GENOMICS, V13, P237, DOI 10.1016/0888-7543(92)90235-K; PAUNIO T, 1994, AMYLOID, V1, P80, DOI 10.3109/13506129409148629; PAUNIO T, 1994, HUM MOL GENET, V3, P2223, DOI 10.1093/hmg/3.12.2223; Paunio T, 1997, FEBS LETT, V406, P49, DOI 10.1016/S0014-5793(97)00237-8; Ronni T, 1997, J IMMUNOL, V158, P2363; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; STARCK T, 1991, OPHTHALMOLOGY, V98, P1197; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Sunada Y, 1994, AMYLOID AMYLOIDOSIS, P623; Tienari PJ, 1996, EMBO J, V15, P5218, DOI 10.1002/j.1460-2075.1996.tb00907.x; Vouyiouklis DA, 1997, J NEUROCHEM, V69, P995; Wen DY, 1996, BIOCHEMISTRY-US, V35, P9700, DOI 10.1021/bi960920n; YIN HL, 1984, J BIOL CHEM, V259, P5271	36	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16319	16324		10.1074/jbc.273.26.16319	http://dx.doi.org/10.1074/jbc.273.26.16319			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632693	hybrid			2022-12-25	WOS:000074436600064
J	Boge, M; Wyss, S; Bonifacino, JS; Thali, M				Boge, M; Wyss, S; Bonifacino, JS; Thali, M			Membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CYTOPLASMIC DOMAIN; SORTING SIGNALS; PROTEIN; GP41; TAIL; ENDOCYTOSIS; ASSOCIATION; MECHANISM; MATRIX	The envelope glycoprotein (Env) of human immunodeficiency virus, type 1 (HIV-1) undergoes rapid internalization after its transport to the cell surface. Env internalization is dependent upon information contained within the cytosolic domain of the protein, Here, we report that the cytosolic domain of Env binds specifically to the medium chain, mu 2, of the clathrin-associated protein complex AP-2, as well as to the complete AP-2 complex. The Env cytosolic domain contains two highly conserved tyrosine-based motifs ((YSPL)-S-712 and (YHRL)-H-768), both of which are capable of binding to mu 2 when presented as short peptides, However, only the membrane-proximal motif (YSPL)-S-712 binds to mu 2 and is required for internalization in the context of the whole cytosolic domain of Env, A glycine residue (Gly(711)) adjacent to the (YSPL)-S-712 motif is also important for binding to mu 2/AP-2 and internalization. These observations suggest that the accessibility of the membrane-proximal GY(712)SPL to mu 2/AP-2 determines its function as a signal for recruitment of HIV-1 Env into clathrin-coated pits and its ensuing internalization.	CHU Vaudois, Inst Microbiol, CH-1011 Lausanne, Switzerland; NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Thali, M (corresponding author), CHU Vaudois, Inst Microbiol, CH-1011 Lausanne, Switzerland.	Markus.Thali@inst.hospvd.ch		Bonifacino, Juan S./0000-0002-5673-6370; Thali, Markus/0000-0001-8621-2095				Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Cosson P, 1996, EMBO J, V15, P5783, DOI 10.1002/j.1460-2075.1996.tb00964.x; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Egan MA, 1996, J VIROL, V70, P6547, DOI 10.1128/JVI.70.10.6547-6556.1996; Freed EO, 1996, J VIROL, V70, P341, DOI 10.1128/JVI.70.1.341-351.1996; FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883; GABUZDA DH, 1992, J VIROL, V66, P3306, DOI 10.1128/JVI.66.6.3306-3315.1992; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; HAFFAR OK, 1991, VIROLOGY, V180, P439, DOI 10.1016/0042-6822(91)90054-F; Hammarskjold ML, 1997, SEMIN CELL DEV BIOL, V8, P83, DOI 10.1006/scdb.1996.0127; HUNTER E, 1994, SEMIN VIROL, V5, P71, DOI 10.1006/smvy.1994.1008; Lodge R, 1997, EMBO J, V16, P695, DOI 10.1093/emboj/16.4.695; LODGE R, 1994, J VIROL, V68, P4857, DOI 10.1128/JVI.68.8.4857-4861.1994; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Myers GK, 1995, HUMAN RETROVIRUSES A; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; Ohno H, 1997, VIROLOGY, V238, P305, DOI 10.1006/viro.1997.8839; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; ROBEN P, 1994, J VIROL, V71, P6869; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; RODRIGUEZBOULAN E, 1993, J CELL SCI, P9; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Rost B, 1996, METHOD ENZYMOL, V266, P525; ROWELL JF, 1995, J IMMUNOL, V155, P473; Sauter MM, 1996, J CELL BIOL, V132, P795, DOI 10.1083/jcb.132.5.795; SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121; THALI M, 1994, J VIROL, V68, P674, DOI 10.1128/JVI.68.2.674-680.1994; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WILK T, 1992, VIROLOGY, V189, P167, DOI 10.1016/0042-6822(92)90692-I	31	162	163	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15773	15778		10.1074/jbc.273.25.15773	http://dx.doi.org/10.1074/jbc.273.25.15773			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624176	hybrid			2022-12-25	WOS:000074284200070
J	Chang, SC; Heacock, PN; Mileykovskaya, E; Voelker, DR; Dowhan, W				Chang, SC; Heacock, PN; Mileykovskaya, E; Voelker, DR; Dowhan, W			Isolation and characterization of the gene (CLS1) encoding cardiolipin synthase in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CLS; PHOSPHOLIPID BIOSYNTHESIS; PHOSPHATIDYLGLYCEROPHOSPHATE SYNTHASE; CYTOCHROME-OXIDASE; PHOSPHATIDYLSERINE SYNTHASE; ACIDIC PHOSPHOLIPIDS; PRESEQUENCE PEPTIDE; MITOCHONDRIAL DECAY; SECONDARY STRUCTURE; 2D H-1-NMR	In eukaryotic cells, cardiolipin (CL) synthase catalyzes the final step in the synthesis of CL from phosphatidylglycerol and CDP-diacylglycerol. CL and its synthesis are localized predominantly to the mitochondrial inner membrane, and CL is generally thought to be an essential component of many mitochondrial processes. By using homology searches for genes potentially encoding phospholipid biosynthetic enzymes, we have cloned the gene (CLS1) encoding CL synthase in Saccharomyces cerevisiae, Overexpression of the CLS1 gene under its endogenous promoter or the inducible GAL1 promoter in yeast and expression of CLS1 in baculovirus-infected insect cells resulted in elevated CL synthase activity. Disruption of the CLS1 gene in a haploid yeast strain resulted in the loss of CL synthase activity, no detectable CL, a 5-fold elevation in phosphatidylglycerol levels, and lack of staining of mitochondria by a dye with high affinity for CL. The cls1::TRP1 null mutant grew on both fermentable and non-fermentable carbon sources but more poorly on the latter. The level and activity of cytochrome c oxidase was normal, and a dye whose accumulation is dependent on membrane proton electrochemical potential effectively stained the mitochondria, These results definitively identify the gene encoding the CL synthase of yeast.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Natl Jewish Ctr Immunol & Resp Med, Denver, CO 80206 USA	University of Texas System; National Jewish Health	Dowhan, W (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA.	wdowhan@bmb.med.uth.tmc.edu		Mileykovskaya, Eugenia/0000-0002-8775-4467	NIGMS NIH HHS [GM32453, GM20478, GM54273] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054273, R37GM032453, R01GM020478, R37GM020478, R01GM032453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADOLPHUS, 1983, EMBO J, V2, P1765, DOI 10.1002/j.1460-2075.1983.tb01655.x; AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; AWASTHI YC, 1971, BIOCHIM BIOPHYS ACTA, V226, P42, DOI 10.1016/0005-2728(71)90176-9; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BEREITERHAHN J, 1976, BIOCHIM BIOPHYS ACTA, V423, P1, DOI 10.1016/0005-2728(76)90096-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chang SC, 1997, FASEB J, V11, pA1079; Chupin V, 1996, BIOCHEMISTRY-US, V35, P3141, DOI 10.1021/bi952482a; CHUPIN V, 1995, FEBS LETT, V373, P239, DOI 10.1016/0014-5793(95)01054-I; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; DOWHAN W, 1992, METHOD ENZYMOL, V209, P7; Dryden SC, 1996, J BACTERIOL, V178, P1030, DOI 10.1128/jb.178.4.1030-1038.1996; EILERS M, 1989, J BIOL CHEM, V264, P2945; ENDO T, 1989, J BIOL CHEM, V264, P2951; ESKO JD, 1980, J BIOL CHEM, V255, P4474; FINE JB, 1982, J LIPID RES, V23, P660; Gallet PF, 1997, BIOCHEM J, V324, P627, DOI 10.1042/bj3240627; GALLET PF, 1995, EUR J BIOCHEM, V228, P113, DOI 10.1111/j.1432-1033.1995.tb20238.x; Greenberg ML, 1996, MICROBIOL REV, V60, P1; Hatch GM, 1996, MOL CELL BIOCHEM, V159, P139, DOI 10.1007/BF00420916; HEACOCK PN, 1987, J BIOL CHEM, V262, P13044; HIRAOKA S, 1993, FEBS LETT, V336, P221, DOI 10.1016/0014-5793(93)80807-7; HIRSCHBERG CB, 1972, P NATL ACAD SCI USA, V69, P648, DOI 10.1073/pnas.69.3.648; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P5094; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Innis MA, 1990, PCR PROTOCOLS GUIDE; Janitor M, 1996, FEMS MICROBIOL LETT, V140, P43; JANITOR M, 1993, CURR GENET, V24, P307, DOI 10.1007/BF00336781; JANITOR M, 1995, YEAST, V11, P1223, DOI 10.1002/yea.320111302; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; KELLY BL, 1990, BIOCHIM BIOPHYS ACTA, V1046, P144, DOI 10.1016/0005-2760(90)90181-V; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KREBS JJR, 1979, J BIOL CHEM, V254, P5308; Maniatis T., 1982, MOL CLONING LAB MANU; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; NISHIJIMA S, 1988, J BACTERIOL, V170, P775, DOI 10.1128/jb.170.2.775-780.1988; OHTSUKA T, 1993, J BIOL CHEM, V268, P22914; OHTSUKA T, 1993, J BIOL CHEM, V268, P22908; OU WJ, 1988, J BIOCHEM-TOKYO, V103, P589, DOI 10.1093/oxfordjournals.jbchem.a122312; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAND RP, 1972, BIOCHIM BIOPHYS ACTA, V225, P484, DOI 10.1016/0005-2736(72)90152-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schlame M, 1997, BBA-LIPID LIPID MET, V1348, P201, DOI 10.1016/S0005-2760(97)00117-3; SCHLAME M, 1993, EUR J BIOCHEM, V212, P727, DOI 10.1111/j.1432-1033.1993.tb17711.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIBUYA I, 1992, METHOD ENZYMOL, V209, P321; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SIKORSKI RS, 1989, GENETICS, V122, P19; Spencer J.F.T., 1989, YEAST GENETICS MANUA; SUBIK J, 1974, FEBS LETT, V42, P309, DOI 10.1016/0014-5793(74)80753-2; TAMAI KT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P214, DOI 10.1016/0005-2760(90)90192-Z; TROPP BE, 1995, J BACTERIOL, V177, P5155, DOI 10.1128/jb.177.17.5155-5157.1995; Tuller G, 1998, FEBS LETT, V421, P15, DOI 10.1016/S0014-5793(97)01525-1; USUI M, 1994, J BACTERIOL, V176, P3389, DOI 10.1128/jb.176.11.3389-3392.1994; WIKSTROM M, 1992, J BIOL CHEM, V267, P10266; Zhao M, 1998, J BIOL CHEM, V273, P2402, DOI 10.1074/jbc.273.4.2402; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	62	165	167	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14933	14941		10.1074/jbc.273.24.14933	http://dx.doi.org/10.1074/jbc.273.24.14933			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614098	hybrid			2022-12-25	WOS:000074160400040
J	Feranchak, AP; Roman, RM; Schwiebert, EM; Fitz, JG				Feranchak, AP; Roman, RM; Schwiebert, EM; Fitz, JG			Phosphatidylinositol 3-kinase contributes to cell volume regulation through effects on ATP release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; PDGF BETA-RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; 3T3-L1 ADIPOCYTES; BINDING-SITE; PROTEIN; WORTMANNIN; KINASE; LIVER	Regulated changes in cell volume represent a signal that modulates a broad range of cell and organ functions. In HTC hepatoma cells, increases in volume are coupled to membrane ion permeability through a pathway involving (i) ATP efflux, (ii) autocrine stimulation of P-2 receptors, and (iii) increases in anion permeability and Cl- efflux, contributing to recovery of volume toward basal values. Based on recent evidence that cell volume increases also stimulate phosphoinositide kinases, the purpose of these studies was to determine if phosphatidylinositol 3-kinase (PI 3-kinase) modulates these pathways. Exposure of cells to hypotonic buffer (20 or 40% less NaCl) caused an initial increase in cell volume and stimulated a rapid increase in ATP release. Subsequent opening of Cl- channels was followed by recovery of cell volume toward basal values, despite the continuous presence of hypotonic buffer. Inhibition of PI 3-kinase with wortmannin (K-i = 3 nM) significantly inhibited both the rate of volume recovery and activation of Cl- currents; similar results were obtained with LY294002 (10 mu M). Additionally, current activation was inhibited by intracellular dialysis with antibodies specific for the 110-kDa catalytic subunit of PI 3-kinase. Since release of ATP is a critical element in the volume-regulatory pathway, the role of PP 3-kinase on volume-stimulated ATP release was assessed. Both wortmannin and LY294002 decreased basal and volume-stimulated ATP permeability hut had no effect on the current response to exogenous ATP (10 mu M). These findings indicate that PI 3-kinase plays a significant role in regulation of cell volume and suggest that the effects are mediated in part through modulation of cellular ATP release.	Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA; Childrens Hosp, Dept Pediat, Denver, CO 80262 USA; Childrens Hosp, Dept Med, Denver, CO 80262 USA; Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado; Children's Hospital Colorado; University of Alabama System; University of Alabama Birmingham	Feranchak, AP (corresponding author), Univ Colorado, Hlth Sci Ctr, Campus Box B-158,Room 6412,4200 E 9th Ave, Denver, CO 80262 USA.	drew.feranchak@UCHSC.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043278, R01DK046082, R37DK046082] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-46082, DK-43278] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALHABORI M, 1992, BIOCHEM J, V282, P789, DOI 10.1042/bj2820789; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BASAVAPPA S, 1993, GASTROENTEROLOGY, V104, P1796, DOI 10.1016/0016-5085(93)90661-U; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Bodily K, 1997, HEPATOLOGY, V25, P403; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHANG D, 1988, COMPUT BIOL MED, V18, P351, DOI 10.1016/0010-4825(88)90022-4; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FITZ JG, 1994, AM J PHYSIOL, V266, pG677, DOI 10.1152/ajpgi.1994.266.4.G677; FITZ JG, 1994, AM J PHYSIOL, V266, pG544, DOI 10.1152/ajpgi.1994.266.4.G544; Folli F, 1997, GASTROENTEROLOGY, V113, P954, DOI 10.1016/S0016-5085(97)70192-6; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HAUSSINGER D, 1994, AM J PHYSIOL, V267, pE343, DOI 10.1152/ajpendo.1994.267.3.E343; HAUSSINGER D, 1996, PROGR LIVER DIS, P29; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Katagiri H, 1997, AM J PHYSIOL-ENDOC M, V272, pE326, DOI 10.1152/ajpendo.1997.272.2.E326; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; LIDOFSKY SD, 1993, J BIOL CHEM, V268, P14632; Lidofsky SD, 1997, AM J PHYSIOL-GASTR L, V273, pG849, DOI 10.1152/ajpgi.1997.273.4.G849; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Meng XJ, 1996, AM J PHYSIOL-CELL PH, V271, pC112, DOI 10.1152/ajpcell.1996.271.1.C112; Merlin D, 1996, AM J PHYSIOL-CELL PH, V271, pC612, DOI 10.1152/ajpcell.1996.271.2.C612; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Noe B, 1996, GASTROENTEROLOGY, V110, P858, DOI 10.1053/gast.1996.v110.pm8608896; OKADA T, 1994, J BIOL CHEM, V269, P3563; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walters RJ, 1996, FEBS LETT, V392, P66, DOI 10.1016/0014-5793(96)00679-5; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WONG K, 1994, J BIOL CHEM, V269, P28878	48	103	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14906	14911		10.1074/jbc.273.24.14906	http://dx.doi.org/10.1074/jbc.273.24.14906			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614094	hybrid			2022-12-25	WOS:000074160400036
J	Gilchrist, A; Mazzoni, MR; Dineen, B; Dice, A; Linden, J; Proctor, WR; Lupica, CR; Dunwiddie, TV; Hamm, HE				Gilchrist, A; Mazzoni, MR; Dineen, B; Dice, A; Linden, J; Proctor, WR; Lupica, CR; Dunwiddie, TV; Hamm, HE			Antagonists of the receptor-G protein interface block G(1)-coupled signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; A(1) ADENOSINE RECEPTORS; HIPPOCAMPAL-FORMATION; SYNTHETIC PEPTIDES; PERTUSSIS TOXIN; CEREBRAL-CORTEX; BOVINE BRAIN; RAT-BRAIN; CONFORMATIONAL-CHANGES; TERMINAL MUTATIONS	The carboxyl terminus of heterotrimeric G protein alpha subunits plays an important Pole in receptor interaction. We demonstrate that peptides corresponding to the last 11 residues of G alpha(i1/2) or G alpha(o1) impair agonist binding to A(1) adenosine receptors, whereas G alpha(s) or G alpha(t) peptides have mo effect. Previously, by using a combinatorial library we identified a series of G alpha(t) peptide analogs that bind rhodopsin with high affinity (Martin, E. L., Rens-Domiano, S., Schatz, P. J., and Hamm, H. E. (1996) J. Biol. Chem. 271, 361-366). Native G alpha(i1/2) peptide as well as several analogs were tested for their ability to modulate agonist binding or antagonist-agonist competition using cells overexpressing human A(1) adenosine receptors. Three peptide analogs decreased the K-i, suggesting that they disrupt the high affinity receptor-G protein interaction and stabilize am intermediate affinity state. To study the ability of the peptides to compete with endogenous G alpha(i) proteins and block signal transduction in a native setting we measured activation of G protein-coupled K+ channels through A(1) adenosine or gamma-aminobutyric acid, type B, receptors in hippocampal CA1 pyramidal neurons. Native G alpha(i1/2), peptide, and certain analog peptides inhibited receptor-mediated K+ channel gating, dependent can which receptor was activated. This differential perturbation of receptor-G protein interaction suggests that receptors that act on the same G protein can be selectively disrupted.	Northwestern Univ, Inst Neurosci, Dept Mol Pharmacol & Biochem, Chicago, IL 60611 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA; Univ Pisa, Dept Psychiat Neurobiol Pharmacol & Biotechnol, Neurobiol & Pharmacol Lab, I-56126 Pisa, Italy; Univ Virginia, Dept Internal Med, Div Cardiovasc, Charlottesville, VA 22908 USA; Univ Colorado, Dept Pharmacol, Denver, CO 80262 USA	Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Pisa; University of Virginia; University of Colorado System; University of Colorado Denver	Hamm, HE (corresponding author), Northwestern Univ, Inst Neurosci, Dept Mol Pharmacol & Biochem, 320 E Super 5-555 Searle, Chicago, IL 60611 USA.		Gilchrist, Annette/I-4465-2014; Hamm, Heidi E/G-2374-2014; Lupica, Carl/AAY-3193-2021; Mazzoni, Maria Rosa/AAA-2366-2022	Gilchrist, Annette/0000-0003-2386-7646; Lupica, Carl/0000-0002-5375-3263; Mazzoni, Maria Rosa/0000-0003-2612-432X	NEI NIH HHS [EY 06062, EY10291] Funding Source: Medline; NHLBI NIH HHS [HL 37942] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006062, R01EY010291] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL037942, R01HL037942] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; ASANO T, 1985, J BIOL CHEM, V260, P2653; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Beindl W, 1996, MOL PHARMACOL, V50, P415; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; Danialou G, 1997, BRIT J PHARMACOL, V121, P1355, DOI 10.1038/sj.bjp.0701247; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; DUTAR P, 1988, NEURON, V1, P585, DOI 10.1016/0896-6273(88)90108-0; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; FASTBOM J, 1987, ACTA PHYSIOL SCAND, V131, P467, DOI 10.1111/j.1748-1716.1987.tb08263.x; Figler RA, 1997, BIOCHEMISTRY-US, V36, P16288, DOI 10.1021/bi972000q; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; FREUND S, 1994, N-S ARCH PHARMACOL, V350, P49; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GERWINS P, 1992, P NATL ACAD SCI USA, V89, P7330, DOI 10.1073/pnas.89.16.7330; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hohenegger M, 1998, P NATL ACAD SCI USA, V95, P346, DOI 10.1073/pnas.95.1.346; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KNOWLES WD, 1992, J CLIN NEUROPHYSIOL, V9, P252; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LEE KS, 1986, NEUROSCIENCE, V19, P535, DOI 10.1016/0306-4522(86)90279-4; LINDEN J, 1985, CIRC RES, V56, P279, DOI 10.1161/01.RES.56.2.279; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; Mei YA, 1996, J NEUROENDOCRINOL, V8, P85, DOI 10.1111/j.1365-2826.1996.tb00827.x; MORISHITA R, 1990, FEBS LETT, V271, P231, DOI 10.1016/0014-5793(90)80413-D; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; MUNSHI R, 1989, J BIOL CHEM, V264, P14853; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; OLAH ME, 1995, ARCH INT PHARMACOD T, V329, P135; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; PALM D, 1990, FEBS LETT, V261, P294, DOI 10.1016/0014-5793(90)80575-4; PALMER TM, 1995, NEUROPHARMACOLOGY, V34, P683, DOI 10.1016/0028-3908(95)00044-7; RAMKUMAR V, 1988, J PHARMACOL EXP THER, V246, P1194; RARICK HM, 1994, METHOD ENZYMOL, V238, P13; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; REPPERT SM, 1991, MOL ENDOCRINOL, V5, P1037, DOI 10.1210/mend-5-8-1037; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RIVKEES SA, 1994, ENDOCRINOLOGY, V135, P2307, DOI 10.1210/en.135.6.2307; RIVKEES SA, 1995, BRAIN RES, V677, P193, DOI 10.1016/0006-8993(95)00062-U; Schreibmayer W, 1996, NATURE, V380, P624, DOI 10.1038/380624a0; SCOTT RH, 1987, INHIBITION NEURONAL, P549; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; STILES GL, 1992, J BIOL CHEM, V267, P6451; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; Swanson TH, 1995, J COMP NEUROL, V363, P517, DOI 10.1002/cne.903630402; SWEENEY MI, 1995, J NEUROCHEM, V64, P2034; TETZLAFF W, 1987, NEUROSCIENCE, V21, P869, DOI 10.1016/0306-4522(87)90043-1; Tomura H, 1997, J BIOL CHEM, V272, P23130, DOI 10.1074/jbc.272.37.23130; TRUSSELL LO, 1987, J NEUROSCI, V7, P3306; VANCALKER D, 1979, J NEUROCHEM, V33, P999, DOI 10.1111/j.1471-4159.1979.tb05236.x; Verrall S, 1997, J BIOL CHEM, V272, P6898, DOI 10.1074/jbc.272.11.6898; WEAVER DR, 1992, AM J PHYSIOL, V263, pF991, DOI 10.1152/ajprenal.1992.263.6.F991; WEST RE, 1985, J BIOL CHEM, V260, P4428; Zapata R, 1997, J NEUROCHEM, V69, P2546	69	84	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14912	14919		10.1074/jbc.273.24.14912	http://dx.doi.org/10.1074/jbc.273.24.14912			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614095	hybrid			2022-12-25	WOS:000074160400037
J	Halvorson, LM; Ito, M; Jameson, JL; Chin, WW				Halvorson, LM; Ito, M; Jameson, JL; Chin, WW			Steroidogenic factor-1 and early growth response protein 1 act through two composite DNA binding sites to regulate luteinizing hormone beta-subunit gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; FACTOR-I; TRANSGENIC MICE; CHORIONIC-GONADOTROPIN; KEY REGULATOR; PITUITARY; PROMOTER; ENCODES; CELL; LH	Recent in vivo and in vitro studies have implicated the orphan nuclear receptor, steroidogenic factor-1 (SF-1), and the early growth response protein 1 (Egr-1) in the transcriptional regulation of the luteinizing hormone beta-subunit (LH beta) gene. We have previously demonstrated the ability of SF-1 to bind to and transactivate the rat LH beta gene promoter acting at a consensus gonadotrope-specific element (GSE) located at position -127. We have now identified a second functional GSE site at position -59. In addition, based on electrophoretic mobility shift assay, in vitro translated Egr-1 is shown to bind to two putative Egr-1 binding sites (positions -112 and -50), which appear to be paired with the identified GSE sites. By transient transfection assay in pituitary-derived GH, cells, it was seen that Egr-1 increases promoter activity of region -207/+5 of the rat LH beta gene promoter through action at both Egr-1 sites. Furthermore, LHP gene promoter activity is markedly augmented in the presence of both factors together relative to activity in the presence of SF-1 or Egr-1 alone (150-fold versus 14-fold and 12-fold, respectively). These data define two composite SF-1-Egr-1 response-elements in the proximal LH beta gene promoter and suggest that SF-1 and Egr-1 act synergistically to increase expression of the LH beta gene in the gonadotrope.	Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02111 USA; Northwestern Univ, Sch Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Tufts University; Northwestern University	Halvorson, LM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Genet, GW Thorn Res Bldg,Rm 1013,20 Shattuck St, Boston, MA 02115 USA.	Halvorson@rascal.med.harvard.edu		Jameson, James/0000-0001-9538-4059	NICHD NIH HHS [R01-HD19938, R03-HD34692, U54-HD29164] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD019938] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029164, R03HD034692] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BROWN P, 1993, MOL CELL ENDOCRINOL, V93, P157, DOI 10.1016/0303-7207(93)90119-5; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLAYTON RN, 1991, MOL CELL ENDOCRINOL, V80, P193, DOI 10.1016/0303-7207(91)90156-M; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EZASHI T, 1990, J MOL ENDOCRINOL, V5, P137, DOI 10.1677/jme.0.0050137; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Halvorson LM, 1996, J BIOL CHEM, V271, P6645, DOI 10.1074/jbc.271.12.6645; HONDA S, 1993, J BIOL CHEM, V268, P7494; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; JAMESON L, 1984, J BIOL CHEM, V259, P5474; Kaiser UB, 1995, P NATL ACAD SCI USA, V92, P12280, DOI 10.1073/pnas.92.26.12280; Keri RA, 1996, J BIOL CHEM, V271, P10782, DOI 10.1074/jbc.271.18.10782; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; MORRIS AE, 1990, GENE, V94, P289, DOI 10.1016/0378-1119(90)90400-L; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; Sambrook J., 2002, MOL CLONING LAB MANU; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHERMAN GB, 1992, MOL ENDOCRINOL, V6, P951, DOI 10.1210/me.6.6.951; SHUPNIK MA, 1989, J BIOL CHEM, V264, P80; SUEN CS, 1993, MOL CELL BIOL, V13, P1719, DOI 10.1128/MCB.13.3.1719; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; Thomas P, 1996, ENDOCRINOLOGY, V137, P2979, DOI 10.1210/en.137.7.2979; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; VIRGIN JB, 1985, J BIOL CHEM, V260, P7072; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	40	116	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14712	14720		10.1074/jbc.273.24.14712	http://dx.doi.org/10.1074/jbc.273.24.14712			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614069	hybrid			2022-12-25	WOS:000074160400011
J	Arts, EJ; Miller, JT; Ehresmann, B; Le Grice, SFJ				Arts, EJ; Miller, JT; Ehresmann, B; Le Grice, SFJ			Mutating a region of HIV-1 reverse transcriptase implicated in tRNA(Lys-3) binding and the consequences for (-)-strand DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GEL RETARDATION ASSAYS; PRIMER TRANSFER-RNA; ANGSTROM RESOLUTION; TRANSFER RNA(LYS-3); CRYSTAL-STRUCTURE; TYPE-1 PARTICLES; WILD-TYPE; SITE; TRNA(3)(LYS)	Recently, tRNA(Lys-3) Was cross-linked via its anticodon loop to human immunodeficiency virus type I (HIV-1) reverse transcriptase (RT) between residues 230 and 357 (Mishima, Y., and Steitz, J. A. (1995) EMBO J. 14, 2679-2687), Scanning the surface of this region identified three basic amino acids Lys(249), Arg(307), and Lys(311) flanking a small crevice on the p66 thumb subdomain outside the primer-template binding cleft. To assess an interaction of this region with the tRNA anticodon loop, these p66 residues were altered to Glu or Gin. p66 subunits containing K249Q, K311Q, K311E, and a dual R307E/K311E K311E mutation formed a stable dimer with wild type p51. All mutants showed reduced affinity for tRNA(Lys-3) and supported significantly less (-)-strand DNA synthesis from this primer than the parental heterodimer. In contrast, these variants efficiently synthesized HIV-1 (-)-strand strong-stop DNA from oligonucleotide primers and had minimal effect on RNase H activity, retaining endonucleolytic and directed cleavage of an RNA/DNA hybrid. Structural features of binary RT.tRNA(Lys-3) complexes were examined by in situ footprinting, via susceptibility to 1,10-phenanthroline-copper-mediated cleavage. Unlike wild type RT, mutants p66(K311Q)/p51 and p66(K311E)/p51 failed to protect the tRNA anticodon domain from chemical cleavage, indicating a significant structural alteration in the binary RT tRNA complex. These results suggest a crevice in the p66 thumb subdomain of HIV-1 RT supports an interaction with the tRNA(Lys-3) anticodon loop critical for efficient (-)-strand DNA synthesis.	Case Western Reserve Univ, Univ Hosp Cleveland, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr AIDS Res, Cleveland, OH 44106 USA; CNRS, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Le Grice, SFJ (corresponding author), Case Western Reserve Univ, Univ Hosp Cleveland, Dept Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.	sfl@po.cwru.edu		Arts, Eric/0000-0002-4880-7968	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147, P30AI036219] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36219, AI31147] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agris PF, 1997, RNA, V3, P420; Arion D, 1996, BIOCHEM BIOPH RES CO, V225, P839, DOI 10.1006/bbrc.1996.1260; ARTS EJ, 1994, J GEN VIROL, V75, P1605, DOI 10.1099/0022-1317-75-7-1605; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; Arts Eric J., 1995, Journal of Biomedical Science, V2, P314, DOI 10.1007/BF02255218; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; Berkhout B, 1997, NUCLEIC ACIDS RES, V25, P4013, DOI 10.1093/nar/25.20.4013; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; Canard B, 1997, P NATL ACAD SCI USA, V94, P11279, DOI 10.1073/pnas.94.21.11279; DAS AT, 1995, J VIROL, V69, P3090, DOI 10.1128/JVI.69.5.3090-3097.1995; Essink BBO, 1996, J MOL BIOL, V264, P243, DOI 10.1006/jmbi.1996.0638; ESSINK BBO, 1995, J BIOL CHEM, V270, P23867, DOI 10.1074/jbc.270.40.23867; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; Hermann T, 1995, RNA, V1, P1009; Huang Y, 1997, J VIROL, V71, P726, DOI 10.1128/JVI.71.1.726-728.1997; ISEL C, 1993, J BIOL CHEM, V268, P25269; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P1388; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Leis J, 1993, REVERSE TRANSCRIPTAS, P33; LI XG, 1994, J VIROL, V68, P6198, DOI 10.1128/JVI.68.10.6198-6206.1994; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; Mak J, 1997, J MOL BIOL, V265, P419, DOI 10.1006/jmbi.1996.0742; MAK J, 1994, J VIROL, V68, P2065, DOI 10.1128/JVI.68.4.2065-2072.1994; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; MISHIMA Y, 1995, EMBO J, V14, P2679, DOI 10.1002/j.1460-2075.1995.tb07266.x; Myers GK, 1995, HUMAN RETROVIRUSES A; NAGASHUNMUGAM T, 1992, P NATL ACAD SCI USA, V89, P4114, DOI 10.1073/pnas.89.9.4114; PEARSON L, 1994, NUCLEIC ACIDS RES, V22, P2255, DOI 10.1093/nar/22.12.2255; Rausch JW, 1996, J MOL BIOL, V257, P500, DOI 10.1006/jmbi.1996.0181; RHIM H, 1991, J VIROL, V65, P4555, DOI 10.1128/JVI.65.9.4555-4564.1991; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P15952; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; SARIHCOTTIN L, 1992, J MOL BIOL, V226, P1, DOI 10.1016/0022-2836(92)90117-3; Thrall SH, 1996, BIOCHEMISTRY-US, V35, P4609, DOI 10.1021/bi9526387; WAKEFIELD JK, 1994, J VIROL, V68, P1605, DOI 10.1128/JVI.68.3.1605-1614.1994; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; WOHRL BM, 1993, J BIOL CHEM, V268, P13617; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343	50	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14523	14532		10.1074/jbc.273.23.14523	http://dx.doi.org/10.1074/jbc.273.23.14523			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603966	hybrid			2022-12-25	WOS:000074021500068
J	Emery, JG; McDonnell, P; Burke, MB; Deen, KC; Lyn, S; Silverman, C; Dul, E; Appelbaum, ER; Eichman, C; DiPrinzio, R; Dodds, RA; James, IE; Rosenberg, M; Lee, JC; Young, PR				Emery, JG; McDonnell, P; Burke, MB; Deen, KC; Lyn, S; Silverman, C; Dul, E; Appelbaum, ER; Eichman, C; DiPrinzio, R; Dodds, RA; James, IE; Rosenberg, M; Lee, JC; Young, PR			Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-RECEPTOR; DOMAIN-CONTAINING RECEPTOR; SURFACE-PLASMON RESONANCE; DEATH-DOMAIN; TNF RECEPTOR; FAMILY; APOPTOSIS; BINDING; MEMBER; PROTEINS	TRAIL is a tumor necrosis factor-related ligand that induces apoptosis upon binding to its death domain-containing receptors, DR4 and DR5. Two additional TRAIL receptors, TRID/DcR1 and DcR2, lack functional death domains and function as decoy receptors for TRAIL. We have identified a fifth TRAIL receptor, namely osteoprotegerin (OPG), a secreted tumor necrosis factor receptor homologue that inhibits osteoclastogenesis and increases bone density in vivo. OPG-Fc binds TRAIL with an affinity of 3.0 nM, which is slightly weaker than the interaction of TRID-Fc or DR5-Fc with TRAIL. OPG inhibits TRAIL-induced apoptosis of Jurkat cells, Conversely, TRAIL blocks the anti-osteoclastogenic activity of OPG, These data suggest potential cross-regulatory mechanisms by OPG and TRAIL.	SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Biol Struct, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Mol & Cellular Immunol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Bone & Cartilage Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Antiinfect, Collegeville, PA 19426 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Young, PR (corresponding author), SmithKline Beecham Pharmaceut, Dept Mol Biol, Mail Code UW2101,709 Swedeland Rd, King Of Prussia, PA 19406 USA.							AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Harlow E., 1988, ANTIBODIES LAB MANUA; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KUMAR S, 1995, J BIOL CHEM, V270, P27905, DOI 10.1074/jbc.270.46.27905; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; LACEY DL, 1995, ENDOCRINOLOGY, V136, P2367, DOI 10.1210/en.136.6.2367; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; Lotz M, 1996, J LEUKOCYTE BIOL, V60, P1; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OSHANNESSY DJ, 1994, METHOD ENZYMOL, V240, P323; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PENNICA D, 1992, J BIOL CHEM, V267, P21172; Pinckard JK, 1997, J IMMUNOL, V158, P3869; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sedger L, 1996, IMMUNOL CELL BIOL, V74, P538, DOI 10.1038/icb.1996.87; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	37	997	1082	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14363	14367		10.1074/jbc.273.23.14363	http://dx.doi.org/10.1074/jbc.273.23.14363			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603945	hybrid			2022-12-25	WOS:000074021500047
J	von der Kammer, H; Mayhaus, M; Albrecht, C; Enderich, J; Wegner, M; Nitsch, RM				von der Kammer, H; Mayhaus, M; Albrecht, C; Enderich, J; Wegner, M; Nitsch, RM			Muscarinic acetylcholine receptors activate expression of the Egr gene family of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; RAT-BRAIN; CHOLINERGIC STIMULATION; DIFFERENTIAL DISPLAY; MEDIATED INDUCTION; NG108-15 CELLS; CULTURED-CELLS; GROWTH-FACTORS; BETA-PROTEIN; SUBTYPES	In order to search for genes that are activated by muscarinic acetylcholine receptors (mAChRs), we used an mRNA differential display approach in HEK293 cells expressing m1AChR. The zinc-finger transcription factor genes Egr-1, Egr-2, and Egr-3 were identified. Northern blot analyses confirmed that mRNA levels of Egr-1, Egr-2, and Egr-3 increased readily after m1AChR stimulation and that a maximum was attained within 50 min. At that time, Egr-4 mRNA was also detectable. Western blots and electromobility shift assays demonstrated synthesis of EGR-1 and EGR-3, as well as binding to DNA recognition sites in response to m1AChR activation. Activation of m1AChR increased transcription from EGR-dependent promoters, including the acetylcholinesterase gene promoter. Activity-dependent regulation of Egr-1 mRNA expression and EGR-1 protein synthesis was also observed in cells expressing m2, m3, or m4AChR subtypes, Increased EGR-1 synthesis was mimicked by phorbol myristate acetate, but not by forskolin, and receptor-stimulated EGR-1 synthesis was partially inhibited by phorbol myristate acetate down-regulation. Together, our results demonstrate that muscarinic receptor signaling activates the EGR transcription factor family and that PKC may be involved in intracellular signaling. The data suggest that transcription of EGR-dependent target genes, including the AChE gene, can be under the control of extracellular and intracellular signals coupled to muscarinic receptors.	Univ Hamburg, Ctr Mol Neurobiol, D-20246 Hamburg, Germany; Univ Hamburg, Alzheimers Dis Res Grp, D-20246 Hamburg, Germany	University of Hamburg; University of Hamburg	Nitsch, RM (corresponding author), Univ Hamburg, Ctr Mol Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.	nitsch@plexus.uke.uni-hamburg.de		Wegner, Michael/0000-0002-4586-3294				ABUSHAKRA SR, 1994, MOL BRAIN RES, V26, P55, DOI 10.1016/0169-328X(94)90073-6; ALTIN JG, 1991, J BIOL CHEM, V266, P5401; BERNARD V, 1993, EUR J NEUROSCI, V5, P1218, DOI 10.1111/j.1460-9568.1993.tb00976.x; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Coleman BA, 1996, J BIOL CHEM, V271, P4410; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DICHIARA G, 1994, TRENDS NEUROSCI, V17, P228, DOI 10.1016/0166-2236(94)90005-1; Dragunow M, 1996, BEHAV GENET, V26, P293, DOI 10.1007/BF02359385; EBHIHARA T, 1997, J NEUROCHEM, V68, P1001; FARBER SA, 1995, J NEUROSCI, V15, P7442; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P1706, DOI 10.1073/pnas.90.5.1706; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; HUGHES P, 1994, MOL BRAIN RES, V24, P166, DOI 10.1016/0169-328X(94)90129-5; HUGHES P, 1993, NEUROSCI LETT, V150, P122, DOI 10.1016/0304-3940(93)90122-2; HUNG AY, 1993, J BIOL CHEM, V268, P22959; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KATAYAMA N, 1993, J NEUROCHEM, V60, P902, DOI 10.1111/j.1471-4159.1993.tb03235.x; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; LIM RW, 1987, ONCOGENE, V1, P263; LIN Y, 1991, BRAIN RES, V551, P342, DOI 10.1016/0006-8993(91)90955-U; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Morita K, 1996, J NEUROCHEM, V67, P1344; MULLER HJ, 1991, P NATL ACAD SCI USA, V88, P10079, DOI 10.1073/pnas.88.22.10079; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; Nitsch RM, 1997, J NEUROCHEM, V69, P704; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; POMBOVILLAR E, 1992, EUR J PHARM-MOLEC PH, V226, P317, DOI 10.1016/0922-4106(92)90049-2; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; Sambrook J., 2002, MOL CLONING LAB MANU; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; ZHAO S, 1995, BIOTECHNIQUES, V18, P842	62	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14538	14544		10.1074/jbc.273.23.14538	http://dx.doi.org/10.1074/jbc.273.23.14538			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603968	hybrid			2022-12-25	WOS:000074021500070
J	Ward, DT; Brown, EM; Harris, HW				Ward, DT; Brown, EM; Harris, HW			Disulfide bonds in the extracellular calcium-polyvalent cation-sensing receptor correlate with dimer formation and its response to divalent cations in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; ELECTROPHORETIC TRANSFER; CA2+-SENSING RECEPTOR; MEMBRANE PROTEINS; XENOPUS-OOCYTES; SOLUBILIZATION; BINDING; KIDNEY	Extracellular calciun/polyvalent cation-sensing receptors (CaR) couple to G proteins and contain highly conserved extracellular cysteine residues. Immunoblotting of proteins from rat kidney inner medullary collecting duct endosomes with CaR-specific antibodies reveals alterations in the apparent molecular mass of CaR depending on protein denaturation conditions. When denatured by SDS under nonreducing conditions, CaR migrates as a putative dimer ic species of 240-310 kDa, This is twice the predicted molecular mass of the CaR monomer observed after SDS denaturation in the presence of sulfhydryl-reducing agents. In sucrose density gradients, Triton X-100-solubilized CaR sediments as a 220-kDa complex, not explainable by binding of G proteins to CaR monomers. Treatment of Triton-soluble CaR with divalent (Ca2+, Mg2+) and trivalent (Gd3+) metal ion CaR agonists, but not monovalent ions (Na+), partially shifts the electrophoretic mobility of CaR under reducing conditions from a predominantly monomeric to this putative dimeric species on immunoblots in a manner similar to their rank order of functional potency for CaR activation (Gd3+ much greater than Ca2+ > Mg2+). This Ca2+ effect is blocked by pretreatment with N-ethyl-maleimide. We conclude that disulfide bonds present in CaRs mediate formation of dimers that are preserved in Triton X-100 solution. In addition, CaR exposure to Ca2+ induces formation of additional disulfide bonds within the Triton-soluble CaR complex.	Harvard Univ, Childrens Hosp, Sch Med, Renal Res Lab,Div Nephrol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Endocrine Hypertens, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Harris, HW (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Renal Res Lab,Div Nephrol, Enders Bldg,Rm 1260,300 Longwood Ave, Boston, MA 02115 USA.	harris@hub.tch.harvard.edu	Centeno, Patricia Pacios/O-8368-2016	Ward, Donald/0000-0003-1342-9458	NHLBI NIH HHS [HL-15157] Funding Source: Medline; NIDDK NIH HHS [DK-38874, DK-43955] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043955, R01DK038874] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE T, 1992, J BIOL CHEM, V267, P13361; AIDA K, 1995, BIOCHEM BIOPH RES CO, V214, P524, DOI 10.1006/bbrc.1995.2318; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BARRETT P, 1994, J NEUROENDOCRINOL, V6, P509, DOI 10.1111/j.1365-2826.1994.tb00613.x; Bobovnikova Y, 1997, ENDOCRINOLOGY, V138, P588, DOI 10.1210/en.138.2.588; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; BROWN EM, 1991, J BONE MINER RES, V6, P1217; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Chattopadhyay N, 1996, ENDOCR REV, V17, P289, DOI 10.1210/er.17.4.289; Chattopadhyay N, 1996, AM J PHYSIOL-RENAL, V271, pF736, DOI 10.1152/ajprenal.1996.271.3.F736; CHEN TH, 1994, J BONE MINER RES, V9, P293; CHEN YH, 1992, BIOCHEMISTRY-US, V31, P2415, DOI 10.1021/bi00123a029; CLARKE S, 1975, J BIOL CHEM, V250, P5459; Cook JVF, 1996, ENDOCRINOLOGY, V137, P2851, DOI 10.1210/en.137.7.2851; Cook JVF, 1997, ENDOCRINOLOGY, V138, P2800, DOI 10.1210/en.138.7.2800; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; FELDMAN RI, 1990, J BIOL CHEM, V265, P17364; FURTHMAYR H, 1976, BIOCHEMISTRY-US, V15, P1137, DOI 10.1021/bi00650a028; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; HAMMERLAND LG, 1995, J BONE MINER RES, V10, P156; HARRIS HW, 1994, J BIOL CHEM, V269, P11993; Hebert SC, 1997, J EXP BIOL, V200, P295; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; KERMODE JC, 1992, J BIOL CHEM, V267, P3382; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKINO S, 1973, J BIOL CHEM, V248, P4926; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MAZELLA J, 1988, J BIOL CHEM, V263, P144; OFRI D, 1992, J NEUROCHEM, V58, P628, DOI 10.1111/j.1471-4159.1992.tb09764.x; Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987; Petralia RS, 1996, NEUROSCIENCE, V71, P949, DOI 10.1016/0306-4522(95)00533-1; RACKE FK, 1993, FEBS LETT, V333, P132, DOI 10.1016/0014-5793(93)80390-G; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; ROGERS KV, 1995, ENDOCRINOLOGY, V136, P499, DOI 10.1210/en.136.2.499; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; SanchezMargalet V, 1997, ENDOCRINOLOGY, V138, P1712, DOI 10.1210/en.138.4.1712; Sands JM, 1997, J CLIN INVEST, V99, P1399, DOI 10.1172/JCI119299; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANFORD C, 1976, BIOCHIM BIOPHYS ACTA, V457, P133, DOI 10.1016/0304-4157(76)90009-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAISH A, 1991, J RECEPTOR RES, V11, P965, DOI 10.3109/10799899109064691; WANG K, 1989, METHOD ENZYMOL, V172, P687, DOI 10.1016/S0076-6879(89)72038-3; YU J, 1975, J BIOL CHEM, V250, P9176; ZIEGRA CJ, 1992, P NATL ACAD SCI USA, V89, P4134, DOI 10.1073/pnas.89.9.4134	49	155	161	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14476	14483		10.1074/jbc.273.23.14476	http://dx.doi.org/10.1074/jbc.273.23.14476			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603961	hybrid			2022-12-25	WOS:000074021500063
J	Laharrague, P; Larrouy, D; Fontanilles, AM; Truel, N; Campfield, A; Tenenbaum, R; Galitzky, J; Corberand, JX; Penicaud, L; Casteilla, L				Laharrague, P; Larrouy, D; Fontanilles, AM; Truel, N; Campfield, A; Tenenbaum, R; Galitzky, J; Corberand, JX; Penicaud, L; Casteilla, L			High expression of leptin by human bone marrow adipocytes in primary culture	FASEB JOURNAL			English	Article						adipose tissue; ob; corticosteroids; hematopoiesis	ADIPOSE-TISSUE; CELL-LINE; HUMAN LEUKOCYTES; OBESE GENE; OB GENE; DIFFERENTIATION; PROLIFERATION; BETA(3)-ADRENOCEPTORS; PHOSPHATASE; ISOENZYME	Adipocytes participate in the microenvironment of the bone marrow (BM), but their exact role remains to be determined. It has recently been shown that leptin, a hormone secreted from extramedullary adipocytes, could be involved in hematopoiesis. Therefore we have developed a primary culture system of human BM adipocytes to characterize their differentiation and determine whether leptin is also secreted from these adipocytes. BM cells were cultured with fetal calf and horse sera. In the presence of dexamethasone, cells with vesicles containing lipids appeared within 15 days. They expressed glycerol phosphate dehydrogenase activity and a lipolytic activity in response to isoproterenol, but expressed neither the adrenergic beta 3 receptor nor the mitochondrial uncoupling protein UCP1. The addition of insulin alone to the culture media did not promote adipocyte differentiation. Leptin was expressed and secreted at high levels during adipocyte differentiation. Acute exposure of differentiated adipocytes to insulin had little effect on leptin expression whereas forskolin strongly inhibited it. These results show that although human BM adipocytes differ from extramedullary adipose tissues in their sensitivity to different effecters, they are a secondary source of leptin production. They suggest that BM adipocytes could contribute to hematopoiesis via the secretion of leptin in the vicinity of hematopoietic stem cells.	Fac Med, IFR L Bugnard, CNRS, UPRESA 5018, Toulouse, France; Fac Med, IFR L Bugnard, INSERM, U317, Toulouse, France; Hoffmann La Roche Inc, Nutley, NJ 07110 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Roche Holding	Laharrague, P (corresponding author), Hop Toulouse Rangueil, CNRS, UPRESA 5018, F-31403 Toulouse, France.		Galitzky, Jean/R-6599-2017	Casteilla, Louis/0000-0001-9647-3248; Larrouy, Dominique/0000-0002-4120-5593				Barbe P, 1996, BRIT J PHARMACOL, V117, P907, DOI 10.1111/j.1476-5381.1996.tb15279.x; BATHIJA A, 1978, AM J HEMATOL, V5, P315, DOI 10.1002/ajh.2830050406; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; BENNETT JH, 1991, J CELL SCI, V99, P131; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; Cheng SL, 1996, J CELL BIOCHEM, V61, P182, DOI 10.1002/(SICI)1097-4644(19960501)61:2<182::AID-JCB3>3.0.CO;2-Q; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DORHEIM MA, 1993, J CELL PHYSIOL, V154, P317, DOI 10.1002/jcp.1041540215; EMORINE L, 1994, TRENDS PHARMACOL SCI, V15, P3, DOI 10.1016/0165-6147(94)90118-X; FOREST C, 1987, EXP CELL RES, V168, P218, DOI 10.1016/0014-4827(87)90430-7; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; GIMBLE J M, 1990, New Biologist, V2, P304; Gimble JM, 1996, BONE, V19, P421, DOI 10.1016/S8756-3282(96)00258-X; GIMBLE JM, 1990, EUR J IMMUNOL, V20, P379, DOI 10.1002/eji.1830200222; HANGOC G, 1993, EXP HEMATOL, V21, P502; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; KAPLOW LS, 1965, BLOOD-J HEMATOL, V26, P215, DOI 10.1182/blood.V26.2.215.215; KAPLOW LS, 1963, AM J CLIN PATHOL, V39, P439; Kosaki A, 1996, DIABETES, V45, P1744, DOI 10.2337/diabetes.45.12.1744; LANOTTE M, 1981, J CELL SCI, V50, P281; Leroy P, 1996, J BIOL CHEM, V271, P2365, DOI 10.1074/jbc.271.5.2365; LI CY, 1973, J HISTOCHEM CYTOCHEM, V21, P1; LI CY, 1970, J HISTOCHEM CYTOCHEM, V18, P901, DOI 10.1177/18.12.901; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; MARKO O, 1995, ENDOCRINOLOGY, V136, P4582, DOI 10.1210/en.136.10.4582; MASON DY, 1978, J CLIN PATHOL, V31, P454, DOI 10.1136/jcp.31.5.454; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; Mikhail AA, 1997, BLOOD, V89, P1507, DOI 10.1182/blood.V89.5.1507.1507_1507_1512; Oreffo ROC, 1997, EUR J CELL BIOL, V74, P251; PETRAKIS NL, 1966, AM J PHYS ANTHROPOL, V25, P119, DOI 10.1002/ajpa.1330250203; Rentsch J, 1996, FEBS LETT, V379, P55, DOI 10.1016/0014-5793(95)01485-3; ROZMAN C, 1989, EXP HEMATOL, V17, P34; SHEEHAN HL, 1947, J PATHOL BACTERIOL, V59, P336, DOI 10.1002/path.1700590142; ViguerieBascands N, 1996, J CLIN ENDOCR METAB, V81, P368, DOI 10.1210/jc.81.1.368; WEISS LP, 1956, ANAT REC, V123, P143; WISE LS, 1979, J BIOL CHEM, V254, P273; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	39	151	163	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1998	12	9					747	752		10.1096/fasebj.12.9.747	http://dx.doi.org/10.1096/fasebj.12.9.747			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619453				2022-12-25	WOS:000074011000014
J	Ong, ST; Hackbarth, ML; Degenstein, LC; Baunoch, DA; Anastasi, J; McKeithan, TW				Ong, ST; Hackbarth, ML; Degenstein, LC; Baunoch, DA; Anastasi, J; McKeithan, TW			Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice	ONCOGENE			English	Article						BCL3; NF-kappa B; transgenic mice	NF-KAPPA-B; CANDIDATE PROTOONCOGENE BCL-3; CHRONIC LYMPHOCYTIC-LEUKEMIA; TRANSCRIPTION FACTOR; ONCOPROTEIN BCL-3; DNA-BINDING; CELL; ENCODES; EXPRESSION; HOMODIMERS	The candidate proto-oncogene BCL3 was isolated through its involvement in the t(14;19) found in chronic lymphocytic leukemia and other B-cell neoplasms. As a member of the I kappa B family, BCL3 plays a role in the immune response by interactions with the NF-kappa B family of transcription factors. In order to study the role of BCL3 overexpression in lymphoid malignancies, we generated five lines of E mu-BCL3 transgenic mice. Transgenic animals develop normally but show splenomegaly and an accumulation of mature B cells in lymph nodes, bone marrow and peritoneal cavity. A hyperresponsive immune system is suggested by the follicular hyperplasia and plasmacytosis in lymph nodes of unimmunized animals, increased incidence of antibodies to self-antigens, and a heightened response to crosslinking of surface ISM. Statistically significant decreases in serum IgM and IgG3, but an increase in IgG1 and IgA were also observed. No lymphoid neoplasms have been identified in transgenic animals. The expansion of B cells in vivo is consistent with the overexpression of BCL3 as being one step in the multi-step process of leukemogenesis. The phenotype also suggests that BCL3 plays a part in B cell proliferation and isotype switching.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	McKeithan, TW (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.			McKeithan, Timothy/0000-0003-2242-3074; Ong, S. Tiong/0000-0001-9460-3483	NCI NIH HHS [P30CA14599, CA55356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055356, P30CA014599] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASOU H, 1993, BRIT J HAEMATOL, V85, P492; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BHATIA K, 1991, ONCOGENE, V6, P1569; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; CROSSEN PE, 1993, GENE CHROMOSOME CANC, V8, P60, DOI 10.1002/gcc.2870080110; Datta SK, 1997, J CLIN IMMUNOL, V17, P11, DOI 10.1023/A:1027328226918; FOY TM, 1994, J EXP MED, V180, P157, DOI 10.1084/jem.180.1.157; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FULLER KA, 1993, J IMMUNOL, V151, P4505; GERONDAKIS S, 1991, IMMUNOGENETICS, V34, P392, DOI 10.1007/BF01787490; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; JOHNSON GG, 1988, J BIOL CHEM, V263, P9079; KENTER AL, 1993, J IMMUNOL, V151, P4718; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; Lin SC, 1996, MOL CELL BIOL, V16, P4591; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MADAIO MP, 1984, J IMMUNOL, V132, P872; MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x; McKeithan TW, 1997, GENE CHROMOSOME CANC, V20, P64, DOI 10.1002/(SICI)1098-2264(199709)20:1<64::AID-GCC10>3.0.CO;2-F; Michaux L, 1997, CANCER GENET CYTOGEN, V94, P36, DOI 10.1016/S0165-4608(96)00247-6; NAKAJIMA A, 1995, EUR J IMMUNOL, V25, P3060, DOI 10.1002/eji.1830251112; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; SCHRIEVER F, 1992, ADV IMMUNOL, V51, P243, DOI 10.1016/S0065-2776(08)60489-7; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Snapper CM, 1996, J IMMUNOL, V156, P183; UESHIMA Y, 1985, INT J CANCER, V36, P287, DOI 10.1002/ijc.1985.36.3.287; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	39	62	64	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2333	2343		10.1038/sj.onc.1201771	http://dx.doi.org/10.1038/sj.onc.1201771			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620550				2022-12-25	WOS:000073428000005
J	Langton, KP; Barker, MD; McKie, N				Langton, KP; Barker, MD; McKie, N			Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby's fundus dystrophy mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIMP GENE FAMILY; MOLECULAR-CLONING; IV COLLAGENASE; 21-KDA PROTEIN; EXPRESSION; COMPLEX; CDNA; TRANSFORMATION; FIBROBLASTS; ACTIVATION	A transient COS-7 cell expression system was used to investigate the functional domain arrangement of tissue inhibitor of metalloproteinases-3 (TIMP-3), specifically to assess the contribution of the amino- and carboxyl-terminal domains of the molecule to its matrix metalloproteinase (MMP) inhibitory and extracellular matrix (ECM) binding properties. Wild type TIMP-3 was entirely localized to the ECM in both its glycosylated (27 kDa) and unglycosylated (24 kDa) forms. A COOH-terminally truncated TIMP-3 molecule was found to be a non-ECM bound MMP inhibitor, whereas a chimeric TIMP molecule, consisting of the NH2-terminal domain of TIMP-2 fused to the COOH-terminal domain of TIMP-3, displayed ECM binding, albeit with a lower affinity than the wild type TIMP-3 molecule. Thus the functional domain arrangement of TIMP-3 is analogous to that seen in TIMP-1 and -2, namely that the NH2-terminal domain is responsible for MMP inhibition whereas the COOH-terminal domain is most important in mediating the specific functions of the molecule. A mutant TIMP-3 in which serine 181 was changed to a cysteine, found in Sorsby's fundus dystrophy, a hereditary macular degenerative disease, was also expressed in COS-7 cells. This gave rise to an additional 48-kDa species (possibly a TIMP-3 dimer) that retained its ability to inhibit MMPs and localize to the ECM, These data favor the hypothesis that the TIMP-3 mutations seen in Sorsby's fundus dystrophy contribute to disease progression by accumulation of mutant protein rather than by the loss of functional TIMP-3.	Univ Sheffield, Sch Med, Dept Pathol, Krebs Inst Biomol Res, Sheffield S10 2RX, S Yorkshire, England; Univ Newcastle Upon Tyne, Sch Med, Dept Rheumatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Sheffield; Newcastle University - UK	Barker, MD (corresponding author), Univ Sheffield, Sch Med, Dept Pathol, Krebs Inst Biomol Res, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.							Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; Celentano DC, 1997, J CLIN PHARMACOL, V37, P991, DOI 10.1002/j.1552-4604.1997.tb04278.x; CHESLER L, 1995, BLOOD, V86, P4506, DOI 10.1182/blood.V86.12.4506.bloodjournal86124506; DECLERCK YA, 1993, BIOCHEM J, V289, P65, DOI 10.1042/bj2890065; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; Fariss RN, 1997, AM J PATHOL, V150, P323; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27; LECO KJ, 1994, J BIOL CHEM, V269, P9352; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; MURPHY G, 1992, J RHEUMATOL, V19, P61; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; POLKINGHORNE PJ, 1989, OPHTHALMOLOGY, V96, P1763; SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67; STASKUS PW, 1991, J BIOL CHEM, V266, P449; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; Thorgeirsson UP, 1996, IN VIVO, V10, P137; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WICK M, 1994, J BIOL CHEM, V269, P18953; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676	38	99	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16778	16781		10.1074/jbc.273.27.16778	http://dx.doi.org/10.1074/jbc.273.27.16778			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642234	Green Accepted, hybrid			2022-12-25	WOS:000074545200024
J	Bose, S; Chapin, SJ; Seetharam, S; Feix, J; Mostov, KE; Seetharam, B				Bose, S; Chapin, SJ; Seetharam, S; Feix, J; Mostov, KE; Seetharam, B			Brefeldin A (BFA) inhibits basolateral membrane (BLM) delivery and dimerization of transcobalamin II receptor in human intestinal epithelial Caco-2 cells - BFA effects on BLM cholesterol content	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; MDCK CELLS; G-PROTEIN; INTRACELLULAR TRAFFICKING; ORGANELLE STRUCTURE; PLASMA-MEMBRANE; EXPRESSION; BINDING; SURFACE; RAT	Brefeldin A (BFA) treatment of Caco-2 cells (5 mu g/ml for 12 h) reduced by 90% the cholesterol, but not the phospholipid (PL), levels of the basolateral membrane (BLM), thus altering its PL/cholesterol molar ratio from 2.6 to 22.0, and decreasing its steady state fluorescent anisotropy (r(s)) from 0.27 to 0.15. BFA treatment for 12 h also resulted in complete loss of transcobalamin II receptor (TC II-R) activity/protein levels in the BLM and the disappearance of trans-Golgi network (TGN) morphology as revealed by confocal immunofluorescence microscopy using antibody to TGN 38. However, BFA treatment had no effect on either total cellular cholesterol, TC II-R activity, or PL levels. When cells treated with BFA for 12 h were exposed to BFA-free medium for 0-24 h, all of the effects were reversed, including reappearance of normal TGN morphology. TC H-R delivered to the BLM. during this period was progressively sialylated and changed its physical state from a monomer (8 h) to a dimer (12 h), coinciding with increased delivery (11-53 pmol) of cholesterol to the BLM and an increase in the BLM r(s) from 0.15 to 0.21. These results indicate that cholesterol, but not FL, delivery to the BLM of Caco-2 cells is BFA-sensitive, and cholesterol, by influencing the higher order of the BLM, is essential for TC II-R dimerization.	Med Coll Wisconsin, MACC Fund Ctr, Dept Med, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, MACC Fund Ctr, Dept Biochem, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, MACC Fund Ctr, Dept Biophys, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Vet Affairs Med Ctr, Milwaukee, WI 53226 USA; Univ Calif San Francisco, Dept Anat & Cell Biol, San Francisco, CA 94143 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Seetharam, B (corresponding author), Med Coll Wisconsin, MACC Fund Ctr, Dept Med, Div Gastroenterol & Hepatol, Room 6061,8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.			mostov, keith/0000-0002-8123-6247	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050052] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 50052] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APODACA G, 1993, J BIOL CHEM, V268, P20380; Bose S, 1996, J BIOL CHEM, V271, P4195; BOSE S, 1995, BIOCHEM J, V310, P923, DOI 10.1042/bj3100923; Bose S, 1997, J BIOL CHEM, V272, P20920, DOI 10.1074/jbc.272.33.20920; Bose S, 1997, J BIOL CHEM, V272, P3538, DOI 10.1074/jbc.272.6.3538; BOSE S, 1995, J BIOL CHEM, V270, P8152, DOI 10.1074/jbc.270.14.8152; Bose S, 1996, J BIOL CHEM, V271, P11718, DOI 10.1074/jbc.271.20.11718; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHAPMAN D, 1975, Q REV BIOPHYS, V8, P185, DOI 10.1017/S0033583500001797; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DAMKE H, 1992, BIOCHEM BIOPH RES CO, V185, P719, DOI 10.1016/0006-291X(92)91685-J; DAMKE H, 1991, J BIOL CHEM, V266, P24829; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ELLIS JA, 1992, BIOCHEM J, V283, P553, DOI 10.1042/bj2830553; HIDALGO J, 1992, EUR J CELL BIOL, V58, P214; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; LAU KS, 1965, BLOOD-J HEMATOL, V26, P202, DOI 10.1182/blood.V26.2.202.202; LINDEMANS J, 1986, SCAND J CLIN LAB INV, V46, P223, DOI 10.3109/00365518609083663; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; ORLANDI PA, 1993, J BIOL CHEM, V268, P12010; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; REINHART MP, 1987, J BIOL CHEM, V262, P9649; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; STEIN O, 1992, BIOCHIM BIOPHYS ACTA, V1125, P28, DOI 10.1016/0005-2760(92)90151-K; URBANI L, 1990, J BIOL CHEM, V265, P1919; VAN MEER G, 1993, J CELL SCI, V104, P833; VANBLITTERSWIJK WJ, 1981, BIOCHIM BIOPHYS ACTA, V644, P323, DOI 10.1016/0005-2736(81)90390-4; VANCE JE, 1991, J BIOL CHEM, V266, P8241; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YOUNGDAHLTURNER P, 1978, J CLIN INVEST, V61, P133, DOI 10.1172/JCI108911	40	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16163	16169		10.1074/jbc.273.26.16163	http://dx.doi.org/10.1074/jbc.273.26.16163			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632671	hybrid			2022-12-25	WOS:000074436600042
J	Ito, T; Hayashi, Y; Ohmori, S; Oda, S; Seo, H				Ito, T; Hayashi, Y; Ohmori, S; Oda, S; Seo, H			Molecular cloning of sucrase-isomaltase cDNA in the house musk shrew Suncus murinus and identification of a mutation responsible for isolated sucrase deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCROSE INTOLERANT PATIENTS; MALTASE-GLUCOAMYLASE; RESIDUAL ISOMALTASE; BIOSYNTHESIS; TRANSPORT; SEQUENCE; RAT; COMPLEX; SUBUNIT; PROTEIN	Isolated sucrase deficiency has been demonstrated in a line of house musk shrew, Suncus murinus (laboratory name: suncus). This animal belongs to the order Insectivore and is phylogenetically different from ordinarily used laboratory animals. They are believed to have evolved with mainly animal food without sucrose. To study the molecular basis of the sucrase deficiency in suncus, we cloned 6.0-kilobase (kb) sucrase-isomaltase (SI, EC 3.2.1.48-10) cDNA from suncus intestinal cDNA library, The cDNA clone contained a 5442-base pair (bp)-long open reading frame preceded by an in frame termination codon. The deduced 1813-amino acid sequence showed 68.6, 71.2, and 74.7% similarity with those of rat, rabbit, and human, respectively. A cleavage site between isomaltase and sucrase as well as the region surrounding the catalytic sites for sucrase and isomaltase were conserved among the species. Out of 18 potential N-linked glycosylation sites, 5 were common among all 4 species. In the connecting segment which was enriched with O-linked glycosylation sites in the other species, only two sites were present in suncus. Northern blot analysis revealed that the 6.0-kb SI mRNA was expressed in the KAT line with intact sucrase-isomaltase activity. In contrast, 3.0-kb SI mRNA was expressed in suncus of the MI line with isolated sucrase deficiency. The 3.0-kb mRNA cosegregated with sucrase deficiency phenotype as an autosomal recessive trait. Sequence analysis revealed a a-nucleotide deletion at position 2767-2768, which results in a frameshift and an immature termination codon, The cDNA of the MI line diverged from that of the KAT line at position 2865, having an 18-bp unique sequence followed by a poly(A) tail. The mutant cDNA encodes 922 amino acid residues which preserves the region for isomaltase but lacks that for whole sucrase. While the cells transfected with the plasmids expressing SI in the RAT line showed both sucrase and isomaltase activity, the plasmids expressing MI line cDNA showed only isomaltase activity. Thus it was concluded that the mutation in the SI gene was responsible for isolated sucrase deficiency in the MI line.	Nagoya Univ, Environm Med Res Inst, Dept Endocrinol & Metab, Div Mol & Cellular Adaptat, Nagoya, Aichi 46401, Japan; Nagoya Univ, Sch Agr Sci, Lab Anim Management, Nagoya, Aichi 46401, Japan	Nagoya University; Nagoya University	Hayashi, Y (corresponding author), Nagoya Univ, Environm Med Res Inst, Dept Endocrinol & Metab, Div Mol & Cellular Adaptat, Nagoya, Aichi 46401, Japan.		Hayashi, Yoshitaka/I-6168-2014	Hayashi, Yoshitaka/0000-0002-7557-4303				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CHANDRASENA G, 1994, GENE, V150, P355, DOI 10.1016/0378-1119(94)90452-9; CHANTRET I, 1992, BIOCHEM J, V285, P915, DOI 10.1042/bj2850915; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colbert E.H., 1969, EVOLUTION VERTEBRATE, V2nd; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; GALAND G, 1989, COMP BIOCHEM PHYS B, V94, P1, DOI 10.1016/0305-0491(89)90002-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY GM, 1992, J NUTR, V122, P172, DOI 10.1093/jn/122.1.172; Gudmand-Hoyer E, 1984, Adv Nutr Res, V6, P233; GUDMANDHOYER E, 1987, SCAND J GASTROENTERO, V22, P24, DOI 10.3109/00365528708991851; GUNTAKA RV, 1993, MICROBIOL REV, V57, P511, DOI 10.1128/MMBR.57.3.511-521.1993; HAUERJENSEN M, 1987, PANCREAS, V2, P295, DOI 10.1097/00006676-198705000-00008; HAURI HP, 1985, P NATL ACAD SCI USA, V82, P4423, DOI 10.1073/pnas.82.13.4423; HAURI HP, 1982, J BIOL CHEM, V257, P4522; Hayashi Y, 1997, BIOCHEM BIOPH RES CO, V236, P83, DOI 10.1006/bbrc.1997.6911; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; ITO T, 1996, ANN RES I ENV MED, V47, P201; NAIM HY, 1988, J CLIN INVEST, V82, P667, DOI 10.1172/JCI113646; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Oda S, 1977, Jikken Dobutsu, V26, P273; ODA S, 1994, MAMM SCI, V34, P59; ODA S, 1991, EDITION FDN M MERIEU, P137; ODA S, 1985, SUNCUS; OHNO T, 1994, EXP ANIM TOKYO, V43, P111, DOI 10.1538/expanim1978.43.1_111; Ouwendijk J, 1996, J CLIN INVEST, V97, P633, DOI 10.1172/JCI118459; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERMAN JA, 1978, J PEDIATR-US, V93, P17, DOI 10.1016/S0022-3476(78)80592-7; Sambrook J., 2002, MOL CLONING LAB MANU; SEMENZA G, 1981, CLIN GASTROENTEROL, V10, P691; SJOSTROM H, 1980, J BIOL CHEM, V255, P1332; SKOVBJERG H, 1986, J PEDIATR GASTR NUTR, V5, P365, DOI 10.1097/00005176-198605000-00005; SKOVBJERG H, 1981, PEDIATR RES, V15, P214, DOI 10.1203/00006450-198103000-00004; STERCHI EE, 1990, BAILLIERE CLIN GASTR, V4, P79, DOI 10.1016/0950-3528(90)90040-N; TREEM WR, 1995, J PEDIATR GASTR NUTR, V21, P1, DOI 10.1097/00005176-199507000-00001; YOKOTA K, 1992, COMP BIOCHEM PHYS B, V103, P629, DOI 10.1016/0305-0491(92)90381-Z	37	9	10	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16464	16469		10.1074/jbc.273.26.16464	http://dx.doi.org/10.1074/jbc.273.26.16464			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632713	hybrid			2022-12-25	WOS:000074436600084
J	Sunahara, RK; Beuve, A; Tesmer, JJG; Sprang, SR; Garbers, DL; Gilman, AG				Sunahara, RK; Beuve, A; Tesmer, JJG; Sprang, SR; Garbers, DL; Gilman, AG			Exchange of substrate and inhibitor specificities between adenylyl and guanylyl cyclases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC ACTIVITY; ACTIVITY REQUIRES; ENZYME SUBUNITS; EXPRESSION; MUTANTS; FORM	The active sites of guanylyl and adenylyl cyclases are closely related. The crystal structure of adenylyl cyclase and modeling studies suggest that specificity for ATP or GTP is dictated in part by a few amino acid residues, invariant in each family, that interact with the purine ring of the substrate. By exchanging these residues between guanylyl cyclase and adenylyl cyclase, we can completely change the nucleotide specificity of guanylyl cyclase and convert adenylyl cyclase into a nonselective purine nucleotide cyclase. The activities of these mutant enzymes remain fully responsive to their respective stimulators, sodium nitroprusside and G(s)alpha. The specificity of nucleotide inhibitors of guanylyl and adenylyl cyclases that do not act competitively with respect to substrate are similarly altered, indicative of their action at the active sites of these enzymes.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gilman, AG (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	alfred.gilman@email.swmed.edu	Sunahara, Roger/AAJ-8667-2020	Tesmer, John/0000-0003-1125-3727	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371, R56DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1998, IN PRESS ACTA CRYS D; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; Friebe A, 1997, BIOCHEMISTRY-US, V36, P1194, DOI 10.1021/bi962047w; GARBERS DL, 1994, MOL BIOL CELL, V5, P1; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; NAKANE M, 1990, J BIOL CHEM, V265, P16841; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; YOUNG C, 1997, PERSISTENCE VISION R; YUEN PST, 1994, J BIOL CHEM, V269, P791; ZHANG G, 1997, NATURE, V386, P284	28	182	186	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16332	16338		10.1074/jbc.273.26.16332	http://dx.doi.org/10.1074/jbc.273.26.16332			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632695	hybrid			2022-12-25	WOS:000074436600066
J	Tang, DM; Gururajan, R; Kidd, VJ				Tang, DM; Gururajan, R; Kidd, VJ			Phosphorylation of PITSLRE p110 isoforms accompanies their processing by caspases during Fas-mediated cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PROTEOLYTIC ACTIVATION; IDENTIFICATION; EXPRESSION; APOPTOSIS; FAMILY	A number of cellular proteins have been identified as caspase targets during cell death, including the PITSLRE protein kinases. These targets generally fall into one of three possible categories: 1) other caspases, 2) proteins that are inactivated during apoptosis, and 3) proteins that are required for execution of the cell death program. However, not all proteins are cleaved by caspases during apoptosis. Why only specific proteins are destined to be processed by caspases during cell death is currently not clear. Here we show that multiple caspase-like activities are involved in the processing of the PITSLRE p110 isoforms during Fas-induced apoptosis in Jurkat T-cells. Three p110 caspase cleavage sites have been mapped to the amino-terminal domain of p110 and verified by site-directed mutagenesis. Curiously, the mutagenesis studies revealed that cleavage of two juxtaposed caspase sites is necessary for the complete processing of this protein during cell death in vivo. Finally, we demonstrate that the PITSLRE p110 protein is rapidly phosphorylated during Fas-induced apoptosis in Jurkat cells and that phosphorylation of an aminoterminal portion of the protein may enhance caspase cleavage in this region.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA	St Jude Children's Research Hospital	Kidd, VJ (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38101 USA.	vincent.kidd@stjude.org	Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044088] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 44088] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FRAKER PJ, 1995, METHOD CELL BIOL, V46, P57; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; LOYER P, 1998, IN PRESS J CELL SCI; MALEK SN, 1994, J BIOL CHEM, V269, P33009; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; Rheaume E, 1997, EMBO J, V16, P6346, DOI 10.1093/emboj/16.21.6346; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sauer K, 1996, MOL BIOL CELL, V7, P1759, DOI 10.1091/mbc.7.11.1759; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Ubeda M, 1997, J BIOL CHEM, V272, P19562, DOI 10.1074/jbc.272.31.19562; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; XIANG JL, 1994, J BIOL CHEM, V269, P15786; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhu HJ, 1997, CELL DEATH DIFFER, V4, P590, DOI 10.1038/sj.cdd.4400284	35	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16601	16607		10.1074/jbc.273.26.16601	http://dx.doi.org/10.1074/jbc.273.26.16601			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632733	hybrid			2022-12-25	WOS:000074436600104
J	Wang, HN; Zhang, LX; Liddington, R; Fu, HI				Wang, HN; Zhang, LX; Liddington, R; Fu, HI			Mutations in the hydrophobic surface of an amphipathic groove of 14-3-3 zeta disrupt its interaction with Raf-1 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SIGNALING PATHWAYS; CELL ANTIGEN RECEPTOR; PROTEIN-KINASE; 14-3-3-PROTEINS ASSOCIATE; JURKAT CELLS; T-CELLS; PHOSPHORYLATION; ACTIVATION; CBL; TRANSDUCTION	14-3-3 proteins bind to a diverse group of regulatory molecules such as Raf-1, Cbl, and c-Bcr that are involved in signal transduction pathways. The crystal structure of 14-3-3 zeta reveals a conserved amphipathic groove that may mediate the association of 14-3-3 with diverse ligands. Consistently, mutations on the charged surface of the groove (Lys-49, Arg-56, and Arg-60) decrease the binding of 14-3-3 zeta to the ligands tested (Zhang, L., Wang, H., Liu, D., Liddington, R., and Fu, H. (1997) J. Biol. Chem. 272, 13717-13724). Here we report that mutations that altered the hydrophobic property of the groove, V176D, L216D, L220D, and L227D, disrupted the interaction of 14-3-3 zeta with Raf-l kinase. The reduced binding of the 14-3-3 zeta mutants to Raf-1 was apparently not because of gross structural changes in the mutants as judged by their ability to form dimers, by partial proteolysis profiles, and by circular dichroism analysis. These hydrophobic residues appeared to be required for the binding of 14-3-3 zeta to distinct activation states of Raf-1 because mutations V176D, L216D, L220D, and L227D reduced the interaction of 14-3-3 zeta with Raf-1 from both phorbol 12-myristate 13-acetate-stimulated and unstimulated Jurkat T cells. These same mutations also disrupted the association of 14-3-3 zeta with other regulatory molecules such as Cbl and c-Bcr, suggesting that the hydrophobic surface of the amphipathic groove represents part of a binding site shared by a number of 14-3-3-associated proteins. The conservation of the hydrophobic residues Val-176, Leu-216, Leu-220, and Leu-227 among known 14-3-3 family members implies their general importance in ligand binding.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Cell & Dev Biol, Atlanta, GA 30322 USA; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	Emory University; Emory University; University of Leicester	Fu, HI (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd NE, Atlanta, GA 30322 USA.	haianfu@bimcore.emory.edu		Zhang, Lixin/0000-0003-0894-9520	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053165, R01GM053165] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53165] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Craparo A, 1997, J BIOL CHEM, V272, P11663; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Reuther GW, 1996, VITAM HORM, V52, P149, DOI 10.1016/S0083-6729(08)60410-0; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Rommel C, 1996, ONCOGENE, V12, P609; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	47	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16297	16304		10.1074/jbc.273.26.16297	http://dx.doi.org/10.1074/jbc.273.26.16297			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632690	hybrid			2022-12-25	WOS:000074436600061
J	Yu, G; Chen, FS; Levesque, G; Nishimura, M; Zhang, DM; Levesque, L; Rogaeva, E; Xu, DH; Liang, Y; Duthie, M; St George-Hyslop, PH; Fraser, PE				Yu, G; Chen, FS; Levesque, G; Nishimura, M; Zhang, DM; Levesque, L; Rogaeva, E; Xu, DH; Liang, Y; Duthie, M; St George-Hyslop, PH; Fraser, PE			The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; MISSENSE MUTATIONS; CHROMOSOME-1; GENE	The presenilin (PS) genes associated with Alzheimer disease encode polytopic transmembrane proteins which undergo physiologic endoproteolytic cleavage to generate stable NH2- and COOH-terminal fragments (NTF or CTF) which co-localize in intracellular membranes, but are tightly regulated in their stoichiometry and abundance. We have used linear glycerol velocity and discontinuous sucrose gradient analysis to investigate the distribution and native conformation of PS1 and PS2 during this regulated processing in cultured cells and in brain. The PS1 NTF and CTF co-localize in the endoplasmic reticulum (ER) and in the Golgi apparatus, where they are components of a similar to 250-kDa complex. This complex also contains beta-catenin but not beta-amyloid precursor protein (APP). In contrast, the PS1 holoprotein precursor is predominantly localized to the rough ER and smooth ER, where it is a component of a similar to 180-kDa native complex. PS2 forms similar but independent complexes. Restricted incorporation of the presenilin NTF and CTF along with a potentially functional ligand (beta-catenin) into a multimeric complex in the ER and Golgi apparatus may provide an explanation for the regulated accumulation of the NTF and CTF.	Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med, Toronto, ON M5S 3H2, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Toronto Hosp, Dept Med, Div Neurol, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	St George-Hyslop, PH (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med, Tanz Neurosci Bldg,6 Queens Pk Crescent, Toronto, ON M5S 3H2, Canada.							BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Fraser PE, 1998, NEUROBIOL AGING, V19, pS19, DOI 10.1016/S0197-4580(98)00029-3; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PIND S, 1994, J BIOL CHEM, V269, P12784; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WEIDEMANN A, 1997, NAT MED, V3, P323; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	28	364	372	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16470	16475		10.1074/jbc.273.26.16470	http://dx.doi.org/10.1074/jbc.273.26.16470			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632714	hybrid			2022-12-25	WOS:000074436600085
J	Benes, C; Roisin, MP; Van Tan, H; Creuzet, C; Miyazaki, J; Fagard, R				Benes, C; Roisin, MP; Van Tan, H; Creuzet, C; Miyazaki, J; Fagard, R			Rapid activation and nuclear translocation of mitogen-activated protein kinases in response to physiological concentration of glucose in the MIN6 pancreatic beta cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; MAP KINASE; GLUTAMATE-RECEPTOR; GROWTH-FACTOR; AMPA SUBTYPE; CALCIUM; ISLETS; STIMULATION; RAS; INHIBITION	MING is one of the few pancreatic beta cell lines that respond to physiological concentrations of glucose by secreting insulin, and little is known about the triggered molecular mechanisms. We report below that the response to glucose in the MIN6 cells includes an activation of the p42 and p44 mitogen-activated protein (MAP) kinases (ERK2 and ERK1), This activation also occurred with the antidiabetic sulfonylurea glibenclamide and kainate, a specific agonist of a subtype of the ionotropic glutamate receptors, which depolarize the cytoplasmic membrane. The requirement for a. calcium entry through the L-type voltage-gated channels and other characteristics of the regulation of the MAP kinase activity, such as the effect of the elevation of the cAMP concentration by forskolin, were similar to those: of the secretion of insulin. However, the activation of the MAP kinases is not required for the secretion of insulin, inasmuch as this effect of glucose was not abolished when the MAP kinases were prevented from activation by PD098059, an inhibitor of the MAP kinase kinase, However, as the MAP kinases were translocated into the nucleus, they might be implicated in the calcium-dependent transcriptional response of the cells to glucose and thus regulate the expression of the insulin gene.	Osaka Univ, Sch Med, Dept Physiol Chem & Nutr, Suita, Osaka 565, Japan; Univ Paris 05, UFR Cochin, Lab Signalisat Cellulaire & Parisites, F-75674 Paris, France	Osaka University; UDICE-French Research Universities; Universite Paris Cite	Fagard, R (corresponding author), Osaka Univ, Sch Med, Dept Physiol Chem & Nutr, 2-2 Yamadaoka, Suita, Osaka 565, Japan.	fagard@infobiogen.fr	Miyazaki, Jun-ichi/N-1976-2015; Tuluc, Petronel/C-2527-2011	Miyazaki, Jun-ichi/0000-0003-2475-589X; 				AGBOTOUNOU WK, 1994, BIOCHEM PHARMACOL, V48, P505, DOI 10.1016/0006-2952(94)90280-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARKHAMMAR P, 1994, J BIOL CHEM, V269, P2743; ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Baron C, 1996, J NEUROCHEM, V66, P1005; BERTRAND G, 1993, EUR J PHARMACOL, V237, P45, DOI 10.1016/0014-2999(93)90091-U; BERTRAND G, 1992, BRIT J PHARMACOL, V106, P354, DOI 10.1111/j.1476-5381.1992.tb14340.x; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Eliasson L, 1996, SCIENCE, V271, P813, DOI 10.1126/science.271.5250.813; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GONOI T, 1994, J BIOL CHEM, V269, P16989; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P338; JOLLY YC, 1993, BIOCHEMISTRY-US, V32, P12209, DOI 10.1021/bi00096a034; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; KNIGHT DE, 1989, TRENDS NEUROSCI, V12, P451, DOI 10.1016/0166-2236(89)90095-7; KOMATSU M, 1995, P NATL ACAD SCI USA, V92, P10728, DOI 10.1073/pnas.92.23.10728; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUMOTO K, 1995, ENDOCRINOLOGY, V136, P3784, DOI 10.1210/en.136.9.3784; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MOSJOV S, 1989, J CLIN INVEST, V79, P616; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Olson LK, 1998, MOL ENDOCRINOL, V12, P207, DOI 10.1210/me.12.2.207; Persaud SJ, 1996, BIOCHEM J, V313, P119, DOI 10.1042/bj3130119; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Tian YM, 1996, MOL CELL ENDOCRINOL, V119, P185, DOI 10.1016/0303-7207(96)03811-7; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Weaver CD, 1996, J BIOL CHEM, V271, P12977, DOI 10.1074/jbc.271.22.12977; Wheal H. V., 1991, EXCITATORY AMINO ACI; WOLF BA, 1991, BIOCHEMISTRY-US, V30, P6372, DOI 10.1021/bi00240a004; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921	49	77	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15507	15513		10.1074/jbc.273.25.15507	http://dx.doi.org/10.1074/jbc.273.25.15507			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624138	hybrid			2022-12-25	WOS:000074284200032
J	Boland, MP; O'Neill, LAJ				Boland, MP; O'Neill, LAJ			Ceramide activates NF kappa B by inducing the processing of p105	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAUNORUBICIN-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; CELL-FREE SYSTEM; SIGNAL-TRANSDUCTION; TNF-ALPHA; HL-60 CELLS; NEUTRAL SPHINGOMYELINASE; ACIDIC SPHINGOMYELINASE; PROTEIN-KINASE; PRECURSOR P105	The role of ceramide as a second messenger in tumor necrosis factor (TNF)-mediated signal transduction has been much debated, It is supported by recent reports describing an expanding number of potential targets for this lipid, but is opposed by those describing how ceramide is not necessary for many TNF-mediated cellular events. In this paper, we directly compare the effects of the cell-permeable ceramide analogue, N-acetylsphingosine (C-2-ceramide), with TNF, on NF kappa B function, a transcription factor whose activation is central to many TNF-mediated effects. We describe how C-2-ceramide failed to drive kappa B-linked chloramphenicol acetyltransferase gene expression in either HL60 promyelocytic or Jurkat T lymphoma cells. Furthermore, it had no effect on TNF-mediated transcription of this reporter gene. However, electrophoretic mobility shift analysis following cell stimulation with this ceramide analogue revealed a dose-responsive activation of NF kappa B, which was mot apparent following cell treatment with the inactive dihydro form. Activated complexes from treated cells were shown to contain predominantly the p50 subunit, in contrast to complexes from TNF-treated cells, where both p50 and p65/ReIA subunits were present. The specific activation of p50 homodimeric complexes by C(2)ceramide, which are known to lack trans-activating activity, was strongly suggested from these data, Further investigations revealed that C-2-ceramide had only a marginal effect on I kappa B alpha degradation but strongly promoted the processing of p105 to its p50 product as revealed by immunoblot analysis. The increase in p50 arising from the processing of its p105 precursor was further established from p105/p50 ratios obtained by scanning densitometric analysis of bands from immunoblots. TNF, on the other hand, stimulated both I kappa B alpha degradation and p105 processing, in accordance with previous findings. Furthermore, the effect of TNF on NF kappa B activation was rapid, whereas C-2-ceramide required an optimal treatment time of 1 h. Interestingly, TNF was found to increase ceramide ire cells but only after a 1 h contact Lime. Our data therefore suggest that ceramide promotes the activation of NF kappa B complexes that lack transactivating activity by enhanced processing of p105.	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland	Trinity College Dublin	Boland, MP (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland.							Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BETTS JC, 1994, J BIOL CHEM, V269, P8455; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; CHEN JQ, 1995, J BIOL CHEM, V270, P25233, DOI 10.1074/jbc.270.42.25233; CIFONE MG, 1993, J EXP MED, V177, P1547; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Higuchi M, 1996, J IMMUNOL, V157, P297; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JOHNS LD, 1994, J IMMUNOL, V152, P5877; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KIM MY, 1991, J BIOL CHEM, V266, P484; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V265, P1596; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P707; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Sawai H, 1997, J BIOL CHEM, V272, P2452; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; STRUM JC, 1994, J BIOL CHEM, V269, P15493; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, MOL CELL BIOL, V16, P5015; YANG ZH, 1993, J BIOL CHEM, V268, P20520; Zumbansen M, 1997, J BIOL CHEM, V272, P10904	62	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15494	15500		10.1074/jbc.273.25.15494	http://dx.doi.org/10.1074/jbc.273.25.15494			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624136	Green Published, hybrid			2022-12-25	WOS:000074284200030
J	Gao, L; Dong, LQ; Whitlock, JP				Gao, L; Dong, LQ; Whitlock, JP			A novel response to dioxin - Induction of ecto-ATPase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE HEPATOMA-CELLS; AH RECEPTOR; TRANSCRIPTIONAL REGULATION; CHROMATIN STRUCTURE; WILD-TYPE; MECHANISM; ACTIVATION; CYP1A1; TCDD; CYTOCHROME-P1-450	We used differential display to discover a mew gene that the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) regulates in mouse hepatoma cells. Its predicted amino acid sequence suggests that the gene encodes an ecto-ATPase that contains multiple glycosylation sites, conserved cysteine residues, and apyrase conserved regions. cDNA expression experiments in mouse hepatoma cells confirm that the new gene encodes an ecto-ATPase, Wild-type mouse hepatoma cells contain both constitutive and TCDD-inducible ecto-ATPase activity. Induction of ecto-ATPase gene expression by TCDD is direct and occurs at the transcriptional level. Studies in mutant hepatoma cells indicate that induction requires both the aromatic hydrocarbon receptor (AhR) and the AhR nuclear translocator (Arnt). Furthermore, induction requires AhR's transactivation domain, but not that of Arnt. Our findings reveal new aspects of dioxin's biological effects and TCDD-dependent gene regulation.	Stanford Univ, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA	Stanford University	Whitlock, JP (corresponding author), Stanford Univ, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003719] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03719] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BRUNS RF, 1990, ANN NY ACAD SCI, V603, P648; BURNSTOCK G, 1971, NATURE, V229, P282, DOI 10.1038/229282d0; BURNSTOCK G, 1985, METHOD PHARMACOL, V6, P193; Demby K B, 1996, Prog Clin Biol Res, V394, P113; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; Dong LQ, 1997, J BIOL CHEM, V272, P29614, DOI 10.1074/jbc.272.47.29614; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FILIPPINI A, 1990, J BIOL CHEM, V265, P334; FleschJanys D, 1996, J TOXICOL ENV HEALTH, V47, P363, DOI 10.1080/009841096161708; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; HUFF J, 1994, ANNU REV PHARMACOL, V34, P343; ISRAEL DI, 1983, J BIOL CHEM, V258, P390; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KANSAS GS, 1991, J IMMUNOL, V146, P2235; Kegel B, 1997, NEUROPHARMACOLOGY, V36, P1189, DOI 10.1016/S0028-3908(97)00115-9; Kirley TL, 1997, J BIOL CHEM, V272, P1076, DOI 10.1074/jbc.272.2.1076; Ko HP, 1997, MOL CELL BIOL, V17, P3497, DOI 10.1128/MCB.17.7.3497; Ko HSP, 1996, MOL CELL BIOL, V16, P430; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; LI H, 1994, J BIOL CHEM, V269, P28098; LIANG P, 1992, SCIENCE, V257, P1319; LUSSKA A, 1992, J BIOL CHEM, V267, P15146; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MILLER AG, 1983, J BIOL CHEM, V258, P3523; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PLESNER L, 1995, INT REV CYTOL, V158, P141; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; Reppert SM, 1997, CELL, V89, P487, DOI 10.1016/S0092-8674(00)80229-9; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; STROM DK, 1992, ARCH BIOCHEM BIOPHYS, V294, P707, DOI 10.1016/0003-9861(92)90745-I; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; WALKER NJ, 1995, CARCINOGENESIS, V16, P1319, DOI 10.1093/carcin/16.6.1319; Wang XH, 1996, BIOCHEM BIOPH RES CO, V220, P784, DOI 10.1006/bbrc.1996.0481; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157; WU L, 1992, P NATL ACAD SCI USA, V89, P4811, DOI 10.1073/pnas.89.11.4811; WU L, 1993, NUCLEIC ACIDS RES, V21, P119, DOI 10.1093/nar/21.1.119	52	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15358	15365		10.1074/jbc.273.25.15358	http://dx.doi.org/10.1074/jbc.273.25.15358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624117	hybrid			2022-12-25	WOS:000074284200011
J	Sessa, G; D'Ascenzo, M; Loh, YT; Martin, GB				Sessa, G; D'Ascenzo, M; Loh, YT; Martin, GB			Biochemical properties of two protein kinases involved in disease resistance signaling in tomato	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR KINASE; TYROSINE KINASE; GENE; TRANSDUCTION; THREONINE; AUTOPHOSPHORYLATION; PHOSPHORYLATION; SPECIFICITY	In tomato plants, resistance to bacterial speck disease is mediated by a phosphorylation cascade, which is triggered by the specific recognition between the plant serine/threonine protein kinase Pto and the bacterial AvrPto protein, In the present study, we investigated in vitro biochemical properties of Pto, which appears to function as arm intracellular receptor for the AvrPto signal molecule. Pto and its downstream effector Pti1, which is also a serine/threonine protein kinase, were expressed in Escherichia coli as maltose-binding protein and glutathione S-transferase fusion proteins, respectively, The two kinases each autophosphorylated at multiple sites as determined by phosphopeptide mapping. In addition, Pto and PLi1 autophosphorylation occurred via an intramolecular mechanism, as their specific activity was not affected by their molar concentration in the assay, Moreover, an active glutathione S-transferase-Pto fusion failed to phosphorylate an inactive maltose-binding protein-Pto(K69Q) fusion excluding ale intermolecular mechanism of phosphorylation for Pto, Pti1 phosphorylation by Pto was also characterized and found to occur with a K-m of 4.1 mu M at sites similar to those autophosphorylated by Pti1, Pto and the product of the recessive allele pto phosphorylated Pti1 at similar sites, as observed by phosphopeptide mapping. This suggests that the inability of the kinase pto to confer resistance to bacterial speck disease in tomato is not caused by altered recognition specificity for Pti1 phosphorylation sites.	Purdue Univ, Dept Agron, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Martin, GB (corresponding author), Purdue Univ, Dept Agron, Lilly Hall Life Sci, W Lafayette, IN 47907 USA.		Martin, Gregory B/F-6262-2011	Martin, Gregory B/0000-0003-0044-6830				Alfano JR, 1996, PLANT CELL, V8, P1683, DOI 10.1105/tpc.8.10.1683; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; Cheng M, 1996, J BIOL CHEM, V271, P12057, DOI 10.1074/jbc.271.20.12057; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; DADD CA, 1993, BIOTECHNIQUES, V14, P266; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HORN MA, 1994, BBA-PROTEIN STRUCT M, V1208, P65, DOI 10.1016/0167-4838(94)90160-0; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jia YL, 1997, PLANT CELL, V9, P61, DOI 10.1105/tpc.9.1.61; Jones DA, 1997, ADV BOT RES, V24, P89; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; LOH YT, 1995, PLANT PHYSIOL, V108, P1735, DOI 10.1104/pp.108.4.1735; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.1105/tpc.7.2.173; Roe JL, 1997, J BIOL CHEM, V272, P5838, DOI 10.1074/jbc.272.9.5838; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; SchulzeMuth P, 1996, J BIOL CHEM, V271, P26684, DOI 10.1074/jbc.271.43.26684; Scofield SR, 1996, SCIENCE, V274, P2063, DOI 10.1126/science.274.5295.2063; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; VandenAckerveken G, 1997, TRENDS MICROBIOL, V5, P394, DOI 10.1016/S0966-842X(97)01124-4; Zhou JM, 1997, EMBO J, V16, P3207, DOI 10.1093/emboj/16.11.3207; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	34	37	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15860	15865		10.1074/jbc.273.25.15860	http://dx.doi.org/10.1074/jbc.273.25.15860			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624187	hybrid			2022-12-25	WOS:000074284200081
J	Yawata, A; Adachi, M; Okuda, H; Naishiro, Y; Takamura, T; Hareyama, M; Takayama, S; Reed, JC; Imai, K				Yawata, A; Adachi, M; Okuda, H; Naishiro, Y; Takamura, T; Hareyama, M; Takayama, S; Reed, JC; Imai, K			Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells	ONCOGENE			English	Article						Bcl-2; BAG-1; gastric adenocarcinoma; peritoneal dissemination	BCL-2 PROTEIN; HGF RECEPTOR; GENE; EXPRESSION; BAG-1; APOPTOSIS; CARCINOMA; ADHESION; MATRIX; CHAIN	Bcl-2 and a Bcl-2-binding protein BAG-1 function in protection from apoptosis induced by a variety of stimuli. Deregulated expression of Bcl-2 leads to inhibition of apoptosis and is correlated with development of various cancers, Here, we provide evidence that prolonged cell survival introduced by overproduction of Bcl-2 or BAG-1 strongly enhances peritoneal dissemination of human gastric cancer MKN74 cells. Gene transfer-mediated overexpression of Bcl-2 or BAG-1 led to prolonged cell survival of MKN74 cells against serum-starved apoptosis and anoikis, When the viable transfectants were inoculated into the intraperitoneal cavity of BALB/c nude mice, the Bcl-2-expressing MKN74 cells and the BAG-1-expressing MKN74 cells exhibited strongly enhanced peritoneal dissemination in BALB/c nude mice and whole disseminated tumor weights were increased by ii-fold and 3.3-fold, respectively, compared with the control transfectants. The enhanced peritoneal dissemination of MKN74-Bcl-2 and MKN74-BAG-1 transfectants correlated well with resistance to cell death induced by serum-starvation and anoikis, However, the overexpression of Bcl-2 or BAG-1 caused no significant difference among the transfectants in cell growth rates, either in vitro of in vivo. Taken together, these studies demonstrate that resistance to apoptosis is a crucial factor for development of peritoneal dissemination of human gastric cancer cells.	Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 060, Japan; Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sapporo Medical University; Sanford Burnham Prebys Medical Discovery Institute	Adachi, M (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 060, Japan.				NCI NIH HHS [CA-67329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; Adachi M, 1996, BLOOD, V88, P4118, DOI 10.1182/blood.V88.11.4118.bloodjournal88114118; ASAO T, 1994, CANCER LETT, V78, P57, DOI 10.1016/0304-3835(94)90031-0; ASAO T, 1995, CANCER, V75, P1539, DOI 10.1002/1097-0142(19950315)75:6+<1539::AID-CNCR2820751526>3.0.CO;2-L; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRONNER MP, 1995, AM J PATHOL, V146, P20; BUCK RC, 1973, CANCER RES, V33, P3181; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAUWERS GY, 1995, CANCER, V75, P2209, DOI 10.1002/1097-0142(19950501)75:9<2209::AID-CNCR2820750904>3.0.CO;2-M; MCDONNELL TJ, 1992, CANCER RES, V52, P6904; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; REED JC, 1993, J CELL BIOL, V124, P1; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	20	120	123	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2681	2686		10.1038/sj.onc.1201792	http://dx.doi.org/10.1038/sj.onc.1201792			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632144				2022-12-25	WOS:000073698200012
J	Sorokin, A; Reed, E; Nnkemere, N; Dulin, NO; Schlessinger, J				Sorokin, A; Reed, E; Nnkemere, N; Dulin, NO; Schlessinger, J			Crk protein binds to PDGF receptor and insulin receptor substrate-1 with different modulating effects on PDGF- and insulin-dependent signaling pathways	ONCOGENE			English	Article						Crk; PDGF receptor; IRS-1; ERK cascade	EPIDERMAL-GROWTH-FACTOR; MEDIATED CELL-ADHESION; STIMULATES TYROSINE PHOSPHORYLATION; GUANINE-NUCLEOTIDE EXCHANGE; GTPASE-ACTIVATING PROTEIN; SH3 DOMAINS; C-CRK; V-CRK; FACTOR-I; BETA-SUBUNIT	We have studied the involvement of murine c-Crk, an SH2/SH3 containing adaptor protein, in signaling pathways stimulated by different receptor tyrosine kinases. We show here that c-Crk is associated with components of insulin-and PDGF-dependent signaling pathways. Insulin treatment of murine myoblast cells induces the formation of stable complex of endogenous c-Crk with insulin receptor substrate-1 (IRS-1) mediated via the SH2 domain of Crk. The ligand dependent physical association of c-Crk with IRS-1 is direct. However IRS-1 is also co-precipitated with c-Crk from quiescent L6 cells. The association of IRS-1 with c-Crk in quiescent cells is probably not direct since Far Western blot analysis did not reveal the binding of neither SH2 domain nor amino-terminal SH3 domain of c-Crk to IRS-1 from unstimulated cells. We also show that PDGF treatment of murine myoblast cells induces association of c-Crk with the PDGF receptor and tyrosine phosphorylation of c-Crk. Overexpression of c-Crk enhanced insulin-but not PDGF-induced activation of MAP kinases when compared to parental cell lines. Thus, the formation of the direct IRS-1/Crk complex appears to be crucial for Crk-mediated insulin-induced activation of MAP kinase, whereas Crk is probably involved in other PDGF-induced responses. These data provide support to the hypothesis that insulin and PDGF employ different mechanisms for activation of MAP kinase cascade.	Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA	Medical College of Wisconsin; Case Western Reserve University; New York University	Sorokin, A (corresponding author), Med Coll Wisconsin, Dept Med, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.			Sorokin, Andrey/0000-0002-5660-0190	NHLBI NIH HHS [HL22563] Funding Source: Medline; NIDDK NIH HHS [DK41684] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022563, R01HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041684] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hansen K, 1997, FEBS LETT, V409, P195, DOI 10.1016/S0014-5793(97)00495-X; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; HERRERA R, 1986, J BIOL CHEM, V261, P1980; Hoeve J.T., 1993, ONCOGENE, V8, P2469; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; Khwaja A, 1996, ONCOGENE, V12, P2491; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARUTA H, 1994, BIOESSAYS, V16, P489, DOI 10.1002/bies.950160708; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NANBERG E, 1993, J BIOL CHEM, V268, P18187; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ODA T, 1994, J BIOL CHEM, V269, P22925; OGAWA S, 1994, ONCOGENE, V9, P1669; OSTEROP APRM, 1993, EUR J BIOCHEM, V212, P477, DOI 10.1111/j.1432-1033.1993.tb17684.x; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; QUON MJ, 1994, J BIOL CHEM, V269, P27920; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RICE KM, 1994, BIOCHEM BIOPH RES CO, V198, P523, DOI 10.1006/bbrc.1994.1077; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHLESINGER J, 1994, CURR BIOL, V7, P25; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P24058; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VRIESSMITS AMM, 1992, NATURE, V357, P602; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1	94	16	16	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2425	2434		10.1038/sj.onc.1201781	http://dx.doi.org/10.1038/sj.onc.1201781			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627109				2022-12-25	WOS:000073672300001
J	Huang, HJ; Qian, JQ; Proffit, J; Wilber, K; Jenkins, R; Smith, DI				Huang, HJ; Qian, JQ; Proffit, J; Wilber, K; Jenkins, R; Smith, DI			FRA7G extends over a broad region: coincidence of human endogenous retroviral sequences (HERV-H) and small polydispersed circular DNAs (spcDNA) and fragile sites	ONCOGENE			English	Article						chromosome fragility; FRA7G; spcDNA; human endogenous retroviral sequence; fluorescence in situ hybridization	TUMOR-SUPPRESSOR GENE; HUMAN-CHROMOSOMES; FREQUENT LOSS; X-SYNDROME; PROSTATE-CANCER; BREAST-CANCER; FHIT GENE; INTEGRATION; 3P14.2; CELL	FRA7G is an aphidicolin-inducible common fragile site at human chromosomal band 7q31.2. This region is frequently altered in a number of different tumor types including prostate, breast, and ovarian cancer. It has also been hypothesized that this region contains an important tumor suppressor gene which is mutated during the development of these cancers or an oncogene which is amplified, We previously used a FISH-based approach to isolate YAC clones which spanned FRA7G. In this report, we describe the Isolation and restriction endonuclease mapping of three overlapping P1 clones which cover FRA7G and the region frequently altered in the different cancers. FISH-based analysis of these clones reveals that aphidicolin-induced breakage in the FRA7G region occurs over a region of at least 300 Kb in length, We have also localized a previously sequenced BAC clone to this region. The sequence obtained from this clone reveals the presence of an endogenous retroviral sequence (HERV-H) in the midst of the FRA7G region as well as sequences with homology to small polydispersed circular DNAs (spcDNAs). Thus for the first two cloned common fragile sites, FRA7G and FRA3B, there is an association with both spcDNAs and hot-spots for viral integration.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA; Vysis Inc, Downers Grove, IL USA	Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL CANCER INSTITUTE [R01CA048031, P20CA058225] Funding Source: NIH RePORTER; NCI NIH HHS [CA58225, CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BOLDOG FL, 1994, GENE CHROMOSOME CANC, V11, P216, DOI 10.1002/gcc.2870110403; CANNIZZARO LA, 1988, CANCER GENET CYTOGEN, V33, P93, DOI 10.1016/0165-4608(88)90054-4; CAPOROSSI D, 1991, CANCER GENET CYTOGEN, V54, P39, DOI 10.1016/0165-4608(91)90028-S; CHAMPEME MH, 1995, GENE CHROMOSOME CANC, V12, P304, DOI 10.1002/gcc.2870120411; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Cohen S, 1996, MOL CELL BIOL, V16, P2002; Devilee P, 1997, GENE CHROMOSOME CANC, V18, P193; DURNAM D, 1986, CANCER CELL, V4, P349; GLOVER TW, 1984, HUM GENET, V67, P882; GREEN ED, 1991, GENOMICS, V11, P548, DOI 10.1016/0888-7543(91)90062-J; GREEN ED, 1994, HUM MOL GENET, V3, P489, DOI 10.1093/hmg/3.3.489; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HIRSCH B, 1991, HUM GENET, V87, P302; HUANG H, 1998, IN PRESS GENES CHROM; JONES C, 1994, HUM MOL GENET, V3, P2123, DOI 10.1093/hmg/3.12.2123; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; JONES NJ, 1990, MUTAGENESIS, V5, P15, DOI 10.1093/mutage/5.1.15; Kastury K, 1996, CANCER RES, V56, P978; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; KUWANO A, 1990, HUM GENET, V84, P527; LAIRD C, 1987, TRENDS GENET, V3, P274, DOI 10.1016/0168-9525(87)90268-X; LATIL A, 1995, B CANCER, V82, P589; LEBEAU MM, 1998, IN PRESS HUM MOL GEN; LEDBETTER SA, 1990, GENOMICS, V8, P614, DOI 10.1016/0888-7543(90)90247-R; Lin JC, 1996, ONCOGENE, V13, P2001; MacLaren DC, 1996, GENOMICS, V35, P299, DOI 10.1006/geno.1996.0360; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pandis N, 1997, GENE CHROMOSOME CANC, V18, P241, DOI 10.1002/(SICI)1098-2264(199704)18:4<241::AID-GCC1>3.3.CO;2-7; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; PENNY LA, 1995, AM J HUM GENET, V56, P676; RASSOOL FV, 1991, P NATL ACAD SCI USA, V88, P6657, DOI 10.1073/pnas.88.15.6657; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; RASSOOL FV, 1992, AM J HUM GENET, V50, P1243; RITCHIE RJ, 1994, HUM MOL GENET, V3, P2115, DOI 10.1093/hmg/3.12.2115; Sambrook J., 2002, MOL CLONING LAB MANU; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SHIFMAN MI, 1995, J NEUROSCI METH, V59, P205, DOI 10.1016/0165-0270(94)00184-I; Shridhar R, 1996, CANCER RES, V56, P4347; Shridhar V, 1997, ONCOGENE, V14, P1269, DOI 10.1038/sj.onc.1201100; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; SMITH PP, 1992, GENE CHROMOSOME CANC, V5, P150, DOI 10.1002/gcc.2870050209; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SUNNERHAGEN P, 1989, SOMAT CELL MOLEC GEN, V15, P61, DOI 10.1007/BF01534670; SUTHERLAND GR, 1995, OXFORD MONOGRAPHS ME, V13; TAKAHASHI S, 1995, CANCER RES, V55, P4114; VANDERDRIFT P, 1994, HUM MOL GENET, V3, P2131, DOI 10.1093/hmg/3.12.2131; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WAGATSUMA M, 1990, J VIROL, V64, P813, DOI 10.1128/JVI.64.2.813-821.1990; Wang L, 1997, GENOMICS, V41, P485, DOI 10.1006/geno.1997.4690; WANG L, 1998, IN PRESS ONCOGENE; WILKE CM, 1996, HUM MOL GENET, V5, P973; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; Yu S, 1997, CELL, V88, P367, DOI 10.1016/S0092-8674(00)81875-9; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zimonjic DB, 1997, CANCER RES, V57, P1166	65	64	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2311	2319		10.1038/sj.onc.1200202	http://dx.doi.org/10.1038/sj.onc.1200202			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620548				2022-12-25	WOS:000073428000003
J	Soucek, T; Holzl, G; Bernaschek, G; Hengstschlager, M				Soucek, T; Holzl, G; Bernaschek, G; Hengstschlager, M			A role of the tuberous sclerosis gene-2 product during neuronal differentiation	ONCOGENE			English	Article						neuronal differentiation; tuberin; tuberous sclerosis; TSC2	DOMINANTLY INHERITED CANCER; TUBEROUS-SCLEROSIS-2 TSC2 GENE; NEUROBLASTOMA CELL-LINES; EKER RAT MODEL; RETINOIC ACID; RENAL-CARCINOMA; DNA-SYNTHESIS; EXPRESSION; HETEROZYGOSITY; BLASTOMA	Tuberous sclerosis is an autosomal dominant disorder, Besides the development of benign growths (hamartomas) in different tissues, one hallmark of this disease is the presence of highly epileptogenic dysplastic lesions in the cerebral cortex (tubers) composed of abnormal shaped neurones. Patients often show evidence of severe mental retardation. Linkage analysis revealed two disease-determining genes on chromosome 9 and chromosome 16, The TSC2 gene on chromosome 16 encodes a 1784-amino acid putative tumour suppressor protein, tuberin, that functions as a GTPase-activating protein. Here me show that tuberin expression is upregulated upon induction of neuronal differentiation in the neuroblastoma cell lines SK-N-SH and LAN-1. This upregulation occurs at post-transcriptional level and is independent of the proliferation status. TSC2 expression is unaffected during differentiation of C2C12 myoblasts into myotubes and of F9 embryonal carcinoma cells into cells resembling parietal endoderm, Antisense inhibition of tuberin expression in SK-N-SH or LAN-1 cells inhibits neuronal differentiation, but does not affect the differentiation of F9 cells, Ectopic overexpression of TSC2 not only reverts the antisense-associated phenotype but furthermore accelerates the neuronal differentiation process. Our data show for the first time that tuberin plays a critical role in neuronal differentiation. Such role is consistent with the phenotype of tuberous sclerosis patients, who inherit one defective TSC2 allele, and frequently lose the remaining normal allele in many of the tubers/hamartomas which develop in the central nervous system of these patients.	Univ Vienna, Dept Prenatal Diag & Therapy, A-1090 Vienna, Austria	University of Vienna	Hengstschlager, M (corresponding author), Univ Vienna, Dept Prenatal Diag & Therapy, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.							ABEMAYOR E, 1989, ENVIRON HEALTH PERSP, V80, P3, DOI 10.2307/3430727; Carbonara C, 1996, GENE CHROMOSOME CANC, V15, P18, DOI 10.1002/(SICI)1098-2264(199601)15:1<18::AID-GCC3>3.0.CO;2-7; Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; DEHOOP MJ, 1994, NEURON, V13, P11, DOI 10.1016/0896-6273(94)90456-1; GEIST RT, 1995, CELL GROWTH DIFFER, V6, P1477; Gomez MR, 1988, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Hengstschlager M, 1996, ONCOGENE, V12, P1635; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; HUTTENLOCHER PR, 1991, ANN NY ACAD SCI, V615, P140; JANSSEN B, 1994, HUM GENET, V94, P437, DOI 10.1007/BF00201608; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kerfoot C, 1996, BRAIN PATHOL, V6, P367, DOI 10.1111/j.1750-3639.1996.tb00866.x; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; KUMAR A, 1995, HUM MOL GENET, V4, P1471, DOI 10.1093/hmg/4.8.1471; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Menchine M, 1996, MODERN PATHOL, V9, P1071; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NELLIST M, 1993, CELL, V75, P1305; Orimoto K, 1996, BIOCHEM BIOPH RES CO, V219, P70, DOI 10.1006/bbrc.1996.0183; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; Pusch O, 1997, DNA CELL BIOL, V16, P737, DOI 10.1089/dna.1997.16.737; SAMPSON JR, 1994, HUM MOL GENET, V3, P1477, DOI 10.1093/hmg/3.suppl_1.1477; SAMPSON JR, 1992, J MED GENET, V29, P861, DOI 10.1136/jmg.29.12.861; SCHLINGENSIEPEN KH, 1992, GENE REGULATION BIOL, P317; SEEGER RC, 1977, CANCER RES, V37, P1364; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; SOUCEK T, 1997, J BIOL CHEM, V272, P29031; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; TAHIRA T, 1991, ONCOGENE, V6, P2333; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WALKER C, 1992, SCIENCE, V255, P1693, DOI 10.1126/science.1553556; WIEDERHOLT WC, 1985, NEUROLOGY, V35, P600, DOI 10.1212/WNL.35.4.600; Wienecke R, 1996, ONCOGENE, V13, P913; Wienecke R, 1997, AM J PATHOL, V150, P43; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wilson PJ, 1996, HUM MOL GENET, V5, P249, DOI 10.1093/hmg/5.2.249; XIAO GH, 1995, ONCOGENE, V11, P81; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407	47	59	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	1998	16	17					2197	2204		10.1038/sj.onc.1201743	http://dx.doi.org/10.1038/sj.onc.1201743			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619828				2022-12-25	WOS:000073298000004
J	Willems, L; Grimonpont, C; Kerkhofs, P; Capiau, C; Gheysen, D; Conrath, K; Roussef, R; Mamoun, R; Portetelle, D; Burny, A; Adam, E; Lefebvre, L; Twizere, JC; Heremans, H; Kettmann, R				Willems, L; Grimonpont, C; Kerkhofs, P; Capiau, C; Gheysen, D; Conrath, K; Roussef, R; Mamoun, R; Portetelle, D; Burny, A; Adam, E; Lefebvre, L; Twizere, JC; Heremans, H; Kettmann, R			Phosphorylation of bovine leukemia virus Tax protein is required for in vitro transformation but not for transactivation	ONCOGENE			English	Article						ras cooperation; B lymphocyte; sheep; HTLV	CASEIN KINASE-II; NF-KAPPA-B; HTLV-I; CELLULAR-TRANSFORMATION; VIRAL REPLICATION; BZIP PROTEINS; RAS ONCOGENE; BINDING; SITE; GENE	The Tax proteins of the oncovirinae viruses are phosphorylated transcriptional activators that exhibit oncogenic potential. The role of phosphorylation in their functional activities remains unknown. As a model for the Human T-cell leukemia virus type I (HTLV-I), Bovine Leukemia Virus (BLV) permits the characterization of viral replication and leukemogenesis in vitro. Here, we show that the BLV Tax protein is phosphorylated on serine residues 106 and 293 both in insect and in mammalian cells. These sites can also be efficiently phosphorylated by the cdc2 and MAP kinases in vitro. Mutation of these residues does not affect the capacity of the Tax protein to function as a transactivator. Indeed, the Tax proteins mutated at one or both serines increase LTR-directed viral transcription at levels similar to those obtained with wild-type Tax in cell culture, Moreover, inhibition of Tax phosphorylation by W7, a calmodulin antagonist, does not alter its transactivation activity. Thus, phosphorylation on serines 106 and 293 is not required for transactivation by Tax, However, simultaneous substitution of both serines into alanine residues destroys the capacity of Tax to cooperate with the Haras oncogene to transform primary rat embryo fibroblasts and induce tumors in nude mice, When the serines were replaced with aspartic acid residues, the oncogenic potential of Tax was maintained indicating that the negative charge rather than the phosphate group itself was required for Tax oncogenicity, Finally, to assess the role of the serine residues in vivo, recombinant viruses which express the Tax mutants were constructed and injected into sheep. It appeared that the mutated proviruses replicate at levels similar to the wild-type virus in vivo. We conclude that Tax phosphorylation is dispensable for transactivation and viral replication in vivo but is required for its oncogenic potential in vitro.	Fac Univ Sci Agron, Dept Mol Biol, B-5030 Gembloux, Belgium; Smithkline Beecham, B-1330 Rixensart, Belgium; Inst Natl Rech Vet, Dept Bovine Virol, B-1120 Ucclc, Belgium; Bulgarian Acad Sci, Inst Expt Pathol & Parasitol, Sofia, Bulgaria; Univ Bordeaux 2, INSERM, F-33076 Bordeaux, France; Katholieke Univ Leuven, Rega Inst, B-3000 Louvain, Belgium	University of Liege; GlaxoSmithKline; Bulgarian Academy of Sciences; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; KU Leuven	Willems, L (corresponding author), Fac Univ Sci Agron, Dept Mol Biol, B-5030 Gembloux, Belgium.		robert, mamoun/G-3242-2013; Twizere, Jean-Claude/AAG-3706-2019	TWIZERE, Jean-Claude/0000-0002-8683-705X; Willems, Luc/0000-0002-0563-2213				Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BOROS IM, 1995, VIROLOGY, V214, P207, DOI 10.1006/viro.1995.9939; CHEN G, 1989, VIROLOGY, V172, P343; Cockerell GL, 1996, BLOOD, V87, P1030, DOI 10.1182/blood.V87.3.1030.bloodjournal8731030; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; FONTES JD, 1993, J VIROL, V67, P4436, DOI 10.1128/JVI.67.7.4436-4441.1993; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GREEN PL, 1995, J VIROL, V69, P387, DOI 10.1128/JVI.69.1.387-394.1995; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; Kettmann R., 1994, RETROVIRIDAE, V3, P39, DOI DOI 10.1007/978-1-4899-1730-0_2; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NYUNOYA H, 1988, VIROLOGY, V167, P538, DOI 10.1016/S0042-6822(88)90116-X; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PORTETELLE D, 1989, J VIROL METHODS, V23, P211, DOI 10.1016/0166-0934(89)90135-3; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; WILLEMS L, 1992, P NATL ACAD SCI USA, V89, P3957, DOI 10.1073/pnas.89.9.3957; WILLEMS L, 1993, J VIROL, V67, P4078, DOI 10.1128/JVI.67.7.4078-4085.1993; WILLEMS L, 1994, P NATL ACAD SCI USA, V91, P11532, DOI 10.1073/pnas.91.24.11532; WILLEMS L, 1990, EMBO J, V9, P1577, DOI 10.1002/j.1460-2075.1990.tb08277.x; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 1996, J ACQ IMMUN DEF SYND, V13, pS63, DOI 10.1097/00042560-199600001-00012; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	40	24	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2165	2176		10.1038/sj.onc.1201765	http://dx.doi.org/10.1038/sj.onc.1201765			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619825	Green Published			2022-12-25	WOS:000073298000001
J	Bosilevac, JM; Gilchrist, CA; Jankowski, PE; Paul, S; Rees, AR; Hinrichs, SH				Bosilevac, JM; Gilchrist, CA; Jankowski, PE; Paul, S; Rees, AR; Hinrichs, SH			Inhibition of activating transcription factor 1- and cAMP-responsive element-binding protein-activated transcription by an intracellular single chain Fv fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBODY FRAGMENTS; VARIABLE FRAGMENTS; TARGETED MUTATION; ESCHERICHIA-COLI; COMBINING SITES; T-LYMPHOCYTES; CREB; EXPRESSION; AFFINITY; INFECTION	Activating transcription factor 1 (ATF1) and cAMP-responsive element (CRE)-binding protein (CREB) activate transcription through CREs located in the promoters of cellular and viral genes. We previously described a monoclonal antibody (mAb41.4) that prevents ATF1 binding to DNA and reduces CRE-driven promoter activity in vitro (Orten, D. J., Strawhecker, J. M., Sanderson, S. D., Huang, D., Prytowsky, M. B., and Hinrichs, S. H. (1994) J. Biol. Chem. 269, 32254-32263). A single chain Fv (scFv) fragment from the mAb41.4-expressing hybridoma was generated to provide a means to investigate transcription factor function via intracellular expression of the scFv fragment. The affinity of scFv4 (subgroup: V-L kappa-III, V-H miscellaneous) for ATF1 was similar to that of the parental mAb and the Fab fragment, but it demonstrated greater inhibitory activity and reacted with CREB. scFv4 disrupted the binding of both ATF1 and CREB in electrophoretic mobility shift assays and reduced expression of CRE-driven expression in vitro. Transient expression of scFv had no effect on the non-CRE-containing adenovirus major late promoter. The proliferating cell nuclear antigen promoter, containing two CREs, was significantly more sensitive to inhibition by scFv than the cytomegalovirus immediate-early promoter, containing five CREs. Cotransfection of either ATF1 or CREB in the presence of scFv restored basal levels of expression. The intracellular expression of scFv provides a unique means to investigate the roles of the transcription factors ATF1 and CREB.	Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Univ Bath, Dept Biochem, Bath BA2 7AY, Avon, England; Univ Texas, Hlth Sci Ctr, Dept Pathol & Lab Med, Houston, TX 77030 USA	University of Nebraska System; University of Nebraska Medical Center; University of Bath; University of Texas System; University of Texas Health Science Center Houston	Hinrichs, SH (corresponding author), Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, 600 S 42nd St, Omaha, NE 68198 USA.	shinrich@mail.unmc.edu		Bosilevac, Joseph/0000-0002-0258-6581				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Chaika OV, 1997, J BIOL CHEM, V272, P11968, DOI 10.1074/jbc.272.18.11968; CHEN JX, 1992, MOL IMMUNOL, V29, P1121, DOI 10.1016/0161-5890(92)90045-Y; DAVIES J, 1995, BIO-TECHNOL, V13, P475, DOI 10.1038/nbt0595-475; DESPLANCQ D, 1994, PROTEIN ENG, V7, P1027, DOI 10.1093/protein/7.8.1027; Duan LX, 1995, HUM GENE THER, V6, P1561, DOI 10.1089/hum.1995.6.12-1561; FEUERSTEIN N, 1995, J IMMUNOL, V154, P68; FLINT KJ, 1991, ONCOGENE, V6, P2019; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; Gao Q S, 1995, Methods Mol Biol, V51, P281; Gilchrist CA, 1995, ANTIBODY IMMUNOCONJ, V8, P281; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Grim J, 1996, AM J RESP CELL MOL, V15, P348, DOI 10.1165/ajrcmb.15.3.8810638; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HORWITZ MS, 1996, FIELDS VIROLOGY, V2, P1679; HSUEH YP, 1995, J IMMUNOL, V154, P5675; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; KINGSTON R, 1994, CURRENT PROTOCOLS MO, V1; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEMAIGRE FP, 1993, NUCLEIC ACIDS RES, V21, P2907, DOI 10.1093/nar/21.12.2907; LevyMintz P, 1996, J VIROL, V70, P8821, DOI 10.1128/JVI.70.12.8821-8832.1996; MACIEJEWSKI JP, 1995, NAT MED, V1, P667, DOI 10.1038/nm0795-667; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MARTIN ACR, 1989, P NATL ACAD SCI USA, V86, P9268, DOI 10.1073/pnas.86.23.9268; MARTIN ACR, 1991, METHOD ENZYMOL, V203, P121; MCCAFFERTY J, 1994, APPL BIOCHEM BIOTECH, V47, P157, DOI 10.1007/BF02787932; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILSTEIN C, 1974, PROGR IMMUNOLOGY, V2, P157; ORTEN DJ, 1994, J BIOL CHEM, V269, P32254; OWENS RJ, 1994, J IMMUNOL METHODS, V168, P149, DOI 10.1016/0022-1759(94)90051-5; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; PEDERSEN JT, 1992, IMMUNOMETHODS, V1, P126; RAAG R, 1995, FASEB J, V9, P73, DOI 10.1096/fasebj.9.1.7821762; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; Sambrook J, 1989, MOL CLONING LAB MANU, V3; Song BW, 1997, VIROLOGY, V235, P109, DOI 10.1006/viro.1997.8677; TSUMOTO K, 1994, BIOCHEM BIOPH RES CO, V201, P546, DOI 10.1006/bbrc.1994.1736; WEIGERT M, 1978, NATURE, V276, P785, DOI 10.1038/276785a0; WHITLOW M, 1994, PROTEIN ENG, V7, P1017, DOI 10.1093/protein/7.8.1017; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; ZAISS S, 1983, EUR J IMMUNOL, V13, P508, DOI 10.1002/eji.1830130614	48	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16874	16879		10.1074/jbc.273.27.16874	http://dx.doi.org/10.1074/jbc.273.27.16874			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642248	hybrid			2022-12-25	WOS:000074545200038
J	Gervais, FG; Thornberry, NA; Ruffolo, SC; Nicholson, DW; Roy, S				Gervais, FG; Thornberry, NA; Ruffolo, SC; Nicholson, DW; Roy, S			Caspases cleave focal adhesion kinase during apoptosis to generate a FRNK-like polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; V-SRC; PP125(FAK); EXPRESSION; ASSOCIATION; INHIBITION; POLYMERASE; 3-KINASE; DOMAIN; TUMORS	Focal adhesion kinase (Fak) is a non-receptor protein-tyrosine kinase that stimulates cell spreading and motility by promoting the formation of contact sites between the cell and the extracellular matrix (focal adhesions). It suppresses apoptosis by transducing survival signals that emanate from focal adhesions via the clustering of transmembrane integrins by components of the extracellular matrix. We demonstrate that Fak is cleaved by caspases at two distinct sites during apoptosis. The sites were mapped to DQTD(772), which was preferentially cleaved by caspase-3, and VSWD704, which was preferentially cleaved by caspase-6 and cytotoxic T lymphocyte-derived granzyme B. The cleavage of Fak. during apoptosis separates the tyrosine kinase domain from the focal adhesion targeting (FAT) domain. The carboxyl-terminal fragments that are generated suppress phosphorylation of endogenous Fak. and thus resemble a natural variant of Fak, FRNK, that inhibits Fak activity by preventing the localization of Fak to focal adhesions. The cleavage of Fak by caspases may thus play an important role in the execution of the suicide program by disabling the anti-apoptotic function of Fak, Interestingly, rodent Fak lacks an optimal caspase-3 consensus cleavage site although it is cleaved in murine cells undergoing apoptosis at an upstream site. This appears to be the first example of a caspase substrate where the cleavage sites are not conserved between species.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck Res Labs, Dept Enzymol, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Roy, S (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada.							CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Crouch DH, 1996, ONCOGENE, V12, P2689; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Otey CA, 1996, INT REV CYTOL, V167, P161, DOI 10.1016/S0074-7696(08)61347-9; OWENS LV, 1995, CANCER RES, V55, P2752; Owens LV, 1996, ANN SURG ONCOL, V3, P100, DOI 10.1007/BF02409059; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1993, MOL CELL BIOL, V13, P786; SCHLAEPFER DD, 1994, NATURE, V372, P786; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; WEINER TM, 1994, ANN SURG ONCOL, V1, P18, DOI 10.1007/BF02303537; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413	27	172	175	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17102	17108		10.1074/jbc.273.27.17102	http://dx.doi.org/10.1074/jbc.273.27.17102			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642276	hybrid			2022-12-25	WOS:000074545200066
J	Ringerike, T; Stang, E; Johannessen, LE; Sandnes, D; Levy, FO; Madshus, IH				Ringerike, T; Stang, E; Johannessen, LE; Sandnes, D; Levy, FO; Madshus, IH			High-affinity binding of epidermal growth factor (EGF) to EGF receptor is disrupted by overexpression of mutant dynamin (K44A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; KINASE; CELLS; INTERNALIZATION; ENDOCYTOSIS; PHOSPHORYLATION; CYTOSKELETON; MEMBRANE; DOMAIN; GTPASE	Activation of the epidermal growth factor receptor (EGFR) kinase was analyzed in cells conditionally defective for clathrin-dependent endocytosis by overexpression of mutant dynamin (K44A). EGF-induced autophosphorylation of the EGFR on ice was strongly reduced in cells overexpressing mutant dynamin, and consistently, binding analyses showed that high-affinity EGFRs were lost. In the absence of mutant dynamin the cells displayed both high-and low-affinity EGFR. At 4 degrees C EGF-EGFR localized mainly outside coated pits regardless of expression of mutant dynamin. However, also low-affinity EGFR efficiently moved to coated pits upon incubating cells at 37 degrees C, Thus, expression of mutant dynamin disrupts high-affinity binding of EGF, but not ligand-induced recruitment of EGFR to clathrin-coated pits.	Univ Oslo, Inst Pathol, N-0316 Oslo, Norway; Univ Oslo, Natl Hosp, Inst Surg Res, N-0027 Oslo, Norway; Univ Oslo, Dept Pharmacol, N-0316 Oslo, Norway	University of Oslo; University of Oslo; National Hospital Norway; University of Oslo	Madshus, IH (corresponding author), Natl Hosp Norway, Inst Pathol, N-0027 Oslo, Norway.							BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; Bergeron JJM, 1995, BIOSCIENCE REP, V15, P411, DOI 10.1007/BF01204345; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HENEGOUWEN PMP, 1989, J CELL BIOCHEM, V39, P455; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KING AC, 1982, J BIOL CHEM, V257, P3053; LANDRETH GE, 1985, J CELL BIOL, V101, P1341, DOI 10.1083/jcb.101.4.1341; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; McClure SJ, 1996, MOL MEMBR BIOL, V13, P189, DOI 10.3109/09687689609160598; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; ROY LM, 1989, J CELL PHYSIOL, V140, P295, DOI 10.1002/jcp.1041400215; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VANBELZEN N, 1990, J CELL PHYSIOL, V145, P365, DOI 10.1002/jcp.1041450223; VanderHeyden MAG, 1997, FEBS LETT, V410, P265, DOI 10.1016/S0014-5793(97)00599-1; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WEIGANT FAC, 1986, J CELL BIOL, V103, P87	31	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16639	16642		10.1074/jbc.273.27.16639	http://dx.doi.org/10.1074/jbc.273.27.16639			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642213	hybrid			2022-12-25	WOS:000074545200003
J	Westwick, JK; Lee, RJ; Lambert, QT; Symons, M; Pestell, RG; Der, CJ; Whitehead, IP				Westwick, JK; Lee, RJ; Lambert, QT; Symons, M; Pestell, RG; Der, CJ; Whitehead, IP			Transforming potential of Dbl family proteins correlates with transcription from the cyclin D1 promoter but not with activation of Jun NH2-terminal kinase, p38/Mpk2, serum response factor, or c-Jun	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEINS; JNK/SAPK SIGNALING PATHWAY; EXPRESSION CDNA CLONING; RAS TRANSFORMATION; SEQUENCE SIMILARITY; ONCOGENE FUNCTION; RHO; GENE; REGULATORS	The dbl family of oncogenes encodes a large, structurally related, family of growth-regulatory molecules that possess guanine nucleotide exchange factor activity for specific members of the Rho family of Pas-related GTPases. We have evaluated matched sets of weakly and strongly transforming versions of five Dbl family proteins (Lfc, Lsc, Ect2, Dbl, and Dbs) to determine their ability to stimulate signaling pathways that are activated by Rho family proteins, We found that the transforming potential of this panel did not correlate directly with their ability to activate Jun NH2-terminal kinase, p38/Mpk2, serum response factor, or c-Jun. In contrast, transient stimulation of transcription from the cyclin DI promoter provided a strong correlation with transforming potential, and we found constitutive up-regulation of cyclin D1 protein in Dbl family protein-transformed cells, In addition, we observed that at least two Dbl family members (Lfc and Ect2) induced changes in the actin cytoskeleton and exhibited nuclear signaling profiles that are consistent with a broader range of in vivo substrate utilization than is predicted from their in vitro exchange specificities. In summary, although Dbl family proteins exhibit signaling profiles that are consistent with their in vivo activation of Rho proteins, stimulation of cyclin D1 transcription is the only activity that correlates with transforming potential, thus suggesting that deregulated cell cycle progression may be important for Dbl family protein transformation.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Whitehead, IP (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.			Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA063071, R01CA055008, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA55008, CA42978, CA63071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chan AML, 1996, ONCOGENE, V12, P1259; CHAN AML, 1994, ONCOGENE, V9, P1057; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; OSLON MF, 1995, SCIENCE, V269, P1270; PASTERIS NG, 1994, CELL, V79, P669; Pepper Daniel S., 1997, Nature (London), V386, P177; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; RON D, 1991, NEW BIOL, V3, P372; Sambrook J., 2002, MOL CLONING LAB MANU; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TOKSOZ D, 1994, ONCOGENE, V9, P621; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; Watanabe G, 1997, J BIOL CHEM, V272, P20063, DOI 10.1074/jbc.272.32.20063; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; WHITEHEAD I, 1995, J BIOL CHEM, V271, P18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZOHN IE, 1998, IN PRESS ONCOGENE	70	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16739	16747		10.1074/jbc.273.27.16739	http://dx.doi.org/10.1074/jbc.273.27.16739			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642229	hybrid, Green Published			2022-12-25	WOS:000074545200019
J	Akamatsu, E; Tanaka, T; Kato, J				Akamatsu, E; Tanaka, T; Kato, J			Transcription factor E2F and cyclin E Cdk2 complex cooperate to induce chromosomal DNA replication in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR DEVELOPMENTAL TRANSITION; MEIOTIC MATURATION; S-PHASE; RETINOBLASTOMA PROTEIN; CYTOPLASMIC CONTROL; DEPENDENT KINASES; CELL-CYCLES; LAEVIS; G(1); INHIBITORS	Although no chromosomal DNA replication actually occurs during Xenopus oocyte maturation, the capability develops during the late meiosis I (MI) phase in response to progesterone. This ability, however, is suppressed by Mos proteins and maturation/mitosis promoting factor during the second meiosis phase (meiosis II; MII) until fertilization. Inhibition of RNA synthesis by actinomycin D during early MI prevented induction of the replication ability, but did not interfere with initiation of the meiotic cell cycle progression characterized by oscillation of the maturation/mitosis promoting factor activity and germinal vesicle breakdown. Microinjection of recombinant proteins such as dominant-negative E2F or universal Gdk inhibitors, p21 and p27, but not wild type human E2F-1 or Cdk4-specific inhibitor, pig, into maturing oocytes during MI abolished induction of the DNA replication ability. Go-injection of human E2F-1 and cyclin E proteins into immature oocytes allowed them to initiate DNA replication even in the absence of progesterone treatment. Injection of cyclin E alone, which was sufficient to activate endogenous Cdk2 kinase, failed to induce DNA replication. Moreover, the activation of Cdk2 was not affected under the conditions where DNA replication was blocked by actinomycin D. Thus, like somatic cells, both activities of E2F and cyclin E-Cdk2 complex are required for induction of the DNA replication ability in maturing Xenopus oocytes, and enhancement of both activities enables oocytes to override DNA-replication inhibitory mechanisms that specifically lie in maturing oocytes.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan	Nara Institute of Science & Technology	Kato, J (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.		Tanaka, Toshiaki/C-5567-2013	Tanaka, Toshiaki/0000-0002-9448-1452				BENBOW RM, 1975, P NATL ACAD SCI USA, V72, P2437, DOI 10.1073/pnas.72.6.2437; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BRACHET J, 1967, EXP CELL RES, V48, P233, DOI 10.1016/0014-4827(67)90312-6; BRACHET J, 1974, MOL CELL BIOCHEM, V3, P189, DOI 10.1007/BF01686644; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Furuno N, 1997, EMBO J, V16, P3860, DOI 10.1093/emboj/16.13.3860; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GELFAND RA, 1983, DEV BIOL, V99, P427, DOI 10.1016/0012-1606(83)90292-0; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; GURDON JB, 1967, P NATL ACAD SCI USA, V58, P545, DOI 10.1073/pnas.58.2.545; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HOFMANN F, 1996, GENE DEV, V10, P3949; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAMARCA MJ, 1975, DEV BIOL, V47, P384, DOI 10.1016/0012-1606(75)90292-4; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Murray A, 1993, CELL CYCLE INTRO; NEVINS JR, 1992, SCIENCE, V258, P424; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PHILPOTT A, 1994, MOL CELL BIOL, V14, P5000, DOI 10.1128/MCB.14.7.5000; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Smith L D, 1970, Curr Top Dev Biol, V5, P1, DOI 10.1016/S0070-2153(08)60051-4; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; WEBB AC, 1975, DEV BIOL, V45, P44, DOI 10.1016/0012-1606(75)90239-0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZIEGLER D, 1976, J CELL BIOL, V68, P620, DOI 10.1083/jcb.68.3.620	49	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16494	16500		10.1074/jbc.273.26.16494	http://dx.doi.org/10.1074/jbc.273.26.16494			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632717	hybrid			2022-12-25	WOS:000074436600088
J	Xu, J; Yeh, CH; Chen, SW; He, LM; Sensi, SL; Canzoniero, LMT; Choi, DW; Hsu, CY				Xu, J; Yeh, CH; Chen, SW; He, LM; Sensi, SL; Canzoniero, LMT; Choi, DW; Hsu, CY			Involvement of de novo ceramide biosynthesis in tumor necrosis factor-alpha cycloheximide-induced cerebral endothelial cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INDUCED APOPTOSIS; TNF-ALPHA; SPHINGOLIPID BIOSYNTHESIS; MULTIPLE-SCLEROSIS; PROTEIN-SYNTHESIS; BRAIN INJURY; CYTOKINES; PATHWAY; SPHINGOSINE	Cytokines, including tumor necrosis factor-alpha (TNF-alpha), may elicit cytotoxic response through the sphingomyelin-ceramide signal transduction pathway by activation of sphingomyelinases and the subsequent release of ceramide: the universal lipid second messenger. Treatment of bovine cerebral endothelial cells (BCECs) with TNF-alpha for 16 h followed by cycloheximide (CHX) for 6 h resulted in an increase in ceramide accumulation, DNA fragmentation, and cell death. Application of a cell permeable ceramide analogue C-2 ceramide, but not the biologically inactive C-2 dihydroceramide, also induced DNA laddering and BCEC death in a concentration- and time-dependent manner, TNF-alpha/CHX-mediated ceramide production apparently is not a result of sphingomyelin hydrolysis because sphingomyelin content does not decrease in this death paradigm, In addition, an acidic sphingomyelinase inhibitor, desipramine, had no effect on TNF-alpha/CHX-induced cell. death, However, addition of fumonisin B1, a selective ceramide synthase inhibitor, attenuated TNF-alpha/CHX-induced intracellular ceramide elevation and BCEC death. Together, these findings suggest that ceramide plays at least a partial role in this paradigm of BCEC death. Our results show, for the first time, that ceramide derived from de novo synthesis is an alternative mechanism to sphingomyelin hydrolysis in the BCEC death process initiated by TNF-alpha/CHX.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Hsu, CY (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	hsuc@neuro.wustl.edu	Sensi, Stefano L./J-3164-2016; Sensi, Stefano L./O-1335-2019	Sensi, Stefano L./0000-0002-0710-2574; Sensi, Stefano L./0000-0002-0710-2574; Hsu, Chung Y./0000-0002-5632-2733; CANZONIERO, Lorella Maria Teresa/0000-0003-2255-5341	NINDS NIH HHS [NS 37230, NS 28995, NS 32636] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028995, R01NS037230, P01NS032636] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; CRUZ R, 1995, FASEB J, V9, pA127; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; Gianani R, 1996, P NATL ACAD SCI USA, V93, P2257, DOI 10.1073/pnas.93.6.2257; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hsu CY, 1997, ANN NY ACAD SCI, V823, P148, DOI 10.1111/j.1749-6632.1997.tb48387.x; Hsu CY, 1996, NEUROTRAUMA, P1433; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; Liu XZ, 1997, J NEUROSCI, V17, P5395; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL JE, 1995, FASEB J, V9, P611, DOI 10.1096/fasebj.9.8.7768352; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; PATTERSON PH, 1995, CURR OPIN NEUROBIOL, V5, P642, DOI 10.1016/0959-4388(95)80070-0; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; RAINE CS, 1994, J NEUROPATH EXP NEUR, V53, P328, DOI 10.1097/00005072-199407000-00002; Shaikh AY, 1997, NEUROSCI LETT, V229, P193, DOI 10.1016/S0304-3940(97)00307-8; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Slowik MR, 1997, LAB INVEST, V77, P257; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wang JH, 1996, SHOCK, V6, P331, DOI 10.1097/00024382-199611000-00006; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; XU J, 1992, J NEUROCHEM, V58, P1930, DOI 10.1111/j.1471-4159.1992.tb10071.x; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	45	175	182	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16521	16526		10.1074/jbc.273.26.16521	http://dx.doi.org/10.1074/jbc.273.26.16521			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632721	hybrid			2022-12-25	WOS:000074436600092
J	Hong, JX; Lee, FJS; Patton, WA; Lin, CY; Moss, J; Vaughan, M				Hong, JX; Lee, FJS; Patton, WA; Lin, CY; Moss, J; Vaughan, M			Phospholipid- and GTP-dependent activation of cholera toxin and phospholipase D by human ADP-ribosylation factor-like protein 1 (HARL1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; ARF-FAMILY; SELECTIVE AMPLIFICATION; CLONING; PURIFICATION; EXPRESSION; MEMBER; BRAIN; GENE; RIBOSYLTRANSFERASE	AY)P-ribosylation factors (ARFs), 20-kDa guanine nucleotide-binding proteins named for their ability to activate cholera toxin (CT) ADP-ribosyltransferase activity, have a critical role in vesicular transport slid activate a phospholipase D (PLD) isoform. Although ARF-like (ARL) proteins are very similar in sequence to ARFs, they were initially believed not to activate CT or PLD. mRNA for human ATL1. (hARL1), which is 57% identical in amino acid sequence to hARF1, is present in all tissues, with the highest amounts in kidney and pancreas and barely detectable amounts in brain. Relative amounts of hARL1 protein were similar to mRNA levels. Purified hARL1 (rARL1) synthesized in Escherichia coli had less activity toward PLD than did rARF1, although PLD activation by both proteins was guanosine guanosine 5'-(gamma-thio)triphosphate (GTP gamma S)-dependent. ARL1 stimulation of CT-catalyzed ADP-ribosylation was considerably less than that by rARF1 and was phospholipid dependent. GTP gamma S-binding by rARL1 was also phospholipid- and detergent-dependent, and in assays containing phosphatidylserine, was greater than that by rARF1. In vitro, the activities of rARL1 and rARF1 are similar. Rather than being a member of a separate subfamily, hARL1, which activates PLD and CT in a phospholipid-dependent manner, appears to be part of a continuum of ARF family proteins.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; Natl Taiwan Univ, Sch Med, Inst Mol Med, Taipei 100, Taiwan	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Taiwan University	Lee, FJS (corresponding author), 7 Chung Shan S Rd, Taipei, Taiwan.			LEE, FANG-JEN/0000-0002-2167-2426				BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; Breiner M, 1996, BBA-GENE STRUCT EXPR, V1308, P1, DOI 10.1016/0167-4781(96)00081-4; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Han JS, 1996, J BIOL CHEM, V271, P11163, DOI 10.1074/jbc.271.19.11163; Harlow E., 1988, ANTIBODIES LAB MANUA; HONG JX, 1994, J BIOL CHEM, V269, P9743; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1995, GUIDEBOOK SMALL GTPA, P429; KIM J, 1996, THESIS KOREAN RES I; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; LEE FJS, 1992, J BIOL CHEM, V267, P24441; Lowe SL, 1996, J CELL SCI, V109, P209; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MOSS J, 1981, J BIOL CHEM, V256, P7830; NODA M, 1990, BIOCHIM BIOPHYS ACTA, V1034, P195, DOI 10.1016/0304-4165(90)90076-9; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERVENTI IM, 1993, J BIOL CHEM, V268, P4863; SMITH SA, 1995, GENOMICS, V28, P113, DOI 10.1006/geno.1995.1115; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WELSH CF, 1994, J BIOL CHEM, V269, P15583; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	31	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15872	15876		10.1074/jbc.273.25.15872	http://dx.doi.org/10.1074/jbc.273.25.15872			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624189	hybrid			2022-12-25	WOS:000074284200083
J	Mester, T; Field, JA				Mester, T; Field, JA			Characterization of a novel manganese peroxidase-lignin peroxidase hybrid isozyme produced by Bjerkandera species strain BOS55 in the absence of manganese	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM; WHITE-ROT FUNGUS; VERATRYL ALCOHOL; DEGRADING BASIDIOMYCETE; DEPENDENT PEROXIDASE; TRAMETES-VERSICOLOR; CERIPORIOPSIS-SUBVERMISPORA; CATALYTIC PROPERTIES; DICHOMITUS-SQUALENS; KINETIC-ANALYSIS	A novel manganese-dependent peroxidase (MnP) isozyme produced in manganese-free cultures of Bjerkandera sp. strain BOS55 was purified and characterized, The production of the enzyme was greatly stimulated by the exogenous addition of various physiological organic acids such as glycolate, glyoxylate, and oxalate, The physical properties of the enzyme are similar to those of MnP isozymes from different white rot fungi (M-r = 43,000, pi 3.88, and epsilon(407) (nm) = 123 mM(-1) cm(-1)). The Bjerkandera MnP was efficient ire the oxidation of Mn(II), as indicated by the kinetic constants (low K-m of 51 mu m and turnover number of 59 s(-1)). Furthermore, the isozyme was able to oxidize various substrates in the absence of manganese, such as 2,6-dimethoxyphenol, guaiacol, ABTS, 3-hydroxyanthranilic acid, and o- and p-anisidine. An interesting characteristic of the isozyme was its ability to oxidize nonphenolic substrates, veratryl alcohol and 1,4-dimethoxybenzene, without manganese addition. The affinity for veratryl alcohol (K-m = 116 mu M) and its turnover number (2.8 s(-1)) are comparable tee those of lignin peroxidase (LiP) isozymes from other white rot fungi, Manganese at concentrations greater than 0.1 mM severely inhibited the oxidation of veratryl alcohol. The results suggest that this single isozyme is a hybrid between MnP and LiP found in other white rot fungi. The N-terminal amino acid sequence showed a very high homology to those of both MnP and LiP isozymes from Trametes versicolor.	Wageningen Univ Agr, Dept Food Technol & Nutr Sci, Div Ind Microbiol, NL-6700 EV Wageningen, Netherlands	Wageningen University & Research	Mester, T (corresponding author), Wageningen Univ Agr, Dept Food Technol & Nutr Sci, Div Ind Microbiol, POB 8129, NL-6700 EV Wageningen, Netherlands.	Tunde.Mester@algemeen.im.wau.nl						Alic M, 1997, BBA-PROTEIN STRUCT M, V1338, P1, DOI 10.1016/S0167-4838(96)00235-X; BONNARME P, 1990, APPL ENVIRON MICROB, V56, P210, DOI 10.1128/AEM.56.1.210-217.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JA, 1991, J BACTERIOL, V173, P4101, DOI 10.1128/jb.173.13.4101-4106.1991; CANCEL AM, 1993, APPL ENVIRON MICROB, V59, P2909, DOI 10.1128/AEM.59.9.2909-2913.1993; D'Annibale A, 1996, J BIOTECHNOL, V48, P231, DOI 10.1016/0168-1656(96)01513-1; DEJONG E, 1994, FEMS MICROBIOL REV, V13, P153, DOI 10.1016/0168-6445(94)90078-7; Dutton MV, 1996, CAN J MICROBIOL, V42, P881, DOI 10.1139/m96-114; FARRELL RL, 1989, ENZYME MICROB TECH, V11, P322, DOI 10.1016/0141-0229(89)90014-8; FORRESTER IT, 1990, APPL MICROBIOL BIOT, V33, P359, DOI 10.1007/BF00164536; GLENN JK, 1986, ARCH BIOCHEM BIOPHYS, V251, P688, DOI 10.1016/0003-9861(86)90378-4; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; GOLD MH, 1993, MICROBIOL REV, V57, P605, DOI 10.1128/MMBR.57.3.605-622.1993; GOODWIN DC, 1995, BIOCHEMISTRY-US, V34, P5060, DOI 10.1021/bi00015a017; HAEMMERLI SD, 1987, FEBS LETT, V220, P149, DOI 10.1016/0014-5793(87)80893-1; HAMMEL KE, 1993, J BIOL CHEM, V268, P12274; HAMMEL KE, 1994, BIOCHEMISTRY-US, V33, P13349, DOI 10.1021/bi00249a022; HU ZC, 1993, ENZYME MICROB TECH, V15, P567, DOI 10.1016/0141-0229(93)90018-W; JOHANSSON T, 1993, ARCH BIOCHEM BIOPHYS, V300, P49, DOI 10.1006/abbi.1993.1007; JOHANSSON T, 1993, ARCH BIOCHEM BIOPHYS, V300, P57, DOI 10.1006/abbi.1993.1008; KERSTEN PJ, 1987, J BACTERIOL, V169, P2195, DOI 10.1128/jb.169.5.2195-2201.1987; KHINDARIA A, 1994, ARCH BIOCHEM BIOPHYS, V314, P301, DOI 10.1006/abbi.1994.1446; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; KODURI RS, 1994, BIOCHEMISTRY-US, V33, P4225, DOI 10.1021/bi00180a016; KUAN IC, 1993, J BIOL CHEM, V268, P20064; KUAN IC, 1993, P NATL ACAD SCI USA, V90, P1242, DOI 10.1073/pnas.90.4.1242; LOBOS S, 1994, MICROBIOL-UK, V140, P2691, DOI 10.1099/00221287-140-10-2691; Martinez MJ, 1996, EUR J BIOCHEM, V237, P424, DOI 10.1111/j.1432-1033.1996.0424k.x; Matsubara M, 1996, APPL ENVIRON MICROB, V62, P4066, DOI 10.1128/AEM.62.11.4066-4072.1996; MAYFIELD MB, 1994, APPL ENVIRON MICROB, V60, P4303, DOI 10.1128/AEM.60.12.4303-4309.1994; Mester T, 1996, APPL MICROBIOL BIOT, V44, P778; Mester T, 1997, FEMS MICROBIOL LETT, V155, P161, DOI 10.1111/j.1574-6968.1997.tb13873.x; MESTER T, 1995, APPL ENVIRON MICROB, V61, P1881, DOI 10.1128/AEM.61.5.1881-1887.1995; MESTER T, 1998, IN PRESS HOLZFORSCHU; Moreira MT, 1997, APPL ENVIRON MICROB, V63, P1749, DOI 10.1128/AEM.63.5.1749-1755.1997; PEASE EA, 1989, J BIOL CHEM, V264, P13531; Perie FH, 1996, BBA-PROTEIN STRUCT M, V1297, P139, DOI 10.1016/S0167-4838(96)00096-9; PERIE FH, 1991, APPL ENVIRON MICROB, V57, P2240; PRIBNOW D, 1989, J BIOL CHEM, V264, P5036; ROY BP, 1993, APPL ENVIRON MICROB, V59, P1855, DOI 10.1128/AEM.59.6.1855-1863.1993; RUTTIMANNJOHNSON C, 1994, APPL ENVIRON MICROB, V60, P599; Sarkar S, 1997, BBA-PROTEIN STRUCT M, V1339, P23, DOI 10.1016/S0167-4838(96)00201-4; SHIMADA M, 1994, FEMS MICROBIOL REV, V13, P285, DOI 10.1111/j.1574-6976.1994.tb00049.x; Sundaramoorthy M, 1997, J BIOL CHEM, V272, P17574, DOI 10.1074/jbc.272.28.17574; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; ten Have R, 1998, FEBS LETT, V422, P391, DOI 10.1016/S0014-5793(98)00044-1; TIEN M, 1986, J BIOL CHEM, V261, P1687; TIEN M, 1988, METHOD ENZYMOL, V161, P238; URZUA U, 1995, FEBS LETT, V371, P132, DOI 10.1016/0014-5793(95)00874-9; WARIISHI H, 1988, BIOCHEMISTRY-US, V27, P5365, DOI 10.1021/bi00414a061; WARIISHI H, 1992, J BIOL CHEM, V267, P23688; WOLFENDEN BS, 1982, J CHEM SOC PERK T 2, P805, DOI 10.1039/p29820000805; Zapanta LS, 1997, J BIOTECHNOL, V53, P93, DOI 10.1016/S0168-1656(96)01678-1	53	221	232	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15412	15417		10.1074/jbc.273.25.15412	http://dx.doi.org/10.1074/jbc.273.25.15412			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624124	hybrid			2022-12-25	WOS:000074284200018
J	Schmalfeldt, M; Dours-Zimmermann, MT; Winterhalter, KH; Zimmermann, DR				Schmalfeldt, M; Dours-Zimmermann, MT; Winterhalter, KH; Zimmermann, DR			Versican V-2 is a major extracellular matrix component of the mature bovine brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; LARGE AGGREGATING PROTEOGLYCAN; HYALURONATE-BINDING PROTEIN; PG-M; NEURITE OUTGROWTH; NERVOUS-TISSUE; AGGRECAN; CARTILAGE; EXPRESSION; GENE	We have isolated and characterized the proteoglycan isoforms of versican from bovine brain extracts. Our approach included (i) cDNA cloning and sequencing of the entire open reading frame encoding the bovine versican splice variants; (ii) preparation of antibodies against bovine versican using recombinant core protein fragments and synthetic peptides; (iii) isolation of versican isoforms by ammonium sulfate precipitation followed by anion exchange and hyaluronan affinity chromatography; and (iv) characterization by SDS-polyacrylamide gel electrophoresis and Coomassie Blue staining or immunoblotting. Our results demonstrate that versican V-2 is, together with brevican, a major component of the mature brain extracellular matrix. Versicans V-0 and V-1 are only present in relatively small amounts. Versican V-2 migrates after chondroitinase ABC digestion with an apparent molecular mass of about 400 kDa, whereas it barely enters a 4-15% polyacrylamide gel without the enzyme treatment. The 400-kDa product is recognized by antibodies against the glycosaminoglycan-alpha domain and against synthetic NH2- and COOH-terminal peptides. Our preparations contain no major proteolytic products of versican, e.g, hyaluronectin or glial hyaluronate-binding protein. Having biochemical quantities of versican V-2 available will allow us to test its putative modulatory role in neuronal cell adhesion and axonal growth.	Univ Zurich, Inst Clin Pathol, Dept Pathol, CH-8091 Zurich, Switzerland; Swiss Fed Inst Technol, Biochem Lab 1, CH-8092 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Zimmermann, DR (corresponding author), Univ Zurich, Inst Clin Pathol, Dept Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	dieterzi@pathol.unizh.ch						Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; DELPECH B, 1981, J NEUROCHEM, V36, P855, DOI 10.1111/j.1471-4159.1981.tb01672.x; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; Domowicz M, 1996, INT J DEV NEUROSCI, V14, P191, DOI 10.1016/0736-5748(96)00007-X; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; FRYER HJL, 1992, J BIOL CHEM, V267, P9874; FULOP C, 1993, J BIOL CHEM, V268, P17377; GROVER J, 1993, BIOCHEM J, V291, P361, DOI 10.1042/bj2910361; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; HOCKFIELD S, 1990, COLD SPRING HARB SYM, V55, P505; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; LANDOLT RM, 1995, DEVELOPMENT, V121, P2303; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Li H, 1996, MOL BRAIN RES, V36, P309, DOI 10.1016/0169-328X(95)00269-X; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MEYERPUTTLITZ B, 1995, J NEUROCHEM, V65, P2327; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; NASO MF, 1994, J BIOL CHEM, V269, P32999; Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005; PERIDES G, 1989, J BIOL CHEM, V264, P5981; PERIDES G, 1992, J BIOL CHEM, V267, P23883; PERIDES G, 1995, BIOCHEM J, V312, P377, DOI 10.1042/bj3120377; Rauch U, 1997, CELL TISSUE RES, V290, P349, DOI 10.1007/s004410050940; Rauch U, 1997, GENOMICS, V44, P15, DOI 10.1006/geno.1997.4853; RAUCH U, 1992, J BIOL CHEM, V267, P19536; Rauch U, 1997, J BIOL CHEM, V272, P26905, DOI 10.1074/jbc.272.43.26905; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; SEIDENBECHER CI, 1995, J BIOL CHEM, V270, P27206, DOI 10.1074/jbc.270.45.27206; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SNOW DM, 1991, DEVELOPMENT, V113, P1473; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; Yamada H, 1997, J NEUROSCI, V17, P7784; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; Zako M, 1997, J BIOL CHEM, V272, P9325, DOI 10.1074/jbc.272.14.9325; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	44	105	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15758	15764		10.1074/jbc.273.25.15758	http://dx.doi.org/10.1074/jbc.273.25.15758			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624174	hybrid			2022-12-25	WOS:000074284200068
J	Appleyard, MVCL; Sloan, J; Kana'n, GJM; Heck, IS; Kinghorn, JR; Unkles, SE				Appleyard, MVCL; Sloan, J; Kana'n, GJM; Heck, IS; Kinghorn, JR; Unkles, SE			The Aspergillus nidulans cnxF gene and its involvement in molybdopterin biosynthesis - Molecular characterization and analysis of in vivo generated mutans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NITRATE REDUCTASE; NEUROSPORA MUTANT; CONVERTING FACTOR; CLONING; ENZYMES	The product of the Aspergillus nidulans cnxF gene was found by biochemical analysis of cnxF mutants to be involved in the conversion of precursor Z to molybdopterin, Mutants cnxF1242 and cnxF8 accumulate precursor Z, while the level of molybdopterin is undetectable. The DNA sequence of the cnxF gene was determined, and the inferred protein of 560 amino acids was found to contain a central region (residues around 157 to 396) similar in sequence to the prokaryotic proteins MoeB, which is thought to encode molybdopterin synthase sulfurylase, ThiF, required for thiamine biosynthesis, and HesA, involved in heterocyst formation, as well as eukaryotic ubiquitin-activating protein E1. Based on these similarities, a possible mechanism of action is discussed. Sequence comparisons indicate the presence of one and possibly two nucleotide binding motifs, Gly-X-Gly-X-X-Gly, as well as two metal binding Cys-X-X-Cys motifs in this central region of the CnxF protein, Seven in vivo generated A. nidulans cnxF mutants were found to have amino acid substitutions of conserved residues within this central region of similarity to molybdopterin synthase sulfurylase, indicating that these seven amino acids are essential and that this domain is crucial for function. Of these seven, the cnxF1285 mutation results in the replacement of Gly-178, the last glycine residue of the N-proximal Gly-X-Gly-X-X-Gly motif, indicating that this motif is essential. Mutation of the conserved Arg-208, also probably involved in nucleotide binding, leads to a loss-of-function phenotype in cnxF200, Alteration of Cys-263, the only conserved Cys residue (apart from the metal binding motifs), in cnxF472 suggests this residue as a candidate for thioester formation between molybdopterin synthase and the sulfurylase, Substitution of Gly-160 in two independently isolated mutants, cnxF21 and cnxF24, results in temperature-sensitive phenotypes and indicates that this residue is important in protein conformation. The C-terminal CnxF stretch (residues 397-560) shows substantial sequence conservation to a yeast hypothetical protein, Yhr1, such conservation between species suggesting that this region has function. Not inconsistent with this proposition is the observation that mutant cnxF8 results from loss of the 34 C-terminal residues of CnxF, There is no obvious similarity of the CnxF C-terminal region with other proteins of known function. Two cnxF transcripts are found in low abundance and similar levels were observed in nitrate- or ammonium-grown cells.	Univ St Andrews, Sch Environm & Evolutionary Biol, St Andrews KY16 9TH, Fife, Scotland; Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia	University of St Andrews; Monash University	Unkles, SE (corresponding author), Univ St Andrews, Sch Environm & Evolutionary Biol, St Andrews KY16 9TH, Fife, Scotland.	shiela.unkles@med.monash.edu.au						ABERG B, 1947, KUNGL LANTBRUKSHOGSK, V15, P37; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARST HN, 1997, MICROBIOLOGY, V143, P1437; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; BORTHAKUR D, 1990, MOL GEN GENET, V221, P227, DOI 10.1007/BF00261725; Bragg PD, 1997, ARCH BIOCHEM BIOPHYS, V338, P57, DOI 10.1006/abbi.1996.9797; BRODY H, 1991, NUCLEIC ACIDS RES, V19, P3105, DOI 10.1093/nar/19.11.3105; Clutterbuck A.J, 1974, HDB GENETICS, V1, P447; COVE DJ, 1963, NATURE, V198, P262, DOI 10.1038/198262a0; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; GARRETT RG, 1976, MOL GEN GENET, V147, P179; GEMS DH, 1993, CURR GENET, V24, P520, DOI 10.1007/BF00351716; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; HINTON SM, 1990, CRIT REV MICROBIOL, V17, P169, DOI 10.3109/10408419009105724; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; KETCHUM PA, 1970, P NATL ACAD SCI USA, V66, P1016, DOI 10.1073/pnas.66.3.1016; KETCHUM PA, 1973, BIOCHEM BIOPH RES CO, V552, P1450; MACCABE AP, 1990, EMBO J, V9, P279, DOI 10.1002/j.1460-2075.1990.tb08106.x; MACDONALD DW, 1974, EUR J BIOCHEM, V47, P107, DOI 10.1111/j.1432-1033.1974.tb03673.x; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; NASON A, 1971, P NATL ACAD SCI USA, V68, P3242, DOI 10.1073/pnas.68.12.3242; NOHNO T, 1988, J BACTERIOL, V170, P4097, DOI 10.1128/jb.170.9.4097-4102.1988; PATEMAN JA, 1964, NATURE, V201, P58, DOI 10.1038/201058a0; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; RAJAGOPALAN KV, 1996, ESCHERICHIA COLI SAL, P674; Unkles SE, 1997, J BIOL CHEM, V272, P28381, DOI 10.1074/jbc.272.45.28381; VANDERHORN PB, 1993, J BACTERIOL, V175, P982, DOI 10.1128/JB.175.4.982-992.1993; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WEILAND KL, 1991, BIOCHEM J, V275, P227, DOI 10.1042/bj2750227	33	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14869	14876		10.1074/jbc.273.24.14869	http://dx.doi.org/10.1074/jbc.273.24.14869			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614089	hybrid			2022-12-25	WOS:000074160400031
J	Mitrovic, AD; Amara, SG; Johnston, GAR; Vandenberg, RJ				Mitrovic, AD; Amara, SG; Johnston, GAR; Vandenberg, RJ			Identification of functional domains of the human glutamate transporters EAAT1 and EAAT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; HIGH-AFFINITY; ION FLUXES; EXPRESSION; CLONING	Glutamate transporters serve the important function of mediating removal of glutamate released at excitatory synapses and maintaining extracellular concentrations below excitotoxic levels. Excitatory amino acid transporter subtypes EAAT1 and EAAT2 have a high degree of sequence homology and similar predicted topology and yet display a number of functional differences. Several recombinant chimeric transporters were generated to identify domains that contribute to functional differences between EAAT1 and EAAT2. Wild-type transporters and chimeric transporters were expressed in Xenopus laevis oocytes, and electrogenic transport was studied under voltage clamp conditions. The differential sensitivity of EAAT1 and EAAT2 to transport blockers, kainate, threo-3-methylglutamate, and (2S,4R)-4-methylglutamate as well as L-serine-O-sulfate transport and chloride permeability were employed to characterize chimeric transporters. One particular region, transmembrane domains 9 and 10, plays an important role in defining these functional differences. The intracellular carboxyl-terminal region may also play a minor role in conferring an effect on chloride permeability. This study provides important insight into the identification of functional domains that determine differences among glutamate transporter subtypes.	Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia; Oregon Hlth & Sci Univ, Vollum Inst Adv Biomed Res, Howard Hughes Med Inst, Portland, OR 97201 USA	University of Sydney; Howard Hughes Medical Institute; Oregon Health & Science University	Vandenberg, RJ (corresponding author), Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia.	robv@pharmacol.usyd.edu.au	Vandenberg, Robert John/E-6018-2016; Johnston, Graham/AAJ-9569-2021; Johnston, Graham AR/B-9827-2009	Vandenberg, Robert John/0000-0003-1523-4814; Johnston, Graham/0000-0001-8872-4078; Amara, Susan/0000-0001-8914-1106				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; CONRADT M, 1995, J BIOL CHEM, V270, P25207, DOI 10.1074/jbc.270.42.25207; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Kanai Y., 1997, Society for Neuroscience Abstracts, V23, P1485; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Lebrun B, 1997, J BIOL CHEM, V272, P20336, DOI 10.1074/jbc.272.33.20336; Otis TS, 1997, SCIENCE, V277, P1515, DOI 10.1126/science.277.5331.1515; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; SEAL B, 1995, SOC NEUR ABSTR, V21, P1861; Slotboom DJ, 1996, J BIOL CHEM, V271, P31317, DOI 10.1074/jbc.271.49.31317; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; Vandenberg RJ, 1997, MOL PHARMACOL, V51, P809, DOI 10.1124/mol.51.5.809; Vandenberg RJ, 1998, BRIT J PHARMACOL, V123, P1593, DOI 10.1038/sj.bjp.0701776; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Wahle S, 1996, J CELL BIOL, V135, P1867, DOI 10.1083/jcb.135.6.1867	23	42	43	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14698	14706		10.1074/jbc.273.24.14698	http://dx.doi.org/10.1074/jbc.273.24.14698			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614067	hybrid			2022-12-25	WOS:000074160400009
J	Ushio-Fukai, M; Alexander, RW; Akers, M; Griendling, KK				Ushio-Fukai, M; Alexander, RW; Akers, M; Griendling, KK			p38 mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II - Role in vascular smooth muscle cell hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; HYDROGEN-PEROXIDE; PHOSPHORYLATION; STRESS; GROWTH; INHIBITION; S6; INDUCTION; PLATELETS; CASCADE	Angiotensin II induces an oxidant stress-dependent hypertrophy in cultured vascular smooth muscle cells. To investigate the growth-related molecular targets of H2O2, we examined the redox sensitivity of agonist-stimulated activation of the mitogen-activated protein kinase (MAPK) family. We show here that angiotensin II elicits a rapid increase in intracellular H2O2 and a rapid and robust phosphorylation of both p42/44MAPK (16-fold) and p38MAPK (15-fold). However, exogenous H2O2 activates only p38MAPK (14-fold), and diphenylene iodonium, an NADH/NADPH oxidase inhibitor, attenuates angiotensin II-stimulated phosphorylation of p38MAPK, but not p42/44MAPK. Furthermore, in cells stably transfected with human catalase, angiotensin II-induced intracellular H2O2 generation is almost completely blocked, resulting in inhibition of phosphorylation of p38MAPK,, but not p42/44MAPK, and a subsequent partial decrease in angiotensin II-induced hypertrophy. Specific inhibition of either the p38MAPK pathway with SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole) or the p42/44MAPK pathway with PD98059 (2-(2'-amino-3'-methoxyphenyl)oxanaphthalen-4-one) also partially, but significantly, attenuates angiotensin II-induced hypertrophy; however, simultaneous blockade of both pathways has an additive inhibitory effect, indicating that the hypertrophic response to angiotensin II requires parallel, independent activation of both MAPK pathways. These results provide the first evidence that p38MAPK is a critical component of the oxidant stress (H2O2)-sensitive signaling pathways activated by angiotensin II in vascular smooth muscle cells and indicate that it plays a crucial role in vascular hypertrophy.	Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA 30322 USA	Emory University	Ushio-Fukai, M (corresponding author), Emory Univ, Sch Med, Dept Med, Div Cardiol, 1639 Pierce Dr,Rm 319, Atlanta, GA 30322 USA.			Griendling, Kathy/0000-0002-9456-8582	NHLBI NIH HHS [HL38206] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038206, R37HL038206, R29HL038206] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BOSCOBOINIK D, 1991, J BIOL CHEM, V266, P6188; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; FIORANI M, 1995, BBA-MOL CELL RES, V1269, P98, DOI 10.1016/0167-4889(95)00109-6; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GRIENDLING KK, 1991, J BIOL CHEM, V266, P15498; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LASSEGUE B, 1995, MOL PHARMACOL, V48, P601; Li PF, 1997, FEBS LETT, V404, P249, DOI 10.1016/S0014-5793(97)00093-8; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; NIELSEN PJ, 1982, P NATL ACAD SCI-BIOL, V79, P2937, DOI 10.1073/pnas.79.9.2937; NOVAKHOFER I, 1985, J BIOL CHEM, V260, P314; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; SOCORRO L, 1990, BIOCHEM J, V265, P799, DOI 10.1042/bj2650799; Tsai JC, 1996, J BIOL CHEM, V271, P3667; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Wang XM, 1997, BIOCHEM BIOPH RES CO, V238, P207, DOI 10.1006/bbrc.1997.7273; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	54	553	575	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15022	15029		10.1074/jbc.273.24.15022	http://dx.doi.org/10.1074/jbc.273.24.15022			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614110	hybrid			2022-12-25	WOS:000074160400052
J	Wang, ZX; Berson, JF; Zhang, TY; Cen, YH; Sun, Y; Sharron, M; Lu, ZH; Peiper, SC				Wang, ZX; Berson, JF; Zhang, TY; Cen, YH; Sun, Y; Sharron, M; Lu, ZH; Peiper, SC			CXCR4 sequences involved in coreceptor determination of human immunodeficiency virus type-1 tropism - Unmasking of activity with M-tropic Env glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 ENTRY; ENVELOPE GLYCOPROTEIN; MONONUCLEAR PHAGOCYTES; CD4-MEDIATED FUSION; MACROPHAGE TROPISM; CELL-LINES; T-CELLS; RECEPTOR; INFECTION; DOMAIN	The interaction of human immunodeficiency virus type 1 (HIV-1) with CD4 and one of a cadre of chemokine receptors triggers conformational changes in the HIV-1 envelope (Env) glycoprotein that lead to membrane fusion. The coreceptor activity of the second extracellular loop of CXCR4, which is restricted to dual tropic and T-tropic strains, was insensitive to the removal of charged residues either singly or in combinations by alanine scanning mutagenesis or to the conversion of acidic residues to lysine. Conversion of Asp-187 to a neutral residue exclusively unmasked activity with M-tropic Env in fusion and infection experiments. Insertion of the D187V mutation into chimeras containing extracellular loop 2 of CXCR4 in a CXCR2 framework also resulted in the acquisition of M-tropic coreceptor activity. The independence of CXCR4 coreceptor activity from charged residues and the extension of its repertoire by removing Asp-187 suggest that this interaction is not electrostatic and that coreceptors have the potential to be utilized by a spectrum of Env, which may be masked by charged amino acids in extracellular domains. These findings indicate that the primary structural determinants of coreceptors that program reactivity with M-, dual, and T-tropic Env are surprisingly subtle and that relatively insignificant changes in CXCR4 can dramatically alter utilization by Env of varying tropism.	Univ Louisville, James Graham Brown Canc Ctr, Henry Vogt Canc Res Inst, Louisville, KY 40202 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Univ Louisville, Dept Pathol & Lab Med, Louisville, KY 40202 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Louisville; University of Louisville; University of Louisville; University of Pennsylvania	Peiper, SC (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, Henry Vogt Canc Res Inst, 529 S Jackson St, Louisville, KY 40202 USA.	scp@bcc.louisville.edu			NIAID NIH HHS [AI 41346] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041346] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, J BIOL CHEM, V272, P19771, DOI 10.1074/jbc.272.32.19771; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Doranz BJ, 1997, J VIROL, V71, P6305, DOI 10.1128/JVI.71.9.6305-6314.1997; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; Endres MJ, 1997, SCIENCE, V278, P1462, DOI 10.1126/science.278.5342.1462; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; Jansson M, 1996, P NATL ACAD SCI USA, V93, P15382, DOI 10.1073/pnas.93.26.15382; LANDAU NR, 1988, NATURE, V334, P159, DOI 10.1038/334159a0; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; Mebatsion T, 1997, CELL, V90, P841, DOI 10.1016/S0092-8674(00)80349-9; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; Platt EJ, 1997, J VIROL, V71, P883, DOI 10.1128/JVI.71.2.883-890.1997; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; Rana S, 1997, J VIROL, V71, P3219, DOI 10.1128/JVI.71.4.3219-3227.1997; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; Schnell MJ, 1997, CELL, V90, P849, DOI 10.1016/S0092-8674(00)80350-5; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WYATT LS, 1995, VIROLOGY, V210, P202, DOI 10.1006/viro.1995.1332	56	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15007	15015		10.1074/jbc.273.24.15007	http://dx.doi.org/10.1074/jbc.273.24.15007			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614108	hybrid			2022-12-25	WOS:000074160400050
J	Zisch, AH; Kalo, MS; Chong, LD; Pasquale, EB				Zisch, AH; Kalo, MS; Chong, LD; Pasquale, EB			Complex formation between EphB2 and Src requires phosphorylation of tyrosine 611 in the EphB2 juxtamembrane region	ONCOGENE			English	Article						autophosphorylation sites; neuronal signaling pathways; receptor tyrosine kinase; two-hybrid system	PROTEIN KINASE-C; GROWTH-FACTOR; IN-VITRO; SIGNAL-TRANSDUCTION; NEURAL RETINA; COMMISSURAL AXONS; DOMAIN BINDING; CDNA CLONING; SH2 DOMAIN; RECEPTOR	The cellular components of the neuronal signaling pathways of Eph receptor tyrosine kinases are only beginning to be elucidated. Here we show that in vivo tyrosine phosphorylation sites of the Eph receptors EphA3, EphA4, and EphB2 in embryonic retina serve as binding sites for the Src-homology 2 (SH2) domain of Src kinase, Furthermore, tyrosine-phosphorylated EphB2 was detected in Src immunoprecipitates from transfected Cos cells, indicating that EphB2 and Src can physically associate. Interestingly, a form of Src with reduced electrophoretic mobility and increased tyrosine phosphorylation was detected in Cos cells expressing tyrosine-phosphorylated EphB2, suggesting a functional interaction between EphB2 and Src. Yeast two-hybrid analysis in conjunction with site-directed mutagenesis demonstrated that phosphorylated tyrosine 611 in the juxtamembrane region of EphB2 is crucial for the interaction with the SH2 domain of Src, In contrast, binding of the carboxy-terminal SH2 domain of phospholipase C gamma was not abolished upon mutation of tyrosine 611 in EphB2, Phosphopeptide mapping of autophosphorylated full-length EphB2, and wild-type and tyrosine to phenylalanine mutants of the EphB2 cytoplasmic domain fused to LexA, showed tyrosine 611 in the sequence motif YEDP as a major site of autophosphorylation in EphB2, Our mutational analysis also indicated that tyrosines 605 and 611 are important for EphB2 kinase activity. We propose Src kinase as a downstream effector that mediates the neuron's response to Eph receptor activation.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, La Jolla, CA 92037 USA.				NEI NIH HHS [EY105576] Funding Source: Medline; NICHD NIH HHS [HD25938] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BIXBY JL, 1993, J NEUROSCI, V13, P3421; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Flanagan JG, 1997, CELL, V90, P403; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; FOX GM, 1995, ONCOGENE, V10, P897; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; Hall CL, 1996, ONCOGENE, V13, P2213; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; INGRAHAM CA, 1992, ONCOGENE, V7, P95; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Lombardo CR, 1995, BIOCHEMISTRY-US, V34, P16456, DOI 10.1021/bi00050a029; Maness P.F., 1992, Seminars in Cell Biology, V3, P117; Meima L, 1997, MOL CELL NEUROSCI, V9, P314, DOI 10.1006/mcne.1997.0621; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; SAJJADI FG, 1993, ONCOGENE, V8, P1807; Schindelholz B, 1997, J NEUROSCI, V17, P8391; SHAO HN, 1994, J BIOL CHEM, V269, P26606; Soans C, 1996, J CELL BIOL, V135, P781, DOI 10.1083/jcb.135.3.781; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stover DR, 1996, J BIOL CHEM, V271, P12481, DOI 10.1074/jbc.271.21.12481; SUDOL M, 1993, ONCOGENE, V8, P823; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; TWAMLEYSTEIN GM, 1993, ONCOGENE, V7, P1893; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; ZHENG XF, 1989, ONCOGENE, V4, P99; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U; ZISCH AH, 1995, MOL CELL NEUROSCI, V6, P263, DOI 10.1006/mcne.1995.1021	83	100	103	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	1998	16	20					2657	2670		10.1038/sj.onc.1201823	http://dx.doi.org/10.1038/sj.onc.1201823			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632142				2022-12-25	WOS:000073698200010
J	Rubino, D; Driggers, P; Arbit, D; Kemp, L; Miller, B; Coso, O; Pagliai, K; Gray, K; Gutkind, S; Segars, J				Rubino, D; Driggers, P; Arbit, D; Kemp, L; Miller, B; Coso, O; Pagliai, K; Gray, K; Gutkind, S; Segars, J			Characterization of Brx, a novel Dbl family member that modulates estrogen receptor action	ONCOGENE			English	Article						estrogen receptor; signal transduction; Rho GTPase; Cdc42Hs; Dbl; Rho GEF; Lbc	GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEINS; LIGAND-INDEPENDENT ACTIVATION; STEROID-HORMONE RECEPTORS; HUMAN BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; MEDIATED TRANSCRIPTION; SIGNALING PATHWAYS; STRUCTURAL SIMILARITIES; SEQUENCE SIMILARITY	Regulation of gene activation by the estrogen receptor (ER) is complex and involves co-regulatory proteins, oncoproteins (such as Fos and Jun), and phosphorylation signaling pathways. Here we report the cloning and initial characterization of a novel protein, Err, that contains a region of identity to the oncogenic Rho-guanine nucleotide exchange (Rho-GEF) protein Lbc, and a unique region capable of binding to nuclear hormone receptors, including the ER, Western and immunohistochemistry studies showed Brx to be expressed in estrogen-responsive reproductive tissues, including breast ductal epithelium, Err bound specifically to the ER via an interaction that required distinct regions of ER and Brx. Furthermore, overexpression of Brx in transfection experiments using an estrogen-responsive reporter revealed that Err augmented gene activation by the ER in an element-specific and ligand-dependent manner, Moreover, activation of ER by Brx could be specifically inhibited by a dominant-negative mutant of Cdc42Hs, but not by dominant negative mutants of RhoA or Rac1. Taken together, these data suggest that Err represents a novel modular protein that may integrate cytoplasmic signaling pathways involving Rho family GTPases and nuclear hormone receptors.	NICHHD, Off Sci Director, NIH, Bethesda, MD 20892 USA; NICHD, DEB, NIH, Bethesda, MD 20892 USA; NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Obstet & Gynecol, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Uniformed Services University of the Health Sciences - USA	Segars, J (corresponding author), NICHHD, Off Sci Director, NIH, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; Rubino, Domenica/0000-0002-3072-2819				ADAMS JM, 1992, ONCOGENE, V7, P611; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; ANZANO MA, 1994, CANCER RES, V54, P4614; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; Beatson GW, 1896, LANCET, V2, P162, DOI DOI 10.1016/S0140-6736(01)72384-7; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CARR DW, 1992, J BIOL CHEM, V267, P13376; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN AML, 1994, ONCOGENE, V9, P1057; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GALLAND F, 1992, ONCOGENE, V7, P585; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MA ZQ, 1994, MOL ENDOCRINOL, V8, P910, DOI 10.1210/me.8.7.910; MARKS MS, 1992, MOL ENDOCRINOL, V6, P219, DOI 10.1210/me.6.2.219; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nunez SB, 1997, MOL CELL ENDOCRINOL, V127, P27, DOI 10.1016/S0303-7207(96)03980-9; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OMALLEY BW, 1995, RECENT PROG HORM RES, V50, P333; ONATE SA, 1995, SCIENCE, V270, P1354; PASTERIS NG, 1994, CELL, V79, P669; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TOKSOZ D, 1994, ONCOGENE, V9, P621; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	76	68	73	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2513	2526		10.1038/sj.onc.1201783	http://dx.doi.org/10.1038/sj.onc.1201783			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627117				2022-12-25	WOS:000073672300009
J	Buzzard, KA; Giaccia, AJ; Killender, M; Anderson, RL				Buzzard, KA; Giaccia, AJ; Killender, M; Anderson, RL			Heat shock protein 72 modulates pathways of stress-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-DEATH; BREAST-CANCER; ACTIVATION; HSP70; THERMOTOLERANCE; FIBROBLASTS; PROTEASES; INDUCTION; GENE	The resistance to stress-induced apoptosis conferred by the thermotolerant state or by exogenous expression of HSP72 was measured in mouse embryo fibroblasts. The induction of thermotolerance protects cells from heat, tumor necrosis factor alpha (TNF alpha), and ceramide-induced apoptosis but not from ionizing radiation. Because the development of thermotolerance is associated with increased levels of heat shock proteins, we determined whether constitutive expression of one of the major inducible heat shock proteins, HSP72, could also protect cells from stress-induced apoptosis. Cells expressing constitutive HSP72 were shown to have significantly reduced levels of apoptosis after heat, TNF alpha, and ceramide but not after ionizing radiation. Activation of stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) was found to be strongly inhibited in thermotolerant cells after heat shock but not after other stresses. Cells that constitutively express HSP72 did not demonstrate decreased SAPK/JNK activation after any of these stresses. Thus, factors other than HSP72 that are induced in the thermotolerant state are able to reduce activation of SAPK/JNK after heat stress, Notably, the level of activation of SAPK/JNK did not correlate with the amount of apoptosis detected after different stresses. Constitutive HSP72 expression inhibited poly(ADP-ribose) polymerase cleavage in cells after heat shock and TNF alpha but not after ceramide or ionizing radiation. The results suggest either that SAPK/JNK activation is not required for apoptosis in mouse embryo fibroblasts or that HSP72 acts downstream of SAPK/JNK. Furthermore, the data support the concept that caspase activity, which can be down-regulated by HSP72, is a crucial step in stress-induced apoptosis. Based on data presented here and elsewhere, we propose that the heat shock protein family can be classified as a class of anti-apoptotic genes, in addition to the Bcl-2 and inhibitor of apoptosis protein families of genes.	Peter MacCallum Canc Inst, Trescowthick Res Labs, E Melbourne, Vic 3002, Australia; Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA	Peter Maccallum Cancer Center; Stanford University	Anderson, RL (corresponding author), Peter MacCallum Canc Inst, Locked Bag 1,ABeckett St, Melbourne, Vic 3000, Australia.	r.anderson@pmci.unimelb.edu.au	Anderson, Robin/K-6966-2019; Anderson, Robin/I-2306-2013; Anderson, Robin/S-1005-2017	Anderson, Robin/0000-0002-6841-7422				Bellmann K, 1996, FEBS LETT, V391, P185, DOI 10.1016/0014-5793(96)00730-2; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Dorstyn L, 1997, CELL DEATH DIFFER, V4, P570, DOI 10.1038/sj.cdd.4400281; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Garrido C, 1997, CANCER RES, V57, P2661; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; JAATTELA M, 1993, J IMMUNOL, V151, P4286; JAMEEL A, 1992, INT J CANCER, V50, P409, DOI 10.1002/ijc.2910500315; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KIMURA E, 1993, J CLIN ONCOL, V11, P891, DOI 10.1200/JCO.1993.11.5.891; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; Li WX, 1996, RADIAT RES, V145, P324, DOI 10.2307/3578988; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOSSER DD, 1992, J CELL PHYSIOL, V151, P561, DOI 10.1002/jcp.1041510316; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NEALE ML, 1988, IMMUNOLOGY, V64, P81; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; STRASSER A, 1995, CELL GROWTH DIFFER, V6, P1; SUBJECK JR, 1982, BRIT J RADIOL, V55, P579, DOI 10.1259/0007-1285-55-656-579; Tavaria M, 1996, CELL STRESS CHAPERON, V1, P23, DOI 10.1379/1466-1268(1996)001<0023:AHSGTT>2.3.CO;2; TAVARIA M, 1997, GUIDEBOOK MOL CHAPER, P49; THOR A, 1991, J NATL CANCER I, V83, P170, DOI 10.1093/jnci/83.3.170; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhivotovsky B, 1996, EXPERIENTIA, V52, P968, DOI 10.1007/BF01920106	49	257	278	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17147	17153		10.1074/jbc.273.27.17147	http://dx.doi.org/10.1074/jbc.273.27.17147			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642282	hybrid			2022-12-25	WOS:000074545200072
J	Engel, LS; Hill, JM; Caballero, AR; Green, LC; O'Callaghan, RJ				Engel, LS; Hill, JM; Caballero, AR; Green, LC; O'Callaghan, RJ			Protease IV, a unique extracellular protease and virulence factor from Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOFT CONTACT-LENSES; ALKALINE PROTEASE; DEFICIENT MUTANTS; CYSTIC-FIBROSIS; TOXIN-A; ELASTASE; INFECTIONS; EPIDEMIOLOGY; KERATITIS; PROTEINS	Comparisons of virulence between a Pseudomonas parent strain and an isogenic mutant devoid of protease TV have demonstrated a significant role for this enzyme during infection. We have characterized purified Pseudomonas aeruginosa protease TV in terms of its biochemical and enzymatic properties, and found it to be a unique extracellular protease. The N-terminal decapeptide sequence of protease IV is not homologous with any published protein sequence. Protease IV has a molecular mass of 26 kDa, an isoelectric point of 8.70, and optimum enzymatic activity at pH 10.0 and 45 degrees C. Purified protease TV demonstrates activity for the carboxyl side of lysine-containing peptides and can digest a number of biologically important proteins, including immunoglobulin, complement components, fibrinogen, and plasminogen. Protease IV is not inhibited by thiol-, carboxyl-, or metalloproteinase inhibitors. The total loss of enzyme activity in the presence of N-p-tosyl-L-chloro-methyl ketone and the partial inhibition of enzyme activity by diisopropyl fluorophosphate or phenylmethylsulfonyl fluoride imply that protease TV is a serine protease. Inhibition by dithiothreitol and beta-mercaptoethanol suggests that intramolecular disulfide bonds are essential for enzyme activity. The characteristics of this enzyme suggest that inhibitors of serine proteases could be developed into a medication designed to arrest tissue damage during Pseudomonas infection.	Louisiana State Univ, Med Ctr, Dept Microbiol Immunol & Parasitol, Ctr Eye,Sch Med, New Orleans, LA 70112 USA; Louisiana State Univ, Sch Med, Ctr Eye, Dept Ophthalmol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University System	O'Callaghan, RJ (corresponding author), Louisiana State Univ, Med Ctr, Dept Microbiol Immunol & Parasitol, Ctr Eye,Sch Med, 1901 Perdido St, New Orleans, LA 70112 USA.				NEI NIH HHS [EY02377, EY08871, EY10974] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008871, R01EY010974, P30EY002377] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMS MH, 1959, BACTERIOPHAGES, P446; AQUINO VM, 1995, PEDIATR INFECT DIS J, V14, P140; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; COHEN EJ, 1987, OPHTHALMOLOGY, V94, P109; Daring G., 1993, PSEUDOMONAS AERUGINO, P245; Dart JKG, 1995, EYE, V9, P679, DOI 10.1038/eye.1995.178; DIXON GH, 1958, J BIOL CHEM, V233, P1373; ELLIOTT BW, 1986, J BIOL CHEM, V261, P1259; Engel LS, 1998, INVEST OPHTH VIS SCI, V39, P662; FLANIGAN MJ, 1994, PERITON DIALYSIS INT, V14, P248; FLORES G, 1993, CLIN INFECT DIS, V16, P698; GAMBELLO MJ, 1991, J BACTERIOL, V173, P3000, DOI 10.1128/JB.173.9.3000-3009.1991; GILLIGAN PH, 1991, CLIN MICROBIOL REV, V4, P35, DOI 10.1128/CMR.4.1.35-51.1991; GOLD AM, 1964, BIOCHEMISTRY-US, V3, P783, DOI 10.1021/bi00894a009; Holder I.A., 1993, PSEUDOMONAS AERUGINO, P275; Holland Simon P., 1993, P159; HOWE TR, 1984, INFECT IMMUN, V43, P1058, DOI 10.1128/IAI.43.3.1058-1063.1984; IMAYASU M, 1994, OPHTHALMOLOGY, V101, P371; JARVIS WR, 1992, J ANTIMICROB CHEMOTH, V29, P19, DOI 10.1093/jac/29.suppl_A.19; KERNACKI KA, 1995, INVEST OPHTH VIS SCI, V36, P1371; KESSLER E, 1993, J BIOL CHEM, V268, P7503; KILLINGSWORTH DW, 1989, ARCH OPHTHALMOL-CHIC, V107, P795, DOI 10.1001/archopht.1989.01070010817012; MOOS M, 1988, J BIOL CHEM, V263, P6005; O'Callaghan R.J., 1996, INVEST OPHTH VIS SCI, V37, P1; OHMAN DE, 1980, J INFECT DIS, V142, P547, DOI 10.1093/infdis/142.4.547; OHMAN DE, 1980, INFECT IMMUN, V28, P899; PAVLOVSKIS OR, 1979, INFECT IMMUN, V24, P181, DOI 10.1128/IAI.24.1.181-187.1979; ROLSTON KVI, 1992, CANCER INVEST, V10, P43, DOI 10.3109/07357909209032787; SHAW ELLIOTT, 1965, BIOCHEMISTRY, V4, P2219, DOI 10.1021/bi00886a039; STRAND CL, 1982, JAMA-J AM MED ASSOC, V248, P1615, DOI 10.1001/jama.248.13.1615; SUTER S, 1994, AM J RESP CRIT CARE, V150, pS118, DOI 10.1164/ajrccm/150.6_Pt_2.S118; TODER SD, 1992, 92 GEN M AM SOC MICR, pD51; TRUEB RM, 1994, PEDIATR DERMATOL, V11, P35, DOI 10.1111/j.1525-1470.1994.tb00071.x; TWINING SS, 1993, INVEST OPHTH VIS SCI, V34, P2699	34	129	131	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16792	16797		10.1074/jbc.273.27.16792	http://dx.doi.org/10.1074/jbc.273.27.16792			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642237	hybrid			2022-12-25	WOS:000074545200027
J	McCarthy, JV; Ni, J; Dixit, VM				McCarthy, JV; Ni, J; Dixit, VM			RIP2 is a novel NF-kappa B-activating and cell death-inducing kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; GROWTH-FACTOR RECEPTOR; CYTOPLASMIC DOMAIN; PROTEIN; APOPTOSIS; CD40; ANTIGEN; FAMILY; SIGNAL; INTERACTS	Through specific interactions with members of the tumor necrosis receptor (TNFR) family, adapter molecules such as the serine/threonine (Ser/Thr) kinase RIP mediate divergent signaling pathways including NF-KB activation and cell death. In this study, we have identified and characterized a novel 61-kDa protein kinase related to RIP that is a component of both the TNFR-1 and the CD40 signaling complexes. Receptor interacting protein-2 (RIP2) contains an N-terminal domain with homology to Ser/Thr kinases and a C-terminal caspase activation and recruitment domain (CARD), a homophilic interaction motif that mediates the recruitment of caspase death proteases. Overexpression of RIPS signaled both NF-KB activation and cell death. Mutational analysis revealed the pro-apoptotic function of RIPS to be restricted to its C-terminal CARD domain, whereas the intact molecule was necessary for NF-KB activation. RIPS interacted with other members of the TNFR-1 signaling complex, including inhibitor of apoptosis protein cIAP1 and with members of the TNFR-associated factor (TRAF) family, specifically TRAF1, TRAF5, and TRAF6, but not with TRAF2, TRAF3, or TRAF4. These TRAF interactions mediate the recruitment of RIPS to receptor signaling complexes.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Human Genome Sci Inc, Rockville, MD 20850 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc; Roche Holding; Genentech	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,Bldg 10,Rm 290, San Francisco, CA 94080 USA.	dixit@gene.com	mccarthy, justin/AAG-7550-2019; dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; mccarthy, justin/0000-0002-2667-7365				ADAMS MD, 1995, NATURE S, V377, P173; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CAMERINI D, 1991, J IMMUNOL, V147, P3165; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DEFRANCE T, 1992, EUR J IMMUNOL, V22, P2831, DOI 10.1002/eji.1830221112; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; HANKS SK, 1991, METHOD ENZYMOL, V200, P525; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LING NR, 1987, LEUCOCYTE TYPING, V3, P302; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHRIEVER F, 1989, J EXP MED, V169, P2043, DOI 10.1084/jem.169.6.2043; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175	44	351	387	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16968	16975		10.1074/jbc.273.27.16968	http://dx.doi.org/10.1074/jbc.273.27.16968			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642260	hybrid			2022-12-25	WOS:000074545200050
J	Mote, J; Reines, D				Mote, J; Reines, D			Recognition of a human arrest site is conserved between RNA polymerase II and prokaryotic RNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ELONGATION-FACTOR; AMINO-ACID SUBSTITUTIONS; INITIATION FACTOR-ALPHA; ESCHERICHIA-COLI; NASCENT RNA; TERNARY COMPLEXES; TERMINATION EFFICIENCY; INTRINSIC TERMINATION; HYDROLYTIC CLEAVAGE; CRYSTAL-STRUCTURE	DNA sequences that arrest transcription by either eukaryotic RNA polymerase II or Escherichia coli RNA polymerase have been identified previously. Elongation factors SH and GreB are RNA polymerase-binding proteins that enable readthrough of arrest sites by these enzymes, respectively. This functional similarity has led to general models of elongation applicable to both eukaryotic and prokaryotic enzymes. Here we have transcribed with phage and bacterial RNA polymerases, a human DNA sequence previously defined as an arrest site for RNA polymerase II. The phage and bacterial enzymes both respond efficiently to the arrest signal in vitro at limiting levels of nucleoside triphosphates. The E. coli polymerase remains in a template-engaged complex for many hours, can be isolated, and is potentially active. The enzyme displays a relatively slow first-order loss of elongation competence as it dwells at the arrest site. Bacterial RNA polymerase arrested at the human site is reactivated by GreB in the same way that RNA polymerase II arrested at this site is stimulated by SII, Very efficient readthrough can be achieved by phage, bacterial, and eukaryotic RNA polymerases in the absence of elongation factors if 5-Br-UTP is substituted for UTP. These findings provide additional and direct evidence for functional similarity between prokaryotic and eukaryotic transcription elongation and readthrough mechanisms.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Reines, D (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.	dreines@emory.edu	excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NIGMS NIH HHS [GM46331, R01 GM046331] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; Bobkova EV, 1997, J BIOL CHEM, V272, P22832, DOI 10.1074/jbc.272.36.22832; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; Chamberlin M J, 1992, Harvey Lect, V88, P1; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; Chen Y, 1996, J BIOL CHEM, V271, P5993, DOI 10.1074/jbc.271.11.5993; CHRISTIE GE, 1981, P NATL ACAD SCI-BIOL, V78, P4180, DOI 10.1073/pnas.78.7.4180; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; Conaway RC, 1996, METHOD ENZYMOL, V273, P194; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; Deng L, 1997, J BIOL CHEM, V272, P695; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FARNHAM PJ, 1980, CELL, V20, P739, DOI 10.1016/0092-8674(80)90320-7; GOLOMB M, 1974, J BIOL CHEM, V249, P2858; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAGLER J, 1993, J BIOL CHEM, V268, P2166; Hartvig L, 1996, EMBO J, V15, P4767, DOI 10.1002/j.1460-2075.1996.tb00854.x; Heisler LM, 1996, J BIOL CHEM, V271, P14572, DOI 10.1074/jbc.271.24.14572; INMAN RB, 1962, J MOL BIOL, V5, P172, DOI 10.1016/S0022-2836(62)80082-5; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KASH SF, 1993, MOL CELL BIOL, V13, P2718, DOI 10.1128/MCB.13.5.2718; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Koulich D, 1997, J BIOL CHEM, V272, P7201, DOI 10.1074/jbc.272.11.7201; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; Labhart P, 1997, J BIOL CHEM, V272, P9055; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; Landick R, 1996, SCIENCE, V273, P202, DOI 10.1126/science.273.5272.202; LUO Y, 1991, J BIOL CHEM, V266, P13303; Lyakhov DL, 1997, J MOL BIOL, V269, P28, DOI 10.1006/jmbi.1997.1015; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; Morin PE, 1996, P NATL ACAD SCI USA, V93, P10604, DOI 10.1073/pnas.93.20.10604; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1991, J BIOL CHEM, V266, P10510; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; Sastry SS, 1997, J BIOL CHEM, V272, P8644, DOI 10.1074/jbc.272.13.8644; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; Schnapp G, 1996, MOL GEN GENET, V252, P412, DOI 10.1007/s004380050245; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; THAYER GC, 1985, MOL GEN GENET, V199, P55, DOI 10.1007/BF00327509; Tschochner H, 1996, P NATL ACAD SCI USA, V93, P12914, DOI 10.1073/pnas.93.23.12914; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wang DG, 1997, P NATL ACAD SCI USA, V94, P8433, DOI 10.1073/pnas.94.16.8433; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299; WIEST DK, 1992, J BIOL CHEM, V267, P7733; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	82	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16843	16852		10.1074/jbc.273.27.16843	http://dx.doi.org/10.1074/jbc.273.27.16843			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642244	Green Accepted, hybrid			2022-12-25	WOS:000074545200034
J	Anderson, GW; Larson, RJ; Oas, DR; Sandhofer, CR; Schwartz, HL; Mariash, CN; Oppenheimer, JH				Anderson, GW; Larson, RJ; Oas, DR; Sandhofer, CR; Schwartz, HL; Mariash, CN; Oppenheimer, JH			Chicken ovalbumin upstream promoter-transcription factor (COUP-TF) modulates expression of the Purkinje cell protein-2 gene - A potential role for COUP-TF in repressing premature thyroid hormone action in the developing brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR ORPHAN RECEPTORS; RETINOIC ACID RECEPTORS; RESPONSE ELEMENTS; ROR-ALPHA; VITAMIN-D; BINDING; TRIIODOTHYRONINE; IDENTIFICATION; FAMILY; HYPOTHYROIDISM	The cerebellar Purkinje cell-specific PCP-2 gene is transcriptionally activated by thyroid hormone during the 2nd and 3rd weeks of postnatal life in the rat. In contrast, thyroid hormone has no detectable effects on PCP-2 expression in the fetal rat. We now present data that suggest that the orphan nuclear receptor chicken ovalbumin upstream promoter-transcription factor (COUP-TF) represses triiodothyronine (T3)-dependent transcriptional activation of PCP-2 in the immature Purkinje cell. Gel shift assays show that the PCP-2 A1TRE and adjoining sequences (-295/-199 region) bind to rat and mouse brain nucleoproteins in a developmentally regulated fashion and that one of these nucleoproteins could be the orphan nucleoprotein COUP-TF. In support of this hypothesis, in vitro translated COUP-TF binds to the -295/-199 region and COUP-TF represses T3-dependent activation of the PCP-S promoter in transient transfection analyses. Finally, immunohistochemical studies reveal that COUP-TF is specifically expressed in the immature fetal and early neonatal Purkinje cell. and that this expression diminishes coincident with thyroid hormone induction of POP-a expression. Our findings are consistent with the hypothesis that the presence or absence of inhibitory proteins bound to the thyroid hormone response element of T3-responsive genes governs the responsivity of these genes to thyroid hormone during brain development.	Univ Minnesota, Dept Med, Div Endocrinol & Diabet, Thyroid Res Unit, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Cell Biol & Neuroanat, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Oppenheimer, JH (corresponding author), Univ Minnesota, Dept Med, Div Endocrinol & Diabet, Thyroid Res Unit, Box 101 UMHC, Minneapolis, MN 55455 USA.				NIADDK NIH HHS [AM 19812] Funding Source: Medline; NIDDK NIH HHS [DK09295] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM019812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009295] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMAN J, 1997, RELATION ITS EVOLUTI, P99; ALTMAN J, 1997, RELATION ITS EVOLUTI, P173; ALTMAN J, 1997, DEV CEREBELLAR SYSTE, P379; Anderson GW, 1997, MOL CELL ENDOCRINOL, V131, P79, DOI 10.1016/S0303-7207(97)00095-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; Brubaker K, 1996, DEV BRAIN RES, V93, P198, DOI 10.1016/0165-3806(96)00007-7; CALVO R, 1990, J CLIN INVEST, V86, P889, DOI 10.1172/JCI114790; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; CORREAROTTER R, 1992, BIOTECHNIQUES, V12, P154; DASILVA SL, 1995, MOL BRAIN RES, V30, P131, DOI 10.1016/0169-328X(94)00289-Q; DEESCOBAR GM, 1985, ENDOCRINOLOGY, V117, P1890, DOI 10.1210/endo-117-5-1890; DELONG R, 1989, IODINE BRAIN; DEONA CR, 1988, PEDIATR RES, V24, P588, DOI 10.1203/00006450-198811000-00010; FALCONE M, 1992, ENDOCRINOLOGY, V131, P2419, DOI 10.1210/en.131.5.2419; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Hagen SG, 1996, J MOL NEUROSCI, V7, P245, DOI 10.1007/BF02737062; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; Jacobson M., 1991, DEV NEUROBIOL, P401, DOI DOI 10.1007/978-1-4757-4954-0_10; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; LEGRAND J, 1967, ARCH ANAT MICROSC MO, V56, P291; Legrand J, 1986, THYROID HORMONE META, P503; LU XP, 1994, MOL ENDOCRINOL, V8, P1774, DOI 10.1210/me.8.12.1774; LUCAS PC, 1991, MOL CELL BIOL, V11, P5164, DOI 10.1128/MCB.11.10.5164; MARIASH CN, 1980, ENDOCRINOLOGY, V106, P22, DOI 10.1210/endo-106-1-22; MUSCAT GEO, 1995, NUCLEIC ACIDS RES, V23, P1311, DOI 10.1093/nar/23.8.1311; NEUMAN K, 1995, J NEUROSCI RES, V41, P39, DOI 10.1002/jnr.490410106; NORDQUIST DT, 1988, J NEUROSCI, V8, P4780; ORTIZ MA, 1995, MOL ENDOCRINOL, V9, P1679, DOI 10.1210/me.9.12.1679; QUI Y, 1994, P NATL ACAD SCI USA, V91, P4451; QUI Y, 1997, GENE DEV, V11, P1925; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SANDHOFER C, 1998, IN PRESS MOL CELL EN; SAWAYA BE, 1995, NUCLEIC ACIDS RES, V23, P2206, DOI 10.1093/nar/23.12.2206; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; Schwartz HL, 1997, ENDOCRINOLOGY, V138, P3119, DOI 10.1210/en.138.8.3119; SHUPNIK MA, 1989, ENDOCR REV, V10, P459, DOI 10.1210/edrv-10-4-459; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; STRAIT KA, 1992, MOL ENDOCRINOL, V6, P1874, DOI 10.1210/me.6.11.1874; SURKS MI, 1972, J CLIN INVEST, V51, P3104, DOI 10.1172/JCI107137; TACHA DE, 1994, J HISTOTECHNOL, V17, P365, DOI 10.1179/his.1994.17.4.365; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; Yen PM, 1996, J BIOL CHEM, V271, P10910, DOI 10.1074/jbc.271.18.10910; ZOU LL, 1994, J BIOL CHEM, V269, P13346	49	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16391	16399		10.1074/jbc.273.26.16391	http://dx.doi.org/10.1074/jbc.273.26.16391			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632703	hybrid			2022-12-25	WOS:000074436600074
J	Garcia, JJ; Capaldi, RA				Garcia, JJ; Capaldi, RA			Unisite catalysis without rotation of the gamma-epsilon domain in Escherichia coli F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART MITOCHONDRIAL ATPASE; ADENOSINE-TRIPHOSPHATASE; CRYOELECTRON MICROSCOPY; CYSTEINE RESIDUES; ELEMENTARY STEPS; RATE CONSTANTS; BETA-SUBUNIT; F1-ATPASE; HYDROLYSIS; SITES	Unisite [gamma-P-32]ATP hydrolysis was studied in ECF1 from the mutant beta E381C after generating a single disulfide bond between beta and gamma subunits to prevent the rotation of the gamma/epsilon domain. The single beta-gamma cross-link was obtained by removal of the delta subunit from F-1 and then treating with CuCl2 as described previously (Aggeler, R,, Haughton, M, A., and Capaldi, R, k (1996) J. Biol, Chem. 270, 9185-9191), The mutant enzyme, beta E381C, had an increased overall rate of unisite hydrolysis of [gamma-P-32]ATP compared with the wild type ECF1 due to increases in the rate of ATP binding (k(+1)), P-i release (k(+3)), and ADP release (K+4). Release of bound substrate ([gamma-P-32]ATP) was also increased in the beta E381C mutant. Cross-linking between Cys-381 and the intrinsic Cys-87 of gamma caused a further increase in the rate of unisite catalysis, mainly by additional effects on nucleotide binding in the high affinity catalytic site (k(+1) and k(+4)), In delta-subunit-free ECF1 from wild type or beta E381C F-1, addition of an excess of ATP accelerated unisite catalysis. After cross-linking, unisite catalysis of beta E381C was not enhanced by the cold chase. The covalent linkage of gamma to beta increased the rate of unisite catalysis to that obtained by cold chase of ATP of the noncross-linked enzyme, It is concluded that the conversion of Glu-381 of beta to Cys induces an activated conformation of the high affinity catalytic site with low affinity for substrate and products. This state is stabilized by cross-linking the Cys at beta 381 to Cys-87 of gamma, We infer from the data that rotation of the gamma/epsilon rotor in ECF1 is not linked to unisite hydrolysis of ATP at the high affinity catalytic site but to ATP binding to a second or third catalytic site on the enzyme.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Capaldi, RA (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.				NHLBI NIH HHS [HL24526] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AlShawi MK, 1997, BIOCHEMISTRY-US, V36, P12954, DOI 10.1021/bi971477z; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; ALSHAWI MK, 1990, J BIOL CHEM, V265, P4402; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DEGOMEZPUYOU MT, 1995, J BIOL CHEM, V270, P16820, DOI 10.1074/jbc.270.28.16820; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Garcia JJ, 1997, J BIOENERG BIOMEMBR, V29, P61, DOI 10.1023/A:1022463822929; Garcia JJ, 1997, EUR J BIOCHEM, V249, P622, DOI 10.1111/j.1432-1033.1997.00622.x; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; Gruber G, 1996, J BIOL CHEM, V271, P32623, DOI 10.1074/jbc.271.51.32623; GRUBER G, 1996, BIOCHEMISTRY-US, V35, P3877; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; HARRIS DA, 1989, BIOCHIM BIOPHYS ACTA, V974, P156, DOI 10.1016/S0005-2728(89)80368-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; Maldonado E, 1998, BBA-BIOENERGETICS, V1363, P70, DOI 10.1016/S0005-2728(97)00083-2; MUNEYUKI E, 1991, BIOCHIM BIOPHYS ACTA, V1058, P304, DOI 10.1016/S0005-2728(05)80251-8; NALIN CM, 1984, J BIOL CHEM, V259, P7275; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PENEFSKY HS, 1985, P NATL ACAD SCI USA, V82, P1589, DOI 10.1073/pnas.82.6.1589; PENEFSKY HS, 1986, METHOD ENZYMOL, V126, P608; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; TURINA P, 1994, J BIOL CHEM, V269, P13465; TURINA P, 1994, BIOCHEMISTRY-US, V33, P14275, DOI 10.1021/bi00251a040; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1994, J BIOL CHEM, V269, P11261; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 1997, BIOPHYS CHEM, V68, P95, DOI 10.1016/S0301-4622(97)00018-5; XIAO R, 1994, J BIOL CHEM, V269, P19232; ZEIGLER M, 1994, J BIOL CHEM, V269, P4233; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381; [No title captured]	46	49	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15940	15945		10.1074/jbc.273.26.15940	http://dx.doi.org/10.1074/jbc.273.26.15940			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632641	hybrid			2022-12-25	WOS:000074436600012
J	Huss, JM; Kasper, CB				Huss, JM; Kasper, CB			Nuclear receptor involvement in the regulation of rat cytochrome P450 3A23 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; FUNCTION OXIDASE SYSTEM; TRANSCRIPTION FACTOR; COUP-TF; PREGNENOLONE 16-ALPHA-CARBONITRILE; TESTOSTERONE 6-BETA-HYDROXYLASE; HEPATIC CYTOCHROME-P-450; DEPENDENT EXPRESSION; LIVER MICROSOMES; ORPHAN RECEPTORS	Many genes of the cytochrome P450 3A (CYP3A) subfamily, including several human and rat isoforms, are inducible by glucocorticoids. In the rat CYP3A23 gene, a 110-base pair segment of the proximal 5'-flanking region mediates dexamethasone activation, Three binding sites (DexRE-1, DexRE-2, and Site A), identified by DNase I footprinting analysis, were characterized for their relative contribution to both basal activity and dexamethasone inducibility. Site-directed mutagenesis of DexRE-1 (-144 to -169) and DexRE-2 (-118 to -136) demonstrated that each contained a core imperfect AGGTCA direct repeat, which comprised a consensus nuclear receptor binding site, and was essential for dexamethasone responsiveness but was not required for basal activity. Competition gel shift and supershift analyses revealed that both sites can bind the orphan nuclear receptor chicken ovalbumin upstream promoter-transcription factor. Site A (-85 to -110) was shown to be important for both basal activity and dexamethasone responsiveness. Point mutants displayed a reduced (2-3-fold) induction response, compared with 15-fold far wild-type, which was accompanied by a 40-60% drop in basal activity. Site A was shown to bind the liver-enriched nuclear receptor hepatocyte nuclear factor 4. Our studies demonstrate that the mechanism mediating glucocorticoid-inducible transcriptional activity of CYP3A23 involves multiple binding sites for members of the nuclear receptor superfamily.	Univ Wisconsin, Mcardle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA; Univ Wisconsin, Mcardle Lab Canc Res, Environm Toxicol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kasper, CB (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, Dept Oncol, 1400 Univ Ave, Madison, WI 53706 USA.				NCI NIH HHS [T32-CA-09135, CA0920, CA22484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA000920, T32CA009135, P01CA022484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOYAMA T, 1989, J BIOL CHEM, V264, P10388; BEAUNE PH, 1986, P NATL ACAD SCI USA, V83, P8064, DOI 10.1073/pnas.83.21.8064; BURGER HJ, 1992, P NATL ACAD SCI USA, V89, P2145, DOI 10.1073/pnas.89.6.2145; Cairns W, 1996, J BIOL CHEM, V271, P25269, DOI 10.1074/jbc.271.41.25269; CHEN D, 1994, DNA CELL BIOL, V13, P771, DOI 10.1089/dna.1994.13.771; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; COOPER KO, 1993, ARCH BIOCHEM BIOPHYS, V301, P345, DOI 10.1006/abbi.1993.1154; ELSHOURBAGY NA, 1980, J BIOL CHEM, V255, P1279; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; GONZALEZ FJ, 1986, MOL CELL BIOL, V6, P2969, DOI 10.1128/MCB.6.8.2969; GONZALEZ FJ, 1985, J BIOL CHEM, V260, P7435; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; HALPERT JR, 1988, ARCH BIOCHEM BIOPHYS, V263, P59, DOI 10.1016/0003-9861(88)90613-3; HARDWICK JP, 1983, J BIOL CHEM, V258, P182; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huss JM, 1996, P NATL ACAD SCI USA, V93, P4666, DOI 10.1073/pnas.93.10.4666; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; KIMURA A, 1993, J BIOL CHEM, V268, P11125; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KOMORI M, 1994, J BIOCHEM-TOKYO, V116, P114, DOI 10.1093/oxfordjournals.jbchem.a124482; LU AYH, 1972, ARCH BIOCHEM BIOPHYS, V152, P457, DOI 10.1016/0003-9861(72)90239-1; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MIYATA M, 1995, ARCH BIOCHEM BIOPHYS, V318, P71, DOI 10.1006/abbi.1995.1206; MIYATA M, 1994, ARCH BIOCHEM BIOPHYS, V314, P351, DOI 10.1006/abbi.1994.1453; NAGATA K, 1990, J BIOCHEM-TOKYO, V107, P718, DOI 10.1093/oxfordjournals.jbchem.a123115; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; PASTORCIC M, 1986, MOL CELL BIOL, V6, P2784, DOI 10.1128/MCB.6.8.2784; PRICHARD L, 1990, DRUG METAB DISPOS, V18, P595; QUATTROCHI LC, 1995, J BIOL CHEM, V270, P28917, DOI 10.1074/jbc.270.48.28917; RIBEIRO V, 1992, ARCH BIOCHEM BIOPHYS, V293, P147, DOI 10.1016/0003-9861(92)90377-9; SCHUETZ EG, 1984, J BIOL CHEM, V259, P1999; SCHUETZ EG, 1984, J BIOL CHEM, V259, P2007; Schuetz JD, 1996, MOL PHARMACOL, V49, P63; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; SIMMONS DL, 1989, ARCH BIOCHEM BIOPHYS, V271, P10, DOI 10.1016/0003-9861(89)90250-6; SIMMONS DL, 1987, J BIOL CHEM, V262, P326; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; TEHLADA MB, 1992, ARCH BIOCHEM BIOPHYS, V298, P715; THOMAS PE, 1977, MOL PHARMACOL, V13, P819; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; UMENSONO K, 1991, CELL, V65, P1255; VAMVAKOPOULOS NC, 1992, STEROIDS, V57, P282, DOI 10.1016/0039-128X(92)90061-D; VENEPALLY P, 1992, J BIOL CHEM, V267, P17333; WAXMAN DJ, 1985, BIOCHEMISTRY-US, V24, P4409, DOI 10.1021/bi00337a023; Wright MC, 1996, MOL PHARMACOL, V50, P856; WRIGHTON SA, 1989, MOL PHARMACOL, V36, P97; WRIGHTON SA, 1985, BIOCHEMISTRY-US, V24, P2171, DOI 10.1021/bi00330a010; ZHOU XJ, 1993, BIOCHEM PHARMACOL, V45, P853, DOI 10.1016/0006-2952(93)90169-W	50	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16155	16162		10.1074/jbc.273.26.16155	http://dx.doi.org/10.1074/jbc.273.26.16155			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632670	hybrid			2022-12-25	WOS:000074436600041
J	Lew, BM; Mills, KV; Paulus, H				Lew, BM; Mills, KV; Paulus, H			Protein splicing in vitro with a semisynthetic two-component minimal intein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Protein splicing elements, or inteins, catalyze their own excision from flanking polypeptide sequences, or exteins, thereby leading to the formation of new proteins in which the exteins are linked directly by a peptide bond. A trans-splicing system, using separately purified and expressed N- and C-terminal intein fragments of about 100 amino acids each, fused to appropriate exteins, was recently derived from the Mycobacterium tuberculosis RecA intein (Mills, K, V,, Lew, B, M,, Jiang, S,-Q,, and Paulus, H, (1998) Proc. Natl. Acad Sci, U, S, A. 95, 3543-3548), We have replaced the C-terminal intein fragment of this system with synthetic peptides comprising 35-50 of the C-terminal residues of the RecA intein, The N-terminal intein fragment and the synthetic peptide were reconstituted by renaturation from guanidinium chloride. In the absence of added reductants, a disulfide-linked dimer of the N-terminal fragment and the peptide accumulated and could be induced to splice by reduction of its disulfide bond. The intermediate and spliced products were identified by polyacrylamide gel electrophoresis, mass spectrometry, and derivatization with thiol-reactive biotin followed by Western blotting with a streptavidin-enzyme conjugate, This is the first example of protein splicing involving a synthetic intein fragment and opens the way for studying the active site structure and function of the intein by the use of different synthetic peptides, including ones with non-natural amino acids.	Boston Biomed Res Inst, Boston, MA 02114 USA; Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Harvard University; Harvard Medical School	Paulus, H (corresponding author), Boston Biomed Res Inst, 20 Staniford St, Boston, MA 02114 USA.	paulus@bbri.harvard.edu	Wood, David W/B-2992-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055875] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM55875] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAIKEN IM, 1973, J BIOL CHEM, V248, P884; Chong SR, 1997, J BIOL CHEM, V272, P15587, DOI 10.1074/jbc.272.25.15587; Derbyshire V, 1997, P NATL ACAD SCI USA, V94, P11466, DOI 10.1073/pnas.94.21.11466; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mills KV, 1998, P NATL ACAD SCI USA, V95, P3543, DOI 10.1073/pnas.95.7.3543; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; Shao Y, 1997, CHEM BIOL, V4, P187, DOI 10.1016/S1074-5521(97)90287-8; Shingledecker K, 1998, GENE, V207, P187, DOI 10.1016/S0378-1119(97)00624-0; Southworth MW, 1998, EMBO J, V17, P918, DOI 10.1093/emboj/17.4.918	13	39	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15887	15890		10.1074/jbc.273.26.15887	http://dx.doi.org/10.1074/jbc.273.26.15887			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632632	hybrid			2022-12-25	WOS:000074436600003
J	Magrangeas, F; Pitiot, G; Dubois, S; Bragado-Nilsson, E; Cherel, M; Jobert, S; Lebeau, B; Boisteau, O; Lethe, B; Mallet, J; Jacques, Y; Minvielle, S				Magrangeas, F; Pitiot, G; Dubois, S; Bragado-Nilsson, E; Cherel, M; Jobert, S; Lebeau, B; Boisteau, O; Lethe, B; Mallet, J; Jacques, Y; Minvielle, S			Cotranscription and intergenic splicing of human galactose-1-phosphate uridylyltransferase and interleukin-11 receptor alpha-chain genes generate a fusion mRNA in normal cells - Implication for the production of multidomain proteins during evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; TRANSCRIPTIONAL INTERFERENCE; URIDYLTRANSFERASE GENE; NUCLEOTIDE-SEQUENCE; MEASLES-VIRUS; SUPERFAMILY; BINDING; ANTIGEN; DISEASE; IL11RA	In the past 10 years, much attention has been focused on transcription preinitiation complex formation as a target for regulating gene expression, and other targets such as transcription termination complex assemblage have been less intensively investigated. We established the existence of poly(A) site choice and fusion splicing of two adjacent genes, galactose-1-phosphate uridylyl-transferase (GALT) and interleukin-11 receptor alpha-chain (IL-11R alpha), in normal human cells. This 16-kilobase (kb) transcription unit contains two promoters (the first one is constitutive, and the second one, 8 kb downstream, is highly regulated) and two cleavage/polyadenylation signals separated by 12 kb, The promoter from the GALT gene yields two mRNAs, a 1,4-kb mRNA encoding GALT and a 3-kb fusion mRNA when the first poly(A) site is spliced out and the second poly(A) is used, The 3-kb mRNA codes for a fusion protein of unknown function, containing part of the GALT protein and the entire IL-11R alpha protein. The GALT promoter/IL-11R alpha poly(A) transcript results from leaky termination and alternative splicing. This feature of RNA polymerase (pol) II transcription, which contrasts with efficient RNA pol I and pol III termination, may be involved, together with chromosome rearrangements, in the generation of fusion proteins with multiple domains and would have major evolutionary implications in terms of natural processes to generate novel proteins with common motifs, Our results, together with accumulation of genomic informations, will stimulate new considerations and experiments in gene expression studies.	INSERM, U463, F-44035 Nantes, France; Lab Genet Mol Neurotransmiss & Proc Neurodegenera, CNRS, UMR 9923, F-75013 Paris, France; Univ Catholique Louvain, Cellular Genet Unit, B-1200 Brussels, Belgium; Ludwig Inst Canc Res, B-1200 Brussels, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite Catholique Louvain; Ludwig Institute for Cancer Research	Pitiot, G (corresponding author), Hop La Pitie Salpetriere, Lab Genet Mol Neurotransmiss & Proc Neurodegenera, CNRS, UMR 9923, Bat CERVI,83 Bld Hop, F-75013 Paris, France.		Magrangeas, Florence/L-3080-2015; Minvielle, Stéphane/K-8251-2015; Chérel, Michel/F-8298-2013	Magrangeas, Florencce/0000-0002-5031-3748; Minvielle, Stephane/0000-0003-1389-312X				AFZAL MA, 1990, J GEN VIROL, V71, P615, DOI 10.1099/0022-1317-71-3-615; ANSARI LM, 1997, GENOME RES, V7, P268; BATEMAN E, 1988, CELL, V54, P985, DOI 10.1016/0092-8674(88)90113-4; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BHAT BM, 1986, J VIROL, V60, P54, DOI 10.1128/JVI.60.1.54-63.1986; Bousse T, 1997, VIROLOGY, V232, P44, DOI 10.1006/viro.1997.8524; CERVINI R, 1995, J BIOL CHEM, V270, P24654, DOI 10.1074/jbc.270.42.24654; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHEREL M, 1995, BLOOD, V86, P2534; Cherel M, 1996, GENOMICS, V32, P49, DOI 10.1006/geno.1996.0075; CHIN LS, 1993, VIROLOGY, V192, P473, DOI 10.1006/viro.1993.1063; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOWLING PC, 1986, J GEN VIROL, V67, P1987, DOI 10.1099/0022-1317-67-9-1987; Du XX, 1997, BLOOD, V89, P3897, DOI 10.1182/blood.V89.11.3897; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; Gaschet J, 1996, BLOOD, V87, P2345, DOI 10.1182/blood.V87.6.2345.bloodjournal8762345; GATHOF BS, 1995, HUM GENET, V96, P721, DOI 10.1007/BF00210306; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; Hardy RW, 1998, J VIROL, V72, P520, DOI 10.1128/JVI.72.1.520-526.1998; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; KALCKAR HM, 1991, ANNU REV BIOCHEM, V60, P1; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lebeau B, 1997, FEBS LETT, V407, P141, DOI 10.1016/S0014-5793(97)00326-8; LESLIE ND, 1992, GENOMICS, V14, P474, DOI 10.1016/S0888-7543(05)80244-7; Maxfield LF, 1997, J VIROL, V71, P8321, DOI 10.1128/JVI.71.11.8321-8329.1997; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEERA KP, 1978, CYTOGENET CELL GENET, V22, P207; MELLMAN WJ, 1965, J LAB CLIN MED, V66, P980; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; NAKAGAWA Y, 1994, J BIOL CHEM, V269, P10905; Nandurkar HH, 1996, ONCOGENE, V12, P585; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; Quimby BB, 1996, J BIOL CHEM, V271, P26835, DOI 10.1074/jbc.271.43.26835; RIMA BK, 1986, J GEN VIROL, V67, P1971, DOI 10.1099/0022-1317-67-9-1971; ROWLING C, 1997, CURR OPIN GENE DEV, V7, P416; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Segal S, 1989, METABOLIC BASIS INHE, P453; STAMATOYANNOPOU.G, 1994, HEMOGLOBIN SWITCHING, P107; SWAIN A, 1993, J VIROL, V67, P6265, DOI 10.1128/JVI.67.10.6265-6269.1993; VanLeuven F, 1996, GENOMICS, V31, P65, DOI 10.1006/geno.1996.0010; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; WILDE A, 1984, J VIROL, V51, P71, DOI 10.1128/JVI.51.1.71-76.1984; WONG TC, 1987, J VIROL, V61, P584, DOI 10.1128/JVI.61.2.584-589.1987; YANG YC, 1992, BIOFACTORS, V4, P15	48	54	55	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16005	16010		10.1074/jbc.273.26.16005	http://dx.doi.org/10.1074/jbc.273.26.16005			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632650	hybrid			2022-12-25	WOS:000074436600021
J	Majidi, M; Hubbs, AE; Lichy, JH				Majidi, M; Hubbs, AE; Lichy, JH			Activation of extracellular signal-regulated kinase 2 by a novel Abl binding protein, ST5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; SH3 DOMAIN; SUBSTRATE RECOGNITION; HUMAN CHROMOSOME-11; IDENTIFICATION; GRB2; GENE; TRANSDUCTION; MAP	The human ST5 gene encodes three proteins with predicted molecular masses of 126, 82, and 70 kDa. These widely expressed proteins share a C-terminal region that bears significant sequence homology to a group of GDP/GTP exchange proteins for the Rab3 family of small GTP binding proteins. The N-terminal region of the largest ST5 protein, p126, contains two proline-rich sequences, PR1 and PR2, with consensus motifs similar to Src homology 3 (SH3) binding regions and to mitogen-activated protein kinase (MAPK) phosphorylation sites. Based on these properties, we sought to investigate the activity of ST5 proteins in signal transduction pathways, In vitro, p126 displayed preferential binding to c-Abl SH3, as compared with other SH3 domains. This interaction was mediated by the PR2 sequence. In vivo, expression of p126, but not p82 or p70, activated MAPK/ERK2 in response to EGF in COS-7 cells. Expression of c-Abl with p126 greatly enhanced this activity. Deletion of PR1 blocked the ability of p126 to activate ERK2. Deletion of PR2 did not affect the basal activity, but blocked the stimulatory effect of c-Abl. Whereas p82 expression had no effect on ERK2 activation by p126, p70 completely abrogated this activity. These observations suggest that ST5 can function as a signaling protein and can provide a link between c-Abl and ERK2.	Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA	United States Department of Defense	Lichy, JH (corresponding author), Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA.				NATIONAL CANCER INSTITUTE [R01CA064114] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA64114] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; HARLOW E, 1988, ANTIBODIES; Iwasaki K, 1997, NEURON, V18, P613, DOI 10.1016/S0896-6273(00)80302-5; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lichy JH, 1996, NUCLEIC ACIDS RES, V24, P4700, DOI 10.1093/nar/24.23.4700; LICHY JH, 1992, CELL GROWTH DIFFER, V3, P541; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MODI WS, 1991, CYTOGENET CELL GENET, V58, P1968; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARD CW, 1993, AM J HUM GENET, V52, P915; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	30	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16608	16614		10.1074/jbc.273.26.16608	http://dx.doi.org/10.1074/jbc.273.26.16608			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632734	hybrid			2022-12-25	WOS:000074436600105
J	Rusnati, M; Tulipano, G; Urbinati, C; Tanghetti, E; Giuliani, R; Giacca, M; Ciomei, M; Corallini, A; Presta, M				Rusnati, M; Tulipano, G; Urbinati, C; Tanghetti, E; Giuliani, R; Giacca, M; Ciomei, M; Corallini, A; Presta, M			The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FIBROBLAST GROWTH-FACTOR; KAPOSIS-SARCOMA; TRANSGENIC MICE; ENDOTHELIAL-CELLS; SULFATED POLYSACCHARIDES; PLASMINOGEN-ACTIVATOR; STIMULATES GROWTH; PROMOTER ACTIVITY; RECEPTOR-BINDING	Heparin binds extracellular HIV-1 Tat protein and modulates its HIV long terminal repeat (LTR)-transactivating activity (M, Rusnati, D. Coltrini, P. Oreste, G. Zoppetti, A Albini, D. Noonan, F. d'Adda di Fagagna, M. Giacca, and M. Presta (1997) J. Biol. Chem. 272, 11313-11320). On this basis, the glutathione S-transferase (GST)-Tat(R49/52/53/55/56/57A) mutant, in which six arginine residues within the basic domain of Tat were mutagenized to alanine residues, was compared with GST-Tat for its capacity to bind immobilized heparin. Dissociation of the GST-Tat(R49/52/53/55/56/57A). heparin complex occurred at ionic strength significantly lower than that required to dissociate the GST-Tat heparin complex. Accordingly, heparin binds immobilized GST-Tat and GST-Tat(R49/52/53/55/56/57A) with a dissociation constant equal to 0.3 and 1.0 mu M, respectively. Also, the synthetic basic domain Tat-(41-60) competes with GST-Tat for heparin binding. Suramin inhibits [H-3]heparin/Tat interaction, I-125-GST-Tat internalization, and the LTR-transactivating activity of extracellular Tat in HL3T1 cells and prevents I-125-GST-Tat binding and cell proliferation in Tat-overexpressing T53 cells. The suramin derivative C-14-PNU 145156E binds immobilized GST-Tat with a dissociation constant 5 times higher than heparin and is unable to bind GST-Tat(R49/52/53/55/56/57A). Although heparin was an antagonist more potent than suramin, modifications of the backbone structure in selected suramin derivatives originated Tat antagonists whose potency was close to that shown by heparin. In conclusion, suramin derivatives bind the basic domain of Tat, prevent Tat/heparin and Tat/cell surface interactions, and inhibit the biological activity of extracellular Tat. Our data demonstrate that tailored polysulfonated compounds represent potent extracellular Tat inhibitors of possible therapeutic value.	Univ Brescia, Dept Biomed Sci & Biotechnol, I-25123 Brescia, Italy; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Pharmacia Upjohn, I-20014 Milan, Italy; Univ Ferrara, Inst Microbiol, I-44100 Ferrara, Italy; Univ Ferrara, Interdept Ctr Biotechnol, I-44100 Ferrara, Italy	University of Brescia; International Center for Genetic Engineering & Biotechnology (ICGEB); Pfizer; University of Ferrara; University of Ferrara	Presta, M (corresponding author), Univ Brescia, Dept Biomed Sci & Biotechnol, Via Valsabbina 19, I-25123 Brescia, Italy.	presta@med.unibs.it	Presta, Marco/B-4345-2010; Giacca, Mauro/J-9287-2016; Rusnati, Marco/F-1168-2010	Giacca, Mauro/0000-0003-2927-7225; Rusnati, Marco/0000-0001-9968-5908; Urbinati, Chiara Eva/0000-0002-0138-7871; PRESTA, Marco/0000-0002-4398-8376				ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; Albini A, 1996, ONCOGENE, V12, P289; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Barton CH, 1996, J GEN VIROL, V77, P1643, DOI 10.1099/0022-1317-77-8-1643; BEHRENDT N, 1993, J BIOL CHEM, V268, P5985; BRADDOCK PS, 1994, BRIT J CANCER, V69, P890, DOI 10.1038/bjc.1994.172; CALLAHAN LN, 1991, J VIROL, V65, P1543, DOI 10.1128/JVI.65.3.1543-1550.1991; CAMPIONI D, 1995, AIDS RES HUM RETROV, V11, P1039, DOI 10.1089/aid.1995.11.1039; CIOMEI M, 1994, BIOCHEM PHARMACOL, V47, P295, DOI 10.1016/0006-2952(94)90020-5; CLANTON DJ, 1995, ANTIVIR RES, V27, P335, DOI 10.1016/0166-3542(95)00017-G; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COLTRINI D, 1993, EUR J BIOCHEM, V214, P51, DOI 10.1111/j.1432-1033.1993.tb17895.x; CORALLINI A, 1993, CANCER RES, V53, P5569; Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DECLERCQ E, 1979, CANCER LETT, V8, P9, DOI 10.1016/0304-3835(79)90017-X; DECLERCQ E, 1987, ANTIVIR RES, V7, P1, DOI 10.1016/0166-3542(87)90034-9; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; Dewhurst S, 1996, MOL MED TODAY, V2, P16, DOI 10.1016/1357-4310(96)88754-5; ENDO S, 1989, VIRUS GENES, V2, P99; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FAN TPD, 1995, TRENDS PHARMACOL SCI, V16, P57, DOI 10.1016/S0165-6147(00)88979-8; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FURLINI MCRG, 1995, J ACQ IMMUN DEF SYND, V10, P408, DOI 10.1097/00042560-199512000-00003; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; Goldstein G, 1996, NAT MED, V2, P960, DOI 10.1038/nm0996-960; Gregoire CJ, 1996, J BIOL CHEM, V271, P22641, DOI 10.1074/jbc.271.37.22641; HATTON MWC, 1980, ANAL BIOCHEM, V106, P417, DOI 10.1016/0003-2697(80)90542-4; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; Hawkins Michael J., 1995, Current Opinion in Oncology, V7, P90; HOFMAN FM, 1994, J NEUROIMMUNOL, V54, P19, DOI 10.1016/0165-5728(94)90226-7; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; KIM CM, 1992, ONCOGENE, V7, P1525; KIM YS, 1993, J VIROL, V67, P3739, DOI 10.1128/JVI.67.7.3739-3747.1993; Lachgar A, 1996, BIOMED PHARMACOTHER, V50, P13, DOI 10.1016/0753-3322(96)85092-X; Lafrenie RM, 1996, J IMMUNOL, V156, P1638; Lafrenie RM, 1996, J IMMUNOL, V157, P974; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LOPALCO L, 1994, AIDS RES HUM RETROV, V10, P787, DOI 10.1089/aid.1994.10.787; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Maroder M, 1996, CELL IMMUNOL, V168, P49, DOI 10.1006/cimm.1996.0048; MCCLURE MO, 1992, AIDS RES HUM RETROV, V8, P19, DOI 10.1089/aid.1992.8.19; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; MONTEFIORI DC, 1990, J ANTIMICROB CHEMOTH, V25, P313, DOI 10.1093/jac/25.3.313; NABELL LM, 1994, CELL GROWTH DIFFER, V5, P87; NAKAJIMA M, 1991, J BIOL CHEM, V266, P9661; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; OPALENIK SR, 1995, J BIOL CHEM, V270, P17457, DOI 10.1074/jbc.270.29.17457; PESENTI E, 1992, BRIT J CANCER, V66, P367, DOI 10.1038/bjc.1992.272; Peterlin B. Matija, 1993, P75; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; POCSIK E, 1992, LYMPHOKINE CYTOK RES, V11, P317; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; PURI RK, 1992, CANCER RES, V52, P3787; PURVIS SF, 1992, CELL IMMUNOL, V144, P32, DOI 10.1016/0008-8749(92)90223-C; Rusnati M, 1997, AIDS, V11, P727, DOI 10.1097/00002030-199706000-00005; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; Rusnati M, 1996, MOL BIOL CELL, V7, P369, DOI 10.1091/mbc.7.3.369; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; Sastry KJ, 1996, ONCOGENE, V13, P487; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; SOLA F, 1993, INVAS METAST, V13, P163; STEINAA L, 1994, ARCH VIROL, V139, P263, DOI 10.1007/BF01310790; STRIJBOS PJLM, 1995, NEUROSCI LETT, V197, P215, DOI 10.1016/0304-3940(95)11940-X; TAYLOR JP, 1992, P NATL ACAD SCI USA, V89, P9617, DOI 10.1073/pnas.89.20.9617; VACCA A, 1994, BIOCHEM BIOPH RES CO, V205, P467, DOI 10.1006/bbrc.1994.2689; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WEEKS BS, 1995, J NEUROSCI RES, V42, P34, DOI 10.1002/jnr.490420105; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; WITVROUW M, 1994, ANTIVIR CHEM CHEMOTH, V5, P345, DOI 10.1177/095632029400500601; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693; ZABRENETZKY VS, 1990, CANCER RES, V50, P5937; ZAULI G, 1993, MICROBIOLOGICA, V16, P115; ZAULI G, 1993, CANCER RES, V53, P4481; ZAULI G, 1995, J ACQ IMMUN DEF SYND, V10, P306; ZAULI G, 1992, BLOOD, V80, P3036	95	103	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16027	16037		10.1074/jbc.273.26.16027	http://dx.doi.org/10.1074/jbc.273.26.16027			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632653	hybrid			2022-12-25	WOS:000074436600024
J	Messana, I; Angeletti, M; Castagnola, M; De Sanctis, G; Di Stasio, E; Giardina, B; Pucciarelli, S; Coletta, M				Messana, I; Angeletti, M; Castagnola, M; De Sanctis, G; Di Stasio, E; Giardina, B; Pucciarelli, S; Coletta, M			Thermodynamics of inositol hexakisphosphate interaction with human oxyhemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-HEMOGLOBIN; HUMAN DEOXYHEMOGLOBIN; BINDING; 2,3-DIPHOSPHOGLYCERATE	The interaction of inositol hexakisphosphate (IHP) with oxygenated human adult hemoglobin (Hb) was investigated at 25 degrees C. The affinity of IHP for oxygenated Hb is strongly pH-dependent, and potentiometric measurements of proton uptake and release upon IHP addition have shown that over the range between pH 8.0 and pH 6.0 in oxygenated Hb there are three groups of residues that change their pK(a) values after IHP addition, likely because of their interaction with negative charges of the heterotropic effector. On the basis of previous calculations on the electrostatic properties of human Hb (Matthew, J. B., Hanania, G, I. H., and Curd, F. R. N. (1979) Biochemistry 18, 1919-1928; Lee,.A W.-m., Karplus, M., Poyart, C., and Bursaux, E, (1988) Biochemistry 27, 1285-1301), two of these groups might be Val(1 beta) and His(143 beta), which are located in the beta(1)beta(2)dyad axis, where they have been also proposed to interact with 2,3-diphosphoglycerate, whereas the third group does not appear easily identifiable. Calorimetric measurements of the heat associated with IHP binding at different pH values over the same range indicate that IHP binding is mostly enthalpy-driven at pH < 7 and mostly entropy-driven at pH > 7.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Cattolica Sacro Cuore, CNR, Ctr Receptor Chem, I-00168 Rome, Italy; Univ Cattolica Sacro Cuore, Inst Chem & Clin Chem, I-00168 Rome, Italy; Univ Camerino, Dept Mol Cellular & Anim Biol, I-62032 Camerino, MC, Italy; Univ Cagliari, Inst Biol Chem, I-0926 Cagliari, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy	University of Rome Tor Vergata; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Camerino; University of Cagliari; University of Rome Tor Vergata	Coletta, M (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Tor Vergata 135, I-00133 Rome, Italy.	massimo.coletta@uniroma2.it	di stasio, enrico/AAL-3082-2020; Angeletti, Mauro/C-2960-2014; Angeletti, Mauro/AAC-5597-2019; Coletta, Massimo/N-9049-2015; Castagnola, Massimo/AAB-2825-2019; Pucciarelli, Stefania/F-9168-2010; Coletta, Massimiliano/GSN-5927-2022; Messana, Irene/L-2478-2019; Castagnola, Massimo/AAM-6355-2021	Angeletti, Mauro/0000-0001-6719-5517; Angeletti, Mauro/0000-0001-6719-5517; Castagnola, Massimo/0000-0002-0959-7259; Messana, Irene/0000-0002-1436-6105; COLETTA, Massimiliano/0000-0002-5489-9467; Pucciarelli, Stefania/0000-0003-2137-5517				AMICONI G, 1981, J MOL BIOL, V152, P111, DOI 10.1016/0022-2836(81)90097-8; ANTONINI E, 1982, EUR J BIOCHEM, V121, P325, DOI 10.1111/j.1432-1033.1982.tb05789.x; ANTONINI E, 1965, J BIOL CHEM, V240, P1096; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; ARNONE A, 1974, NATURE, V249, P34, DOI 10.1038/249034a0; BONAVENTURA J, 1975, J BIOL CHEM, V250, P9250; CHRISTENSEN JJ, 1976, HDB PROTON IONISATIO; COLETTA M, 1995, J MOL BIOL, V249, P800, DOI 10.1006/jmbi.1995.0338; COLETTA M, 1993, BIOCHIM BIOPHYS ACTA, V1162, P309, DOI 10.1016/0167-4838(93)90295-3; de Bruin S H, 1973, Biochem Biophys Res Commun, V55, P193, DOI 10.1016/S0006-291X(73)80078-6; GILL SJ, 1980, J BIOL CHEM, V255, P7855; GILL SJ, 1987, BIOCHEMISTRY-US, V26, P3995, DOI 10.1021/bi00387a038; HO C, 1987, BIOCHEMISTRY-US, V26, P6299, DOI 10.1021/bi00394a001; JOHNSON LF, 1969, CAN J CHEMISTRY, V47, P63, DOI 10.1139/v69-008; KISTER J, 1987, BIOPHYS J, V52, P527, DOI 10.1016/S0006-3495(87)83242-3; LEE AWM, 1988, BIOCHEMISTRY-US, V27, P1285, DOI 10.1021/bi00404a031; MATTHEW JB, 1979, BIOCHEMISTRY-US, V18, P1919, DOI 10.1021/bi00577a011; MCKINNON IR, 1984, ANAL BIOCHEM, V139, P134, DOI 10.1016/0003-2697(84)90398-1; NOLL LA, 1979, BIOCHEM BIOPH RES CO, V88, P1288, DOI 10.1016/0006-291X(79)91120-3; OHE H, 1980, BIOCHEMISTRY-US, V19, P4445; PERUTZ MF, 1980, J MOL BIOL, V138, P649, DOI 10.1016/S0022-2836(80)80022-2; Riggs A., 1981, Methods in Enzymology, V76, P5; ROBERT CH, 1988, BIOCHEMISTRY-US, V27, P6835, DOI 10.1021/bi00418a028; RUSSU IM, 1990, BIOCHEMISTRY-US, V29, P3785, DOI 10.1021/bi00467a027; SHIH DTB, 1987, J MOL BIOL, V195, P419, DOI 10.1016/0022-2836(87)90660-7; Wyman J., 1990, BINDING LINKAGE; ZUIDERWEG ERP, 1981, EUR J BIOCHEM, V118, P95, DOI 10.1111/j.1432-1033.1981.tb05490.x; ZUIDERWEG ERP, 1981, EUR J BIOCHEM, V118, P85, DOI 10.1111/j.1432-1033.1981.tb05489.x	29	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15329	15334		10.1074/jbc.273.25.15329	http://dx.doi.org/10.1074/jbc.273.25.15329			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624112	hybrid			2022-12-25	WOS:000074284200006
J	Norden, B; Wittung-Stafshede, P; Ellouze, C; Kim, HK; Mortensen, K; Takahashi, M				Norden, B; Wittung-Stafshede, P; Ellouze, C; Kim, HK; Mortensen, K; Takahashi, M			Base orientation of second DNA in RecA center dot DNA filaments - Analysis by combination of linear dichroism and small angle neutron scattering in flow-oriented solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FLUORESCENCE SPECTROSCOPY; 3-STRANDED DNA; PROTEIN; COMPLEXES; BINDING; RECOMBINATION; STOICHIOMETRY; TRIPLER	To gain insight into the mechanism of pairing two complementary DNA strands by the RecA protein, we have determined the nucleobase orientation of the first and the second bound DNA strands in the RecA DNA filament by combined measurements of linear dichroism and small angle neutron scattering on flow-oriented samples. An etheno-modified DNA, poly(d epsilon A) was adapted as the first DNA and an oligo(dT) as the second DNA, making it possible to distinguish between the linear dichroism signals of the two DNA strands, The results indicate that binding of the second DNA does not alter the nucleobase orientation of the first bound strand and that the bases of the second DNA are almost coplanar to the bases of the first strand although somewhat more tilted (60 degrees relative to the fiber axis compared with 70 degrees for the first DNA strand). Similar results were obtained for the RecA DNA complex formed with unmodified poly(dA) and oligo(dT). An almost coplanar orientation of nucleobases of two DNA strands in a RecA-DNA filament would facilitate scanning for, and recognition of, complementary base sequences. The slight deviation from co-planarity could increase the free energy of the duplex to facilitate dissociation in case of mismatching base sequences.	Ctr Univ Paris Sud, Inst Curie, F-91405 Orsay, France; Chalmers Univ Technol, Dept Phys Chem, S-41296 Gothenburg, Sweden; CNRS, Unite Mixte Rech 216, F-91405 Orsay, France; Riso Natl Lab, Dept Phys, DK-4000 Roskilde, Denmark	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Chalmers University of Technology; Centre National de la Recherche Scientifique (CNRS); Technical University of Denmark	Takahashi, M (corresponding author), Ctr Univ Paris Sud, Inst Curie, Bat 110, F-91405 Orsay, France.	Masa.Takahashi@curie.u-psud.fr	Mortensen, Kell/A-5066-2009; wittung-stafshede, pernilla/AAV-4392-2021; Norden, Bengt/ABE-3675-2020	Mortensen, Kell/0000-0002-8998-9390; wittung-stafshede, pernilla/0000-0003-1058-1964; Norden, Bengt/0000-0002-7946-200X				CHABBERT M, 1991, J BIOL CHEM, V266, P5395; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; COX MM, 1995, J BIOL CHEM, V270, P26021, DOI 10.1074/jbc.270.44.26021; HAGMAR P, 1992, J MOL BIOL, V226, P1193, DOI 10.1016/0022-2836(92)91061-S; HOLMEN A, 1994, J PHYS CHEM-US, V98, P13460, DOI 10.1021/j100102a006; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; KIM SK, 1995, BBA-GENE STRUCT EXPR, V1264, P129, DOI 10.1016/0167-4781(95)00137-6; KUBISTA M, 1988, NUCLEOS NUCLEOT, V7, P783, DOI 10.1080/07328318808056330; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; NORDEN B, 1985, APPL SPECTROSC, V39, P647, DOI 10.1366/0003702854250356; NORDEN B, 1992, Q REV BIOPHYS, V25, P51, DOI 10.1017/S0033583500004728; NORDEN B, 1992, J MOL BIOL, V226, P1175, DOI 10.1016/0022-2836(92)91060-3; RADHAKRISHNAN I, 1993, STRUCTURE, V1, P135, DOI 10.1016/0969-2126(93)90028-F; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; Simonson T., 1994, Journal of Molecular Recognition, V7, P199, DOI 10.1002/jmr.300070307; TAKAHASHI M, 1991, FEBS LETT, V279, P270, DOI 10.1016/0014-5793(91)80165-Y; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TAKAHASHI M, 1989, J BIOL CHEM, V264, P288; Takahashi Masayuki, 1994, Journal of Molecular Recognition, V7, P221, DOI 10.1002/jmr.300070311; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9; WITTUNG P, 1995, FEBS LETT, V368, P64, DOI 10.1016/0014-5793(95)00600-E; WITTUNG P, 1994, J BIOL CHEM, V269, P5799; ZHURKIN VB, 1994, J MOL BIOL, V239, P181, DOI 10.1006/jmbi.1994.1362	25	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15682	15686		10.1074/jbc.273.25.15682	http://dx.doi.org/10.1074/jbc.273.25.15682			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624163	hybrid			2022-12-25	WOS:000074284200057
J	Qi, WW; Loh, E; Vilaire, G; Bennett, JS				Qi, WW; Loh, E; Vilaire, G; Bennett, JS			Regulation of alpha IIb beta 3 function in human B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; IIB-IIIA COMPLEX; PLATELET INTEGRIN ALPHA-IIB-BETA-3; STIMULATED LIGAND-BINDING; SIGNAL-TRANSDUCTION; CHEMOATTRACTANT RECEPTORS; FIBRINOGEN RECEPTOR; SELECTIVE INHIBITOR; LEUKOCYTE ADHESION; ADP-RIBOSYLATION	We studied the function of the platelet integrin alpha IIb beta 3 using a B lymphocyte model in which alpha II beta 3 can be induced to interact with fibrinogen using phorbol myristate acetate (PMA). To determine whether a G protein-coupled receptor could also activate alpha IIb beta 3 in lymphocytes, we coexpressed the human formyl peptide receptor (fPR) and alpha IIb beta 3, finding that the fPR agonist formyl Met-Leu-Phe (fMLP)-stimulated lymphocyte adherence to immobilized fibrinogen and binding of soluble fibrinogen to the lymphocyte surface. The response to fMLP, but not PMA, was abrogated by pertussis toxin, indicating that the fPR was coupled to the G-protein G alpha(i), whereas the protein kinase C inhibitor bisindolyl-maleimide I inhibited the response to both fMLP and PMA, indicating that signaling from the fPR included protein kinase C, On the other hand, the tyrosine kinase inhibitor genistein, the Syk inhibitor piceatannol, and the RhoA inhibitor C3 exoenzyme had no effect, implying that neither tyrosine phosphorylation nor the GTPase RhoA were involved. Furthermore, whereas micromolar concentrations of cytochalasin D inhibited the PMA-stimulated interaction of alpha IIb beta 3 with fibrinogen, nanomolar concentrations actually induced fibrinogen binding to unstimulated cells. Our studies demonstrate that alpha IIb beta 3 expressed in B lymphocytes can be activated by a physiologic agonist and outline an activating pathway that includes G alpha(i), protein kinase C, and the actin cytoskeleton.	Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Bennett, JS (corresponding author), 1005 Stellar Chance Labs, Div Hematol Oncol, 422 Curie Blvd, Philadelphia, PA 19014 USA.				NHLBI NIH HHS [HL51258, HL40387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL051258] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS C, 1994, J BIOL CHEM, V269, P18781; AKIYAMA T, 1991, METHODS ENZYMOLOGY B, P362; Allen WE, 1997, J CELL SCI, V110, P707; Bennett JS, 1996, TRENDS CARDIOVAS MED, V6, P31, DOI 10.1016/1050-1738(95)00126-3; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; Brass Lawrence F., 1995, P1536; BRASS LF, 1986, J BIOL CHEM, V261, P6838; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, J BIOL CHEM, V269, P28859; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; FOX JEB, 1993, J BIOL CHEM, V268, P25973; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HONDA S, 1994, J IMMUNOL, V152, P4026; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; Leng L., 1997, Blood, V90, p430A; LOH E, 1995, J BIOL CHEM, V270, P18631, DOI 10.1074/jbc.270.31.18631; Loh E, 1996, J BIOL CHEM, V271, P30233, DOI 10.1074/jbc.271.47.30233; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MILLER CL, 1998, IMMUNITY, V5, P155; MORII N, 1992, J BIOL CHEM, V267, P20921; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SILVER SM, 1987, BLOOD, V69, P1031; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WALKER TR, 1993, BIOCHEM J, V289, P277, DOI 10.1042/bj2890277; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; WEISEL JW, 1992, J BIOL CHEM, V267, P16637	50	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15271	15278		10.1074/jbc.273.24.15271	http://dx.doi.org/10.1074/jbc.273.24.15271			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614143	hybrid			2022-12-25	WOS:000074160400085
J	Hirabayashi, J; Dutta, SK; Kasai, K				Hirabayashi, J; Dutta, SK; Kasai, K			Novel galactose-binding proteins in annelida - Characterization of 29-kDa tandem repeat-type lectins from the earthworm Lumbricus terrestris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; AMINO-ACID-SEQUENCE; ANIMAL LECTINS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; SERINE-PROTEASE; CDNA CLONING; RICIN; PURIFICATION; GALECTIN	Novel type lectins were found in the phylum Annelida, i.e. in the earthworm, tubifex, leech, and lugworm. The lectins (29-31 kDa) were extracted from the worms without the use of detergent and purified by affinity chromatography on asialofetuin-agarose. On the basis of the partial primary structures of the earthworm Lumbricus terrestris 29-kDa lectin (EW29), degenerate primers were synthesized for use in the reverse transcriptase-polymerase chain reaction. An amplified 155-base pair fragment was used to screen a cDNA library. Four types of full-length clones were obtained, all of which encoded 260 amino acids, but which were found to differ at 29 nucleotide positions. Since three of them resulted in non-silent substitutions, EW29 mRNA was considered to be a mixture of at least three distinct polynucleotides encoding the following proteins: Ala(44)-Gln(191)-Ile(213) (clone 5), Gly(44)-Gln(197)-Val(213) (clone 7) and Ala(44)-His(197)-Ile(213) (clones 8 and 9; different at the nucleotide level, but encoding an identical polypeptide). Genomic polymerase chain reaction using DNA hom a single worm revealed that the single worm already had four sets of cDNAs. The EW29 protein showed two features. First, the lectin was composed of two homologous domains (14,500 Da) showing 27% identity with each other. When each of the domains was separately expressed in Escherichia coli, the C-terminal domain was found to bind to asialofetuin-agarose as strongly as the whole protein, whereas the N-terminal domain did not bind and only retardation was observed. EW29 was found to exist as st monomer under non-denaturing conditions. It had significant hemagglutinating activity, which was inhibited by a wide range of galactose-containing saccharides. Second, EW29 contained multiple short conserved motifs, "GBy-X-X-X-Gln-X-Trp." Similar motifs have been found in many carbohydrate-recognizing proteins from an extensive variety of organisms, e.g. plant lectin ricin B-chain and Clostridium botulinum 33-kDa hemagglutinin, Therefore, these carbohydrate-recognition proteins appear to form a protein superfamily.	Teikyo Univ, Fac Pharmaceut Sci, Dept Biol Chem, Sagamiko, Kanagawa 1990195, Japan	Teikyo University	Hirabayashi, J (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Dept Biol Chem, Sagamiko, Kanagawa 1990195, Japan.	j-hira@pharm.teikyo-u.ac.jp						Arata Y, 1996, HISTOCHEM J, V28, P201, DOI 10.1007/BF02331444; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BLAKE C, 1983, NATURE, V306, P535, DOI 10.1038/306535a0; CHIU ML, 1992, J CELL BIOL, V119, P1689, DOI 10.1083/jcb.119.6.1689; COLE RN, 1994, J NEUROCHEM, V63, P66; COLE RN, 1994, J NEUROCHEM, V63, P75; Cooper DNW, 1997, J BIOL CHEM, V272, P1514, DOI 10.1074/jbc.272.3.1514; DEWAARD A, 1976, J BIOL CHEM, V251, P7581; Doyle R. J., 1994, P1; GABIUS HJ, 1992, ANTICANCER RES, V12, P669; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; HAKOMORI SI, 1992, HISTOCHEM J, V24, P771, DOI 10.1007/BF01046348; Hirabayashi J, 1996, Q REV BIOL, V71, P365, DOI 10.1086/419443; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; Hirabayashi J, 1996, J BIOL CHEM, V271, P2497, DOI 10.1074/jbc.271.5.2497; HIRABAYASHI J, 1984, BIOCHEM BIOPH RES CO, V122, P938, DOI 10.1016/0006-291X(84)91181-1; HIRABAYASHI J, 1987, J BIOCHEM-TOKYO, V101, P775, DOI 10.1093/jb/101.3.775; HIRABAYASHI J, 1997, TRENDS GLYCOSCI GLYC, V9; HIRABAYASHI J, 1993, LECTINS GLYCOBIOLOGY, P474; HUGHES RC, 1994, GLYCOBIOLOGY, V4, P5, DOI 10.1093/glycob/4.1.5; Kaku H, 1996, J BIOL CHEM, V271, P1480, DOI 10.1074/jbc.271.3.1480; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KLION AD, 1994, MOL BIOCHEM PARASIT, V65, P305, DOI 10.1016/0166-6851(94)90081-7; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; MATSUI T, 1984, BIOL BULL, V166, P178, DOI 10.2307/1541440; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; Newton SE, 1997, MOL BIOCHEM PARASIT, V86, P143, DOI 10.1016/S0166-6851(97)02834-X; NOWAK TP, 1976, BIOCHEM BIOPH RES CO, V68, P650, DOI 10.1016/0006-291X(76)91195-5; ODA T, 1994, J BIOL CHEM, V269, P22925; Ozeki Y, 1997, COMP BIOCHEM PHYS B, V118, P1, DOI 10.1016/S0305-0491(97)00014-X; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; READY M, 1984, J BIOL CHEM, V259, P5252; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; ROBERTS LM, 1985, J BIOL CHEM, V260, P5682; Rojo MA, 1997, ARCH BIOCHEM BIOPHYS, V340, P185, DOI 10.1006/abbi.1997.9927; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEKI N, 1994, J BIOL CHEM, V269, P1370; SHARECK F, 1991, GENE, V107, P75, DOI 10.1016/0378-1119(91)90299-Q; SHEN SH, 1991, J BIOL CHEM, V266, P1058; SHIMOI H, 1992, J BIOL CHEM, V267, P25189; SPECK JC, 1958, ADV CARBOHYD CHEM, V13, P63; Tai MH, 1996, J COMP NEUROL, V371, P235, DOI 10.1002/(SICI)1096-9861(19960722)371:2<235::AID-CNE4>3.0.CO;2-3; TRIMBLE RB, 1995, TRENDS GLYCOSCI GLYC, V7, P1, DOI 10.4052/tigg.7.1; TSUZUKI K, 1990, INFECT IMMUN, V58, P3173, DOI 10.1128/IAI.58.10.3173-3177.1990; WOOD KA, 1991, EUR J BIOCHEM, V198, P723, DOI 10.1111/j.1432-1033.1991.tb16072.x	47	78	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14450	14460		10.1074/jbc.273.23.14450	http://dx.doi.org/10.1074/jbc.273.23.14450			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603958	hybrid			2022-12-25	WOS:000074021500060
J	Izzotti, A; Balansky, RM; Blagoeva, PM; Mircheva, ZI; Tulimiero, L; Cartiglia, C; De Flora, S				Izzotti, A; Balansky, RM; Blagoeva, PM; Mircheva, ZI; Tulimiero, L; Cartiglia, C; De Flora, S			DNA alterations in rat organs after chronic exposure to cigarette smoke and/or ethanol ingestion	FASEB JOURNAL			English	Article						alcohol; synergisms; DNA adducts; lung cancer; esophageal cancer; heart diseases	N-ACETYLCYSTEINE; TOBACCO-SMOKE; P-32-POSTLABELING ANALYSIS; ALVEOLAR MACROPHAGES; ALCOHOL-CONSUMPTION; ADDUCTS; DAMAGE; LUNG; CARCINOGENS; CANCER	In spite of the epidemiological evidence supporting a synergism between alcohol consumption and cigarette smoking in the pathogenesis of cancers of the aerodigestive tract, there is a paucity of experimental studies evaluating the effects of these agents under well-controlled conditions and exploring the mechanisms involved. We exposed groups of female BD6 rats, aged 8 months, to ethanol (5% in drinking water for 8 consecutive months) and/or whole-body to mainstream cigarette smoke (1 h/day, 5 days/week for 8 months). DNA was purified from different organs and analyzed for the presence of DNA-protein crosslinks and P-32-postlabeled DNA adducts after butanol enrichment. No significant increase of DNA-protein crosslinks, compared to untreated controls, was induced by any treatment in liver, lung, or heart. 'Spontaneous' nucleotidic modifications were detected by P-32-postlabeling in organs of untreated rats, with the highest levels occurring in the heart. Ingestion of ethanol did not affect DNA adduct levels in any of the organs examined: esophagus, liver, lung, and heart. Exposure to cigarette smoke induced formation of DNA adducts in the lung and heart, but not in the esophagus or liver. The combined ingestion of ethanol resulted in a significant formation of smoke-related DNA adducts in the esophagus and in their further, dramatic increase in the heart. It thus appears that ethanol consumption increases the bioavailability of DNA binding smoke components in the upper digestive tract and favors their systemic distribution. The mechanisms responsible for the interaction between ethanol and smoke and for the selective localization of DNA alterations in different organs are discussed. Formation of DNA adducts in the organs examined may be relevant in the pathogenesis of lung and esophageal cancers as well as in the pathogenesis of other types of chronic degenerative diseases, such as chronic obstructive pulmonary diseases and cardiomyopathies.	Univ Genoa, Inst Hyg & Prevent Med, I-16132 Genoa, Italy; Natl Oncol Ctr, Sofia 1756, Bulgaria	University of Genoa; National Oncology Center - Bulgaria	De Flora, S (corresponding author), Univ Genoa, Inst Hyg & Prevent Med, Via Pastore 1, I-16132 Genoa, Italy.			izzotti, alberto/0000-0002-8588-0347				ALEXANDROV K, 1992, CANCER RES, V52, P6248; ANDERSON LM, 1995, ALCOHOL, V12, P97, DOI 10.1016/0741-8329(94)00089-1; BAGNASCO M, 1992, MUTAGENESIS, V7, P295, DOI 10.1093/mutage/7.4.295; Balansky R, 1996, CANCER RES, V56, P1642; BALANSKY RB, 1992, CANCER LETT, V64, P123, DOI 10.1016/0304-3835(92)90072-4; BALANSKY RM, 1989, MUTAT RES, V223, P1, DOI 10.1016/0165-1218(89)90056-6; BALANSKY RM, 1993, CANCER LETT, V72, P183, DOI 10.1016/0304-3835(93)90127-U; BALANSKY RM, 1988, MUTAT RES, V208, P237, DOI 10.1016/0165-7992(88)90067-X; BALANSKY RM, 1987, MUTAT RES, V188, P13, DOI 10.1016/0165-1218(87)90109-1; BARTSCH H, 1986, ANTIMUTAGENESIS ANTI, V39, P87; BLOT WJ, 1992, CANCER RES, V52, pS2119; CARMICHAEL PL, 1992, CARCINOGENESIS, V13, P1127, DOI 10.1093/carcin/13.7.1127; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; Chen LH, 1996, BIOCHEM ARCH, V12, P95; DeFlora S, 1996, MUTAT RES-REV GENET, V366, P197, DOI 10.1016/S0165-1110(96)00043-7; DEFLORA S, 1995, MUTAGENESIS, V10, P47; FOILES PG, 1989, CARCINOGENESIS, V10, P1429, DOI 10.1093/carcin/10.8.1429; GAIROLA CG, 1991, ENVIRON MOL MUTAGEN, V17, P253, DOI 10.1002/em.2850170406; GAUBATZ JW, 1986, J MOL CELL CARDIOL, V18, P1317, DOI 10.1016/S0022-2828(86)80435-7; GONZALEZ FJ, 1994, DRUG METAB REV, V26, P165, DOI 10.3109/03602539409029789; GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943; GUPTA RC, 1985, CANCER RES, V45, P5656; *INT AG RES CANC, 1986, IARC MON EV CARC RIS, V44; International Agency for Research on Cancer, 1986, IARC MON EV CARC RIS, V38; IZZOTTI A, 1991, CARCINOGENESIS, V12, P1281, DOI 10.1093/carcin/12.7.1281; IZZOTTI A, 1995, CARCINOGENESIS, V16, P669, DOI 10.1093/carcin/16.3.669; IZZOTTI A, 1992, CARCINOGENESIS, V13, P2187, DOI 10.1093/carcin/13.11.2187; IZZOTTI A, 1998, IN PRES FREE RAD RES; JOHNSON KA, 1992, INT J ADDICT, V27, P749, DOI 10.3109/10826089209068767; KNASMULLER S, 1994, CARCINOGENESIS, V15, P263, DOI 10.1093/carcin/15.2.263; LEWTAS J, 1993, ENV HLTH PERSPECT, V99, P88; LIEBER CS, 1987, MUTAT RES, V186, P201, DOI 10.1016/0165-1110(87)90004-2; MISSLBECK N, 1986, DIET NUTRITION CANCE, V2, P101; MUFTI SI, 1988, BIOCHEM BIOPH RES CO, V152, P423, DOI 10.1016/S0006-291X(88)80731-9; MUFTI SI, 1989, CARCINOGENESIS, V10, P303, DOI 10.1093/carcin/10.2.303; Muller T, 1997, CARCINOGENESIS, V18, P295, DOI 10.1093/carcin/18.2.295; NORDMANN R, 1992, FREE RADICAL BIO MED, V12, P219, DOI 10.1016/0891-5849(92)90030-K; RANDERATH E, 1989, J NATL CANCER I, V81, P341, DOI 10.1093/jnci/81.5.341; RANDERATH E, 1988, CARCINOGENESIS, V9, P75, DOI 10.1093/carcin/9.1.75; ROTHMAN KJ, 1980, PREV MED, V9, P174, DOI 10.1016/0091-7435(80)90072-9; SWANN PF, 1987, MUTAT RES, V186, P261, DOI 10.1016/0165-1110(87)90008-X; TSUSUMI M, 1989, HEPATOLOGY, V10, P437; WronskaNofer T, 1997, MUTAT RES-GEN TOX EN, V392, P229, DOI 10.1016/S1383-5718(97)00067-3; ZHITKOVICH A, 1992, CARCINOGENESIS, V13, P1485, DOI 10.1093/carcin/13.8.1485	44	45	46	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1998	12	9					753	758		10.1096/fasebj.12.9.753	http://dx.doi.org/10.1096/fasebj.12.9.753			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619454	Bronze			2022-12-25	WOS:000074011000015
J	Kawata, Y; Mizukami, Y; Fujii, Z; Sakumura, T; Yoshida, K; Matsuzaki, M				Kawata, Y; Mizukami, Y; Fujii, Z; Sakumura, T; Yoshida, K; Matsuzaki, M			Applied pressure enhances cell proliferation through mitogen-activated protein kinase activation in mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; GLOMERULAR CAPILLARY HYPERTENSION; SIGNAL-TRANSDUCTION PATHWAYS; TERNARY COMPLEX-FORMATION; SERUM RESPONSE ELEMENT; MAP KINASE; TRANSCRIPTION FACTOR; RENAL ABLATION; CYCLIN D1; GENE-EXPRESSION	progressive renal diseases lead to prolonged glomerular hypertension, which induces the proliferation of mesangial cells. This proliferation is thought to be involved in the development of renal injury. Here we investigate mitogen-activated protein kinase (MAPK) activation and cell proliferation in mesangial cells under conditions of high pressure. After pressure-load, the phosphorylation level of MAPK (at Tyr-204) increases rapidly with a peak at I min, although the amount of MAPK remains almost constant during pressure-load, To confirm the activation of MAPK, we carried out an immunoprecipitation-kinase assay. MAPK activity during pressure-load shows kinetics similar to that of the tyrosine phosphorylation. In contrast, c-Jun N-terminal kinase 1 (JNK1) phosphorylation falls below basal levels in response to high pressure. Immunocytochemical observations show phosphorylated MAPK in the nucleus at 10 min. The expression of c-Fos, a nuclear transcription factor, is induced by high pressure, and the induction is significantly inhibited by PD98059 (50 mu M), an upstream MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitor of MAPK. The expression of the c-Jun that is induced by JNR1 activation remains unchanged during pressure-load. MAPK phosphorylation and cell proliferation by applied pressure are significantly inhibited by genistein, a tyrosine kinase inhibitor in a dose-dependent manner, but not by protein kinase C inhibitors, chelerythrine and GF109203X, Genistein also blocks pressure-induced tyrosine phosphorylation of proteins with molecular masses of 35, 53, and 180 kDa. To clarify the physiological role in MAPK activation under high pressure conditions, we transfected antisense MAPK DNA into mesangial cells. The antisense DNA (2 mu M) inhibited MAPK expression by 80% compared with expression in the presence of sense or scrambled DNA, and significantly blocked pressure-induced cell proliferation. Treatment of cells with: MEK inhibitor also produced a similar result. MEK inhibitor strongly suppresses DNA synthesis induced by pressure-load. Cyclin D1 expression is significantly increased under high pressure conditions, and the increase is blocked by treatment with MEK inhibitor. These findings show that pressure-load, a novel activator of MAPK, induces the activation of tyrosine kinases, and enhances the proliferation of mesangial cells, probably through cyclin D1 expression.	Yamaguchi Univ, Dept Legal Med, Yamaguchi 7558505, Japan; Yamaguchi Univ, Dept Internal Med, Yamaguchi 7558505, Japan	Yamaguchi University; Yamaguchi University	Mizukami, Y (corresponding author), Yamaguchi Univ, Dept Legal Med, 1144 Kogushi, Yamaguchi 7558505, Japan.			Mizukami, Yoichi/0000-0002-3290-0754				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANDERSON S, 1985, J CLIN INVEST, V76, P612, DOI 10.1172/JCI112013; Bianchini L, 1997, J BIOL CHEM, V272, P271; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bokemeyer D, 1997, J CLIN INVEST, V100, P582, DOI 10.1172/JCI119568; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CORTES P, 1994, KIDNEY INT, V45, pS11; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DWORKIN LD, 1986, J CLIN INVEST, V77, P797, DOI 10.1172/JCI112377; DWORKIN LD, 1984, J CLIN INVEST, V73, P1448, DOI 10.1172/JCI111349; FLOEGE J, 1993, J CLIN INVEST, V92, P2952, DOI 10.1172/JCI116918; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; HARPER PA, 1984, KIDNEY INT, V26, P875, DOI 10.1038/ki.1984.231; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HISHIKAWA K, 1994, J CLIN INVEST, V93, P1975, DOI 10.1172/JCI117189; HOSTETTER TH, 1981, AM J PHYSIOL, V241, pF85, DOI 10.1681/ASN.V1261315; HOSTETTER TH, 1981, KIDNEY INT, V19, P410, DOI 10.1038/ki.1981.33; ISAKA Y, 1993, J CLIN INVEST, V92, P2597, DOI 10.1172/JCI116874; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JIANG W, 1993, ONCOGENE, V8, P3447; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; Kawata Y, 1998, BBA-MOL CELL RES, V1401, P195, DOI 10.1016/S0167-4889(97)00112-2; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRIZ W, 1990, KIDNEY INT, V38, pS2; KRIZ W, 1995, J AM SOC NEPHROL, V5, P1731; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LUKAS J, 1995, ONCOGENE, V10, P2125; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Martin M, 1997, ONCOGENE, V15, P981, DOI 10.1038/sj.onc.1201433; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mizukami Y, 1997, BIOCHEM J, V323, P785, DOI 10.1042/bj3230785; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OFSTAD J, 1992, KIDNEY INT, V41, pS8; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; PURKERSON ML, 1988, J CLIN INVEST, V81, P69, DOI 10.1172/JCI113312; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SAUNIER B, 1995, J BIOL CHEM, V270, P3693, DOI 10.1074/jbc.270.8.3693; SELVA E, 1993, J BIOL CHEM, V268, P2250; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Suzuki H, 1996, J BIOL CHEM, V271, P18981, DOI 10.1074/jbc.271.31.18981; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; YAN MH, 1994, NATURE, V372, P798; YOSHIDA K, 1988, BIOCHEM J, V249, P487, DOI 10.1042/bj2490487; Yoshida K, 1996, BBA-MOL BASIS DIS, V1317, P36, DOI 10.1016/0925-4439(96)00035-X; YOSHIDA K, 1987, J BIOL CHEM, V262, P16048; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521	73	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16905	16912		10.1074/jbc.273.27.16905	http://dx.doi.org/10.1074/jbc.273.27.16905			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642252	hybrid			2022-12-25	WOS:000074545200042
J	Chen, ZG; Blandl, T; Prorok, M; Warder, SE; Li, LP; Zhu, Y; Pedersen, LG; Ni, F; Castellino, FJ				Chen, ZG; Blandl, T; Prorok, M; Warder, SE; Li, LP; Zhu, Y; Pedersen, LG; Ni, F; Castellino, FJ			Conformational changes in conantokin-G induced upon binding of calcium and magnesium as revealed by NMR structural analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-D-ASPARTATE; GAMMA-CARBOXYGLUTAMATE; H-1-NMR SPECTRA; SPECTROSCOPY; PEPTIDES; PROTEINS; COSY; ASSIGNMENT; RESOLUTION; CONSTANTS	The apo- and metal-bound solution conformations of synthetic conantokin-G (con-G, G(1)E gamma gamma L(5)Q gamma NQ gamma(10)- LIR gamma (KSN)-S-15-CONH2, gamma = gamma-carboxyglutamic acid), an antagonist of N-methyl-D-aspartate receptor-derived neuronal ion channels, have been examined by one- and two-dimensional H-1 NMR at neutral pH. A complete structure for the Mg2+-loaded peptide was defined by use of distance geometry calculations and was found to exist as an cc-helix that spans the entire peptide. The a-helical nature of Mg2+/con-G was also supported by the small values (<5.5 Hz) of the (3)J(HN alpha) coupling constants measured for amino acid residues 3-5, 8, 9, and 11-16, and the small values (<4 ppb/K) of the temperature coefficients observed for the alpha NH protons of residues 5-17. This conformation contrasted with that obtained for apo-con-G, which was nearly structureless in solution. Docking of Mg2+ into con-G was accomplished by use of the genetic algorithm/molecular dynamics simulation method, employing the NMR-derived Mg2+-loaded structure for initial coordinates in the midpoint calculations. For the 3 Mg2+/con-G model, it was found that binding of one Mg2+ ion is stabilized by oxygen atoms from three gamma-carboxylates of Gla(3), Gla(4), and Gla(7); another Mg2+ is coordinated by two oxygen atoms, one from each of the gamma-carboxylates of Gla(7); and a third metal ion through three donor oxygen atoms of gamma-carboxylates from Gla(10) and Gla(14). As shown from direct metal binding measurements to mutant con-G) peptides, these latter two Gla residues probably stabilized the tightest binding Mg2+ ion. Circular dichroism studies of these same peptide variants demonstrated that all Gla residues contribute to the adoption of the Mg2+-dependent alpha-helical conformation in con-G. The data obtained in this investigation provide a molecular basis for the large conformational alteration observed in apo-con-G as a result of divalent cation binding and allow assessment of the roles of individual Gla residues in defining certain of the structure-function properties of con-G.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Natl Res Council Canada, Biotechnol Res Inst, Biomol NMR Lab, Montreal, PQ H4P 2R2, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal Joint Ctr Struct Biol, Montreal, PQ H4P 2R2, Canada; NIEHS, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of Notre Dame; National Research Council Canada; National Research Council Canada; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	Castellino, FJ (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	castellino.1@nd.edu	Li, Leping/F-6497-2019; Pedersen, Lee G/E-3405-2013; Ni, Feng/AAN-6388-2020	Li, Leping/0000-0003-4208-0259; Pedersen, Lee G/0000-0003-1262-9861; 	NHLBI NIH HHS [HL-27995, HL-19982] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blandl T, 1997, BIOCHEM J, V328, P777, DOI 10.1042/bj3280777; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; COLPITTS TL, 1993, INT J PEPT PROT RES, V41, P567; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; HAACK JA, 1990, J BIOL CHEM, V265, P6025; KADKHODAEI M, 1993, J MAGN RESON SER A, V105, P104, DOI 10.1006/jmra.1993.1257; KIM YM, 1989, J MAGN RESON, V84, P9, DOI 10.1016/0022-2364(89)90003-6; Li LP, 1997, BIOCHEMISTRY-US, V36, P2132, DOI 10.1021/bi962250r; Lin CH, 1997, FEBS LETT, V407, P243, DOI 10.1016/S0014-5793(97)00354-2; LIPPENS G, 1995, J BIOMOL NMR, V5, P327, DOI 10.1007/BF00211762; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MYERS RA, 1990, J TOXICOL-TOXIN REV, V9, P179, DOI 10.3109/15569549009033113; NEMETHY G, 1992, J PHYS CHEM-US, V96, P6472, DOI 10.1021/j100194a068; NI F, 1992, BIOCHEMISTRY-US, V31, P2545, DOI 10.1021/bi00124a015; NI F, 1995, J MOL BIOL, V252, P656, DOI 10.1006/jmbi.1995.0527; NI F, 1989, BIOCHEMISTRY-US, V28, P3106, DOI 10.1021/bi00433a054; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PEARLMAN DA, 1995, AMBER; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P6906, DOI 10.1021/bi970321w; Skjaerbaek N, 1997, J BIOL CHEM, V272, P2291; SKOLNICK P, 1992, J NEUROCHEM, V59, P1516, DOI 10.1111/j.1471-4159.1992.tb08468.x; VASQUEZ M, 1988, J BIOMOL STRUCT DYN, V5, P757, DOI 10.1080/07391102.1988.10506426; Warder SE, 1998, J BIOL CHEM, V273, P7512, DOI 10.1074/jbc.273.13.7512; Warder SE, 1997, FEBS LETT, V411, P19, DOI 10.1016/S0014-5793(97)00573-5; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zhou LM, 1996, J NEUROCHEM, V66, P620	35	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16248	16258		10.1074/jbc.273.26.16248	http://dx.doi.org/10.1074/jbc.273.26.16248			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632684	Green Published			2022-12-25	WOS:000074436600055
J	Gerstin, EH; McMahon, T; Dadgar, J; Messing, RO				Gerstin, EH; McMahon, T; Dadgar, J; Messing, RO			Protein kinase C delta mediates ethanol-induced up-regulation of L-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; RAT-BRAIN; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; PHYSICAL-DEPENDENCE; ALCOHOL-CONSUMPTION; MOLECULAR-CLONING; SENSORY NEURONS; PREFERRING RATS; DOWN-REGULATION	Brief ethanol exposure inhibits L-type, voltage-gated calcium channels in neural cells, whereas chronic exposure increases the number of functional channels. In PC12 cells, this adaptive response is mediated by protein kinase C (PKC), but the PKC isozyme responsible is unknown. Since chronic ethanol exposure increases expression of PKC delta and PKC epsilon, we investigated the role these isozymes play in up-regulation of L-type channels by ethanol, Incubation with the PKC inhibitor GF 109203X or expression of a PKC delta fragment that inhibits phorbol ester-induced PKC delta translocation largely prevented ethanol-induced increases in dihydropyridine binding and K+-stimulated Ca-45(2+) uptake. A corresponding PKC epsilon fragment had no effect on this response. These findings indicate that PKC delta mediates up-regulation of L-type channels by ethanol, Remaining responses to ethanol in cells expressing the PKC delta fragment were not inhibited by GF 109203X, indicating that PKC delta-independent mechanisms also contribute. PKC delta overexpression increased binding sites for dihydropyridine and L-channel antagonists, but did not increase R+-stimulated Ca-45(2+) uptake, possibly because of homeostatic responses that maintain base-line levels of channel function, Since L-type channels modulate drinking behavior and contribute to neuronal hyperexcitability during alcohol withdrawal, these findings suggest an important role for PKC delta in alcohol consumption and dependence.	Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Grad Program Neurosci, San Francisco, CA 94110 USA; Univ Calif San Francisco, Grad Program Biomed Sci, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Messing, RO (corresponding author), Bldg 1,Rm 101,1001 Potrero Ave, San Francisco, CA 94110 USA.	romes@itsa.ucsf.edu	Messing, Robert/D-3642-2015	Messing, Robert/0000-0002-5345-4431				AIGNER L, 1993, J CELL BIOL, V123, P417, DOI 10.1083/jcb.123.2.417; BONE GHA, 1989, PSYCHOPHARMACOLOGY, V99, P386, DOI 10.1007/BF00445563; BRENNAN CH, 1990, NEUROPHARMACOLOGY, V29, P429, DOI 10.1016/0028-3908(90)90163-L; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLOMBO G, 1994, EUR J PHARMACOL, V265, P167, DOI 10.1016/0014-2999(94)90427-8; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; DELORME EM, 1986, BRAIN RES, V397, P189, DOI 10.1016/0006-8993(86)91385-5; DOLIN S, 1987, NEUROPHARMACOLOGY, V26, P275, DOI 10.1016/0028-3908(87)90220-6; FADDA F, 1992, ALCOHOL CLIN EXP RES, V16, P449, DOI 10.1111/j.1530-0277.1992.tb01398.x; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Goldstein DB, 1983, PHARM ALCOHOL; GRANT AJ, 1993, BRAIN RES, V600, P280, DOI 10.1016/0006-8993(93)91384-5; GREENBERG DA, 1986, J PHARMACOL EXP THER, V238, P1021; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HARRIS RA, 1980, J PHARMACOL EXP THER, V213, P562; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; IVINS KJ, 1993, J NEUROCHEM, V60, P626, DOI 10.1111/j.1471-4159.1993.tb03194.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; LESLIE SW, 1983, J PHARMACOL EXP THER, V225, P571; Li WQ, 1996, ONCOGENE, V13, P731; LINDBLAD B, 1976, JAMA-J AM MED ASSOC, V236, P1600, DOI 10.1001/jama.236.14.1600; LITTLE HJ, 1986, LIFE SCI, V39, P2059, DOI 10.1016/0024-3205(86)90356-5; LITTLETON JM, 1990, PSYCHOPHARMACOLOGY, V100, P387, DOI 10.1007/BF02244612; Liu HY, 1996, J NEUROSCI, V16, P7557; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSA E, 1995, MOL PHARMACOL, V47, P707; McCleskey Edwin W., 1994, Current Opinion in Neurobiology, V4, P304, DOI 10.1016/0959-4388(94)90090-6; MESSING RO, 1991, J BIOL CHEM, V266, P23428; MESSING RO, 1986, P NATL ACAD SCI USA, V83, P6213, DOI 10.1073/pnas.83.16.6213; MESSING RO, 1990, J NEUROCHEM, V55, P1383, DOI 10.1111/j.1471-4159.1990.tb03150.x; Miettinen S, 1996, J NEUROSCI, V16, P6236; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; MULLIKINKILPATRICK D, 1995, J PHARMACOL EXP THER, V272, P489; MULLIKINKILPATRICK D, 1995, MOL PHARMACOL, V47, P997; NIKODIJEVIC B, 1994, J NEUROSCI RES, V37, P71, DOI 10.1002/jnr.490370110; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OAKES SG, 1982, DEV BRAIN RES, V5, P251, DOI 10.1016/0165-3806(82)90123-7; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PANZA G, 1985, NEUROPHARMACOLOGY, V24, P1113, DOI 10.1016/0028-3908(85)90200-X; PEREZGARCIA MT, 1995, J GEN PHYSIOL, V105, P289, DOI 10.1085/jgp.105.2.289; RAMKUMAR V, 1988, EUR J PHARMACOL, V146, P73, DOI 10.1016/0014-2999(88)90488-8; REZVANI AH, 1991, ALCOHOL ALCOHOLISM, V26, P161, DOI 10.1093/oxfordjournals.alcalc.a045097; REZVANI AH, 1990, PROG NEURO-PSYCHOPH, V14, P623, DOI 10.1016/0278-5846(90)90013-7; Roivainen R, 1994, MOL BASIS ALCOHOL US, P29; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SKATTEBOL A, 1987, BIOCHEM PHARMACOL, V36, P2227, DOI 10.1016/0006-2952(87)90156-0; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TWOMBLY DA, 1990, J PHARMACOL EXP THER, V254, P1029; URSO T, 1981, LIFE SCI, V28, P1053, DOI 10.1016/0024-3205(81)90752-9; Victor M, 1953, RES PUBL ASSOC RES N, V32, P526; WANG XM, 1994, J NEUROSCI, V14, P5453; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q	63	64	64	5	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16409	16414		10.1074/jbc.273.26.16409	http://dx.doi.org/10.1074/jbc.273.26.16409			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632705	hybrid			2022-12-25	WOS:000074436600076
J	Jackson, DT; Froehlich, JE; Keegstra, K				Jackson, DT; Froehlich, JE; Keegstra, K			The hydrophilic domain of Tic110, an inner envelope membrane component of the chloroplastic protein translocation apparatus, faces the stromal compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; IMPORT MACHINERY; SMALL SUBUNIT; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; PRECURSOR PROTEINS; PEA-CHLOROPLASTS; OUTER-MEMBRANE; IDENTIFICATION; TRANSPORT	It has previously been found that Tic110, an integral protein of the chloroplast inner envelope membrane, is a component of the chloroplastic protein import apparatus. However, conflicting reports exist concerning the topology of this protein within the inner envelope membrane. In this report, we provide,evidence that indicates that the large (>90-kDa) hydrophilic domain of Tic110 is localized within the chloroplast stroma. Trypsin, a protease that cannot penetrate the permeability barrier of the inner envelope membrane, degrades neither Tic110 nor other proteins exposed to the stromal compartment but is able to digest proteins exposed to the intermembrane space between the two envelope membranes. Previous reports indicating that trypsin is able to degrade Tic110 were influenced by incomplete quenching of protease activity.When trypsin is not sufficiently quenched, it is able to digest Tic110, but only after chloroplasts have been ruptured. It is therefore necessary to employ adequate quenching protocols, such as the one reported here, whenever trypsin is utilized as an analytical tool. Based on a stromal localization for the majority of Tic110, we propose that this protein may be involved in the recruitment of stromal factors, possibly molecular chaperones, to the translocation apparatus during protein import.	Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA	Michigan State University	Keegstra, K (corresponding author), Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA.							Akita M, 1997, J CELL BIOL, V136, P983, DOI 10.1083/jcb.136.5.983; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; Bruce BD, 1994, PLANT MOL BIOL MAN J, VJ1, P1; CHUA NH, 1978, P NATL ACAD SCI USA, V75, P6110, DOI 10.1073/pnas.75.12.6110; CLINE K, 1981, P NATL ACAD SCI-BIOL, V78, P3595, DOI 10.1073/pnas.78.6.3595; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; DAUM G, 1982, J BIOL CHEM, V257, P3028; ETEMADI AH, 1980, BIOCHIM BIOPHYS ACTA, V604, P347; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HIGHFIELD PE, 1978, NATURE, V271, P420, DOI 10.1038/271420a0; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; HWANG ST, 1991, J BIOL CHEM, V266, P21083; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kouranov A, 1996, J BIOL CHEM, V271, P31009, DOI 10.1074/jbc.271.49.31009; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lubeck J, 1997, J CELL BIOL, V137, P1279, DOI 10.1083/jcb.137.6.1279; Lubeck J, 1996, EMBO J, V15, P4230, DOI 10.1002/j.1460-2075.1996.tb00797.x; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; MOORE T, 1993, PLANT MOL BIOL, V21, P525, DOI 10.1007/BF00028809; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; NIELSEN EE, 1997, THESIS MICHIGAN STAT, P131; OHBA M, 1987, EMBO J, V6, P2117, DOI 10.1002/j.1460-2075.1987.tb02478.x; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; ROSPERT S, 1994, J BIOL CHEM, V269, P17279; SCHMIDT GW, 1979, J CELL BIOL, V83, P615, DOI 10.1083/jcb.83.3.615; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; Tranel PJ, 1996, PLANT CELL, V8, P2093, DOI 10.1105/tpc.8.11.2093; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WU CB, 1994, J BIOL CHEM, V269, P32264	38	137	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16583	16588		10.1074/jbc.273.26.16583	http://dx.doi.org/10.1074/jbc.273.26.16583			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632730	hybrid			2022-12-25	WOS:000074436600101
J	Cao, ZY; Jefferson, DM; Panjwani, N				Cao, ZY; Jefferson, DM; Panjwani, N			Role of carbohydrate-mediated adherence in cytopathogenic mechanisms of Acanthamoeba	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTAMOEBA-HISTOLYTICA; CORNEAL EPITHELIUM; CELL-CULTURE; CASTELLANII; PROTEASES; PATHOGENICITY; TROPHOZOITES; PROTEINASE; EXPRESSION; VIRULENCE	Acanthamoeba keratitis is a vision-threatening corneal infection. The mannose-binding protein of Acanthamoeba is thought to mediate adhesion of parasites to host cells. We characterized the amoeba lectin with respect to its carbohydrate binding properties and the role in amoeba-induced cytopathic effect (CPE), Sugar inhibition assays revealed that the amoeba lectin has the highest affinity for alpha-Man and Man(alpha 1-3)Man units. In vitro cytopathic assays indicated that mannose-based saccharides which inhibit amoeba adhesion to corneal epithelial cells were also potent inhibitors of amoeba-induced CPE, Another major finding was that N-acetyl-D-glucosamine (GlcNAc) which does not inhibit adhesion of amoeba to host cells is also an inhibitor of amoeba-induced CPE. The Acanthamoebae are thought to produce CPE by secreting cytotoxic proteinases. By zymography, one metalloproteinase and three serine proteinases were detected in the conditioned media obtained after incubating amoebae with the host cells. The addition of free alpha-Man and GlcNAc to the co-culture media inhibited the secretion of the metalloproteinase and serine proteinases, respectively. In summary, we have shown that the lectin-mediated adhesion of the Acanthamoeba to host cells is a prerequisite for the amoeba-induced cytolysis of target cells and have implicated a contact-dependent metalloproteinase in the cytopathogenic mechanisms of Acanthamoeba.	Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University; Tufts University	Panjwani, N (corresponding author), Tufts Univ, Sch Med, Dept Ophthalmol, 136 Harrison Ave, Boston, MA 02111 USA.	NPanjwani@infonet.tufts.edu			NATIONAL EYE INSTITUTE [R01EY009349] Funding Source: NIH RePORTER; NEI NIH HHS [EY07088, EY09349] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALIZADEH H, 1994, INFECT IMMUN, V62, P1298, DOI 10.1128/IAI.62.4.1298-1303.1994; ALIZADEH H, 1997, DIS CORNEA, V2, P1267; BADENOCH PR, 1995, INT J PARASITOL, V25, P229, DOI 10.1016/0020-7519(94)00075-Y; BONALDO MC, 1991, EXP PARASITOL, V73, P44, DOI 10.1016/0014-4894(91)90006-I; BORNES JT, 1970, J PARASITOL, V56, P904; CURSONS RTM, 1978, J CLIN PATHOL, V31, P1, DOI 10.1136/jcp.31.1.1; DEJONCKHEERE JF, 1980, APPL ENVIRON MICROB, V39, P681, DOI 10.1128/AEM.39.4.681-685.1980; DEJONCKHEERE JF, 1981, J PROTOZOOL, V28, P56; HADAS E, 1993, TROP MED PARASITOL, V44, P197; HARE DF, 1989, EXP PARASITOL, V68, P168, DOI 10.1016/0014-4894(89)90094-5; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; JAMES GT, 1978, ANAL BIOCHEM, V86, P574, DOI 10.1016/0003-2697(78)90784-4; JUMBLATT MM, 1983, INVEST OPHTH VIS SCI, V24, P1139; KEENE WE, 1990, EXP PARASITOL, V71, P199, DOI 10.1016/0014-4894(90)90022-5; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN DFP, 1991, EYE, V5, P70, DOI 10.1038/eye.1991.14; Leippe M, 1997, PARASITOL TODAY, V13, P178, DOI 10.1016/S0169-4758(97)01038-7; Martinez AJ, 1997, BRAIN PATHOL, V7, P583, DOI 10.1111/j.1750-3639.1997.tb01076.x; MCCOY JJ, 1994, INFECT IMMUN, V62, P3045, DOI 10.1128/IAI.62.8.3045-3050.1994; MCKERROW JH, 1993, ANNU REV MICROBIOL, V47, P821, DOI 10.1146/annurev.mi.47.100193.004133; MITRA MM, 1995, MOL BIOCHEM PARASIT, V73, P157, DOI 10.1016/0166-6851(94)00109-Z; MITRO K, 1994, EXP PARASITOL, V78, P377, DOI 10.1006/expr.1994.1041; MOORE MB, 1991, CORNEA, V10, P291, DOI 10.1097/00003226-199107000-00003; MORTON LD, 1991, INFECT IMMUN, V59, P3819, DOI 10.1128/IAI.59.10.3819-3822.1991; PANJWANI N, 1995, J BIOL CHEM, V270, P14015, DOI 10.1074/jbc.270.23.14015; PANJWANI N, 1990, INVEST OPHTH VIS SCI, V31, P689; Panjwani N, 1997, INVEST OPHTH VIS SCI, V38, P1858; PERRONE RD, 1995, AM J PHYSIOL-GASTR L, V269, pG335, DOI 10.1152/ajpgi.1995.269.3.G335; Petri WA, 1996, J INVEST MED, V44, P24; Powers J.C., 1986, PROTEINASE INHIBITOR, P219; PRESTON TM, 1984, J GEN MICROBIOL, V130, P2317; PRINA E, 1990, INFECT IMMUN, V58, P1730, DOI 10.1128/IAI.58.6.1730-1737.1990; RAGLAND BD, 1994, EXP PARASITOL, V79, P460, DOI 10.1006/expr.1994.1107; REED SL, 1989, J CLIN MICROBIOL, V27, P2772, DOI 10.1128/JCM.27.12.2772-2777.1989; STANLEY SL, 1995, J BIOL CHEM, V270, P4121, DOI 10.1074/jbc.270.8.4121; VANKLINK F, 1992, CURR EYE RES, V11, P1207, DOI 10.3109/02713689208999546; VARKI A, 1994, METHOD ENZYMOL, V230, P16; VISVESVARA GS, 1975, J PROTOZOOL, V22, P245, DOI 10.1111/j.1550-7408.1975.tb05860.x; Yang ZT, 1997, INFECT IMMUN, V65, P439, DOI 10.1128/IAI.65.2.439-445.1997	41	90	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15838	15845		10.1074/jbc.273.25.15838	http://dx.doi.org/10.1074/jbc.273.25.15838			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624184	hybrid			2022-12-25	WOS:000074284200078
J	Desrivieres, S; Cooke, FT; Parker, PJ; Hall, MN				Desrivieres, S; Cooke, FT; Parker, PJ; Hall, MN			MSS4, a phosphatidylinositol-4-phosphate 5-kinase required for organization of the actin cytoskeleton in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; 4-PHOSPHATE 5-KINASE; YEAST SACCHAROMYCES; PHOSPHATIDIC-ACID; ALPHA-ACTININ; CELL-CYCLE; PATHWAY; HOMOLOG; GENE	The Saccharomyces cerevisiae protein MSS4 is essential and homologous to mammalian phosphatidylinositol-4-phosphate (PI(4)P) 5-kinases. Here, we demonstrate that MSS4 is a lipid kinase. MSS4 has dual substrate specificity in vitro, converting PI(4)P to PI(4,5)P-2 and to a lesser extent PI(S)P to PI(3, 4)P-2; no activity was detected with PI or PI(S)P as a substrate. Cells overexpressing MSS4 contain an elevated level specifically of PI(4,5)P,, whereas mss4 mutant cells have only approximately 10% of the normal amount of this phosphorylated phosphoinositide. Furthermore, cells lacking MSS4 are unable to form actin cables and to properly localize their actin cytoskeleton during polarized cell growth. Overexpression of RHO2, encoding a Rho-type GTPase involved in regulation of the actin cytoskeleton, restores growth and polarized distribution of actin in an mss4 mutant. These results suggest that MSS4 is the major PI(4)P B-kinase in yeast and provide a link between phosphoinositide metabolism and organization of the actin cytoskeleton in vivo.	Univ Basel, Biozentrum, Dept Biochem, CH-4056 Basel, Switzerland; Imperial Canc Res Fund, London WC2A 3PX, England	University of Basel; Cancer Research UK	Hall, MN (corresponding author), Univ Basel, Biozentrum, Dept Biochem, Klingelbergstr 70, CH-4056 Basel, Switzerland.	hall@ubaclu.unibas.ch	Desrivieres, Sylvane/B-7399-2011; Parker, Peter j/D-5192-2013; Desrivières, Sylvane/ABC-4336-2021	Desrivieres, Sylvane/0000-0002-9120-7060; Desrivières, Sylvane/0000-0002-9120-7060; Hall, Michael N/0000-0002-2998-0757; parker, peter/0000-0002-6218-2933				ADAMS AE, 1984, J CELL BIOL, V9, P934; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Helliwell SB, 1998, GENETICS, V148, P99; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MAZZONI C, 1993, J CELL BIOL, V123, P1821, DOI 10.1083/jcb.123.6.1821; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; SCHMIDT A, 1998, IN PRESS ANN REV CEL; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	53	172	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15787	15793		10.1074/jbc.273.25.15787	http://dx.doi.org/10.1074/jbc.273.25.15787			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624178	hybrid, Green Accepted			2022-12-25	WOS:000074284200072
J	Paakkonen, K; Annila, A; Sorsa, T; Pollesello, P; Tilgmann, C; Kilpelainen, I; Karisola, P; Ulmanen, I; Drakenberg, T				Paakkonen, K; Annila, A; Sorsa, T; Pollesello, P; Tilgmann, C; Kilpelainen, I; Karisola, P; Ulmanen, I; Drakenberg, T			Solution structure and main chain dynamics of the regulatory domain (residues 1-91) of human cardiac troponin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HETERONUCLEAR NMR-SPECTROSCOPY; CHEMICAL-SHIFT ANISOTROPY; MODEL-FREE APPROACH; SKELETAL-MUSCLE; CALCIUM-BINDING; BACKBONE DYNAMICS; RELAXATION; PROTEINS; CONTRACTION	The three-dimensional structure of calcium-loaded regulatory, i.e. N-terminal, domain (1-91) of human cardiac troponin C (cNTnC) was determined by NMR in water/trifluoroethanol (91:9 v/v) solution. The single-calcium-loaded cardiac regulatory domain is in a "closed"? conformation with comparatively little exposed hydrophobic surface. Difference distance matrices computed from the families of Ca2+-cNTnC, the apo and two-calcium forms of the skeletal TnC (sNTnC) structures reveal similar relative orientations for the N, A, and D helices, The B and C helices are closer to the NAD framework in Ca2+-cNTnC and in apo-sNTnC than in 2 . Ca2+-sNTnC, However, there is an indication of a conformational exchange based on broad N-15 resonances for several amino acids measured at several temperatures. A majority of the amides in the alpha-helices and in the calcium binding loop exhibit very fast motions with comparatively small amplitudes according to the Lipari-Szabo model. A few residues at the N and C termini are flexible. Data were recorded from nonlabeled and N-15-labeled samples, and backbone dynamics was investigated by N-15 T-1,T- T-2, and heteronuclear nuclear Overhauser effect as well as by relaxation interference measurements.	VTT Chem Technol, FIN-02044 VTT, Finland; Orion Corp, Orion Pharma, R&D, FIN-02101 Espoo, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	VTT Technical Research Center Finland; Orion Corporation; University of Helsinki	Annila, A (corresponding author), VTT Chem Technol, POB 1401, FIN-02044 VTT, Finland.		Pollesello, Piero/I-6884-2019	Pollesello, Piero/0000-0001-6994-768X; Tilgmann, Carola/0000-0001-6241-2359				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; Dong WJ, 1996, J BIOL CHEM, V271, P688, DOI 10.1074/jbc.271.2.688; Dong WJ, 1997, J BIOL CHEM, V272, P19229, DOI 10.1074/jbc.272.31.19229; Evenas J, 1997, BIOCHEMISTRY-US, V36, P3448, DOI 10.1021/bi9628275; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Fushman D, 1997, J MOL BIOL, V266, P173, DOI 10.1006/jmbi.1996.0771; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; GOLDMAN M, 1984, J MAGN RESON, V60, P437, DOI 10.1016/0022-2364(84)90055-6; HERZBERG O, 1986, CIBA F SYMP, V122, P120; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; Jansson M, 1996, J BIOMOL NMR, V7, P131; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI MX, 1995, BIOCHEMISTRY-US, V34, P8330, DOI 10.1021/bi00026a014; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9764; Palmer AG, 1997, CURR OPIN STRUC BIOL, V7, P732, DOI 10.1016/S0959-440X(97)80085-1; PENG JW, 1992, J MAGN RESON, V98, P308, DOI 10.1016/0022-2364(92)90135-T; POLLESELLO P, 1994, J BIOL CHEM, V269, P28584; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SCHULZKI HD, 1990, EUR J BIOCHEM, V189, P683, DOI 10.1111/j.1432-1033.1990.tb15537.x; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; SLUPSKY CM, 1995, BIOCHEMISTRY-US, V34, P7365, DOI 10.1021/bi00022a009; SLUPSKY CM, 1995, PROTEIN SCI, V4, P1279, DOI 10.1002/pro.5560040704; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P162	35	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15633	15638		10.1074/jbc.273.25.15633	http://dx.doi.org/10.1074/jbc.273.25.15633			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624156	hybrid			2022-12-25	WOS:000074284200050
J	Gangur, V; Simons, FER; Hayglass, KT				Gangur, V; Simons, FER; Hayglass, KT			Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses	FASEB JOURNAL			English	Article						environmental antigens; Th1/Th2 subsets; chemokine; TNF; interleukin; interferon gamma	INTERFERON-INDUCIBLE PROTEIN-10; PERIPHERAL-BLOOD LYMPHOCYTES; IMMUNE-RESPONSE; T-LYMPHOCYTES; IN-VIVO; CHEMOKINES; EXPRESSION; CYTOKINE; RANTES; PROLIFERATION	Human interferon-inducible protein 10 (IP-10) differs from most chemokines in its apparent specificity for activated T lymphocytes, We hypothesized that LP-10 was relevant not only for recruiting T cells to inflammatory sites, but also for regulating cytokine synthesis patterns. We examined the effect of recombinant human LP-10 (rhIP-10) on human interferon gamma (IFN-gamma) and interleukin 4 (IL-4) production by fresh peripheral blood mononuclear cells. We demonstrate for the first time that this CXC chemokine selectively up-regulates human T cell cytokine synthesis, with enhancement selectively targeted to promotion of Th1-like dominance. Superantigen (TSST-1), soluble anti-CD3 mAb, and phytohemagglutinin were used to activate distinct intracellular signaling pathways, thereby inducing quantitatively different IFN-gamma:IL-4 ratios. Selective enhancement of IFN-gamma responses was consistently observed, with median increases of 105-470%. Environmental antigens (Ag) were used to evaluate IP-10's effect on CD4-dependent, chloroquine-sensitive cytokine synthesis. Ag-driven IFN-gamma responses exhibited median 19- to 30-fold increases in the presence of nanomolar concentrations of rhIP-10, IL-4 responses were neither enhanced nor inhibited under any of the conditions tested. These findings suggest a potential role for this T cell-focused chemokine in maintenance of the default Th1-like responses usually seen to environmental Ag and indicate a potential application in the modulation of Ag-driven responses in vivo.	Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3E 0W3, Canada	University of Manitoba; University of Manitoba	Hayglass, KT (corresponding author), Univ Manitoba, Dept Immunol, 730 William Ave, Winnipeg, MB R3E 0W3, Canada.	HayGlass@ms.umanitoba.ca		HayGlass, Kent/0000-0002-4621-7737				Abe M, 1996, J INVEST DERMATOL, V107, P360, DOI 10.1111/1523-1747.ep12363337; Adams DH, 1997, LANCET, V349, P490, DOI 10.1016/S0140-6736(96)07524-1; Amichay D, 1996, J IMMUNOL, V157, P4511; Angiolillo AL, 1996, ANN NY ACAD SCI, V795, P158, DOI 10.1111/j.1749-6632.1996.tb52664.x; ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Cassatella MA, 1997, EUR J IMMUNOL, V27, P111, DOI 10.1002/eji.1830270117; CONLON K, 1995, EUR J IMMUNOL, V25, P751, DOI 10.1002/eji.1830250319; DEWALD B, 1992, IMMUNOL LETT, V32, P81, DOI 10.1016/0165-2478(92)90203-Z; Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246, DOI 10.1002/jlb.61.3.246; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Gao JL, 1997, J EXP MED, V185, P1959, DOI 10.1084/jem.185.11.1959; GOTTLIEB AB, 1988, J EXP MED, V168, P941, DOI 10.1084/jem.168.3.941; Hedrick JA, 1996, CURR OPIN IMMUNOL, V8, P343, DOI 10.1016/S0952-7915(96)80123-3; IMADA M, 1995, INT IMMUNOL, V7, P229, DOI 10.1093/intimm/7.2.229; KAPLAN G, 1987, J EXP MED, V166, P1098, DOI 10.1084/jem.166.4.1098; Karpus WJ, 1997, J IMMUNOL, V158, P4129; Lloyd AR, 1996, J IMMUNOL, V156, P932; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Lukacs NW, 1997, AM J PATHOL, V150, P1861; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Maghazachi AA, 1997, FASEB J, V11, P765, DOI 10.1096/fasebj.11.10.9271361; MireSluis AR, 1996, J IMMUNOL METHODS, V194, P13, DOI 10.1016/0022-1759(96)00069-5; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; SARRIS AH, 1995, BLOOD, V86, P651, DOI 10.1182/blood.V86.2.651.bloodjournal862651; SARRIS AH, 1993, J EXP MED, V178, P1127, DOI 10.1084/jem.178.3.1127; Schrum S, 1996, J IMMUNOL, V157, P3598; Sgadari C, 1996, BLOOD, V87, P3877, DOI 10.1182/blood.V87.9.3877.bloodjournal8793877; Strieter RM, 1996, J IMMUNOL, V156, P3583; Tannenbaum CS, 1996, J IMMUNOL, V156, P693; Taub DD, 1996, J IMMUNOL, V156, P2095; Taub DD, 1996, BLOOD, V87, P1423, DOI 10.1182/blood.V87.4.1423.bloodjournal8741423; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; Taub DD, 1996, J LEUKOCYTE BIOL, V59, P81, DOI 10.1002/jlb.59.1.81; vanAcker FAA, 1996, MEDIAT INFLAMM, V5, P393, DOI 10.1155/S0962935196000567	40	123	124	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1998	12	9					705	713		10.1096/fasebj.12.9.705	http://dx.doi.org/10.1096/fasebj.12.9.705			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619449				2022-12-25	WOS:000074011000009
J	Suc, I; Meilhac, O; Lajoie-Mazenc, I; Vandaele, J; Jurgens, G; Salvayre, R; Negre-Salvayre, A				Suc, I; Meilhac, O; Lajoie-Mazenc, I; Vandaele, J; Jurgens, G; Salvayre, R; Negre-Salvayre, A			Activation of EGF receptor by oxidized LDL	FASEB JOURNAL			English	Article						signaling; 4-hydroxynonenal; tyrosine phosphorylation	LOW-DENSITY-LIPOPROTEIN; EPIDERMAL GROWTH-FACTOR; FACTOR GENE-EXPRESSION; MACROPHAGE-LIKE CELLS; PHOSPHOTYROSINE PHOSPHATASE; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; PROTEIN-KINASE; SH2 DOMAINS	Oxidized low density lipoproteins (oxLDL) are thought to play a major role: in atherosclerosis, OxLDL exhibit a wide variety of biological effects resulting from their ability to interfere with intracellular signaling, The cellular targets and primary signaling events of oxLDL are unknown. We report that oxLDL elicit, in intact cells, tyrosine phosphorylation of the epithelial growth factor receptor (EGFR) and activation of its signaling pathway. This activation triggered by oxLDL was associated with derivatization of reactive amino groups of EGFR and was mimicked by 4-hydroxynonenal (4-HNE, a major lipid peroxidation product of oxLDL), Immunopurified EGFR was derivatized and activated in vitro by oxLDL lipid extracts and 4-HNE, thus indicating that 1) EGFR may be a primary target of oxidized lipids and 2) EGFR derivatization may be associated with activation. The reported data suggest that EGFR acts as a sensor for oxidized lipids. We therefore propose a novel concept of the mechanism by which oxidized lipids (contained in oxLDL or more generally produced during oxidative stress) are able to activate receptor tyrosine kinase and subsequent signaling pathways, resulting finally in a gain of function.	CHU Rangueil, INSERM, U466, IFR 31, F-31403 Toulouse 4, France; CHU Rangueil, Inst Louis Bugnard, Dept Biochem, F-31403 Toulouse, France; Karl Franzens Univ Graz, Inst Med Biochem, Graz, Austria	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; University of Graz	Negre-Salvayre, A (corresponding author), CHU Rangueil, INSERM, U466, IFR 31, 1 Ave Jean Pouhles, F-31403 Toulouse 4, France.		Meilhac, Olivier/N-4385-2017; Jürgens, Günther/B-8818-2011; Lajoie-Mazenc, Isabelle/M-4636-2014	Meilhac, Olivier/0000-0002-3740-7539; Negre-Salvayre, Anne/0000-0003-2136-5706				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; CLARK S, 1993, BIOCHEM J, V292, P217, DOI 10.1042/bj2920217; Claus R, 1996, BIOCHEMISTRY-US, V35, P4911, DOI 10.1021/bi952036n; COFFER PJ, 1995, ONCOGENE, V11, P561; Deigner HP, 1996, FEBS LETT, V385, P149, DOI 10.1016/0014-5793(96)00371-7; EscargueilBlanc I, 1997, ARTERIOSCL THROM VAS, V17, P331, DOI 10.1161/01.ATV.17.2.331; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; ESTERBAUER H, 1985, BIOCHEM J, V228, P363, DOI 10.1042/bj2280363; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; Hajjar DP, 1997, J BIOL CHEM, V272, P22975, DOI 10.1074/jbc.272.37.22975; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; JURGENS G, 1993, ARTERIOSCLER THROMB, V13, P1689, DOI 10.1161/01.ATV.13.11.1689; KASLAUKAS A, 1994, CURR OPIN GENE DEV, V4, P5; KOSAKI A, 1995, J BIOL CHEM, V270, P20816, DOI 10.1074/jbc.270.35.20816; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NATARAJAN V, 1995, J LIPID RES, V36, P2005; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARHAMI F, 1995, ARTERIOSCL THROM VAS, V15, P2019, DOI 10.1161/01.ATV.15.11.2019; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; TAN MS, 1994, BIOCHEM BIOPH RES CO, V202, P1001, DOI 10.1006/bbrc.1994.2028; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WICK G, 1995, IMMUNOL TODAY, V16, P27, DOI 10.1016/0167-5699(95)80067-0; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5	45	124	127	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1998	12	9					665	671		10.1096/fasebj.12.9.665	http://dx.doi.org/10.1096/fasebj.12.9.665			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619445				2022-12-25	WOS:000074011000005
J	Falasca, M; Iurisci, C; Carvelli, A; Sacchetti, A; Corda, D				Falasca, M; Iurisci, C; Carvelli, A; Sacchetti, A; Corda, D			Release of the mitogen lysophosphatidylinositol from H-Ras-transformed fibroblasts; a possible mechanism of autocrine control of cell proliferation	ONCOGENE			English	Article						lysophospholipids; glycerophosphoinositols; inositol 1 : 2-cyclic phosphate; lipid metabolism; ras oncogene; thyroid cells	THYROID EPITHELIAL-CELLS; AORTIC ENDOTHELIAL-CELLS; LYMPHOCYTE-T ACTIVATION; MURINE SARCOMA-VIRUS; PROTEIN-KINASE-C; PHOSPHOLIPASE-C; INOSITOL 2-PHOSPHATE; SIGNALING PATHWAYS; ADENYLATE-CYCLASE; IONOPHORE A23187	Lysophosphatidylinositol (LysoPtdIns) is formed by a constitutively-active phosphoinositide-specific phospholipase A(2) in Ras-transformed cells and can stimulate cell proliferation. To evaluate whether LysoPtdIns could function as an autocrine modulator of cell growth, we examined whether LysoPtdIns can be released in the medium of Ras-transformed FRT-Fibro fibroblasts and thyroid cells. Here, we report that LysoPtdIns accumulates in the extracellular space of these lines and reaches levels up to tenfold higher than in the case of normal cells. Moreover, the ionophore A23187 increased the levels of the lysolipid in the extracellular medium. Extracellular LysoPtdIns was rapidly hydrolyzed to inositol 1:2-cyclic phosphate. LysoPtdIns induced thymidine incorporation in FRT-Fibro Ha-Ras fibroblasts, whereas inositol cyclic 1:2-cyclic phosphate did not affect cell growth per se, nor did it interfere with the LysoPtdIns mitogenic activity. We hypothesize that in Ras-transformed fibroblasts the formation and release of LysoPtdIns may function as an autocrine mechanism that participates in the Ras-dependent stimulation of cell growth.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Corda, D (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Via Nazl, I-66030 Santa Maria Imbaro, Chieti, Italy.		Corda, Daniela/K-6385-2016; Sacchetti, Andrea/H-8763-2019; Falasca, Marco/S-4020-2016	Corda, Daniela/0000-0002-3614-751X; Falasca, Marco/0000-0002-9801-7235				ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; ALONSO T, 1990, BIOCHEM BIOPH RES CO, V171, P14, DOI 10.1016/0006-291X(90)91349-W; AMBESIIMPIOMBAT.FS, 1989, FRTL 5 TODAY; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ASAOKA Y, 1991, BIOCHEM BIOPH RES CO, V178, P1378, DOI 10.1016/0006-291X(91)91046-F; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; BARAN DT, 1988, ENDOCRINOLOGY, V122, P930, DOI 10.1210/endo-122-3-930; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BICKNELL R, 1988, P NATL ACAD SCI USA, V85, P5961, DOI 10.1073/pnas.85.16.5961; BILLAH MM, 1982, J BIOL CHEM, V257, P5196; BIRRELL GB, 1995, BIOCHEM BIOPH RES CO, V211, P318, DOI 10.1006/bbrc.1995.1813; CHIARIOTTI L, 1992, ONCOGENE, V7, P2507; COLETTA G, 1983, MOL CELL BIOL, V3, P2099; Corda D, 1996, ANTICANCER RES, V16, P1341; DAWSON RMC, 1971, BIOCHEM J, V122, P605, DOI 10.1042/bj1220605; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Falasca M, 1997, MOL BIOL CELL, V8, P443, DOI 10.1091/mbc.8.3.443; FALASCA M, 1995, ONCOGENE, V10, P2113; Falasca M, 1996, EUR J BIOCHEM, V241, P386, DOI 10.1111/j.1432-1033.1996.00386.x; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; FRANCEL P, 1988, BIOCHEM BIOPH RES CO, V152, P724, DOI 10.1016/S0006-291X(88)80098-6; FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GRAHAM RA, 1987, J BIOL CHEM, V262, P35; HONG SL, 1985, THROMB RES, V38, P1; HONG SL, 1982, J BIOL CHEM, V257, P7151; IACOVELLI L, 1993, J BIOL CHEM, V268, P20402; IMAGAWA W, 1995, EXP CELL RES, V216, P178, DOI 10.1006/excr.1995.1022; KAYA H, 1989, J BIOL CHEM, V264, P4972; KIM JW, 1989, BIOCHEM BIOPH RES CO, V163, P177, DOI 10.1016/0006-291X(89)92117-7; KOLAROVIC L, 1986, ANAL BIOCHEM, V156, P244, DOI 10.1016/0003-2697(86)90179-X; LAMBERT TL, 1986, J BIOL CHEM, V261, P5288; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MARCOCCI C, 1983, J ENDOCRINOL INVEST, V6, P463, DOI 10.1007/BF03348346; MARTIN TM, 1986, J BIOL CHEM, V262, P13086; METZ SA, 1986, BIOCHEM BIOPH RES CO, V138, P720, DOI 10.1016/S0006-291X(86)80556-3; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; ROSS TS, 1991, J BIOL CHEM, V266, P9086; ROSS TS, 1991, J BIOL CHEM, V266, P851; ROSS TS, 1992, J BIOL CHEM, V267, P19924; SASAKAWA N, 1995, BIOCHEM PHARMACOL, V50, P137, DOI 10.1016/0006-2952(95)00059-9; SEKAR MC, 1993, BIOCHEM BIOPH RES CO, V192, P1079, DOI 10.1006/bbrc.1993.1527; SMITH DM, 1992, J LEUKOCYTE BIOL, V52, P670, DOI 10.1002/jlb.52.6.670; TING AE, 1991, EUR J CELL BIOL, V56, P401; TING AE, 1990, J BIOL CHEM, V265, P5337; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VALITUTTI S, 1991, CELL SIGNAL, V3, P321, DOI 10.1016/0898-6568(91)90061-X; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VOLWERK JJ, 1992, J CELL PHYSIOL, V151, P613, DOI 10.1002/jcp.1041510322; WEILTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; ZOELLER RA, 1987, J BIOL CHEM, V262, P17212	55	49	51	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2357	2365		10.1038/sj.onc.1201758	http://dx.doi.org/10.1038/sj.onc.1201758			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620553				2022-12-25	WOS:000073428000008
J	Deb, TB; Wong, L; Salomon, DS; Zhou, GC; Dixon, JE; Gutkind, JS; Thompson, SA; Johnson, GR				Deb, TB; Wong, L; Salomon, DS; Zhou, GC; Dixon, JE; Gutkind, JS; Thompson, SA; Johnson, GR			A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors - A specific role for SHP-2 in MAP, but not c-jun amino-terminal kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; INSULIN; SEVENLESS; SHPTP2; CELLS; PHOSPHORYLATION; STIMULATION; EXPRESSION; HEREGULIN	The ErbB family of receptors, which include the epidermal growth factor receptor (EGFR), ErbB2, ErbB3, and ErbB4 mediate the actions of a family of bioactive polypeptides. EGF signals through EGFR, whereas heregulin (HRG) signaling is initiated through binding to either ErbB3 or ErbB4. In this report we studied the role of protein-tyrosine phosphatase SHP-2 in ErbB-mediated activation of mitogen-activated protein kinase (MAPK) by overexpressing SHP-2 mutants in COS-7 cells. We demonstrate that enzymatic activity and both NH2- and COOH-terminal SH2 domains of SHP-2 are required for EGF-induced MAPK activation, but not for c-Jun amino-terminal kinase stimulation or MAPK activation which occurred in response to myristoylated son of sevenless, activated Ras, or phorbol ester. Dominant-negative forms of SHP-2 had no effect on EGF-stimulated interaction of GRB2 with EGFR or SHC, nor did they influence phosphorylation of SHC and SHC/EGFR association. The same mutant SHP-2 structures that inhibited EGF-mediated stimulation of MAPK also blocked HRG alpha/beta-induced MAPK activation. EGF or HRG beta caused SHP-2 SH2 domains to engage multiple phosphotyrosine proteins, and mutation of either domain disrupted these associations. These results demonstrate that SHP-2 performs a common and essential function(s) in ligand-stimulated MAPK activation by the ErbB family of receptors.	US FDA, Ctr Biol Evaluat & Res, Div Cytokine Biol, Bethesda, MD 20892 USA; NCI, NIH, Tumor Immunol & Biol Lab, Bethesda, MD 20892 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; NIDR, NIH, Oral & Pharyngeal Canc Branch, Bethesda, MD 20892 USA; Berlex Biosci, Dept Prot Chem & Biophys, Richmond, CA 94804 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Johnson, GR (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Cytokine Biol, Bldg 29A,Rm 3B-16,8800 Rockville Pike, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				Allard JD, 1996, DEVELOPMENT, V122, P1137; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Wong L, 1996, J BIOL CHEM, V271, P20981, DOI 10.1074/jbc.271.35.20981; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	25	79	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16643	16646		10.1074/jbc.273.27.16643	http://dx.doi.org/10.1074/jbc.273.27.16643			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642214	hybrid			2022-12-25	WOS:000074545200004
J	Yeung, YG; Wang, Y; Einstein, DB; Lee, PSW; Stanley, ER				Yeung, YG; Wang, Y; Einstein, DB; Lee, PSW; Stanley, ER			Colony-stimulating factor-1 stimulates the formation of multimeric cytosolic complexes of signaling proteins and cytoskeletal components in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR; CELL-LINE; F-ACTIN; PHALLOIDIN BINDING; CSF-1; ACTIVATION; PHOSPHORYLATION; MOUSE	Stimulation of macrophages with colony-stimulating factor-1 (CSF-1) results in the protein tyrosine phosphorylation of the CSF-1 receptor (CSF-1R) and many other, primarily cytosolic, proteins. Stimulation by CSF-1 at 4 degrees C was used to facilitate the purification and identification of the proteins of the cytosolic anti-phosphotyrosine (PY)-reactive fraction (alpha PY-RF) involved in downstream signaling pathways. Confocal microscopy revealed that the PY proteins are in close proximity to the CSF-1R at the plasma membrane. The alpha PY-RF contained pre-existing complexes of PY proteins and non-PY proteins which generally increased in size and PY protein content following CSF-1 stimulation. PY proteins identified by microsequencing and Western blotting include Cbl, STAT3, STAT5a, STAT5b, SHP-1, She, and two novel proteins pp57 and pp37. Other proteins included cytoskeletal/contractile proteins (paxillin, vimentin, elongation factor-1 alpha, F-actin, tropomyosin, and myosin regulatory light chain), Ras family signaling proteins (p85 (phosphoinositide 3-kinase), Vav, Ras-GTPase-activating protein SH3 domain-binding protein, and Grb2), DnaJ-like protein, and glyceraldehyde-3-phosphate dehydrogenase. CSF-1 induced the de novo recruitment of Cbl, STAT3, STAT5a, STAT5b, p85, SHP-1, She, vimentin, and Grb2 to complexes and caused preexisting complexes involving Vav, elongation factor-1 alpha, and F-actin to increase in size. These studies indicate that CSF-l-induced protein tyrosine phosphorylation is associated with the reorganization of complexes of cytoskeletal, signaling, and other proteins that mediate CSF-l-regulated motility and growth.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Stanley, ER (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rstanley@aecom.yu.edu	Stanley, Evan R/J-9154-2013	Stanley, Evan R/0000-0002-2910-2065	NCI NIH HHS [CA 26504] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026504, R37CA026504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen WE, 1997, J CELL SCI, V110, P707; Baccarini M, 1991, Receptor, V1, P243; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BOOCOCK CA, 1989, J CELL SCI, V93, P447; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; BUSCHER D, 1993, ONCOGENE, V8, P3323; CANO ML, 1992, CELL MOTIL CYTOSKEL, V21, P147, DOI 10.1002/cm.970210208; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; CECCHINI MG, 1994, DEVELOPMENT, V120, P1357; Chan AY, 1998, J CELL SCI, V111, P199; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DE LA CRUZ EM, 1994, BIOCHEMISTRY-US, V33, P14387, DOI 10.1021/bi00252a003; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; Edmonds BT, 1996, J CELL SCI, V109, P2705; GUILBERT LJ, 1980, J CELL BIOL, V85, P153, DOI 10.1083/jcb.85.1.153; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KUMAGAI H, 1983, J BIOCHEM-TOKYO, V93, P1259, DOI 10.1093/oxfordjournals.jbchem.a134260; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LI W, 1991, J BIOL CHEM, V266, P6808; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MCCORMICK MB, 1993, J CELL BIOL, V122, P395, DOI 10.1083/jcb.122.2.395; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MORI S, 1995, BIOCHEM BIOPH RES CO, V213, P32, DOI 10.1006/bbrc.1995.2094; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Murray JW, 1996, J CELL BIOL, V135, P1309, DOI 10.1083/jcb.135.5.1309; NAITO M, 1991, AM J PATHOL, V139, P657; Novak U, 1996, J BIOL CHEM, V271, P18350, DOI 10.1074/jbc.271.31.18350; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Parker F, 1996, MOL CELL BIOL, V16, P2561; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; Pollard JW., 1996, ADV D BIOCH, V4, P153; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Sirover MA, 1997, J CELL BIOCHEM, V66, P133, DOI 10.1002/(SICI)1097-4644(19970801)66:2<133::AID-JCB1>3.3.CO;2-V; STANLEY ER, 1994, CYTOKINE HDB, P387; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Webb SE, 1996, J CELL SCI, V109, P793; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YEUNG YG, 1987, P NATL ACAD SCI USA, V84, P1268, DOI 10.1073/pnas.84.5.1268; ZECHEL K, 1980, EUR J BIOCHEM, V110, P343, DOI 10.1111/j.1432-1033.1980.tb04873.x	60	100	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17128	17137		10.1074/jbc.273.27.17128	http://dx.doi.org/10.1074/jbc.273.27.17128			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642280	hybrid			2022-12-25	WOS:000074545200070
J	Arakane, F; Kallen, CB; Watari, H; Foster, JA; Sepuri, NBV; Pain, D; Stayrook, SE; Lewis, M; Gerton, GL; Strauss, JF				Arakane, F; Kallen, CB; Watari, H; Foster, JA; Sepuri, NBV; Pain, D; Stayrook, SE; Lewis, M; Gerton, GL; Strauss, JF			The mechanism of action of steroidogenic acute regulatory protein (StAR) - StAR acts on the outside of mitochondria to stimulate steroidogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; FUNCTIONAL-ACTIVITY; LEYDIG-CELLS; EXPRESSION; PHOSPHORYLATION; PHOSPHOPROTEIN; IDENTIFICATION; BIOSYNTHESIS; GENE	Steroidogenic acute regulatory protein (StAR) plays an essential role in steroidogenesis, facilitating delivery of cholesterol to cytochrome P450(scc) on the inner mitochondrial membrane. StAR is synthesized in the cytoplasm and is subsequently imported by mitochondria and processed to a mature form by cleavage of the NH,terminal mitochondrial targeting sequence. To explore the mechanism of StAR action, we produced 6-histidine-tagged N-62 StAR (His-tag StAR) constructs lacking the NH2-terminal 62 amino acids that encode the mitochondrial targeting sequence and examined their steroidogenic activity in intact cells and on isolated mitochondria, His-tag StAR proteins stimulated pregnenolone synthesis to the same extent as wild-type StAR when expressed in COS-1 cells transfected with the cholesterol side-chain cleavage system. His-tag StAR was diffusely distributed in the cytoplasm of transfected COS-1 cells whereas wild-type StAR was localized to mitochondria, There was no evidence at the light or electron microscope levels for selective localization of His-tag StAR protein to mitochondrial membranes. In vitro import assays demonstrated that wild-type StAR preprotein was imported and processed to mature protein that was protected from subsequent trypsin treatment. In contrast, His-tag StAR was not imported and protein associated with mitochondria was sensitive to trypsin, Using metabolically labeled COS-1 cells transfected with wild-type or His-tag StAR constructs, we confirmed that wild-type StAR preprotein was imported and processed by mitochondria, whereas His-tag StAR remained largely cytosolic and unprocessed To determine whether cytosolic factors are required for StAR action, we developed an assay system using washed mitochondria isolated from bovine corpora lutea and purified recombinant His-tag StAR proteins expressed in Escherichia coli. Recombinant His-tag StAR stimulated pregnenolone production in a dose- and time-dependent manner, functioning at nanomolar concentrations. A point mutant of StAR (A218V) that causes lipoid congenital adrenal hyperplasia was incorporated into the His-tag protein. This mutant was steroidogenically inactive in COS-1 cells and on isolated mitochondria. Our observations conclusively document that StAR acts on the outside of mitochondria, independent of mitochondrial import, and in the absence of cytosol, The ability to produce bioactive recombinant StAR protein paves the way for refined structural studies of StAR and StAR mutants.	Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Strauss, JF (corresponding author), Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, 778 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	jstrauss@mail.med.upenn.edu	Gerton, George L/A-1039-2007; Sepuri, Naresh/AAF-2704-2020	Gerton, George L/0000-0001-9894-5640; Stayrook, Steven/0000-0002-1677-8293; Kallen, Caleb/0000-0002-4156-6719	NICHD NIH HHS [HD-06274] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; ARAKANE F, 1998, J SOC GYNECOL INVE S, V5, pA50; BELFIORE CJ, 1994, J STEROID BIOCHEM, V51, P283, DOI 10.1016/0960-0760(94)90041-8; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; CARON MK, 1997, P NATL ACAD SCI USA, V94, P11540; CHEN ZJ, 1994, ENDOCRINOLOGY, V134, P2360, DOI 10.1210/en.134.6.2360; Cherradi N, 1997, J BIOL CHEM, V272, P7899, DOI 10.1074/jbc.272.12.7899; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; GRADI A, 1995, BBA-LIPID LIPID MET, V1258, P228, DOI 10.1016/0005-2760(95)00140-8; HARTIGAN JA, 1995, J STEROID BIOCHEM, V53, P95, DOI 10.1016/0960-0760(95)00026-V; JUENGEL JL, 1995, ENDOCRINOLOGY, V136, P5423, DOI 10.1210/en.136.12.5423; King SR, 1996, ENDOCR RES, V22, P505, DOI 10.1080/07435809609043739; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; KOWLURU R, 1995, MOL CELL ENDOCRINOL, V107, P181, DOI 10.1016/0303-7207(94)03441-U; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Mukhopadhyay A, 1997, J BIOL CHEM, V272, P13055, DOI 10.1074/jbc.272.20.13055; Nakae J, 1997, HUM MOL GENET, V6, P571, DOI 10.1093/hmg/6.4.571; PAAVOLA LG, 1983, J CELL BIOL, V97, P593, DOI 10.1083/jcb.97.3.593; Papadopoulos V, 1997, J BIOL CHEM, V272, P32129, DOI 10.1074/jbc.272.51.32129; PAYNE AH, 1995, BIOL REPROD, V52, P217, DOI 10.1095/biolreprod52.2.217; Pollack SE, 1997, J CLIN ENDOCR METAB, V82, P4243, DOI 10.1210/jc.82.12.4243; PON LA, 1986, J BIOL CHEM, V261, P3309; Schulke N, 1997, P NATL ACAD SCI USA, V94, P7314, DOI 10.1073/pnas.94.14.7314; STOCCO DM, 1993, J STEROID BIOCHEM, V46, P337, DOI 10.1016/0960-0760(93)90223-J; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Sugawara T, 1997, BIOCHEMISTRY-US, V36, P7249, DOI 10.1021/bi9628984; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295	30	166	168	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16339	16345		10.1074/jbc.273.26.16339	http://dx.doi.org/10.1074/jbc.273.26.16339			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632696	hybrid			2022-12-25	WOS:000074436600067
J	Labbe-Jullie, C; Barroso, S; Nicolas-Eteve, D; Reversat, JL; Botto, JM; Mazella, J; Bernassau, JM; Kitabgi, P				Labbe-Jullie, C; Barroso, S; Nicolas-Eteve, D; Reversat, JL; Botto, JM; Mazella, J; Bernassau, JM; Kitabgi, P			Mutagenesis and modeling of the neurotensin receptor NTR1 - Identification of residues that are critical for binding SR 48692, a nonpeptide neurotensin antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROKININ-1 RECEPTOR; ANGIOTENSIN-II; SUBSTANCE-P; AMINO-ACID; LIGAND; SITE; PEPTIDE; EXPRESSION; EPITOPES; DOPAMINE	The two neurotensin receptor subtypes known to date, NTR1 and NTR2, belong to the family of G-protein-coupled receptors with seven putative transmembrane domains (TM). SR 48692, a nonpeptide neurotensin antagonist, is selective for the NTR1. In the present study we attempted, through mutagenesis and computer-assisted modeling, to identify residues in the rat NTR1 that are involved in antagonist binding and to provide a tentative molecular model of the SR 48692 binding site. The seven putative TMs of the NTR1 were defined by sequence comparison and alignment of bovine rhodopsin and G-protein-coupled receptors. Thirty-five amino acid residues within or flanking the TMs were mutated to alanine. Additional mutations were performed for basic residues. The wild type and mutant receptors were expressed in COS M6 cells and tested for their ability to bind I-125-NT and [H-3]SR 48692. A tridimensional model of the SR 48692 binding site was constructed using frog rhodopsin as a template. SR 48692 was docked into the receptor, taking into account the mutagenesis data for orienting the antagonist. The model shows that the antagonist binding pocket lies near the extracellular side of the transmembrane helices within the first two helical turns. The data identify one residue in TM 4, three in TM 6, and four in TM 7 that are involved in SR 48692 binding, Two of these residues, Arg(327) in TM 6 and Tyr(351) in TM 7, play a key role in antagonist/receptor interactions. The former appears to form an ionic link with the carboxyIic group of SR 48692, as further supported by structure-activity studies using SR 48692 analogs. The data also show that the agonist and antagonist binding sites in the rNTR1 are different and help formulate hypotheses as to the structural basis for the selectivity of SR 48692 toward the NTR1 and NTR2.	Univ Nice, CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Sanofi Rech, Ctr Montpellier, F-34184 Montpellier 04, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Sanofi-Aventis; Sanofi France	Kitabgi, P (corresponding author), Univ Nice, CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	kitabgi@ipmc.cnrs.fr	Mazella, Jean/A-6767-2012	Labbe-Jullie, Catherine/0000-0001-6398-3807				BALDWIN JM, 1997, J MOL BIOL, V213, P899; Befort K, 1996, J BIOL CHEM, V271, P10161, DOI 10.1074/jbc.271.17.10161; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BHOGAL N, 1994, J BIOL CHEM, V269, P27269; BIDARD JN, 1993, BIOCHEM J, V291, P225, DOI 10.1042/bj2910225; BISSETTE G, 1976, NATURE, V262, P607, DOI 10.1038/262607a0; Botto JM, 1997, MOL BRAIN RES, V46, P311, DOI 10.1016/S0169-328X(97)00006-5; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLINESCHMIDT BV, 1982, ANN NY ACAD SCI, V400, P283, DOI 10.1111/j.1749-6632.1982.tb31576.x; CRAIG DA, 1993, TRENDS PHARMACOL SCI, V14, P89, DOI 10.1016/0165-6147(93)90070-Z; Cusack B, 1996, J BIOL CHEM, V271, P15054, DOI 10.1074/jbc.271.25.15054; DUBUC I, 1994, BRIT J PHARMACOL, V112, P352, DOI 10.1111/j.1476-5381.1994.tb13077.x; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1993, NATURE, V362, P350; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; Gully D, 1995, FUNDAM CLIN PHARM, V9, P513, DOI 10.1111/j.1472-8206.1995.tb00528.x; HIBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7, DOI 10.1016/0165-6147(93)90106-T; JI H, 1994, J BIOL CHEM, V269, P16533; KITABGI P, 1989, NEUROCHEM INT, V14, P111, DOI 10.1016/0197-0186(89)90110-1; LABBEJULLIE C, 1995, MOL PHARMACOL, V47, P1050; LAZARUS LH, 1977, J BIOL CHEM, V252, P7180; Mazella J, 1996, J NEUROSCI, V16, P5613; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEMEROFF CB, 1980, BIOL PSYCHIAT, V15, P283; Pang YP, 1996, J BIOL CHEM, V271, P15060, DOI 10.1074/jbc.271.25.15060; Perlman S, 1997, MOL PHARMACOL, V51, P301, DOI 10.1124/mol.51.2.301; Quere L, 1996, J CHEM SOC PERK T 2, P2639, DOI 10.1039/p29960002639; Rostene W, 1997, ANN NY ACAD SCI, V814, P125, DOI 10.1111/j.1749-6632.1997.tb46151.x; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; SMITH RD, 1992, ANNU REV PHARMACOL, V32, P135; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; WATLING KJ, 1993, TRENDS PHARMACOL SCI, V14, P81, DOI 10.1016/0165-6147(93)90067-T; WOODRUFF GN, 1991, ANNU REV PHARMACOL, V31, P469	41	66	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16351	16357		10.1074/jbc.273.26.16351	http://dx.doi.org/10.1074/jbc.273.26.16351			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632698	hybrid			2022-12-25	WOS:000074436600069
J	Petosa, C; Masters, SC; Bankston, LA; Pohl, J; Wang, BC; Fu, HI; Liddington, RC				Petosa, C; Masters, SC; Bankston, LA; Pohl, J; Wang, BC; Fu, HI; Liddington, RC			14-3-3 zeta binds a phosphorylated Raf peptide and an unphosphorylated peptide via its conserved amphipathic groove	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SIGNALING PATHWAYS; PROTEIN-KINASE; 14-3-3-PROTEINS; ASSOCIATION; PROGRAM; BCR	14-3-3 proteins bind a variety of molecules involved in signal transduction, cell cycle regulation and apoptosis. 14-3-3 binds ligands such as Raf-1 kinase and Bad by recognizing the phosphorylated consensus motif, RSX-pSXP, but must bind unphosphorylated ligands, such as glycoprotein Ib and Pseudomonas aeruginosa exoenzyme S, via a different motif. Here we report the crystal structures of the zeta isoform of 14-3-3 in complex with two peptide ligands: a Raf-derived phosphopeptide (pS-Raf-259, LSQRQRSTpSTPNVHMV) and an unphosphorylated peptide derived from phage display (R18, PH-CVPRDLSWLDLEANMCLP) that inhibits binding of exoenzyme S and Raf-1. The two peptides bind within a conserved amphipathic groove on the surface of 14-3-3 at overlapping but distinct sites. The phosphoserine of pS-Raf-259 engages a cluster of basic residues (Lys(49) Arg(56), Arg(60), and Arf(127)), whereas R18 binds via the amphipathic sequence, WLDLE, with its two acidic groups coordinating the same basic cluster. 14-3-3 is dimeric, and its two peptide-binding grooves are arranged in an antiparallel fashion, 30 Angstrom apart. The ability of each groove to bind different peptide motifs suggests how 14-3-3 can act in signal transduction by inducing either homodimer or heterodimer formation in its target proteins.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Grad Program Mol Therapeut & Toxicol, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA; Case Western Reserve Univ, Rammelkamp Ctr Res, Cleveland, OH 44109 USA	University of Leicester; Emory University; Emory University; Emory University; Case Western Reserve University; MetroHealth System	Liddington, RC (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.	RCL6@LEICESTER.AC.UK	Wang, Binghe/D-4257-2009	Wang, Binghe/0000-0002-2200-5270; Petosa, Carlo/0000-0002-9975-1167	NIGMS NIH HHS [GM08602, GM53165] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053165, R29GM053165, T32GM008602] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Craparo A, 1997, J BIOL CHEM, V272, P11663; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PEREIRA HA, 1993, P NATL ACAD SCI USA, V90, P4733, DOI 10.1073/pnas.90.10.4733; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	33	274	284	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16305	16310		10.1074/jbc.273.26.16305	http://dx.doi.org/10.1074/jbc.273.26.16305			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632691	hybrid			2022-12-25	WOS:000074436600062
J	Weng, QP; Kozlowski, M; Belham, C; Zhang, AH; Comb, MJ; Avruch, J				Weng, QP; Kozlowski, M; Belham, C; Zhang, AH; Comb, MJ; Avruch, J			Regulation of the p70 S6 kinase by phosphorylation in vivo - Analysis using site-specific anti-phosphopeptide antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; RAPAMYCIN; INSULIN; ACTIVATION; P70(S6K); WORTMANNIN; INHIBITION	The p70 S6 kinase is activated by diverse stimuli through a multisite phosphorylation directed at three separate domains as follows: a cluster of (Ser/Thr) Pro sites in an autoinhibitory segment in the noncatalytic carboxyl-terminal tail; Thr-252 in the activation loop of the catalytic domain; and Ser-394 and Thr-412 in a segment immediately carboxyl-terminal to the catalytic domain. Phosphorylation of Thr-252 in vitro by the enzyme phosphatidylinositol 3-phosphate-dependent kinase-1 or mutation of Thr-412 --> Glu has each been shown previously to engender some activation of the p70 S6 kinase, whereas both modifications together produce 20-30-fold more activity than either alone. We employed phospho-specific anti-peptide antibodies to examine the relative phosphorylation at several of these sites in wild type and various p70 mutants, in serum-deprived cells, and in response to activators and inhibitors of p70 S6 kinase activity. Substantial phosphorylation of p70 Thr-252 and Ser-434 was present in serum-deprived cells, whereas Thr-412 and Thr-444/Ser-447 were essentially devoid of phospho-specific immunoreactivity, Activation of p70 by insulin was accompanied by a coordinate increase in phosphorylation at all sites examined, together with a slowing in mobility on SDS-PAGE of a portion of p70 polypeptides. Upon addition of rapamycin or wortmannin to insulin-treated cells, the decrease in activity of p70 was closely correlated with the disappearance of anti-Thr-412(P) immunoreactivity and the most slowly migrating p70 polypeptides, whereas considerable phosphorylation at Ser-434 and Thr-252 persisted after the disappearance of 40 S kinase activity. The central role of Thr-412 phosphorylation in the regulation of kinase activity was further demonstrated by the close correlation of the effects of various deletions and point mutations on p70 activity and Thr-412 phosphorylation. In conclusion, although p70 activity depends on a disinhibition from the carboxyl-terminal tail and the simultaneous phosphorylation at both Thr-252 and Thr-412, p70 activity in vivo is most closely related to the state of phosphorylation at Thr-412.	Massachusetts Gen Hosp, Dept Biol Mol, Diabet Res Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; New England Biolabs Inc, Beverly, MA 01915 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Avruch, J (corresponding author), Massachusetts Gen Hosp, Dept Biol Mol, Diabet Res Lab, 50 Blossom St, Boston, MA 02114 USA.	avruch@helix.mgh.harvard.edu			NIDDK NIH HHS [DK17776] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017776, R01DK017776] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI D, 1997, CURR BIOL, V8, P69; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Scott PH, 1997, FEBS LETT, V409, P171, DOI 10.1016/S0014-5793(97)00500-0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333	24	324	332	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16621	16629		10.1074/jbc.273.26.16621	http://dx.doi.org/10.1074/jbc.273.26.16621			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632736	hybrid			2022-12-25	WOS:000074436600107
J	Humke, EW; Ni, J; Dixit, VM				Humke, EW; Ni, J; Dixit, VM			ERICE, a novel FLICE-activatable caspase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; DEATH GENE CED-3; CELL-DEATH; GRANZYME-B; CYSTEINE PROTEASE; POLY(ADP-RIBOSE) POLYMERASE; PROTEOLYTIC ACTIVATION; ICE/CED-3 PROTEASE; APOPTOTIC ACTIVITY; MOLECULAR-CLONING	Programmed cell death, or apoptosis, is a process of fundamental importance to cellular homeostasis in metazoan organisms (Ellis, R. E., Yuan, J., and Horvitz, H. R. (1991) Annu. Rev. Cell Biol. 7, 663-698). The caspase family of mammalian proteases, related to the nematode death protein CED-3, plays a crucial role in apoptosis and inflammation. We report here the isolation and characterization of a new caspase, tentatively termed ERICE (Evolutionarily Related Interleukin-lp Converting Enzyme). Based on phylogenetic analysis, ERICE (caspase-13) is a member of the ICE subfamily of caspases which includes caspase-1 (ICE), caspase-4 (ICErel-II, TX, ICH-2), and caspase-5 (ICErel-III, TY). Overexpression of ERICE induces apoptosis of 293 human embryonic kidney cells and MCF7 breast carcinoma cells. Like other members of the subfamily, ERICE is not activated by the serine protease granzyme B, a caspase-activating component of cytotoxic T cell granules. Therefore, ERICE most likely does not play a role in granzyme B-induced cell death. ERICE, however, was activated by caspase-8 (FLICE, MACH, Mch-B), the apical caspase activated upon engagement of death receptors belonging to the tumor necrosis factor family. This is consistent with a potential role for ERICE in this receptor-initiated death pathway.	Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; Univ Michigan, Sch Med, Dept Cellular & Mol Biol, Ann Arbor, MI 48109 USA; Human Genome Sci, Rockville, MD 20850 USA	Roche Holding; Genentech; University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,Bldg 10,Rm 290,M-S 40, S San Francisco, CA 94080 USA.	dixit@gene.com	dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013671] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG13671] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07863-16] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1995, NATURE, V377, P3; Allet B, 1996, J CELL BIOL, V135, P479, DOI 10.1083/jcb.135.2.479; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, CURR BIOL, V6, P897, DOI 10.1016/S0960-9822(02)00614-0; Clayton LK, 1997, EMBO J, V16, P2282, DOI 10.1093/emboj/16.9.2282; Crouch DH, 1996, ONCOGENE, V12, P2689; DARMON AJ, 1994, J BIOL CHEM, V269, P32043; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gu Y, 1996, J BIOL CHEM, V271, P10816, DOI 10.1074/jbc.271.18.10816; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Ni J, 1997, J BIOL CHEM, V272, P10853; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry N A, 1997, Adv Pharmacol, V41, P155, DOI 10.1016/S1054-3589(08)61058-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; Wang WH, 1996, J BIOL CHEM, V271, P27863, DOI 10.1074/jbc.271.44.27863; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN Y, 1995, Patent No. 00160	63	96	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15702	15707		10.1074/jbc.273.25.15702	http://dx.doi.org/10.1074/jbc.273.25.15702			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624166	hybrid			2022-12-25	WOS:000074284200060
J	Sharma, KK; Kumar, GS; Murphy, AS; Kester, K				Sharma, KK; Kumar, GS; Murphy, AS; Kester, K			Identification of 1,1 '-bi(4-anilino)naphthalene-5,5 '-disulfonic acid binding sequences in alpha-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE; LENS CRYSTALLINS; A-CRYSTALLIN; QUATERNARY STRUCTURE; CROSS-LINKING; ASCORBIC-ACID; B-CRYSTALLIN; TISSUES	The hydrophobic binding sites in alpha-crystallin were evaluated using fluorescent probes 1,1'-bi(4-anilino)naphthalenesulfonic acid (bis-ANS), 8-anilino-1-naphthalene sulfonate; (ANS), and 1-azidonaphthalene 5-sulfonate (1,5-AZNS). The photolysis of bis-ANS-alpha-crystallin complex resulted in incorporation of the probe to both alpha A- and alpha B-subnnits, Prior binding of denatured alcohol dehydrogenase to alpha-crystallin significantly decreased the photoincorporation of bis-ANS to alpha-crystallin. Localization of bis-ANS incorporated into alpha A-cryskallin resulted in the identification of residues QSLFR and HFSPEDLTVK as the fluorophore binding regions, In alpha B-crystallin, sequences DRFSVNLNVK and VLGDVIEVHGK were found to be the Ibis-ANS binding regions, Of the bis-ANS binding sequences, HFSPEDLTVK of alpha-A-crystallin and DRFSVNLNVK and VLGDVIEVHGK of alpha B-crystallin were earlier identified as part of the sequences involved in their interaction with target proteins during the molecular chaperone-like action. The hydrophobic probe, 1,5-AZNS, also interacted with both subunits of alpha-crystallin. Localization of 1,5-AZNS binding site in alpha B-crystallin lead to the identification of HFSPEEK sequence as the interacting site in this subunit of alpha-crystallin, Glycated alpha-crystallin displayed decreased ANS fluorescence and loss of chaperone-like function, suggesting the involvement of glycation site as well as ANS binding site ire chaperone-like activity display.	Univ Missouri, Mason Eye Inst, Dept Ophthalmol, Columbia, MO 65212 USA; Univ Missouri, Dept Biochem, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Sharma, KK (corresponding author), Univ Missouri, Mason Eye Inst, Dept Ophthalmol, Columbia, MO 65212 USA.		Kumar, Dr Suresh/HHZ-2615-2022; KUMAR, P. SURESH/AAT-8951-2020; Kumar, Gopinatha Suresh/W-1461-2019	Kumar, Dr Suresh/0000-0002-2539-6553; KUMAR, P. SURESH/0000-0003-3222-2604; 	NATIONAL EYE INSTITUTE [R01EY011981] Funding Source: NIH RePORTER; NEI NIH HHS [EY 11981] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bloemendal H, 1981, MOL CELLULAR BIOL EY, P1; Bloemendal M, 1995, EXP EYE RES, V61, P757, DOI 10.1016/S0014-4835(05)80027-2; Borkman RF, 1996, EXP EYE RES, V62, P141, DOI 10.1006/exer.1996.0018; CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391; Clark JI, 1996, P NATL ACAD SCI USA, V93, P15185, DOI 10.1073/pnas.93.26.15185; Das BK, 1997, BIOCHEM BIOPH RES CO, V236, P370, DOI 10.1006/bbrc.1997.6950; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; DOCKTER ME, 1983, BIOCHEMISTRY-US, V22, P3954, DOI 10.1021/bi00285a035; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; MERK KB, 1993, J BIOL CHEM, V268, P1046; ORTWERTH BJ, 1992, BIOCHIM BIOPHYS ACTA, V1117, P207, DOI 10.1016/0304-4165(92)90081-5; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; PRABHAKARAM M, 1992, EXP EYE RES, V55, P451, DOI 10.1016/0014-4835(92)90118-C; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; Sharma KK, 1997, FASEB J, V11, pA908; SHARMA KK, 1995, EXP EYE RES, V61, P413; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; Sharma KK, 1997, BIOCHEM BIOPH RES CO, V239, P217, DOI 10.1006/bbrc.1997.7460; Smith JB, 1996, EXP EYE RES, V63, P125, DOI 10.1006/exer.1996.0100; Smulders RHPH, 1997, FEBS LETT, V409, P101, DOI 10.1016/S0014-5793(97)00498-5; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; STEVENS DJ, 1980, J BIOL CHEM, V255, P379; Sudhakar K, 1996, J BIOL CHEM, V271, P23015, DOI 10.1074/jbc.271.38.23015; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; TAKEMOTO L, 1993, BIOCHEM J, V294, P435, DOI 10.1042/bj2940435; WANG KY, 1994, J BIOL CHEM, V269, P13601	43	127	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15474	15478		10.1074/jbc.273.25.15474	http://dx.doi.org/10.1074/jbc.273.25.15474			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624133	hybrid			2022-12-25	WOS:000074284200027
J	Belkin, AM; Retta, SF				Belkin, AM; Retta, SF			beta D-1 integrin inhibits cell cycle progression in normal myoblasts and fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CYTOPLASMIC DOMAIN; RAS TRANSFORMATION; EXPRESSION; PROTEIN; DIFFERENTIATION; ACTIVATION; SUBUNIT; PROLIFERATION; LOCALIZATION	Integrins are alpha beta heterodimeric transmembrane receptors involved in the regulation of cell growth and differentiation. The beta(1) integrin subunit is widely expressed in vivo and is represented by four alternatively spliced cytoplasmic domain isoforms, beta(1)D is a muscle-specific variant of beta(1) integrin and a predominant beta(1) isoform in striated muscles. In the present study we showed that expression of the exogenous beta(1)D integrin in C2C12 myoblasts and NIH 3T3 or REF 52 fibroblasts inhibited cell proliferation. Unlike the case of the common beta(1)A isoform, adhesion of beta(1)D-transfected C2C12 myoblasts specifically via the expressed integrin did not activate mitogen-activated protein kinases, The beta(1)D-induced growth inhibitory signal was shown to occur late in the G(1) phase of the cell cycle, before the G(1)-S transition. Ha-(12R)Ras, but not (Delta 22W)Raf-1 oncogene, was able to overcome completely the beta(1)D-triggered cell growth arrest in NIH 3T3 fibroblasts, Since perturbation of the beta(1)D amino acid sequence in beta(1)A/beta(1)D chimeric integrins decreased the growth inhibitory signal, the entire cytoplasmic domain of beta(1)D appeared to be important for this function, However, an interleukin-2 receptor-beta(1)D chimera containing the cytoplasmic domain of beta(1)D still efficiently inhibited cell growth, showing that the ectodomain and the ligand-binding site in beta(1)D were not required for the growth inhibitory signal. Together, our data showed a new specific function for the alternatively spliced beta(1)D integrin isoform, Since the onset of beta(1)D expression during myodifferentiation coincides with the timing of myoblast withdrawal from the cell cycle, the growth inhibitory properties of beta(1)D demonstrated in this study might reflect the major function for this integrin in commitment of differentiating skeletal muscle cells in vivo.	Amer Red Cross, Dept Biochem, Rockville, MD 20855 USA; Univ Palermo, Inst Biol, I-90133 Palermo, Italy; Univ Turin, Dept Genet Biol & Med Chem, I-10126 Turin, Italy	American Red Cross; University of Palermo; University of Turin	Belkin, AM (corresponding author), Amer Red Cross, Dept Biochem, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	belkina@usa.redcross.org	Retta, Saverio Francesco/Q-4770-2019	Retta, Saverio Francesco/0000-0001-9761-2959	NATIONAL CANCER INSTITUTE [R29CA077697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA77697] Funding Source: Medline; NIGMS NIH HHS [GM29860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BALZAC F, 1994, J CELL BIOL, V127, P557, DOI 10.1083/jcb.127.2.557; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BURRIDGE K, 1992, J CELL BIOL, V119, P793; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Clark GJ, 1996, ONCOGENE, V12, P169; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; CRESCENZI M, 1994, J CELL BIOL, V125, P1137, DOI 10.1083/jcb.125.5.1137; FORNARO M, 1995, J BIOL CHEM, V270, P24666, DOI 10.1074/jbc.270.42.24666; Fornaro M, 1997, MATRIX BIOL, V16, P185, DOI 10.1016/S0945-053X(97)90007-X; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; HOWLETT AR, 1995, J CELL SCI, V108, P1945; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; Lin TH, 1997, J BIOL CHEM, V272, P8849; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	35	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15234	15240		10.1074/jbc.273.24.15234	http://dx.doi.org/10.1074/jbc.273.24.15234			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614138	hybrid, Green Published			2022-12-25	WOS:000074160400080
J	Lu, CF; Oxvig, C; Springer, TA				Lu, CF; Oxvig, C; Springer, TA			The structure of the beta-propeller domain and C-terminal region of the integrin alpha M subunit - Dependence on beta subunit association and prediction of domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIB; INTRACHAIN DISULFIDE BONDS; I-DOMAIN; LIGAND-BINDING; MONOCLONAL-ANTIBODIES; ELECTRON-MICROSCOPY; DYNAMIC REGULATION; OVERLAP EXTENSION; CRYSTAL-STRUCTURE; MAC-1 CD11B/CD18	The alpha M subunit of integrin Mac-1 contains several distinct regions in its extracellular segment. The N-terminal region has been predicted to fold into a beta-propeller domain composed of seven beta-sheets each about 60 amino acid residues long, with the I-domain inserted between beta-sheets 2 and 3. The structure of the C-terminal region is unknown. We have used monoclonal antibodies (mAbs) as probes to study the dependence of the structure of different regions of the alpha M subunit on association with the beta 2 subunit in the alpha M/beta 2 heterodimer. All of the mAbs to the I-domain immunoprecipitated the unassociated alpha M precursor and reacted with the alpha M subunit expressed alone on the surface of COS cells. By contrast, four mAbs to the beta-propeller domain did not react with the unassociated alpha M precursor nor with the uncomplexed alpha M subunit expressed on COS cell surface. The four mAbs were mapped to three subregions in three different beta-sheets, making it unlikely that each recognized an interface between the alpha and beta subunits. These results suggest that folding of different beta-propeller subregions is coordinate and is dependent on association with the beta 2 subunit. The segment C-terminal to the beta-propeller domain, residues 599-1092, was studied with nine mAbs. A subset of four mAbs that reacted with the alpha M/beta 2 complex but not with the unassociated alpha M subunit were mapped to one subregion, residues 718-759, and five other mAbs that recognized both the unassociated and the complexed alpha M subunit were localized to three other subregions, residues 599-679, 820-882, and 943-1047. This suggests that much of the region C-terminal to the beta-propeller domain folds independently of association with the beta 2 subunit. Our data provide new insights irate how different domains in the integrin alpha and beta subunits may interact.	Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School	Springer, TA (corresponding author), Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.	springer@sprsgi.med.harvard.edu		Oxvig, Claus/0000-0002-4715-9719	NATIONAL CANCER INSTITUTE [R37CA031799, R01CA031799] Funding Source: NIH RePORTER; NCI NIH HHS [CA31799] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BILSLAND CAG, 1994, J LEUKOCYTE BIOL, V55, P501, DOI 10.1002/jlb.55.4.501; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CALVETE JJ, 1992, BIOCHEM J, V282, P523, DOI 10.1042/bj2820523; CALVETE JJ, 1989, BIOCHEM J, V261, P551, DOI 10.1042/bj2610551; CALVETE JJ, 1994, BIOCHEM J, V298, P1; CALVETE JJ, 1989, BIOCHEM J, V261, P561, DOI 10.1042/bj2610561; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; GINSBERG MH, 1995, BIOCHEM SOC T, V23, P439, DOI 10.1042/bst0230439; Gotoh O, 1996, J MOL BIOL, V264, P823, DOI 10.1006/jmbi.1996.0679; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; HO MK, 1983, J BIOL CHEM, V258, P2766; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3156, DOI 10.1073/pnas.94.7.3156; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3162, DOI 10.1073/pnas.94.7.3162; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1992, J BIOL CHEM, V267, P5649; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Lu CF, 1997, J IMMUNOL, V159, P268; MILLER LJ, 1987, J IMMUNOL, V139, P842; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; PETRUZZELLI L, 1995, J IMMUNOL, V155, P854; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rost B, 1996, METHOD ENZYMOL, V266, P525; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Uciechowski P., 1989, LEUCOCYTE TYPING, P543; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	51	58	59	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15138	15147		10.1074/jbc.273.24.15138	http://dx.doi.org/10.1074/jbc.273.24.15138			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614126	hybrid			2022-12-25	WOS:000074160400068
J	Parekh, AB				Parekh, AB			Slow feedback inhibition of calcium release-activated calcium current by calcium entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPLETION; CELLS; RECEPTOR; INACTIVATION; STORES; INFLUX	In many nonexcitable cells, depletion of the inositol 1,4,5-trisphosphate-sensitive store activates Ca(2+) influx, a process termed store-operated Ca(2+) entry. In rat basophilic leukemia cells, emptying of the stores activates a highly selective Ca(2+) release-activated Ca(2+) current (CRAC), I(CRAC). We have recently found that I(CRAC) activates in an essentially all-or-none manner when the current is evoked by receptor stimulation, dialysis with inositol 1,4,5-trisphosphate via the patch pipette, or through the Ca(2+) ATPase inhibitor thapsigargin (Parekh, A. B., Fleig, A., and Penner, R. (1997) Cell 89, 973-980), Regulatory mechanisms must therefore operate to control the overall amount of Ca(2+) that enters through CRAC channels. Such mechanisms include membrane potential and protein kinase C. In the present study, we have investigated additional inhibitory pathways that serve to determine just how much Ca(2+) can enter through I(CRAC). We have directly measured the current using the whole cell patch clamp technique. We report the presence of a slow Ca(2+)-dependent inactivation mechanism that curtails Ca(2+) entry through CRAC channels. This inactivation mechanism is switched on by Ca(2+) entering through CRAC channels, and therefore constitutes a slow negative feedback process. Although it requires a rise in intracellular Ca(2+) for activation, it maintains CRAC channels inactive even under conditions that lower intracellular Ca(2+) levels. The inactivation mechanism does not involve store refilling, protein phosphorylation, G proteins, nor Ca(2+)-dependent enzymes. It accounts for up to 70% of the total inactivation of I(CRAC), and therefore appears to be a dominant inhibitory mechanism. It is likely to be an important factor that shapes the profile of the Ca(2+) signal in these non-excitable cells.	Univ Oxford, Dept Physiol, Oxford OX1 3PT, England	University of Oxford	Parekh, AB (corresponding author), Univ Oxford, Dept Physiol, Parks Rd, Oxford OX1 3PT, England.	anant.parekh@physiol.ox.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Lewis RS, 1996, SOC GEN PHY, V51, P241; Louzao MC, 1996, J BIOL CHEM, V271, P14807, DOI 10.1074/jbc.271.25.14807; Parekh AB, 1995, J PHYSIOL-LONDON, V489, P377, DOI 10.1113/jphysiol.1995.sp021058; Parekh AB, 1996, J BIOL CHEM, V271, P23161, DOI 10.1074/jbc.271.38.23161; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	19	87	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14925	14932		10.1074/jbc.273.24.14925	http://dx.doi.org/10.1074/jbc.273.24.14925			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614097	hybrid			2022-12-25	WOS:000074160400039
J	Mio, T; Yabe, T; Arisawa, M; Yamada-Okabe, H				Mio, T; Yabe, T; Arisawa, M; Yamada-Okabe, H			The eukaryotic UDP-N-acetylglucosamine pyrophosphorylases - Gene cloning, protein expression, and catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; N-ACETYLGLUCOSAMINE-1-PHOSPHATE URIDYLTRANSFERASE; GLUCOSE PYROPHOSPHORYLASE; SACCHAROMYCES-CEREVISIAE; DNA-SEQUENCE; YEAST; ENZYME; TRANSCRIPTION; PURIFICATION; SYNTHETASE	A search of the yeast data base for a protein homologous to Escherichia coli UDP-N-acetylglucosamine pyrophosphorylase yielded UAP1 (UDP-N-acetylglucosamine pyrophosphorylase), the Saccharomyces cerevisiae gene for UDP-N-acetylglucosamine pyrophosphorylase. The Candida albicans and human homologs were also cloned by screening a C. albicans genomic library and a human testis cDNA library, respectively. Sequence analysis revealed that the human UAP1 cDNA was identical to previously reported AGX1., A null mutation of the S. cerevisiae UAP1 (ScUAP1) gene was lethal, and when expressed under the control of ScUAP1 promoter, both C. albicans and Homo sapiens UAP1 (CaUAP1 and HsUAP1) rescued the ScUAP1-deficient S., cerevisiae cells. All the recombinant ScUap1p, CaUap1p, and HsUap1p possessed UDP-N-acelylglucosamine pyrophosphorylase activities in vitro. The yeast Uap1p utilized N-acetylglucosamirne-1-phosphate as the substrate, and together with Agm1p, it produced UDP-N-acetylglucosamine from N-acetylglucosamine-6-phosphate. These results demonstrate that the UAP1 genes indeed specify eukaryotic UDP-GlcNAc pyrophosphorylase and that phosphomutase reaction precedes uridyltransfer., Sequence comparison with other UDP-sugar pyrophosphorylases revealed that amino acid residues, Gly(112) Gly(114), Thr(115), Arg(116), Pro(122), and Lys(123) of ScUap1p are highly conserved in UDP-sugar pyrophosphorylases reported to date, Among these amino acids, alanine substitution for Gly(112), Arg(116), or Lys(123) severely diminished the activity, suggesting that Gly(112), Arg(116), or Lys(123) are possible catalytic residues of the enzyme.	Nippon Roche Res Ctr, Dept Mycol, Kamakura, Kanagawa 2478530, Japan	Roche Holding	Yamada-Okabe, H (corresponding author), Nippon Roche Res Ctr, Dept Mycol, 200 Kajiwara, Kamakura, Kanagawa 2478530, Japan.	hisafumi.okabe@roche.com	Yabe, Tomio/B-5900-2013	Yabe, Tomio/0000-0002-9295-8560				BOLES E, 1994, EUR J BIOCHEM, V220, P83, DOI 10.1111/j.1432-1033.1994.tb18601.x; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; Cabib E.., 1981, ENCY PLANT PHYSL N B, V13, P395; DARAN JM, 1995, EUR J BIOCHEM, V233, P520, DOI 10.1111/j.1432-1033.1995.520_2.x; DIEKMAN AB, 1994, BIOL REPROD, V50, P1087, DOI 10.1095/biolreprod50.5.1087; DOBROGOS.WJ, 1968, J BACTERIOL, V95, P578, DOI 10.1128/JB.95.2.578-584.1968; DUTKAMALEN S, 1988, BIOCHIMIE, V70, P287, DOI 10.1016/0300-9084(88)90073-9; FloresDiaz M, 1997, J BIOL CHEM, V272, P23784, DOI 10.1074/jbc.272.38.23784; Freese EB, 1970, J BACTERIOL, V101, P1046, DOI 10.1128/JB.101.3.1046-1062.1970; GUHA SK, 1985, ARCH BIOCHEM BIOPHYS, V243, P168, DOI 10.1016/0003-9861(85)90785-4; Hashimoto H, 1997, J BIOL CHEM, V272, P16308, DOI 10.1074/jbc.272.26.16308; HASHIMOTOGOTOH T, 1995, GENE, V152, P271, DOI 10.1016/0378-1119(94)00750-M; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HOFMANN M, 1994, EUR J BIOCHEM, V221, P741, DOI 10.1111/j.1432-1033.1994.tb18787.x; HOLTJE JV, 1985, MOL CYTOLOGY ESCHERI, P77; KEPES F, 1988, J BIOL CHEM, V263, P9155; MENGINLECREULX D, 1994, J BACTERIOL, V176, P5788, DOI 10.1128/JB.176.18.5788-5795.1994; MENGINLECREULX D, 1993, J BACTERIOL, V175, P6150, DOI 10.1128/JB.175.19.6150-6157.1993; Oesterhelt C, 1997, FEBS LETT, V401, P35, DOI 10.1016/S0014-5793(96)01425-1; OH D, 1990, MOL CELL BIOL, V10, P1415, DOI 10.1128/MCB.10.4.1415; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; PENG HL, 1993, FEBS LETT, V329, P153, DOI 10.1016/0014-5793(93)80213-E; RAETZ CRH, 1987, ESCHERICHIA COLI SAL, V1, P498; RANDERATH K, 1965, ANAL BIOCHEM, V13, P575, DOI 10.1016/0003-2697(65)90356-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DJ, 1992, MOL CELL BIOL, V12, P2924, DOI 10.1128/MCB.12.7.2924; Tajima M, 1985, Yeast, V1, P67, DOI 10.1002/yea.320010108; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; WATZELE G, 1989, J BIOL CHEM, V264, P8753; WEISSBORN AC, 1994, J BACTERIOL, V176, P2611, DOI 10.1128/JB.176.9.2611-2618.1994; WHITE RJ, 1968, BIOCHEM J, V106, P847, DOI 10.1042/bj1060847; WU HC, 1971, J BACTERIOL, V105, P455, DOI 10.1128/JB.105.2.455-466.1971; YamadaOkabe T, 1996, MICROBIOL-UK, V142, P2515, DOI 10.1099/00221287-142-9-2515	34	126	135	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14392	14397		10.1074/jbc.273.23.14392	http://dx.doi.org/10.1074/jbc.273.23.14392			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603950	hybrid			2022-12-25	WOS:000074021500052
J	Needham, LK; Rozengurt, E				Needham, LK; Rozengurt, E			G alpha(12) and G alpha(13) stimulate rho-dependent tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130 Crk-associated substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; STRESS FIBER FORMATION; MUTANT ALPHA-SUBUNITS; LYSOPHOSPHATIDIC ACID; GROWTH-FACTOR; G-PROTEINS; TRANSFORMING ACTIVITY; ACTIN CYTOSKELETON; RAT-1 FIBROBLASTS; PHOSPHOLIPASE-C	We examined whether constitutively active mutants of the G alpha proteins G alpha(12) and G alpha(13), which together comprise the G(12) subfamily of G alpha proteins, induce Rho-dependent tyrosine phosphoaylation of the focal adhesion proteins p125 focal adhesion kinase, paxillin, and p130 Crk-associated substrate. We report that transient expression of the constitutively active mutants of G alpha(12) Or of G alpha(13) in human embryonic kidney 293 cells stimulates tyrosine phosphorylation of a set of proteins of M-r of 110,000-130,000, 97,000, and 60,000-70,000. We identified p125 focal adhesion kinase, paxillin, and p130 Crk-associated substrate as prominent tyrosine-phosphorylated proteins in human embryonic kidney 293 cells expressing constitutively active G alpha(12) and G alpha(13). In common with the increased tyrosine phosphorylation of these proteins mediated by mitogens acting through heptahelical receptors, the G alpha(12)- and G alpha(13)-mediated increase in tyrosine phosphorylation is blocked by cytochalasin D, which specifically disrupts the actin cytoskeleton, and by the Clostridium botulinum C3 exoenzyme, which ADP-ribosylates and inactivates Rho. Our results support the hypothesis that G alpha(12) and G alpha(13) activate Rho and suggest that G alpha(12) and G alpha(13) may mediate the tyrosine phosphorylation of p125 focal adhesion kinase, paxillin, and p130 Crk-associated substrate.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 900 Vet Ave,Warren Hall Room 11-124, Los Angeles, CA 90095 USA.							Aktories K, 1997, J CLIN INVEST, V99, P827, DOI 10.1172/JCI119245; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Charlesworth A, 1996, ONCOGENE, V12, P1337; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Flinn HM, 1996, J CELL SCI, V109, P1133; FOHLA A, 1998, J BIOL CHEM, V273, P4653; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HAYCOCK JW, 1993, ANAL BIOCHEM, V208, P397, DOI 10.1006/abio.1993.1068; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Ilic D, 1997, J CELL SCI, V110, P401; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; KUMAGAI N, 1993, J BIOL CHEM, V268, P24536; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LACH EB, 1995, CELL GROWTH DIFFER, V6, P1427; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZENGURT E, 1995, CANCER SURV, V24, P81; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1994, J CELL SCI, V107, P1583; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WILSON SP, 1995, ANAL BIOCHEM, V226, P212, DOI 10.1006/abio.1995.1216; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU DQ, 1992, J BIOL CHEM, V267, P1811; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; YULE DI, 1992, J BIOL CHEM, V267, P13830; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	76	100	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14626	14632		10.1074/jbc.273.23.14626	http://dx.doi.org/10.1074/jbc.273.23.14626			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603980	hybrid			2022-12-25	WOS:000074021500082
J	Anderson, DH; Ismail, PM				Anderson, DH; Ismail, PM			V-fps causes transformation by inducing tyrosine phosphorylation and activation of the PDGF beta receptor	ONCOGENE			English	Article						Fps/Fes; PDGF beta receptor; down-regulation; tyrosine phosphorylation	GROWTH-FACTOR RECEPTORS; COLONY-STIMULATING FACTOR; FUJINAMI SARCOMA-VIRUS; C-FES PROTEIN; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; TRANSGENIC MICE; KINASE FUNCTION; SRC ONCOGENE; FACTOR-I	The v-fps oncogene encodes an activated tyrosine kinase which is capable of transforming fibroblasts. In this report, we provide evidence that within a few minutes of activation of the tyrosine kinase activity of v-Fps, tyrosine phosphorylation of the platelet derived growth factor (PDGF) beta receptor is observed. Further, sustained expression of activated v-Fps results in a downregulation of the PDGF receptor both at the level of the mRNA (similar to 4-8-fold), but even more markedly at the level of the receptor protein (>100-fold). The kinase activity of the v-Fps oncoprotein was found to be required for both the induction of PDGF receptor tyrosine phosphorylation and ultimately the reduced receptor protein levels. Tyrosine phosphorylation of a kinase inactive PDGF receptor was also demonstrated in cells which also express v-fps, but this was not sufficient to induce transformation. Only cells expressing both v-fps and a wild type PDGF receptor were able to form colonies in soft agar. These findings suggest that wild type v-fps may use tyrosine phosphorylation of the PDGF beta receptor to constitutively activate the kinase activity of the receptor, resulting in a sustained proliferative signal and fibroblast transformation.	Saskatoon Canc Ctr, Res Unit, Saskatoon, SK S7N 4H4, Canada	University of Saskatchewan	Anderson, DH (corresponding author), Saskatoon Canc Ctr, Res Unit, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.							BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; CARE A, 1994, ONCOGENE, V9, P739; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FOSTER DA, 1985, CELL, V42, P105, DOI 10.1016/S0092-8674(85)80106-9; FUKUI Y, 1991, ONCOGENE, V6, P407; GARRETT JS, 1984, P NATL ACAD SCI-BIOL, V81, P7466, DOI 10.1073/pnas.81.23.7466; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; Hawking F, 1978, Adv Pharmacol Chemother, V15, P289, DOI 10.1016/S1054-3589(08)60486-X; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; HUANG SS, 1988, J BIOL CHEM, V263, P12608; INGMANBAKER J, 1984, J VIROL, V50, P572, DOI 10.1128/JVI.50.2.572-578.1984; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LANFRANCONE L, 1989, INT J CANCER, P35; LETWIN K, 1988, ONCOGENE, V3, P621; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MARU Y, 1995, MOL CELL BIOL, V15, P835; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MORAN MF, 1988, ONCOGENE, V3, P665; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; PANTAZIS P, 1990, EUR J HAEMATOL, V45, P127; PANTAZIS P, 1991, P NATL ACAD SCI USA, V88, P2481, DOI 10.1073/pnas.88.6.2481; PARK WY, 1995, BIOCHEM BIOPH RES CO, V211, P447, DOI 10.1006/bbrc.1995.1834; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAKE JB, 1991, J BIOL CHEM, V266, P5348; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; SODROSKI JG, 1984, P NATL ACAD SCI-BIOL, V81, P3039, DOI 10.1073/pnas.81.10.3039; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TZENG DY, 1985, BLOOD, V66, P179; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; YAN XQ, 1993, J IMMUNOL, V150, P2440; YAN XQ, 1994, ONCOGENE, V9, P163; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	64	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	1998	16	18					2321	2331		10.1038/sj.onc.1201780	http://dx.doi.org/10.1038/sj.onc.1201780			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620549				2022-12-25	WOS:000073428000004
J	Hrycyna, CA; Ramachandra, M; Ambudkar, SV; Ko, YH; Pedersen, PL; Pastan, I; Gottesman, MM				Hrycyna, CA; Ramachandra, M; Ambudkar, SV; Ko, YH; Pedersen, PL; Pastan, I; Gottesman, MM			Mechanism of action of human P-glycoprotein ATPase activity - Photochemical cleavage during a catalytic transition state using orthovanadate reveals cross-talk between the two ATP sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING SITES; MULTIDRUG TRANSPORTER; VANADATE; MYOSIN; RESISTANCE; PHOTOCLEAVAGE; ANTIBODIES; PROTEINS; CELLS; MUTANTS	Human P-glycoprotein (P-gp), an ATP-dependent efflux pump responsible for cross-resistance of human cancers to a variety of lipophilic compounds, is composed of two homologous halves, each containing six transmembrane domains and an ATP-binding/utilization domain. To determine whether each site can hydrolyze ATP simultaneously, we used an orthovanadate (Vi)-induced ADP-trapping technique (P-gp.MgADP.Vi). In analogy with other ATPases, a photochemical peptide bond cleavage reaction occurs within the Walker A nucleotide binding domain consensus sequence (GX(4)GK(T/S)) when the molecule is trapped with Vi in an inhibited catalytic transition state (P-gp.MgADP.Vi) and incubated in the presence of ultraviolet light. Upon reconstitution into proteoliposomes, histidine-tagged purified P-gp from baculovirus-infected insect cells had drug-stimulated ATPase activity. Reconstituted P-gp was incubated with either ATP or 8-azido-ATP in the presence or absence of Vi under ultraviolet (365 nm) light on ice for 60 min. The resultant products were separated by SDS-polyacrylamide gel electrophoresis and subjected to immunoblotting with seven different human P-gp-specific antibodies covering the entire length of the molecule. Little to no degradation of P-gp was observed in the absence of Vi. In the presence of Vi, products of approximately 28, 47, 94, and 110 kDa were obtained, consistent with predicted molecular weights from cleavage at either of the ATP sites but not both sites, An additional Vi-dependent cleavage site was detected at or near the trypsin site in the linker region of P-gp. These results suggest that both the amino-and carboxyl-terminal ATP sites can hydrolyze ATP. However, there is no evidence that ATE can be hydrolyzed simultaneously by both sites.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Mol Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Gottesman, MM (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 1A-09,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	mgottesman@nih.gov	Ambudkar, Suresh V/B-5964-2008; Ambudkar, Suresh V/L-1317-2016; pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270; Ramachandra, Murali/0000-0003-4039-1491				AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BRUGGEMANN EP, 1991, BIOTECHNIQUES, V10, P202; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; CREMO CR, 1989, J BIOL CHEM, V264, P6608; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P7982, DOI 10.1021/bi00486a029; CREMO CR, 1992, BIOCHEMISTRY-US, V31, P491, DOI 10.1021/bi00117a027; CREMO CR, 1991, METHOD ENZYMOL, V196, P442; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GIBBONS IR, 1991, METHOD ENZYMOL, V196, P428; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Grammer JC, 1996, BIOCHEMISTRY-US, V35, P15582, DOI 10.1021/bi961901g; Ko YH, 1997, J BIOL CHEM, V272, P18875, DOI 10.1074/jbc.272.30.18875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; Muller M, 1996, J BIOL CHEM, V271, P1877; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	28	108	109	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16631	16634		10.1074/jbc.273.27.16631	http://dx.doi.org/10.1074/jbc.273.27.16631			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642211	hybrid			2022-12-25	WOS:000074545200001
J	Rawal, N; Pangburn, MK				Rawal, N; Pangburn, MK			C5 convertase of the alternative pathway of complement - Kinetic analysis of the free and surface-bound forms of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C3-C5 CONVERTASE; 3RD COMPONENT; FLUID PHASE; CLASSICAL PATHWAY; SERINE PROTEASES; HUMAN C3; ACTIVATION; SYSTEM; BINDING; C4B	Although proteolytic activation of the complement protein C5 initiates important defensive and occasionally pathological inflammatory reactions, the enzymatic properties of the enzymes responsible for this cleavage have never been examined. We have studied the kinetic parameters of the C5 convertase of the alternative pathway of complement, either bound to a zymosan surface or in its monomeric soluble form. C5 convertase enzymatic activity was measured as a function of C5 concentration by quantitating production of C5b,6 under physiological conditions of temperature, pH, and ionic strength. The C5 convertases appeared to follow Michaelis-Menten kinetics and exhibited similar catalytic rate constants (k(cat)). However, the surface-bound enzyme, ZymC3b,Bb had a K-m (1.4 mu M) that was 17 times lower than that of the soluble monomeric form of the enzyme, C3b,Bb (K-m = 24 mu M). The k(cat) for the cell-bound enzyme, ZymC3b,Bb was 0.0048 s(-1) and that for soluble C3b,Bb was 0.0110 s(-1). Both forms of the enzyme had a low turnover number at V-max (0.23 to 0.68 C5/min/enzyme). Substituting Mg2+ for Ni2+ did not alter the kinetic parameters but lowered the half-life of the enzyme by 5-7-fold. The kinetic data presented demonstrate that the fluid phase C5 convertase, C3b,Bb, can cleave C5 without the aid of a second C3b molecule. The results also show that the greater enzymatic activity previously observed for the surface-bound C5 convertases is not due to higher catalytic efficiency but is solely due to higher affinity for the substrate C5. In blood, C5 concentrations are 3-4-fold below the K-m determined for the surface-bound C5 convertase suggesting a direct correlation between the local C5 concentration and production of the anaphylatoxin C5a and the cytolytic C5b-9 complex.	Univ Texas, Hlth Sci Ctr, Dept Biochem, Tyler, TX 75710 USA	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Pangburn, MK (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, Tyler, TX 75710 USA.				NIDDK NIH HHS [DK-35081] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035081, R01DK035081] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbas CF, 1997, SCIENCE, V278, P2085, DOI 10.1126/science.278.5346.2085; BHAKDI S, 1988, J IMMUNOL, V141, P3117; Byrne G, 1997, TRANSPLANTATION, V63, P149, DOI 10.1097/00007890-199701150-00027; CHRISTOPHERSON RI, 1983, METHOD ENZYMOL, V91, P278; DAHA MR, 1976, J IMMUNOL, V117, P630; DALMASSO AP, 1998, COMPLEMENT SYSTEM, P471; DESSAUER A, 1984, ACTA PATH MICRO IM C, V92, P75; DISCIPIO RG, 1981, BIOCHEM J, V199, P485, DOI 10.1042/bj1990485; DISCIPIO RG, 1983, J BIOL CHEM, V258, P629; DISCIPIO RG, 1981, BIOCHEM J, V199, P497, DOI 10.1042/bj1990497; FEARON DT, 1977, P NATL ACAD SCI USA, V74, P1683, DOI 10.1073/pnas.74.4.1683; GLOVER GI, 1988, MOL IMMUNOL, V25, P1261, DOI 10.1016/0161-5890(88)90040-5; GOTZE O, 1974, J EXP MED, V139, P44, DOI 10.1084/jem.139.1.44; GOTZE O, 1971, J EXP MED          2, V134, P90; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; HETLAND G, 1986, SCAND J IMMUNOL, V24, P603, DOI 10.1111/j.1365-3083.1986.tb02176.x; Higgins PJ, 1997, J IMMUNOL, V158, P2872; HOMEISTER JW, 1994, ANNU REV PHARMACOL, V34, P17, DOI 10.1146/annurev.pa.34.040194.000313; HONG KS, 1991, J IMMUNOL, V146, P1868; ISENMAN DE, 1980, J IMMUNOL, V124, P326; ISSEKUTZ AC, 1990, INT J IMMUNOPHARMACO, V12, P1, DOI 10.1016/0192-0561(90)90062-R; KAM CM, 1992, J IMMUNOL, V149, P163; KIM YU, 1992, J BIOL CHEM, V267, P4171; KINOSHITA T, 1988, J IMMUNOL, V141, P3895; KITAMURA H, 1986, IMMUNOLOGY, V58, P459; KOZONO H, 1990, J BIOL CHEM, V265, P14444; LESAVRE PH, 1979, J IMMUNOL, V123, P529; MASAKI T, 1991, J IMMUNOL, V147, P927; MATIS LA, 1995, NAT MED, V1, P839, DOI 10.1038/nm0895-839; MEDICUS RG, 1976, P NATL ACAD SCI USA, V73, P612, DOI 10.1073/pnas.73.2.612; MEDICUS RG, 1976, J EXP MED, V144, P1076, DOI 10.1084/jem.144.4.1076; MOORE FD, 1994, ADV IMMUNOL, V56, P267, DOI 10.1016/S0065-2776(08)60454-X; PANGBURN MK, 1980, J EXP MED, V152, P1102, DOI 10.1084/jem.152.4.1102; PANGBURN MK, 1987, J IMMUNOL METHODS, V102, P7, DOI 10.1016/S0022-1759(87)80003-0; PANGBURN MK, 1986, BIOCHEM J, V235, P723, DOI 10.1042/bj2350723; PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416; ROTHER K, 1998, COMPLEMENT SYSTEM, P462; ROTHMAN BL, 1994, IMMUNOPHARM IMMUNOT, V16, P525, DOI 10.3109/08923979409019738; SAHU A, 1994, BIOCHEM J, V302, P429, DOI 10.1042/bj3020429; Sahu A, 1996, J IMMUNOL, V157, P884; Sahu A, 1996, BIOCHEM PHARMACOL, V51, P797, DOI 10.1016/0006-2952(95)02398-4; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; TAKATA Y, 1987, J EXP MED, V165, P1494, DOI 10.1084/jem.165.6.1494; VANDENBERG CW, 1990, J IMMUNOL METHODS, V133, P199, DOI 10.1016/0022-1759(90)90360-8; VOGEL CW, 1981, P NATL ACAD SCI-BIOL, V78, P7707, DOI 10.1073/pnas.78.12.7707; VOGT W, 1978, IMMUNOLOGY, V34, P29; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562	48	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16828	16835		10.1074/jbc.273.27.16828	http://dx.doi.org/10.1074/jbc.273.27.16828			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642242	hybrid			2022-12-25	WOS:000074545200032
J	Wang, WY; Gorrell, A; Hou, ZL; Honzatko, RB; Fromm, HJ				Wang, WY; Gorrell, A; Hou, ZL; Honzatko, RB; Fromm, HJ			Ambiguities in mapping the active site of a conformationally dynamic enzyme by directed mutation - Role of dynamics in structure-function correlations in Escherichia coli adenylosuccinate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURES; MOLECULAR-CLONING; SEQUENCE; BINDING; PURA; GENE	On the basis of ligated crystal structures, Asn(21), Asn(38), Thr(42), and Arg(419) are not involved in the chemical mechanism of adenylosuccinate synthetase from Escherichia coli, yet these residues are well conserved across species. Purified mutants (Asp(21) --> Ala, Asn(38) --> Ala, Asn(38) --> Asp, Asn(38) --> Glu, Thr(42) --> Ala, and Arg(419) --> Leu) were studied by kinetics, circular dichroism spectroscopy, and equilibrium ultracentrifugation. Asp(21) and Ar-419 are not part of the active site, yet mutations at positions 21 and 419 lower k(cat) 20- and 10-fold, respectively. Thr(42) interacts only through its backbone amide with the guanine nucleotide, yet its mutation to alanine significantly increases K-m for all substrates. Asn(38) hydrogen-bonds directly to the 5'-phosphoryl group of IMP, yet its mutation to alanine and glutamate has no effect on K-m values, but reduces k(cat) by 100-fold. The mutation Asn(38) --> Asp causes 10-57-fold increases in K-m for all substrates along with a 30-fold decrease in k(cat). At pH 5.6, however, the Asn(38) --> Asp mutant is more active, yet binds IMP 100-fold more weakly, than the wild-type enzyme. Proposed mechanisms of ligand-induced conformational change and subunit aggregation can account for the properties of mutant enzymes reported here. The results underscore the difficulty of using directed mutations alone as a means of mapping the active site of an enzyme.	Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA	Iowa State University	Fromm, HJ (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA.	hjfromm@iastate.edu			NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS010546, R01NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P355; Bouyoub A, 1996, J MOL BIOL, V261, P144, DOI 10.1006/jmbi.1996.0448; Boyer, 1970, ENZYMES, P341, DOI DOI 10.1016/S1874-6047(08)60170-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FROMM HJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P255, DOI 10.1016/0006-3002(58)90182-3; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; Kang C, 1996, J BIOL CHEM, V271, P29722, DOI 10.1074/jbc.271.47.29722; KANG CH, 1994, ARCH BIOCHEM BIOPHYS, V310, P475, DOI 10.1006/abbi.1994.1195; Kang CH, 1997, J BIOL CHEM, V272, P11881, DOI 10.1074/jbc.272.18.11881; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; MANTSALA P, 1992, J BACTERIOL, V174, P1883; MCRORIE DD, 1993, SELFASSOCIATING SYST, P8; Poland BW, 1996, J MOL BIOL, V264, P1013, DOI 10.1006/jmbi.1996.0693; POLAND BW, 1993, J BIOL CHEM, V268, P25334; Poland BW, 1996, J BIOL CHEM, V271, P15407, DOI 10.1074/jbc.271.26.15407; Poland BW, 1997, J BIOL CHEM, V272, P15200, DOI 10.1074/jbc.272.24.15200; Poland BW, 1996, BIOCHEMISTRY-US, V35, P15753, DOI 10.1021/bi961758r; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHABES AV, 1993, J BIOL CHEM, V268, P20191; SILVA MM, 1995, J MOL BIOL, V254, P431, DOI 10.1006/jmbi.1995.0629; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; Wang WY, 1997, J BIOL CHEM, V272, P7078, DOI 10.1074/jbc.272.11.7078; Wang WY, 1997, J BIOL CHEM, V272, P16911, DOI 10.1074/jbc.272.27.16911; WIESMULLER L, 1991, J BIOL CHEM, V266, P2480; WOLFE SA, 1988, J BIOL CHEM, V263, P19147	29	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16000	16004		10.1074/jbc.273.26.16000	http://dx.doi.org/10.1074/jbc.273.26.16000			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632649	hybrid			2022-12-25	WOS:000074436600020
J	Duncan, JA; Gilman, AG				Duncan, JA; Gilman, AG			A cytoplasmic acyl-protein thioesterase that removes palmitate from G protein alpha subunits and p21(RAS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; NITRIC-OXIDE SYNTHASE; MOLECULAR-CLONING; PLASMA-MEMBRANE; COENZYME-A; H-RAS; PALMITOYLATION; ACTIVATION; RECEPTOR; PURIFICATION	Thioacylation is one of a handful of reversible covalent protein modifications, but the enzymes responsible for addition and removal of long chain fatty acids from protein cysteine residues in vivo have not yet been identified. The alpha subunits of some heterotrimeric G proteins cycle between thioacylated and deacylated states in a receptor-regulated fashion. We have identified, purified, and characterized an enzyme acyl-protein thioesterase that deacylates G alpha proteins and at least some other thioacyl protein substrates, including Ha-RAS. The action of this enzyme oil thioacylated heterotrimeric G(s) is regulated by activation of the G protein. Although native and recombinant acyl-protein thioesterases act as both acyl-protein thioesterases and lysophospholipases in vitro, we demonstrate by transfection that the enzyme can accelerate the turnover of thioacyl groups on G(s)alpha in vivo.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Duncan, JA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062, R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34497, GM07062] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; Broustas CG, 1996, J BIOL CHEM, V271, P10470, DOI 10.1074/jbc.271.18.10470; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gauen LKT, 1996, J CELL BIOL, V133, P1007, DOI 10.1083/jcb.133.5.1007; GRASSIE MA, 1994, BIOCHEM J, V302, P913, DOI 10.1042/bj3020913; Hayashi MK, 1997, ARCH BIOCHEM BIOPHYS, V340, P376, DOI 10.1006/abbi.1997.9906; Hellsten E, 1996, EMBO J, V15, P5240, DOI 10.1002/j.1460-2075.1996.tb00909.x; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HRYCYNA CA, 1993, PHARMACOL THERAPEUT, V59, P281, DOI 10.1016/0163-7258(93)90071-K; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; Jones TLZ, 1997, BIOCHEMISTRY-US, V36, P7185, DOI 10.1021/bi9628376; Laposata M, 1996, LIPIDS, V31, pS217, DOI 10.1007/BF02637079; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEE KS, 1994, J BIOL CHEM, V269, P19725; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; Liu L, 1996, J BIOL CHEM, V271, P23269, DOI 10.1074/jbc.271.38.23269; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; Loudon RP, 1997, J BIOL CHEM, V272, P27422, DOI 10.1074/jbc.272.43.27422; Lu JY, 1996, P NATL ACAD SCI USA, V93, P10046, DOI 10.1073/pnas.93.19.10046; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MOLLNER S, 1995, FEBS LETT, V371, P241, DOI 10.1016/0014-5793(95)00864-6; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; PATTERSON SI, 1995, METHOD ENZYMOL, V250, P284; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schriner JE, 1996, GENOMICS, V34, P317, DOI 10.1006/geno.1996.0292; Song JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/bi961846b; Sugimoto H, 1996, J BIOL CHEM, V271, P7705, DOI 10.1074/jbc.271.13.7705; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Verkruyse LA, 1996, J BIOL CHEM, V271, P15831, DOI 10.1074/jbc.271.26.15831; Wang AJ, 1997, J BIOL CHEM, V272, P12723, DOI 10.1074/jbc.272.19.12723; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	45	300	305	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15830	15837		10.1074/jbc.273.25.15830	http://dx.doi.org/10.1074/jbc.273.25.15830			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624183	hybrid			2022-12-25	WOS:000074284200077
J	Hunziker, W; Peters, PJ				Hunziker, W; Peters, PJ			Rab17 localizes to recycling endosomes and regulates receptor-mediated transcytosis in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; BASOLATERAL ENDOCYTIC PATHWAYS; POLARIZED CACO-2 CELLS; MDCK CELLS; PLASMA-MEMBRANE; APICAL ENDOSOME; G-PROTEIN; WILD-TYPE; TRANSPORT	The small GTPase Rab17 is restricted to epithelial cells and its expression is induced during cell polarization. This observation has led to the suggestion that the protein may function in transcytosis, a pathway connecting the apical and basolateral endocytic systems. To analyze whether Rab17 plays a Pole in transcellular transport, we generated Madin-Darby canine kidney (MDCK) cell lines stably coexpressing wild-type or mutant Rab17 and the transcytotic polymeric immunoglobulin receptor (pIgR), Rab17 expressed in MDCK cells was found on small vesicles and tubules in the apical region of the cells. A significant fraction of the Rab17-positive structures was accessible to dimeric IgA internalized from the apical or basolateral cell surface via the pIgR. Furthermore, basolateral to apical transcytosis of dimeric IgA was impaired in MDCK cells overexpressing Rab17. Our data provides morphological and biochemical evidence for a role of Rab17 in the regulation of transcellular traffic through apical recycling endosomes in epithelial cells.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Univ Utrecht, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands	University of Lausanne; Utrecht University	Hunziker, W (corresponding author), Univ Lausanne, Inst Biochem, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.	Walter.Hunziker@ib.unil.ch	Hunziker, Walter/B-3140-2010; Hunziker, Walter/GSM-8190-2022	Hunziker, Walter/0000-0002-5265-4933; 				APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BRE MH, 1987, J CELL BIOL, V105, P1283, DOI 10.1083/jcb.105.3.1283; DEHOOP M, 1995, J CELL BIOL, V130, P1447, DOI 10.1083/jcb.130.6.1447; EOLZ RW, 1994, J BIOL CHEM, V269, P10229; FUJITA M, 1990, J CELL SCI, V97, P385; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HUBBARD AL, 1989, ANNU REV PHYSIOL, V51, P755, DOI 10.1146/annurev.physiol.51.1.755; HUGHSON EJ, 1990, J CELL BIOL, V110, P337, DOI 10.1083/jcb.110.2.337; HUNZIKER W, 1994, J BIOL CHEM, V269, P29003; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; Hunziker W, 1998, J MAMMARY GLAND BIOL, V3, P287, DOI 10.1023/A:1018715511178; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; Jin MJ, 1996, J BIOL CHEM, V271, P30105, DOI 10.1074/jbc.271.47.30105; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; KNIGHT A, 1995, MOL BIOL CELL, V6, P597, DOI 10.1091/mbc.6.5.597; LUTCKE A, 1993, J CELL BIOL, V121, P553, DOI 10.1083/jcb.121.3.553; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; YAMASHIRO DJ, 1983, J CELL BIOL, V97, P929, DOI 10.1083/jcb.97.3.929; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2713, DOI 10.1083/jcb.105.6.2713; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	42	79	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15734	15741		10.1074/jbc.273.25.15734	http://dx.doi.org/10.1074/jbc.273.25.15734			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624171	hybrid			2022-12-25	WOS:000074284200065
J	Kocken, CHM; van der Wel, AM; Dubbeld, MA; Narum, DL; van de Rijke, FM; van Gemert, GJ; van der Linde, X; Bannister, LH; Janse, C; Waters, AP; Thomas, AW				Kocken, CHM; van der Wel, AM; Dubbeld, MA; Narum, DL; van de Rijke, FM; van Gemert, GJ; van der Linde, X; Bannister, LH; Janse, C; Waters, AP; Thomas, AW			Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL MEMBRANE ANTIGEN; STABLE TRANSFECTION; MEROZOITE ANTIGEN; FULL-LENGTH; KNOWLESI; MALARIA; PF83/AMA-1; PARASITES	The development of transfection technology for malaria parasites holds significant promise for a more detailed characterization of molecules targeted by vaccines or drugs. One asexual blood stage vaccine candidate, apical membrane antigen-1 (AMA-1) of merozoite rhoptries has been shown to be the target of inhibitory, protective antibodies in both in vitro and in vivo studies. We have investigated heterologous (trans-species) expression of the human malaria Plasmodium falciparum AMA-1 (PF83/AMA-1) in the rodent parasite Plasmodium berghei, Transfected P. berghei expressed correctly folded and processed PF83/AMA-1 under control of both pb66/ama-1 and dhfr-ts promoters. Timing of expression was highly promoter-dependent and was critical for subsequent subcellular localization. Under control of pb66/ama-1, PF83/AMA-1 expression and localization in P. berghei was limited to the rhoptries of mature schizonts, similar to that observed for PF83/AMA-1 in P. falciparum. In contrast the dhfr-ts promoter permitted PF83/AMA-1 expression throughout schizogony as well as in gametocytes and gametes, Localization was aberrant and included direct expression at the merozoite and gamete surface, Processing from the full-length 83-kDa protein to a 66-kDa protein was observed not only in schizonts but also in gametocytes, indicating that processing could be mediated outside of rhoptries by a common protease, Trans-species expressed PF83/AMA-1 was highly immunogenic in mice, resulting in a response against a functionally critical domain of the molecule.	Biomed Primate Res Ctr, Dept Parasitol, NL-2280 GJ Rijswijk, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, Lab Cytochem & Cytometry, NL-2333 AL Leiden, Netherlands; Univ Nijmegen, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands; Guys Hosp, Sch Med, Dept Anat, London SE1 9RT, England; Leiden Univ, Dept Parasitol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Radboud University Nijmegen; Guy's & St Thomas' NHS Foundation Trust; Leiden University; Leiden University - Excl LUMC	Thomas, AW (corresponding author), Biomed Primate Res Ctr, Dept Parasitol, Lange Kleiweg 157, NL-2280 GJ Rijswijk, Netherlands.	thomas@bprc.nl	Waters, Andy P/C-9377-2009	Waters, Andy P/0000-0001-8900-2982; Narum, David/0000-0003-3041-5402; Janse, Chris J/0000-0002-6410-6205; Voorberg - van der Wel, Annemarie/0000-0001-9403-0515; Kocken, Clemens/0000-0002-4784-1734	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bannister L H, 1993, Methods Mol Biol, V21, P415; COLLINS WE, 1994, AM J TROP MED HYG, V51, P711, DOI 10.4269/ajtmh.1994.51.711; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; Crabb BS, 1997, CELL, V89, P287, DOI 10.1016/S0092-8674(00)80207-X; Crewther PE, 1996, INFECT IMMUN, V64, P3310, DOI 10.1128/IAI.64.8.3310-3317.1996; DEANS JA, 1988, PARASITE IMMUNOL, V10, P535, DOI 10.1111/j.1365-3024.1988.tb00241.x; DEANS JA, 1987, MOL BIOCHEM PARASIT, V26, P155, DOI 10.1016/0166-6851(87)90139-3; ELING W, 1977, TROPENMED PARASITOL, V28, P158; HARLOW E, 1988, ANTIBODIES LAB MANUA, P321; Hodder AN, 1996, J BIOL CHEM, V271, P29446, DOI 10.1074/jbc.271.46.29446; Horrocks P, 1996, MOL BIOCHEM PARASIT, V82, P207, DOI 10.1016/0166-6851(96)02737-5; HYMAN BC, 1979, J PARASITOL, V65, P421, DOI 10.2307/3280288; JAIKARIA NS, 1993, MOL BIOCHEM PARASIT, V57, P269, DOI 10.1016/0166-6851(93)90203-A; JANSE CJ, 1995, PARASITOL TODAY, V11, P138, DOI 10.1016/0169-4758(95)80133-2; LANZER M, 1993, EXP PARASITOL, V77, P121, DOI 10.1006/expr.1993.1068; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; MONS B, 1985, ANN SOC BELG MED TR, V65, P1; NARUM DL, 1993, J CHROMATOGR A, V657, P357, DOI 10.1016/0021-9673(93)80291-F; NARUM DL, 1994, MOL BIOCHEM PARASIT, V67, P59, DOI 10.1016/0166-6851(94)90096-5; Sambrook J., 2002, MOL CLONING LAB MANU; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; THOMAS AW, 1990, PARASITE IMMUNOL, V12, P105, DOI 10.1111/j.1365-3024.1990.tb00940.x; THOMAS AW, 1994, AM J TROP MED HYG, V51, P730, DOI 10.4269/ajtmh.1994.51.730; THOMAS AW, 1990, MOL BIOCHEM PARASIT, V42, P285, DOI 10.1016/0166-6851(90)90172-I; THOMAS AW, 1984, MOL BIOCHEM PARASIT, V13, P187, DOI 10.1016/0166-6851(84)90112-9; TOMAS AM, 1998, IN PRESS PARASITOL T; vanderWel AM, 1997, J EXP MED, V185, P1499, DOI 10.1084/jem.185.8.1499; VANDIJK MR, 1995, SCIENCE, V268, P1358, DOI 10.1126/science.7761856; vanDijk MR, 1997, MOL BIOCHEM PARASIT, V86, P155, DOI 10.1016/S0166-6851(97)02843-0; vanDijk MR, 1996, SCIENCE, V271, P662, DOI 10.1126/science.271.5249.662; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973	31	138	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15119	15124		10.1074/jbc.273.24.15119	http://dx.doi.org/10.1074/jbc.273.24.15119			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614123	hybrid			2022-12-25	WOS:000074160400065
J	Kometiani, P; Li, J; Gnudi, L; Kahn, BB; Askari, A; Xie, ZJ				Kometiani, P; Li, J; Gnudi, L; Kahn, BB; Askari, A; Xie, ZJ			Multiple signal transduction pathways link Na+/K+-ATPase to growth-related genes in cardiac myocytes - The roles of Ras and mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE CELL HYPERTROPHY; ANGIOTENSIN-II; VENTRICULAR MYOCYTES; DEPENDENT PATHWAYS; TYROSINE KINASE; IN-VITRO; POTENTIAL ROLE; S6 KINASE; EXPRESSION; CASCADE	We showed before that in neonatal rat cardiac myocytes partial inhibition of Na+/K+-ATPase by nontoxic concentrations of ouabain causes hypertrophic growth and transcriptional regulations of genes that are markers of cardiac hypertrophy, In view of the suggested roles of Ras and p42/44 mitogen-activated protein kinases (MAPKs) as key mediators of cardiac hypertrophy, the aim of this work was to explore their roles in ouabain-initiated signal pathways regulating four growth-related genes of these myocytes, i.e. these for c-Fos, skeletal alpha-actin, atrial natriuretic factor, and the alpha(3)-subunit of Na+/K+-ATPase, Ouabain caused rapid activations of Ras and p42/44 MAPKs; the latter was sustained longer than 90 min. Using high efficiency adenoviral-mediated expression of a dominant-negative Ras mutant, and a specific inhibitor of MAPK kinase (MEK), activation of Ras-Raf-MEK-p42/44 MAPK cascade by ouabain was shown. The effects of the mutant Ras, an inhibitor of Ras farnesylation, and the MEK inhibitor on ouabain-in duced changes in mRNAs of the four genes indicated that (a) skeletal alpha-actin induction was dependent on Rat; but not on p42/44 MAPKs, (b) alpha(3) repression was depend ent on the Ras-p42/44 MAPK cascade, and (c) induction of c-fos or atrial natriuretic factor gene occurred partly through the Ras-p42/44 MAPK cascade, and partly through pathways independent of Ras and p42/44 MAPKs, All ouabain effects required extracellular Ca2+ and were attenuated by a Ca2+/calmodulin antagonist or a protein kinase C inhibitor. The findings show that (a) signal pathways linked to sarcolemmal Na+/K+-ATPase share early segments involving Ca2+ and protein kinase C, but diverge into multiple branches only some of which involve Pas, or p42/44 MAPKs, or both; and (b) there are significant differences between this network and the related gene regulatory pathways activated by other hypertrophic stimuli, including those whose responses involve increases in intracellular free Ca2+ through different mechanisms.	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Xie, ZJ (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.	xie@opus.mco.edu		gnudi, luigi/0000-0002-6353-630X	NHLBI NIH HHS [HL-36573] Funding Source: Medline; NIDDK NIH HHS [R01 DK043051] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043051] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdellatif M, 1997, J BIOL CHEM, V272, P525; ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Askari FK, 1997, FEBS LETT, V405, P5, DOI 10.1016/S0014-5793(97)00087-2; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; Boluyt MO, 1997, CIRC RES, V81, P176, DOI 10.1161/01.RES.81.2.176; CALDERONE A, 1995, CIRCULATION, V92, P2385, DOI 10.1161/01.CIR.92.9.2385; Colucci WS., 1997, HEART DIS TXB CARDIO, P394; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; EISNER DA, 1992, HEART CARDIOVASCULAR, V1, P863; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; GOTOH H, 1993, BIOCHEM BIOPH RES CO, V194, P72, DOI 10.1006/bbrc.1993.1786; Hefti MA, 1997, J MOL CELL CARDIOL, V29, P2873, DOI 10.1006/jmcc.1997.0523; Huang LY, 1997, J MOL CELL CARDIOL, V29, P429, DOI 10.1006/jmcc.1996.0320; Huang LY, 1997, J MOL CELL CARDIOL, V29, P3157, DOI 10.1006/jmcc.1997.0546; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KELLY RA, 1993, J AM COLL CARDIOL, V22, pA107, DOI 10.1016/0735-1097(93)90472-D; KIM D, 1987, CIRC RES, V60, P185, DOI 10.1161/01.RES.60.2.185; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; Liang PQ, 1997, J BIOL CHEM, V272, P28050, DOI 10.1074/jbc.272.44.28050; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; Mestril R, 1996, J MOL CELL CARDIOL, V28, P2351, DOI 10.1006/jmcc.1996.0228; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Perry G, 1997, NEW ENGL J MED, V336, P525; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; Takano H, 1996, FEBS LETT, V379, P255, DOI 10.1016/0014-5793(95)01523-X; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	57	262	267	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15249	15256		10.1074/jbc.273.24.15249	http://dx.doi.org/10.1074/jbc.273.24.15249			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614140	hybrid, Green Submitted			2022-12-25	WOS:000074160400082
J	Murakami, M; Shimbara, S; Kambe, T; Kuwata, H; Winstead, MV; Tischfield, JA; Kudo, I				Murakami, M; Shimbara, S; Kambe, T; Kuwata, H; Winstead, MV; Tischfield, JA; Kudo, I			The functions of five distinct mammalian phospholipase A(2)S in regulating arachidonic acid release - Type IIA and type V secretory phospholipase A(2)S are functionally redundant and act in concert with cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR ACETYLHYDROLASE; LOW-MOLECULAR-WEIGHT; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1; TUMOR-NECROSIS-FACTOR; RAT MESANGIAL CELLS; MOUSE MAST-CELLS; P388D(1) MACROPHAGES; NUCLEAR-ENVELOPE; RECOMBINANT EXPRESSION; CALCIUM IONOPHORE	We examined the relative contributions of five distinct mammalian phospholipase A(2) (PLA(2)) enzymes (cytosolic PLA(2) (cPLA(2); type IV), secretory PLA(2)s (sPLA(2)s; types IIA, V, and IIC), and Ca2+-independent PLA(2) (iPLA(2); type VI)) to arachidonic acid (AA) metabolism by overexpressing them in human embryonic kidney 293 fibroblasts and Chinese hamster ovary cells. Analyses using these transfectants revealed that cPLA(2) was a prerequisite for both the calcium ionophore-stimulated immediate and the interleukin (IL)-1- and serum-induced delayed phases of AA release, Type IIA sPLA, (sPLA(2)-IIA) mediated delayed AA release and, when expressed in larger amounts, also participated in immediate AA release. sPLA(2)-V, but not sPLA(2)-IIC, behaved in a manner similar to sPLA(2)-IIA. Both sPLA(2)s-IIA and -V, but not sPLA(2)-IIC, were heparin-binding PLA(2)s that exhibited significant affinity for cell-surface proteoglycans, and site-directed mutations in residues responsible for their membrane association or catalytic activity markedly reduced their ability to release AA from activated cells. Pharmacological studies using selective inhibitors as well as co-expression experiments supported the proposal that cPLA(2) is crucial for these sPLA(2)s to act properly. The AA-releasing effects of these sPLA(2)s were independent of the expression of the M-type sPLA(2) receptor. Both cPLA(2) sPLA(2)s-IIA, and -V were able to supply AA to downstream cyclooxygenase-2 for IL-1-induced prostaglandin E-2 biosynthesis, iPLA(2) increased the spontaneous release of fatty acids, and this was further augmented by serum but not by IL-1, Finally, iPLA(2)-derived AA was not metabolized to prostaglandin E-2. These observations provide evidence for the functional cross-talk or segregation of distinct PLA(2)s in mammalian cells in regulating AA metabolism and phospholipid turnover.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 142, Japan; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Showa University; Indiana University System; Indiana University-Purdue University Indianapolis	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.		Kuwata, Hiro/N-2023-2019	Kuwata, Hiro/0000-0002-5023-1777; Tischfield, Jay/0000-0003-3217-8287	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038185] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38185] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atsumi G, 1997, BBA-LIPID LIPID MET, V1349, P43, DOI 10.1016/S0005-2760(97)00082-9; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1997, J BIOL CHEM, V272, P20373, DOI 10.1074/jbc.272.33.20373; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen J, 1997, J CELL BIOCHEM, V64, P369, DOI 10.1002/(SICI)1097-4644(19970301)64:3<369::AID-JCB3>3.0.CO;2-T; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHEN J, 1994, BBA-LIPID LIPID MET, V1215, P115, DOI 10.1016/0005-2760(94)90099-X; Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; DOLE VP, 1960, J BIOL CHEM, V235, P2595; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HARA S, 1995, BBA-LIPID LIPID MET, V1257, P11, DOI 10.1016/0005-2760(95)00011-Z; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1994, J BIOL CHEM, V269, P23150; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; Hofmeister R, 1997, J BIOL CHEM, V272, P27730, DOI 10.1074/jbc.272.44.27730; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; Huang Z., 1994, MEDIAT INFLAMM, V3, P307; Huwiler A, 1997, BBA-LIPID LIPID MET, V1348, P257, DOI 10.1016/S0005-2760(97)00073-8; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Kim TS, 1997, J BIOL CHEM, V272, P2542; KISHINO J, 1995, J BIOCHEM-TOKYO, V117, P420, DOI 10.1093/jb/117.2.420; Koumanov K, 1997, BIOCHEM J, V326, P227, DOI 10.1042/bj3260227; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Marshall LA, 1997, J BIOL CHEM, V272, P759, DOI 10.1074/jbc.272.2.759; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 1997, J BIOL CHEM, V272, P19891, DOI 10.1074/jbc.272.32.19891; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; MURAKAMI M, 1989, BIOCHIM BIOPHYS ACTA, V1043, P34; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; Naraba H, 1998, J IMMUNOL, V160, P2974; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROLDAN ERS, 1993, J BIOL CHEM, V268, P13962; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Soubeyrand S, 1997, J BIOL CHEM, V272, P222, DOI 10.1074/jbc.272.1.222; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	84	329	335	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14411	14423		10.1074/jbc.273.23.14411	http://dx.doi.org/10.1074/jbc.273.23.14411			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603953	hybrid			2022-12-25	WOS:000074021500055
J	Topham, MK; Carveth, HJ; McIntyre, TM; Prescott, SM; Zimmerman, GA				Topham, MK; Carveth, HJ; McIntyre, TM; Prescott, SM; Zimmerman, GA			Human endothelial cells regulate polymorphonuclear leukocyte degranulation	FASEB JOURNAL			English	Article						monoclonal antibodies; neutrophils; PMN adhesion; cytokine; tumor necrosis factor	PLATELET-ACTIVATING-FACTOR; TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; HUMAN NEUTROPHIL ADHERENCE; TRANSENDOTHELIAL MIGRATION; SUBCELLULAR-LOCALIZATION; CHEMOTACTIC FACTOR; RESPIRATORY BURST; MAC-1 CD11B/CD18; DE-GRANULATION	Neutrophil degranulation is an important event in inflammatory responses. We examined the regulation of neutrophil (PMN) degranulation by resting and activated human endothelial cells. Whereas PMNs adherent to endothelial cells that were stimulated to express P-selectin and platelet-activating factor did not release the specific granule marker lactoferrin or the primary granule enzyme, elastase, PMNs adherent to endothelial cells stimulated with interleukin-1 (IL-1) or tumor necrosis factor secreted both. PMN degranulation was dependent on the time of incubation of endothelial cells with the cytokine, its concentration, and the time of incubation of the PMNs with endothelial cells. Degranulation of PMNs and their adhesion to stimulated endothelial cells are correlated events, but they could be dissociated by blocking the tethering molecules used by the endothelial cells and neutrophils under these conditions. This suggested that paracrine signaling molecules that induce PMN degranulation are produced by cytokine-stimulated endothelial cells. We found that endothelial cells stimulated with IL-1 release newly synthesized degranulating factors that require transcription and translation. IL-8 was synthesized, released, and signaled granular secretion by PMNs, However, experiments with blocking antibodies indicated the presence of an additional degranulating factor not accounted for by IL-8. These experiments demonstrate that human endothelial cells regulate degranulation of neutrophils by generating signaling factors that are expressed differentially depending on the endothelial agonist and other features. Active modification of neutrophil granular secretion by endothelial cells can influence physiologic acute inflammatory responses but may also contribute to pathologic vascular and tissue damage.	Univ Utah, Sch Med, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Zimmerman, GA (corresponding author), Univ Utah, Sch Med, Nora Eccles Harrison Cardiovasc Res & Training In, 95 S 2000 E Back, Salt Lake City, UT 84112 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044525, R01HL034127] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL076, R01 HL34127, R01 HL44525] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOHNSACK JF, 1990, J EXP MED, V171, P1221, DOI 10.1084/jem.171.4.1221; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BOXER LA, 1982, J CLIN INVEST, V70, P1049, DOI 10.1172/JCI110692; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; BROCK J, 1995, IMMUNOL TODAY, V16, P417, DOI 10.1016/0167-5699(95)80016-6; BRUMELL JH, 1995, J IMMUNOL, V155, P5750; DEWALD B, 1982, J CLIN INVEST, V70, P518, DOI 10.1172/JCI110643; DEWALD B, 1986, BIOCHIM BIOPHYS ACTA, V888, P42, DOI 10.1016/0167-4889(86)90069-8; Ebnet K, 1996, ANNU REV IMMUNOL, V14, P155, DOI 10.1146/annurev.immunol.14.1.155; ENGLISH D, 1992, BLOOD, V80, P776; FEHR J, 1985, J CLIN INVEST, V76, P535, DOI 10.1172/JCI112003; FURIE MB, 1992, J IMMUNOL, V148, P2395; GALLIN JI, 1978, J CLIN INVEST, V62, P1364, DOI 10.1172/JCI109257; GALLIN JI, 1985, ANNU REV MED, V36, P263; GALLIN JI, 1980, J CLIN INVEST, V65, P298, DOI 10.1172/JCI109672; Gill EA, 1998, FASEB J, V12, P673, DOI 10.1096/fasebj.12.9.673; HAKKERT BC, 1991, BLOOD, V78, P2721, DOI 10.1182/blood.V78.10.2721.bloodjournal78102721; HARLAN JM, 1981, J CLIN INVEST, V68, P1394, DOI 10.1172/JCI110390; HARLAN JM, 1985, LAB INVEST, V52, P141; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HENSON PM, 1992, INFLAMMATION BASIC P, P511; HIBBS MS, 1989, J CLIN INVEST, V84, P1395, DOI 10.1172/JCI114312; HOFFSTEIN ST, 1982, J CELL BIOL, V95, P234, DOI 10.1083/jcb.95.1.234; HUBER AR, 1989, J CLIN INVEST, V83, P1122, DOI 10.1172/JCI113992; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; HUGHES BJ, 1992, J CLIN INVEST, V90, P1687, DOI 10.1172/JCI116041; Imaizumi TA, 1997, AM J RESP CELL MOL, V17, P181, DOI 10.1165/ajrcmb.17.2.2818; Introna M, 1997, ARTERIOSCL THROM VAS, V17, P423, DOI 10.1161/01.ATV.17.3.423; KISHIMOTO TK, 1991, BLOOD, V78, P805; KOBAYASHI T, 1991, J CELL BIOL, V113, P743, DOI 10.1083/jcb.113.4.743; KUIJPERS TW, 1992, J CELL BIOL, V117, P565, DOI 10.1083/jcb.117.3.565; KUIJPERS TW, 1992, J IMMUNOL, V148, P72; KUIJPERS TW, 1991, J IMMUNOL, V147, P1369; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MARTICH GD, 1991, J EXP MED, V173, P1021, DOI 10.1084/jem.173.4.1021; MCINTYRE TM, 1986, P NATL ACAD SCI USA, V83, P2204, DOI 10.1073/pnas.83.7.2204; Modur V, 1997, J CLIN INVEST, V100, P158, DOI 10.1172/JCI119508; MOSER R, 1989, J CLIN INVEST, V83, P444, DOI 10.1172/JCI113903; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; OSEAS R, 1981, BLOOD, V57, P939; OZAKI Y, 1987, J LEUKOCYTE BIOL, V42, P621, DOI 10.1002/jlb.42.6.621; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; POHLMAN TH, 1986, J IMMUNOL, V136, P4548; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; SCHLEIFFENBAUM B, 1989, J IMMUNOL, V142, P3537; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SINGER II, 1989, J CELL BIOL, V109, P3169, DOI 10.1083/jcb.109.6.3169; SMEDLY LA, 1986, J CLIN INVEST, V77, P1233, DOI 10.1172/JCI112426; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPERTINI O, 1991, J IMMUNOL, V147, P2565; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; TODD RF, 1984, J CLIN INVEST, V74, P1280, DOI 10.1172/JCI111538; VARANI J, 1989, AM J PATHOL, V135, P435; VERCELLOTTI GM, 1989, J LEUKOCYTE BIOL, V45, P483, DOI 10.1002/jlb.45.6.483; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; WALTZ G, 1990, SCIENCE, V250, P1132; Watson F, 1997, J BIOL CHEM, V272, P17944, DOI 10.1074/jbc.272.29.17944; WRIGHT DG, 1979, J IMMUNOL, V123, P285; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; ZIMMERMAN GA, 1990, METHOD ENZYMOL, V187, P520; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351; Zimmerman GA, 1996, J CLIN INVEST, V98, P1699, DOI 10.1172/JCI118967; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	77	48	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1998	12	9					733	746		10.1096/fasebj.12.9.733	http://dx.doi.org/10.1096/fasebj.12.9.733			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619452				2022-12-25	WOS:000074011000013
J	Yoshida, Y; Matsuda, S; Ikematsu, N; Kawamura-Tsuzuku, J; Inazawa, J; Umemori, H; Yamamoto, T				Yoshida, Y; Matsuda, S; Ikematsu, N; Kawamura-Tsuzuku, J; Inazawa, J; Umemori, H; Yamamoto, T			ANA, a novel member of Tob/BTG1 family, is expressed in the ventricular zone of the developing central nervous system	ONCOGENE			English	Article						Tob/BTG1 family; antiproliferative activity; ventricular zone; cartilage	SONIC HEDGEHOG; MESSENGER-RNA; GENE; CELL; PROTEIN; ALLELOTYPE; CARCINOMA; INDUCTION; PRODUCT; PC3	Using a polymerase chain reaction-mediated cloning procedure, we have identified a novel member, termed ANA (from Abundant in Nueroepithelium Area), of Tob/BTG1 family of antiproliferative genes, Molecular cloning and analysis of cDNAs revealed that the human and mouse ANA encoded a protein of 252 amino acids, The amino-terminal half of ANA was homologous to the previously characterized antiproliferative gene products, BTG1, PC3/TIS21/BTG2, and Tob, The human, ANA gene was localized at chromosome 21q11.2-q21.1, ANA ,vas expressed in a variety of tissues and cell lines, its expression being high in the ovary, testis, prostate, thymus, and lung. Further analysis revealed that ANA expression was high in the ventricular zone of the developing central nervous system, Finally, overexpression of ANA impaired serum-induced cell cycle progression from the G(0)/G(1) to S phase. In conclusion, ANA is a fourth member of the Tob/BTG1 family that might play roles in neurogenesis in the central nervous system.	Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 108, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 108, Japan	University of Tokyo; University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.			Umemori, Hisashi/0000-0001-7198-2062				AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GILBERT SF, 1994, DEV BIOL, P244; GRAHAM A, 1991, DEVELOPMENT, V112, P255; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; IACOPETTI P, 1994, MECH DEVELOP, V47, P127, DOI 10.1016/0925-4773(94)90085-X; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; JOHNSTON MC, 1985, TERATOLOGY, V31, pA26; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MANTAGNOLI A, 1996, CELL GROWTH DIFFER, V7, P1327; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Matsuda S, 1996, ONCOGENE, V12, P705; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sambrook J., 2002, MOL CLONING LAB MANU; SATO S, 1994, CANCER RES, V54, P5652; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; TAN SS, 1985, CELL TISSUE RES, V240, P403; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8	27	93	102	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2687	2693		10.1038/sj.onc.1201805	http://dx.doi.org/10.1038/sj.onc.1201805			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632145				2022-12-25	WOS:000073698200013
J	Houldsworth, J; Xiao, H; Murty, VVVS; Chen, WY; Ray, B; Reuter, VE; Bosl, GJ; Chaganti, RSK				Houldsworth, J; Xiao, H; Murty, VVVS; Chen, WY; Ray, B; Reuter, VE; Bosl, GJ; Chaganti, RSK			Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation	ONCOGENE			English	Article						TP53; mutation; resistance; germ cell tumor	P53 PROTEIN; TESTICULAR CANCER; SUPPRESSOR GENE; GROWTH ARREST; APOPTOSIS; EXPRESSION; TESTIS; DEATH	Male germ cell tumors (GCTs) are uniquely sensitive to cisplatin-based chemotherapy, with more than 90% of newly diagnosed cases cured. The underlying cause for resistance to treatment in 20-30% of metastatic lesions remains to be identified. Unlike other solid tumors, no mutations in the TP53 gene have been identified to date in random panels of GCT specimens, which could account for the exquisite sensitivity of these tumors to genotoxic insult. However, in a panel of resistant GCTs that did either not respond to cisplatin-based chemotherapy or subsequently relapsed and resulted in the death of the patient, we have now identified a subset of tumors to contain TP53 mutations within exons 6-9. A cell line derived from one of these tumors (228A) displayed the same TP53 mutation as the tumor specimen, expressed only mutant TP53 mRNA, and exhibited a relative resistance to cisplatin in vitro in comparison to a cell line (218A) derived from a responsive tumor with wild-type TP53. The resistant cell line displayed a much reduced apoptotic cell death and did not exhibit an induction of transcription of the p53-responsive genes WAF1 and MDM2 following cisplatin treatment, compared to that observed in the sensitive cell line. The levels of bax, an agonist of apoptosis, were found to be reduced in the resistant cell line. The simplest explanation for the resistance of this subset of GCTs that are resistant to cisplatin-based chemotherapy, is the inability of the cells to mount an apoptotic response following exposure due to a functionally inactivating mutation in the TP53 gene.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chaganti, RSK (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.							BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARTKOVA J, 1991, INT J CANCER, V49, P196, DOI 10.1002/ijc.2910490209; BOSL GJ, 1997, CANC PRINCIPLES PRAC; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHAGANTI RSK, 1996, COMPREHENSIVE TXB GE, P932; Chresta CM, 1996, CANCER RES, V56, P1834; ELDIERY WS, 1993, CELL, V75, P817; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; PENG HQ, 1993, CANCER RES, V53, P3574; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; ULBRIGHT TM, 1993, AM J SURG PATHOL, V17, P1075, DOI 10.1097/00000478-199311000-00001; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XU L, 1994, INT J CANCER, V59, P383, DOI 10.1002/ijc.2910590316; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	22	126	129	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2345	2349		10.1038/sj.onc.1201770	http://dx.doi.org/10.1038/sj.onc.1201770			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620551				2022-12-25	WOS:000073428000006
J	Bridges, A; Gruenke, L; Chang, YT; Vakser, IA; Loew, G; Waskell, L				Bridges, A; Gruenke, L; Chang, YT; Vakser, IA; Loew, G; Waskell, L			Identification of the binding site on cytochrome P450 2B4 for cytochrome b(5) and cytochrome P450 reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; ESCHERICHIA-COLI; DIRECTED MUTAGENESIS; RABBIT LIVER; NADPH-CYTOCHROME-P450 REDUCTASE; LYSINE RESIDUES; EXPRESSION; PURIFICATION; PROTEIN; RESOLUTION	A model of cytochrome P450 2B4, which was constructed by homology modeling with the four known crystal structures of the cytochromes P450 (Chang, T.-T., Stiffelman, O. B., Vakser, I. A, Loew, G. H., Bridges, A, and Waskell, L. (1997) Protein Eng. 10, 119-129), was used to select amino acids predicted, by computer docking studies and numerous previous biochemical and site-directed mutagenesis studies, to be involved in binding the heme domain of cytochrome b(5),. Twenty-four amino acid residues located on both the distal and the proximal surface of the molecule were chosen for mutagenesis. These 24 mutant proteins were expressed in Escherichia coli, purified, and characterized with respect to their ability to bind cytochrome b(5), and support substrate oxidation. Seven mutants, R122A, R126A, R133A, F135A, M137A, K139A, and K433A, all on the proximal surface of cytochrome P450 2B4 near the heme ligand, were identified that exhibited decreased ability to bind cytochrome b(5),. All of the mutants except K433A are located in either the C or C*: helices or their termini. In addition, these seven mutants and two additional mutants on the proximal surface of cytochrome P450, R422A and R443A, were shown to exhibit decreased binding to cytochrome P450 reductase. These studies indicate that the binding sites for cytochrome b(5), and cytochrome P450 reductase are, as predicted, located on the proximal surface of cytochrome P450 2B4 and are partially overlapping but not identical.	Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, Dept Anesthesia, San Francisco, CA 94121 USA; Mol Res Inst, Palo Alto, CA 94304 USA; Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Medical University of South Carolina	Waskell, L (corresponding author), Vet Adm Med Ctr, Anesthesia Serv 129, 4150 Clement St, San Francisco, CA 94121 USA.	waskell@quicmail.ucsf.edu			NIGMS NIH HHS [GM35533] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035533] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1975, J BIOL CHEM, V250, P747; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BORDERS CL, 1994, PROTEIN SCI, V3, P541; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CANOVADAVIS E, 1984, J BIOL CHEM, V259, P2541; Chang YT, 1997, PROTEIN ENG, V10, P119, DOI 10.1093/protein/10.2.119; CINTI DL, 1975, BIOCHIM BIOPHYS ACTA, V410, P32, DOI 10.1016/0005-2744(75)90205-3; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COON MJ, 1992, FASEB J, V6, P669, DOI 10.1096/fasebj.6.2.1537454; DAVYDOV DR, 1992, ARCH BIOCHEM BIOPHYS, V297, P304, DOI 10.1016/0003-9861(92)90677-O; Durley RCE, 1996, ACTA CRYSTALLOGR D, V52, P65, DOI 10.1107/S0907444995007827; Estabrook R W, 1978, Methods Enzymol, V52, P212; ESTABROOK RW, 1971, BIOCHEM BIOPH RES CO, V42, P132, DOI 10.1016/0006-291X(71)90372-X; FREEMAN JE, 1994, BIOCHEMISTRY-US, V33, P13963, DOI 10.1021/bi00251a002; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; GASSER R, 1988, MOL PHARMACOL, V33, P22; GILLAM EMJ, 1995, ARCH BIOCHEM BIOPHYS, V317, P374, DOI 10.1006/abbi.1995.1177; GILLAM EMJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P540, DOI 10.1006/abbi.1995.1329; GILLAM EMJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P59, DOI 10.1006/abbi.1994.1280; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; GORSKY LD, 1986, DRUG METAB DISPOS, V14, P89; GRUENKE LD, 1995, J BIOL CHEM, V270, P24707, DOI 10.1074/jbc.270.42.24707; GUO ZY, 1994, ARCH BIOCHEM BIOPHYS, V312, P436, DOI 10.1006/abbi.1994.1330; HARADA N, 1984, J BIOL CHEM, V259, P3005; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; INGELMANSUNDBERG M, 1980, BIOCHEM BIOPH RES CO, V97, P582, DOI 10.1016/0006-291X(80)90303-4; JANSSON I, 1990, ARCH BIOCHEM BIOPHYS, V283, P285, DOI 10.1016/0003-9861(90)90644-E; JOHN GH, 1994, ARCH BIOCHEM BIOPHYS, V314, P367, DOI 10.1006/abbi.1994.1455; JUVONEN RO, 1992, BIOCHEMISTRY-US, V31, P11519, DOI 10.1021/bi00161a033; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNERER M, 1995, BBA-GEN SUBJECTS, V1245, P107, DOI 10.1016/0304-4165(95)00075-M; LOOMAN AC, 1987, EMBO J, V6, P2489, DOI 10.1002/j.1460-2075.1987.tb02530.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIWA GT, 1979, J BIOL CHEM, V254, P5695; MULLERENOCH D, 1984, J BIOL CHEM, V259, P8174; NAKAMURA K, 1994, BBA-PROTEIN STRUCT M, V1207, P40, DOI 10.1016/0167-4838(94)90049-3; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OMATA Y, 1994, FEBS LETT, V346, P241, DOI 10.1016/0014-5793(94)00482-X; OMATA Y, 1994, BIOCHEM BIOPH RES CO, V201, P1090, DOI 10.1006/bbrc.1994.1817; Omura T., 1967, METHOD ENZYMOL, P556, DOI [DOI 10.1016/0076-6879(67)10096-7, 10.1016/0076-6879(67)10096-7.]; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; REID LS, 1982, J AM CHEM SOC, V104, P841, DOI 10.1021/ja00367a032; RICHARDSON TH, 1993, ARCH BIOCHEM BIOPHYS, V300, P510, DOI 10.1006/abbi.1993.1069; RODGERS KK, 1991, J MOL BIOL, V221, P1453, DOI 10.1016/0022-2836(91)90945-3; SHEN SJ, 1993, ARCH BIOCHEM BIOPHYS, V304, P257, DOI 10.1006/abbi.1993.1347; SHEN SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P83, DOI 10.1016/0003-9861(92)90140-R; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; STAYTON PS, 1989, BIOCHEMISTRY-US, V28, P8201, DOI 10.1021/bi00446a035; STAYTON PS, 1990, BIOCHEMISTRY-US, V29, P7381, DOI 10.1021/bi00484a005; STRITTMATTER P, 1956, J BIOL CHEM, V221, P253; TAMBURINI PP, 1987, P NATL ACAD SCI USA, V84, P11, DOI 10.1073/pnas.84.1.11; TAMBURINI PP, 1985, J BIOL CHEM, V260, P4007; TARTOF KD, 1987, FOCUS, V9, P12; Vakser IA, 1996, BIOPOLYMERS, V39, P455, DOI 10.1002/(SICI)1097-0282(199609)39:3<455::AID-BIP16>3.3.CO;2-8; VERGERES G, 1993, ARCH BIOCHEM BIOPHYS, V305, P231, DOI 10.1006/abbi.1993.1416; VERGERES G, 1995, BIOCHIMIE, V77, P604, DOI 10.1016/0300-9084(96)88176-4; WADA A, 1992, J BIOL CHEM, V267, P22877; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WASKELL LA, 1991, METHOD ENZYMOL, V206, P523; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YOSHIKAWA K, 1992, BIOCHIM BIOPHYS ACTA, V1122, P41, DOI 10.1016/0167-4838(92)90124-V	69	251	260	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17036	17049		10.1074/jbc.273.27.17036	http://dx.doi.org/10.1074/jbc.273.27.17036			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642268	hybrid			2022-12-25	WOS:000074545200058
J	He, QY; Mason, AB; Woodworth, RC; Tam, BM; MacGillivray, RTA; Grady, JK; Chasteen, ND				He, QY; Mason, AB; Woodworth, RC; Tam, BM; MacGillivray, RTA; Grady, JK; Chasteen, ND			Mutations at nonliganding residues Tyr-85 and Glu-83 in the N-lobe of human serum transferrin - Functional second shell effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL HALF-MOLECULE; CRYSTAL-STRUCTURE; HEN OVOTRANSFERRIN; HUMAN LACTOFERRIN; ANION-BINDING; IRON RELEASE; SITE; RESOLUTION; PH; SPECTROSCOPY	The x-ray crystal structure of the N-lobe of human serum transferrin has shown that there is a hydrogen bond network, the so-called "second shell," around the transferrin iron binding site. Tyrosine at position 85 and glutamic acid at position 83 are two nonliganding residues in this network in the human serum transferrin N-lobe (hTF/2N). Mutation of each of these two amino acids has a profound effect on the metal binding properties of hTF/2N. When Tyr-85 is mutated to phenylalanine, iron release from the resulting mutant Y85F is much more facile than from the parent protein. Elimination of the hydrogen bond between Tyr-85 and Lys-296 appears to interfere with the "di-lysine (Lys-206-Lys-296) trigger," which affects the iron binding stability of the protein. Surprisingly, mutation of Glu-83 to alanine leads to the absence of one of the normal iron binding ligands; introduction of a monovalent anion is able to restore the normal first coordination sphere. The missing ligand appears to be His-249, as revealed by comparison of the metal binding behaviors of mutants H249Q and E83A and structural analysis. Glu-83 has a strong H bond linkage with His-249 in apo-hTF/2N, which helps to hold the His-249 in the proper position for iron binding. Disabling Glu 83 by mutation to an alanine seriously disturbs the H bond network, allowing His-249 to move away. A monovalent anion can help reestablish the normal network by providing a negative charge near the position of Glu-83 to reach charge balance, so that ligand His-249 is available again for iron binding.	Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ New Hampshire, Dept Chem, Durham, NH 03824 USA	University of Vermont; University of British Columbia; University System Of New Hampshire; University of New Hampshire	He, QY (corresponding author), Univ Vermont, Coll Med, Dept Biochem, Given Bldg, Burlington, VT 05405 USA.		He, Qing-Yu/H-7078-2014; Mason, Anne B/A-6754-2008	He, Qing-Yu/0000-0003-0503-9492; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021739] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 21739] Funding Source: Medline; PHS HHS [R37 20194] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON BF, 1987, P NATL ACAD SCI USA, V84, P1769, DOI 10.1073/pnas.84.7.1769; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; Baker E., 1994, ADV INORG CHEM, P389, DOI [10.1016/S0898-8838(08)60176-2, DOI 10.1016/S0898-8838(08)60176-2]; Baker HM, 1996, BIOCHEMISTRY-US, V35, P9007, DOI 10.1021/bi960288y; BALDWIN GS, 1993, COMP BIOCHEM PHYS B, V106, P203, DOI 10.1016/0305-0491(93)90028-4; CHASTEEN ND, 1990, IRON TRANSPORT STORA, P67; CHENG YG, 1995, BIOCHEMISTRY-US, V34, P14879, DOI 10.1021/bi00045a032; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DEWAN JC, 1993, BIOCHEMISTRY-US, V32, P11963, DOI 10.1021/bi00096a004; Faber HR, 1996, J MOL BIOL, V256, P352; GABER BP, 1974, J AM CHEM SOC, V96, P6868, DOI 10.1021/ja00829a010; GRADY JK, 1995, BIOCHEM J, V309, P403, DOI 10.1042/bj3090403; Griffiths E, 1987, IRON INFECTION, P1; Harris D., 1989, IRON CARRIERS IRON P, P239; He QY, 1997, BIOCHEM J, V328, P439, DOI 10.1042/bj3280439; He QY, 1997, BIOCHEMISTRY-US, V36, P14853, DOI 10.1021/bi9719556; He QY, 1997, BIOCHEMISTRY-US, V36, P5522, DOI 10.1021/bi963028p; Huang CC, 1996, BIOCHEMISTRY-US, V35, P3439, DOI 10.1021/bi9526692; KUROKAWA H, 1995, J MOL BIOL, V254, P196, DOI 10.1006/jmbi.1995.0611; LIN LN, 1993, BIOCHEM J, V293, P517, DOI 10.1042/bj2930517; MACGILLIVRAY RT, 1998, IN PRESS BIOCHEMISTR; Mason A B, 1991, Protein Expr Purif, V2, P214, DOI 10.1016/1046-5928(91)90074-S; Mason AB, 1996, BIOCHEM J, V319, P361, DOI 10.1042/bj3190361; Mason AB, 1997, BIOCHEM J, V326, P77, DOI 10.1042/bj3260077; Mertz P, 1997, J BIOL CHEM, V272, P21296, DOI 10.1074/jbc.272.34.21296; PATCH MG, 1981, INORG CHIM A-BIOINOR, V56, pL71, DOI 10.1016/S0020-1693(00)88536-9; PECORARO VL, 1981, BIOCHEMISTRY-US, V20, P7033, DOI 10.1021/bi00527a040; SCHLABACH MR, 1975, J BIOL CHEM, V250, P2182; SMITH RM, 1976, CRITICAL STABILITY C, V3, P139; SMITH RM, 1976, CRITICAL STABILITY C, V4, P139; SMITH RM, 1976, CRITICAL STABILITY C, V5, P139; TAN AT, 1969, BIOCHEMISTRY-US, V8, P3711, DOI 10.1021/bi00837a033; WOODWORTH RC, 1991, BIOCHEMISTRY-US, V30, P10824, DOI 10.1021/bi00109a002; WOODWORTH RC, 1975, PROTEINS IRON STORAG, P39; ZAK O, 1995, BIOCHEMISTRY-US, V34, P14428, DOI 10.1021/bi00044a020; ZUCCOLA HJ, 1993, THESIS GEORGIA I TEC	36	36	37	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17018	17024		10.1074/jbc.273.27.17018	http://dx.doi.org/10.1074/jbc.273.27.17018			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642266	hybrid			2022-12-25	WOS:000074545200056
J	Kubo, A; Minamino, N; Isumi, Y; Katafuchi, T; Kangawa, K; Dohi, K; Matsuo, H				Kubo, A; Minamino, N; Isumi, Y; Katafuchi, T; Kangawa, K; Dohi, K; Matsuo, H			Production of adrenomedullin in macrophage cell line and peritoneal macrophage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NECROSIS-FACTOR-ALPHA; LOW-DENSITY-LIPOPROTEIN; INTERFERON-GAMMA; IFN-GAMMA; RAW-264.7 MACROPHAGES; HYPOTENSIVE PEPTIDE; RAT ADRENOMEDULLIN; MURINE MACROPHAGES; ENDOTHELIAL-CELLS	We demonstrate that adrenomedullin (AM) is produced and secreted from cultured murine monocyte/macrophage cell line (RAW 264.7) as well as mouse peritoneal macrophage. Immunoreactive (IR) AM secreted from RAW 264.7 cells was chromatographically identified to be native AM. To elucidate the regulation mechanism of AM production in macrophage, we examined the effects of various substances inducing differentiation or activation of monocyte/macrophage. Phorbol ester (TPA), retinoic acid (RA), lipopolysaccharide (LPS), and interferon-gamma (IFN-gamma) increased AM production 1.5-7-fold in RAW 264.7 cells in a dose- as well as time-dependent manner. By LPS stimulation, the AM mRNA level in RAW 264.7 cells was augmented up to 7-fold after 14 h incubation. RA exerted a synergistic effect when administered with TPA, LPS, or IFN-gamma, whereas IFN-gamma completely suppressed AM production in RAW 264.7 cells stimulated with LPS. Dexamethasone, hydrocortisone, estradiol, and transforming growth factor-beta dose-dependently suppressed AM production in RAW 264.7 cells. AM production was also investigated in mouse peritoneal macrophage. Primary mouse macrophage secreted IR-AM at a rate similar to that of RAW 264.7 cells, and its production was enhanced 9-fold by LPS stimulation. AM was found to increase basal secretion of tumor necrosis factor alpha (TNF-alpha) from RAW 264.7 cells, whereas AM suppressed the secretion of TNF-alpha and interleukin-6 from that stimulated with LPS. Thus, macrophage should be recognized as one of the major sources of AM circulating in the blood. Especially in cases of sepsis and inflammation, AM production in macrophage is augmented, and the secreted AM is deduced to function as a modulator of cytokine production.	Natl Cardiovasc Ctr, Res Inst, Suita, Osaka 5658565, Japan; Nara Med Univ, Dept Internal Med 1, Kashihara, Nara 6340813, Japan	National Cerebral & Cardiovascular Center - Japan; Nara Medical University	Minamino, N (corresponding author), Natl Cardiovasc Ctr, Res Inst, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.	minamino@ri.ncvc.go.jp						AKESON AL, 1991, J LIPID RES, V32, P1699; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; Boyte WR, 1996, SHOCK, V6, P218, DOI 10.1097/00024382-199609010-00011; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chujor CSN, 1996, EUR J IMMUNOL, V26, P1253, DOI 10.1002/eji.1830260611; DI RM, 1990, BIOCHEM BIOPH RES CO, V172, P1246; DIAZGUERRA MJM, 1996, J BIOL CHEM, V271, P32038; DILLEHAY DL, 1988, J LEUKOCYTE BIOL, V44, P353, DOI 10.1002/jlb.44.5.353; FRENDSCHO MH, 1990, CLIN EXP IMMUNOL, V82, P404; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GRENETT HE, 1990, NUCLEIC ACIDS RES, V18, P6455, DOI 10.1093/nar/18.21.6455; HAN J, 1990, J EXP MED, V172, P391, DOI 10.1084/jem.172.1.391; HAUSMANN EHS, 1994, INFECT IMMUN, V62, P3625, DOI 10.1128/IAI.62.9.3625-3632.1994; HAYASHI T, 1991, AM J PHYSIOL, V261, pC106, DOI 10.1152/ajpcell.1991.261.1.C106; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hirata Y, 1996, J CLIN ENDOCR METAB, V81, P1449, DOI 10.1210/jc.81.4.1449; ISHIMITSU T, 1994, BIOCHEM BIOPH RES CO, V203, P631, DOI 10.1006/bbrc.1994.2229; Isumi Y, 1998, ENDOCRINOLOGY, V139, P838, DOI 10.1210/en.139.3.838; KAMOI H, 1995, BIOCHEM BIOPH RES CO, V211, P1031, DOI 10.1006/bbrc.1995.1914; Kano H, 1996, J HYPERTENS, V14, P209, DOI 10.1097/00004872-199602000-00009; KITAMURA K, 1992, BIOCHEM BIOPH RES CO, V185, P134, DOI 10.1016/S0006-291X(05)80966-0; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kubo A, 1998, FEBS LETT, V426, P233, DOI 10.1016/S0014-5793(98)00349-4; LAMBERT LE, 1989, CELL IMMUNOL, V120, P401, DOI 10.1016/0008-8749(89)90208-6; MARTINEZ A, 1995, ENDOCRINOLOGY, V136, P4099, DOI 10.1210/en.136.9.4099; MCDOWELL MA, 1995, J IMMUNOL, V155, P4933; MIGLIORINI P, 1991, J IMMUNOL METHODS, V139, P107, DOI 10.1016/0022-1759(91)90357-L; Miller MJ, 1996, J BIOL CHEM, V271, P23345; MINAMINO N, 1995, BIOCHEM BIOPH RES CO, V211, P686, DOI 10.1006/bbrc.1995.1866; Nishio K, 1997, CRIT CARE MED, V25, P953, DOI 10.1097/00003246-199706000-00010; Okazaki T, 1996, GENOMICS, V37, P395, DOI 10.1006/geno.1996.0576; PRADINESFIGUERES A, 1992, J BIOL CHEM, V267, P23261; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; REDDY ST, 1994, J LEUKOCYTE BIOL, V55, P192, DOI 10.1002/jlb.55.2.192; RINEHART JJ, 1982, J IMMUNOL, V129, P1436; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SAKATA J, 1993, BIOCHEM BIOPH RES CO, V195, P921, DOI 10.1006/bbrc.1993.2132; SAKATA J, 1994, FEBS LETT, V352, P105, DOI 10.1016/0014-5793(94)00928-7; SATO A, 1992, HYPERTENSION, V19, P109, DOI 10.1161/01.HYP.19.1.109; SHIMEKAKE Y, 1995, J BIOL CHEM, V270, P4412, DOI 10.1074/jbc.270.9.4412; SHOJI H, 1995, BIOCHEM BIOPH RES CO, V215, P531, DOI 10.1006/bbrc.1995.2497; SNYDER DS, 1982, J IMMUNOL, V129, P1803; SPENGLER RN, 1989, INFECT IMMUN, V57, P2837, DOI 10.1128/IAI.57.9.2837-2841.1989; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUGO S, 1995, BIOCHEM BIOPH RES CO, V207, P25, DOI 10.1006/bbrc.1995.1148; SUGO S, 1995, FEBS LETT, V369, P311, DOI 10.1016/0014-5793(95)00769-6; SUGO S, 1994, BIOCHEM BIOPH RES CO, V201, P1160, DOI 10.1006/bbrc.1994.1827; SUGO S, 1994, BIOCHEM BIOPH RES CO, V203, P719, DOI 10.1006/bbrc.1994.2241; VEY E, 1992, J IMMUNOL, V149, P2040; WANG WW, 1995, BIOCHEM BIOPH RES CO, V210, P1009, DOI 10.1006/bbrc.1995.1757; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; ZANKER B, 1990, TRANSPLANTATION, V49, P183, DOI 10.1097/00007890-199001000-00040; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768; ZIEGLERHEITBROCK HWL, 1995, J INFLAMM, V45, P13	55	153	156	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16730	16738		10.1074/jbc.273.27.16730	http://dx.doi.org/10.1074/jbc.273.27.16730			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642228	hybrid			2022-12-25	WOS:000074545200018
J	Vandergon, TL; Riggs, CK; Gorr, TA; Colacino, JM; Riggs, AF				Vandergon, TL; Riggs, CK; Gorr, TA; Colacino, JM; Riggs, AF			The mini-hemoglobins in neural and body wall tissue of the nemertean worm, Cerebratulus lacteus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MOLLUSK SCAPHARCA-INAEQUIVALVIS; PHORONIS-ARCHITECTA PHORONIDA; PARAMECIUM-CAUDATUM; PROTOZOAN MYOGLOBIN; NUCLEOTIDE-SEQUENCE; STRUCTURAL-ANALYSIS; PETROMYZON-MARINUS; CRYSTAL-STRUCTURE; GLOBIN GENES	Hemoglobin (Hb) occurs in circulating red blood cells, neural tissue, and body wall muscle tissue of the nemertean worm, Cerebratubus lacteus. The neural and body wall tissue each express single major Hb components for which the amino acid sequences have been deduced from cDNA and genomic DNA. These 109-residue globins form the smallest stable Hbs known. The globin genes have three exons and two introns with splice sites in the highly conserved positions of most globin genes. Alignment of the sequences with those of other globins indicates that the A, B, and H helices are about one-half the typical length. Phylogenetic analysis indicates that shortening results in a small tendency of globins to group together regardless of their actual relationships. The neural and body wall Hbs in situ are half-saturated with O-2 at 2.9 and 4.1 torr, respectively. The Hill coefficient for the neural Hb in situ, similar to 2.8, suggests that the neural Hb self-associates in the deoxy state at least to tetramers at the 2-3 mM (heme) concentration estimated in the cells. The Hb must dissociate upon oxygenation and dilution because the weight-average molecular mass of the HbO(2) in vitro is only about 18 kDa at 2-3 mu M heme concentration. Calculations suggest that the Hb can function as an O-2 store capable of extending neuronal activity in an anoxic environment for 5-30 min.	Univ Texas, Dept Zool, Austin, TX 78712 USA; Clemson Univ, Dept Biol Sci, Clemson, SC 29631 USA	University of Texas System; University of Texas Austin; Clemson University	Vandergon, TL (corresponding author), Univ Texas, Dept Zool, Austin, TX 78712 USA.	tvanderg@pepperdine.edu		Gorr, Thomas/0000-0002-6023-4234	NIGMS NIH HHS [GM35847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN HT, 1966, PHYSIOL REV, V46, P212, DOI 10.1152/physrev.1966.46.2.212; ANTOINE M, 1984, NATURE, V310, P795, DOI 10.1038/310795a0; ARENTS G, 1989, J MOL BIOL, V210, P149, DOI 10.1016/0022-2836(89)90297-0; ARONSON HEG, 1994, PROTEIN SCI, V3, P1706, DOI 10.1002/pro.5560031009; ARVANITAKI A, 1960, B I OCEANOG, V57, P1; ATKINSON HJ, 1975, J EXP BIOL, V62, P1; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Bevington PR, 1969, DATA REDUCTION ERROR; BLESSING MH, 1972, COMP BIOCHEM PHYSIOL, V41, P475, DOI 10.1016/0300-9629(72)90005-9; Bonaventura J., 1973, COMP PHYSL, P493; CHALAZONITIS N, 1965, C R SOC BIOL, V159, P240; CHIANCONE E, 1981, J MOL BIOL, V152, P577, DOI 10.1016/0022-2836(81)90270-9; COBB JA, 1992, J BIOL CHEM, V267, P1183; COLACINO JM, 1984, COMP BIOCHEM PHYS A, V79, P363, DOI 10.1016/0300-9629(84)90528-0; COLACINO JM, 1987, J THEOR BIOL, V126, P437, DOI 10.1016/S0022-5193(87)80150-9; COUTURE M, 1994, MOL GEN GENET, V243, P184; DESANCTIS G, 1988, J MOL BIOL, V200, P725, DOI 10.1016/0022-2836(88)90483-4; DESANCTIS G, 1994, P NATL ACAD SCI USA, V91, P11507, DOI 10.1073/pnas.91.24.11507; DESANCTIS G, 1992, J MOL BIOL, V222, P637; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; DIXON B, 1992, J MOL EVOL, V35, P131, DOI 10.1007/BF00183224; DOELLER JE, 1988, BIOL BULL, V174, P67, DOI 10.2307/1541760; DONAHUE RA, 1992, THESIS U TEXAS AUSTI; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FELSENSTEIN J, 1993, PHYLIP VERSION 3 5 D; FERMI G, 1981, ATLAS MOL STRUCTURES, V2, P26; FOX HM, 1957, NATURE, V179, P148, DOI 10.1038/179148a0; FOX HM, 1955, PROC R SOC SER B-BIO, V143, P203, DOI 10.1098/rspb.1955.0005; FUSHITANI K, 1988, J BIOL CHEM, V263, P6502; GAREY JR, 1986, J BIOL CHEM, V261, P6446; GERSTEIN M, 1994, J MOL BIOL, V236, P1067, DOI 10.1016/0022-2836(94)90012-4; HARDISON RC, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P272; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11300, DOI 10.1021/bi960372d; HOMBRADOS I, 1983, BIOCHIMIE, V65, P247, DOI 10.1016/S0300-9084(83)80276-4; HONZATKO RB, 1985, J MOL BIOL, V184, P147, DOI 10.1016/0022-2836(85)90049-X; HYLDIGNIELSEN JJ, 1982, NUCLEIC ACIDS RES, V10, P689, DOI 10.1093/nar/10.2.689; IWAASA H, 1990, J BIOL CHEM, V265, P8603; IWAASA H, 1992, J MOL BIOL, V227, P948, DOI 10.1016/0022-2836(92)90236-D; IWAASA H, 1989, J MOL BIOL, V208, P355, DOI 10.1016/0022-2836(89)90395-1; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; KAPP OH, 1995, PROTEIN SCI, V4, P2179, DOI 10.1002/pro.5560041024; KENNEDY D, 1960, J GEN PHYSIOL, V44, P277, DOI 10.1085/jgp.44.2.277; KHOSLA C, 1988, MOL GEN GENET, V214, P158, DOI 10.1007/BF00340195; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P579; KOLATKAR PR, 1994, J MOL BIOL, V237, P87, DOI 10.1006/jmbi.1994.1211; KRAUS DW, 1986, SCIENCE, V232, P90, DOI 10.1126/science.232.4746.90; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSMANN J, 1986, NATURE, V324, P166, DOI 10.1038/324166a0; Lankester E.R, 1872, P ROY SOC LONDON, V21, P70; MANWELL C, 1960, ARCH BIOCHEM BIOPHYS, V89, P194, DOI 10.1016/0003-9861(60)90042-4; MITCHELL DT, 1995, J MOL BIOL, V251, P421, DOI 10.1006/jmbi.1995.0445; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; MOENS L, 1992, FEBS LETT, V312, P105, DOI 10.1016/0014-5793(92)80915-4; OLLIS DL, 1983, AUST J CHEM, V36, P451, DOI 10.1071/CH9830451; PETRUZZELLI R, 1985, FEBS LETT, V184, P328, DOI 10.1016/0014-5793(85)80632-3; POLUHOWICH JJ, 1970, COMP BIOCHEM PHYSIOL, V36, P817, DOI 10.1016/0010-406X(70)90537-2; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; QIU Y, 1997, THESIS U TEXAS AUSTI; RITCHIE JM, 1979, J PHYSIOL-LONDON, V287, P315, DOI 10.1113/jphysiol.1979.sp012661; ROBERTS MS, 1984, COMP BIOCHEM PHYS B, V77, P237, DOI 10.1016/0305-0491(84)90250-5; ROYER WE, 1989, J BIOL CHEM, V264, P21052; SACK JS, 1978, HEMOGLOBIN, V2, P153, DOI 10.3109/03630267809074782; SCHINDELMEISER I, 1979, COMP BIOCHEM PHYS B, V64, P149, DOI 10.1016/0305-0491(79)90153-6; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; STRITTMATTER P, 1963, BIOCHIM BIOPHYS ACTA, V78, P562, DOI 10.1016/0006-3002(63)90928-4; TAKAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1173, P75, DOI 10.1016/0167-4781(93)90245-9; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; THOMAS PW, 1994, THESIS U TEXAS AUSTI; TROTMAN CNA, 1991, J BIOL CHEM, V266, P13789; TSUBAMOTO Y, 1990, EUR J BIOCHEM, V193, P55, DOI 10.1111/j.1432-1033.1990.tb19303.x; TURBEVILLE JM, 1992, MOL BIOL EVOL, V9, P235; VANASSENDELFT OW, 1970, SPECTROPHOTOMETRY HA, P57; VANDERGON TL, 1989, COMP BIOCHEM PHYS B, V94, P31, DOI 10.1016/0305-0491(89)90006-0; VANDERGON TL, 1991, PHYSIOL ZOOL, V64, P1561, DOI 10.1086/physzool.64.6.30158231; VANDERGON TL, 1989, AM ZOOL, V29, P59; VANDERGON TL, 1990, AM ZOOL, V31, P72; VARNDELL IM, 1980, J EXP MAR BIOL ECOL, V45, P157, DOI 10.1016/0022-0981(80)90057-X; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; VERNET G, 1973, COMP BIOCHEM PHYSIOL, V44, P1053, DOI 10.1016/0300-9629(73)90242-9; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; Weber R.E., 1978, P393; WITTENBERG BA, 1965, BIOCHEM J, V96, P363, DOI 10.1042/bj0960363; WITTENBERG JB, 1965, BIOCHIM BIOPHYS ACTA, V109, P518, DOI 10.1016/0926-6585(65)90177-9; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; YAMAUCHI K, 1992, BIOCHIM BIOPHYS ACTA, V1171, P81, DOI 10.1016/0167-4781(92)90142-M; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	87	40	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16998	17011		10.1074/jbc.273.27.16998	http://dx.doi.org/10.1074/jbc.273.27.16998			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642264	hybrid			2022-12-25	WOS:000074545200054
J	Halfon, S; Ford, J; Foster, J; Dowling, L; Lucian, L; Sterling, M; Xu, YM; Weiss, M; Ikeda, M; Liggett, D; Helms, A; Caux, C; Lebecque, S; Hannum, C; Menon, S; McClanahan, T; Gorman, D; Zurawski, G				Halfon, S; Ford, J; Foster, J; Dowling, L; Lucian, L; Sterling, M; Xu, YM; Weiss, M; Ikeda, M; Liggett, D; Helms, A; Caux, C; Lebecque, S; Hannum, C; Menon, S; McClanahan, T; Gorman, D; Zurawski, G			Leukocystatin, a new class II cystatin expressed selectively by hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE CYSTATIN; CYSTEINE PROTEINASE-INHIBITOR; RAY CRYSTAL-STRUCTURE; PAPAIN; REGION; GENE; IDENTIFICATION; ORGANIZATION; TRUNCATION; MECHANISM	We describe a new cystatin in both mice and humans, which we termed leukocystatin. This protein has all the features of a Class II secreted inhibitory cystatin but contains lysine residues in the normally hydrophobic binding regions. As determined by cDNA library Southern blots, this cystatin is expressed selectively in hematopoietic cells, although fine details of the distribution among these cell types differ between the human and mouse mRNAs. In addition, we have determined the genomic organization of mouse leukocystatin, and we found that in contrast to most cystatins, the leukocystatin gene contains three introns. The recombinant proteins corresponding to these cystatins were expressed in Escherichia coli as N-terminal glutathione S-transferase or FLAG(TM) fusions, and studies showed that they inhibited papain and cathepsin L but with affinities lower than other cystatins. The unique features of leukocystatin suggests that this cystatin plays a role in immune regulation through inhibition of a unique target in the hematopoietic system.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Biol Mol, Palo Alto, CA 94304 USA; DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, Palo Alto, CA 94304 USA; Lab Immunol Res, F-69572 Dardilly, France	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Zurawski, G (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Biol Mol, 901 Calif Ave, Palo Alto, CA 94304 USA.			Caux, Christophe/0000-0003-2438-833X; lebecque, serge/0000-0003-4006-8061				ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUERSWALD EA, 1992, EUR J BIOCHEM, V209, P837, DOI 10.1111/j.1432-1033.1992.tb17355.x; BALBIN M, 1994, J BIOL CHEM, V269, P23156; Bieth J., 1974, BAYER S, P463; BJORK I, 1994, BIOCHEM J, V299, P219, DOI 10.1042/bj2990219; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; Bolin LM, 1997, J NEUROSCI, V17, P5493; CALKINS CC, 1995, BIOL CHEM H-S, V376, P71; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; DIECKMANN T, 1993, J MOL BIOL, V234, P1048, DOI 10.1006/jmbi.1993.1658; FREIJE JP, 1993, J BIOL CHEM, V268, P15737; GOLLOB KJ, 1994, J IMMUNOL, V152, P5180; Hakansson K, 1996, COMP BIOCHEM PHYS B, V114, P303, DOI 10.1016/0305-0491(96)00025-9; HALL A, 1995, J BIOL CHEM, V270, P5115, DOI 10.1074/jbc.270.10.5115; Henskens YMC, 1996, BIOL CHEM H-S, V377, P71; Johnston SC, 1997, EMBO J, V16, P3787, DOI 10.1093/emboj/16.13.3787; LINDAHL P, 1992, BIOCHEM J, V281, P49, DOI 10.1042/bj2810049; LINDAHL P, 1994, BIOCHEMISTRY-US, V33, P4384, DOI 10.1021/bi00180a036; MACHLEIDT W, 1989, FEBS LETT, V243, P234, DOI 10.1016/0014-5793(89)80135-8; Misaka T, 1996, EUR J BIOCHEM, V240, P609, DOI 10.1111/j.1432-1033.1996.0609h.x; MURPHY E, 1993, J IMMUNOL METHODS, V162, P211, DOI 10.1016/0022-1759(93)90386-L; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Ni J, 1997, J BIOL CHEM, V272, P10853; Pennacchio LA, 1996, GENOME RES, V6, P1103, DOI 10.1101/gr.6.11.1103; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; SAITOH E, 1993, CRIT REV ORAL BIOL M, V4, P487, DOI 10.1177/10454411930040033301; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SATO N, 1992, GENE, V114, P257, DOI 10.1016/0378-1119(92)90584-C; SHIBUYA K, 1995, J BIOCHEM, V118, P635, DOI 10.1093/oxfordjournals.jbchem.a124957; SHIBUYA K, 1995, BIOCHEMISTRY-US, V34, P12185, DOI 10.1021/bi00038a012; Shortman K, 1997, STEM CELLS, V15, P409, DOI 10.1002/stem.150409; Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; WILKINSON KD, 1992, BIOCHEM SOC T, V20, P631, DOI 10.1042/bst0200631; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Williams J W, 1979, Methods Enzymol, V63, P437	38	93	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16400	16408		10.1074/jbc.273.26.16400	http://dx.doi.org/10.1074/jbc.273.26.16400			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632704	hybrid			2022-12-25	WOS:000074436600075
J	Herrmann, C; Ahmadian, MR; Hofmann, F; Just, I				Herrmann, C; Ahmadian, MR; Hofmann, F; Just, I			Functional consequences of monoglucosylation of Ha-Ras at effector domain amino acid threonine 35	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SORDELLII LETHAL TOXIN; GTPASE-ACTIVATING PROTEINS; CLOSTRIDIUM-DIFFICILE; EXCHANGE FACTOR; RHO-PROTEINS; BINDING PROTEINS; GLUCOSYLATION; NEUROFIBROMIN; COMPLEX; KINASE	Monoglucosylation of low molecular mass GTPases is an important post-translational modification by which microbes interfere with eukaryotic cell signaling. Ha-Ras is monoglucosylated at effector domain amino acid threonine 35 by Clostridium sordellii lethal toxin, resulting in a blockade of the downstream mitogen-activated protein kinase cascade. To understand the molecular consequences of this modification, effects of glucosylation on each step of the GTPase cycle of Ras were analyzed. Whereas nucleotide binding was not significantly altered, intrinsic GTPase activity was markedly decreased, and GTPase stimulation by the GTPase-activating protein p120(GAP) and neurofibromin NF-1 was completely blocked, caused by failure to bind to glucosylated Ras. Guanine nucleotide exchange factor (Cdc25)-catalyzed GTP loading was decreased, but not completely inhibited. A dominant-negative property of modified Ras to sequester exchange factor was not detectable. However, the crucial step in downstream signaling, Ras-effector coupling, was completely blocked. The K-d for the interaction between Ras.GTP and the Ras-binding domain of Raf was 15 nM, whereas glucosylation increased the K-d to >1 mM. Because the affinity of Ras.GDP for Raf (K-d = 22 mu M) is too low to allow functional interaction, a glucose moiety at threonine 35 of Ras seems to block completely the interaction with Raf. The net effect of lethal toxin-catalyzed glucosylation of Ras is the complete blockade of Ras downstream signaling.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany; Max Planck Inst Mol Physiol, D-44139 Dortmund, Germany	University of Freiburg; Max Planck Society	Just, I (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.	justingo@ruf.uni-freiburg.de						ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Ahmadian MR, 1996, J BIOL CHEM, V271, P16409, DOI 10.1074/jbc.271.27.16409; Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; AKTORIES K, 1993, GTPASES BIOL, V1, P87; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEN SY, 1994, ONCOGENE, V9, P2691; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; FIORENTINI C, 1991, TOXICON, V29, P543, DOI 10.1016/0041-0101(91)90050-2; Genth H, 1996, BIOCHEM BIOPH RES CO, V229, P370, DOI 10.1006/bbrc.1996.1812; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; Herrmann C, 1996, PROG BIOPHYS MOL BIO, V66, P1, DOI 10.1016/S0079-6107(96)00015-6; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hofmann F, 1996, BIOCHEM BIOPH RES CO, V227, P77, DOI 10.1006/bbrc.1996.1470; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; JOHN J, 1989, J BIOL CHEM, V264, P13086; JOHN J, 1993, J BIOL CHEM, V268, P923; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KNOOP FC, 1993, CLIN MICROBIOL REV, V6, P251, DOI 10.1128/CMR.6.3.251-265.1993; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Wittinghofer A, 1997, FEBS LETT, V410, P63, DOI 10.1016/S0014-5793(97)00321-9	39	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16134	16139		10.1074/jbc.273.26.16134	http://dx.doi.org/10.1074/jbc.273.26.16134			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632667	hybrid			2022-12-25	WOS:000074436600038
J	Moutoussamy, S; Renaudie, F; Lago, F; Kelly, PA; Finidori, J				Moutoussamy, S; Renaudie, F; Lago, F; Kelly, PA; Finidori, J			Grb10 identified as a potential regulator of growth hormone (GH) signaling by cloning of GH receptor target proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTED TYROSYL PHOSPHORYLATION; SERUM RESPONSE ELEMENT; C-FOS PROMOTER; TRANSCRIPTION FACTOR; INSULIN-RECEPTOR; EXPRESSION CLONING; INTERFERON-GAMMA; GENE-EXPRESSION; TERNARY COMPLEX; KINASE	The cloning of receptor targets procedure, used so far to identify proteins associated with tyrosine kinase receptors was modified to clone SH2 proteins able to bind to the growth hormone receptor (GHR). The cytoplasmic region of GHR, a member of the cytokine receptor superfamily does not contain tyrosine kinase activity. It was thus phosphorylated in bacteria by the Elk tyrosine kinase and radiolabeled to screen a mouse expression library. With this probe, we identified Shc and the p85 subunit of phosphatidylinositol 3-kinase as direct targets of the receptor. The other proteins identified, Csk, Shb, Grb4, and Grb10 are new potential transducers for cytokine receptors, We show in Huh-7 hepatoma cells that Grb10 and GHR associate under GH stimulation, Co-transfections in 293 cells further show that Grb10 interacts with both the GHR and Jak2, Functional tests demonstrate that Grb10 inhibits transcription of two reporter genes containing, respectively, the serum response element of c-fos and the GH response element 2 of the Spi2.1 gene, whereas it has no effect on a reporter gene containing only Stat5 binding elements. Our results suggest that Grb10 is a new target for a member of the cytokine receptor family that down-regulates some GH signaling pathways downstream of Jak2 and independently of Stat5.	Fac Med Necker, INSERM, U344, F-75730 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Finidori, J (corresponding author), Fac Med Necker, INSERM, U344, 156 Rue Vaugirard, F-75730 Paris 15, France.		Kelly, Paul/A-7951-2008					ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; DINERSTEIN H, 1995, MOL ENDOCRINOL, V9, P1701, DOI 10.1210/me.9.12.1701; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; EDMONDSON SR, 1995, ENDOCRINOLOGY, V136, P4602, DOI 10.1210/en.136.10.4602; ESPOSITO N, 1994, MOL CELL ENDOCRINOL, V103, P13, DOI 10.1016/0303-7207(94)90064-7; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; Galsgaard ED, 1996, MOL ENDOCRINOL, V10, P652, DOI 10.1210/me.10.6.652; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; HANSEN H, 1996, J BIOL CHEM, V271, P23588; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Karlsson T, 1996, ONCOGENE, V13, P955; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; LECOM A, 1994, J BIOL CHEM, V269, P21532; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Manser J, 1997, DEV BIOL, V184, P150, DOI 10.1006/dbio.1997.8516; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARGOLIS B, 1995, METHOD ENZYMOL, V255, P360; METZ R, 1991, ONCOGENE, V6, P2165; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; MULLIS PE, 1991, MOL CELL ENDOCRINOL, V76, P125, DOI 10.1016/0303-7207(91)90267-V; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOLER C, 1994, J BIOL CHEM, V269, P12320; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WANG XY, 1993, J BIOL CHEM, V268, P3573; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; WELSH M, 1994, ONCOGENE, V9, P19; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; XU XO, 1995, ENDOCRINOLOGY, V136, P4551, DOI 10.1210/en.136.10.4551; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	56	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15906	15912		10.1074/jbc.273.26.15906	http://dx.doi.org/10.1074/jbc.273.26.15906			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632636	hybrid			2022-12-25	WOS:000074436600007
J	Irie, A; Koyama, S; Kozutsumi, Y; Kawasaki, T; Suzuki, A				Irie, A; Koyama, S; Kozutsumi, Y; Kawasaki, T; Suzuki, A			The molecular basis for the absence of N-glycolylneuraminic acid in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; MOUSE-LIVER CYTOSOL; ACETYLNEURAMINIC ACID; SIALIC-ACID; IMMUNOGLOBULIN SUPERFAMILY; GLYCOLYNEURAMINIC ACID; CELL GLYCOLIPIDS; HYDROXYLATION; BIOSYNTHESIS; GANGLIOSIDES	N-Glycolylneuraminic acid (NeuGc) is abundantly expressed in most mammals, but it is not detectable in humans. The expression of NeuGc is controlled by cytidine monophospho-N-acetylneuraminic acid (CMPNeuAc) hydroxylase activity. We previously cloned a cDNA for mouse CMP-NeuAc hydroxylase and found that the human genome contains a homologue, We report here the molecular basis for the absence of NeuGc in humans. We cloned a cDNA for human CMP-NeuAc hydroxylase from a HeLa cell cDNA library. The cDNA encodes a 486-amino acid protein, and its deduced amino acid sequence lacks a domain corresponding to the N-terminal 104 amino acids of the mouse CMP-NeuAc hydroxylase protein, although the human protein is highly identical (93%) to the rest of the mouse hydroxylase protein. The N-terminal truncation of the human hydroxylase is caused by deletion of a 92-base pair-long exon in human genomic DNA. The human by. droxylase expressed in COS-7 cells exhibited no enzymatic activity, and a mouse hydroxylase mutant, which lacks the N-terminal domain, was also inactive. A chimera composed of the human hydroxylase and the N-terminal domain of the mouse hydroxylase displayed the enzyme activity. These results indicate that the human homologue of CMP-NeuAc hydroxylase is inactive because it lacks an N-terminal domain that is essential for enzyme activity. The absence of NeuGc in human glycoconjugates is due to a partial deletion in the gene that encodes CMP-NeuAc hydroxylase.	Tokyo Metropolitan Inst Med Sci, Dept Membrane Biochem, Bunkyo Ku, Tokyo 1138613, Japan; Kyoto Univ, Fac Pharmaceut Sci, Dept Biol Chem, Sakyo Ku, Kyoto 6068304, Japan	Tokyo Metropolitan Institute of Medical Science; Kyoto University	Suzuki, A (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Membrane Biochem, Bunkyo Ku, Tokyo 1138613, Japan.	asuzuki@rinshoken.or.jp						BOUHOURS D, 1988, J BIOL CHEM, V263, P15540; BUSCHER HP, 1977, EUR J BIOCHEM, V77, P297, DOI 10.1111/j.1432-1033.1977.tb11668.x; DENEKE CF, 1984, INFECT IMMUN, V45, P522, DOI 10.1128/IAI.45.2.522-524.1984; FURUKAWA K, 1988, J BIOL CHEM, V263, P18507; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1985, J EXP MED, V162, P573, DOI 10.1084/jem.162.2.573; HAMANAKA S, 1979, J BIOCHEM-TOKYO, V86, P695, DOI 10.1093/oxfordjournals.jbchem.a132573; HASHIMOTO Y, 1984, J BIOCHEM-TOKYO, V96, P1777, DOI 10.1093/oxfordjournals.jbchem.a135010; HIGA HH, 1985, VIROLOGY, V144, P279, DOI 10.1016/0042-6822(85)90325-3; HIGASHI H, 1977, BIOCHEM BIOPH RES CO, V79, P388, DOI 10.1016/0006-291X(77)90169-3; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; KAWANO T, 1995, J BIOL CHEM, V270, P16458, DOI 10.1074/jbc.270.27.16458; KAWANO T, 1993, GLYCOCONJUGATE J, V10, P109, DOI 10.1007/BF00731194; KAWANO T, 1994, J BIOL CHEM, V269, P9024; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; Kelm S, 1996, GLYCOCONJUGATE J, V13, P913, DOI 10.1007/BF01053186; Koyama S, 1996, GLYCOCONJUGATE J, V13, P353, DOI 10.1007/BF00731467; KOZUTSUMI Y, 1991, J BIOCHEM, V110, P429, DOI 10.1093/oxfordjournals.jbchem.a123598; KOZUTSUMI Y, 1990, J BIOCHEM, V108, P704, DOI 10.1093/oxfordjournals.jbchem.a123268; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LEPERS A, 1990, EUR J BIOCHEM, V193, P715, DOI 10.1111/j.1432-1033.1990.tb19391.x; Marquina G, 1996, CANCER RES, V56, P5165; MERRICK JM, 1978, INT ARCH ALLER A IMM, V57, P477, DOI 10.1159/000232140; MUCHMORE EA, 1989, J BIOL CHEM, V264, P20216; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SCHAUER R, 1971, H-S Z PHYSIOL CHEM, V352, P1282, DOI 10.1515/bchm2.1971.352.2.1282; SCHAUER R, 1982, CELL BIOL MONOGR, V10, P374; Schlenzka W, 1996, FEBS LETT, V385, P197, DOI 10.1016/0014-5793(96)00384-5; SHAW L, 1988, BIOL CHEM H-S, V369, P477, DOI 10.1515/bchm3.1988.369.1.477; SHAW L, 1989, BIOCHEM J, V263, P355, DOI 10.1042/bj2630355; SMIT H, 1984, INFECT IMMUN, V46, P578, DOI 10.1128/IAI.46.2.578-584.1984; SUZUKI Y, 1987, BIOCHIM BIOPHYS ACTA, V903, P417, DOI 10.1016/0005-2736(87)90048-4; TAKEMATSU H, 1994, J BIOCHEM-TOKYO, V115, P381, DOI 10.1093/oxfordjournals.jbchem.a124347; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; YASUE S, 1978, J BIOCHEM-TOKYO, V83, P1101, DOI 10.1093/oxfordjournals.jbchem.a131999	38	280	297	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15866	15871		10.1074/jbc.273.25.15866	http://dx.doi.org/10.1074/jbc.273.25.15866			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624188	hybrid			2022-12-25	WOS:000074284200082
J	Saxena, M; Williams, S; Gilman, J; Mustelin, T				Saxena, M; Williams, S; Gilman, J; Mustelin, T			Negative regulation of T cell antigen receptor signal transduction by hematopoietic tyrosine phosphatase (HePTP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; PHOSPHORYLATION; ACTIVATION; KINASE; CD45; INVOLVEMENT; INHIBITION; EXPRESSION; P72(SYK)	The hematopoietic tyrosine phosphatase (HePTP) is predominantly expressed in thymocytes and T lymphocytes and at lower levels in other hematopoietic cells. Expression of the gene is enhanced by the T cell growth factor interleukin-2, suggesting a role for HePTP in T cell proliferation or differentiation. We report that HePTP blocks T cell antigen receptor (TCR)-induced transcriptional activation of a reporter gene drivels by a nuclear factor of activated T cells(NFAT)/AP-1 element taken from the interleukin-2 genre promotes. This effect was specific to HePTP and was abolished by a mutation (C270S) that impaired its phosphatase activity. Co-expression of HePTP also reduced TCR-induced activation of the mitogen-activated protein kinase Erk2 and the TCR-induced appearance of phosphorylated Erk. In contrast, HePTP did not affect the activation of the N-terminal e-Jun kinase, Jnk. Together these findings suggest that HePTP plays an active negative role in TCR signaling by dephosphorylating one or several signaling molecules between the receptor and the mitogen-activated protein kinase pathway.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Mustelin, T (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.			Mustelin, Tomas/0000-0001-5912-8840	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI141481, R01AI041481, R01AI035603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048960] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35603, AI41481] Funding Source: Medline; NIGMS NIH HHS [GM48960] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAICHI M, 1994, ONCOGENE, V9, P3031; ADAICHI M, 1994, FEBS LETT, V338, P47; ADAICHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; FARGNOLI J, 1995, J BIOL CHEM, V270, P26533, DOI 10.1074/jbc.270.44.26533; FONATSCH C, 1991, CANCER GENET CYTOGEN, V56, P243, DOI 10.1016/0165-4608(91)90177-V; IMBODEN JB, 1995, CURR BIOL, V5, P727, DOI 10.1016/S0960-9822(95)00145-X; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; MAMAEV N, 1988, CANCER GENET CYTOGEN, V35, P21, DOI 10.1016/0165-4608(88)90116-1; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSTELIN T, 1990, ONCOGENE, V5, P809; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6502; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Schultz Leonard D., 1993, Cell, V73, P1445; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SWIETER M, 1995, J BIOL CHEM, V270, P21902, DOI 10.1074/jbc.270.37.21902; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; Tailor P, 1996, EUR J BIOCHEM, V237, P736, DOI 10.1111/j.1432-1033.1996.0736p.x; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; Williams S, 1997, EUR J BIOCHEM, V245, P84, DOI 10.1111/j.1432-1033.1997.00084.x; ZANKE B, 1994, LEUKEMIA, V8, P236; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134	29	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15340	15344		10.1074/jbc.273.25.15340	http://dx.doi.org/10.1074/jbc.273.25.15340			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624114	hybrid			2022-12-25	WOS:000074284200008
J	Yeilding, NM; Procopio, WN; Rehman, MT; Lee, WMF				Yeilding, NM; Procopio, WN; Rehman, MT; Lee, WMF			c-myc mRNA is down-regulated during myogenic differentiation by accelerated decay that depends on translation of regulatory coding elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; PROTEIN-SYNTHESIS; POSTTRANSCRIPTIONAL REGULATION; CELL-DIFFERENTIATION; GENE-EXPRESSION; GROWTH-FACTORS; DAUDI CELLS; F9 CELLS; TRANSCRIPTION	Murine C2C12 myoblasts induced to differentiate into multinucleated myotubes decrease their levels of c-myc mRNA 3-10-fold through posttranscriptional mechanisms that recognize regulatory elements contained in protein-coding sequences in exons 2 and 3 of the mRNA, To determine the mechanism by which these elements mediate c-myc mRNA down-regulation, we examined the regulation of mutant MYC and human beta-globin-MYC fusion mRNAs, Regulation of mRNAs containing MYC exon 2 or 3 is abolished by insertion of an upstream termination codon indicating that regulatory function depends on their translation. Exploiting this translation dependence, we show that pharmacologic inhibition of translation with cycloheximide abolishes the down-regulation of regulated MYC and globin-MYC mRNAs and induces their levels in differentiating C2C12 cells. We exclude the possibility that this induction in mRNA levels results from cycloheximide effects on transcription or processing of parts of the RNA other than the regulatory elements, leading to the conclusion that cycloheximide induction results from mRNA stabilization. We show that the magnitude of cycloheximide induction can be used to estimate turnover rates of mRNAs whose decay is translation-dependent. By using cycloheximide inducibility to examine turnover rates of MYC and globin-MYC mRNAs, we show that the MYB:exon 2 and exon 3 regulatory elements, but not MYC 3'-untranslated region or chloramphenicol acetyltransferase coding sequences, mediate accelerated mRNA decay in differentiating, but not undifferentiated, C2C12 cells. We show that these regulatory elements must be translated to confer accelerated mRNA decay and that increased turnover occurs in the cytoplasm and not in the nucleus. Finally, using cycloheximide induction to examine mRNA half-lives, we show that mRNA turnover is increased sufficiently by mechanisms targeting the exon 2 and 3 regulatory elements to account for the magnitude of c-myc mRNA down-regulation during differentiation. We conclude from these results that c-myc mRNA downregulation during myogenic differentiation is due to translation-dependent mechanisms that target mRNAs containing myc exon 2 and 3 regulatory elements for accelerated decay.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Lee, WMF (corresponding author), Univ Penn, Dept Med, 663 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	leemingf@mail.med.upenn.edu			NIAMS NIH HHS [AR01956] Funding Source: Medline; NIGMS NIH HHS [GM47147] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047147] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BLAU HM, 1985, SCIENCE, V230, P458; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DONY C, 1985, NATURE, V317, P637; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; GROSSO LE, 1985, CANCER RES, V45, P847; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KNIGHT E, 1985, P NATL ACAD SCI USA, V82, P1151, DOI 10.1073/pnas.82.4.1151; LASKI FA, 1982, NUCLEIC ACIDS RES, V10, P4609, DOI 10.1093/nar/10.15.4609; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAVENU A, 1995, MOL CELL BIOL, V15, P4410; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PARKER R, 1990, P NATL ACAD SCI USA, V87, P2780, DOI 10.1073/pnas.87.7.2780; Pistoi S, 1996, MOL CELL BIOL, V16, P5107; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; THEODORAKIS NG, 1996, TRANSLATIONAL CONTRO, P631; WANG XM, 1995, MOL CELL BIOL, V15, P1769; WHITTEMORE LA, 1990, MOL CELL BIOL, V10, P1329, DOI 10.1128/MCB.10.4.1329; WISDOM R, 1990, J BIOL CHEM, V265, P19015; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; Yeilding NM, 1997, MOL CELL BIOL, V17, P2698, DOI 10.1128/MCB.17.5.2698; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	41	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15749	15757		10.1074/jbc.273.25.15749	http://dx.doi.org/10.1074/jbc.273.25.15749			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624173	hybrid			2022-12-25	WOS:000074284200067
J	Bridgewater, LC; Lefebvre, V; de Crombrugghe, B				Bridgewater, LC; Lefebvre, V; de Crombrugghe, B			Chondrocyte-specific enhancer elements in the Col11a2 gene resemble the Col2a1 tissue-specific enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ALPHA-1(II) COLLAGEN GENE; AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; TRANSGENIC MICE; CAMPOMELIC DYSPLASIA; EXPRESSION; CARTILAGE; SOX9; DIFFERENTIATION; CHONDROGENESIS	Type XI collagen and type II collagen are coexpressed in all cartilage, and both are essential for normal cartilage differentiation and skeletal morphogenesis, This laboratory has recently identified a 48-base pair (bp) enhancer element in the type II collagen gene Col2a1 that contains several HMG-type protein-binding sites and that can direct chondrocyte-specific expression in transient transfection and in transgenic mice. The present study has identified two short chondrocyte-specific enhancer elements within a region in the 5' portion of the type XI collagen gene Col11a2 that has previously been shown to influence chondrocyte-specific expression in transgenic mice. These Col11a2 enhancer elements, like the Col2a1 enhancer, contain several sites with homology to the high mobility group (HMG) protein-binding consensus sequence. In electrophoretic mobility shift assays, the Col11a2 elements formed a DNA-protein complex that was dependent on the presence of the HMG-like sites. It had the same mobility as the complex formed with the Col2a1 48-bp enhancer and appeared to contain the same or similar proteins, including SOX9, The Col11a2 elements directed gene expression in transient transfections of chondrocytes but not fibroblasts, and their activity was abolished by mutation of the HMG-like sites. Ectopically expressed SOX9 activated these enhancers in non-chondrocytic cells, as it also activates the Col2a1 enhancer. Finally, the Col11a2 enhancer elements both directed transgene expression to cartilage in developing mouse embryos. Overall, our results indicate that the two Col11a2 chondrocyte-specific enhancer elements share many similarities with the Col2a1 48-bp enhancer. These similarities suggest the existence of a genetic program designed to coordinately regulate the expression of these and perhaps other genes involved in the chondrocyte differentiation pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	de Crombrugghe, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Bridgewater, Laura C/I-2999-2015	Bridgewater, Laura C/0000-0002-4664-6144	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NIAMS NIH HHS [AR42919] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; CHAN D, 1995, J BIOL CHEM, V270, P1747, DOI 10.1074/jbc.270.4.1747; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GAROFALO S, 1991, P NATL ACAD SCI USA, V88, P9648, DOI 10.1073/pnas.88.21.9648; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HARLOW E, 1988, ANTIBODIES LAB MANUA, P314; Healy C, 1996, ANN NY ACAD SCI, V785, P261, DOI 10.1111/j.1749-6632.1996.tb56278.x; KWOK C, 1995, AM J HUM GENET, V57, P1028; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LI SW, 1995, GENE DEV, V9, P2821, DOI 10.1101/gad.9.22.2821; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Sudbeck P, 1996, NAT GENET, V13, P230, DOI 10.1038/ng0696-230; Tsumaki N, 1996, J CELL BIOL, V134, P1573, DOI 10.1083/jcb.134.6.1573; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; von der Mark K, 1980, Curr Top Dev Biol, V14, P199; VUORISTO MM, 1995, J BIOL CHEM, V270, P22873, DOI 10.1074/jbc.270.39.22873; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989; ZHOU G, 1995, J CELL SCI, V108, P3677	28	220	229	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14998	15006		10.1074/jbc.273.24.14998	http://dx.doi.org/10.1074/jbc.273.24.14998			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614107	hybrid			2022-12-25	WOS:000074160400049
J	Chen, SRW; Ebisawa, K; Li, XL; Zhang, L				Chen, SRW; Ebisawa, K; Li, XL; Zhang, L			Molecular identification of the ryanodine receptor Ca2+ sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; CDNA; EXPRESSION; ISOFORMS; CLONING; CELL	We have investigated the molecular basis for ryanodine receptor (RyR) activation by Ca2+ by using site-directed mutagenesis together with functional assays consisting of Ca2+ release measurements and single channel recordings in planar lipid bilayers, We report here that a single substitution of alanine for glutamate at position 3885 (located in the putative transmembrane sequence M2 of the type 3 RyR) reduces the Ca2+ sensitivity, as measured by single channel activation, by more than 10,000-fold, without apparent changes in channel conductance and in modulation by other ligands (e.g. ATP and ryanodine). Co-expression of the wild type and mutant RyR proteins results in the synthesis of single channels that have intermediate Ca2+ sensitivities. These results suggest that the glutamates at position 3885 of each monomer may act in a coordinated way to form the Ca2+ sensor in the tetrameric structure corresponding to RyR.	Univ Calgary, Dept Med Biochem, Cardiovasc Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	Chen, SRW (corresponding author), Univ Calgary, Dept Med Biochem, Cardiovasc Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	swchen@acs.ucalgary.ca						BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; EBASHI E, 1991, ANNU REV PHYSIOL, V53, P1; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Meissner G, 1997, J BIOL CHEM, V272, P1628, DOI 10.1074/jbc.272.3.1628; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Mickelson JR, 1996, PHYSIOL REV, V76, P537, DOI 10.1152/physrev.1996.76.2.537; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; OTSU K, 1990, J BIOL CHEM, V265, P13472; Ottini L, 1996, BIOCHEM J, V315, P207, DOI 10.1042/bj3150207; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; Sakube Y, 1997, J MOL BIOL, V267, P849, DOI 10.1006/jmbi.1997.0910; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1994, FEBS LETT, V337, P81, DOI 10.1016/0014-5793(94)80634-9; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; Zucchi R, 1997, PHARMACOL REV, V49, P1	29	109	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14675	14678		10.1074/jbc.273.24.14675	http://dx.doi.org/10.1074/jbc.273.24.14675			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614063	hybrid			2022-12-25	WOS:000074160400005
J	Lavagna-Sevenier, C; Marchetto, S; Birnbaum, D; Rosnet, O				Lavagna-Sevenier, C; Marchetto, S; Birnbaum, D; Rosnet, O			The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE RECEPTOR; EPIDERMAL GROWTH-FACTOR; C-CBL; HEMATOPOIETIC-CELLS; ANTIGEN RECEPTOR; EXCHANGE PROTEIN; BINDING-SITE; JURKAT CELLS; EGF RECEPTOR; MURINE FLT3	The FLT3 receptor tyrosine kinase and its ligand, FL, play an important role in early hematopoietic development. We have found that CBLB, a recently characterized molecule closely related to the CBL protooncogene product, is phosphorylated on tyrosine(s) following FL treatment of JEA2 human pro-B cells and THP1 monocytic cells. Treatment of JEA2 cells with interleukin (IL)-7 induces CBLB phosphorylation as well. FL and IL-7, respectively, induce and increase association of tyrosine-phosphorylated SHC and the p85 subunit of phosphatidylinositol 3'-kinase with CBLB. In these cells, CBLB constitutively binds the GRB2 adaptor predominantly through its N-terminal SH3 domain, to form a complex that is distinct from the GRB2.CBL and GRB2.SOS1 complexes. Together with the fact that CBLB is consistently found in blast cells from acute leukemias and in peripheral blood mononuclear cells, this suggests that CBLB has a role in tyrosine kinase-regulated signaling pathways in many hematolymphoid cells.	INSERM, U119, Mol Oncol Lab, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Rosnet, O (corresponding author), INSERM, U119, Mol Oncol Lab, 27 Blvd Lei Roure, F-13009 Marseille, France.	rosnet@marseille.inserm.fr	Rosnet, Olivier/G-3536-2013	Rosnet, Olivier/0000-0002-3020-910X				BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; BIRG F, 1992, BLOOD, V80, P2584; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BRASEL K, 1995, LEUKEMIA, V9, P1212; Brizzi MF, 1996, ONCOGENE, V13, P2067; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CASTERAN N, 1994, CELL MOL BIOL, V40, P443; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; Drexler HG, 1996, LEUKEMIA, V10, P588; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FOURNIER E, 1995, ONCOGENE, V11, P921; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GABBIANELLI M, 1995, BLOOD, V86, P1661, DOI 10.1182/blood.V86.5.1661.bloodjournal8651661; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; Hunte BE, 1996, J IMMUNOL, V156, P489; KEANE MM, 1995, ONCOGENE, V10, P2367; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; LANGDON W, 1996, AUST NZ J MED, V25, P859; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lavagna-Sevenier C, 1998, LEUKEMIA, V12, P301, DOI 10.1038/sj.leu.2400921; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lyman S D, 1995, Curr Opin Hematol, V2, P177; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Rappold I, 1997, BLOOD, V90, P111; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Rosnet O, 1996, LEUKEMIA, V10, P238; ROSNET O, 1991, ONCOGENE, V6, P1641; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Veiby OP, 1996, BLOOD, V88, P1256, DOI 10.1182/blood.V88.4.1256.bloodjournal8841256; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WASSERMAN R, 1995, J IMMUNOL, V155, P644; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	48	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14962	14967		10.1074/jbc.273.24.14962	http://dx.doi.org/10.1074/jbc.273.24.14962			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614102	hybrid			2022-12-25	WOS:000074160400044
J	Muzzin, O; Campbell, EA; Xia, LL; Severinova, E; Darst, SA; Severinov, K				Muzzin, O; Campbell, EA; Xia, LL; Severinova, E; Darst, SA; Severinov, K			Disruption of Escherichia coli HepA, an RNA polymerase-associated protein, causes UV sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE HELICASES; DNA; EXPRESSION; FAMILY; CHROMATOGRAPHY; RECOMBINATION; SIMILARITY; ELONGATION; REPAIR; SNF2	During the development of purification procedures for Escherichia coli RNA polymerase (RNAP), we noticed the consistent co-purification of a 110-kDa polypeptide. Here, we report the identification of the 110-kDa protein as the product of the hepA gene, a member of the SNF2 family of putative helicases. We have cloned the hepA gene and overexpressed and purified the HepA protein. We show in vitro that RNAP preparations have an ATPase activity only in the presence of HepA and that HepA binds core RNAP competitively with the promoter specificity sigma(70) subunit with a 1:1 stoichiometry and a dissociation constant (K-d) Of 75 nM. An E. coli strain with a disruption in the hepA gene shows sensitivity to ultraviolet light.	Rockefeller Univ, New York, NY 10021 USA; Rutgers State Univ, Waksman Inst, Piscataway, NJ 08855 USA	Rockefeller University; Rutgers State University New Brunswick	Darst, SA (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	darst@rockvax.rockefeller.edu	Severinov, Konstantin/C-8545-2016	Campbell, Elizabeth/0000-0002-1332-128X				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P852; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; IWASAKI H, 1991, MOL GEN GENET, V226, P24, DOI 10.1007/BF00273583; KOLSTO AB, 1993, J MOL BIOL, V230, P684, DOI 10.1006/jmbi.1993.1185; LEWIS LK, 1992, J BACTERIOL, V174, P3377, DOI 10.1128/jb.174.10.3377-3385.1992; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; PEREZCASAL J, 1991, J BACTERIOL, V173, P2617, DOI 10.1128/jb.173.8.2617-2624.1991; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; YURA T, 1992, NUCLEIC ACIDS RES, V20, P3305, DOI 10.1093/nar/20.13.3305; ZOU C, 1994, J MOL BIOL, V236, P1283, DOI 10.1016/0022-2836(94)90057-4	22	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15157	15161		10.1074/jbc.273.24.15157	http://dx.doi.org/10.1074/jbc.273.24.15157			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614128	hybrid			2022-12-25	WOS:000074160400070
J	Ruscetti, T; Lehnert, BE; Halbrook, J; Le Trong, H; Hoekstra, MF; Chen, DJ; Peterson, SR				Ruscetti, T; Lehnert, BE; Halbrook, J; Le Trong, H; Hoekstra, MF; Chen, DJ; Peterson, SR			Stimulation of the DNA-dependent protein kinase by poly(ADP-ribose) polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-BREAK-REPAIR; V(D)J RECOMBINATION; BINDING-PROTEIN; CATALYTIC SUBUNIT; KU AUTOANTIGEN; END-BINDING; NUCLEAR; INHIBITION; CELLS; PK	The DNA-dependent protein kinase (DNA-PK) is a heterotrimeric enzyme that binds to double-stranded DNA and is required for the rejoining of double-stranded DNA breaks in mammalian cells. It has been proposed that DNA-PK functions in this DNA repair pathway by binding to the ends of broken DNA molecules and phosphorylating proteins that bind to the damaged DNA ends. Another enzyme that binds to DNA strand breaks and may also function in the cellular response to DNA damage is the poly(ADP-ribose) polymerase (PARP), Here, we show that PARP can be phosphorylated by purified DNA-PK, and the catalytic subunit of DNA-PK is ADP-ribosylated by PARP, The protein kinase activity of DNA-PK can be stimulated by PARP in the presence of NAD(+) in a reaction that is blocked by the PARP inhibitor 1,5-dihydroxyiso-quinoline. The stimulation of DNA-PK by PARP-mediated protein ADP-ribosylation occurs independent of the Ku70/80 complex. Taken together, these results show that PARP can modify the activity of DNA-PK in vitro and suggest that these enzymes may function coordinately in vivo in response to DNA damage.	Univ Calif Los Alamos Natl Lab, Cell & Mol Biol Grp LS4, Los Alamos, NM 87545 USA; Univ Calif Los Alamos Natl Lab, Div Life Sci, DNA Damage & Repair Grp LS6, Los Alamos, NM 87545 USA; ICOS Corp, Bothell, WA 98021 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; Icos Corporation	Peterson, SR (corresponding author), Mail Stop M888, Los Alamos, NM 87545 USA.				NCI NIH HHS [CA50519] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050519, R37CA050519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BAUER PI, 1992, BIOCHEM BIOPH RES CO, V187, P730, DOI 10.1016/0006-291X(92)91256-P; BAUER PI, 1994, BBA-MOL CELL RES, V1223, P234, DOI 10.1016/0167-4889(94)90231-3; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; BOULIKAS T, 1993, TOXICOL LETT, V67, P129, DOI 10.1016/0378-4274(93)90051-X; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; CHEN F, 1995, MUTAT RES, V362, P9; DARBY MK, 1985, EMBO J, V4, P2129, DOI 10.1002/j.1460-2075.1985.tb03903.x; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; FERRO AM, 1983, J BIOL CHEM, V258, P6000; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEESMILLER SP, 1991, CANCER CELL-MON REV, V3, P341; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LI LL, 1992, EXP CELL RES, V199, P262, DOI 10.1016/0014-4827(92)90433-9; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Peterson SR, 1997, J BIOL CHEM, V272, P10227; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SASTRY SS, 1989, BIOCHEMISTRY-US, V28, P5670, DOI 10.1021/bi00439a050; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Shah GM, 1996, BBA-MOL CELL RES, V1312, P1, DOI 10.1016/0167-4889(96)00004-3; SIMBULAN CMG, 1993, J BIOL CHEM, V268, P93; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TSUTSUI K, 1993, J BIOL CHEM, V268, P12886; VONKRIES JP, 1994, NUCLEIC ACIDS RES, V22, P1215, DOI 10.1093/nar/22.7.1215; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4	53	197	206	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14461	14467		10.1074/jbc.273.23.14461	http://dx.doi.org/10.1074/jbc.273.23.14461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603959	hybrid			2022-12-25	WOS:000074021500061
J	Yamashita, RA; May, GS				Yamashita, RA; May, GS			Constitutive activation of endocytosis by mutation of myoA, the myosin I gene of Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; SACCHAROMYCES-CEREVISIAE; YEAST; ACTIN; IDENTIFICATION; MORPHOGENESIS; CYTOSKELETON; INVOLVEMENT; EXPRESSION; SECRETION	Class I myosins function in cell motility, intracellular vesicle trafficking and endocytosis, Recently, it was shown that class I myosins are phosphorylated by a member of the pal-activated kinase (PAK) family. PAK phosphorylates a conserved serine or threonine residue in the myosin heavy chain. Phosphorylation at this site is required for maximal activation of the actin-activated Mg2+-ATPase activity in vitro. This serine or threonine residue is conserved En all known class I myosins of microbial origin and in the human and mouse class VI myosins. We have investigated the in vivo significance of this phosphorylation by mutating serine 371 of the class I myosin heavy chain gene myoA of Aspergillus nidulans. Mutation to glutamic acid, which mimics phosphorylation and therefore activation of the myosin, results in ale accumulation of membranes in growing hyphae. This accumulation of membranes results from an activation of endocytosis, In contrast, mutation of serine 371 to alanine had no discernible effect ore endocytosis. These studies are the first to demonstrate the in vivo significance of a regulatory phosphorylation on a class I myosin. Furthermore, our results suggest that MYOA has two functions, one dependent and one independent of phosphorylation.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	May, GS (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.							AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HANSON T, 1995, CURR OPIN CELL BIOL, V7, P587; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; LAZZARINO DA, 1994, MOL BIOL CELL, V5, P807, DOI 10.1091/mbc.5.7.807; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; LIU HP, 1992, J CELL BIOL, V118, P285, DOI 10.1083/jcb.118.2.285; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; RODRIGUEZ JR, 1990, CELL MOTIL CYTOSKEL, V17, P301, DOI 10.1002/cm.970170405; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SIMON VR, 1995, J CELL BIOL, V130, P345, DOI 10.1083/jcb.130.2.345; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WARING RB, 1989, GENE, V79, P119, DOI 10.1016/0378-1119(89)90097-8; WEATHERBEE JA, 1985, J CELL BIOL, V101, P706, DOI 10.1083/jcb.101.3.706	26	70	74	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14644	14648		10.1074/jbc.273.23.14644	http://dx.doi.org/10.1074/jbc.273.23.14644			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603982	hybrid			2022-12-25	WOS:000074021500084
J	Stachowiak, O; Dolder, M; Wallimann, T; Richter, C				Stachowiak, O; Dolder, M; Wallimann, T; Richter, C			Mitochondrial creatine kinase is a prime target of peroxynitrite-induced modification and inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-FREE-RADICALS; NITRIC-OXIDE; SARCOPLASMIC-RETICULUM; HYDROGEN-PEROXIDE; BINDING; MUSCLE; HEART; SUPEROXIDE; CA2+; RESPIRATION	The reaction of peroxynitrite (PN) with sarcomeric mitochondrial creatine kinase (Mi(b)-CK; EC 2.7.3.2) was observed at different stages of complexity (i) with purified Mi-CK, (ii) with enzyme bound on isolated mitoplasts, and (iii) within intact respiring mitochondria. Creatine-stimulated respiration was abolished by PN concentrations likely to be physiological and far before the respiratory chain itself was affected, thus demonstrating that Mi-CK is a prime target for inactivation by PN in intact mitochondria. The inactivation by PN of Mi CK was reversed by 22% with 2-mercaptoethanol. More remarkable protective effects were noticed with the full set of CK substrates, e.g. 30 and 50% protection with MgATP plus creatine and MgADP plus phosphocreatine, respectively, but not with each substrate alone. These data indicate an involvement of the active-site Cys-278 residue of Mi CK in this process. Furthermore, changes in endogenous tryptophan fluorescence intensity and spectral changes after reaction of Mi-CK with PN suggest additional modifications of Trp and Tyr residues. PN-inactivated Mi-CK can no longer be efficiently converted into dimers by incubation with reagents inducing a transition state analog complex at the active site. Thus, obviously, upon reaction of octameric Mi-CK with PN, the octamer-dimer equilibrium of Mi-CK is also affected. The consequences for cellular energy homeostasis and calcium handling are discussed.	ETH Zurich, Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland; ETH Zurich, Biochem Lab 1, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Wallimann, T (corresponding author), ETH Zurich, Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland.	walliman@cell.biol.ethz.ch	Wallimann, Theo/C-6047-2008	Wallimann, Theo/0000-0003-4957-5836				AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; BANERJEE A, 1991, AM J PHYSIOL, V261, pH590, DOI 10.1152/ajpheart.1991.261.2.H590; Bates TE, 1996, BIOCHEM BIOPH RES CO, V218, P40, DOI 10.1006/bbrc.1996.0008; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY MR, 1995, BIOCHEMISTRY-US, V34, P2006, DOI 10.1021/bi00006a022; DARLEYUSMAR V, 1995, FEBS LETT, V369, P131, DOI 10.1016/0014-5793(95)00764-Z; DENICOLA A, 1993, ARCH BIOCHEM BIOPHYS, V304, P279, DOI 10.1006/abbi.1993.1350; EPPENBERGER HM, 1981, J CELL BIOL, V89, P185, DOI 10.1083/jcb.89.2.185; Forstner M, 1996, J MOL STRUCT, V383, P217, DOI 10.1016/S0022-2860(96)09289-7; FURTER R, 1992, BIOCHEM J, V288, P771, DOI 10.1042/bj2880771; FURTER R, 1993, BIOCHEMISTRY-US, V32, P7022, DOI 10.1021/bi00078a030; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; GROSS M, 1994, PROTEIN SCI, V3, P1058, DOI 10.1002/pro.5560030708; GROSS M, 1993, BIOCHEMISTRY-US, V32, P13933, DOI 10.1021/bi00213a024; Gross WL, 1996, P NATL ACAD SCI USA, V93, P5604, DOI 10.1073/pnas.93.11.5604; HAMMAN BL, 1995, AM J PHYSIOL-HEART C, V269, pH1030, DOI 10.1152/ajpheart.1995.269.3.H1030; KAUL N, 1993, J PHARMACOL TOX MET, V30, P55, DOI 10.1016/1056-8719(93)90008-3; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; KORGE P, 1994, AM J PHYSIOL, V267, pC357, DOI 10.1152/ajpcell.1994.267.2.C357; KORGE P, 1993, ARCH BIOCHEM BIOPHYS, V304, P420, DOI 10.1006/abbi.1993.1370; KOTTKE M, 1988, BIOCHIM BIOPHYS ACTA, V935, P87, DOI 10.1016/0005-2728(88)90111-9; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MCCORD JM, 1994, CURR TOP BIOENERG, V17, P173; Mekhfi H, 1996, CIRC RES, V78, P1016, DOI 10.1161/01.RES.78.6.1016; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; OGorman E, 1996, BBA-BIOENERGETICS, V1276, P161, DOI 10.1016/0005-2728(96)00074-6; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; Padmaja S, 1996, REDOX REP, V2, P173, DOI 10.1080/13510002.1996.11747045; RADI R, 1991, J BIOL CHEM, V266, P4244; Ramezanian MS, 1996, CHEM RES TOXICOL, V9, P232, DOI 10.1021/tx950135w; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; RICHTER C, 1993, FEBS LETT, V325, P104, DOI 10.1016/0014-5793(93)81423-W; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SCHLAME M, 1985, BIOMED BIOCHIM ACTA, V44, P1083; Schweizer M, 1996, BIOCHEMISTRY-US, V35, P4524, DOI 10.1021/bi952708+; Stachowiak O, 1996, BIOCHEMISTRY-US, V35, P15522, DOI 10.1021/bi961838v; STACHOWIAK O, 1998, IN PRESS MOL CELL BI; STADHOUDERS AM, 1994, P NATL ACAD SCI USA, V91, P5089, DOI 10.1073/pnas.91.11.5089; SUZUKI YJ, 1992, FREE RADICAL RES COM, V16, P131, DOI 10.3109/10715769209049166; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; TURRENS JF, 1991, FREE RADICAL RES COM, V12-3, P681, DOI 10.3109/10715769109145847; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; Wolosker H, 1996, FEBS LETT, V392, P274, DOI 10.1016/0014-5793(96)00829-0; YUAN GX, 1992, BIOCHIM BIOPHYS ACTA, V1140, P78, DOI 10.1016/0005-2728(92)90022-T	54	155	156	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16694	16699		10.1074/jbc.273.27.16694	http://dx.doi.org/10.1074/jbc.273.27.16694			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642223	hybrid			2022-12-25	WOS:000074545200013
J	Albini, A; Benelli, R; Giunciuglio, D; Cai, T; Mariani, G; Ferrini, S; Noonan, DM				Albini, A; Benelli, R; Giunciuglio, D; Cai, T; Mariani, G; Ferrini, S; Noonan, DM			Identification of a novel domain of HIV Tat involved in monocyte chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; KAPOSIS-SARCOMA; GROWTH-FACTOR; ENDOTHELIAL-CELLS; TRANSGENIC MICE; IN-VIVO; PROTEIN; TYPE-1; BINDING; INDUCTION	Human immunodeficiency virus (HIV) Tat is chemotactic for monocytes and dendritic cells, an activity that could play a hey role in the expansion of HIV infection of accessory cells. To date, domains of Tat previously found to interact with cell surface molecules have shown only partial chemotactic activity toward monocytes. Using overlapping Tat peptides, we identify a novel region of Tat with a potent chemotactic activity for monocytes, reaching levels equal to Tat itself. This peptide also provokes monocyte polarization similar to Tat and is able to compete with Tat for induction of monocyte migration. Specific high affinity (k(d) = 3 x 10(-9) M) cell surface binding sites on monocyte cell surfaces for this region of Tat are demonstrated. These data indicate that the majority of Tat effects on monocytes are mediated by a novel region in the cysteine-rich and core domains. These domains are highly conserved among different HIV isolates, suggesting an important role in the establishment of HIV infection.	Ist Nazl Ric Canc, Ctr Biotechnol Avanzate, I-16132 Genoa, Italy; Univ Genoa, Dipartimento Med Interna, I-16132 Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Genoa	Albini, A (corresponding author), Ist Nazl Ric Canc, Ctr Biotechnol Avanzate, Largo Rosanna Benzi N10, I-16132 Genoa, Italy.	albini@sirio.cba.unige.it	Benelli, Roberto/AAF-3143-2019; Noonan, Douglas M/A-8620-2010	Benelli, Roberto/0000-0002-9769-0954; Noonan, Douglas M/0000-0001-8058-0719; Mariani, Giuliano/0000-0002-1900-4488; Albini, Adriana/0000-0002-9624-5103; Ferrini, Silvano/0000-0001-7254-2616				ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; Albini A, 1996, ONCOGENE, V12, P289; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Balter M, 1996, SCIENCE, V274, P1464, DOI 10.1126/science.274.5292.1464; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; Benelli R, 1998, AIDS, V12, P261, DOI 10.1097/00002030-199803000-00003; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BRAKE DA, 1990, J CELL BIOL, V111, P1275, DOI 10.1083/jcb.111.3.1275; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; CORALLINI A, 1993, CANCER RES, V53, P5569; Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FRANCHINI G, 1987, BLOOD, V69, P437; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FURLINI MCRG, 1995, J ACQ IMMUN DEF SYND, V10, P408, DOI 10.1097/00042560-199512000-00003; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JEANG KT, 1994, HUMAN RETROVIRUSES A; Lafrenie RM, 1996, J IMMUNOL, V156, P1638; Lafrenie RM, 1996, J IMMUNOL, V157, P974; LOCATI M, 1994, J BIOL CHEM, V269, P4746; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MARTINET Y, 1994, J IMMUNOL METHODS, V174, P209, DOI 10.1016/0022-1759(94)90024-8; MCPHEE DA, 1988, FEBS LETT, V233, P393, DOI 10.1016/0014-5793(88)80468-X; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; Mitola S, 1997, BLOOD, V90, P1365, DOI 10.1182/blood.V90.4.1365.1365_1365_1372; Neuveut C, 1996, J VIROL, V70, P5572, DOI 10.1128/JVI.70.8.5572-5581.1996; Rubartelli A., 1997, UNUSUAL SECRETORY PA, P87, DOI [10.1007/978-3-662-22581-3_3, DOI 10.1007/978-3-662-22581-3_3]; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WEEKS BS, 1993, J BIOL CHEM, V268, P5279; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Weissman D, 1997, NATURE, V389, P981, DOI 10.1038/40173; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898	41	103	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15895	15900		10.1074/jbc.273.26.15895	http://dx.doi.org/10.1074/jbc.273.26.15895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632634	hybrid			2022-12-25	WOS:000074436600005
J	Bhisutthibhan, J; Pan, XQ; Hossler, PA; Walker, DJ; Yowell, CA; Carlton, J; Dame, JB; Meshnick, SR				Bhisutthibhan, J; Pan, XQ; Hossler, PA; Walker, DJ; Yowell, CA; Carlton, J; Dame, JB; Meshnick, SR			The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA; ENDOPEROXIDES; HEMOZOIN; CULTURE; BINDING; INVITRO; HEMIN	Artemisinin and its derivatives are important new antimalarial drugs. When Plasmodium falciparum-infected erythrocytes are incubated with [10-H-3]dihydroartemisinin, several malaria-specific proteins become labeled. One of these proteins is the P. falciparum translationally controlled tumor protein (TCTP) homolog. In vitro, dihydroartemisinin reacts covalently with recombinant TCTP in the presence of hemin. The association between drug and protein increases with increasing drug concentration, plateauing at approximately 1 drug/TCTP molecule. By Scatchard analysis, there appear to be 2 hemin binding sites on TCTP with dissociation constants of similar to 18 mu M, When the single cysteine moiety is blocked by pretreatment with iodoacetamide, hemin binding is not affected, whereas drug binding is reduced by two-thirds. Thus, TCTP reacts with artemisinin in situ and in vitro in the presence of hemin and appears to bind to hemin, The function of the malarial TCTP and the role of this reaction in the mechanism of action of artemisinin await elucidation.	Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA; Univ Florida, Coll Vet Med, Dept Infect Dis, Gainesville, FL 32610 USA	University of Michigan System; University of Michigan; State University System of Florida; University of Florida	Meshnick, SR (corresponding author), Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.	meshnick@umich.edu		Dame, John B./0000-0002-5772-5454	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI026848, R01AI026848, R22AI026848] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26848] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASAWAMAHASAKDA W, 1994, ANTIMICROB AGENTS CH, V38, P1854, DOI 10.1128/AAC.38.8.1854; ASAWAMAHASAKDA W, 1994, MOL BIOCHEM PARASIT, V67, P183, DOI 10.1016/0166-6851(94)00128-6; BEAVEN GH, 1974, EUR J BIOCHEM, V41, P539, DOI 10.1111/j.1432-1033.1974.tb03295.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cumming J N, 1997, Adv Pharmacol, V37, P253; Dame JB, 1996, MOL BIOCHEM PARASIT, V79, P1, DOI 10.1016/0166-6851(96)02641-2; DAME JB, 1994, MOL BIOCHEM PARASIT, V64, P177, DOI 10.1016/0166-6851(94)90024-8; GACHET Y, 1997, BIOCHEM SOC T, V25, P269; HAGHIGHAT NG, 1992, MOL BIOCHEM PARASIT, V51, P99, DOI 10.1016/0166-6851(92)90205-X; HARLOW B, 1988, ANTIBODIES LAB MANUA, P288; HONG YL, 1994, MOL BIOCHEM PARASIT, V63, P121, DOI 10.1016/0166-6851(94)90014-0; Kamchonwongpaisan S, 1997, AM J TROP MED HYG, V56, P7, DOI 10.4269/ajtmh.1997.56.7; KEMP DJ, 1985, NATURE, V315, P347, DOI 10.1038/315347a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Meshnick SR, 1996, MICROBIOL REV, V60, P301, DOI 10.1128/MMBR.60.2.301-315.1996; MESHNICK SR, 1991, MOL BIOCHEM PARASIT, V49, P181, DOI 10.1016/0166-6851(91)90062-B; MESHNICK SR, 1994, LANCET, V344, P1441; Robert A, 1997, J AM CHEM SOC, V119, P5968, DOI 10.1021/ja970412g; Sanchez JC, 1997, ELECTROPHORESIS, V18, P150, DOI 10.1002/elps.1150180127; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWARTZ S, 1983, CLIN CHEM, V29, P2061; Sullivan AD, 1996, PARASITOLOGY, V112, P285, DOI 10.1017/S003118200006580X; TERKUILE F, 1993, EXP PARASITOL, V76, P85, DOI 10.1006/expr.1993.1010; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; YOUNG DA, 1983, METHOD ENZYMOL, V91, P190	26	196	216	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16192	16198		10.1074/jbc.273.26.16192	http://dx.doi.org/10.1074/jbc.273.26.16192			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632675	hybrid			2022-12-25	WOS:000074436600046
J	Chang, MY; Olin, KL; Tsoi, C; Wight, TN; Chait, A				Chang, MY; Olin, KL; Tsoi, C; Wight, TN; Chait, A			Human monocyte-derived macrophages secrete two forms of proteoglycan-macrophage colony-stimulating factor that differ in their ability to bind low density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; SMOOTH-MUSCLE CELLS; MOLECULAR-WEIGHT; ARTERIAL PROTEOGLYCANS; PLASMA-LIPOPROTEINS; BLOOD MONOCYTES; GROWTH-FACTOR; FACTOR-I; EXPRESSION; ATHEROSCLEROSIS	This study evaluated whether human monocyte-derived macrophages synthesize specific types of proteoglycans with lipoprotein-binding capability that could contribute to lipid retention in the arterial wall. After labeling with either [S-36]SO4 or [S-36]methionine, macrophages secreted a high molecular mass proteoglycan, with glycosaminoglycan chains of similar to 18 kDa and core protein bands of similar to 100 and 55 kDa, Both core protein bands were recognized by an antibody to PG-100, an antibody that recognizes the proteoglycan form of macrophage colony-stimulating factor PG-100/PG-MCSF), The interaction between PG-100/PG-MCSF and low density lipoproteins (LDL) was examined by gel mobility shift. In this system, PG-100/PG-MCSF was resolved further into two forms. The two forms had the same core proteins but differed in their overall size and glycosaminoglycan content. The larger form contained glycosaminoglycan chains that were entirely chondroitin ABC lyase-sensitive, whereas the smaller form contained chains that were sensitive to both chondroitin ABC lyase and heparinase, Both forms bound native LDL with high affinity, but the larger form bound LDL with higher affinity than the smaller form. The glycosaminoglycan chains of PG-100/PG-MCSF, but not the core proteins, were responsible for binding to native LDL, Mildly oxidized LDL and methyl-LDL, which have an electrophoretic charge similar to that of native LDL, also bound PG-100/PG-MCSF. In contrast, extensively oxidized LDL and acetyl-LDL, which are more electronegative than native LDL, did not bind to either form of PG-100/PG-MCSF. The demonstration of two forms of human monocyte-derived macrophage PG-100/PG-MCSF which bind LDL may represent an additional role for macrophages in the extracellular trapping of lipoproteins in atherosclerosis.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chait, A (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.				NHLBI NIH HHS [HL 18645] Funding Source: Medline; NIDDK NIH HHS [DK 02456] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVES CS, 1988, ATHEROSCLEROSIS, V73, P113, DOI 10.1016/0021-9150(88)90032-9; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Buege J A, 1978, Methods Enzymol, V52, P302; CAMEJO G, 1993, J BIOL CHEM, V268, P14131; Camejo German, 1993, Current Opinion in Lipidology, V4, P385, DOI 10.1097/00041433-199310000-00007; CHAIT A, 1982, METABOLISM, V31, P721, DOI 10.1016/0026-0495(82)90204-9; CHANG MY, 1995, CIRCULATION S1, V92, P288; CHRISTNER JE, 1988, ARTERIOSCLEROSIS, V8, P535, DOI 10.1161/01.ATV.8.5.535; CHUNG BH, 1980, J LIPID RES, V21, P284; DEVILLIERS WJS, 1994, J EXP MED, V180, P705, DOI 10.1084/jem.180.2.705; EDELSON PJ, 1976, IN VITRO METHODS CEL, P333; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; EDWARDS IJ, 1993, J LIPID RES, V34, P1155; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; HEINECKE JW, 1991, ARTERIOSCLER THROMB, V11, P1643, DOI 10.1161/01.ATV.11.6.1643; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HORIGUCHI J, 1988, MOL CELL BIOL, V8, P3951, DOI 10.1128/MCB.8.9.3951; HURTCAMEJO E, 1992, ARTERIOSCLER THROMB, V12, P569, DOI 10.1161/01.ATV.12.5.569; INOUE I, 1992, ATHEROSCLEROSIS, V93, P245, DOI 10.1016/0021-9150(92)90261-E; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; ISMAIL NAE, 1994, ATHEROSCLEROSIS, V105, P79, DOI 10.1016/0021-9150(94)90010-8; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KOLSET SO, 1983, BIOCHEM J, V210, P661, DOI 10.1042/bj2100661; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lebaron RG, 1996, PERSPECT DEV NEUROBI, V3, P261; LEE MT, 1990, J LEUKOCYTE BIOL, V47, P275, DOI 10.1002/jlb.47.3.275; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; MAYNE R, 1986, ARTERIOSCLEROSIS, V6, P585, DOI 10.1161/01.ATV.6.6.585; MORTON LF, 1982, ATHEROSCLEROSIS, V42, P41, DOI 10.1016/0021-9150(82)90124-1; OOSHIMA A, 1981, SCIENCE, V213, P666, DOI 10.1126/science.7256267; OWENS RT, 1991, ATHEROSCLEROSIS, V91, P229, DOI 10.1016/0021-9150(91)90170-8; PARTENHEIMER A, 1995, J IMMUNOL, V155, P5557; RADHAKRISHNAMURTHY B, 1990, EUR HEART J, V11, P148, DOI 10.1093/eurheartj/11.suppl_E.148; REZVIN A, 1989, BIOTECHNIQUES, V7, P346; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; Schonherr E, 1997, ARCH BIOCHEM BIOPHYS, V339, P353, DOI 10.1006/abbi.1996.9854; SCHWARZ K, 1990, J BIOL CHEM, V265, P22023; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STOUDEMIRE JB, 1991, BLOOD, V77, P750; SUZU S, 1994, J CLIN INVEST, V94, P1637, DOI 10.1172/JCI117506; SUZU S, 1992, J BIOL CHEM, V267, P4345; SUZU S, 1992, J BIOL CHEM, V267, P16812; UHLINHANSEN L, 1989, J BIOL CHEM, V264, P14916; UHLINHANSEN L, 1988, J BIOL CHEM, V263, P2526; UHLINHANSEN L, 1993, BLOOD, V82, P2880; UHLINHANSEN L, 1992, BLOOD, V80, P1058; VIJAYAGOPAL P, 1994, BIOCHEM J, V301, P675, DOI 10.1042/bj3010675; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WIESER M, 1989, BLOOD, V73, P1105; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; YAMADA N, 1992, P SOC EXP BIOL MED, V200, P240	58	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15985	15992		10.1074/jbc.273.26.15985	http://dx.doi.org/10.1074/jbc.273.26.15985			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632647	hybrid			2022-12-25	WOS:000074436600018
J	Chatterjee-Kishore, M; Kishore, R; Hicklin, DJ; Marincola, FM; Ferrone, S				Chatterjee-Kishore, M; Kishore, R; Hicklin, DJ; Marincola, FM; Ferrone, S			Different requirements for signal transducer and activator of transcription 1 alpha and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA CLASS-I; PEPTIDASE ACTIVITIES; T-CELLS; GAMMA; PROTEASOMES; IRF-1; TAP1; IFN; ELEMENTS; LMP2	The components of the antigen processing machinery, low molecular mass polypeptide (LMP) 2 and transporter associated with antigen processing (TAP) 1, are encoded by closely linked genes within the major histocompatibility complex class II subregion. Although the two genes share a bi-directional promoter, LMP2 and TAP1 have differential cellular expression. TAP1 is expressed constitutively. However, LMP2 expression requires induction by interferon-gamma in most cells. The regulatory elements within the LMP2/TAP1 promoter and the transcription factors that bind these elements have been defined, However, how these transactivators regulate differential TAP1 and LMP2 gene transcription is not known. We have addressed this question by analyzing three human melanoma cell lines with distinct phenotypes of LMP2 and TAP1 expression.Whereas binding of either interferon regulatory factor 1 or Stat1 to the overlapping interferon consensus sequence-2/GAS is sufficient for regulating transcription of the TAP1 gene, binding of both factors is required for LMP2 gene transcription. This conclusion is supported by restoration of LMP2 gene transcription following transfection of wild type Stat1 alpha or interferon regulatory factor 1 cDNA into cells lacking these transcription factors. The flexibility in the regulation of the TAP1 gene may reflect its role in maintaining immune surveillance. Furthermore, lack of LMP2 gene transcription in quiescent human cells suggests that LMP2 expression reflects a state of cell activation.	New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA; NCI, Surg Branch, NIH, Bethesda, MD 20892 USA	New York Medical College; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ferrone, S (corresponding author), New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA.				NATIONAL CANCER INSTITUTE [R01CA067108] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67108] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; ELHODIRI HM, 1995, MOL CELL BIOL, V15, P3587; Elliott T, 1997, ADV IMMUNOL, V65, P47, DOI 10.1016/S0065-2776(08)60741-5; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Griffin TA, 1998, J EXP MED, V187, P97, DOI 10.1084/jem.187.1.97; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; HANIEL A, 1995, J BIOL CHEM, V270, P11209, DOI 10.1074/jbc.270.19.11209; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HICKLIN DJ, 1996, IMMUNOLOGY HUMAN MEL, P95; HOMBACH J, 1995, J EXP MED, V182, P1615, DOI 10.1084/jem.182.5.1615; Kishore R, 1998, TISSUE ANTIGENS, V51, P129; Min W, 1996, J IMMUNOL, V156, P3174; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NGUYEN H, 1995, ONCOGENE, V11, P537; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; Nonaka M, 1997, J IMMUNOL, V159, P734; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Seliger B, 1997, CLIN CANCER RES, V3, P573; Singal DP, 1996, INT J CANCER, V68, P629, DOI 10.1002/(SICI)1097-0215(19961127)68:5<629::AID-IJC13>3.0.CO;2-X; Tanaka K, 1997, ADV IMMUNOL, V64, P1, DOI 10.1016/S0065-2776(08)60885-8; TANAKA K, 1994, J LEUKOCYTE BIOL, V56, P571, DOI 10.1002/jlb.56.5.571; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WEBERNORT RM, 1996, BLOOD, V1, P809; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928	34	85	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16177	16183		10.1074/jbc.273.26.16177	http://dx.doi.org/10.1074/jbc.273.26.16177			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632673	hybrid			2022-12-25	WOS:000074436600044
J	Feick, P; Gilhaus, S; Schulz, I				Feick, P; Gilhaus, S; Schulz, I			Pervanadate stimulates amylase release and protein tyrosine phosphorylation of paxillin and p125(FAK) in differentiated AR4-2J pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SWISS 3T3 CELLS; RAT ADIPOCYTES; PHORBOL ESTER; GROWTH-FACTOR; CROSS-TALK; SECRETION; BOMBESIN; INSULIN; CHOLECYSTOKININ	We have studied the role of protein tyrosine phosphorylation in amylase secretion from differentiated AR4-2J cells, The secretagogue bombesin, the protein kinase C activator phorbol 12-myristate 13-acetate (PMA), and the protein-tyrosine phosphatase inhibitor pervanadate induced tyrosine phosphorylation of different proteins, including paxillin and p125(FAK), which was reduced or blocked by the tyrosine kinase inhibitors genistein and tyrphostin B56, respectively. Both PMA and pervanadate continuously increased amylase secretion with a similar time course, reaching the level of bombesin-induced amylase release after 60 min. Their effects were not additive and could be inhibited by preincubation of AR4-2J cells with genistein or tyrphostin B56, respectively. Inhibition of protein kinase C with Ro 31-8220 nearly abolished the effects of PMA, but had no effect on either pervanadate-induced protein tyrosine phosphorylation or amylase secretion, An increase in cytosolic free Ca2+ concentration by thapsigargin or A23187 caused a rapid increase in amylase release within the initial 5 min, In the presence of PMA or pervanadate, amylase secretion was further stimulated to levels comparable to those induced by bombesin after 30 min of stimulation. Inhibition of PMA-induced amylase secretion by Ro 31-8220 was less at elevated cytosolic free Ca2+ concentrations than without Ca2+. Furthermore, an increase in cytosolic free Ca2+ concentration had no effect on protein tyrosine phosphorylation in either the absence or presence of PMA or pervanadate, We therefore conclude that in the cascade of events that lead to bombesin-induced protein secretion from AR4-2J cells, protein tyrosine phosphorylation occurs downstream of protein kinase C activation, A further step in secretion that is Ca2+-dependent occurs distal to protein tyrosine phosphorylation.	Univ Saarlandes, Inst Physiol 2, D-66421 Homburg, Germany	Saarland University	Schulz, I (corresponding author), Univ Saarlandes, Inst Physiol 2, D-66421 Homburg, Germany.							BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BENGTSSON T, 1991, J LEUKOCYTE BIOL, V49, P236, DOI 10.1002/jlb.49.3.236; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DEPONT JJHHM, 1984, FEBS LETT, V170, P64, DOI 10.1016/0014-5793(84)81369-1; DUAN RG, 1994, AM J PHYSIOL, V266, pG303, DOI 10.1152/ajpgi.1994.266.2.G303; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; Garcia LJ, 1997, BIOCHEM J, V327, P461; Hamawy MM, 1997, J BIOL CHEM, V272, P30498, DOI 10.1074/jbc.272.48.30498; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; KADOTA S, 1987, BIOCHEM BIOPH RES CO, V147, P259, DOI 10.1016/S0006-291X(87)80115-8; KELLER HU, 1993, BIOCHEM BIOPH RES CO, V194, P1111, DOI 10.1006/bbrc.1993.1936; KIMURA T, 1986, AM J PHYSIOL, V250, pG698, DOI 10.1152/ajpgi.1986.250.5.G698; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGSDON CD, 1986, J BIOL CHEM, V261, P2096; LUTZ MP, 1993, J BIOL CHEM, V268, P11119; MATOZAKI T, 1991, AM J PHYSIOL, V260, pG858, DOI 10.1152/ajpgi.1991.260.6.G858; MAY JM, 1979, J BIOL CHEM, V254, P9017; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; PANDOL SJ, 1985, J BIOL CHEM, V260, P81; PIIPER A, 1994, AM J PHYSIOL, V266, pG363, DOI 10.1152/ajpgi.1994.266.3.G363; RANKIN S, 1994, J BIOL CHEM, V269, P704; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; Ruff SJ, 1997, J BIOL CHEM, V272, P1263, DOI 10.1074/jbc.272.2.1263; SCHULZ I, 1989, HDB PHYSL GASTROINTE, V3, P443; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHECHTER Y, 1993, ENDEAVOUR, V17, P27, DOI 10.1016/0160-9327(93)90008-Q; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; WILLIAMS JA, 1993, PHYSIOL REV, V73, P701, DOI 10.1152/physrev.1993.73.4.701; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	43	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16366	16373		10.1074/jbc.273.26.16366	http://dx.doi.org/10.1074/jbc.273.26.16366			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632700	hybrid			2022-12-25	WOS:000074436600071
J	Helman, D; Staten, NR; Grosclaude, J; Daniel, N; Nespoulous, C; Djiane, J; Gertler, A				Helman, D; Staten, NR; Grosclaude, J; Daniel, N; Nespoulous, C; Djiane, J; Gertler, A			Novel recombinant analogues of bovine placental lactogen - G133K and G133R provide a tool to understand the difference between the action of prolactin and growth hormone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL-ACTIVITY; ESCHERICHIA-COLI; TYROSINE KINASE; EXTRACELLULAR DOMAIN; RATIONAL DESIGN; NB2 CELLS; PROTEINS; BINDING; PROLIFERATION; MUTAGENESIS	Two new analogues of bovine placental lactogen (bPL), bPL(G133K) and bPL(G133R), were expressed in Escherichia coli, refolded, and purified to a native form. Binding experiments, which are likely to represent the binding to site 1 only, to intact FDC-P1 cells transfected with rabbit (rb) growth hormone receptor (GHR) or with human (h) GHR, to Nb2 rat lymphoma cells, or to rabbit mammary gland membranes prolactin receptor (PRLR), revealed only small or no reduction in binding capacity, The complex formation between these analogues and receptor extracellular domains (R-ECD) of various hormones was determined by gel filtration. Wild type bPL yielded 1:2 complex with hGHR-ECD, rat PRLR-ECD, and rbPRLR-ECD, whereas both analogues formed only 1:1 complexes with all R-ECDs tested. Real time kinetics experiments demonstrated that the ability of the analogues to form homodimeric complexes was compromised in both PRLR- and GHR-ECDs. The biological activity transduced through lactogenic receptors in in vitro bioassays in rabbit mammary gland acini culture and in Nb2 cells was almost fully retained, whereas the activity transduced through somatogenic receptors in FDC-P1 cells transfected with rbGHRs or with hGHRs was abolished, Both analogues exhibited antagonistic activity in the latter cells. To explain the discrepancy between the effect of the mutation on the signal transduced by PLR versus GHRs we suggest that: 1) the mutation impairs the ability of site 2 of bPL to form a stable homodimeric complex with both lactogenic and somatogenic receptors by a drastic shortening of the half-life of 2:1 complex; 2) the transient existence of the homodimeric complex is still sufficient to initiate the signal transduced through lactogenic receptors but not through somatogenic receptors; and 3) one possible reason for this difference is that JAK2, which serves as a mediator of both receptors, is already associated with lactogenic receptors prior to hormone binding-induced receptor dimerization, whereas in somatogenic receptors the JAK2 receptor association occurs subsequently to receptor dimerization.	Hebrew Univ Jerusalem, Fac Agr, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel; INRA, Unite Endocrinol Mol, F-78352 Jouy En Josas, France; INRA, Unite Virol & Immunol Mol, F-78352 Jouy En Josas, France; INRA, Unite Biochim & Struct Prot, F-78352 Jouy En Josas, France; Monsanto Co, Dept Biol Mol, St Louis, MO 63198 USA; Monsanto Co, Div Anim Sci, St Louis, MO 63198 USA	Hebrew University of Jerusalem; INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Monsanto; Monsanto	Gertler, A (corresponding author), Hebrew Univ Jerusalem, Fac Agr, Inst Biochem Food Sci & Nutr, POB 12, IL-76100 Rehovot, Israel.	gertler@agri.huji.ac.il						ANTHONY RV, 1995, J REPROD FERTIL, P83; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BIGNON C, 1994, J BIOL CHEM, V269, P3318; BINDER L, 1989, MOL ENDOCRINOL, V3, P923, DOI 10.1210/mend-3-6-923; BYATT JC, 1990, ENDOCRINOLOGY, V127, P1041, DOI 10.1210/endo-127-3-1041; CHEN WY, 1995, MOL ENDOCRINOL, V9, P292, DOI 10.1210/me.9.3.292; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CHRISTINGER HW, 1998, IN PRESS ACTA CRYS D; COLLIER RJ, 1995, INTERCELLULAR SIGNALLING IN THE MAMMARY GLAND, P13; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; Daniel N, 1996, MOL CELL ENDOCRINOL, V118, P25, DOI 10.1016/0303-7207(95)03763-2; DATTANI MT, 1995, J BIOL CHEM, V270, P9222, DOI 10.1074/jbc.270.16.9222; DJIANE J, 1982, ENDOCRINOLOGY, V110, P791, DOI 10.1210/endo-110-3-791; FORSYTH IA, 1986, J DAIRY SCI, V69, P886, DOI 10.3168/jds.S0022-0302(86)80479-9; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GERTLER A, 1992, J BIOL CHEM, V267, P12655; Gertler A, 1996, J BIOL CHEM, V271, P24482, DOI 10.1074/jbc.271.40.24482; Gertler A, 1997, J MAMMARY GLAND BIOL, V2, P69, DOI 10.1023/A:1026377614430; GOFFIN V, 1994, J BIOL CHEM, V269, P32598; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Goffin V, 1997, J MAMMARY GLAND BIOL, V2, P7, DOI 10.1023/A:1026313211704; Helman D, 1997, ENDOCRINOLOGY, V138, P4069, DOI 10.1210/en.138.10.4069; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KANE JF, 1992, NUCLEIC ACIDS RES, V20, P6707, DOI 10.1093/nar/20.24.6707; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; KELLY PA, 1995, HORM RES, V42, P133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; NESPOULOUS C, 1992, PLANTA, V186, P551, DOI 10.1007/BF00198035; OBUKOWICZ MG, 1992, APPL ENVIRON MICROB, V58, P1511, DOI 10.1128/AEM.58.5.1511-1523.1992; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Rowlinson SW, 1996, ENDOCRINOLOGY, V137, P90, DOI 10.1210/en.137.1.90; ROWLINSON SW, 1995, J BIOL CHEM, V270, P16833, DOI 10.1074/jbc.270.28.16833; RUI H, 1992, J BIOL CHEM, V267, P24076; Sakal E, 1997, FEBS LETT, V410, P289, DOI 10.1016/S0014-5793(97)00581-4; SANDOWSKI Y, 1995, MOL CELL ENDOCRINOL, V115, P1, DOI 10.1016/0303-7207(95)03664-S; SHAMAY A, 1990, MOL CELL ENDOCRINOL, V69, P217, DOI 10.1016/0303-7207(90)90015-Z; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; TARTOF KD, 1987, FOCUS, V9, P12; TCHELET A, 1993, PEDIAT AD E, V24, P114; VASHDI D, 1992, FEBS LETT, V305, P101, DOI 10.1016/0014-5793(92)80873-F; VashdiElberg D, 1996, J BIOL CHEM, V271, P5558, DOI 10.1074/jbc.271.10.5558	43	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16067	16074		10.1074/jbc.273.26.16067	http://dx.doi.org/10.1074/jbc.273.26.16067			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632658	hybrid			2022-12-25	WOS:000074436600029
J	Howland, DS; Trusko, SP; Savage, MJ; Reaume, AG; Lang, DM; Hirsch, JD; Maeda, N; Siman, R; Greenberg, BD; Scott, RM; Flood, DG				Howland, DS; Trusko, SP; Savage, MJ; Reaume, AG; Lang, DM; Hirsch, JD; Maeda, N; Siman, R; Greenberg, BD; Scott, RM; Flood, DG			Modulation of secreted beta-amyloid precursor protein and amyloid beta peptide in brain by cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E GENOTYPE; CENTRAL-NERVOUS-SYSTEM; CARBOXYL-TERMINAL DERIVATIVES; FAMILIAL ALZHEIMER-DISEASE; GOLGI-APPARATUS; CEREBROSPINAL-FLUID; DEFICIENT MICE; BLOOD-PRESSURE; TYPE-4 ALLELE; CELLS	The effects of dietary cholesterol on brain amyloid precursor protein (APP) processing were examined using an APP gene-targeted mouse, genetically humanized in the amyloid beta-peptide (A beta) domain and expressing the Swedish familial Alzheimer's disease mutations. These mice express endogenous levels of APP holoprotein and abundant human A beta. Increased dietary cholesterol led to significant reductions in brain levels of secreted APP derivatives, including sAPP alpha, sAPP beta, A beta 1-40, and A beta 1-42, while having little to no effect on cell-associated species, including full-length APP and the COOH-terminal APP processing derivatives. The changes in levels of sAPP and A beta in brain all were negatively correlated with serum cholesterol levels and levels of serum and brain apoE, These results demonstrate that secreted APP processing derivatives and A beta can be modulated in the brain of an animal by diet and provide evidence that cholesterol plays a role in the modulation of APP processing in vivo. APP gene-targeted mice lacking apoE, also have high serum cholesterol levels but do not show alterations in APP processing, suggesting that effects of cholesterol on APP processing require the presence of apoE.	Cephalon Inc, W Chester, PA 19380 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA	Teva Pharmaceutical Industries; Cephalon Inc.; University of North Carolina; University of North Carolina Chapel Hill	Flood, DG (corresponding author), Cephalon Inc, 145 Brandywine Pkwy, W Chester, PA 19380 USA.	dflood@cephalon.com	Taylor, Graham/A-4027-2012					Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Beffert U., 1996, Society for Neuroscience Abstracts, V22, P2117; BERTRAND P, 1995, MOL BRAIN RES, V33, P174, DOI 10.1016/0169-328X(95)00097-C; Blacker D, 1997, NEUROLOGY, V48, P139, DOI 10.1212/WNL.48.1.139; BLENNOW K, 1994, NEUROREPORT, V5, P2534, DOI 10.1097/00001756-199412000-00032; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Bullido MJ, 1998, NAT GENET, V18, P69, DOI 10.1038/ng0198-69; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CHEUNG TT, 1994, AMYLOID, V1, P30, DOI 10.3109/13506129409148622; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CRIADO M, 1982, BIOCHEMISTRY-US, V21, P3622, DOI 10.1021/bi00258a015; DAVISSALINAS J, 1994, J BIOL CHEM, V269, P22623; Dehouck B, 1997, J CELL BIOL, V138, P877, DOI 10.1083/jcb.138.4.877; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FOLCH J, 1957, J BIOL CHEM, V226, P497; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; Guillaume D, 1996, J NEUROCHEM, V66, P2410; GUILLAUME D, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P385; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Igbavboa U, 1996, J NEUROCHEM, V66, P1717; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; JARVIK GP, 1994, GENET EPIDEMIOL, V11, P375, DOI 10.1002/gepi.1370110407; Klafki HW, 1996, ANAL BIOCHEM, V237, P24, DOI 10.1006/abio.1996.0195; KLEIN I, 1978, BIOCHIM BIOPHYS ACTA, V506, P42, DOI 10.1016/0005-2736(78)90433-9; Koo EH, 1996, J CELL SCI, V109, P991; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LAUNER LJ, 1995, JAMA-J AM MED ASSOC, V274, P1846, DOI 10.1001/jama.274.23.1846; LEHTIMAKI T, 1995, HUM GENET, V95, P39; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; ONER P, 1991, RES COMMUN CHEM PATH, V72, P337; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; POIRIER J, 1990, ADV BEHAV BIOL, V38, P191; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Racchi M, 1997, BIOCHEM J, V322, P893, DOI 10.1042/bj3220893; Reaume AG, 1996, J BIOL CHEM, V271, P23380, DOI 10.1074/jbc.271.38.23380; ROHER AE, 1993, J BIOL CHEM, V268, P3072; ROTH GS, 1995, TRENDS NEUROSCI, V18, P203, DOI 10.1016/0166-2236(95)93902-A; ROUSER G, 1972, ADV LIPID RES, V10, P236; SAKAKIHARA Y, 1985, J NEUROCHEM, V44, P1535, DOI 10.1111/j.1471-4159.1985.tb08792.x; SAUNDERS AM, 1993, NEUROLOGY, V43, P1462; Savage MJ, 1998, J NEUROSCI, V18, P1743; SAVAGE MJ, 1994, NEUROSCIENCE, V60, P607, DOI 10.1016/0306-4522(94)90490-1; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHROEDER F, 1995, MOL MEMBR BIOL, V12, P113, DOI 10.3109/09687689509038505; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SIMAN R, 1993, J BIOL CHEM, V268, P16602; SIMAN R, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P675; SINHA AK, 1977, J BIOL CHEM, V252, P3310; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; Sparks DL, 1997, NUTR METAB CARDIOVAS, V7, P255; SPARKS DL, 1990, NEUROBIOL AGING, V11, P601, DOI 10.1016/0197-4580(90)90024-T; SPARKS DL, 1995, NEUROSCI LETT, V187, P142, DOI 10.1016/0304-3940(95)11357-6; Srivastava RAK, 1996, MOL CELL BIOCHEM, V155, P153, DOI 10.1007/BF00229312; Streit WJ, 1997, J MOL MED-JMM, V75, P130, DOI 10.1007/s001090050097; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; UTERMANN G, 1979, CLIN GENET, V15, P27; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhang YY, 1996, NEUROBIOL AGING, V17, P869, DOI 10.1016/S0197-4580(96)00076-0	90	229	242	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16576	16582		10.1074/jbc.273.26.16576	http://dx.doi.org/10.1074/jbc.273.26.16576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632729	hybrid, Green Published			2022-12-25	WOS:000074436600100
J	Li, S; Choksi, S; Shan, SM; Hu, XY; Gao, JM; Korngold, R; Huang, ZW				Li, S; Choksi, S; Shan, SM; Hu, XY; Gao, JM; Korngold, R; Huang, ZW			Identification of the CD8 DE loop as a surface functional epitope - Implications for major histocompatibility complex class I binding and CD8 inhibitor design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTES-T; PROTEIN STRUCTURES; ALPHA-3 DOMAIN; MHC CLASS; MOLECULES; RECOGNITION; IMMUNOGLOBULIN; GENE	We used an approach of protein surface epitope mapping by synthetic peptides to analyze the surface structure-function relationship of the CD8 protein. Small synthetic peptide mimics of the CD8 DE loop were shown to effectively block CD8 binding to major histocompatibility complex (MHC) class I molecules and possess significant inhibitory activity on in vitro CD8(+) T cell function. These results suggested that the DE loop region of the CD8 protein is an important functional epitope mediating CD8-MHC class I interaction and the activation of CD8(+) T cells, a finding that is consistent with the recently reported crystal structure of the CDS-MHC class I complex. The structural basis for the biological activity of the DE loop peptide was further analyzed in a series of analogs containing alanine substitutions. This study provides support for the concept of bioactive peptide design based on protein surface epitopes and suggests that such an approach may be applicable to other protein-protein complexes, particularly those of immunoglobulin superfamily molecules.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Jefferson University	Huang, ZW (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, 233 S 10th St, Philadelphia, PA 19107 USA.	zhuang@nana.jci.tju.edu	Korngold, Robert/AAF-2686-2020					Choksi S, 1998, NAT MED, V4, P309, DOI 10.1038/nm0398-309; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; GIBLIN PA, 1994, P NATL ACAD SCI USA, V91, P1716, DOI 10.1073/pnas.91.5.1716; Huang ZW, 1997, BIOPOLYMERS, V43, P367, DOI 10.1002/(SICI)1097-0282(1997)43:5<367::AID-BIP3>3.0.CO;2-T; Huang ZW, 1997, MED CHEM RES, V7, P137; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Li S, 1997, P NATL ACAD SCI USA, V94, P73, DOI 10.1073/pnas.94.1.73; LI S, 1998, IN PRESS IMMUNOL TOD; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MISICKA A, 1994, J MED CHEM, V37, P141, DOI 10.1021/jm00027a017; MOEBIUS U, 1992, P NATL ACAD SCI USA, V89, P12008, DOI 10.1073/pnas.89.24.12008; NAKANISHI H, 1993, GENE, V137, P51, DOI 10.1016/0378-1119(93)90250-7; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SANDERS SK, 1991, J EXP MED, V174, P371, DOI 10.1084/jem.174.2.371; Satoh T, 1996, BIOCHEM BIOPH RES CO, V224, P438, DOI 10.1006/bbrc.1996.1045; Satoh T, 1997, J BIOL CHEM, V272, P12175, DOI 10.1074/jbc.272.18.12175; SNOW PM, 1983, J BIOL CHEM, V258, P4675; SUKHATME VP, 1985, CELL, V40, P591, DOI 10.1016/0092-8674(85)90207-7; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TYKOCINSKI ML, 1984, J IMMUNOL, V133, P2261; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Zhang X, 1997, NAT BIOTECHNOL, V15, P150, DOI 10.1038/nbt0297-150	32	15	18	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16442	16445		10.1074/jbc.273.26.16442	http://dx.doi.org/10.1074/jbc.273.26.16442			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632710	hybrid			2022-12-25	WOS:000074436600081
J	Yamashita, J; Yoshimasa, T; Arai, H; Hiraoka, J; Takaya, K; Miyamoto, Y; Ogawa, Y; Itoh, H; Nakao, K				Yamashita, J; Yoshimasa, T; Arai, H; Hiraoka, J; Takaya, K; Miyamoto, Y; Ogawa, Y; Itoh, H; Nakao, K			Identification of cis-elements of the human endothelin-A receptor gene and inhibition of the gene expression by the decoy strategy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER ELEMENTS; SENSITIVE METHOD; B RECEPTOR; ANTAGONIST; CLONING; BQ-123; CELLS; CDNA; BINDING; INTRON	Previously, we succeeded in molecular cloning of the cDNA and the gene for human endothelin-A receptor (ET-AR). In the present study, we define cis-elements in the 5'-flanbing region of the ET-AR gene. Deletion analyses were performed in A7r5 cells, rat vascular smooth muscle cell line, and Chinese hamster ovary cells using ET-AR promoter-luciferase gene constructs including 5 kilobases of the 5'-Banking region. These analyses demonstrated the existence of one negative regulatory element (-2.0 kilobases to -857 bases) and two positive regulatory elements (-137 to -53 and -53 to +251). Gel mobility shift assay revealed a nuclear protein binding to the region (-104 to -78) (RI). DNase I footprinting analysis showed a footprint spanning from -91 to -83 whose sequence is CCCCACCTT (ETA-PI). When a plasmid including R1 fragments (R1 decoy) was co-transfected into A7r5 cells with ET-AR (-137 to 251)-luciferase gene construct, it significantly reduced the luciferase activity in a dose-dependent manner. Moreover, RI decoy down-regulated the endogenous ET-AR mRNA in A7r5 cells by a maximum of 75%. Thus, we identified cia-elements that regulate basal transcriptional activity of the ET-AR gene and proved the feasibility to suppress the expression of the ET-AR gene by the DNA decoy strategy using the positive regulatory element we identified.	Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, Kyoto 606, Japan; Grad Sch Human & Environm Studies, Kyoto 606, Japan	Kyoto University	Yoshimasa, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 606, Japan.	taka@kuhp.kyoto-u.ac.jp	Miyamoto, Yoshihiro/L-8583-2013	Miyamoto, Yoshihiro/0000-0002-1337-0508; Ogawa, Yoshihiro/0000-0002-0834-2836				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; CLOZEL M, 1993, LIFE SCI, V52, P825, DOI 10.1016/0024-3205(93)90081-D; Dimondo JP, 1996, DNA SEQUENCE, V6, P285, DOI 10.3109/10425179609020875; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; GROVER GJ, 1993, CARDIOVASC RES, V27, P1613, DOI 10.1093/cvr/27.9.1613; HAGA N, 1989, J CLIN BIOCHEM NUTR, V7, P175; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; HOSODA K, 1992, J BIOL CHEM, V267, P18797; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; JONATHAN DS, 1988, J BIOL CHEM, V263, P8300; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEVIN ER, 1995, NEW ENGL J MED, V333, P356, DOI 10.1056/NEJM199508103330607; MAUTNER J, 1995, NUCLEIC ACIDS RES, V23, P72, DOI 10.1093/nar/23.1.72; MIHARA SI, 1994, J PHARMACOL EXP THER, V268, P1122; MINO N, 1992, EUR J PHARMACOL, V221, P77; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; RAINES EW, 1993, BRIT HEART J, V69, P30; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHANKE JT, 1994, NUCLEIC ACIDS RES, V22, P5425, DOI 10.1093/nar/22.24.5425; SHACHTER NS, 1993, J LIPID RES, V34, P1699; SIU G, 1994, EMBO J, V13, P3570, DOI 10.1002/j.1460-2075.1994.tb06664.x; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374	30	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15993	15999		10.1074/jbc.273.26.15993	http://dx.doi.org/10.1074/jbc.273.26.15993			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632648	hybrid			2022-12-25	WOS:000074436600019
J	Bugos, RC; Hieber, AD; Yamamoto, HY				Bugos, RC; Hieber, AD; Yamamoto, HY			Xanthophyll cycle enzymes are members of the lipocalin family, the first identified from plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIOLAXANTHIN DE-EPOXIDASE; RETINOL-BINDING PROTEIN; CHLOROPHYLL-A FLUORESCENCE; SECONDARY STRUCTURE; ZEAXANTHIN-EPOXIDASE; MOLECULAR-STRUCTURE; BETA-LACTOGLOBULIN; CHLOROPLAST; LETTUCE; BIOSYNTHESIS	Violaxanthin de-epoxidase and zeaxanthin epoxidase catalyze the addition and removal of epoxide groups in carotenoids of the xanthophyll cycle in plants. The xanthophyll cycle is implicated in protecting the photosynthetic apparatus from excessive light. Two new sequences for violaxanthin de-epoxidase from tobacco and Arabidopsis are described. Although the mature proteins are well conserved, the transit peptides of these proteins are divergent, in contrast to transit peptides from other proteins targeted to the thylakoid lumen. Sequence analyses of both violaxanthin de-epoxidase and zeaxanthin epoxidase establish the xanthophyll cycle enzymes as members of the lipocalin family of proteins. The lipocalin family is a diverse group of proteins that bind small hydrophobic (lipophilic) molecules and share a conserved tertiary structure of eight P-strands forming a barrel configuration. This is the first reported identification of lipocalin proteins in plants.	Univ Hawaii, Dept Plant Mol Physiol, Honolulu, HI 96822 USA	University of Hawaii System	Yamamoto, HY (corresponding author), Univ Hawaii, Dept Plant Mol Physiol, 3190 Maile Way, Honolulu, HI 96822 USA.							Barker A, 1997, MICROBIOL-SGM, V143, P1805, DOI 10.1099/00221287-143-6-1805; Bouvier F, 1996, J BIOL CHEM, V271, P28861, DOI 10.1074/jbc.271.46.28861; BRATT CE, 1995, PHOTOSYNTH RES, V45, P169, DOI 10.1007/BF00032588; BUCH K, 1995, FEBS LETT, V376, P45, DOI 10.1016/0014-5793(95)01243-9; Bugos RC, 1996, P NATL ACAD SCI USA, V93, P6320, DOI 10.1073/pnas.93.13.6320; Burbidge A, 1997, J EXP BOT, V48, P1749, DOI 10.1093/jexbot/48.314.1749; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DEMMIG B, 1987, PLANT PHYSIOL, V84, P218, DOI 10.1104/pp.84.2.218; DemmigAdams B, 1996, TRENDS PLANT SCI, V1, P21, DOI 10.1016/S1360-1385(96)80019-7; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; Flower DR, 1996, BIOCHEM J, V318, P1; GILMORE AM, 1994, FEBS LETT, V350, P271, DOI 10.1016/0014-5793(94)00784-5; GILMORE AM, 1995, P NATL ACAD SCI USA, V92, P2273, DOI 10.1073/pnas.92.6.2273; Gilmore AM, 1996, PHOTOSYNTH RES, V48, P171, DOI 10.1007/BF00041007; GILMORE AM, 1993, PHOTOSYNTH RES, V35, P67, DOI 10.1007/BF02185412; GILMORE AM, 1992, P NATL ACAD SCI USA, V89, P1899, DOI 10.1073/pnas.89.5.1899; HAGER A, 1969, PLANTA, V89, P224, DOI 10.1007/BF00385028; HAGER A, 1975, BER DEUT BOT GES, V88, P27; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; HUBER R, 1987, J MOL BIOL, V198, P499, DOI 10.1016/0022-2836(87)90296-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; Marin E, 1996, EMBO J, V15, P2331, DOI 10.1002/j.1460-2075.1996.tb00589.x; MOHANTY N, 1995, AUST J PLANT PHYSIOL, V22, P231, DOI 10.1071/PP9950231; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PERVAIZ S, 1985, SCIENCE, V228, P335, DOI 10.1126/science.2580349; PERVAIZ S, 1987, FASEB J, V1, P209, DOI 10.1096/fasebj.1.3.3622999; Rockholm DC, 1996, PLANT PHYSIOL, V110, P697, DOI 10.1104/pp.110.2.697; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SIEFERMANN D, 1974, BIOCHIM BIOPHYS ACTA, V357, P144, DOI 10.1016/0005-2728(74)90119-4; SIEFERMANN D, 1975, ARCH BIOCHEM BIOPHYS, V171, P70, DOI 10.1016/0003-9861(75)90008-9; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; TAKEGUCH.CA, 1968, BIOCHIM BIOPHYS ACTA, V153, P459, DOI 10.1016/0005-2728(68)90087-X; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; YAMAMOTO HY, 1962, ARCH BIOCHEM BIOPHYS, V97, P168, DOI 10.1016/0003-9861(62)90060-7; YAMAMOTO HY, 1978, ARCH BIOCHEM BIOPHYS, V190, P514, DOI 10.1016/0003-9861(78)90305-3; YAMAMOTO HY, 1972, PLANT PHYSIOL, V49, P224, DOI 10.1104/pp.49.2.224; YAMAMOTO HY, 1972, BIOCHIM BIOPHYS ACTA, V267, P538, DOI 10.1016/0005-2728(72)90182-X	46	117	136	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15321	15324		10.1074/jbc.273.25.15321	http://dx.doi.org/10.1074/jbc.273.25.15321			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624110	hybrid			2022-12-25	WOS:000074284200004
J	Janicke, RU; Ng, P; Sprengart, ML; Porter, AG				Janicke, RU; Ng, P; Sprengart, ML; Porter, AG			Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; INTERLEUKIN-1-BETA-CONVERTING ENZYME; POLY(ADP-RIBOSE) POLYMERASE; TUMOR-CELLS; LAMIN-A; PROTEASE; SPECTRIN; PROTEINASE; EXECUTION; DISTINCT	Although the commonly activated death protease caspase-3 appears not to be essential for apoptosis during development except in the brain, it was not shown whether substrates known tea he cleaved by caspase-3 are still proteolyzed in its absence, We have addressed this question with MCF-7 breast carcinoma cells that we recently showed lack caspase-3 owing to the functional deletion of the CASP-3 gene. Tumor necrosis factor-or staurosporine-induced apoptosis of caspase-3-deficient MCF-7 cells resulted in cleavage of the death substrates PARP, Rb, PAK2, DNA-PKcs, gelsolin, and DFF-45, but not alpha-fodrin. In contrast, all these substrates including alpha-fodrin were cleaved in apoptotic HeLa cells expressing caspase-3. Introduction of CASP-3 cDNA, but not CASP-10 cDNA, into MCF-7 cells restored alpha-fodrin cleavage. In addition, tumor necrosis factor-os staurosporine-induced apoptosis of MCF-7 cells stably expressing pso-caspase-3 also resulted in alpha-fodrin cleavage. Although the specific caspase inhibitory peptides Z-VAD-fmk and Z-DEVD-fmk prevented apoptosis of MCF-7 cells, we were unable to detect activation of caspases 2 and 7, which are known tee be inhibited by Z-DEVD-fmk, Together our results suggest that caspase-3 is essential for cleavage of Lu-fodrin, but dispensable for the cleavage of PARP, Rb, PAK2, DNA-PKcs, gelsolin, and DFF-45 and imply that one or more caspases other theta caspases 2, 3, and 7 is activated and plays a crucial role in the cleavage of these substrates in MCF-7 cells.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Janicke, RU (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.			Duriez, Patrick/0000-0003-1814-2552				BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Faucheu C, 1996, EUR J BIOCHEM, V236, P207, DOI 10.1111/j.1432-1033.1996.t01-1-00207.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Morrow JS, 1989, CURR OPIN CELL BIOL, V1, P23, DOI 10.1016/S0955-0674(89)80032-8; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9	48	431	441	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15540	15545		10.1074/jbc.273.25.15540	http://dx.doi.org/10.1074/jbc.273.25.15540			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624143	hybrid			2022-12-25	WOS:000074284200037
J	Bing, W; Razzaq, A; Sparrow, J; Marston, S				Bing, W; Razzaq, A; Sparrow, J; Marston, S			Tropomyosin and troponin regulation of wild type and E93K mutant actin filaments from Drosophila flight muscle - Charge reversal on actin changes actin-tropomyosin from on to off state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO MOTILITY; MYOSIN SUBFRAGMENT-1; THIN FILAMENT; DIFFRACTION DATA; F-ACTIN; MOVEMENT; BINDING; CALCIUM; SMOOTH; MODEL	In the Drosophila flight muscle actin mutant E93K there is a charge reversal on the surface of actin close to the proposed position of tropomyosin when it is in the off state. Using a quantitative in vitro motility assay we have found that the wild type Drosophila ACT88F actin behaved like rabbit skeletal muscle actin when tropomyosin and troponin were added at pCa5 and pCa9. In contrast the effect of tropomyosin upon the E93K mutant actin filament movement was completely different from wild type and resembled the response of wild type with tropomyosin+troponin at pCa9 (i.e. the filaments were switched off), Velocity of E93K actin did not increase, and the fraction of filaments motile was reduced to less than 15% by adding up to 30 nM tropomyosin. When myosin subfragment-1 modified by N-ethylmaleimide was mixed with mutant E93K actin-tropomyosin filaments we observed that it restored motility of the filaments to the level observed with E93K actin alone. We conclude that electrostatic charge on the surface of domain 2 of actin plays a critical role in determining the state of actin-tropomyosin that is a central feature of the steric blocking mechanism of actin filament regulation.	Imperial Coll, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England; Univ York, Dept Biol, York YO1 5YW, N Yorkshire, England	Imperial College London; University of York - UK	Marston, S (corresponding author), Imperial Coll, Sch Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	s.marston@ic.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALHILLAWI E, 1995, EUR J BIOCHEM, V228, P962; ALKHAYAT HA, 1995, J MOL BIOL, V252, P611, DOI 10.1006/jmbi.1995.0524; ANSON M, 1995, BIOPHYS J, V68, P1991, DOI 10.1016/S0006-3495(95)80376-0; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; BULLARD B, 1973, BIOCHEM J, V135, P277, DOI 10.1042/bj1350277; DOSREMEDIOS CG, 1995, BBA-BIOENERGETICS, V1228, P99, DOI 10.1016/0005-2728(94)00169-6; EGELMAN EH, 1985, J MUSCLE RES CELL M, V6, P129, DOI 10.1007/BF00713056; ELSALEH SC, 1984, J BIOL CHEM, V259, P1014; ELSALEH SC, 1986, J MUSCLE RES CELL M, V7, P387, DOI 10.1007/BF01753582; FRASER IDC, 1995, J BIOL CHEM, V270, P19688, DOI 10.1074/jbc.270.34.19688; FRASER IDC, 1995, J BIOL CHEM, V270, P7836, DOI 10.1074/jbc.270.14.7836; GEEVES MA, 1987, BIOPHYS J, V52, P215, DOI 10.1016/S0006-3495(87)83208-3; Gerson Jack H., 1997, Biophysical Journal, V72, pA57; Gordon AM, 1997, BIOPHYS J, V72, P1295, DOI 10.1016/S0006-3495(97)78776-9; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HOLMES KC, 1995, BIOPHYS J S, V68, P2; Homsher E, 1996, BIOPHYS J, V70, P1881, DOI 10.1016/S0006-3495(96)79753-9; Korman V, 1998, BIOPHYS J, V74, pA347; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Landis CA, 1997, J BIOL CHEM, V272, P14051, DOI 10.1074/jbc.272.22.14051; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHMAN W, 1995, J MOL BIOL, V251, P191, DOI 10.1006/jmbi.1995.0425; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; LEVINE BA, 1988, EUR J BIOCHEM, V172, P389, DOI 10.1111/j.1432-1033.1988.tb13899.x; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MAHAFFEY JW, 1987, CELL, V40, P101; MARSTON S, 1995, INT J BIOCHEM CELL B, V27, P97, DOI 10.1016/1357-2725(94)00080-U; Marston S. B., 1996, Biophysical Journal, V70, pA25; Marston SB, 1996, J MUSCLE RES CELL M, V17, P497, DOI 10.1007/BF00123365; MOLLOY JE, 1995, BIOPHYS J, V68, pS198; NAGASHIMA H, 1982, J MOL BIOL, V155, P409, DOI 10.1016/0022-2836(82)90479-X; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Perry SV, 1979, BIOCHEM SOC T, V7, P593, DOI 10.1042/bst0070593; PERRY SV, 1972, COLD SPRING HARB SYM, V37, P251; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; Razzaq A., 1997, Biophysical Journal, V72, pA56; Saeki K, 1996, BIOCHEMISTRY-US, V35, P14465, DOI 10.1021/bi961292c; SAIDE JD, 1989, J CELL BIOL, V109, P2157, DOI 10.1083/jcb.109.5.2157; Snyder C. H., 1995, Biophysical Journal, V68, pA164; SPARROW J, 1991, J MOL BIOL, V222, P963, DOI 10.1016/0022-2836(91)90588-W; SWARTZ DR, 1992, J BIOL CHEM, V267, P20497; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WANG F, 1993, J BIOL CHEM, V268, P3776; WERTMAN KF, 1992, GENETICS, V132, P337; WILLIAMS DL, 1984, BIOCHEMISTRY-US, V23, P4150, DOI 10.1021/bi00313a022; Wong WW, 1998, BIOPHYS J, V74, pA264; WU B, 1997, BIOCHEM BIOPH RES CO, V236, P760; WU B, 1997, BIOCHEM J, V327, P335	49	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15016	15021		10.1074/jbc.273.24.15016	http://dx.doi.org/10.1074/jbc.273.24.15016			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614109	hybrid			2022-12-25	WOS:000074160400051
J	Cieslik, K; Zembowicz, A; Tang, JL; Wu, KK				Cieslik, K; Zembowicz, A; Tang, JL; Wu, KK			Transcriptional regulation of endothelial nitric-oxide synthase by lysophosphatidylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MAMMALIAN-CELLS; GENE-EXPRESSION; CULTURED HUMAN; SP1; ACTIVATION; INDUCTION; GROWTH; MESSENGER; PROTEIN	We have shown that lysophosphatidylcholine (lyso-PC) increases endothelial nitric-oxide synthase (eNOS) expression at the transcriptional level (Zembowicz, A., Tang, J.-L., and Wu, K. K. (1995) J. Biol. Chem. 270, 17006-17010). To elucidate the mechanism by which lyso-PC increases the eNOS transcription, we identified Sp1 sites at -104 to -90 and PEA3 sites at -40 to -24 as being involved in lyso-PC-induced promoter activity. Site-directed mutagenesis of Sp1 sites resulted in a marked reduction of basal and lyso-PC-induced activity whereas PEA3 site mutation abrogated response to lyso-PC. Band shift assays revealed that lyso-PC augmented Sp1 binding activity. Pretreatment of cells or nuclear extracts with okadaic acid reduced the Sp1 binding activity. Furthermore, okadaic acid treatment abrogated the lyso-PC induced promoter augmentation. Lyse-PC increased the nuclear extract protein phosphatase 2A (PP2A) activity, which was suppressed by okadaic acid treatment. These results suggest that lyso-PC up-regulates eNOS transcription by a PP2A-dependent increase in Sp1 binding activity.	Univ Texas, Sch Med, Vasc Biol Res Ctr, Houston, TX 77030 USA; Univ Texas, Sch Med, Div Hematol, Houston, TX 77030 USA; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan	University of Texas System; University of Texas System; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital	Wu, KK (corresponding author), Univ Texas, Sch Med, Vasc Biol Res Ctr, 6431 Fannin,MSB 5-016, Houston, TX 77030 USA.		Cieslik, Katarzyna/AAO-1982-2021; Wu, Kenneth Kun-Yu/B-1070-2010	Cieslik, Katarzyna/0000-0002-2167-7921; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-50675] Funding Source: Medline; NINDS NIH HHS [P50 NS-23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Arnet UA, 1996, J BIOL CHEM, V271, P15069, DOI 10.1074/jbc.271.25.15069; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Fang XJ, 1997, J BIOL CHEM, V272, P13683, DOI 10.1074/jbc.272.21.13683; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Felgner P L, 1991, Methods Mol Biol, V7, P81, DOI 10.1385/0-89603-178-0:81; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; HIRATA K, 1995, CIRC RES, V76, P958, DOI 10.1161/01.RES.76.6.958; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nadaud S, 1996, CIRC RES, V79, P857, DOI 10.1161/01.RES.79.4.857; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; PORTMAN OW, 1969, J LIPID RES, V10, P158; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; TANG JL, 1995, BIOCHEM BIOPH RES CO, V213, P673, DOI 10.1006/bbrc.1995.2184; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; Wu K K, 1995, Adv Pharmacol, V33, P179, DOI 10.1016/S1054-3589(08)60669-9; ZEMBOWICZ A, 1995, J CLIN INVEST, V96, P1688, DOI 10.1172/JCI118211; ZEMBOWICZ A, 1995, J BIOL CHEM, V270, P17006, DOI 10.1074/jbc.270.28.17006	33	72	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14885	14890		10.1074/jbc.273.24.14885	http://dx.doi.org/10.1074/jbc.273.24.14885			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614091	hybrid			2022-12-25	WOS:000074160400033
J	Dennis, PB; Pullen, N; Pearson, RB; Kozma, SC; Thomas, G				Dennis, PB; Pullen, N; Pearson, RB; Kozma, SC; Thomas, G			Phosphorylation sites in the autoinhibitory domain participate in p70(s6k) activation loop phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; P70 S6 KINASE; RAPAMYCIN SENSITIVITY; CELL-CYCLE; IN-VIVO; DEPHOSPHORYLATION; INACTIVATION; ENTRY; PHASE; GENE	Here we have employed p70(s6k) truncation and point mutants to elucidate the role played by the carboxyl-terminal autoinhibitory domain <(S/T)under bar>P phosphorylation sites in kinase activation. Earlier studies showed that truncation of the p70(s6k) amino terminus severely impaired kinase activation but that this effect was reversed by deleting the carboxyl terminus, which in parallel led to deregulation of Thr(229) phosphorylation in the activation loop (Dennis, P. B., Pullen, N., Kozma, S. C., and Thomas, G. (1996) Mol. Cell. Biol. 16, 6242-6251). In this study, substitution of acidic residues for the four autoinhibitory domain <(S/T)under bar>P sites mimics the carboxyl-terminal deletion largely by rescuing kinase activation caused by the amino-terminal truncation. However, these mutations do not deregulate Thr(229) phosphorylation, suggesting the involvement of another regulatory element in the intact kinase. This element appears to be Thr(389) phosphorylation, because substitution of an acidic residue at this position in the p70(s6k) variant containing the <(S/T)under bar>P mutations leads to a large increase in basal Thr(229) phosphorylation and kinase activity. In contrast, an alanine substitution at Thr(389) blocks both responses. Consistent with these data, we, show that a mutant harboring the acidic <(S/T)under bar>P and Thr(389) substitutions is an excellent in vitro substrate for the newly identified Thr(229) kinase, phosphoinositide-dependent kinase-1 (Pullen, N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S., Hemmings, B. A., and Thomas, G. (1998) Science 279, 707-710), whereas phosphoinositide-dependent kinase-l poorly utilizes the two p70(s6k) variants that have only one set of mutations. These findings indicate that phosphorylation of the <(S/T)under bar>P sites, in cooperation with Thr(389) phosphorylation, controls Thr(229) phosphorylation through an intrasteric mechanism.	Friedrich Miescher Inst, Dept Growth Control, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Thomas, G (corresponding author), Friedrich Miescher Inst, Dept Growth Control, POB 2543, CH-4002 Basel, Switzerland.		Pearson, Richard Bruce/I-1451-2013; Thomas, George/K-9235-2014	Pearson, Richard Bruce/0000-0001-5919-5090; Thomas, George/0000-0003-3518-8149; Pullen, Nicholas/0000-0002-4014-9278				Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Fadden P, 1997, J BIOL CHEM, V272, P10240; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FRANCO R, 1990, J BIOL CHEM, V265, P4321; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HANKS SK, 1995, PROTEIN KINASE FACTS, P7; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; ORR JW, 1994, J BIOL CHEM, V269, P8383; Pearson R B, 1995, Prog Cell Cycle Res, V1, P21; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Stewart MJ, 1996, P NATL ACAD SCI USA, V93, P10791, DOI 10.1073/pnas.93.20.10791; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Watson KL, 1996, P NATL ACAD SCI USA, V93, P13694, DOI 10.1073/pnas.93.24.13694; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957	43	118	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14845	14852		10.1074/jbc.273.24.14845	http://dx.doi.org/10.1074/jbc.273.24.14845			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614086	hybrid			2022-12-25	WOS:000074160400028
J	Helms, JB; Helms-Brons, D; Brugger, B; Gkantiragas, I; Eberle, H; Nickel, W; Nurnberg, B; Gerdes, HH; Wieland, FT				Helms, JB; Helms-Brons, D; Brugger, B; Gkantiragas, I; Eberle, H; Nickel, W; Nurnberg, B; Gerdes, HH; Wieland, FT			A putative heterotrimeric G protein inhibits the fusion of COPI-coated vesicles - Segregation of heterotrimeric G proteins from COPI-coated vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEINS; GOLGI MEMBRANES; EPITHELIAL-CELLS; ALPHA-SUBUNITS; TRANSPORT; COATOMER; ACTIVATION; COMPLEXES; FLUORIDE	Heterotrimeric G proteins have been implicated in the regulation of intracellular protein transport, but their mechanism of action remains unclear, bn vivo, secretion of chromogranin B, tagged with the green fluorescent protein, was inhibited by the addition of a general activator of trimeric G proteins (AlF4-) to stably transfected Vero cells and resulted in an accumulation of the tagged protein in the Gels apparatus. In an in vitro assay that reconstitutes intra-Golgi protein transport, we find that a membrane-bound and AlF4--sensitive factor is involved in the fusion reaction. To determine whether this effect is mediated by a heterotrimeric G protein localized to COPI-coated transport vesicles, we determined the presence of G proteins on these vesicles and found that they were segregated relative to the donor membranes. Because G proteins do not have an obvious sorting, retention, or retrieval signal, we considered the possibility that other interactions might be responsible for this segregation. In agreement with this, we found that trimeric G proteins from isolated Golgi membranes were partially insoluble in Triton X-100. Identification of the proteins that interact with the heterotrimeric G proteins in the Golgi-derived detergent-insoluble complex might help to reveal the regulation of protein secretion mediated by heterotrimeric G proteins.	Heidelberg Univ, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany; Free Univ Berlin, Klinikum Rudolf Virchow, Inst Pharmakol, D-14195 Berlin, Germany; Heidelberg Univ, Dept Neurobiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg	Helms, JB (corresponding author), Heidelberg Univ, Biochem Zentrum Heidelberg, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	Helms@urz.uni-heidelberg.de		Nurnberg, Bernd/0000-0002-5995-6555				Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BEG ZH, 1978, P NATL ACAD SCI USA, V75, P3678, DOI 10.1073/pnas.75.8.3678; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; DENKER BM, 1992, J BIOL CHEM, V267, P6272; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FINAZZI D, 1994, J BIOL CHEM, V269, P13325; HELMS JB, 1995, FEBS LETT, V369, P84, DOI 10.1016/0014-5793(95)00620-O; Jamora C, 1997, CELL, V91, P617, DOI 10.1016/S0092-8674(00)80449-3; KAETHER C, 1995, FEBS LETT, V369, P267, DOI 10.1016/0014-5793(95)00765-2; KAHN RA, 1991, J BIOL CHEM, V266, P15595; Leopoldt D, 1997, N-S ARCH PHARMACOL, V356, P216, DOI 10.1007/PL00005044; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sonnichsen B, 1996, J CELL BIOL, V134, P1411, DOI 10.1083/jcb.134.6.1411; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; Wacker I, 1997, J CELL SCI, V110, P1453; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Yamaguchi T, 1997, J BIOL CHEM, V272, P25260, DOI 10.1074/jbc.272.40.25260; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	48	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15203	15208		10.1074/jbc.273.24.15203	http://dx.doi.org/10.1074/jbc.273.24.15203			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614134	hybrid			2022-12-25	WOS:000074160400076
J	Kozaki, K; Miyaishi, O; Koiwai, O; Yasui, Y; Kashiwai, A; Nishikawa, Y; Shimizu, S; Saga, S				Kozaki, K; Miyaishi, O; Koiwai, O; Yasui, Y; Kashiwai, A; Nishikawa, Y; Shimizu, S; Saga, S			Isolation, purification, and characterization of a collagen-associated serpin, caspin, produced by murine colon adenocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; EMBRYO FIBROBLASTS; BINDING-PROTEIN; STRESS PROTEIN; HUMAN-PLASMA; INHIBITORS; HSP47; ALPHA-1-ANTITRYPSIN; IDENTIFICATION; VITRONECTIN	A 45-kDa serpin secreted by a murine colon adenocarcinoma cell line, colon26, was isolated, purified, and characterized, It was found to bind specifically to type I collagen with high affinity and to type III collagen with lower affinity, Immunohistochemical studies of murine embryonic tissues showed a specific distribution of this collagen-associated serpin, named caspin, in relation to the formation of bone, cartilage, teeth, and basement membrane. The expression of caspin in high and low lung metastatic subclones of colon26 cell lines was inversely correlated with their metastatic capacity: low lung metastatic cells secreted higher amounts of caspin than their high lung metastatic counterparts. Caspin also demonstrated high homology with human pigment epithelium-derived factor/early population doubling level cDNA-1, which reportedly induces neuronal differentiation of human retinoblastoma cells and is expressed in association with G(0) growth arrest. These findings suggest that caspin/pigment epithelium-derived factor/early population doubling level cDNA-1 is a novel factor that might play a crucial role in embryogenesis and tumor metastasis through binding to the extracellular matrix.	Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Biochem Lab, Chikusa Ku, Aichi 4648681, Japan; Natl Inst Longev Sci, Dept Basic Gerontol, Pathol Lab, Aichi 4748522, Japan; Tokyo Univ Sci, Fac Sci & Technol, Dept Appl Biol Sci, Noda, Chiba 2788510, Japan; Aichi Human Serv Ctr, Inst Dev Res, Aichi 4800304, Japan; Aichi Med Univ, Dept Pathol 2, Aichi 4801195, Japan	Aichi Cancer Center; Aichi Cancer Center; Tokyo University of Science; Aichi Medical University	Kozaki, K (corresponding author), Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Aichi 4648681, Japan.	kkozaki@aichi-cc.pref.aichi.jp	Kozaki, Ken-ichi/M-6281-2014	Kozaki, Ken-ichi/0000-0003-3286-819X				CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DONOVAN FM, 1994, J BIOL CHEM, V269, P17199; HIRAYOSHI K, 1991, MOL CELL BIOL, V11, P4036, DOI 10.1128/MCB.11.8.4036; HOPKINS PCR, 1994, SCIENCE, V265, P1893; Horton William A., 1993, P73; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KOZAKI KI, 1994, EXP CELL RES, V213, P348, DOI 10.1006/excr.1994.1209; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; NAGATA K, 1986, J CELL BIOL, V103, P223, DOI 10.1083/jcb.103.1.223; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; PIGNOLO RJ, 1993, J BIOL CHEM, V268, P8949; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RINEHART AR, 1993, AM J RESP CELL MOL, V9, P666, DOI 10.1165/ajrcmb/9.6.666; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; Sakata K, 1996, JPN J CANCER RES, V87, P78, DOI 10.1111/j.1349-7006.1996.tb00203.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shimizu S, 1996, CANCER RES, V56, P3366; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	24	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15125	15130		10.1074/jbc.273.24.15125	http://dx.doi.org/10.1074/jbc.273.24.15125			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614124	hybrid			2022-12-25	WOS:000074160400066
J	Whitworth, ST; Blum, MS; Travis, J				Whitworth, ST; Blum, MS; Travis, J			Proteolytic enzymes from larvae of the fire ant, Solenopsis invicta - Isolation and characterization of four serine endopeptidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYMENOPTERA; FORMICIDAE; COMPONENTS; VENOM	The imported red fire ant (Solenopsis invicta) is a problematic pest in the Southern United States. The stages of development for these ants are as follows: egg, 1st, 2nd, 3rd, and 4th instar larvae, prepupae, pupae, and adult. The 4th instar larvae plays an important role in the survival of the colony in that it is totally responsible for the digestion of solid foods and the source of nutrients for the queen and adult workers. In our studies we have been successful in purifying and characterizing four proteinases from the 4th instar larvae. Based on substrate specificity, they appear to represent two chymotrypsin-like and two elastase-like proteinases. These are referred to as Soli C1, Soli C2, Soli E1, and Soli E2, with molecular masses of 25, 28, 23, and 24 kDa, respectively, based on SDS-PAGE. All enzymes were inhibited by diisopropyl fluorophosphate, a general serine class inhibitor. Various synthetic substrates with either Phe or Val in the P-1 position, were readily cleaved by Soli C1/C2 or E1/E2, respectively. Each enzyme has been characterized as to pH optimum, pH stability, isoelectrofocusing and susceptibility to inhibition by a broad range of natural and synthetic proteinase inhibitors. Such compounds may prove useful for the development of insecticides to control fire ant infestation.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Dept Entomol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Travis, J (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Life Sci Bldg, Athens, GA 30602 USA.	jtravis@uga.cc.uga.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026148] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26148] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAER H, 1979, TOXICON, V17, P397, DOI 10.1016/0041-0101(79)90267-8; BRAND JM, 1972, TOXICON, V10, P259, DOI 10.1016/0041-0101(72)90011-6; BUREN W F, 1972, Journal of the Georgia Entomological Society, V7, P1; DREES BM, 1990, J ENTOMOL SCI, V25, P317, DOI 10.18474/0749-8004-25.2.317; GLANCEY B M, 1973, Journal of the Georgia Entomological Society, V8, P237; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P818, DOI 10.1016/0091-6749(88)90084-X; Holldobler B., 1990, pi; HUNG ACF, 1974, ANN ENTOMOL SOC AM, V67, P909, DOI 10.1093/aesa/67.6.909; LOCKEY RF, 1979, ADV ALLERGOLOGY CLIN, P441; Lofgren C.S., 1986, P227; MACCONNELL JG, 1971, TETRAHEDRON, V27, P1129, DOI 10.1016/S0040-4020(01)90860-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PETRALIA RS, 1978, ANN ENTOMOL SOC AM, V71, P643, DOI 10.1093/aesa/71.4.643; PORTER SD, 1991, J ECON ENTOMOL, V84, P866, DOI 10.1093/jee/84.3.866; SHAGGAR H, 1987, ANAL BIOCHEM, V166, P168; SORENSEN AA, 1983, J INSECT PHYSIOL, V29, P163, DOI 10.1016/0022-1910(83)90140-3; TSCHINKEL WR, 1987, ENTOMOL SOC AM, V81, P76; Vinson SB, 1986, IMPORTED FIRE ANTS L	18	21	23	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14430	14434		10.1074/jbc.273.23.14430	http://dx.doi.org/10.1074/jbc.273.23.14430			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603955	hybrid			2022-12-25	WOS:000074021500057
J	Chen, CY; Liou, J; Forman, LW; Faller, DV				Chen, CY; Liou, J; Forman, LW; Faller, DV			Differential regulation of discrete apoptotic pathways by Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION PATHWAY; CELL-SURFACE ANTIGEN; MATURE T-CELLS; NIH 3T3 CELLS; DEATH DOMAIN; MONOCLONAL-ANTIBODY; DNA FRAGMENTATION; MOLECULAR-CLONING	The products of the ras genes are known to regulate cell proliferation and differentiation; recently, they have been found to play a role in apoptosis, The expression of oncogenic p21(ras) in a number of cell types, including Jurkat (a human T lymphoblastoid cell line) and murine fibroblasts, makes the cells susceptible to apoptosis following suppression of protein kinase C (PKC) activity (PKC/Ras-mediated apoptosis), Engagement of Fas antigen, a potent effector of apoptosis, activates cellular p21(ras), which may be required for completion of the cell death program. To further investigate the role of p21(ras) in the regulation of apoptosis, the cellular mechanisms employed in these two apoptotic processes in which Ras activity is involved (PKC/Ras-related and Fas-triggered apoptosis), was explored. Increasing p21(ras) activity by expressing v-ras or by treatment with an antisense oligonucleotide to the GTPase-activating protein was found to accelerate the Fas-mediated apoptotic process in Jurkat and mouse LF cells. PKC/Ras-related apoptosis was associated with, and required, cell cycle progression, accompanied by the expression of the G(1)/S cyclins, In contrast, Fas engagement, although inducing a vigorous and PKC-independent activation of endogenous p21(ras), did not alter cell cycle progression, nor did it require such progression for apoptosis, Both the protein synthesis inhibitor cycloheximide and cyclin E antisense oligonucleotides partially abolished PKC/Ras-mediated apoptosis but had only a moderate effect on Fas-induced apoptosis, In contrast, the CED-3/interleukin-1 beta-converting enzyme (ICE) protease inhibitor Z-VADfmk efficiently suppressed Fas-induced apoptosis and only marginally inhibited PKC/Ras-mediated apoptosis, Induction of both pathways resulted in activation of the Jun NH2-terminal kinase/JUN signaling system. These results suggest that different cell death programs, such as PKC/Ras-mediated and Ras-mediated apoptosis, may be interconnected via p21(ras) and perhaps Jun NH2-terminal kinase/JUN, In response to various death stimuli, p21(ras) may act as a common intermediate regulator in the transduction of apoptotic signals.	Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Lab Med, Boston, MA 02118 USA	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University	Faller, DV (corresponding author), Boston Univ, Sch Med, Canc Res Ctr, 80 E Concord St,Room K-701, Boston, MA 02118 USA.	dfaller@bu.edu			NCI NIH HHS [CA50459] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050459] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chen CY, 1996, MOL CELL BIOL, V16, P6582; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; FU T, 1991, EXP CELL RES, V203, P230; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GILLETTEFERGUSON I, 1994, EUR J IMMUNOL, V24, P1181, DOI 10.1002/eji.1830240526; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; ILLERA VA, 1993, J IMMUNOL, V151, P2965; Itano Y, 1996, J NEUROCHEM, V67, P131; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOKA P, 1991, J IMMUNOL, V146, P2417; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Leszczynski D, 1996, CANCER J - FRANCE, V9, P308; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LUCAS M, 1994, BIOCHEM PHARMACOL, V47, P667, DOI 10.1016/0006-2952(94)90129-5; LUCAS S, 1990, FEBS LETT, V260, P53, DOI 10.1016/0014-5793(90)80064-P; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Masuda Y, 1997, INT J CANCER, V71, P691, DOI 10.1002/(SICI)1097-0215(19970516)71:4<691::AID-IJC29>3.0.CO;2-D; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Messmer UK, 1997, BRIT J PHARMACOL, V121, P625, DOI 10.1038/sj.bjp.0701156; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OEHM A, 1992, J BIOL CHEM, V267, P10709; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; RAMSDELL F, 1994, EUR J IMMUNOL, V24, P928, DOI 10.1002/eji.1830240422; Romanova LY, 1996, BIOCHEMISTRY-US, V35, P9900, DOI 10.1021/bi9525886; RuizRuiz MD, 1997, EUR J IMMUNOL, V27, P1442, DOI 10.1002/eji.1830270622; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUGIMOTO Y, 1992, EXP CELL RES, V213, P203; TAKAHASHI T, 1994, CELL, V76, P966; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; Weiss E, 1997, INT J ONCOL, V10, P1119; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	74	48	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16700	16709		10.1074/jbc.273.27.16700	http://dx.doi.org/10.1074/jbc.273.27.16700			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642224	hybrid			2022-12-25	WOS:000074545200014
J	Sato, T; Watanabe, S; Ishii, E; Tsuji, K; Nakahata, T				Sato, T; Watanabe, S; Ishii, E; Tsuji, K; Nakahata, T			Induction of the erythropoietin receptor gene and acquisition of responsiveness to erythropoietin by stem cell factor in HML/SE, a human leukemic cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; ERYTHROID-DIFFERENTIATION; GM-CSF; INTERLEUKIN-3; GATA-1; PROLIFERATION; TRANSCRIPTION; ESTABLISHMENT; PROGENITORS; EXPRESSION	HML/SE is a cytokine-dependent cell line established from childhood acute megakaryoblastic leukemia. Granulocyte-macrophage colony-stimulating factor or stem cell factor (SCF) alone could stimulate proliferation of HML/SE cells, however interleukin-3, interleukin-6, granulocyte colony-stimulating factor and thrombopoietin could not. Although erythropoietin (EPO) alone stimulated neither proliferation nor differentiation of HML/SE cells, it did stimulate proliferation of HML/SE cells and production of hemoglobin in the presence of SCF. SCF activated the human EPO receptor promoter and induced EPO receptor gene expression. Given these results, we speculate that HML/SE cells acquired responsiveness to EPO via the EPO receptor induced by SCF. Mutation analysis of putative transcription factor binding sites in the human EPO receptor promoter suggested that Spl, rather than the GATA-1 binding site, contributed to the induction of the hEPOR gene. Although it is well documented that hematopoietic stem cells and primitive progenitors require both an early-acting cytokine and a lineage-specific cytokine to differentiate to a certain lineage, related mechanisms are not well understood. HML/SE may serve as an excellent model system to analyze functions of early-acting cytokine SCF and lineage-specific cytokine EPO related to proliferation and differentiation of hematopoietic stem cells.	Univ Tokyo, Dept Clin Oncol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Dept Mol & Dev Biol, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; Nagano Childrens Hosp, Dept Hematol & Oncol, Nagano 39982, Japan	University of Tokyo; University of Tokyo	Nakahata, T (corresponding author), Univ Tokyo, Dept Clin Oncol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							BUSFIELD SJ, 1995, EUR J BIOCHEM, V230, P475; CHIBA S, 1991, BLOOD, V78, P2261; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CHIN K, 1995, NUCLEIC ACIDS RES, V23, P3041, DOI 10.1093/nar/23.15.3041; DALYOT N, 1993, NUCLEIC ACIDS RES, V21, P4031, DOI 10.1093/nar/21.17.4031; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOIKE K, 1986, J CLIN INVEST, V77, P894, DOI 10.1172/JCI112387; KOMATSU N, 1991, CANCER RES, V51, P341; Ma F, 1998, BRIT J HAEMATOL, V100, P427, DOI 10.1046/j.1365-2141.1998.00553.x; METCALF D, 1993, BLOOD, V82, P3515; Migliaccio AR, 1996, INT J HEMATOL, V64, P1; MINEGISHI N, 1994, J BIOL CHEM, V269, P27700; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOGUCHI CT, 1991, BLOOD, V78, P2548; OGAWA M, 1993, BLOOD, V81, P2844; OKUMURA N, 1992, BLOOD, V80, P642; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; SONODA Y, 1988, P NATL ACAD SCI USA, V85, P4360, DOI 10.1073/pnas.85.12.4360; Sui XW, 1996, J EXP MED, V183, P837, DOI 10.1084/jem.183.3.837; Tajima S, 1996, J EXP MED, V184, P1357, DOI 10.1084/jem.184.4.1357; UOSHIMA N, 1995, BRIT J HAEMATOL, V91, P30, DOI 10.1111/j.1365-2141.1995.tb05240.x; WATANABE S, 1995, MOL BIOL CELL, V6, P627, DOI 10.1091/mbc.6.6.627; WATANABE S, 1995, EUR J IMMUNOL, V25, P126, DOI 10.1002/eji.1830250122; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	32	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16921	16926		10.1074/jbc.273.27.16921	http://dx.doi.org/10.1074/jbc.273.27.16921			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642254	hybrid			2022-12-25	WOS:000074545200044
J	Schnappauf, G; Krappmann, S; Braus, GH				Schnappauf, G; Krappmann, S; Braus, GH			Tyrosine and tryptophan act through the same binding site at the dimer interface of yeast chorismate mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; R-STATE; BIOSYNTHESIS; PATHWAY	Tyrosine and tryptophan are the regulators of the dimeric yeast chorismate mutase. Biochemical studies reveal two binding sites per molecule for both effecters, tyrosine or tryptophan, A single binding site is built up by helix 8 and helices 4 and 5 of two different subunits, The binding sites have been analyzed in the active enzyme by site directed mutagenesis of critical codons of the coding gene, AR07, Gly-141 and Ser-142, which both reside on helix 8, are involved in the binding of tyrosine or tryptophan presumably by interacting specifically with the amino- and carboxylate-groups of these amino acid effecters. Interaction with Thr-145 of helix 8 is required for a strong tyrosine binding to the allosteric site. Replacement of Arg-75, which connects helices 4 and 5 or of Arg-76, which is part of helix 5 by alanine residues, resulted in unregulated enzymes. These two residues are bonded to the carboxylate group and phenolic hydroxyl group of tyrosine, respectively, but do not interact with tryptophan by hydrogen bonding in the crystal structures. Phenylalanine, which has low binding affinity slightly activated the chorismate mutase, A T145V mutant chorismate mutase, however, showed increased activation by phenylalanine. Our results support a mechanism by which tyrosine contracts the allosteric site by interacting with its phenolic hydroxyl group. Tryptophan works in an inverse way by opening the allosteric site through the steric size of its side chain.	Univ Gottingen, Inst Mikrobiol & Genet, D-37077 Gottingen, Germany	University of Gottingen	Braus, GH (corresponding author), Univ Gottingen, Inst Mikrobiol & Genet, Grisebachstr 8, D-37077 Gottingen, Germany.		Braus, Gerhard H/G-3999-2012; Krappmann, Sven/K-2615-2012; Braus, Gerhard/ABC-6293-2021	Braus, Gerhard H/0000-0002-3117-5626; Braus, Gerhard/0000-0002-3117-5626; Krappmann, Sven/0000-0002-8299-7777				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUS GH, 1991, MICROBIOL REV, V55, P349, DOI 10.1128/MMBR.55.3.349-370.1991; DIMROTH P, 1986, METHOD ENZYMOL, V125, P530; EBERHARD J, 1993, FEBS LETT, V334, P233, DOI 10.1016/0014-5793(93)81718-F; FLETCHER R, 1963, COMPUT J, V6, P163, DOI 10.1093/comjnl/6.2.163; Ganem B., 1996, ANGEW CHEM INT EDIT, V35, P936, DOI [10.1002/anie.19960936, DOI 10.1002/ANIE.199609361]; GIEBEL LB, 1990, NUCLEIC ACIDS RES, V18, P4947, DOI 10.1093/nar/18.16.4947; GRAF R, 1995, J BACTERIOL, V177, P1645, DOI 10.1128/jb.177.6.1645-1648.1995; Haslam E., 1974, SHIKIMATE PATHWAY; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AY, 1995, CHEM BIOL, V2, P195, DOI 10.1016/1074-5521(95)90269-4; MIOZZARI G, 1978, J BACTERIOL, V134, P48, DOI 10.1128/JB.134.1.48-59.1978; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NEWELL JO, 1990, BIOPHYS CHEM, V37, P183, DOI 10.1016/0301-4622(90)88018-N; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDHEINI T, 1990, BIOCHEMISTRY-US, V29, P3660, DOI 10.1021/bi00467a011; SCHMIDHEINI T, 1989, J BACTERIOL, V171, P1245, DOI 10.1128/jb.171.3.1245-1253.1989; Strater N, 1997, STRUCTURE, V5, P1437, DOI 10.1016/S0969-2126(97)00294-3; Strater N, 1996, P NATL ACAD SCI USA, V93, P3330, DOI 10.1073/pnas.93.8.3330; XUE YF, 1994, P NATL ACAD SCI USA, V91, P10814, DOI 10.1073/pnas.91.23.10814	21	20	20	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17012	17017		10.1074/jbc.273.27.17012	http://dx.doi.org/10.1074/jbc.273.27.17012			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642265	hybrid			2022-12-25	WOS:000074545200055
J	Zhou, KM; Wang, Y; Gorski, JL; Nomura, N; Collard, J; Bokoch, GM				Zhou, KM; Wang, Y; Gorski, JL; Nomura, N; Collard, J; Bokoch, GM			Guanine nucleotide exchange factors regulate specificity of downstream signaling from Rac and Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DBL-ONCOGENE PRODUCT; PLECKSTRIN HOMOLOGY DOMAINS; GTP-BINDING PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN POLYMERIZATION; TERMINAL REGION; RHO; MEMBRANE; EFFECTOR	The Rac and Cdc42 GTPases regulate diverse cellular behaviors involving the actin cytoskeleton, gene transcription, and the activity of multiple protein and lipid kinases, All of these pathways can potentially become activated when GTP-Rac or GTP-Cdc42 is formed in response to external cell signals, yet it is evident that each activity must also be able to be controlled individually. The mechanisms by which such specificity of GTPase signaling in response to upstream stimuli is achieved remains unclear, We investigated the action of several well characterized guanine nucleotide exchange factors (GEF(Rho)) to activate Rac- and/or Cdc42-dependent kinase pathways. Coexpression studies in COS-7 cells revealed that the ability of individual guanine nucleotide exchange factors (GEFs) to activate the pal-activated kinase PAK1 could be dissociated from activation of c-Jun amino-terminal kinase, even though activation of both pathways requires the action of the GEFs on Rac and/or Cdc42. In contrast, expression of constitutively active forms of Rac or Cdc42 effectively stimulated both downstream kinases. We conclude that GEFs can be important determinants of downstream signaling specificity for members of the Rho GTPase family.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Netherlands Canc Inst, NL-1066 CS Amsterdam, Netherlands	Scripps Research Institute; Scripps Research Institute; University of Michigan System; University of Michigan; Netherlands Cancer Institute	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.	bokoch@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434, R01GM044428] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44428, GM39434] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Benian GM, 1996, J CELL BIOL, V132, P835, DOI 10.1083/jcb.132.5.835; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DHARMAWARDHANE S, 1995, CURR OPIN HEMATOL, V4, P12; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; PASTERIS NG, 1994, CELL, V79, P669; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1989, ONCOGENE, V4, P1067; SELF AJ, 1993, ONCOGENE, V8, P655; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h; XU XM, 1994, J BIOL CHEM, V269, P23569; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	55	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16782	16786		10.1074/jbc.273.27.16782	http://dx.doi.org/10.1074/jbc.273.27.16782			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642235	hybrid			2022-12-25	WOS:000074545200025
J	Chu, ZL; DiDonato, JK; Hawiger, J; Ballard, DW				Chu, ZL; DiDonato, JK; Hawiger, J; Ballard, DW			The tax oncoprotein of human T-cell leukemia virus type 1 associates with and persistently activates I kappa B kinases containing IKK alpha and IKK beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; TRANSCRIPTION FACTORS; EXPRESSION; SIGNAL; HTLV; UBIQUITINATION; PROTEINS; MICE; GENE; PROTEOLYSIS	The Tax oncoprotein of human T-cell leukemia virus type 1 (HTLV1) chronically activates transcription factor NF-kappa B by a mechanism involving degradation of I kappa B alpha, an NF-kappa B-associated cytoplasmic inhibitor. Tax-induced breakdown of I kappa B alpha requires phosphorylation of the inhibitor at Ser-32 and Ser-36, which is also a prerequisite for the transient activation of NF-kappa B in cytokine-treated T lymphocytes. However, it remained unclear how Tax interfaces with the cellular NF-kappa B/I kappa B signaling machinery to generate a chronic rather than a transient NF-kappa B response. We now demonstrate that Tax associates with cytokine-inducible I kappa B kinase (IKK) complexes containing catalytic subunits IKK alpha and IKK beta, which mediate phosphorylation of I kappa B alpha at Ser-32 and Ser-36, Unlike their transiently activated counterparts in cytokine-treated cells, Tax-associated forms of Wt are constitutively active in either Tax transfectants or HTLV1-infected T lymphocytes. Moreover, point mutations in Tax that ablate its IKK-binding function also prevent Tax-mediated activation of IKK and NF-kappa B, Together, these findings suggest that the persistent activation of NF-kappa B in HTLV1-infected T-cells is mediated by a direct Tax/IKK coupling mechanism.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; Cleveland Clinic Foundation	Ballard, DW (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 802 Rudolph Light Hall, Nashville, TN 37232 USA.	dean.ballard@mcmail.vanderbilt.edu			NCI NIH HHS [T32 CA09385] Funding Source: Medline; NHLBI NIH HHS [R01 HL45994] Funding Source: Medline; NIAID NIH HHS [R01 AI33839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033839] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Doi TS, 1997, J EXP MED, V185, P953, DOI 10.1084/jem.185.5.953; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Esslinger CW, 1997, J IMMUNOL, V158, P5075; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KOEFFLER HP, 1984, BLOOD, V64, P482; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIYOSHI I, 1981, GANN, V72, P978; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	40	131	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15891	15894		10.1074/jbc.273.26.15891	http://dx.doi.org/10.1074/jbc.273.26.15891			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632633	hybrid			2022-12-25	WOS:000074436600004
J	Factor, VM; Kiss, A; Woitach, JT; Wirth, PJ; Thorgeirsson, SS				Factor, VM; Kiss, A; Woitach, JT; Wirth, PJ; Thorgeirsson, SS			Disruption of redox homeostasis in the transforming growth factor-alpha c-myc transgenic mouse model of accelerated hepatocarcinogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTERY ENDOTHELIAL-CELLS; REACTIVE-OXYGEN; HYDROGEN-PEROXIDE; THIOREDOXIN REDUCTASE; MITOCHONDRIAL-DNA; FACTOR-BETA; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; HUMAN-FIBROBLASTS; OXIDATIVE DAMAGE	In previous studies we have demonstrated that transforming growth factor (TGF)-alpha/c-myc double transgenic mice exhibit an enhanced rate of cell proliferation, accumulate extensive DNA damage, and develop multiple liver tumors between 4 and 8 months of age. To clarify the biochemical events that mag be responsible for the genotoxic and carcinogenic effects observed in this transgenic model, several parameters of redox homeostasis in the liver were examined prior to development of hepatic tumors, By 2 months of age, production of reactive oxygen species, determined by the peroxidation-sensitive fluorescent dye, 2',7'-dichlorofluorescin diacetate, was significantly elevated in TGF-alpha/c-myc transgenic hepatocytes versus either wild type or c-myc single transgenic cells, and occurred in parallel with an increase in Lipid peroxidation. Concomitantly with a rise in oxidant levels, antioxidant defenses were decreased, including total glutathione content and the activity of glutathione peroxidase, whereas thioredoxin reductase activity was not changed. However; hepatic tumors which developed in TGF-alpha/c-myc mice exhibited an increase in thioredoxin reductase activity and a very low activity of glutathiolae peroxidase. Furthermore, specific deletions were detected in mtDNA as early as 5 weeks of age in the transgenic mice. These data provide experimental evidence that co-expression of TGF-alpha and c-myc transgenes in mouse liver promotes overproduction of reactive oxygen species and thus creates an oxidative stress environment. This phenomenon may account for the massive DNA damage and acceleration of hepatocarcinogenesis observed in the TGF-alpha/c-myc mouse model.	NCI, Expt Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thorgeirsson, SS (corresponding author), NCI, Expt Carcinogenesis Lab, NIH, 37 Convent Dr,MSC4255,Bldg 37,Rm 3C28, Bethesda, MD 20892 USA.	snorri_thorgeirsson@nih.gov						Ahmad S., 1995, OXIDATIVE STRESS ANT, P238, DOI DOI 10.1007/978-1-4615-9689-9_7; AMES BN, 1992, ANN NY ACAD SCI, V663, P85, DOI 10.1111/j.1749-6632.1992.tb38652.x; AMES BN, 1991, PROG CLIN BIOL RES, V369, P1; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BarcellosHoff MH, 1996, MOL ENDOCRINOL, V10, P1077, DOI 10.1210/me.10.9.1077; BASS DA, 1983, J IMMUNOL, V130, P1910; Bjornstedt M, 1997, BIOMED ENVIRON SCI, V10, P271; Bladier C, 1997, CELL GROWTH DIFFER, V8, P589; Brunk U.T., 1981, AGE PIGMENTS 1981, P243; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Cahill A, 1997, BIOCHEM BIOPH RES CO, V235, P286, DOI 10.1006/bbrc.1997.6774; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CERUTTI PA, 1994, LANCET, V344, P862, DOI 10.1016/S0140-6736(94)92832-0; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; CHOE M, 1995, FREE RADICAL BIO MED, V18, P977, DOI 10.1016/0891-5849(94)00217-8; DAS SK, 1991, AM J PHYSIOL, V261, pL249, DOI 10.1152/ajplung.1991.261.4.L249; deHaan JB, 1996, HUM MOL GENET, V5, P283, DOI 10.1093/hmg/5.2.283; DELEVE LD, 1991, PHARMACOL THERAPEUT, V52, P287, DOI 10.1016/0163-7258(91)90029-L; DIANZANI MU, 1993, CRIT REV ONCOL HEMAT, V15, P125, DOI 10.1016/1040-8428(93)90052-6; Dreher D, 1996, EUR J CANCER, V32A, P30, DOI 10.1016/0959-8049(95)00531-5; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Factor VM, 1997, HEPATOLOGY, V26, P1434; Filser N, 1997, BIOCHEM BIOPH RES CO, V233, P102, DOI 10.1006/bbrc.1997.6409; FRAMPTON J, 1987, NUCLEIC ACIDS RES, V15, P3671, DOI 10.1093/nar/15.9.3671; FROMENTY B, 1995, GASTROENTEROLOGY, V108, P193, DOI 10.1016/0016-5085(95)90024-1; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JI LL, 1990, AM J PHYSIOL, V258, pR918, DOI 10.1152/ajpregu.1990.258.4.R918; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; JONES SA, 1994, FEBS LETT, V355, P178, DOI 10.1016/0014-5793(94)01201-6; Kao CY, 1996, BIOCHEM BIOPH RES CO, V222, P64, DOI 10.1006/bbrc.1996.0698; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Lee CM, 1997, FREE RADICAL BIO MED, V22, P1259, DOI 10.1016/S0891-5849(96)00546-1; Leonarduzzi G, 1997, FASEB J, V11, P851, DOI 10.1096/fasebj.11.11.9285483; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Luetteke N C, 1990, Semin Cancer Biol, V1, P265; Mansouri A, 1997, J HEPATOL, V27, P96, DOI 10.1016/S0168-8278(97)80286-3; Mansouri A, 1997, GASTROENTEROLOGY, V113, P599, DOI 10.1053/gast.1997.v113.pm9247482; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MURAKAMI H, 1993, CANCER RES, V53, P1719; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NEWMAN MJ, 1990, P NATL ACAD SCI USA, V87, P5543, DOI 10.1073/pnas.87.14.5543; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; POWERS SK, 1992, J APPL PHYSIOL, V72, P1068, DOI 10.1152/jappl.1992.72.3.1068; RETEL J, 1993, MUTAT RES, V299, P165, DOI 10.1016/0165-1218(93)90094-T; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Rubin H, 1996, P NATL ACAD SCI USA, V93, P1825, DOI 10.1073/pnas.93.5.1825; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SANCHEZ A, 1995, J CELL PHYSIOL, V165, P398, DOI 10.1002/jcp.1041650221; Sanchez A, 1997, HEPATOLOGY, V26, P935, DOI 10.1002/hep.510260420; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; SantoniRugiu E, 1996, AM J PATHOL, V149, P407; Sargent LM, 1996, CANCER RES, V56, P2137; Sastre J, 1996, HEPATOLOGY, V24, P1199, DOI 10.1002/hep.510240536; Sharrow S., 1991, CURRENT PROTOCOLS IM; SHIBANUMA M, 1991, CELL GROWTH DIFFER, V2, P583; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; SWAIM MW, 1988, J LEUKOCYTE BIOL, V43, P365, DOI 10.1002/jlb.43.4.365; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769; THANNICKAL VJ, 1993, AM J PHYSIOL, V265, pL622, DOI 10.1152/ajplung.1993.265.6.L622; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Woitach JT, 1997, J CELL BIOCHEM, V64, P651; Xu Y, 1997, J CELL PHYSIOL, V170, P192, DOI 10.1002/(SICI)1097-4652(199702)170:2<192::AID-JCP11>3.0.CO;2-K; YEN TC, 1994, FREE RADICAL BIO MED, V16, P207, DOI 10.1016/0891-5849(94)90145-7	81	145	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15846	15853		10.1074/jbc.273.25.15846	http://dx.doi.org/10.1074/jbc.273.25.15846			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624185	hybrid			2022-12-25	WOS:000074284200079
J	Nagata, K; Driessens, M; Lamarche, N; Gorski, JL; Hall, A				Nagata, K; Driessens, M; Lamarche, N; Gorski, JL; Hall, A			Activation of G(1) progression, JNK mitogen-activated protein kinase, and actin filament assembly by the exchange factor FGD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; SIGNALING PATHWAY; STRESS FIBERS; CDC42 GTPASES; JUN KINASE; RHO; RAC; FAMILY; POLYMERIZATION; FILOPODIA	Cdc42 has been shown to control bifurcating pathways leading to filopodia formation/G(1) cell cycle progression and to JNK mitogen-activated protein kinase activation. To dissect these pathways further, the cellular effects induced by a Cdc42 guanine nucleotide exchange factor, FGD1, have been examined. All exchange factors acting on the Rho GTPase family have juxtaposed Dbl homology (DH) and pleckstrin homology (PH) domains. We report here that FGD1 triggers G(1) cell cycle progression and filopodia formation in Swiss 3T3 fibroblasts as well as JNK mitogen-activated protein kinase activation in COS cell transfection assays. FGD1-induced filopodia formation is Cdc42-dependent, and both the DH and PH domains are essential. Although expression of the FGD1 DH domain alone does not activate Cdc42 and induce filopodia, it does trigger both the JNK cascade in COS cells and G(1) progression in quiescent Swiss 3T3 cells. We conclude that FGD1 can trigger G(1) progression independently of actin polymerization or integrin adhesion complex assembly. Furthermore, since FGD1 activates JNK and G(1) progression in a Cdc42-independent manner, it must have additional, as yet unidentified, targets.	Univ London Univ Coll, MRC, Mol Cell Biol Lab,Canc Res Campaign, Oncogene & Signal Transduct Grp, London WC1E 6BT, England; Univ London Univ Coll, Dept Biochem, London WC1E 6BT, England; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA	University of London; University College London; University of London; University College London; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hall, A (corresponding author), Univ London Univ Coll, MRC, Mol Cell Biol Lab,Canc Res Campaign, Oncogene & Signal Transduct Grp, Gower St, London WC1E 6BT, England.							Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1995, CELL, V81, P1145; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; PASTERIS NG, 1994, CELL, V79, P669; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; TOKSOZ D, 1994, ONCOGENE, V9, P621; Wang DS, 1997, BIOCHEM BIOPH RES CO, V234, P183, DOI 10.1006/bbrc.1997.6589; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169	33	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15453	15457		10.1074/jbc.273.25.15453	http://dx.doi.org/10.1074/jbc.273.25.15453			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624130	hybrid			2022-12-25	WOS:000074284200024
J	Altomare, DA; Lyons, GE; Mitsuuchi, Y; Cheng, JQ; Testa, JR				Altomare, DA; Lyons, GE; Mitsuuchi, Y; Cheng, JQ; Testa, JR			Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin	ONCOGENE			English	Article						Akt; serine-threonine kinase; oncogene; expression; insulin; phosphatidylinositol 3-kinase	RAC-PROTEIN KINASE; HUMAN PANCREATIC-CANCER; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3-KINASE; HEAT-SHOCK; C-AKT; ONCOGENE; CELLS; AMPLIFICATION; LOCALIZATION	Akt2 encodes a protein-serine/threonine kinase containing a pleckstrin homology domain characteristic of many signaling molecules. Although there has been extensive interest in the mechanism by which the closely-related Akt kinase participates in phosphatidylinositol S-kinase-mediated signaling, comparatively little is known regarding the expression and function of Akt2. This manuscript is the first to describe Akt2 mRNA expression in the developing mouse and the activation of AKT2 by insulin. These studies demonstrate that Akt2 is especially abundant in brown fat and, to a lesser extent, skeletal muscle and liver, tissues which are highly insulin-responsive and play a role in glucose metabolism. Endogenous Akt2 expression also is upregulated in fully-differentiated C2Cl2 myotubes and 3T3-L1 adipocytes, suggesting that these murine cell lines represent useful in vitro models for studies of Akt2 function. We show that HA-tagged AKTZ is activated in response to insulin stimulation in vitro and that activation of AKT2 is not induced in cells pretreated with wortmannin, an inhibitor of phosphatidylinositol 3-kinase. These data suggest that Akr2 expression is fundamental to the differentiated state of fat and muscle cells and that activation of AKT2 kinase by insulin is mediated through the phosphatidylinositol 3-kinase signaling pathway.	Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; Univ Wisconsin, Sch Med, Dept Anat, Madison, WI 53706 USA	Fox Chase Cancer Center; University of Wisconsin System; University of Wisconsin Madison	Testa, JR (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [R01 CA077429, P30 CA006927, CA-06927, CA-09035] Funding Source: Medline; NICHD NIH HHS [HD29471] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029471] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA077429, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALTOMARE DA, 1995, ONCOGENE, V11, P1055; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1993, ONCOGENE, V8, P745; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GUO K, 1995, MOL CELL BIOL, V15, P3823; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Klaus S, 1997, BIOESSAYS, V19, P215, DOI 10.1002/bies.950190307; Kobayashi M, 1996, NEUROSCI LETT, V213, P103, DOI 10.1016/0304-3940(96)12845-7; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; Matsuzaki H, 1996, FEBS LETT, V396, P305, DOI 10.1016/0014-5793(96)01120-9; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034	30	104	106	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2407	2411		10.1038/sj.onc.1201750	http://dx.doi.org/10.1038/sj.onc.1201750			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620559				2022-12-25	WOS:000073428000014
J	Lee, YI; Lee, S; Lee, Y; Bong, YS; Hyun, SW; Do Yoo, Y; Kim, SJ; Kim, YW; Poo, HR				Lee, YI; Lee, S; Lee, Y; Bong, YS; Hyun, SW; Do Yoo, Y; Kim, SJ; Kim, YW; Poo, HR			The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter 4	ONCOGENE			English	Article						hepatitis B virus; insulin-like growth factor-II; hepatocellular carcinoma; transactivation	BOX-BINDING-PROTEINS; LONG TERMINAL REPEAT; DNA-BINDING; SP1-MEDIATED TRANSCRIPTION; TRANS-ACTIVATION; MESSENGER-RNA; EXPRESSION; LIVER; CELLS; SEQUENCES	Human hepatitis B virus (HBV) is one of the causative agents of hepatocellular carcinoma (HCC). The virus encodes a 17 kDa protein, X, which is known to be a causative agent in the formation of HCC. An insulin-like growth factor-II (IGF-II) is expressed during the formation of HCC. Among the four promoters of the IGF-II gene, promoters 2, 3 and 4 become activated during the formation of HCC. The high frequency of detection of hepatitis B virus X (HBV-X) antigen in liver cells from patients with chronic hepatitis, cirrhosis, and liver cancer suggested that the expressions of HBV-X and IGF-II are associated. Studies were carried out to test the relationship between the HBV-X gene product and the activation of IGF-II promoter 4, We demonstrated that the HBV-X protein increases the endogenous IGF-II expression from promoter 3 and 4 of IGF-II gene. Analysis of the fourth promoter of IGF-II gene showed that the HBV-X gene product positively regulates transcription. Two copies of a motif are responsible for conferring HBV-X regulation on the fourth promoter of IGF-II. These motifs have been identified as Sp1 binding sites, Sp1 binding to IGF-II P4 promoter was identified by gel mobility shift assay using purified Sp1. By using a GAL4-Sp1 fusion protein it was demonstrated that HBV-X positively regulates the Sp1 mediated transcriptional activity of IGF-II in vivo. A protein-affinity chromatography experiment showed that HBV-X protein does not bind directly to Sp1, but HBV-X does augment the DNA binding activity of the phosphorylated form of Sp1 in HepG2 cells. Sp1 was phosphorylated by HBV-X and its DNA-binding activity was up-regulated upon HBV-X transfections. Various HBV-X mutant expression vectors were used for the demonstration of specific interactions between Sp1 and HBV-X. These results indicate that HBV-X functions as a positive regulator of transcription, and that Sp1 is a direct target for the transcriptional regulation of IGF-II. Increasing the DNA binding ability of the phosphorylated form of Sp1 by HBV-X might be an important mechanism for regulating the IGF-II gene expression and possibly promoting cell division during hepatic carcinogenesis. Our experimental results suggest that expression of HBV-X might induce the expression of IGF-II and the IGF-II might play a role in hepatitis B virus pathogenesis during the formation of HCC.	Korea Adv Inst Sci & Technol, Korea Res Inst Biosci & Biotechnol, Mol Cell Biol Res Div, Liver Cell Signal Transduct Lab, Taejon 305606, South Korea; NCI, Chemoprevent Lab, NIH, Bethesda, MD 20892 USA	Korea Advanced Institute of Science & Technology (KAIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lee, YI (corresponding author), Korea Adv Inst Sci & Technol, Korea Res Inst Biosci & Biotechnol, Mol Cell Biol Res Div, Liver Cell Signal Transduct Lab, Taejon 305606, South Korea.							BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; CARIANI E, 1988, CANCER RES, V48, P6844; CAROLYN ND, 1991, HEPATOLOGY, V13, P310; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN XR, 1992, ONCOGENE, V7, P1805; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHOU PY, 1978, ADV ENZYMOLOGY RELAT, V0047, P00145; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DARVILLE CN, 1991, HEPATOLOGY, V13, P310, DOI 10.1002/hep.1840130217; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; FLORINI JR, 1992, GROWTH REGULAT, V2, P23; FLORINI JR, 1986, AM J PHYSIOL, V250, pC771, DOI 10.1152/ajpcell.1986.250.5.C771; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY A, 1987, DNA-J MOLEC CELL BIO, V6, P283, DOI 10.1089/dna.1987.6.283; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HYUN SW, 1993, FEBS LETT, V332, P153, DOI 10.1016/0014-5793(93)80503-M; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM YH, 1993, BIOCHEM BIOPH RES CO, V197, P894, DOI 10.1006/bbrc.1993.2563; KIM YS, 1984, KOREAN BIOCH J, V17, P7076; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; LAMAS E, 1989, FALK S OCT 15 17 BAS, V55, P45; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LO SJ, 1988, VIROLOGY, V167, P289, DOI 10.1016/0042-6822(88)90081-5; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; NANCY CA, 1991, NUCLEIC ACIDS RES, V19, P2499; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; RITTER SE, 1991, VIROLOGY, V182, P841, DOI 10.1016/0042-6822(91)90626-M; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SOARES MB, 1985, NUCLEIC ACIDS RES, V13, P1119, DOI 10.1093/nar/13.4.1119; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; TAKADA S, 1994, ONCOGENE, V9, P341; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; TWU JS, 1989, P NATL ACAD SCI USA, V86, P2046, DOI 10.1073/pnas.86.6.2046; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; VEDA K, 1996, J VIROL, V70, P1375; WANG WL, 1991, CANCER RES, V51, P4971; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; YANG D, 1993, CANCER RES, V53, P2020; Yang DY, 1996, J VIROL, V70, P6260, DOI 10.1128/JVI.70.9.6260-6268.1996; YANG DY, 1991, CARCINOGENESIS, V12, P1893, DOI 10.1093/carcin/12.10.1893; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427	68	71	79	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	1998	16	18					2367	2380		10.1038/sj.onc.1201760	http://dx.doi.org/10.1038/sj.onc.1201760			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620554				2022-12-25	WOS:000073428000009
J	Matheson, NR; Travis, J				Matheson, NR; Travis, J			Purification and characterization of a novel peptidase (IImes) from mesquite (Prosopis velutina) pollen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ANGIOTENSIN-II; CATHEPSIN-B; ALLERGENS; RAGWEED; ASTHMA; ENDOPEPTIDASE; NEUROPEPTIDES; RESPONSES; BINDING	Although the mesquite plant (Prosopis velutina) is not as widely distributed as some other allergenic species, its pollen can induce serious pollinosis in areas where it is localized. We previously isolated and characterized a peptidase from mesquite pollen with trypsin-like specificity (peptidase I-mes) (Matheson, N., Schmidt, J., and Travis, J. (1995) Am, J. Respir. Cell Mol. Biol. 12, 441-448). Now we have characterized a second enzyme with specificity for hydrophobic residues (mesquite pollen peptidase IImes). This enzyme has a molecular mass near 92 kDa and activity that was not affected by reducing or chelating agents but was inhibited by specific synthetic serine proteinase inhibitors and the aminopeptidase inhibitor bestatin. However, it was not inhibited by human plasma proteinase inhibitors, nor did it inactivate any of those tested. The enzyme possessed amidolytic activity against p-nitroanilide substrates most effectively after alanine residues and also displayed aminopeptidase activity against non-p-nitroanilide peptides with a preference for phenylalanine. This specificity for hydrophobic amino acid residues was corroborated by inhibition studies with chloromethyl ketone and organophosphonate inhibitors. More interesting from a physiological point of view is that the bioactive peptides, angiotensins I and II and vasoactive intestinal peptide, were also hydrolyzed rapidly, indicating an ability of peptidase IImes to act also as an oligopeptidase. Because these bioactive peptides play a role in the inflammatory responses in allergic asthma, our data suggest that the purified mesquite pollen peptidase IImes may be involved in the degradation of neuro- and vasoactive peptides during pollen-initiated allergic reactions.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Travis, J (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	jtravis@uga.cc.uga.edu						ALBANI D, 1991, PLANT MOL BIOL, V16, P501, DOI 10.1007/BF00023417; ALLEN RL, 1992, PLANT MOL BIOL, V20, P343, DOI 10.1007/BF00014505; ASHWELL JD, 1986, NATURE, V320, P176, DOI 10.1038/320176a0; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; Bagarozzi DA, 1996, J BIOL CHEM, V271, P26227, DOI 10.1074/jbc.271.42.26227; Bagarozzi DA, 1998, AM J RESP CELL MOL, V18, P363, DOI 10.1165/ajrcmb.18.3.2825; BARNES PJ, 1987, J ALLERGY CLIN IMMUN, V79, P285, DOI 10.1016/0091-6749(87)90143-6; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BARNES PJ, 1986, LANCET, V1, P242; BARNES PJ, 1993, ALLERGY PRINCIPLES P, V1, P243; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BARRETT AJ, 1994, METHOD ENZYMOL, V244, P11; BARRETT AJ, 1994, METHOD ENZYMOL, V244, P39; CASALE TB, 1988, AM J RHINOL, V2, P121; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; DEBONO E, 1963, CLIN SCI, V25, P123; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; FROSSARD N, 1989, J PHARMACOL EXP THER, V248, P292; GOETZL EJ, 1980, BIOCHEM BIOPH RES CO, V97, P1097, DOI 10.1016/0006-291X(80)91488-6; Guo ZJ, 1998, PHYTOCHEMISTRY, V47, P547, DOI 10.1016/S0031-9422(97)00441-X; HARTUNG HP, 1986, J IMMUNOL, V136, P3856; HOLGATE ST, 1993, ALLERGY PRINCIPLES P, V1, P267; IPSEN H, 1991, MOL IMMUNOL, V28, P1279, DOI 10.1016/0161-5890(91)90015-C; KNOX RB, 1973, J CELL SCI, V12, P421; LAUZURICA P, 1988, MOL IMMUNOL, V25, P337, DOI 10.1016/0161-5890(88)90028-4; LEWIS WH, 1980, AIRBORNE ALLERGIC PO, P45; LEWIS WH, 1980, ALLERGY IMMUNOLOGY M, P124; MATHESON N, 1995, AM J RESP CELL MOL, V12, P441, DOI 10.1165/ajrcmb.12.4.7695924; MCKAY MJ, 1983, BIOCHEM J, V213, P467, DOI 10.1042/bj2130467; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; POLO F, 1990, MOL IMMUNOL, V27, P151, DOI 10.1016/0161-5890(90)90110-L; ROSENSTREICH DL, 1981, CELLULAR FUNCTIONS I, P138; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STANISZ AM, 1988, ANN NY ACAD SCI, V527, P478; TANIAI M, 1988, FEBS LETT, V239, P329, DOI 10.1016/0014-5793(88)80945-1; TURCICH MP, 1993, PLANT MOL BIOL, V23, P1061, DOI 10.1007/BF00021820; VILIALBA M, 1990, BIOCHEM BIOPH RES CO, V172, P523; ZUBAY GL, 1995, PRINCIPLES BIOCH, P144	40	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16771	16777		10.1074/jbc.273.27.16771	http://dx.doi.org/10.1074/jbc.273.27.16771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642233	hybrid			2022-12-25	WOS:000074545200023
J	Tamai, E; Shimamoto, T; Tsuda, M; Mizushima, T; Tsuchiya, T				Tamai, E; Shimamoto, T; Tsuda, M; Mizushima, T; Tsuchiya, T			Conversion of temperature-sensitive to -resistant gene expression due to mutations in the promoter region of the melibiose operon in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; REGULATORY REGION; MELAB PROMOTER; PROTEIN; TRANSPORT; CARRIER	The melibiose utilization system of Escherichia coli W3133, a derivative of K12, is nonfunctional between 37 and 42 degrees C, The reason for this temperature sensitivity was thought to be that the melibiose transporter (MelB) of W3133 cells was temperature-sensitive. A mutant W3133-2 has been isolated as a temperature-resistant strain that can utilize melibiose between 37 and 42 degrees C, However, we found that the melibiose transporter of the W3133-2 was still temperature-sensitive. Half-life activities of the melibiose transporter at 37 degrees C (or 40 degrees C) in both E. coli W3133 and W3133-2 were exactly the same. Furthermore, we found that the nucleotide sequence of coding region of the melB structural gene (the second gene of the melibiose operon) of W3133-2 was exactly the same as that of W3133, Activity of cu-galactosidase (product of the first gene, melA, of the melibiose operon) of W3133 cells grown at 40 degrees C was very low, although that of W3133-2 cells grown at 40 degrees C was high. These observations suggested that expression of the melibiose operon in W3133 is also temperature-sensitive. In fact, we found that the expression in W3133 cells was temperature-sensitive, while that in W3133-2 cells was temperature-resistant, by analyzing mRNA levels using the Northern blot method. Furthermore, we identified mutations in the promoter region of the melibiose operon of W3133-2 that resulted in the elongation of an 18 nucleotide inverted repeat sequence to a 28-nucleotide repeat sequence present immediately upstream of the -35 region. This may stabilize a possible stem structure due to the inverted repeat at 37-42 degrees C.	Okayama Univ, Fac Pharmaceut Sci, Dept Microbiol, Okayama 7008530, Japan; Okayama Univ, Ctr Gene Res, Okayama 7008530, Japan	Okayama University; Okayama University	Tsuchiya, T (corresponding author), Okayama Univ, Fac Pharmaceut Sci, Dept Microbiol, Okayama 7008530, Japan.		Shimamoto, Tadashi/A-7109-2018	Shimamoto, Tadashi/0000-0002-5538-0595; TAMAI, EIJI/0000-0002-0338-5095				AIBA H, 1981, J BIOL CHEM, V256, P1905; ALBERTS B, 1983, MOL BIOL CELL, P611; BERNS KI, 1965, J MOL BIOL, V11, P476, DOI 10.1016/S0022-2836(65)80004-3; BURSTEIN C, 1971, BIOCHIM BIOPHYS ACTA, V230, P52, DOI 10.1016/0304-4165(71)90053-5; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; HANATANI M, 1984, J BIOL CHEM, V259, P1807; Keen J, 1996, BIOCHEM J, V318, P443, DOI 10.1042/bj3180443; KENNEDY EP, 1970, LACTOSE OPERON, P49; LEVINTHAL M, 1971, J BACTERIOL, V105, P1047, DOI 10.1128/JB.105.3.1047-1052.1971; LOPILATO J, 1978, J BACTERIOL, V134, P147, DOI 10.1128/JB.134.1.147-156.1978; MANIATIS T, 1982, MOL CLONING LABORATO, P440; NAGAO Y, 1988, BIOCHEM BIOPH RES CO, V151, P236, DOI 10.1016/0006-291X(88)90584-0; OHTANI K, 1995, J NEUROCHEM, V65, P605; PRESTIDGE LS, 1965, BIOCHIM BIOPHYS ACTA, V100, P591, DOI 10.1016/0304-4165(65)90029-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT R, 1968, J BACTERIOL, V96, P462, DOI 10.1128/JB.96.2.462-471.1968; SHIMAMOTO T, 1984, BIOCHEM BIOPH RES CO, V121, P41, DOI 10.1016/0006-291X(84)90685-5; SHIMAMOTO T, 1994, J BIOCHEM-TOKYO, V115, P1185, DOI 10.1093/oxfordjournals.jbchem.a124477; TANAKA S, 1967, J BACTERIOL, V93, P642, DOI 10.1128/JB.93.2.642-648.1967; TSUCHIYA T, 1978, J MEMBRANE BIOL, V42, P45, DOI 10.1007/BF01870393; WEBSTER C, 1987, GENE, V59, P253, DOI 10.1016/0378-1119(87)90333-7; WEBSTER C, 1989, GENE, V83, P207, DOI 10.1016/0378-1119(89)90106-6; WILLIAMS J, 1994, BIOCHEM J, V300, P757, DOI 10.1042/bj3000757; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; YAZYU H, 1984, J BIOL CHEM, V259, P4320	25	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16860	16864		10.1074/jbc.273.27.16860	http://dx.doi.org/10.1074/jbc.273.27.16860			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642246	hybrid			2022-12-25	WOS:000074545200036
J	Feldman, JD; Vician, L; Crispino, M; Tocco, G; Marcheselli, VL; Bazan, NG; Baudry, M; Herschman, HR				Feldman, JD; Vician, L; Crispino, M; Tocco, G; Marcheselli, VL; Bazan, NG; Baudry, M; Herschman, HR			KID-1, a protein kinase induced by depolarization in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; LONG-TERM POTENTIATION; REPRESENTATIONAL DIFFERENCE ANALYSIS; PC12 PHEOCHROMOCYTOMA CELLS; PLATELET-ACTIVATING-FACTOR; 3' UNTRANSLATED REGION; IMMEDIATE-EARLY GENE; MESSENGER-RNA; MEMBRANE DEPOLARIZATION; SYNAPTIC ACTIVITY	Membrane depolarization leads to changes in gene expression that modulate neuronal plasticity. Using representational difference analysis, we have identified a previously undiscovered cDNA,KID-1 (kinase induced by depolarization), that is induced by membrane depolarization or forskolin, but not by neurotrophins or growth factors, in PC12 pheochromocytoma cells, KID-1 is an immediate early gene that shares a high degree of sequence similarity with the family of PIM-1 serine/threonine protein kinases, Recombinant KID-1 fusion protein is able to catalyze both histone phosphorylation and autophosphorylation, KID-1 mRNA is present in a number of unstimulated tissues, including brain. In response to kainic acid and electroconvulsive shock-induced seizures, KID-1 is induced in specific regions of the hippocampus and cortex.	Univ Calif Los Angeles, Ctr Hlth Sci, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Pediat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ So Calif, Neurosci Program, Los Angeles, CA 90089 USA; Louisiana State Univ, Med Ctr, Ctr Neurosci, New Orleans, LA 70112 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Southern California; Louisiana State University System	Herschman, HR (corresponding author), Univ Calif Los Angeles, Ctr Hlth Sci, Inst Mol Biol, 611 Circle Dr E, Los Angeles, CA 90095 USA.		Bazan, Nicolas/AAN-4121-2020; Crispino, Marianna/ABD-3702-2020	Bazan, Nicolas/0000-0002-9243-5444; CRISPINO, Marianna/0000-0002-5797-8830	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K11AR001870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018427, R01NS028660] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR01870] Funding Source: Medline; NINDS NIH HHS [NS28660, NS18427] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIN JG, 1991, J BIOL CHEM, V266, P5401; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARENANDER AT, 1993, NEUROTROPHIC FACTORS, P1; Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu CC, 1997, P NATL ACAD SCI USA, V94, P2507, DOI 10.1073/pnas.94.6.2507; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; deOrtiz SP, 1996, MOL BRAIN RES, V38, P1, DOI 10.1016/0169-328X(95)00263-R; DOMEN J, 1993, BLOOD, V82, P1445; Edman CF, 1997, BIOCHEM J, V323, P113, DOI 10.1042/bj3230113; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HEMMINGS HC, 1989, FASEB J, V3, P1583, DOI 10.1096/fasebj.3.5.2493406; HOOVER D, 1991, J BIOL CHEM, V266, P14018; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; KUJUBU DA, 1987, ONCOGENE, V1, P257; LASLOP A, 1994, NEUROSCIENCE, V59, P477, DOI 10.1016/0306-4522(94)90611-4; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MARCHESELLI VL, 1994, J NEUROSCI RES, V37, P54, DOI 10.1002/jnr.490370108; Marcheselli VL, 1996, J BIOL CHEM, V271, P24794, DOI 10.1074/jbc.271.40.24794; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MELEGA WP, 1984, P NATL ACAD SCI USA, V81, P6536; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Murphy DD, 1997, P NATL ACAD SCI USA, V94, P1482, DOI 10.1073/pnas.94.4.1482; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; PADMA R, 1991, CANCER RES, V51, P2486; Palaty CK, 1997, J BIOL CHEM, V272, P10514; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; Sambrook J., 2002, MOL CLONING LAB MANU; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SCHREIBER SS, 1993, NEUROSCI LETT, V153, P17, DOI 10.1016/0304-3940(93)90066-T; SCHREIBER SS, 1993, NEUROREPORT, V5, P269, DOI 10.1097/00001756-199312000-00022; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; THOMPSON ME, 1992, MOL BRAIN RES, V12, P195, DOI 10.1016/0169-328X(92)90084-O; Tocco G, 1996, MOL BRAIN RES, V40, P229, DOI 10.1016/0169-328X(96)00055-1; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Vician L, 1997, J NEUROSCI RES, V50, P32, DOI 10.1002/(SICI)1097-4547(19971001)50:1<32::AID-JNR4>3.0.CO;2-M; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; VONLOHUIZEN M, 1989, CELL, V56, P673; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333	56	83	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16535	16543		10.1074/jbc.273.26.16535	http://dx.doi.org/10.1074/jbc.273.26.16535			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632723	hybrid			2022-12-25	WOS:000074436600094
J	Hanner, M; Vianna-Jorge, R; Kamassah, A; Schmalhofer, WA; Knaus, HG; Kaczorowski, GJ; Garcia, ML				Hanner, M; Vianna-Jorge, R; Kamassah, A; Schmalhofer, WA; Knaus, HG; Kaczorowski, GJ; Garcia, ML			The beta subunit of the high conductance calcium-activated potassium channel - Identification of residues involved in charybdotoxin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNEL; AORTIC SMOOTH-MUSCLE; FUNCTIONAL RECONSTITUTION; MODULATION; EXPRESSION; VOLTAGE; BRAIN; HSLO; SITE	Coexpression of alpha and beta subunits of the high conductance Ca2+-activated K+ (maxi-K) channel leads to a 50-fold increase in the affinity for I-125-charybdotoxin (I-125-ChTX) as compared with when the alpha subunit is expressed alone (Hanner, M., Schmalhofer, W. A., Munujos, P., Knaus, H.-G., Kaczorowski, G. J., and Garcia, M. L. (1997) Proc. Natl. Acad Sci. U. S. A. 94, 2853-2858). To identify those residues in the P subunit that are responsible for this change in binding affinity, Ala scanning mutagenesis was carried out along the extracellular loop of beta and the resulting effects on I-125-ChTX binding were determined after coexpression with the alpha subunit, Mutagenesis of each of the four Cys residues present in the loop causes a large reduction in toxin binding affinity, suggesting that these residues could be forming disulfide bridges. The existence of two disulfide bridges in the extracellular loop of beta was demonstrated after comparison of reactivities of native beta and single-Cys-mutated subunits to N-biotin-maleimide. Negatively charged residues in the loop of beta, when mutated individually or in combinations, had no effect on toxin binding with the exception of Glu(94), whose alteration modifies kinetics of ligand association and dissociation. Further mutagenesis studies targeting individual residues between Cys(76) and Cys(103) indicate that four positions, Leu(90), Tyr(91), Thr(93), and Glu(94) are critical in conferring high affinity I-125-ChTX binding to the alpha.beta subunit complex. Mutations at these positions cause large effects on the kinetics of ligand association and dissociation, but they do not alter the physical interaction of beta with the alpha subunit. All these data, taken together, suggest that the large extracellular loop of the maxi-K channel beta subunit has a restricted conformation. Moreover, they are consistent with the view that four residues appear to be important for inducing an appropriate conformation within the alpha subunit that allows high affinity ChTX binding.	Merck Res Labs, Dept Membrane Biochem & Biophys, Rahway, NJ 07065 USA; Univ Innsbruck, Inst Biochem Pharmacol, A-6020 Innsbruck, Austria	Merck & Company; University of Innsbruck	Garcia, ML (corresponding author), Merck Res Labs, Dept Membrane Biochem & Biophys, Rahway, NJ 07065 USA.	maria_garcia@merck.com	Vianna-Jorge, Rosane/AAC-7301-2020; Vianna-Jorge, Rosane/A-1230-2013	Vianna-Jorge, Rosane/0000-0001-5407-4695; Vianna-Jorge, Rosane/0000-0001-5407-4695				ANDERSON CS, 1988, J GEN PHYSIOL, V91, P317, DOI 10.1085/jgp.91.3.317; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GIANGIACOMO KM, 1995, BIOCHEMISTRY-US, V34, P15849, DOI 10.1021/bi00048a031; Hanner M, 1997, P NATL ACAD SCI USA, V94, P2853, DOI 10.1073/pnas.94.7.2853; Hanner M, 1998, BIOPHYS J, V74, pA112; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Knaus HG, 1996, J NEUROSCI, V16, P955; KNAUS HG, 1994, J BIOL CHEM, V269, P23336; Koch Robert O. A., 1996, Society for Neuroscience Abstracts, V22, P1754; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Koschak A, 1997, BIOCHEMISTRY-US, V36, P1943, DOI 10.1021/bi962074m; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Meera P, 1997, P NATL ACAD SCI USA, V94, P14066, DOI 10.1073/pnas.94.25.14066; Meera P., 1995, Biophysical Journal, V68, pA3; MUNUJOS P, 1995, BIOCHEMISTRY-US, V34, P10771, DOI 10.1021/bi00034a009; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; SUN TY, 1994, BIOCHEMISTRY-US, V33, P9992, DOI 10.1021/bi00199a024; Tanaka Y, 1997, J PHYSIOL-LONDON, V502, P545, DOI 10.1111/j.1469-7793.1997.545bj.x; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; VAZQUEZ J, 1989, J BIOL CHEM, V264, P20902; Vogalis F, 1996, AM J PHYSIOL-GASTR L, V271, pG629, DOI 10.1152/ajpgi.1996.271.4.G629; Wallner M, 1996, P NATL ACAD SCI USA, V93, P14922, DOI 10.1073/pnas.93.25.14922; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185	26	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16289	16296		10.1074/jbc.273.26.16289	http://dx.doi.org/10.1074/jbc.273.26.16289			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632689	hybrid			2022-12-25	WOS:000074436600060
J	Li, Y; Sternweis, PM; Charnecki, S; Smith, TF; Gilman, AG; Neer, EJ; Kozasa, T				Li, Y; Sternweis, PM; Charnecki, S; Smith, TF; Gilman, AG; Neer, EJ; Kozasa, T			Sites for G alpha binding on the G protein beta subunit overlap with sites for regulation of phospholipase C beta and adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; GAMMA-SUBUNITS; CRYSTAL-STRUCTURE; SF9 CELLS; LIMITED PROTEOLYSIS; PURIFICATION; COMPLEX; MUTAGENESIS; RESOLUTION; TRANSDUCIN	Heterotrimeric G proteins, composed of alpha and beta gamma subunits, forward signals from transmembrane receptors to intracellular effector enzymes and ion channels. Free beta gamma activates downstream targets, but its action is terminated by association with GDP-liganded alpha subunits. Because alpha can inhibit activation of many effectors by beta gamma, it is likely that the alpha subunit binding surfaces on beta gamma overlap the surfaces necessary for effector activation. To test this hypothesis, we mutated residues on beta shown to contact a in the recently published crystal structures of the alpha beta gamma heterotrimer (Wall, M. A., Coleman, D. E., Lee, E., Iniguez-Lluhi, J. A. Posner, B. A., Gilman, A. G., and Sprang, S. R. (1995) Cell 83, 1047-1058; Lambright, D. G., Sondek, J., Bohm, A., Skiba, N. P., Hamm, H. E., and Sigler, P. B. (1996) Nature 379, 311-319.). The alpha subunit binds to the flat, top surface of the toroidal beta subunit and also extends a helix along the side of the beta subunit at blade I. We mutated four residues on the top surface of beta (H beta(1)[L117A], H beta(1)[D228R], H beta(1)[D246S], and H beta(1)[W332A]) and two residues on the side of beta that contacts alpha (H beta(1)[N88A/K89A]). Each of the mutant proteins was able to form py dimers, but they differed in their ability to bind a and to activate phospholipase C beta(2) (PLC beta(2)), PLC beta(3), and adenylyl cyclase II. Mutation of residues along the side of the torus at blade I diminish affinity for alpha but do not prevent activation of any of the effectors. Mutations on the a binding surface differentially affected PLC beta(2), PLC beta(3), and adenylyl cyclase II. Residues that affect PLC beta and adenylyl cyclase II activity are found on opposite sides of the central tunnel, suggesting that PLC and adenylyl cyclase, like the a subunit, make many contacts on the top surface. None of the mutations affected the ability of beta gamma to inhibit adenylyl cyclase I. We conclude that alpha, PLC beta(2), PLC beta(3), and adenylyl cyclase II share an interaction on the top surface of beta. The importance of individual residues is different for a binding and for effector activation and differs even between closely related isoforms of the same effector.	Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Boston Univ, Biomol Engn Res Ctr, Boston, MA 02111 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Neer, EJ (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.				NIGMS NIH HHS [GM34497, GM362569] Funding Source: Medline; NLM NIH HHS [P1 LM05252] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BLANK JL, 1993, J BIOL CHEM, V268, P25184; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CASEY PJ, 1991, METHOD ENZYMOL, V195, P315; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Chen YB, 1997, P NATL ACAD SCI USA, V94, P2711, DOI 10.1073/pnas.94.6.2711; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DENKER BM, 1992, J BIOL CHEM, V267, P6272; FUNG BKK, 1983, J BIOL CHEM, V258, P503; Garcia-Higuera I, 1998, J BIOL CHEM, V273, P9041, DOI 10.1074/jbc.273.15.9041; GarciaHiguera I, 1996, J BIOL CHEM, V271, P528, DOI 10.1074/jbc.271.1.528; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SUMMERS MD, 1987, MANNUAL METHODS BACU, V1555; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597	35	99	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16265	16272		10.1074/jbc.273.26.16265	http://dx.doi.org/10.1074/jbc.273.26.16265			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632686	hybrid			2022-12-25	WOS:000074436600057
J	Rivers, A; Gietzen, KF; Vielhaber, E; Virshup, DM				Rivers, A; Gietzen, KF; Vielhaber, E; Virshup, DM			Regulation of casein kinase I epsilon and casein kinase I delta by an in vivo futile phosphorylation cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; 40 DNA-REPLICATION; REPAIR; FAMILY; YEAST; GENE	Casein kinase I delta (CKI delta) and casein kinase I epsilon (CKI epsilon) have been implicated in the response to DNA damage, but the understanding of how these kinases are regulated remains incomplete. In vitro, these kinases rapidly autophosphorylate, predominantly on their carboxyl-terminal extensions, and this autophosphorylation markedly inhibits kinase activity (Cegielska, A., Gietzen, K. F., Rivers, A., and Virshup, D. M. (1998) J. Biol. Chem. 273, 1357-1364). However, we now report that while these kinases are able to autophosphorylate in vivo, they are actively maintained in the dephosphorylated, active state by cellular protein phosphatases. Treatment of cells with the cell-permeable serine/threonine phosphatase inhibitors okadaic acid or calyculin A leads to rapid increases in kinase intramolecular autophosphorylation. Since CKI autophosphorylation decreases kinase activity, this dynamic autophosphorylation/dephosphorylation cycle provides a mechanism for kinase regulation in vivo.	Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Div Mol Biol & Genet, Salt Lake City, UT 84132 USA; Univ Utah, Dept Pediat, Div Hematol Oncol, Salt Lake City, UT 84132 USA; Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84132 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Virshup, DM (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Div Mol Biol & Genet, 50 N Med Dr,5C334 Hlth Sci Ctr, Salt Lake City, UT 84132 USA.		Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X	NCI NIH HHS [R01 CA71074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; CHEN J, 1994, J BIOL CHEM, V269, P7957; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; HO U, 1997, P NATL ACAD SCI USA, V94, P581; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Lin RT, 1996, MOL CELL BIOL, V16, P1401; MANNO S, 1995, J BIOL CHEM, V270, P5659, DOI 10.1074/jbc.270.10.5659; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Meek DW, 1997, BIOCHEM SOC T, V25, P416, DOI 10.1042/bst0250416; Santos JA, 1996, J CELL SCI, V109, P1847; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; WOLD MS, 1989, J BIOL CHEM, V264, P2801; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	25	96	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15980	15984		10.1074/jbc.273.26.15980	http://dx.doi.org/10.1074/jbc.273.26.15980			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632646	hybrid			2022-12-25	WOS:000074436600017
J	Ahmed, S; Prigmore, E; Govind, S; Veryard, C; Kozma, R; Wientjes, FB; Segal, AW; Lim, L				Ahmed, S; Prigmore, E; Govind, S; Veryard, C; Kozma, R; Wientjes, FB; Segal, AW; Lim, L			Cryptic Rac-binding and p21(Cdc42HS/Rac)-activated kinase phosphorylation sites of NADPH oxidase component p67(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-3 DOMAINS; ACTIN STRESS FIBERS; PROTEIN N-CHIMAERIN; HUMAN NEUTROPHILS; TYROSINE KINASE; 2-HYBRID SYSTEM; CDC42 GTPASES; SH3 DOMAINS; ACTIVATION; RHO	Rad is a member of the Rho family of small molecular mass GTPases that act as molecular switches to control actin-based cell morphology as well as cell growth and differentiation. Rac1 and Rac2 are specifically required for superoxide formation by components of the NADPH oxidase, In binding assays, Rad interacts directly with p67(phox), but not with the other oxidase components: cytochrome b, p40(phox), or p47(phox) (Prigmore, E., Ahmed, S., Best, A., Kozma, R., Manser, E., Segal, A. W., and Lim, L. (1995) J. Biol. Chem. 270, 10717-10722), Here, the Rac1/2 interaction with p67(phox) has been characterized further. Rac1 and Rac2 can bind to p67(phox) amino acid residues 170-199, and the N terminus (amino acids 1-192) of p67(phox) can be used as a specific inhibitor of Rac signaling. Deletion of p67(phox) C-terminal sequences (amino acids 193-526), the C-terminal SH3 domain (amino acids 470-526), or the polyproline-rich motif (amino acids 226-236) stimulates Rad binding by similar to 8-fold. p21(Cdc42Hs/Rac)-activated kinase (PAK) phosphorylates p67(phox) amino acid residues adjacent to the Rac1/2-binding site, and this phosphorylation is stimulated by deletion of the C-terminal SH3 domain or the polyproline-rich motif, These data suggest a role for cryptic Rac-binding and PAK phosphorylation sites of p67(phox) in control of the NADPH oxidase.	Inst Neurol, Dept Neurochem, London WC1N 1PJ, England; Glaxo IMCB Grp, Inst Mol & Cell Biol, Singapore 119076, Singapore; Univ London Univ Coll, Dept Med, London WC1E 6JJ, England	University of London; University College London; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; University of London; University College London	Lim, L (corresponding author), Inst Neurol, Dept Neurochem, 1 Wakefield St, London WC1N 1PJ, England.		Kozma, Robert/C-6365-2013	Kozma, Robert/0000-0001-7011-5768; Segal, Anthony/0000-0001-7602-9043; Veryard, Claire/0000-0002-6637-1686	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AHMED S, 1994, J BIOL CHEM, V269, P17642; AHMED S, 1993, J BIOL CHEM, V268, P10709; BENNA JE, 1994, J BIOL CHEM, V269, P6729; Best A, 1996, J BIOL CHEM, V271, P3756; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINAN P, 1994, J BIOL CHEM, V269, P13752; Fuchs A, 1996, BBA-MOL CELL RES, V1312, P39, DOI 10.1016/0167-4889(96)00020-1; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; HAYWORTH PG, 1994, J BIOL CHEM, V269, P30749; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kobayashi K, 1998, J BIOL CHEM, V273, P291, DOI 10.1074/jbc.273.1.291; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Leusen JHW, 1996, J EXP MED, V184, P1243, DOI 10.1084/jem.184.4.1243; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; Sathyamoorthy M, 1997, J BIOL CHEM, V272, P9141; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; Wientjes FB, 1996, BIOCHEM J, V317, P919, DOI 10.1042/bj3170919; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; YAMMAGUCHI M, 1985, BIOCHEM BIOPH RES CO, V216, P203	51	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15693	15701		10.1074/jbc.273.25.15693	http://dx.doi.org/10.1074/jbc.273.25.15693			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624165	hybrid			2022-12-25	WOS:000074284200059
J	Homma, K; Terui, S; Minemura, M; Qadota, H; Anraku, Y; Kanaho, Y; Ohya, Y				Homma, K; Terui, S; Minemura, M; Qadota, H; Anraku, Y; Kanaho, Y; Ohya, Y			Phosphatidylinositol-4-phosphate 5-kinase localized on the plasma membrane is essential for yeast cell morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; SACCHAROMYCES-CEREVISIAE; ACID PHOSPHOLIPIDS; GUANINE-NUCLEOTIDE; BREFELDIN-A; 4,5-BISPHOSPHATE; GENE; MUTANTS; PROFILIN	Phosphatidylinositol 4,5-biphosphate (PtdIns(4,5)P-2), an important element in eukaryotic signal transduction, is synthesized either by phosphatidylinositol-4-phosphate 5-kinase (PtdIns(4)P 5K) from phosphatidylinositol 4-phosphate (PtdIns(4)P) or by phosphatidylinositol-5-phosphate 4-kinase (PtdIns(S)P 4K) from phosphatidylinositol B phosphate (PtdIns(B)P). Two Saccharomyces cerevisiae genes, MSS4 and FAB1, are homologous to mammalian PtdIns(4)P 5Ks and PtdIns(S)P 4:Ks. We show here that MSS4 is a functional homolog of mammalian PtdIns(4)P 5K but not of PtdIns(B)P 4K in vivo. We constructed a hemagglutinin epitope-tagged form of Mss4p and found that Mss4p has PtdIns(4)P SK activity. Immunofluorescent and fractionation studies of the epitope-tagged Mss4p suggest that Mss4p is localized on the plasma membrane, whereas Fab1p is reportedly localized on the vacuolar membrane. A temperature-sensitive mss4-1 mutant was isolated, and its phenotypes at restrictive temperatures were found to include increased cell size, round shape, random distribution of actin patches, and delocalized staining of cell wall chitin. Thus, biochemical and genetic analyses on Mss4p indicated that yeast PtdIns(4)P 5K localized on the plasma membrane is required for actin organization.	Univ Tokyo, Grad Sch Sci, Dept Sci Biol, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Inst Technol, Dept Life Sci, Yokohama, Kanagawa 2260026, Japan; Univ Tokyo, Japan Sci & Technol Corp, Grad Sch Sci,Unit Proc & Combined Circuit, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; Tokyo Institute of Technology; Japan Science & Technology Agency (JST); University of Tokyo	Ohya, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Sci Biol, Bunkyo Ku, Tokyo 1130033, Japan.	ohya@biol.s.u-tokyo.ac.jp						ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; AMEH LE, 1997, NATURE, V390, P192; BELDE PJM, 1993, FEBS LETT, V323, P113, DOI 10.1016/0014-5793(93)81460-H; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Cutler NS, 1997, J BIOL CHEM, V272, P27671, DOI 10.1074/jbc.272.44.27671; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kaiser C., 1994, METHODS YEAST GENETI; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; Ohya Y, 1996, MOL GEN GENET, V252, P1, DOI 10.1007/BF02173199; OSTRANDER DB, 1995, J BIOL CHEM, V270, P27045, DOI 10.1074/jbc.270.45.27045; PAYNE WE, 1993, MOL CELL BIOL, V13, P4351, DOI 10.1128/MCB.13.7.4351; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; SCHUMAKER KS, 1987, J BIOL CHEM, V262, P3944; SIKORSKI RS, 1989, GENETICS, V122, P19; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TAKITA Y, 1995, MOL GEN GENET, V246, P269, DOI 10.1007/BF00288599; TERUI T, 1994, J BIOL CHEM, V269, P28130; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YOKOO T, 1995, MOL GEN GENET, V247, P148, DOI 10.1007/BF00705644; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; YOSHIHISA T, 1989, BIOCHEM BIOPH RES CO, V163, P908, DOI 10.1016/0006-291X(89)92308-5; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	53	136	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15779	15786		10.1074/jbc.273.25.15779	http://dx.doi.org/10.1074/jbc.273.25.15779			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624177	hybrid			2022-12-25	WOS:000074284200071
J	Jiang, XC; D'Armiento, J; Mallampalli, RK; Mar, J; Yan, SF; Lin, M				Jiang, XC; D'Armiento, J; Mallampalli, RK; Mar, J; Yan, SF; Lin, M			Expression of plasma phospholipid transfer protein mRNA in normal and emphysematous lungs and regulation by hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CHOLESTEROL; SURFACTANT; CONVERSION; EXCHANGE; DISEASE; CELLS	The lung is the major site expressing plasma phospholipid transfer protein (PLTP) mRNA in humans and mice, suggesting that this protein might have an important role in maintaining normal function of this organ. In the lung of human collagenase transgenic mice, an emphysematous animal model, PLTP mRNA was 3-fold higher than in control mice. However, the mRNA in other tissues was not changed. To further assess the expression and function of PLTP, we measured PLTP mRNA level in lung tissue of two emphysematous patients and found that the mRNA was I-fold higher than in control subjects. In situ hybridization on mouse lung suggested positive staining in alveolar type II epithelial cells. In addition, immortalized rat alveolar pre-type II epithelial cells and freshly isolated mature rat alveolar type II epithelial cells both highly expressed PLTP mRNA, and the former cells actively secreted PLTP activity into the medium. To examine the possible mechanisms leading to high levels of PLTP expression in vivo, we exposed the pre-type II cells to hypoxia and demonstrated induction of PLTP mRNA and a coordinate increase in secreted PLTP activity. Thus, the PLTP gene is highly expressed in alveolar type II epithelial cells and is induced during hypoxia and in emphysema. These observations suggest that a hypoxic stimulus occurring in emphysema may be a novel mechanism that contributes to enhanced expression of PLTP.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Med Ctr, Dept Vet Affairs, Iowa City, IA 52242 USA	Columbia University; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Jiang, XC (corresponding author), Columbia Univ, Dept Med, Div Mol Med, 630 W 168th ST, New York, NY 10032 USA.				NHLBI NIH HHS [HL54591, HL55584] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055584, R29HL055584, P01HL054591] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; BARLOW Y, 1985, THORAX, V40, P214; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; DAY JR, 1994, J BIOL CHEM, V269, P9388; FINLEY TN, 1972, NEW ENGL J MED, V286, P223, DOI 10.1056/NEJM197202032860501; Foger B, 1997, J BIOL CHEM, V272, P27393, DOI 10.1074/jbc.272.43.27393; FUJIWARA T, 1980, LANCET, V1, P55; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GUILLEMIN K, 1997, CELL, V81, P9; HIGHENBOTTAM T, 1987, EUR J RESP DIS S153, V71, P222; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; JIANG XC, 1995, J BIOL CHEM, V270, P17133, DOI 10.1074/jbc.270.29.17133; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; Kurashima K, 1997, CLIN EXP ALLERGY, V27, P337; Longo CA, 1997, AM J RESP CELL MOL, V16, P605, DOI 10.1165/ajrcmb.16.5.9160843; MALLAMPALLI RK, 1992, IN VITRO CELL DEV-AN, V28A, P181; Mallampalli RK, 1997, J CLIN INVEST, V99, P2020, DOI 10.1172/JCI119370; MASON R J, 1987, European Journal of Respiratory Diseases Supplement, V71, P229; POWNALL HJ, 1991, J LIPID RES, V32, P793; SCHMITZ G, 1991, J LIPID RES, V32, P1539; SHENOI A, 1992, ACTA PAEDIATR, V81, P150, DOI 10.1111/j.1651-2227.1992.tb12192.x; SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122; STRANG LB, 1977, NEONATAL RESPIRATION, P181; TALL AR, 1983, J BIOL CHEM, V258, P2174; TALL AR, 1985, J LIPID RES, V26, P842; TISI GM, 1981, METABOLISM, V30, P340, DOI 10.1016/0026-0495(81)90113-X; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; TU AY, 1993, J BIOL CHEM, V268, P23098; VOYNOYASENETSKAYA TA, 1993, P NATL ACAD SCI USA, V90, P4256, DOI 10.1073/pnas.90.9.4256; Walmrath D, 1996, AM J RESP CRIT CARE, V154, P57, DOI 10.1164/ajrccm.154.1.8680699; WALSH A, 1989, J BIOL CHEM, V264, P6488; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837	32	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15714	15718		10.1074/jbc.273.25.15714	http://dx.doi.org/10.1074/jbc.273.25.15714			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624168	hybrid			2022-12-25	WOS:000074284200062
J	Koppel, AM; Raper, JA				Koppel, AM; Raper, JA			Collapsin-1 covalently dimerizes, and dimerization is necessary for collapsing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; GROWTH-FACTOR; SEMAPHORIN-III; BINDING; FAMILY; SYSTEM; CD100	Chick collapsin-1, the first identified vertebrate member of the semaphorin family of axon guidance proteins, repels specific growth cones, Like all family members, collapsin-1 contains within its sequence a semaphorin domain that is necessary for specifying activity. Two additional structural domains of collapsin-1, the immunoglobulin (Ig) domain and the basic tail, each potentiate collapsin-1 activity. We identify in this study another structural feature of collapsin-1 that is necessary for its function, Collapsin-1 covalently dimerizes, and dimerization is necessary for collapse activity. This dimerization is mediated through a cysteine at residue 723, between the Ig domain and basic tail. The semaphorin domain alone is not active since it cannot dimerize, The collapsing activity of the semaphorin domain can be reconstituted when made as a chimeric construct with an immunoglobin Fc domain, which promotes dimerization.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA	University of Pennsylvania	Raper, JA (corresponding author), Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA.							Adams RH, 1997, EMBO J, V16, P6077, DOI 10.1093/emboj/16.20.6077; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; FRETTO LJ, 1993, J BIOL CHEM, V268, P3625; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; HEROLD C, 1995, INT IMMUNOL, V7, P1, DOI 10.1093/intimm/7.1.1; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Koppel AM, 1997, NEURON, V19, P531, DOI 10.1016/S0896-6273(00)80369-4; LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; MIYAZAKI J, 1989, GENE, V79, P269; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Shepherd I, 1996, DEV BIOL, V173, P185, DOI 10.1006/dbio.1996.0016; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; YING SY, 1989, J STEROID BIOCHEM, V33, P705	24	80	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15708	15713		10.1074/jbc.273.25.15708	http://dx.doi.org/10.1074/jbc.273.25.15708			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624167	hybrid			2022-12-25	WOS:000074284200061
J	Lee, SR; Kwon, KS; Kim, SR; Rhee, SG				Lee, SR; Kwon, KS; Kim, SR; Rhee, SG			Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOREDOXIN REDUCTASE; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; CATALYTIC ROLE; HUMAN-PLACENTA; PURIFICATION; PHOSPHORYLATION; SEQUENCE; H2O2; DEPHOSPHORYLATION	Stimulation of various cells with growth factors results in a transient increase in the intracellular concentration of H2O2 that is required for growth factor-induced protein tyrosine phosphorylation. The effect of H2O2 produced in response to epidermal growth factor (EGF) on the activity of protein-tyrosine phosphatase PB (PTP1B) was investigated in A431 human epidermoid carcinoma cells. H2O2 inactivated recombinant PTP1B in vitro by oxidizing its catalytic site cysteine, most likely to sulfenic acid. The oxidized enzyme was reactivated more effectively by thioredoxin than by glutaredoxin or glutathione at their physiological concentrations. Oxidation by H2O2 prevented modification of the catalytic cysteine of PTP1B by iodoacetic acid, suggesting that it should be possible to monitor the oxidation state of PTP1B in cells by measuring the incorporation of radioactivity into the enzyme after lysis of the cells in the presence of radiolabeled iodoacetic acid. The amount of such radioactivity associated with PTP1B immunoprecipitated from A431 cells that lead been stimulated with EGF for 10 min was 27% less than that associated with PTP1B from unstimulated cells. The amount of iodoacetic acid-derived radioactivity associated with PTP1B reached a minimum PO min after stimulation of cells with EGF and returned to base line values by 40 min, suggesting that the oxidation of PTP1B is reversible in cells. These results indicate that the activation of a receptor tyrosine kinase by binding of the corresponding growth factor may not be sufficient to increase the steady state level of protein tyrosine phosphorylation in cells and that concurrent inhibition of protein-tyrosine phosphatases by N2O2 might also be required.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 3,Rm 122, Bethesda, MD 20892 USA.	sgrhee@helix.nih.gov						ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; CASELLI A, 1994, J BIOL CHEM, V269, P24878; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FERNANDO MR, 1992, EUR J BIOCHEM, V209, P917, DOI 10.1111/j.1432-1033.1992.tb17363.x; Fialkow L, 1997, J IMMUNOL, V158, P5409; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GALISTEO EM, 1993, BIOCHIMIE, V75, P803; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HOLMGREN A, 1978, BIOCHEMISTRY-US, V17, P4071, DOI 10.1021/bi00612a031; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; Lee SR, 1997, FASEB J, V11, pA1356; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; LUTHMAN M, 1982, J BIOL CHEM, V257, P6686; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; POT DA, 1991, J BIOL CHEM, V266, P19688; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; Skorey K, 1997, J BIOL CHEM, V272, P22472, DOI 10.1074/jbc.272.36.22472; STONE RL, 1994, J BIOL CHEM, V269, P31323; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; SULLIVAN SG, 1994, FREE RADICAL BIO MED, V16, P399, DOI 10.1016/0891-5849(94)90042-6; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TONISSEN KF, 1989, NUCLEIC ACIDS RES, V17, P3973, DOI 10.1093/nar/17.10.3973; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; YOSHITAKE S, 1994, J BIOCHEM-TOKYO, V116, P42, DOI 10.1093/oxfordjournals.jbchem.a124500; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	54	795	826	3	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15366	15372		10.1074/jbc.273.25.15366	http://dx.doi.org/10.1074/jbc.273.25.15366			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624118	hybrid			2022-12-25	WOS:000074284200012
J	Loughnan, M; Bond, T; Atkins, A; Cuevas, J; Adams, DJ; Broxton, NM; Livett, BG; Down, JG; Jones, A; Alewood, PF; Lewis, RJ				Loughnan, M; Bond, T; Atkins, A; Cuevas, J; Adams, DJ; Broxton, NM; Livett, BG; Down, JG; Jones, A; Alewood, PF; Lewis, RJ			alpha-conotoxin EpI, a novel sulfated peptide from Conus episcopatus that selectively targets neuronal nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE SULFATION; SOLID-PHASE SYNTHESIS; CHANNELS; ANTAGONIST; SPECIFICITY; RESIDUES; BLOCKADE; CURRENTS; VENOM; CELLS	We have isolated and characterized ol-conotoxin EpI, a novel sulfated peptide from the venom of the molluscivorous snail, Conus episcopatus, The peptide was classified as an cy-conotoxin based on sequence, disulfide connectivity, and pharmacological target. EpI has ho mology to sequences of previously described cu-conotoxins, particularly PnIA, PnIB, and ImI, However, EpI differs from previously reported conotoxins in that it has a sulfotyrosine residue, identified by amino acid analysis and mass spectrometry, Native EpI was shown to coelute with synthetic EpI, The peptide sequence is consistent with most, but not all, recognized criteria for predicting tyrosine sulfation sites in proteins and peptides, The activities of synthetic EpI and its unsulfated analogue [Tyr(15)]EpI were similar. Both peptides caused competitive inhibition of nicotine action on bovine adrenal chromaffin cells (neuronal nicotinic ACh receptors) but had no effect on the rat phrenic nerve-diaphragm (muscle nicotinic ACh receptors), Both EpI and [Tyr(15)]EpI partly inhibited acetylcholine-evoked currents in isolated parasympathetic neurons of rat intracardiac ganglia, These results indicate that EPI and [Tyr(15)]EpI selectively inhibit alpha 3 beta 2 and alpha 3 beta 4 nicotinic acetylcholine receptors.	Univ Queensland, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4067, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia	University of Queensland; University of Queensland; University of Melbourne	Lewis, RJ (corresponding author), Univ Queensland, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia.		Adams, David/J-9125-2014; Cuevas, Javier/I-4941-2012; Loughnan, Marion/B-4508-2009; Milne, Trudy J/G-2630-2011; Lewis, Richard/T-8763-2019; Adams, David John/K-3578-2019; Lewis, Richard J/E-8674-2013	Adams, David/0000-0002-7030-2288; Lewis, Richard/0000-0003-3470-923X; Adams, David John/0000-0002-7030-2288; Lewis, Richard J/0000-0003-3470-923X; Alewood, Paul/0000-0001-7454-6522; Atkins, Annette/0000-0003-2558-7058				Albuquerque EX, 1997, J PHARMACOL EXP THER, V280, P1117; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BLOUNT K, 1992, TOXICON, V30, P835, DOI 10.1016/0041-0101(92)90381-E; BROXTON NM, 1996, P AUST NEUROSCI SOC, V7, P164; BULBRING E, 1946, BRIT J PHARM CHEMOTH, V1, P38; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; CamposCaro A, 1997, J NEUROCHEM, V68, P488; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; CHIAPPINELLI VA, 1993, NATURAL SYNTHETIC NE, P656; Coggan JS, 1997, J NEUROSCI, V17, P5798; Craig AG, 1997, J BIOL CHEM, V272, P4689, DOI 10.1074/jbc.272.8.4689; Criado M, 1997, J NEUROSCI, V17, P6554; Cuevas J, 1996, J PHYSIOL-LONDON, V493, P503, DOI 10.1113/jphysiol.1996.sp021399; CUEVAS J, 1994, BRIT J PHARMACOL, V111, P663, DOI 10.1111/j.1476-5381.1994.tb14789.x; EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P469, DOI 10.1146/annurev.ph.57.030195.002345; FAINZILBER M, 1994, BIOCHEMISTRY-US, V33, P9523, DOI 10.1021/bi00198a018; FAINZILBER M, 1994, J BIOL CHEM, V269, P2574; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P215, DOI 10.1113/jphysiol.1991.sp018466; FIGL A, 1992, FEBS LETT, V308, P245, DOI 10.1016/0014-5793(92)81284-S; GIBSON BW, 1990, BIOLOGICAL MASS SPECTROMETRY /, P315; GRAY WR, 1981, J BIOL CHEM, V256, P4734; GROEBE DR, 1995, MOL PHARMACOL, V48, P105; Groebe DR, 1997, BIOCHEMISTRY-US, V36, P6469, DOI 10.1021/bi970195w; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harvey SC, 1997, MOL PHARMACOL, V51, P336, DOI 10.1124/mol.51.2.336; HOPKINS C, 1995, J BIOL CHEM, V270, P22361, DOI 10.1074/jbc.270.38.22361; Hu SH, 1996, STRUCTURE, V4, P417, DOI 10.1016/S0969-2126(96)00047-0; Hu SH, 1997, BIOCHEMISTRY-US, V36, P11323, DOI 10.1021/bi9713052; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; KAISER E, 1980, ANAL CHIM ACTA, V118, P149, DOI 10.1016/S0003-2670(01)93726-2; Kulak JM, 1997, J NEUROSCI, V17, P5263; Lewis R., 1996, TODAYS LIFE SCI, V8, P16; LIVETT BG, 1987, IN VITRO METHODS STU, P171; MARTINEZ JS, 1995, BIOCHEMISTRY-US, V34, P14519, DOI 10.1021/bi00044a030; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; MYERS RA, 1993, CHEM REV, V93, P1923, DOI 10.1021/cr00021a013; PAUWELS S, 1989, BIOCHIM BIOPHYS ACTA, V996, P82, DOI 10.1016/0167-4838(89)90098-8; Poth K, 1997, J NEUROSCI, V17, P586; PRITCHARD CI, 1986, BIOCHEM SOC T, V14, P1286, DOI 10.1042/bst0141286; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; YAGAMI T, 1993, CHEM PHARM BULL, V41, P376; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065	49	103	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15667	15674		10.1074/jbc.273.25.15667	http://dx.doi.org/10.1074/jbc.273.25.15667			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624161	hybrid, Green Published			2022-12-25	WOS:000074284200055
J	Meyer, O; Kirpotin, D; Hong, KL; Sternberg, B; Park, JW; Woodle, MC; Papahadjopoulos, D				Meyer, O; Kirpotin, D; Hong, KL; Sternberg, B; Park, JW; Woodle, MC; Papahadjopoulos, D			Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STERICALLY STABILIZED LIPOSOMES; TRANSFECTION; LIPIDS; CELLS	Modification of liposome surface with polyethylene glycol was used to improve oligodeoxyribonucleotide (ODN) loading, stability of the resulting complexes, and specificity of cellular delivery of ODN by cationic liposomes. Liposomes composed of a cationic lipid (DOTAP, DOGS, DDAB), a neutral lipid (DOPE), and a phospholipid derivative of polyethylene glycol (PEG-PE) formed a complex with 18-mer phosphorothioate up to ODN/lipid molar ratio of 0.25, The complexes showed intact vesicular structures similar to original liposomes and their size (100-130 nm) was unchanged after several weeks of storage, whereas complexes lacking PEG-PE showed progressive aggregation and/or precipitation. After exposure to human plasma, PEG-modified cationic liposomes retained over 60% of the originally bound ODN, PEG-coated complexes resulted in 4-13-fold enhancement of the ODN uptake by human breast cancer cells in serum-supplemented growth medium, relative to free ODN, Complexes containing conjugated anti-HER2 F(ab') fragments at the distal termini of PEG chains efficiently delivered ODN primarily irate che cytoplasm and nuclei of HERS overexpressing cancer cells and greatly enhanced the biological activity of antisense ODN. The development of PEG-modified cationic liposomes may lead to improved ODN potency in vivo.	Calif Pacific Med Ctr, Res Inst, Liposome Res Lab, San Francisco, CA 94115 USA; Genet Therapy Inc, Gaithersburg, MD 20878 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; Novartis; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Papahadjopoulos, D (corresponding author), Calif Pacific Med Ctr, Res Inst, Liposome Res Lab, 2200 Webster St, San Francisco, CA 94115 USA.	papah@cooper.cpmc.org	Hong, Kunlun/E-9787-2015	Hong, Kunlun/0000-0002-2852-5111; Kirpotin, Dmitri/0000-0002-1726-4040	NCI NIH HHS [P50CA58207] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN TM, 1995, BBA-BIOMEMBRANES, V1237, P99, DOI 10.1016/0005-2736(95)00085-H; BAGG A, 1993, ONCOGENES TUMOR SUPP, P141; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; HALDAR S, 1994, CANCER RES, V54, P2095; Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X; HUNSTON DL, 1975, ANAL BIOCHEM, V63, P99, DOI 10.1016/0003-2697(75)90193-1; JAASKELAINEN I, 1994, BBA-BIOMEMBRANES, V1195, P115, DOI 10.1016/0005-2736(94)90017-5; KENWORTHY AK, 1995, BIOPHYS J, V68, P1903, DOI 10.1016/S0006-3495(95)80368-1; Kirpotin D, 1997, BIOCHEMISTRY-US, V36, P66, DOI 10.1021/bi962148u; LAPPALAINEN K, 1994, BBA-BIOMEMBRANES, V1196, P201, DOI 10.1016/0005-2736(94)00224-X; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MORRISON WR, 1964, ANAL BIOCHEM, V7, P281; NAGEL KM, 1993, PHARMACOTHERAPY, V13, P177; OLON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P19; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; PAPAHADJOPOULOS D, 1995, LIPOSOMES TOOLS BASI, P177; PARK JW, 1995, P NATL ACAD SCI USA, V92, P1327, DOI 10.1073/pnas.92.5.1327; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Sternberg B., 1992, LIPOSOME TECHNOLOGY, P363; THIERRY AR, 1995, DELIVERY STRATEGIES, P199; UZIELY B, 1995, J CLIN ONCOL, V13, P1777, DOI 10.1200/JCO.1995.13.7.1777; WOODLE MC, 1992, BIOPHYS J, V61, P902, DOI 10.1016/S0006-3495(92)81897-0; Woodle MC, 1997, NUCLEOS NUCLEOT NUCL, V16, P1731, DOI 10.1080/07328319708006265; WOODLE MC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P171, DOI 10.1016/0304-4157(92)90038-C; YUAN F, 1995, CANCER RES, V55, P3752; Zelphati O, 1996, PHARMACEUT RES, V13, P1367, DOI 10.1023/A:1016026101195	29	195	217	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15621	15627		10.1074/jbc.273.25.15621	http://dx.doi.org/10.1074/jbc.273.25.15621			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624154	Green Published, hybrid			2022-12-25	WOS:000074284200048
J	Morozov, I; Lotan, O; Joseph, G; Gorzalczany, Y; Pick, E				Morozov, I; Lotan, O; Joseph, G; Gorzalczany, Y; Pick, E			Mapping of functional domains in p47(phox) involved in the activation of NADPH oxidase by "peptide walking"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; DEPENDENT SUPEROXIDE PRODUCTION; SODIUM DODECYL-SULFATE; SRC HOMOLOGY-3 DOMAINS; PROTEIN-KINASE-C; CYTOSOLIC COMPONENTS; HUMAN-NEUTROPHILS; SH3 DOMAINS	The superoxide generating NADPH oxidase. of phagocytes consists, in resting cells, of a membrane-associated electron transporting flavocytochrome (cytochrome b(559)) and four cytosolic proteins as follows: p47(phox), p67(phox), p40(phox), and the small GTPase, Rac(1 or 2). Activation of the oxidase is consequent to the assembly of a membrane-localized multimolecular complex consisting of cytochrome b(559) and the cytosolic components. We used "peptide walking" (Joseph, G., and Pick, E. (1995) J. Biol. Chem. 270, 29079-29082) for mapping domains in the amino acid sequence of p47(phox) participating in the molecular events leading to the activation of NADPH oxidase, Ninety-five overlapping pentadecapeptides, with a four-residue offset between neighboring peptides, spanning the complete p47(phox) sequence, were tested for the ability to inhibit NADPH oxidase activation in a cell-free system. This consisted of solubilized macrophage membranes, recombinant p47(phox), p67(phox), and Rad, and lithium dodecyl sulfate, as the activator. Eight functional domains were identified and labeled a-h. These were (N- and C-terminal residue numbers are given for each domain) as follows: a (21-35); b (105-119): c (149-159); d (193-207); e (253-267); f (305-319); g (325-339), and h (373-387). Four of these domains (c, d? e, and g) correspond to or form parts of regions shown before to participate in NADPH oxidase assembly. Thus, domain c corresponds to a region on the N-terminal boundary of the first src homology 3 (SH3) domain, whereas domains d and e represent more precisely defined sites within the full-length first and second SH3 domains, respectively. Domain g overlaps an extensively investigated arginine-rich region. Domains a and b, in the N-terminal half of p47(phox), and domains f and h, in the C-terminal half, represent newly identified entities, for which there is no earlier experimental evidence of involvement in NADPH oxidase activation. "Peptide walking" was also applied to the identification of domains in p47(phox) mediating binding to p67(phox). This was done by quantifying, by enzyme-linked immunosorbent assay, the binding of p67(phox), in solution, to a series of 95 overlapping biotinylated p47(phox) peptides, attached to streptavidin-coated 96-well plates. A single proline-rich domain (residues 357-371) was found to bind p67(phox) in the absence and presence of lithium dodecyl sulfate.	Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, JF Cohnheim Minerva Ctr Phagocyte Res, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Pick, E (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, JF Cohnheim Minerva Ctr Phagocyte Res, IL-69978 Tel Aviv, Israel.		; Pick, Edgar/B-1795-2008	Morozov, Giora/0000-0002-2605-6075; Pick, Edgar/0000-0003-4625-3233				ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; FINAN P, 1994, J BIOL CHEM, V269, P13752; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Gorman C, 1996, J BIOL CHEM, V271, P6713, DOI 10.1074/jbc.271.12.6713; Hata K, 1997, BIOCHEM BIOPH RES CO, V241, P226, DOI 10.1006/bbrc.1997.7807; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; IYER SS, 1994, J BIOL CHEM, V269, P22405; JESAITIS AJ, 1995, J IMMUNOL, V155, P3286; JOSEPH G, 1995, J BIOL CHEM, V270, P29079, DOI 10.1074/jbc.270.49.29079; JOSEPH G, 1994, J BIOL CHEM, V269, P29024; JOUAN A, 1993, BIOCHEM BIOPH RES CO, V197, P1296, DOI 10.1006/bbrc.1993.2618; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; KRECK ML, 1994, J BIOL CHEM, V269, P4161; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; LETO TL, 1991, J BIOL CHEM, V266, P19812; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MALECH HL, 1993, CLIN RES, V41, P323; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; PARK JW, 1992, J BIOL CHEM, V267, P17327; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; PICK E, 1993, EUR J BIOCHEM, V217, P441, DOI 10.1111/j.1432-1033.1993.tb18264.x; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Sathyamoorthy M, 1997, J BIOL CHEM, V272, P9141; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Swain SD, 1997, J BIOL CHEM, V272, P29502, DOI 10.1074/jbc.272.47.29502; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; TOPORIK A, 1998, IN PRESS BIOCHEMISTR; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V187, P940, DOI 10.1016/0006-291X(92)91288-2; VALERIO RM, 1991, ANAL BIOCHEM, V197, P168, DOI 10.1016/0003-2697(91)90374-3; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; Wientjes FB, 1996, BIOCHEM J, V317, P919, DOI 10.1042/bj3170919; Wilson L, 1997, INFLAMM RES, V46, P265, DOI 10.1007/s000110050185	70	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15435	15444		10.1074/jbc.273.25.15435	http://dx.doi.org/10.1074/jbc.273.25.15435			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624128	hybrid			2022-12-25	WOS:000074284200022
J	Serra-Pages, C; Medley, QG; Tang, M; Hart, A; Streuli, M				Serra-Pages, C; Medley, QG; Tang, M; Hart, A; Streuli, M			Liprins, a family of LAR transmembrane protein-tyrosine phosphatase-interacting proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; AXON GUIDANCE; COILED COILS; ASSOCIATION; DROSOPHILA; EXPRESSION; ISOFORMS; KINASES; DELTA; SUPERFAMILY	LAR family transmembrane protein-tyrosine phosphatases function in axon guidance and mammary gland development. In cultured cells, LAR binds to the intracellular, coiled coil LAB-interacting protein at discrete ends of focal adhesions, implicating these proteins in the regulation of cell-matrix interactions. We describe seven LAB-interacting protein-like genes in humans and Caenorhabditis elegans that form the liprin gene family, Based on sequence similarities and binding characteristics, liprins are subdivided into alpha-type and beta-type liprins. The C-terminal, non-coiled coil regions of alpha-liprins bind to the membrane-distal phosphatase domains of LAR family members, as well as to the C-terminal, non-coiled coil region of beta-liprins. Both alpha- and beta-liprins homodimerize via their N-terminal, coiled coil regions. Liprins are thus multivalent proteins that potentially form complex structures. Some liprins have broad mRNA tissue distributions, whereas others are predominately expressed in the brain. Go-expression studies indicate that liprin-alpha 2 alters LAR cellular localization and induces LAR clustering. We propose that liprins function to localize LAR family tyrosine phosphatases at specific sites on the plasma membrane, possibly regulating their interaction with the extracellular environment and their association with substrates.	Dana Farber Canc Inst, Div Tumor Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Streuli, M (corresponding author), Dana Farber Canc Inst, Div Tumor Immunol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA055547] Funding Source: NIH RePORTER; NCI NIH HHS [CA55547] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AICHER B, 1997, J CELL BIOL, V138, P381; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Desai CJ, 1997, DEVELOPMENT, V124, P1941; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MIZUNO K, 1993, MOL CELL BIOL, V13, P5513, DOI 10.1128/MCB.13.9.5513; NobenTrauth K, 1997, BBA-GENE STRUCT EXPR, V1352, P133, DOI 10.1016/S0167-4781(97)00050-X; PULIDO R, 1995, P NATL ACAD SCI USA, V92, P11686, DOI 10.1073/pnas.92.25.11686; PULIDO R, 1995, J BIOL CHEM, V270, P6722, DOI 10.1074/jbc.270.12.6722; Saito H, 1993, Semin Cell Biol, V4, P379, DOI 10.1006/scel.1993.1045; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SERRAPAGES C, 1994, J BIOL CHEM, V269, P23632; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; STOKER AW, 1994, MECH DEVELOP, V46, P201, DOI 10.1016/0925-4773(94)90071-X; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAN H, 1993, J BIOL CHEM, V268, P24880	39	224	243	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15611	15620		10.1074/jbc.273.25.15611	http://dx.doi.org/10.1074/jbc.273.25.15611			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624153	hybrid			2022-12-25	WOS:000074284200047
J	Wolters, PJ; Raymond, WW; Blount, JL; Caughey, GH				Wolters, PJ; Raymond, WW; Blount, JL; Caughey, GH			Regulated expression, processing, and secretion of dog mast cell dipeptidyl peptidase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-C; MOLECULAR-CLONING; ACTIVATION; TRYPTASE; GRANULES; LUNG; INHIBITION; PROTEASE; HEPARIN; COMPLEX	Dipeptidyl peptidase I (DPPI) is a cysteine protease found predominantly in myelomonocytic cells, cytotoxic T-cells, and mast cells. Recent studies identify an intracellular role for mast cell-DPPI (MC-DPPI) by activating prochymase and protryptase to their mature forms, To better define MC-DPPI and to explore the possibility of extracellular roles, we purified MC-DPPI from mastocytoma cells. We found the dog C2 mastocytoma cell line to be the richest source yet described for DPPI, purifying up to 200 mu g of enzyme per g of cells. Dog MC-DPPI has an M-r of similar to 175,000 and consists of four subunits, each composed of a propeptide, light chain, and heavy chain. The heavy chain is N-glycosylated and is heterogeneously processed to three different forms. NH2-terminal sequences of the heavy chain and propeptide are identical to those predicted from a cDNA clone we sequenced from a mastocytoma cDNA library. The dog cDNA-derived sequence is 86% identical to that of human DPPI. Dog mastocytoma cells incubated with 12-O-tetradecanoylphorbol-13-acetate increase expression of MC-DPPI mRNA. MC-DPPI maintains its activity for dipeptide substrates at a neutral to alkaline pH. Cells stimulated with ionophore or substance P secrete MCDPPI in parallel with the granule-associated mediators tryptase and histamine. Thus, dog mastocytoma cells secrete DPPI that is active at the pH of extracellular fluids, suggesting that MC-DPPI may act outside the cell.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Caughey, GH (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	ghc@itsa.ucsf.edu	Wolters, Paul/A-7181-2009		NHLBI NIH HHS [HL-24136, HL-07185, HL-54774] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054774, P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARIZONO N, 1990, LAB INVEST, V62, P626; Authier F, 1996, FEBS LETT, V389, P55, DOI 10.1016/0014-5793(96)00368-7; BARRETT AJ, 1986, BIOMED BIOCHIM ACTA, V45, P1367; BIRKTOFT JJ, 1972, J MOL BIOL, V68, P187, DOI 10.1016/0022-2836(72)90210-0; CAUGHEY GH, 1988, IMMUNOLOGY, V63, P399; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; DAGROSA RM, 1988, BIOCHEM BIOPH RES CO, V157, P770, DOI 10.1016/S0006-291X(88)80316-4; DEVINNEY R, 1990, AM J RESP CELL MOL, V3, P413, DOI 10.1165/ajrcmb/3.5.413; DIKOV MM, 1994, J BIOL CHEM, V269, P25897; DOLENC I, 1995, J BIOL CHEM, V270, P21626, DOI 10.1074/jbc.270.37.21626; DOUGHTY MJ, 1987, BIOCHEM CELL BIOL, V65, P617, DOI 10.1139/o87-082; DVORAK AM, 1993, MAST CELL HLTH DIS, P1; ISHIDOH K, 1991, J BIOL CHEM, V266, P16312; JOHNSON RG, 1980, FEBS LETT, V120, P75, DOI 10.1016/0014-5793(80)81050-7; LYNTH GW, 1988, THROMB HAEMOSTASIS, V59, P372; Maniatis T., 1982, MOL CLONING LAB MANU; MCDONALD JK, 1969, J BIOL CHEM, V244, P2693; MCDONALD JK, 1966, J BIOL CHEM, V241, P1494; MCDONALD JK, 1977, PROTEINASES MAMMALIA, P311; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCGUIRE MJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P280, DOI 10.1016/0003-9861(92)90519-3; METRIONE RM, 1975, BIOCHEMISTRY-US, V14, P5249, DOI 10.1021/bi00695a002; MIZUOCHI T, 1994, IMMUNOL LETT, V43, P189, DOI 10.1016/0165-2478(94)90221-6; MURAKAMI M, 1995, J BIOL CHEM, V270, P2218, DOI 10.1074/jbc.270.5.2218; PARIS A, 1995, FEBS LETT, V369, P326, DOI 10.1016/0014-5793(95)00777-7; PHARM CTN, 1997, J BIOL CHEM, V272, P10695; Podobnik M, 1997, J MOL BIOL, V271, P774, DOI 10.1006/jmbi.1997.1218; Rao NV, 1997, J BIOL CHEM, V272, P10260; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; SCHWARTZ LB, 1981, J IMMUNOL, V126, P1290; SERAFIN WE, 1991, P NATL ACAD SCI USA, V88, P5984, DOI 10.1073/pnas.88.14.5984; SHIMIZU Y, 1997, ASTHMA, P353; SLOANE BF, 1990, SEMIN CANCER BIOL, V1, P153; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; STORER AC, 1994, METHOD ENZYMOL, V244, P486; Thiele DL, 1997, J IMMUNOL, V158, P5200; Ulbricht B, 1996, EXP CELL RES, V226, P255, DOI 10.1006/excr.1996.0226; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; VARUGHESE KI, 1989, BIOCHEMISTRY-US, V28, P1330, DOI 10.1021/bi00429a058	41	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15514	15520		10.1074/jbc.273.25.15514	http://dx.doi.org/10.1074/jbc.273.25.15514			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624139	hybrid			2022-12-25	WOS:000074284200033
J	Zeitlmann, L; Knorr, T; Knoll, M; Romeo, C; Sirim, P; Kolanus, W				Zeitlmann, L; Knorr, T; Knoll, M; Romeo, C; Sirim, P; Kolanus, W			T cell activation induced by novel gain-of-function mutants of Syk and ZAP-70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; RECEPTOR ZETA-CHAIN; DOMAIN-CONTAINING PROTEINS; TANDEM SH2 DOMAINS; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; EXPRESSION SYSTEM; BINDING; PHOSPHORYLATION; TCR	The Syk family tyrosine kinases play a crucial role in antigen receptor-mediated signal transduction, but their regulation and cellular targets remain incompletely defined. Following receptor engagement, phosphorylation of tyrosine residues within ZAP-70 and Syk is thought to control both kinase activity and recruitment of modulatory factors. We report here the characterization of novel mutants of ZAP-70 and Syk, in which conserved C-terminal tyrosine residues have been replaced by phenylalanines (ZAP YF-C, Syk YF-C), Both mutant kinases display a prominent gain-of-function phenotype in Jurkat T cells, as demonstrated by lymphokine promoter activation, tyrosine phosphorylation of potential targets in vivo, and elevated intracellular calcium mobilization. While the presence of p56-Lck was required for ZAP YF-C-induced signaling, Syk YF-C showed enhanced functional activity in Lck-deficient JCaM1 Jurkat cells. Our results implicate the C terminus of Syk family kinases as an important regulatory region modulating T cell activation.	Univ Munich, Mol Biol Lab, Genzentrum, D-81377 Munich, Germany; NIEHS, NIH, Res Triangle Pk, NC 27709 USA	University of Munich; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kolanus, W (corresponding author), Univ Munich, Mol Biol Lab, Genzentrum, Feodor Lynen Str 25, D-81377 Munich, Germany.	kolanus@lmb.uni-muenchen.de	Zeitlmann, Lutz/AAF-3586-2019					ARUFFO A, 1987, EMBO J, V6, P3313, DOI 10.1002/j.1460-2075.1987.tb02651.x; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Couture C, 1997, EUR J BIOCHEM, V246, P447, DOI 10.1111/j.1432-1033.1997.00447.x; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Furlong MT, 1997, BBA-MOL CELL RES, V1355, P177, DOI 10.1016/S0167-4889(96)00131-0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KATZAV S, 1994, J BIOL CHEM, V269, P32579; Keshvara LM, 1997, J BIOL CHEM, V272, P10377; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; Kong GH, 1996, MOL CELL BIOL, V16, P5026; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Madrenas J, 1997, J EXP MED, V185, P219, DOI 10.1084/jem.185.2.219; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; Mege D, 1996, J BIOL CHEM, V271, P32644, DOI 10.1074/jbc.271.51.32644; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Northrop JP, 1996, MOL CELL BIOL, V16, P2255; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Straus DB, 1996, J BIOL CHEM, V271, P9976, DOI 10.1074/jbc.271.17.9976; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WATTS JD, 1994, J BIOL CHEM, V269, P29520; Williams S, 1997, EUR J BIOCHEM, V245, P84, DOI 10.1111/j.1432-1033.1997.00084.x; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; Zhao QH, 1996, MOL CELL BIOL, V16, P6765	48	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15445	15452		10.1074/jbc.273.25.15445	http://dx.doi.org/10.1074/jbc.273.25.15445			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624129	hybrid			2022-12-25	WOS:000074284200023
J	Charpentier, S; Amiche, M; Mester, J; Vouille, V; Le Caer, JP; Nicolas, P; Delfour, A				Charpentier, S; Amiche, M; Mester, J; Vouille, V; Le Caer, JP; Nicolas, P; Delfour, A			Structure, synthesis, and molecular cloning of dermaseptins B, a family of skin peptide antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; DELTA-OPIOID RECEPTORS; FROG-SKIN; ANTIMICROBIAL PEPTIDES; DEFENSIVE PEPTIDES; AMPHIBIAN SKIN; RANA-ESCULENTA; HIGH-AFFINITY; SEQUENCE; DERMORPHIN	Analysis of antimicrobial activities that are present in the skin secretions of the South American frog Phyllomedusa bicolor revealed six polycationic (lysine-rich) and amphipathic alpha-helical peptides, 24-33 residues long, termed dermaseptins B1 to B6, respectively, Prepro-dermaseptins B all contain an almost identical signal peptide, which is followed by a conserved acidic propiece, a processing signal Lys-Arg, and a dermaseptin progenitor sequence. The 22-residue signal peptide plus the first 3 residues of the acidic propiece are encoded by conserved nucleotides encompassed by the first coding exon of the dermaseptin genes. The 25-residue amino-terminal region of prepro-dermaseptins B shares 50% identity with the corresponding region of precursors for D-amino acid containing opioid peptides or for antimicrobial peptides originating from the skin of distantly related frog species. The remarkable similarity found between prepro-proteins that encode end products with strikingly different sequences, conformations, biological activities and modes of action suggests that the corresponding genes have evolved through dissemination of a conserved "secretory cassette" exon.	Univ Paris 07, Inst Jacques Monod, Lab Bioactivat Peptides, F-75251 Paris 05, France; INSERM, U55, F-75571 Paris, France; ESPCI, Lab Neurobiol & Divers Cellulaire, CNRS, URA 2054, F-75231 Paris 05, France	UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Delfour, A (corresponding author), Univ Paris 07, Inst Jacques Monod, Lab Bioactivat Peptides, 2 Pl Jussieu, F-75251 Paris 05, France.		Nicolas, Pierre/C-7908-2009; AMICHE, Mohamed/R-3684-2018					AMICHE M, 1994, J BIOL CHEM, V269, P17847; AMICHE M, 1993, BIOCHEM BIOPH RES CO, V191, P983, DOI 10.1006/bbrc.1993.1314; BIERBAUM G, 1993, ZBL BAKT-INT J MED M, V278, P1; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; BUCHOU T, 1989, EXP CELL RES, V182, P129, DOI 10.1016/0014-4827(89)90285-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALY JW, 1992, P NATL ACAD SCI USA, V89, P10960, DOI 10.1073/pnas.89.22.10960; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; ERSPAMER V, 1989, P NATL ACAD SCI USA, V86, P5188, DOI 10.1073/pnas.86.13.5188; Fleury Y, 1996, J BIOL CHEM, V271, P14421, DOI 10.1074/jbc.271.24.14421; GRAY HE, 1987, EXP CELL RES, V169, P95, DOI 10.1016/0014-4827(87)90228-X; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; James R, 1992, BACTERIOCINS MICROCI; JUNG G, 1991, ANGEW CHEM INT EDIT, V30, P1051, DOI 10.1002/anie.199110513; KLAENHAMMER TR, 1993, FEMS MICROBIOL REV, V12, P39, DOI 10.1111/j.1574-6976.1993.tb00012.x; KOLTER R, 1992, ANNU REV MICROBIOL, V46, P141, DOI 10.1146/annurev.mi.46.100192.001041; KREIL G, 1989, EUR J PHARMACOL, V162, P123, DOI 10.1016/0014-2999(89)90611-0; LAZARUS LH, 1989, J BIOL CHEM, V264, P3047; LAZARUS LH, 1993, PROG NEUROBIOL, V41, P473, DOI 10.1016/0301-0082(93)90027-P; MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V17, P275; MOR A, 1994, BIOCHEMISTRY-US, V33, P6642, DOI 10.1021/bi00187a034; MOR A, 1994, J BIOL CHEM, V269, P31635; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; MORIKAWA N, 1992, BIOCHEM BIOPH RES CO, V189, P184, DOI 10.1016/0006-291X(92)91542-X; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; PARK JM, 1995, BBA-GENE STRUCT EXPR, V1264, P23, DOI 10.1016/0167-4781(95)00149-B; PARK JM, 1994, BIOCHEM BIOPH RES CO, V205, P948, DOI 10.1006/bbrc.1994.2757; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; SAGAN S, 1989, J BIOL CHEM, V264, P17100; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMMACO M, 1993, FEBS LETT, V324, P159, DOI 10.1016/0014-5793(93)81384-C; SIMMACO M, 1994, J BIOL CHEM, V269, P11956; Simmaco M, 1996, EUR J BIOCHEM, V242, P788, DOI 10.1111/j.1432-1033.1996.0788r.x; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Vouille V, 1997, FEBS LETT, V414, P27, DOI 10.1016/S0014-5793(97)00972-1; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; ZAVA DT, 1977, SCIENCE, V196, P663, DOI 10.1126/science.193182	41	93	102	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14690	14697		10.1074/jbc.273.24.14690	http://dx.doi.org/10.1074/jbc.273.24.14690			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614066	hybrid			2022-12-25	WOS:000074160400008
J	Rosen, H; Reshef, A; Maeda, N; Lippoldt, A; Shpizen, S; Triger, L; Eggertsen, G; Bjorkhem, I; Leitersdorf, E				Rosen, H; Reshef, A; Maeda, N; Lippoldt, A; Shpizen, S; Triger, L; Eggertsen, G; Bjorkhem, I; Leitersdorf, E			Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; DILUTION MASS-SPECTROMETRY; CAUSES CEREBROTENDINOUS XANTHOMATOSIS; PREMATURE TERMINATION CODON; RAT-LIVER; MITOCHONDRIAL CYTOCHROME-P-450; BIOSYNTHETIC ENZYME; MOLECULAR-GENETICS; MESSENGER-RNA; SERUM LEVELS	Sterol 27-hydroxylase is important for the degradation of the steroid side chain in conversion of cholesterol into bile acids and has been ascribed a regulatory role in cholesterol homeostasis. Its deficiency causes the autosomal recessive disease cerebrotendinous xanthomatosis (CTX), characterized by progressive dementia, xanthomatosis, and accelerated atherosclerosis. Mice with a disrupted cyp27 (cyp27(-/-)) had normal plasma levels of cholesterol, retinol, tocopherol, and 1,25-dihydroxyvitamin D. Excretion of fecal bile acids was decreased (<20% of normal), and formation of bile acids from tritium-labeled 7 alpha-hydroxycholesterol was less than 15% of normal. Compensatory upregulation of hepatic cholesterol 7 alpha-hydroxylase and hydroxymethylglutaryl-CoA reductase (9- and 2-3-fold increases in mRNA levels, respectively) was found. No CTX-related pathological abnormalities were observed. In CTX, there is an increased formation of 25-hydroxylated bile alcohols and cholestanol. In bile and feces of the cyp27(-/-) mice only traces of bile alcohols were found, and there was no cholestanol accumulation. It is evident that sterol 27-hydroxylase is more important for bile acid synthesis in mice than in humans. The results do not support the contention that 27-hydroxylated steroids are critical for maintenance of cholesterol homeostasis or levels of vitamin D metabolites in the circulation.	Hadassah Univ Hosp, Dept Med, Ctr Res Prevent & Treatment Atherosclerosis, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Fac Med, Dept Mol Virol, Jerusalem, Israel; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Max Delbruck Ctr Mol Med, Dept Nephrol Hypertens & Genet, D-13122 Berlin, Germany; Huddinge Univ Hosp, Karolinska Inst, Dept Med Lab Sci & Technol, Div Clin Chem, S-14186 Huddinge, Sweden	Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of North Carolina; University of North Carolina Chapel Hill; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Karolinska Institutet	Leitersdorf, E (corresponding author), Hadassah Univ Hosp, Dept Med, Ctr Res Prevent & Treatment Atherosclerosis, IL-91120 Jerusalem, Israel.			Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190	NHLBI NIH HHS [HL42630] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042630, R01HL042630] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERLUND JE, 1990, J LIPID RES, V31, P2159; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AXEN E, 1994, P NATL ACAD SCI USA, V91, P10014, DOI 10.1073/pnas.91.21.10014; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BELSEY R, 1974, AM J MED, V57, P50, DOI 10.1016/0002-9343(74)90767-0; BERGINER VM, 1989, NEUROL CLIN, V7, P55, DOI 10.1016/S0733-8619(18)30828-4; BJORKHEM I, 1979, BIOCHEM BIOPH RES CO, V90, P615, DOI 10.1016/0006-291X(79)91279-8; BJORKHEM I, 1975, J CLIN INVEST, V55, P478, DOI 10.1172/JCI107954; BJORKHEM I, 1973, EUR J BIOCHEM, V36, P201, DOI 10.1111/j.1432-1033.1973.tb02902.x; BJORKHEM I, 1987, J LIPID RES, V28, P889; BJORKHEM I, 1983, SCAND J CLIN LAB INV, V43, P163, DOI 10.3109/00365518309168239; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1987, J LIPID RES, V28, P1137; BJORKHEM I, 1974, CLIN CHIM ACTA, V54, P185, DOI 10.1016/0009-8981(74)90236-8; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; BJORKHEM I, 1994, METABOLIC BASIS INHE, P2073; CALI JJ, 1991, J BIOL CHEM, V266, P7774; CALI JJ, 1991, J BIOL CHEM, V266, P7779; CATAGNINI GL, 1983, CLIM CHEM, V29, P708; DANIELSS.H, 1966, J BIOL CHEM, V241, P1449; DUANE WC, 1988, J CLIN INVEST, V82, P82, DOI 10.1172/JCI113605; DUANE WC, 1988, HEPATOLOGY, V8, P613, DOI 10.1002/hep.1840080329; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; EGESTAD B, 1985, SCAND J CLIN LAB INV, V45, P443, DOI 10.3109/00365518509155241; GEHRING MR, 1987, J BIOL CHEM, V262, P446; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; HOLLIS BW, 1986, CLIN CHEM, V32, P2060; JAVITT NB, 1990, J LIPID RES, V31, P1527; KIM KS, 1994, J LIPID RES, V35, P1031; LEITERSDORF E, 1994, AM J HUM GENET, V55, P907; LEITERSDORF E, 1993, J CLIN INVEST, V91, P2488, DOI 10.1172/JCI116484; LINDBACK B, 1987, CLIN CHEM, V33, P1226; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; LUND E, 1989, SCAND J CLIN LAB INV, V49, P165, DOI 10.3109/00365518909105417; LUND E, 1992, J BIOL CHEM, V267, P25092; LUND E, 1995, ACCOUNTS CHEM RES, V28, P241, DOI 10.1021/ar00054a001; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MEINER V, 1994, HUM MOL GENET, V3, P193, DOI 10.1093/hmg/3.1.193; MEINER V, 1994, NEUROLOGY, V44, P288, DOI 10.1212/WNL.44.2.288; NAKASHIMA N, 1994, J LIPID RES, V35, P663; OFTEBRO H, 1980, J CLIN INVEST, V65, P1418, DOI 10.1172/JCI109806; OHYAMA Y, 1991, J BIOCHEM-TOKYO, V109, P389, DOI 10.1093/oxfordjournals.jbchem.a123391; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; RESHEF A, 1994, J LIPID RES, V35, P478; Sambrook J., 2002, MOL CLONING LAB MANU; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SEGEV H, 1995, HUM GENET, V95, P238; SKREDE S, 1988, J LIPID RES, V29, P157; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; SUDJANASUGIAMAN E, 1994, J LIPID RES, V35, P319; SUDJANASUGIAMAN E, 1994, BIOCHEM BIOPH RES CO, V202, P896, DOI 10.1006/bbrc.1994.2014; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; USUI E, 1990, FEBS LETT, V262, P135, DOI 10.1016/0014-5793(90)80172-F; Watts GF, 1996, QJM-MON J ASSOC PHYS, V89, P55, DOI 10.1093/oxfordjournals.qjmed.a030138	56	196	196	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14805	14812		10.1074/jbc.273.24.14805	http://dx.doi.org/10.1074/jbc.273.24.14805			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614081	hybrid, Green Published			2022-12-25	WOS:000074160400023
J	Strock, C; Cavagna, M; Peiffer, WE; Sumbilla, C; Lewis, D; Inesi, G				Strock, C; Cavagna, M; Peiffer, WE; Sumbilla, C; Lewis, D; Inesi, G			Direct demonstration of Ca2+ binding defects in sarco-endoplasmic reticulum Ca2+ ATPase mutants overexpressed in COS-1 cells transfected with adenovirus vectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; CALCIUM-BINDING; TRANSMEMBRANE DOMAIN; HIGH-AFFINITY; AMINO-ACIDS; CA2+-ATPASE; MECHANISM; SITE; PHOSPHORYLATION; CA-2+-ATPASE	Single mutations of specific amino acids within the membrane-bound region of the sarco-endoplasmic reticulum Ca2+ (SERCA)-1 ATPase interfere with Ca2+ inhibition of ATPase phosphorylation by P-i (1), suggesting that these residues may be involved in complexation of two Ca2+ that are known to bind to the enzyme. However, direct measurements of Ca2+ binding in the absence of ATP have been limited by the low quantities of available mutant protein. We have improved the transfection efficiency by means of recombinant adenovirus vectors, yielding sufficient expression of wild type and mutant SERCA-1 ATPase for measurements of Ca2+ binding to the microsomal fraction of the transfected cells. We find that in the presence of 20 mu M Ca2+ and in the absence of ATP, the Glu(771) --> Gln, Thr(799), Ala, Asp(800) --> Asn, and Glu(908) --> Ala mutants exhibit negligible binding, indicating that the oxygen functions of Glu(771), Thr(799), Asp(800) and Glu(908) are involved in interactions whose single disruption causes major changes in the highly cooperative "duplex" binding. Total loss of Ca2+ binding is accompanied by loss of Ca2+ inhibition of the P-i reaction. We also find that, at pK 7.0, the Glu(309) --> Gln and the Asn(796) --> APa mutants bind approximately half as much Ca2+ as the wild type ATPase and do not interfere with Ca2+ inhibition of the P-i reaction. At pH 6.2, the Glu(309), Gln mutant does not bind any Ca2+, and its phosphorylation by P-i is not inhibited by Ca2+, On the contrary, the Asn(796) --> Ala mutant retains the behavior displayed at pH 7.0. This suggests that in the Glu(309) --> Gln mutant, ionization of acidic functions in other amino acids (e.g. Glu(771) and Asp(800)) occurs as the pH is shifted, thereby rendering Ca2+ binding possible. In the Asn(796) --> Ala mutant, on the other hand, the Glu(309) carboxylic function allows binding of inhibitory Ca2+ even at pH 6.2, In all eases mutational interference with the inhibition of the P-i reaction by Ca2+ can be overcome by raising the Ca2+ concentration to the mM range, consistent with a general effect of mutations on the affinity of the ATPase for Ca2+.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Inesi, G (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	ginesi@umaryland.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007592] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL-27867] Funding Source: Medline; NIAMS NIH HHS [5-T32-AR07592] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; FUJIMORI T, 1992, J BIOL CHEM, V267, P18475; GRAHAM FL, 1992, VACCINES NEW APPROAC, P363; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; INESI G, 1980, J BIOL CHEM, V255, P3025; INESI G, 1988, METHOD ENZYMOL, V157, P154; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1992, FEBS LETT, V306, P247, DOI 10.1016/0014-5793(92)81010-J	27	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15104	15109		10.1074/jbc.273.24.15104	http://dx.doi.org/10.1074/jbc.273.24.15104			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614121	hybrid			2022-12-25	WOS:000074160400063
J	Taylor, BS; de Vera, ME; Ganster, RW; Wang, Q; Shapiro, RA; Morris, SM; Billiar, TR; Geller, DA				Taylor, BS; de Vera, ME; Ganster, RW; Wang, Q; Shapiro, RA; Morris, SM; Billiar, TR; Geller, DA			Multiple NF-kappa B enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT-SPECIFIC REGULATION; ADHESION MOLECULE-1; INFLAMMATORY CYTOKINES; FUNCTIONAL-ANALYSIS; HUMAN HEPATOCYTES; EPITHELIAL-CELLS; INTERFERON-GAMMA; PROMOTER; EXPRESSION; TRANSCRIPTION	The human inducible nitric oxide synthase (iNOS) gene is overexpressed in a number of human inflammatory diseases. Previously, we observed that the human iNOS gene is transcriptionally regulated by cytokines and demonstrated that the cytokine-responsive regions are upstream of -3.8 kilobase pairs (kb), Therefore, the purpose of this study was to further localize the functional enhancer elements and to assess the role of the transcription factor NF-kappa B in both human liver (AKN-1) and human lung (A549) epithelial cell lines. The addition of NF-kappa B inhibitors significantly suppressed cytokine-stimulated iNOS mRNA expression and NO synthesis, indicating that NF-kappa B is involved in the induction of the human iNOS gene. Analysis of the first 4.7 kb of the 5'-flanking region demonstrated basal promoter activity and failed to show any cytokine-inducible activity. However, promoter constructs extending to -5.8 and -7.2 kb revealed 2-3-fold and 4-5-fold induction, respectively, in the presence of cytokines, DNA sequence analysis from -3.8 to -7.2 kh identified five putative NF-kappa B cis-regulatory transcription factor binding sites upstream of -4.7 kb. Site-directed mutagenesis of these sites revealed that the NF-kappa B motif at -5.8 kb is required for cytokine-indluced promoter activity, while the sites at -5.2, -5.5, and -6.1 kb elicit a cooperative effect. Electromobility shift assays using a site-specific oligonucleotide and nuclear extracts from cells stimulated with cytokine-mixture, tumor necrosis factor-alpha or interleukin-1 beta, but not interferon-gamma, exhibited inducible DNA binding activity for NF-kappa B. These data indicate that NF-kappa B activation is required for cytokine induction of the human iNOS gene and identifies four NF-kappa B enhancer elements upstream in the human iNOS promoter that confer inducibility to tumor necrosis factor-alpha and interleukin-1 beta.	Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Taylor, BS (corresponding author), Univ Pittsburgh, Dept Surg, 497 Scaife Hall, Pittsburgh, PA 15261 USA.	bsta@med.pitt.edu	Morris, Sidney M/I-3440-2015		NIGMS NIH HHS [GM-44100, GM-52021, GM-37753] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM052021, R37GM044100, R01GM044100, R01GM052021, R01GM037753, R29GM044100] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; CHENG Q, 1994, J BIOL CHEM, V269, P13551; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GELLER DA, 1995, J IMMUNOL, V155, P4890; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; HARBRECHT BG, 1995, SHOCK, V4, P332, DOI 10.1097/00024382-199511000-00004; HAYASHI T, 1992, P NATL ACAD SCI USA, V89, P11259, DOI 10.1073/pnas.89.23.11259; Hierholzer C, 1998, J EXP MED, V187, P917, DOI 10.1084/jem.187.6.917; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kleinert H, 1996, MOL PHARMACOL, V49, P15; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Laubach VE, 1997, BBA-GENE STRUCT EXPR, V1351, P287, DOI 10.1016/S0167-4781(96)06909-6; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LINN SC, 1997, AM J PHYSIOL, V35, pG1499; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; MIDDLETON SJ, 1993, LANCET, V341, P465, DOI 10.1016/0140-6736(93)90211-X; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Murphy WJ, 1996, J ENDOTOXIN RES, V3, P381, DOI 10.1177/096805199600300502; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NUNOKAWA Y, 1994, BIOCHEM BIOPH RES CO, V200, P802, DOI 10.1006/bbrc.1994.1522; Nunokawa Y, 1996, BIOCHEM BIOPH RES CO, V223, P347, DOI 10.1006/bbrc.1996.0897; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Saavedra JE, 1997, J MED CHEM, V40, P1947, DOI 10.1021/jm9701031; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; Spitsin SV, 1997, MOL MED, V3, P315, DOI 10.1007/BF03401810; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	64	352	366	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15148	15156		10.1074/jbc.273.24.15148	http://dx.doi.org/10.1074/jbc.273.24.15148			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614127	hybrid			2022-12-25	WOS:000074160400069
J	Van Dort, HM; Moriyama, R; Low, PS				Van Dort, HM; Moriyama, R; Low, PS			Effect of band 3 subunit equilibrium on the kinetics and affinity of ankyrin binding to erythrocyte membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELL; ELECTRON-PARAMAGNETIC RESONANCE; SOUTHEAST-ASIAN OVALOCYTOSIS; SER THR-PHOSPHORYLATION; ANION TRANSPORT; CYTOPLASMIC DOMAIN; HEREDITARY SPHEROCYTOSIS; ROTATIONAL DIFFUSION; SELF-ASSOCIATION; COVALENT DIMERS	The membrane-spanning protein, band 3, anchors the spectrin-based membrane skeleton to the lipid bilayer via the bridging protein, ankyrin, To understand how band 3 subunit stoichiometry influences this membrane-skeletal junction, we have induced changes in the band 3 association equilibrium and assayed the kinetics and equilibrium properties of ankyrin binding. We observe that band 3 oligomers convert slowly to dimers and ultimately monomers following removal of ankyrin. Addition of excess ankyrin back to these membranes enriched in dissociated band 3 then shifts band 3 almost entirely to tetramers, confirming that the tetrameric form of band 3 constitutes the preferred oligomeric state of ankyrin binding. 4,4'-Diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) labeling of band 3, which is shown to shift most of the band 3 population to dimers, eliminates the majority of ankyrin-binding sites on the membrane and greatly reduces retention of band 3 in detergent-extracted membrane skeletons. Furthermore, DIDS- modified membranes lack all low affinity ankyrin-binding sites and roughly half of all high affinity sites. Since labeled membranes lack the rapid kinetic phase of ankyrin binding and exhibit only half of the normal amplitude of the slow kinetic phase, it can be concluded that the rapid phase of ankyrin association involves low affinity sites and the slow phase involves high affinity sites. A model accounting for these data and most previous data on ankyrin-band 3 interactions is provided.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Low, PS (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.			Low, Philip/0000-0001-9042-5528	NIGMS NIH HHS [GM 24417] Funding Source: Medline; PHS HHS [T32 G08296] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024417, R37GM024417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER SL, 1992, PROG CELL RES, V2, P9; Ando K, 1997, ARCH BIOCHEM BIOPHYS, V339, P250, DOI 10.1006/abbi.1996.9831; APPELL KC, 1981, J BIOL CHEM, V256, P1104; APPELL KC, 1982, BIOCHEMISTRY-US, V21, P2151, DOI 10.1021/bi00538a026; BAGGIO B, 1993, BIOCHIM BIOPHYS ACTA, V1148, P157, DOI 10.1016/0005-2736(93)90173-W; BENNETT V, 1979, J BIOL CHEM, V254, P2533; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1983, METHOD ENZYMOL, V70, P247; BETH AH, 1981, P NATL ACAD SCI-BIOL, V78, P4955, DOI 10.1073/pnas.78.8.4955; BRUCE LJ, 1993, BIOCHEM J, V293, P317, DOI 10.1042/bj2930317; CABANTCHIK ZI, 1978, BIOCHIM BIOPHYS ACTA, V515, P239; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CASSOLY R, 1982, BIOCHIM BIOPHYS ACTA, V689, P203, DOI 10.1016/0005-2736(82)90252-8; CHE A, 1993, J CELL SCI, V105, P655; CLARI G, 1992, BIOCHEM INT, V26, P1065; COHEN CM, 1993, SEMIN HEMATOL, V30, P119; DAVIS L, 1989, J BIOL CHEM, V264, P9665; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; DEMPSEY CE, 1986, BIOCHEMISTRY-US, V25, P2180, DOI 10.1021/bi00356a049; Ding Y, 1996, J BIOL CHEM, V271, P22494, DOI 10.1074/jbc.271.37.22494; DING Y, 1994, J BIOL CHEM, V269, P32201; DUCIS J, 1988, J BIOL CHEM, V263, P8544; EATON JW, 1980, AM J HEMATOL, V9, P391; FUKUDA MN, 1986, BLOOD, V68, P521; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; HANSPAL M, 1994, BLOOD, V84, pA4; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; IDEGUCHI H, 1992, BRIT J HAEMATOL, V82, P122, DOI 10.1111/j.1365-2141.1992.tb04603.x; IMAMURA T, 1984, JPN J MED, V23, P216; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; JAROLIM P, 1994, J CLIN INVEST, V93, P121, DOI 10.1172/JCI116935; JENKINS JD, 1985, J BIOL CHEM, V260, P426; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; JENNINGS ML, 1985, J BIOL CHEM, V260, P15714; KANNAN R, 1991, BIOCHEM J, V278, P57, DOI 10.1042/bj2780057; KUNIMOTO M, 1989, J BIOCHEM-TOKYO, V105, P190, DOI 10.1093/oxfordjournals.jbchem.a122638; LEPKE S, 1992, BIOCHIM BIOPHYS ACTA, V1106, P13, DOI 10.1016/0005-2736(92)90215-8; LEPKE S, 1976, BIOCHIM BIOPHYS ACTA, V455, P353, DOI 10.1016/0005-2736(76)90311-4; LING E, 1988, J BIOL CHEM, V263, P2209; LIU SC, 1995, BLOOD, V86, P349, DOI 10.1182/blood.V86.1.349.bloodjournal861349; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LOW PS, 1978, BIOCHIM BIOPHYS ACTA, V514, P264, DOI 10.1016/0005-2736(78)90297-3; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOW PS, 1984, J BIOL CHEM, V259, P3070; LOW PS, 1985, SCIENCE, V227, P531, DOI 10.1126/science.2578228; LOW PS, 1993, J BIOL CHEM, V268, P14627; LOW PS, 1992, PROG CELL RES, V2, P219; LUTZ HU, 1987, P NATL ACAD SCI USA, V84, P7368, DOI 10.1073/pnas.84.21.7368; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MALIK S, 1993, BIOCHEMISTRY-US, V32, P10078, DOI 10.1021/bi00089a024; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; MOHANDAS N, 1992, J CLIN INVEST, V89, P686, DOI 10.1172/JCI115636; MORGAN M, 1985, EMBO J, V4, P1927, DOI 10.1002/j.1460-2075.1985.tb03872.x; MORI A, 1995, J BIOCHEM-TOKYO, V118, P1192, DOI 10.1093/oxfordjournals.jbchem.a125006; MORIYAMA R, 1993, J BIOL CHEM, V268, P10990; MUHLEBACH T, 1985, BIOCHEMISTRY-US, V24, P975; MULZER K, 1989, STUD BIOPHYS, V134, P17; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; PINDER JC, 1995, BLOOD, V85, P2951, DOI 10.1182/blood.V85.10.2951.bloodjournal85102951; RICE WR, 1977, BIOCHIM BIOPHYS ACTA, V468, P305, DOI 10.1016/0005-2736(77)90123-7; SALHANY JM, 1980, BIOCHEMISTRY-US, V19, P1447, DOI 10.1021/bi00548a028; SALHANY JM, 1990, J BIOL CHEM, V265, P17688; SALHANY JM, 1991, BIOCHEM BIOPH RES CO, V174, P975, DOI 10.1016/0006-291X(91)91514-D; SALHANY JM, 1992, PROG CELL RES, V2, P191; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; SCHUBERT D, 1983, FEBS LETT, V163, P81, DOI 10.1016/0014-5793(83)81168-5; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; THEVENIN BJM, 1989, J BIOL CHEM, V264, P15886; THEVENIN BJM, 1994, P NATL ACAD SCI USA, V91, P1741, DOI 10.1073/pnas.91.5.1741; TOMIDA M, 1988, BIOCHIM BIOPHYS ACTA, V943, P493, DOI 10.1016/0005-2736(88)90382-3; TSUJI A, 1988, BIOCHEMISTRY-US, V27, P7447, DOI 10.1021/bi00419a041; TURRINI F, 1993, BLOOD, V81, P3146; Vince JW, 1997, BBA-BIOMEMBRANES, V1326, P295, DOI 10.1016/S0005-2736(97)00033-3; WALDER JA, 1984, J BIOL CHEM, V259, P238; WAUGH SM, 1987, BIOCHEMISTRY-US, V26, P1777, DOI 10.1021/bi00380a041; WAUGH SM, 1986, J CLIN INVEST, V78, P1155, DOI 10.1172/JCI112696; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; YAMAGUCHI T, 1992, BIOCHEMISTRY-US, V31, P1968, DOI 10.1021/bi00122a010; YUAN J, 1992, BLOOD, V79, P3007	86	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14819	14826		10.1074/jbc.273.24.14819	http://dx.doi.org/10.1074/jbc.273.24.14819			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614083	hybrid			2022-12-25	WOS:000074160400025
J	Wagle, A; Jivraj, S; Garlock, GL; Stapleton, SR				Wagle, A; Jivraj, S; Garlock, GL; Stapleton, SR			Insulin regulation of glucose-6-phosphate dehydrogenase gene expression is rapamycin-sensitive and requires phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GLYCOGEN-SYNTHASE KINASE-3; MESSENGER-RNA LEVELS; PHOSPHOENOLPYRUVATE CARBOXYKINASE; SIGNAL-TRANSDUCTION; 3T3-L1 ADIPOCYTES; PHOSPHOINOSITIDE 3-KINASE; GLUCOSE-TRANSPORT; GLUCOKINASE GENE; RESPONSE ELEMENT	Glucose-6-phosphate dehydrogenase (G6PDH) controls the flow of carbon through the pentose phosphate pathway and also produces NADPH needed for maintenance of reduced glutathione and reductive biosynthesis. Hepatic expression of G6PDH is known to respond to several dietary and hormonal factors, but the mechanism behind regulation of this expression has not been characterized. We show that insulin similarly induces expression of endogenous hepatic G6PDH and a reporter construct containing 935 base pairs of the G6PDH promoter linked to luciferase in transient transfection assays. Using well tested and structurally distinct inhibitors of Ras farnesylation, lovastatin and B581, and a specific inhibitor of mitogen-activated protein kinase kinase activation, PD 98059, we show that the Ras/Raf/mitogen-activated protein kinase pathway is not utilized for the insulin-induced stimulation of G6PDH gene expression in primary rat hepatocytes, Similarly, using well characterized inhibitors of phosphatidylinositol 3-kinase, wortmannin and LY 294002, me show that PI 3-kinase activity is necessary for the induction of G6PDH expression by insulin. Rapamycin, an inhibitor of FRAP protein, which is involved in the activation of pp70 S6 kinase, blocks the insulin induction of G6PDH, suggesting that SG kinase is also necessary for the insulin induction of G6PDH expression.	Western Michigan Univ, Dept Chem, Kalamazoo, MI 49008 USA; Western Michigan Univ, Dept Biol Sci, Kalamazoo, MI 49008 USA; Western Michigan Univ, Ctr Res Environm Signal Transduct, Kalamazoo, MI 49008 USA	Western Michigan University; Western Michigan University; Western Michigan University	Stapleton, SR (corresponding author), Western Michigan Univ, Dept Chem, Kalamazoo, MI 49008 USA.	stapleton@wmich.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R15DK043917] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43917] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; COHEN P, 1993, BIOCHEM SOC T, V21, P555, DOI 10.1042/bst0210555; COX AD, 1994, J BIOL CHEM, V269, P19203; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DECLUE JE, 1991, CANCER RES, V51, P712; DEFEOJONES D, 1991, MOL CELL BIOL, V11, P2307, DOI 10.1128/MCB.11.4.2307; Fourney R.M., 1988, FOCUS, V10, P5; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; FRITZ RS, 1986, BIOCHEM J, V237, P637; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KLETZIEN RF, 1985, J BIOL CHEM, V260, P5621; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lefebvre V, 1996, J BIOL CHEM, V271, P22289, DOI 10.1074/jbc.271.37.22289; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MCGUIRE TF, 1994, BIOCHEM BIOPH RES CO, V204, P399, DOI 10.1006/bbrc.1994.2472; MCGUIRE TF, 1993, J BIOL CHEM, V268, P22227; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OKADA T, 1994, J BIOL CHEM, V269, P3568; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RANK KB, 1994, BIOCHIM BIOPHYS ACTA, V1212, P90; REUSCH JEB, 1995, J BIOL CHEM, V270, P2036, DOI 10.1074/jbc.270.5.2036; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SERUNIAN LA, 1991, METHOD ENZYMOL, V271, P77; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Stapleton SR, 1997, BBA-MOL CELL RES, V1355, P259, DOI 10.1016/S0167-4889(96)00140-1; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; STAPLETON SR, 1993, BIOCHIMIE, V75, P971, DOI 10.1016/0300-9084(93)90147-K; STUMPO DJ, 1984, EUR J BIOCHEM, V144, P497, DOI 10.1111/j.1432-1033.1984.tb08493.x; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; TOBE K, 1992, J BIOL CHEM, V267, P21089; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; Xu XQ, 1996, ARCH BIOCHEM BIOPHYS, V326, P233, DOI 10.1006/abbi.1996.0070; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YANG SH, 1995, BIOCHEM J, V310, P375, DOI 10.1042/bj3100375	67	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14968	14974		10.1074/jbc.273.24.14968	http://dx.doi.org/10.1074/jbc.273.24.14968			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614103	hybrid			2022-12-25	WOS:000074160400045
J	Hashemolhosseini, S; Nagamine, Y; Morley, SJ; Desrivieres, S; Mercep, L; Ferrari, S				Hashemolhosseini, S; Nagamine, Y; Morley, SJ; Desrivieres, S; Mercep, L; Ferrari, S			Rapamycin inhibition of the G(1) to S transition is mediated by effects on cyclin D1 mRNA and protein stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; INITIATION-FACTOR 4E; FIBROBLAST CELL-CYCLE; GROWTH-FACTOR-BETA; TRANSLATION INITIATION; MESSENGER-RNA; G1 PHASE; MAMMALIAN-CELLS; NUCLEAR-PROTEIN; CDK INHIBITORS	The immunosuppressant rapamycin has been shown previously to inhibit the G(1)/S transition in several cell types by prolonging the G, phase of the cell cycle. This process appears to be controlled in part, by the rapamycin-sensitive FK506-binding protein-rapamycin-associated protein-p70 S6 kinase (p70(S6k)) pathway and the cyclin-dependent kinases (Cdk). We now show that in serum-stimulated NIH 3T3 cells, rapamycin treatment delays the accumulation of cyclin D1 mRNA during progression through G,. Rapamycin also appears to affect stability of the transcript. The combined transcriptional and post-transcriptional effects of the drug ultimately result in decreased levels of cyclin D1 protein. Moreover, degradation of newly synthesized cyclin D1 protein is accelerated by rapamycin, a process prevented by inclusion of the proteasome inhibitor, N-acetyl-Leu-Leu-norleucinal. The overall effect of rapamycin on cyclin D1 leads, in turn, to impaired formation of active complexes with Cdk4, a process which triggers retargeting of the p27(Kip1) inhibitor to cyclin E/Cdk2. In view of this novel experimental evidence, we discuss a possible mechanism for the rapamycin-induced cell cycle arrest at the G(1)/S transition.	Inst Expt Canc Res, Tumor Biol Ctr, D-79011 Freiburg, Germany; Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England	Friedrich Miescher Institute for Biomedical Research; University of Sussex	Ferrari, S (corresponding author), Novartis Pharma Ltd, Dept Oncol, Klybeckstr 141, CH-4002 Basel, Switzerland.	stefferrari@hotmail.com	Hashemolhosseini, Said/N-2464-2013; Ferrari, Stefano/I-7357-2016; Desrivières, Sylvane/ABC-4336-2021; Desrivieres, Sylvane/B-7399-2011	Hashemolhosseini, Said/0000-0002-6564-5649; Ferrari, Stefano/0000-0002-6607-215X; Desrivières, Sylvane/0000-0002-9120-7060; Desrivieres, Sylvane/0000-0002-9120-7060	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; ALBERS MW, 1993, J BIOL CHEM, V268, P22825; Avni D, 1997, NUCLEIC ACIDS RES, V25, P995, DOI 10.1093/nar/25.5.995; Banholzer R, 1997, MOL CELL BIOL, V17, P3254, DOI 10.1128/MCB.17.6.3254; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DOU QP, 1993, CANCER RES, V53, P1493; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; FROST V, 1995, J BIOL CHEM, V270, P26698, DOI 10.1074/jbc.270.44.26698; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERBER B, 1994, ONCOGENE, V9, P1295; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Luo Y, 1996, MOL CELL BIOL, V16, P6744; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Meyuhas Oded, 1996, V30, P363; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORICE WG, 1993, J BIOL CHEM, V268, P3734; MORLEY SJ, 1995, J CELL SCI, V108, P1751; MORLEY SJ, 1995, BIOCHEM J, V312, P627, DOI 10.1042/bj3120627; MORLEY SJ, 1996, PROTEIN PHOSPHORYLAT, P197; MULLER H, 1994, P NATL ACAD SCI USA, V91, P1945; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; REDDY KB, 1994, J CELL BIOCHEM, V56, P418, DOI 10.1002/jcb.240560318; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; TERADA N, 1993, J BIOL CHEM, V268, P12062; TERADA N, 1995, J IMMUNOL, V155, P3418; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welcker M, 1996, ONCOGENE, V13, P419; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910	71	279	295	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14424	14429		10.1074/jbc.273.23.14424	http://dx.doi.org/10.1074/jbc.273.23.14424			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603954	hybrid			2022-12-25	WOS:000074021500056
J	Sacchi, N; Tamanini, F; Willemsen, R; Denis-Donini, S; Campiglio, S; Hoogeveen, AT				Sacchi, N; Tamanini, F; Willemsen, R; Denis-Donini, S; Campiglio, S; Hoogeveen, AT			Subcellular localization of the oncoprotein MTG8 (CDR/ETO) in neural cells	ONCOGENE			English	Article						MTG8 protein; neural cells; cellular localization	ACUTE MYELOID-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; FUSION TRANSCRIPT; AML1; GENE; IDENTIFICATION; PROTEIN; ETO; TRANSLOCATIONS; BREAKPOINTS	The t(8;21) translocation associated with acute myeloid leukemia (AML) disrupts two genes, the AML1 gene also known as the core binding factor A2 (CBFA2) on chromosome 21, and a gene on chromosome 8, hereafter referred to as MTG8, but also known as CDR and ETO, Extensive information is available on AML1, a member of the CBF family of transcription factors, containing a highly conserved domain, the runt box, of the Drosophila segmentation gene runt. This gene is essential for the hematopoietic development and is found disrupted in several leukemias, In contrast, the function of the MTG8 gene is poorly understood. The predicted protein sequence shows two unusual, putative zinc-fingers, three proline-rich regions, a PEST domain and several phosphorylation sites. In addition, we found a region encompassing aa 443-514 predicted to have a significant propensity to form coiled coil structures. MTG8 displays a high degree of similarity with nervy, a homeotic target gene of Drosophila, expressed in the nervous system. Human and mouse wild-type MTG8 are also highly expressed in brain relative to other tissues. For these reasons, we set out to investigate the expression and subcellular localization of the MTG8 protein in neural cells. Immunohistochemical experiments in a 12.5-day-old mouse embryo clearly showed that the protein was expressed in the neural cells of the developing brain and the spinal cord. In primary cultures of hippocampal neurons of 2-3 day-old mice, MTG8 was found in the nucleus, in the cytoplasm and as fine granules in the neurites, Cytoplasmic localization of the protein was observed in Purkinje cells of both human and mouse cerebellum. The molecular mass of MTG8 in total human and mouse brain was analysed by immunoblotting and determined to be between 70 and 90 kDa, Isoforms with the same molecular mass were demonstrated in synaptosomes isolated from mouse forebrain, The evidence of MTG8 in the nucleus and cytoplasm of neural cells suggests a specific mechanism regulating the subcellular localization of the protein.	Univ Milan, Sch Med, Dept Biol & Genet, Milan, Italy; Univ Milan, Sch Biol Sci, Dept Biol, Milan, Italy; Erasmus Univ, Sch Med, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; CNR, Ctr Cytopharmacol, I-20133 Milan, Italy	University of Milan; University of Milan; Erasmus University Rotterdam; Consiglio Nazionale delle Ricerche (CNR)	Sacchi, N (corresponding author), Univ Milan, Sch Med, Dept Biol & Genet, Milan, Italy.							Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; ERA T, 1995, LEUKEMIA, V9, pS26; ERA T, 1995, GENE CHROMOSOME CANC, V13, P25, DOI 10.1002/gcc.2870130105; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; Erickson PF, 1996, BLOOD, V88, P1813; FEINSTEIN PG, 1995, GENETICS, V140, P573; HARLOW E, 1988, ANTIBODIES; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; LI CY, 1987, J HISTOCHEM CYTOCHEM, V35, P1457, DOI 10.1177/35.12.2824601; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCIFORA G, 1993, BLOOD, V82, P712; NUCIFORA G, 1995, BLOOD, V86, P1; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; RAO A, 1991, J NEUROSCI, V11, P2881; Sacchi N, 1996, ONCOGENE, V12, P437; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Saunders MJ, 1996, LEUKEMIA, V10, P1139; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Tamanini F, 1997, HUM MOL GENET, V6, P1315, DOI 10.1093/hmg/6.8.1315; TIGHE JE, 1994, BLOOD, V84, P2115, DOI 10.1182/blood.V84.7.2115.bloodjournal8472115; VANDELOCHT LTF, 1994, LEUKEMIA, V8, P1780; WANG J, 1997, CANCER RES, V12, P2951; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	34	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	1998	16	20					2609	2615		10.1038/sj.onc.1201824	http://dx.doi.org/10.1038/sj.onc.1201824			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632137				2022-12-25	WOS:000073698200005
J	Huang, C; Taki, T; Adachi, M; Konishi, T; Higashiyama, M; Miyake, M				Huang, C; Taki, T; Adachi, M; Konishi, T; Higashiyama, M; Miyake, M			Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer	ONCOGENE			English	Article						p53; mutation; prognostic factor; SSCP; lung cancer	TUMOR-SUPPRESSOR GENE; MUTANT P53; CYCLE; SURVIVAL; PROTEIN; TRANSACTIVATION; OVEREXPRESSION; ACCUMULATION; ONCOPROTEIN; MODULATION	This study was performed to clarify the different effects of each mutant exon of p53 as indicators of a poor prognosis in patients with non-small cell lung cancer (NSCLC), Tumor tissues of 204 patients with NSCLC were analysed; 96 tumors were stage I, 22 stage II, and 86 stage III. DNA was extracted from frozen specimens and polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing were performed to investigate mutations of p53 from exon 5 to exon 8, Seventy-five patients with NSCLC (36.8%) had mutations in p53 which included 72 cases of missense mutations and three cases of non-missense mutations, The overall survival rate of patients with mutant p53 adenocarcinomas was strikingly worse than that of patients whose tumors had wild-type p53 (35.7% vs 53.8%; P = 0.041), but no significant difference in survival was found in the patients with NSCLC and squamous cell carcinoma, Mutations in exon 5 of p53 occurred in 33 cases (16.2%), mutation in exon 6 was detected in only one case (0.5%), mutations in exon 7 in 20 cases (9.8%), and mutations in exon 8 in 18 cases (8.8%), The overall survival rate of patients with mutations in exon 7 was worse than that of patients with wild-type p53 in NSCLCs and adenocarcinomas (42.9% vs 56.0%; P = 0.025 and 33.3% vs 53.8%; P = 0.048, respectively), whereas the overall survival of patients with mutations in exon 5 was almost the same as that of patients with wild-type p53, In addition, the overall survival rate of patients with mutations in exon 8 was strikingly worse than that of patients with wild-type p53 in NSCLCs, adenocarcinomas and squamous cell carcinomas (22.9% vs 56.0%; P < 0.001, 19.0% vs 53.8%; P = 0.004 and 33.3% vs 62.5%; P = 0.042, respectively). Multivariate analysis with the Cox regression model of patients with NSCLC, adenocarcinoma and squamous cell carcinoma indicated that mutations in exon 8 mere best correlated with the overall survival rate, followed by lymph node status (P < 0.001, P = 0.015 and P = 0.006, respectively), and mutations in exon 7 of NSCLC were also revealed to have good correlation, followed by lymph node status and mutations in exon 8 (P = 0.031), Mutation of p53 was a poor prognostic factor for adenocarcinoma as described previously, Moreover, mutations in exon 8 were more useful indicators of prognosis not only for adenocarcinoma but also for NSCLC, Worse overall survival of the patients with mutations in exon 8 of p53 was suggested to be associated with codon 273 mutations as well as mutations between codon 280 and 285 included into the H2 alpha helix corresponding to residues 278-286, These results suggested that abnormal conformation of H2 alpha helix might play an important role not only in the loss of normal function but also in the acquisition of tumorigenesis, Investigation of mutations in exon 8, especially codon 273 mutation and mutant H2 alpha helix was considered to be a clinically useful approach for determining the prognosis of patients with NSCLC.	Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Kita Ku, Osaka 530, Japan; Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Oncol 5, Kita Ku, Osaka 530, Japan; Ctr Adult Dis, Dept Surg, Osaka 537, Japan	Kitano Hospital; Kitano Hospital	Miyake, M (corresponding author), Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Kita Ku, 13-3 Kamiyama Cho, Osaka 530, Japan.							CHIBA I, 1990, ONCOGENE, V5, P1603; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; COX DR, 1972, J R STAT SOC B, V34, P187; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EBINA M, 1994, CANCER RES, V54, P2496; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Fukuyama Y, 1997, BRIT J CANCER, V75, P1125, DOI 10.1038/bjc.1997.194; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HANN BC, 1995, NAT GENET, V9, P221, DOI 10.1038/ng0395-221; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HERMANEK P, 1987, TNM CLASSIFICATION M, P75; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P1; Iwamoto KS, 1996, CANCER RES, V56, P3862; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATSURAGI K, 1995, BIOMED RES-TOKYO, V16, P273, DOI 10.2220/biomedres.16.273; Kawamura M, 1996, ONCOGENE, V12, P2361; LEE JS, 1995, J CLIN ONCOL, V13, P1893, DOI 10.1200/JCO.1995.13.8.1893; LEVINE AJ, 1992, CANCER SURV, V12, P59; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARTIN HM, 1992, INT J CANCER, V50, P859, DOI 10.1002/ijc.2910500604; MCLAREN R, 1992, BRIT J CANCER, V66, P735, DOI 10.1038/bjc.1992.348; MITSUDOMI T, 1993, JNCI-J NATL CANCER I, V85, P2018, DOI 10.1093/jnci/85.24.2018; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Park DJ, 1996, MOL CARCINOGEN, V16, P101, DOI 10.1002/(SICI)1098-2744(199606)16:2<101::AID-MC6>3.0.CO;2-L; PASSLICK B, 1995, J THORAC CARDIOV SUR, V109, P1205, DOI 10.1016/S0022-5223(95)70204-0; QUINLAN DC, 1992, CANCER RES, V52, P4828; Sambrook J., 1989, MOL CLONING LAB MANU, pE3; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; Velculescu VE, 1996, CLIN CHEM, V42, P858; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZENG ZS, 1994, J CLIN ONCOL, V12, P2043, DOI 10.1200/JCO.1994.12.10.2043	41	69	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2469	2477		10.1038/sj.onc.1201776	http://dx.doi.org/10.1038/sj.onc.1201776			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627113				2022-12-25	WOS:000073672300005
J	Hanford, MG; Rushton, BC; Gowen, LC; Farber, RA				Hanford, MG; Rushton, BC; Gowen, LC; Farber, RA			Microsatellite mutation rates in cancer cell lines deficient or proficient in mismatch repair	ONCOGENE			English	Article						microsatellite instability; mismatch repair; colorectal cancer; fluctuation analysis	NONPOLYPOSIS COLON-CANCER; COLORECTAL-CANCER; GENOMIC INSTABILITY; HOMOLOG; GENE; DNA; HYPERMUTABILITY; SEQUENCES; HMSH2	A selectable system has been used to determine mutation rates within a microsatellite sequence in human cancer cell lines with or without defects in mismatch repair. A sequence consisting of 17 repeats of poly (dC-dA).poly(dT-dG) [abbreviated as (Ca)(17)] was inserted near the 5' end of the bacterial neomycin-resistance gene in a plasmid vector, such that the reading frame of the neo gene is disrupted. This plasmid was introduced into cancer cell lines, where it became integrated into the cellular genome. Clones with insertions or deletions of CA-repeats that restored the normal reading frame of the neo gene were selected in G418, and mutation rates were determined by fluctuation analysis. The rates of reversion in LoVo cells, which are deficient for hMSH2, were about one in a thousand per generation, which is approximately two orders of magnitude higher than in the repair-proficient HT-1080 human fibrosarcoma cell line. The mutation rates in H6 cells, which are derived from the hMLH1-deficient HCT116 line, were more heterogeneous than in LoVo, but all were considerably higher than in the repair-proficient line. Nearly all of the revertants of the repair-deficient lines had deletions of a single CA-repeat from the microsatellite sequence, whereas repair-proficient cells had a broader spectrum of mutations.	Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Farber, RA (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, CB 7525, Chapel Hill, NC 27599 USA.				NCI NIH HHS [CA63264] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063264] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BRATTAIN MG, 1993, CELL, V75, P1227; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Bubb VJ, 1996, ONCOGENE, V12, P2641; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; DREWINKO B, 1976, CANCER RES, V36, P467; FARBER RA, 1994, HUM MOL GENET, V3, P253, DOI 10.1093/hmg/3.2.253; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HAUGE XY, 1993, HUM MOL GENET, V2, P411, DOI 10.1093/hmg/2.4.411; HONCHEL R, 1995, SEMIN CELL BIOL, V6, P45, DOI 10.1016/1043-4682(95)90014-4; KAHN SM, 1995, CARCINOGENESIS, V16, P1223, DOI 10.1093/carcin/16.5.1223; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOTHE RA, 1993, CANCER RES, V53, P5849; Luria SE, 1943, GENETICS, V28, P491; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Riedinger KL, 1996, ENVIRON MOL MUTAGEN, V28, P276, DOI 10.1002/(SICI)1098-2280(1996)28:3<276::AID-EM12>3.0.CO;2-C; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Sia EA, 1997, MUTAT RES-DNA REPAIR, V383, P61, DOI 10.1016/S0921-8777(96)00046-8; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; TALBOT CC, 1995, HUM MOL GENET, V4, P1193, DOI 10.1093/hmg/4.7.1193; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367	35	35	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2389	2393		10.1038/sj.onc.1201751	http://dx.doi.org/10.1038/sj.onc.1201751			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620556				2022-12-25	WOS:000073428000011
J	Bolivar, J; Guelman, S; Iglesias, C; Ortiz, M; Valdivia, MM				Bolivar, J; Guelman, S; Iglesias, C; Ortiz, M; Valdivia, MM			The fragile-X-related gene FXR1 is a human autoantigen processed during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; RNA-BINDING; CGG REPEAT; ANTIBODIES; PROTEIN; FMR1; ANTINUCLEAR; SCLEROSIS; BIOLOGY; SNURPS	We describe a new human autoimmune antigen in a patient suffering from scleroderma with high levels of antibodies to nucleolus and cytoplasmic antigens, Using a Chinese hamster ovary cell expression library, we have shown that this antigen corresponds to the auto somal Fragile-X-related gene FXR1, The deduced amino acid sequence from the hamster cDNA is 97, 98, and 58% homologous to the human, mouse, and Xenopus laevis FXR1 genes, respectively. Expression of the hamster cDNA clone in Escherichia coli and antibody production indicates unequivocally the location of the FXR1 protein in the cytoplasm of hamster cells. Affinity chromatography followed by immunofluorescence microscopy analysis and immunoblots demonstrated the presence of autoimmune IgGs to FXR1 in the scleroderma patient. Immunolabeling studies in Jurkat cells, induced to apoptosis by anti-Fas/APO1 serum, indicated that the FXR1 antigens were clearly displaced from their original cytoplasmic location to several punctuated foci, resembling the bleb-like membranous structures characteristic of cells at certain stages of apoptosis, This phenomenon could be part of a putative mechanism in which the FXR1 protein is presented as a target for the autoimmune response in humans.	Univ Cadiz, Fac Ciencias, Dept Bioquim & Biol Mol, Puerto Real 11510, Cadiz, Spain; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Area Biol Mol, RA-2000 Rosario, Argentina	Universidad de Cadiz; National University of Rosario	Valdivia, MM (corresponding author), Univ Cadiz, Fac Ciencias, Dept Bioquim & Biol Mol, Puerto Real 11510, Cadiz, Spain.	manuel.valdivia@uca.es	BOLIVAR, JORGE/G-4322-2015; Valdivia, Manuel Jesús Martínez/ABG-8867-2020	BOLIVAR, JORGE/0000-0002-2645-9528; Valdivia, Manuel Jesús Martínez/0000-0002-2888-849X; Ortiz Santesteban, Maria Manuela/0000-0001-9398-6259				ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BERNSTEIN RM, 1982, CLIN EXP IMMUNOL, V48, P43; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Conrad K, 1997, CLIN EXP RHEUMATOL, V15, P457; COY JF, 1995, HUM MOL GENET, V4, P2209, DOI 10.1093/hmg/4.12.2209; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; LERNER MR, 1981, CELL, V25, P298, DOI 10.1016/0092-8674(81)90047-7; MATTIOLI M, 1974, ARTHRITIS RHEUM-US, V17, P421, DOI 10.1002/art.1780170413; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OOSTRA BA, 1995, BIOESSAYS, V17, P941, DOI 10.1002/bies.950171107; Peng SL, 1997, NAT MED, V3, P276, DOI 10.1038/nm0397-276; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI MC, 1995, EMBO J, V14, P2401, DOI 10.1002/j.1460-2075.1995.tb07237.x; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; STEITZ JA, 1988, SCI AM, V258, P56, DOI 10.1038/scientificamerican0688-56; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TAN EM, 1982, ADV IMMUNOL, V33, P167, DOI 10.1016/S0065-2776(08)60836-6; VALDIVIA MM, 1985, J CELL BIOL, V101, P1124, DOI 10.1083/jcb.101.3.1124; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; White Barbara, 1995, Current Opinion in Rheumatology, V7, P541, DOI 10.1097/00002281-199511000-00013; WHYTE J, 1994, J AUTOIMMUN, V7, P509, DOI 10.1006/jaut.1994.1037; ZHANG Y, 1995, EMBO J, V14, P5358, DOI 10.1002/j.1460-2075.1995.tb00220.x	30	10	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17122	17127		10.1074/jbc.273.27.17122	http://dx.doi.org/10.1074/jbc.273.27.17122			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642279	hybrid			2022-12-25	WOS:000074545200069
J	Kantak, SS; Kramer, RH				Kantak, SS; Kramer, RH			E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; BETA-CATENIN; TERMINAL DIFFERENTIATION; EXTRACELLULAR-MATRIX; DNA FRAGMENTATION; APOPTOSIS; INVASION; IDENTIFICATION; EXPRESSION; CANCER	Integrin-basement membrane interactions provide essential signals that promote survival and growth of epithelial cells, whereas loss of such adhesions triggers programmed cell death. We found that HSC-3 human squamous carcinoma cells survived and grew readily as monolayers, but when they were suspended as single cells, they ceased proliferating and entered into the apoptotic death pathway, characterized by DNA fragmentation. In contrast, if the suspended carcinoma cells were permitted to form E-cadherin-mediated multicellular aggregates, they not only survived but proliferated. However, aggregated normal keratinocytes were unable to survive in suspension culture and rapidly became apoptotic, Anchorage independence and resistance to apoptosis of HSC-3 cell aggregates required high levels of extracellular Ca2+ and was inhibited with function-perturbing anti-E-cadherin antibody. Resistance to suspension-induced apoptosis in cell aggregates paralleled the up-regulation of Bcl-2 but occurred in the absence of focal adhesion kinase activation. Analysis of suspension-induced death in a set of cloned squamous epithelial cell lines with different levels of E-cadherin expression revealed that receptor-positive cell clones evaded apoptosis and proliferated in three-dimensional aggregate culture, whereas cadherin-negative clones failed to survive, Collectively, these observations indicate that cadherin-mediated intercellular adhesions generate a compensatory mechanism that promotes anchorage-independent growth and suppresses apoptosis.	Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Dent, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kramer, RH (corresponding author), Univ Calif San Francisco, Dept Stomatol, Box 0512, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011436, P50DE011912, R56DE011436] Funding Source: NIH RePORTER; NCI NIH HHS [CA 11912] Funding Source: Medline; NIDCR NIH HHS [DE 11912, DE 11436] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Allen E, 1996, J CELL BIOL, V133, P1367, DOI 10.1083/jcb.133.6.1367; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CROIX BS, 1996, NAT MED, V2, P1204; FREYER JP, 1986, CANCER RES, V46, P3504; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HINK L, 1994, TRENDS BIOCHEM SCI, V19, P538; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Jensen PJ, 1997, CELL TISSUE RES, V288, P307, DOI 10.1007/s004410050816; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KATAYAMA M, 1994, INT J ONCOL, V5, P1049; Kinch M S, 1997, Cell Adhes Commun, V4, P425, DOI 10.3109/15419069709004459; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kotelnikov VM, 1996, HEAD NECK-J SCI SPEC, V18, P522, DOI 10.1002/(SICI)1097-0347(199611/12)18:6<522::AID-HED6>3.0.CO;2-4; Kyo S, 1997, J GEN VIROL, V78, P401, DOI 10.1099/0022-1317-78-2-401; LEIGH IM, 1995, BRIT J DERMATOL, V133, P501, DOI 10.1111/j.1365-2133.1995.tb02696.x; MATSUMOTO K, 1989, J ORAL PATHOL MED, V18, P498, DOI 10.1111/j.1600-0714.1989.tb01350.x; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MATTIJSSEN V, 1993, INT J CANCER, V55, P580, DOI 10.1002/ijc.2910550411; MonierGavelle F, 1997, J CELL BIOL, V137, P1663, DOI 10.1083/jcb.137.7.1663; MORI C, 1994, ANAT EMBRYOL, V190, P21; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Peluso JJ, 1996, ENDOCRINOLOGY, V137, P1196, DOI 10.1210/en.137.4.1196; POLLACK AL, 1997, J CELL BIOL, V137, P651; Ramos DM, 1997, INT J CANCER, V72, P369, DOI 10.1002/(SICI)1097-0215(19970717)72:2<369::AID-IJC28>3.3.CO;2-7; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SAKAKI T, 1994, PATHOL INT, V44, P280; Shibata T, 1996, ONCOGENE, V13, P883; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; Trolice MP, 1997, ENDOCRINOLOGY, V138, P107, DOI 10.1210/en.138.1.107; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; Xu YR, 1997, J BIOL CHEM, V272, P13463, DOI 10.1074/jbc.272.21.13463; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Zhang K, 1996, CELL ADHES COMMUN, V4, P159, DOI 10.3109/15419069609014220; Zhu AJ, 1996, J CELL SCI, V109, P3013	53	201	208	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16953	16961		10.1074/jbc.273.27.16953	http://dx.doi.org/10.1074/jbc.273.27.16953			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642258	hybrid			2022-12-25	WOS:000074545200048
J	Foster, DC; Garbers, DL				Foster, DC; Garbers, DL			Dual role for adenine nucleotides in the regulation of the atrial natriuretic peptide receptor, guanylyl cyclase-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CYCLIC-GMP ACCUMULATION; SMOOTH-MUSCLE CELLS; MEDIATED INHIBITION; ACTIVATION; RAT; DEPHOSPHORYLATION; DESENSITIZATION; HYPERTENSION; DECREASES	The ability to both sensitize and desensitize a guanylyl cyclase receptor has not been previously accomplished in a broken cell or membrane preparation. The guanylyl cyclase-A (GC-A) receptor is known to require both atrial natriuretic peptide (ANP) and an adenine nucleotide for maximal cyclase activation. When membranes from NIH 3T3 cells stably overexpressing GC-A were incubated with ATP, AMPPNP, or ATP gamma S, only ATP gamma S dramatically potentiated ANP-dependent cyclase activity. When the membranes were incubated with ATP gamma S and then washed, GC-A now became sensitive to ANP/AMPPNP stimulation, suggestive that thiophosphorylation had sensitized GC-A to ligand and adenine nucleotide binding. Consistent with this hypothesis, the ATP gamma S effects were both time- and concentration-dependent. Protein phosphatase stability of thiophosphorylation (ATP gamma S) relative to phosphorylation (ATP) appeared to explain the differential effects of the two nucleotides since microcystin, beta-glycerol phosphate, or okadaic acid coincident with ATP or ATP gamma S effectively sensitized GC-A to ligand stimulation over prolonged periods of time in either case, GC-A was phosphorylated in the presence of [gamma(32)P]ATP, and the mag nitude of the phosphorylation was increased by the addition of microcystin. Thus, the phosphorylation of GC-A correlates with the acquisition of ligand sensitivity. The establishment of an in vitro system to sensitize GC-A demonstrates that adenine nucleotides have a daul function in the regulation of GC-A through both phosphorylation of and binding to regulatory sites.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Garbers, DL (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	garbers@utsw.smmed.edu			NIGMS NIH HHS [5-T32-GM08203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008203] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANANDSRIVASTAVA MB, 1987, J BIOL CHEM, V262, P4931; CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FULLE HJ, 1995, P NATL ACAD SCI USA, V92, P3571, DOI 10.1073/pnas.92.8.3571; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GARBERS DL, 1992, CELL, V71, P1; JAISWAL RK, 1992, BIOCHEM BIOPH RES CO, V182, P395, DOI 10.1016/S0006-291X(05)80158-5; JAISWAL RK, 1988, FEBS LETT, V227, P47, DOI 10.1016/0014-5793(88)81411-X; John SWM, 1996, AM J PHYSIOL-REG I, V271, pR109, DOI 10.1152/ajpregu.1996.271.1.R109; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; Kishimoto I, 1996, P NATL ACAD SCI USA, V93, P6215, DOI 10.1073/pnas.93.12.6215; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; Melo LG, 1998, AM J PHYSIOL-REG I, V274, pR255, DOI 10.1152/ajpregu.1998.274.1.R255; NAMBI P, 1986, P NATL ACAD SCI USA, V83, P8492, DOI 10.1073/pnas.83.22.8492; NAMBI P, 1987, BIOCHEM J, V244, P481, DOI 10.1042/bj2440481; POTTER LR, 1992, J BIOL CHEM, V267, P14531; POTTER LR, 1994, J BIOL CHEM, V269, P14636; Schulz S, 1998, J BIOL CHEM, V273, P1032, DOI 10.1074/jbc.273.2.1032; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; SMITH JB, 1987, AM J PHYSIOL, V253, pC147, DOI 10.1152/ajpcell.1987.253.1.C147; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; Wong SKF, 1995, J BIOL CHEM, V270, P30818, DOI 10.1074/jbc.270.51.30818; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384	33	52	54	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16311	16318		10.1074/jbc.273.26.16311	http://dx.doi.org/10.1074/jbc.273.26.16311			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632692	hybrid			2022-12-25	WOS:000074436600063
J	Sam, JW; Takahashi, S; Lippai, I; Peisach, J; Rousseau, DL				Sam, JW; Takahashi, S; Lippai, I; Peisach, J; Rousseau, DL			Sequence-specific changes in the metal site of ferric bleomycin induced by the binding of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSPRAY MASS-SPECTROMETRY; IRON-BLEOMYCIN; ACTIVATED BLEOMYCIN; A2 GREEN; STRUCTURAL CHARACTERIZATION; CYTOSINE RELEASE; DEGRADATION; COMPLEXES; CLEAVAGE; NMR	The binding of the iron complex of the antineoplastic glycopeptide bleomycin A(2) (Fe-BLM) to calf thymus DNA and the self-complementary oligonucleotides d(CGCGCG) and d(ATATAT) has been studied using optical, EPR, and resonance Raman spectroscopies. An increase in the intensity of the bands at 365 and 384 nm is observed in the optical spectrum of Fe(III)-BLM when the drug binds to either oligonucleotide. However, in the presence of phosphate, this increase is observed only with d(CGCGCG) and not with d(ATATAT). In addition, the g(max) feature in the EPR spectrum of low spin Fe(III)-BLM is narrowed in a way suggesting a reduction of possible conformers that the drug can achieve when it is bound to d(CGCGCG) or to calf thymus DNA but not when bound to d(ATATAT). When Fe(III)-BLM is bound to d(CGCGCG), changes in the resonance Raman spectrum of the metal drug complex suggest conformational changes in three of the ligands to iron: the beta-hydroxyhistidyl amide, the pyrimidine, and the axial hydroxide. In addition, the Fe-OH band undergoes narrowing, again consistent, with the reduction of conformers of the drug. No such resonance Raman changes are observed upon binding to d(ATATAT). The changes in the pyrimidine modes upon binding d(CGCGCG) to the drug are consistent with a recently proposed model (Wu, W., Vanderwall, D. E., Turner, C. J., Kozarich, J. W., and Stubbe, J. (1996) J. Am. Chem. Soc. 118, 1281-1294) of DNA recognition by activated bleomycin, HOO-Fe(III)-BLM, in which the pyrimidine moiety of the drug is important for the preferential cleavage of 5'-GpPy-3' sequences.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; AT&T Bell Labs, Murray Hill, NJ 07974 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; AT&T; Nokia Corporation; Nokia Bell Labs	Peisach, J (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.				NCRR NIH HHS [RR-02583] Funding Source: Medline; NIGMS NIH HHS [GM40168, GM48714] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040168, R01GM040168, R01GM048714] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTINI JP, 1984, BIOCHEMISTRY-US, V23, P47, DOI 10.1021/bi00296a008; BOGER DL, 1994, J AM CHEM SOC, V116, P5607, DOI 10.1021/ja00092a011; Boger DL, 1998, J AM CHEM SOC, V120, P53, DOI 10.1021/ja971889v; BURGER RM, 1981, J BIOL CHEM, V256, P1636; BURGER RM, 1985, BIOCHEMISTRY-US, V24, P3623, DOI 10.1021/bi00335a034; CARTER BJ, 1990, J BIOL CHEM, V265, P4193; CARTER BJ, 1990, P NATL ACAD SCI USA, V87, P9373, DOI 10.1073/pnas.87.23.9373; CHIEN M, 1977, BIOCHEMISTRY-US, V16, P3641, DOI 10.1021/bi00635a021; DABROWIAK JC, 1979, BIOCHEM BIOPH RES CO, V91, P721, DOI 10.1016/0006-291X(79)91940-5; DABROWIAK JC, 1982, ADV INORG BIOCHEM, V4, P69; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; DEDON PC, 1992, CHEM RES TOXICOL, V5, P311, DOI 10.1021/tx00027a001; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; FREEDMAN TB, 1983, J RAMAN SPECTROSC, V14, P266, DOI 10.1002/jrs.1250140411; GAMCSIK MP, 1990, J BIOMOL STRUCT DYN, V7, P1117, DOI 10.1080/07391102.1990.10508550; GUAJARDO RJ, 1993, J AM CHEM SOC, V115, P7971, DOI 10.1021/ja00071a006; HORI M, 1979, BLEOMYCIN CHEM BIOCH, P195; KANE SA, 1994, PROG NUCLEIC ACID RE, V49, P313; KUWAHARA J, 1988, P NATL ACAD SCI USA, V85, P2459, DOI 10.1073/pnas.85.8.2459; KUWAHARA J, 1988, NUCLEIC ACIDS RES, V19, P131; LOEB KE, 1995, J AM CHEM SOC, V117, P4545, DOI 10.1021/ja00121a013; MAGLIOZZO RS, 1989, MOL PHARMACOL, V35, P428; MANDERVILLE RA, 1995, J AM CHEM SOC, V117, P7891, DOI 10.1021/ja00135a007; MANDERVILLE RA, 1994, J AM CHEM SOC, V116, P10851, DOI 10.1021/ja00102a087; OWA T, 1992, TETRAHEDRON, V48, P1193, DOI 10.1016/S0040-4020(01)90783-5; PETERING DH, 1990, CHEM-BIOL INTERACT, V73, P133, DOI 10.1016/0009-2797(90)90001-4; POVIRK LF, 1981, BIOCHEMISTRY-US, V20, P665, DOI 10.1021/bi00506a034; RABOW L, 1986, J AM CHEM SOC, V108, P7130, DOI 10.1021/ja00282a063; RABOW LE, 1990, J AM CHEM SOC, V112, P3203, DOI 10.1021/ja00164a050; RAJASEKHARAN RP, 1980, BIOCHEM BIOPH RES CO, V97, P270; SAM JW, 1994, J AM CHEM SOC, V116, P5250, DOI 10.1021/ja00091a032; SAM JW, 1995, J AM CHEM SOC, V117, P1012, DOI 10.1021/ja00108a017; SAUSVILLE EA, 1978, BIOCHEMISTRY-US, V17, P2746, DOI 10.1021/bi00607a008; Stubbe J, 1996, ACCOUNTS CHEM RES, V29, P322, DOI 10.1021/ar9501333; SUGIURA Y, 1980, J AM CHEM SOC, V102, P5208, DOI 10.1021/ja00536a015; SUZUKI H, 1969, J ANTIBIOT, V22, P446, DOI 10.7164/antibiotics.22.446; TAKAHASHI S, 1994, J AM CHEM SOC, V116, P4408, DOI 10.1021/ja00089a032; TAKESHITA M, 1978, P NATL ACAD SCI USA, V75, P5983, DOI 10.1073/pnas.75.12.5983; TAKITA T, 1978, J ANTIBIOT, V31, P1073, DOI 10.7164/antibiotics.31.1073; THOMAS GA, 1984, BIOCHEMISTRY-US, V23, P3202, DOI 10.1021/bi00309a014; WU JC, 1985, BIOCHEMISTRY-US, V24, P7562, DOI 10.1021/bi00347a009; WU JC, 1983, J BIOL CHEM, V256, P8608; Wu W, 1996, J AM CHEM SOC, V118, P1268, DOI 10.1021/ja9524964; Wu W, 1996, J AM CHEM SOC, V118, P1281, DOI 10.1021/ja952497w; WU W, 1994, J AM CHEM SOC, V116, P10843, DOI 10.1021/ja00102a083	45	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16090	16097		10.1074/jbc.273.26.16090	http://dx.doi.org/10.1074/jbc.273.26.16090			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632661	hybrid			2022-12-25	WOS:000074436600032
J	Santagata, S; Aidinis, V; Spanopoulou, E				Santagata, S; Aidinis, V; Spanopoulou, E			The effect of Me2+ cofactors at the initial stages of V(D)J recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORV RESTRICTION-ENDONUCLEASE; DIVALENT METAL-IONS; DNA-RECOGNITION; RETROVIRAL INTEGRATION; STRUCTURE REQUIREMENTS; RAG-1-DEFICIENT MICE; RAG2 PROTEINS; 2 STEPS; SEQUENCE; CLEAVAGE	V(D)J site-specific recombination mediates the somatic assembly of the antigen receptor gene segments. This process is initiated by the recombination activating proteins RAG1 and RAG2, which recognize the recombination signal sequences (RSS) and cleave the DNA at the coding/RSS junction, In this study, we show that RAG1 and RAG2 have the ability to directly interact in solution before binding to the DNA. RAG1 forms a homodimer, which leads to the appearance of two distinct RAG1.RAG2 complexes bound to DNA. To investigate the properties of the two RAG1.RAG2 complexes in the presence of different Me2+ cofactors, we established an in vitro Mg2+-based cleavage reaction on a single RSS. Using this system, we found that Mg2+ confers a specific pattern of DNA binding and cleavage. In contrast, Mn2+ allows aberrant binding of RAG1.RAG2 to single-stranded RSS and permits cleavage independent of binding to the nonamer. To determine the contribution of Me2+ ions at the early stages of V(D)J recombination, we analyzed specific DNA recognition and cleavage by RAG1 RAG2 on phosphorothioated substrates. These experiments revealed that Me2+ ions directly coordinate the binding of RAG1.RAG2 to the RSS DNA.	CUNY Mt Sinai Sch Med, Howard Hughes Med Inst, Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Howard Hughes Medical Institute; Icahn School of Medicine at Mount Sinai	Spanopoulou, E (corresponding author), CUNY Mt Sinai Sch Med, Howard Hughes Med Inst, Ruttenberg Canc Ctr, 1425 Madison Ave, New York, NY 10029 USA.		Santagata, Sandro/A-7714-2009; Aidinis, Vassilis/AAF-5380-2021	Aidinis, Vassilis/0000-0001-9531-7729; Santagata, Sandro/0000-0002-7528-9668	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007280] Funding Source: NIH RePORTER; NIAID NIH HHS [1R01 AI40191-01A1] Funding Source: Medline; NIGMS NIH HHS [T32-GM07280-21] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; AKAMATSU Y, 1994, J IMMUNOL, V153, P4520; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Cuomo CA, 1996, MOL CELL BIOL, V16, P5683; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ENGELMAN A, 1995, J VIROL, V69, P5908, DOI 10.1128/JVI.69.9.5908-5911.1995; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; HSU MT, 1978, BIOCHEMISTRY-US, V17, P131, DOI 10.1021/bi00594a019; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JELTSCH A, 1995, BIOCHEMISTRY-US, V34, P6239, DOI 10.1021/bi00018a028; Junop MS, 1997, EMBO J, V16, P2646, DOI 10.1093/emboj/16.10.2646; Junop MS, 1996, EMBO J, V15, P2547, DOI 10.1002/j.1460-2075.1996.tb00612.x; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; Kirch SA, 1996, EUR J IMMUNOL, V26, P886, DOI 10.1002/eji.1830260425; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nagawa F, 1998, MOL CELL BIOL, V18, P655, DOI 10.1128/MCB.18.1.655; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; QUYANG H, 1997, J EXP MED, V186, P921; RAMSDEN DA, 1994, NUCLEIC ACIDS RES, V22, P1785, DOI 10.1093/nar/22.10.1785; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; Sawchuk DJ, 1997, J EXP MED, V185, P2025, DOI 10.1084/jem.185.11.2025; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; Steen SB, 1997, EMBO J, V16, P2656, DOI 10.1093/emboj/16.10.2656; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	60	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16325	16331		10.1074/jbc.273.26.16325	http://dx.doi.org/10.1074/jbc.273.26.16325			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632694	hybrid			2022-12-25	WOS:000074436600065
J	Sun, WL; Godson, GN				Sun, WL; Godson, GN			Synthesis of polyribonucleotide chains from the 3 '-hydroxyl terminus of oligodeoxynucleotides by Escherichia coli primase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST DNA PRIMASE; RNA-POLYMERASE; NUCLEOTIDE-SEQUENCES; STRAND SYNTHESIS; DROSOPHILA-MELANOGASTER; MUTATIONAL ANALYSIS; RIBONUCLEIC-ACID; PRIMER SYNTHESIS; PHAGE-G4 ORIGIN; REPLICATION	Escherichia coli primase synthesizes RNA primers on DNA templates for the initiation of DNA replication. The sole known activity of primase is to catalyze synthesis of short RNA chains de novo. We now report a novel activity of primase, namely that it can synthesize RNA from the 3'-hydroxyl terminus of a pre-existing oligodeoxynucleotide. The oligonucleotide-primed synthesis of RNA by primase occurs in both of the G4oric-specific priming system and the dnaB protein associated general priming system. This priming reaction of primase is verified by a number of biochemical methods, including inhibition by modified 3'-phosphate of oligonucleotides and deoxyribonuclease I and ribonuclease H cleavages. We also show that the primed RNA is an effective primer for the synthesis of DNA chain by E. coli DNA polymerase III holoenzyme. The significance of this finding to primases generating multimeric length RNA is discussed.	NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA	New York University	Godson, GN (corresponding author), NYU, Med Ctr, Dept Biochem, 550 1st Ave, New York, NY 10016 USA.				NIGMS NIH HHS [GM32898] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; BADARACCO G, 1985, EMBO J, V4, P1313, DOI 10.1002/j.1460-2075.1985.tb03778.x; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; BOUCHE JP, 1978, J BIOL CHEM, V253, P765; BROOKS M, 1989, J BIOL CHEM, V264, P3602; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P4585, DOI 10.1073/pnas.79.15.4585; COTTERILL S, 1987, J BIOL CHEM, V262, P16105; DOWNEY KM, 1971, BIOCHEMISTRY-US, V10, P4970, DOI 10.1021/bi00802a021; FIDDES JC, 1978, P NATL ACAD SCI USA, V75, P1081, DOI 10.1073/pnas.75.3.1081; GODSON GN, 1991, GENE, V100, P59, DOI 10.1016/0378-1119(91)90350-K; GRACHEV MA, 1984, NUCLEIC ACIDS RES, V12, P8509, DOI 10.1093/nar/12.22.8509; HIASA H, 1989, GENE, V84, P9, DOI 10.1016/0378-1119(89)90133-9; HIASA H, 1990, NUCLEIC ACIDS RES, V18, P4825, DOI 10.1093/nar/18.16.4825; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KORNBERG A, 1992, DNA REPLICATION, P279; LAMBERT PF, 1986, J VIROL, V58, P450, DOI 10.1128/JVI.58.2.450-458.1986; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEWIS MK, 1980, J BIOL CHEM, V255, P4928; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; Moore DD, 1995, GLOB MOB SURV; MOORE S, 1981, ENZYMES A, V14, P281; NATH K, 1974, J BIOL CHEM, V249, P2605; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; NOMURA N, 1982, P NATL ACAD SCI USA, V79, P2853; ROWEN L, 1978, J BIOL CHEM, V253, P758; ROWEN L, 1978, J BIOL CHEM, V253, P770; RUETSCH N, 1987, J BIOL CHEM, V262, P1674; SAKAI H, 1985, BIOCHIM BIOPHYS ACTA, V826, P30, DOI 10.1016/S0167-4781(85)80005-1; SALUJA D, 1995, J BACTERIOL, V177, P1104, DOI 10.1128/jb.177.4.1104-1111.1995; Sambrook J., 2002, MOL CLONING LAB MANU; SIMS J, 1978, P NATL ACAD SCI USA, V75, P3094, DOI 10.1073/pnas.75.7.3094; SINGH H, 1984, J BIOL CHEM, V259, P7936; SINGH H, 1986, J BIOL CHEM, V261, P8564; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sun WL, 1998, J MOL BIOL, V276, P689, DOI 10.1006/jmbi.1997.1471; SUN WL, 1994, P NATL ACAD SCI USA, V91, P11462, DOI 10.1073/pnas.91.24.11462; SUN WL, 1993, J BIOL CHEM, V268, P8026; TSENG BY, 1983, J BIOL CHEM, V258, P9845; WICKNER S, 1977, P NATL ACAD SCI USA, V74, P2815, DOI 10.1073/pnas.74.7.2815; WICKNER S, 1972, BIOCHEM BIOPH RES CO, V48, P619, DOI 10.1016/0006-291X(72)90393-2; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P6176, DOI 10.1073/pnas.79.20.6176; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YODA K, 1991, MOL GEN GENET, V227, P1, DOI 10.1007/BF00260698; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	49	3	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16358	16365		10.1074/jbc.273.26.16358	http://dx.doi.org/10.1074/jbc.273.26.16358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632699	hybrid			2022-12-25	WOS:000074436600070
J	Zardo, G; Caiafa, P				Zardo, G; Caiafa, P			The unmethylated state of CpG islands in mouse fibroblasts depends on the poly(ADP-ribosyl)ation process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; DE-NOVO METHYLATION; CHROMATIN STRUCTURE; DENOVO METHYLATION; STRANDED-DNA; RICH ISLANDS; GENE; PROMOTER; TRANSCRIPTION; SITE	In vivo and in vitro experiments carried out on L929 mouse fibroblasts suggested that the poly(ADP-ribosyl) ation process acts somehow as a protecting agent against full methylation of CpG dinucleotides in genomic DNA. Since CpG islands, which are found almost exclusively at the 5'-end of housekeeping genes, are rich in CpG dinucleotides, which are the target of mammalian DNA methyltransferase, we examined the possibility that the poly(ADP-ribosyl)ation reaction is involved in maintaining the unmethylated state of these DNA sequences. Experiments were conducted by two different strategies, using either methylation-dependent restriction enzymes on purified genomic DNA or a sequence-dependent restriction enzyme on an aliquot of the same DNA, previously modified by a bisulfite reaction. With the methylation-dependent restriction enzymes, it was observed that the "HpaII tiny fragments" greatly decreased when the cells were preincubated with 3-aminobenzamide, a well known inhibitor of poly(ADP-ribose) polymerase, The other experimental approach allowed us to prove that, as a consequence of the inhibition of the poly(ADP-ribosyl)ation process, an anomalous methylation pattern could be evidenced in the CpG island of the promoter fragment of the Htf9 gene, amplified from DNA obtained from fibroblasts preincubated with 3-aminobenzamide. These data confirm the hypothesis that, at least for the Htf9 promoter region, an active poly(ADP-ribosyl)ation protects the unmethylated state of the CpG island.	Univ Aquila, Dipartimento Sci & Tecnol Biomed, I-67100 Laquila, Italy; CNR, Ctr Biol Mol, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of L'Aquila; Consiglio Nazionale delle Ricerche (CNR)	Caiafa, P (corresponding author), Univ Aquila, Dipartimento Sci & Tecnol Biomed, Via Vetoio,Loc Coppito, I-67100 Laquila, Italy.							ASIEDU CK, 1994, BBA-GENE STRUCT EXPR, V1219, P55, DOI 10.1016/0167-4781(94)90246-1; BELIKOV SV, 1993, NUCLEIC ACIDS RES, V21, P1031, DOI 10.1093/nar/21.4.1031; BESTOR TH, 1992, GENET ANAL-BIOMOL E, V9, P48, DOI 10.1016/1050-3862(92)90030-9; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; BRUHAT A, 1995, P NATL ACAD SCI USA, V92, P3678, DOI 10.1073/pnas.92.9.3678; CAROTTI D, 1989, NUCLEIC ACIDS RES, V17, P9219, DOI 10.1093/nar/17.22.9219; CHRISTMAN JK, 1995, P NATL ACAD SCI USA, V92, P7347, DOI 10.1073/pnas.92.16.7347; DAVIS T, 1986, BIOCHIM BIOPHYS ACTA, V866, P233, DOI 10.1016/0167-4781(86)90048-5; DErme M, 1996, BIOCHEM J, V316, P475, DOI 10.1042/bj3160475; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; HASSE A, 1994, J BIOL CHEM, V269, P1821; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HUANG LH, 1984, NATURE, V308, P293, DOI 10.1038/308293a0; JACOBSON MK, 1989, ADP RIBOSE TRANSFER; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; Kaludov NK, 1997, J BIOL CHEM, V272, P15120, DOI 10.1074/jbc.272.24.15120; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KHAN R, 1988, J BIOL CHEM, V263, P14374; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; NAEGELI H, 1991, J BIOL CHEM, V266, P10596; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; PANZETER PL, 1992, BIOCHEMISTRY-US, V31, P1379, DOI 10.1021/bi00120a014; PAWLAK A, 1991, NUCLEIC ACIDS RES, V19, P1029; SANTORO R, 1993, BIOCHEM BIOPH RES CO, V190, P86, DOI 10.1006/bbrc.1993.1014; SANTORO R, 1995, BIOCHEM J, V305, P739, DOI 10.1042/bj3050739; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; SZYF M, 1991, BIOCHEM CELL BIOL, V69, P764, DOI 10.1139/o91-117; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; Tollefsbol TO, 1997, J MOL BIOL, V269, P494, DOI 10.1006/jmbi.1997.1064; VANHOLDE K, 1988, CHROMATIN, P357; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; YISRAELI J, 1984, GENE METHYLATION 16, P353; Zardo G, 1997, BIOCHEMISTRY-US, V36, P7937, DOI 10.1021/bi970241s; Zardo G, 1996, BIOCHEM BIOPH RES CO, V220, P102, DOI 10.1006/bbrc.1996.0364; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810; ZHANG XY, 1995, NUCLEIC ACIDS RES, V23, P3026, DOI 10.1093/nar/23.15.3026; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387; ZLATANOVA J, 1992, J CELL SCI, V103, P889; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E	55	49	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16517	16520		10.1074/jbc.273.26.16517	http://dx.doi.org/10.1074/jbc.273.26.16517			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632720	hybrid			2022-12-25	WOS:000074436600091
J	Adelmant, G; Gilbert, JD; Freytag, SO				Adelmant, G; Gilbert, JD; Freytag, SO			Human translocation liposarcoma CCAAT enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBP beta function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 PREADIPOCYTES; TRANSCRIPTION FACTOR; MYXOID LIPOSARCOMA; GENE-EXPRESSION; NUCLEAR-PROTEIN; PPAR-GAMMA; ADIPOGENESIS; ALPHA; RNA; FUSION	Human translocation liposarcoma (TLS)-CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP) is a fusion oncoprotein found specifically in a malignant tumor of adipose tissue and results from a t(12;16) translocation that fuses the amino-terminal part of TLS to the entire coding region of CHOP. Being that CHOP is a member of the C/EBP transcription factor family, proteins that comprise part of the adipocyte differentiation machinery, we examined whether TLS-CHOP blocked adipocyte differentiation by directly interfering with C/EBP function, Using a single-step retroviral infection protocol, either wild-type or mutant TLS-CHOP were co-expressed along with C/EBP beta in naive NIH3T3 cells, and their ability to inhibit C/EBP beta driven adipogenesis was determined, TLS-CHOP was extremely effective at blocking adipocyte differentiation when expressed at a level comparable to that observed in human myxoid liposarcoma. This effect of TLS-CHOP required a functional leucine zipper domain and correlated with its ability to heterodimerize with C/EBP beta and inhibit C/EBP beta DNA binding and transactivation activity in situ. In contrast, the TLS-CHOP basic region was dispensable, making it unlikely that the inhibitory effect of TLS-CHOP is attributable to unscheduled gene expression resulting from TLS-CHOP's putative transactivation activity. Another adipogenic transcription factor, PPAR gamma 2, was able to rescue TLS-CHOP-inhibited cells, indicating that TLS-CHOP interferes primarily with C/EBP beta-driven adipogenesis and not with other requisite events of the adipocyte differentiation program. Together, the results demonstrate that TLS-CHOP blocks adipocyte differentiation by directly preventing C/EBP beta from binding to and transactivating its target genes. Moreover, they provide strong support for the thesis that a blockade to normal differentiation is an important aspect of the cancer process.	Henry Ford Hlth Syst, Dept Biol Mol, Detroit, MI 48202 USA; Henry Ford Hlth Syst, Dept Radiat Oncol, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital	Freytag, SO (corresponding author), Henry Ford Hlth Syst, Dept Biol Mol, 1 Ford Pl,Wing 5D, Detroit, MI 48202 USA.				NCI NIH HHS [CA62295] Funding Source: Medline; NATIONAL CANCER INSTITUTE [S15CA062295] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V14, P1654; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Panagopoulos I, 1996, ONCOGENE, V12, P489; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	32	61	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15574	15581		10.1074/jbc.273.25.15574	http://dx.doi.org/10.1074/jbc.273.25.15574			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624148	hybrid			2022-12-25	WOS:000074284200042
J	Prockop, DJ; Fertala, A				Prockop, DJ; Fertala, A			Inhibition of the self-assembly of collagen I into fibrils with synthetic peptides - Demonstration that assembly is driven by specific binding sites on the monomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; POINTED TIPS; GROWING TIPS; PC-COLLAGEN; INVITRO; FIBRILLOGENESIS; PROCOLLAGEN; CLEAVAGE; PACKING; MODEL	A series of experiments mere carried out to test the hypothesis that the self-assembly of collagen I monomers into fibrils depends on the interactions of specific binding sites in different regions of the monomer. Six synthetic peptides were prepared with sequences found either in the collagen triple helix or in the N- or C-telopeptides of collagen I. The four peptides with sequences found in the telopeptides were found to inhibit self-assembly of collagen I in a purified in vitro system. At concentrations of 2.5 mM, peptides with sequences in the C-telopeptides of the alpha 1(I) and alpha 2(I) chain inhibited assembly at about 95%. The addition of the peptide with the alpha 2-telopeptide sequence was effective in inhibiting assembly if added during the lag phase and early propagation phase but mot later in the assembly process. Experiments with biotinylated peptides indicated that both the N- and C-telopeptides bound to a region between amino acid 776 and 822 of the ol(I) chain. A fragment of nine amino acids with sequences in the alpha 2-telopeptide was effective in inhibiting fibril assembly. Mutating two aspartates in the 9-mer peptide to serine had no effect on inhibition of fibril assembly, but mutating two tyrosine residues and one phenylalanine residue abolished the inhibitory action. Molecular modeling of the binding sites demonstrated favorable hydrophobic and electrostatic interactions between the alpha 2-telopeptide and residues 781-794 of the alpha(I) chain.	Allegheny Univ Hlth Sci, Ctr Gene Therapy, Philadelphia, PA 19102 USA	Drexel University	Fertala, A (corresponding author), Allegheny Univ Hlth Sci, Ctr Gene Therapy, 245 N 15 St,MS 421, Philadelphia, PA 19102 USA.	fertala@auhs.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39740] Funding Source: Medline; PHS HHS [R043366] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bhatnagar RS, 1997, J BIOMOL STRUCT DYN, V14, P547, DOI 10.1080/07391102.1997.10508155; BIRK DE, 1989, P NATL ACAD SCI USA, V86, P4549, DOI 10.1073/pnas.86.12.4549; BRODSKY B, 1982, METHOD ENZYMOL, V82, P127; BROWN RA, 1977, BIOCHEM BIOPH RES CO, V74, P1102, DOI 10.1016/0006-291X(77)91632-1; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P1367, DOI 10.1002/bip.360280803; CHEN JM, 1995, J BIOMOL STRUCT DYN, V12, P1129, DOI 10.1080/07391102.1995.10508804; Fertala A, 1996, J BIOL CHEM, V271, P14864, DOI 10.1074/jbc.271.25.14864; FUJISAWA R, 1995, CALCIFIED TISSUE INT, V56, P140, DOI 10.1007/BF00296346; Galloway J., 1985, BIOL INVERTEBRATE LO, P73; GELMAN RA, 1980, J BIOL CHEM, V255, P8098; HELSETH DL, 1979, BIOPOLYMERS, V18, P3005, DOI 10.1002/bip.1979.360181208; HELSETH DL, 1981, J BIOL CHEM, V256, P7118; HOLMES DF, 1993, J BIOL CHEM, V268, P15758; HOLMES DF, 1979, BIOCHEM BIOPH RES CO, V87, P993, DOI 10.1016/S0006-291X(79)80005-4; HOLMES DF, 1992, P NATL ACAD SCI USA, V89, P9855, DOI 10.1073/pnas.89.20.9855; HULMES DJS, 1985, J MOL BIOL, V184, P473, DOI 10.1016/0022-2836(85)90295-5; HULMES DJS, 1981, P NATL ACAD SCI-BIOL, V78, P3567, DOI 10.1073/pnas.78.6.3567; HULMES DJS, 1979, NATURE, V282, P878, DOI 10.1038/282878a0; HULMES DJS, 1995, BIOPHYS J, V68, P1661, DOI 10.1016/S0006-3495(95)80391-7; JONES EY, 1991, J MOL BIOL, V218, P209, DOI 10.1016/0022-2836(91)90885-A; KADLER KE, 1990, ANN NY ACAD SCI, V580, P214, DOI 10.1111/j.1749-6632.1990.tb17930.x; Kadler KE, 1996, BIOCHEM J, V316, P1; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KADLER KE, 1990, BIOCHEM J, V268, P339, DOI 10.1042/bj2680339; MIYAHARA M, 1982, J BIOL CHEM, V257, P8442; MOULD AP, 1982, J MOL BIOL, V195, P543; NAGAN N, 1994, J BIOL CHEM, V269, P22366; PARKINSON J, 1994, PHYS REV E, V50, P2963, DOI 10.1103/PhysRevE.50.2963; PIEZ KA, 1981, BIOSCIENCE REP, V1, P801, DOI 10.1007/BF01114803; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; POTSCHKA M, 1988, BIOCHEMISTRY-US, V27, P8481, DOI 10.1021/bi00422a028; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; SILVER D, 1992, P NATL ACAD SCI USA, V89, P9860, DOI 10.1073/pnas.89.20.9860; SMITH JW, 1968, NATURE, V219, P157, DOI 10.1038/219157a0; VEIS A, 1988, COLLAGEN BIOCH, P113; VITAGLIANO L, 1995, J MOL BIOL, V247, P69, DOI 10.1006/jmbi.1994.0123; WARD NP, 1986, J MOL BIOL, V190, P107, DOI 10.1016/0022-2836(86)90079-3; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WOODHEADGALLOWA.J, 1984, CONNECTIVE TISSUE MA, P133	39	106	108	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15598	15604		10.1074/jbc.273.25.15598	http://dx.doi.org/10.1074/jbc.273.25.15598			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624151	hybrid			2022-12-25	WOS:000074284200045
J	Ross, SL; Martin, F; Simonet, L; Jacobsen, F; Deshpande, R; Vassar, R; Bennett, B; Luo, Y; Wooden, S; Hu, S; Citron, M; Burgess, TL				Ross, SL; Martin, F; Simonet, L; Jacobsen, F; Deshpande, R; Vassar, R; Bennett, B; Luo, Y; Wooden, S; Hu, S; Citron, M; Burgess, TL			Amyloid precursor protein processing in sterol regulatory element-binding protein site 2 protease-deficient Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; BETA-PROTEIN; RECEPTOR; GENE; EXPRESSION; CLEAVAGE; CLONING; LINES	Amyloid peptides of 39-43 amino acids (A beta) are the major constituents of amyloid plaques present in the brains of Alzheimer's (AD) patients. Proteolytic processing of the amyloid precursor protein (APP) by the yet unidentified beta- and gamma-secretases leads to the generation of the amyloidogenic A beta peptides. Recent data suggest that all of the known mutations leading to early onset familial AD alter the processing of APP such that increased amounts of the 42-amino acid form of A beta are generated by a gamma-secretase activity. Identification of the beta- and/or gamma-secretases is a major goal of current AD research, as they are prime targets for therapeutic intervention in AD. It has been suggested that the sterol regulatory element-binding protein site 2 protease (S2P) may be identical to the long sought gamma-secretase. We have directly tested this hypothesis using over-expression of the S2P cDNA in cells expressing APP and by characterizing APP processing in mutant Chinese hamster ovary cells that are deficient in S2P activity and expression. The data demonstrate that S2P does not play an essential role in the generation or secretion of A beta peptides from cells, thus it is unlikely to be a gamma-secretase.	Amgen Inc, Dept Mammalian Cell Mol Biol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Neurosci, Thousand Oaks, CA 91320 USA	Amgen; Amgen	Burgess, TL (corresponding author), Amgen Inc, Dept Mammalian Cell Mol Biol, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.	tburgess@amgen.com						ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chang TY, 1997, CURR OPIN LIPIDOL, V8, P65, DOI 10.1097/00041433-199704000-00003; CHIN J, 1981, J BIOL CHEM, V256, P6304; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; EVIN G, 1994, AMYLOID, V1, P263, DOI 10.3109/13506129409146118; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Klafki HW, 1996, ANAL BIOCHEM, V237, P24, DOI 10.1006/abio.1996.0195; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LINENBERGER ML, 1995, EXP HEMATOL, V23, P1104; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332	32	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15309	15312		10.1074/jbc.273.25.15309	http://dx.doi.org/10.1074/jbc.273.25.15309			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624107	hybrid			2022-12-25	WOS:000074284200001
J	Zhou, G; Kuo, MT				Zhou, G; Kuo, MT			Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN GENES; MULTIDRUG-RESISTANCE; HEPATOCELLULAR CARCINOMAS; REGULATORY ELEMENTS; MURINE FIBROBLASTS; MAMMALIAN-CELLS; GROWTH ARREST; P53 MUTATIONS; LIVER; PROMOTER	The expression of P-glycoproteins encoded by the mdr gene family is associated with the emergence of the multidrug resistance phenotype in animal cells. mdr expression can be induced by many extracellular stimulants including cytotoxic drugs and chemical carcinogens. However, little is known about the mechanisms involved. Here, we report that the expression of the rat mdr1b can be induced by anticancer drug daunorubicin. Further analysis identified a bona fide p53-binding site spanning from base pairs - 199 to - 180 (5'-GAACATGTAGAGACATGTCT-3') in the rat mdr1b promoter that is essential for basal and daunorubicin-inducible promoter activities. In addition, our results show that wildtype p53 can up-regulate not only the promoter function but also endogenous expression of the rat mdr1b.. To the best of our knowledge, this is the first report showing that a specific p53-binding site is involved in the transcriptional regulation of mdr gene by wild-type p53. Since p53 is a sensor for a wide variety of genotoxic stresses, our finding has broad implications for understanding the mechanisms involved in the inducible expression of mdr gene by anticancer drugs, chemical carcinogens, UV light, and other DNA-damaging agents.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kuo, MT (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.	t_kuo@path.mdacc.tmc.edu			NCI NIH HHS [CA72404, CA56846, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA056846, R01CA072404] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; BRADLEY G, 1992, CANCER RES, V52, P5154; BURT RK, 1988, J NATL CANCER I, V80, P1383, DOI 10.1093/jnci/80.17.1383; CARR BI, 1987, CANCER RES, V47, P5577; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; DIGMAN JD, 1983, NUCLEIC ACIDS RES, V11, P1475; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; Fardel O, 1997, EUR J BIOCHEM, V246, P186, DOI 10.1111/j.1432-1033.1997.t01-1-00186.x; GANT TW, 1991, MOL CARCINOGEN, V4, P499, DOI 10.1002/mc.2940040614; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GOLDSMITH ME, 1995, J BIOL CHEM, V270, P1894, DOI 10.1074/jbc.270.4.1894; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HO YS, 1995, MOL CARCINOGEN, V13, P182, DOI 10.1002/mc.2940130308; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE CH, 1995, CELL GROWTH DIFFER, V6, P347; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; NGUYEN KT, 1994, ONCOL RES, V6, P71; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; RENZING J, 1995, ONCOGENE, V10, P1865; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; Schrenk D, 1996, BIOCHEM PHARMACOL, V52, P1453, DOI 10.1016/S0006-2952(96)00512-6; SCOTTO KW, 1986, SCIENCE, V232, P751, DOI 10.1126/science.2421411; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SILVERMAN JA, 1995, MOL CARCINOGEN, V13, P50, DOI 10.1002/mc.2940130109; SONG RD, 1995, J BIOL CHEM, V270, P25468, DOI 10.1074/jbc.270.43.25468; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; TEETER LD, 1991, MOL CARCINOGEN, V4, P358, DOI 10.1002/mc.2940040506; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TOKUSASHI Y, 1994, MOL CARCINOGEN, V10, P45, DOI 10.1002/mc.2940100108; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; vanGijssel HE, 1997, CARCINOGENESIS, V18, P1027, DOI 10.1093/carcin/18.5.1027; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174; Zhou G, 1996, CELL GROWTH DIFFER, V7, P1369	66	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15387	15394		10.1074/jbc.273.25.15387	http://dx.doi.org/10.1074/jbc.273.25.15387			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624121	hybrid			2022-12-25	WOS:000074284200015
J	Cho, HS; Ha, NC; Kang, LW; Chung, KM; Back, SH; Jang, SK; Oh, BH				Cho, HS; Ha, NC; Kang, LW; Chung, KM; Back, SH; Jang, SK; Oh, BH			Crystal structure of RNA helicase from genotype 1b hepatitis C virus - A feasible mechanism of unwinding duplex RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI REP HELICASE; NONSTRUCTURAL PROTEIN-3; NS3 PROTEIN; DNA; BINDING; ENZYME; REPLICATION; SEPARATION; CLEAVAGE; ENCODES	Crystal structure of RNA helicase domain from genotype 1b hepatitis C virus has been determined at 2.3 Angstrom resolution by the multiple isomorphous replacement method. The structure consists of three domains that form a Y-shaped molecule. One is a NTPase domain containing two highly conserved NTP binding motifs. Another is an RNA binding domain containing a conserved RNA binding motif. The third is a helical domain that contains no beta-strand. The RNA binding domain of the molecule is distinctively separated from the other two domains forming an interdomain cleft into which single stranded RNA can be modeled. A channel is found between a pair of symmetry-related molecules which exhibit the most extensive crystal packing interactions. A stretch of single stranded RNA can be modeled with electrostatic complementarity into the interdomain cleft and continuously through the channel. These observations suggest that some form of this dimer is likely to be the functional form that unwinds double stranded RNA processively by passing one strand of RNA through the channel and passing the other strand outside of the dimer. A "descending molecular see-saw" model is proposed that is consistent with directionality of unwinding and other physicochemical properties of RNA helicases.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Sch Environm Engn, Pohang 790784, Kyungbuk, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Oh, BH (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea.	bhoh@vision.postech.ac.kr	Oh, Byung-Ha/C-2061-2011					ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; ECKART MR, 1993, BIOCHEM BIOPH RES CO, V192, P399, DOI 10.1006/bbrc.1993.1429; Egelman EH, 1996, STRUCTURE, V4, P759, DOI 10.1016/S0969-2126(96)00081-0; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; Gross CH, 1996, J VIROL, V70, P1706, DOI 10.1128/JVI.70.3.1706-1713.1996; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Gwack Y, 1996, BIOCHEM BIOPH RES CO, V225, P654, DOI 10.1006/bbrc.1996.1225; HAHM B, 1995, J VIROL, V69, P2534, DOI 10.1128/JVI.69.4.2534-2539.1995; Heilek GM, 1997, J VIROL, V71, P6264, DOI 10.1128/JVI.71.8.6264-6266.1997; JONES TA, 1993, O VERSION 6 0; Kang LW, 1998, ACTA CRYSTALLOGR D, V54, P121, DOI 10.1107/S0907444997008883; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE CG, 1992, J BIOL CHEM, V267, P4398; LEONARD GA, 1994, STRUCTURE, V2, P483, DOI 10.1016/S0969-2126(00)00049-6; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; OTWINOWSKI Z, 1993, P CCP 4 STUD WEEK; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; RAY BK, 1985, J BIOL CHEM, V260, P7651; RICE CM, 1986, TOGAVIRIDAE FLAVIVIR; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARRENER P, 1995, J VIROL, V69, P1720, DOI 10.1128/JVI.69.3.1720-1726.1995; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	42	166	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15045	15052		10.1074/jbc.273.24.15045	http://dx.doi.org/10.1074/jbc.273.24.15045			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614113	hybrid			2022-12-25	WOS:000074160400055
J	Kojima, Y; Heeb, MJ; Gale, AJ; Hackeng, TM; Griffin, JH				Kojima, Y; Heeb, MJ; Gale, AJ; Hackeng, TM; Griffin, JH			Binding site for blood coagulation factor Xa involving residues 311-325 in factor Va	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; PEPTIDE-BOND CLEAVAGES; PROTHROMBINASE COMPLEX; FACTOR-VIII; STRUCTURAL MODEL; FACTOR VA(R506Q); COMPLETE CDNA; MASS ANALYSIS; INACTIVATION; SEQUENCE	Factor Va inactivation by activated protein C is associated with cleavages at Arg(306), Arg(506), and Arg(679) with Arg(306) cleavage causing the major activity loss. To study functional roles of the Arg(306) region, overlapping 15-mer peptides representing the sequence of factor Va residues 271-345 were synthesized and screened for anticoagulant activities. The peptide containing residues 311-325 (VP311) noncompetitively inhibited prothrombin activation by factor Xa, but only in the presence of factor Va. Fluorescence studies showed that VP311 bound to fluorescence-labeled 5-dimethylaminonaphthalene-1-sulfonyl-Glu-Gly-Arg factor Xa in solution with a K-d of 70 mu M. Diisopropylphosphoryl factor Xa and factor Xa but not factor VII/VIIa or prothrombin bound to immobilized VP311 with relatively high affinity, These results support the hypothesis that residues 311-325, which are positioned between the A1 and A2 domains of factor Va and likely exposed to solvent, contribute to the binding of factor Xa by factor Va. Based on this hypothesis, it is suggested that cleavage by activated protein C at Arg(306) ire factor Va not only severs the covalent connection between the A1 and A2 domains but also disrupts the environment and structure of residues 311-325, thereby down-regulating the binding of factor Xa to factor Va.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Griffin, JH (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, SBR-5,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Griffin, John/0000-0002-4302-2547; Hackeng, Tilman/0000-0003-0142-0843	NHLBI NIH HHS [R37HL52246, R01HL21544] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544, R37HL052246] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNAMALAI AE, 1987, BLOOD, V70, P139; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; ESMON CT, 1979, J BIOL CHEM, V254, P964; FOWLER WE, 1990, P NATL ACAD SCI USA, V87, P7648, DOI 10.1073/pnas.87.19.7648; GALE AJ, 1997, THROMB HAEMOSTASIS S, P599; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HEEB MJ, 1994, P NATL ACAD SCI USA, V91, P2728, DOI 10.1073/pnas.91.7.2728; HEEB MJ, 1995, BLOOD, V85, P3405, DOI 10.1182/blood.V85.12.3405.bloodjournal85123405; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JANE SM, 1991, BLOOD COAGUL FIBRIN, V2, P723, DOI 10.1097/00001721-199112000-00005; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KANE WH, 1988, BLOOD, V71, P539; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LILES DK, 1997, BLOOD, V90, P463; Mann K G, 1981, Ann N Y Acad Sci, V370, P378, DOI 10.1111/j.1749-6632.1981.tb29750.x; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; MESTERS RM, 1993, BIOCHEMISTRY-US, V32, P12656, DOI 10.1021/bi00210a014; MOSESSON MW, 1990, J CLIN INVEST, V85, P1983, DOI 10.1172/JCI114662; MOSESSON MW, 1990, J BIOL CHEM, V265, P8863; MOUNIER C, 1997, THROMB HAEMOSTASIS S, V20, P293; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; PAN Y, 1995, NAT STRUCT BIOL, V2, P740, DOI 10.1038/nsb0995-740; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; ROSING J, 1980, J BIOL CHEM, V255, P274; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; STENFLO J, 1976, J BIOL CHEM, V251, P355; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	45	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14900	14905		10.1074/jbc.273.24.14900	http://dx.doi.org/10.1074/jbc.273.24.14900			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614093	hybrid			2022-12-25	WOS:000074160400035
J	Kullmann, M; Schneikert, J; Moll, J; Heck, S; Zeiner, M; Gehring, U; Cato, ACB				Kullmann, M; Schneikert, J; Moll, J; Heck, S; Zeiner, M; Gehring, U; Cato, ACB			RAP46 is a negative regulator of glucocorticoid receptor action and hormone-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ANDROGEN RECEPTOR; THYROID-HORMONE; CELL-DEATH; PROTEIN; BAG-1; CLONING; FAMILY; IDENTIFICATION; OVEREXPRESSION	RAP46 was first identified by its ability to bind the glucocorticoid receptor. It has since been reported to bind several cellular proteins, including the anti-apoptotic protein Bcl-2, but the biological significance of these interactions is unknown. Here we show that RAP46 binds the hinge region of the glucocorticoid receptor and inhibits DNA binding and transactivation by the receptor. We further show that overexpression of RAP46 in mouse thymoma S49.1 cells inhibits glucocorticoid-induced apoptosis, Conversely, glucocorticoid-induced apoptosis and transactivation mere enhanced after treating S49.1 cells with the immunosuppressant rapamycin, which down-regulates cellular levels of BAG-1, the mouse homolog of RAP46, The effect of rapamycin can, however, be overcome by overexpression of RAP46. These results together identify RAP46 as a protein that controls glucocorticoid-induced apoptosis through its negative regulatory action on the transactivation property of the glucocorticoid receptor.	Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Univ Heidelberg, Inst Biol Chem, D-69120 Heidelberg, Germany	Helmholtz Association; Karlsruhe Institute of Technology; Ruprecht Karls University Heidelberg	Cato, ACB (corresponding author), Forschungszentrum Karlsruhe, Inst Genet, Postfach 3640, D-76021 Karlsruhe, Germany.	andrew.cato@igen.fzk.de	Kullmann, Michael Keith/AGY-4711-2022; Cato, Andrew C. B./H-2071-2013	Cato, Andrew C. B./0000-0001-8508-3834; Kullmann, Michael Keith/0000-0003-3567-3806				Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Adachi M, 1996, BLOOD, V88, P4118, DOI 10.1182/blood.V88.11.4118.bloodjournal88114118; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ANNWEILER A, 1991, NUCLEIC ACIDS RES, V19, P3750, DOI 10.1093/nar/19.13.3750; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CHEN DJ, 1995, NATURE, V377, P454; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; DIEHL EE, 1993, BIOCHEMISTRY-US, V32, P13510, DOI 10.1021/bi00212a016; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GAO XM, 1994, BIOCHEM BIOPH RES CO, V199, P734, DOI 10.1006/bbrc.1994.1290; GAST A, 1995, MOL CELL ENDOCRINOL, V111, P93, DOI 10.1016/0303-7207(95)03554-K; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Henriksson A, 1997, MOL CELL BIOL, V17, P3065, DOI 10.1128/MCB.17.6.3065; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ishizuka T, 1997, BIOCHEM BIOPH RES CO, V230, P386, DOI 10.1006/bbrc.1996.5967; Jeon SH, 1997, J EXP MED, V185, P1827, DOI 10.1084/jem.185.10.1827; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; Miyashita T, 1997, BIOCHEM BIOPH RES CO, V233, P781, DOI 10.1006/bbrc.1997.6559; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NEBL G, 1994, J BIOL CHEM, V269, P7371; NEBL G, 1995, CELL MOL BIOL RES, V41, P85; NING YM, 1993, J BIOL CHEM, V268, P6073; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; SANCHEZ ER, 1995, GLUCOCORTICOID RECEP, P105; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Takayama S, 1996, GENOMICS, V35, P494, DOI 10.1006/geno.1996.0389; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	46	118	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14620	14625		10.1074/jbc.273.23.14620	http://dx.doi.org/10.1074/jbc.273.23.14620			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603979	hybrid			2022-12-25	WOS:000074021500081
J	Lee, HK; Lee, YK; Park, SH; Kim, YS; Park, SH; Lee, JW; Kwon, HB; Soh, J; Moore, DD; Choi, HS				Lee, HK; Lee, YK; Park, SH; Kim, YS; Park, SH; Lee, JW; Kwon, HB; Soh, J; Moore, DD; Choi, HS			Structure and expression of the orphan nuclear receptor SHP gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; SUPERFAMILY	To determine the organization of the orphan nuclear receptor SHP gene (Seol, W., Choi, H.-S., and Moore, D.D. (1996) Science 272, 1336-1339), genomic clones were isolated from human and mouse genomic Libraries. The SLIP gene was composed of two exons interrupted by a single intron spanning approximately 1.8 kilobases in human and 1.2 kilobases in mouse. Genomic Southern blot analysis and fluorescence in situ hybridization of human metaphase chromosomes indicated that the SRP gene is located at the human chromosome 1p36.1 sub-band. The 5'-flanking regions of human and mouse SHP genes were highly conserved, showing 77% homology in the resell of approximately 600 nucleotides upstream from the transcription start site. Primer extension analysis was carried out to determine the transcription start site of human SHP to 32 nucleotides downstream of a potential TATA box. The human SHP gene was specifically expressed En fetal liver, fetal adrenal gland, adult spleen, and adult small intestine, As expected from this expression pattern, the activity of the mouse SHP promoter measured by transient transfection was significantly higher in the adrenal-derived YI cells than HeLa cells.	Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Korea Univ, Coll Med, Dept Anat, Seoul 136750, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110799, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea	Chonnam National University; Chonnam National University; Baylor College of Medicine; Korea University; Korea University Medicine (KU Medicine); Seoul National University (SNU); Chonnam National University	Choi, HS (corresponding author), Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea.	hsc@chonnam.chonnam.ac.kr	Park, Seong Hoe/C-7353-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046546] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46546] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BALE SJ, 1991, NEW ENGL J MED, V324, P925; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; CHOI HS, 1993, MOL ENDOCRINOL, V7, P1596, DOI 10.1210/me.7.12.1596; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; GENUARDI M, 1989, AM J HUM GENET, V45, P73; Guo WW, 1996, J CLIN ENDOCR METAB, V81, P2481, DOI 10.1210/jc.81.7.2481; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Masuda N, 1997, BBA-GENE STRUCT EXPR, V1350, P27, DOI 10.1016/S0167-4781(96)00196-0; Miyamoto K, 1997, MOL ENDOCRINOL, V11, P1165, DOI 10.1210/me.11.8.1165; MOLEY JF, 1992, CANCER RES, V52, P770; Park SH, 1997, MOL CELLS, V7, P200; SAKURAI A, 1990, MOL CELL ENDOCRINOL, V71, P83; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; ZENNARO MC, 1995, J BIOL CHEM, V270, P21016, DOI 10.1074/jbc.270.36.21016	26	88	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14398	14402		10.1074/jbc.273.23.14398	http://dx.doi.org/10.1074/jbc.273.23.14398			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603951	hybrid			2022-12-25	WOS:000074021500053
J	Kim, JH; Shirouzu, M; Kataoka, T; Bowtell, D; Yokoyama, S				Kim, JH; Shirouzu, M; Kataoka, T; Bowtell, D; Yokoyama, S			Activation of Ras and its downstream extracellular signal-regulated protein kinases by the CDC25 homology domain of mouse Son-of-sevenless 1 (mSos1)	ONCOGENE			English	Article						Son-of-sevenless (Sos); Dbl-homology (DH) domain; Ras; ERK; guanine nucleotide exchange factor; Pleckstrin homology (PH) domain	NUCLEOTIDE EXCHANGE FACTOR; TYROSINE KINASE; PLECKSTRIN; GRB2; RECEPTOR; PATHWAY; BINDING; SOS1; TRANSDUCTION; ASSOCIATION	A fragment consisting of residues 584-1071 of the mouse Son-of-sevenless 1 (mSos1) protein was found to be sufficient for stimulation of the guanine nucleotide exchange of Ras in vitro, which defines the CDC25 homology (CDC25H) domain of mSos1, Furthermore, we found that the CDC25H-domain fragment activated the extracellular signal-regulated protein kinases (ERKs), and was mainly membrane localized, when expressed in unstimulated human embryonic kidney 293 cells, Then, we examined the roles of other mSos1 domains in autoinhibition of the CDC25H-domain functions in unstimulated cellular environments. First, longer fragments that have the CDC25H domain and the following proline-rich Grb2-binding domain exhibited negligible membrane localization, and accordingly much lower ERK-activation activities, under serum-starved conditions. On the other hand, the preceding Pleckstrin-homology (PH) domain affects neither the ERK-activation activity nor the membrane-localization activity of the CDC25H domain. By contrast, the cells expressing a fragment containing the Dbl homology (DH) domain in addition to the PH and CDC25H domains exhibited remarkably low ERK activities under serum-starved conditions. This autoinhibitory effect of the DH domain on the CDC25H-domain function was shown to be relieved when cells were stimulated with epidermal growth factor. The DH-domain extention affected neither the irt vitro guanine nucleotide exchange activity nor the membrane-localization activity of the CDC25H domain. Therefore, one of the roles of the DH domain is to exert an autoinhibition over the CDC25H-domain function on the cell membrane, in the absence, but not in the presence, of extracellular stimuli.	Inst Phys & Chem Res, Cellular Signaling Lab, Wako, Saitama 35101, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 113, Japan; Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, Kobe, Hyogo 650, Japan; Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia	RIKEN; University of Tokyo; Kobe University; Peter Maccallum Cancer Center	Yokoyama, S (corresponding author), Inst Phys & Chem Res, Cellular Signaling Lab, 2-1 Hirosawa, Wako, Saitama 35101, Japan.		Yokoyama, Shigeyuki/N-6911-2015; Bowtell, David/H-1007-2016; Shirouzu, Mikako/A-6521-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; Bowtell, David/0000-0001-9089-7525; 				Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P7100; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Byrne JL, 1996, ONCOGENE, V13, P2055; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHARDIN P, 1993, SCIENCE, V260, P1388; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; COCCETTI P, 1995, BIOCHEM BIOPH RES CO, V206, P253, DOI 10.1006/bbrc.1995.1035; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Garreau H, 1996, BIOL CELL, V86, P93, DOI 10.1016/0248-4900(96)84771-X; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hu YL, 1996, ONCOGENE, V12, P1865; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KIMURA M, 1994, BBA-GENE STRUCT EXPR, V1219, P653, DOI 10.1016/0167-4781(94)90224-0; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WHELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	12	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2597	2607		10.1038/sj.onc.1201822	http://dx.doi.org/10.1038/sj.onc.1201822			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632136				2022-12-25	WOS:000073698200004
J	Omri, B; Blancher, C; Neron, B; Marty, MC; Rutin, J; Molina, TJ; Pessac, B; Crisanti, P				Omri, B; Blancher, C; Neron, B; Marty, MC; Rutin, J; Molina, TJ; Pessac, B; Crisanti, P			Retinal dysplasia in mice lacking p56(lck)	ONCOGENE			English	Article						Lck; neuroretina; dysplasia	TYROSINE KINASE; INDUCED RETINOPATHY; NEURAL RETINA; NEURONS; FYN; RAT; LCK; PROTOONCOGENE; EXPRESSION; LSTRA	The product of the proto-oncogene p56(lck) is a nonreceptor tyrosine kinase member of the Src family. It is found in T cells (Marth ef al,, 1985, 1988) and in the mouse brain (Omri et al., 1996; Van Tan et al., 1996). In this report, we describe experiments showing that Lck is present in the mouse retina neurons. Lck gene expression was identified after isolating and sequencing the specific 5' and 3' part of the cDNA obtained by RT-PCR. In adult retina Lck immunoreactivity was most abundant in photoreceptor cells and within the outer plexiform layers. Staining was also observed in the inner nuclear and plexiform layers. In transgenic mice, the disruption of the Lck gene had serious consequences on the organization of the retina causing retinal dysplasia. These mice have partial retinal detachment with infolding and rosette formation in the photoreceptor sheet. These retinal abnormalities observed in Lck deficient mice lead to the loss of normal architecture of the photoreceptor and the inner nuclear layers, and provide an important role of Lck protein in the retina development. The lack of the Lck protein produces a spectrum of retinal pathology that resembles human retinopathy of prematurity (ROP).	CNRS, UPR 9035, F-75270 Paris 06, France; Hotel Dieu, Fac Med Broussais, Dept Pathol, F-75270 Paris, France; Univ Paris 06, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Sorbonne Universite	Crisanti, P (corresponding author), CNRS, UPR 9035, F-75270 Paris 06, France.		Molina, Thierry/ABA-5214-2020	Molina, Thierry/0000-0002-3929-9754				CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; FISCHER S, 1987, BIOCHEM BIOPH RES CO, V143, P819, DOI 10.1016/0006-291X(87)90322-6; FLEXNER RA, 1981, J HOPKINS HOSP B, V2, P115; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; HAMMER ME, 1986, AM J OPHTHALMOL, V102, P1; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; INGRAHAM CA, 1992, ONCOGENE, V7, P95; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Omri B, 1996, J NEUROCHEM, V67, P1360; OMRI B, 1994, INT IMMUNOL, V6, P377, DOI 10.1093/intimm/6.3.377; PENN JS, 1992, CURR EYE RES, V11, P939, DOI 10.3109/02713689209033492; POPOFF N, 1969, J ULTRA MOL STRUCT R, V29, P535, DOI 10.1016/S0022-5320(69)90072-0; QUINN GE, 1990, DOC OPHTHALMOL, V74, P223, DOI 10.1007/BF02482612; RAJAOFETRA N, 1992, DEV BRAIN RES, V67, P237, DOI 10.1016/0165-3806(92)90224-K; SADDA SR, 1994, INVEST OPHTH VIS SCI, V35, P1202; SILVERSTEIN AM, 1971, AM J OPHTHALMOL, V72, P13, DOI 10.1016/0002-9394(71)91586-8; SIRA BS, 1985, SURV OPHTHALMOL, V33, P1; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; TSO MOM, 1969, ARCH PATHOL, V88, P664; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; VanTan H, 1996, J NEUROCHEM, V67, P2306; YAGI T, 1994, DEV GROWTH DIFFER, V36, P543; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZIERLER S, 1988, RETINOPATHY PREMATUR, P23	28	28	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2351	2356		10.1038/sj.onc.1201761	http://dx.doi.org/10.1038/sj.onc.1201761			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620552				2022-12-25	WOS:000073428000007
J	Baden, HA; Sarma, SP; Kapust, RB; Byrd, RA; Waugh, DS				Baden, HA; Sarma, SP; Kapust, RB; Byrd, RA; Waugh, DS			The amino-terminal domain of human STAT4 - Overproduction, purification, and biophysical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-15 NMR RELAXATION; ESCHERICHIA-COLI; BACKBONE DYNAMICS; DNA-BINDING; PROTEINS; CODONS; SPECTROSCOPY; SENSITIVITY; EXPRESSION; DIFFUSION	The multifunctional signal transducer and activator of transcription (STAT) proteins relay signals from the cell membrane to the nucleus in response to cytokines and growth factors. STAT4 becomes activated when cells are treated with interleukin-12, a key cytokine regulator of cell-mediated immunity. Upon activation, dimers of STAT4 bind cooperatively to tandem interferon-gamma activation sequences (GAS elements) near the interferon-gamma gene and stimulate its transcription. The amino-terminal domain of STAT4 (STAT4(1-124)) is required for cooperative binding interactions between STAT4 dimers and activation of interferon-gamma transcription in response to interleukin-12. me have overproduced this domain of human STAT4 (hSTAT4(1-124)) in Escherichia coli and purified it to homogeneity for structural studies. The circular dichroism spectrum of hSTAT4(1-124) indicates that it has a well ordered conformation in solution. The translational diffusion constant of hSTAT4(1-124) was determined by nuclear magnetic resonance methods and found to be consistent with that of a dimer. The rotational correlation time (tau(c)) of hSTAT4(1-124) was estimated from N-15 relaxation to be 16 ns; this value is consistent with a 29-kDa dimeric protein. These results, together with the number of signals observed in the two-dimensional H-1-N-15 heteronuclear single quantum coherence spectrum of uniformly N-15-labeled protein, indicate that hSTAT4(1-124) forms a stable, symmetric homodimer in solution. Cooperativity in native STAT4 probably results from a similar or identical interaction between the amino-terminal domains of adjacent dimers bound to DNA.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Prot Engn Grp, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Macromol NMR Sect, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Waugh, DS (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Prot Engn Grp, Frederick, MD 21702 USA.		Byrd, R. Andrew/F-8042-2015	Byrd, R. Andrew/0000-0003-3625-4232				Altieri AS, 1997, FEBS LETT, V415, P221, DOI 10.1016/S0014-5793(97)01128-9; ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Calderone TL, 1996, J MOL BIOL, V262, P407, DOI 10.1006/jmbi.1996.0524; CHEN GFT, 1994, GENE DEV, V8, P2641, DOI 10.1101/gad.8.21.2641; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GARCIA GM, 1986, CELL, V45, P453, DOI 10.1016/0092-8674(86)90331-4; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Hu XY, 1996, PROTEIN EXPRES PURIF, V7, P289, DOI 10.1006/prep.1996.0041; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mandel AM, 1996, BIOCHEMISTRY-US, V35, P16009, DOI 10.1021/bi962089k; Miller J. H., 1972, EXPT MOL GENETICS, P431; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Seder RA, 1996, J IMMUNOL, V157, P2745; STUDIER FW, 1991, METHOD ENZYMOL, V186, P60; Tjandra N, 1996, J BIOMOL NMR, V8, P273, DOI 10.1007/BF00410326; Tjandra N, 1997, NAT STRUCT BIOL, V4, P443, DOI 10.1038/nsb0697-443; TREMBLEAU S, 1995, IMMUNOL TODAY, V16, P383, DOI 10.1016/0167-5699(95)80006-9; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794	29	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17109	17114		10.1074/jbc.273.27.17109	http://dx.doi.org/10.1074/jbc.273.27.17109			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642277	hybrid			2022-12-25	WOS:000074545200067
J	Cardozo, C; Kohanski, RA				Cardozo, C; Kohanski, RA			Altered properties of the branched chain amino acid-preferring activity contribute to increased cleavages after branched chain residues by the "immunoproteasome"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEASOME-RELATED GENE; CLASS-I MOLECULES; NF-KAPPA-B; PROTEOLYTIC ACTIVITY; INTERFERON-GAMMA; ANTIGEN PRESENTATION; 20S PROTEASOME; HUMAN MHC	The multicatalytic proteinase complex (MPC, proteasome) is assembled from 14 nonidentical protein subunits. It expresses five distinct proteolytic activities, including a chymotrypsin-like activity, cleaving after hydrophobic residues, and a branched chain amino acid-preferring component (BrAAP), cleaving preferentially after branched chain residues. Exposure of cells to interferons leads to replacement of the X, Y, and Z subunits by the LMP2, LMP7, and MECL1 subunits. This "immunoproteasome" is critical to processing of certain antigens. The enzymatic basis for enhanced antigen processing has not been determined. To gain insight into this question, we examined sites and relative rates of cleavage of bonds in denatured, reduced, carboxy-amidomethylated lysozyme, a 129-amino acid protein, by MPC from bovine spleen, in which the X, Y, and Z subunits are replaced by LMP2, LMP7, and MECL1. We compared cleavages to those catalyzed by MPC from bovine pituitary, which contains only the X,Y, and Z subunits. We found marked increases in the rates and number of cleavages after branched chain residues in reduced, carboxyamidomethylated lysozyme by the spleen MPC. This was largely due to accelerated cleavages of bonds after a Phi-X-Br motif, where Phi is a hydrophobic residue, Xis a small neutral or polar residue, and Br is a branched chain residue. Inhibitors with these structural properties were selective and potent inhibitors of the BrAAP activity of the spleen MPC. The above findings indicate that alterations in activity and substrate specificity of the BrAAP activity are important factors underlying the altered cleavages after hydrophobic residues associated with incorporation of interferon-inducible subunits. The potential relevance of the findings to antigen processing functions of MPC is discussed.	CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Cardozo, C (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Box 1215,1 Gustave L Levy Pl, New York, NY 10029 USA.		Cardozo, Christopher/R-6021-2019	Cardozo, Christopher/0000-0003-4013-2537	NIDDK NIH HHS [DK25377, DK50074] Funding Source: Medline; NIOSH CDC HHS [KOHL02835] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025377, R01DK050074] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIOSH CDC HHS; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMENOFF J, 1983, BIOCHEMISTRY-US, V22, P590, DOI 10.1021/bi00272a011; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; CARDOZO C, 1992, BIOCHEMISTRY-US, V31, P7373, DOI 10.1021/bi00147a023; CARDOZO C, 1994, BIOCHEMISTRY-US, V33, P6483, DOI 10.1021/bi00187a014; CERUNDOLO V, 1995, EUR J IMMUNOL, V25, P554, DOI 10.1002/eji.1830250238; Cerundolo V, 1997, EUR J IMMUNOL, V27, P336, DOI 10.1002/eji.1830270148; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Eleuteri AM, 1997, J BIOL CHEM, V272, P11824, DOI 10.1074/jbc.272.18.11824; ELLIOTT T, 1993, CURR BIOL, V3, P854, DOI 10.1016/0960-9822(93)90219-E; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HARDING CV, 1995, J IMMUNOL, V155, P1767; Hisamatsu H, 1996, J EXP MED, V183, P1807, DOI 10.1084/jem.183.4.1807; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KOHANSKI RA, 1986, BIOCHEM BIOPH RES CO, V134, P1312, DOI 10.1016/0006-291X(86)90393-1; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; Mykles DL, 1996, ARCH BIOCHEM BIOPHYS, V325, P77, DOI 10.1006/abbi.1996.0009; Nandi D, 1996, J IMMUNOL, V156, P2361; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; Orlowski M, 1997, BIOCHEMISTRY-US, V36, P13946, DOI 10.1021/bi970666e; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PFITZNER KE, 1965, J AM CHEM SOC, V87, P5661, DOI 10.1021/ja00952a026; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SIBILLE C, 1995, CURR BIOL, V5, P923, DOI 10.1016/S0960-9822(95)00182-5; TANAKA K, 1995, MOL BIOL REP, V21, P21, DOI 10.1007/BF00990966; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; Yang Y, 1996, IMMUNOL RES, V15, P208, DOI 10.1007/BF02918250	47	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16764	16770		10.1074/jbc.273.27.16764	http://dx.doi.org/10.1074/jbc.273.27.16764			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642232	hybrid			2022-12-25	WOS:000074545200022
J	Matsumoto, R; Matsumoto, H; Seki, M; Hata, M; Asano, Y; Kanegasaki, S; Stevens, RL; Hirashima, M				Matsumoto, R; Matsumoto, H; Seki, M; Hata, M; Asano, Y; Kanegasaki, S; Stevens, RL; Hirashima, M			Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GALACTOSIDE-BINDING LECTIN; REED-STERNBERG CELLS; ALLERGIC INFLAMMATION; FUNCTIONAL-HETEROGENEITY; CHEMOTACTIC LYMPHOKINES; MOLECULAR-CLONING; HODGKINS-DISEASE; MESSENGER-RNA; MAST-CELLS	A 1.6-kilobase pair cDNA was isolated from a human T-cell-derived expression library that encodes a novel eosinophil chemoattractant (designated ecalectin) expressed during allergic and parasitic responses. Based on its deduced amino acid sequence, ecalectin is a 36kDa protein consisting of 323 amino acids. Although ecalectin lacks a hydrophobic signal peptide, it is secreted from mammalian cells. Ecalectin is not related to any known cytokine or chemokine but rather is a variant of human galectin-9, a member of the large family of animal lectins that have affinity for P-galactosides. Recombinant ecalectin, expressed in COS cells and insect cells, exhibited potent eosinophil chemoattractant activity and attracted eosinophils in vitro and in vivo in a dose-dependent manner but not neutrophils, lymphocytes, or monocytes. The finding that the ecalectin transcript is present in abundance in various lymphatic tissues and that its expression increases substantially in antigen-activated peripheral blood mononuclear cells suggests that ecalectin is an important T-cell-derived regulator of eosinophil recruitment in tissues during inflammatory reactions. We believe that this is the first report of the expression of an immunoregulatory galectin expressed by a T-cell line that is selective for eosinophils.	Univ Tokyo, Inst Med Sci, Dept Bacterial Infect, Minato Ku, Tokyo 108, Japan; Hiroshima Univ, Fac Appl Biol Sci, Higashihiroshima 739, Japan; Kagawa Med Sch, Dept Immunol & Immunopathol, Kagawa 76107, Japan; Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	University of Tokyo; Hiroshima University; Kagawa University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Matsumoto, R (corresponding author), Univ Tokyo, Inst Med Sci, Dept Bacterial Infect, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.	ryoji@hgc.ims.u-tokyo.ac.jp	Kanegasaki, Shiro/AAM-4921-2021					ALMA R, 1997, J ALLERGY CLIN IMMUN, V99, P273; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; COTRAN RS, 1994, ROBBINS PATHOLOGIC B, P771; COTRAN RS, 1994, ROBBINS PATHOLOGIC B, P643; CRAIG SS, 1995, ANAT RECORD, V242, P211, DOI 10.1002/ar.1092420210; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; FREW AJ, 1988, J IMMUNOL, V141, P4158; Fukuda T, 1995, J ALLERGY CLIN IMMUN, V96, P1076, DOI 10.1016/S0091-6749(95)70193-1; GAGA M, 1991, J IMMUNOL, V147, P816; GERARD NP, 1989, J BIOL CHEM, V264, P1760; GITT MA, 1986, P NATL ACAD SCI USA, V83, P7603, DOI 10.1073/pnas.83.20.7603; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; Gonzalo JA, 1996, IMMUNITY, V4, P1, DOI 10.1016/S1074-7613(00)80293-9; GRUSS HJ, 1992, CANCER RES, V52, P3353; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HIRASHIMA M, 1992, LYMPHOKINE CYTOK RES, V11, P331; HIRASHIMA M, 1991, LYMPHOKINE CYTOK RES, V10, P481; HO MK, 1982, J IMMUNOL, V128, P1221; JENG KCG, 1994, IMMUNOL LETT, V42, P113, DOI 10.1016/0165-2478(94)90072-8; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; Kita H, 1996, J EXP MED, V183, P2421, DOI 10.1084/jem.183.6.2421; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KLEIN S, 1992, HEMATOL ONCOL, V10, P319, DOI 10.1002/hon.2900100605; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; Kuwabara I, 1996, J IMMUNOL, V156, P3939; LIU FT, 1993, IMMUNOL TODAY, V14, P486, DOI 10.1016/0167-5699(93)90263-K; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; ODA Y, 1993, J BIOL CHEM, V268, P5929; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; RAND TH, 1991, J EXP MED, V173, P1521, DOI 10.1084/jem.173.6.1521; RAND TH, 1991, J CLIN INVEST, V88, P825, DOI 10.1172/JCI115383; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; ROTHENBERG ME, 1988, J BIOL CHEM, V263, P13901; SAMOSZUK M, 1990, BLOOD, V75, P13; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWENK U, 1992, J BIOL CHEM, V267, P12482; SCHWENK U, 1995, J BIOL CHEM, V270, P15029, DOI 10.1074/jbc.270.25.15029; SEHMI R, 1991, J IMMUNOL, V147, P2276; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TRUONG MJ, 1993, EUR J IMMUNOL, V23, P3230, DOI 10.1002/eji.1830231228; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Tureci O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/jbc.272.10.6416; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WARRINGA RAJ, 1991, BLOOD, V77, P2694; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; YAMAOKA A, 1995, J IMMUNOL, V154, P3479; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737	69	221	238	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16976	16984		10.1074/jbc.273.27.16976	http://dx.doi.org/10.1074/jbc.273.27.16976			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642261	hybrid			2022-12-25	WOS:000074545200051
J	Waugh, MG; Lawson, D; Tan, SK; Hsuan, JJ				Waugh, MG; Lawson, D; Tan, SK; Hsuan, JJ			Phosphatidylinositol 4-phosphate synthesis in immunoisolated caveolae-like vesicles and low buoyant density non-caveolar membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GPI-ANCHORED PROTEINS; KINASE-ACTIVITY; FACTOR RECEPTOR; CELLS; MICRODOMAINS; SECRETION; PIP2; PHOSPHORYLATION; LOCALIZATION	This study examined phosphatidylinositol 4-phosphate (PtdIns4P) synthesis in caveolae that have been suggested to be discrete signaling microdomains of the plasma membrane and are enriched in the marker protein caveolin. Caveolin-rich light membranes (CLMs) were isolated from A431 cells by detergent-free, discontinuous density-gradient centrifugation method. The CLM fraction was separated from the bulk of the cellular protein and was greatly enriched in PtdIns, PtdIns4P, and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) and an adenosine-sensitive type II PtdIns 4-kinase activity. Preparation of CLMs by an OptiPrep-based cell fractionation procedure confirmed the co-localization of PtdIns 4-kinase and caveolin, Electron microscopy confirmed that an anti-caveolin antiserum immunopurified vesicles from CLMs that were within the size range described for caveolae in other systems, Co-immunoprecipitated PtdIns C-kinase activity could utilize endogenous PtdIns, present within the caveolae-like vesicles, to produce PtdIns4P, The addition of recombinant phosphatidylinositol transfer protein increased PtdIns 4-kinase activity both in immunoisolated caveolae and CLMs. However, less than 1% of the total cellular PtdIns and PtdIns 4-kinase activity was present in caveolae-like vesicles, indicating that non-caveolar light membrane rafts are the main site for cellular PtdIns4P production.	UCL, Sch Med, Ludwig Inst Canc Res, London W1P 8BT, England; Univ London Univ Coll, Dept Biochem & Mol Biol, London WC1E 6BT, England; UCL, Windeyer Inst Med Sci, Dept Mol Pathol, London W1P 6DB, England	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; University of London; University College London; University of London; University College London	Hsuan, JJ (corresponding author), UCL, Sch Med, Ludwig Inst Canc Res, Courtauld Bldg,91 Riding House St, London W1P 8BT, England.	justin@ludwig.ucl.ac.uk	Waugh, Mark/K-5232-2013; Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Waugh, Mark/0000-0002-7241-3168				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Batty IH, 1998, BIOCHEM J, V330, P1069; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; BROWN D, 1992, J AM SOC NEPHROL, V3, P895; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUNS RR, 1968, J CELL BIOL, V37, P244, DOI 10.1083/jcb.37.2.244; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; COCHET C, 1991, J BIOL CHEM, V266, P637; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; FRA AM, 1994, J BIOL CHEM, V269, P30745; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; IMAI A, 1987, NATURE, V325, P726, DOI 10.1038/325726a0; KAUFFMANNZEH A, 1994, J BIOL CHEM, V269, P31243; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; Kular G, 1997, BIOCHEM J, V325, P299, DOI 10.1042/bj3250299; LAWSON D, 1983, J CELL BIOL, V97, P1891, DOI 10.1083/jcb.97.6.1891; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mirre C, 1996, AM J PHYSIOL-CELL PH, V271, pC887, DOI 10.1152/ajpcell.1996.271.3.C887; MONACO ME, 1992, ENDOCR REV, V13, P707, DOI 10.1210/er.13.4.707; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; PIKE MC, 1988, J IMMUNOL, V140, P1967; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; THOMPSON DM, 1985, J BIOL CHEM, V260, P8824; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; WALKER DH, 1987, P NATL ACAD SCI USA, V84, P7513, DOI 10.1073/pnas.84.21.7513; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353	59	93	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17115	17121		10.1074/jbc.273.27.17115	http://dx.doi.org/10.1074/jbc.273.27.17115			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642278	hybrid			2022-12-25	WOS:000074545200068
J	Arnold, DA; Bianco, PR; Kowalczykowski, SC				Arnold, DA; Bianco, PR; Kowalczykowski, SC			The reduced levels of chi recognition exhibited by the RecBC(1004)D enzyme reflect its recombination defect in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECBCD ENZYME; HOT SPOT ACTIVITY; ESCHERICHIA-COLI; BIOCHEMICAL-CHARACTERIZATION; HOMOLOGOUS RECOMBINATION; BACTERIOPHAGE-LAMBDA; RECB(2109)CD ENZYME; HELICASE ACTIVITY; NUCLEASE ACTIVITY; HOTSPOT ACTIVITY	Homologous recombination in Escherichia coli is initiated by the RecBCD enzyme and is stimulated by an 8-nucleotide element known as Chi (chi) We present a detailed biochemical characterization of a mutant RecBCD enzyme, designated RecBC(1004)D, that displays a reduced level of chi site recognition. Initially characterized genetically as unable to respond to the chi sequence, we provide evidence to indicate that the ability of this mutant enzyme to respond to chi is reduced rather than lost; the mutant displays about 20-fold lower chi recognition than wild-type RecBCD enzyme. Although this enzyme exhibits wild-type levels of double-stranded DNA exonuclease, helicase, and ATPase activity, its ability to degrade single-stranded DNA is enhanced 2-3-fold. The data presented here suggest that the reduced recombination proficiency of the recBC(1004)D strain observed in vivo results from a basal level of modification of the RecBC(1004)D enzyme at both chi-specific, as well as nonspecific, DNA sequences.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Genet Grad Grp, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, 1 Shields Ave, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41347] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN SK, 1990, GENETICS, V126, P25; AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Anderson DG, 1997, GENES CELLS, V2, P117, DOI 10.1046/j.1365-2443.1997.1130311.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1613; CAPALDOK.F, 1971, J BACTERIOL, V106, P204, DOI 10.1128/JB.106.1.204-212.1971; CHAUDHURY AM, 1984, J BACTERIOL, V160, P788, DOI 10.1128/JB.160.2.788-791.1984; CHENG KC, 1984, J MOL BIOL, V180, P371, DOI 10.1016/S0022-2836(84)80009-1; CHENG KC, 1987, J MOL BIOL, V194, P747, DOI 10.1016/0022-2836(87)90252-X; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1995, J BIOL CHEM, V270, P16360, DOI 10.1074/jbc.270.27.16360; DIXON DA, 1994, P NATL ACAD SCI USA, V91, P2980, DOI 10.1073/pnas.91.8.2980; EGGLESTON AK, 1993, J MOL BIOL, V231, P621, DOI 10.1006/jmbi.1993.1314; EGGLESTON AK, 1993, J MOL BIOL, V231, P605, DOI 10.1006/jmbi.1993.1313; EICHLER DC, 1977, J BIOL CHEM, V252, P499; EMMERSON PT, 1968, GENETICS, V60, P19; ENNIS DG, 1987, GENETICS, V115, P11; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; Handa N, 1997, GENES CELLS, V2, P525, DOI 10.1046/j.1365-2443.1997.1410339.x; HOWARD-FLANDERS P., 1966, Radiation Research, V6, P156, DOI 10.2307/3583555; KOPPEN A, 1995, P NATL ACAD SCI USA, V92, P6249, DOI 10.1073/pnas.92.14.6249; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LAM ST, 1974, GENETICS, V77, P425; LEBOWITZ J, 1985, THESIS J HOPKINS U B; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MURPHY KC, 1994, J BIOL CHEM, V269, P22507; MYERS RS, 1995, P NATL ACAD SCI USA, V92, P6244, DOI 10.1073/pnas.92.14.6244; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; SCHULTZ DW, 1983, J BACTERIOL, V155, P664, DOI 10.1128/JB.155.2.664-680.1983; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; STAHL FW, 1975, J MOL BIOL, V94, P203, DOI 10.1016/0022-2836(75)90078-9; STAHL FW, 1977, GENETICS, V86, P715; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TELANDERMUSKAVI.KM, 1982, J BIOL CHEM, V257, P2641; VINOGRAD J, 1966, J GEN PHYSIOL, V49, P103, DOI 10.1085/jgp.49.6.103	41	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16476	16486		10.1074/jbc.273.26.16476	http://dx.doi.org/10.1074/jbc.273.26.16476			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632715	hybrid			2022-12-25	WOS:000074436600086
J	Ciesla, WP; Bobak, DA				Ciesla, WP; Bobak, DA			Clostridium difficile toxins A and B are cation-dependent UDP-glucose hydrolases with differing catalytic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE; RHO-PROTEINS; CHOLERAGEN; ACTIVATION; MECHANISM	Toxins A and B of Clostridium difficile are UDP-glucose glucosyltransferases that exert their cellular toxicity primarily through their abilities to monoglucosylate, and thereby inactivate, Rho family small GTPases. Toxin A also hydrolyzes UDP-glucose, although this activity is not well characterized. In this study, we measured the kinetics of UDP-glucose hydrolysis by toxins A and Il and found significant differences in the catalytic activities of these two structurally homologous toxins. The toxins displayed similar Michaelis constants (K-m) for UDP-glucose, but the maximal velocity (V-max) of toxin B was similar to 5-fold greater than that of toxin A. Toxins A and B exert their enzymatic actions intracellularly, and, interestingly, we found that each toxin absolutely required K+ for optimal hydrolase activity; Na+ was inactive. The toxins also required certain divalent cations for activity and exhibited a significantly greater V-max and lower K-m in the presence of Mn2+ as compared with Mg2+. We conclude that C. difficile toxins A and B are cation-dependent UDP-glucose hydrolases that differ significantly in their catalytic activities, a finding that may have important implications in understanding their different cytotoxic effects.	Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Bobak, DA (corresponding author), Univ Virginia, Sch Med, Dept Med, Box 485-HSC, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054572] Funding Source: NIH RePORTER; NIAID NIH HHS [5T32 AI07046] Funding Source: Medline; NIGMS NIH HHS [R01GM54572] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; BARROSO LA, 1994, MICROB PATHOGENESIS, V16, P297, DOI 10.1006/mpat.1994.1030; BONAGAERTS GPA, 1994, MICROB PATHOG, V17, P1; BONGAERTS GPA, 1994, MICROB PATHOGENESIS, V17, P1, DOI 10.1006/mpat.1994.1047; ChavesOlarte E, 1997, J CLIN INVEST, V100, P1734, DOI 10.1172/JCI119698; ChavesOlarte E, 1996, J BIOL CHEM, V271, P6925, DOI 10.1074/jbc.271.12.6925; CONSLER TG, 1988, J BIOL CHEM, V263, P2794; GLASER L, 1967, J BIOL CHEM, V242, P1944; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Hofmann F, 1997, J BIOL CHEM, V272, P11074; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KACHMAR JF, 1953, J BIOL CHEM, V200, P669; LAUGHLIN MR, 1988, J BIOL CHEM, V263, P2285; Lyerly David M., 1995, P867; LYERLY DM, 1985, INFECT IMMUN, V47, P349, DOI 10.1128/IAI.47.2.349-352.1985; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MERELLO S, 1995, J BIOL CHEM, V270, P7281, DOI 10.1074/jbc.270.13.7281; MONCRIEF JS, 1997, CLOSTRIDIA MOL BIOL, P370; MOSS J, 1976, P NATL ACAD SCI USA, V73, P4424, DOI 10.1073/pnas.73.12.4424; MOSS J, 1977, J BIOL CHEM, V252, P2455; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOWAK T, 1972, BIOCHEMISTRY-US, V11, P2819, DOI 10.1021/bi00765a014; NOWAK T, 1981, MOL CELL BIOCHEM, V35, P65, DOI 10.1007/BF02354821; RIEGLER M, 1995, J CLIN INVEST, V95, P2004, DOI 10.1172/JCI117885; Schweins T, 1997, J MOL BIOL, V266, P847, DOI 10.1006/jmbi.1996.0814; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; Thorne J. E., 1995, Journal of Investigative Medicine, V43, p291A; VILLEMEZ CL, 1979, J BIOL CHEM, V254, P4814; vonEichelStreiber C, 1996, TRENDS MICROBIOL, V4, P375, DOI 10.1016/0966-842X(96)10061-5; VONEICHELSTREIBER C, 1992, MOL GEN GENET, V233, P260, DOI 10.1007/BF00587587; Wedler F C, 1993, Prog Med Chem, V30, P89, DOI 10.1016/S0079-6468(08)70376-X; ZAKIM D, 1973, BIOCHEM BIOPH RES CO, V52, P453, DOI 10.1016/0006-291X(73)90733-X	34	65	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16021	16026		10.1074/jbc.273.26.16021	http://dx.doi.org/10.1074/jbc.273.26.16021			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632652	hybrid			2022-12-25	WOS:000074436600023
J	Severinov, K; Muir, TW				Severinov, K; Muir, TW			Expressed protein ligation, a novel method for studying protein-protein interactions in transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; CHEMICAL LIGATION; SIGMA-70 SUBUNIT; PROMOTER; CONSTRUCTION; ACTIVATION; FRAGMENTS; SEQUENCES; PEPTIDES; TARGET	Expressed protein ligation is a novel protein semisynthesis method that permits the in vitro ligation of a chemically synthesized C-terminal segment of a protein to a recombinant N-terminal segment fused through its C terminus to an intein protein splicing element. In principle, the practical convenience of this method, combined with the expanded opportunities in protein engineering that it provides, makes it well suited for probing the molecular basis of complex processes such as transcription. Here we describe the successful application of expressed protein ligation to the similar to 600 amino acid sigma(70) subunit of Escherichia coli RNA polymerase. The resulting semi-synthetic sigma(70) constructs are shown to be fully functional and have been used to map the binding region of the bacteriophage T4 anti-sigma protein, AsiA, to within amino acids 567-600 of sigma(70). The success of these semi-synthesis studies sets the stage for the future generation of semi-synthetic sigma(70) molecules in which unnatural amino acids and biophysical probes are site-specifically incorporated in the RNA polymerase complex.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; Rockefeller Univ, Lab Synthet Prot Chem, New York, NY 10021 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rockefeller University	Severinov, K (corresponding author), Rutgers State Univ, Waksman Inst, 190 Frelinghuysen Rd, Piscataway, NJ 08854 USA.		Wood, David W/B-2992-2012; Severinov, Konstantin/C-8545-2016; Muir, Tom/AHD-0860-2022	Muir, Tom/0000-0001-9635-0344	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055843, R29GM055843] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55843] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURTON Z, 1981, NUCLEIC ACIDS RES, V9, P2889, DOI 10.1093/nar/9.12.2889; Camarero JA, 1998, J PEPT RES, V51, P303; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Colland F, 1998, MOL MICROBIOL, V27, P819, DOI 10.1046/j.1365-2958.1998.00729.x; CORNISH VW, 1995, ANGEW CHEM INT EDIT, V34, P621, DOI 10.1002/anie.199506211; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Dawson PE, 1997, J AM CHEM SOC, V119, P4325, DOI 10.1021/ja962656r; GAERTNER HF, 1992, BIOCONJUGATE CHEM, V3, P262, DOI 10.1021/bc00015a010; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; Hubbell WL, 1996, STRUCTURE, V4, P779, DOI 10.1016/S0969-2126(96)00085-8; KEMP DS, 1993, J ORG CHEM, V58, P2216, DOI 10.1021/jo00060a043; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; KUMAR A, 1993, J MOL BIOL, V232, P406, DOI 10.1006/jmbi.1993.1400; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; LIU CF, 1994, J AM CHEM SOC, V116, P4149, DOI 10.1021/ja00089a001; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MINCHIN S, 1993, BIOCHEM J, V289, P771, DOI 10.1042/bj2890771; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; MUIR TW, 1995, STRUCTURE, V3, P649, DOI 10.1016/S0969-2126(01)00200-3; MUIR TW, 1998, IN PRESS P NATL ACAD; NEFZI A, 1995, TETRAHEDRON LETT, V36, P229, DOI 10.1016/0040-4039(94)02230-9; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; ROSE K, 1994, J AM CHEM SOC, V116, P30, DOI 10.1021/ja00080a004; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Severinov K, 1997, P NATL ACAD SCI USA, V94, P13481, DOI 10.1073/pnas.94.25.13481; Severinova E, 1996, J MOL BIOL, V263, P637, DOI 10.1006/jmbi.1996.0604; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; WALLACE CJA, 1995, CURR OPIN BIOTECH, V6, P403, DOI 10.1016/0958-1669(95)80069-7; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	31	160	198	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16205	16209		10.1074/jbc.273.26.16205	http://dx.doi.org/10.1074/jbc.273.26.16205			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632677	hybrid			2022-12-25	WOS:000074436600048
J	Smine, A; Xu, XM; Nishiyama, K; Katada, T; Gambetti, P; Yadav, SP; Wu, X; Shi, YC; Yasuhara, S; Homburger, V; Okamoto, T				Smine, A; Xu, XM; Nishiyama, K; Katada, T; Gambetti, P; Yadav, SP; Wu, X; Shi, YC; Yasuhara, S; Homburger, V; Okamoto, T			Regulation of brain G-protein G(o) by Alzheimer's disease gene presenilin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC-G-PROTEINS; IN-VIVO; ENDOPLASMIC-RETICULUM; MISSENSE MUTATIONS; GLIOMA-CELLS; PRECURSOR; RECEPTOR; TRANSPORT; TOXIN; LOCALIZATION	To investigate a possible association between G-proteins and presenilin-1 (PS-1), a series of glutathione S-transferase-fusion proteins containing portions of PS-1 were prepared and used in vitro in binding experiments with tissue and recombinant G-proteins. The results demonstrate that the 39 C-terminal amino acids of PS-1 selectively bind the brain G-protein, G(o). Addition of guanosine 5'-3-O-(thio)triphosphate promoted G(o) dissociation from PS-1, indicating that this domain mimics the function of G-protein-coupling domains found in receptors. The 39-amino acid synthetic polypeptide activated G(o) in a magnesium ion-dependent manner, Physical interaction of full-length PS-1 and G(o) was also demonstrated. Following transfection of G(o alpha) and N-terminally FLAG-tagged PS-1 in COS-7 cells, G(o) was immunoprecipitated by FLAG antibodies. In addition, endogenous PS-1 and G(o alpha) were colocalized immunocytochemically in human glioma cell lines. The results indicate that PS-1 regulates G(o) activities in living cells.	Cleveland Clin Fdn, Dept Neurosci, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Mol Biotechnol Core Facil, Cleveland, OH 44195 USA; Univ Tokyo, Fac Pharmaceut Sci, Tokyo 113, Japan; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Massachusetts Gen Hosp, Dept Anesthesia, Boston, MA 02114 USA; CNRS, UPR 9023, CCIPE, F-34094 Montpellier 5, France	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Tokyo; Case Western Reserve University; Harvard University; Massachusetts General Hospital; Centre National de la Recherche Scientifique (CNRS)	Okamoto, T (corresponding author), Cleveland Clin Fdn, Dept Neurosci, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	OKAMOTT@CESMTP.CCF.ORG		xu, xuemin/0000-0002-7426-272X	NIMH NIH HHS [MH-56036] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH056036] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; DUBOIS DH, 1995, ADV EXP MED BIOL, V376, P105; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAYASHI Y, 1992, BIOCHEM BIOPH RES CO, V187, P1249, DOI 10.1016/0006-291X(92)90437-P; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATADA T, 1994, METHOD ENZYMOL, V237, P131; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; Lagriffoul A, 1996, J BIOL CHEM, V271, P31508, DOI 10.1074/jbc.271.49.31508; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; MULLER L, 1994, MOL CELL NEUROSCI, V5, P556, DOI 10.1006/mcne.1994.1068; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; OKAMOTO T, 1931, CELL, V709, P90; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROSS EM, 1994, METHOD ENZYMOL, V237, P26; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STOW JL, 1993, J CELL SCI, P33; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; WILSON BS, 1993, P NATL ACAD SCI USA, V90, P1681, DOI 10.1073/pnas.90.5.1681; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; ZUBIAUR M, 1993, J NEUROSCI RES, V35, P207, DOI 10.1002/jnr.490350212	47	48	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16281	16288		10.1074/jbc.273.26.16281	http://dx.doi.org/10.1074/jbc.273.26.16281			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632688	hybrid			2022-12-25	WOS:000074436600059
J	Wilson, MC; Jackson, VN; Heddle, C; Price, NT; Pilegaard, H; Juel, C; Bonen, A; Montgomery, I; Hutter, OF; Halestrap, AP				Wilson, MC; Jackson, VN; Heddle, C; Price, NT; Pilegaard, H; Juel, C; Bonen, A; Montgomery, I; Hutter, OF; Halestrap, AP			Lactic acid efflux from white skeletal muscle is catalyzed by the monocarboxylate transporter isoform MCT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOLEMMAL GIANT VESICLES; INTRACELLULAR PH INDICATOR; LACTATE TRANSPORTER; CDNA CLONING; INHIBITOR SPECIFICITY; FIBER TYPE; RAT; CELLS; IDENTIFICATION; SUBSTRATE	The newly cloned proton-linked monocarboxylate transporter MCT3 was shown by Western blotting and immunofluorescence confocal microscopy to be expressed in all muscle fibers. In contrast, MCT1 is expressed most abundantly in oxidative fibers but is almost totally absent in fast-twitch glycolytic fibers. Thus MCT3 appears to be the major MCT isoform responsible for efflux of glycolytically derived lactic acid from white skeletal muscle. MCT3 is also expressed in several other tissues requiring rapid lactic acid efflux. The expression of both MCT3 and MCT1 was decreased by 40-60% 3 weeks after denervation of rat hind limb muscles, whereas chronic stimulation of the muscles for 7 days increased expression of MCT1 2-3-fold but had no effect on MCT3 expression. The kinetics and substrate and inhibitor specificities of monocarboxylate transport into cell lines expressing only MCT3 or MCT1 have been determined. Differences in the properties of MCT1 and MCT3 are relatively modest, suggesting that the significance of the two isoforms may be related to their regulation rather than their intrinsic properties.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Copenhagen, August Krogh Inst, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark; Univ Waterloo, Dept Kinesiol, Waterloo, ON N2L 3G1, Canada; Univ Glasgow, Dept Physiol, Glasgow G12 8QQ, Lanark, Scotland	University of Bristol; University of Copenhagen; University of Waterloo; University of Glasgow	Halestrap, AP (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.	a.halestrap@Bristol.ac.uk	Halestrap, Andrew P/G-7275-2011; Juel, Carsten/J-5328-2014; Pilegaard, Henriette/M-2315-2014	Juel, Carsten/0000-0002-2373-6358; Pilegaard, Henriette/0000-0002-1071-0327; Wilson, Marieangela/0000-0001-6218-3533; Halestrap, Andrew/0000-0001-5374-2778	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; Carpenter L, 1996, BBA-BIOMEMBRANES, V1279, P157, DOI 10.1016/0005-2736(95)00254-5; CARPENTER L, 1994, BIOCHEM J, V304, P751, DOI 10.1042/bj3040751; DOYLE FA, 1992, BIOCHEM J, V281, P95, DOI 10.1042/bj2810095; GARCIA CK, 1994, GENOMICS, V23, P500, DOI 10.1006/geno.1994.1532; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; Halestrap AP, 1997, AM J CARDIOL, V80, pA17, DOI 10.1016/S0002-9149(97)00454-2; Handberg A, 1996, AM J PHYSIOL-ENDOC M, V271, pE50, DOI 10.1152/ajpendo.1996.271.1.E50; Jackson VN, 1996, J BIOL CHEM, V271, P861, DOI 10.1074/jbc.271.2.861; Jackson VN, 1997, BIOCHEM J, V324, P447, DOI 10.1042/bj3240447; JACKSON VN, 1995, BBA-BIOMEMBRANES, V1238, P193, DOI 10.1016/0005-2736(95)00160-5; Johannsson E, 1997, CIRC RES, V80, P400, DOI 10.1161/01.res.0000435856.47954.71; JUEL C, 1991, ACTA PHYSIOL SCAND, V143, P361, DOI 10.1111/j.1748-1716.1991.tb09246.x; Juel C, 1996, BBA-BIOMEMBRANES, V1283, P106, DOI 10.1016/0005-2736(96)00084-3; Juel C, 1997, PHYSIOL REV, V77, P321, DOI 10.1152/physrev.1997.77.2.321; MASON MJ, 1988, J PHYSIOL-LONDON, V400, P459, DOI 10.1113/jphysiol.1988.sp017132; McCullagh KJA, 1997, AM J PHYSIOL-ENDOC M, V273, pE239, DOI 10.1152/ajpendo.1997.273.2.E239; McCullagh KJA, 1996, AM J PHYSIOL-ENDOC M, V271, pE143, DOI 10.1152/ajpendo.1996.271.1.E143; PHILP N, 1995, EXP CELL RES, V219, P64, DOI 10.1006/excr.1995.1205; PILEGAARD H, 1995, AM J PHYSIOL-ENDOC M, V269, pE679, DOI 10.1152/ajpendo.1995.269.4.E679; POOLE RC, 1992, BIOCHEM J, V283, P855, DOI 10.1042/bj2830855; Poole RC, 1996, BIOCHEM J, V320, P817, DOI 10.1042/bj3200817; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; Poole RC, 1997, J BIOL CHEM, V272, P14624, DOI 10.1074/jbc.272.23.14624; Price NT, 1998, BIOCHEM J, V329, P321; Spurway NC, 1996, J ANAT, V188, P455; Wang X, 1996, AM J PHYSIOL-HEART C, V270, pH476, DOI 10.1152/ajpheart.1996.270.2.H476; WANG XM, 1994, AM J PHYSIOL-HEART C, V267, pH1759, DOI 10.1152/ajpheart.1994.267.5.H1759; WANG XM, 1993, BIOCHEM J, V290, P249, DOI 10.1042/bj2900249; Yoon HY, 1997, BIOCHEM BIOPH RES CO, V234, P90, DOI 10.1006/bbrc.1997.6588; ZHANG B, 1991, J BIOL CHEM, V266, P990	32	225	228	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15920	15926		10.1074/jbc.273.26.15920	http://dx.doi.org/10.1074/jbc.273.26.15920			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632638	hybrid			2022-12-25	WOS:000074436600009
J	Spillmann, D; Witt, D; Lindahl, U				Spillmann, D; Witt, D; Lindahl, U			Defining the interleukin-8-binding domain of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; 3-DIMENSIONAL STRUCTURE; NEUTROPHIL ELASTASE; BINDING; CHEMOKINES; GLYCOSAMINOGLYCANS; CYTOKINES; PROTEOGLYCANS; ANTITHROMBIN; MECHANISM	Interleukin-8, a member of the CXC chemokine family, has been shown to bind to glycosaminoglycans, It has been suggested that heparan sulfate on cell surfaces could provide specific ligand sites on endothelial cells to retain the highly diffusible inflammatory chemokine for presentation to leukocytes, By using selectively modified heparin and heparan sulfate fragments in a nitrocellulose filter trapping system, we have analyzed sequence requirements for interleukin-8 binding to heparin/heparan sulfate. We demonstrate that the affinity of a monomeric interleukin-8 molecule for heparin/ heparan sulfate is too weak to allow binding at physiological ionic strength, whereas the dimeric form of the protein mediates binding to two sulfated domains of heparan sulfate. These domains, each :In N-sulfated block of similar to 6 monosaccharide units, are contained within an similar to 22-24-mer sequence and are separated by a region of less than or equal to 14 monosaccharide residues that may be fully N-acetylated. Binding to interleukin-8 correlates with the occurrence of the di-O-sulfated disaccharide unit -Id-ceA(2-OSO3)-GlcNSO(3)(6-OSO3)-. We suggest that the heparan sulfate sequence binds in horseshoe fashion over two antiparallel-oriented helical regions on the dimeric protein.	Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Repligen Corp, Needham, MA 02194 USA	Uppsala University	Spillmann, D (corresponding author), Univ Uppsala, Dept Med Biochem & Microbiol, POB 575, S-75123 Uppsala, Sweden.							Atkins E D, 1975, Adv Exp Med Biol, V52, P19; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; BURROWS SD, 1994, BIOCHEMISTRY-US, V33, P12741, DOI 10.1021/bi00209a002; CADENE M, 1995, J BIOL CHEM, V270, P13204, DOI 10.1074/jbc.270.22.13204; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; DALY TJ, 1995, J BIOL CHEM, V270, P23282, DOI 10.1074/jbc.270.40.23282; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GRONENBORN AM, 1991, PROTEIN ENG, V4, P263, DOI 10.1093/protein/4.3.263; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NIEDUSZYNSKI IA, 1977, ACS SYM SER, V48, P73; PADRINES M, 1994, FEBS LETT, V352, P231, DOI 10.1016/0014-5793(94)00952-X; PEJLER G, 1987, J BIOL CHEM, V262, P5036; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; Thiery Jean Paul, 1992, Current Opinion in Cell Biology, V4, P782, DOI 10.1016/0955-0674(92)90101-H; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9	48	227	237	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15487	15493		10.1074/jbc.273.25.15487	http://dx.doi.org/10.1074/jbc.273.25.15487			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624135	hybrid			2022-12-25	WOS:000074284200029
J	Thurmond, DC; Baillie, RA; Goodridge, AG				Thurmond, DC; Baillie, RA; Goodridge, AG			Regulation of the action of steroid/thyroid hormone receptors by medium-chain fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO HEPATOCYTES; PROLIFERATOR-ACTIVATED RECEPTORS; S14 GENE-TRANSCRIPTION; MALIC ENZYME GENE; THYROID-HORMONE; TRANSACTIVATION DOMAIN; FUNCTIONAL-ANALYSIS; RESPONSE ELEMENTS; NUCLEAR RECEPTOR; ORPHAN RECEPTORS	Triiodothyronine (T-3) causes a 30-fold increase in transcription of the malic enzyme gene in chick embryo hepatocytes; medium-chain fatty acids (MCFAs) inhibit this increase. T-3 action is mediated by T-3 receptors (TRs) that bind to T-3 response elements (T3REs) in this gene's 5'-flanking DNA. In transiently transfected hepatocytes, fragments of 5'-flanking DNA of the malic enzyme gene or artificial T3REs that conferred T-3 stimulation also conferred MCFA inhibition to linked reporter genes, Thus, MCFA inhibition may be mediated through cis-acting T3REs and trans-acting TRs, distinguishing MCFA action from that of other fatty acids which act through unique sequence elements. Using binding assays and overexpression of TR, we showed that MCFAs inhibited the transactivating but not the silencing function of TR and did not alter binding of T-3 Ito TR or of TR to T3RE. The C-terminal ligand-binding domain of TR was sufficient to confer stimulation by T-3, but not inhibition by MCFA. Inhibition of transactivation by MCFA was specific: ligand-stimulated transcription from T-3 or estrogen response elements was inhibited, but that from glucocorticoid or cyclic AMP response elements was mot. We propose that MCFAs or metabolites thereof influence the activity of a factor(s) that interacts with the T-3 and estrogen receptors to inhibit ligand-stimulated transcription.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Goodridge, AG (corresponding author), Ohio State Univ, Coll Biol Sci, 484 W 12th Ave, Columbus, OH 43210 USA.		baillie, rebecca/AAQ-3400-2020	baillie, rebecca/0000-0003-3966-6320	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R01DK021594] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 21594, DK 25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAILLIE RA, 1993, J NUTR BIOCHEM, V4, P431, DOI 10.1016/0955-2863(93)90074-7; BAJAR A, 1991, P NATL ACAD SCI USA, V88, P8208, DOI 10.1073/pnas.88.18.8208; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; CHRISTENSEN E, 1991, BIOCHIM BIOPHYS ACTA, V1081, P167, DOI 10.1016/0005-2760(91)90022-A; CONOVER W. J, 1980, PRACTICAL NONPARAMET; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Goodridge AG, 1996, PROG NUCLEIC ACID RE, V52, P89, DOI 10.1016/S0079-6603(08)60965-4; GOODRIDGE AG, 1968, BIOCHEM J, V108, P655, DOI 10.1042/bj1080655; GOODRIDGE AG, 1968, BIOCHEM J, V108, P663, DOI 10.1042/bj1080663; GOODRIDGE AG, 1976, J BIOL CHEM, V251, P3027; GOODRIDGE AG, 1989, J NUTR, V119, P299, DOI 10.1093/jn/119.2.299; GREENE S, 1990, MUTAT RES, V333, P101; Hodnett DW, 1996, ARCH BIOCHEM BIOPHYS, V334, P309, DOI 10.1006/abbi.1996.0460; Hunter J, 1996, MOL CELL ENDOCRINOL, V116, P213, DOI 10.1016/0303-7207(95)03717-9; INOUE A, 1989, EUR J BIOCHEM, V183, P565, DOI 10.1111/j.1432-1033.1989.tb21085.x; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; Jump DB, 1997, J BIOL CHEM, V272, P27778, DOI 10.1074/jbc.272.44.27778; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LI QL, 1990, J BIOCHEM-TOKYO, V107, P699, DOI 10.1093/oxfordjournals.jbchem.a123111; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MA XJ, 1990, J BIOL CHEM, V265, P18435; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; ONATE SA, 1995, SCIENCE, V270, P1354; ORELLANA M, 1993, FEBS LETT, V322, P61, DOI 10.1016/0014-5793(93)81111-C; PARK HY, 1993, MOL ENDOCRINOL, V7, P319, DOI 10.1210/me.7.3.319; PODILA GK, 1988, SCIENCE, V242, P922, DOI 10.1126/science.242.4880.922; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; RONCERO C, 1992, J BIOL CHEM, V267, P14918; SALATI LM, 1991, J BIOL CHEM, V266, P4010; Sambrook J., 2002, MOL CLONING LAB MANU; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Thurmond DC, 1998, J BIOL CHEM, V273, P1613, DOI 10.1074/jbc.273.3.1613; TONE Y, 1994, J BIOL CHEM, V269, P31157; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; TSERNG KY, 1991, BIOCHEMISTRY-US, V30, P2508, DOI 10.1021/bi00223a030; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WIERSINGA WM, 1988, METABOLISM, V37, P996, DOI 10.1016/0026-0495(88)90159-X; WOLOSHUK CP, 1986, P NATL ACAD SCI USA, V83, P1704, DOI 10.1073/pnas.83.6.1704; Zhang X, 1996, J BIOL CHEM, V271, P14825, DOI 10.1074/jbc.271.25.14825	50	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15373	15381		10.1074/jbc.273.25.15373	http://dx.doi.org/10.1074/jbc.273.25.15373			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624119	hybrid			2022-12-25	WOS:000074284200013
J	Nicholson, B; Sawamura, T; Masaki, T; MacLeod, CL				Nicholson, B; Sawamura, T; Masaki, T; MacLeod, CL			Increased Cat3-mediated cationic amino acid transport functionally compensates in Cat1 knockout cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC RETROVIRUS RECEPTOR; GENE-EXPRESSION; HIGH-AFFINITY; SYSTEM; IDENTIFICATION; DEPRIVATION; PROTEIN	Arginine transport is important for a number of biological processes in vertebrates, and its transport may be rate-limiting for the production of nitric oxide. The majority of L-Arg transport is mediated by System y(+), although several other carriers have been kinetically defined. System y(+) cationic amino acid transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3, High affinity L-arginine transport was investigated in embryonic fibroblast cells derived from Cat1 knockout mice that lack functional Cat1. Both wild type and knockout cells transport arginine with comparable K-m and V-max. However, the apparent affinity for lysine transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of Cat3-mediated transport. Northern analysis-documented Cat2 mRNA increased 2-fold, whereas Cat3 mRNA levels increased 11-fold in Cat1(-/-) relative to Cat1(+/+) cells. The low affinity Cat2a mRNA was not detectably expressed in these cells. Even though Cat3 expression is normally limited to adult brain, there was a large increase in the amount of Cats protein present at the plasma membrane of Cat1(-/-) embryonic fibroblast cells. These results suggest that Cat3 compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity arginine transport.	Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 606, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; Kyoto University	MacLeod, CL (corresponding author), Univ Calif San Diego, Ctr Canc, 9500 Gilman Dr,0684, La Jolla, CA 92093 USA.		Sawamura, Tatsuya/E-7103-2010					ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; CHRISTENSEN HN, 1969, J BIOL CHEM, V244, P1497; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; Closs EI, 1996, AMINO ACIDS, V11, P193, DOI 10.1007/BF00813860; Closs EI, 1997, BIOCHEMISTRY-US, V36, P6462, DOI 10.1021/bi962829p; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; DURANTE W, 1995, AM J PHYSIOL-HEART C, V268, pH1158; Fink D, 1997, CANCER RES, V57, P1841; Hosokawa H, 1997, J BIOL CHEM, V272, P8717, DOI 10.1074/jbc.272.13.8717; ITO K, 1997, J BIOL CHEM, V272, P2670; Kakuda DK, 1993, TRANSGENE, V1, P91; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; MacLeod CL, 1996, AMINO ACIDS, V11, P171, DOI 10.1007/BF00813859; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MacLeod CL, 1996, BIOCHEM SOC T, V24, P846, DOI 10.1042/bst0240846; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; Nicholson B, 1996, J BIOL CHEM, V271, P12159, DOI 10.1074/jbc.271.21.12159; Palacin M, 1996, AMINO ACIDS, V11, P225, DOI 10.1007/BF00813862; Perkins CP, 1997, GENE DEV, V11, P914, DOI 10.1101/gad.11.7.914; PLAKIDOUDYMOCK S, 1993, BIOCHEM J, V295, P749, DOI 10.1042/bj2950749; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WOODARD MH, 1994, AM J PHYSIOL, V266, pE817, DOI 10.1152/ajpendo.1994.266.5.E817	25	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14663	14666		10.1074/jbc.273.24.14663	http://dx.doi.org/10.1074/jbc.273.24.14663			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614060	hybrid			2022-12-25	WOS:000074160400002
J	Ruano, MLF; Perez-Gil, J; Casals, C				Ruano, MLF; Perez-Gil, J; Casals, C			Effect of acidic pH on the structure and lipid binding properties of porcine surfactant protein A - Potential role of acidification among its exocytic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG LAMELLAR BODIES; TRANS-GOLGI NETWORK; PULMONARY SURFACTANT; SP-A; II CELLS; SECRETORY GRANULES; SP-B; BIOPHYSICAL ACTIVITY; INTRACELLULAR PH; CHROMOGRANIN-B	Pulmonary surfactant protein A (SP-A) is synthesized by type II cells and stored intracellularly in secretory granules (lamellar bodies) together with surfactant lipids and hydrophobic surfactant proteins B and C (SP-B and SP-C), We asked whether the progressive decrease in pH along the exocytic pathway could influence the secondary structure and lipid binding and aggregation properties of porcine SP-A. Conformational analysis from CD spectra of SP-A at various pH values indicated that the percentage of alpha-helix progressively decreased and that of beta-sheet increased as the pH was reduced. The protein underwent a marked self-aggregation at mildly acidic pH in the presence of Ca2+, conditions thought to resemble those existing in the trans-Golgi network. Protein aggregation was greater as the pH was reduced. We also found that both neutral and acidic vesicles either with or without SP-B or SP-C bound to SP-A at acidic pH as demonstrated by co-migration during centrifugation. However, the binding of acidic but not neutral vesicles to SP-A led to 1) a striking change in the CD spectra of the protein, which was interpreted as a decrease of the level of SP-A self-aggregation, and 2) a protection of the protein from endoproteinase Glu-C degradation at pH 4.5. SP-A massively aggregated acidic vesicles but poorly aggregated neutral vesicles at acidic pH. Aggregation of dipalmitoylphosphatidylcholine (DPPC) vesicles either with or without SP-B and/or SP-C strongly depended on pH, being progressively decreased as the pH was reduced and markedly increased when pH was shifted back to 7.0. At the pH of lamellar bodies, SP-A-induced aggregation of DPPC vesicles containing SP-B or a mixture of SP-B and SP-C was very low, although SP-A bound to these vesicles. These results indicate that I) DPPC binding and DPPC aggregation are different phenomena that probably have different SP-A structural requirements and 2) aggregation of membranes induced by SP-A at acidic pH is critically dependent on the presence of acidic phospholipids, which affect protein structure, probably preventing the formation of large aggregates of protein.	Univ Complutense Madrid, Fac Biol, Dept Biochem & Mol Biol, E-28040 Madrid, Spain	Complutense University of Madrid	Casals, C (corresponding author), Univ Complutense Madrid, Fac Biol, Dept Biochem & Mol Biol, E-28040 Madrid, Spain.		Perez-Gil, Jesus/H-3102-2019; Casals, Cristina/H-4658-2015	Perez-Gil, Jesus/0000-0003-3587-7147; Casals, Cristina/0000-0003-2696-0918				Beers MF, 1996, J BIOL CHEM, V271, P14361, DOI 10.1074/jbc.271.24.14361; BRESLIN JS, 1992, AM J PHYSIOL, V262, pL699, DOI 10.1152/ajplung.1992.262.6.L699; CASALS C, 1994, BIOCHEM SOC T, V22, pS370, DOI 10.1042/bst022370s; CASALS C, 1989, BIOCHIM BIOPHYS ACTA, V1003, P201, DOI 10.1016/0005-2760(89)90256-7; CASALS C, 1993, BIOCHEM J, V296, P585, DOI 10.1042/bj2960585; Casals C, 1998, AM J RESP CRIT CARE, V157, P43, DOI 10.1164/ajrccm.157.1.9611106; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHANDER A, 1986, J BIOL CHEM, V261, P6126; Chander A, 1996, BIOCHEM J, V318, P271, DOI 10.1042/bj3180271; CHANDER A, 1991, BIOCHIM BIOPHYS ACTA, V1086, P157, DOI 10.1016/0005-2760(91)90003-Z; CHANDER A, 1989, AM J PHYSIOL, V257, pL354, DOI 10.1152/ajplung.1989.257.6.L354; CHANDER A, 1990, AM J PHYSIOL, V258, P241; Clements JA, 1997, ANNU REV PHYSIOL, V59, P1, DOI 10.1146/annurev.physiol.59.1.1; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; CURSTEDT T, 1987, EUR J BIOCHEM, V168, P255, DOI 10.1111/j.1432-1033.1987.tb13414.x; ECKENHOFF RG, 1989, J CLIN INVEST, V84, P1295, DOI 10.1172/JCI114297; EFRATI H, 1987, BIOCHEMISTRY-US, V26, P7986, DOI 10.1021/bi00398a066; HAAGSMAN HP, 1990, BIOCHEMISTRY-US, V29, P8894, DOI 10.1021/bi00490a003; Hawgood S, 1992, PULMONARY SURFACTANT, P33; Johansson J, 1997, EUR J BIOCHEM, V244, P675, DOI 10.1111/j.1432-1033.1997.00675.x; KING RJ, 1983, J BIOL CHEM, V258, P672; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; Lin S, 1996, J BIOL CHEM, V271, P19689, DOI 10.1074/jbc.271.33.19689; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V969, P176, DOI 10.1016/0167-4889(88)90073-0; PEREZGIL J, 1993, BIOCHIM BIOPHYS ACTA, V1168, P261, DOI 10.1016/0005-2760(93)90181-8; PEREZGIL J, 1995, BIOCHEMISTRY-US, V34, P3964, DOI 10.1021/bi00012a014; POULAIN FR, 1992, AM J PHYSIOL, V262, pL730, DOI 10.1152/ajplung.1992.262.6.L730; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; ROSS GF, 1986, J BIOL CHEM, V261, P14283; ROUSER G, 1966, LIPIDS, V12, P505; Ruano MLF, 1996, BIOCHEM J, V313, P683, DOI 10.1042/bj3130683; SCHLAME M, 1988, BIOCHEM J, V253, P209, DOI 10.1042/bj2530209; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; SREERAMA N, 1994, BIOCHEMISTRY-US, V33, P10022, DOI 10.1021/bi00199a028; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; VANIWAARDEN JF, 1995, LUNG BIOL HEALTH DIS, V84, P75; VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479, DOI 10.1152/ajplung.1992.263.4.L479; VOORHOUT WF, 1993, MICROSC RES TECHNIQ, V26, P366, DOI 10.1002/jemt.1070260504; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; Yoo SH, 1996, J BIOL CHEM, V271, P1558; YOUNG SL, 1989, J APPL PHYSIOL, V66, P1336, DOI 10.1152/jappl.1989.66.3.1336	49	31	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15183	15191		10.1074/jbc.273.24.15183	http://dx.doi.org/10.1074/jbc.273.24.15183			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614132	hybrid			2022-12-25	WOS:000074160400074
J	Zhao, YQ; Ratnayake-Lecamwasam, M; Parker, SK; Cocca, E; Camardella, L; di Prisco, G; Detrich, HW				Zhao, YQ; Ratnayake-Lecamwasam, M; Parker, SK; Cocca, E; Camardella, L; di Prisco, G; Detrich, HW			The major adult alpha-globin gene of Antarctic teleosts and its remnants in the hemoglobinless icefishes - Calibration of the mutational clock for nuclear genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL-CHLOROFORM EXTRACTION; SINGLE-STEP METHOD; RNA ISOLATION; DNA; EXPRESSION; EVOLUTION; SEQUENCES; PROMOTER; FISHES; ACID	The icefishes of the Southern Ocean (family Channichthyidae, suborder Notothenioidei) are unique among vertebrates in their inability to synthesize hemoglobin. We have shown previously (Cocca, E., Ratnayake-Lecamwasam, M., Parker, S. K., Camardella, L., Ciaramella, M., di Prisco, G., and Detrich, H. W., III (1995) Proc. Natl. Acad. Sci. U.S. A. 92, 1817-1821); that icefishes retain inactive genomic remnants of adult notothenioid alpha-globin genes but have lost the gene that encodes adult beta-globin, Here we demonstrate that loss of expression of the major adult alpha-globin, alpha 1, in two specie's of icefish (Chaenocephalus aceratus and Chionodraco rastrospinosus) results from truncation of the 5' end of the notothenioid alpha 1-globin gene. The wild-type, functional alpha 1-globin gene of the Antarctic yellowbelly rockcod, Notothenia coriiceps, contains three exons and two A + T-rich introns, and its expression may be controlled by two or three distinct promoters. Retained in both icefish genomes are a portion of intron 2, exon 3, and the 3'-untranslated region of the notothenioid alpha 1-globin gene. The residual, nonfunctional alpha-globin gene, no longer under positive selection pressure for expression, has apparently undergone random mutational drift at an estimated rate of 0.12-0.33%/million years. We propose that abrogation of hemoglobin synthesis in icefishes most likely resulted from a single mutational event in the ancestral channichthyid that deleted the entire beta-globin gene and the 5' end of the linked alpha 1-globin gene.	Northeastern Univ, Dept Biol, Boston, MA 02115 USA; CNR, Ist Biochim Prot & Enzimol, I-80125 Naples, Italy	Northeastern University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Detrich, HW (corresponding author), Northeastern Univ, Dept Biol, 414 Mugar Hall,360 Huntington Ave, Boston, MA 02115 USA.			Cocca, Ennio/0000-0003-2432-9663				Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BARBER DL, 1981, J FISH BIOL, V19, P11, DOI 10.1111/j.1095-8649.1981.tb05807.x; BARGELLONI L, 1994, MOL BIOL EVOL, V11, P854; BERNARDI G, 1986, J MOL EVOL, V24, P1, DOI 10.1007/BF02099946; BERNARDI G, 1988, J MOL EVOL, V28, P7, DOI 10.1007/BF02143493; BERNARDI G, 1985, SCIENCE, V228, P953, DOI 10.1126/science.4001930; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Chan FY, 1997, BLOOD, V89, P688, DOI 10.1182/blood.V89.2.688; Chen LB, 1997, P NATL ACAD SCI USA, V94, P3811, DOI 10.1073/pnas.94.8.3811; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCCA E, 1995, P NATL ACAD SCI USA, V92, P1817, DOI 10.1073/pnas.92.6.1817; d'Avino R., 1991, P15; DAVINO R, 1989, EUR J BIOCHEM, V179, P699, DOI 10.1111/j.1432-1033.1989.tb14603.x; DAYHOFF MO, 1979, ATLAS PROTEIN SEQUEN; di Prisco G., 1991, P263; DIPRISCO G, 1992, EXPERIENTIA, V48, P473; DIPRISCO G, 1998, IN PRESS FISHES ANTA; Eastman J. T, 1993, ANTARCTIC FISH BIOL; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Hu ZZ, 1996, J BIOL CHEM, V271, P10242, DOI 10.1074/jbc.271.17.10242; HUREAU JC, 1977, ADAPTATIONS ANTARCTI, P459; KELLER EB, 1984, P NATL ACAD SCI-BIOL, V81, P7417, DOI 10.1073/pnas.81.23.7417; King SM, 1997, BIOCHEMISTRY-US, V36, P1306, DOI 10.1021/bi962229q; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LANFRANCHI G, 1994, DEV BIOL, V164, P402, DOI 10.1006/dbio.1994.1210; LIEBHABER SA, 1980, P NATL ACAD SCI-BIOL, V77, P7054, DOI 10.1073/pnas.77.12.7054; LOENEN WAM, 1983, GENE, V26, P171, DOI 10.1016/0378-1119(83)90187-7; MACDONALD JA, 1987, ADV MAR BIOL, V24, P321; MARTIN AP, 1993, P NATL ACAD SCI USA, V90, P4087, DOI 10.1073/pnas.90.9.4087; MARTIN AP, 1992, NATURE, V357, P153, DOI 10.1038/357153a0; McMorrow T, 1996, DNA CELL BIOL, V15, P407, DOI 10.1089/dna.1996.15.407; Miyata M, 1997, BBA-GENE STRUCT EXPR, V1354, P127, DOI 10.1016/S0167-4781(97)00111-5; MIYATA M, 1993, NIPPON SUISAN GAKK, V59, P1077, DOI 10.2331/suisan.59.1077; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PATIENT RK, 1980, CELL, V20, P565; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RUUD JT, 1954, NATURE, V173, P848, DOI 10.1038/173848a0; Sambrook J., 2002, MOL CLONING LAB MANU; SAUGER F, 1977, P NATL ACAD SCI USA, V74, P5463; SMALL DJ, 1998, IN PRESS J MOL EVOL; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TRIEZENBERG SJ, 1995, CURRENT PROTOCOLS MO; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726	48	57	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14745	14752		10.1074/jbc.273.24.14745	http://dx.doi.org/10.1074/jbc.273.24.14745			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614073	hybrid			2022-12-25	WOS:000074160400015
J	Zhou, G; Lefebvre, V; Zhang, ZP; Eberspaecher, H; de Crombrugghe, B				Zhou, G; Lefebvre, V; Zhang, ZP; Eberspaecher, H; de Crombrugghe, B			Three high mobility group-like sequences within a 48-base pair enhancer of the Col2a1 gene are required for cartilage-specific expression in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL SEX REVERSAL; PRO-ALPHA-1(II) COLLAGEN GENE; SRY-RELATED GENE; CAMPOMELIC DYSPLASIA; TRANSGENIC MICE; BINDING-SITE; MOUSE; SOX9; DNA; MUTATIONS	To understand the molecular mechanisms by which mesenchymal cells differentiate into chondrocytes, we have used the gene for an early and abundant marker of chondrocytes, the mouse pro-alpha 1(II) collagen gene (Col2a1), to delineate a minimal sequence needed for chondrocyte-specific expression and to identify the DNA-binding proteins that mediate its activity, We show here that a 48-base pair (bp) Col2a1 intron 1 sequence specifically targets the activity of a heterologous promoter to chondrocytes in transgenic mice. Mutagenesis studies of this 48-bp element identified three separate sites (sites 1-3) that were essential for its chondrocyte-specific enhancer activity in both transgenic mice and transient transfections. Mutations in sites 1 and 2 also severely inhibited the chondrocyte-specific enhancer activity of a 468-bp Col2a1 intron 1 sequence in vivo, SOX9, an SRY-related high mobility group (HMG) domain transcription factor, was previously shown to bind site 3, to bend the 48-bp DNA at this site, and to strongly activate this 48-bp enhancer as well as larger Col2a1 enhancer elements. All three sites correspond to imperfect binding sites for HMG domain proteins and appear to be involved in the formation of a large chondrocyte-specific complex between the 48-bp element, Sox9, and other protein(s), Indeed, mutations in each of the three HMG-like sites of the 48-bp element, which abolished chondrocyte-specific expression of reporter genes in transgenic mice and in transiently transfected cells, inhibited formation of this complex, Overall our results suggest a model whereby both Sox9 and these other proteins bind to several HMG-like sites in the Col2a1 gene to cooperatively control its expression in cartilage.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	de Crombrugghe, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919, R01AR042909] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NIAMS NIH HHS [R01 AR42909, P01 AR42919-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; CONNER F, 1994, NUCLEIC ACIDS RES, V22, P3339, DOI 10.1093/nar/22.16.3339; CONNOR F, 1995, NUCLEIC ACIDS RES, V23, P3365, DOI 10.1093/nar/23.17.3365; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; French SW, 1996, MOL CELL BIOL, V16, P5393; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HOSKING BM, 1995, NUCLEIC ACIDS RES, V23, P2626, DOI 10.1093/nar/23.14.2626; Kent J, 1996, DEVELOPMENT, V122, P2813; KWOK C, 1995, AM J HUM GENET, V57, P1028; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LI SW, 1995, GENE DEV, V9, P2821, DOI 10.1101/gad.9.22.2821; MORAISDASILVA S, 1996, NAT GENET, V13, P62; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Sudbeck P, 1996, NAT GENET, V13, P230, DOI 10.1038/ng0696-230; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WEGNER M, 1990, BIOCHEM BIOPH RES CO, V166, P1110, DOI 10.1016/0006-291X(90)90981-R; Wirth J, 1996, HUM GENET, V97, P186, DOI 10.1007/BF02265263; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F; ZHOU G, 1995, J CELL SCI, V108, P3677	37	141	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14989	14997		10.1074/jbc.273.24.14989	http://dx.doi.org/10.1074/jbc.273.24.14989			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614106	hybrid			2022-12-25	WOS:000074160400048
J	Sharma, SV; Agatsuma, T; Nakano, H				Sharma, SV; Agatsuma, T; Nakano, H			Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol	ONCOGENE			English	Article						radicicol; molecular chaperones; transformation suppression; HSP90; Raf	HEAT-SHOCK PROTEIN; KINASE KINASE KINASE; ROUS-SARCOMA VIRUS; MAP KINASE; FARNESYLTRANSFERASE INHIBITORS; HETEROPROTEIN COMPLEX; TYROSINE KINASE; RAS; RAF-1; ACTIVATION	Radicicol, a macrocyclic anti-fungal antibiotic, has the ability to suppress transformation by diverse oncogenes such as Src, Ras and Mos. Despite this useful property, the mechanism by which radicicol exerts its anti-transformation effects is currently unknown, To understand the transformation-suppressing effects of radicicol, a biotinylated derivative of radicicol was chemically synthesized and used as a probe in a Western-blot format to visualize cellular proteins that interact with radicicol, In transformed and untransformed mouse fibroblasts, the most prominent cellular protein that bound to radicicol had a molecular weight of approximately 90 kDa, Further analysis revealed that this protein was the mouse homologue of the 90 kDa heat shock protein (HSP90). This was confirmed by demonstrating the ability of radicicol to specifically bind purified human HSP90, Specificity of binding was demonstrated by the inhibition of binding of biotinylated radicicol by the native drug, Taken together with other studies the present observations suggest that the anti-transformation effects of radicicol may be mediated, at least in part, by the association of radicicol with HSP90 and the consequent dissociation of the Raf/HSP90 complex leading to the attenuation of the Ras/MAP kinase signal transduction pathway.	Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 194, Japan	University of Tennessee System; University of Tennessee Health Science Center; Kyowa Kirin Ltd	Sharma, SV (corresponding author), Univ Tennessee, Dept Microbiol & Immunol, 858 Madison Ave, Memphis, TN 38163 USA.				NCI NIH HHS [R01 CA55983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1997, CANCER CHEMOTH PHARM, V40, P60, DOI 10.1007/s002800050626; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; AYER WA, 1980, CAN J MICROBIOL, V26, P766, DOI 10.1139/m80-133; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Gibbs JB, 1996, BREAST CANCER RES TR, V38, P75, DOI 10.1007/BF01803786; GRENERT JP, 1997, IN PRESS J BIOL CHEM; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Koblan KS, 1996, BIOCHEM SOC T, V24, P688, DOI 10.1042/bst0240688; KWON HJ, 1995, J BIOCHEM-TOKYO, V118, P221, DOI 10.1093/oxfordjournals.jbchem.a124882; KWON HJ, 1992, CANCER RES, V52, P6926; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Marais R, 1996, CANCER SURV, V27, P101; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARSHALL CJ, 1995, ANN ONCOL, V6, P63; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOORE SK, 1990, DNA CELL BIOL, V9, P387, DOI 10.1089/dna.1990.9.387; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Oliff A, 1996, SCI AM, V275, P144, DOI 10.1038/scientificamerican0996-144; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; REBBE NF, 1989, J BIOL CHEM, V264, P15006; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Sharma SV, 1997, ONCOGENE, V14, P2641, DOI 10.1038/sj.onc.1201115; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; ZHAO JF, 1995, ONCOGENE, V11, P161	45	235	239	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2639	2645		10.1038/sj.onc.1201790	http://dx.doi.org/10.1038/sj.onc.1201790			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632140				2022-12-25	WOS:000073698200008
J	Amlal, H; Wang, ZH; Burnham, C; Soleimani, M				Amlal, H; Wang, ZH; Burnham, C; Soleimani, M			Functional characterization of a cloned human kidney Na+: HCO3- cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE-VESICLES; RENAL PROXIMAL TUBULE; HUMAN-ERYTHROCYTE-MEMBRANE; CATION-TRANSPORT; RAT HEPATOCYTES; BICARBONATE; SODIUM; CELLS; PH; EXCHANGE	Functional properties of a cloned human kidney Naf: HCO3- cotransporter (NBC-1) were studied in cultured HEK-293 cells that were transiently transfected with NBC-1 cDNA. The Na+:HCO3-, cotransporter activity was assayed as the Na+ and HCO3- dependent pH(i) recovery from intracellular acidosis with the use of the pH sensitive dye 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein In acid-loaded cells and in the presence of amiloride (to block Na+/H+ exchange), switching to a Na+ containing solution (115 mM) resulted in rapid pH(i), recovery only in the presence of HCO3-. This recovery was completely abolished by 300 mu m 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid. Replacing the Na+ with Li+ (115 mM) caused significant HCO3- dependent, DIDS-sensitive pHi recovery from intracellular acidosis, with Li+ showing lower affinity than Na+, Potassium (K+) had no affinity for the Na+:HCO3-, cotransporter. The Na+-dependent HCO3- cotransport was abolished in the presence of 0.2 mM harmaline. The Na+:HCO3- cotransporter could also function in Na+:OH- cotransport mode, although only at high external pH (7.8), Based on functional similarities with the mammalian kidney experiments, we propose that NBC-1 is the proximal tubule Na+:HCO3- cotransporter.	Univ Cincinnati, Med Ctr, Sch Med, Dept Med, Cincinnati, OH 45267 USA; Vet Affairs Med Ctr, Cincinnati, OH 45267 USA	University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center	Soleimani, M (corresponding author), Univ Cincinnati, Med Ctr, Sch Med, Dept Med, 231 Bethesda Ave,MSB 5502, Cincinnati, OH 45267 USA.	manoocher.soleimani@uc.edu		soleimani, m/0000-0002-3446-8870	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052821, R01DK046789] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46789, DK 52821] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERN RJ, 1990, PHYSIOL REV, V70, P79, DOI 10.1152/physrev.1990.70.1.79; Amlal H, 1997, AM J PHYSIOL-CELL PH, V273, pC1194, DOI 10.1152/ajpcell.1997.273.4.C1194; ARONSON PS, 1991, SEMIN NEPHROL, V11, P28; BECKER BF, 1978, J PHYSIOL-LONDON, V282, P149, DOI 10.1113/jphysiol.1978.sp012454; BORON WF, 1989, KIDNEY INT, V36, P392, DOI 10.1038/ki.1989.208; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; Burnham CE, 1997, J BIOL CHEM, V272, P19111, DOI 10.1074/jbc.272.31.19111; BURNHAM CE, 1998, IN PRESS AM J PHYSL; CHRISTOPHER NL, 1971, GASTROENTEROLOGY, V60, P845; deHurtado MCC, 1996, CIRC RES, V79, P698, DOI 10.1161/01.RES.79.4.698; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; FITZ JG, 1989, AM J PHYSIOL, V256, pG491, DOI 10.1152/ajpgi.1989.256.3.G491; FUNDER J, 1980, ACTA PHYSIOL SCAND, V108, P31, DOI 10.1111/j.1748-1716.1980.tb06497.x; GLEESON D, 1989, J CLIN INVEST, V84, P312, DOI 10.1172/JCI114156; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRASSL SM, 1987, J BIOL CHEM, V262, P2682; HOGAN EM, 1995, J GEN PHYSIOL, V106, P821, DOI 10.1085/jgp.106.5.821; KRAPF R, 1993, J MEMBRANE BIOL, V131, P1, DOI 10.1007/BF02258529; LAGADICGOSSMANN D, 1992, J PHYSIOL-LONDON, V458, P361, DOI 10.1113/jphysiol.1992.sp019422; LEVIEL F, 1992, J CLIN INVEST, V90, P869, DOI 10.1172/JCI115962; LUBMAN RL, 1995, RESP PHYSIOL, V100, P15, DOI 10.1016/0034-5687(94)00114-F; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; PREISIG PA, 1989, AM J PHYSIOL, V256, pF756; RAJENDRAN VM, 1991, J CLIN INVEST, V88, P1379, DOI 10.1172/JCI115444; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; SOLEIMANI M, 1995, J INVEST MED, V43, P419; SOLEIMANI M, 1989, J BIOL CHEM, V264, P18302; SOLEIMANI M, 1991, J BIOL CHEM, V266, P8706; SOLEIMANI M, 1995, CIRC RES, V76, P530, DOI 10.1161/01.RES.76.4.530; SOLEIMANI M, 1994, J BIOL CHEM, V269, P27973; SOLEIMANI M, 1987, J CLIN INVEST, V79, P1276, DOI 10.1172/JCI112948; SOLEIMANI M, 1989, J CLIN INVEST, V83, P945, DOI 10.1172/JCI113980; WIETH JO, 1970, ACTA PHYSIOL SCAND, V79, P76, DOI 10.1111/j.1748-1716.1970.tb04703.x; YOSHITOMI K, 1985, PFLUG ARCH EUR J PHY, V405, P360, DOI 10.1007/BF00595689	34	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16810	16815		10.1074/jbc.273.27.16810	http://dx.doi.org/10.1074/jbc.273.27.16810			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642239	hybrid			2022-12-25	WOS:000074545200029
J	Borggrefe, T; Wabl, M; Akhmedov, AT; Jessberger, R				Borggrefe, T; Wabl, M; Akhmedov, AT; Jessberger, R			A B-cell-specific DNA recombination complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-SWITCH RECOMBINATION; SINGLE-STRANDED FRAGMENTS; CHAIN CLASS SWITCH; ESCHERICHIA-COLI; RECA PROTEIN; BINDING PROTEIN; CIRCULAR DNA; POLY(ADP-RIBOSE) POLYMERASE; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION	We have purified and biochemically characterized a multiprotein complex designated SWAP. In a DNA transfer assay, SWAP preferentially recombines ("swaps") sequences derived from Ig heavy chain switch regions. We identified four of the proteins in the SWAP complex: B23 (nucleophosmin), C23 (nucleolin), poly(ADP-ribose) polymerase (PARP), and SWAP-70. The first three are proteins known to be present in most cells. B23 promotes single-strand DNA reannealing and the formation of joint molecules in a D-loop assay between homologous, but also between S-mu and S-gamma sequences. SWAP-70 is a novel protein of 70 kDa. Its cDNA was cloned and sequenced, and the protein was overexpressed in Escherichia coli. SWAP-70 protein expression was found only in B lymphocytes that had been induced to switch to various Ig isotypes and in switching B-cell lines. SWAP-70 is a nuclear protein, has a weak affinity for DNA, binds ATP, and forms specific, high affinity complexes with B23, C23, and poly(ADP-ribose) polymerase. These findings are consistent with SWAP being the long elusive "switch recombinase" and with SWAP-70 being the specific recruiting element that assembles the switch recombinase from universal components.	Basel Inst Immunol, CH-4005 Basel, Switzerland; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Jessberger, R (corresponding author), Basel Inst Immunol, CH-4005 Basel, Switzerland.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037699] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37699] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEATTIE KL, 1977, J MOL BIOL, V116, P783, DOI 10.1016/0022-2836(77)90271-6; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; BOCKHEIMSTEEN S, 1996, CURR TOP MICROBIOL I, V217, P61; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BURROWS PD, 1983, NATURE, V306, P243, DOI 10.1038/306243a0; BURROWS PD, 1981, P NATL ACAD SCI-BIOL, V78, P564, DOI 10.1073/pnas.78.1.564; CHAN PK, 1986, J BIOL CHEM, V261, P14335; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CROCE CM, 1993, SEMIN ONCOL, V20, P31; Daniels GA, 1996, CURR TOP MICROBIOL, V217, P171; DEMURCIA G, 1988, BIOCHEM CELL BIOL, V66, P626, DOI 10.1139/o88-072; DEPINHO R, 1984, MOL CELL BIOL, V4, P2905, DOI 10.1128/MCB.4.12.2905; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; GELLERT M, 1992, ANNU REV GENET, V22, P425; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; HARRIMAN W, 1993, ANNU REV IMMUNOL, V11, P361, DOI 10.1146/annurev.iy.11.040193.002045; HOLLOMAN WK, 1975, P NATL ACAD SCI USA, V72, P2394, DOI 10.1073/pnas.72.6.2394; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; JACK HM, 1988, P NATL ACAD SCI USA, V85, P1581, DOI 10.1073/pnas.85.5.1581; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; JESSBERGER R, 1991, MOL CELL BIOL, V11, P445, DOI 10.1128/MCB.11.1.445; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Jessberger R, 1996, CURR TOP MICROBIOL, V217, P191; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KNIGHT KL, 1985, J BIOL CHEM, V260, P867; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; Lorenz M, 1996, CURR TOP MICROBIOL, V217, P151; LUISIDELUCA C, 1995, J BACTERIOL, V177, P566, DOI 10.1128/jb.177.3.566-572.1995; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; Mussmann R, 1997, EUR J IMMUNOL, V27, P2610, DOI 10.1002/eji.1830271021; RAMSAMOOJ P, 1995, RADIAT RES, V143, P158, DOI 10.2307/3579152; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; SANDERSON RJ, 1976, ANAL BIOCHEM, V71, P615, DOI 10.1016/S0003-2697(76)80036-X; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHULTZ CL, 1991, INT IMMUNOL, V3, P109, DOI 10.1093/intimm/3.2.109; SHIBATA T, 1982, J BIOL CHEM, V257, P3981; SHIBATA T, 1980, P NATL ACAD SCI-BIOL, V77, P2606, DOI 10.1073/pnas.77.5.2606; SHIMIZU A, 1984, CELL, V36, P801, DOI 10.1016/0092-8674(84)90029-1; SHOCKETT P, 1993, J IMMUNOL, V151, P6962; SIEBENKOTTEN G, 1992, EUR J IMMUNOL, V22, P1827, DOI 10.1002/eji.1830220723; Snapper CM, 1997, IMMUNITY, V6, P217, DOI 10.1016/S1074-7613(00)80324-6; Stasiak A, 1996, SCIENCE, V272, P828, DOI 10.1126/science.272.5263.828; Stavnezer J, 1996, CURR OPIN IMMUNOL, V8, P199, DOI 10.1016/S0952-7915(96)80058-6; TAKAHASHI N, 1980, GENE, V11, P117; VanGent DC, 1996, CURR TOP MICROBIOL, V217, P1; VONSCHWEDLER U, 1990, NATURE, V345, P452, DOI 10.1038/345452a0; WABL M, 1985, NATURE, V313, P687, DOI 10.1038/313687a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WATERS SH, 1989, MOL CELL BIOL, V9, P5594, DOI 10.1128/MCB.9.12.5594; WILLIAMS M, 1991, GENE DEV, V5, P2353, DOI 10.1101/gad.5.12a.2353; WUERFFEL RA, 1990, MOL CELL BIOL, V10, P1714, DOI 10.1128/MCB.10.4.1714	61	135	150	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17025	17035		10.1074/jbc.273.27.17025	http://dx.doi.org/10.1074/jbc.273.27.17025			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642267	hybrid			2022-12-25	WOS:000074545200057
J	Descamps, S; Lebourhis, X; Delehedde, M; Boilly, B; Hondermarck, H				Descamps, S; Lebourhis, X; Delehedde, M; Boilly, B; Hondermarck, H			Nerve growth factor is mitogenic for cancerous but not normal human breast epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE PROTEIN; HUMAN PROSTATE; NEUROTROPHIN RECEPTORS; EXPRESSION; INHIBITOR; LINES	We show here that nerve growth factor (NGF), the archetypal neurotrophic factor, is able to stimulate the proliferation of breast cancer cells (MCF-7 and MDA-MB-231 cell lines), although it is unable to stimulate growth of normal breast epithelial cells (NBEC), This stimulation induced cells in the G(0) phase to reenter the cell cycle, as well as shortening cell cycle duration. Immunoblotting experiments revealed that both the two cancer cell lines and the NBEC express high affinity (p140(trk)) and low affinity (p75) NGF receptors. Inhibition of the NGF growth-promoting effect by the drugs K-252a and PD98059 indicated that activation of Trk-tyrosine kinase activity and the mitogen-activated protein kinase cascade are necessary to obtain the mitogenic effect. Activation of mitogen-activated protein kinase can be detected in breast cancer cells after 10 min of NGF stimulation, whereas no change was detected in NBEC. These results demonstrate that NGF is a mitogenic factor for human breast cancer cells and that it might constitute a new regulator of breast tumor growth.	Univ Lille, Ctr Biol Cellulaire, Unite Dynam Cellules Embryonnaires & Cancereuses, F-59655 Villeneuve Dascq, France	Universite de Lille - ISITE; Universite de Lille	Hondermarck, H (corresponding author), Univ Lille, Ctr Biol Cellulaire, Unite Dynam Cellules Embryonnaires & Cancereuses, F-59655 Villeneuve Dascq, France.	Hubert.Hondermarck@univ-lille1.fr	Le+Bourhis, Xuefen/AAL-5141-2021	DELEHEDDE, Maryse/0000-0003-2724-143X				ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Bourhis XFDL, 1997, INT J CANCER, V71, P42, DOI 10.1002/(SICI)1097-0215(19970328)71:1<42::AID-IJC9>3.0.CO;2-3; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; DELEHEDDE M, 1995, ONCOL RES, V7, P399; DIMARCO E, 1993, J BIOL CHEM, V268, P22838; DJAKIEW D, 1993, CANCER RES, V53, P1416; DJAKIEW D, 1991, CANCER RES, V51, P3304; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; GRUETERS A, 1985, PEDIATR RES, V19, P934, DOI 10.1203/00006450-198509000-00014; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; LOSSING C, 1993, PLAST RECONSTR SURG, V91, P1277, DOI 10.1097/00006534-199306000-00014; MURPHY RA, 1977, P NATL ACAD SCI USA, V74, P2330, DOI 10.1073/pnas.74.6.2330; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; PFLUG BR, 1992, CANCER RES, V52, P5403; PFLUG BR, 1995, ENDOCRINOLOGY, V136, P262, DOI 10.1210/en.136.1.262; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; SASAKI K, 1987, CYTOMETRY, V8, P526, DOI 10.1002/cyto.990080514; TAPLEY P, 1992, ONCOGENE, V7, P371; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821	24	109	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16659	16662		10.1074/jbc.273.27.16659	http://dx.doi.org/10.1074/jbc.273.27.16659			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642218	hybrid			2022-12-25	WOS:000074545200008
J	Hahm, SH; Eiden, LE				Hahm, SH; Eiden, LE			Five discrete cis-active domains direct cell type-specific transcription of the vasoactive intestinal peptide (VIP) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; OCTAMER-BINDING-PROTEINS; NEURON-SPECIFIC ENHANCER; ACHAETE-SCUTE HOMOLOG-1; STAT PROTEINS; DNA-BINDING; EXPRESSION; SEQUENCE; COACTIVATOR; POLYPEPTIDE	Vasoactive intestinal peptide (VIP) is a neuromodulator expressed with great anatomical specificity throughout the nervous system. Cell-specific expression of the VIP gene is mediated by a tissue specifier element (TSE) located within a 2.7-kilobase (kb) region between -5.2 and -2.5 kb upstream from the transcription start site, and requires an intact promoter proximal VIP-CRE (cyclic AMP-responsive element) (Hahm, S, H,, and Eiden, L, E, (1997) J, Neurochem, 67, 1872-1881), We now report that the TSE comprises a 425 base pair domain located between -4.7 and -4.2 kb containing two AT-rich octamer-like sequences. The 425-base pair TSE is sufficient to provide full cell-specific regulation of the VIP gene, when fused to the 5' proximal 1.55 kb of the VIP gene. Mutational analysis and gel shift assays of these octamer-like sequences indicate that the binding of proteins related to the ubiquitously expressed POU-homeodomain proteins Oct-1 and/or Oct-2 to these octamer-like sequences plays a central role for the function of the TSE, The TSE interacts with three additional discrete domains besides the cAMP response element, which are located within the proximal 1.55 kb of the VIP gene, to provide cell-specific expression. An upstream domain from -1.55 to -1.37 kb contains E-boxes and MEF2-like motifs, and deletion of this domain results in complete abrogation of cell-specific transcriptional activity, The region from -1.37 to -1.28 kb contains a STAT motif, and further removal of this domain allows the upstream TSE to act as an enhancer in both SH-EP and HeLa cells. The sequence from -1.28 to -0.9 kb containing a noncanonical AP-1 binding sequence (Symes, A, Gearan, T,, Eby, J,, and Fink, J, S, (1997) J. Biol, Chem. 272, 9648-9654), is absolutely required for TSE-dependent cell-specific expression of the VIP gene. Thus, five discrete domains of the VIP gene provide a combination of enhancer and repressor activities, each completely contingent on VIP gene context, that together result in cell-specific transcription of the VIP gene.	NIMH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Hahm, SH (corresponding author), NIMH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, 36 Convent Dr,MSC 4090,Bldg 36,Rm 2D10, Bethesda, MD 20892 USA.	sungho@codon.nih.gov		Eiden, Lee/0000-0001-7524-944X				AGOSTON DV, 1990, J NEUROSCI RES, V27, P479, DOI 10.1002/jnr.490270407; Ausubel, 1994, CURR PROTOC MOL BIOL, V2, P1; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; BRENNEMAN DE, 1990, J NEUROSCI RES, V25, P386, DOI 10.1002/jnr.490250316; Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; COOPER MJ, 1990, CELL GROWTH DIFFER, V1, P149; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; EMSON PC, 1979, BRAIN RES, V177, P437, DOI 10.1016/0006-8993(79)90462-1; FAHRENKRUG J, 1979, DIGESTION, V19, P149, DOI 10.1159/000198339; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; GOZES I, 1989, MOL NEUROBIOL, V3, P201, DOI 10.1007/BF02740606; GRESSENS P, 1993, NATURE, V362, P155, DOI 10.1038/362155a0; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Hahm SH, 1996, J NEUROCHEM, V67, P1872; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; JONES EG, 1986, J NEUROSURG, V65, P135, DOI 10.3171/jns.1986.65.2.0135; KAGEYAMA R, 1995, CRIT REV NEUROBIOL, V9, P177; Mao ZX, 1996, J BIOL CHEM, V271, P14371, DOI 10.1074/jbc.271.24.14371; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MUTT V, 1988, ANN NY ACAD SCI, V527, P1; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; ROSTENE WH, 1984, PROG NEUROBIOL, V22, P103, DOI 10.1016/0301-0082(84)90022-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SENA M, 1994, DNA SEQUENCE, V5, P25, DOI 10.3109/10425179409039701; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; Symes A, 1997, J BIOL CHEM, V272, P9648; SYMES AJ, 1993, P NATL ACAD SCI USA, V90, P572, DOI 10.1073/pnas.90.2.572; SYMES AJ, 1995, J NEUROCHEM, V65, P1926; WASCHEK JA, 1987, ANN NY ACAD SCI, V493, P308, DOI 10.1111/j.1749-6632.1987.tb27215.x; WASCHEK JA, 1988, P NATL ACAD SCI USA, V85, P9547, DOI 10.1073/pnas.85.24.9547; WHYTE DB, 1995, MOL ENDOCRINOL, V9, P467, DOI 10.1210/me.9.4.467	37	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17086	17094		10.1074/jbc.273.27.17086	http://dx.doi.org/10.1074/jbc.273.27.17086			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642274	hybrid			2022-12-25	WOS:000074545200064
J	Guo, JH; Wang, HY; Malbon, CC				Guo, JH; Wang, HY; Malbon, CC			Conditional, tissue-specific expression of Q205L G alpha(i2) in vivo mimics insulin activation of c-Jun N-terminal kinase and p38 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; TYROSINE KINASE; PROTEIN-KINASE; GLYCOGEN-SYNTHASE; GROWTH; CELLS; PHOSPHORYLATION; STIMULATION; INDUCTION; PATHWAY	Deficiency of the G-protein subunit G alpha(i2) impairs insulin action (Moxham, C, M,, and MaIbon, C, C, (1996) Nature 379, 840-844), By using the promoter for the phosphoenolpyruvate carboxykinase gene, conditional, tissue-specific expression of the constitutively active mutant form (Q205L) of G alpha(i2) was achieved in mice harboring the transgene, Expression of Q205L Get, was detected in skeletal muscle, liver, and adipose tissue of transgenic mice. Whereas the G alpha(i2)-deficient mice displayed blunted insulin action, the Q205L G alpha(i2)-expressing mice displayed enhanced insulin-like effects. Glycogen synthase in skeletal muscle was found to be activated in Q205L G alpha(i2)-expressing mice, in the absence of the administration of insulin. Analysis of members of mitogen-activated protein kinase family revealed that both c-Jun N-terminal kinase and p38 are constitutively activated in vivo in the mice that express the Q205L G alpha(i2) ERK1,2, in contrast, are unaffected in the Q205L G alpha(i2)-expressing mice, Insulin, like expression of Q205L G alpha(i2), activates both p38 and c-Jun N-terminal kinases as well as glycogen synthase, Activation of c-Jun N-terminal and p38 kinases in vivo with anisomycin, however, was insufficient to activate glycogen synthase, Much like G alpha(i2), deficiency provokes insulin resistance, expression of Q205L constitutively active G alpha(i2) mimics insulin action in vivo, sharing with insulin the activation of two mitogen-activated protein kinase members, p38 and c-Jun N-terminal kinases.	SUNY Stony Brook, Sch Med HSC,Diabet & Metab Dis Res Ctr, Pharmacol HSC, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med HSC,Diabet & Metab Dis Res Ctr, Diabet & Metab Dis Res Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Malbon, CC (corresponding author), SUNY Stony Brook, Sch Med HSC,Diabet & Metab Dis Res Ctr, Pharmacol HSC, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.		malbon, craig/ABF-3604-2020					Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Chen JF, 1997, J MOL MED, V75, P283, DOI 10.1007/s001090050113; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; GAWLER D, 1987, NATURE, V327, P229, DOI 10.1038/327229a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; RECORD RD, 1993, EXP CELL RES, V206, P36, DOI 10.1006/excr.1993.1117; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1994, J BIOL CHEM, V269, P1; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771	24	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16487	16493		10.1074/jbc.273.26.16487	http://dx.doi.org/10.1074/jbc.273.26.16487			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632716	hybrid			2022-12-25	WOS:000074436600087
J	Sainz, E; Akeson, M; Mantey, SA; Jensen, RT; Battey, JF				Sainz, E; Akeson, M; Mantey, SA; Jensen, RT; Battey, JF			Four amino acid residues are critical for high affinity binding of neuromedin B to the neuromedin B receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIN-RELEASING PEPTIDE; BOMBESIN-LIKE PEPTIDES; LUNG-CARCINOMA CELLS; SWISS 3T3 CELLS; STIMULATES GROWTH; MOLECULAR-CLONING; SUBSTANCE-P; NONPEPTIDE; DNA; ANTAGONISTS	Three mammalian bombesin receptor subtypes have been characterized: the gastrin-releasing peptide receptor (GRP-R), the neuromedin B receptor (NMB-R), and bombesin receptor subtype 3 (BRS-3). In a previous report we identified four amino acids that are critical for high affinity binding of bombesin and gastrin-releasing peptide (GRP) to the GRP-R. These four amino acids are conserved in all species variants of the GRP-R and NMB-R which bind bombesin with high affinity, but they are diverged in BRS-3, the bombesin receptor subtype that binds bombesin with much lower affinity. Substituting these four divergent amino acids in BRS-3 for the conserved amino acids in either GRP-R or NMB-R increased the affinity of the mutated BRS-3 (4 Delta BRS-3) for bombesin compared with wild-type BRS-3 We hypothesized that the same four amino acids might be critical for high affinity NMB binding to the NMB-R. hr this study we confirm this hypothesis by showing that the affinity of NMB is increased in a mutant BRS-3 receptor (4 Delta BRS-3) that contains these four substitutions resulting in an affinity that is close to the affinity of wild-type NMB-R for NMB. In contrast, these four amino acid substitutions in BRS-3 did not result in the formation of a high affinity binding site for the recently described non-peptide NMB-R antagonist PD168368.	NINCD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Battey, JF (corresponding author), 5 Res Ct,Rm 2B28, Rockville, MD 20850 USA.	jbattey@pop.nidcd.nih.gov						Akeson M, 1997, J BIOL CHEM, V272, P17405, DOI 10.1074/jbc.272.28.17405; ANASTASI A, 1971, EXPERIENTIA, V27, P166, DOI 10.1007/BF02145873; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BENYA RV, 1992, MOL PHARMACOL, V42, P1058; BENYA RV, 1994, MOL PHARMACOL, V46, P235; BOLOGNA M, 1989, CANCER, V63, P1714; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHUNG DH, 1992, SURGERY, V112, P1059; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DAVIS L, 1994, BASIC METHODS MOL BI, P319; Eden JM, 1996, BIOORG MED CHEM LETT, V6, P2617, DOI 10.1016/0960-894X(96)00481-7; ERSPAMER GF, 1988, REGUL PEPTIDES, V21, P1; FATHI Z, 1993, J BIOL CHEM, V268, P5979; FONG TM, 1992, J BIOL CHEM, V267, P25664; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; JI H, 1994, J BIOL CHEM, V269, P16533; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; LACH EB, 1995, CELL GROWTH DIFFER, V6, P1427; LEBACQVERHEYDEN AM, 1990, HDB EXPT PHARM, V95, P71; Mantey SA, 1997, J BIOL CHEM, V272, P26062, DOI 10.1074/jbc.272.41.26062; MCDONALD TJ, 1979, BIOCHEM BIOPH RES CO, V90, P227, DOI 10.1016/0006-291X(79)91614-0; Meng F, 1996, J BIOL CHEM, V271, P32016, DOI 10.1074/jbc.271.50.32016; MINAMINO N, 1983, BIOCHEM BIOPH RES CO, V114, P541, DOI 10.1016/0006-291X(83)90814-8; Pradhan TK, 1998, EUR J PHARMACOL, V343, P275, DOI 10.1016/S0014-2999(97)01527-6; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SPINDEL E, 1986, TRENDS NEUROSCI, V9, P130, DOI 10.1016/0166-2236(86)90042-1; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4	32	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15927	15932		10.1074/jbc.273.26.15927	http://dx.doi.org/10.1074/jbc.273.26.15927			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632639	hybrid			2022-12-25	WOS:000074436600010
J	Satriano, J; Matsufuji, S; Murakami, Y; Lortie, MJ; Schwartz, D; Kelly, CJ; Hayashi, S; Blantz, RC				Satriano, J; Matsufuji, S; Murakami, Y; Lortie, MJ; Schwartz, D; Kelly, CJ; Hayashi, S; Blantz, RC			Agmatine suppresses proliferation by frameshift induction of antizyme and attenuation of cellular polyamine levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE-ANTIZYME; CELLS; TRANSPORT; CHEMOTHERAPY; DEPRIVATION; METABOLISM; EXPRESSION; INHIBITOR; PROTEIN; GROWTH	Polyamines are required for entry and progression of the cell cycle. As such, augmentation of polyamine levels is essential for cellular transformation. Polyamines are autoregulated through induction of antizyme, which represses both the rate-limiting polyamine biosynthetic enzyme ornithine decarboxylase and cellular polyamine transport. In the present study we demonstrate that agmatine, a metabolite of arginine via arginine decarboxylase (an arginine pathway distinct from that of the classical polyamines), also serves the dual regulatory functions of suppressing polyamine biosynthesis and cellular polyamine uptake through induction of antizyme, The capacity of agmatine to induce antizyme is demonstrated by: (a) an agmatine-dependent translational frameshift of antizyme mRNA to produce a full-length protein and (b) suppression of agmatine-dependent inhibitory activity by either anti-antizyme IgG or antizyme inhibitor. Furthermore, agmatine administration depletes intracellular polyamine levels to suppress cellular proliferation in a transformed cell lime. This suppression is reversible with polyamine supplementation. We propose a novel regulatory pathway in which agmatine acts as an antiproliferative molecule and potential tumor suppressor by restricting the cellular polyamine supply required to support growth.	Univ Calif San Diego, Vet Affairs Med Ctr, Div Nephrol Hypertens, Dept Med, San Diego, CA 92161 USA; Univ Calif San Diego, Program Mol Pathol, Dept Med, San Diego, CA 92161 USA; Jikei Univ, Sch Med, Dept Biochem 2, Minato Ku, Tokyo 105, Japan	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; Jikei University	Satriano, J (corresponding author), Univ Calif San Diego, Vet Affairs Med Ctr, Div Nephrol Hypertens, Dept Med, Mail Code 9111 H,3350 La Jolla Village Dr, San Diego, CA 92161 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042155, R01DK028602] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48108] Funding Source: Medline; NIDDK NIH HHS [DK42155, DK28602] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Aziz SM, 1996, J PHARMACOL EXP THER, V278, P185; BOGLE RG, 1994, AM J PHYSIOL, V266, pC776, DOI 10.1152/ajpcell.1994.266.3.C776; DAVIS RH, 1992, MICROBIOL REV, V56, P280, DOI 10.1128/MMBR.56.2.280-290.1992; FREDLUND JO, 1995, EXP CELL RES, V216, P86, DOI 10.1006/excr.1995.1011; HAVERTY TP, 1988, J CELL BIOL, V107, P1359, DOI 10.1083/jcb.107.4.1359; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HOLLEY JL, 1992, CANCER RES, V52, P4190; JANNE J, 1966, ACTA CHEM SCAND, V20, P1174, DOI 10.3891/acta.chem.scand.20-1174; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; LAULAJAINEN T, 1993, LAB INVEST, V69, P183; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; LINDEN M, 1985, J CELL PHYSIOL, V125, P273, DOI 10.1002/jcp.1041250215; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MOULINOUX JP, 1991, CELL MOL BIOL, V37, P773; MURAKAMI Y, 1993, BIOCHEM J, V295, P305, DOI 10.1042/bj2950305; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; QUEMENER V, 1994, ANTICANCER RES, V14, P443; Regunathan S, 1996, J PHARMACOL EXP THER, V276, P1272; Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; White FC, 1997, GROWTH FACTORS, V14, P199, DOI 10.3109/08977199709021520; WOLF G, 1992, AM J PATHOL, V140, P95	28	120	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15313	15316		10.1074/jbc.273.25.15313	http://dx.doi.org/10.1074/jbc.273.25.15313			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624108	hybrid			2022-12-25	WOS:000074284200002
J	Dai, Q; Choy, E; Chiu, V; Romano, J; Slivka, SR; Steitz, SA; Michaelis, S; Philips, MR				Dai, Q; Choy, E; Chiu, V; Romano, J; Slivka, SR; Steitz, SA; Michaelis, S; Philips, MR			Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; PLASMA-MEMBRANE; SACCHAROMYCES-CEREVISIAE; ISOPRENYLATED PEPTIDES; CYSTEINE RESIDUES; PROTEIN; METHYLATION; SEQUENCE; BINDING; YEAST	Prenylcysteine carboxyl methyltransferase (pcCMT) is the third of three enzymes that posttranslationally modify C-terminal CAAX motifs and thereby target CAAX proteins to the plasma membrane. Here we report the molecular characterization and subcellular localization of the first mammalian (human myeloid) pcCMT. The deduced amino acid sequence of mammalian pcCMT predicts a multiple membrane-spanning protein with homologies to the yeast pcCMT, STE14, and the mammalian band 3 anion transporter. The human gene complemented a ste14 mutant. pcCMT mRNAs were ubiquitously expressed in human tissues. An anti-pc-CMT antiserum detected a 33-kDa protein in myeloid cell membranes. Ectopically expressed recombinant pc-CMT had enzymatic activity identical to that observed in neutrophil membranes. Mammalian pcCMT was not expressed at the plasma membrane but rather restricted to the endoplasmic reticulum. Thus, the final enzyme in the sequence that modifies CAAX motifs is located in membranes topologically removed from the CAAX protein target membrane.	NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA; Tanabe Res Labs USA Inc, San Diego, CA 92121 USA	New York University; New York University; Johns Hopkins University	Philips, MR (corresponding author), NYU, Sch Med, Dept Med, New York, NY 10016 USA.	mark.philips@mcccm.med.nyu.edu		Romano, Julia/0000-0001-8956-7377; Mark, Philips/0000-0002-1179-8156	NIAID NIH HHS [R01 AI036224, AI36224] Funding Source: Medline; NIGMS NIH HHS [GM55279, GM41223] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036224, R29AI036224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041223] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HUZOORAKBAR W, 1993, P NATL ACAD SCI USA, V90, P868; Imai Y, 1997, MOL CELL BIOL, V17, P1543, DOI 10.1128/MCB.17.3.1543; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KASINATHAN C, 1990, J BIOL CHEM, V265, P5139; LEE J, 1993, J BIOL CHEM, V268, P19192; MA YT, 1992, P NATL ACAD SCI USA, V89, P6275, DOI 10.1073/pnas.89.14.6275; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Parish CA, 1996, BIOCHEMISTRY-US, V35, P8473, DOI 10.1021/bi960603g; PHILIPS MR, 1995, METHOD ENZYMOL, V256, P49; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PILLINGER MH, 1994, J BIOL CHEM, V269, P1486; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; THISSEN JA, 1993, J BIOL CHEM, V268, P13780; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x	33	236	244	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15030	15034		10.1074/jbc.273.24.15030	http://dx.doi.org/10.1074/jbc.273.24.15030			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614111	hybrid			2022-12-25	WOS:000074160400053
J	Morimoto, A; Tanaka, M; Takahashi, S; Ishimori, K; Hori, H; Morishima, I				Morimoto, A; Tanaka, M; Takahashi, S; Ishimori, K; Hori, H; Morishima, I			Detection of a tryptophan radical as an intermediate species in the reaction of horseradish peroxidase mutant (Phe-221 -> Trp) and hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; ELECTRON-PARAMAGNETIC RESONANCE; NUCLEAR DOUBLE-RESONANCE; ENDOGENOUS CALCIUM-ION; COMPOUND-ES; ESCHERICHIA-COLI; DISTAL SITE; CRYSTAL-STRUCTURE; SODIUM-AZIDE; WILD-TYPE	The crucial reaction intermediate in the reaction of peroxidase with hydrogen peroxide (H2O2), compound I, contains a porphyrin pi-cation radical in horseradish peroxidase (HRP), which catalyzes oxidation of small organic and inorganic compounds, whereas cytochrome c peroxidase (CcP) has a radical center on the tryptophan residue (Trp-191) and oxidizes the redox partner, cytochrome c. To investigate the roles of the amino acid residue near the heme active center in discriminating the function of the peroxidases in these two enzymes, we prepared a CcP-like HRP mutant, F221W (Phe-221 --> Trp). Although the rapid spectral scanning and stopped-flow experiments confirmed that the F221W mutant reacts with H2O2 to form the porphyrin pi-cation radical at the same rate as for the wild-type enzyme, the characteristic spectral features of the porphyrin pi-cation radical disappeared rapidly, and were converted to the compound II-type spectrum. The EPR spectrum of the resultant species produced by reduction of the porphyrin pi-cation radical, however, was quite different from that of compound II in HRP, showing typical signals from a Trp radical as found for CcP. The sequential radical formation from the porphyrin ring to the Trp residue implies that the proximal Trp is a key residue in the process of the radical transfer from the porphyrin ring, which differentiates the function of peroxidases.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan; Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Osaka 5608531, Japan	Kyoto University; Osaka University	Morishima, I (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan.		Ishimori, Koichiro/S-1247-2016; Ishimori, Koichiro/AAQ-4434-2021; Tanaka, Motomasa/N-5064-2015	Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462; Tanaka, Motomasa/0000-0002-2994-7703				ADACHI S, 1991, BIOCHEM BIOPH RES CO, V180, P138, DOI 10.1016/S0006-291X(05)81266-5; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P330; ATOR MA, 1987, J BIOL CHEM, V262, P1542; BLUMBERG WE, 1968, J BIOL CHEM, V243, P1854; Bonagura CA, 1996, BIOCHEMISTRY-US, V35, P6107, DOI 10.1021/bi960122x; COULSON AFW, 1971, J BIOL CHEM, V246, P917; DeGray JA, 1997, J BIOL CHEM, V272, P2359; DEPILLIS GD, 1990, ARCH BIOCHEM BIOPHYS, V280, P217, DOI 10.1016/0003-9861(90)90539-B; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; FARHANGRAZI ZS, 1995, BIOCHEMISTRY-US, V34, P2866, DOI 10.1021/bi00009a017; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FISHEL LA, 1991, BIOCHEMISTRY-US, V30, P1986, DOI 10.1021/bi00221a036; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; GAZARYAN IG, 1994, FEBS LETT, V354, P248, DOI 10.1016/0014-5793(94)01125-7; GOODIN DB, 1987, J BIOL CHEM, V262, P7719; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; HARRIS RZ, 1991, J BIOL CHEM, V266, P8751; HASCHKE RH, 1978, BIOCHEM BIOPH RES CO, V80, P1039, DOI 10.1016/0006-291X(78)91350-5; HEWSON WD, 1979, J BIOL CHEM, V254, P3182; HOFFMAN BM, 1981, J BIOL CHEM, V256, P6556; HORI H, 1985, J BIOL CHEM, V260, P349; HOUSEMAN ALP, 1993, BIOCHEMISTRY-US, V32, P4430, DOI 10.1021/bi00067a036; KELMAN DJ, 1994, J BIOL CHEM, V269, P7458; LAMAR GN, 1980, J BIOL CHEM, V255, P6646; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; MILLER MA, 1995, BIOCHEMISTRY-US, V34, P12048, DOI 10.1021/bi00037a048; MILLER VP, 1992, J BIOL CHEM, V267, P8936; MORISHIMA I, 1986, J BIOL CHEM, V261, P9391; Musah RA, 1997, BIOCHEMISTRY-US, V36, P11665, DOI 10.1021/bi9708038; NAGANO S, 1995, BIOCHEM BIOPH RES CO, V207, P417, DOI 10.1006/bbrc.1995.1204; Nagano S, 1996, BIOCHEMISTRY-US, V35, P14251, DOI 10.1021/bi961740g; OGAWA S, 1979, BIOCHEM BIOPH RES CO, V90, P674, DOI 10.1016/0006-291X(79)91288-9; PATTERSON WR, 1994, J BIOL CHEM, V269, P17020; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; PENNERHAHN JE, 1986, J AM CHEM SOC, V108, P7819, DOI 10.1021/ja00284a054; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1980, J BIOL CHEM, V255, P322; RUPP H, 1979, BIOCHIM BIOPHYS ACTA, V548, P16, DOI 10.1016/0005-2728(79)90183-X; SAUNDERS BC, 1964, PEROXIDASE; SCHULZ CE, 1984, BIOCHEMISTRY-US, V23, P4743, DOI 10.1021/bi00315a033; SCHULZ CE, 1979, FEBS LETT, V23, P4743; SHIRO Y, 1986, J BIOL CHEM, V261, P9382; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SMITH AT, 1990, J BIOL CHEM, V265, P13335; Sutherland GRJ, 1997, BIOCHEMISTRY-US, V36, P3654, DOI 10.1021/bi962195m; Tanaka M, 1998, BIOCHEMISTRY-US, V37, P2629, DOI 10.1021/bi9725273; Tanaka M, 1997, BIOCHEMISTRY-US, V36, P9791, DOI 10.1021/bi9706172; Tanaka M, 1996, BIOCHEM BIOPH RES CO, V227, P393, DOI 10.1006/bbrc.1996.1518; Tanaka M, 1997, BIOCHEMISTRY-US, V36, P9889, DOI 10.1021/bi970906q; VEITCH NC, 1992, EUR J BIOCHEM, V207, P521, DOI 10.1111/j.1432-1033.1992.tb17078.x; Williams R.J.P., 1974, IRON BIOCH MED, P183; YAMADA H, 1975, ARCH BIOCHEM BIOPHYS, V169, P344, DOI 10.1016/0003-9861(75)90350-1; YAMAGUCHI K, 1993, J AM CHEM SOC, V115, P4058, DOI 10.1021/ja00063a026; YONETANI T, 1987, J BIOL CHEM, V262, P9547	57	41	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14753	14760		10.1074/jbc.273.24.14753	http://dx.doi.org/10.1074/jbc.273.24.14753			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614074	hybrid			2022-12-25	WOS:000074160400016
J	Newbolt, A; Stoop, R; Virginio, C; Surprenant, A; North, RA; Buell, G; Rassendren, F				Newbolt, A; Stoop, R; Virginio, C; Surprenant, A; North, RA; Buell, G; Rassendren, F			Membrane topology of an ATP-gated ion channel (P2X receptor)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-2X RECEPTOR; SEGMENTS; GLUTAMATE; CLONING; FAMILY; SITES	Western blots of Xenopus oocyte membrane preparations showed that the apparent molecular mass of the wild type P2X(2) receptor (about 65 kDa) was reduced by pretreatment with endoglycosidase H. Mutagenesis of one or more of three potential asparagines (N182S, N239S, and N298S) followed by Western blots showed that each of the sites was glycosylated in the wild type receptor. Functional channels were formed by receptors. lacking any single asparagine, but not by channels mutated in two or three positions. Artificial consensus sequences (N-X-S/T) introduced into the W-terminal region (asparagine at position 9, 16, or 26) were not glycosylated, Asparagines were glycosylated when introduced at the C-terminal end of the first hydrophobic domain (positions 62 and 66) and at the N-terminal end of the second hydrophobic domain (position 324), A protein in which the C terminus of one P2X(2) subunit was joined to the N terminus of a second P2X(2) subunit (from a concatenated cDNA) had twice the molecular mass of the P2X(2) receptor subunit, and formed fully functional channels. The experiments provide direct evidence for the topology originally proposed for the P2X receptor, with intracellular N and C termini, two membrane-spanning domains, and a large extracellular loop.	Glaxo Wellcome Res & Dev Ltd, Geneva Biomed Res Inst, CH-1228 Geneva, Switzerland	GlaxoSmithKline	Rassendren, F (corresponding author), Glaxo Wellcome Res & Dev Ltd, Geneva Biomed Res Inst, CH-1228 Geneva, Switzerland.	rassendren@serono.com	North, Richard/GQA-6156-2022; Rassendren, Francois/AAA-6190-2021	Rassendren, Francois/0000-0003-3320-2461				Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Collo G, 1996, J NEUROSCI, V16, P2495; DANI JA, 1995, CURR OPIN NEUROBIOL, V5, P310, DOI 10.1016/0959-4388(95)80043-3; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; GarciaGuzman M, 1997, MOL PHARMACOL, V51, P109, DOI 10.1124/mol.51.1.109; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; KAWASHIMA E, 1998, IN PRESS RECEPTORS C; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; North RA, 1996, CURR OPIN CELL BIOL, V8, P474, DOI 10.1016/S0955-0674(96)80023-8; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Radford KM, 1997, J NEUROSCI, V17, P6529; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; RENARD S, 1994, J BIOL CHEM, V269, P12981; Stoop R., 1997, Society for Neuroscience Abstracts, V23, P376; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Valera S, 1995, RECEPTOR CHANNEL, V3, P283; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485	28	111	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15177	15182		10.1074/jbc.273.24.15177	http://dx.doi.org/10.1074/jbc.273.24.15177			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614131	hybrid			2022-12-25	WOS:000074160400073
J	Papst, PJ; Sugiyama, H; Nagasawa, M; Lucas, JJ; Maller, JL; Terada, N				Papst, PJ; Sugiyama, H; Nagasawa, M; Lucas, JJ; Maller, JL; Terada, N			Cdc2-cyclin B phosphorylates p70 S6 kinase on Ser(411) at mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; CELL-CYCLE PROGRESSION; MOUSE 3T3 FIBROBLASTS; HUMAN T-CELLS; NUCLEAR LAMINA; MAP2 KINASE; CDC2 KINASE; RAPAMYCIN; P70(S6K); SITES	The carboxyl terminus of p70 S6 kinase (p70(s6k)) has a set of Ser and Thr residues (Ser(411), Ser(418), Ser(424), and Thr(421)) phosphorylated in vivo by an unidentified kinase(s). These Ser/Thr sites are immediately followed by proline, a motif that is commonly seen in the substrates of cyclin-dependent kinases (Cdk) and mitogen-activated protein kinases, A previous study has shown that Cdc2 (Cdk1) indeed phosphorylates these p70(s6k) Ser/Thr residues in vitro. Here, we demonstrate that Cdc2-cyclin B complex phosphorylates Ser(411) in the KIR (S) under bar PRR sequence, whereas other Cdk-cyclin complexes including those containing Cdk2, Cdk4, or Cdk6 do not. Additionally, Ser(411) phosphorylation in vivo was increased at mitosis in parallel with Cdc2 activation, and it was suppressed by a dominant negative form of Cdc2. These data indicate that p70(s6k) is a physiological substrate of Cdc2-cyclin B in mitosis. Since the activity of p70(s6k) is low during mitosis, Cdc2-cyclin B may play a role in inactivating p70(s6k) during mitosis, where protein synthesis is suppressed.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Terada, N (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA.	teradan@njc.org	Nagasawa, Masayuki/AAX-1734-2020; Nagasawa, Masayuki/CAI-8101-2022	Nagasawa, Masayuki/0000-0002-8085-4940; 	NCI NIH HHS [CA-64685] Funding Source: Medline; NIDDK NIH HHS [DK-28353] Funding Source: Medline; NIGMS NIH HHS [GM-26743] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANDI HR, 1993, J BIOL CHEM, V268, P4530; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOZMA SC, 1993, J BIOL CHEM, V268, P7134; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LUCAS JJ, 1992, J IMMUNOL, V148, P1804; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; SALB JM, 1965, P NATL ACAD SCI USA, V54, P1353, DOI 10.1073/pnas.54.5.1353; SRINIVASAN J, 1995, BIOCHEM J, V309, P927, DOI 10.1042/bj3090927; Sugiyama H, 1996, J IMMUNOL, V157, P656; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; TERADA N, 1991, J IMMUNOL, V147, P698; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TERADA N, 1993, J BIOL CHEM, V268, P12062; TERADA N, 1995, J IMMUNOL, V155, P3418; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; ZHANG JW, 1994, ARCH BIOCHEM BIOPHYS, V315, P415, DOI 10.1006/abbi.1994.1519; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	45	48	49	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15077	15084		10.1074/jbc.273.24.15077	http://dx.doi.org/10.1074/jbc.273.24.15077			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614117	hybrid			2022-12-25	WOS:000074160400059
J	Takeshita, A; Imai, K; Kato, S; Kitano, S; Hanazawa, S				Takeshita, A; Imai, K; Kato, S; Kitano, S; Hanazawa, S			1 alpha,25-dehydroxyvitamin D-3 synergism toward transforming growth factor-beta 1-induced AP-1 transcriptional activity in mouse osteoblastic cells via its nuclear receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT JE; RAT OSTEOSARCOMA CELLS; HUMAN OSTEOCALCIN GENE; I COLLAGEN-SYNTHESIS; OSTEO-SARCOMA CELLS; LACKING C-FOS; FACTOR-BETA; VITAMIN-D; MC3T3-E1 CELLS; RETINOIC-ACID	The present study demonstrates 1 alpha,25-dehydroxyvitamin D-3 (1 alpha-25-(OH)(2)D-3) synergism toward transforming growth factor (TGF)-beta 1-induced activation protein-1 (AP-1) activity in mouse osteoblastic MC3T3-E1 cells via the nuclear receptor of the vitamin. 1 alpha-25-(OH)(2)D-3 synergistically stimulated TGF-beta 1-induced expression of the c-jun gene in the cells but not that of the c-fos gene. We actually showed by a gel mobility shift assay 1 alpha-25(OH)(2)D-3 synergism of TGF-beta 1-induced AP-1 binding to the 12-(O-tetradecanoylphorbol-13-acetate response element (TRE), 1 alpha-25-(OH)(2)D-3 markedly stimulated the transient activity of TGF-beta 1-induced AP-1 in the cells transfected with a TRE-chloramphenicol acetyltransferase (CAT) reporter gene. Also, a synergistic increase in TGF-beta 1-induced CAT activity was observed in the cells cotransfected with an expression vector encoding vitamin D-3 receptor (VDR) and the reporter gene. However, the synergistic CAT activity was inhibited by pretreatment with VDR antisense oligonucleotides. In addition, in a Northern blot assay, we observed 1 alpha-25(OH)(2)D-3 synergism of TGF-beta 1-induced expression of the c-jun gene in the cells transfected with the VDR expression vector and also found that the synergistic action was clearly blocked by VDR antisense oligonucleotide pretreatment. The present study strongly suggests a novel positive regulation by 1 alpha-25-(OH)(2)D-3 of TGF-beta 1-induced AP-1 activity in osteoblasts via "genommc action.".	Meikai Univ, Sch Dent, Dept Oral Microbiol, Sakado, Saitama 35002, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan	Meikai University; University of Tokyo	Hanazawa, S (corresponding author), Meikai Univ, Sch Dent, Dept Oral Microbiol, Sakado, Saitama 35002, Japan.							BONEWALD LF, 1992, J BIOL CHEM, V267, P8943; BOSKEY AL, 1992, CLIN ORTHOP RELAT R, P244; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNETTE E, 1992, NUCLEIC ACIDS RES, V20, P1151, DOI 10.1093/nar/20.5.1151; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; CHANG PL, 1989, CANCER RES, V264, P9682; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; CHENU C, 1988, P NATL ACAD SCI USA, V85, P5683, DOI 10.1073/pnas.85.15.5683; CIVITELLI R, 1990, ENDOCRINOLOGY, V127, P2253, DOI 10.1210/endo-127-5-2253; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARACHCARSON MC, 1991, ENDOCRINOLOGY, V129, P1876, DOI 10.1210/endo-129-4-1876; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Felix R, 1996, EUR J ENDOCRINOL, V134, P143, DOI 10.1530/eje.0.1340143; FRANCESCHI RT, 1988, J BIOL CHEM, V263, P18938; FRANCESCHI RT, 1990, J BONE MINER RES, V5, P1157; Geilen CC, 1996, FEBS LETT, V378, P88, DOI 10.1016/0014-5793(95)01421-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HANAZAWA S, 1994, J BIOL CHEM, V269, P21379; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HAUSCHKA PV, 1988, CIBA F SYMP, V136, P207; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; INGRAM RT, 1994, DIFFERENTIATION, V55, P153, DOI 10.1046/j.1432-0436.1994.5520153.x; INOUE M, 1992, LIFE SCI, V51, P1105, DOI 10.1016/0024-3205(92)90511-M; JENNINGS JC, 1990, ENDOCRINOLOGY, V126, P1014, DOI 10.1210/endo-126-2-1014; KRUSE K, 1995, J PEDIATR-US, V126, P736, DOI 10.1016/S0022-3476(95)70401-9; KUROKI Y, 1994, CLIN EXP IMMUNOL, V95, P536; KUROKI Y, 1995, J CELL PHYSIOL, V164, P459, DOI 10.1002/jcp.1041640303; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; Maniatis T, 1982, MOL CLONING LABORATO, P194; MIYAUCHI A, 1994, BIOCHEM BIOPH RES CO, V205, P1547, DOI 10.1006/bbrc.1994.2843; MURRAY IA, 1991, NUCLEIC ACIDS RES, V19, P6648; NODA M, 1987, J CELL PHYSIOL, V133, P426, DOI 10.1002/jcp.1041330303; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OKADA S, 1994, MOL CELL BIOL, V14, P382, DOI 10.1128/MCB.14.1.382; OKANO T, 1989, J NUTR SCI VITAMINOL, V35, P529, DOI 10.3177/jnsv.35.529; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OURSLER MJ, 1994, J BONE MINER RES, V9, P443; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; OZONO K, 1990, J BIOL CHEM, V265, P21881; OZONO K, 1991, J BONE MINER RES, V6, P1021; PRICE PA, 1980, J BIOL CHEM, V255, P1660; RAISZ LG, 1972, SCIENCE, V175, P768, DOI 10.1126/science.175.4023.768; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SLATER M, 1994, AM J PHYSIOL-ENDOC M, V267, pE990, DOI 10.1152/ajpendo.1994.267.6.E990; SONE T, 1989, J BIOL CHEM, V264, P20230; SREIN GS, 1993, ENDOCR REV, V14, P424; Staal A, 1996, ENDOCRINOLOGY, V137, P2001, DOI 10.1210/en.137.5.2001; STAAL A, 1994, BONE MINER, V26, P27, DOI 10.1016/S0169-6009(08)80160-2; TAKESHITA A, 1995, J IMMUNOL, V155, P419; TANAKA H, 1991, J BIOL CHEM, V266, P10888; Udagawa N, 1996, BONE, V18, P511, DOI 10.1016/8756-3282(96)00076-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANLEEUWEN JPTM, 1992, J BIOL CHEM, V267, P12562; VERMA IM, 1990, CIBA F SYMP, V150, P128; WALI RK, 1990, J CLIN INVEST, V85, P1296, DOI 10.1172/JCI114567; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; YUKIHIRO S, 1994, J BIOL CHEM, V269, P23889	62	33	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14738	14744		10.1074/jbc.273.24.14738	http://dx.doi.org/10.1074/jbc.273.24.14738			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614072	hybrid			2022-12-25	WOS:000074160400014
J	Webb, NR; Connell, PM; Graf, GA; Smart, EJ; de Villiers, WJS; de Beer, FC; van der Westhuyzen, DR				Webb, NR; Connell, PM; Graf, GA; Smart, EJ; de Villiers, WJS; de Beer, FC; van der Westhuyzen, DR			SR-BII, an isoform of the scavenger receptor BI containing an alternate cytoplasmic tail, mediates lipid transfer between high density lipoprotein and cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; TRANSGENIC MICE; GENE FAMILY; CHOLESTEROL; IDENTIFICATION; PLASMA; RAT; METABOLISM; EXPRESSION; TRANSPORT	The scavenger receptor class B, type I (SR-BI), binds high density lipoprotein (HDL) and mediates selective uptake of cholesteryl ester from HDL and HDL-dependent cholesterol efflux from cells. We recently identified a new mRNA variant that differs from the previously characterized form in that the encoded C-terminal cytoplasmic domain is almost completely different. In the present study, we demonstrate that the mRNAs for mouse SR-BI and SR-BII (previously termed SR-BI.2) are the alternatively spliced products of a single gene. The translation products predicted from human, bovine, mouse, hamster, and rat cDNAs exhibit a high degree of sequence similarity within the SR-BII C-terminal domain (62-67% identity when compared with the human sequence), suggesting that this variant is biologically important. SR-BII protein represents approximately 12% of the total immunodetectable SR-BI/II protein in mouse liver. Subcellular fractionation of transfected Chinese hamster ovary cells showed that SR-BII, like SR-BI, is enriched in caveolae, indicating that the altered cytoplasmic tail does not affect targeting of the receptor. SR-BII mediated both selective cellular uptake of cholesteryl ether from HDL as well as HDL-dependent cholesterol efflux from cells, although with approximately 4-fold lower efficiency than SR-BI, In vivo studies using adenoviral vectors showed that SR-BII was relatively less efficient than SR-BI in reducing plasma HDL cholesterol, These studies show that SR-BII, an HDL, receptor isoform containing a distinctly different cytoplasmic tail, mediates selective lipid transfer between HDL and cells, but with a lower efficiency than the previously characterized variant.	Univ Kentucky, Med Ctr MN520, Dept Internal Med, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Physiol, Lexington, KY 40536 USA; Vet Affairs Med Ctr, Lexington, KY 40511 USA	University of Kentucky; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center	van der Westhuyzen, DR (corresponding author), Univ Kentucky, Med Ctr MN520, Dept Internal Med, 800 Rose St, Lexington, KY 40536 USA.	dvwest1@pop.uky.edu	Webb, Nancy/AAL-7030-2021; Eckhardt, Erik/G-1567-2010	Graf, Gregory/0000-0002-0130-9929	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058475, R01HL058475] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-58475] Funding Source: Medline; NIA NIH HHS [AG-14668] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; CALVO D, 1995, GENOMICS, V25, P100, DOI 10.1016/0888-7543(95)80114-2; CALVO D, 1993, J BIOL CHEM, V268, P18929; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GLASS C, 1985, J BIOL CHEM, V260, P744; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HEDRICK CC, 1993, J BIOL CHEM, V268, P20676; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Johnson MSC, 1998, ENDOCRINOLOGY, V139, P72, DOI 10.1210/en.139.1.72; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LIU MS, 1994, J BIOL CHEM, V269, P11417; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mizutani T, 1997, BIOCHEM BIOPH RES CO, V234, P499, DOI 10.1006/bbrc.1997.6646; Ng DS, 1997, J BIOL CHEM, V272, P15777, DOI 10.1074/jbc.272.25.15777; OLSON EN, 1985, J BIOL CHEM, V260, P3784; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Rajapaksha WRAKJS, 1997, MOL CELL ENDOCRINOL, V134, P59, DOI 10.1016/S0303-7207(97)00173-1; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Webb NR, 1997, J LIPID RES, V38, P1490; WEBB NR, 1997, J LIPID RESHEDR, V38, P45; Welch CL, 1997, MAMM GENOME, V8, P942, DOI 10.1007/s003359900643	37	195	199	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15241	15248		10.1074/jbc.273.24.15241	http://dx.doi.org/10.1074/jbc.273.24.15241			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614139	hybrid			2022-12-25	WOS:000074160400081
J	Skaper, SD; Ancona, B; Facci, L; Franceschini, D; Giusti, P				Skaper, SD; Ancona, B; Facci, L; Franceschini, D; Giusti, P			Melatonin prevents the delayed death of hippocampal neurons induced by enhanced excitatory neurotransmission and the nitridergic pathway	FASEB JOURNAL			English	Article						synaptic transmission; hippocampus; excitotoxicity; NO center dot; ROS; neuroprotection; GSH; astrocytes	NITRIC-OXIDE SYNTHASE; GLUTAMATE NEUROTOXICITY; PYRAMIDAL NEURONS; NERVOUS-SYSTEM; CELL-CULTURE; BRAIN-DAMAGE; GLUTATHIONE; NEURODEGENERATION; EXCITOTOXICITY; DEGENERATION	The mechanisms by which neurons die after stroke and status epilepticus and related neuropathological conditions are unclear, but may involve voltage-dependent Na+ channels, glutamate receptors, and nitric oxide (NO.). These questions were investigated using an in vitro primary cell culture model in which hippocampal pyramidal neurons undergo a gradual and delayed neurodegeneration induced by enhanced excitatory neurotransmission. When cells were treated with Mg2+-free, glycine-supplemented medium for a brief period (15 nain) and examined 24 h later, similar to 30-40% of the neurons had died. Cell death could be inhibited by blockers of voltage-sensitive Na+ channels and by N-methyl-D-aspartate receptor antagonists. Application of either the endogenous antioxidant melatonin (EC50: 19.2+/-2.8 mu M) or the NO. synthase inhibitor N-omega-nitro-L-arginine after, but not during, Mg2+-free exposure protected against delayed neuronal death; significant neuroprotection was observed when the addition was delayed for up to 4 h, This operational time window suggests that an enduring production of NO. and reactive oxygen species from neuronal sources is responsible for delayed cell death. A role fbr reactive oxygen species in this injury process was strengthened by the finding that, whereas neurons cocultured with astroglia were more resistant to killing, agents capable of lowering intracellular glutathione negated this protection. Because secretion levels of melatonin are decreased with aging, reductions in this pineal hormone may place neurons at a heightened risk for damage by excitatory synaptic transmission.	Univ Padua, Dept Pharmacol, I-35131 Padua, Italy; Univ Padua, Dept Organ Chem, I-35131 Padua, Italy; CNR, Biopolymer Res Ctr, I-35131 Padua, Italy	University of Padua; University of Padua; Consiglio Nazionale delle Ricerche (CNR)	Giusti, P (corresponding author), Univ Padua, Dept Pharmacol, Largo E Meneghetti 2, I-35131 Padua, Italy.	stephenskaper-1@sbphrd.com; giusti@dfem.unipd.it		GIUSTi, Pietro/0000-0001-9352-4046				ABELE AE, 1990, NEURON, V4, P413, DOI 10.1016/0896-6273(90)90053-I; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bolanos JP, 1996, FREE RADICAL BIO MED, V21, P995, DOI 10.1016/S0891-5849(96)00240-7; BOTTENSTEIN JE, 1980, EXP CELL RES, V125, P183, DOI 10.1016/0014-4827(80)90202-5; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLIFFORD DB, 1989, EXP NEUROL, V105, P272, DOI 10.1016/0014-4886(89)90130-1; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CROUCHER MJ, 1982, SCIENCE, V216, P899, DOI 10.1126/science.7079744; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; DAWSON VL, 1993, J NEUROSCI, V13, P2651; Desagher S, 1996, J NEUROSCI, V16, P2553; DUBOCOVICH ML, 1988, J PHARMACOL EXP THER, V246, P902; Escames G, 1997, NEUROSCI LETT, V230, P147, DOI 10.1016/S0304-3940(97)00498-9; Floreani M, 1997, FASEB J, V11, P1309, DOI 10.1096/fasebj.11.14.9409550; FURSHPAN EJ, 1989, NEURON, V3, P199, DOI 10.1016/0896-6273(89)90033-0; Gilad E, 1997, LIFE SCI, V60, pPL169, DOI 10.1016/S0024-3205(97)00008-8; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Hou JGG, 1997, J NEUROCHEM, V69, P76; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; IGUCHI H, 1982, J CLIN ENDOCR METAB, V55, P27, DOI 10.1210/jcem-55-1-27; KLATT P, 1994, J BIOL CHEM, V269, P1674; KU RH, 1986, ARCH BIOCHEM BIOPHYS, V247, P183, DOI 10.1016/0003-9861(86)90547-3; Leist M, 1997, EUR J NEUROSCI, V9, P1488, DOI 10.1111/j.1460-9568.1997.tb01503.x; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; Matuszak Z, 1997, FREE RADICAL BIO MED, V23, P367, DOI 10.1016/S0891-5849(96)00614-4; Meister A., 1995, BIOTHIOLS HLTH DIS, P165; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; MODY I, 1987, J NEUROPHYSIOL, V57, P869, DOI 10.1152/jn.1987.57.3.869; MURPHY SN, 1989, MOL PHARMACOL, V35, P671; Olney J W, 1986, Adv Neurol, V44, P857; OLNEY JW, 1969, SCIENCE, V166, P383; Pappolla MA, 1997, J NEUROSCI, V17, P1683; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Pozo D, 1997, J CELL BIOCHEM, V65, P430, DOI 10.1002/(SICI)1097-4644(19970601)65:3<430::AID-JCB12>3.0.CO;2-J; Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; SAGARA J, 1993, J NEUROCHEM, V61, P1672, DOI 10.1111/j.1471-4159.1993.tb09802.x; SKAPER SD, 1991, NEUROSCI LETT, V126, P98, DOI 10.1016/0304-3940(91)90381-3; Skaper SD, 1996, J NEUROCHEM, V66, P1157; SKAPER SD, 1998, IN PRESS J NEUROCHEM; SKAPER SD, 1990, METHODS NEUROSCIENCE, V2, P17; SLIVKA A, 1987, BRAIN RES, V409, P275, DOI 10.1016/0006-8993(87)90712-8; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SOUETRE E, 1989, AM J PSYCHIAT, V146, P1037; Strijbos PJLM, 1996, J NEUROSCI, V16, P5004; Tan DX, 1993, ENDOCR J, V1, P57; VIBULSRETH S, 1987, BRAIN RES, V422, P303, DOI 10.1016/0006-8993(87)90937-1; WOLFF DJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P290, DOI 10.1006/abbi.1995.1040; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213	56	74	77	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1998	12	9					725	731		10.1096/fasebj.12.9.725	http://dx.doi.org/10.1096/fasebj.12.9.725			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619451				2022-12-25	WOS:000074011000011
J	Chiariello, M; Visconti, R; Carlomagno, F; Melillo, RM; Bucci, C; de Franciscis, V; Fox, GM; Jing, SQ; Coso, OA; Gutkind, JS; Fusco, A; Santoro, M				Chiariello, M; Visconti, R; Carlomagno, F; Melillo, RM; Bucci, C; de Franciscis, V; Fox, GM; Jing, SQ; Coso, OA; Gutkind, JS; Fusco, A; Santoro, M			Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret	ONCOGENE			English	Article						tyrosine kinase; transformation; jun; MEN2; thyroid	GTP-BINDING PROTEINS; THYROID PAPILLARY CARCINOMAS; SIGNALING PATHWAY; GROWTH-FACTOR; HIRSCHSPRUNGS-DISEASE; ACTIVATION DOMAIN; RET/PTC1 ONCOGENE; ADAPTER PROTEINS; RESPONSE GENES; AP-1 ACTIVITY	The RET proto-oncogene encodes a functional receptor tyrosine kinase (Ret) for the Glial cell line Derived Neurotrophic Factor (GDNF). RET is involved in several neoplastic and non-neoplastic human diseases. Oncogenic activation of RET is detected in human papillary thyroid tumours and in multiple endocrine neoplasia type 2 syndromes. Inactivating mutations of RET have been associated to the congenital megacolon, i.e. Hirschprung's disease. In order to identify pathways that are relevant for Ret signalling to the nucleus, we have investigated its ability to induce the c-Jun NH2-terminal protein kinases (JNK). Here we show that triggering the endogenous Pet, expressed in PC12 cells, induces JNK activity; moreover, Ret is able to activate JNK either when transiently transfected in COS-1 cells or when stably expressed in NIH3T3 fibroblasts or in PC Cl 3 epithelial thyroid cells. JNK activation is dependent on the Pet kinase function, as a kinase-deficient RET mutant, associated with Hirschsprung's disease, fails to activate JNK. The pathway leading to the activation of JNK by RET is clearly divergent from that leading to the activation of ERK: substitution of the tyrosine 1062 of Pet, the Shc binding site, for phenylalanine abrogates ERK but not JNK activation. Experiments conducted with dominant negative mutants or with negative regulators demonstrate that JNK activation by Pet is mediated by Rho/Rac related small GTPases and, particularly, by Cdc42.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Amgen Inc, Thousand Oaks, CA 91320 USA; NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Univ Reggio Calabria, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Amgen; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria	Santoro, M (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.		Gutkind, J. Silvio/J-1201-2016; Chiariello, Mario/O-3642-2014; Gutkind, J. Silvio/A-1053-2009; Bucci, Cecilia/F-6699-2012; melillo, rosa marina/O-5255-2015; Visconti, Roberta/C-5299-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Chiariello, Mario/0000-0001-8434-5177; Bucci, Cecilia/0000-0002-6232-6183; Fusco, Alfredo/0000-0003-3332-5197; MELILLO, Rosa Marina/0000-0002-9233-5275; Visconti, Roberta/0000-0001-7613-3801				Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CALIFANO D, 1995, ONCOGENE, V11, P107; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRIECO D, 1995, ONCOGENE, V11, P113; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro M, 1996, ONCOGENE, V12, P1821; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	71	104	108	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2435	2445		10.1038/sj.onc.1201778	http://dx.doi.org/10.1038/sj.onc.1201778			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627110	Green Accepted			2022-12-25	WOS:000073672300002
J	Di Como, CJ; Prives, C				Di Como, CJ; Prives, C			Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	ONCOGENE			English	Review						p53; tumor-derived mutants; transactivation; Saccharomyces cerevisiae; FASAY	WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION DOMAIN; C-TERMINAL DOMAIN; DNA-BINDING; MUTANT P53; CELL-LINES; MONOCLONAL-ANTIBODIES; GENE-EXPRESSION; GROWTH ARREST; FISSION YEAST	p53 is a sequence-specific transcriptional activator with a number of known target genes which contain p53-responsive elements. Mutations in p53 have been identified ,within its sequence-specific DNA binding domain in more than half of all human tumors, although a subset of tumor-derived p53 mutants have retained the ability to bind DNA and activate transcription under certain conditions. In order to broaden our understanding of this transactivating ability, we examined the efficacy by which p53 mutants bind to and activate reporters in an Saccharomyces cerevisiae-based assay. Analysis of 19 human tumor-derived p53 mutants, spanning the DNA binding domain of p53 and including the 'hot-spot' class, revealed a broad array of transcriptional transactivation abilities at 24 degrees C, 30 degrees C and 37 degrees C, despite the fact that each mutant had originally been identified as being inactive for transactivation in yeast against a single p53-responsive RGC site-containing reporter. One class of mutants (P177L, R267W, C277Y and R283H) retained wild-type or near wild-type activity that is binding site-selective, even at physiological temperature (37 degrees C). Another class of mutants (V143A, M160I/A161T, H193R, Y220C and I254F), all positioned for maintaining the beta-scaffold of p53, also retained selective activity, but preferentially at sub-physiological temperatures (24 degrees and 30 degrees C). Strikingly, however, in contrast to the other tumor derived mutants, all of the previously identified 'hot-spot' mutants were completely inactive with all sites tested. Moreover, a double mutant, L22E/W23S, located within the activation region and previously shown to be transcriptionally inactive in fibroblasts, retained wildtype or near wild-type binding site-selective activity in yeast. Finally, we found that transcriptional activity in vivo does not necessarily correlate with DNA binding in vitro.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.			DiComo, Charles/0000-0003-2818-9215				ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; BRAIN R, 1994, ONCOGENE, V9, P1775; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; DICOMO CJ, 1995, MOL CELL BIOL, V15, P1835; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gagnebin J, 1998, ONCOGENE, V16, P685, DOI 10.1038/sj.onc.1201568; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUTHRIE JA, 1991, METHODS ENZYMOLOGY, V194; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOVAR H, 1993, ONCOGENE, V8, P2683; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LEGROS Y, 1994, ONCOGENE, V9, P2071; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MILLER CW, 1993, ONCOGENE, V8, P1815; MIYASHITA T, 1995, CELL, V80, P293; NIEWOLIK D, 1995, ONCOGENE, V10, P881; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PARK DJ, 1994, ONCOGENE, V9, P1899; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PICKSLEY SM, 1992, ONCOGENE, V7, P1649; PIENTENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rose M, 1990, LAB COURSE MANUAL ME; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Scolnick DM, 1997, CANCER RES, V57, P3693; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, ONCOGENE, V6, P2055; Shaw P, 1996, ONCOGENE, V12, P921; SIEGEL J, 1995, ONCOGENE, V11, P1363; Silhavy T.J., 1984, EXPT GENE FUSIONS; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WAGNER P, 1993, EUR J BIOCHEM, V217, P731, DOI 10.1111/j.1432-1033.1993.tb18299.x; WAGNER P, 1991, ONCOGENE, V6, P1539; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	110	77	80	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2527	2539						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627118				2022-12-25	WOS:000073672300010
J	Evans, MF; Koreth, J; Bakkenist, CJ; Herrington, CS; McGee, JOD				Evans, MF; Koreth, J; Bakkenist, CJ; Herrington, CS; McGee, JOD			Allelic deletion at 11q23.3-q25 is an early event in cervical neoplasia	ONCOGENE			English	Article						human chromosome 11; clonality; HPV; cervix	CHROMOSOME-11 SUPPRESSES TUMORIGENICITY; HUMAN PAPILLOMAVIRUS INFECTION; TERM FOLLOW-UP; SQUAMOUS CARCINOMA; PROGNOSTIC FACTORS; EPITHELIAL-CELLS; UTERINE CERVIX; HPV GENOTYPES; CANCER; HETEROZYGOSITY	Twenty per cent of cervical intraepithelial neoplasias-III (CIN-III) progress to invasive cancer. Human papillomavirus (HPV) infection alone does not determine progression. GIN-III lesions were collected from 161 women. Each tissue was microdissected into a maximum of 32 contiguous units and assayed at multiple microsatellite loci on chromosome 11q, a region frequently deleted in invasive cervical and other cancers. Eight of 108 informative cases (7%) had 11q23.3-q25 deletions; focally intra-lesional in six tone with focal loss of alternate alleles), and pan-lesional in two cases. Hence, 11q deletion can occur early in cervical neoplasia, and possibly predisposes to invasion.	John Radcliffe Hosp, Nuffield Dept Pathol & Bacteriol, Oxford OX3 9DU, England	University of Oxford	McGee, JOD (corresponding author), John Radcliffe Hosp, Nuffield Dept Pathol & Bacteriol, Oxford OX3 9DU, England.		Herrington, C Simon/I-4895-2014; Herrington, C Simon/O-4688-2017	Herrington, C Simon/0000-0001-9177-8165; Herrington, C Simon/0000-0001-9177-8165				ALNAFUSSI AI, 1994, J CLIN PATHOL, V47, P799, DOI 10.1136/jcp.47.9.799; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; BURGHARDT E, 1983, OBSTET GYNECOL, V62, P117; BURGHARDT E, 1992, LANCET, V340, P1543, DOI 10.1016/0140-6736(92)92793-F; DOWNEY GP, 1994, LANCET, V344, P432, DOI 10.1016/S0140-6736(94)91768-X; FUJINAGA Y, 1991, J GEN VIROL, V72, P1039, DOI 10.1099/0022-1317-72-5-1039; Gabra H, 1996, CANCER RES, V56, P950; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HINCHLIFFE SA, 1995, BRIT J CANCER, V72, P943, DOI 10.1038/bjc.1995.438; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; Horikawa I, 1995, CANCER GENET CYTOGEN, V85, P97, DOI 10.1016/0165-4608(95)00147-6; HUETTNER PC, 1996, LAB INVESTIG S, V74, pA91; HUGHES JR, 1995, NONISOTOPIC METHODS, P145; KENTER GG, 1993, CANCER-AM CANCER SOC, V71, P397, DOI 10.1002/1097-0142(19930115)71:2&lt;397::AID-CNCR2820710221&gt;3.0.CO;2-G; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; Larson AA, 1997, CANCER RES, V57, P4171; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; Muliokandov MR, 1996, CANCER RES, V56, P197; MUNGER K, 1992, CANCER SURV, V12, P197; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; Park TW, 1996, J NATL CANCER I, V88, P355, DOI 10.1093/jnci/88.6.355; PECORARO G, 1991, AM J PATHOL, V138, P1; REMMINK AJ, 1995, INT J CANCER, V61, P306, DOI 10.1002/ijc.2910610305; RochaZavaleta L, 1997, BRIT J CANCER, V75, P1144, DOI 10.1038/bjc.1997.197; Romanini C., 1995, Journal of Obstetrics and Gynaecology (Abingdon), V15, P324, DOI 10.3109/01443619509030933; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; SPRIGGS AI, 1974, CHROMOSOMES CANCER, P423; SREEKANTAIAH C, 1991, CANCER GENET CYTOGEN, V53, P75, DOI 10.1016/0165-4608(91)90116-C; TOMLINSON IPM, 1995, J CLIN PATHOL, V48, P424, DOI 10.1136/jcp.48.5.424; TSUTSUMI K, 1992, AM J PATHOL, V140, P255; VANBOMMEL PFJ, 1993, GYNECOL ONCOL, V48, P333, DOI 10.1006/gyno.1993.1058; WAGGONER SE, 1990, GYNECOL ONCOL, V38, P407, DOI 10.1016/0090-8258(90)90082-V; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; YAJIMA A, 1979, TOHOKU J EXP MED, V129, P75, DOI 10.1620/tjem.129.75	39	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2557	2564		10.1038/sj.onc.1202039	http://dx.doi.org/10.1038/sj.onc.1202039			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627121				2022-12-25	WOS:000073672300013
J	Bull, EK; Chakrabarty, S; Brodsky, I; Haines, DS				Bull, EK; Chakrabarty, S; Brodsky, I; Haines, DS			mdm2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells	ONCOGENE			English	Article						mdm2-P2 transcripts; p53 functional assay	NON-HODGKINS-LYMPHOMAS; WILD-TYPE P53; GENE; EXPRESSION; PROTEIN; ACTIVATION; INDUCTION; APOPTOSIS; OVEREXPRESSION; ONCOGENE	The mdm2-P2 promoter is a transcriptional target of the p53 tumor suppressor. The aim of this study was to determine if there is an association between the level of these transcripts and the status of the p53 gene in human leukemic cells, A correlation between mdm2-P2 transcript levels and p53 gene status was observed in all cell lines examined. Primary malignant cells from 10 leukemic patients were also analysed for both mdm2-P2 levels and p53 gene status, All five patients with detectable mdm2-P2 transcripts possessed wild-type p53 alleles, However, only two of five patients with undetectable mdm2-P2 transcripts possessed mutant p53, mdm2-P2 levels were also determined in primary leukemic cells from 14 additional cases both before and after in vitro exposure to cisplatin. The p53 gene was found to be wild-type in all cases where mdm2-P2 levels were induced by cisplatin, There were four cases where no, or only modest, increases in mdm2-P2 levels were detected after cisplatin exposure, Two of these patients were found to harbor mutant p53 while one other possessed leukemic cells with elevated levels of mdm2 protein, These results show that induction of mdm2-P2 transcripts can be used to predict the presence of transcriptionally active p53 in primary leukemic cells.	Allegheny Univ Hlth Sci, Barry Ashbee Leukemia Res Labs, Philadelphia, PA 19102 USA	Drexel University	Haines, DS (corresponding author), Allegheny Univ Hlth Sci, Barry Ashbee Leukemia Res Labs, MS412,Broad & Vine St, Philadelphia, PA 19102 USA.							BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Bukholm IK, 1997, J PATHOL, V181, P140, DOI 10.1002/(SICI)1096-9896(199702)181:2<140::AID-PATH745>3.0.CO;2-A; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chilosi M, 1996, BLOOD, V88, P4012, DOI 10.1182/blood.V88.10.4012.bloodjournal88104012; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Landers JE, 1997, CANCER RES, V57, P3562; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MAESTRO R, 1995, BLOOD, V85, P3239, DOI 10.1182/blood.V85.11.3239.bloodjournal85113239; Marks DI, 1996, BRIT J HAEMATOL, V92, P890, DOI 10.1046/j.1365-2141.1996.439978.x; Marks DI, 1997, J CLIN ONCOL, V15, P1158, DOI 10.1200/JCO.1997.15.3.1158; MARTINEZ JC, 1995, J PATHOL, V177, P27, DOI 10.1002/path.1711770106; MIYASHITA T, 1995, CELL, V80, P293; MOSNER J, 1994, ONCOGENE, V9, P3321; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Velculescu VE, 1996, CLIN CHEM, V42, P858; WATANABE T, 1994, BLOOD, V84, P3158; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	40	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2249	2257		10.1038/sj.onc.1201757	http://dx.doi.org/10.1038/sj.onc.1201757			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619834				2022-12-25	WOS:000073298000010
J	Healy, E; Belgaid, C; Takata, M; Harrison, D; Zhu, NW; Burd, DAR; Rigby, HS; Matthews, JNS; Rees, JL				Healy, E; Belgaid, C; Takata, M; Harrison, D; Zhu, NW; Burd, DAR; Rigby, HS; Matthews, JNS; Rees, JL			Prognostic significance of allelic losses in primary melanoma	ONCOGENE			English	Article						loss of heterozygosity; fractional allelic loss; tumour suppressor gene; proliferation; p53; p21(WAF1)	HUMAN-MALIGNANT MELANOMA; PRIMARY CUTANEOUS MELANOMA; TUMOR-SUPPRESSOR GENE; P53 PROTEIN; HOMOZYGOUS DELETIONS; METASTATIC MELANOMA; SPORADIC MELANOMA; FAMILIAL MELANOMA; CELL CARCINOMA; POOR-PROGNOSIS	Loss of genetic material, including loss of loci on chromosome arms 6q, 9p, and 10q, occurs frequently in cutaneous melanoma but infrequently in benign melanocytic nevi or other melanocytic lesions, suggesting that these genetic alterations are important in the development and progression of melanoma, To examine whether allelic loss is of prognostic importance in melanoma, disease-free survival was related to loss of heterozygosity on 6q, 9p and 10q in 83 individuals with sporadic primary cutaneous melanoma, Loss of chromosome arms 6q and 10q were each significantly associated with a poorer clinical outcome (P = 0.013 and P = 0.001 respectively). In a subgroup of 41 subjects whose primary tumours mere allelotyped, the fractional allelic loss (FAL) at 39 autosomal arms also significantly correlated with disease-free survival (P = 0.013), with an increase in FAL associated with a poorer outcome; this association remained significant when controlled for tumour thickness (P = 0.035). In addition, a greater proportion of cells were immunopositive for Ki67 antigen, p53 and p21(WAF1) protein in the primary melanomas than in the benign melanocytic nevi, however, only p53 overexpression was significantly associated with improved survival (P = 0.041).	Univ Newcastle Upon Tyne, Dept Dermatol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Newcastle Upon Tyne, Dept Stat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Frenchay Hosp, Dept Plast Surg, Bristol BS16 1LE, Avon, England; Frenchay Hosp, Dept Pathol, Bristol BS16 1LE, Avon, England	Newcastle University - UK; Newcastle University - UK	Rees, JL (corresponding author), Univ Newcastle Upon Tyne, Dept Dermatol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.		Matthews, John N S/H-7502-2013	Matthews, John N S/0000-0003-2559-037X; Healy, Eugene/0000-0001-5591-6970				ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; Barth A, 1995, J Am Coll Surg, V181, P193; Boni R, 1996, J AM ACAD DERMATOL, V35, P416, DOI 10.1016/S0190-9622(96)90607-6; BOUZUBAR N, 1989, BRIT J CANCER, V59, P943, DOI 10.1038/bjc.1989.200; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; Collett D, 1994, MODELLING SURVIVAL D; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FIELD JK, 1995, BRIT J CANCER, V72, P1180, DOI 10.1038/bjc.1995.483; FLORENES VA, 1994, BRIT J CANCER, V69, P253, DOI 10.1038/bjc.1994.48; Flores JF, 1996, CANCER RES, V56, P5023; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FURIHATA M, 1993, CANCER RES, V53, P4823; Gabra H, 1996, CANCER RES, V56, P950; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GRUIS NA, 1995, AM J PATHOL, V146, P1199; HARPER JW, 1993, CELL, V75, P805; Healy E, 1996, J INVEST DERMATOL, V107, P318, DOI 10.1111/1523-1747.ep12363118; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; Healy E, 1996, CANCER RES, V56, P589; HEATON KM, 1993, AM J SURG, V166, P648, DOI 10.1016/S0002-9610(05)80672-5; HERBST RA, 1994, CANCER RES, V54, P3111; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISHIDA T, 1993, CANCER RES, V53, P5000; ISSHIKI K, 1994, ONCOGENE, V9, P1649; ISSHIKI K, 1993, GENE CHROMOSOME CANC, V8, P178, DOI 10.1002/gcc.2870080307; JACKSON DP, 1992, PCR PRACTICAL APPROA, P29; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1995, ONCOGENE, V10, P1855; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kim SK, 1997, CANCER RES, V57, P400; LEE SM, 1995, BRIT MED BULL, V51, P609, DOI 10.1093/oxfordjournals.bmb.a072982; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LUBBE J, 1994, J INVEST DERMATOL, V102, P819, DOI 10.1111/1523-1747.ep12381544; MAEDA K, 1994, CANCER, V73, P528, DOI 10.1002/1097-0142(19940201)73:3<528::AID-CNCR2820730306>3.0.CO;2-P; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MILLIKIN D, 1991, CANCER RES, V51, P5449; MONTANO X, 1994, ONCOGENE, V9, P1455; MORTON DL, 1993, CANCER-AM CANCER SOC, V71, P3737, DOI 10.1002/1097-0142(19930601)71:11<3737::AID-CNCR2820711143>3.0.CO;2-7; MUHONEN T, 1992, BRIT J CANCER, V66, P528, DOI 10.1038/bjc.1992.307; OHTA M, 1994, CANCER RES, V54, P5269; Prescher G, 1996, LANCET, V347, P1222; PUIG S, 1995, AM J HUM GENET, V57, P395; QUELLE DE, 1995, CELL, V83, P993; QUINLAN DC, 1992, CANCER RES, V52, P4828; RAMSAY JA, 1995, J INVEST DERMATOL, V105, P22, DOI 10.1111/1523-1747.ep12312431; Ray ME, 1997, P NATL ACAD SCI USA, V94, P3229, DOI 10.1073/pnas.94.7.3229; Rees JL, 1996, CLIN EXP DERMATOL, V21, P253, DOI 10.1111/j.1365-2230.1996.tb00089.x; ROSES DF, 1983, ANN SURG, V198, P65, DOI 10.1097/00000658-198307000-00013; SCHEISTROEN M, 1995, CANCER, V75, P72, DOI 10.1002/1097-0142(19950101)75:1<72::AID-CNCR2820750113>3.0.CO;2-G; *STATA CORP, 1997, STATA STAT SOFTW REL; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STRETCH JR, 1991, CANCER RES, V51, P5976; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; TAKAHASHI S, 1995, CANCER RES, V55, P4114; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; TRENT JM, 1990, NEW ENGL J MED, V322, P1508, DOI 10.1056/NEJM199005243222107; UMEBAYASHI Y, 1995, ARCH DERMATOL RES, V287, P718, DOI 10.1007/BF01105795; Valverde P, 1996, HUM MOL GENET, V5, P1663, DOI 10.1093/hmg/5.10.1663; VIDAL MJ, 1995, MELANOMA RES, V5, P243, DOI 10.1097/00008390-199508000-00006; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; Wang YP, 1996, ONCOGENE, V12, P1069; Weinberg RA, 1995, CANCER SURV, V25, P3; Wiest JS, 1997, CANCER RES, V57, P1	70	72	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2213	2218		10.1038/sj.onc.1200203	http://dx.doi.org/10.1038/sj.onc.1200203			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619830	Bronze			2022-12-25	WOS:000073298000006
J	Takeda, K; Ichijo, H; Fujii, M; Mochida, Y; Saitoh, M; Nishitoh, H; Sampath, TK; Miyazono, K				Takeda, K; Ichijo, H; Fujii, M; Mochida, Y; Saitoh, M; Nishitoh, H; Sampath, TK; Miyazono, K			Identification of a novel bone morphogenetic protein-responsive gene that may function as a noncoding RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS HOMEOBOX GENE; TGF-BETA SUPERFAMILY; OSTEOGENIC PROTEIN-1; SIGNALING PATHWAYS; MAD PROTEINS; XIST GENE; H19 GENE; DIFFERENTIATION; BMP-4; RECEPTOR	Bone morphogenetic proteins (BMPs)/osteogenic proteins (OPs), members of the transforming growth factor-beta superfamily, have a wide variety of effects on many cell types including osteoblasts and chondroblasts, and play critical roles in embryonic development, BMPs transduce their effects through binding to two different types of serine/threonine kinase receptors, type I and type II. Signaling by these receptors is mediated by the recently identified Smad proteins. Despite the rapid progress in understanding of the signaling mechanism downstream of BMP receptors, the target genes of BMPs are poorly understood in mammals. Here we identified a novel gene, termed BMP/OP-responsive gene (BORG), in C2C12 mouse myoblast cell line which trans-differentiates into osteoblastic cells in response to BMPs. Expression of BORG was dramatically induced in C2C12 cells by the treatment with BMP-2 or OP-l within 2 h and peaked at 12-24 h, whereas transforming growth factor-beta had a minimal effect. BMP-dependent expression of BORG was also detected in other cell types which are known to respond to BMPs, suggesting that BORG is a common target gene of BMPs. Cloning and sequence analysis of BORG; cDNA and the genomic clones revealed that, unexpectedly, the transcript of BORG lacks any extensive open reading frames and contains a cluster of multiple interspersed repetitive sequences in its middle part. The unusual structural features suggested that BORG may function as a noncoding RNA, although it is spliced and polyadenylated as authentic protein-coding mRNAs. Together with the observation that transfection of antisense oligonucleotides of BORG partially inhibited BMP-induced differentiation in C2C12 cells, it is possible that a new class of RNA molecules may have certain roles in the differentiation process induced by BMPs.	Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Tokyo 1708455, Japan; Creat Biomol Inc, Hopkinton, MA 01748 USA	Japanese Foundation for Cancer Research	Ichijo, H (corresponding author), Tokyo Med & Dent Univ, Dept Biomat Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.			Ichijo, Hidenori/0000-0002-5005-6438; Mochida, Yoshiyuki/0000-0002-2115-4303; Takeda, Kohsuke/0000-0002-8359-8399; Nishitoh, Hideki/0000-0002-8652-4109				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asahina I, 1996, EXP CELL RES, V222, P38, DOI 10.1006/excr.1996.0005; ASKEW DS, 1994, MOL CELL BIOL, V14, P1743, DOI 10.1128/MCB.14.3.1743; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Ault KT, 1996, P NATL ACAD SCI USA, V93, P6415, DOI 10.1073/pnas.93.13.6415; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; FINI ME, 1989, J CELL BIOL, V108, P2045, DOI 10.1083/jcb.108.6.2045; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Kuroda MI, 1997, CELL, V91, P9, DOI 10.1016/S0092-8674(01)80003-9; Ladher R, 1996, DEVELOPMENT, V122, P2385; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Mead PE, 1996, NATURE, V382, P357, DOI 10.1038/382357a0; Nishitoh H, 1996, J BIOL CHEM, V271, P21345, DOI 10.1074/jbc.271.35.21345; Okada N, 1991, CURR OPIN GENET DEV, V1, P498, DOI 10.1016/S0959-437X(05)80198-4; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; Padgett Richard W., 1997, Cytokine and Growth Factor Reviews, V8, P1, DOI 10.1016/S1359-6101(96)00050-0; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; Schmidt JE, 1996, DEVELOPMENT, V122, P1711; SMIT AFA, 1993, NUCLEIC ACIDS RES, V21, P1863, DOI 10.1093/nar/21.8.1863; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Suzuki A, 1997, DEVELOPMENT, V124, P3037; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; VELLECA MA, 1994, MOL CELL BIOL, V14, P7095, DOI 10.1128/MCB.14.11.7095; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XU RH, 1997, MOL CELL BIOL, V17, P486; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; YULUG IG, 1995, GENOMICS, V27, P544, DOI 10.1006/geno.1995.1090; Zhang HB, 1996, DEVELOPMENT, V122, P2977	61	46	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17079	17085		10.1074/jbc.273.27.17079	http://dx.doi.org/10.1074/jbc.273.27.17079			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642273	hybrid			2022-12-25	WOS:000074545200063
J	Tang, J; Gary, JD; Clarke, S; Herschman, HR				Tang, J; Gary, JD; Clarke, S; Herschman, HR			PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ZINC-FINGER; S-ADENOSYLMETHIONINE; TRANSCRIPTION FACTOR; BINDING; CLONING; GENE; RNA; METHYLATION; EXPRESSION	Methylation is one of the many post-translational modifications that modulate protein function. Although asymmetric N-G,N-G-dimethylation of arginine residues in glycine-arginine-rich domains of eucaryotic proteins, catalyzed by type I protein arginine N-methyltransferases (PRMT), has been known for some time, members of this enzyme class have only recently been cloned. The first example of this type of enzyme, designated PRMT1, cloned because of its ability to interact with the mammalian TIS21 immediate-early protein, was then shown to have protein arginine methyltransferase activity, We have now isolated rat and human cDNA orthologues that encode proteins with substantial sequence similarity to PRMT1. A recombinant glutathione S-transferase (GST) fusion product of this new rat protein, named PRMT3, asymmetrically dimethylates arginine residues present both in the designed substrate GST-GAR and in substrate proteins present in hypomethylated extracts of a yeast rmt1 mutant that lacks type I arginine methyltransferase activity; PRMT3 is thus a functional type I protein arginine N-methyltransferase, However, rat PRMT1 and PRMT3 glutathione S-transferase fusion proteins have distinct enzyme specificities for substrates present in both hypomethylated rmt1 yeast extract and hypomethylated RAT1 embryo cell extract. TIS21 protein modulates the enzymatic activity of recombinant GST-PRMT1 fusion protein but not the activity of GST-PRMT3, Western blot analysis of gel filtration fractions suggests that PRMT3 is present as a monomer in RAT1 cell extracts. In contrast, PRMT1 is present in an oligomeric complex. Immunofluorescence analysis localized PRMT1 predominantly to the nucleus of RAT1 cells. In contrast, PRMT3 is predominantly cytoplasmic.	Univ Calif Los Angeles, Mol Biol Inst 341, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Herschman, HR (corresponding author), Univ Calif Los Angeles, Mol Biol Inst 341, 611 Circle Dr E, Los Angeles, CA 90095 USA.	hherschman@mednet.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020, R01GM024797] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26020, GM24797] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bailey JL, 1967, TECHNIQUES PROTEIN C, P340; BOEHM T, 1990, ONCOGENE, V5, P1103; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; GOTTSCHLING H, 1962, NATURE, V196, P829, DOI 10.1038/196829a0; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; HEINE MA, 1993, MOL BIOL CELL, V4, P1189, DOI 10.1091/mbc.4.11.1189; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Katsanis N, 1997, MAMM GENOME, V8, P526, DOI 10.1007/s003359900491; Kim S, 1997, INT J BIOCHEM CELL B, V29, P743, DOI 10.1016/S1357-2725(97)00009-5; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KUJUBU DA, 1987, ONCOGENE, V1, P257; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LAPEYRE B, 1985, NUCLEIC ACIDS RES, V13, P5805, DOI 10.1093/nar/13.16.5805; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LIM RW, 1987, ONCOGENE, V1, P263; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LIU Q, 1995, MOL CELL BIOL, V15, P2800; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; PIELER T, 1994, MOL BIOL REP, V20, P1, DOI 10.1007/BF00999848; RAWAL N, 1995, BBA-PROTEIN STRUCT M, V1248, P11, DOI 10.1016/0167-4838(94)00213-Z; RAWAL N, 1994, BIOCHEM J, V300, P483, DOI 10.1042/bj3000483; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Tang J, 1998, ARCH BIOCHEM BIOPHYS, V349, P192, DOI 10.1006/abbi.1997.0453; WANG C, 1982, J BIOL CHEM, V257, P8356; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; XIE HY, 1993, J BIOL CHEM, V268, P13364	41	268	272	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16935	16945		10.1074/jbc.273.27.16935	http://dx.doi.org/10.1074/jbc.273.27.16935			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642256	hybrid			2022-12-25	WOS:000074545200046
J	Antinozzi, PA; Segall, L; Prentki, M; McGarry, JD; Newgard, CB				Antinozzi, PA; Segall, L; Prentki, M; McGarry, JD; Newgard, CB			Molecular or pharmacologic perturbation of the link between glucose and lipid metabolism is without effect on glucose-stimulated insulin secretion - A re-evaluation of the long-chain acyl-CoA hypothesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS-MEDIATED TRANSFER; MALONYL-COA; PANCREATIC-ISLETS; CARNITINE PALMITOYLTRANSFERASE; FATTY-ACIDS; RAT; LANGERHANS; KETOGENESIS; OBESITY; ESTERS	The mechanism by which glucose stimulates insulin secretion from the pancreatic islets of Langerhans is incompletely understood. It has been suggested that malonyl-CoA plays a regulatory role by inhibiting fatty acid oxidation and promoting accumulation of cytosolic long-chain acyl-CoA (LC-CoA). In the current study, we have re evaluated this "long-chain acyl-CoA hypothesis" by using molecular and pharmacologic methods to perturb lipid metabolism in INS-1 insulinoma cells or rat islets during glucose stimulation. First, we constructed a recombinant adenovirus containing the cDNA encoding malonyl-CoA decarboxylase (AdCMV-MCD), an enzyme that decarboxylates malonyl-CoA to acetyl-CoA. INS-1 cells treated with AdCMV-MCD had dramatically lowered intracellular malonyl CoA levels compared with AdCMV-beta Gal-treated cells at both 3 and 20 mM glucose. Further, at 20 mM glucose, AdCMV-MCD-treated cells were less effective at suppressing [1-C-14]palmitate oxidation and incorporated 43% less labeled palmitate and 50% less labeled glucose into cellular lipids than either AdCMV-beta GAL-treated or untreated INS-1 cells. Despite the large metabolic changes caused by expression of MCD, insulin secretion in response to glucose was unaltered relative to controls. The alternative, pharmacologic approach for perturbing lipid metabolism was to use triacsin C to inhibit long-chain acyl-CoA synthetase. This agent caused potent attenuation of palmitate oxidation and glucose or palmitate incorporation into cellular lipids and also caused a 47% decrease in total LC-CoA. Despite this, the drug had no effect on glucose-stimulated insulin secretion in islets or INS-1 cells. We conclude that significant disruption of the link between glucose and lipid metabolism does not impair glucose-stimulated insulin secretion in pancreatic islets or INS-1 cells.	Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Montreal, Inst Canc Montreal, Ctr Rech LC Simard, Dept Nutr,Mol Nutr Unit, Montreal, PQ H2L 4M1, Canada	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Universite de Montreal	Newgard, CB (corresponding author), Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Rm Y8-212,5323 Harry Hines Blvd, Dallas, TX 75235 USA.	Newgard@utsw.swmed.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018573, R01DK046492, R37DK046492, R37DK018573] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 18573, DK 46492-05] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARCON C, 1993, J BIOL CHEM, V268, P4276; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BECKER TC, 1994, METHOD CELL BIOL, V43, P162; BEDOYA FJ, 1984, DIABETES, V33, P858, DOI 10.2337/diabetes.33.9.858; CHEN SY, 1994, DIABETES, V43, P878, DOI 10.2337/diabetes.43.7.878; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DOBBINS RL, 1997, IN PRESS J CLIN INVE; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hosokawa H, 1997, DIABETOLOGIA, V40, P392, DOI 10.1007/s001250050692; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; JANG SH, 1989, J BIOL CHEM, V264, P3500; Koyama K, 1997, DIABETES, V46, P1276, DOI 10.2337/diabetes.46.8.1276; LIANG Y, 1991, DIABETES, V40, P327, DOI 10.2337/diabetes.40.3.327; McCrory W.J., 1988, VIROLOGY, V163, P614; MCGARRY JD, 1979, J BIOL CHEM, V254, P8163; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Noel RJ, 1997, J BIOL CHEM, V272, P18621, DOI 10.1074/jbc.272.30.18621; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; SENER A, 1991, BIOCHIMIE, V73, P1287, DOI 10.1016/0300-9084(91)90090-N; Stein DT, 1997, J CLIN INVEST, V100, P398, DOI 10.1172/JCI119546; Stein DT, 1996, J CLIN INVEST, V97, P2728, DOI 10.1172/JCI118727; TAMARITRODRIGUEZ J, 1984, BIOCHEM J, V221, P317, DOI 10.1042/bj2210317; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Zhang SY, 1998, CELL SIGNAL, V10, P35, DOI 10.1016/S0898-6568(97)00070-3; ZHOU YP, 1995, J CLIN ENDOCR METAB, V80, P1584, DOI 10.1210/jc.80.5.1584	33	136	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16146	16154		10.1074/jbc.273.26.16146	http://dx.doi.org/10.1074/jbc.273.26.16146			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632669	hybrid			2022-12-25	WOS:000074436600040
J	Li, N; Seetharam, S; Seetharam, B				Li, N; Seetharam, S; Seetharam, B			Characterization of the human transcobalamin II promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; THYMIDYLATE SYNTHASE PROMOTER; BOX-BINDING-PROTEINS; LONG TERMINAL REPEAT; TRANSCRIPTION INITIATION; LESS PROMOTER; SP1; FAMILY; GENE; ELEMENT	Deletion and mutagenesis of the 5'-flanking region of the human transcobalamin II (TC II) transfected in hu man intestinal epithelial Caco-2 cells have revealed that TC II promoter activity is: (a) very weak; (b) restricted to a core region (-29 to -163) that contained multiple transcription initiation sites; (c) not dependent on other potential elements, such as a distally localized CCAAT box, a CF1, a HIP1 binding motif and a MED-1 element; (d) modulated weakly by a positive-acting GC box (-568-GAGGCGGTGC) and strongly by a proximal GC/GT overlapping box (-179 CCCCCGCCCCACCCC). Gel shift and immunosupershift analyses demonstrated that both the positive-acting GC box and the negative-acting GC/GT box were recognized by Sp1 and Sp3. Co-transfection studies using Sp1 and/or Sp3 expression plasmids revealed that while Sp1 stimulated, Sp3 repressed Sp1-mediated transactivation of TC II transcription. The proximal GC/GT box also acted as a negative element in human chronic myelogenous leukemia K-562 and HeLa cells. These results suggest that tissue/cell specific expression of the TC II gene may be controlled by the relative ratios of Sp1 and Sp3 that bind to the GC/GT box and the weak promoter activity of TC II is due to the transcriptional repression caused by the binding of Sp3 to the proximal GC/GT box.	Med Coll Wisconsin, MACC Fund Ctr, Dept Med, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, MACC Fund Ctr, Dept Biochem, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Ctr Vet Med, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Seetharam, B (corresponding author), Med Coll Wisconsin, MACC Fund Ctr, Dept Med, Div Gastroenterol & Hepatol, Rm 6061,8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	seethara@post.itsmcw.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026638, R01DK050052] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-26638, DK-50052] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER RS, 1994, J BIOL CHEM, V269, P4381; COOPER BA, 1987, ANNU REV NUTR, V7, P291, DOI 10.1146/annurev.nu.07.070187.001451; COUNREY A, 1992, KINGSCRIPTIONAL REGU, P743; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GENG YP, 1993, MOL CELL BIOL, V13, P4894, DOI 10.1128/MCB.13.8.4894; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HANDY DE, 1995, BIOCHEM J, V311, P541, DOI 10.1042/bj3110541; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; JACOB E, 1980, PHYSIOL REV, V60, P918, DOI 10.1152/physrev.1980.60.3.918; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; LANS MS, 1994, J BIOL CHEM, V269, P14170; LI N, 1994, BIOCHEM BIOPH RES CO, V204, P1111, DOI 10.1006/bbrc.1994.2577; LI N, 1995, BIOCHEM BIOPH RES CO, V208, P756, DOI 10.1006/bbrc.1995.1402; LI N, 1994, HUM MOL GENET, V3, P1835, DOI 10.1093/hmg/3.10.1835; LI N, 1994, BIOCHEM J, V301, P585, DOI 10.1042/bj3010585; LI N, 1993, BIOCHIM BIOPHYS ACTA, V1219, P515; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; LIAO WC, 1994, GENE, V146, P183, DOI 10.1016/0378-1119(94)90291-7; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; Okumura K, 1996, J BIOL CHEM, V271, P12944, DOI 10.1074/jbc.271.22.12944; QUADROS EV, 1986, J BIOL CHEM, V261, P5455; RAMANUJAM KS, 1991, AM J PHYSIOL, V260, pG416, DOI 10.1152/ajpgi.1991.260.3.G416; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; Rolland V, 1996, J BIOL CHEM, V271, P21297, DOI 10.1074/jbc.271.35.21297; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Sjottem E, 1996, J VIROL, V70, P188; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767	46	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16104	16111		10.1074/jbc.273.26.16104	http://dx.doi.org/10.1074/jbc.273.26.16104			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632663	hybrid			2022-12-25	WOS:000074436600034
J	Wu, P; Brockenbrough, JS; Metcalfe, AC; Chen, SP; Aris, JP				Wu, P; Brockenbrough, JS; Metcalfe, AC; Chen, SP; Aris, JP			Nop5p is a small nucleolar ribonucleoprotein component required for pre-18 S rRNA processing in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							18S RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; PRERIBOSOMAL RNA; U3 SNRNA; PROTEIN; FIBRILLARIN; METHYLATION; IDENTIFICATION; HOMOLOGY; COMMON	We have identified a novel nucleolar protein, Nop5p, that is essential for growth in Saccharomyces cerevisiae. Monoclonal antibodies B47 and 37C12 recognize Nop5p, which has a predicted size of 57 kDa and possesses a KKX repeat motif at its carboxyl terminus. Truncations that removed the KKX motif were functional and localized to the nucleolus, but conferred slow growth at 37 degrees C. Nop5p shows significant sequence homology with yeast Sik1p/Nop56p, and putative homologues in archaebacteria, plants, and human. Depletion of Nop5p in a GAL-NOP5 strain lengthened the doubling time about 5-fold, and selectively reduced steady-state levels of 40 S ribosomal subunits and 18 S rRNA relative to levels of free 60 S subunits and 25 S rRNA. Northern blotting and primer extension analyses showed that Nop5p depletion impairs processing of 35 S pre-rRNA at the A(0) and A(2) cleavage sites. Nop5p is associated with the small nucleolar RNAs U3, snR13, U14, and U18. Depletion of Nop5p caused the nucleolar protein Nop1p (yeast fibrillarin) to be localized to the nucleus and cytosol. Also, 37C12 coimmunoprecipitated Nop1p. These results suggest that Nop5p functions with Nop1p in the execution of early pre-rRNA processing steps that lead to formation of 18 S rRNA.	Univ Florida, Hlth Sci Ctr, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Aris, JP (corresponding author), Univ Florida, Hlth Sci Ctr, Dept Anat & Cell Biol, Box 100235, Gainesville, FL 32610 USA.	johnaris@college.med.ufl.edu	Davies, Angela/AAU-9716-2020	Davies, Angela/0000-0002-3365-7231; Aris, John/0000-0002-6475-064X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048586] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48586, R01 GM048586-05] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V1; BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; BousquetAntonelli C, 1997, EMBO J, V16, P4770, DOI 10.1093/emboj/16.15.4770; Cadwell C, 1997, MOL CELL BIOL, V17, P6175, DOI 10.1128/MCB.17.10.6175; Chen SP, 1997, J BIOL CHEM, V272, P10839; DEBEUS E, 1994, J CELL BIOL, V127, P1799, DOI 10.1083/jcb.127.6.1799; Dove JE, 1998, METHOD CELL BIOL, V53, P33; Dujon B, 1997, NATURE, V387, P98, DOI 10.1038/387s098; Dunbar DA, 1997, MOL CELL BIOL, V17, P5803, DOI 10.1128/MCB.17.10.5803; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; ENGLAND TE, 1978, NATURE, V275, P560, DOI 10.1038/275560a0; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Hong B, 1997, MOL CELL BIOL, V17, P378, DOI 10.1128/MCB.17.1.378; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JANSEN R, 1993, EMBO J, V12, P2549, DOI 10.1002/j.1460-2075.1993.tb05910.x; JARMOLOWSKI A, 1990, EMBO J, V9, P4503, DOI 10.1002/j.1460-2075.1990.tb07901.x; JIANG WD, 1993, MOL CELL BIOL, V13, P4884, DOI 10.1128/MCB.13.8.4884; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MORIN PJ, 1995, CELL GROWTH DIFFER, V6, P789; Morrissey JP, 1997, CHROMOSOMA, V105, P515, DOI 10.1007/BF02510488; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; Saavedra C, 1996, GENE DEV, V10, P1608, DOI 10.1101/gad.10.13.1608; Sambrook J., 1989, MOL CLONING, pA1; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLLNERWEBB B, 1996, RIBOSOMAL RNA STRUCT, P469; TERNS MP, 1994, SCIENCE, V264, P959, DOI 10.1126/science.8178154; TERNS MP, 1995, EMBO J, V14, P4860, DOI 10.1002/j.1460-2075.1995.tb00167.x; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Tollervey D, 1996, EXP CELL RES, V229, P226, DOI 10.1006/excr.1996.0364; Venema J, 1997, MOL CELL BIOL, V17, P3398, DOI 10.1128/MCB.17.6.3398; Venema J, 1996, EMBO J, V15, P5701, DOI 10.1002/j.1460-2075.1996.tb00954.x; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; Weaver PL, 1997, MOL CELL BIOL, V17, P1354, DOI 10.1128/MCB.17.3.1354	45	120	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16453	16463		10.1074/jbc.273.26.16453	http://dx.doi.org/10.1074/jbc.273.26.16453			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632712	hybrid, Green Accepted			2022-12-25	WOS:000074436600083
J	Cao, MY; Huber, M; Beauchemin, N; Famiglietti, J; Albelda, SM; Veillette, A				Cao, MY; Huber, M; Beauchemin, N; Famiglietti, J; Albelda, SM; Veillette, A			Regulation of mouse PECAM-1 tyrosine phosphorylation by the Src and Csk families of protein-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE-1 PECAM-1; CELL-ADHESION; CYTOPLASMIC DOMAIN; NEGATIVE REGULATION; T-LYMPHOCYTES; SH2 DOMAIN; GENE; LIGAND; CD31; CLONING	PECAM-1 is an adhesion molecule expressed on hemopoietic and endothelial cells. Recently, it was observed that PECAM-1 becomes tyrosine-phosphorylated in response to a variety of physiological stimuli. Furthermore, tyrosine-phosphorylated PECAM-1 was shown to associate with SHP-2, a Src homology 2 (SH2) domain-containing protein-tyrosine phosphatase expressed ubiquitously. In light of the significance of tyrosine protein phosphorylation as a regulatory mechanism, we wished to understand better the nature and impact of the protein-tyrosine kinases (PTKs) mediating PECAM-1 tyrosine phosphorylation. Through reconstitution experiments in COS-l cells, we determined that mouse PECAM-1 could be tyrosine-phosphorylated by Src-related PTKs and Csk-related PTKs, but not by other kinases such as Syk, Itk, and Pyk2. Using site-directed mutagenesis and peptide phosphorylation studies, we found that these PTKs were efficient at phosphorylating Tyr-686, but not Tyr-663, of PECARI-1. Src-related enzymes also phosphorylated mouse PECAM-1 at one or more yet to be identified sites. In other studies, we demonstrated that phosphorylation of PECAM-1 by Src or Csk family kinases was sufficient to trigger its association with SHP-2, Moreover, it was able to promote binding of PECAM-1 to SHP-1, a SHP-8-related protein-tyrosine phosphatase expressed in hemopoietic cells. Taken together, these findings indicated that the Src and Csk families of kinases are strong candidates for mediating tyrosine phosphorylation of PECAM-1 and triggering its association with SH2 domain-containing phosphatases under physiological circumstances.	McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; Montreal Gen Hosp, Dept Med, Montreal, PQ H3G 1A4, Canada; Montreal Gen Hosp, Dept Oncol, Montreal, PQ H3G 1A4, Canada; Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19014 USA	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; University of Pennsylvania	Veillette, A (corresponding author), McGill Univ, Ctr Canc, Rm 715,McIntyre Med Sci Bld,3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046311, R01HL046311] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46311] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; Buckley CD, 1996, J CELL SCI, V109, P437; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Chow L M, 1995, Semin Immunol, V7, P207, DOI 10.1006/smim.1995.0026; CHOW LML, 1994, ONCOGENE, V9, P3437; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Deaglio S, 1996, J IMMUNOL, V156, P727; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; Famiglietti J, 1997, J CELL BIOL, V138, P1425, DOI 10.1083/jcb.138.6.1425; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Jackson DE, 1997, J BIOL CHEM, V272, P24868, DOI 10.1074/jbc.272.40.24868; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Joukov V, 1997, BIOCHEM J, V322, P927, DOI 10.1042/bj3220927; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Law CL, 1996, MOL CELL BIOL, V16, P1305; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lu TT, 1997, J BIOL CHEM, V272, P14442, DOI 10.1074/jbc.272.22.14442; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; Masuda M, 1997, FEBS LETT, V408, P331, DOI 10.1016/S0014-5793(97)00457-2; MCVICAR DW, 1994, ONCOGENE, V9, P2037; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Osawa M, 1997, EUR J CELL BIOL, V72, P229; PERI KG, 1993, ONCOGENE, V8, P2765; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Prager E, 1996, J EXP MED, V184, P41, DOI 10.1084/jem.184.1.41; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; Sagawa K, 1997, J BIOL CHEM, V272, P13412, DOI 10.1074/jbc.272.20.13412; Sagawa K, 1997, J BIOL CHEM, V272, P31086, DOI 10.1074/jbc.272.49.31086; SHARENBERG AM, 1996, CELL, V87, P961; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; Sun J, 1996, J BIOL CHEM, V271, P18561, DOI 10.1074/jbc.271.31.18561; Sun QH, 1996, J BIOL CHEM, V271, P11090, DOI 10.1074/jbc.271.19.11090; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; van Oers N S, 1995, Semin Immunol, V7, P227, DOI 10.1006/smim.1995.0027; WATT SM, 1993, BLOOD, V82, P2649	52	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15765	15772		10.1074/jbc.273.25.15765	http://dx.doi.org/10.1074/jbc.273.25.15765			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624175	hybrid			2022-12-25	WOS:000074284200069
J	Gonzalez-Barroso, MM; Fleury, C; Bouillaud, F; Nicholls, DG; Rial, E				Gonzalez-Barroso, MM; Fleury, C; Bouillaud, F; Nicholls, DG; Rial, E			The uncoupling protein UCP1 does not increase the proton conductance of the inner mitochondrial membrane by functioning as a fatty acid anion transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; ADP/ATP CARRIER; H+ TRANSPORT; GUINEA-PIG; MECHANISM; ACTIVATION; ENERGETICS	The activity of the brown fat uncoupling protein (UCP1) is regulated by purine nucleotides and fatty acids, Although the inhibition by nucleotides is well established, the activation by fatty acids is still controversial. It has been reported that the ADP/ATP carrier, and possibly other members of the mitochondrial carrier family, mediate fatty acid uncoupling of mitochondria from a variety of sources by facilitating the transibilayer movement of the fatty acid anion. Brown fat mitochondria are known to be more sensitive to fatty acid uncoupling, a property that has been assigned to the presence of UCP1. We have analyzed the transport properties of UCP1 and conclude that fatty acids are not essential for UCP1 function, although they increase its uncoupling activity. Hn order to establish the difference between the proposed carrier-mediated uncoupling and that exerted through UCP1, we have studied the facility with which fatty acids uncouple respiration in mitochondria from control yeast and strains expressing UCP1 or the mutant Cys-304 --> Gly. The concentration of free palmitate required for half-maximal activation of respiration in UCP1-expressing mitochondria is 80 or 40 nM for the mutant protein. These concentrations have virtually no effect on the respiration of mitochondria from control yeast and are nearly 3 orders of magnitude lower than those reported for carrier-mediated uncoupling We propose that there exist two modes of fatty acid-mediated uncoupling; nanomolar concentrations activate proton transport through UCP1, but only if their concentrations rise to the micromolar range do they become substrates for nonspecific carrier-mediated uncoupling.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; CNRS, Ctr Rech Endocrinol Mol & Dev, F-92190 Meudon, France; Univ Dundee, Ninewells Med Sch, Inst Neurosci, Dundee DD1 9SY, Scotland	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Centre National de la Recherche Scientifique (CNRS); University of Dundee	Gonzalez-Barroso, MM (corresponding author), CSIC, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.	rial@fresno.csic.es	Rial, Eduardo/A-4242-2008; NICHOLLS, DAVID G/K-4300-2012; Bouillaud, Frédéric R/L-3238-2017	Rial, Eduardo/0000-0001-8634-8902; Bouillaud, Frédéric R/0000-0002-7518-9237; GONZALEZ BARROSO, MARIA DEL MAR/0000-0002-0278-8298				ANDREYEV AY, 1988, FEBS LETT, V226, P265, DOI 10.1016/0014-5793(88)81436-4; ANDREYEV AY, 1989, EUR J BIOCHEM, V182, P585, DOI 10.1111/j.1432-1033.1989.tb14867.x; ARECHAGA I, 1993, BIOCHEM J, V296, P693, DOI 10.1042/bj2960693; BRUSTOVETSKY N, 1994, J BIOL CHEM, V269, P27329; CUNNINGHAM SA, 1986, EUR J BIOCHEM, V157, P415, DOI 10.1111/j.1432-1033.1986.tb09683.x; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; GonzalezBarroso MM, 1996, EUR J BIOCHEM, V239, P445, DOI 10.1111/j.1432-1033.1996.0445u.x; HOHORST HJ, 1968, H-S Z PHYSIOL CHEM, V349, P268; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; JEZEK P, 1994, J BIOL CHEM, V269, P26184; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; Laloi M, 1997, NATURE, V389, P135, DOI 10.1038/38156; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LOCKE RM, 1982, EUR J BIOCHEM, V129, P373, DOI 10.1111/j.1432-1033.1982.tb07060.x; LOCKE RM, 1982, EUR J BIOCHEM, V129, P381, DOI 10.1111/j.1432-1033.1982.tb07061.x; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; NICHOLLS DG, 1976, EUR J BIOCHEM, V62, P223, DOI 10.1111/j.1432-1033.1976.tb10151.x; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NICHOLLS DG, 1977, EUR J BIOCHEM, V77, P349, DOI 10.1111/j.1432-1033.1977.tb11674.x; PALMIERI F, 1993, J BIOENERG BIOMEMBR, V25, P525, DOI 10.1007/BF01108409; Polcic P, 1997, FEBS LETT, V412, P207, DOI 10.1016/S0014-5793(97)00778-3; PRESSMAN BC, 1956, BIOCHIM BIOPHYS ACTA, V21, P458, DOI 10.1016/0006-3002(56)90182-2; RAFAEL J, 1969, H-S Z PHYSIOL CHEM, V350, P1121, DOI 10.1515/bchm2.1969.350.2.1121; RIAL E, 1984, BIOCHEM J, V222, P685, DOI 10.1042/bj2220685; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; Samartsev VN, 1997, BBA-BIOENERGETICS, V1319, P251, DOI 10.1016/S0005-2728(96)00166-1; Schonfeld P, 1996, EUR J BIOCHEM, V240, P387, DOI 10.1111/j.1432-1033.1996.0387h.x; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; VAARTJES WJ, 1978, BIOCHIM BIOPHYS ACTA, V503, P437, DOI 10.1016/0005-2728(78)90143-3; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; Wieckowski MR, 1997, BIOCHEM BIOPH RES CO, V232, P414; WINKLER E, 1994, J BIOL CHEM, V269, P2508; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y; WOJTCZAK L, 1967, BIOCHEM BIOPH RES CO, V28, P76, DOI 10.1016/0006-291X(67)90409-3	36	83	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15528	15532		10.1074/jbc.273.25.15528	http://dx.doi.org/10.1074/jbc.273.25.15528			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624141	Green Published, hybrid			2022-12-25	WOS:000074284200035
J	Gum, RJ; McLaughlin, MM; Kumar, S; Wang, ZL; Bower, MJ; Lee, JC; Adams, JL; Livi, GP; Goldsmith, EJ; Young, PR				Gum, RJ; McLaughlin, MM; Kumar, S; Wang, ZL; Bower, MJ; Lee, JC; Adams, JL; Livi, GP; Goldsmith, EJ; Young, PR			Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; CYTOKINE BIOSYNTHESIS; IDENTIFICATION; DOMAINS; FAMILY; YEAST	Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase compete with ATP for binding, Mutation of 23 residues in the ATP pocket indicated that several residues which affected binding of pyridinyl imidazole photoaffinity cross-linker I-125-SB 206718 did not affect kinase activity, and vice versa, suggesting that pyridinyl imidazoles bind p38 differently than ATP. Two close homologues of p38, SAPK3 and SAPK4, are not inhibited by SE 203580 and differ from p38 by three amino acids near the hinge of the ATP pocket. Substitution of the three amino acids in p38 by those in SAPK3/4 (Thr-106, His-107, and Leu-108 to Met, I?ro, and Phe) resulted in decreased I-125-SB 206718 cross-linking and loss of inhibition by SE 203580. Substitution of just Thr-106 by Met resulted in incomplete loss of inhibition. Conversely, substitution of the three amino acids of p38 into SAPK3, SAPK4, or the more distantly related JNK1 resulted in inhibition by SE 203580, whereas mutation of just Met-106 to Thr resulted in weaker inhibition. These results indicate that these three amino acids can confer specificity and sensitivity to SE 203580 for at least two different classes of MAPKs.	SmithKline Beecham Pharmaceut, Dept Biol Mol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Comparat Genet, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Cellular Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Phys & Struct Chem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Med Chem, King Of Prussia, PA 19406 USA; Univ Texas, SW Med Ctr, Dept Biochem & Biophys, Dallas, TX 75235 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Young, PR (corresponding author), SmithKline Beecham Pharmaceut, Dept Biol Mol, POB 1539, King Of Prussia, PA 19406 USA.	peter_r_young@sbphrd.com						BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Gallagher TF, 1997, BIOORGAN MED CHEM, V5, P49, DOI 10.1016/S0968-0896(96)00212-X; Garnes KT, 1996, J LABELLED COMPD RAD, V38, P637, DOI 10.1002/(SICI)1099-1344(199607)38:7<637::AID-JLCR871>3.0.CO;2-T; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KUMAR S, 1995, J BIOL CHEM, V270, P29043, DOI 10.1074/jbc.270.49.29043; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	28	210	231	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15605	15610		10.1074/jbc.273.25.15605	http://dx.doi.org/10.1074/jbc.273.25.15605			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624152	hybrid			2022-12-25	WOS:000074284200046
J	Nakamura, H; Oda, T; Hamada, K; Hirano, T; Shimizu, N; Utiyama, H				Nakamura, H; Oda, T; Hamada, K; Hirano, T; Shimizu, N; Utiyama, H			Survival by Mac-1-mediated adherence and anoikis in phorbol ester-treated HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE-C; MYELOID-LEUKEMIA CELLS; CULTURED HUMAN-MONOCYTES; TERMINAL DIFFERENTIATION; PROMYELOCYTIC LEUKEMIA; SPHINGOSINE KINASE; DNA FRAGMENTATION; INDUCED APOPTOSIS; PROTOONCOGENE EXPRESSION	During the exposure of human myelocytic leukemia HL-60 cells to phorbol diester, nonadherent cells die by apoptosis, but adherent cells survive rand growth-arrest at G(1) phase of the cell cycle. Here we have shown that the adherent cells rapidly died by apoptosis after forced detachment (anoikis), indicating that phorbol diester induced apoptosis by default. Dimethylsphingosine induced apoptosis in the adherent cells, and sphingosine-1-phosphate rescued the detached cells from apoptosis, Sphingosine kinase activity in adherent cells was higher than that in nonadherent cells and was decreased by forced detachment. It is likely that the phorbol diester-induced apoptosis and the adhesion-mediated survival are modulated by sphingosine and sphinposine-1-phosphate, respectively. The adherent cells were reverted and reproliferated when allowed to spontaneously detach from plastic surfaces by removal of phorbol tliester, This result suggests that after removal of phorbol diester, the commitment signal of apoptosis by default is lost faster than the survival signal by adherence.	Hiroshima Univ, Fac Integrated Arts & Sci, Life Sci Grp, Higashihiroshima 7398521, Japan; Helix Res Inst, Kisarazu 2920812, Japan	Hiroshima University	Utiyama, H (corresponding author), Hiroshima Univ, Fac Integrated Arts & Sci, Life Sci Grp, Kagamiyama 1-7-1, Higashihiroshima 7398521, Japan.		Oda, Tsukasa/ABI-1855-2020; Hirano, Tetsuo/N-1808-2019	Hirano, Tetsuo/0000-0002-2495-4998; Oda, Tsukasa/0000-0002-8941-161X				ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARNAOUT MA, 1990, BLOOD, V75, P1037; Baran J, 1996, INFECT IMMUN, V64, P4242, DOI 10.1128/IAI.64.10.4242-4248.1996; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; Buehrer BM, 1996, BBA-LIPID LIPID MET, V1303, P233, DOI 10.1016/0005-2760(96)00092-6; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1987, BLOOD, V70, P1233; COOPER RA, 1982, P NATL ACAD SCI-BIOL, V79, P2865, DOI 10.1073/pnas.79.9.2865; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DALTON WT, 1988, BLOOD, V71, P242; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; ECK SL, 1993, MOL CELL BIOL, V13, P6530, DOI 10.1128/MCB.13.10.6530; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; GALLAGHER R, 1979, BLOOD, V54, P713; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GUNJI H, 1992, J CLIN INVEST, V89, P954, DOI 10.1172/JCI115677; HASEGAWASASAKI H, 1985, BIOCHEM J, V232, P99, DOI 10.1042/bj2320099; HASS R, 1991, CELL GROWTH DIFFER, V2, P541; HICKSTEIN DD, 1987, J IMMUNOL, V138, P513; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISHIZAKI Y, 1995, MOL BIOL CELL, V6, P1443, DOI 10.1091/mbc.6.11.1443; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; LEE LS, 1978, J ENVIRON PATHOL TOX, V1, P627; Liles WC, 1997, CURR OPIN INFECT DIS, V10, P165, DOI 10.1097/00001432-199706000-00002; Mano N, 1997, ANAL BIOCHEM, V244, P291, DOI 10.1006/abio.1996.9891; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; MEINHARDT G, 1995, LEUKEMIA RES, V19, P699, DOI 10.1016/0145-2126(95)00040-U; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MILLER LJ, 1986, J IMMUNOL, V137, P2891; MUNN DH, 1995, J EXP MED, V181, P127, DOI 10.1084/jem.181.1.127; NAUMOVSKI L, 1994, BLOOD, V83, P2261; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; ODA T, 1993, INT J HEMATOL, V58, P125; OHTA H, 1995, CANCER RES, V55, P691; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PAHL HL, 1992, BLOOD, V79, P865; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROSMARIN AG, 1989, BLOOD, V73, P131; ROSMARIN AG, 1992, BLOOD, V79, P2598; ROVERA G, 1980, NATURE, V284, P69, DOI 10.1038/284069a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sakakura C, 1996, FEBS LETT, V379, P177, DOI 10.1016/0014-5793(95)01508-6; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHIMIZU N, 1994, CANCER RES, V54, P3561; SKOGLUND G, 1988, CANCER RES, V48, P3168; SOKOLOSKI JA, 1993, BLOOD, V82, P625; SOLARY E, 1994, LEUKEMIA, V8, P792; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; TERUI Y, 1995, J BIOCHEM-TOKYO, V117, P77, DOI 10.1093/oxfordjournals.jbchem.a124725; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; WRIGHT SD, 1984, J CELL BIOL, V99, P336, DOI 10.1083/jcb.99.1.336; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	61	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15345	15351		10.1074/jbc.273.25.15345	http://dx.doi.org/10.1074/jbc.273.25.15345			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624115	hybrid			2022-12-25	WOS:000074284200009
J	Schirmer, EC; Queitsch, C; Kowall, AS; Parsell, DA; Lindquist, S				Schirmer, EC; Queitsch, C; Kowall, AS; Parsell, DA; Lindquist, S			The ATPase activity of Hsp104, effects of environmental conditions and mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ACTIVATED ATPASE; DEPENDENT CLP PROTEASE; T7 RNA-POLYMERASE; ESCHERICHIA-COLI; BINDING SITES; SACCHAROMYCES-CEREVISIAE; EXPRESSION; COMPONENT; GENES; IDENTIFICATION	Hspl04 is crucial for stress tolerance in Saccharomyces cerevisiae, and both of its nucleotide-binding domains (NBD1 and NBD2) are required. Here, we characterize the ATPase activity and oligomerization properties of wild-type (WT) Hsp104 and of NBD mutants, In physiological ionic strength buffers (pH 7.5, 37 degrees C) WT Hsp104 exhibits Michaelis-Menten kinetics between 0.5 and 25 mM ATP (K-m similar to 5 mM, V-max similar to 2 nmol min(-1) mu g(-1)). ATPase activity is strongly influenced by factors that vary with cell stress (e.g. temperature, pH, and ADP). Mutations in the P-loop of NBD1 (G217V or K218T) severely reduce ATP hydrolysis but have little effect on oligomerization. Analogous mutations in NBD2 (G619V or K620T) have smaller effects on ATPase activity but impair oligomerization. The opposite relationship was reported for another member of the HSP100 protein family, the Escherichia coli ClpA protein, in studies employing lower ionic strength buffers. Ire such buffers, the K-m of WT Hsp104 for ATP hydrolysis decreased 10-fold and its stability under stress conditions increased, but the effects of the NBD mutations on ATPase activity and oligomerization remained opposite to those of ClpA Either the functions of the two NBDs in ClpA and Hsp104 have been reversed or both contribute to ATP hydrolysis and oligomerization in a complex manner that can be idiosyncratically affected by such mutations.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	University of Chicago; Howard Hughes Medical Institute; University of Chicago	Lindquist, S (corresponding author), 5841 S Maryland Ave,MC1028,Rm AMB N339, Chicago, IL 60637 USA.	s-lindquist@uchicago.edu		Schirmer, Eric/0000-0003-2635-1338	NIGMS NIH HHS [6 T32 GM07183-19] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; KAKEI M, 1986, FEBS LETT, V208, P63, DOI 10.1016/0014-5793(86)81533-2; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lindquist S, 1995, COLD SPRING HARB SYM, V60, P451, DOI 10.1101/SQB.1995.060.01.050; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; PAINTER GR, 1989, P NATL ACAD SCI USA, V86, P2239, DOI 10.1073/pnas.86.7.2239; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SEOL JH, 1995, J BIOL CHEM, V270, P8087, DOI 10.1074/jbc.270.14.8087; Shin DH, 1996, FEBS LETT, V398, P151, DOI 10.1016/S0014-5793(96)01223-9; SINGH SK, 1994, J BIOL CHEM, V269, P29537; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Turgay K, 1997, GENE DEV, V11, P119, DOI 10.1101/gad.11.1.119; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEITZEL G, 1987, EXP CELL RES, V170, P64, DOI 10.1016/0014-4827(87)90117-0; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WILSON SA, 1995, J BIOL CHEM, V270, P18818, DOI 10.1074/jbc.270.32.18818; WOO KM, 1992, J BIOL CHEM, V267, P20429	34	105	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15546	15552		10.1074/jbc.273.25.15546	http://dx.doi.org/10.1074/jbc.273.25.15546			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624144	hybrid			2022-12-25	WOS:000074284200038
J	Stratikos, E; Gettins, PGW				Stratikos, E; Gettins, PGW			Mapping the serpin-proteinase complex using single cysteine variants of alpha(1)-proteinase inhibitor Pittsburgh	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-PROTEINASE INHIBITOR; PROTEASE COMPLEXES; POTENT INHIBITOR; ANTI-THROMBIN; FACTOR-XII; ALPHA-1-ANTITRYPSIN; KALLIKREIN; TRYPSIN; REACTIVITY; SITE	To probe the covalent serpin-proteinase complex, we used wild-type and 4 new single cysteine variants (T85C, S121C, D159C, and D298C) of alpha(1)-proteinase inhibitor Pittsburgh. Cysteines in each variant could be labeled both in native and proteinase-complexed alpha(1)-proteinase inhibitors. Pre-reaction with 7-nitrobenz-2-oxa-1,3-diazole-chloride or fluorescein prevented complex formation only with the D298C variant. Label at Cys(121) greatly increased the stoichiometry of inhibition for thrombin and gave an emission spectrum that discriminated between native, cleaved, and proteinase-complexed serpin and between complexes with trypsin and thrombin, whereas fluorophore at residue 159 ore helix F was almost insensitive to complex formation. Fluorescence resonance energy transfer measurements for covalent and non-covalent complexes were consistent with a location of the proteinase at the end of the serpin distal from the original location of the reactive center loop, Taken together, these findings are consistent with a serpin-proteinase complex in which the reactive center loop is fully inserted into beta-sheet A, and the proteinase is at the far end of the serpin from its initial site of docking with the reactive center loop close to, but not obscuring, residue 121.	Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gettins, PGW (corresponding author), Univ Illinois, Dept Biochem & Mol Biol, M-C 536,1819-1853 W Polk St, Chicago, IL 60612 USA.	pgettins@tigger.cc.uic.edu	Stratikos, Efstratios/N-2969-2014	Stratikos, Efstratios/0000-0002-3566-2309	NHLBI NIH HHS [HL49234] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049234, R01HL049234] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKO H, 1972, BIOCHEM BIOPH RES CO, V47, P1402, DOI 10.1016/0006-291X(72)90228-8; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; JOHANSEN H, 1987, MOL BIOL MED, V4, P291; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LEWIS JH, 1978, BLOOD, V51, P129; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PANNELL R, 1974, BIOCHEMISTRY-US, V13, P5439, DOI 10.1021/bi00723a031; PATSTON PA, 1994, SEMIN THROMB HEMOST, V20, P410, DOI 10.1055/s-2007-1001929; PATSTON PA, 1990, J BIOL CHEM, V265, P10786; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; SCHAPIRA M, 1986, J CLIN INVEST, V77, P635, DOI 10.1172/JCI112347; SCOTT CF, 1986, J CLIN INVEST, V77, P631, DOI 10.1172/JCI112346; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Whisstock J, 1996, PROTEINS, V26, P288, DOI 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	22	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15582	15589		10.1074/jbc.273.25.15582	http://dx.doi.org/10.1074/jbc.273.25.15582			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624149	hybrid			2022-12-25	WOS:000074284200043
J	Heitmeier, MR; Scarim, AL; Corbett, JA				Heitmeier, MR; Scarim, AL; Corbett, JA			Double-stranded RNA-induced inducible nitric-oxide synthase expression and interleukin-1 release by murine macrophages requires NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; BETA-CELLS; INHIBITION; REPLICATION; SYSTEM; SIGNAL	The effects of double-stranded RNA (synthetic polyi nosinic-polycytidylic acid; poly(I-C)) on macrophage expression of inducible nitric-oxide synthase (iNOS), production of nitric oxide, and release of interleukin-1 (IL-1) were investigated. Individually, poly(I-C), interferon-gamma (IFN-gamma), and lipopolysaccharide (LPS) stimulate late nitrite production and iNOS expression by RAW 264.7 cells. In combination, the effects of poly(I-C) + IFN-gamma are additive, while poly(I-C) does not further potentiate LPS-induced nitrite production. These re suits suggest that poly(I-C) and LPS may stimulate iNOS expression by similar signaling pathways, which may be independent of pathways activated by IFN-gamma, LPS-induced iNOS expression is associated with the activation of NF-kappa B. We show that inhibition of NF-kappa B by pyrrolidine dithiocarbamate prevents poly(I-C) + IFN-gamma-, poly(I-C) + LPS-, and LPS-induced iNOS expression, nitrite production and I kappa B degradation by RAW 264.7 cells. The effects of poly(I-C) on iNOS expression appear to be cell-type specific. Poly(I-C), alone or in combination with IFN-gamma, does not stimulate, nor does poly(I-C) potentiate, IL-1-induced nitrite production by rat insulinoma RINm5F cells. In addition, we show that the combination of poly(I-C) + IFN-gamma stimulates iNOS expression, nitrite production I kappa B degradation, and the release of IL-1 by primary mouse macrophages, and these effects are prevented by pyrrolidinedithiocarbamate. These findings indicate that double-stranded RNA, in the presence of IFN-gamma, is a potent activator of macrophages, stimulating iNOS expression, nitrite production, and IL-1 release by a mechanism which requires the activation of NF-kappa B.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Corbett, JA (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	corbettj@wpogate.slu.edu			NIDDK NIH HHS [DK-52194] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052194] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER P, 1971, NATURE-NEW BIOL, V232, P76, DOI 10.1038/newbio232076a0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BEDOYA FJ, 1995, BIOCHEM BIOPH RES CO, V210, P816, DOI 10.1006/bbrc.1995.1731; BROWN T, 1991, CURRENT PROTOCOLS MO, V1; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; BURATOWSKI S, 1991, CURRENT PROTOCOLS MO, V1; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CORBETT JA, 1992, DIABETES, V41, P552, DOI 10.2337/diabetes.41.4.552; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; HIBBS JB, 1990, INT CONGR SER, V897, P189; Hill JR, 1996, ANAL BIOCHEM, V236, P14, DOI 10.1006/abio.1996.0125; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; KIM HK, 1995, J IMMUNOL, V154, P4741; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; Kreil TR, 1996, VIROLOGY, V219, P304, DOI 10.1006/viro.1996.0252; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mannick JB, 1995, RES IMMUNOL, V146, P693, DOI 10.1016/0923-2494(96)84920-0; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MARCUS PI, 1984, INTERFERON, V3, P113; MCNAIR ANB, 1992, PHARMACOL THERAPEUT, V56, P79, DOI 10.1016/0163-7258(92)90038-2; MELKOVA Z, 1995, J IMMUNOL, V155, P5711; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULSCH A, 1993, FEBS LETT, V321, P215, DOI 10.1016/0014-5793(93)80111-7; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; SCHMIDT HHHW, 1992, FEBS LETT, V307, P102, DOI 10.1016/0014-5793(92)80910-9; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; TORRES BA, 1985, BIOCHEM BIOPH RES CO, V131, P395, DOI 10.1016/0006-291X(85)91815-7	39	94	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15301	15307		10.1074/jbc.273.24.15301	http://dx.doi.org/10.1074/jbc.273.24.15301			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614147	hybrid			2022-12-25	WOS:000074160400089
J	Swope, MD; Sun, HW; Klockow, B; Blake, P; Lolis, E				Swope, MD; Sun, HW; Klockow, B; Blake, P; Lolis, E			Macrophage migration inhibitory factor interactions with glutathione and S-hexylglutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MIF; TRANSFERASE HOMOLOGS; PURIFICATION; CYTOKINE; PROTEINS; BINDING	Macrophage migration inhibitory factor (MIF) has been reported to interact with glutathione and S-hexylglutathione and to possess glutathione S-transferase activity. However, contrary to these reports, a recent NMR study concluded that MIF shows no affinity for glutathione. Re-examination of the glutathione-MIF interactions indicates that the reported increase in fluorescence upon addition of glutathione is because of pH-induced unfolding of the protein and not to any direct interactions. Circular dichroism shows that MIF remains folded from pH 4.5-7.5 but is 50% unfolded at pH 2.9 +/- 0.2. The reported increase in fluorescence can be achieved by acid titration. Under strongly buffered conditions, no fluorescence change is observed upon addition of glutathione. In contrast to the results with glutathione, MIF binds S-hexylglutathione with a K-d of 2.5 +/- 0.6 mM. Using NMR spectroscopy, a binding site which clusters around the N-terminal proline was identified. These data indicate that the binding site for S-hexylglutathione is the same as the catalytic site for the dopachrome tautomerase activity of MIF. Consequently, the binding of S-hexylglutathione as well as hexanethiol inhibits this catalytic activity.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; Bayer Corp, Div Pharmaceut, Inst Chem, W Haven, CT 06516 USA	Yale University; Bayer AG	Lolis, E (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06510 USA.			Lolis, Elias/0000-0002-7902-7868				Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Bernhagen J, 1996, J EXP MED, V183, P277, DOI 10.1084/jem.183.1.277; BLOCKI FA, 1993, PROTEIN SCI, V2, P2095, DOI 10.1002/pro.5560021210; BLOCKI FA, 1992, NATURE, V360, P269, DOI 10.1038/360269a0; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; DROGE W, 1994, FASEB J, V8, P1131; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; IRITA K, 1994, CIRC SHOCK, V42, P115; Meinhardt A, 1996, ENDOCRINOLOGY, V137, P5090, DOI 10.1210/en.137.11.5090; Mikulowska A, 1997, J IMMUNOL, V158, P5514; Muhlhahn P, 1996, PROTEIN SCI, V5, P2095; NISHIHIRA J, 1993, BIOCHEM MOL BIOL INT, V31, P841; PEARSON WR, 1994, PROTEIN SCI, V3, P525; RAIMBAULT C, 1995, EUR J BIOCHEM, V234, P570, DOI 10.1111/j.1432-1033.1995.570_b.x; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Rosengren E, 1997, FEBS LETT, V417, P85, DOI 10.1016/S0014-5793(97)01261-1; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Suzuki H, 1996, IMMUNOL LETT, V51, P141, DOI 10.1016/0165-2478(96)02543-6; SWOPE M, 1998, IN PRESS EMBO J; Waeber G, 1997, P NATL ACAD SCI USA, V94, P4782, DOI 10.1073/pnas.94.9.4782	27	24	24	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14877	14884		10.1074/jbc.273.24.14877	http://dx.doi.org/10.1074/jbc.273.24.14877			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614090	hybrid			2022-12-25	WOS:000074160400032
J	Cheng, HL; Feldman, EL				Cheng, HL; Feldman, EL			Bidirectional regulation of p38 kinase and c-Jun N-terminal protein kinase by insulin-like growth factor-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; CELL-DEATH; MAP KINASE; DIFFERENTIAL ACTIVATION; INFLAMMATORY CYTOKINES; TRANSCRIPTION FACTORS; SYMPATHETIC NEURONS; INDUCED APOPTOSIS; MAMMALIAN-CELLS; JNK ACTIVATION	We have previously shown that insulin-like growth factor I (IGF-I) activation of the IGF-I receptor rescues SH-SY5Y human neuroblastoma cells from high glucose-mediated programmed cell death (PCD). In the current study, we further explored the potential points in the cell death cascade where IGF-I receptor activation may afford neuroprotection. As an initial step, we examined the effects of the PCD stimulus, high glucose, on stress-activated protein kinases, specifically the two mitogen-activated protein kinases p38 kinase and c-Jun N-terminal kinase (JNK). High glucose treatment activated the tyrosine phosphorylation of both p38 kinase and JNK in a dose- and time-dependent fashion. We next examined the effects of IGF-I on JNF and p38 kinase under normoglycemic and hyperglycemic conditions. IGF-I activated p38 kinase alone and had additive effects on glucose-induced p38 kinase phosphorylation. In contrast, IGF-I inhibited glucose activation of JNK phosphorylation and JNK activity. IGF-I also inhibited the glucose-induced nuclear translocation of JNK, but did not effect glucose-induced translocation of p38 kinase. Finally, IGF-I inhibition of JNK phosphorylation was blocked by the mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor, PD98059, Collectively, these data imply cross-talk between the mitogen-activated protein kinase pathway and JNK and suggest that IGF-I activation of mitogen-activated protein kinases interferes with JNK activation and protects cells from PCD.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, 200 Zina Pitcher Pl,4414 Kresge III, Ann Arbor, MI 48109 USA.			Feldman, Eva/0000-0002-9162-2694	NINDS NIH HHS [R01 NS36778, R29 NS32843] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032843, R01NS036778] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P40; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FANGER CR, 1997, CURR OPIN GENE DEV, V7, P67; FELDMAN EL, 1993, ANN NY ACAD SCI, V692, P262; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gandhi D, 1995, INT CONGR SER, V1084, P183; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Heidenreich KA, 1996, J BIOL CHEM, V271, P9891, DOI 10.1074/jbc.271.17.9891; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; ISHII DN, 1994, PHARMACOL THERAPEUT, V62, P125, DOI 10.1016/0163-7258(94)90007-8; Jessell TM, 1996, CURR OPIN NEUROBIOL, V6, P1, DOI 10.1016/S0959-4388(96)80001-8; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; KOLBE M, 1990, CONNECT TISSUE RES, V25, P77, DOI 10.3109/03008209009009814; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1995, ANN NY ACAD SCI, V766, P303, DOI 10.1111/j.1749-6632.1995.tb26683.x; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; LAVENIUS E, 1994, GROWTH FACTORS, V10, P29, DOI 10.3109/08977199409019601; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Lim R, 1996, J BIOL CHEM, V271, P22953, DOI 10.1074/jbc.271.38.22953; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARTIN DM, 1993, REGUL PEPTIDES, V48, P225, DOI 10.1016/0167-0115(93)90351-8; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Matthews CC, 1997, NEUROSCIENCE, V79, P525, DOI 10.1016/S0306-4522(96)00611-2; MATTHEWS CC, 1996, J CELL PHYSL, V166, P323; McCormick SD, 1996, GEN COMP ENDOCR, V101, P3, DOI 10.1006/gcen.1996.0002; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; RUSSELL JW, 1996, ANN NEUROL, V40, P954; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SARA VR, 1986, P NATL ACAD SCI USA, V83, P4904, DOI 10.1073/pnas.83.13.4904; Singleton JR, 1996, CANCER RES, V56, P4522; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; SULLIVAN KA, 1994, ENDOCRINOLOGY, V135, P540, DOI 10.1210/en.135.2.540; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Syu LJ, 1997, J CELL BIOCHEM, V67, P367, DOI 10.1002/(SICI)1097-4644(19971201)67:3<367::AID-JCB8>3.3.CO;2-N; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Virdee K, 1997, J NEUROCHEM, V69, P550; WAKIEWICZ AJ, 1997, EMBO J, V16, P1909; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WOODGETT JR, 1995, CLIN EXP PHARMACOL P, V22, P281, DOI 10.1111/j.1440-1681.1995.tb01995.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; ZACKENFELS K, 1995, NEURON, V14, P731, DOI 10.1016/0896-6273(95)90217-1	73	98	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14560	14565		10.1074/jbc.273.23.14560	http://dx.doi.org/10.1074/jbc.273.23.14560			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603971	hybrid			2022-12-25	WOS:000074021500073
J	Chu, DM; Francis, SH; Thomas, JW; Maksymovitch, EA; Fosler, M; Corbin, JD				Chu, DM; Francis, SH; Thomas, JW; Maksymovitch, EA; Fosler, M; Corbin, JD			Activation by autophosphorylation or cGMP binding produces a similar apparent conformational change in cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CARDIAC-MUSCLE; REGULATORY SUBUNIT; CYCLIC-AMP; CAMP; PHOSPHORYLATION; DOMAINS; HEART; PURIFICATION; INHIBITION; INCREASES	Binding of cyclic nucleotide to or autophosphorylation of cGMP-dependent protein kinase (PKG) activates this kinase, but the molecular mechanism of activation for either process is unknown. Activation of PKG by cGMP binding produces a conformational change in the enzyme (Chu, D.-M., Corbin, J. D., Grimes, K. A., and Francis, S. H. (1997) J. Biol. Chem. 272, 31922-31928; Zhao, J., Trewhella, J., Corbin, J., Francis, S., Mitchell, R., Brushia, R., and Walsh, D. (1997) J. Biol. Chem. 272, 39129-31936). In the present studies, activation of type Ip PKG by either autophosphorylation or cGMP-binding alone causes (i) an electronegative charge shift on ion exchange chromatography, (ii) a similar increase (similar to 3.5 Pi) in the Stokes radius as determined by gel filtration chromatography, and (iii) a similar decrease in the mobility of the enzyme on native gel electrophoresis. Consistent with these results, cGMP binding increases the rate of phosphoprotein phosphatase-l catalyzed dephosphorylation of PKG which is autophosphorylated only at Ser-63 (not activated); however, dephosphorylation of PKC: that is highly autophosphorylated (activated) is not stimulated by cGMP. The combined results suggest that activation of PKG by either autophosphorylation or cGMP binding alone produces a similar apparent elongation of the enzyme, implying that either process activates the enzyme by a similar molecular mechanism.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Corbin, JD (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041269] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40029] Funding Source: Medline; NIGMS NIH HHS [GM41269] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P219, DOI 10.1016/0167-4838(84)90025-6; CADENA DL, 1994, J BIOL CHEM, V269, P260; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; COHN EJ, 1943, PROTEINS AMINO ACIDS, P424; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1988, METHOD ENZYMOL, V159, P74; ERLICHMAN J, 1974, J BIOL CHEM, V249, P5000; FLOCKHART DA, 1980, J BIOL CHEM, V255, P4435; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; Francis SH, 1998, METHODS, V14, P81, DOI 10.1006/meth.1997.0567; GAO ZH, 1992, BIOCHEMISTRY-US, V31, P6126, DOI 10.1021/bi00141a024; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; HOFMANN F, 1983, EUR J BIOCHEM, V130, P599, DOI 10.1111/j.1432-1033.1983.tb07191.x; Johnson LN, 1997, ADV SEC MESS PHOSPH, V31, P11; LANDGRAF W, 1986, EUR J BIOCHEM, V154, P113, DOI 10.1111/j.1432-1033.1986.tb09365.x; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PoteetSmith CE, 1997, J BIOL CHEM, V272, P379; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; RANNELS SR, 1983, METHOD ENZYMOL, V99, P55; Rosen O M, 1975, Adv Cyclic Nucleotide Res, V5, P253; ROSSI S, 1992, CELL SIGNAL, V4, P443, DOI 10.1016/0898-6568(92)90038-A; SCOTT CW, 1985, J BIOL CHEM, V260, P2274; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Smith JA, 1996, J BIOL CHEM, V271, P20756, DOI 10.1074/jbc.271.34.20756; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAKIO K, 1982, P NATL ACAD SCI-BIOL, V79, P2544, DOI 10.1073/pnas.79.8.2544; VEREB G, 1989, INT J BIOCHEM, V21, P1137, DOI 10.1016/0020-711X(89)90056-6; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WOLFE L, 1989, J BIOL CHEM, V264, P7734; Zhao JK, 1997, J BIOL CHEM, V272, P31929, DOI 10.1074/jbc.272.50.31929	35	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14649	14656		10.1074/jbc.273.23.14649	http://dx.doi.org/10.1074/jbc.273.23.14649			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603983	hybrid			2022-12-25	WOS:000074021500085
J	Liang, FQ; Gardner, DC				Liang, FQ; Gardner, DC			Autocrine/paracrine determinants of strain-activated brain natriuretic peptide gene expression in cultured cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-VENTRICULAR HYPERTROPHY; RENIN-ANGIOTENSIN SYSTEM; GROWTH FACTOR-BETA(1) EXPRESSION; MESSENGER-RNA; RAT CARDIOMYOCYTES; CELL HYPERTROPHY; OVERLOAD; ENDOTHELIN-1; RECEPTOR; PROTEIN	The application of mechanical strain leads to activation of human brain natriuretic peptide gene promoter activity, a marker of hypertrophy, in cultured neonatal rat ventricular myocytes. We have used a combination of transient transfection analysis and reverse transcriptase-polymerase chain reaction to examine the role of locally produced factors in contributing to this activation. Conditioned media from strained, but not static, cultures led to a dose-dependent increase in human brain natriuretic peptide gene promoter activity. This increase was completely blocked by losartan or BQ-123, implying a role for angiotensin and endothelin as autocrine/paracrine mediators of the response to strain. Inclusion of the same antagonists in the cultures themselves led to only partial inhibition (similar to 60%), whereas inclusion of exogenous endothelin or angiotensin II resulted in amplification of the strain response. Angiotensin II and endothelin appear to be arrayed in series in the regulatory circuitry; the angiotensin response was blocked by BQ-123, whereas the endothelin response was unaffected by losartan. Mechanical strain was also shown to stimulate expression of the endogenous angiotensinogen, angiotensin-converting enzyme, and endothelin genes in this system. Collectively, these data indicate that locally generated angiotensin II and endothelin, acting in series, play an important autocrine/paracrine role in mediating strain-dependent activation of cardiac-specific gene expression.	Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gardner, DC (corresponding author), Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035753] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 35753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER KM, 1990, AM J PHYSIOL, V259, pH324, DOI 10.1152/ajpheart.1990.259.2.H324; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BENES AJ, 1985, J CELL SCI, V75, P35; BOER PH, 1994, AM J PHYSIOL-HEART C, V267, pH1630, DOI 10.1152/ajpheart.1994.267.4.H1630; BRUCKSCHLEGEL G, 1995, HYPERTENSION, V25, P250, DOI 10.1161/01.HYP.25.2.250; Clavell AL, 1996, J CLIN INVEST, V97, P1286, DOI 10.1172/JCI118544; DESCHEPPER CF, 1990, HYPERTENSION, V16, P147, DOI 10.1161/01.HYP.16.2.147; DOSTAL DE, 1992, AM J HYPERTENS, V5, P276; EVERETT AD, 1994, HYPERTENSION, V23, P587, DOI 10.1161/01.HYP.23.5.587; FUJISAKI H, 1995, J CLIN INVEST, V96, P1059, DOI 10.1172/JCI118092; Harada M, 1997, CIRCULATION, V96, P3737; HASEGAWA K, 1993, CIRCULATION, V88, P372, DOI 10.1161/01.CIR.88.2.372; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITO H, 1994, CIRCULATION, V89, P2198, DOI 10.1161/01.CIR.89.5.2198; IWAI N, 1995, CIRCULATION, V92, P2690, DOI 10.1161/01.CIR.92.9.2690; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KOVACICMILIVOJEVIC B, 1992, MOL CELL BIOL, V12, P292, DOI 10.1128/MCB.12.1.292; LaPointe MC, 1996, HYPERTENSION, V27, P715, DOI 10.1161/01.HYP.27.3.715; LEE AA, 1995, J MOL CELL CARDIOL, V27, P2347, DOI 10.1016/S0022-2828(95)91983-X; Lee YA, 1996, P NATL ACAD SCI USA, V93, P11035, DOI 10.1073/pnas.93.20.11035; LIANG F, 1928, J BIOL CHEM, P272; LINZ W, 1989, CLIN EXP HYPERTENS A, V11, P1325, DOI 10.3109/10641968909038172; MUKHERJEE DP, 1993, HYPERTENSION, V21, P142, DOI 10.1161/01.HYP.21.2.142; NAKAGAWA O, 1995, J CLIN INVEST, V96, P1280, DOI 10.1172/JCI118162; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PAUL M, 1995, HYPERTENSION, V25, P683, DOI 10.1161/01.HYP.25.4.683; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; PFEFFER JM, 1982, P NATL ACAD SCI-BIOL, V79, P3310, DOI 10.1073/pnas.79.10.3310; RAMAN VK, 1995, AM J CARDIOL, V76, pD18, DOI 10.1016/S0002-9149(99)80487-1; ROBERTS AB, 1992, J CLIN INVEST, V90, P2056, DOI 10.1172/JCI116087; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; SHYU KG, 1995, BIOCHEM BIOPH RES CO, V211, P241, DOI 10.1006/bbrc.1995.1802; TAKAHASHI N, 1994, J CLIN INVEST, V94, P1470, DOI 10.1172/JCI117485; VONLUTTEROTTI N, 1994, CIRCULATION, V89, P458, DOI 10.1161/01.CIR.89.1.458; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; WOOZ GW, 1996, HYPERTENSION, V28, P635; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054	43	74	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14612	14619		10.1074/jbc.273.23.14612	http://dx.doi.org/10.1074/jbc.273.23.14612			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603978	hybrid			2022-12-25	WOS:000074021500080
J	Pancholi, V; Fischetti, VA				Pancholi, V; Fischetti, VA			alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; PLASMINOGEN-BINDING; CANDIDA-ALBICANS; GLYCOLYTIC ENZYME; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; RECEPTOR; IDENTIFICATION; CLONING	The plasmin(ogen) binding property of group A streptococci is incriminated in tissue invasion processes. We have characterized a novel 45-kDa protein displaying strong plasmin(ogen) binding activity from the streptococcal surface. Based on its biochemical properties, we confirmed the identity of this protein as cu-enolase, a key glycolytic enzyme. Dose-dependent cy-enolase activity, immune electron microscopy of whole streptococci using specific antibodies, and the opsonic nature of polyclonal and monoclonal antibodies concluded the presence of this protein on the streptococcal surface. We, henceforth, termed the 45-kDa protein, SEN (streptococcal Surface enolase). SEN is found ubiquitously on the surface of most streptococcal groups and serotypes and showed significantly greater plasmin(ogen) binding affinity compared with previously reported streptococcal plasminogen binding proteins. Both the C-terminal lysine residue of SEN and a region N-terminal to it play a critical role in plasminogen binding. Results from competitive plasminogen binding inhibition assays and cross linking studies with intact streptococci indicate that SEN contributes significantly to the overall streptococcal ability to bind plasmin(ogen), Our findings, showing both the protected protease activity of SEN-bound plasmin and SEN-specific immune responses, provide evidence for an important role of SEN in the disease process and post-streptococcal autoimmune diseases.	Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA	Rockefeller University	Pancholi, V (corresponding author), Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, 1230 York Ave, New York, NY 10021 USA.	panchov@rockvax.rockfeller.edu	Pancholi, Vijay/E-3810-2011		NIAID NIH HHS [AI11822] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI011822, R01AI011822] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALGIERY AG, 1992, BIOCHIM BIOPHYS ACTA, V1159, P134, DOI 10.1016/0167-4838(92)90017-8; Angiolella L, 1996, J INFECT DIS, V173, P684, DOI 10.1093/infdis/173.3.684; BERGE A, 1993, J BIOL CHEM, V268, P25417; BOTTALICO LA, 1993, ARTERIOSCLER THROMB, V13, P264, DOI 10.1161/01.ATV.13.2.264; Boyle MDP, 1997, THROMB HAEMOSTASIS, V77, P1; BROESEKER TA, 1988, MICROB PATHOGENESIS, V5, P19, DOI 10.1016/0882-4010(88)90077-0; Castellino F J, 1976, Methods Enzymol, V45, P244; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; CHRISTENSEN LR, 1945, J GEN PHYSIOL, V28, P363, DOI 10.1085/jgp.28.4.363; FISCHETTI VA, 1992, ZBL BAKT S, V22, P165; FISCHETTI VA, 1991, GENETICS MOL BIOL ST, P290; FLUIT AC, 1993, FEBS LETT, V316, P103, DOI 10.1016/0014-5793(93)81745-L; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; Gase K, 1996, EUR J BIOCHEM, V239, P42, DOI 10.1111/j.1432-1033.1996.0042u.x; HUANG TT, 1989, MOL MICROBIOL, V3, P197, DOI 10.1111/j.1365-2958.1989.tb01808.x; HUNTHER FJ, 1990, INFECT IMMUN, V58, P1043; JANKOVIC BD, 1985, J IMMUNOL, V135, P853; JONES JD, 1997, JAMA-J AM MED ASSOC, V105, P571; KEHOE MA, 1994, BACTERIAL CELL WALL, P217; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; LANCEFIELD RC, 1957, J EXP MED, V106, P525, DOI 10.1084/jem.106.4.525; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOPEZALEMANY R, 1994, THROMB RES, V75, P371, DOI 10.1016/0049-3848(94)90252-6; LOTTENBERG R, 1987, INFECT IMMUN, V55, P1914, DOI 10.1128/IAI.55.8.1914-1918.1987; LOTTENBERG R, 1992, J BACTERIOL, V174, P5204, DOI 10.1128/JB.174.16.5204-5210.1992; Lottenberg Richard, 1994, Trends in Microbiology, V2, P20, DOI 10.1016/0966-842X(94)90340-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; NAKAJIMA K, 1994, J NEUROCHEM, V63, P2048; Pancholi V, 1997, J EXP MED, V186, P1633, DOI 10.1084/jem.186.10.1633; PANCHOLI V, 1993, P NATL ACAD SCI USA, V90, P8154, DOI 10.1073/pnas.90.17.8154; PANCHOLI V, 1989, J EXP MED, V170, P2119, DOI 10.1084/jem.170.6.2119; PANCHOLI V, 1988, J BACTERIOL, V170, P2618, DOI 10.1128/jb.170.6.2618-2624.1988; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; Peterson P, 1996, CLIN DIAGN LAB IMMUN, V3, P290, DOI 10.1128/CDLI.3.3.290-294.1996; PLOW EF, 1991, THROMB HAEMOSTASIS, V66, P32; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; RATTNER JB, 1991, J IMMUNOL, V146, P2341; REDLITZ A, 1995, EUR J BIOCHEM, V227, P407, DOI 10.1111/j.1432-1033.1995.tb20403.x; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Sirover MA, 1996, LIFE SCI, V58, P2271, DOI 10.1016/0024-3205(96)00123-3; SPRING TG, 1971, J BIOL CHEM, V246, P6797; SUNDSTROM P, 1992, J BACTERIOL, V174, P6789, DOI 10.1128/JB.174.21.6789-6799.1992; SUNDSTROM P, 1994, J INFECT DIS, V169, P452, DOI 10.1093/infdis/169.2.452; TAKEI N, 1991, J NEUROCHEM, V57, P1178, DOI 10.1111/j.1471-4159.1991.tb08277.x; Tillett WS, 1933, J EXP MED, V58, P485, DOI 10.1084/jem.58.4.485; ULLBERG M, 1992, APMIS, V100, P21, DOI 10.1111/j.1699-0463.1992.tb00835.x; WALSH TJ, 1991, NEW ENGL J MED, V324, P1026, DOI 10.1056/NEJM199104113241504; WILLIAMS LA, 1985, EXP EYE RES, V40, P741, DOI 10.1016/0014-4835(85)90143-5; WIMAN B, 1981, METHOD ENZYMOL, V80, P395; Winram SB, 1995, DEV BIOL STAND, V85, P199; Winram SB, 1996, MICROBIOL-SGM, V142, P2311, DOI 10.1099/13500872-142-8-2311; WOLD F, 1957, J BIOL CHEM, V227, P301; Wold F., 1971, ENZYMES, P499	56	448	458	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14503	14515		10.1074/jbc.273.23.14503	http://dx.doi.org/10.1074/jbc.273.23.14503			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603964	hybrid			2022-12-25	WOS:000074021500066
J	Breivogel, CS; Selley, DE; Childers, SR				Breivogel, CS; Selley, DE; Childers, SR			Cannabinoid receptor agonist efficacy for stimulating [S-35]GTP gamma S binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; RECONSTITUTED PHOSPHOLIPID-VESICLES; G-PROTEINS; ADENYLATE-CYCLASE; BRAIN MEMBRANES; GUANOSINE-5'-O-(3-<S-35>THIO)TRIPHOSPHATE BINDING; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); REGULATORY COMPONENT; ADENOSINE RECEPTOR; CARDIAC MEMBRANES	The relationship between GDP and cannabinoid-stimulated [S-35]guanosine-5'-O-(3-thiotriphosphate) ([S-35]GTP gamma S) binding was investigated in rat cerebellar membranes. Kinetic analyses showed that [35S]GTP gamma S binding reached steady-state levels and that the association rate was increased by the agonist WIN 55212-2 proportional to the concentration of GDP. Dissociation of [S-35]GTP gamma S occurred with two rates (t(1/2) = 7 and 170 min), and WIN 55212-2 increased the proportion of sites exhibiting the faster rate. Without GDP, [S-35]GTP gamma S bound to membranes with high and low affinity, and WIN 55212-2 had no effect. With 30 mu M GDP, [S-35]GTP gamma S bound to low and intermediate affinity sites, and WIN 55212-2 induced high affinity [S-35]GTP gamma S binding without affecting low affinity sites, GDP competed for high affinity [S-35]GTP gamma S binding with high and intermediate affinity in the absence of WIN 55212-2 and with high and low affinity in the presence of WIN 55212-2. Cannabinoid ligands displayed differential abilities to maximally stimulate [S-35]GTP gamma S binding in the presence of GDP. Efficacy differences among ligands increased with increasing GDP concentrations. GDP competition curves revealed that agonists induced low affinity GDP Ki values that were proportional to agonist E-max values, indicating that agonist efficacy is determined by displacement of GDP from G-proteins.	Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Ctr Neurobiol Invest Drug Abuse, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Investigat Neurosci, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Childers, SR (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Ctr Neurobiol Invest Drug Abuse, Med Ctr Blvd, Winston Salem, NC 27157 USA.			Breivogel, Chris/0000-0001-5657-2735	NIDA NIH HHS [DA-06784, DA-07246] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007246, R01DA006784] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ASANO T, 1984, BIOCHEMISTRY-US, V23, P5467, DOI 10.1021/bi00318a014; BIDAUTRUSSELL M, 1990, J NEUROCHEM, V55, P21, DOI 10.1111/j.1471-4159.1990.tb08815.x; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breivogel CS, 1997, J NEUROCHEM, V68, P1462; Breivogel CS, 1997, J PHARMACOL EXP THER, V282, P1632; Burkey TH, 1997, EUR J PHARMACOL, V323, pR3, DOI 10.1016/S0014-2999(97)00146-5; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHILDERS SR, 1994, BIOCHEM PHARMACOL, V47, P711, DOI 10.1016/0006-2952(94)90134-1; COMPTON DR, 1993, J PHARMACOL EXP THER, V265, P218; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; Gifford AN, 1996, J PHARMACOL EXP THER, V277, P1431; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Glass M, 1997, J NEUROSCI, V17, P5327, DOI 10.1523/jneurosci.17-14-05327.1997; HAMPSON RE, 1995, LIFE SCI, V56, P2081, DOI 10.1016/0024-3205(95)00192-9; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HILF G, 1992, EUR J BIOCHEM, V204, P725, DOI 10.1111/j.1432-1033.1992.tb16687.x; HILF G, 1989, EUR J BIOCHEM, V186, P725, DOI 10.1111/j.1432-1033.1989.tb15266.x; HOWLETT AC, 1995, ANNU REV PHARMACOL, V35, P607, DOI 10.1146/annurev.pharmtox.35.1.607; KEEN M, 1991, TRENDS PHARMACOL SCI, V12, P371, DOI 10.1016/0165-6147(91)90606-S; Kenalin T, 1993, PHARM ANAL DRUG RECE, P249; Lorenzen A, 1996, MOL PHARMACOL, V49, P915; LORENZEN A, 1993, MOL PHARMACOL, V44, P115; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MACKIE K, 1993, MOL PHARMACOL, V44, P498; MACKIE K, 1995, J NEUROSCI, V15, P6552; Maneuf YP, 1997, BRIT J PHARMACOL, V120, P1397, DOI 10.1038/sj.bjp.0701101; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUBIG RR, 1993, MOL PHARMACOL, V43, P734; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; SanudoPena MC, 1997, NEUROSCI LETT, V223, P125, DOI 10.1016/S0304-3940(97)13424-3; Selley DE, 1997, MOL PHARMACOL, V51, P87, DOI 10.1124/mol.51.1.87; Selley DE, 1996, LIFE SCI, V59, P659, DOI 10.1016/0024-3205(96)00347-5; Shen MX, 1996, J NEUROSCI, V16, P4322; SHIRE D, 1995, J BIOL CHEM, V270, P3726, DOI 10.1074/jbc.270.8.3726; Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989; Sim Laura J., 1997, V31, P1; SIM LJ, 1995, P NATL ACAD SCI USA, V92, P7242, DOI 10.1073/pnas.92.16.7242; Sim LJ, 1996, J NEUROSCI, V16, P8057; SIM LJ, 1996, EUR J PHARMACOL, V307, P95; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; SLIPETZ DM, 1995, MOL PHARMACOL, V48, P352; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; WATKINS DC, 1987, J BIOL CHEM, V262, P10651	55	157	159	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16865	16873		10.1074/jbc.273.27.16865	http://dx.doi.org/10.1074/jbc.273.27.16865			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642247	hybrid			2022-12-25	WOS:000074545200037
J	El Nemer, W; Gane, P; Colin, Y; Bony, V; Rahuel, C; Galacteros, F; Cartron, JP; Le Van Kim, C				El Nemer, W; Gane, P; Colin, Y; Bony, V; Rahuel, C; Galacteros, F; Cartron, JP; Le Van Kim, C			The Lutheran blood group glycoproteins, the erythroid receptors for laminin, are adhesion molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE GLYCOPROTEIN; IMMUNOGLOBULIN SUPERFAMILY; MEMBRANE; ATTACHMENT; PROTEINS; CLONING; BINDING; LIGAND	The Lutheran antigens are recently characterized glycoproteins in which the extracellular region contains five immunoglobulin like domains, suggesting some recognition function. A recent abstract suggests that the Lutheran glycoproteins (Lu gps) act as erythrocyte receptors for soluble laminin (Udani, M., Jefferson, S., Daymont, C., Zen, Q., and Telen, M. J. (1996) Blood 88, Suppl. 1, 6 (abstr.)). In the present report, we provided the definitive proof of the laminin receptor function of the Lu gps by demonstrating that stably transfected cells (murine L929 and human K562 cell lines) expressing the Lu gps bound laminin in solution and acquired adhesive properties to laminin-coated plastic dishes but not to fibronectin, vitronectin, transferrin, fibrinogen, or fibrin. Furthermore, expression of either the long-tail (85 kDa) or the short-tail (78 kDa) Lu gps, which differ by the presence or the absence of the last 40 amino acids of the cytoplasmic domain, respectively, conferred to transfected cells the same laminin binding capacity. We also confirmed by flow cytometry analysis that the level of laminin binding to red cells is correlated with the level of Lu antigen expression. Indeed, Lu-null cells did not bind to laminin, whereas sickle cells from most patients homozygous for hemoglobin S overexpressed Lu antigens and exhibited an increased binding to laminin, as compared with normal red cells. Laminin binding to normal and sickle red cells as well as to Lu transfected cells was totally inhibited by a soluble Lu-Fc chimeric fragment containing the extracellular domain of the Lu gps. During in vitro erythropoiesis performed by two-phase liquid cultures of human peripheral blood, the appearance of Lu antigens in late erythroid differentiation was concomitant with the laminin binding capacity of the cultured erythroblasts. Altogether, our results demonstrated that long-tail and short-tail Lu gps are adhesion molecules that bind equally well laminin and strongly suggested that these glycoproteins are the unique receptors for laminin in normal and sickle mature red cells as well as in erythroid progenitors.	Inst Natl Transfus Sanguine, INSERM, U76, F-75015 Paris, France; Hop Henri Mondor, INSERM, U91, F-94100 Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Le Van Kim, C (corresponding author), Inst Natl Transfus Sanguine, INSERM, U76, 6 Rue Alexandre Cabanel, F-75015 Paris, France.	clvkim@infobiogen.fr	Nemer, Wassim El/N-4247-2017; le van kim, caroline/O-7030-2017; colin, yves/O-1910-2017	Nemer, Wassim El/0000-0001-8184-427X; le van kim, caroline/0000-0002-3251-1310; colin, yves/0000-0001-5196-4254				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; BUNN HF, 1992, NEW ENGL J MED, V337, P762; CAMPBELL IG, 1994, CANCER RES, V54, P5761; CARLOS TM, 1994, BLOOD, V84, P2068; CHESAGARIN P, 1994, INT J ONCOL, V5, P1261; CUTBUSH M, 1956, NATURE, V178, P855, DOI 10.1038/178855b0; DANIELS G, 1989, VOX SANG, V57, P137, DOI 10.1111/j.1423-0410.1989.tb01151.x; DANIELS G, 1995, HUMAN BLOOD GROUPS, P356; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; ElNemer W, 1997, BLOOD, V89, P4608, DOI 10.1182/blood.V89.12.4608; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; FIBACH E, 1990, AM J HEMATOL, V35, P151, DOI 10.1002/ajh.2830350303; FRANCK PFH, 1985, J CLIN INVEST, V75, P183, DOI 10.1172/JCI111672; GREENWALT TJ, 1967, TRANSFUSION, V7, P189, DOI 10.1111/j.1537-2995.1967.tb05509.x; Hanspal M, 1997, Curr Opin Hematol, V4, P142; HEBBEL RP, 1991, BLOOD, V77, P214; Hillery CA, 1996, BLOOD, V87, P4879, DOI 10.1182/blood.V87.11.4879.bloodjournal87114879; INGLIS G, 1993, TRANSFUS MED S, V3, P94; JOHANSSON S, 1981, J CELL BIOL, V90, P260, DOI 10.1083/jcb.90.1.260; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; MANTHORPE M, 1983, J CELL BIOL, V97, P1882, DOI 10.1083/jcb.97.6.1882; MCCARTHY JB, 1983, J CELL BIOL, V97, P772, DOI 10.1083/jcb.97.3.772; Parsons SF, 1997, BLOOD, V89, P4219, DOI 10.1182/blood.V89.11.4219; PARSONS SF, 1987, TRANSFUSION, V27, P61, DOI 10.1046/j.1537-2995.1987.27187121477.x; PARSONS SF, 1995, P NATL ACAD SCI USA, V92, P5496, DOI 10.1073/pnas.92.12.5496; RACE RR, 1975, BLOOD GROUPS MAN, P261; Rahuel C, 1996, BLOOD, V88, P1865; RETTIG WJ, 1988, P NATL ACAD SCI USA, V85, P3110, DOI 10.1073/pnas.85.9.3110; RIWOM S, 1994, VOX SANG, V66, P61, DOI 10.1111/j.1423-0410.1994.tb00279.x; Solovey A, 1997, NEW ENGL J MED, V337, P1584, DOI 10.1056/NEJM199711273372203; SOUTHCOTT MJG, 1997, BLOOD S, V90, P175; TELEN MJ, 1995, BLOOD CELL BIOCH, V6, P281; TERRANOVA VP, 1982, CANCER RES, V42, P2265; TERRANOVA VP, 1983, P NATL ACAD SCI-BIOL, V80, P444, DOI 10.1073/pnas.80.2.444; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; UDANI M, 1996, BLOOD S, V88, P6; Wick T M, 1996, Curr Opin Hematol, V3, P118; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YURCHENKO PD, 1993, MOL CELLULAR ASPECTS, P121	40	99	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16686	16693						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642222				2022-12-25	WOS:000074545200012
J	Motojima, K; Passilly, P; Peters, JM; Gonzalez, FJ; Latruffe, N				Motojima, K; Passilly, P; Peters, JM; Gonzalez, FJ; Latruffe, N			Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; LIPOPROTEIN-LIPASE; BINDING-PROTEIN; PPAR-GAMMA; RAT-LIVER; DIFFERENTIATION; CLONING; HEPATOCARCINOGENICITY; LIGAND; MOUSE	Regulation of gene expression of three putative long-chain fatty acid transport proteins, fatty acid translocase (FAT), mitochondrial aspartate aminotransferase (mAspAT), and fatty acid transport protein (FATP), by drugs that activate peroxisome proliferator-activated receptor (PPAR) alpha and gamma were studied using normal and obese mice and rat hepatoma cells. FAT mRNA was induced in liver and intestine of normal mice and in hepatoma cells to various extents only by PPAR alpha-activating drugs. FATP mRNA was similarly induced in liver, but to a lesser extent in intestine. The induction time course in the liver was slower for FAT and FATP mRNA than that of an mRNA encoding a peroxisomal enzyme. An obligatory role of PPAR alpha in hepatic FAT and FATP induction was demonstrated, since an increase in these mRNAs was not observed in PPAR alpha-null mice. Levels of mAspAT mRNA were higher in liver and intestine of mice treated with peroxisome proliferators, while levels in hepatoma cells were similar regardless of treatment. In white adipose tissue of KKAy obese mice, thiazolidinedione PPAR gamma activators (pioglitazone and troglitazone) induced FAT and FATP more efficiently than the PPAR alpha activator, clofibrate. This effect was absent in brown adipose tissue. Under the same conditions, levels of mAspAT mRNA did not change significantly in these tissues. In conclusion, tissue-specific expression of FAT and FATP genes involves both PPAR alpha and -gamma. Our data suggest that among the three putative long-chain fatty acid transporters, FAT and FATP appear to have physiological roles. Thus, peroxisome proliferators not only influence the metabolism of intracellular fatty acids but also cellular uptake, which is likely to be an important regulatory step in lipid homeostasis.	Toho Univ, Sch Pharmaceut Sci, Dept Biochem, Funabashi, Chiba 274, Japan; Univ Bourgogne, Lab Biol Mol & Cellulaire, F-21004 Dijon, France; NIH, Lab Metab, Bethesda, MD 20892 USA	Toho University; Universite de Bourgogne; National Institutes of Health (NIH) - USA	Motojima, K (corresponding author), Toho Univ, Sch Pharmaceut Sci, Dept Biochem, Funabashi, Chiba 274, Japan.	motojima@phar.toho-u.ac.jp	Peters, Jeffrey/D-8847-2011; Passilly-Degrace, Patricia/AAF-5903-2021	Peters, Jeffrey/0000-0003-2782-2998				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVCHAND PR, 1996, NATURE, V384, P34; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Goldberg IJ, 1996, J LIPID RES, V37, P693; GORDON JI, 1983, J BIOL CHEM, V258, P3356; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; ISOLA LM, 1995, P NATL ACAD SCI USA, V92, P9866, DOI 10.1073/pnas.92.21.9866; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; KIRSCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MARSMAN DS, 1988, CANCER RES, V48, P6739; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Motojima K, 1996, ANN NY ACAD SCI, V804, P413, DOI 10.1111/j.1749-6632.1996.tb18632.x; Motojima K, 1997, BIOCHEM BIOPH RES CO, V230, P155, DOI 10.1006/bbrc.1996.5906; Motojima K, 1997, BIOCHIMIE, V79, P101, DOI 10.1016/S0300-9084(97)81498-8; MOTOJIMA K, 1992, BIOCHEM BIOPH RES CO, V188, P799, DOI 10.1016/0006-291X(92)91127-C; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; PHILLIPS M, 1986, J BIOL CHEM, V261, P821; REDDY JK, 1986, ENVIRON HEALTH PERSP, V65, P317, DOI 10.2307/3430199; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; SAHA AK, 1994, AM J PHYSIOL, V267, pE95, DOI 10.1152/ajpendo.1994.267.1.E95; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; TIGRATTI BL, 1996, BIOCHEM J, V313, P487; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	32	433	451	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16710	16714		10.1074/jbc.273.27.16710	http://dx.doi.org/10.1074/jbc.273.27.16710			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642225	hybrid			2022-12-25	WOS:000074545200015
J	Previs, SF; Hallowell, PT; Neimanis, KD; David, F; Brunengraber, H				Previs, SF; Hallowell, PT; Neimanis, KD; David, F; Brunengraber, H			Limitations of the mass isotopomer distribution analysis of glucose to study gluconeogenesis - Heterogeneity of glucose labeling in incubated hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE; RAT-LIVER; GLYCEROL; TURNOVER; ZONATION; PATTERN	We previously reported (Previs, S, F,, Fernandez, C, A, Yang, D,, Soloviev, M, V., David, F,, and Brunengraber, H. (1995) J, Biol. Chem. 270, 19806-19815) that glucose made in isolated livers from starved rats perfused with physiological concentrations of lactate, pyruvate, and either [2-C-13]- or [U-C-13(3)]glycerol had a mass isotopomer distribution incompatible with glucose being made from a homogeneously labeled pool of triose phosphates, Similar data were obtained in live rats infused with [U-C-13(3)]glycerol, We ascribed the labeling heterogeneity to major decreases in glycerol concentration and enrichment across the liver, We concluded that [C-13]glycerol is unsuitable for tracing the contribution of gluconeogenesis to total glucose production. We now report isotopic heterogeneity of gluconeogenesis in hepatocytes, even when all cells are in contact with identical concentrations and enrichments of gluconeogenic substrates, Total rat hepatocytes were incubated with concentrations of glycerol, lactate, and pyruvate that were kept constant by substrate infusions. To modulate competition between substrates, the (glycerol)/(lactate + pyruvate) infusion ratio ranged from 0.23 to 3.60, Metabolic and isotopic steady states were achieved in all cases. The apparent contribution of gluconeogenesis to glucose production (f) was calculated from the mass isotopomer distribution of glucose. When all substrates were C-13-labeled, f was 97%, as expected in glycogen-deprived hepatocytes, As the infusion ratio ([C-13]glycerol)/(lactate C pyruvate) increased, f increased from 73% to 94%, In contrast, as the infusion ratio (glycerol)/([C-13]lactate + [C-13]pyruvate) increased, f decreased from 93% to 76%, In all cases, f increased with the rate of supply of the substrate that was labeled. Variations in f show that the C-13 labeling of triose phosphates was not equal in all hepatocytes, even when exposed to the same substrate concentrations and enrichments, We also showed that zonation of glycerol kinase activity is minor in rat liver. We conclude that zonation of other processes than glycerol phosphorylation contributes to the heterogeneity of triose phosphate labeling from glycerol in rat liver.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Surg, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Brunengraber, H (corresponding author), Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA.				NIDDK NIH HHS [DK35543] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN B, 1984, HISTOCHEMISTRY, V80, P97, DOI 10.1007/BF00492778; BARTELS H, 1993, HISTOCHEMISTRY, V99, P303, DOI 10.1007/BF00269103; BERGMEYER HU, 1984, METHOD ENZYMAT AN, P574; BEYLOT M, 1993, ANAL BIOCHEM, V212, P526, DOI 10.1006/abio.1993.1363; Brunengraber H, 1997, ANNU REV NUTR, V17, P559, DOI 10.1146/annurev.nutr.17.1.559; Dekker E, 1997, J CLIN ENDOCR METAB, V82, P2514, DOI 10.1210/jc.82.8.2514; Fernandez CA, 1996, J MASS SPECTROM, V31, P255, DOI 10.1002/(SICI)1096-9888(199603)31:3<255::AID-JMS290>3.0.CO;2-3; GUDER WG, 1976, H-S Z PHYSIOL CHEM, V357, P1793, DOI 10.1515/bchm2.1976.357.2.1793; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; Jungermann K, 1996, ANNU REV NUTR, V16, P179, DOI 10.1146/annurev.nu.16.070196.001143; KELLEHER JK, 1986, AM J PHYSIOL, V250, pE296, DOI 10.1152/ajpendo.1986.250.3.E296; KELLEHER JK, 1994, AM J PHYSIOL, V266, pE384, DOI 10.1152/ajpendo.1994.266.3.E384; LANDAU BR, 1995, AM J PHYSIOL-ENDOC M, V269, pE18, DOI 10.1152/ajpendo.1995.269.1.E18; Landau BR, 1996, AM J PHYSIOL-ENDOC M, V271, pE1110, DOI 10.1152/ajpendo.1996.271.6.E1110; LANDAU BR, 1993, ADV EXP MED BIOL, V334, P209; LEE WNP, 1992, BIOL MASS SPECTROM, V21, P114, DOI 10.1002/bms.1200210210; LEE WNP, 1994, J CLIN RES, V42, pA28; MCMENAMY RH, 1981, ANAL BIOCHEM, V112, P117, DOI 10.1016/0003-2697(81)90268-2; Meister A., 1970, METHOD ENZYMOL, V17, P900, DOI 10.1016/0076-6879(71)17304-1; NEESE RA, 1995, J BIOL CHEM, V270, P14464; NEESE RA, 1995, J BIOL CHEM, V270, P14452, DOI 10.1074/jbc.270.24.14452; OSYPIW JC, 1994, BIOCHEM J, V304, P617, DOI 10.1042/bj3040617; Patterson M K Jr, 1979, Methods Enzymol, V58, P141; PERONI O, 1995, AM J PHYSIOL-ENDOC M, V269, pE516, DOI 10.1152/ajpendo.1995.269.3.E516; Peroni O, 1997, METABOLISM, V46, P1358, DOI 10.1016/S0026-0495(97)90244-4; Peroni O, 1996, METABOLISM, V45, P897, DOI 10.1016/S0026-0495(96)90166-3; PREVIS SF, 1995, J BIOL CHEM, V270, P19806, DOI 10.1074/jbc.270.34.19806; Previs SF, 1996, AM J PHYSIOL-ENDOC M, V271, pE1118, DOI 10.1152/ajpendo.1996.271.6.E1118; ROGNSTAD R, 1979, J BIOL CHEM, V254, P1875; ROSENBLATT J, 1992, AM J PHYSIOL, V263, pE584, DOI 10.1152/ajpendo.1992.263.3.E584; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SESTOFT L, 1975, BIOCHIM BIOPHYS ACTA, V375, P462, DOI 10.1016/0005-2736(75)90360-0; SHIOTA M, 1993, AM J PHYSIOL, V265, pE559, DOI 10.1152/ajpendo.1993.265.4.E559; TENG CT, 1953, J BIOL CHEM, V202, P705; WEIDEMANN MJ, 1969, BIOCHEM J, V112, P149, DOI 10.1042/bj1120149; Wieland O.H., 1984, METHOD ENZYMAT AN, VVI, P504	36	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16853	16859		10.1074/jbc.273.27.16853	http://dx.doi.org/10.1074/jbc.273.27.16853			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642245	hybrid			2022-12-25	WOS:000074545200035
J	Hisabori, T; Motohashi, K; Kroth, P; Strotmann, H; Amano, T				Hisabori, T; Motohashi, K; Kroth, P; Strotmann, H; Amano, T			The formation or the reduction of a disulfide bridge on the gamma subunit of chloroplast ATP synthase affects the inhibitory effect of the epsilon subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; PROTON-TRANSLOCATING ATPASE; ESCHERICHIA-COLI; ADENOSINE-TRIPHOSPHATASE; THERMOPHILIC BACTERIUM; NUCLEOTIDE-SEQUENCE; ALPHA-SUBUNITS; BETA-SUBUNITS; F1-ATPASE; SPINACH	We have studied the change of the catalytic activity of chimeric complexes that were formed by chloroplast coupling factor 1 (CF1) -gamma, alpha and beta subunits of thermophilic bacterial F-1 after formation or reduction of the disulfide bridge of different gamma subunits modified by oligonucleotide-directed mutagenesis techniques. For this purpose, three mutant gamma subunits were produced: gamma(Delta 194-230), here 37 amino acids from Pro-194 to Ile-230 are deleted, gamma(C199A), Cys-199 is changed to Ala, and gamma(Delta 200-204), amino acids from Asp-200 to Lys-204 are deleted. All of the chimeric subunit complexes produced from each of these mutant CF1-gamma subunits and alpha and beta subunits from thermophilic bacterial F-1 lost the sensitivity against thiol reagents when compared with the complex containing wild-type CF1-gamma. The pH optimum (pH 8.5-9.0) and the concentration of methanol to stimulate ATPase activities were not affected by these mutations, These indicate that the introduction of the mutations did not change the main features of ATPase activity of the chimeric complex, However, the interaction between gamma subunit and epsilon subunit was strongly influenced by the type of gamma subunit itself. Although the ATPase activity of the chimeric complex that contained gamma(Delta 200-204) or gamma(C199A) was inhibited by the addition of recombinant epsilon subunit from CF1 similarly to complexes containing the reduced wild-type gamma subunit, the recombinant epsilon subunit did not inhibit the ATPase of the complex, which contained the oxidized form of gamma subunit, Therefore the affinity of the epsilon subunit to the gamma subunit may be dependent on the state of the gamma subunit or the epsilon subunit may bind to the oxidized form of gamma subunit in a mode that does not inhibit the activity. The ATPase activity of the complex that contains gamma Delta 194-230 was not efficiently inhibited by epsilon subunit, These results show that the formation or reduction of the disulfide bond on the gamma subunit may induce a conformational change in the region that directly affects the interaction of this subunit with the adjacent epsilon subunit.	Tokyo Inst Technol, Resources Utilizat Res Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Univ Dusseldorf, Inst Biochem Pflanzen, D-40225 Dusseldorf, Germany	Tokyo Institute of Technology; Heinrich Heine University Dusseldorf	Hisabori, T (corresponding author), Tokyo Inst Technol, Resources Utilizat Res Lab, Midori Ku, Nagatsuta 4259, Yokohama, Kanagawa 2268503, Japan.	thisabor@res.titech.ac.jp	Kroth, Peter G/A-9728-2008; Motohashi, Ken/I-4970-2019; Hisabori, Toru/E-5205-2014	Kroth, Peter G/0000-0003-4734-8955; Motohashi, Ken/0000-0002-8414-2836; Hisabori, Toru/0000-0003-2046-0277				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ANDRALOJC PJ, 1990, BIOCHIM BIOPHYS ACTA, V1016, P55, DOI 10.1016/0005-2728(90)90006-P; ANTHON GE, 1984, BIOCHIM BIOPHYS ACTA, V723, P358; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Cruz JA, 1997, PLANT PHYSIOL, V113, P1185, DOI 10.1104/pp.113.4.1185; CRUZ JA, 1995, PLANT PHYSIOL, V109, P1379, DOI 10.1104/pp.109.4.1379; DUHE RJ, 1990, BIOCHIM BIOPHYS ACTA, V1017, P70, DOI 10.1016/0005-2728(90)90180-C; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; GABRYS H, 1994, PLANT PHYSIOL, V104, P769, DOI 10.1104/pp.104.2.769; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; Hisabori T, 1997, EUR J BIOCHEM, V247, P1158, DOI 10.1111/j.1432-1033.1997.01158.x; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P87, DOI 10.1016/0003-9861(92)90054-Z; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; KANAZAWA H, 1981, BIOCHEM BIOPH RES CO, V103, P604, DOI 10.1016/0006-291X(81)90494-0; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MUNN AL, 1991, BIOCHIM BIOPHYS ACTA, V1060, P82, DOI 10.1016/S0005-2728(05)80122-7; NALIN CM, 1984, J BIOL CHEM, V259, P7275; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; OHTSUBO M, 1987, BIOCHEM BIOPH RES CO, V146, P705, DOI 10.1016/0006-291X(87)90586-9; Ross SA, 1996, J BIOENERG BIOMEMBR, V28, P49; ROSS SA, 1995, J BIOL CHEM, V270, P9813, DOI 10.1074/jbc.270.17.9813; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SAKURAI H, 1981, J BIOCHEM, V90, P95, DOI 10.1093/oxfordjournals.jbchem.a133473; SARASTE M, 1981, NUCLEIC ACIDS RES, V9, P5287, DOI 10.1093/nar/9.20.5287; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; Schwarz O, 1997, J BIOL CHEM, V272, P16924, DOI 10.1074/jbc.272.27.16924; SELMANREIMER S, 1981, BIOCHEMISTRY-US, V20, P5476, DOI 10.1021/bi00522a020; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; SOTEROPOULOS P, 1992, J BIOL CHEM, V267, P10348; STROTMANN H, 1984, ANNU REV PLANT PHYS, V35, P97; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; YOSHIDA M, 1977, J BIOL CHEM, V252, P3348; ZHANG Y, 1994, J BIOL CHEM, V269, P10221	41	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15901	15905		10.1074/jbc.273.26.15901	http://dx.doi.org/10.1074/jbc.273.26.15901			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632635	hybrid			2022-12-25	WOS:000074436600006
J	Jean, D; Gershenwald, JE; Huang, SY; Luca, M; Hudson, MJ; Tainsky, MA; Bar-Eli, M				Jean, D; Gershenwald, JE; Huang, SY; Luca, M; Hudson, MJ; Tainsky, MA; Bar-Eli, M			Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; HUMAN-MALIGNANT MELANOMA; PRIMARY CUTANEOUS MELANOMA; INDUCIBLE ENHANCER; ADHESION MOLECULE; BCL-2 EXPRESSION; GENE-EXPRESSION; SUPPRESSOR GENE; PHORBOL ESTER; MESSENGER-RNA	MCAM/MUC18 is a cell-surface glycoprotein of 113 kDa, originally identified as a melanoma antigen, whose expression is associated with tumor progression and the development of metastatic potential. We have previously shown that enforced expression of MCAM/MUC18 in primary cutaneous melanoma led to increased tumor growth and metastatic potential in nude mice. The mechanism for up-regulation of MCAM/MUC18 during melanoma progression is unknown. Here we show that up-regulation of MCAM/MUC18 expression in highly metastatic cells correlates with loss of expression of the transcription factor AP-2. The MCAM/MUC18 promoter contains four binding sites for AP-2, and electrophoretic mobility shift assay gels demonstrated that the AP-2 protein bound directly to the MCAM/MUC18 promoter. Transfection of AP-2 into highly metastatic A375SM melanoma cells (AP-a-negative and MCAM/MUC18-poposive) inhibited MCAM/MUC18 promoter-driven chloramphenicol acetyltransferase reporter gene in a dose-dependent manner. MCAM/MUC18 mRNA and protein expression were down-regulated in AP-2-transfected but not in control cells. In addition, re-expression of AP-2 in A375SM cells inhibited their tumorigenicity and metastatic potential in nude mice. These results indicate that the expression of MCAM/MUC18 is regulated by AP-2 and that enforced AP-2 expression suppresses tumorigenicity and metastatic potential of human melanoma cells, possibly by dawn-regulating MCAM/MUC18 gene expression. Since AP-2 also regulates other genes that are involved in the progression of human melanoma such as c-KIT, E-cadherin, MMP-2, and p21(WAF-1), We propose that loss of AP-2 is a crucial event in the development of malignant melanoma.	Univ Texas, Md Anderson Canc Ctr, Dept Cell Biol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bar-Eli, M (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Cell Biol, Houston, TX 77030 USA.	mbareli@notes.mdacc.tmc.edu	Jean, Didier/A-1615-2009; Gershenwald, Jeff/AAX-4367-2020	Jean, Didier/0000-0001-5823-7404; Gershenwald, Jeff/0000-0003-4519-5369; Tainsky, Michael/0000-0002-0261-831X	NATIONAL CANCER INSTITUTE [R21CA064137] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64137] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariizumi K, 1996, J DERMATOL SCI, V12, P147, DOI 10.1016/0923-1811(95)00474-2; Bani MR, 1996, CANCER RES, V56, P3075; BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; COPEMAN MC, 1992, PATHOLOGY, V24, P307, DOI 10.3109/00313029209068886; Cowley GP, 1996, J PATHOL, V179, P183, DOI 10.1002/(SICI)1096-9896(199606)179:2<183::AID-PATH554>3.0.CO;2-W; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DIGNAM J, 1983, MOL CELL BIOL, V13, P3415; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FIDLER IJ, 1992, CUTANEOUS MELANOMA, V2, P112; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAYNOR RB, 1991, GENOMICS, V10, P1100, DOI 10.1016/0888-7543(91)90209-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; Grover R, 1996, EUR J SURG ONCOL, V22, P347, DOI 10.1016/S0748-7983(96)90176-6; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; HOLMAN CDJ, 1980, INT J CANCER, V25, P317, DOI 10.1002/ijc.2910250303; HOLZMANN B, 1987, INT J CANCER, V39, P466, DOI 10.1002/ijc.2910390410; HUANG S, 1996, ONCOGENE, V123, P2339; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; JIANG HP, 1995, ONCOGENE, V10, P1855; Johnson JP, 1997, INT J CANCER, V73, P769; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEHMANN JM, 1987, CANCER RES, V47, P841; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; Luca M, 1997, AM J PATHOL, V151, P1105; LUCA M, 1995, ONCOGENE, V11, P1399; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NATALI PG, 1994, INT J CANCER, V56, P341, DOI 10.1002/ijc.2910560308; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; PATHAK S, 1983, CYTOGENET CELL GENET, V36, P573, DOI 10.1159/000131975; RADINSKY R, 1994, ONCOGENE, V9, P1977; ROMERDAHL CA, 1988, CANCER RES, V48, P4007; Rummel MM, 1996, CANCER RES, V56, P2218; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; Shih IM, 1997, CANCER RES, V57, P3835; SHIH IM, 1994, AM J PATHOL, V145, P837; SHIH IM, 1994, CANCER RES, V54, P2514; SINGH RK, 1995, CANCER RES, V55, P3669; SOBER AJ, 1984, CUTANEOUS MELANOMA P, P126; TAIRA E, 1994, NEURON, V12, P861, DOI 10.1016/0896-6273(94)90338-7; TRENT JM, 1989, CANCER RES, V49, P420; VANDENOORD JJ, 1994, AM J PATHOL, V145, P294; VIDAL MJ, 1995, MELANOMA RES, V5, P243, DOI 10.1097/00008390-199508000-00006; WALKER GJ, 1994, INT J CANCER, V59, P771, DOI 10.1002/ijc.2910590611; WELCH DR, 1994, ONCOGENE, V9, P255; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; XIE S, 1902, ONCOGENE, V15, P2069; Xie SH, 1997, CANCER RES, V57, P2295; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; ZHANG J, 1995, CANCER RES, V55, P4640; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	67	129	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16501	16508		10.1074/jbc.273.26.16501	http://dx.doi.org/10.1074/jbc.273.26.16501			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632718	hybrid			2022-12-25	WOS:000074436600089
J	Fleming, KG; Hohl, TM; Yu, RC; Muller, SA; Wolpensinger, B; Engel, A; Engelhardt, H; Brunger, AT; Sollner, TH; Hanson, PI				Fleming, KG; Hohl, TM; Yu, RC; Muller, SA; Wolpensinger, B; Engel, A; Engelhardt, H; Brunger, AT; Sollner, TH; Hanson, PI			A revised model for the oligomeric state of the N-ethylmaleimide-sensitive fusion protein, NSF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; ELECTRON-MICROSCOPY; BOUNDARY ANALYSIS; LIGHT-SCATTERING; MEMBRANE-FUSION; ALPHA-SNAP; COMPLEX; ATP; DOCKING; MACROMOLECULES	The N-ethylmaleimide-sensitive fusion protein (NSF) is an ATPase that plays an essential role in intracellular membrane trafficking, Previous reports have concluded that NSF forms either a tetramer or a trimer in solution, and that assembly of the oligomer is essential for efficient activity in membrane transport reactions. However, in recent electron microscopic analyses NSF appears as a hexagonal cylinder similar in size to related ATPases known to be hexamers. We have therefore reevaluated NSF's oligomeric state using a variety of quantitative biophysical techniques. Sedimentation equilibrium and sedimentation velocity analytical ultracentrifugation, transmission electron microscopy with rotational image analysis, scanning transmission electron microscopy, and multiangle light scattering all demonstrate that, in the presence of nucleotide, NSF is predominantly a hexamer. Sedimentation equilibrium results further suggest that the NSF hexamer is held together by oligomerization of its D2 domains. The sedimentation coefficient, s(20,w)(0), of 13.4 (+/-0.1) S indicates that NSF has unusual hydrodynamic characteristics that cannot be solely explained by its shape. The demonstration that NSF is a hexameric oligomer highlights structural similarities between it and several related ATPases which act by switching the conformational states of their protein substrates in order to activate them for subsequent reactions.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Basel, Maurice E Muller Inst, Bioctr, CH-4056 Basel, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Yale University; Memorial Sloan Kettering Cancer Center; University of Basel; Max Planck Society; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Hanson, PI (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid,Campus Box 8228, St Louis, MO 63110 USA.		Hanson, Phyllis/E-9420-2012; Fleming, Karen/E-7892-2011	Hohl, Tobias/0000-0002-9097-5412; Brunger, Axel/0000-0001-5121-2036	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027044, R01DK027044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016769] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK2704420] Funding Source: Medline; NIGMS NIH HHS [GM54160, GM16769] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; Beyer A, 1997, PROTEIN SCI, V6, P2043; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Boudier JA, 1996, EUR J NEUROSCI, V8, P545, DOI 10.1111/j.1460-9568.1996.tb01239.x; DELATORRE JG, 1994, BIOPHYS J, V67, P530, DOI 10.1016/S0006-3495(94)80512-0; ENGEL A, 1978, ULTRAMICROSCOPY, V3, P273, DOI 10.1016/S0304-3991(78)80037-0; FRANK J, 1982, J MOL BIOL, V161, P134, DOI 10.1016/0022-2836(82)90282-0; FROHLICH KU, 1995, BBA-PROTEIN STRUCT M, V1253, P25, DOI 10.1016/0167-4838(95)00136-I; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hegerl R, 1996, J STRUCT BIOL, V116, P30, DOI 10.1006/jsbi.1996.0006; Hensley P, 1996, STRUCTURE, V4, P367, DOI 10.1016/S0969-2126(96)00042-1; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Matveeva EA, 1997, J BIOL CHEM, V272, P26413, DOI 10.1074/jbc.272.42.26413; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P314; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Pamnani V, 1997, FEBS LETT, V404, P263, DOI 10.1016/S0014-5793(97)00138-5; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Saxton WO, 1996, J STRUCT BIOL, V116, P230, DOI 10.1006/jsbi.1996.0035; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; STAFFORD WF, 1996, BIOPHYS J, V70; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871	39	76	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15675	15681		10.1074/jbc.273.25.15675	http://dx.doi.org/10.1074/jbc.273.25.15675			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624162	hybrid			2022-12-25	WOS:000074284200056
J	Borg, JP; Yang, YN; De Taddeo-Borg, M; Margolis, B; Turner, RS				Borg, JP; Yang, YN; De Taddeo-Borg, M; Margolis, B; Turner, RS			The X11 alpha protein slows cellular amyloid precursor protein processing and reduces A beta 40 and A beta 42 secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; BETA-PROTEIN; CYTOPLASMIC DOMAIN; TRANSGENIC MICE; HUMAN NEURONS; IN-VIVO; PRESENILIN-1; DISTINCT; PATHWAY; CELLS	Constitutive amyloid precursor protein (APP) metabolism results in the generation of soluble APP (APPs) and A beta peptides, including A beta 40 and A beta 42-the major component of amyloid plaques in Alzheimer's disease brain. The phosphotyrosine binding (PTB) domain of X11 binds to a peptide containing a YENPTY motif found in the carboxyl terminus of APP. We have cloned the full-length X11 gene now referred to as X11 alpha. Coexpression of X11 alpha with APP results in comparatively greater levels of cellular APP and less APPs, A beta 40, and A beta 42 recovered in conditioned medium of transiently transfected HEK 293 cells. These effects are impaired by a single missense mutation of either APP (Y682G within the YENPTY motif) or X11 alpha (F608V within the PTB domain), which diminishes their interaction, thus demonstrating specificity. The inhibitory effect of X11 alpha on A beta 40 and A beta 42 secretion is amplified by coexpression with the Swedish mutation of APP (K595N/M596L), which promotes its amyloidogenic processing. Pulse-chase analysis demonstrates that X11 alpha prolongs the half-life of APP from similar to 2 h to similar to 4 h. The effects of X11 alpha on cellular APP and APPs recovery were confirmed in a 293 cell line stably transfected with APP. The specific binding of the PTB domain of X11 alpha to the YENPTY motif-containing peptide of APP appears to slow cellular APP processing and thus reduces recovery of its soluble fragments APPs, A beta 40, and A beta 42 in conditioned medium of transfected HEK 293 cells, X11 alpha may be involved in APP trafficking and metabolism in neurons and thus may be implicated in amyloidogenesis in normal aging and Alzheimer's disease brain.	Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Ann Arbor, MI 48105 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, Dept Internal Med & Biol Chem, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, Deptt Internal Med & Biol Chem, Ann Arbor, MI 48109 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Turner, RS (corresponding author), Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, 2214 Fuller Rd, Ann Arbor, MI 48105 USA.	raymondt@umich.edu	Turner, Raymond Scott/G-2263-2011; Borg, Jean-Paul/AAX-8096-2020	Turner, Raymond Scott/0000-0001-7534-2935; Borg, Jean-Paul/0000-0001-8418-3382	NIA NIH HHS [P50 AG08671, P50 AG008671] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG008671] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1998, CURR TOP MICROBIOL, V228, P23; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Cataldo AM, 1997, J NEUROSCI, V17, P6142; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; COOK KG, 1997, NAT MED, V3, P1021; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; ESSELMANI R, 1996, BIOCHEM BIOPH RES CO, V218, P89; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; McLoughlin DM, 1996, FEBS LETT, V397, P197; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Yaich L, 1998, J BIOL CHEM, V273, P10381, DOI 10.1074/jbc.273.17.10381; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141	40	184	190	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14761	14766		10.1074/jbc.273.24.14761	http://dx.doi.org/10.1074/jbc.273.24.14761			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614075	hybrid			2022-12-25	WOS:000074160400017
J	Brozinick, JT; Birnbaum, MJ				Brozinick, JT; Birnbaum, MJ			Insulin, but not contraction, activates Akt/PKB in isolated rat skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLUCOSE TRANSPORTERS; PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSLOCATION; AKT; PHOSPHORYLATION; DISSOCIATION; STIMULATION; INCREASES; DISTINCT	Insulin and muscle contraction potently stimulate glucose uptake in mammalian skeletal muscle. Studies in muscle and adipose tissue have shown that insulin induces its receptor-dependent phosphorylation of insulin receptor substrates 1 and 2, which leads to activation of polyphosphatidylinositol (PI) 3'-kinase. In contrast, muscle contraction stimulates glucose transport via a mechanism that is independent of insulin, but the two pathways may converge downstream at the level of stimulation of GLUT4 translocation. In the present study, we have examined the role of Akt, an insulin-activated serine threonine kinase that has previously been shown to increase glucose transport in adipocytes. Either insulin or in vitro muscle contraction significantly elevated glucose transport in isolated rat epitrochlearis and soleus muscles. However, Akt kinase activity was significantly stimulated by insulin and not contraction. Moreover, wortmannin, an inhibitor of PI 3'-kinase, completely blocked the insulin-stimulated increase in Akt activity and glucose transport but did not alter either of these parameters in contracting muscles. The increases in Akt activity were paralleled by a decrease in the electrophoretic mobility of Akt, indicative of phosphorylation of Akt by an upstream kinase. These changes in Akt mobility appeared to be at least partially because of phosphorylation of Akt on serine 473. Mutative down-stream target of Akt, p70 S6 kinase, showed similar changes in mobility in response to insulin but not contraction. These data support the view that Akt is a downstream target of PI 3'-kinase and is involved in the signaling pathways involved in insulin but not contraction stimulation of glucose transport in skeletal muscle. These data provide further evidence that two distinct pathways exist for the stimulation of glucose transport in mammalian skeletal muscle.	Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Cox Inst, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Birnbaum, MJ (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Med, CRB 322,415 Curie Blvd, Philadelphia, PA 19104 USA.			Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK 39615] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039615] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROZINICK JT, 1994, AM J PHYSIOL, V267, pR236, DOI 10.1152/ajpregu.1994.267.1.R236; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARTEE GD, 1992, AM J PHYSIOL, V263, pR70, DOI 10.1152/ajpregu.1992.263.1.R70; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CODERRE L, 1995, J BIOL CHEM, V270, P27584, DOI 10.1074/jbc.270.46.27584; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; Etgen GJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE294, DOI 10.1152/ajpendo.1996.271.2.E294; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; GOODYEAR LJ, 1995, AM J PHYSIOL-ENDOC M, V268, pE987, DOI 10.1152/ajpendo.1995.268.5.E987; GOODYEAR LJ, 1990, AM J PHYSIOL, V258, pE667, DOI 10.1152/ajpendo.1990.258.4.E667; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HENRIKSEN EJ, 1991, ACTA PHYSIOL SCAND, V143, P381, DOI 10.1111/j.1748-1716.1991.tb09249.x; HENRIKSEN EJ, 1989, AM J PHYSIOL, V256, pE662, DOI 10.1152/ajpendo.1989.256.5.E662; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HIRSHMAN MF, 1988, FEBS LETT, V238, P235, DOI 10.1016/0014-5793(88)80486-1; Holloszy JO, 1996, REV PHYSIOL BIOCH P, V128, P99; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Krook A, 1997, DIABETES, V46, P2110, DOI 10.2337/diabetes.46.12.2110; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; NESHER R, 1985, AM J PHYSIOL, V249, pC226, DOI 10.1152/ajpcell.1985.249.3.C226; PLOUG T, 1984, AM J PHYSIOL, V247, pE726, DOI 10.1152/ajpendo.1984.247.6.E726; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Shepherd PR, 1997, DIABETOLOGIA, V40, P1172, DOI 10.1007/s001250050803; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; vanderKaay J, 1997, J BIOL CHEM, V272, P5477, DOI 10.1074/jbc.272.9.5477; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; Zhou Q, 1997, BIOCHEM BIOPH RES CO, V236, P647, DOI 10.1006/bbrc.1997.7028	39	123	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14679	14682		10.1074/jbc.273.24.14679	http://dx.doi.org/10.1074/jbc.273.24.14679			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614064	hybrid			2022-12-25	WOS:000074160400006
J	Ferreira, MCD; Helies-Toussaint, C; Imbert-Teboul, M; Bailly, C; Verbavatz, JM; Bellanger, AC; Chabardes, D				Ferreira, MCD; Helies-Toussaint, C; Imbert-Teboul, M; Bailly, C; Verbavatz, JM; Bellanger, AC; Chabardes, D			Co-expression of a Ca2+-inhibitable adenylyl cyclase and of a Ca2+-sensing receptor in the cortical thick ascending limb cell of the rat kidney - Inhibition of hormone-dependent camp accumulation by extracellular Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PARATHYROID CELLS; PERTUSSIS TOXIN; MOLECULAR-CLONING; BINDING PROTEIN; GLIOMA-CELLS; CA-2+; LOCALIZATION; VASOPRESSIN; IDENTIFICATION; CALCIUM	The Ca2+-sensing receptor protein and the Ca2+-inhibitable type 6 adenylyl cyclase mRNA are present in a defined segment of the sat renal tubule leading to the hypothesis of their possible functional co-expression in a same cell and thus to a possible inhibition of cAMP content by extracellular Ca2+. By using microdissected segments, we compared the properties of regulation of extracellular Ca2+-mediated activation of Ca2+ receptor to those elicited by prostaglandin E-2 and angiotensin II. The three agents inhibited a common pool of hormone-stimulated cAMP content by different mechanisms as follows. (i) Extracellular Ca2+, coupled to phospholipase C activation via a pertussis toxin-insensitive G protein, induced a dose-dependent inhibition of cAMP content (1.25 mM Ca2+ eliciting 50% inhibition) resulting from both stimulation of cAMP hydrolysis and inhibition of cAMP synthesis; this latter effect was mediated by capacitive Ca2+ influx as well as release of intracellular Ca2+. (ii) Angiotensin II, coupled to the same transduction pathway, also decreased cAMP content; however, its inhibitory effect on cAMP was mainly accounted for by an increase of cAMP hydrolysis, although angiotensin II and extracellular Ca2+ can induce comparable release of intracellular Ca2+. (iii) Prostaglandin E-2, coupled to pertussis toxin-sensitive G protein, inhibited the same pool of adenylyl cyclase units as extracellular Ca2+ but by a different mechanism, The functional properties of the adenylyl cyclase were similar to those described for type 6. The results establish that the co-expression of a Ca2+-inhibitable adenylyl cyclase and of a Ca2+-sensing receptor in a same cell allows an inhibition of cAMP accumulation by physiological concentrations of extracellular Ca2+.	CEA Saclay, Dept Biol Cellulaire & Mol, Serv Biol Cellulaire, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Chabardes, D (corresponding author), CEA Saclay, Dept Biol Cellulaire & Mol, Serv Biol Cellulaire, Bat 520, F-91191 Gif Sur Yvette, France.	chabardes@dsvidf.cea.fr		Verbavatz, Jean-Marc/0000-0002-4654-1174				AARAB L, 1993, PFLUG ARCH EUR J PHY, V423, P397, DOI 10.1007/BF00374933; ABE T, 1995, J CLIN INVEST, V96, P657, DOI 10.1172/JCI118108; ANTONI FA, 1995, J BIOL CHEM, V270, P28055; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bouby N, 1997, J AM SOC NEPHROL, V8, P1658; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1997, BONE, V20, P303, DOI 10.1016/S8756-3282(97)00002-1; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; BUSH KT, 1994, J BIOL CHEM, V269, P23694; Chabardes D, 1996, J BIOL CHEM, V271, P19264, DOI 10.1074/jbc.271.32.19264; Champigneulle A, 1997, J MEMBRANE BIOL, V156, P117, DOI 10.1007/s002329900194; CHEN CJ, 1989, ENDOCRINOLOGY, V124, P233, DOI 10.1210/endo-124-1-233; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; COOPER DMF, 1994, CELL SIGNAL, V6, P823, DOI 10.1016/0898-6568(94)90016-7; DEBERNARDI MA, 1993, MOL PHARMACOL, V43, P451; FIRSOV D, 1994, PFLUG ARCH EUR J PHY, V429, P79, DOI 10.1007/BF02584033; FIRSOV D, 1995, PFLUG ARCH EUR J PHY, V429, P636, DOI 10.1007/BF00373984; HAWKINS D, 1989, ENDOCRINOLOGY, V124, P838, DOI 10.1210/endo-124-2-838; HOEY M, 1990, BIOCHEM PHARMACOL, V40, P193, DOI 10.1016/0006-2952(90)90678-E; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; Kifor O, 1997, J BONE MINER RES, V12, P715, DOI 10.1359/jbmr.1997.12.5.715; KOCH B, 1993, MOL CELL ENDOCRINOL, V92, P175, DOI 10.1016/0303-7207(93)90005-5; KOCH B, 1994, CELL SIGNAL, V6, P467, DOI 10.1016/0898-6568(94)90094-9; Kriz W, 1992, KIDNEY PHYSL PATHOPH, P707; Meneton P, 1996, AM J PHYSIOL-RENAL, V271, pF382, DOI 10.1152/ajprenal.1996.271.2.F382; MOREL F, 1987, KIDNEY INT, V31, P512, DOI 10.1038/ki.1987.30; MOREL F, 1986, PHYSIOL REV, V66, P377, DOI 10.1152/physrev.1986.66.2.377; MOREL F, 1982, KIDNEY INT S11, V21, pS55; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Paulais M, 1996, AM J PHYSIOL-RENAL, V271, pF1052, DOI 10.1152/ajprenal.1996.271.5.F1052; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Riccardi D, 1996, AM J PHYSIOL-RENAL, V271, pF951, DOI 10.1152/ajprenal.1996.271.4.F951; SHANMUGAM S, 1995, AM J PHYSIOL-RENAL, V268, pF922, DOI 10.1152/ajprenal.1995.268.5.F922; Shen TS, 1997, AM J PHYSIOL-CELL PH, V273, pC323, DOI 10.1152/ajpcell.1997.273.1.C323; SMITH JA, 1993, FEBS LETT, V327, P137, DOI 10.1016/0014-5793(93)80157-P; STEVENS T, 1995, P NATL ACAD SCI USA, V92, P2696, DOI 10.1073/pnas.92.7.2696; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; TAKAICHI K, 1986, AM J PHYSIOL, V250, pF770, DOI 10.1152/ajprenal.1986.250.5.F770; TAKAICHI K, 1988, J CLIN INVEST, V82, P1437, DOI 10.1172/JCI113749; TAKAICHI K, 1986, MINER ELECTROL METAB, V12, P342; TAKEUCHI K, 1993, BIOCHEM BIOPH RES CO, V194, P885, DOI 10.1006/bbrc.1993.1904; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TORIKAI S, 1983, AM J PHYSIOL, V245, pF58, DOI 10.1152/ajprenal.1983.245.1.F58; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677; Wang WH, 1996, AM J PHYSIOL-CELL PH, V271, pC103, DOI 10.1152/ajpcell.1996.271.1.C103; Yang TX, 1997, AM J PHYSIOL-RENAL, V272, pF751, DOI 10.1152/ajprenal.1997.272.6.F751; Ye CP, 1996, BIOCHEM BIOPH RES CO, V226, P572, DOI 10.1006/bbrc.1996.1396	53	80	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15192	15202		10.1074/jbc.273.24.15192	http://dx.doi.org/10.1074/jbc.273.24.15192			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614133	hybrid			2022-12-25	WOS:000074160400075
J	Henzinger, T; Reed, SI				Henzinger, T; Reed, SI			Cyclin D3 is rate-limiting for the G(1)/S phase transition in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; RETINOBLASTOMA-PROTEIN; GENE-EXPRESSION; MAMMALIAN-CELLS; KINASE-ACTIVITY; D1; OVEREXPRESSION; ONCOGENESIS; PROGRESSION; INHIBITION	D-type cyclins are induced in response to mitogens and are believed to control progression through the G(1) phase of the cell cycle by activating their corresponding kinase partners (cyclin-dependent kinases). To investigate the function of individual D-type cyclins we have constructed rat fibroblast lines that allow controllable overexpression of a human cyclin D3 cDNA. Overexpression of cyclin D3 led to accelerated passage through G(1) in actively proliferating cells with no effect on the overall population doubling time. In cells re-entering the division cycle from a quiescent state, cyclin D3 caused an even more dramatic advancement of S phase entry. Accelerated progression through G(0)/G(1)-to-S correlated with premature phosphorylation of the pith tumor suppressor protein and its relatives, p107 and p130. We conclude that cyclin D3 can act as a rate-limiting G(1) cyclin and that this effect involves, in part, the premature phosphorylation of critical substrates.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIGMS NIH HHS [GM40006] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; JIANG W, 1993, ONCOGENE, V8, P3447; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; NEUMAN E, 1997, MOL CELL BIOL, V17, P538; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Reed SI, 1997, CANCER SURV, V29, P7; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLF DA, 1995, ONCOGENE, V10, P2067; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	27	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14958	14961		10.1074/jbc.273.24.14958	http://dx.doi.org/10.1074/jbc.273.24.14958			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614101	hybrid			2022-12-25	WOS:000074160400043
J	Previato, JO; Sola-Penna, M; Agrellos, OA; Jones, C; Oeltmann, T; Travassos, LR; Mendonca-Previato, L				Previato, JO; Sola-Penna, M; Agrellos, OA; Jones, C; Oeltmann, T; Travassos, LR; Mendonca-Previato, L			Biosynthesis of O-N-acetylglucosamine-linked glycans in Trypanosoma cruzi - Characterization of the novel uridine diphospho-N-acetylglucosamine : polypeptide-N-acetylglucosaminyltransferase- catalyzing formation of N-acetylglucosamine alpha 1 -> O-threonine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; SIALIC-ACID; CYTOPLASMIC PROTEINS; EPIMASTIGOTE FORMS; MAMMALIAN-CELLS; NUCLEAR-PORE; MUCIN GENES; GLYCOPROTEINS; GLYCOSYLATION; GLCNAC	In this study, we have characterized the activity of a uridine diphospho-N-acetylglucosamine:polypeptide-alpha-N-acetylglucosaminyltransferase (O-alpha-GlcNAc-transferase) from Trypanosoma cruzi. The activity is present in microsomal membranes and is responsible for the addition of O-linked alpha-N-acetylglucosamine to cell surface proteins. This preparation adds N-acetylglucosamine to a synthetic peptide KPPTTTTTTTTKPP containing the consensus threonine-rich dodecapeptide encoded by T. cruzi MUC gene (Di Noia, J. M., Sanchez D. O., and Frasch, A. C. C. (1995) J. Biol. Chem. 270, 24146-24149). Incorporation of N-[H-3]acetylglucosamine is linearly dependent on incubation time and concentration of enzyme and substrate. The transferase activity has an optimal pH of 7.5-8.5, requires Mn2+, is unaffected by tunicamycin or amphomycin, and is strongly inhibited by UDP, The optimized synthetic peptide acceptor for the cytosolic O-GlcNAc-transferase (YSDSPSTST) (Haltiwanger, R. S., Holt, G. D., and Hart, G. W. (1990) J. Biol. Chem. 265, 2563-2568) is not a substrate for this enzyme. The glycosylated KPPTTTTTTTTKPP product is susceptible to base-catalyzed beta-elimination, and the presence of N-acetylglucosamine beta-linked to threonine is supported by enzymatic digestion and nuclear magnetic resonance data. These results describe a unique biosynthetic pathway for T. cruzi surface mucin-like molecules, with potential chemotherapeutic implications.	Univ Fed Rio de Janeiro, Inst Microbiol, BR-21944970 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Fac Farm, BR-21944970 Rio De Janeiro, Brazil; Natl Inst Biol Stand & Controls, Mol Struct Lab, Potters Bar EN6 3QG, Herts, England; Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA; Univ Fed Sao Paulo, Disciplina Biol Celular, BR-04023062 Sao Paulo, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; National Institute for Biological Standards & Control; Vanderbilt University; Universidade Federal de Sao Paulo (UNIFESP)	Mendonca-Previato, L (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, CCS-Bloco I, BR-21944970 Rio De Janeiro, Brazil.		Travassos, Luiz R/J-3631-2012; Jones, Chris/AAF-4063-2021; Sola-Penna, Mauro/E-8221-2011; Travassos, Luiz/V-2467-2019	Jones, Chris/0000-0001-7109-492X; Sola-Penna, Mauro/0000-0001-9796-6829; Previato, Jose Osvaldo/0000-0002-9233-9954; Mendonca Previato, Lucia/0000-0003-3927-3244				ALMEIDA IC, 1994, BIOCHEM J, V304, P793, DOI 10.1042/bj3040793; BANERJEE DK, 1981, BIOCHEMISTRY-US, V20, P1561, DOI 10.1021/bi00509a024; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; BOCK K, 1974, J CHEM SOC PERK T 2, P293, DOI 10.1039/p29740000293; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; BURLEIGH BA, 1995, ANNU REV MICROBIOL, V49, P175, DOI 10.1146/annurev.mi.49.100195.001135; Cazzulo JJ, 1997, BIOL CHEM, V378, P1; DABROWSKI J, 1994, 2 DIMENSIONAL NMR SP; DAVOUST D, 1985, CARBOHYD RES, V143, P233, DOI 10.1016/S0008-6215(00)90712-2; DIECKMANNSCHUPPERT A, 1993, EUR J BIOCHEM, V216, P779, DOI 10.1111/j.1432-1033.1993.tb18198.x; DiNoia JM, 1996, J BIOL CHEM, V271, P32078, DOI 10.1074/jbc.271.50.32078; DINOIA JM, 1995, J BIOL CHEM, V270, P24146, DOI 10.1074/jbc.270.41.24146; Dische Z., 1962, METHODS CARBOHYDRATE, V1, P507; Do KY, 1997, GLYCOBIOLOGY, V7, P183, DOI 10.1093/glycob/7.2.183; ERICSON MC, 1977, J BIOL CHEM, V252, P7431; GOLDSTEIN I. J., 1965, METHOD CARBOHYD CHEM, V5, P361; GOT R, 1967, BIOCHIM BIOPHYS ACTA, V136, P320, DOI 10.1016/0304-4165(67)90078-5; Gowda DC, 1997, J BIOL CHEM, V272, P6428, DOI 10.1074/jbc.272.10.6428; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; HART GW, 1993, C MOSBACH, V44, P91; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; Klich G, 1997, CARBOHYD RES, V299, P33, DOI 10.1016/S0008-6215(96)00337-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu JY, 1996, CARBOHYD RES, V296, P1, DOI 10.1016/S0008-6215(96)00240-6; MENDONCAPREVIATO L, 1983, BIOCHEMISTRY-US, V22, P4980, DOI 10.1021/bi00290a016; ORTEGABARRIA E, 1990, MOL BIOCHEM PARASIT, V43, P151, DOI 10.1016/0166-6851(90)90141-8; Pao YL, 1996, BIOCHEM BIOPH RES CO, V219, P157, DOI 10.1006/bbrc.1996.0198; PAPANASTASIOU P, 1997, GLYCOCONJUGATE S1, V14, pS55; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; PREVIATO JO, 1995, J BIOL CHEM, V270, P7241, DOI 10.1074/jbc.270.13.7241; PREVIATO JO, 1994, BIOCHEM J, V301, P151, DOI 10.1042/bj3010151; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; PREVIATO JO, 1991, MEM I O CRUZ S1, V86, P53; SAHA UK, 1997, CARBOHYD RES, V304, P233; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; Seitz O, 1997, J AM CHEM SOC, V119, P8766, DOI 10.1021/ja971383c; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; Tvaroska I, 1995, ADV CARBOHYD CHEM BI, V51, P15, DOI 10.1016/S0065-2318(08)60191-2; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WIDER G, 1993, J MAGN RESON SER B, V102, P239, DOI 10.1006/jmrb.1993.1092; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; YEN PH, 1974, BIOCHEMISTRY-US, V13, P2420, DOI 10.1021/bi00708a029	46	66	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14982	14988		10.1074/jbc.273.24.14982	http://dx.doi.org/10.1074/jbc.273.24.14982			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614105	hybrid			2022-12-25	WOS:000074160400047
J	Roesler, WJ; Park, EA; McFie, PJ				Roesler, WJ; Park, EA; McFie, PJ			Characterization of CCAAT/enhancer-binding protein alpha as a cyclic AMP-responsive nuclear regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; SERUM-ALBUMIN GENE; TRANSCRIPTION FACTORS; 3T3-L1 PREADIPOCYTES; CAMP RESPONSIVENESS; MAMMALIAN-CELLS; HEPATOMA-CELLS; C/EBP-ALPHA; ENHANCER; EXPRESSION	The alpha isoform of CCAAT/enhancer-binding protein (C/EBP alpha) is a transcription factor that regulates expression of genes linked to adipose differentiation and hepatic nutrient metabolism. Recently, our laboratory has characterized a role for C/EBP alpha in mediating hormonal responsiveness. For example, the cAMP responsiveness of the phosphoenolpyruvate carboxykinase gene promoter in liver requires synergism among the cAMP response element-binding protein (CREB), C/EBP alpha, and activator protein-1. in the present study, we show that C/EBP alpha can functionally substitute for CREB in this cAMP response unit, i.e. cAMP responsiveness can occur in the absence of CREB. This observation is physiologically relevant since both CREB and C/EBP alpha have been shown to hind with high affinity to the cAMP response element in this particular promoter. Structure/function analysis of C/EBP alpha identified specific mutations that differentially affected its constitutive and protein kinase A-inducible activities. This finding suggests that the mechanism whereby C/EBP alpha mediates constitutive transactivation is distinct from that whereby it mediates cAMP responsiveness. These delta support the hypothesis that C/EBP alpha plays a critical role in metabolism, in part by participating in the hormonal regulation of expression of metabolically important genes.	Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; Univ Tennessee, Dept Pharmacol, Memphis, TN 38163 USA	University of Saskatchewan; University of Tennessee System; University of Tennessee Health Science Center	Roesler, WJ (corresponding author), Univ Saskatchewan, Dept Biochem, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046399] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46399] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LIU JS, 1991, J BIOL CHEM, V266, P19095; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; Park EA, 1997, BIOCHEM J, V322, P343, DOI 10.1042/bj3220343; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; QUINN PG, 1993, J BIOL CHEM, V268, P16999; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; Roesler WJ, 1998, MOL CELL BIOCHEM, V178, P1, DOI 10.1023/A:1006886421795; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; ROESLER WJ, 1994, J BIOL CHEM, V269, P14276; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VANOOIJ C, 1992, MOL CELL BIOL, V12, P3023, DOI 10.1128/MCB.12.7.3023; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	48	54	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14950	14957		10.1074/jbc.273.24.14950	http://dx.doi.org/10.1074/jbc.273.24.14950			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614100	hybrid			2022-12-25	WOS:000074160400042
J	Albrieux, M; Lee, HC; Villaz, M				Albrieux, M; Lee, HC; Villaz, M			Calcium signaling by cyclic ADP-ribose, NAADP, and inositol trisphosphate are involved in distinct functions in ascidian oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE; CIONA-INTESTINALIS; CRYSTAL-STRUCTURE; SKELETAL-MUSCLE; EGG; FERTILIZATION; ACTIVATION; MEIOSIS; CONTRACTION; METABOLITE	ADP-ribosyl cyclase catalyzes the synthesis of two structurally and functionally different Ca2+ releasing molecules, cyclic ADP-ribose (cADPR) from beta-NAD and nicotinic acid-adenine dinucleotide phosphate (NAADP) from beta-NADP, Their Ca2+-mobilizing effects in ascidian oocytes were characterized ire connection with that induced by inositol 1,4,5-trisphosphate (InsP(3)). Fertilization of the oocyte is accompanied by a decrease in the oocyte Ca2+ current and an increase in membrane capacitance due to the addition of membrane to the cell surface, Both of these electrical changes could be induced by perfusion, through a patch pipette, of nanomolar concentrations of cADPR or its precursor, beta-NAD, into unfertilized oocytes. The changes induced by beta-NAD showed a distinctive delay consistent with its enzymatic conversion to cADPR. The cADPR-induced changes were inhibited by preloading the oocytes with a Ca2+ chelator, indicating the effects were due to Ca2+ release induced by cADPR. Consistently, ryanodine (at high concentration) or 8-amino-cADPR, a specific antagonist of cADPR, but not heparin, inhibited the cADPR induced changes. Both inhibitors likewise blocked the membrane insertion that normally occurred at fertilization consistent with it being mediated by a ryanodine receptor. The effects of NAADP were different from those of cADPR, Although NAADP induced a similar decrease in the Ca2+ current, no membrane insertion occurred. Moreover, pretreatment of the oocytes with NAADP inhibited the post-fertilization Ca2+ oscillation while cADPR did not. A similar Ca2+ oscillation could be artificially induced by perfusing into the oocytes a high concentration of InsP(3) and NAADP could likewise inhibit such an InsP(3)-induced oscillation. This work shows that three independent Ca2+ signaling pathways are present in the oocytes and that each is involved in mediating distinct changes associated with fertilization. The results are consistent with a hierarchical organization of Ca2+ stores in the oocyte.	DBMS, DSV, Lab Canaux Ion & Signalisat, F-38054 Grenoble, France; Univ Minnesota, Dept Physiol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Villaz, M (corresponding author), DBMS, DSV, Lab Canaux Ion & Signalisat, 17 Rue Martyrs, F-38054 Grenoble, France.		Lee, Hon Cheung/C-4329-2009; Albrieux, Mireille/H-3824-2017	Albrieux, Mireille/0000-0002-2817-2563	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; AARHUS R, 1995, J BIOL CHEM, V270, P30827; Albrieux M, 1997, DEV BIOL, V189, P174, DOI 10.1006/dbio.1997.8674; Arnoult C, 1997, CELL CALCIUM, V21, P93, DOI 10.1016/S0143-4160(97)90033-6; ARNOULT C, 1994, DEV BIOL, V166, P1, DOI 10.1006/dbio.1994.1292; ARNOULT C, 1994, J MEMBRANE BIOL, V137, P127; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; COOMBS JL, 1992, DEV BIOL, V153, P272, DOI 10.1016/0012-1606(92)90112-T; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Grumetto L, 1997, BIOCHEM BIOPH RES CO, V239, P723, DOI 10.1006/bbrc.1997.7537; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guse AH, 1997, J BIOL CHEM, V272, P8546, DOI 10.1074/jbc.272.13.8546; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Jacobson EL, 1997, ADV EXP MED BIOL, V419, P371; JOHNSON JD, 1976, NATURE, V262, P661, DOI 10.1038/262661a0; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; Li PL, 1997, ADV EXP MED BIOL, V419, P437; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; MCDOUGALL A, 1995, ZYGOTE, V3, P251, DOI 10.1017/S0967199400002641; MCDOUGALL A, 1995, CURR BIOL, V5, P318, DOI 10.1016/S0960-9822(95)00062-5; MOODY WJ, 1985, DEV BIOL, V112, P396, DOI 10.1016/0012-1606(85)90412-9; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; Rakovic S, 1996, CURR BIOL, V6, P989, DOI 10.1016/S0960-9822(02)00643-7; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; Russo GL, 1996, DEVELOPMENT, V122, P1995; SARDET C, 1989, DEVELOPMENT, V105, P237; SPEKSNIJDER JE, 1990, J CELL BIOL, V110, P1589, DOI 10.1083/jcb.110.5.1589; SPEKSNIJDER JE, 1989, DEV BIOL, V135, P182, DOI 10.1016/0012-1606(89)90168-1; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y	43	97	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14566	14574		10.1074/jbc.273.23.14566	http://dx.doi.org/10.1074/jbc.273.23.14566			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603972	hybrid			2022-12-25	WOS:000074021500074
J	Cunnick, JM; Dorsey, JF; Standley, T; Turkson, J; Kraker, AJ; Fry, DW; Jove, R; Wu, J				Cunnick, JM; Dorsey, JF; Standley, T; Turkson, J; Kraker, AJ; Fry, DW; Jove, R; Wu, J			Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION; EGF RECEPTOR; MAP KINASE; PHOSPHATASE CATALYSIS; RAT-1 FIBROBLASTS; PHOSPHORYLATION; INTERMEDIATE; REQUIREMENT; COMPLEX	Recent evidence indicates that the epidermal growth factor (EGF) receptor mediates a branch of lysophosphatidic acid (LPA)-induced signal transduction pathways that activate mitogen-activated protein (MAP) kinase. However, it is unclear whether the intrinsic tyrosine kinase activity of EGF receptor is involved, We previously showed that reactive oxygen species (ROS) were involved in the LPA-stimulated MAP kinase pathway. Here, we identify tyrosine phosphorylation of EGF receptor as an LPA signaling step that requires ROS. To evaluate the role of the tyrosine kinase activity of EGF receptor in the LPA-stimulated MAP kinase pathway, we examined the effects of are EGF receptor-specific tyrosine kinase inhibitor, PD158780. PD158780 potently inhibited the LPA-stimulated MAP kinase kinase 1/2 (MKK1/2) activation and EGF receptor tyrosine phosphorylation in HeLa cells, while it had no detectable effect on c-Src kinase activity, PD158780 also inhibited LPA-induced MKK1/2 activation and DNA synthesis in NIH 3T3 cells. Furthermore, we compared LPA-stimulated MKK1/2 and MAP kinase activation, transcriptional activity of the c-fos promoter, and DNA synthesis in B82L cells, which lack endogenous EGF receptor, and B82L cells expressing kinase-defective or wild-type human EGF receptor. Results obtained from analysis of these cell Lines suggest that the EGF receptor tyrosine kinase contributes to the LPA-stimulated MAP kinase activation, c-fos transcription, and mitogenesis.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Ann Arbor, MI 48105 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Pfizer	Wu, J (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, MDC 44,12902 Magnolia Dr, Tampa, FL 33612 USA.		Cunnick, Jess/F-1715-2018; Wu, Jie/R-2404-2019	Wu, Jie/0000-0002-2864-1606	NCI NIH HHS [CA55652] Funding Source: Medline; NIDA NIH HHS [T32 DA 07245] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007245] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BAE SY, 1997, J BIOL CHEM, V272, P217; BASUMODAK S, 1993, CANCER RES, V53, P4505; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Chuprun JK, 1997, J BIOL CHEM, V272, P773, DOI 10.1074/jbc.272.2.773; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Dixon JE, 1996, RECENT PROG HORM RES, V51, P405; Fry DW, 1997, BIOCHEM PHARMACOL, V54, P877, DOI 10.1016/S0006-2952(97)00242-6; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Rewcastle GW, 1996, J MED CHEM, V39, P1823, DOI 10.1021/jm9508651; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; SAVILLE MK, 1994, BIOCHEM J, V301, P407, DOI 10.1042/bj3010407; Sekharam M, 1998, TOXICOL APPL PHARM, V149, P210, DOI 10.1006/taap.1997.8361; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204, DOI 10.1152/ajpcell.1994.267.1.C204; TONKS NK, 1988, J BIOL CHEM, V263, P6731; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Yurchak LK, 1996, J BIOL CHEM, V271, P12549, DOI 10.1074/jbc.271.21.12549	48	140	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14468	14475		10.1074/jbc.273.23.14468	http://dx.doi.org/10.1074/jbc.273.23.14468			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603960	hybrid			2022-12-25	WOS:000074021500062
J	Johnson, MR; Valentine, C; Basilico, C; Mansukhani, A				Johnson, MR; Valentine, C; Basilico, C; Mansukhani, A			FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells	ONCOGENE			English	Article						fibroblast growth factor; estrogen receptor; MAP kinase; STAT1; MCF-7 growth inhibition; breast cancer	FIBROBLAST GROWTH-FACTOR; HUMAN BREAST-CANCER; RECEPTOR SUPERFAMILY; GENE-EXPRESSION; TRANSGENIC MICE; MAMMARY-GLAND; INDUCTION; PATHWAYS; FAMILY; KINASE	Normal breast tissue as well as most breast tumors are dependent on estrogen for growth, Breast tumors often progress to a hormone-independent state which is associated with poor prognosis, It has been proposed that activation of growth factor signaling pathways in the tumor cells may free them from hormonal control. Certain growth factors can mimic estrogen responses by activating the estrogen receptor via its phosphorylation by mitogen-activated protein (MAP) kinase, In this report, however, we show that fibroblast growth factor (FGF), despite activating MAP kinase, is growth-inhibitory for estrogen-dependent MCF-7 breast cancer cells, MCF-7 cells treated with FGFs exhibit slower growth than controls in both the presence and absence of estrogen, with a concomitant increase in the number of cells in G0/G1, Expression of a constitutively activated FGF receptor in these cells further decreases their growth rate, which is no longer influenced by FGF treatment. Activation of the FGF signaling pathway also reduces the induction of an estrogen-responsive CAT reporter plasmid by estrogen, an effect which appears to be independent of serine 118 in the estrogen receptor, a MAP kinase target site. The inhibitory effects of FGF are probably mediated through the sustained induction of the cyclin kinase inhibitor p21/WAF1/CIP1, which is upregulated at the mRNA and protein level by FGF, FGF treatment also results in the phosphorylation of STAT1, This upregulation of p21 and phosphorylation of STAT1 is not detectable in T47D breast cancer cells upon which FGF has no inhibitory effect.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University	Basilico, C (corresponding author), NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.			Mansukhani, Alka/0000-0003-1020-3242	NCI NIH HHS [CA42568] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1991, ONCOGENE, V6, P659; Altucci L, 1996, ONCOGENE, V12, P2315; BANSAL GS, 1995, BRIT J CANCER, V72, P1420, DOI 10.1038/bjc.1995.524; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CHALBOS D, 1994, SEMIN CANCER BIOL, V5, P361; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DICKSON RB, 1986, SCIENCE, V232, P1540, DOI 10.1126/science.3715461; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; Fenig E, 1997, CLIN CANCER RES, V3, P135; GOMM JJ, 1991, CANCER RES, V51, P4685; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HORWITZ KB, 1978, CANCER RES, V38, P2434; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; Li Y, 1997, ONCOGENE, V14, P1397, DOI 10.1038/sj.onc.1200983; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; Luqmani YA, 1996, EUR J CANCER, V32A, P518, DOI 10.1016/0959-8049(95)00563-3; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MCLESKEY SW, 1994, CANCER RES, V54, P523; MICHIELI P, 1994, CANCER RES, V54, P3391; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MURAKAMI A, 1990, CELL GROWTH DIFFER, V1, P225; ORNITZ DM, 1996, J BIOL CHEM, V271, P1592; Payson RA, 1996, ONCOGENE, V13, P47; PETERS G, 1991, SEMIN VIROL, V2, P319; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Wang HS, 1997, CANCER RES, V57, P1750; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	48	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2647	2656		10.1038/sj.onc.1201789	http://dx.doi.org/10.1038/sj.onc.1201789			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632141				2022-12-25	WOS:000073698200009
J	Schiemann, WP; Nathanson, NM				Schiemann, WP; Nathanson, NM			Raf-1 independent stimulation of mitogen-activated protein kinase by leukemia inhibitory factor in 3T3-L1 cells	ONCOGENE			English	Article						cytokine; leukemia inhibitory factor; MAP kinase; signal transduction	TRANSDUCING RECEPTOR COMPONENT; SIGNAL-REGULATED KINASE-2; EPIDERMAL GROWTH-FACTOR; MAP KINASE; PC12 CELLS; SERINE PHOSPHORYLATION; C-RAF; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; MYELOID-LEUKEMIA	We show here that treatment of 3T3-L1 cells with leukemia inhibitory factor (LIF) stimulated Raf-l activity in a time-and dose-dependent manner, Although phorbol ester failed to activate Raf-l directly, a protein kinase C-stimulated signal was found to be necessary, but not sufficient, for LIF-mediated activation of Raf-l, Elevation of intracellular cAMP levels completely blocked Raf-l activation by LIF, but was without effect on the magnitude of mitogen-activated protein kinase (MAPK) stimulation by the cytokine, suggesting the presence of a Raf-l-independent, cAMP-insensitive MAPK kinase kinase (MAPKKK) pathway in 3T3-L1 cells, Mono Q-fractionation of LIF-stimulated 3T3-L1 extracts identified a single peak of MAPKKK activity that was largely insensitive to elevated intracellular levels of cAMP, and that failed to correlate with stimulation of either Raf-l or MEKK1 protein kinases, Our results demonstrate that LIF-mediated activation of the MAP kinase cascade in 3T3-L1 cells proceeds through both Raf-l-dependent and -independent pathways which differ in their sensitivity to inhibition by intracellular cAMP.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Nathanson, NM (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007750] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM07750] Funding Source: Medline; NINDS NIH HHS [NS30410] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMANN H, 1992, J BIOL CHEM, V267, P19744; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FAURE M, 1994, J BIOL CHEM, V269, P7851; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GARDNER AM, 1994, MEHTODS ENZYMOL, V238, P528; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; ICHIKAWA Y, 1970, J CELL PHYSIOL, V76, P175, DOI 10.1002/jcp.1040760207; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Keller JR, 1996, CURR TOP MICROBIOL, V211, P43; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRYIAKIS JM, 1992, NATURE, V358, P417; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; METCALF D, 1991, INT J CELL CLONING, V9, P95, DOI 10.1002/stem.5530090201; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; PORRAS A, 1994, J BIOL CHEM, V269, P12741; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; SOZERI O, 1992, ONCOGENE, V7, P2259; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; Taga T, 1996, J NEUROCHEM, V67, P1; THOMA B, 1994, J BIOL CHEM, V269, P6215; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YIN TG, 1994, J BIOL CHEM, V269, P3731; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	54	6	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2671	2679		10.1038/sj.onc.1201800	http://dx.doi.org/10.1038/sj.onc.1201800			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632143				2022-12-25	WOS:000073698200011
J	Barzegar, C; Meazza, R; Pereno, R; Pottin-Clemenceau, C; Scudeletti, M; Brouty-Boye, D; Doucet, C; Taoufik, Y; Ritz, J; Musselli, C; Mishal, Z; Jasmin, C; Indiveri, F; Ferrini, S; Azzarone, B				Barzegar, C; Meazza, R; Pereno, R; Pottin-Clemenceau, C; Scudeletti, M; Brouty-Boye, D; Doucet, C; Taoufik, Y; Ritz, J; Musselli, C; Mishal, Z; Jasmin, C; Indiveri, F; Ferrini, S; Azzarone, B			IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops	ONCOGENE			English	Article						melanomas; IL-15; IL-15R; secretion pattern; tumor progression immunotherapy	NATURAL-KILLER-CELLS; RECEPTOR-GAMMA CHAIN; INTERLEUKIN-2 RECEPTOR; BETA-CHAIN; FUNCTIONAL INTERLEUKIN-2; GROWTH-FACTOR; ALPHA-CHAIN; EXPRESSION; LINE; IDENTIFICATION	IL-15 is a novel cytokine active through the IL-2R beta gamma. Since several human melanoma cell lines display functional IL-2Rs, we studied the IL-15/melanoma cells interactions. Ten out of 17 melanoma cell lines express the IL-15 transcript and four of them express levels of IL-15 mRNA similar to those detected in control activated monocytes, Nine out of ten cell lines also express two transcripts for the IL-15R alpha originated by the alternative splicing of exon'3'. Two melanoma cell lines, MELP and MELREO, derived from patients with rapidly progressive primary melanomas, co-express the two IL-15 transcripts, originated by alternative splicing of exon 'A'. Intracellular II-15 protein was only detected in these two cells lines and it is mainly retained in the Endoplasmic Reticulum (ER), However, a small amount of IL-15 is also found in the GoIgi apparatus and in the early endosomes, suggesting production and intercellular trafficking of endogenous IL-15 protein. Nevertheless, no biologically active IL-15 could be detected in the supernatant of all melanoma cells. The anti IL-15 blocking mAb M111 causes the up regulation of;HLA Class I in dense MELP and MELREO cultures, These data suggest that IL-15 is probably active through juxtacrine loops negatively controlling KLA Class I molecules expression. These data offer, for the first time, a likely explanation to the controversal issue of IL-15 secretion and constitute a natural model for understanding IL-15 routing. Moreover, me identify a subset of melanoma cells producing IL-15, possibly involved in tumor escape mechanisms.	Hop Paul Brousse, INSERM, U268, F-94807 Villejuif, France; IST, CBA, I-16132 Genoa, Italy; Fac Med, DIMI, I-16132 Genoa, Italy; INSERM, U4, CRI, F-94276 Le Kremlin Bicetre, France; Dana Farber Canc Inst, Boston, MA 02115 USA; CNRS, UPS 47, Lab Cytometrie, F-94800 Villejuif, France; Fac Med, DOCS, I-16132 Genoa, Italy	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Harvard University; Dana-Farber Cancer Institute; Centre National de la Recherche Scientifique (CNRS)	Azzarone, B (corresponding author), Hop Paul Brousse, INSERM, U268, F-94807 Villejuif, France.		Ritz, Jerome/C-7929-2009; Meazza, Raffaella/AAC-2425-2019; Azzarone, Bruno/AAH-9251-2019; Indiveri, Francesco/AAE-9086-2020	Ritz, Jerome/0000-0001-5526-4669; Meazza, Raffaella/0000-0003-0242-3157; Azzarone, Bruno/0000-0002-5962-3849; Induveri, Francesco/0000-0002-9280-2232; Ferrini, Silvano/0000-0001-7254-2616				ALILECHE A, 1993, ONCOGENE, V8, P1791; ALTOMONTE M, 1992, NEW ENGL J MED, V327, P959; ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; Azzarone B, 1996, EUR CYTOKINE NETW, V7, P27; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; Care A, 1996, MOL CELL BIOL, V16, P4842; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; Carson WE, 1995, J CLIN INVEST, V96, P2578, DOI 10.1172/JCI118321; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; deJong JLO, 1996, J IMMUNOL, V156, P1339; DOUCET C, 1997, MELANOMA RES S, V7, P75; Ferrini S, 1996, GENE THER, V3, P656; GAMERO AM, 1995, CANCER RES, V55, P4988; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HANS DS, 1996, ONCOGENE, V8, P1015; KATANO M, 1994, CANCER IMMUNOL IMMUN, V39, P161, DOI 10.1007/BF01533381; KAWAHARA A, 1994, MOL CELL BIOL, V14, P5433, DOI 10.1128/MCB.14.8.5433; KAWAMI H, 1993, BIOTHERAPY, V6, P33, DOI 10.1007/BF01877384; LENTER M, 1994, J BIOL CHEM, V269, P12263; Meazza R, 1996, ONCOGENE, V12, P2187; MEAZZA R, 1997, IN PRESS EUR J IMMUN; MOHAMADZADEH M, 1995, J IMMUNOL, V155, P4492; MORIMOTO K, 1994, BLOOD, V83, P657; Mrozek E, 1996, BLOOD, V87, P2632, DOI 10.1182/blood.V87.7.2632.bloodjournal8772632; NAKARAI T, 1994, J EXP MED, V180, P241, DOI 10.1084/jem.180.1.241; PLAISANCE S, 1993, INT J CANCER, V55, P164, DOI 10.1002/ijc.2910550129; RIMOLDI D, 1993, ANTICANCER RES, V13, P555; Tagaya Y, 1996, EMBO J, V15, P4928, DOI 10.1002/j.1460-2075.1996.tb00873.x; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; WALDMANN TA, 1993, IMMUNOL TODAY, V14, P264, DOI 10.1016/0167-5699(93)90043-K	34	40	49	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2503	2512		10.1038/sj.onc.1201775	http://dx.doi.org/10.1038/sj.onc.1201775			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627116				2022-12-25	WOS:000073672300008
J	Duan, CM; Clemmons, DR				Duan, CM; Clemmons, DR			Differential expression and biological effects of insulin-like growth factor-binding protein-4 and -5 in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I GENE-EXPRESSION; IGF-I; MYOBLAST DIFFERENTIATION; BALLOON DENUDATION; HUMAN-FIBROBLASTS; MESSENGER-RNA; RAT AORTA; RECEPTOR; IDENTIFICATION; PROLIFERATION	Insulin-like growth factor-I (IGF-I) plays an important role in regulating vascular smooth muscle cell (VSMC) proliferation, migration, and apoptosis, The bioactivity of IGF-I is modulated by a group of high affinity, specific binding proteins (IGF-binding proteins; IGFBPs) that are present in the interstitial fluid, Previously, we have reported that porcine VSMCs synthesize and secrete IGF-I and several forms of IGFBPs, including IGFBP-2, IGFBP-4, and IGFBP-5, In this study, we examined the role of autocrine/paracrine secreted IGF-I in controlling the expression of IGFBP-4 and IGFBP-5 as well as the effects of these IGFBPs in modulating the cellular replication response to IGF-I. The concentrations of IGFBP-4 in the conditioned medium increased significantly from <50 ng/ml to 742 +/- 105 ng/ml, This increase was associated with a decrease in the activity of an IGF-I-regulated IGFBP-4 protease, In contrast, the synthesis of IGFBP-5 was inversely correlated with culture density, and its concentration decreased from 792 +/- 91 to 44 +/- 14 ng/ml, IGFBP-5 mRNA in sparse cultures was 3-fold higher compared with those in confluent cultures. This culture density-dependent change in IGFBP-5 mRNA correlated closely with endogenous IGF-I levels. Since treatment of VSMC with exogenous IGF-I increased IGFBP-5 mRNA levels, we neutralized the effect of endogenously secreted IGF-I with an anti-IGF-I antibody to determine if it would alter IGFBP-5 mRNA abundance. This resulted in a 4.4-fold decrease in IGFBP-5 mRNA levels. When added together with IGF-I, exogenous IGFBP-4 inhibited IGF-I-induced DNA synthesis in a concentration-dependent manner. IGFBP-5, on the other hand, potentiated the effect of IGF-I, Therefore, IGFBP-4 and IGFBP-5 appear to be differentially regulated by autocrine/paracrine IGF-I through distinct mechanisms. These two proteins, in turn, play opposing roles in modulating IGF-I action in stimulating VSMC proliferation.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of Michigan System; University of Michigan; University of North Carolina; University of North Carolina Chapel Hill	Duan, CM (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	cduan@umich.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056850] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56850] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; Boes M, 1996, ENDOCRINOLOGY, V137, P5357, DOI 10.1210/en.137.12.5357; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BORNFELDT KE, 1990, J ENDOCRINOL, V125, P381, DOI 10.1677/joe.0.1250381; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CERCEK B, 1990, CIRC RES, V66, P1755, DOI 10.1161/01.RES.66.6.1755; CLEMMONS DR, 1985, CIRC RES, V56, P418, DOI 10.1161/01.RES.56.3.418; CLEMMONS DR, 1985, J CLIN INVEST, V75, P1914, DOI 10.1172/JCI111906; COHICK WS, 1993, J CELL PHYSIOL, V157, P52, DOI 10.1002/jcp.1041570107; DAVENPORT ML, 1988, J CLIN ENDOCR METAB, V67, P1231, DOI 10.1210/jcem-67-6-1231; DELAFONTAINE P, 1991, HYPERTENSION, V18, P742, DOI 10.1161/01.HYP.18.6.742; DU J, 1995, CIRC RES, V76, P963, DOI 10.1161/01.RES.76.6.963; Duan CM, 1996, J BIOL CHEM, V271, P4280; EWTON DZ, 1995, J ENDOCRINOL, V144, P539, DOI 10.1677/joe.0.1440539; GIANNELLANETO D, 1992, CIRC RES, V71, P646, DOI 10.1161/01.RES.71.3.646; GOCKERMAN A, 1995, ENDOCRINOLOGY, V136, P4168, DOI 10.1210/en.136.10.4168; GRANT MB, 1994, CIRCULATION, V89, P1511, DOI 10.1161/01.CIR.89.4.1511; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Imai Y, 1997, J CLIN INVEST, V100, P2596, DOI 10.1172/JCI119803; JAMES PL, 1993, J BIOL CHEM, V268, P22305; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAMYAR A, 1994, CIRC RES, V74, P576, DOI 10.1161/01.RES.74.4.576; KATO M, 1995, J BIOL CHEM, V270, P12373, DOI 10.1074/jbc.270.21.12373; KHORSANDI MJ, 1992, J CLIN INVEST, V90, P1926, DOI 10.1172/JCI116070; LIAU G, 1989, J BIOL CHEM, V264, P10315; MIN BH, 1990, J BIOL CHEM, V265, P16667; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; PARKER A, 1995, ENDOCRINOLOGY, V136, P2470, DOI 10.1210/en.136.6.2470; Parker A, 1996, J BIOL CHEM, V271, P13523, DOI 10.1074/jbc.271.23.13523; Singh P, 1996, ENDOCRINOLOGY, V137, P1764, DOI 10.1210/en.137.5.1764; STRAUCH AR, 1989, J BIOL CHEM, V264, P8345; THRAILKILL KM, 1995, ENDOCRINOLOGY, V136, P3527, DOI 10.1210/en.136.8.3527; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; VEVERIS J, 1994, AM J MED SCI, V307, P77	37	80	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16836	16842		10.1074/jbc.273.27.16836	http://dx.doi.org/10.1074/jbc.273.27.16836			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642243	Green Published, hybrid			2022-12-25	WOS:000074545200033
J	Gasman, S; Chasserot-Golaz, S; Hubert, P; Aunis, D; Bader, MF				Gasman, S; Chasserot-Golaz, S; Hubert, P; Aunis, D; Bader, MF			Identification of a potential effector pathway for the trimeric G(o) protein associated with secretory granules - G(o) stimulates a granule-bound phosphatidylinositol 4 kinase by activating RhoA in chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; ANTERIOR-PITUITARY-CELLS; SERINE-THREONINE KINASE; REGULATED EXOCYTOSIS; MAST-CELLS; CA2+-ACTIVATED SECRETION; ESCHERICHIA-COLI; PLASMA-MEMBRANE; PUTATIVE TARGET; ALPHA-SUBUNIT	Besides having a role in signal transduction, heterotrimeric G proteins may be involved in membrane trafficking events. In chromaffin cells, G, is associated with secretory organelles, and its activation inhibits the ATP-dependent priming of exocytosis, By using permeabilized cells, we previously described that the control exerted by the granule-bound G, on exocytosis may be related to effects on the cortical actin network through a sequence possibly involving Rho, To provide further insight into the function of Rho in exocytosis, we focus here on its intracellular localization in chromaffin cells. By immunoreplica analysis, immunoprecipitation, and confocal immunofluorescence, we found that RhoA is specifically associated with the membrane of secretory chromaffin granules, Parallel subcellular fractionation experiments revealed the occurrence of a mastoparan-stimulated phosphatidylinositol 4-kinase activity in purified chromaffin granule membranes. This stimulatory effect of mastoparan was mimicked by GAP-43, an activator of the granule-associated G,, and specifically inhibited by antibodies against G alpha(0). In addition, Clostridium botulinum C3 exoenzyme completely blocked the activation of phosphatidylinositol 4-kinase by mastoparan. We propose that the control exerted by G, on peripheral actin and exocytosis is related to the activation of a downstream RhoA-dependent phosphatidylinositol 4-kinase associated with the membrane of secretory granules.	INSERM, U338, F-67084 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bader, MF (corresponding author), INSERM, U338, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	bader@neurochem.u-strasbg.fr	stéphane, gasman/Q-1145-2019; Gasman, Stephane/D-5113-2017; Bader, Marie-France/O-2098-2016; Hubert, Pierre/C-6678-2013; Dominique, Aunis/W-1419-2019; Chasserot-Golaz, Sylvette/K-7625-2017	stéphane, gasman/0000-0001-8415-1276; Gasman, Stephane/0000-0001-8415-1276; Hubert, Pierre/0000-0002-7549-8910; 				AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; AUNIS D, 1973, BIOCHEM PHARMACOL, V22, P2581, DOI 10.1016/0006-2952(73)90066-X; BADER MF, 1986, J CELL BIOL, V102, P636, DOI 10.1083/jcb.102.2.636; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BURGOYNE RD, 1989, CELL SIGNAL, V1, P323, DOI 10.1016/0898-6568(89)90051-X; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Cussac D, 1996, MOL CELL ENDOCRINOL, V119, P195, DOI 10.1016/0303-7207(96)03814-2; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DELCASTILLO AR, 1992, J CELL BIOL, V119, P797, DOI 10.1083/jcb.119.4.797; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; EHRHART M, 1986, J HISTOCHEM CYTOCHEM, V34, P1673, DOI 10.1177/34.12.2878021; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; Gasman S, 1997, J BIOL CHEM, V272, P20564, DOI 10.1074/jbc.272.33.20564; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; HUSEBYE ES, 1988, BIOCHIM BIOPHYS ACTA, V968, P261, DOI 10.1016/0167-4889(88)90015-8; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; LANG J, 1995, EMBO J, V14, P3635, DOI 10.1002/j.1460-2075.1995.tb00033.x; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Mariot P, 1996, EMBO J, V15, P6476, DOI 10.1002/j.1460-2075.1996.tb01038.x; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NISHIOKA H, 1989, J ANTIBIOT, V42, P823, DOI 10.7164/antibiotics.42.823; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; OSullivan AJ, 1996, MOL BIOL CELL, V7, P397, DOI 10.1091/mbc.7.3.397; PERELLE S, 1993, INFECT IMMUN, V61, P5147, DOI 10.1128/IAI.61.12.5147-5156.1993; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; RUPNIK M, 1995, NEUROREPORT, V6, P853, DOI 10.1097/00001756-199504190-00007; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Vitale N, 1996, EUR J NEUROSCI, V8, P1275, DOI 10.1111/j.1460-9568.1996.tb01296.x; Vitale N, 1997, CELL MOL NEUROBIOL, V17, P71, DOI 10.1023/A:1026329121099; VITALE N, 1994, J BIOL CHEM, V269, P30293; VITALE N, 1993, J BIOL CHEM, V268, P14715; VITALE N, 1994, BIOCHEM J, V300, P217, DOI 10.1042/bj3000217; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; Zhang L, 1996, NEURON, V17, P287, DOI 10.1016/S0896-6273(00)80160-9	63	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16913	16920		10.1074/jbc.273.27.16913	http://dx.doi.org/10.1074/jbc.273.27.16913			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642253	hybrid			2022-12-25	WOS:000074545200043
J	Schandar, M; Laugwitz, KL; Boekhoff, I; Kroner, C; Gudermann, T; Schultz, G; Breer, H				Schandar, M; Laugwitz, KL; Boekhoff, I; Kroner, C; Gudermann, T; Schultz, G; Breer, H			Odorants selectively activate distinct G protein subtypes in olfactory cilia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; NEMATODE CAENORHABDITIS-ELEGANS; ADIPOCYTE PLASMA-MEMBRANES; 2ND MESSENGER PATHWAYS; ALPHA-SUBUNITS; SIGNAL TRANSDUCTION; ADENYLYL-CYCLASE; PHOSPHOINOSITIDE TURNOVER; MOLECULAR-CLONING; XENOPUS-OOCYTES	Chemoelectrical signal transduction in olfactory neurons appears to involve intracellular reaction cascades mediated by heterotrimeric GTP-binding proteins. In this study attempts were made to identify the G protein subtype(s) in olfactory cilia that are activated by the primary (odorant) signal. Antibodies directed against the alpha subunits of distinct G protein subtypes interfered specifically with second messenger reponses elicited by defined subsets of odorants; odor-induced cAMP-formation was attenuated by G alpha(s) antibodies, whereas G alpha(o) antibodies blocked odor-induced inositol 1,4,5-trisphosphate (IP3) formation. Activation-dependent photolabeling of G alpha subunits with [alpha-(32)p]GTP azidoanilide followed by immunoprecipitation using subtype-specific antibodies enabled identification of particular individual G protein subtypes that were activated upon stimulation of isolated olfactory cilia by chemically distinct odorants, For example odorants that elicited a cAMP response resulted in labeling of a G alpha(s)-like protein, whereas odorants that elicited an IP3 response led to the labeling of a G alpha(o)-like protein. Since odorant-induced IP3 formation was also blocked by G(beta) antibodies, activation of olfactory phospholipase C might be mediated by beta gamma subunits of a G(o)-like G protein. These results indicate that different subsets of odorants selectively trigger distinct reaction cascades and provide evidence for dual transduction pathways in olfactory signaling.	Univ Stuttgart Hohenheim, Inst Physiol, D-70593 Stuttgart, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	University Hohenheim; Free University of Berlin	Breer, H (corresponding author), Univ Stuttgart Hohenheim, Inst Physiol, D-70593 Stuttgart, Germany.	physiol1@uni-hohenheim.de						Ache Barry W., 1994, Seminars in Cell Biology, V5, P55, DOI 10.1006/scel.1994.1008; ANHOLT RRH, 1987, BIOCHEMISTRY-US, V26, P788, DOI 10.1021/bi00377a020; ANHOLT RRH, 1986, J NEUROSCI, V6, P1962; Berghard A, 1996, J NEUROSCI, V16, P909; BLITZER RD, 1993, J BIOL CHEM, V268, P7532; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BREER H, 1991, CHEM SENSES, V16, P19, DOI 10.1093/chemse/16.1.19; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; CHEN Z, 1986, J BIOL CHEM, V261, P1299; Dellacorte C, 1996, NEUROSCIENCE, V74, P261, DOI 10.1016/0306-4522(96)00115-7; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HINSCH KD, 1988, FEBS LETT, V238, P191, DOI 10.1016/0014-5793(88)80254-0; HSU WH, 1990, J BIOL CHEM, V265, P11220; HUQUE T, 1986, BIOCHEM BIOPH RES CO, V137, P36, DOI 10.1016/0006-291X(86)91172-1; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; JONES DT, 1988, COLD SPRING HARB SYM, V53, P349, DOI 10.1101/SQB.1988.053.01.042; JONES DT, 1987, J BIOL CHEM, V262, P14241; KRIEGER J, 1994, EUR J BIOCHEM, V219, P829, DOI 10.1111/j.1432-1033.1994.tb18564.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; LIEBMAN PA, 1974, SCIENCE, V185, P457, DOI 10.1126/science.185.4149.457; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; MANIAFARNELL B, 1990, DEV BRAIN RES, V51, P103, DOI 10.1016/0165-3806(90)90262-W; MCKENZIE FR, 1988, BIOCHEM J, V249, P653, DOI 10.1042/bj2490653; MENCO B, 1992, MICROSC RES TECHNIQ, V22, P215; MENCO BPM, 1994, J NEUROCYTOL, V23, P708, DOI 10.1007/BF01181645; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P268; PACE U, 1986, P NATL ACAD SCI USA, V83, P4947, DOI 10.1073/pnas.83.13.4947; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PERSHADSINGH HA, 1980, J BIOL CHEM, V255, P4087; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; Restrepo D, 1996, J NEUROBIOL, V30, P37; RONNETT GV, 1993, J NEUROSCI, V13, P1751; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; SILVA IF, 1990, J MOL BIOL, V215, P483, DOI 10.1016/S0022-2836(05)80160-3; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; STEINER AL, 1972, J BIOL CHEM, V247, P1114; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Zwaal RR, 1997, GENETICS, V145, P715	57	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16669	16677		10.1074/jbc.273.27.16669	http://dx.doi.org/10.1074/jbc.273.27.16669			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642220	hybrid			2022-12-25	WOS:000074545200010
J	Baudino, TA; Kraichely, DM; Jefcoat, SC; Winchester, SK; Partridge, NC; MacDonald, PN				Baudino, TA; Kraichely, DM; Jefcoat, SC; Winchester, SK; Partridge, NC; MacDonald, PN			Isolation and characterization of a novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION FUNCTION AF-2; NUCLEAR RECEPTORS; POLYTENE CHROMOSOMES; HORMONE-RECEPTOR; RETINOIC ACID; EXPRESSION; SEQUENCE; CBP; INTERACTS; PUFFS	The vitamin D receptor (VDR) forms a heterodimeric complex with retinoid X receptor (RXR) and binds to vitamin D-responsive promoter elements to regulate the transcription of specific genes or gene networks. The precise mechanism of transcriptional regulation by the VDR RXR heterodimer is not well understood, but it may involve interactions of VDR RXR with transcriptional coactivator or corepressor proteins. Here, a yeast two-hybrid strategy was used to isolate proteins that selectively interacted with VDR and other nuclear receptors, One cDNA clone designated NCoA-62, encoded a 62,000-Da protein that is highly related to BX42, a Drosophila melanogaster nuclear protein involved in ecdysone-stimulated gene expression. Yeast two-hybrid studies and in vitro protein-protein interaction assays using glutathione S-transferase fusion proteins demonstrated that NCoA-62 formed a direct protein-protein contact with the ligand binding domain of VDR, Coexpression of NCoA-62 in a vitamin D-responsive transient gene expression system augmented 1,25-dihydroxyvitamin D-3-activated transcription, but it had little or no effect on basal transcription or gal4-VP16-activated transcription. NCoA-62 also interacted with retinoid receptors, and its expression enhanced retinoic acid-, estrogen-, and glucocorticoid-mediated gene expression. These data indicate that NCoA-62 may be classified into an emerging set of transcriptional coactivator proteins that function to facilitate vitamin D- and other nuclear receptor-mediated transcriptional pathways.	St Louis Univ, Hlth Sci Ctr, Dept Pharmacol & Physiol Sci, Cell & Mol Biol Program, St Louis, MO 63104 USA	Saint Louis University	MacDonald, PN (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand, St Louis, MO 63104 USA.			Partridge, Nicola/0000-0002-5406-4814	NIDDK NIH HHS [R01DK50348] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050348] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FRASCH M, 1989, CHROMOSOMA, V97, P272, DOI 10.1007/BF00371966; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MACDONALD PN, 1994, SEMIN NEPHROL, V14, P101; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Summers MD, 1987, MANUAL METHODS BACUL; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; VONBAUR E, 1996, EMBO J, V15, P110; WIELAND C, 1992, CHROMOSOMA, V101, P517, DOI 10.1007/BF00352475	35	117	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16434	16441		10.1074/jbc.273.26.16434	http://dx.doi.org/10.1074/jbc.273.26.16434			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632709	hybrid			2022-12-25	WOS:000074436600080
J	Ho, DH; Badellino, K; Baglia, FA; Walsh, PN				Ho, DH; Badellino, K; Baglia, FA; Walsh, PN			A binding site for heparin in the Apple 3 domain of factor XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; MOLECULAR-WEIGHT KININOGEN; FACTOR-IX; HUMAN-PLATELETS; HUMAN-PLASMA; DISULFIDE BONDS; HEAVY-CHAIN; ACTIVATION; IDENTIFICATION; MECHANISM	Since heparin potentiates activated factor XI (FXIa) inhibition by protease nexin-2 by providing a template to which both proteins bind (Zhang, Y., Scandura, J. M., Van Nostrand, W. E., and Walsh, P. N. (1997) J. Biol. Chem. 272, 26139-26144), we examined binding of factor XI (FXI) and FXIa to heparin. FXIa binds to heparin (K-d -0.7 x 10(-9) M) > 150-fold more tightly than FXI (K-d similar to 1.1 x 10(-7) M). To localize the heparin-binding site on FXI, rationally designed conformationally constrained synthetic peptides were used to compete with I-125-FXI binding to heparin. A peptide derived from the Apple 3 (A3) domain of FXI (Asn(235)-Arg(266)) inhibited FXI binding to heparin (K-d similar to 3.4 x 10(-6) M), whereas peptides from the A1 domain (Phe(56)-Ser(86)), A2 domain (Ala(134)-Ala(176)), and A4 domain (Ala(317)-Gly(350)) had no such effect. The recombinant A3 domain (rA3, Ala(181)-Val(271)) inhibited FXI binding to heparin (K-i similar to 1.4 x 10(-7) M) indicating that all the information necessary for FXI binding to heparin is contained entirely within the A3 domain. The A3 domain also contains a platelet-binding site (Asn(235)-Arg(266)), consisting of three surface-exposed loop structures, Pro(229)-Gln(233), Thr(741)-Leu(246), and Thr(249)-Phe(260) (Baglia, F. A., Jameson, B. A., and Walsh, P. N. (1995) J. Biol. Chem. 270, 6734-6740). Only peptide Thr(249-)Phe(260) (which contains a heparin binding consensus sequence, RIKKSKA) inhibits FXI binding to heparin (K-i = 2.1 x 10(-7) M), whereas peptides Pro(229)-Gln(233) and Thr(241)-Leu(246) had no effect. Fine mapping of the heparin-binding site using prekallikrein analogue amino acid substitutions of the synthetic peptide Thr(249)-Phe(260) and alanine scanning of the recombinant A3 indicated that the amino acids Lys(252) and Lys(253) are important for heparin binding. Thus, the sequence Thr(249)-Phe(260) which contains most of the binding energy for FXI interaction with platelets also mediates the binding of FXI to heparin.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.				NHLBI NIH HHS [HL56153, HL46213, HL45486] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL045486, R01HL046213, R01HL056153] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1989, J BIOL CHEM, V264, P3244; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAGLIA FA, 1995, BLOOD, V85, P2078, DOI 10.1182/blood.V85.8.2078.bloodjournal8582078; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; Baglia FA, 1996, J BIOL CHEM, V271, P3652; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; BAILEY JL, 1959, J BIOL CHEM, V234, P1733; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Davie E W, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P277; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; Ho D. H., 1996, Blood, V88, p283A; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; KENT SBH, 1985, SYNTHETIC PEPTIDES B, P29; KLOMPMAKERS AA, 1986, ANAL BIOCHEM, V153, P80, DOI 10.1016/0003-2697(86)90064-3; KURACHI K, 1980, BIOCHEMISTRY-US, V19, P1330, DOI 10.1021/bi00548a011; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MEIJERS JCM, 1988, BIOCHEMISTRY-US, V27, P4231, DOI 10.1021/bi00412a005; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; NAITO K, 1991, J BIOL CHEM, V266, P7353; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SINHA D, 1985, J BIOL CHEM, V260, P714; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; SINHA D, 1984, J CLIN INVEST, V73, P1550, DOI 10.1172/JCI111361; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; WALSH PN, 1993, METHOD ENZYMOL, V222, P65; WALSH PN, 1981, BLOOD, V57, P106; ZAMMIT A, 1993, THROMB HAEMOSTASIS, V70, P951; Zhang Y, 1997, J BIOL CHEM, V272, P26139, DOI 10.1074/jbc.272.42.26139	41	65	68	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16382	16390		10.1074/jbc.273.26.16382	http://dx.doi.org/10.1074/jbc.273.26.16382			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632702	hybrid			2022-12-25	WOS:000074436600073
J	Huang, S; Shao, G; Liu, LM				Huang, S; Shao, G; Liu, LM			The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION-EFFECT VARIEGATION; TRANSCRIPTION FACTOR; ACUTE LEUKEMIAS; DROSOPHILA-TRITHORAX; MYELOID-LEUKEMIA; ALL-1 GENE; TRANSLOCATIONS; HETEROZYGOSITY; CHROMOSOME-1; REPRESSOR	The PR domain, first noted as the PRDI-BF1-RIZ1 homologous region, defines a sub-class of zinc finger genes that appear to function as negative regulators of tumorigenesis. This family includes the MDS1-EVI1 gene inactivated in myeloid leukemia, the PRDI-BF1/BLIMP1 transcription repressor of c-myc involved in driving B-cell differentiation, and the RIZ gene, which encodes proteins capable of binding to the retinoblastoma tumor suppressor protein (Rb). The PR domain of MDS1-EVI1 is disrupted by translocations linked to myeloid leukemia, resulting in the activation of the PR-minus oncogenic product EVI1. Remarkably similar to MDS1-EVI1, RIZ gene also normally produces two protein products of different length, and the smaller protein RIZ2 lacks the PR domain of RIZ1 but is otherwise identical to RIZ1. These observations raise considerable interest to determine the function of PR. We show here that RIZ1 PR domain mediates protein-protein interaction. Recombinant fusion proteins of PR can bind to in vitro translated RIZ1 and RIZ2 proteins. The binding can be disrupted by amino acid substitutions at conserved residues of PR, suggesting that binding is specific. Of the three conserved exons of PR, the first two appear dispensable for binding, whereas the third exon is required. A region in the carboxyl terminus of RIZ proteins was mapped to be necessary and sufficient for PR binding. We also found that the PR domain shares significant sequence identity to the SET domain present in chromosomal proteins that function in modulating gene expression from yeast to mammals. Our data suggest that the PR domain is a derivative of SET domain and may function as protein binding interface in the regulation of chromatin-mediated gene expression.	Burnham Inst, Program Oncogenes & Tumor Suppressor Genes, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Huang, S (corresponding author), Burnham Inst, Program Oncogenes & Tumor Suppressor Genes, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA76146, R01CA57496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076146, R01CA057496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel FM, 1995, CURRENT PROTOCOLS MO, V1; BAFFA R, 1995, P NATL ACAD SCI USA, V92, P4922, DOI 10.1073/pnas.92.11.4922; BARDI G, 1993, CANCER RES, V53, P1895; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Buyse IM, 1996, GENOMICS, V34, P119, DOI 10.1006/geno.1996.0249; DeRubertis F, 1996, NATURE, V384, P589; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; Ekwall K, 1996, J CELL SCI, V109, P2637; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FONG CT, 1992, CANCER RES, V52, P1780; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KNOCHEL W, 1989, P NATL ACAD SCI USA, V86, P6097, DOI 10.1073/pnas.86.16.6097; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mock BA, 1996, GENOMICS, V37, P24, DOI 10.1006/geno.1996.0516; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Muraosa Y, 1996, EUR J BIOCHEM, V235, P471, DOI 10.1111/j.1432-1033.1996.00471.x; NAGAI H, 1995, CANCER RES, V55, P1752; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; ROSATI M, 1991, NUCLEIC ACIDS RES, V19, P5661, DOI 10.1093/nar/19.20.5661; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; Seum C, 1996, DEVELOPMENT, V122, P1949; SIMON D, 1991, ONCOGENE, V6, P765; Soderholm J, 1997, LEUKEMIA, V11, P352, DOI 10.1038/sj.leu.2400584; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Xie M, 1997, J BIOL CHEM, V272, P26360, DOI 10.1074/jbc.272.42.26360; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	47	131	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15933	15939		10.1074/jbc.273.26.15933	http://dx.doi.org/10.1074/jbc.273.26.15933			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632640	hybrid			2022-12-25	WOS:000074436600011
J	Hara, K; Yonezawa, K; Weng, QP; Kozlowski, MT; Belham, C; Avruch, J				Hara, K; Yonezawa, K; Weng, QP; Kozlowski, MT; Belham, C; Avruch, J			Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN INITIATION; CAP-DEPENDENT TRANSLATION; ACTIVATED PROTEIN-KINASE; RAT SKELETAL-MUSCLE; HAMSTER OVARY CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; HEPATIC PROTEOLYSIS; PLASMA-MEMBRANE; FACTOR 4E; IN-VIVO	The present study identifies the operation of a signal tranduction pathway in mammalian cells that provides a checkpoint control, linking amino acid sufficiency to the control of peptide chain initiation. Withdrawal of amino acids from the nutrient medium of CHO-IR cells results in a rapid deactivation of p70 SG kinase and dephosphorylation of eIF-4E BP1, which become unresponsive to all agonises. Readdition of the amino acid mixture quickly restores the phosphorylation and responsiveness of p70 and eIF-4E BP1 to insulin. Increasing the ambient amino acids to twice that usually employed increases basal p70 activity to the maximal level otherwise attained in the presence of insulin and abrogates further stimulation by insulin, withdrawal of most individual amino acids also inhibits p70, although with differing potency. Amino acid withdrawal from CHO-IR cells does not significantly alter insulin stimulation of tyrosine phosphorylation, phosphotyrosine-associated phosphatidylinositol 3-kinase activity, c-Akt/protein kinase B activity, or mitogen-activated protein kinase activity. The selective inhibition of p70 and eIF-4E BP1 phosphorylation by amino acid withdrawal resembles the response to rapamycin, which prevents p70 reactivation by amino acids, indicating that mTOR is required for the response to amino acids. A p70 deletion mutant, p70 Delta 2-46/Delta CT104, that is resistant to inhibition by rapamycin (but sensitive to wortmannin) is also resistant to inhibition by amino acid withdrawal, indicating that amino acid sufficiency and mTOR signal to p70 through a common effector, which could be mTOR itself, or an mTOR-controlled downstream element, such as a protein phosphatase.	Massachusetts Gen Hosp, Med Serv, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 657, Japan; Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Diabet Unit, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Kobe University; Harvard University; Massachusetts General Hospital	Avruch, J (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Diabet Unit, 50 Blossom St, Boston, MA 02114 USA.	avruch@helix.mgh.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017776, R37DK017776] Funding Source: NIH RePORTER; NCI NIH HHS [CA73818] Funding Source: Medline; NIDDK NIH HHS [DK17776] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, CURR OPIN IMMUNOL, V8, P412, DOI 10.1016/S0952-7915(96)80132-4; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Arnez JG, 1997, TRENDS BIOCHEM SCI, V22, P211, DOI 10.1016/S0968-0004(97)01052-9; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CLEMENS MJ, 1987, J BIOL CHEM, V262, P767; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Diggle TA, 1996, BIOCHEM J, V316, P447, DOI 10.1042/bj3160447; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; Fadden P, 1997, J BIOL CHEM, V272, P10240; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; KADOWAKI M, 1992, J BIOL CHEM, V267, P22060; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KELLY FJ, 1985, J BIOL CHEM, V260, P6677; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; KUNURAK I, 1996, SCIENCE, V273, P245; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MIOTTO G, 1994, J BIOL CHEM, V269, P25348; MIOTTO G, 1992, J BIOL CHEM, V267, P22066; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; POLLARD JW, 1989, EUR J BIOCHEM, V182, P1, DOI 10.1111/j.1432-1033.1989.tb14793.x; PREEDY VR, 1986, BIOSCIENCE REP, V6, P177, DOI 10.1007/BF01115004; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; Svanberg E, 1997, AM J PHYSIOL-ENDOC M, V272, pE841, DOI 10.1152/ajpendo.1997.272.5.E841; SVANBERG E, 1996, ENDOCRINOL METAB, V33, pE614; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; WENG QP, IN PRESS J BIOL CHEM; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	62	1070	1104	0	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14484	14494		10.1074/jbc.273.23.14484	http://dx.doi.org/10.1074/jbc.273.23.14484			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603962	Green Published, hybrid			2022-12-25	WOS:000074021500064
J	Mok, SC; Chan, WY; Wong, KK; Cheung, KK; Lau, CC; Ng, SW; Baldini, A; Colitti, CV; Rock, CO; Berkowitz, RS				Mok, SC; Chan, WY; Wong, KK; Cheung, KK; Lau, CC; Ng, SW; Baldini, A; Colitti, CV; Rock, CO; Berkowitz, RS			DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer	ONCOGENE			English	Article						ovary; cancer; DOC-2; Dab; tumor suppressor	PROLINE-RICH PEPTIDES; SH3 DOMAINS; P53 GENE; BINDING; RAS; PHOSPHOTYROSINE; CARCINOMA; RNA; IDENTIFICATION; ACTIVATION	Using RNA fingerprinting (RAP) strategy and Northern blot analysis, we identified a differentially expressed sequence DOC-2 which is detectable in all normal human ovarian surface epithelial (HOSE) cell cultures but not in ovarian cancer cell lines and tissues. Subsequent cloning of DOC-2 from a cDNA library generated from the HOSE cells was carried out using the 3' and 5' RACE approach. A 3268 base pair full length cDNA of DOC-2 was isolated and sequenced. The predicted protein has a length of 770 amino acids. Homology search of all NCBI sequences indicated that the amino acid sequence of DOC-2 shares 93% homology with the mouse p96/mDab2 phosphoprotein and has a phosphotyrosine interacting domain (PID) and multiple SH3 binding motifs. Chromosomal localization by FISH showed that the DOC-2 gene is located on 5p13. Western blot analysis showed that the 105 kDa DOC-2 protein was down-regulated in all the carcinoma cell lines. In-situ immunohistochemistry performed on normal ovaries, and benign, borderline and invasive ovarian tumor tissues showed down regulation of DOC-2 protein particularly in serous ovarian tumor tissues. When DOC-2 was transfected into the ovarian carcinoma cell line SKOV3, the stable transfectants showed significantly reduced growth rate and ability to form tumors in nude mice. These data suggest that down-regulation of DOC-2 may play an important role in ovarian carcinogenesis.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol,Lab Gynecol Oncol, Boston, MA 02115 USA; Chinese Univ Hong Kong, Dept Anat, Shatin, Peoples R China; Pacific NW Lab, Richland, WA 99352 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38101 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Chinese University of Hong Kong; United States Department of Energy (DOE); Pacific Northwest National Laboratory; Baylor College of Medicine; Baylor College of Medicine; St Jude Children's Research Hospital	Mok, SC (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol,Lab Gynecol Oncol, Boston, MA 02115 USA.		Wong, K.-k./AAA-6589-2020; Chan, Wood Yee/R-6692-2018; genes, anthony/F-2541-2012; Baldini, Antonio/M-2355-2015	Wong, K.-k./0000-0002-0375-6669; Chan, Wood Yee/0000-0002-7114-1463; Cheung, Kwok Kuen/0000-0001-7367-9171; Baldini, Antonio/0000-0002-5330-0256	NATIONAL CANCER INSTITUTE [R01CA063381, R01CA069453, R01CA069291] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA69453, R01CA63381, R01CA69291] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ENOMOTO T, 1991, AM J PATHOL, V139, P777; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FILMUS JE, 1985, CANCER RES, V45, P4468; JACOBS IJ, 1992, J NATL CANCER I, V84, P1793, DOI 10.1093/jnci/84.23.1793; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MARKS JR, 1991, CANCER RES, V51, P2979; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; MOK SC, 1993, CANCER RES, V52, P5119; MOK SCH, 1993, CANCER RES, V53, P1489; OKAMOTO A, 1991, CANCER RES, V51, P5171; PIVER MS, 1992, GYNECOL ONCOL, P250; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TSAO SW, 1993, GYNECOL ONCOL, V48, P5, DOI 10.1006/gyno.1993.1002; TSAO SW, 1991, ANTICANCER RES, V11, P1975; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VANTVEER LJ, 1988, ONCOGENE, V2, P157; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; WONG KK, 1993, INT J ONCOL, V3, P13; XU X, 1997, AM ASS CANC RES P, V38, P157; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YUNIS JJ, 1976, SCIENCE, V191, P1268, DOI 10.1126/science.1257746; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	31	141	146	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	1998	16	18					2381	2387		10.1038/sj.onc.1201769	http://dx.doi.org/10.1038/sj.onc.1201769			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620555				2022-12-25	WOS:000073428000010
J	Kilbey, A; Bartholomew, C				Kilbey, A; Bartholomew, C			Evi-1 ZF1 DNA binding activity and a second distinct transcriptional repressor region are both required for optimal transformation of Rat1 fibroblasts	ONCOGENE			English	Article						Evi-1; transcriptional repression; leukaemogenesis	ZINC-FINGER GENE; MYELOID-LEUKEMIA; PROTEIN; EXPRESSION; SEQUENCE; ACTIVATION; CELL; IDENTIFICATION; DOMAIN; FAMILY	The Evi-1 gene encodes a zinc finger transcriptional repressor protein that normally plays a role in development and is frequently activated in myeloid leukaemias, Evi-1 has two distinct DNA binding domains, ZF1 and ZF2, and a defined repressor domain but the function of the remainder of the molecule is unknown. The ZF2 and repressor domains have been shown to be required for transformation and we show here that ZF1 is also required. An alternative splice variant of Evi-1, designated Delta 324, encodes a protein which lacks a portion of the ZF1 DNA binding domain and the intervening amino acids 239-514 (designated IR) located between ZF1 and the repressor domain, We show that Delta 324 can neither bind ZF1, repress transcription through this site nor transform Rat1 fibroblasts, Reconstitution studies demonstrate that the defect in Delta 324 is partially complemented by recreating the ZF1 DNA binding activity. However, full function also requires the IR region which has transcriptional repressor activity. This study shows therefore, that ZF1, ZF2 and repressor domains and the IR region all contribute to the transformation efficiency of the Evi-1 protein.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow, Lanark, Scotland	Beatson Institute	Bartholomew, C (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow, Lanark, Scotland.							Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; BARTHOLOMEW C, 1994, ONCOGENE, V9, P939; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; BORDEREAUX D, 1990, ONCOGENE, V5, P925; Brooks DJ, 1996, BRIT J CANCER, V74, P1518, DOI 10.1038/bjc.1996.583; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FUNABIKI T, 1994, ONCOGENE, V9, P1575; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; KUROKAWA M, 1995, ONCOGENE, V11, P833; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Ogawa S, 1996, ONCOGENE, V13, P183; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Soderholm J, 1997, LEUKEMIA, V11, P352, DOI 10.1038/sj.leu.2400584; Suzukawa K, 1997, GENOMICS, V42, P356, DOI 10.1006/geno.1997.4732	24	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2287	2291		10.1038/sj.onc.1201732	http://dx.doi.org/10.1038/sj.onc.1201732			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619838				2022-12-25	WOS:000073298000014
J	Pyronnet, S; Gingras, AC; Bouisson, M; Kowalski-Chauvel, A; Seva, C; Vaysse, N; Sonenberg, N; Pradayrol, L				Pyronnet, S; Gingras, AC; Bouisson, M; Kowalski-Chauvel, A; Seva, C; Vaysse, N; Sonenberg, N; Pradayrol, L			Gastrin induces phosphorylation of eIF4E binding protein 1 and translation initiation of ornithine decarboxylase mRNA	ONCOGENE			English	Article							PANCREATIC-CELL LINE; MESSENGER-RNA; FACTOR 4E; TRANSFORMATION; 4E-BP1; KINASE; GROWTH; CHOLECYSTOKININ; ASSOCIATION; STIMULATION	Gastrin via its G-protein coupled specific receptor induces transcription of c-fos and c-jun genes through a ras-MAPK pathway. Ornithine Decarboxylase (ODC), a growth regulated proto-oncogene, was chosen to investigate gastrin effects on translation initiation of mRNAs exhibiting a 5'UnTranslated Region (5'UTR) responsible for translation repression in quiescent cells. In AR4-2J tumoral cells, we first demonstrated that gastrin increases ODC mRNA translation. Transient transfections with various CAT chimeric constructs suggested a direct involvement of the 5'UTR in this observation. Translation of this group of mRNAs is enhanced by the availability of the cap-binding protein (eIF4E) that is increased after phosphorylation of its specific binding protein eIF4E-BP1, We found that AR4-2J cells overexpressed eIF4E protein which was not modulated by gastrin treatment. Rapamycin which inhibits 4E-BP1 phosphorylation, completely prevents gastrin-mediated increase of ODC translation indicating that 4E-BP1 could be involved in regulating ODC translation. Implication of 4E-BP1 in mediating gastrin effects is corroborated by the capacity of the ligand to affect 4E-BP1 phosphorylation, These results indicate that gastrin enhances ornithine decarboxylase mRNA translation through a rapamycin sensitive pathway and provide the first evidence in the control of 4E-BP1 phosphorylation after occupancy of a G protein-coupled receptor.	CHU Rangueil, Inst Louis Bugnard, IFR 31, INSERM,U151, F-31403 Toulouse 4, France; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); McGill University	Pradayrol, L (corresponding author), CHU Rangueil, Inst Louis Bugnard, IFR 31, INSERM,U151, F-31403 Toulouse 4, France.		Gingras, Anne-Claude/E-9982-2010; Pyronnet, Stéphane/P-2419-2014; Kowalski-Chauvel, Aline/O-9212-2014; SEVA, Catherine/O-9166-2014; Gingras, Anne-Claude/ABA-8341-2020	Gingras, Anne-Claude/0000-0002-6090-4437; SEVA, Catherine/0000-0002-4265-7372; Gingras, Anne-Claude/0000-0002-6090-4437				AMSTERDA.A, 1974, J CELL BIOL, V63, P1037, DOI 10.1083/jcb.63.3.1037; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BARNEJI J, 1983, CELL, V33, P729; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BERTRAND V, 1994, INT J CANCER, V56, P427, DOI 10.1002/ijc.2910560324; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; GREENS A, 1990, J BIOL CHEM, V265, P11810; HAYASHI SI, 1995, BIOCHEM J, V306, P1; HICKOK NJ, 1986, P NATL ACAD SCI USA, V83, P594, DOI 10.1073/pnas.83.3.594; JOHNSON LR, 1977, ANNU REV PHYSIOL, V39, P135, DOI 10.1146/annurev.ph.39.030177.001031; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; KUZYK CJ, 1986, AM J PHYSIOL, V251, pG597; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEIJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Pyronnet S, 1996, CANCER RES, V56, P1742; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Sambrook J., 2002, MOL CLONING LAB MANU; SCEMAMA JL, 1989, AM J PHYSIOL, V256, pG846, DOI 10.1152/ajpgi.1989.256.5.G846; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SETHI T, 1992, CANCER RES, V52, P6031; SEVA C, 1994, REGUL PEPTIDES, V52, P31, DOI 10.1016/0167-0115(94)90018-3; SEVA C, 1990, CANCER RES, V50, P5829; SHANTZ LM, 1994, CANCER RES, V54, P2313; SINGH P, 1986, CANCER RES, V46, P1612; SOLOMON TE, 1987, GASTROENTEROLOGY, V92, P429, DOI 10.1016/0016-5085(87)90138-7; Sonenberg Nahum, 1993, Gene Expression, V3, P317; TAMORI A, 1995, CANCER RES, V55, P3500; TODISCO A, 1995, J BIOL CHEM, V270, P28337; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WALLON UM, 1990, FEBS LETT, V268, P161, DOI 10.1016/0014-5793(90)80998-X	36	33	33	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2219	2227		10.1038/sj.onc.1201748	http://dx.doi.org/10.1038/sj.onc.1201748			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619831				2022-12-25	WOS:000073298000007
J	Liu, JQ; Dairi, T; Itoh, N; Kataoka, M; Shimizu, S; Yamada, H				Liu, JQ; Dairi, T; Itoh, N; Kataoka, M; Shimizu, S; Yamada, H			A novel metal-activated pyridoxal enzyme with a unique primary structure, low specificity D-threonine aldolase from Arthrobacter sp. strain DK-38 - Molecular cloning and cofactor characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMINO ACIDS; DEPSIPEPTIDE; ALIGNMENT	The gene encoding low specificity D-threonine aldolase, catalyzing the interconversion of D-threonine/D-allo-threonine and glycine plus acetaldehyde, was cloned from the chromosomal DNA of Arthrobacter sp, strain DK-38, The gene contains an open reading frame consisting of 1,140 nucleotides corresponding to 379 amino acid residues. The enzyme was overproduced in recombinant Escherichia coli cells and purified to homogeneity by ammonium sulfate fractionation and three-column chromatography steps. The recombinant aldolase was identified as a pyridoxal enzyme with the capacity of binding 1 mol of pyridoxal 5'-phosphate per mol of subunit, and Lys(59) Of the enzyme was determined to be the cofactor binding site by chemical modification with NaBH4. In addition, Mn2+ ion was demonstrated to be an activator of the enzyme, although the purified enzyme contained no detectable metal ions. Equilibrium dialysis and atomic absorption studies revealed that the recombinant enzyme could bind 1 mol of Mn2+ ion per mol of subunit, Remarkably, the predicted amino acid sequence of the enzyme showed no significant similarity to those of the currently known pyridoxal 5'-phosphate-dependent enzymes, indicating that low specificity D-threonine aldolase is a new pyridoxal enzyme with a unique primary structure. Taken together, low specificity D-threonine aldolase from Arthrobacter sp. strain DK-38, with a unique primary structure, is a novel metal-activated pyridoxal enzyme.	Toyama Univ, Biotechnol Res Ctr, Lab Biocatalyt Chem, Toyama 9390398, Japan; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan	University of Toyama; Kyoto University	Yamada, H (corresponding author), Toyama Univ, Biotechnol Res Ctr, Lab Biocatalyt Chem, Kurokawa 5180,Kosugi Machi, Toyama 9390398, Japan.	ryu@pu-toyama.ac.jp	Kataoka, Michihiko/E-5847-2011; Dairi, Tohru/A-5448-2012	Dairi, Tohru/0000-0002-3406-7970				ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BURKE TR, 1989, TETRAHEDRON LETT, V30, P519, DOI 10.1016/S0040-4039(00)95242-0; DAINTY RH, 1970, BIOCHEM J, V117, P585, DOI 10.1042/bj1170585; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FUKUSHIMA T, 1995, BIOL PHARM BULL, V18, P1130; HERBERT RB, 1994, CAN J CHEM, V72, P114, DOI 10.1139/v94-018; HERBERT RB, 1993, J CHEM SOC CHEM COMM, P205, DOI 10.1039/c39930000205; Kajimura Y, 1996, J ANTIBIOT, V49, P129, DOI 10.7164/antibiotics.49.129; Kataoka M, 1997, EUR J BIOCHEM, V248, P385, DOI 10.1111/j.1432-1033.1997.00385.x; Kataoka M, 1997, FEMS MICROBIOL LETT, V151, P245, DOI 10.1016/S0378-1097(97)00168-7; KUMAGAI H, 1972, BIOCHIM BIOPHYS ACTA, V258, P779, DOI 10.1016/0005-2744(72)90179-9; Liu JQ, 1997, EUR J BIOCHEM, V245, P289, DOI 10.1111/j.1432-1033.1997.00289.x; Liu JQ, 1998, APPL ENVIRON MICROB, V64, P549; Liu JQ, 1997, J BACTERIOL, V179, P3555, DOI 10.1128/jb.179.11.3555-3560.1997; MARCEAU M, 1988, J BIOL CHEM, V263, P16926; MATSUO Y, 1959, J BIOL CHEM, V234, P507; Mildvan A.S., 1970, ENZYMES, P445; OHASHI N, 1984, Patent No. 0128684; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PAZ MA, 1965, ARCH BIOCHEM BIOPHYS, V109, P548, DOI 10.1016/0003-9861(65)90400-5; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIRCH L, 1962, J BIOL CHEM, V237, P2578; Shibata K, 1996, TETRAHEDRON LETT, V37, P2791, DOI 10.1016/0040-4039(96)00430-3; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; Takeyama H, 1997, MICROBIOL-UK, V143, P2725, DOI 10.1099/00221287-143-8-2725; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VASSILEV VP, 1995, TETRAHEDRON LETT, V36, P4081, DOI 10.1016/0040-4039(95)00720-W; VASSILEV VP, 1995, TETRAHEDRON LETT, V36, P5063, DOI 10.1016/0040-4039(95)00924-2; WADA H, 1961, J BIOL CHEM, V236, P2089; WOEHL EU, 1995, COORDIN CHEM REV, V144, P147, DOI 10.1016/0010-8545(94)08001-8; YAMADA H, 1970, BIOCHEM BIOPH RES CO, V39, P53, DOI 10.1016/0006-291X(70)90756-4	33	45	49	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16678	16685		10.1074/jbc.273.27.16678	http://dx.doi.org/10.1074/jbc.273.27.16678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642221	hybrid			2022-12-25	WOS:000074545200011
J	Smith, MD; Ensor, EA; Coffin, RS; Boxer, LM; Latchman, DS				Smith, MD; Ensor, EA; Coffin, RS; Boxer, LM; Latchman, DS			Bcl-2 transcription from the proximal P2 promoter is activated in neuronal cells by the Brn-3a POU family transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; EXPRESSION; GENE; SURVIVAL; PROTEIN; APOPTOSIS; DIFFERENTIATION; REGION; DEATH; DISTINCT	The BCL-2 protein is able to protect neuronal and other cell types from apoptotic programmed cell death and plays a key role in regulating the rate of apoptosis during development of the nervous system. We have previously demonstrated that the Brn-3a POU domain transcription factor protects sensory neurons from apoptotic programmed cell death induced by nerve growth factor withdrawal. We report here that Bcl-2 transcription is predominantly initiated from the Bcl-2 Pa promoter in both the ND7 neuronal cell line and primary dorsal root ganglion neurons, in contrast to the predominant use of the Bcl-2 P1 promoter in other cell types. Moreover, Bcl-2 transcription initiated from the P2 region increases in ND7 cells stably overexpressing Brn-3a, resulting in enhanced BCL-2 protein levels. Similarly, the Bcl-2 P2 promoter is directly activated by Brn-3a in co-transfection assays in both ND7 cells and dorsal, root ganglion neurons. Analysis of the Bcl-2 regulatory sequence revealed a binding site for Brn-3a that is required for maximal activation by Brn-3a both in transfected cells and during differentiation of ND7 cells. Together these data identify Brn-3a as the first transcription factor regulating Bcl-2 activity specifically in neuronal cells and indicate that the anti-apoptotic effect of Brn-3a is likely to be mediated, at least in part, via the up-regulation of Bcl-2 expression.	UCL, Windeyer Inst Med Sci, Dept Mol Pathol, London W1P 6DB, England; Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA	University of London; University College London; Stanford University	Latchman, DS (corresponding author), UCL, Windeyer Inst Med Sci, Dept Mol Pathol, Cleveland St, London W1P 6DB, England.	d.latchman@ucl.ac.uk			NATIONAL CANCER INSTITUTE [R56CA056764, R01CA056764] Funding Source: NIH RePORTER; NCI NIH HHS [CA56764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP TE, 1995, EUR J NEUROSCI, V7, P1266, DOI 10.1111/j.1460-9568.1995.tb01116.x; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BATISTATOU A, 1993, J NEUROSCI, V13, P4422; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; BUDHRAMMAHADEO V, 1995, NEUROSCI LETT, V185, P48, DOI 10.1016/0304-3940(94)11222-5; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; Coffin RS, 1996, GENE THER, V3, P886; Davies A. M., 1995, NEURAL CELL CULTURE, P153; Dawson SJ, 1996, J BIOL CHEM, V271, P11631, DOI 10.1074/jbc.271.20.11631; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; HEWITT SM, 1995, CANCER RES, V55, P5386; HIGUSHI R, 1990, PCR PROTOCOLS GUIDE, P173; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MACPHERSON I, 1962, VIROLOGY, V16, P147, DOI 10.1016/0042-6822(62)90290-8; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; MERRY DE, 1994, DEVELOPMENT, V120, P301; Middleton G, 1996, DEVELOPMENT, V122, P695; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Smith MD, 1997, J BIOL CHEM, V272, P1382, DOI 10.1074/jbc.272.2.1382; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	46	108	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16715	16722		10.1074/jbc.273.27.16715	http://dx.doi.org/10.1074/jbc.273.27.16715			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642226	hybrid			2022-12-25	WOS:000074545200016
J	Sommarin, Y; Wendel, M; Shen, ZX; Hellman, U; Heinegard, D				Sommarin, Y; Wendel, M; Shen, ZX; Hellman, U; Heinegard, D			Osteoadherin, a cell-binding keratan sulfate proteoglycan in bone, belongs to the family of leucine-rich repeat proteins of the extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; IN-GEL DIGESTION; CORE PROTEIN; COLLAGEN FIBRILLOGENESIS; OSTEOINDUCTIVE FACTOR; CONNECTIVE TISSUES; MOLECULAR-CLONING; DECORIN; CARTILAGE; EXPRESSION	Osteoadherin is a recently described bone proteoglycan containing keratan sulfate. It promotes integrin (alpha(v)beta(3))-mediated cell binding (Wendel, M., Sommarin, Y., and Heinegard, D. (1998) J. Cell Biol. 141, 839-847). The primary structure of bovine osteoadherin has now been determined by nucleotide sequencing of a cDNA clone from a primary bovine osteoblast expression library. The entire translated primary sequence corresponds to a 49,116-Da protein with a calculated isoelectric point for the mature protein of 5.2. The dominating feature is a central region.consisting of 11 B-type, leucine-rich repeats ranging in length from 20 to 30 residues. The full, primary sequence contains four putative sites for tyrosine sulfation, three of which are at the N-terminal end of the molecule. There are six potential sites for N-linked glycosylation present, Osteoadherin shows highest sequence identity, 42%, to bovine keratocan and 31-38% identity to bovine fibromodulin, lumican, and human PRELP. Unique to osteoadherin is the presence of a large and very acidic C-terminal domain. The distribution of cysteine residues resembles that of other leucine-rich repeat proteins except for two centrally located cysteines. Northern blot analysis of RNA samples from various bovine tissues showed a 4.5-kilobase pair message for osteoadherin to be expressed in bone only. Osteoadherin mRNA was detected by in situ hybridization in mature osteoblasts located superficially on trabecular bone.	Univ Lund, Dept Cellular & Mol Biol, Sect Connect Tissue Biol, S-22100 Lund, Sweden; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Lund University; Ludwig Institute for Cancer Research	Sommarin, Y (corresponding author), Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, POB 94, S-22100 Lund, Sweden.							ADAMS ME, 1992, ANAL BIOCHEM, V202, P89, DOI 10.1016/0003-2697(92)90211-O; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; Camper L, 1997, J CELL BIOL, V138, P1159, DOI 10.1083/jcb.138.5.1159; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; CHRISTOFFERSEN J, 1991, ANAT RECORD, V230, P435, DOI 10.1002/ar.1092300402; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; FISHER LW, 1989, J BIOL CHEM, V264, P4571; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HULTENBY K, 1991, MATRIX, V11, P206, DOI 10.1016/S0934-8832(11)80160-5; HULTENBY K, 1994, EUR J CELL BIOL, V63, P230; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Janel N, 1995, GENE, V167, P291, DOI 10.1016/0378-1119(95)00696-6; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Landgren C, 1998, GENOMICS, V47, P84, DOI 10.1006/geno.1997.5085; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; NIEHRS C, 1994, CHEM-BIOL INTERACT, V92, P257, DOI 10.1016/0009-2797(94)90068-X; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; Oldberg A, 1996, FEBS LETT, V386, P29, DOI 10.1016/0014-5793(96)00407-3; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; ROBEY PG, 1995, OSTEOPOROSIS, P95; ROSAPIMENTEL E, 1992, ARTICULAR CARTILAGE, P95; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCOTT JE, 1985, BIOSCIENCE REP, V5, P71, DOI 10.1007/BF01117443; Shen ZX, 1995, MATRIX BIOL, V14, P773, DOI 10.1016/S0945-053X(05)80020-4; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; SOMMARIN Y, 1989, EXP CELL RES, V184, P181, DOI 10.1016/0014-4827(89)90376-5; SOMMARIN Y, 1983, BIOCHEM J, V214, P777, DOI 10.1042/bj2140777; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Wendel M, 1998, J CELL BIOL, V141, P839, DOI 10.1083/jcb.141.3.839; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	50	77	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16723	16729		10.1074/jbc.273.27.16723	http://dx.doi.org/10.1074/jbc.273.27.16723			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642227	hybrid			2022-12-25	WOS:000074545200017
J	D'Silva, PR; Lala, AK				D'Silva, PR; Lala, AK			Unfolding of diphtheria toxin - Identification of hydrophobic sites exposed on lowering of pH by photolabeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; IMMUNOCHEMICAL ANALYSIS; MEMBRANE TRANSLOCATION; TRANSMEMBRANE DOMAIN; DEPENDENT INSERTION; ALPHA-LACTALBUMIN; REFINED STRUCTURE; PLASMA-MEMBRANE; B-FRAGMENT; 3 DOMAINS	We report here the use of a hydrophobic photoactivable reagent, 2-[H-3]diazofluorene (DAF), to map the hydrophobic sites exposed when the pH is lowered in diphtheria toxin (DT), The reagent binds to DT, and on photolysis with light of wavelength >350 nm, it covalently attaches itself to DT. The labeling was observed to increase considerably when the pH was lowered from 7.4 to 5.2. Although both A- and B-chains were labeled to a similar degree at pH 7,4, at lower pH (5.2), B-chain was labeled to a much higher extent. Subsequent chemical and enzymatic fragmentation of DT followed by separation indicated that the putative transmembrane domain was labeled to its maximum extent at pH 5,2, with the bulk of labeling associated with residues 340-459. Protein sequencing analysis indicated that the two buried hydrophobic helices, identified in the crystal structure and suggested to insert and span the membrane bilayer, corresponding to residues 326-347 and 358-376, are strongly labeled. The Pro-345 residue was observed to be labeled maximally at lower pH values. Finally, the DAF labeling pattern indicated that the parent structural motifs are retained at low pH, suggesting that the low pH conformation of DT corresponds to an equilibrium molten globule state.	Indian Inst Technol, Dept Chem, Biomembrane Lab, Bombay 400076, Maharashtra, India; Indian Inst Technol, Ctr Biotechnol, Bombay 400076, Maharashtra, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay	Lala, AK (corresponding author), Indian Inst Technol, Dept Chem, Biomembrane Lab, Bombay 400076, Maharashtra, India.	anillala@chem.iitb.ernet.in	D'Silva, Patrick/L-6653-2019					BENNETT MJ, 1994, PROTEIN SCI, V3, P1464, DOI 10.1002/pro.5560030912; BENNETT MJ, 1994, PROTEIN SCI, V3, P1444, DOI 10.1002/pro.5560030911; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BRASSEUR R, 1986, BIOCHEM BIOPH RES CO, V136, P160, DOI 10.1016/0006-291X(86)90890-9; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DELEERS M, 1983, FEBS LETT, V160, P82, DOI 10.1016/0014-5793(83)80941-7; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; ENGELHARD M, 1995, PROTEIN SCI, V4, P1553, DOI 10.1002/pro.5560040813; HARTER C, 1989, J BIOL CHEM, V264, P6459; HONJO T, 1968, J BIOL CHEM, V243, P3553; JOHNSON VG, 1993, J BIOL CHEM, V268, P3514; Kaul P, 1996, PROTEIN SCI, V5, P687; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1983, PRINCIPLES FLOURESCE; LALA AK, 1995, J PROTEIN CHEM, V14, P601, DOI 10.1007/BF01886886; LALA AK, 1995, J BIOL CHEM, V270, P11348, DOI 10.1074/jbc.270.19.11348; LALA AK, 1992, J BIOL CHEM, V267, P19914; LOH SN, 1995, P NATL ACAD SCI USA, V92, P5446, DOI 10.1073/pnas.92.12.5446; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADSHUS IH, 1994, J BIOL CHEM, V269, P4648; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P45; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P29; MINDELL JA, 1994, P NATL ACAD SCI USA, V91, P5272, DOI 10.1073/pnas.91.12.5272; MONTECUCCO C, 1992, FEMS MICROBIOL IMMUN, V105, P101; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOZDZANOWSKI J, 1992, ANAL BIOCHEM, V207, P11, DOI 10.1016/0003-2697(92)90492-P; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; OKEEFE DO, 1992, P NATL ACAD SCI USA, V89, P6202, DOI 10.1073/pnas.89.13.6202; Paliwal R, 1996, BIOCHEMISTRY-US, V35, P2374, DOI 10.1021/bi952469q; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PRADHAN D, 1987, J BIOL CHEM, V262, P8242; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; PTITSYN OB, 1995, CURR OPIN STRUC BIOL, V5, P74, DOI 10.1016/0959-440X(95)80011-O; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SHEN WH, 1994, J BIOL CHEM, V269, P29077; SILVERMAN JA, 1994, J MEMBRANE BIOL, V137, P17; SILVERMAN JA, 1994, J BIOL CHEM, V269, P22524; STEINBERG IZ, 1960, J AM CHEM SOC, V82, P5263, DOI 10.1021/ja01505a001; TORTORELLA D, 1995, J BIOL CHEM, V270, P27439, DOI 10.1074/jbc.270.46.27439; TORTORELLA D, 1995, J BIOL CHEM, V270, P27446, DOI 10.1074/jbc.270.46.27446; WEISS MS, 1995, BIOCHEMISTRY-US, V34, P773, DOI 10.1021/bi00003a010; ZHAN HJ, 1995, BIOCHEMISTRY-US, V34, P4856, DOI 10.1021/bi00014a043	49	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16216	16222		10.1074/jbc.273.26.16216	http://dx.doi.org/10.1074/jbc.273.26.16216			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632679	hybrid			2022-12-25	WOS:000074436600050
J	Rossi, A; Elia, G; Santoro, MG				Rossi, A; Elia, G; Santoro, MG			Activation of the heat shock factor 1 by serine protease inhibitors - An effect associated with nuclear factor-kappa B inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-BINDING ACTIVITY; FACTOR NF-KAPPA; TRANSCRIPTION FACTOR; HUMAN-CELLS; GENE-TRANSCRIPTION; STRESS; HSP70; EXPRESSION; PROTEINS	Heat shock proteins (HSPs) have a cytoprotective role in several human diseases, including ischemia and viral infection. Nuclear factor-kappa B (NF-kappa B) is a critical regulator of inflammation and virus replication. Here we report that a class of serine protease inhibitors with NF-kappa B-inhibitory activity are potent HSP inducers via activation of heat shock transcription factor 1 (HSF1) in human cells. 3,4-Dichloroisocoumarin, the most effective compound, rapidly induces HSF1 DNA binding activity and phosphorylation, leading to transcription and translation of heat shock genes for a period of several hours. HSF1 activation is independent of de novo protein synthesis and is correlated in a concentration- and time-dependent manner with NF-kappa B inhibition. Cysteine protease inhibitors E64 and calpain inhibitor II, which do not block NF-kappa B activation, do not induce HSF DNA binding activity. HSP induction by 3,4-dichloroisocoumarin is associated with antiviral activity during rhabdovirus infection. These results identify a new class of HSP inducers and indicate a link between the regulatory pathways of HSF and NF-kappa B, suggesting novel strategies to simultaneously switch on cytoprotective genes and down-regulate inflammatory and viral genes.	CNR, Inst Expt Med, I-00185 Rome, Italy; Univ Rome Tor Vergata, Dept Biol, I-00133 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata	Santoro, MG (corresponding author), CNR, Inst Expt Med, Via Fosso Cavaliere, I-00185 Rome, Italy.	santoro@biocell.irmkant.rm.cnr.it	Elia, Giuliano/H-3438-2011; Elia, Giuliano/P-4725-2019	Elia, Giuliano/0000-0001-8216-9560; Elia, Giuliano/0000-0002-7941-223X; ROSSI, ANTONIO/0000-0003-0383-3828; Santoro, Maria Gabriella/0000-0003-1432-4949				AMICI C, 1994, J VIROL, V68, P6890, DOI 10.1128/JVI.68.11.6890-6899.1994; AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; AMICI C, 1993, EXP CELL RES, V207, P230, DOI 10.1006/excr.1993.1188; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BANERJI SS, 1984, MOL CELL BIOL, V4, P2437, DOI 10.1128/MCB.4.11.2437; Bush KT, 1997, J BIOL CHEM, V272, P9086; Conant K, 1996, J VIROL, V70, P1384, DOI 10.1128/JVI.70.3.1384-1389.1996; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Elia G, 1996, J BIOL CHEM, V271, P16111, DOI 10.1074/jbc.271.27.16111; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIGUCHI M, 1995, BLOOD, V86, P2248, DOI 10.1182/blood.V86.6.2248.bloodjournal8662248; IAATTELA M, 1992, EMBO J, V11, P3507; KIM HK, 1995, J IMMUNOL, V154, P4741; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Lu WY, 1997, J MOL BIOL, V266, P441, DOI 10.1006/jmbi.1996.0781; MARBER MS, 1994, J CLIN INVEST, V93, P1087, DOI 10.1172/JCI117059; MESTRIL R, 1994, J CLIN INVEST, V93, P759, DOI 10.1172/JCI117030; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Rossi A, 1996, J BIOL CHEM, V271, P32192, DOI 10.1074/jbc.271.50.32192; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; RUSBRIDGE NM, 1990, FEBS LETT, V268, P133, DOI 10.1016/0014-5793(90)80991-Q; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; Santoro MG, 1997, TRENDS MICROBIOL, V5, P276, DOI 10.1016/S0966-842X(97)01066-4; SANTORO MG, 1996, STRESS INDUCIBLE CEL, P337; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHOELLMANN G, 1963, BIOCHEMISTRY-US, V2, P252, DOI 10.1021/bi00902a008; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VIJAYALAKSHMI J, 1991, BIOCHEMISTRY-US, V30, P2175, DOI 10.1021/bi00222a022; VILLAR J, 1993, AM REV RESPIR DIS, V147, P177, DOI 10.1164/ajrccm/147.1.177; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; ZABEL U, 1991, J BIOL CHEM, V266, P252	40	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16446	16452		10.1074/jbc.273.26.16446	http://dx.doi.org/10.1074/jbc.273.26.16446			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632711	hybrid			2022-12-25	WOS:000074436600082
J	Yoshida, T; Imai, T; Kakizaki, M; Nishimura, M; Takagi, S; Yoshie, O				Yoshida, T; Imai, T; Kakizaki, M; Nishimura, M; Takagi, S; Yoshie, O			Identification of single C motif-1 lymphotactin receptor XCR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CHEMOKINE; EXPRESSION; SCM-1	Single C motif-1 (SCM-1)/lymphotactin is a member of the chemokine superfamily, but retains only the and and 4th of the four cysteine residues conserved in other chemokines. In humans, there are two highly homologous SCM-1 genes encoding SCM-1 alpha and SCM-1 beta with two amino acid substitutions. To identify a specific receptor for SCM-1 proteins, we produced recombinant SCM-1 alpha and SCM-1 beta by the baculovirus expression system and tested them on murine L1.2 cells stably expressing eight known chemokine receptors and three orphan receptors. Both proteins specifically induced migration in cells expressing an orphan receptor, GPR5. The migration was chemotactic and suppressed by pertussis toxin, indicating coupling to a G alpha type of G protein. Both proteins also induced intracellular calcium mobilization in GPR5-expressing L1.2 cells with efficient mutual cross desensitization. SCM-1 alpha bound specifically to GPR5-expressing L1.2 cells with a K-d of 10 nM. By Northern blot analysis, GPR5 mRNA of about 5 kilobases was detected strongly in placenta and weakly in spleen and thymus among various human tissues. Identification of a specific receptor for SCM-1 would facilitate our investigation on its biological function. Following the set rule for the chemokine receptor nomenclature, we propose to designate GPR5 as XCR1 from XC chemokine receptor-1.	Shionogi Inst Med Sci, Settsu, Osaka 5660022, Japan	Shionogi & Company Limited	Yoshie, O (corresponding author), Kinki Univ, Sch Med, Dept Bacteriol, 377-2 Ohno Higashi, Osaka 5898511, Japan.			Yoshie, Osamu/0000-0003-4353-5809				Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BIANCHI G, 1996, EUR J IMMUNOL, V26, P3238; Boismenu R, 1996, J IMMUNOL, V157, P985; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; Dorner B, 1997, J BIOL CHEM, V272, P8817, DOI 10.1074/jbc.272.13.8817; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; Hedrick JA, 1997, J IMMUNOL, V158, P1533; HEIBER M, 1995, DNA CELL BIOL, V14, P25, DOI 10.1089/dna.1995.14.25; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Maghazachi AA, 1997, FASEB J, V11, P765, DOI 10.1096/fasebj.11.10.9271361; Mueller Sabine, 1995, European Journal of Immunology, V25, P1744; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nagira M, 1997, J BIOL CHEM, V272, P19518, DOI 10.1074/jbc.272.31.19518; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rumsaeng V, 1997, J IMMUNOL, V158, P1353; Yoshida T, 1996, FEBS LETT, V395, P82, DOI 10.1016/0014-5793(96)01004-6; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O; Yoshie O, 1997, J LEUKOCYTE BIOL, V62, P634, DOI 10.1002/jlb.62.5.634	24	122	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16551	16554		10.1074/jbc.273.26.16551	http://dx.doi.org/10.1074/jbc.273.26.16551			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632725	hybrid			2022-12-25	WOS:000074436600096
J	Yamashita, T; Kaneko, S; Shirota, Y; Qin, WP; Nomura, T; Kobayashi, K; Murakami, S				Yamashita, T; Kaneko, S; Shirota, Y; Qin, WP; Nomura, T; Kobayashi, K; Murakami, S			RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE NONSTRUCTURAL PROTEINS; NON-B-HEPATITIS; POLIOVIRUS RNA; REPLICATION COMPLEXES; IN-VITRO; NON-A; HEPATOCELLULAR-CARCINOMA; JAPANESE PATIENTS; HELICASE ACTIVITY; ESCHERICHIA-COLI	The hepatitis C virus (HCV) NS5B protein encodes an RNA-dependent RNA polymerase (RdRP), which is the central catalytic enzyme of HCV replicase, We established a new method to purify soluble HCV NS5B in the glutathione S-transferase-fused form NS5Bt from Escherichia coli which lacks the C-terminal 21 amino acid residues encompassing a putative anchoring domain (anino acids 2990-3010). The recombinant soluble protein exhibited RdRP activity in vitro which was dependent upon the template and primer, but it did not exhibit the terminal transferase activity that has been reported to be associated with the recombinant NS5B protein from insect cells. The RdRP activity of purified glutathione S-transferase-NS5Bt and thrombin-cleavaged non-fused NS5Bt shares most of the properties. Substitution mutations of NS5Bt at the GDD motif, which is highly conserved among viral RdRPs, and at the clustered basic residues (amino acids 2919-2924 and 2693-2699) abolished the RdRP activity. The C-terminal region of NS5B, which is dispensable for the RdRP activity, dramatically affected the subcellular localization of NS5B retaining it in perinuclear sites in transiently overexpressed mammalian cells. These results may provide some clues to dissecting the molecular mechanism of the HCV replication and also act as a basis for developing new anti-viral drugs.	Kanazawa Univ, Inst Canc Res, Dept Mol Oncol, Kanazawa, Ishikawa, Japan; Kanazawa Univ, Dept Internal Med 1, Kanazawa, Ishikawa, Japan	Kanazawa University; Kanazawa University	Murakami, S (corresponding author), Kanazawa Univ, Inst Canc Res, Dept Mol Oncol, 13-1 Takara Machi, Kanazawa, Ishikawa, Japan.	semuraka@kenroku.ipc.kanazawa-u.ac.jp		Shirota, Yukihiro/0000-0001-6561-4626				ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; Asabe SI, 1997, J VIROL, V71, P790, DOI 10.1128/JVI.71.1.790-796.1997; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; BARTON DJ, 1995, J VIROL, V69, P5516, DOI 10.1128/JVI.69.9.5516-5527.1995; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; DeFrancesco R, 1996, METHOD ENZYMOL, V275, P58; ECKART MR, 1993, BIOCHEM BIOPH RES CO, V192, P399, DOI 10.1006/bbrc.1993.1429; Francki RIB, 1991, ARCH VIROL         S, V2, P223; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GRAKOUI A, 1993, P NATL ACAD SCI USA, V90, P10583, DOI 10.1073/pnas.90.22.10583; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HONDA M, 1993, ARCH VIROL, V128, P163, DOI 10.1007/BF01309797; Hwang SB, 1997, VIROLOGY, V227, P439, DOI 10.1006/viro.1996.8357; JABLONSKI SA, 1991, J VIROL, V65, P4565, DOI 10.1128/JVI.65.9.4565-4572.1991; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAMA J, 1995, J BIOL CHEM, V270, P14430, DOI 10.1074/jbc.270.24.14430; LEMM JA, 1993, J VIROL, V67, P1905, DOI 10.1128/JVI.67.4.1905-1915.1993; LEMM JA, 1994, EMBO J, V13, P2925, DOI 10.1002/j.1460-2075.1994.tb06587.x; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Lutz P, 1996, J VIROL, V70, P3449, DOI 10.1128/JVI.70.6.3449-3460.1996; MANABE S, 1994, VIROLOGY, V198, P636, DOI 10.1006/viro.1994.1075; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; MORROW CD, 1987, P NATL ACAD SCI USA, V84, P6050, DOI 10.1073/pnas.84.17.6050; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; Nakajima N, 1996, J VIROL, V70, P3325, DOI 10.1128/JVI.70.5.3325-3329.1996; NEUFELD KL, 1991, J BIOL CHEM, V266, P24212; Osman TAM, 1996, J VIROL, V70, P6227, DOI 10.1128/JVI.70.9.6227-6234.1996; Owen KE, 1996, J VIROL, V70, P2757, DOI 10.1128/JVI.70.5.2757-2763.1996; Pilipenko EV, 1996, EMBO J, V15, P5428, DOI 10.1002/j.1460-2075.1996.tb00926.x; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; QUADT R, 1995, P NATL ACAD SCI USA, V92, P4892, DOI 10.1073/pnas.92.11.4892; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SCINCLAIR DA, 1997, SCIENCE, V277, P1313; SHIMIZU YK, 1994, J VIROL, V68, P8406, DOI 10.1128/JVI.68.12.8406-8408.1994; SHIMIZU YK, 1992, P NATL ACAD SCI USA, V89, P5477, DOI 10.1073/pnas.89.12.5477; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; SONG CZ, 1995, J VIROL, V69, P4020, DOI 10.1128/JVI.69.7.4020-4028.1995; Sun JH, 1996, VIROLOGY, V226, P1, DOI 10.1006/viro.1996.0622; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Tan BH, 1996, VIROLOGY, V216, P317, DOI 10.1006/viro.1996.0067; Tanaka T, 1996, J VIROL, V70, P3307, DOI 10.1128/JVI.70.5.3307-3312.1996; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; Yi MK, 1997, VIROLOGY, V231, P119, DOI 10.1006/viro.1997.8516; Yi MY, 1997, J VIROL, V71, P5997, DOI 10.1128/JVI.71.8.5997-6002.1997; Yuan ZH, 1997, BIOCHEM BIOPH RES CO, V232, P231, DOI 10.1006/bbrc.1997.6249	62	202	227	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15479	15486		10.1074/jbc.273.25.15479	http://dx.doi.org/10.1074/jbc.273.25.15479			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624134	hybrid			2022-12-25	WOS:000074284200028
J	Lakich, MM; Diagana, TT; North, DL; Whalen, RG				Lakich, MM; Diagana, TT; North, DL; Whalen, RG			MEF-2 and Oct-1 bind to two homologous promoter sequence elements and participate in the expression of a skeletal muscle-specific gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; CREATINE-KINASE ENHANCER; POU-DOMAIN PROTEINS; TRANSCRIPTION FACTORS; DNA-BINDING; HOMEODOMAIN PROTEINS; REGULATORY ELEMENTS; MOUSE MUSCLE; ACTIVATION; CELLS	The murine adult IIB myosin heavy chain (IIB MyHC) gene is expressed only in certain skeletal muscle fibers. Within the proximal promoter are two A + T-rich motifs, mAT1 and mAT2, which greatly enhance muscle-specific transcription; myogenic cells contain proteins that bind to these sequences. MEF-2 binds to both mAT1 and mAT2; a mutation abolishing its binding to mAT1 greatly diminishes the activity of the promoter. Both mAT motifs also form complexes with a protein requiring a target sequence typical of POU domain proteins, which migrate in electrophoretic mobility shift assays to the same position as a complex containing purified Oct-1 and which are supershifted by an antibody specific to Oct-1; this protein is therefore probably Oct-1. Footprinting experiments demonstrate that mAT1 is preferentially occupied by MEF-2 and mAT2 by Oct-1 and that these two proteins appear to bind cooperatively to their respective sites. Although the two mAT motifs have sequences that are very similar, they nonetheless exhibit distinct behaviors and perform differ entry in the activation of the promoter. The contribution. of the IIB MyHC gene to specification of the myogenic phenotype is thus at least in part regulated by MEF-2 and Oct-1.	Inst Pasteur, Dept Biol Mol, Unite Biochim, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Lakich, MM (corresponding author), Rhone Poulenc Rorer Gencell, Mol Biol & Vectorol Dept, 5301 Patrick Henry Dr, Santa Clara, CA 95054 USA.							AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; BANDMAN E, 1992, DEV BIOL, V154, P273, DOI 10.1016/0012-1606(92)90067-Q; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BUTLERBROWNE GS, 1982, NATURE, V299, P830, DOI 10.1038/299830a0; COX RD, 1992, DEV BIOL, V149, P228, DOI 10.1016/0012-1606(92)90279-P; COX RD, 1991, DEV BIOL, V143, P36, DOI 10.1016/0012-1606(91)90052-5; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CSERJESI P, 1994, J BIOL CHEM, V269, P16740; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DAS G, 1993, J BIOL CHEM, V268, P25026; DIAGANA T, 1995, THESIS U PARIS PARIS; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; JAFFE J, 1995, BBA-GENE STRUCT EXPR, V1261, P201, DOI 10.1016/0167-4781(94)00246-Y; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KROPP KE, 1987, J BIOL CHEM, V262, P16536; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Mead J, 1996, MOL CELL BIOL, V16, P2135; MEIJER D, 1990, NUCLEIC ACIDS RES, V18, P7357, DOI 10.1093/nar/18.24.7357; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; PELLERIN I, 1994, MOL CELL BIOL, V14, P4532, DOI 10.1128/MCB.14.7.4532; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUSSELL SD, 1988, J BIOL CHEM, V263, P6370; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SAMBROOK J, 1989, MOL CLONING LAB MANU, P1311; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; SOUSSIYANICOSTAS N, 1993, HUM MOL GENET, V2, P563, DOI 10.1093/hmg/2.5.563; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TAKEDA S, 1995, J BIOL CHEM, V270, P15664, DOI 10.1074/jbc.270.26.15664; TAKEDA S, 1992, J BIOL CHEM, V267, P16957; TAKEDA S, 1992, CR ACAD SCI III-VIE, V315, P467; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WHALEN RG, 1981, NATURE, V292, P805, DOI 10.1038/292805a0; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YOON SJ, 1992, P NATL ACAD SCI USA, V89, P12078, DOI 10.1073/pnas.89.24.12078; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHU H, 1993, MOL CELL BIOL, V13, P4432, DOI 10.1128/MCB.13.7.4432	59	44	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15217	15226		10.1074/jbc.273.24.15217	http://dx.doi.org/10.1074/jbc.273.24.15217			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614136	hybrid			2022-12-25	WOS:000074160400078
J	Marheineke, K; Krude, T				Marheineke, K; Krude, T			Nucleosome assembly activity and intracellular localization of human CAF-1 changes during the cell division cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY SYNTHESIZED HISTONES; DNA-REPLICATION INVITRO; FACTOR-I; NEGATIVE REGULATOR; BINDING PROTEIN; S-PHASE; CHROMATIN; YEAST; DROSOPHILA; HOMOLOG	We characterized changes of nucleosome assembly activity, intracellular localization, and reversible phosphorylation of the human chromatin assembly factor CAF-1 during the somatic cell division cycle. HeLa cells were synchronized in the G(1), S, G(2), and M phases of the cell cycle. All three subunits of human CAF-1 (p150, p60, and p48) are present during the entire cell cycle. In interphase, p150 and p60 are bound to the nucleus, but they predominantly dissociate from chromatin during mitosis, During S phase, p150 and p60 are concentrated at sites of intranuclear DNA replication. Only a fraction of total p48 is associated with p150 and p60, and the majority is present in other high molecular weight complexes. The other nucleosome assembly protein, NAP-1, is predominantly cytosolic throughout the cell cycle, Human CAF-1 efficiently mediates nucleosome assembly during complementary DNA strand synthesis in G(1), S, and G(2) phase cytosolic extracts. Active CAF-1 can be isolated as a 6.5 S complex from G(1), S, and G(2) phase nuclei. In contrast, CAF-1 isolated from mitotic cytosol does not support nucleosome assembly during DNA synthesis. In mitosis, the p60 subunit of inactive CAF-1 is hyperphosphorylated, whereas active CAF-1 in interphase contains hypophosphorylated and/or phosphorylated forms of p60.	Univ Cambridge, Wellcome Canc Res Campaign Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 1TN, England	University of Cambridge; University of Cambridge	Krude, T (corresponding author), Univ Cambridge, Wellcome Canc Res Campaign Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	tk1@mole.bio.cam.ac.uk	Marheineke, Kathrin/C-1797-2008	Krude, Torsten/0000-0002-1842-1933; Marheineke, Kathrin/0000-0002-1514-0167				Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; FRIEDBERG EC, 1996, DNA REPLICATION EUKA, P249; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Harlow E., 1988, ANTIBODIES LAB MANUA; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KRUDE T, 1993, J BIOL CHEM, V268, P14432; Krude T, 1996, CURR BIOL, V6, P511, DOI 10.1016/S0960-9822(02)00529-8; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Krude T, 1996, J CELL SCI, V109, P309; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Romanowski P, 1996, TRENDS CELL BIOL, V6, P184, DOI 10.1016/0962-8924(96)10015-5; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; RUSSEV G, 1982, P NATL ACAD SCI-BIOL, V79, P3143, DOI 10.1073/pnas.79.10.3143; SCHULTE D, 1995, J CELL SCI, V108, P1381; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1991, J BIOL CHEM, V266, P12041; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SOGO JM, 1995, CHROMATIN STRUCTURE, P49; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; van Holde KE., 1989, SPRINGER SERIES MOL; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WOLFFE A, 1992, CHROMATIN STRUCTURE; WU RS, 1981, CELL, V27, P321, DOI 10.1016/0092-8674(81)90415-3; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	52	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15279	15286		10.1074/jbc.273.24.15279	http://dx.doi.org/10.1074/jbc.273.24.15279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614144	hybrid			2022-12-25	WOS:000074160400086
J	Moinova, HR; Mulcahy, RT				Moinova, HR; Mulcahy, RT			An electrophile responsive element (EpRE) regulates p-naphthoflavone induction of the human gamma-glutamylcysteine synthetase regulatory subunit gene - Constitutive expression is mediated by an adjacent AP-1 site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL L2 CELLS; INDUCED OXIDATIVE STRESS; MESSENGER-RNA; BINDING-SITE; RAT-KIDNEY; TRANSCRIPTIONAL REGULATION; DETOXIFY CARCINOGENS; METHYL MERCURY; HEAVY SUBUNIT; GLUTATHIONE	Exposure of HepG2 cells to beta-naphthoflavone (beta-NF) results in time-and dose-dependent increase in the steady-state mRNA levels for both the catalytic (GCS(h)) and regulatory (GCS(1)) subunits of gamma-glutamylcysteine synthetase (GCS) which catalyzes the rate-limiting step in the de novo synthesis of the cellular antioxidant glutathione (GSH) (Mulcahy, R. T., Wartman, M. A., Bailey, H. B., and Gipp, J. J. (1997) J. Biol. Chem. 272, 7445-7454), Cloning and sequencing of the GCS, promoter region is reported. Regulatory sequences mediating basal and beta-NF induced expression of the GCS, gene were identified using a series of promoter/reporter fusion genes transfected into HepG2 cells. Sequences directing basal and beta-NF induced expression were localized between nucleotides -344 and -242 (numbered relative to the translation start site). Mutational analyses indicate that basal expression of the GCS, gene is directed by a consensus AP-1-binding site located 33 base pairs upstream of a consensus electrophile responsive element (EpRE) sequence; both cis-elements are capable of supporting beta-NF inducibility, Elimination of the inducible response requires simultaneous mutation of both sequences, however, in the presence of an intact EpRE the upstream AP-1 site is irrelevant to induction. Regulation of expression of both human GCS subunit genes in response to beta-NF is therefore mediated by cis-elements satisfying the consensus core EpRE motif.	Univ Wisconsin, Sch Med, Dept Human Oncol, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Mulcahy, RT (corresponding author), Univ Wisconsin, Sch Med, Dept Human Oncol, K4-316,600 Highland Ave, Madison, WI 53792 USA.				NCI NIH HHS [R01-CA57549] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057549] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; BORROZ KI, 1994, TOXICOL APPL PHARM, V126, P150, DOI 10.1006/taap.1994.1101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUNG AS, 1981, BIOCHEM PHARMACOL, V30, P3217, DOI 10.1016/0006-2952(81)90521-9; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; GIPP JJ, 1995, BIOCHEM BIOPH RES CO, V206, P584, DOI 10.1006/bbrc.1995.1083; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HUANG CS, 1993, J BIOL CHEM, V268, P19675; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; ITCH K, 1997, BIOCHEM BIOPH RES CO, V236, P313; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; LI Y, 1992, J BIOL CHEM, V267, P15097; LIU RM, 1994, CARCINOGENESIS, V15, P2347, DOI 10.1093/carcin/15.10.2347; Liu RM, 1996, AM J RESP CELL MOL, V14, P192, DOI 10.1165/ajrcmb.14.2.8630270; Liu RM, 1996, AM J RESP CELL MOL, V14, P186, DOI 10.1165/ajrcmb.14.2.8630269; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MEISTER A, 1995, METHOD ENZYMOL, V252, P26; MEISTER A, 1989, COENZYMES COFACTOR A, V3, P367; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; OBrien ML, 1996, EUR J CANCER, V32A, P967, DOI 10.1016/0959-8049(96)00051-2; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; Schroder CP, 1996, CANCER INVEST, V14, P158, DOI 10.3109/07357909609018891; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; Sekhar KR, 1997, BIOCHEM BIOPH RES CO, V234, P588, DOI 10.1006/bbrc.1997.6697; SHI MM, 1994, J BIOL CHEM, V269, P26512; SHI MM, 1994, AM J PHYSIOL-LUNG C, V267, pL414, DOI 10.1152/ajplung.1994.267.4.L414; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WOODS JS, 1995, BIOCHEM PHARMACOL, V50, P1719, DOI 10.1016/0006-2952(95)02075-6; WOODS JS, 1992, ARCH BIOCHEM BIOPHYS, V296, P350, DOI 10.1016/0003-9861(92)90583-I; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; YAO KS, 1995, CANCER RES, V55, P4367	46	233	239	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14683	14689		10.1074/jbc.273.24.14683	http://dx.doi.org/10.1074/jbc.273.24.14683			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614065	hybrid			2022-12-25	WOS:000074160400007
J	Nagel, W; Zeitlmann, L; Schilcher, P; Geiger, C; Kolanus, J; Kolanus, W				Nagel, W; Zeitlmann, L; Schilcher, P; Geiger, C; Kolanus, J; Kolanus, W			Phosphoinositide 3-OH kinase activates the beta(2) integrin adhesion pathway and induces membrane recruitment of cytohesin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; BRUTONS TYROSINE KINASE; NUCLEOTIDE EXCHANGE FACTORS; ADRENERGIC-RECEPTOR KINASE; OUT SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-ADHESION; LIGAND-BINDING	Signal transduction through phosphoinositide 3-OH kinase (PI 3-kinase) has been implicated in the regulation of lymphocyte adhesion mediated by integrin receptors, Cellular phosphorylation products of PI 3-kinases interact with a subset of pleckstrin homology (PH) domains, a module that has been shown to recruit proteins to cellular membranes. We have recently identified cytohesin-1, a cytoplasmic regulator of beta(2) integrin adhesion to intercellular adhesion molecule 1. We describe here that expression of a constitutively active PI 3-kinase is sufficient far the activation of Jurkat cell adhesion to intercellular adhesion molecule 1, and for enhanced membrane association of cytohesin-1. Up-regulation of cell adhesion by PI 3-kinase and membrane association of endogenous cytohesin-1 is abrogated by overexpression of the isolated cytohesin-1 PH domain, but not by a mutant of the PH domain which fails to associate with the plasma membrane. The PH domain of Bruton's tyrosine kinase (Btk), although strongly associated with the plasma membrane, had no effect on either membrane recruitment of cytohesin-1 or on induction of adhesion by PI 3-kinase. Having delineated the critical steps of the beta(2) integrin activation pathway by biochemical and functional analyses, we conclude that PI 3-kinase activates inside-out signaling of beta(2) integrins at least partially through cytohesin-1.	Univ Munchen, Genzentrum, Mol Biol Lab, D-81377 Munich, Germany	University of Munich	Kolanus, W (corresponding author), Univ Munchen, Genzentrum, Mol Biol Lab, Feodor Lynen Str 25, D-81377 Munich, Germany.	kolanus@lmb.uni-muenchen.de	Zeitlmann, Lutz/AAF-3586-2019					Auger KR, 1996, J BIOL CHEM, V271, P23452, DOI 10.1074/jbc.271.38.23452; Carr MW, 1996, IMMUNITY, V4, P179, DOI 10.1016/S1074-7613(00)80682-2; Chan ASH, 1997, J IMMUNOL, V159, P934; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CHEN YP, 1994, J BIOL CHEM, V269, P18307; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DOWNWARD J, 1994, NATURE, V371, P378, DOI 10.1038/371378a0; Driessens MHE, 1997, EXP CELL RES, V231, P242, DOI 10.1006/excr.1996.3463; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; KASSNER PD, 1993, J EXP MED, V178, P649, DOI 10.1084/jem.178.2.649; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Li TJ, 1997, ONCOGENE, V15, P1375, DOI 10.1038/sj.onc.1201308; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Meller N, 1996, MOL CELL BIOL, V16, P5782; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Nielsen M, 1996, J IMMUNOL, V157, P5350; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PHILIPPOT J, 1983, BIOCHIM BIOPHYS ACTA, V734, P137, DOI 10.1016/0005-2736(83)90111-6; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; REIF K, 1996, CURR BIOL, V6, P145; RODRIGUEZ VP, 1996, EMBO J, V15, P2442; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Wang DS, 1995, BIOCHEM BIOPH RES CO, V217, P608, DOI 10.1006/bbrc.1995.2818; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Zauli G, 1997, BLOOD, V89, P883, DOI 10.1182/blood.V89.3.883; Zell T, 1996, J IMMUNOL, V156, P883; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	73	125	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14853	14861		10.1074/jbc.273.24.14853	http://dx.doi.org/10.1074/jbc.273.24.14853			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614087	hybrid			2022-12-25	WOS:000074160400029
J	Saint, N; Lacapere, JJ; Gu, LQ; Ghazi, A; Martinac, B; Rigaud, JL				Saint, N; Lacapere, JJ; Gu, LQ; Ghazi, A; Martinac, B; Rigaud, JL			A hexameric transmembrane pore revealed by two-dimensional crystallization of the large mechanosensitive ion channel (MscL) of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; ELECTRON-DIFFRACTION; PATCH-CLAMP; PHOE PORIN; RESOLUTION	We have established a reconstitution method of the detergent-solubilized recombinant large mechanosensitive ion channel of Escherichia coli (MscL) that yielded two-dimensional crystals. For that purpose, we have developed a new protocol using Triton X-100 to solubilize and purify the MscL protein. This protocol not only allowed an increase in the protein yield but also made it possible to obtain a homogeneous delipidated and reproducible preparation of the purified protein. When examined by the patch-clamp method MscL channels were found to be fully functional, exhibiting characteristic conductance and activation by pressure. For electron crystallography the homogeneous Triton X-100-purified recombinant MscL was further reconstituted at low lipid-to-protein ratios using Bio-Beads SM2 to remove the detergent. Two-dimensional crystals, exhibiting a p6 plane group symmetry, have been produced and examined by negative stain electron microscopy. Image processing of selected micrographs yielded a projection map at 15-Angstrom resolution that provided the first explicit structural information about the molecular boundary and homohexameric organization of the MscL channels in the membrane bilayer.	Univ Western Australia, Dept Pharmacol, Nedlands, WA 6907, Australia; CEA, LRC, F-75231 Paris, France; Univ Paris 11, Lab Biomembranes, CNRS, ERS 571, F-91405 Orsay, France; Inst Curie, CNRS, UMR 168, F-75231 Paris 05, France	University of Western Australia; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie	Rigaud, JL (corresponding author), Inst Curie, CNRS, UMR 168, 11 Rue Pierre & Marie Curie, F-75231 Paris 05, France.	rigaud@curie.fr	Martinac, Boris/A-7178-2018; Saint, Nathalie/S-5286-2016	Martinac, Boris/0000-0001-8422-7082; Saint, Nathalie/0000-0001-5219-9486				Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Cruickshank CC, 1997, BIOPHYS J, V73, P1925, DOI 10.1016/S0006-3495(97)78223-7; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; French RJ, 1996, NEURON, V16, P407, DOI 10.1016/S0896-6273(00)80058-6; GarciaAnoveros J, 1997, ANNU REV NEUROSCI, V20, P567, DOI 10.1146/annurev.neuro.20.1.567; GU L, 1998, IN PRESS BIOPHYS J; HAMILL OP, 1995, AM SCI, V83, P30; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamill OP, 1996, PHARMACOL REV, V48, P231; HAMILL OP, 1994, TRENDS NEUROSCI, V17, P439, DOI 10.1016/0166-2236(94)90125-2; Hase CC, 1997, BIOCHEM BIOPH RES CO, V232, P777, DOI 10.1006/bbrc.1997.6370; Hase CC, 1997, J MEMBRANE BIOL, V157, P17, DOI 10.1007/s002329900212; JAP BK, 1988, J MOL BIOL, V199, P229, DOI 10.1016/0022-2836(88)90393-2; JAP BK, 1990, J STRUCT BIOL, V103, P57, DOI 10.1016/1047-8477(90)90086-R; MARTINAC B, 1993, CRC THERMODYNAMICS M, P327; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; Mosser G, 1997, J BIOL CHEM, V272, P20263, DOI 10.1074/jbc.272.32.20263; North RA, 1996, CURR OPIN CELL BIOL, V8, P474, DOI 10.1016/S0955-0674(96)80023-8; Rigaud JL, 1997, J STRUCT BIOL, V118, P226, DOI 10.1006/jsbi.1997.3848; SACHS F, 1988, CRIT REV BIOMED ENG, V16, P141; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; Sukharev SI, 1996, SOC GEN PHY, V51, P133; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VALPUESTA JM, 1994, J MOL BIOL, V240, P281, DOI 10.1006/jmbi.1994.1445; Young HS, 1997, BIOPHYS J, V72, P2545, DOI 10.1016/S0006-3495(97)78898-2	31	45	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14667	14670		10.1074/jbc.273.24.14667	http://dx.doi.org/10.1074/jbc.273.24.14667			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614061	hybrid			2022-12-25	WOS:000074160400003
J	Wise, ML; Savage, TJ; Katahira, E; Croteau, R				Wise, ML; Savage, TJ; Katahira, E; Croteau, R			Monoterpene synthases from common sage (Salvia officinalis) - cDNA isolation, characterization, and functional expression of (+)-sabinene synthase, 1,8-cineole synthase, and (+)-bornyl diphosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYL PYROPHOSPHATE; ENZYMATIC CYCLIZATION; BORNYL PYROPHOSPHATE; NERYL PYROPHOSPHATE; (-)-LINALYL PYROPHOSPHATE; (-)-BORNYL PYROPHOSPHATE; ISOLATED CHROMOPLASTS; PARTIAL-PURIFICATION; TERPENOID CYCLASE; OLEFIN FORMATION	Common sage (Salvia officinalis) produces an extremely broad range of cyclic monoterpenes bearing diverse carbon skeletons, including members of the p-menthane (1,8-cineole), pinane (alpha- and beta-pinene), thujane (isothujone), camphane (camphene), and bornane (camphor) families. An homology-based polymerase chain reaction cloning strategy was developed and used to isolate the cDNAs encoding three multiproduct monoterpene synthases from this species that were functionally expressed in Escherichia coli. The heterologously expressed synthases produce (+)-bornyl diphosphate, 1,8-cineole, and (+)-sabinene, respectively, as their major products from geranyl diphosphate. The bornyl diphosphate synthase also produces significant amounts of (+)-alpha-pinene, (+)-camphene, and (+/-)-limonene. The 1,8-cineole synthase produces significant amounts of (+)- and (-)-alpha-pinene, (+)- and (-)-beta-pinene, myrcene and (+)-sabinene, and the (+)-sabinene synthase produces significant quantities of gamma-terpinene and terpinolene. All three enzymes appear to be translated as preproteins bearing an amino-terminal plastid targeting sequence, consistent with the plastidial origin of monoterpenes in plants. Deduced sequence analysis and size exclusion chromatography indicate that the recombinant bornyl diphosphate synthase is a homodimer, whereas the other two recombinant enzymes are monomeric, consistent with the size and subunit architecture of their native enzyme counterparts. The distribution and stereochemistry of the products generated by the recombinant (+)-bornyl diphosphate synthase suggest that this enzyme might represent both (+)-bornyl diphosphate synthase and (+)-pinene synthase which were previously assumed to be distinct enzymes.	Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA; Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA	Washington State University; Washington State University	Croteau, R (corresponding author), Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA.	croteau@mail.wsu.edu			NIGMS NIH HHS [GM-31354] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031354, R01GM031354] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY MN, 1990, J BIOL CHEM, V265, P13157; Bohlmann J, 1997, J BIOL CHEM, V272, P21784, DOI 10.1074/jbc.272.35.21784; CANE DE, 1990, CHEM REV, V90, P1089, DOI 10.1021/cr00105a002; CANE DE, 1994, BIOCHEMISTRY-US, V33, P5846, DOI 10.1021/bi00185a024; CANE DE, 1982, J AM CHEM SOC, V104, P5831, DOI 10.1021/ja00385a067; CHEN AJ, 1994, PROTEIN SCI, V3, P600; Chen XY, 1995, ARCH BIOCHEM BIOPHYS, V324, P255, DOI 10.1006/abbi.1995.0038; COLBY SM, 1993, J BIOL CHEM, V268, P23016; COOPER TG, 1977, TOOLS BIOCH, P169; CROTEAU R, 1989, J BIOL CHEM, V264, P15309; CROTEAU R, 1977, ARCH BIOCHEM BIOPHYS, V184, P77, DOI 10.1016/0003-9861(77)90328-9; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; CROTEAU R, 1976, ARCH BIOCHEM BIOPHYS, V176, P734, DOI 10.1016/0003-9861(76)90217-4; CROTEAU R, 1985, J BIOL CHEM, V260, P5956; CROTEAU R, 1979, ARCH BIOCHEM BIOPHYS, V198, P523, DOI 10.1016/0003-9861(79)90527-7; CROTEAU R, 1978, ARCH BIOCHEM BIOPHYS, V188, P182, DOI 10.1016/0003-9861(78)90371-5; CROTEAU R, 1994, ARCH BIOCHEM BIOPHYS, V309, P184, DOI 10.1006/abbi.1994.1101; CROTEAU R, 1986, J BIOL CHEM, V261, P3438; CROTEAU R, 1989, J BIOL CHEM, V264, P2075; CROTEAU R, 1988, J BIOL CHEM, V263, P10063; CROTEAU R, 1979, ARCH BIOCHEM BIOPHYS, V198, P512, DOI 10.1016/0003-9861(79)90526-5; CROTEAU R, 1977, ARCH BIOCHEM BIOPHYS, V179, P257, DOI 10.1016/0003-9861(77)90110-2; CROTEAU R, 1990, ARCH BIOCHEM BIOPHYS, V277, P374, DOI 10.1016/0003-9861(90)90593-N; CROTEAU R, 1985, METHOD ENZYMOL, V110, P383; CROTEAU R, 1992, RECENT DEV FLAVOR FR, P263; CROTEAU RB, 1985, BIOCHEMISTRY-US, V24, P7077, DOI 10.1021/bi00346a009; CROTEAU RB, 1987, BIOCHEMISTRY-US, V26, P5383, DOI 10.1021/bi00391a025; CROTEAU RB, 1992, ACS SYM SER, V490, P8; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Dudareva N, 1996, PLANT CELL, V8, P1137, DOI 10.1105/tpc.8.7.1137; FACCHINI PJ, 1992, P NATL ACAD SCI USA, V89, P11088, DOI 10.1073/pnas.89.22.11088; GAMBLIEL H, 1984, J BIOL CHEM, V259, P740; GAMBLIEL H, 1982, J BIOL CHEM, V257, P2335; *GEN COMP GROUP, 1996, WISC PACK VERS 9 0; GLEIZES M, 1983, PLANTA, V159, P373, DOI 10.1007/BF00393177; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KARP F, 1982, ARCH BIOCHEM BIOPHYS, V216, P616, DOI 10.1016/0003-9861(82)90251-X; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; Lewinsohn E., 1994, Plant Molecular Biology Reporter, V12, P20, DOI 10.1007/BF02668660; LEWINSOHN E, 1992, ARCH BIOCHEM BIOPHYS, V293, P167, DOI 10.1016/0003-9861(92)90380-F; MAU CJD, 1994, P NATL ACAD SCI USA, V91, P8497, DOI 10.1073/pnas.91.18.8497; MCCASKILL D, 1993, ANAL BIOCHEM, V215, P142, DOI 10.1006/abio.1993.1566; MCGEADY P, 1995, ARCH BIOCHEM BIOPHYS, V317, P149, DOI 10.1006/abbi.1995.1147; METTAL U, 1988, EUR J BIOCHEM, V170, P613, DOI 10.1111/j.1432-1033.1988.tb13741.x; PEREZ LM, 1990, PLANT PHYSIOL BIOCH, V28, P221; PORALLA K, 1994, TRENDS BIOCHEM SCI, V19, P157, DOI 10.1016/0968-0004(94)90276-3; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; PYUN HJ, 1994, ARCH BIOCHEM BIOPHYS, V308, P488, DOI 10.1006/abbi.1994.1069; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATTERWHITE DM, 1988, J CHROMATOGR, V454, P61; SAVAGE TJ, 1995, ARCH BIOCHEM BIOPHYS, V320, P257, DOI 10.1016/0003-9861(95)90008-X; SAVAGE TJ, 1994, J BIOL CHEM, V269, P4012; SHI Z, 1994, P NATL ACAD SCI USA, V91, P7370, DOI 10.1073/pnas.91.15.7370; STEELE CL, 1995, P NATL ACAD SCI USA, V92, P4164, DOI 10.1073/pnas.92.10.4164; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TABOR S, 1991, CURRENT PROTOCOLS MO; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAGSCHAL K, 1991, TETRAHEDRON, V47, P5933, DOI 10.1016/S0040-4020(01)86486-3; WAGSCHAL KC, 1994, ARCH BIOCHEM BIOPHYS, V308, P477, DOI 10.1006/abbi.1994.1068; Wise ML, 1998, COMPREHENSIVE NATURA, V2; Yuba A, 1996, ARCH BIOCHEM BIOPHYS, V332, P280, DOI 10.1006/abbi.1996.0343; [No title captured]	64	201	220	3	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14891	14899		10.1074/jbc.273.24.14891	http://dx.doi.org/10.1074/jbc.273.24.14891			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614092	hybrid			2022-12-25	WOS:000074160400034
J	Stoffler, HE; Bahler, M				Stoffler, HE; Bahler, M			The ATPase activity of Myr3, a rat myosin I, is allosterically inhibited by its own tail domain and by Ca2+ binding to its light chain calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA MYOSIN; ACTIN-BINDING; BRUSH-BORDER; UNCONVENTIONAL MYOSIN; MOTOR-ACTIVITY; SH3 DOMAIN; F-ACTIN; PURIFICATION; PROTEIN; IDENTIFICATION	We purified Myr3 (third unconventional myosin from rat), a mammalian "amoeboid" subclass myosin I, from rat liver. The heavy chain of purified Myr3 is associated with a single calmodulin light chain. Myr3 exhibits WEDTA-ATPase and Mg-ATPase activity, The Mg-ATPase activity is stimulated by increasing F-actin concentrations in a complex triphasic manner similar to the Mg-ATPase activity of myosin I molecules from protozoa, Although purified Myr3 was observed to cross-link actin filaments, it bound in an ATP regulated manner to F-actin, and no evidence for a nucleotide-independent high affinity actin binding site that could explain the triphasic activation pattern was obtained, Micromolar concentrations of free Ca2+ reversibly inhibit the Mg-ATPase activity of Myr3 by binding to its light chain calmodulin, which remains bound to the Myr3 heavy chain irrespective of the free Ca2+ concentration. Polyclonal antibodies and Fab fragments directed against the tail domain were found to stimulate the Mg-ATPase activity. A similar stimulation of the Myr3 Mg-ATPase activity is observed upon proteolytic removal of the very C-terminal SH3 domain. These results demonstrate that Myr3 is subject to negative regulation by free calcium and its own tail domain and possibly positive regulation by a tail-domain binding partner.	Ludwigs Maximillian Univ, Adolf Butenandt Inst, D-80336 Munchen, Germany	University of Munich	Bahler, M (corresponding author), Ludwigs Maximillian Univ, Adolf Butenandt Inst, Schillerstr 42, D-80336 Munchen, Germany.							ALBANESI JP, 1985, J BIOL CHEM, V260, P1174; BAHLER M, 1994, J CELL BIOL, V126, P375, DOI 10.1083/jcb.126.2.375; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; BEMENT WM, 1994, J MOL BIOL, V243, P356, DOI 10.1006/jmbi.1994.1662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COLLINS JH, 1984, J BIOL CHEM, V259, P4128; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; COLUCCIO LM, 1987, J CELL BIOL, V105, P325, DOI 10.1083/jcb.105.1.325; COLUCCIO LM, 1993, CELL MOTIL CYTOSKEL, V24, P189, DOI 10.1002/cm.970240306; CONZELMAN KA, 1987, J CELL BIOL, V105, P313, DOI 10.1083/jcb.105.1.313; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COTE GP, 1985, J BIOL CHEM, V260, P4543; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; GOODSON HV, 1995, CELL MOTIL CYTOSKEL, V30, P73, DOI 10.1002/cm.970300109; HALSALL DJ, 1990, FEBS LETT, V267, P126, DOI 10.1016/0014-5793(90)80305-3; JUNG G, 1994, FEBS LETT, V342, P197, DOI 10.1016/0014-5793(94)80500-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; MARUTA H, 1978, J BIOL CHEM, V253, P6297; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; PANTALONI D, 1985, J BIOL CHEM, V260, P1180; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1973, J BIOL CHEM, V248, P4691; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROSENFELD SS, 1994, BIOCHEMISTRY-US, V33, P2322, DOI 10.1021/bi00174a045; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; STOFFLER HE, 1995, J CELL BIOL, V129, P819, DOI 10.1083/jcb.129.3.819; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALLIMANN T, 1981, BIOCHEMISTRY-US, V20, P1188, DOI 10.1021/bi00508a021; WILLIAMS R, 1994, CELL MOTIL CYTOSKEL, V27, P41, DOI 10.1002/cm.970270105; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	34	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14605	14611		10.1074/jbc.273.23.14605	http://dx.doi.org/10.1074/jbc.273.23.14605			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603977	hybrid			2022-12-25	WOS:000074021500079
J	Burger, AM; Zhang, X; Li, H; Ostrowski, JL; Beatty, B; Venanzoni, M; Papas, T; Seth, A				Burger, AM; Zhang, X; Li, H; Ostrowski, JL; Beatty, B; Venanzoni, M; Papas, T; Seth, A			Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas	ONCOGENE			English	Article						molecular cloning; immunohistochemistry; FISH mapping; LOH; breast cancer	EPITHELIAL-CELLS; CANCER CELLS; IDENTIFICATION; EXPRESSION; HETEROZYGOSITY; INHIBITOR	To define genes that are essential to the initiation and progression of breast cancer we utilized subtractive hybridization and differential display cloning techniques and isolated over 950 cDNAs from breast cell-lines derived from matched normal and tumor tissue, Of these, 102 cDNAs mere characterized by DNA sequencing and Northern blot analysis, GenBank searches showed that one of these genes, T1A12 is identical to mac25, an insulin-like growth factor-binding protein related gene. Antibodies generated against the C-terminal region of the T1A12/mac25 protein were used to investigate its expression in 60 primary breast tissues. Sections of 12 benign, 16 ductal carcinoma in situ and 32 infiltrating ductal carcinoma specimens were examined, Strong immunoperoxidase staining was observed in luminal epithelial cells of normal lobules and ducts, in apocrine cells of cysts and fibroadenomas, Moderate to weak protein expression was found in hyperplastic and DCIS cells, but no specific staining was detected in invasive carcinoma cells. FISH mapping using a PAC clone localized the T1A12/mac25 gene to 4q12-13, Microsatellite length polymorphism was studied using markers for 4q in paired normal and tumor breast tissues. Thirty-three per cent (10/30) of the samples mere found to be polymorphic with D4S189 and D4S231 microsatellite markers and LOH was detected in 50% (5/10) of these informative samples. Our data indicate that T1A12/mac25 expression is abrogated during breast cancer progression concomitant with loss of heterozygosity on chromosome 4q, T1A12/mac25 may therefore have a tumor suppressor-like function and its expression could indicate a disease with a more favorable status, having a better prognosis.	Univ Toronto, MRC, Dept Lab Med & Pathobiol, Periodontal Physiol Grp, Toronto, ON M5S 1B2, Canada; Univ Toronto, Womens Coll Hosp, Toronto, ON M5S 1B2, Canada; Univ Freiburg, Tumor Biol Ctr, D-79106 Freiburg, Germany; Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC 29425 USA; Leeds Gen Infirm, Dept Pathol, Leeds LS2 9JT, W Yorkshire, England; Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; Canc Therapy & Prevent Res Assoc, Rome, Italy	University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Freiburg; Medical University of South Carolina; Leeds General Infirmary; University of Leeds; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Seth, A (corresponding author), Univ Toronto, MRC, Dept Lab Med & Pathobiol, Periodontal Physiol Grp, Toronto, ON M5S 1B2, Canada.							Akaogi K, 1996, P NATL ACAD SCI USA, V93, P8384, DOI 10.1073/pnas.93.16.8384; Baserga R, 1997, ENDOCRINOLOGY, V138, P2217, DOI 10.1210/en.138.6.2217; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; BELL SM, 1991, BRIT J CANCER, V64, P174, DOI 10.1038/bjc.1991.264; BOCKER W, 1992, VIRCHOWS ARCH A, V421, P315, DOI 10.1007/BF01660978; BURGER A, IN PRESS ONCOGENE; Burger AM, 1996, INT J ONCOL, V8, P395; BURGER AM, 1996, MIANI SHORT REPORTS, V7, P65; CAWKWELL L, 1993, BRIT J CANCER, V67, P1292; CHEN JC, 1994, CELL PHYSL, V158, P69; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; CULOUSCOU JM, 1991, CANCER RES, V51, P2813; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FIGUEROA JA, 1993, J CELL BIOCHEM, V52, P196, DOI 10.1002/jcb.240520211; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HAMBLY RJ, 1994, THESIS U BRADFORD; KATO MV, 1996, ONCOGENE, V12, P1362; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MCGUIRE WL, 1992, J NATL CANCER I, V84, P1336, DOI 10.1093/jnci/84.17.1336; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; OH Y, 1996, J BIOL CHEM, V271, P33352; OOI GT, 1990, MOL CELL ENDOCRINOL, V71, pC39, DOI 10.1016/0303-7207(90)90243-2; PATTERSON H, 1992, EUR J CANCER, V28A, P258, DOI 10.1016/0959-8049(92)90428-5; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEKONEN F, 1992, CANCER RES, V52, P5204; Plymate SR, 1996, J CLIN ENDOCR METAB, V81, P3709, DOI 10.1210/jc.81.10.3709; POLLAK M, 1990, J NATL CANCER I, V82, P1693, DOI 10.1093/jnci/82.21.1693; RADFORD DM, 1995, CANCER RES, V55, P5180; SALESIOTIS AN, 1995, CANCER LETT, V91, P47, DOI 10.1016/0304-3835(95)03717-B; SATO H, 1995, BIOCHEM BIOPH RES CO, V214, P468, DOI 10.1006/bbrc.1995.2310; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; SOUBEYRAN I, 1995, BREAST CANCER RES TR, V34, P119, DOI 10.1007/BF00665784; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TARMIN L, 1994, CANCER RES, V54, P6094; Tripathy D, 1992, Cancer Treat Res, V63, P15; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; WESTLEY BR, 1995, BRIT J CANCER, V72, P1065, DOI 10.1038/bjc.1995.465; WINQVIST R, 1993, CANCER RES, V53, P4486; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YEE D, 1994, CELL GROWTH DIFFER, V5, P73	41	119	132	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2459	2467		10.1038/sj.onc.1201772	http://dx.doi.org/10.1038/sj.onc.1201772			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627112				2022-12-25	WOS:000073672300004
J	Andres, JL; Fan, SJ; Turkel, GJ; Wang, JA; Twu, NF; Yuan, RQ; Lamszus, K; Goldberg, ID; Rosen, EM				Andres, JL; Fan, SJ; Turkel, GJ; Wang, JA; Twu, NF; Yuan, RQ; Lamszus, K; Goldberg, ID; Rosen, EM			Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents	ONCOGENE			English	Article						breast cancer; BRCA1; BRCA2; MCF-7; DNA damage; adriamycin	TUMOR-SUPPRESSOR PROTEIN; TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; SUSCEPTIBILITY GENE; IN-VIVO; P53; PROGRESSION; INHIBITION; INTERACTS; GROWTH	Germline mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 have been linked Ito the development of breast cancer, ovarian cancer, and other malignancies. Recent studies suggest that the BRCA1 and BRCA2 gene products may function in the sensing and/or repair of DNA damage. To investigate this possibility, we determined the effects of various DNA-damaging agents and other cytotoxic agents on the mRNA levels of BRCA1 and BRCA2 in the MCF-7 and other human breast cancer cell lines. We found that several agents, including adriamycin (a DNA intercalator and inhibitor of topoisomerase II), camptothecin (a topoisomerase I inhibitor), and ultraviolet radiation induced significant decreases in BRCA1 and BRCA2 mRNA levels. Decreased levels of BRCA1 and BRCA2 mRNAs were observed within 6-12 h after treatment with adriamycin and persisted for at least 72 h. Adriamycin also induced decreases in BRCA1 protein levels; but these decreases required several days. U.V. radiation induced dose-dependent down-regulation of BRCA1 and BRCA2 mRNAs, with significant decreases in both mRNAs at doses as low as 2.5 J/m(2), a dose that yielded very little cytotoxicity. Adriamycin-induced down-regulation of BRCA1 and BRCA2 mRNAs was first observed at doses that yielded relatively little cytotoxicity and little or no apoptotic DNA fragmentation, Adriamycin and U.V. radiation induced distinct dose- and time-dependent alterations in the cell cycle distribution; but these alterations did not correlate well with corresponding changes in BRCA1 and BRCA2 mRNA levels. However, the adriamycin-induced reduction in BRCA1 and BRCA2 mRNA levels was correlated with p53 functional status. MCF-7 cells transfected with a dominant negative mutant p53 (143 val-->ala) required at least tenfold higher doses of adriamycin to down-regulate BRCA1 and BRCA2 mRNAs than did parental MCF-7 cells or control-transfected MCF-7 clones. These results suggest that BRCA1 and BRCA2 may play roles in the cellular response to DNA-damaging agents and that there may be a p53-sensitive component to the regulation of BRCA1 and BRCA2 mRNA expression.	Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, New Hyde Park, NY 11040 USA	Northwell Health; Yeshiva University	Rosen, EM (corresponding author), Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New Hyde Park, NY 11040 USA.				NATIONAL CANCER INSTITUTE [R01CA064869] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA64869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; EASTON DF, 1993, AM J HUM GENET, V52, P678; FAN SJ, 1995, CANCER RES, V55, P1649; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GUDAS J, 1996, CELL GROWTH DIFFER, V7, P712; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Hermann M., 1994, NUCLEIC ACIDS RES, V22, P5506; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Larson JS, 1997, CANCER RES, V57, P3351; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rao VN, 1996, ONCOGENE, V12, P523; ROSEN EM, 1991, CANCER RES, V51, P5315; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Shao NS, 1996, ONCOGENE, V13, P1; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Spillman MA, 1996, ONCOGENE, V13, P1639; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1841, DOI 10.1093/carcin/14.9.1841; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Tirkkonen M, 1997, CANCER RES, V57, P1222; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395	42	77	77	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2229	2241		10.1038/sj.onc.1201752	http://dx.doi.org/10.1038/sj.onc.1201752			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619832				2022-12-25	WOS:000073298000008
J	Ono, Y; Shimada, H; Sorimachi, H; Richard, I; Saido, TC; Beckmann, JS; Ishiura, S; Suzuki, K				Ono, Y; Shimada, H; Sorimachi, H; Richard, I; Saido, TC; Beckmann, JS; Ishiura, S; Suzuki, K			Functional defects of a muscle-specific calpain, p94, caused by mutations associated with limb-girdle muscular dystrophy type 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SARCOGLYCAN; ALPHA-FODRIN; GENE; EXPRESSION; SITE; EFFICIENT; DISTINCT; ADHALIN; FAMILY; DNA	p94 (calpain3), a muscle-specific member of the calpain family, has been shown to be responsible for limb-girdle muscular dystrophy type 2A (LGMD2A), a form of autosomal recessive and progressive neuromuscular disorder. To elucidate the molecular mechanism of LGMD2A, we constructed nine p94 missense point mutants found in LGMD2A and analyzed their p94 unique properties, All mutants completely or almost completely lose the proteolytic activity against a potential substrate, fodrin. However, some of the mutants still possess autolytic activity and/or connectin/titin binding ability, indicating these properties are not necessary for the LGMD2A phenotypes, These results provide strong evidence that LGMD2A results from the loss of proteolysis of substrates by p94, suggesting a novel molecular mechanism leading to muscular dystrophies.	Univ Tokyo, Inst Mol & Cellular Biosci, Dept Mol Biol, Lab Mol Struct & Funct,Bunkyo Ku, Tokyo 1130032, Japan; Genethon, F-91000 Evry, France; Tokyo Metropolitan Inst Med Sci, Dept Mol Biol, Bunkyo Ku, Tokyo 1130021, Japan	University of Tokyo; Tokyo Metropolitan Institute of Medical Science	Sorimachi, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Dept Mol Biol, Lab Mol Struct & Funct,Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	sorimach@iam.u-tokyo.ac.jp	Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015; Richard, isabelle/J-8298-2013; Sorimachi, Hiroyuki/C-6448-2009; Beckmann, Jacques S/A-9772-2008	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903; Sorimachi, Hiroyuki/0000-0001-9509-6727; Beckmann, Jacques S/0000-0002-9741-1900				Arthur JSC, 1996, BIOCHEM J, V319, P535, DOI 10.1042/bj3190535; BASHIR R, 1994, HUM MOL GENET, V3, P455, DOI 10.1093/hmg/3.3.455; Blanchard H, 1997, NAT STRUCT BIOL, V4, P532, DOI 10.1038/nsb0797-532; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; Braman J, 1996, Methods Mol Biol, V57, P31; BUSHBY KMD, 1995, NEUROMUSCULAR DISORD, V5, P337, DOI 10.1016/0960-8966(95)00005-8; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; Fardeau M, 1996, NEUROMUSCULAR DISORD, V6, P447, DOI 10.1016/S0960-8966(96)00387-2; HARPER JW, 1993, CELL, V75, P805; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; Kinbara K, 1997, ARCH BIOCHEM BIOPHYS, V342, P99, DOI 10.1006/abbi.1997.0108; Kolmerer B, 1996, J MOL BIOL, V256, P556, DOI 10.1006/jmbi.1996.0108; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Labeit S, 1997, CIRC RES, V80, P290, DOI 10.1161/01.RES.80.2.290; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; Maruyama K, 1997, FASEB J, V11, P341, DOI 10.1096/fasebj.11.5.9141500; MCMAHON AP, 1987, BIOCHEM SOC T, V15, P804, DOI 10.1042/bst0150804; MCNALLY EM, 1994, P NATL ACAD SCI USA, V91, P9690, DOI 10.1073/pnas.91.21.9690; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; PassosBueno MR, 1996, J MED GENET, V33, P97, DOI 10.1136/jmg.33.2.97; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Poussard S, 1996, CELL GROWTH DIFFER, V7, P1461; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Sorimachi H, 1996, ADV BIOPHYS, V33, P101; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VANOMMEN GJ, 1995, NAT MED, V1, P412; WALTON JN, 1988, MUSCULAR DYSTROPHIES	38	123	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17073	17078		10.1074/jbc.273.27.17073	http://dx.doi.org/10.1074/jbc.273.27.17073			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642272	hybrid			2022-12-25	WOS:000074545200062
J	Warren, RA; Green, FA; Stenberg, PE; Enns, CA				Warren, RA; Green, FA; Stenberg, PE; Enns, CA			Distinct saturable pathways for the endocytosis of different tyrosine motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; RECEPTOR-MEDIATED ENDOCYTOSIS; LOW-DENSITY-LIPOPROTEIN; FACTOR-II RECEPTOR; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; COATED PIT ADAPTINS; TRANSFERRIN RECEPTOR; INTERNALIZATION SIGNAL; MANNOSE 6-PHOSPHATE; CYTOPLASMIC DOMAIN	Endocytosis of surface proteins through clathrin-coated pits requires an internalization signal in the cytoplasmic domain. Two types of internalization signal have been described: one requiring a tyrosine as the critical residue (tyrosine-based motif), and the other consisting of either two consecutive leucines or an isoleucine and leucine (dileucine motif), Although it seems that these signals are necessary and sufficient for endocytic targeting, the mechanism of recognition is not well understood. To examine this question, tetracycline-repressible cell lines were used to overexpress one of several receptors bearing a tyrosine-based internalization signal. By measuring the rates of endocytosis for either the over expressed receptor,or that of other en receptors, we were able to show that the endocytosis of identical receptors could be saturated, but a complete lack of competition exists between the transferrin receptor (TfR), the low-density lipoprotein receptor, and the epidermal growth factor receptor. Overexpression of any one of these receptors resulted in its redistribution toward the cell surface, implying that entry into coated pits is limited. During high levels of TfR expression, however, a significant increase in the amount of surface Lamp1, but not low-density lipoprotein receptor, epidermal growth factor receptor, or Lamp2, is detected. This suggests that Lamp1 and TfR compete for the same endocytic sites. Together, these results support the idea that there are at least three distinct saturable components involved in clathrin-mediated endocytosis.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Enns, CA (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040608] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40608] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CARPENTIER JL, 1982, J CELL BIOL, V95, P73, DOI 10.1083/jcb.95.1.73; CHANG M P, 1991, Journal of Cell Biology, V115, p186A; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DICKSON RB, 1983, BIOCHEMISTRY-US, V22, P3667; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; GRIFFITHS G, 1983, METHOD ENZYMOL, V96, P466; HANOVER JA, 1984, CELL, V39, P283, DOI 10.1016/0092-8674(84)90006-0; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MAXFIELD FR, 1978, CELL, V14, P805, DOI 10.1016/0092-8674(78)90336-7; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; NEUTRA MR, 1985, J HISTOCHEM CYTOCHEM, V33, P1134, DOI 10.1177/33.11.2997327; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PEARSE BMF, 1985, EMBO J, V4, P2457, DOI 10.1002/j.1460-2075.1985.tb03956.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; VIA DP, 1982, EXP CELL RES, V141, P15, DOI 10.1016/0014-4827(82)90062-3; Warren RA, 1997, J BIOL CHEM, V272, P2116; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILLIAMS AM, 1991, J BIOL CHEM, V266, P17648; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WILLINGHAM MC, 1983, EXP CELL RES, V146, P163, DOI 10.1016/0014-4827(83)90334-8; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	59	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17056	17063		10.1074/jbc.273.27.17056	http://dx.doi.org/10.1074/jbc.273.27.17056			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642270	hybrid			2022-12-25	WOS:000074545200060
J	Govers, P; van Kerkhof, P; Schwartz, AL; Strous, GJ				Govers, P; van Kerkhof, P; Schwartz, AL; Strous, GJ			Di-leucine-mediated internalization of ligand by a truncated growth hormone receptor is independent of the ubiquitin conjugation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; CYTOPLASMIC DOMAIN; PROTEASOME PATHWAY; PLASMA-MEMBRANE; INDUCED ENDOCYTOSIS; TYROSINE KINASE; BINDING-PROTEIN; DOWN-REGULATION; DEGRADATION; MOTIF	The growth hormone receptor (GHR) is a member of the cytokine receptor family. Its function is to mediate cellular responses upon binding of growth hormone. Ligand binding induces dimerization and activation of the GHR. One mechanism by which the GHR is rapidly inactivated involves the ubiquitin conjugation system, a system implicated in the degradation of cytosolic and nuclear proteins. We have shown previously that the ubiquitin-conjugating system mediates internalization of the GHR. Here, we present evidence that in addition to the ubiquitin-dependent endocytosis signal, the cytosolic tail of the GHR contains a di-leucine motif. Upon truncation of the GHR at amino acid residue 349, this di-leucine motif is activated and mediates ubiquitin-independent internalization of the receptor. wDi-leucine-mediated GHR internalization requires functional clathrin-coated pits and results in GHR transport to the lysosome. Although the full-length GHR internalizes independent of the di-leucine motif, this motif may function in internalization of GHR isoforms.	Univ Utrecht, Fac Med, Dept Cell Biol, Biomembrane Inst, NL-3584 CX Utrecht, Netherlands; Washington Univ, Sch Med, Dept Mol Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	Utrecht University; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Strous, GJ (corresponding author), Univ Utrecht, Fac Med, Dept Cell Biol, Biomembrane Inst, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	strous@med.uu.nl	Govers, Roland/O-5782-2016	Govers, Roland/0000-0003-1359-5333; van Kerkhof, Peter/0000-0002-8954-2230				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; Baxter GT, 1997, J NEUROSCI, V17, P2683; BAXTER RC, 1985, ENDOCRINOLOGY, V117, P650, DOI 10.1210/endo-117-2-650; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chuang PI, 1997, J BIOL CHEM, V272, P24813, DOI 10.1074/jbc.272.40.24813; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CURNOW KM, 1995, MOL ENDOCRINOL, V9, P1250, DOI 10.1210/me.9.9.1250; Dastot F, 1996, P NATL ACAD SCI USA, V93, P10723, DOI 10.1073/pnas.93.20.10723; DELEHAYEZERVAS MC, 1994, J CLIN ENDOCR METAB, V78, P1473; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Egner R, 1996, FEBS LETT, V378, P177, DOI 10.1016/0014-5793(95)01450-0; FINIDORI J, 1995, J ENDOCRINOL, V147, P11, DOI 10.1677/joe.0.1470011; FISHBURN CS, 1995, J BIOL CHEM, V270, P29819; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Goldsmith JF, 1997, AM J PHYSIOL-ENDOC M, V273, pE932, DOI 10.1152/ajpendo.1997.273.5.E932; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; HAFT CR, 1994, J BIOL CHEM, V269, P26286; Heidmann DEA, 1997, J NEUROCHEM, V68, P1372; HERSHKO A, 1998, IN PRESS ANN REV BIO, V67; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; HOCQUETTE JF, 1989, ENDOCRINOLOGY, V125, P2167, DOI 10.1210/endo-125-4-2167; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; ILONDO MM, 1992, ENDOCRINOLOGY, V130, P2037, DOI 10.1210/en.130.4.2037; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LAI ZN, 1991, BRAIN RES, V546, P222, DOI 10.1016/0006-8993(91)91485-J; LAI ZN, 1993, BRAIN RES, V621, P260, DOI 10.1016/0006-8993(93)90114-3; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOBIE PE, 1994, J BIOL CHEM, V269, P21330; Maki CG, 1996, CANCER RES, V56, P2649; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MURPHY LJ, 1984, ENDOCRINOLOGY, V115, P1625, DOI 10.1210/endo-115-4-1625; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Ross RJM, 1997, MOL ENDOCRINOL, V11, P265, DOI 10.1210/me.11.3.265; ROUPAS P, 1986, MOL CELL ENDOCRINOL, V47, P81, DOI 10.1016/0303-7207(86)90018-3; ROUPAS P, 1988, MOL CELL ENDOCRINOL, V57, P93, DOI 10.1016/0303-7207(88)90037-8; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; SU CC, 1996, ANNU REV PHYSIOL, V58, P187; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; URBANEK M, 1992, MOL ENDOCRINOL, V6, P279, DOI 10.1210/me.6.2.279; vanDelft S, 1997, J BIOL CHEM, V272, P14013, DOI 10.1074/jbc.272.22.14013	65	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16426	16433		10.1074/jbc.273.26.16426	http://dx.doi.org/10.1074/jbc.273.26.16426			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632708				2022-12-25	WOS:000074436600079
J	Leonard, DA; Lin, R; Cerione, RA; Manor, D				Leonard, DA; Lin, R; Cerione, RA; Manor, D			Biochemical studies of the mechanism of action of the Cdc42-GTPase-activating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; BINDING-PROTEIN; PHOSPHOINOSITIDE 3-KINASE; NUCLEOTIDE EXCHANGE; CRYSTAL-STRUCTURE; TYROSINE KINASE; N-CHIMAERIN; DOMAIN; RAS; CDC42HS	The small GTP-binding proteins Rac, Rho, and Cdc42 were shown to mediate a variety of signaling pathways including cytoskeletal rearrangements, cell-cycle progression, and transformation. Key to the proper function of these GTP-binding proteins is an efficient shutoff mechanism that ensures the decay of the signal. Regulatory proteins termed GAPs (GTPase-activating proteins) enhance the intrinsic GTP hydrolysis of the GTP-binding proteins, thereby ensuring signal termination. We have used site specific mutagenesis to elucidate the limit domain for GAP activity in Cdc42-GAP, and show that in addition to the known GAP-homology domain (three conserved boxes), a C-terminal region outside that domain is also essential for GAP activity. In addition, we have replaced the conserved arginine (Arg(305)), which was suggested by structural studies to be a key catalytic residue, with an alanine and found that the R305A Cdc42-GAP mutant has a greatly diminished catalytic capacity but is still able to bind Cdc42 with high affinity. Thus, a key catalytic role for this residue is confirmed. However, we also present evidence for the involvement of an additional residue(s), since the R305A Cdc42-GAP mutant still exhibits measurable activity. Some of this residual activity might result from a neighboring arginine, since a double mutant R305A/R306A shows a further decrease in catalytic activity.	Cornell Univ, Ctr Vet Med, Dept Pharmacol, Ithaca, NY 14853 USA	Cornell University	Manor, D (corresponding author), Cornell Univ, Ctr Vet Med, Dept Pharmacol, Ithaca, NY 14853 USA.	dm43@cornell.edu			NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER; NEI NIH HHS [EY06429] Funding Source: Medline; NIGMS NIH HHS [GM47458] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; AHMED S, 1994, J BIOL CHEM, V269, P17642; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CERIONE RA, 1996, CURR OPIN CELL BIOL, V8, P205; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hoffman GR, 1998, J BIOL CHEM, V273, P4392, DOI 10.1074/jbc.273.8.4392; JOHN J, 1993, J BIOL CHEM, V268, P923; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Lackowicz JR., 2006, PRINCIPLES FLUORESCE, V3, DOI 10.1007/978-0-387-46312-4; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; LI A, 1993, NATURE, V363, P85; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; Pal E.F., 1989, NATURE, V341, P209; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; ZHENG Y, 1993, J BIOL CHEM, V268, P24629	42	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16210	16215		10.1074/jbc.273.26.16210	http://dx.doi.org/10.1074/jbc.273.26.16210			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632678	hybrid			2022-12-25	WOS:000074436600049
J	Nemoto, S; Xiang, JL; Huang, S; Lin, AN				Nemoto, S; Xiang, JL; Huang, S; Lin, AN			Induction of apoptosis by SB202190 through inhibition of p38 beta mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P38 MAP KINASE; SIGNAL-TRANSDUCTION; CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; STRESS; PHOSPHORYLATION; CASCADE; PATHWAY; MEMBER; FAMILY	p38, a subfamily of the mitogen-activated protein kinase, regulates gene expression in response to various extracellular stimuli. The pyridinyl imidazoles like SB202190 are specific inhibitors of p38 alpha and p38 beta and have been widely used in investigation of the biological functions of p38. Here we show that SB202190 by itself was sufficient to induce cell death, with typical apoptotic features such as nucleus condensation and intranucleosomal DNA fragmentation. SB202190 stimulated the activity of CPP32-like caspases, and its apoptotic effect was completely blocked by the protease inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone and expression of bcl-2. In addition, SB202190 was able to potentiate apoptosis induced by Fas(APO-1) ligation or UV irradiation. Expression of p38 beta attenuated the apoptotic effect of SB202190 and the cell death induced by Fas ligation and UV irradiation. In contrast, expression of p38 alpha induced cell death mildly. These results indicate that SB202190 induces apoptosis through activation of CPP32-like caspases and suggest that distinct members of the p38 subfamily of mitogen-activated protein kinase have different functions in apoptosis.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Gene Therapy Program, Birmingham, AL 35294 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Scripps Research Institute	Lin, AN (corresponding author), Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.	lin@vh.path.uab.edu			NCI NIH HHS [CA73740] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073740] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GOEDERT M, 1997, EMBO J, V16, P3663; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JACOBSON MJ, 1997, CELL, V91, P347; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PETER J, 1997, MOL CELL BIOL, V17, P24; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rinkenberger JL, 1997, CURR OPIN GENET DEV, V7, P589, DOI 10.1016/S0959-437X(97)80004-4; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; TOMPSON CB, 1995, SCIENCE, V267, P1456, DOI DOI 10.1126/SCIENCE.7878464; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	58	247	255	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16415	16420		10.1074/jbc.273.26.16415	http://dx.doi.org/10.1074/jbc.273.26.16415			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632706	hybrid			2022-12-25	WOS:000074436600077
J	Beger, RD; Bolton, PH				Beger, RD; Bolton, PH			Structures of apurinic and apyrimidinic sites in duplex DNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ABASIC SITES; CELL-CYCLE; CYTOSINE DEAMINATION; REPAIR ENZYMES; GLYCOSYLASE; PROTEIN; NMR; HETERODUPLEXES; CONFORMATION	Natural and exogenous processes can give rise to abasic sites with either a purine or pyrimidine as the base on the opposing strand. The solution state structures of the apyrimidinic DNA duplex, with D(6) indicating an abasic site, d(C(1) G(2) C(3) G(4) A(5) D(6) R(7) C(8) G(9) C(10)C(11)) d( G(22)C(21)G(20)C(19)T(18)A(17)T(16)G(15)C(14)G(13)G(12)) referred to as AD, and the apurinic DNA duplex with a dC(17), referred to as CD, have been determined, A particularly striking difference is that the abasic site in CD is predominantly a beta hemiacetal, whereas in AD the alpha and beta forms are equally present. Hydrogen bonding with water by the abasic site and the base on the opposite strand appears to play a large role in determining the structure near the damaged site. Comparison of these structures with that of a duplex DNA containing a thymine glycol at the same position as the abasic site and with that of a duplex DNA containing an abasic site in the middle of a curved DNA sequence offers some insight into the common and distinct structural features of damaged DNA sites.	Wesleyan Univ, Dept Chem, Middletown, CT 06459 USA	Wesleyan University	Bolton, PH (corresponding author), Wesleyan Univ, Dept Chem, Middletown, CT 06459 USA.	pbolton@wesleyan.edu						[Anonymous], 1985, DNA REPAIR; BALASUBRAMANIAN S, 1994, J BIOL CHEM, V270, P296; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BEGER RD, 1995, J BIOL CHEM, V270, P16840, DOI 10.1074/jbc.270.28.16840; BEGER RD, 1998, IN PRESS J MAGN RESO; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; CATHCART R, 1984, P NATL ACAD SCI-BIOL, V81, P5633, DOI 10.1073/pnas.81.18.5633; Cleaver JE, 1997, BIOCHEM J, V328, P1, DOI 10.1042/bj3280001; CLEAVER JE, 1995, CELL, V80, P825, DOI 10.1016/0092-8674(95)90283-X; Coleman C N, 1996, Oncology (Williston Park), V10, P399; CUNIASSE P, 1987, NUCLEIC ACIDS RES, V15, P8003, DOI 10.1093/nar/15.19.8003; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; Cunningham RP, 1997, MUTAT RES-DNA REPAIR, V383, P189, DOI 10.1016/S0921-8777(97)00008-6; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; Efrati E, 1997, J BIOL CHEM, V272, P2559; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FREDERICO LA, 1993, BIOCHEMISTRY-US, V32, P6523, DOI 10.1021/bi00077a005; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; FREIDBERG EC, 1995, DNA REPAIR MUTAGENES; GANNETT PM, 1993, CHEM RES TOXICOL, V6, P690, DOI 10.1021/tx00035a015; GOLJER I, 1995, J BIOL CHEM, V270, P22980, DOI 10.1074/jbc.270.39.22980; GOODMAN MF, 1994, ANN NY ACAD SCI, V726, P132, DOI 10.1111/j.1749-6632.1994.tb52804.x; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; HANAWALT PC, 1993, MUTAT RES, V289, P7, DOI 10.1016/0027-5107(93)90125-Y; Ide H, 1992, Nucleic Acids Symp Ser, P167; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; Kingma PS, 1997, J BIOL CHEM, V272, P7488, DOI 10.1074/jbc.272.11.7488; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; Krishnamurthy VV, 1996, J MAGN RESON SER B, V113, P46, DOI 10.1006/jmrb.1996.0153; Krokan HE, 1997, BIOCHEM J, V325, P1; Kung HC, 1997, J BIOL CHEM, V272, P9227; Kung HC, 1996, MAGN RESON CHEM, V34, pS47, DOI 10.1002/(SICI)1097-458X(199612)34:13<S47::AID-OMR44>3.0.CO;2-O; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Lundquist AJ, 1997, J BIOL CHEM, V272, P21408, DOI 10.1074/jbc.272.34.21408; MANOHARAN M, 1988, J AM CHEM SOC, V110, P2690, DOI 10.1021/ja00216a074; MANOHARAN M, 1988, J AM CHEM SOC, V110, P1620, DOI 10.1021/ja00213a044; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8209; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1191; Miller H, 1997, BIOCHEMISTRY-US, V36, P15336, DOI 10.1021/bi971927n; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOSBAUGH DW, 1994, PROG NUCL ACID RES, V48, P316; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Plum GE, 1995, BIOCHEMISTRY-US, V34, P16148, DOI 10.1021/bi00049a030; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANCHEZ G, 1994, MUTAT RES LETT, V325, P39, DOI 10.1016/0165-7992(94)90025-6; SANCHEZ G, 1994, ENVIRON MOL MUTAGEN, V23, P32, DOI 10.1002/em.2850230106; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; TAKESHITA M, 1994, NUCLEIC ACIDS RES, V22, P1897, DOI 10.1093/nar/22.10.1897; TESSMAN I, 1994, GENETICS, V136, P439; Vassylyev DG, 1997, CURR OPIN STRUC BIOL, V7, P103, DOI 10.1016/S0959-440X(97)80013-9; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; Wang KY, 1997, BIOCHEMISTRY-US, V36, P11629, DOI 10.1021/bi971464l; WARD JF, 1991, PHYSICAL CHEM MECHAN, V58, P403; WITHKA JM, 1991, BIOCHEMISTRY-US, V30, P9931, DOI 10.1021/bi00105a017; WITHKA JM, 1992, J MAGN RESON, V98, P611, DOI 10.1016/0022-2364(92)90014-X; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189; Young MA, 1995, METHOD ENZYMOL, V261, P121	68	53	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15565	15573		10.1074/jbc.273.25.15565	http://dx.doi.org/10.1074/jbc.273.25.15565			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624147	hybrid			2022-12-25	WOS:000074284200041
J	Gurevich, VV				Gurevich, VV			The selectivity of visual arrestin for light-activated phosphorhodopsin is controlled by multiple nonredundant mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; RHODOPSIN INTERACTION; 48-KDA PROTEIN; OGUCHI DISEASE; BINDING; EXPRESSION; DROSOPHILA; GENE; PHOSPHORYLATION; LOCALIZATION	Arrestin plays an important role in quenching photo transduction via its ability to bind to the phosphorylated light-activated form of the visual receptor rhodopsin (P-Rh*). Remarkable selectivity of visual arrestin toward this functional form is determined by an elegant sequential multisite binding mechanism. Previous structure-function studies have suggested that the COOP-terminal region of arrestin (residues 356-404) is not directly involved in rhodopsin interaction, but instead plays a regulatory role. This region supports basal arrestin conformation and ensures arrestin's transition into a high affinity rhodopsin-binding state upon an encounter with P-Rh*. Overall, our results corroborate this hypothesis and identify three functional subregions (residues 361-368, 369-378, and 379-404) and individual amino acids involved in the control of arrestin stability and binding selectivity. Two of the most potent mutants, arrestin(1-378) and arrestin(F375A,V376A,F377A) belong to a novel class of constitutively active arrestins with high affinity for P-Rh*, dark P-Rh. and Rh* (but not dark Ph), in contrast to earlier constructed mutants arrestin(R175E) and arrestin(Delta 2-16) with high affinity for light-activated forms only. The implications of these findings for the mechanism of arrestin-rhodopsin interaction are discussed in light of the recently determined crystal structure of arrestin.	Sun Hlth Res Inst, Sun City, AZ 85372 USA	Banner Research; Banner Health; Banner Sun Health Research Institute	Gurevich, VV (corresponding author), Sun Hlth Res Inst, 10515 W Santa Fe Dr, Sun City, AZ 85372 USA.	vgurevich@sunhealth.org	Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NEI NIH HHS [EY11500] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CRAFT CM, 1994, J BIOL CHEM, V269, P4613; FUCHS S, 1995, NAT GENET, V10, P360, DOI 10.1038/ng0795-360; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Gurevich VV, 1996, METHOD ENZYMOL, V275, P382; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Langlois G, 1996, P NATL ACAD SCI USA, V93, P4677, DOI 10.1073/pnas.93.10.4677; LEVINE H, 1990, MECH DEVELOP, V33, P19, DOI 10.1016/0925-4773(90)90131-5; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MATSUMOTO H, 1991, BIOCHEM BIOPH RES CO, V177, P1306, DOI 10.1016/0006-291X(91)90683-X; MAW MA, 1995, J MED GENET, V32, P396, DOI 10.1136/jmg.32.5.396; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P319; RAMING K, 1993, CELL SIGNAL, V5, P69, DOI 10.1016/0898-6568(93)90009-B; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1170; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; SMITH WC, 1994, J BIOL CHEM, V269, P15407; SMITH WC, 1993, INVEST OPHTH VIS SCI, V34, P807; SMITH WC, 1995, J NEUROCHEM, V64, P1; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; Vinos J, 1997, SCIENCE, V277, P687, DOI 10.1126/science.277.5326.687; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Yamamoto S, 1997, NAT GENET, V15, P175, DOI 10.1038/ng0297-175	35	98	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15501	15506		10.1074/jbc.273.25.15501	http://dx.doi.org/10.1074/jbc.273.25.15501			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624137	hybrid			2022-12-25	WOS:000074284200031
J	Hortensteiner, S; Wuthrich, KL; Matile, P; Ongania, KH; Krautler, B				Hortensteiner, S; Wuthrich, KL; Matile, P; Ongania, KH; Krautler, B			The key step in chlorophyll breakdown in higher plants - Cleavage of pheophorbide alpha macrocycle by a monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORELLA-PROTOTHECOIDES; STRUCTURE ELUCIDATION; SENESCENT LEAVES; REDUCED FERREDOXIN; A CATABOLITE; IN-VITRO; RAPE; PHAEOPHORBIDE; CONSTITUTION; REQUIREMENT	Chlorophyll breakdown in green plants is a longstanding biological enigma. Recent work has shown that pheophorbide a (Pheide a) derived from chlorophyll (Chl) is converted oxygenolytically into a primary fluorescent catabolite (pFCC-1) via a red Chl catabolite (RCC) intermediate. RCC, the product of the ring cleavage reaction catalyzed by Pheide a oxygenase, which is suggested to be the key enzyme in Chi breakdown in green plants, is converted into pFCC-1 by a reductase. In the present study, an in vitro assay comprising O-18(2) Pheide a oxygenase and RCC reductase yielded labeled pFCC-1. Fast atom bombardment-mass spectrometric analysis of the purified pFCC-1 product revealed that only one of the two oxygen atoms newly introduced into Pheide a in the course of the cleavage reaction is derived from molecular oxygen. Analysis of the fragment ions located the oxygen atom derived from molecular oxygen on the formyl group of pyrrole B, This finding demonstrates that the cleavage of Pheide a in vascular plants is catalyzed by a monooxygenase. Chlorophyll breakdown is therefore indicated to be mechanistically related in higher plants and in the green alga Chlorella protothecoides.	Univ Innsbruck, Inst Organ Chem, A-6020 Innsbruck, Austria; Univ Zurich, Dept Plant Biol, CH-8008 Zurich, Switzerland	University of Innsbruck; University of Zurich	Hortensteiner, S (corresponding author), Univ Innsbruck, Inst Organ Chem, Innrain 52A, A-6020 Innsbruck, Austria.	horten@bbsrc.ac.uk; Bernhard.Kraeutler@uibk.ac.at						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown SB., 1991, CHLOROPHYLLS, P465; CURTY C, 1995, FEBS LETT, V364, P41, DOI 10.1016/0014-5793(95)00348-D; Curty C, 1996, PHYTOCHEMISTRY, V42, P1531, DOI 10.1016/0031-9422(96)00155-0; Engel N, 1996, PLANT PHYSIOL BIOCH, V34, P77; ENGEL N, 1991, FEBS LETT, V293, P131, DOI 10.1016/0014-5793(91)81168-8; GINSBURG S, 1994, PLANT PHYSIOL, V105, P545, DOI 10.1104/pp.105.2.545; Hinder B, 1996, J BIOL CHEM, V271, P27233, DOI 10.1074/jbc.271.44.27233; HORTENSTEINER S, 1995, NEW PHYTOL, V129, P237, DOI 10.1111/j.1469-8137.1995.tb04293.x; ITURRASPE J, 1994, PHYTOCHEMISTRY, V35, P1387, DOI 10.1016/S0031-9422(00)86861-2; ITURRASPE J, 1995, J ORG CHEM, V60, P6664, DOI 10.1021/jo00126a007; Krautler B, 1997, HELV CHIM ACTA, V80, P1355, DOI 10.1002/hlca.19970800504; KRAUTLER B, 1991, ANGEW CHEM INT EDIT, V30, P1315, DOI 10.1002/anie.199113151; Matile P, 1996, PLANT PHYSIOL BIOCH, V34, P55; MATILE P, 1988, P NATL ACAD SCI USA, V85, P9529, DOI 10.1073/pnas.85.24.9529; Mendel JG., 1865, VERHANDLUNGEN NATURF, V4, P3, DOI DOI 10.1093/OXFORDJOURNALS.JHERED.A106151; Muhlecker W, 1996, PLANT PHYSIOL BIOCH, V34, P61; Muhlecker W, 1997, ANGEW CHEM INT EDIT, V36, P401, DOI 10.1002/anie.199704011; MUHLECKER W, 1993, HELV CHIM ACTA, V76, P2976, DOI 10.1002/hlca.19930760822; OSHIO Y, 1969, PLANT CELL PHYSIOL, V10, P41; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rodoni S, 1997, PLANT PHYSIOL, V115, P677, DOI 10.1104/pp.115.2.669; Rodoni S, 1997, PLANT PHYSIOL, V115, P669, DOI 10.1104/pp.115.2.669; SCHELLENBERG M, 1993, PLANTA, V191, P417, DOI 10.1007/BF00195702; Thomas H, 1996, BOT ACTA, V109, P3, DOI 10.1111/j.1438-8677.1996.tb00862.x; VICENTINI F, 1995, NEW PHYTOL, V129, P247, DOI 10.1111/j.1469-8137.1995.tb04294.x	26	129	139	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15335	15339		10.1074/jbc.273.25.15335	http://dx.doi.org/10.1074/jbc.273.25.15335			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624113	hybrid			2022-12-25	WOS:000074284200007
J	Iordanov, MS; Pribnow, D; Magun, JL; Dinh, TH; Pearson, JA; Magun, BE				Iordanov, MS; Pribnow, D; Magun, JL; Dinh, TH; Pearson, JA; Magun, BE			Ultraviolet radiation triggers the ribotoxic stress response in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INDUCED GENE-EXPRESSION; RIBOSOMAL-RNA; GROWTH-FACTOR; UV RESPONSE; DNA-DAMAGE; C-FOS; MECHANISM; PATHWAYS; SIGNAL	The ribotoxic stress response, which is conserved between prokaryotes and eukaryotes, is a cellular reaction to cytotoxic interference with the function of the 3'-end of the large (23 S/28 S) ribosomal RNA. The S'-end of the large rRNA is directly involved in the three sequential steps of translational elongation: the aminoacyl-tRNA binding, the peptidyl transfer, and the ribosomal translocation. In mammalian cells, the ribotoxic stress response involves activation of the stress-activated protein kinase/c-Jun NH2-terminal kinase and the p38 mitogen-activated protein kinase and transcriptional induction of immediate early genes such as c-fos and c-jun. Active ribosomes are essential mediators of the ribotoxic stress response. We demonstrate here that the transcriptional response of mammalian cells to ultraviolet radiation (W response) displays the characteristics of a ribotoxic stress response, inasmuch as (i) the activation of stress kinases and gene expression in response to W requires the presence of active ribosomes at the moment of irradiation; (ii) UV irradiation inhibits protein synthesis; and (iii) irradiation of cells with W causes specific damage to the 3'-end of the 28 S rRNA. Ire contrast, the activation of the stress kinases by hyperosmolarity, by the DNA-cross-linking agent diepoxybutane, or by growth factors and cytokines does not depend on the presence of active ribosomes. Our results identify W as a potential ribotoxic stressor and support the notion that some of the cellular signaling cascades in response to UV might be generated in the ribosome, possibly triggered by damage to rRNA.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University	Magun, BE (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA.				NCI NIH HHS [CA-39360] Funding Source: Medline; NIEHS NIH HHS [ES-08456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; BUSCHER M, 1988, ONCOGENE, V3, P301; CUNDLIFFE E, 1990, RIBOSOME, P479; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; ENDO Y, 1987, J BIOL CHEM, V262, P5908; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GU ZP, 1994, P NATL ACAD SCI USA, V91, P5612, DOI 10.1073/pnas.91.12.5612; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HERRLICH P, 1994, ADV ENZYME REGUL, V34, P381, DOI 10.1016/0065-2571(94)90024-8; HUMMEL H, 1987, NUCLEIC ACIDS RES, V15, P2431, DOI 10.1093/nar/15.6.2431; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; Iordanov MS, 1998, J BIOL CHEM, V273, P3528, DOI 10.1074/jbc.273.6.3528; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRAMER M, 1990, RADIAT ENVIRON BIOPH, V29, P303, DOI 10.1007/BF01210410; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEVIEV IG, 1994, EMBO J, V13, P1682, DOI 10.1002/j.1460-2075.1994.tb06432.x; LIN A, 1995, SCIENCE, V268, P3286; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAGUN BE, 1995, CELL GROWTH DIFFER, V6, P891; PRIBNOW D, 1992, MOL ENDOCRINOL, V6, P1004; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rodland KD, 1997, MOL ENDOCRINOL, V11, P281, DOI 10.1210/me.11.3.281; RODRIGUEZFONSECA C, 1995, J MOL BIOL, V247, P224, DOI 10.1006/jmbi.1994.0135; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Spahn CMT, 1996, J BIOL CHEM, V271, P32849, DOI 10.1074/jbc.271.51.32849; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SWEENEY R, 1991, GENETICS, V127, P327; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANBOGELEN RA, 1990, P NATL ACAD SCI USA, V87, P5589, DOI 10.1073/pnas.87.15.5589; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WOOL IG, 1992, TRENDS BIOCHEM SCI, V17, P266, DOI 10.1016/0968-0004(92)90407-Z; YAN MH, 1994, NATURE, V372, P798; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	44	137	140	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15794	15803		10.1074/jbc.273.25.15794	http://dx.doi.org/10.1074/jbc.273.25.15794			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624179	hybrid			2022-12-25	WOS:000074284200073
J	Hirsh, AJ; Cheeseman, CI				Hirsh, AJ; Cheeseman, CI			Cholecystokinin decreases intestinal hexose absorption by a parallel reduction in SGLT1 abundance in the brush-border membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; EXPRESSION; FRUCTOSE; PROTEIN; COTRANSPORTER; INSULIN; CLONING; HUMANS	The dual lumenaly and vascularly perfused small intestine was used to determine the mechanism by which cholecystokinin octapeptide (CCK-8) decreases the rate of glucose absorption. With CCK-8 in the vascular perfusate the rate of 3-O-methyl-D-glucose absorption decreased, whereas the rate of D-fructose absorption was unaffected. The substrate pool size within the tissue during steady-state transport, in the presence and absence of CCK-8, was estimated by compartmental analysis of the 3-O-methyl-D-glucose washout into the vascular bed. When CCK-8 was included in the vascular perfusate, the absorptive cell pool size decreased when compared with untreated tissue. Both the steady-state hexose absorption data and the washout studies indicated that the locus of action of CCK-8 was the SGLT1 transporter located in the brush-border membrane. The SGLT1 protein abundance in isolated brush-border membranes, as quantified by Western blotting, showed a decrease that paralleled the decrease in the steady-state transport rate induced by CCK-8, These results indicate that CCK-8 diminishes the rate of intestinal hexose absorption by decreasing SGLT1 protein abundance in the brush-border membrane of the rat jejunum and therefore provides evidence for acute enteric hormonal regulation of the rate of glucose absorption across the small intestine.	Univ Alberta, Dept Physiol, Membrane Transport Grp, Edmonton, AB T6G 2H7, Canada	University of Alberta	Cheeseman, CI (corresponding author), Univ Alberta, Dept Physiol, Membrane Transport Grp, 7-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.							BISMUT H, 1993, EUR J BIOCHEM, V213, P721, DOI 10.1111/j.1432-1033.1993.tb17812.x; BOYD CAR, 1979, J PHYSIOL-LONDON, V287, P371, DOI 10.1113/jphysiol.1979.sp012665; BOYD CAR, 1978, J PHYSIOL-LONDON, V274, P17, DOI 10.1113/jphysiol.1978.sp012131; CHEESEMAN CI, 1993, GASTROENTEROLOGY, V105, P1050, DOI 10.1016/0016-5085(93)90948-C; Cheeseman CI, 1996, AM J PHYSIOL-GASTR L, V271, pG477, DOI 10.1152/ajpgi.1996.271.3.G477; Cheeseman CI, 1997, AM J PHYSIOL-REG I, V273, pR1965, DOI 10.1152/ajpregu.1997.273.6.R1965; CHEESEMAN CI, 1981, J PHYSIOL-LONDON, V317, P91, DOI 10.1113/jphysiol.1981.sp013815; CRANE RK, 1962, FED PROC, V21, P891; DAVIDSON NO, 1992, AM J PHYSIOL, V262, pC795, DOI 10.1152/ajpcell.1992.262.3.C795; DEBAS HT, 1975, GASTROENTEROLOGY, V68, P1211; DEBNAM ES, 1995, PFLUG ARCH EUR J PHY, V430, P151, DOI 10.1007/BF00374645; DEBNAM ES, 1975, J PHYSIOL-LONDON, V252, P681, DOI 10.1113/jphysiol.1975.sp011165; HARDIN JA, 1993, AM J PHYSIOL, V264, pG312, DOI 10.1152/ajpgi.1993.264.2.G312; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Hirsch JR, 1996, J BIOL CHEM, V271, P14740, DOI 10.1074/jbc.271.25.14740; Hirsh AJ, 1997, GASTROENTEROLOGY, V113, P205, DOI 10.1016/S0016-5085(97)70096-9; Hirsh AJ, 1996, AM J PHYSIOL-GASTR L, V271, pG755, DOI 10.1152/ajpgi.1996.271.5.G755; HOLLOWAY PAH, 1984, BIOCHEM J, V222, P57, DOI 10.1042/bj2220057; HOPFER U, 1975, P NATL ACAD SCI USA, V72, P2027, DOI 10.1073/pnas.72.6.2027; Ishikawa Y, 1997, BBA-MOL CELL RES, V1357, P306, DOI 10.1016/S0167-4889(97)00043-8; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; LIDDLE RA, 1986, J CLIN INVEST, V77, P992, DOI 10.1172/JCI112401; LIDDLE RA, 1988, J CLIN INVEST, V81, P1675, DOI 10.1172/JCI113505; PENNINGTON AM, 1994, J PHYSIOL-LONDON, V478, P187, DOI 10.1113/jphysiol.1994.sp020241; VEYHL M, 1993, J BIOL CHEM, V268, P25041	25	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14545	14549		10.1074/jbc.273.23.14545	http://dx.doi.org/10.1074/jbc.273.23.14545			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603969	hybrid			2022-12-25	WOS:000074021500071
J	Gilad, E; Wong, HR; Zingarelli, B; Virag, L; O'Connor, M; Salzman, AL; Szabo, C				Gilad, E; Wong, HR; Zingarelli, B; Virag, L; O'Connor, M; Salzman, AL; Szabo, C			Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NF kappa B activation	FASEB JOURNAL			English	Article						inflammation; antioxidants; scavengers; gene expression; LPS; mesangial cells	INDUCED LIPID-PEROXIDATION; NEUROHORMONE MELATONIN; PINEAL-GLAND; ANTIBODY-RESPONSE; INDUCTION; CANCER; CELLS; SHOCK; NEUROIMMUNOTHERAPY; LIPOPOLYSACCHARIDE	The role of melatonin as an immunomodulator is well established. Recent reports showed that melatonin exerts protective effects iu septic and hemorrhagic shock and in inflammation. The expression of the inducible isoform of nitric oxide synthase (iNOS) makes an important contribution to the pathophysiology of shock and inflammation, We studied, in cultured murine macrophages, the role of melatonin in the regulation of the expression of iNOS and defined the mode of melatonin's action. Our results show that melatonin, at 1 mu M-1 mM, decreased the production of nitrite/nitrate (the breakdown products of NO) as well as the production of 6-ketoprostaglandin F-1 alpha (the major stable breakdown product of prostacyclin) in macrophages stimulated with bacterial lipopolysaccharide (10 mu g/ml), We observed that melatonin reduces iNOS steady-state mRNA levels and iNOS protein expression in the same concentration range (1 mu M-1 mM) Melatonin, up to 10 mM, exerted only a slight direct inhibitory effect on iNOS activity. Using iNOS promoter-luciferase constructs, we found that melatonin inhibits iNOS promoter activation, Inhibition of iNOS expression was associated with inhibition of activation of the transcription factor nuclear factor kappa B (NF kappa B), We conclude that melatonin inhibits NO production in immunostimulated macrophages mainly by inhibiting the expression of iNOS, This is due to inhibition of iNOS transcription, in part through inhibition of NF kappa B activation, Inhibition of iNOS-derived NO production by melatonin may contribute to the anti-inflammatory effects of this pineal secretory product.	Childrens Hosp, Med Ctr, Div Crit Care, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Szabo, C (corresponding author), Childrens Hosp, Med Ctr, Div Crit Care, 3333 Burnet Ave, Cincinnati, OH 45229 USA.		Szabo, Csaba/ABG-2644-2021; Virag, Laszlo/E-6124-2010; , Basilia/AAV-7582-2021	Wong, Hector/0000-0001-7989-1173; Virag, Laszlo/0000-0002-7099-6718				AKARASEREENONT P, 1994, BRIT J PHARMACOL, V113, P1522, DOI 10.1111/j.1476-5381.1994.tb17169.x; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Cazevieille C, 1997, BRAIN RES, V755, P91, DOI 10.1016/S0006-8993(97)00090-5; Chuang JI, 1996, CELL BIOL INT, V20, P687, DOI 10.1006/cbir.1996.0091; Conti A, 1995, J PINEAL RES, V19, P103, DOI 10.1111/j.1600-079X.1995.tb00177.x; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; GONZALEZHABA MG, 1995, FASEB J, V9, P1331, DOI 10.1096/fasebj.9.13.7557023; Hasko G, 1996, J IMMUNOL, V157, P4634; HAZELRIGG DG, 1996, ENDOCRINOLOGY, V137, P210; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Invernizzi P, 1997, AM J PHYSIOL-GASTR L, V273, pG131, DOI 10.1152/ajpgi.1997.273.1.G131; Kilbourn RG, 1997, SHOCK, V7, P235, DOI 10.1097/00024382-199704000-00001; KILBOURN RG, 1995, CRIT CARE MED, V23, P1018, DOI 10.1097/00003246-199506000-00005; Lissoni P, 1995, J BIOL REG HOMEOS AG, V9, P155; LISSONI P, 1993, ONCOLOGY-BASEL, V50, P399; LISSONI P, 1994, J BIOL REG HOMEOS AG, V8, P126; LISSONI P, 1990, ANTICANCER RES, V10, P1759; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Maestroni GJM, 1996, J PINEAL RES, V20, P84, DOI 10.1111/j.1600-079X.1996.tb00244.x; MAESTRONI GJM, 1995, J PINEAL RES, V18, P84, DOI 10.1111/j.1600-079X.1995.tb00144.x; MAESTRONI GJM, 1987, CLIN EXP IMMUNOL, V68, P384; MAESTRONI GJM, 1990, J NEUROIMMUNOL, V28, P167, DOI 10.1016/0165-5728(90)90031-H; MAESTRONI GJM, 1986, J NEUROIMMUNOL, V13, P19, DOI 10.1016/0165-5728(86)90047-0; MAESTRONI GJM, 1994, CANCER RES, V54, P4740; MAROTTA P, 1992, BRIT J PHARMACOL, V107, P640, DOI 10.1111/j.1476-5381.1992.tb14499.x; MELCHIORRI D, 1995, FASEB J, V9, P1205, DOI 10.1096/fasebj.9.12.7672513; Mohan N, 1995, BIOCHEM MOL BIOL INT, V37, P1063; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Pierpaoli W, 1993, Int J Neurosci, V68, P123; Pozo D, 1997, J CELL BIOCHEM, V65, P430, DOI 10.1002/(SICI)1097-4644(19970601)65:3<430::AID-JCB12>3.0.CO;2-J; POZO D, 1994, LIFE SCI, V55, P455; REITER RJ, 1995, FRONT NEUROENDOCRIN, V16, P383, DOI 10.1006/frne.1995.1014; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; SEWERYNEK E, 1995, FREE RADICAL BIO MED, V19, P903, DOI 10.1016/0891-5849(95)00101-3; Shaikh AY, 1997, NEUROSCI LETT, V229, P193, DOI 10.1016/S0304-3940(97)00307-8; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; Sullivan DJ, 1996, J SURG RES, V64, P13, DOI 10.1006/jsre.1996.0299; SWIERKOSZ TA, 1995, BRIT J PHARMACOL, V114, P1335, DOI 10.1111/j.1476-5381.1995.tb13353.x; Szabo C, 1995, New Horiz, V3, P2; SZABO C, 1994, BRIT J PHARMACOL, V113, P757, DOI 10.1111/j.1476-5381.1994.tb17058.x; Szabo C, 1997, INT J ONCOL, V10, P1093; VANE JR, 1995, INFLAMM RES, V44, P1, DOI 10.1007/BF01630479; Wichmann MW, 1996, J SURG RES, V65, P109, DOI 10.1006/jsre.1996.0351; Wong HR, 1995, AM J PHYSIOL-LUNG C, V269, pL843, DOI 10.1152/ajplung.1995.269.6.L843; ZINGARELLI B, 1997, BRIT J PHARMACOL, V119, P1; [No title captured]	50	230	249	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1998	12	9					685	693		10.1096/fasebj.12.9.685	http://dx.doi.org/10.1096/fasebj.12.9.685			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619447				2022-12-25	WOS:000074011000007
